From 5d9974e2b9aeb5f8134cfb7b2651eaafe1de50e6 Mon Sep 17 00:00:00 2001 From: Matthijs Berends <5580@certe.nl> Date: Thu, 1 Oct 2026 14:50:25 +0100 Subject: [PATCH] implement EUCAST >= 2019 directly from their source files --- DESCRIPTION | 4 +- NAMESPACE | 4 + NEWS.md | 6 +- R/data.R | 9 +- R/sir.R | 22 + R/sysdata.rda | Bin 118064 -> 117104 bytes R/tidymodels.R | 30 +- R/vctrs.R | 8 + .../reproduction_of_clinical_breakpoints.R | 65 +- ...roduction_of_clinical_breakpoints_eucast.R | 134 +- .../reproduction_of_intrinsic_resistant.R | 2 +- data-raw/breakpoints_eucast.csv | 7664 +++++ data-raw/breakpoints_eucast_raw.csv | 24158 ++++++++-------- data-raw/breakpoints_eucast_raw.rds | Bin 160376 -> 160850 bytes data-raw/interpretive_rules.tsv | 66 - data/antibiotics.rda | Bin 45256 -> 45412 bytes data/antimicrobials.rda | Bin 45392 -> 45400 bytes data/clinical_breakpoints.rda | Bin 72708 -> 92588 bytes data/intrinsic_resistant.rda | Bin 66844 -> 66828 bytes man/AMR.Rd | 2 +- man/clinical_breakpoints.Rd | 9 +- tests/testthat/test-interpretive_rules.R | 6 +- vignettes/datasets.Rmd | 1 + 23 files changed, 19941 insertions(+), 12249 deletions(-) create mode 100644 data-raw/breakpoints_eucast.csv diff --git a/DESCRIPTION b/DESCRIPTION index 782182cf9..e889a0f16 100644 --- a/DESCRIPTION +++ b/DESCRIPTION @@ -1,6 +1,6 @@ Package: AMR -Version: 3.0.1.9091 -Date: 2026-09-08 +Version: 3.0.1.9092 +Date: 2026-10-01 Title: Antimicrobial Resistance Data Analysis Description: Functions to simplify and standardise antimicrobial resistance (AMR) data analysis and to work with microbial and antimicrobial properties by diff --git a/NAMESPACE b/NAMESPACE index 22d01ccd9..aced79f1d 100644 --- a/NAMESPACE +++ b/NAMESPACE @@ -34,6 +34,7 @@ S3method("|",amr_selector) S3method(Complex,mic) S3method(Math,mic) S3method(Ops,mic) +S3method(Ops,sir) S3method(Summary,mic) S3method(all,amr_selector) S3method(all,amr_selector_any_all) @@ -443,6 +444,7 @@ if(getRversion() >= "3.0.0") S3method(vctrs::vec_cast, disk.integer) if(getRversion() >= "3.0.0") S3method(vctrs::vec_cast, double.disk) if(getRversion() >= "3.0.0") S3method(vctrs::vec_cast, double.mic) if(getRversion() >= "3.0.0") S3method(vctrs::vec_cast, factor.mic) +if(getRversion() >= "3.0.0") S3method(vctrs::vec_cast, factor.sir) if(getRversion() >= "3.0.0") S3method(vctrs::vec_cast, integer.disk) if(getRversion() >= "3.0.0") S3method(vctrs::vec_cast, integer.mic) if(getRversion() >= "3.0.0") S3method(vctrs::vec_cast, logical.amr_selector_any_all) @@ -453,6 +455,7 @@ if(getRversion() >= "3.0.0") S3method(vctrs::vec_cast, mic.integer) if(getRversion() >= "3.0.0") S3method(vctrs::vec_cast, mic.mic) if(getRversion() >= "3.0.0") S3method(vctrs::vec_cast, mo.character) if(getRversion() >= "3.0.0") S3method(vctrs::vec_cast, sir.character) +if(getRversion() >= "3.0.0") S3method(vctrs::vec_cast, sir.factor) if(getRversion() >= "3.0.0") S3method(vctrs::vec_cast, sir.sir) if(getRversion() >= "3.0.0") S3method(vctrs::vec_math, mic) if(getRversion() >= "3.0.0") S3method(vctrs::vec_ptype2, ab.ab) @@ -474,6 +477,7 @@ if(getRversion() >= "3.0.0") S3method(vctrs::vec_ptype2, sir.default) if(getRversion() >= "3.0.0") S3method(vctrs::vec_ptype2, sir.sir) if(getRversion() >= "3.0.0") S3method(vctrs::vec_ptype_abbr, disk) if(getRversion() >= "3.0.0") S3method(vctrs::vec_ptype_full, disk) +if(getRversion() >= "4.3.0") S3method(chooseOpsMethod, sir) importFrom(graphics, arrows, axis, diff --git a/NEWS.md b/NEWS.md index 1f19cae7e..a767d7bf1 100644 --- a/NEWS.md +++ b/NEWS.md @@ -1,6 +1,6 @@ -# AMR 3.0.1.9091 +# AMR 3.0.1.9092 -Planned as v3.1.0, end of September 2026. +Planned as v3.1.0, mid October 2026. ### Breaking Changes * The former *kingdoms* Bacteria and Archaea are now each divided into four kingdoms with new top-level *domains* 'Bacteria' and 'Archaea' (Göker and Oren, 2024, DOI: 10.1099/ijsem.0.006242). Following this, a new `domain` column in the `microorganisms` data set was added, and more importantly, `mo_kingdom()` now returns the formal kingdom (e.g. `"Pseudomonadati"` instead of `"Bacteria"`). Use `mo_domain()` for the old behaviour. For non-prokaryotic kingdoms (Fungi, Protozoa, etc.), `kingdom` and `domain` are identical. @@ -27,6 +27,7 @@ Planned as v3.1.0, end of September 2026. ### New * EUCAST 2026 and CLSI 2026 breakpoints: over 5,700 new breakpoints added to the `clinical_breakpoints` data set; EUCAST 2026 is now the default for all MIC and disk diffusion interpretations +* Human EUCAST breakpoints from 2019 (v9.0) on, are now retrieved directly from EUCAST Excel files instead of relying on the WHONET repository. * Wildtype/Non-wildtype (WT/NWT) output when using ECOFF-based interpretation, by setting `breakpoint_type = "ECOFF"` in `as.sir()`; WT/NWT results are fully supported in all resistance/susceptibility functions and plots (#254) * *tidymodels* integration for using SIR, MIC and disk data in modelling pipelines: `step_mic_log2()`, `step_sir_numeric()`, and new column selectors `all_sir()`, `all_mic()`, `all_disk()` * New `esbl_isolates` data set for practising AMR modelling @@ -56,6 +57,7 @@ Planned as v3.1.0, end of September 2026. * BRMO classification now includes bacterial complexes (#275) * Translation fixes for Italian CoNS/CoPS names (#256), Dutch antimicrobials, and `sir_df()` foreign-language output (#272) * Fixed some EUCAST Expert Rules, mostly on *S. pneumoniae* +* Logical comparison (`==`, `!=`) of `sir` class with a `factor` is now possible on R >= 4.3 ### Updated * `top_n_microorganisms()`: new `property_for_each` argument for sub-grouping within top *n* groups; rank ordering enforced (only lower taxonomic ranks allowed); fixed `property = NULL` not being accepted; inner filter now tracks original row indices to prevent cross-group contamination diff --git a/R/data.R b/R/data.R index 41e1199a5..b910fdba2 100755 --- a/R/data.R +++ b/R/data.R @@ -317,11 +317,12 @@ #' From WHONET, imported were: #' #' * All CLSI breakpoints, including ECOFF -#' * EUCAST breakpoints between `r min(as.integer(gsub("[^0-9]", "", subset(AMR::clinical_breakpoints, guideline %like% "EUCAST" & type == "human")$guideline)))` and 2018 +#' * All non-human EUCAST breakpoints, including ECOFF +#' * Human EUCAST breakpoints between `r min(as.integer(gsub("[^0-9]", "", subset(AMR::clinical_breakpoints, guideline %like% "EUCAST" & type == "human")$guideline)))` and 2018 #' -#' EUCAST breakpoints from 2019 onwards, were retrieved directly from . -#' -#' Our import and reproduction script can be found here: . +#' Human EUCAST breakpoints from 2019 onwards, were retrieved directly from using [this script](https://github.com/msberends/AMR/blob/main/data-raw/_reproduction_scripts/reproduction_of_clinical_breakpoints_eucast.R). +#' +#' Our WHONET import script can be [found here](https://github.com/msberends/AMR/blob/main/data-raw/_reproduction_scripts/reproduction_of_clinical_breakpoints.R). #' #' ### Response From CLSI and EUCAST #' The CEO of CLSI and the chairman of EUCAST have endorsed the work and public use of this `AMR` package (and consequently the use of their breakpoints) in June 2023, when future development of distributing clinical breakpoints was discussed in a meeting between CLSI, EUCAST, WHO, developers of WHONET software, and developers of this `AMR` package. diff --git a/R/sir.R b/R/sir.R index 0f84ae677..ccbca02a3 100755 --- a/R/sir.R +++ b/R/sir.R @@ -2340,6 +2340,28 @@ rep.sir <- function(x, ...) { y } +#' @method Ops sir +#' @export +#' @noRd +Ops.sir <- function(e1, e2) { + comparison_ops <- c("==", "!=", "<", ">", "<=", ">=") + if (nargs() == 2 && .Generic %in% comparison_ops) { + # coerce both sides to the current sir structure (identical levels), + # after which comparing the integer codes is exact, including ordering + e1 <- as.sir(e1) + e2 <- as.sir(e2) + return(get(.Generic, mode = "function")(as.integer(e1), as.integer(e2))) + } + NextMethod() +} + +#' @rawNamespace if(getRversion() >= "4.3.0") S3method(chooseOpsMethod, sir) +#' @exportS3Method NULL +#' @noRd +chooseOpsMethod.sir <- function(x, y, mx, my, cl, reverse) { + TRUE +} + coerce_reference_data_columns <- function(x) { ref <- AMR::clinical_breakpoints for (col in names(ref)) { diff --git a/R/sysdata.rda b/R/sysdata.rda index c2f51153a951976665f4c5a1e7f7c3aa1ef7954f..38ec3ffba75b29041ecb2d27ad795564f03e910e 100755 GIT binary patch literal 117104 zcmV(nK=Qx+H+ooF0004LBHlIv03iV!0000G&sfap_15qHT>vQ&2UJ%gRpOV=m z?$kECL5*@;DY6ZZ)ru;32}BQ$TO{Yc@U=h&zpQ}0W>B511U-oOp-WP2COThc$_$>tWq;dbx|5l({JH3 zDXd&nh(7`{&43^03`r+c(LEN7ORUSbYflvmk7xPZ!>NfV@&}!|BEe@6PBMC%st7w~ zN~iT_?L(#|$0qOp@FbW<1#9@-@*eajdIrW_h2Vflq6qJ@5fP6-^eZ3)d4P=xc;);p zmd?F2*%(zl-1LNS43WK4}1@4n^x;973+G5%%_8IMJbM3E?l1m0_~l{^>D}0S8&bs`%U1s{au@`1KAhZzpX2*)8|@BcwsF)3%_pHPtemD91HU zDDt=jDY6@fJb}r|D3<>_q?(A(0@9ElDe|xiLfG)Us#NzW zr6RRo+y@QQW>4G5xLTmjr)Ow4wlo$RKPI)0mj zHu4{2cKjyHyfMRDyb;1VVW;(l6{u8~3bi;t+8Ce7<&xUaz~#tkZ`3pjTTyJo zrIdsbbLcuv7x4A@T0K+R9waSpS+mQB2)aWr{UO8GqRwST=9~S-$^A4TAszn)9aur0 z3U?Zl+@PFpi(LD3K>gW{ukOJ$_JL(Vq~;vw`AEups%=MxY8ATl4l`wih;&P9jO3+R zHY3O`IeE{lASX5~ByI~vpq>^zK#^CJ7Z}5%Jpt}bT?=5#cgd(Vh*dvXEBpqc45+E9 zHL$1xkqe=>?p*Hk&tULK=5tjqWtz2hwpkr=od#%~L-Q(9kVAb6E*t#YFfN$kc3sE9v?% z1?wGgoORhdy_gN3xf)U4%>+}x1n7gjOZIi7vQj7;uz6SXAJ0AT7C;%FFC$H* z0Na2I{}h^CSDsHmKS9NWtBu+X^=uMU$#~_FU*ET^0X|phal20mxaE-gn^r&-BQ%=> z-OneJzRqAe<-1)ZsTJIw9KW#eux(OHssxT@RflVOU?lr6G>M)M>u;GwK@pb@U%F7F1+oJT*MLS6EwRPy)pW)&LdR zF;G^TmORIaqdp`mJ`#gJ4r{7e7$UYXomKQ{QD*%fbB@(@RF>Mc%Holp<;+d~DS-l5 zTGI1nauWLIkL4kTMrA`5D&A=%fm^Ixb`xBbe8Lw*i@UU+`P`UEKC@ zXVC=G!WBXszN-uvo&wX(UkSXt^!7i$-x|QJ&=IJZz%GKCm)q8$FW}|Y;^R$^zIIkL zF1P2DtoFE-xy(y~`TalnACbKy9};7D;Bie_<4W2M5OYH{O*$rl=KUe^HR#U9;;fMy zU145ggd|d)N7XZ`b{2Sp5s#FmoEAJN_e`@Q3n`4(LEQ%FxGvM>G%Z@GGo0R1MTqWl zs+E;v5@Nd&+`;)OcdM7{e-!G^rzYPpCayp#kGu~Wbd-G>A3YG^6RJD9x*vz?_#&yY zH}uj@z0#MIKb76;+O-zHgQ6vx{Ei;STCg@E2ENN6o5ICQc@kyOYGx8Iy%>8{q#nyh zH0i&&C{-1;)cbq~;!cX&jcLi?-_0XEH{pQv@kz8~63ho7sN@O$8_PW|CAxmHzf39) zZO?ZEh(rD^C&aYmA}HU_<`%a!s{yVCzi1(r28A6TevFj5>XoxOrQE+Pv|?l&y@WmO zbv6(cXw{Fk<}~S>bM;APEamMif9M~f-fEW2k#xZ7@@Y` zbSrz~{ha^UQswqJ=1f}NbRzmz!;T}b0{;)9P}EW*Qh7U^Xxbl6ZEkI~lO~U<`PJ`I zo4a_N9@fC~Wc6$+93P{t=l7JFE69wVR{1BUH7t8oZlB?&x5;g&5;u*l#?tdcoPIDc z7t7IqFLKpxt!8hV|2)CA5@NX1Pp_2oAQbUGn+d@EG?tl8h?BD&%y(;N48iT=L-AWB z8pzA!-_BFWMaBGH2m=2Q#_=(o$qn0QWS~o#sG&~?1EZnjB;is>H%3e3GKq>UL_k+{ zpa)`dM|@SNi1n78Hv-+N^aZ;=^GyK8<{(83y%Z~njgyL4OrFkkT+3x!rP24YaWZUk z*6Yiwc%)AS$jIng{;QMu>#!fJMGjgEGN-??25FV`N)E$*))>@&N_jvF^Odq(Hj%j+hXvb zYiZ||esFJorD9`F$&+M#pq->>O6L1Zi|f6`r%6>=bhdTLJR=cDtip}acf{@|bSlWW z>X}Q{fI24xg5c>^i#PT-G6D6ZiJ+2=e}*{A(}m`x5oH2%J1R>XM`<~4H*8H1<>;n* zlJJ-Cf}@Oz&c#0{kM%)}rJy}(`et1=d#9lPc^hEm+ILmctp}TiX-$(3OFTtz(_)jltV-l1r#vdV-Iu5<2QwquEG> zjggj#Le8QXTCA|pU)W#H44QuoZ9AE{hAeZG#LqY{ttmb4Yb*^8h0(2l#`PsZTo`7s zvv@-6jyC0c5M(3??o}+I)2r_YVt$TY82XZ#DzcN`g4g2QHUhKNBIWiM5Xsmd)S9>l z{HHw?=BJaSd;U^pcs7?QbYpav=8dXSleN-^:d=l>?DL&-f-f*GJfu9GV9UdeyEZbTosSS_PkoW9fP^KR4Dn)~eIc zyL-ar=l^xs2(X135-U;5L)d6S3BchhU!y<;gF1+E5QZchEZ8f`NeShe=!Is zOC(!V8XZT99oiH3)dtzGt4TH;UD@jgXP39?UEL|`)!ln;bv;2Y@Adr013 zMK6*VdIdNOMY{Wd!39(#xYh64N5I5cmX`aH$nLb4$U}qSL*tqiYBWcR#^qnB_qpy5 zys4g}*a(9#QeRKBgP|-pfn3jZFn?iuCYpKgxDFLy0R?JeouO<8L#nsrqOC46V+Xv_TecwPbUbKK-WCJRBXI9=efFNre70P(|cY#8m{>t zlty)7XsGT^hI=?A;yHsLSsG?refu^>BY`k7nH_n}iTlP3V5K}vpjw0I2=mL&Yvz58 z&er)72h+8zy@C-|U1%;OC|o>b3gI8Rtb%jRLyOVSa{DWT_O>}@vuaF5Jjq@moAkYF z8kk2}Ll0e&q5KJppjaac0TaMo8{wEd-VV2Q$MIvtrzocUF`pYFzAJzf%E>TJJ+NH! z6gx*~&Yc<2>~Dd~m73ma_V`%Zbipzg7dXbVkFBU-r#8tEeL&-%9cf_wg1BI_dtm?U z&Kh~kQGSxl)>0fy)QZpBcQOMd__z%{SIy<$v65}f)jIu?QUEG#N|lwFfTle6)}>5& zk&wwQdU(du!FU-<5PC61nbF8O%v+^mgetR^qe1DL|Hb(3_pJ_QX_Euj-`3FD@mSLb zf%+<4r?{}NXb)Q0gL zO}09{E`P?V6Mx2N+Rs39WnWWO^Y)yizY378=>Gkwxwg(;v>`BVm%$c=>Fg&2yLTYV z%nJ!;xP>wJXB>jH&x2&d&l!Pi3FDbmJXFCqF{>z+ne*?mDp`SP(~LCl2jQYCd#_+V zqhfnt0o<7?t)G~|woy>;AA6gTch(^Ke5Ox<45eG~h=2UHwum-vL6;8nrZ6|_W_^m|TF@r1q+$8!9iaV%<{@Nx2)r}^Y_)?XY0zO~sthP-HEl)w4DP0JntWMLZvn$TaDW5lNV!b+NJ zM-hHkHrDd)UnlsY_F!S=roF#-FynjF9IZ)R%{X7^ljAUg|*ZC>+`w5kC zToq3QeUe*o1u!6(Z#vvbOe&)_B@6z$dKw~(@Bigi&u(MzT3lLM_Y@@UP??dHe}zDa zop1~>bW~_5C-sZam|pQ8-eix#8U$7y(-%DMg)gl$GF$aku67egaw2k>fW|0@-PB}# zGDyD1^YG7D=Z@@qA;0Tq=fDq-O=P0L%}&-#2wY|F=q6xylKuf-avK6|!G>MB@L$Vu z4;1PbNU%jEUC0K!I~$Uf9YKmmmiG6%LFG*&p}#%YQm>)@JDeBt3J!kE;_cnU6K4jC z9`HSIEIL2y*WDdvjJ|W*F&? zMrU~JzL{UON&$1rzf-o}EQJ#8mub!CYMd;h)$p;Y7!iL2nV(=nTMq4u(1XrdMX5%! zpMnYhrkYq(jR10N{JV=bEh`eE<(V{tTD80Ww&;1T;8%> zS%+uMmm<;;gB(}uS;6}hi$%|{5^poLG*3~f*|-T#x#$)^v$&#wHa`w#HAajT$3|P~ zF0NlRZ+c{hk_qRE#!FM)*$SDHV_kQ(xi!Yi^}*U{-9E325xR9U%M_hI^}dP0$cht+ zLVz;7kl4Hww{`Bn3J|ulfqz03c`UB)tELS74fVu%>@heXYdX#gyMV&RdZ^yU9>59{ zq{rwiVbVw6lKYtjid_Ge@QO)_+=8T{pI$wN>iuLyprHuvX9 zs-Q8V8Zii&Y)~|KDpK?bBAYVr_VE>x-dW}k&~sqvgJEAT5raX=4eyJ79`iu)8=Z3w zT97m|zHro=q$eR)!U5`~{+OH1|I_11Lry;q+Q%_Z@%`?Lz>4#8LNGdgi5WmkJC=MOrZqv);SJ>qNPWXM}4yo{L8uU7(%_tA8J5n(?-M=*)tz?xPn@#X-r z)v&_e6d~e%ZyBZda6gUQxA=Q;`IoZ;zBcZqs;bQ>T?hH6oGwI789g{*YC=*wP0yqZyQ)pU#}~0fkM*kUB<$1@aaAi_hl&ZWD}2nWb& z61vL2Nf`IK1j~9}^Ysw@0o$*`3sblllnrkRf_@QE3J=Tr>83VD`_fUgja`_hE^+s) zv-$RYXjI}tj)CN0VU_UjpRt~$S6S&K^9EvXg=bce=;K?xV)t`$f4=Sb%2(8;4_&cY ztn4mjYApi&OR&GQ{>wmUnJ`R|G?~ad<59mqeyWtia8LF9rZ=T8xo@ny%SjP{6Z>;8 z4m(XLXEBSW0T{a**KT*1YGr8CQH>a`LFPz(_PldKn&W#F?>8g%OesPCwW=tS0yjKK zb2<_bLDQvrt>IV1FZW@U7f{1&*iSk~1=zMR*iFNSU70UArN>|c^cY$aLZmFv=%=wW z8-6A0+?ye&-*+X)oU4Xe>iJ)}kC-3!o?#t&?}ZXSLlm9}cBSjn9I3wGFj}YzI1ZCox>G>?@{{ zwy^_Goeg+AmVB+KIL%2=K;1c@UX>6kR?cdt+1U!pR!3tHfzu=6GmrqaV9<-;E)%dL zjT&jXQV#8AiUo?BsamEb{A?$_@!|Yew2E7Jp4^C1Z(3lt(3A`$)ab0we1VrkYnn7H zM*vJyRp-v^w*E$&xSsd;khe*!!PdZY%*MRKmzv#~?ue-3l=8il#W|p{VFd5v7F-|D ze(8jG)YK4O-3E+ZqKlGZ#hOGm?dNn+^{z9yAX!G1x{Rw2tTl!U zo#jI;c*d3@#%sAk9k@QsX+Gsy6q?p*jl$(Nh*J=er z?K~oULf;zD>oCbJz|1JhYjB7b0F2H-r7Mau+e^CmfQ zJKUY^v^|szUCOQeO$x12fQb$rBMVZ>PW{R&>^|wL>uk;kPxQvz78ec;wXJLgn_ zZb>7vhx8K9wg-D3tm3@%HG8^Fp@qR|+@wUzAM?|pl<4mi^_Vd5d?MV z#D}nwn#ZZZ!^+8X22bTOIwQr}B9mQs$s=0HEddMr_U?05EXrlTpz9vkiA$bGkhXMbF|* z4q^OVds)k)k<~iv;cq(I96Mux;yP}-(`4s(nvELb7i`hI z&CZfol0V(^&}aOpeLQB+@Bd7r;GHOlyM;RbH0@8c2>9k3wU%8Q)A&)}+d=)y&W!0a zb2&u~Zmx&}X9qqDK4pbsC}L(h%IeZ=?1h{+`U)Xr{ygN#3+Z{WI5H23bS>s-w;a5h zA-z*+#=mKjIkl$rMAc=#nR1;)n4mez#xKv#ZaFv6uxlSrH3#5 zmVL@)Pq+*f{c^{pdw~L&s{_g;dCy{PylCi}i_>Lw5=KaUohrUTx@4MjSvk<|Lvmnz zBh}e9(9>ATpuaa38N zU8QPuUYzOUc2xBBE7!<2hgI91HO$#%&TD24D4rw_)y9VMJ0 zq}l*sLmvxaw%cYE&@=mlz#`7@UeX7_FM+%8-L!ID#S?!u@M2SH4dnVQkY+!0I$B6h zRU36lShjvo;IBO-b=TBNfqekW6QKZyQ4l8XE(t!mpl$En3qHJ39SA+1;K*|%R%26C zJo)L+ilx`=L5)1z!z8yy*szpBkFf~56;ja(4@rUJS1IOaq9`_nUmJnql^ViajZMS$ zrVr3gPKBOvujK%5{#v(oC)lzgVE`?=8|)($-nr;ii6x#6!}RGndmTl~d8{MEDwYu( z3zA^#X0{oa$+cSDx^uipZqHQ@?`$ z3s|cSb?*L4--%Mh6FP=sR85?YGgDX0GsAe-o!SMv46#AU93q>XT}mEaGbb%yxJi?e zVc>7bo)Dw|2lD&V(H(vK1k$};I`h6hW|CkN3(Sk49g&V5E&_g`r^Y^W�{M_7@&a_>nirS^h zp@e{om}U9foiyEz>8lWMKc{U2(q_MzQM8>v9bszECPL@{%^BO;tQ84xFbv|ht?tP! zC5BX%B5Avs^_$zw-(mvh|3oMK^7GSB-_=D zN>TOH0N@eDe#@;dMF%EU061kld8?j#U>2&{Ny(4ngrQWj8nr&DA?Y)OFVvZ|r!22h z{XtPdL#g$ol*aE!IpL;PH3TTio}dG=&6qIOqmp`%K(2}$N{x3w~x-A44Ad+bN?+`)yb>Ri7V+660=b~GS$TOylwp@wFwjCh|JJCQV+3A=W0SO%-S$dUH0Iw2S;%udaAdqMsn)?YFTAOJ)q@ z&ORH>1lRSv2^WO2MLd%VyB|o0Y(M@ytnY&2RT_4MTnVfRr9h?1RE`8vBSc(R9{QJK zAqvOuO!brhR)R%-a|x5SADi>8*j<9tSq~&TQ)l`NT1B|8fVh zu@Zi4K^~E6U*2s#XtsgDOX4=1>_|^ZSoOjpa8~>GzlXv@On_XQqe+xYLSVxnhYG9C#H&TN%E+#iXT;o#C-59kX+2pwst$g+a>1?<9XtZ|A{MA+VFQfKue^{n2j1 zim)fR56x+tQ?q7o&GHi+-Ow2k6~|jrt(UyspfzZwdEhH?jBwz=E!^~_o_pkurg|;n zfP3>+^F_q$2qi1TfTKQW4~q8?4+>mUPQD!uqBfQ&CqCFb@JN{q^#$4#xP# zI)@EgRuUStHBj&r;G6;DlNhnGq^aw4xXfk6)i!J(x7z#@{CHblytsuLp+WXootpft zrSB=}hbi1RS=P1lk)?SpvZw_%mv~>N&#n8byFNNTPrk+6Y7rmR^el;H3h7r}J-RJm zsT{xJ^c2hlw6%AT7k=%=m8YF~R_mqb^Yb&V&N9&f4H{l>p^$X9Ho&Fh!XT{z6 z6w<4RW($fN^qq#dGl!*K8~AP(y6S!0gJNaqii`$CYYE&D9;e&EuMAN|F%~OQ*bO4k zl{p)(3&CS%Z0y&xMWP1rzzym|yf5sIy~@71@|zJySYj7RQ*1@1gII_e z;E&4$)CwOmstu(DhDd-np+APlz;++&SKK^;FPhG%HG=6O~9M&qe+uw zmo%5v)C>GpmGw2oL$BCB=|v8+rTGfvmUx5-N`O8*39&MYM*HFI9LTU*HBMP$MBoi;Lij;=1J1IN9P&`DO(AmBW6{`X$oQqu!i z=$-#m;Php=HJsCxrUpnoL-Rnh={Z0qeUy{)u6TZw6n!D-cOgRceA3XEoVl?nD8>JTD=Q>q)-?k)`kFFFW(oN6s z>=Nug-|tnG`dSe>M~DzbL9h8Jr@Dz#D6>z(4C61nc-UKU$%h<@ElW8mFO)b!cDM47 z_X|vdop5DJv@dZpB%eZr<9Ci&xQ#9ZCrsgF6pw!_jIG=4Ho`<#CKm00XWB$S6;jdK z`4~VjI{I-{964x%bFiFqB}6~mHF_^JWofaY5_0iVq75Cwom*n**RY!udEsi5t;&co z{}zkKqr9HX^}dJThG%&aN>AXGCFK~^XOjAe!+F40ueRC zD;H5Vd-S(c)>leg(kK~)WJr-y1Z^|aBv_Co=h7a6{s!*=7+K?KaenFM>~%$u2DZO?FL8mP{a<6HNvOS63LN;KLRR>Nvl}WMglnC>4gz>rB6T>D1n~oxM74spnqR^b#SScy|nGr z*hfl#eiZp4n*6&hE)}@w9w?$SD76-%oU3+Itd{F|vN2O}EYT~Bm2-zZeXh+Y-ujx8 ziAB3$Avz|j_<5cm(X2xkN&pyt(w3bm&}Ocrruxwz!)zY z3SW(;(Z*=81=3jIeRg@e;9Mj`suopp0A3F8(pGiK$eWem*4vhhh^(@ig7Ux(IrVE2 zfms9Jz$&Yb$Lx9EHSF2ZoAzTeSE! z#ayZExi(-}MX;JA5Pa(h+=hu_W64e|hkL!4uF|E0VmuRFHvSJH)eADr#i_nd)OylbqESgQ+ zY+vPPk+C@%UHg^?AuA{1xrGfo03>$qGQ!c^PSft-X>xZ{R0(BzA>Ve<(pRlN%|(z; zI<7pdMGTW5lWAX)3wZiQ`4AaNI5BS6YHpcn5Ub_#;v{2>k@Stdd+2=MqJnnnz>?Qf zOQklUz!P3#3O80^QbBAz+)y$ECJwgOu)?JAT8cS?R4Y-D`-acz#~uZ94OkHyTO!AY zY<86}flBl+sP3;1AYD>29?whp7TnTdq*Wyk? zAEFJZjGadk&Qx?UF<2WKGe>5d+Mwwbcb?d&U&*ayv}qz2cdaJNEC(-RtqdSLtMZmUDFFK%d+c>74 zkV8nWn$KD^8Yj{1Kt}87ir7YE0(Y#|2pz9^ynbRs#Ade`|@UPPf4W6z$J zM{$qk=faik&flgBnGj+z6XvE`0Jy(ytl%u?iOwB9!`PRp0bl`g{BI7EfiY(tQRfsC z?5;D*v2zNGNM5^ZcvXkcoY}3A_rj`a@jK>Lu~z}tH@U5=%gaH%oti-7-F~6DIW#rQ z!oj*}K>8|@(vGzhgVu{VlcAs%SnYst2d~>9xjG{3$Cfh+n9=u{FQv_b9IyW3ZrWxu zOz5zRu|e@xGIz|gp{dq05@E>QvU~4yON?Wm;o)?3T%mcZ(!gAqby}<_>)xe#brJu8 z8<#uW#&%nq5K!+=Dt4Rr&AblIrU;pYe@OKrm4j_)ZcV{q1o5O&-`Z^a@H`nEqfeNN zbchc+=oYR%)WB#ktQA&^+1#zhk6@L(&HW%9sZtNS5i~2ML0dVP@fxJ>58>##D4DZP zr1#Yo%e)P#TN*Quk$5KCNo3kvu{=W2>m^zqcmngC`htZoBR0f>EC2)sv4GO(!V5e7 zR>o;g+JF#{LBA#kvZa^YIZ)3-x$w-y*KU$c6iDlAXTL!I9yChv2)$Re#_xfT1KdiM zQr2|R#HJPmj@L!bEe9dg!FOOi{YT=eba{-!5FrB6UpHs2*{c1L69~ZOlvR%C4z~OA zpd-yk!M3XNR#fmcnmimikj}}E+X}#`V8`8=lx^oJi%jx8(n$>#lTeOdrk^?R zgo>lzBle%%NpkC_*w%BCKndoQw7-kzGeAb7F;=k~Z3j~$nsLNxua$!0(xcoy6R`1# zVCgKa>dgOpg@hDudOeeDLGo@pKq?KXpfDkuPlRStZPGQNGIAm$60KZdz?v8ig#~96 z#Cj5wWpXP1!k)2JwkR3vQZ9Y43n43z?)?^xA?8Q&oP&eBI?4h^^K6lP%N^!pMhP9L z@*)J<$`u2)Z0VWA`@H|A<<>Ih1#hfCh_*{u1RlAz1m7qJRvP~27-qf48lbUNjx;({ z7(|wln)%5vkbgK}HfOqr+E+~(;IQldHKz%UDeVcyiBYhw{JEHC5QBk23zbweG;CAW zRpJL4zcF&z#fC^FXsz~vND^eA@^edF1vB(=;#>sXP_D||fqx|Z_;Y+(J_fJC6q1on z%R|WWYt)nzq?@i!B1PLC17=akdDvX8I?b37e~aZ@7Ik&=o!wr;|1633w(Z*m&OLB!qiGb8gsLNu}SWb(}58HvkIW=(01zo0?aD zN`1{T>(9%FEHd+S-Am7=hwD6Jlqp7^`635_mhOxJ zZGCG0Nw}ilJMM@;2;zw>ahF?t>ZXc5eZ-sANV0xI*@m;dj$MJ2bdOiYAaRU?9;Ri@ zq9Q31zFuBIg6j&vp4Cb2KT0=YElnwp7vm?Z`tKtwIvKRPK)8GazL8);q|TF-q^~eT z#SMzoEZO686YNc5mQ!aJTRH1=JkPn|5Bc;V!h)PJGM+#Krk9G?ANNCpV&p?AHIR^s z6$3SFz6IJ|7Y_@gvC*%xW}^zYyYunL1XEA zDV2AOZ0hg4_m_6v=vm)KoqnHczLI04fDr~_MrUznVZ5-ckF$VlCguN`09@cvNq$EP zEPmxqs^r3Fvg`fE{TI?rZ0jm+J>7*OYoQ9rn!m=3S_4SUBGaPaz|mQdV|RTI3p8F#pR|q-2W?G}m*J zV&*}~+JMzQCt!9)7p&%0GL`msDrrS=b~6#C$!bsC?-;YJJ#<;n$qVrF^q8E7YmlNU z3O^SuXPS{1OsT=<5v(I(!FE7`w5#z=^Pw@=#w2rgxQ;J(*I^GgtnL2LzZ{-Q5=>l* zG&`L-6IF2Kk>`BXv}I|U-&#*kFcL|bWnIw%R0_msuhc{`9_9K>?tv6J@*c$HNjV2(m*i0 zcX960oLN(9fy^)E0y(6S#9yU@e>|luC~oT?v2Mx^=3?0L8BM3&Qq~rIOPyP#rGnvp zv0f^i0J(=9*cPMHrM2E?WB1H_e_hi!B>gY1&UTcfWOhwYzx_&zE0A7(o7cU#50Nd+ zhGJgIL2-3~*2u1lQ_Nf&y%~2@NJpl2JX=6i(3_jWWQ==DVfs%A4y{xa{I&MJ;ZnJ0LB%kaay8uLSSz1asD(DQ}5c$k+R&5dI=|IPoqL_h}zBG5m0CBFz&8 zhwdS1XQpb)TmNO~7*cEF?UMjAdr=@M&6d-J0}ecVqzHgm^ax{E)b%k zOKug?{^f6q9A%{Gus0GgfxwYlBNvLTF1rXtOZ?pZl6gV(*+hm2G4)AU8~`5mTs86Dgq6mGw*sktSQdRlWA}IT zWuPI!ct)f5frQ-jL0eFGWmP6q)Jffai8u61UD$=UuBo`|Pb`I9;nEpiwLgum;Gfnm z`F7CQ{#XisIako+y4?l>dO57sM49HvB9r#0X)Nm-ep6Il-dH1eCYk`RF)&~T>S@lH zOE(LeR575F*QNWDLQ!;j5Jet5467^^5va^qRHcM^7KD;!#h@4KjjG4 zLfdqEX;FvtgaDsbGoe}caYya+`EZKxRbax_eRU_D$@?ZyaWRRIG`M+Z^#!sF-_m)z zz91`WXH(WYBn50{SG=YZ&#c?P9xbt9*NBQUADfwdFs?Z;q%!3cx^s5N7t!KLa>RM2 zeZ?5jT4x6xYN6GqI~Yi4nesHxFc^2#KC@w0*SMB2yBzFI28LqB2!{uclA5a8bebEk zmBG#YSb?S^J&8e?=kd(ecw!`QGE^%ygGe2s9el;)r(s%QUHzm#tZTR?;&a`OvpYqS zZlM*0&)`l*-- z>Ic4=b+?6H84l3RUHDtJ8qTje0WNJp4{b)-)W0}7vs`DXYR-ZLCJxQ`9c{!q2#9Tm z#@Mr+EZY)zjW53EMwO8ZO>A?vv{00FlwW@ED>+f_A)W@i|GjHST2H-bKidG!Q`>yy zyMVbfDZVPVGg(BETiV0a0A_F`tcG3UE%@lismPn9J~yl}M;2W55Ov~kDoG^o33q_` z>#D&=P)M;n-E=h*G(sX{c^|&C|uTmN<`a2 z#}rofXz&=%VsX@M?7wM{nHkIW0TS)5Mjm#9c|dRZsAXoGRSq<4o8JmFaY?DTyw&yF z?LG6llTlfFYZ^q2B!-&?tuR>+A@||LJ7(k`Gpt=C?PA%{YuI?m2S5+Bl&BW26XT%7OKv;A z3b^1jKS6W;T3HS1BIzd?v&B*>eLkgteX%C$@qx(PnNwBl$jVJWqWyvBVBL|1#nMcK zHPaJHUdr#n%|;=#PU>Pv)xV9@h_FtafspEV(^l3w*Sb+9Le-V6Sgc_DrIBZXcSu*I z*gMng!m^u1EkydHNTe#X;2#P)AhHrSdVvqSM%^bIlqM|lEW>CY*@_GSg<>4Y)xwm| ziT5@$yp(I6Pso8DW>@TV1UsieU+@cnw6%qVpu@!|6aHnzJAW&a0-XqiYOea*m6{Vb zzvD~`>Q#GUGA+P7eV;Lim-FrHvgXbV^XCIHvKV)GJ7bsK`RN}|^G>W`fTcdmJimP# z1we@zKBn8T9IuTmhsQcCMffbs5<}^9?H(wU73085OeFf+T}3g;ce~6R-MuBrsWu0K`3zd3PRzEkap*6zoL?^PWETV;+>skG5}$CmYn5R?1Wr_fZ?pSLm7oIp0wIS4f&j$tYZ~nq~2n`A}s9o z_|+HF_Jr{FC8%`L9OU%%R#qPmk{V#Wy-4QsN0p?$#{qS_MT}9$x-7O^g*s=FhJ&RC z3;&)UW`CtfLv){A+PSY0SwdlS1D>>LZ_V6lzr$}i+(Cu7IY$ioj5GVu*_$E#0^M4; zNok?t1-WIfn+3&v3q+|YwX>|-s=4~&?~P=hK}Snm&4cF2C4esHoAtfCq-13Q3_DsV zE!en}Wx!DuY_5mKSfhOQk|A9H^@J7lPg&~!0(3Yc3dyg>`;5W2m6}oCp6jA$ZkVwA znZVnNpY2{(i&5&ojX8>)BYeyUqtH?Tc-@#lK$}1CGulV!yXpld{u)DgM3FT*igA2c z&TI9!28pvDx(xnSI_06S^Afs5PxU`Q+vp)KZ57Z83)7j7xS^o#v}+# zkS!`WihVl)G^53gmJn}?eOi%41>Ehgf6>}060u*D#G!bR4Gm@54D-l=98xu9VmOR3 z(qwc9N9dObLK&sQ$&Y7xasH&=%tTwrUVwbnCBN3-7t4ltN!us2hD_j;8ZgWZvAela zAP^DN=V*iinGKDF&M(6^=X8^jA>D5ofh&>2*xALsC6bEzYeEAM1E@+%1btjmp52%7G6ktk_FR(Zxz|fco1vsdP z3KsH6Bf)d=*HJxznz`y-P89=It1KgROI#sEyG$M^Z6yKVqwr*IQ}U@RvlvifyyhN; zeU!52`af`uJD%O%76kwzQwkMR{ZmgJURe8BVt*jnD=wvg$&0nb_ zKwXOr+k%DCQ#X4;dGO@sx;t(tW{2vVmpP^6t$4~^1NVgS9i%a{M-php9 z7O5cGq=E`k*>z@XJnG~RwCgYHe!CjccdGq%4uU^8=Ze632_(EBja(ONDO0QN=P2F}RsH_+;QRWUO zGDtTINfXbJ!C((UY4X$5+A=^1tTP62lT0M6lC~Ao*Z0woXtQ1} zOitf10dUFoBWDTpIuT2b{qDt!%SPrUS2oU1FvEN@=^>Ds@<%6 zhLGjGL9m}hj2_^#Z9J(3iL)aRfGU2cf^(rH26y04VWb!!9?uBDS@A7W_Xajzb_|7`*AmH_*3((r;+1)s;{j z3C4J3Qq|sIOEzr_F0LzFTEc(v?8y*=X}D%~qsPLJ{5Z9RS{HHaTG%|gF_)jf5D@n) z-|HqC0V{H*@(SHMi6wyMd_C{N)Bd%loAnZd*0((>T_Dkt%N{lHkm`NI#>Ht4I!aSAe7X$jr*S%SZi^N^8mKZ=ZwQWLeSTEz;Bg!Nf}7GbH18Fmk8}Ki1J5|=E~;24 z;!}tAxQkJPHb_nxY-u!dqpUJrTR=ctD|Vgb{(vfk$dw;ZohZ6qBxJmbV25uUeeavH z-Rf6loC{_B7}RWW6tBYuOWBh@euVtK9>p1Gy@e=qiMDI`-_rQ!Gimg=BM+9=cN*w9 zTFO{vdekd}7?KV+4gp0E$q_C+M)a+k(bFUp$%c)t1(lhkhTtnfH&Qc5@4?gLLbf-# zWp$}2p%gGe`F~z{Ct)R-^dO0%ts8K%VgqsItJ}botBDEEORgKlYD0KW9x>B87%FpFM2!)ML^RNR`576P1VTTLWhpdy9^N zaB6wjvNrEipn*#_4a1Ekr-YZ!DaGmmbk)U>H zC%aJB5x(O}`B=Jf&pw)uTa6P{Jk}Kdxu!3)O)=>rG2JS+WH2(V^Z35bQ4-b%?$kQh zIps^0!8wEjOaN!N{c5?21__~6fIc{Qu8xEk1NWX&QK%prC(U8<|7^N0yjtIE{4Fo+ zfU_o z>w%+ezo0%J3RExpq`b`jUY#yp*ZWE|dpU8k;?dfaJjBP`ynM@EZwVe1YMy41WYpP} zBN1{ud-=coK8jLkyhM!)=7i($X`(YIf!+a+Bv3>QIRSaBs|bj%{?y?&mM*`pBH>KqC(Tn%hC{R&cHQdXJ6gMb4g! zA&92Bjs;0Z8LcW8hM+l)pqxrQL{Vfdikuw7exI*p#ktVL!GCkO*zxU#t3pW5?- z(3va_6wxSRLtQe6dhyB7)F0y1Sw7#}!gR%C^2MBlB;U8&wFJ5Uji226wHc z7dMv;cq^~#&GtFTcMpt%rZfsG-Ty4pY%Xl^g|%em?oQtw`5wqBm_XIhG;E*-Dg6=y z%@poCMvwA$-?UyYoNlt@OuGJ6CeI!&EX0%aCzeXBL>Hq$@`C9xAo&f}zomKzsD)NUwWP)8P$+`#6xY|tcfbP2oq!N8g!*+sLa6j? zE`yw+x+^+X>8RKhgL3paPO$e~aG^=HeY4@v^`7bCl?lbgyJjx@m4Pf#-S(wFtuDrJ zVkcFv=gqdb4{{lu`kuHXTY4ptR9ZqkVV-@atI=#+s`rq|Qa3VRzz8#w>OAC=sWxSd z>M5Q6@>FM9Cwb`F(Okk>%?j7wiabB4U<|9CZQpZn5B#gmgr!2hwk=l|l{()QTzLBK zgUaA?fL*=kvUG&@5I1e-T!FnJGZc00Nx0C)ig&Oc^K8oF_%2qimQRx;073rpG*emE zR9K%I4|^>R0M6Hb=J6yaPW;{&P`A9s5DaD7JT!bk_Q zhsT`eTSlbk+~i=t>FyX~8KrnGveZ6)ee(<`x zl+2u^a!cs2^i6LC&T`zc&PwFa{{oH%St5TNKqlqk!b92A{X$4#ya(bh;e1g#+(nAT z$h0ve5@}Hr*=kJ1v`&p?zw4)BP>VeR32R$xcvLbHZ=E!>!sD84s2CsDLKV`jE|3Cj z8{A0R55hqFWQ8;{=6&$kWr|t)ei#NsuQR4$6mdFR1~00isVH3)TsTKS&%J}0>IvLN zgxIf83}>6X)S;GGw4%bj{eB%jr~Yvr2B|pZt0&)C5oQ4)Ie+{X!baQ@ubv~)({@9L zXVFicCFbCEDs%-(vd{G81kbV4Qhi*D3fX5EJl4S@X~hEofO;g-@U72&Ua!`odnFcE z_rxte8|xy`aiy-i z&+Z;Q-#7^B8@+`_ED5A$H7P|3y$25pKVpBshGs1^m6|1=Asmy*MX+_!0paLJ?E!rr) z8$luJ)^1~NcDeb_)X#Y#K*`2;_;fGQ5C%H(+3Af2aTe3=o@LtiN^Xs4= zR~#YDSP}pxAguZJ(B$waj>&bd{xBN)fj1p(rI%d%bFnk`pU^b){m>eVSHU{HVz^3{ zjDGng7+BvMo|osUx5kJcF*LeXp8^k*Ei~=6vl&QCA+M{OTLOtCuPn%g*XI+br%HWD z_0@11@$mQXabSoPXj@Drq+@u+e`Sdn@co%@aucz1Ag;UH?CO&PvI^5Cin*hYOf`Hb zBmjEw4+iJ`Vst1>L?AME0chF76eTY8T{ zJQrgSxO+^n$$@H2nhpN9YaRQ-!{M~m8k!EC&z^&XHN7-ekY=)b@itf%$6gc7x&~TR zpqw)ARgL%5LD$MGR9+uibR0~S^@l4*Dj>l=Ei1gTgGcRRBuQm1qPa#AdL4WYFR!9=w# z6p~Et?Bl5R%14NjHSM^2l0oA|@J|Kjeeq`(e=5 zk@~J+rkl&82jU8HJ%>&8qG!00LaJb5@k{p%Pm~}hKJO3vRHwEsG2*PS!uH%>n*`EH zMw&%c8<#xb(c0_pO=Ey%F<1!WH;I#QLB&*}V*FH*ugkjpmNu%E$@Ujo;(Etj zMVYn#rfGs1dWplYKtY{tfPKSftibyzTd#^D&QivrOJpUbv*P0NAi+nl1oB0?e zpH%Ah#RmSHC2zcGBZREwuDL+1PAT03#S(O9@B~-o6gJMrHy1~&-y#EI2?C$5G4q~q z+Aze=;em@*22d6j;xp%Nyi4^$QV>oSi@tMBUqK zfZahm>sozS4SVuU7=4GfU?tIpLkpmBX zXi1$zDf!mD->)_7!}mN;jsf;9|1#trGLlWVclu$#b|z|tdi1@kHIZ+U3g3LZaD2tO z|8iudm;Xd3`hojJxT7FYX$#Tw10=ocdfRloc4*ifT?*O|tC>y9TB)nL#`r^Z2n$l`N0E6=oI*l{PsofCjzwkX9Nojpj}rtcPxETfLTADgJ8ncaVW7BZ z5B|UkoXZak)(cBc2hN(jV_qX%|8kpHgml;8D6~*7=@O1vqP`86w?SjO z44p^J6eErW?<(xiWqx#5c3=p(pgl#`U5PCuR~`uJ$tcLaKvXU-TLFWR@)Wvow!%Oz z#Yinu3$KQ;*4}33c)QO%@)la-cEjx4i4m--kq(wX#xR6YE*yRQbF*|_?A?~l z?i=THKF{0Fw8nR@saM5YD_5;%3_duJ+~dWaa)NVs-(ibT%@7kJE$0Wy+&giCsigrr zNW%}%p&Ux?L!k0;8~+DW&S>=ebGkC3lGYJ7T3D4~oo(12Ac*W=M%+z}zE~?TVo9r% zEzvQ>me|X>Stc{bl$3qb%4rO7%e~raLcW5aX%yvsASbN2iylS6PS0e(XOt;3y9!!jrm-;#Gdg1x7TxMvgTjG2Qfj8gqqU-T z+Yg~$wc4_4$-uczw=K!eymaugx}0*K1ei<7x!8s{6{YM=8qsK$e-q!8CJYX+?IZ^D zxxPcF?eGY-l*2dii$UQQugVA&26Z$IuL9ZW1&)bU|4y%Lsp3MU7Wg+ zH_#S=p6Dh#GGM=`;l8 zG?hxCO7(+*mJwultv_6Q>`&jI!u`l;AYSJGCl(O?c;r2s^p_A` z3d>2BzgNcAB^UT}{A?pvjON;3#5Gn>K#%d1ytk|buraq8$cU7)SE#+{)DdAeEAKN9 z>Dg9yU+-vfaw5~rkwUhVFc*IaqH#{QOk>T~@LQh1o)Ir$_DJ+=Flg&H*0!N?3s%J7 zNS(}8M=kwTKmz|c23R}=@`b8m7ufXLazu`|XR1P+M!yCEt;D!y8eTPLv9lekliH^M zztd15z0=B_4DTstA-KLR8xo4j$q>=yNl>gkb zPm*krkV28AAl6Si?SZ+NadmylOIfBtBYLMA4vBmu+#|Aa{829$1RQ~xxpHzn+Z(5p&}6L$n=73zPBQ$c6s~_!ozCsSus0 zvKf?15=iqkm8~-aGho7gm%$}7+O-l4K`oh#_?xBkJ%A*j(oAI|Wh(NI0q;({wh2>P zwG>Za*H1KTWhV4Kw+iTA&4^=jhU!f9Nn+e8#5e>jj}5diGa%yI_D2K_T;%@hV|orJ_=rr5KR#cX(*R9 zzH$*dcq>0azfe%PVAV+{fLHb7wXKeQM;VDuaLSDR1RKO0YGnt6OTzPNK2%nO3D6 z@w<#$P#YLX;NMCXn{#>w#5Iw&sp)eV2*eB)Z4QHxwjyjdrCGg89ffOhRhiNLcO)7| z&N-53Lg{Y0eApUUK5=RT9z-2M^`TAqP*%OYO%i*H$qx!Xvka<7w@yVC#GEXliSk16l!smq8qP#%%wygJo zC@SPvT2%mie=>P3Ljk# z61T<28N%VCVn4yO%I5lFH6ST>4eE|>Fq=zVCwmW5#u1z{n+<};W^5lCDv_E+A$5IX zy4vaYyU$(uYh@}^9`d`Y2T|c4;WYx!qK(|KFOsYAAMK}p;TLrS%Zi{I1#O^*z$1EH zv_uKbRO35g(voYJ^tn2Fe<)}XUg(odWJMTcve*7;4q}FU3FHmwF?9chh(rrBa9$lIrVlSKg&idz_ zf2pg_8gY}C@Ne5n(diqTF2GI3 z4{L;arcTfDyWr(>W}KWZyLbe)Eqec=T1&|Bq~$1F&2zGCXEK_fWPsG~`USTex4b1% zyF{zRb%?uDK-|>EF%)_Z@RpiU8*Xp@N(@d*f@o968iUz>-%ijMxnTo+bWlJ$$`%P1 za{B$E=v*Z98ypV(l~Qe8@gIePk_2E=BjSZW({&Ee=B*IBWeZbtEhWJZfTCyDpOf8T zZMO=&{X+WT&Pf@ZpTWv_3nWPj~;)@%eqvA?HHTKFX+M&9C1RM>%zEaHeQI%ll{E^!+uAw zUV@z0r;*tL;V3440Ta^I4#3^WhNta00)Iy9xFiR^l&n@vln8kaj{5B&TX&C&@p{gz zrh;e!HB#{v9m{L-LRa>jD_olb7%RfkU6E~?1ndEn)dyv8X)YusGJ^aJ+oOO;^WsC1 zZ~e3``3FV(w73q1XB?1ArxElo`Oj;hTE|R{it&c>;v{dKv?P{1ay{xd(yAPgY(({b zRK_=+$f^0G7#=F6Sycq^$_y^#^m=3t{bNLj$;+mO*ViuT4Yyn> zl(j2}CzU$P4gLj}nRUi!`A!)Hr?%zscw2f7HJ1KR521cB02A5;)^o(^^IJf-#?;nWbcd`i-xqx%;I#auyILoG-JM5E)1B|wj7s`$13p}M-}jmwoM!m(|cmSZ~qu`}%pekR%jjhlAM z+e_zY5g)fY3M=P?%$v+wHDr=Ez}2MGqKQ%*w{_UlaC4NnaKQ!+txGo3=arTMWpL`XoQ1dg(zb6SSpd!vC17mwQV!|sr*D)UD z!dov)CajCjOSU(;w-)UK z6XRjTrM-AjNPfx)N|UV}2?-`aEe4d6HbxhvD`~Te&bgdKYp<)GTqXb>~`++>e9TpEBowPgs^ z?WtF9Kq~(R`0r2Se*`%@PyIw7dMc!M;DOrxA9!PZI`2{KP0>VGj^D-1tNwZw ze7=kRajD5>Aei~ea56^b{Z@d=lcx%dYg*MM2<6ChpS2+GT~HlwyM~Us71UrAa)=KxK&n=0ZP*Vd@`~Em#>&=bnr#dB>e#W#N48g7>I$ zAxHklTr7^@Qi1&Dc+9SBlVU0C5B9?39HUD_AvE9iyGF?@R7$Rh%T^hatxrXY&KjLT z?N5D?y+N>s9I;5q;oX@U_aHDpDU-?%0GES+bwZu=Vpw%6&y)5I@dwd<2-I`ptjtzc zbGwNs3hAp+UNjjD(F@4)rkn+AA9$`JH-C>l3>;rGeb<>YThx!J4khyNjh!%@ESSut z;4nqW8g0t#)7m+^UOKR7}_62eXV6g+4py zBZ92wOi(~DsNDE4t9USaYh?YwM^^~R+4K1xRJFCgqV$vY_uq=|eM`#|5r?G_m4{!a zT6d}~%C8itBd$KrTgVQBSO|Dii{L18B3ly4L`;g}HE-tk|~=M%{dYmX_N=1&Jm%!b*0RHV+3MlA-vXXb>P z9H61Vssh1-u69Dp-V;&tq=%E`GwP8|xM#m_EMp91GVeS&91b`%&YlHi^i(6A=Aa$1 z8U$cYoI7{oEe-*@*sJh4P>`9^#0XQ#PXT_YL;U@l+DY|_uyi7LH}}bSoRST;idAl7 zQp~eSn9zrVcC~Qdq3}n~Rx~&WBwCZQ)cO@E>K?$>+~`8C!C+pvI5c$sAw@($cYoU1-)tbTpT0vmMyPc8z5h#yX_-$efH;*sB^fh~g#lWy?>#}`Gys)HA#^K4cAKSLOBR1={&lNP(A9qk7wV_2Cq>CgAk({+R|o(?x^YYFj(xFChUVn41$&L zW=$rGm8EKG<%p|1`CW#HOPi{OQvu$6iahn)$+}KzzgT?MgWdW(Xo)0>mdnR*v$_W0 z0`9$)&or2h+*%R`<+TbrLrnJ45P^x;Z+6JI(qZ&Pp21gq*KrNodR0Vpc0XALm(I7n z$?yleg_?i?o2N@G%a%l7<)k$HbW-_T2_4^`U+)zOeII2r0;po`N#?<<>%xk%`=Q5< zeBf01PmF$3oc`zli*sHt1?tU*yUIuIstU%enY;dH2Tspc8vN^hTXzb383<`^Ea?>0 z*qYpa0f0E92q7pD11mI=N1osL{x=;v;z2Gb;4f=Ktt;pZrldC-cP=L9Er~w!)>L4=QS|HJ!g0q+8CdbO=5f#H4MC4EuCp<5DDxX z&q;=(+ED~Yowcx)I*dKpmTsEeY@_F&goyp!i%TSe`^dd@sEuKNYL+O0;dE@U9MrGR zr#L|3@t=`8yE?(@syTw*ew{jhtP;wN@ISwVG&6nyRlMUeBi^}#4=ARFdxg|YfoQ0C zA7{uMS;#B9HNbPufd)KFofcc^-(v?US}Dm94&8eZ6W4ax@Kxox^vPX&pH`DM4 z{@iwN&AD`=TSre@8_GL7K~Z6IVW4kP4O5`_tv2zhD^UExnBe4J;c?oWr*9M+vB<(w zb4tRy8ZOXct=U6gOccxJ|IN&(`Nl#L=Vtq1ETryJ(Fp2b(&R{iGT)diwfB;v z^d`E1D0^IAtayjPRa`>N9bPv1p{frt$X)iC{j+V7i3b|O_S(b0#r%Un%Ok5MztOK-=t_}^yv@HQ=P<=xt9aXv z3J)0JGi`c3UB$|@b@QTWB9k>jQ>b8W?#IE9H)<^9p-#k#&7SN)0srYek>W!_^@AVv zdKaZBsEL;12+DB(0vdd;H~9Ug+)&o5-o7@CV`~Y)OiSRB9~U{xixRjp#gvgdGAA8iQ zfN{_=`+CEB4v9=aaLj_^f{Z>bhjRE-5Pw=OV?X{`b2A-BCgN6oy@*71Qjn}I**vz`*K@LUzmheM zr`6mZneL0L%w{9WP-`I8M!?ot^g`e?4VJB< z2K1A6=vHBsQ{G9~YD=BsM)ZlO-315{E%#j=i5XQEm3Wk}d@t|(;21^#`hJ6ig_Qp# z*mt}*IMSG(3dtH8{k_HLf4FKG)K!6!0{u(32@pppYOLxjB>{@8gNe6=Ti#IN8IjZ0 ztpi~NP{G+7uVua2=<2`{HQa1z%z{ic9Rs^b{=(`t^G3p~dQJem=#T@1*3Kc;kw+{G ztm1$HZ4*k|s1f||ehxI!Q(5zbXcu!mne22G9H*U=l^IsbPK8jMjTPLJm>^9~H5O=* zm+L&XMlb9>B&E)2NDRP!vN9K97@%hdh5)rR^$V9ZoUX_@%<#}l|M^?QN!>cmO= zqxE`n(Z5;Wg5qGqy<~pp#zbjWLh#v|D{o1?u?@KD5U&NN>%$+`*5tZ)FqSwmsrU!90=6Z?~zPbOrj3r1O zU#5`x;?wME3e*I6j-vhz?%g&h{S|!hCjL&Nha^t@NhK@PSpTwZ?Xp*hHGc|Mml>@L zhgkx&J6_sM=!T7$Vc*7LD$UKgk8@7K z9N=kCP3dKVcrjMR2xbP$iQai8D-ki!2aKzdVM2HFh7ZD(v82iehmLf|bOW+v;-~ zJv7s4p;f;r9Z+L>Z{|7NlYB_25BgZLcjlQ@KHe*=NYu#?(!II!Fb+)I^|t*m`iytia#5{pbVM%I zf|kV4xSK|xyvbDub-~bEw@U7d6Yc^-G$d3AO4_dqnIh<{p&F>8J=-p)k1v5)v5T|xD& z3w&%}KQULMUDDl|brV?x`WZ`+Mi-}?kW!gzL74FNrqh^6 zV%pRTM0m-=hYby0YBN>mV7iLI1~HIT2**a#3>Ri1hK^!#8B7l4K9 zJioCIbmG-n@%xyvqlXa)Or>|Usp$PKEL92?%bi98PGzUmPoj)2jq}QCm0M3{ z6c*MOWkUeq7ZB=Dem5q0$V@3tu`IGu_EZL7<--8|91+b&8*@Cuh+gZ3C{)F{qa?Uz z?XohFmqii}wREXK@^g|O2FJN-1W`%B>~9LHCTr5)JR6h5`67GsJk75&>St2N%C@aH zTE|!naQGn`^C&h*60~O~GZMREyZDciCOsuFD_Ju$Y& zqcurdg)QsXvRhlDkzJH}q4d#|FGL zA4$w{qFLX;eM?9+5{}r=%g+m_%16JlXj=cSYQ458i0xFV*ztbpAU2QU;i$Y8N%(1d zb>0cL`F?oMJjbn_98W{^#WY)f5U#P1&#Tly0%Fir5UKZ*pRX}yE*0?%Q_@LW{9Kh( zk$0K=``w@K^3vzx-1>_Y3v#ZwYgLWHeU>-bN8o;RUg**V4WLjtd2c5i(E?4~UdeYA zT-l(+*okft!>;rFd7viOFOO_=Y>t-fNzd}k(RjRY3(MkHw66j**F(on+B_+CYlv7L z(kNe_#+07=kU3m7ZvjawOHKhwDqAz2RXTaM13nQWbI&Tti+|D|N9P5fm32``NZ3CIv9W)%Aa08pP`Kj65b(yHxY%<=w|bbE!2^@BHB4GD?Eez+B@m@($jK zBc4*OfSzStXcdLcM`XG<1KxwH9MZvu#`Ce9XV-0?9M<|0C@pY%*z;JDf>L!|o%dnU zCasf@%A_FQaU}?HY{sJFs${G$<8U2Rb~mz0nvmj1PxP|`y;NO~yWep%yM?zA7$QcH zr&7006R>cUX|8t%tl8Th`F@6|U;`(^XBEK!z=Hq&R@o(z&w}O6!`_9!lQ9Lpa3*S= z>1s+;k#|^)IBS;XX4)R3!Gbb~X-7PkQ^K`c?553bCzuaaUw)aI_xrRWU`_?%m!JI( z$$ypYEXZ4y1ONp6%a#Am%W@!2=2u4!JK5MuqsED4#~N3<2!Bx*@&GZ+>Q!0QBG}|* zzI0>aI;vXdvKVOD3&cuo+z^@@DBwW|i41wk>pQ=Dqz@Y0-vTtZM`~@w5tkPk@+^oO zyDg;&KBYYwA4HLQfw>o4sn7uDNse&9VZ19#dLW}NaATje3Rrc*e4*T-h_+F>A#Jnd@M@Pc zlvFJyGAUM%9mT%8eBKPV-_%*zTf7lj2?+zaz+n%e_8lq>@0d0W+tP@72~=nE2hBUz zQx21l1+x_lBvXkaT-DC@%>)qKY(jLB);EC<%Q%8iv#y?e8%u74<>5vK9 zsMq&#O~z7w>(zEr#!Fk$e?kO66(s%FGDnxJ!qHrhti<>KQ0%zJIq0Rw4B{<_cHk0kUOP zZ!8RCdCnl`s{0QdVamuWr08+kFmA7A zJh(%bZCfV7721WB4m2WkleOkwahb@*{$1CLUS9w7I5nk$_L$W78+3hJu)c2w@<9EAMTA?t?@FAI5`qw^FD)lY%X7!ny8G9)4dXpo~mNxm7-)_>wJak37xN+ z(u8eT((0)KVFegpUv6kkFON2;teonyb&QUtjlZ-AKDsj}o6;=}ErtkMY2~~4aC@BA z;}dtpD_RKCiTlPuwR;$N6DYMli*ZXM5Y{+=xxl+GKpHE0iRnypdzDg3oT*z66gxuvr1c`aVLqgHB;vXELnVAfs?bFH8GuP!^aXXz%?H#&Gk{+%Ir(i~kmdm#C+9JjJ4yIxE<~+iyf|$$vKDZj*#xSZ2q$fK*#Qw<=C3-mrCR z(qBf4p3w#a1u$aJrgu31&+%$CnjqaV{nwmbt z6u)zm8r+M%r^HP0O@4oDXf4ZtvzB2(hG!3i(fJQW+rQR((-tj6?v}7LF^v*FN@*M; zlYz?Ej5RwSwZt-3kWL;FU9PaiNbJ$L@LkB%gPH?49D++`2w*mn9iG-I{u(d)v!Sxk zM=Sx?f}L|lEbDG`d?yWlF;^j9_I;)}ot|p%6_)hVH)SMPV?3%owe3usJs&#A zkp`+&4#B6cyFK?~Xe%FPXq5KbY1OFZt+$rPWvAC9C<2P|8-Si}7#qeQ^w$FLKL)o} zO&Z|VH{AEj6JhE}@Tts%%l2+W5ByL>1#Mk@A}xBQKt*c-z_Ky!_L7<2GOPqwpL`dN zqlL;T9mVQ@BUqBQ=&EJ%m?A| zZ^o?-uazn`HPw0w5$M~}NCSigE5#`_4lgt1I=`TgKBY1fB``d`SEdOVBku;&vApoI zXTsb62=YiX$#J0lk80w0n!JQd~eXV^})L5_4xUw z*#NLK%tS`|keBF2WBSXOK=bL#l~b{JQ3%<|n!8wlMw2zG$n+zd>4&|ncwTFvJKG!u zu&Pn=V=R%6Bn-RAQN=252GPJgI)^DTcn|z67}>SKXc$u8&i+=a{<(s)N&3Bfny0X( zbn+Pk0G{jsM@C3E#IU*T#Ao8jVvSj%`x?N)I5DSZl77cW;(hbu5BlEluJWnJFeH|Q z4eM)WS|9;$jN0D5`q8Ai&3&K={8~qa-}Bl5=zJ8rM?&TBHE%zHvgIqQGhAXyMu1R; zaEF|13d?aezHg%@H)Cmw%v}!CPLsKFyeP(r+&HOXxEdV~6eMwRjsZb5T(L5_k^|T( zCF-p&|C|Nf*zk)Xlq+WO&Q5lOC!RY-;`O+#?0+iEucdB&9uPkIGdqpO{a6RTfxq0~U(Aph%FO$rQ=Bz=kSq>)H*@ z9)xvprDe&y*=hW7<7_sN-K)=RVJNno;uK-ZEwcym236j8Qne|MrMZb$2q)(x$*kK^ zfyPZ|ehvVvORr9p(s_RlXuWf9C=9+Lt9y6WnlU7Qf582cb&r&Ido7W(|&} znJBRn&|TE^qe-3`sdqoftPp2n{{{Ue?Z!+%+_9o304YG$ztUdFeEl>gmKJgh7aCilhf?KX}mLz5cE56bF}xP*Jk)jHMkYq77m+Q@7aiK>_vW zQQ6|qF zHer>PzX$3b5*%-*1$)XSZLtok<^`XJ~7Luhd4GbG9+1X z27QT4W&j;~iHpQXGd+;nUc!whz%G$mhZ)3c9DzyDrXWe>O8?@x0skdxtLG-#)c=OrzF7Ih>uh?u1X)0&N zO#7@E!y49nSd(9BEJmZj`yEK-*iE5j(4YBbptRsoRkm1sL`%gxVeLjTmSNdQ9sA%9c(>c_LkH2E z`rvzwjNG>W%=24*zkFvSY=+BvM-kigG)emXgRwX>`yvc!ij|r_(OOQ4Q!QyX4K4lj z64PGa`j{!)&2%9dU8X#aFi>EV7I!|jj@yv2 z(UKzzLR7l7o_BOL5JCh~Se+@|yd~K%I}ObO1*Y%_P-tRyT&o32luoTe=-q z1&0`7D~O%lIu6IIE&qaspWnhV_~&6k%MC;G51;q0z~a?va|qlaOL6F2u*pR>6Iqp6 zFrpCk=Q=F(euPyYrC*XcDn{MV@Ks&D@2**?O>ydCv|}nT-~-L7eY6$NoC0RUQq}2P z*o!~oGWNruK*eG>TRYws`OrG~fc4k*{^c7kRy2e*B`SY;SBK{00UWlrX`iHtC#HGX zkow`p)k*G&gFBXAd4H$w z$1;)2YkG;UJ$a5Ta*>C? zfpw?~(wPxXn$&qzbzkWHgtg#-DNM}|{C`yNi}TFdJXj(Y1FfC99i9+BN!ga8q?|xP zVL}UF{(5A*H1hm%b)^|3O;gIYQn*w;#rG!GGWmWy5!Q?r(wdCEv5ML zPBL<7j2|ht_dvoeK07Pi4%jLpMC5~~g^7>AK?LEq9%TD42xbn`l-_MYemxdyYE{se%HGqG(I+U>E1} zApn0_J%eAOZ&A2S>bL!L;|6AOkt?xOI&0sVS02CfS+h!S%4#`j2|G)fR4tYD%74_R z!Xp~N0ie7D=RTb9*O=WNuq}!GE#J>ORd3mj0euxmTt}vdMzD1>6fyBOVM6f4UkKRvMo|W3tSFM zz#hbg3FJ>*6?w$DYjON}>u^->%^$|h4PGZGa*^YAnLmJR#I+Jblp%=v8?B=SFz(G6 z2vaB0dLKEp7w^dW-X01M2N+~tTvdN4?a$gg?^;w0ge`la%x#Af4;gy{+>p3Y;xK*b zJVD`?R!PBjb)$_#;|59*Ch@fs!z_nW;`FT&GL4XJj^iy*wc_@j@3>l==uun~+|bHE z-Z%Xw?%o!;cl>P=)rR~ycek%E%S#E{w{&cLPn$p+xA!#Dl4%3BWd38{KVSLQs7wz1 zy<%b_-_5^c91;YX&5w~`7G6io$&+HaAn^0|^WoNPe?nc;9ii%UFhP8y5ShxU1!{$2joW6`% z|APE|_ME&Gi(m3tlMwp@Fy1+dE0^@CbkABukblv&C&a(Le)vE=n!4+UKZ#(}XQA?lrHtZk! zw-a4^a2a@cYwGDGweI>#6082X+RCjI1dT0%Xn6dDCpdD&!?|3Gb>AwL?6Kz%n2`!= zNQKI&RKKW9PkT;C1WT#?JlaAIbcNqmjR)31hZy}R7+lsw4BE~^CimLH!rQbev_a>6 z8~guC*At@k4L~tfH7K)7aU!%Z9oyK+u^aFx4bor*FD^MX4c(;9|6vR5NPI+8#Jab= zb99aoLt9cz?XoBcx`2&g!}eOR!;$gx2lWJ&syn6(ese!}h7y~!%!vVSZ`%$x6GPjq znS7Y2vD}9Z=t7TPF~ELsJoa@~!RdVUu4lG1|N88HxL&GYsan(ev-uVL^mVLB=EXhh zz@<$s(&VAcku@kv@i<7g5%*J19IlZW|M)@&ye_SfAA-5)`DR=IIvi}ac6pr;3tEbB zXa|UNGrA_n53P%Cq)cU7zx6TLl;UcYklRV9kLNLD4W_WWc=i%Q zPS12}EMj${RNR?*eN+vP%JKn5-C`s*aw?w@(_kP&br8rM>uj%x@0g_wp zAfQB=NXSlCVx>EWmjSA9hyu~RAd%M29J6urbxX+&%lhAkl+vD_kzv}gTb@qM2p#<^ zw@^GYiB{_qSD%?#(3`;Pwpcw0(KC%c6W=*pA?_1qq|=~ybD)ix{<$=NiG8!BD5}6j zn}>~d1X~ZH{$92E0y6!voc#)mJBmH}u0X)cPi5+$KiA~CzO00{u5=g)K57j?^SEmB za3mT3|IgSOITW}qPGAGY3(yI8LhPQ>vmFADm3`CC5D=*7`nQ~TBnHs1Ya==v^ix*n zV!O0|DCv|>;erHLK*N8JcyAardp4G`gXqkXT2&gZo9>AQY@ zth1R_>TbRWKVO%zrxrm4dC>i2h-=~vykBo%@}|*tZHRu&@jE=NCrYZMHj69N)IACy zzHA^e5#ekW;>zO%;ob4@un0vC8*$Ye)g(Ac&AlCZjra4tT^m5xEWHr4S+|kgY^k2g zj-AY>sEhj7VD%eyJN?3tcwN8%sOI;O8!W$r+QH}$ES`E7tich-T$t)gW9s9UL#{%F zYb#6GBjMPUc5Ga(EI2NQS!gNuaU7!qLuq zW7pogzESYQS3BEx^$G?Fnx@YYD*2vP-QU|&J>%lVv$1` zwG7?WkyK2Au-*UXM5y}FDYCAsI|%aIirf#kXqjj~d;NkR!&f|HHbWa|+p4D;(<4Ln z^6S@ORUT28H^)p#7bX`wqvDx&)iXDly~SRp6qM-wSR?mt&Xyt%j&X3pB3yqp8$G%; znX!VpH>!TtLgl8eB*bd2UVVHzOc8jtU>{U}D8A;TN5l0@5K#omr^o;lz|05Ks{vYP z?>h!|o8rV%44rzW1 zuC5;BuEg0{yEV%A1|Z+Ye#F1Ho$^N?THbW23V)kIZw8pe@vP43;#M1ns;hE0&{X=% z`f41DDy@LAG$&CLKcwC|i9&Qf(?(&u^ZFdpqBpnQ4=@JpuJSQAB~JKZ=~iXFb^47C z9Fa51&vj{arUq;Z=|;lX7)Q*{KyBN?Om8n)$q8;oaXrMOo=E)Fd5}W4*qAQVUYjVO z+tz768vqVgf9F%PF?6s7-M##`c#zdtukO?@2=h13@y+gl1OD1Ej{pVwRQqTl#Q0)% z+L{#D=o~|irt7Qm_0;TE!k(;|sJn`L zlj2{?_wmXD_7!`a)#-zZGVg(*{!sG!&s#QFiqCoMH7GVz*1{`8@Tj}G@8g|K z*j|WWmwTF{^Z814Eu`pZpixyoS7jZINx1Q@3BED4%+g~@CzAzzv1*AcGtW?cBs^c4 zW(EXuldY;aMFIVUaD(z^J9H4y6%Cw=ebrZjtRs`BCdwp<%&VhSklEecb(^xG(>JNr zMygKCw;t}+=u{M(J2myjpc;=x(40j8&3ikK`q1l=EZ26Yl8hO!1{uM?M=m!bdw|Tf z5&@6WpF|v$^^A>nXp+;(9mpFStE`0Kjn1F%lH4e}y#gvo4=z8q}Agjyqea24_Lx=iTsK(e?f4a`wkD z3JbY!URfRMa$EG>QdjfXbJtw8X(xCl+Ed--Z~>bk1?{mYI|rS;#R zY!Bo{98mW-mpd~Z8OpFOH9!oB=2c7vji~*y0C7zioa8E^`CcEL0OK1gqgn=gkug)_W zElyBP{-^VaKKctS5j+K6sRlOO8FaiIzb@%{`Yl}6fD%J(B~K*Rv%y+K{uJRQ*Knp-n6 zc{(TfelKT~R%A?6?~O^oS6ztErIDV(^U3bn`c3eaa~Si|FIAELsqyj{T`XlIC0il0 z-QffKf-dJhaiN4ZuDGQ5BA4t6MxS|@znrP+!Xvx1zF62eMmf^>k` z{(5NB-a4DOcjAhW9HspT#P{2M#S1EG)QT&*RI?og^#h{#bh*_@a~9lYnxCT=`dn{T z!mJNR`zW2N8=os-ov6~vrZBeNxm8|I(k^WfT6%Cf3t=BGRcB8MC;$d1o^*~+f4&3 zFD;8+P|hdCJQ^t?Aap19OHdE41L7Azkh{MBt zK<^=Oq+yS{{(d&K5Uv8U+b0Nv^p!jc8TwijLnFZgUya+`pF3J+Oh98ai#Ge3>dOH! zga@@12FXseYOO@#~lC~eYc~05% zII65=&s7;Nm6^HENxasf<9iub;FGS97kDV><2d|mmmzSwKPQ`v%UQfultF-DFJ)R} z*0+x@OivWCb7|2C`sC@_YH7tdP(RsUoPW=!;Qn)_qk-a(otQfy%NZLDv4!81iUQ%f z<;yJK3JCh#iEb+t;YL2WuIW$d0NU(w&n`Mh&9ZjeCv93N?||*#Y-4ej|Dl1BLjX%_%;K&Vhy#XYE{U&A}^KDr=&=Vc-XqV<3(8hD*Wv9dIEKs z357den_Q->k277}CV@g{|B2(+)gWF_k}a+7{rJKMOg`2Ur57gukf-J;Fg@ZO z+wj2U1!xp>PH-qoDRy);M*5t(NMg&*)&4(Fczg9H=!ia>=#D&*%$A-@SdJ5e6duR+f z>m{4}A5rfK@9NJA^ZdV_mgw6koV9az;)Zg7TL>K;JJ*A-lY?SI&G#B~TBg_QJB0d{ z=AYI;aVM6~9(ubbh767|_ZN*I(?CI>ZB5}a2UWvW&DbDGRZxGy*LA4)D*-2Omo3|L z(Ce`}kMnr7+&J6?TkTuZEx{7g7WSDTpldLE2|Wkm8wXq?OJN#qA#wPSqL5g|l=epa zO75|x|Ml#csy&B{wqQOAA;@|BU~4*DZT`V)l#=|^3;XJo)Yet$iDB&W7|r}%_&tLC zI!VIiyw$R_WhmHe@-fE0_rh{_g(#6RFB7d7$W{1dZruz2zp0zw3wd{|ZC^=iun3q; z@}WgqS1!v#zqYUkSYDhp-vv~ANLtIVRCPNO>HX`>|1aiT^99KZI!Pg1Z|JAwjbY=y z)CHw=hz`qc?3_?mIjM+}UU#@K0BD?mZPFixAE!`#(Jt-P(awp~heNK^KHxhSQgoye zr4H24qCKs(L~uo(zL;$+!09tL1?gqBireq$)P5I~Hb8#Ou&a6$stST+%L9St zM?;$>;8rJ#_y2ZlbDD*~lvUsZeFcSwN6m?hd!<3MztNp5%;qe`IEsjoU1S+BxH!Df zX8)0We!oTk))K4BsWWOMTl4Pgd&dEBJ6Ty4W& z^f5))7=HMNxECLLAW2N5ttUm@djAl-#5ZnYefKLwH@lU2L0A6l_6w37%kq6J!bUkd zU*%MGw(#Rh&b3Eio95W68vV)4SXe=erjSPmTD0&?mw)V_nqfKeUD&IHeYt)4WA`rP zU4PbEfZ02m4pyaV7Ll^1>oLumZ5y;6r(lY8?x;`HXYfiv!23M(|0 zEiO}d{t%h0lp}%1WjG|Qpc;fg{b8`Vu*4?OOwo;Fwuqs?UWf@C^ z3k~qBLqg+Wt(~wviv#XN=)j&Rf;+j}kZh!nK0b_XARLAvA*bSorrxCIlYW#iSvAHt zv@j!h*r~{W@ZDFnnLaLX(a=xd7h~~{PNO}V$3rK?*PREDYstudi4GEKhzvyyOhakvEO zd;SU2Tm%1|wn8uofFsI2)!t*3E5D6!oIdH8l8d#!It8B%1l1V3)#WaK*t4$ftUQM~ z`UBjVYI%u2%mUPNwqFpd>*(wh!;7E1#5=G!#Uj#YT5AdO?)&rMuY$uo0yPny;Owl; z%j=2z?VmJw@c_iI0{!K+Z?jEt#EmkJLMm%nQ`P+ZL3o2=l6l<^Wjp0ZFRhz_S(HGT z{*j>P{>cxUF}BJSTrM6Jp|rdANdwCfr@>Zn43W#uUy% zhuf51^i6SUs)a*(7$(r$oQ7g}yGc<?eDQch1E!v6blVVHs*ME4f3VsP;+jdZCQm~ocIR_7O(5J-@4<6!= zzPU_Fz#l0CRPe$&6N8PB<|}GTtzgxRf{J2CsMQR7s!x6nLYMNxtMM$nPA~zzSUZ_h ztdE91wt=V}-_81FjBd?Zdw7^LG{^2-rtJjUKZkX|%;)$`*kKP73Z%D4YBIbS-M&z) zV?sl3UXav{esh#?cjZksc7!@^53y#RG#%z*T{Ae*3L9M>IrK?#Qbvk$_AS*cBn|=@ z0taX_o1z&*IHWFydT5)QPksgWnLV$3)WdYk3O3q*-$Ti7@?QC*JD;Z#K926S zccev0S)YriMXqF-5i0~mSI`o=P{b}Co3i;fB(s@$^C*rKp~@5H6=&Mjn>o-|_O$o_ zCNL5kJ}8f!vf>n9^%|{YORezwe2tW32H48520h5hBMEsK0CDx7-Hw)pOmZn-0@mNA zoq?^rgS=+snPI9FX8Jg5F&)YUIZNqVaPfpKs>XQgFLdqdVidN@1;JRW?xCuj>8W=C zTkqWwC$U`YSQ9d-h$Wjr44G-Wr_R;KCTW7MdUggwr))jcy(>x~2mh|nrGV~vn%C(6GX5m zOZ=f*SWKy1gBf*ZWzt~=s6&%S8NC{7_6sI`CP1CY{>h~v&(kl=G~L2MwT<7!JIVh^ zd>MXB5Gw@QK35oD>|aYGw+pGThJ|9%n+V;BPlzc}RvzMr`f6 zC6rwZfkUa(M}L~f{uWjq*!d)1{l_C#wu!h4Svi&>cCuaIbJrA)4h_=@rKm^bicm&& zsw6$k=d=;Y1g)}etrzoDQZY#qBH!J7uJ_@}?-6KWB(chJc33E~?9HY0uNurnoO{Vt z3n5GJMc4!cPkNd^a3|nUG=1eEA4+64M&)&Z79r7!zx)O3s1bHWhK;FHlJqdT{gFC# zx~H=QV0wF6)FRWGfJ#7%B!k?4(~+;M1XvQJqK1vodPZk;!sq9}Mc3niP0sU~@`+OP z(IN@vxb#oojv zszxGMD_BjJ8{h2l?#!HUGzTp=#v!h#*|*Rdv#gcneVW3`jk*`fGt1$Xu!)c&lDWe4 z`4mF#`T_9j-Lx>EFU_`bNaA~?M`z>6tUS+OuJl3a61!ZL zkR)RqYlnjvihWpF4f-!J#W!n7_`i8E z04EEU2ds}Qxr<-7nW7y6J9x6#fSsvrgtP1OwCO5_0p6r(-}{pQm$@f{5kVchzbe9^ zln`F5Smd@m!(jIC;O>;P9yVT;CTu1oQWnI!vJ*C&pYPMOV;z-Gs<8h>+T6 zD(>jcZe?nV!yJ&u02j)L%j!rP<=Ep5ZlxGnKO5lFrX=)`5@lfR^D*FIB^+)47GXcf z@iZ4q!eFwEZ*EA-vjwe)!9hCp zAO}BpYLA4NOGe9wOfeT$K#+o$2ch2G?xSJf%VL?I@(7Ba%m}q2{hDZvYJDX4-DD`v zvEHx1YCj$PE6n|1+!R1vEhDkjf$qfH84P$aa;feaU!YqxUs3e9vecWwQzdV*Z4D_-4jRG-a?-rIt5i zDfHMW+o)d*JqvDQ)4oM%?A3$CfJ8O`I5uE4rvpfD09oHLEhvMA0^R5`!yJMd3ar2m zHv#GjhY?G}F|K{%GADwECM3^0?V?UnqqV5{Nf}=VqNZO!fYRDcuwFE2)rgw>SG?vi z)Cp`%P9UST=bO-tJ6VP1tV^upH#RbF{DJE%!Y3rPV}*0{Y%SLP8 z3T?U+e%h1VU?c1tSsCiVrE5jGt_5p;kuFb2)S+@Aqi=(>GkxI8Nzn=o>v)tX8sd5p zyNVZu`Ur0!|90qv-u~ncdm{irec=8xcz$;v{oSUqjHz)wWB2}knGRoRr;Dfi{nfr` zD3B`89ksW|a8x~2*7^3M&USD+&7qkFBr5g5&=e)&BN3O;NK1A8=F}AQc9{kX|?hY z2QKO$6e*bz3|t$PFUmeZ;bDrX<&y(GF3SI@hzzNcF4@p8!SwG8ijwAg-svaeqByRE z!DVDP6v--~MHH2?V)J4-HXuDVBk9(B^i#Tlp;Mx9ZdMFI$ib=CY_+aj^G*?#x*o8s zYl=J+FD0Nty2NQ|ck^84T9%1xahnl#V?$=X2GmswN$6KkvS!EJO;rbur$)kp?OSm*;TD>>x$o41T zNUHFBg1$3jdo2Joa*&)M8uNZExyO4Hv3)<6iaI5{Ym&K{LtWN-pCA312$j$9*tN`P6Hn`j34 zKJltuWvDa+=@AE^L*Qc$QPjU)i!`E4WxqbIfI7yL2IgR)ZE_4_?v9Rq*c(GShJ0f( z`7gd}f;K+zX2=BzPG?Sr2PWuy3E2XgV+!JseEA-d*UnjAhyKg=J4CytbZsbU*Qu(o zL!aki6@Q3A(WvE+g^d9W07GEK2C`IhPfRd9G-81vE+m$7U{&4J>F0BPCI&$vF7H!v z(94s5&e0a8Mp(Yb4&kV>%IcvqWFGKYIi*Wl8JRB?Q*CNLHEPEHgs({TbMC6zCC^x~ z-db#pa@UBMB-pp9A3c0KGKQ2qdRcr?#@Cb zcD&~RF#nxQG3uE_;^km8HjA;`pmanoXRn-Iigg1uo@H{cMa{~dfIFoLW2`EJwsl^D zVFcBv5$~9nyMZkElr+T!yDyj3+P`)ac5`25N}+0}gizNo+D2~Ajas&MQpXH60RQ#4 z!-2EE^gu*!;84=%=OL58gL7~6!`wNTF(vRGH)o4yr@V=G9m~=3KZ(3c5&qCu(O>ZX zz+@od8?a_+W;&Anq3X#sMpO4SI3rBOkDeL2gxPpQ=dbyv_NGyJ_&0$hUO-!6se$wp zym@cuQriwPDQ*MeqGl5j8q8M}uTP_^(ROOP@XqUBXviUeck2KIuhXah-!Fv&6s!m$ z&P8ogJ}(mRtyI(Kl-0=_xsW?fNwwU;>c!;fkWmcBEo`m%t>l^H3ffBghmf^WDO6=S zpJs~WN&QaaW8Q?wIdf=D7S;oPPG~x{9Io|=;hQ-}Qh&auKKleRuDBy`(l*X%! zu&H!{S4Q(J{hPP|Flowy^eUM2c=H1+NOD+jTSxZ`)CgR$2u8oIO%IB7p46?Dp$Y;} zOgrz*@FDLRVyr6RM@ytmsGx-yRbBzq%NCxR9E z9-L5Igx_TP(;4pM0J$G6NuRvL7>s6Hm?C0McLJz(C@slSt$=#%$=#h0eyg~NJw$=W zS@X3Gq~UqG(jSkb7@xlD_o*N}Tjd{W*JYs$zx?IcoGJt-EgNJ|%P&)Ixzp8iAUH<) z&;dGpUA3a2_v=db&IGm<@oN|!zb*GiU4Q-&nPmMTYOniUAsZ-HY?&lZH{-?fgO};WqVmNR`O)9QMhnVY)=-@nlPWHs^Lx#w9#+KjgT+9yJ+E{ANJOU5+;;&V_rT6 zw-N7Nv?Ns}8f8kFL-SH~!%adh!z6ZsAW+Uv)XIFJ!x!N|)x)`DX3B7-O5w*i!*{En zvfh;<(I;|d_uJ&j8^rs#2RgdHxg1U-Q-6F#ic&{(DfEjjIUY}%hYoOi^(8gtH92hC zBy8Rdo_AtIOd~>GZNZ>(ZdzrsvNq4EFUnf9(8jO&oNWM6J*PtCVq2Q`rZq0Px~>Cv?5DO&+QN+utm zkBQy1_=_K>Af;CfvX{rdW)s2gj8Ek;TP>t#pEeetNs_~ZtafQOp79u5v;yI`ak|>Q zP+mgv$tMj#TNJ9g4_@w>3%!^w*_?{;zF9 zaYye2OPKT-AqQXwj*^mpYSYjl?S%huYqTCX*DVF;v$72cugMofE$WMqKF?ch<)#Ay zNr>nTMW7cHR(R*^NZ*1Mb*4@`+-Rbj`|-2s zNfU7K^w)BD_5S1^tD@SoenOZJKd)6Mv)oM-L^uq=QJoPyFA|uWGE7dW{~{!5+To94 zl6__b_I>2fOw_aDwZ51VeT0m5_{{=iNKv4*Yv_gtl&mdS78#APFHy{`%=}&B*cp*| zQs%vY1D$nb?O5xB4l&gM5iVp@)8}AeUaSSdZ7;*@a&?(oUN?>ykGnsO)YYf*{@KSt z`7j9HIwN1hKpo+CE`%FTDpGjxp;DD6dU~f?)`EALGWRH(v~Gb;b7giCjDX61fr;`k z5Ly^auzwuHHSOGnr_$0%MlcY#AP>mugpt_SeijBHGE}R?wxGqX0D>sDG)3Iq_nL#& zKeiSK9bnrHlFNg|wlsa0_d_uMxV62=icFf4SDC}LSszmb>`z74DlbvfnL!1$Oqw0paa+^kWFQ%C!M$*E3rH>3^%bJd z@Vnf>*<%ecGza>Mv!$ih?mIpAaWOy_bM1UE_ECjqd)6YVYD}AJ>Zoj=M0kdWQJajQ zc4xpTBFcsAtlL9jo|pT-^Bo3t??U9CqrO%Lz`Yygck!4F6*&T{Aoyk8K6y4L9{v{+ zt53T9jgfzyum`_1#UU=OUIt$l4)rp?SuYfWO)9rQRkZv9xg7oQt{O(tLHB$*A&G@U zLwrCmDG}6KL*r*?X?E}rZ#jUUBz))#CYG$u#^&9m(yH4vkyLtz?`Z|(oiY8XaP4Mx zFc{rWW+#@Q<^Y}iW<36*M#@WP+|`swYnirK0tVkIdo1`=)#{30-gl3hYq&R%PnbC$ z^KP9mx}Ml{vO`lMA^)?$XhhH<2&%gO0h(oA8WO_NmjelabUO$@F&&yd6P`D<4C|9H zI`k8-gVVks4v%U@CmPDvYo?LgxU0E+HA1vv{2D2*e~y5+HpJc$>$p_-4swo5gB`Ao#p-b0X7k6U;kiNN1t2&&}ggtts-$<9zk76I3T&sD-Mqd@yAf zrH@Q+;&gc?EeVm;QDT#e@#V9-FA0h$Ar-CZOUpY0F9OiygFE{4#xp4t5x>?RB6Ay4 z2Ieo0wGG7PZBR-Nkeh_r6rHupNqC1s*Gi|-K;*OWSs9>e!Y0At1q|4boDs4jW8 zp#OhtRi(>pEA)|g%J?)CZ+bJgH;qAj0u7vzMgQoPbRHa5dSPUAzh5yfG(n9kja90i z>Yu*zs=bqV4+-b8aMc@0HfNWib0qA1h1yP&uNC=%SZp|U)mn~JthzWjA3raggGCrU zj=z1GN<*_l?O!6a5@O2=oc~)QP#)42yzh^D3mAx!K|~fXB;CfPfm&+B;NF4=2|v|> zwD#5DOJlBLwQoWgno~lzU;mu;-=v04BCLdYh6_g!u>)FaO`?)~>h!ylhaU*jBIwYKavy^RCt~F-}rrCgIvL4%}Tp%pcdSgu9 zO9W9!N+=@$U<~R|O8>Auf{x{18Cq2cMs$Sn689cc17@Z)9Xa-83cFv|tK`=|__Q?k zN&udG?T4kJuS8w*q|NTx0wLcEo#;WN!ZvFOdEUJk&=N#At<_Hg_X#!2ure1ZHscn4 zipYNLb#wlRUfc^r? zz$I`|jEc>VZIITpVc+PG;;2+vQ7<3p-UV$mK~ehDsNAItftN)t!X69?U0r7DfF7&} zTpi#jIz)UqTpoQ60#=b|X7Sz60wkS(8r*y)+vvfZjgJgyhBDMX@L9Jgu4srFG2|HP#Xc)4IgDRA#R}Q|Y43RfP+mZGnPy9!IXM)m zgYusGhhTJ}U)k_2eSn}Bfg%Ew3N?UrHUiKi{jhu6LUW|h(E7b9E4Hwpl2yxM?lPl2V`dRjbgC$j zw9bchGC8GLy&^Cytux#xNyEJ5`=4D(XQ#66mw)U^qpv(KJ+^ky*2$Uy;u^`3 z!=*CbYX|;!H62K;)@w>|(f)}h8W%vFMQ48oMr-`Y$8dwcHKM_=vO3q)FG%D>`VX}*nl$IX@EFjd%g^gr-QAU~`L1#@P zmxX1~UkA-_Z@>PXj=BX{O^(6y4q52z!<)V2*mj_jVBd$TpHfMAw9ILl+cM|W@{c`G z<$5og5AAQbcWezT$2FlbqcHMD1e5PZcefJu&@3iuudn7-4jvb_-#FRJW1A6ljdU7M zbZK{~i|zp@|6xYZPC>(2WDVUuEMXnjAdwipWOV_pp3a1QZy`&ukikb%TmUD5J~v%P z2dvOFCI~13pTGLbnV&L~V5BeygDOdlDN%~?QljcO#d1Z<(VD)8gNxm+8 z22?eN=yb5SGSayUDWby8S6aeNdapJMYKn%IZ~jJXIo!N21l{@VSgWqa3}9r$!@>Kx z@`pZ4RlSX#lJWM8R{c3>$wg7GsP)VP)e6koIW>bBb}g5))q~8WT8_&UF3VD==3-Tzf%;syM)OjL&eUP75AtB>Y!f!{y zc60quE25)prLIPXws^~%l2`Ny=IOUY`}^u<*L*8IVe+371DYWQ})G-5Nx%PvF9n(}K^D zKRG!mnIfS`K^uA%p>U9o#oqE%9j$+@rpjteIrw1;;Z9HoYjEUV^fo@4X_jkN_Hu{B zoDie|ycFVjg#;mmn0FC^R&!n@75bWwCb4AF#;_`F90nH7e_Z&#+a}zUBV3yH7aQ`( zJTPen9zF76bLKglaIe_(!$=x$WJ&9MVI@>t@w8}qn z>5m&7h!xeyoevp55|xh1;T0UU)Jey3|1gXA*CH0r53uGcbS*aiGPl@^2!6W8FcZ+o zCO>&7X3FUw2(yiIHTs(ozeRq?UGt>pGvF4X|Lc zt<=*|^Swy|102Ziv2yNfU_?~hg(-m*N06|}WqJcIGmPC_Iw1!XlKR5S>Izi9Y zNO-he4;mWXKe>viHA_;rixsVU@0Psgs}(Y=zOeXUQc;@`8>#!|Tin3I13?=SL>ugd z9WaVzybC6U)_x%H;`pbJ_{BGwKKg{EhYSqB7n5s8IkM7?K=k+3S?{MYt{sDC9<5

Wwso3-#t%jx7ki{ig;M!G|1n|bGHUD7;WyMAi2;`Ym zo|GR2%|-0-A36jPBg3~}gWt4nkkIm4>%*E#x*0}g#Sv-N~ zA{}^^9v&-!JZKM!Dfh?Sg=!LS2jL0^E3pJ`J?N>*Gg@p-exU9yn7Z#5L6&0bW`_JwkLdh1kpg5P9|LQY!sEmpV%WCyA zi#{I18Pk{df|~liQan@elM86%u*cKzU2^06 zu1-n9a#A#7eK72?X{erjkoxhxhrd%}M%CK@_rwaTgPxS(*C$=$#zXo!R3e0+wl(nq zV6-)dmT!rT(WNhwopna~O%WLsWm_bt>Fwe>MShoyrz!#d=t-`mZ1jg>zsK_^7q<8+ zTwr++ZC@N_18;MPh5@etTd8x3B%}RsxYgsatlS+x@OI%cpzn<`=h?1^b*N~MFHml2 zNTvJMud%CnOdn;YJC1_rfQ3Ey#mApACi(EhQLH73;O87DM$YpB67 zrRR9*hhHj&))NqUOQtm0732HfVOYR}mCEkBlQE6CNVb<|fb4+W#2Nj7w0mvdVjVCp z>S-(YQA=}Qw=?iSNj<-VfXPsGTW4SrhRvmtp+!@My#e36A+E|D=L+vK+U_sBJ^WO? zoDqVP(~bUh6^a!Ss>7dKPe^a%uK4@1_4u#vfy<0AeT#qVgNB7g6=yUMA2l$DC*~+O zGLrIr(cH}V%hSb}MWCbsk|0Jlcty6DpfBD-vK#<4K+3;6sR=eOa|XC`wk^!N{kUsWNl9V>%QTlCFbxA9-w`Ng`zBN7hDoNb(g^?NCVV`JO zAUagbB=b?QYUcv*I+%_(kxiJ_VAND%0n+%nyIyX9;Hi&F{Z{?gsjNxbwYS6yeho2! zDf~EW;=gge>Dfgv)65>7m1vI$VvQRoWym>|IqkqF%?ssipxDKC{`xsU{3eq>JZQJ! zX6-)2=HZlAL=gV-|29nsP;D;o6;B3PwY_Ly>(Laagc2Wkgoc9fox#3ger|w#LL&25nN48o~Wn$4mIkyZ`AMt;?7>uu06$&H<87w*g`cm(&rDE z+#7~ulidetUCP@kv9Kv}!v&ViiJFsI5Pny0Xy?ArhhBi0$bM% z=unmDHy|sSBgAFd)2pW!r9W@~M+}P*xID7^=!-_{1X%S(fD>Sw3-oSjP{7hH0g_NV zQC!&Cx`XUVszRt$tMl~s*-u9vGFUi^{ihh{|oOHKgs7=U9Ab6X~R;=lsX zAbkQhoK!SwsS5l36{68uEwnSgw`xsod0+Gm(NfpK!7_`#2DX>}Ls%G`v{cotB+~5( zlPu7%4H>lr>HDQ+fe8^_zk|KiaRwx-vlp;vH-`7_wQ?JGq>yLh8Q6gbnovuY^V#zt zo@o~E`h(vdUVZy0^HPbS5=Emdu6K>!;9&OPI3NNbu31C*N`v}QG3P`O`=3sU7v4MD zwSvhTGwmfMH^|R$U$uc`chTiy8oL5tMUkn>Xb9#O4oz<2Vqp(=E+b~iLl-*^CqTA?oLMwH%E-z?^{?;=VwikUBZaT9B5Z~QQJGm8%gG$zfDio#(YxrlR zH8N6BTEbHUV3n<$?pmcEPJeg50dv3*A3Z3?Ak7R5;xzd`OZ!w!>0ai|6}AuN>5vt| z{`KrLcvPR;-gfBm!Yw)8U%07nTVpq9cYto84U1=5&M12Vqx&B`6vnANRYI>zJkE?g z6S5LtrZiqQ`WvDqwaq}c?OuJ6JsEd;dW6*HtA+UQN-4YABbuS!M8Hc!P;#k3jt_UA zwP(Fl?xF;j@riO*;te56g<}exX62CY$SoEZPD4tkk>DH)5?@{N^Oh=-|65nHE~JE1 z;H@i!#c*0rS+I`TuB>IF^_foqJ0Yh@q|`cg-&OU2&#tJgui~zdr)+k&Mi@%t6_*ig z_Y;+4Y?LIx32EryNaZx<{krt9+@}qW@@nr6l}X7n|JGe-3nZ$jcE)E3IG1rE0LWd1 ze@%i8{2L^n8pJ)k8lbFgV+26GM$!vhli9ypYTxW5qp$GPokNate3si$^ODssLt=#gt~+eQ z@Nkm%v0vzc0V+M1aCJa`q!p$W)M6EQvxK&z0HZ#?S7&oTxMdPN@ouHp?W)cz#{%!0 zR^B2`ai1b((f|cc50su$qW}G?z+;*nGHj@EbW9PYW7$FuuNd3nq1`3*{%u+&{+4`ZA~!QNfHk43F>M@BaBzp%I-F z5Vnj5?wKa5V!z1?AOM>WaTnIZKL8#i-M*AuZsa=bzp88Z7vO?!x|=!dd?=|m^u=ZN zdGEu?y<7o--tv<)2ej9R3V$V-{ja9nCf3Rmi!pH7pKpq3mnrg^_`<~~|E@^<=ma%x z0p&C$Mt0a)7C$DtTb1>bXoEK%5~wg50G9uJqWlm`*qH)X`I8ubnW}^t(^Yh!=B1zV zq(`Be%K{Kdf{P?^V-?>G=Lqt&hjzE1hVc+bbC>m6Czxw5k*un$fVw*PXh}du$r4M{ zyRAJ|L-9i!M&~#uf!xO#{+r7C<|9l~=tx^T#d-05=_CDRX9qpsXO{jdq6~W7-cR%f zko@buPVXNtc2--L8X2AG*3NO@`NI0o;D2>^xoMOr_|nfP4t}Atg;g|qaVp!%Dt{o% zRg;VW$ap4`N9rS9i%Y-QIGZ{C(EvTEi&N6{b~i=Ft4d-X7K4HG2=w&NpTj`PFJ#FA zS*sj9ZVOwONbISq6^5#6QLWa z2aD6&UQ7y$R6!a?)*sPOg=4bEL#+zZ1hx<5{Ei+I zdKeiJn1D3t0<1Zc-zF5P;m~eMdjvV?J1p~x6mcZU0JcqhZv^n1zfdt zatH~+&p^t0jWN2}B)zS$biqb3gL?c_1ELYST~(}0KUd}=(Z=Bd;{viFZRh8G61uAd za@bdBHWmkC0P%eLq=r6B8AP*6Ppk|#WQbvxR9PFSoc5c6rC~;1x{qCxNw^|w94;>K znta8qHl&Yq|Dt^#gu!ewR>L%fI!klT;xPT_&P;cTD z4lw~ulm`G@a&jCAck1 zKre$=9Key(p@ho>@LI~Ib8&_RJs?F!Ur6xX(>n&b{o!BZG9i#0AN9SS+FW178O1_h zemFE^GztiSSe69!PM%+)HKYr$>~A^@@5RZz4--b@Mi;2lwHq4nkR#G^w0Vcu^RvC0 zcG(7QS?%)#p|hmG{cQ;(5%D5tASKl$&J6Bu9@udX2lE@?%!-%o1x=!q8sYn1qFDT{ zTP;|F&(aHtq9KP6C0RxpBm5=jNa8#Avt}1o?4TK>=;@W5$}fCzna=N9i&bAwhIekk zZ%#F$M||h(q9^`mFDN2mD4PziI|&_9A64It2;&(>CEabS4-j;OgB3Wp9@EX4daY*% zr7xCKYWxHQQKV31-j-6mT5*TBdD>t4FI?Gcb$jrdjjn)!%k zMx<&of+CcWE0MUjhnT7S=I_Ai{moVDreYhboKc{`?|pqv-UCCJLY;#6ui@4oJfdb3 zwDud!8*s;=YNaYj%hh5->Fz`00J|!3R4bz$&2m*IF*iqtd)i!`?$Ax5LJHM8-EBg^ zA!xIgzmy#QicnnbV@18XQObjR4zNC*?8zL*B-fjLPz2W}_);EGT;~HTqFhigQ27)F z@G!0tKs6EOiq>|B0(f^5TqlS1FOCLf1I;^*j%<&_TE&ZLH>!XDGG~PXiWo;~0c1>Q zE-_X-*{9@iUkU7sgXR2vk?I&h4t;-~&N7NIG1?gN$8g>?V)(x&q+n86 zt62iyb#cOzeKR2)W&cQ5_}oYuIGFLrv34-<7RzGFHwf~1?{jELrW3w$t&Xm1= zvhmaIZrLbsiYB(FFf&u3;dn&%#bqc0RtYiwui9j!AD_;XVQ;=pi|y+!NwP>lEuYzy z;7QOu%i;w%xyqd{j8)6?-sRKM1EzHulJEj1b8dK~i+e6rVlg7e85{8xpRYH>ouhib z{^+iEM5s_}RDcOu2Lb57Q>|<%)Eim)bf@v?^c!KZj&RA1Y|~QW;dYN8wur%5JMYZH z6m;Yst5?ogb)EK4v^-F&>m=d4Hn>SK_b99lu|On`ed5?mRxNdJU=Xa9@-MoHW+q#v zO6O_v#11i8WK?IrcRMx5q#7MYJfdvx45h``lnOCV=^kTxS=7!b%#2nv+d_eA$`n?6 z#9D0O*u<@I7L|1{S@CU|DC^=iM0*m@Av ze=$`+Wi#hQk8WO#sMt1r+jbN~AbHh)5iYcl({(+2zYfnO`bnl4P6GnY}d6viB zlwHe^0CZoHY_Q(-P1>r8lv$AnT#zHm)3E?;`Jfn1WH(SA5?t5RfmIsD2Op3D*g#C@ zHfuwHU!teROQt8XfeCwC;Q^5e;x{u1Wajy%flr$k18uNIQ5%2g>98M_dlMh%7^I18 zpctdaTHh>AR&0u0?o609R{&Z4m!U+DmE9>}fLhJY0?|IqkwUw^fs8lNYOaDO!m9X@ zruQcWvqeg<>$2EcjnzvVHcLJKSgBVD`vUjN0E`__wshHhW4ECRqg>n0b4x^yPwyrNDf99e_QVbP zq&dyF;+x7f*N>3r|5j>bcpyYZkKqT_do|BKp;AG9u5(TM{s_0)N0`4&F7MN>bXMUA z<0H6x>i7@d*M8(coG+Nn>edou@{#s|72dDblW1Mnt@bcU0esN5G6Q#=i_pb!yZ{kd@n zlQz0kDqLwO=Ot9y|9JkWf~tC=j#}C*p8++YRG_u5n&?w^F%cY}h9$mmy_@&OUv|@V za=L(eoAj$c89(p+t=_rkhN28tL~k-#?deBrZD~dvb7y3q{OCy`{l z%sT!IfXey`URU!DBZ8nW_w683Y;?Gpf}lkEgK?M`TGUf_ z?Ri^nC2>DyVn4A=)DcEM(866?&!``T6)e|K1iwb*H05ep$OIBdPf7&aQH|8c<_j@t zlZm{24gYs=MLwqvSHMt;r?h;~U%o-ElF(>=G>|?dSCf=@iDu@*2xvpLZ#1m|IW2Y8f8fUOVLNW063eP*c?;u5$1o2+y@N9(FVxJ zw4($Kj2b_?Q}vr(H`0+@-w?Odr(zmpF;Ydf?5*svA&Qe@gS(Fr5@5y_nLfNX1%^sW z>Wl-I;-X%^04Q^&DN)5d(ZM%V)QH5;d1XlTL&iXTQK2s|sLC3;=f90HI8WFzoC)qF z41v$~_lCi0u$7KHC!cqicFZk-S14ruv>=X48O5f0$GQIHGQWs{4C*kx$IEjou>9jF z!c5Vg^%|E{+43iC7H#gtM;q1fb78ucqIJxh`ldDJy5!!N6~q6(01BYQnve7r%5}E! z9(|ItsE>Up5`S4Q`y7&82Y8UiM)t*;sq+p*r@!AyVjxz!O;{{@bSf)gahuMb?j*Be2Pv% zAhf9Z9@JPEtF5U$g{fNugI3!lY&WyMeV}hzjhDw}U!IZQvET$UovtpT=dU3&s_n1P zSdApML{-+PxSdG6X+CDp`g6xk3iJF3-Jo+j94^-r?_f=$jtv5#&w}0cuoL&nFeIz0 zhL(2;7BXu?uxG_U2q{8&MuM~m_qigq>%uEcMME^bgD_L1Ib6Bf3Us(o=%^ZD$PrQJ z>j__VITO*B#RZ_VhZ45jS{g_`9LxtsJf*1@G8esRcB55Ua=C^IxA77m2Oo+lx3?v#xqWdb4Rv22^;;THaZ%L90{kq_I16;V97e zL8}8UCB`lD_+F*D)H+yDHZ1MQ$2oLbgqD#OmF3Ve*4T>(rQ@x#cSlGR%VFaDhLCKU z6_77=IA96{2!vQOHW9YAm1q+JCcG*0SFc*u%7o}s5xNv0dSbhFYyXM+7}RNMGF{6VlfO~H($({YX48iFGei(H zX_wpMP#r8&1#II%&~XgDFLZNWKhU^N5}${1=uW`S67*(QOM+p-oS8a}F0pS`jM4z8 z=s}-c$AngWHP5G6F9J5fe_?oOG7r3w#A8KXRHZcd|^2-SziNG z(wh<>4NDT5={Em|hLCVV37ZQqPFGB2Q_O~oAa+&cbC22!ubRo=ZgR?x z>-W#Z(K=NE9qF3F3G2TL^8=@NvklgLU9`@dZ`MBqmJ_d;SenVqODn{+~46 zoJ>(xn8=8GHM^Oj{cmW9jW=)uf*Vkw_eGj`TaA^WN}`L^X*-<)9Htn$M>~3o;CS+f`ea_Ruk=FE$db{7Z*hui#x4X zh{aHFaQU;EV({>#vVAmJ@9~>YJ$M6hu%PY4^jZoAdm(xFCP=#bjRwi~V~?Cp>LMFS zXr15bHOhN!CEzG9t9RC95U|e#L1acgkg&-9dhEuSQAeo5^ENHmn)G$5>R+nLS7C-d z)=A~F`!@y`u(54hnozJ|G&@?Z;Ls+1vLcl>k+&>;MW)y_y2bAL;MB7^no(Z%jcQ`% z5FPi(AY1G)B~^!6xsD^*>RmkYXkR?(@CMpdaXvb+Y6S}RGuw#dC7bbnBu!(5GS;w3)Y+0Q%B7M>i?#<)IiCY|F$Df1KEQBHAFV!Id^aLEq=k{s&CR0 zlswPo+Nlsqop^XEF_}BFk@$QBaIBz$2ill>Z~q^o52hl7YFd(>W@-U{D=><(fcA%! zurrAfPnK67@hP0eV>W)(K#Q{OJCG9t67;rJSbEYevv41Hk~<`=h~2MM}Zqb;Hx*zrs&YHm!(D4dx4860rDz4unN;{g zHb1nX#m4!P*~ZL+yf(nJ*^f-h_E!!-3uWFo@=18);|f&LSktk38i8!CU>BE!{?oo_ zLWBQHTfmXE-K!AVV^r_DQ$hHrek<&FYAf{Jz@VZX5+HHOF^{!1nd9K=`2`uveoY#s zoBHC-mW~mCMq*>9V(>N^JTHHfkMmw~GQR5;P^ibN5i^*dZCmXh$&EvF1|A&M|UV*P>W`zQ^z2*GZT%?!0b3vXZzsN`V)2(8Laps*tQ|q_r+>=(pQxvDSO#lEMPu5u?bu+W< z_sAMC_!i`$oxptz@hxv3Eg!M0hL8k-ZXHsGy3eOP+{!hZ7n0Z=xi&PUQe^ED)94>H zF-|jDfp}$Yi5{e}djn|q^*a(Sh55DMH*I2aV_&m8@zs|26M%1-T9!@R(Q2!_5WXm3 z6IV1n!^gRdAhk0X`g9ubI~xIf%gq<8aWE4}K566>UKa#^al=LNYW=#1^)Ngj#*;H> z(~%C{7anbCiJHN|CVs(mG&pz5Pap%N+wMEyf}#JH1IXx5<8;x)8Sc}ClMpl}m&ZJ%h5rYZ5XScROVktXjWZt<76 z_{=Qj{$)z;U^*~EA>d_M($Fd#BU*qYV!__g zDNJ4)IUTj|n8_hwr5vN4I=aORoGGVcF{t{q}*;mUR3fz0P^^`=qn1)d>R zsXWEtl44Uk?faJUqjc2ob{8L_bHY9_}i~)d{2cpV>2Gvarrb}{T zDZv{1V^1fHhDwmiC^(J@4(P$gmR9FmVb4I7HjB-^>hiR?rWREvPY|d@YLAI@eEfRkd*caBfjqWb$= z19i+*tfOG_j04lMoq55}f$3&QpVsQU}zXZx(+O zK6kohe75wQ6!6r@VM0f`%!VTJIG8|2oBSz<@YVdT-~uRa4L(vv*9sLQi9Kp z`N#79i{u|r2rIg*=ko7@0e(#OYdjdfcj+5%byT@(bI19BdeS-dhkYaTcW_p4HU#D( zn?0bnvE8vOI=E7ysq1XQXEZ(ziPMrjBGy8-aBRchqepjG&zhPv5f;i=u8|>2fBSOC z7rll0St~M$KIcVuc~%hmT@3L(IA9@`f4lw+CGLPH_$YGA)tjYJN!k*SNbZ}oz#bim<1bbT*4yFiO z;1Sh<>H?`xr`D^rJsYX=< z=~9Tno84wT{|_vLa@*Pd#6NXr(lN?eUGzs)1Ub7GnNcvQ1am(db!5)p3}r5{zlHe+ zlf)h%QT2Iu%4_;jP*ribnsz90RS6MXw z_iVerE#+dwGswWMSk$T9R%1d#0;J99_;QU8BgUd$9;SOP23GaMP2~#|ISTe55 zKS?RFjZE`e_JtHuJRfyz89U8WU=}+a+67DK7btVao@>r%zFt|>>ZWdD-XW*152qg# zNb$|aoHU`l>n7H7E*Gu^Os)>glbucYQiHNcP6^HY0K)c8#ltY20C*{nnM5yx4q>>k zd)eW;C-~IHk5l#$!~Ks1SKSv1w6oVRd!nrQ(1@QXDd}Sy)i&y@4pZP;)+FZec`VP?%LWn5)d=a2q(Qj|)v@+@ug7NMVk)-QRK`a1EJqb4 zkWzyUPs1Qdb?LP3aZz{+}t2{GF zMtuHQzxlRs8e#FCGnj~ViBa_9xi37#8-CHxrQ@9Ym|}7#PV?ExF&%gKhJTOf^sv`%^ z2k-&Oxb0z@hV7i`wwQ+FT1**`YV`h=wZ=n3)SQ=%J# zdo~Z#L>Xl7_&}8b0&9DbE`_ziq%meQORiBxOtiE=2Cj&0JLS)$NhdnJKuFk&_@G%D zmvGZg=K%vf3^Uz@k+Rp;ToeCZ#|;;aVRDI4FbH7tn>r0r8Hd{)f1>*t>Gd{ncUtia zCtcuA#;r1mhCq+Zv;1WNNZW-5i|LTOKdb6bHxladIPd|st4XMapT)ExiYf+J@NLg+{NMfCiTyd}d z4ms=`ROY)%ngCkjqca6IselC3-66T96KDI5d6!$(418U5=r_#$b$im4kmQ_5k$sfIw5hj_))45kKyg$Smn$+_~iIY5hM6snuqd@uleu;rC! zu1U58BUkZxQi|yH+SpdX$Pt}n&P-&Aj{E^avf!z0*s(?0BOnmU#;zHG;C&^y%Z`>KT+jI>4euLuVpw)A@P4;tI zx5kW7wg)x$e2G0iyFlGYLkM?5PEFTL8rzlI^>$Hjz+z1o#@~Bo1OMavn9Bc7WgwP! z2|D}teW$KGkzTQ?2NKM{(a~vx3Z-Up9uboY1ypcMbNZtMm`@1fRY!Tx2}KD`I&Y{c zvQ%khsEDw^f7T{`Yq@8yXq?X`e%#zV3S{ikt9nq9j~h>yF2Rs!GQcl+@%0n@h%S7y zS2`lWr4Y2Dw1(s$Hk}?p{~%0iT3!@V1B!V``#%G9!&b)Aw@wK?B($NHbJQ9a+)*%6 zGnO&;WJk!X9=cc^vu#4s#tm;Y3P2fe;1M84UZ~MXg*gI~{jpfr7;;FR=3m4kkIcxQDHQ5tv;MjZ%UP@ZzRj7?U`>+@NyjHIbtqvS3C5&~(#c(O46 zKPjdXF|@mxP7sarPe4;1?j=Zho%E`Wmrx`e+1=I^aYsnpsrEAHZYDbsLo7KLITlx7 z(Tv?!n_~aEpHQ14WaS_y+QX6XsS(3fDBxO8$?*Su0 z^3Y*GYJ3DhaTwisv#8oq08Bi9zJH%usBtllLqX}^3J;-yh_u{)9;aLB>kRrIVuj2@VZJv5!f{Y9D11ZK zt$@Jv%~EMtt-q}(cm5rt=|GhC_ptWL0+se@sZn+Wdmy}bVeYUuk+dThtXfw%7d1Nc z66NlU_E=POE26l49h;jEL4V;m075P&x*%*OZytRZ_w>{_!Zf}PXjnZ<+~5u8UaE<> zSG&&$Ze!hmVZAnPmrOZaN$pvIOjk&QubUIH?1<5^DbL<-q`~=zN^uGfa*tW{m_5kg zW0?eeb{E1s`Mf=L@r#N4xS8;tk4FCX8;BkUTlFm)A``%EJa@T{Wg2b59z-q7dLcF8 zzdswL{-D_#fYOZDT_w}sn+%uAs5QL$i*79y$hfC+b+2ss&M;o{!pg}vtbEp8`1WY4 zs9J?toDNl;jyQY8q~#>kEm|0GU$5$K%(6K>nvX#Dl%3s65lI${PNWeaWUQf!_Fvn8 zNs^GuG$ci{UUkf?Kvcz5pkdikhQ=pI<^TBBB2&lu}z9+-ku=zyD@v) z+MY*}u} zekNqP^>|5>=lV$ZIPQT3|yoySUiFYfA-}2y)FQwRZKG&Wrlx<<4(oy zxFyl9pi9~R%%Dn3?uWJdW^{Xx=_*NnH{YZ!z}RNpZM&tP3g&79_)0E!Z5xw_m?tw5 z`a_;Qml#ou?2m=yB#K7f8p&dHne-_mOAyJJ~DZPsExp+b@BF5 z5BtsmZy}01OOarjY0BkePOm2Z3}1CpQugDgZVHl4WTRh{z5#JoWmydIWb3N7Mrql_ z4i^fe^mm-^DVf9eztRzGhxzb#xt1!R_VuoY0fX5v06`TW_Rl-Pgqq{N|4t`zd+!LsOqj4DT$S2CGs z4FIhD5gD|DA?|s42(wg<^ss;oKXJ<0m#}`DjEZsgU(0C)1cW^2IoMCfUoK z%j4bGjHlC*WFxQoAzO$N)q0xi{6fj$PPfz0f@op$Q53CA!;d_HhV&gkclde=&DZfh z8R#4Kszc1}XUeH7QshbDs7H?j@%97cBF!Ucv%c#|5_%>rmAd-6=}Qs>-$1Bl6g@_B z^JcY>-)Y9NE0$)U1*Z@wjxA(>=>~C}8HG_s#gJ$2b8}I@3PC$dHK0wiO*Le$ZVjiaZn{HAi1wF$azM4szR8agEI6QxMXego^`wi&O-!S~d2E)lV+Obrr??YNd*Sch= z_Z+Vgt~};EmKa7`&CEt-TA-qKH(KanmBt=xn+X!YlJ+n%!T-d-TF3@w@Wzn*tJp3k zE4Y_<>11$i<4@fY*-_mX8=%D7Yh`gghk#*~_r|``V(Jd$Mi@y)Jod}2Q1&(5o>#54 z`a=rK_<{-E7~T_-0$&imta2-Qy7rUdC{+f z8+VBX9rpVhb{izyU#MWNho4jr*P+ee36&^edUfZjcYOTd7uXtIBI(|@R8m;DKhJ_z z5e?P|W>8k(W56V*{Nv;Jk3}i!53i$3M{9C7vSW_X&SX#ml_yxC zt7OMDD;miQzhcBTpNXW3$i3iv+?oaaFCA1359b{pY0S{<6G=WUYEK)|$g#wMFf8-6 z`&ljT-j=ND|2f*^t>m$HquDr{BR+6-+{N&kE4vnatwwbdo0YNLmc6na%l8wzWw>dx z|FG&za(ooo@o4y)VnY%awH3+V8RAYh*iiuKd525`*r~NbLT97PBKM%;_b32u?z(!If% zU>(LI1Xq~Xc)@ZL6h!Rowe-b{AJ ze@fA^X;XRc!I=@M!d0!#c9f=or3VP-s* zr+Xte>xs$N3j&YH+6pzv+kY?n7ZO5)tEOHup3(h7Qu=!r8exo=*`(he2W#g1Hp z{uyEBb!+qPFmDN9PJOT}KRgxQBZ?%FET*Fzv8%Xt z`aZ`Go)vWw@<5X5DgG&rS2fH*wt;GJM$vki6y9St7os$+wa|poT%WPlEw^V?S-+$t z^@2na{&2txHwD;w(lLjc1~V(vdQdRApJ-^ip=6mRqm4QKwGCJ86$y-(5QVl{m}mmimOY{u3e^C zVTjvd6pp|I`bho1-MBqQ>!epB{XFO({au$eo$=fj!#F782spHfI4B^Qk4iDp%4|Hd zA0^13KjYt^tKh2BO#2NDpy>Xfay}dFs|srOeRI0-0VV&<>Eic!nnqL>k5w`8S7?eu z3HTAI(9}!i>)=~yy7$D3iFB#y4x@W+xxQd@_77efmvx7kOz78HZF9qs2#sRbWghAY zj4wuu^z)v?Ux)$a0CL$pQmgIVWfjbCnfP`-DgMKt)+6wc7f+jS!MtUI|Bq(5uo`Iz zLn<@5O)6|diz5Ks2T>#P=e6NE6KS)JrkvR{O!d0e`a)l7t3;Qemty8U0?#7QjRJZ- zn<0TNuq(u?%jJo^RDVohE{on=3kA`aDAnr&2t`tPq(W$r0q-)ET7hN z5Nh|@J-R;gw2A3$7yFTR4logair4P;_|KlIZ9h+t2b_PfB{ zo;Zl(W%!etJm=xm)oo1AwqHaat&3_%OX%jP+eakE6;m$jhhlEX>5W^z(TcsfhzVr8%Bm}zJ z9lO;XT};a<75CH|-OB6IU2!tQff>u@l1q?<;>>8W{s?H$2D%XTP2q0>0c3G%aoIU& zQLlxvGMqr99*aaQFS12mRYe1ALWP3;x%<@rT;%?v31!g>%h7y6r?M%XN9gJx8qT`9 zojSe6u238mW%GAqbwEd9NR&em%z*38TPIgppa-FzKniMh=7f)2?=<#my(;J7?XORd z<Id4=|Rh{4pRBjhR44A$^|Z#@QE*zeK`hgaEJd3+hu$p9ie4jeHfUF9$gaH`ITN=80)WP60R`s-9U3=7KqRodKh$s{ z2j23(M&`h*yH5wMt}qNa$gOmmN0WBO#AVM?w?}5YiEvk2a`m%-r^nFf9sh!dk@?Wc)`*dt(+#U~iMv`t zFRE#2F{C@`aM(M>0O@~>$S#Q2v@J8+R8kQ7{64BfDNbD{LhuDz{zX#%Ftz_U7Z|&C zJ?$}wcX!%Ai#TTDS(3yQpK&Jq(3WI28(y=f7=8$-+nX=gGDRbuW-^~m3&jRbm7NZD z3l9sI0O}&Vj;-DAb|yeeo%}hW8SzIdgNFmv@gy95>=_X{Hp}t_nw>8kfUoUosJ(d<_0h!>6=IUZkNHi|*MZey30&|wO)lWcM+Ms-g`8XA9@xJk1-nwkG1;nsFH*tqm^ zr2ttf$mC%U(W$#aBRV9vr;7tQ4+_^(A>BTuOe3rJ1z15ZQM4xHzTx|uv{+w!*@m^U zbjs`L(|#3MQQmlUqna9=mI-=a?xqkUJHN_UxikJkk|Af4D&Lr(BC*IV@P?g6fIQjj zPTc(F;%ggGPQGl$!!Lpc5rq`p;e{7YKzjT0GZBYuksiNA%n0^QhTF09g zocYX=%E}F>gxcj5jnt$}b-)7YpRVTDTq)gz^X#1wwQC@c=Wbp!S{OoQ8W7PL8o|F= z%+yiyT+s6;-DubVT*e|hRZ^FEepmq8sPU)&JOHuM5fli|mrBv8q+fx|h9+lDSUpaG z|K%al$MV>9a^dQ=fh5=gJT-JYjwA9C(%%fz0Rw!95Jt(RVt1lr>ZN6;V89bq{T}qm z3DfOMirONtr^R-GbWzS4^WnsG7F>9+vh^D)ytfo`6jQUp0VqwNvrvyiR7Fdff;Ghu zoIOUQcfF7RS+E{r43h^XDyn;Sn>(^BG7hg&ZkN=%e%1*(K0KNF0iob=fjO3x?J)Vp z%t23Bgx#*3Ijna(v?9y8YIHd{agshh_Zth|_N@^NXnQ0D?O3#z2~*Y37>x*7M{P`4 z+Q@)AzNT*1lVSKHi}?-$ID0(wYaOZ{2U{okV1~q->@UtEo7EQj05L$$zmP7-HB}@u ztiT?8#jX(ES5dvBjq`g4_u|QoHtiq0)++_awNJ!7c20H>6_uQnx)|eHi(og-@Cz%n zgEE<@Cm^!%cwVXO?GbhrK({c5!I55{ZqA&lO;qes7J3LuVque}Mx0I}bnv<3n`7bP z+7;oOFx=97=n8MeK5)N(Jj|pwsYB7Y{8Vo33ZUYIe&LNLMLQ&!n0Ff+o1?^NRM+~W z-(p8gi@Xw*2Oz3B^-d6<5T)X`BqH;*wE;XEd2DZjkbCcWYG*wo%TcKo?1+M-6>NNF zM?)`ARJxhtpRm4i<|ENlhtc2Y-vIndTv03h$QBDafzkG4dQOlDX+HG1$XT1@;cM$# z5aF=WR@-nmIn74uw^iAe+jsZwsSFo*zQmgFz8Zpj8C#mC#;h;?~BFy$!xe zQ?5?^$cow7EV=t+e4$o2{)ZDD4P;hYMj0Rzziu2v!B{i|!WzGljmX&IHBIwVPNjaQ zKg4yi*e3%UjEtD`q{eD2mMOvirO0sqSt=4cdSz*b)>s({*g-u(ENIyf5}~@Qt24gi z4-=p=lSkKb8mmlkk78F`C5F?U6pF32-dCn4U(x8FDKa-JuKUk-lh~9wx+P~%<-gJA zijZ2bGPkp%6UlCsz)kXW0H0ZS7BNUCs1d}Sic`tG^N{$?j1orSb5Ussa<8N&iSNk9 zjq2U!prH?8W+-~pI)&UoJC?j^uNsUNH=BkIZQnCx`4T|AQ``Ulwo;ow#>P+v4il8r zEb@!XN$m;M^SR0ZTBEZA;-Sd{Nt=SJaj`p^wUjY=1M0ArCHLKG<_rU~qWP^~J{eCr z4N`$b_?$@8HSckR2RXveINZ?o22q&5(R|X*lt4ST7{fXmZR|!;uEr3p2huS`(HjO= z*{yKTfC?~jrin%*Z%#UO$A_vflpfGG>Gh`MP@(9QNY6(jg=SB=!o8&Pe{ z9p#RfeKJ;+%K+~Q8K?ht_fq8Ji(&c1XdO*7EqRVs2oo%|!)9!H0rPnic=QTpFxHdN zf70L&L=}^2{}QQhc1Otg{;s%wZ6W=kEaeAzOdH<64VjT(;DUpt!|bW3H;a@!(OZ z1|bmMGFZEZ58ukcH+Xb6kH)^Wt&QQl0~S*>X#Oy5_TB%}hf0*>3ykg7nnWn84Xzx0=BlgWa5WiJF-qSvlfp zNhyry$BNk@rhw=uGq=RUK<>DU9t>gN$F;R-eI02VToy0&~K2JfK1`U381 zKxgFFlJt(edb}|oH!G71U$P|7`s$l(ulp*jjp|u@{H#bXw0TZfj@%2)LApC#@~FS; zE`O3Fe+5W;o!`Y5E{<71EMbCV0zQokPt*0VyF~vzQc-ku0t;V%Wma;jPihk3 zAsw|$niOT)CDDq=h}$k!m@up*%aOsJLPvoIjc|>$e3X40YMqGO?;S>;vmtFY!iU zF005U0sld0BX&R;8njgH_Yv|-o|Q|QHo_-oHnQ4k08~8OXj(*Z@Ym@tCoi7ZUwgqg z@@syCF9ML5Ovep_&P51?cG#IBVr!dHEPLp{3Y5I8O0Ihnn2gnNb25be48Ml>{CAsU z|G)Y$tSKKVyu-}xj)@Xr)Tc7Y)Vez8H6gg{qRh-D(oL!$s~Q5W_WvlRu+9kn15uXL z^#5`(LFv(P29!!wA9UwE0nCF!u#NF@$>6$t<Re_5W3xZVg!mW$#!=`v^Gy#aVHjjBq;x+%WhwiFwj@t^NJGY!J#G7{q!2$MLR50uvlQ6Yb|}BFjtW8m@uOoc$vu*0Ik}%FtZ0CY@o>_|zejXwcjyIR`yh zvb1)71d6^R`|62*-!qZd_-0eq7C5>WxEIOm4G~&GocBGsAGgove!JI0y$KF)3=tmR z2QNoF5U3XaKSzInYb#PoEo<}F@J|e|y5zwopAH7oUfp!Lh{?}2x^8UleE(~{Qie9w zzf2>z&2ozPzGYEDr8XQ7&qwH%rG|oz%Z0nov^OcN!37+Hg5XKr*WgcX1}jIa zziKRs#6-rEaoxAM^6tak9N8gG zgT^fC^LT5Yl|UYvb+KwpFue+VnYkK(&zzVZpeBurj?K2kEX20O1u z)r|-x*|OFKAajv5sF!=SAl(Fyq>jI_;~E`y6_#Dg$C5Di4AeS(aTFnSDe%EVKDSsl zk;0?b^_$uSBB0yhqaT#MX)%)BEje?{6?l8AbwZo zT7k5Bo0T!UAkV-Jk9N?bAD`nN2Rt^V>`0y}#P8T>rUQc+4*y<2bisdME6gZX!^6qH z=zgKUMknR65XZOOVhBpF$xJ!1Nx3%ZNqdvUYq<(qh>UVAkONVVR6`-qiYfa0zbcEx zEHZaObj@~G$tcyd66|7nh}ecgkh}Egdg!bR6(E73xU~u+wjhYBks^dMhoQ-^N9`1g z^BrN+pWu?u%2ayM#hujh-_u0EAsyH9aKmANQ|iTsSHG{Bq8~!0o7BaUtCB)zBNn&- zf=YcTc4FOS4)L|-tnQ*8Y5X6&RK=EqYxF92LJ^wMrm6PEO&cIbQZ_aG)1^S#@&(d{ z>wTJ70M0EwE)$p#0IlsfduBtvssHPSdsq9_G`4m{)n-&zw}h*L=fHxGNVAI~9j(Ax z*qaN(({9M+s9FRHp_~8Xq++nhSgYT;I3pL5Ax4j*sA9CCzCD_Qdi)-2e_`dYV|3}4 zBBod38m1k;UwvnuWL&)elWPGu%0DF0hF^m#ZW^|$7?r$=u!Ic$BJ#by;B?kS$CNs-TvNLFFvj_LWeR_2y78Qv_jA&YVQ93k0qIDszap}E2G-{3U z%_|>tHfIS*ZI;eTzdaXQvr=M*a)q}GRgIjj+`G}mVFjL`e4N8!rG94+OjgB{Vo+1S zuxhP0d;*U?b`Js5t?L7vWV2M1d z)#$dnsMx$Ry!kvG=u7bPTGklUFdq6A&RPEAK|WZoZ+OL2tZdhgHN}e#w{4!T7VFGuQRNpvA@@}waUez=L{SZ7Gb?i%5+qt1KX0;c z86~Fk(5;T;sv1Hi)SeJ-Q-O?EtrAl4)$O78H?p4tz<6BQ60#z^aJI2bn8h>0ll?9j zHG~rUDEyDlLJG>iAzGc24k-v05rn)$mxUcrEgOF{VU9KeJI@)kxui0x>nMf4r)ShD^ znbxfN8whA5F!302gAdTp z46I<%Qiib{^n9R6K-B=ZRM#Og_DMW1LTL@H4nxs!I+UEmI1z+Yd6Z3tU}X<%X5kc8 zU4%PRYBhavc!UCv;Z?+>Sxaew6yyv6p(Pe=!nR5|^nwF50U4yDQC@_U{es=XBnVOc zbr}|d$Vxa&J?E4#8kAD+L%(^VkVL*>LoZh@qMGU`hAq!~oC=&IQ0#ZUGkcT%JGDbv z$S7OWS5b(#s286cBlTv|w4An+XH$Gt3Lhf>D=-d~ku2W$^K3K!|HF}QZqa>Hw$cTK z)+?Jlln?mf{O9PiVif0xQ4u9(QG2t%6pE*|y!l@+OjXiMp(>Ek08~7g0_~cjf&3?w zqCH-YIfBXGe#@RF)0gsP>3^an25>W7j~fg-0pEU%e`IN@NxQsjVbHmRI$wvXfeM7C z=lY%jaI`KnTQ)G$%6pBRM%Y&|VQLof>VLCk^Vb_(ShgItLhcVV*$yDt36^=Jin1>? z=QI;(KCXDOV}Kn${aqNUo53^2iJW;GPQti|+!Ma44IlJQ0ensyClAOSjbI6P zYdQoF+%vIFUad3ZY>U8yU~#q#!!YkEb5GG>7a%oE@M~7fM-U_=-&#-74I=B(0J_GJ zyXm~h9b1@SdOFSn$JW5>bT}Quova&$KU-Q-vYvSX8BC_h`(7e&?^o<1CliA9SvZvn z5`j?M&=tDbW@QTDY6 zK;Ka{PP8y6E*v&`HNEvhQEoYGq*%-#EzEyf-4Bkz4IueO1FRi_mLKXwdLkrg@)W2x z?NPQ{HH~D;v-vEi7REsT?cT}Yoo`$1;PGZm0HTUAihrQUB^geYq8xcr9}2s;;`s(^ z?n2{C+sRxbnMF?}l>iT)SHnnlQH_JmAex9-a#>W9<7~J(Gxd|3mLz0A)M3)nV`ggP z0Ov$B*^G>A4lZ()L@2iZL>t7hT+?TXfOn+O#>1=?nRaH+LhJbDn9Mk$OvA3hIzx^N zvNY=im9~e22A_bdEY)xh_{*u8!H>_n?t`wxj#X7Ws5M*|tI>dI_UP&E+gdh8=xx9dECo3F#V9?stlVd2#}ww81oUY?Uc6QFeB$+ccKB~0mr9a9LF zH@!2BXH{;Jn)3~B;~;u@F???+;4N`xRIURJNZzk=ZBLmlhiD(-ZS$Qt@zS!_b71*M zS>nbkfqm8-;pC?Gky%t#*Z(Q+ zDuyZu{fIcNPtfCoq!H4#S|U=c_YmL+1zAhz-z5EE;)v=}>ypU=J7-4)M5cZhg;TB& z*C%BEtu(#7@TZ@*3^>gNQ*CQF<5XFsw=x2K;0X=FiV32#fMs@5w{HustVGMYRuYIA zQW9wNsOiu+ruDYJ66@h>K{PMHwWSro#4a>za@f0UUaDCAn1{k!@52 z!-x6B4_$)KmV|wow`zUFfF>EbaPi(YAdSwFpGv@GSapezmbHpwP1crVFlW(WOhwJT z&@Ik&Hl>6#WCj=@jb*#N_%*xy!ysexzy@=dWs(YiNXkx|+9^#xNOAt~rYoRoyLdZi zvx8Nme}3JIi9}dwY4NoD!D@4F+(6`7vKgy5>Bni>gZF7MlB+(tqt9>)K}+_!QjSH1 zR&Tj7>?rS7_O4_-GxQG-16L(yyHMFBkhWMk&X&Cc;*}VWZbt;e5}u^Olm|%7`LrZH_m(6uNvZpLq}?bQ+k9IUc8ObedtwyhkX)wYX}XX|_@) z&$SkscI*M-);&V? zzw~4T1qeKmr5gMS43C-ps_sXM`U~56M-Fd{- zKzIg0-uUuvDp5{P+cqu!-0#TkHYMGDDRx6C(MTr>VjC0!tHLnoebeW2gs8so7Z_g5 z-1OCD3qa}E6thtYn*Syn*bsr&e*ZgvRCzLy47dW;MYC-l0eAtJ-6ukws^aRK{f z0PU!OkM{gyk}`+BEvk65k>m3!kyP6S_#Ec?<86nVBb*WvX%weKg?8eCecLjMj-Pr&tJg9mDaa+lMp0WDJ@Q0zc^(gC^ z_%nX7CiG(tN`^Gvu5hAsV4Lk7$d^{KDr1@TF2=j%Sv78#0C+8Lfa} z%1IE3Q^2I2z!7E}(u5qDDtM;J4=*x)r2uMcRD=tS*%G=+){3djk5;bFTK1H+t@~wl zHSd2yWyV|}LXh3iIc^8)021i7(W#;Mt!ie4KE2?O3;Urj&x_F)OOGc#McP6Di`J!^ zg%-W*oTT`P$8&HHhg zK2E+@JomePZ#p|m$Yz73$B0d&%t{4j_RsMX^x=vTb!;wkw5@IxxC^|MOS|s$Z<9yd z=h%D2Z7j=hb?@2Dy1pC1vS0OLo9H66bM@glP@TntW#G{gurNo?l)%Cz{SdH!;=vGp zoZl4zJh|*8H;`+S55NN58cP>DSv8T4$@Az7)Gy3vO}{cY2)uPyy-s2t<2`T$EVNK~ zhY%aN+M#UBryjuejB>qKB+Kq+jZ0Jy_V_6r>|gP<0v3V+oLsZa)ILj!-h_4fBq@sj zYf2wRgDAF%o(!>5q#0W>FFMP$(sH%SxF#_BsN-cw3AF^zqT6=~j@vwzRZa>0Hp*C8 zmkioW)=*)q4jbj@VN88B*3yw?9qBzu7$@O#_DIHMam$>k?$n)V&CSHf!H;aQIB(F& zp>T|1Y7R7E4Q^HRtK~^gGc!ty7;;XXgLqMymZTooOtAb=)O;m%HYJVQ7-SbSfGXeD zJ_Hp-7CUzfYDfxb`M1140CP%=r|yxjbv~vlxotmxQsyNd^ZC?*Kg8H=MHa=rO+!3d zjo{f!{2r$P!XvPisr(gSv-40#Q`79w4^W3w8_0^HC9WAs_l^R<@W=D1_5Woa3*U4b zjeay5BilR6PM`qLv;Hio#c;h7W+`$YubbUTRAYu#Plbqfy~bc#T~kCMLs3an!?aSu zEdOWFk=b(&U0abQ`LXPr+ONIi%wj?fDhZ6CPB#4zmn+4n0 zLn-BDWL_%gR1E__OQmm#BWU+;4{u)>AV4XUV)x`)cRz2gZg&v&$B0TqsjOxmBV?Gv z$48wd0n4riO!#+2Hl6W*tkmz#A2T~v)tF<7JSf24;gz3BW){^uOIJ9lJ|U-wqkN|` zP{wF&4Y6Le^gn%v0C)*j*5?X4er@{{4(_UdF7iFY4GiPcKK}s5R>*D!M*vd)rw-j! zAJqFIh|@dn=`S5;k-nRjJdE3!xYRxt_h6I7oXTkt6QFBCtLQ71hvx-k>F+a4e+8Bw zfEB>l@2~@OZK0YQ8gAmvoHJtKTWIh`NS~$VbD}k-05WFH%K~ROkL@qDh^;js%sZ!N zrn+RG5wk$os=Yw}QhxdLzZhw?khX_pl}!o;Uf|G9%f( z*89rw90^k|z!C{k@u8zL{xBUbPK)Y7A<&-^^12;7U~}iYY&u`1;e6IfPd_pTK~#lm z_V3qosPozrnTl|rrEdhW6-r;U!$KbO;bi93Pa*S8{{CETa178J$dyUA74v$a1(}J-c4Ba<2?*btFMJ|~XZ{`am9<|@uV`^)p_bqWz zU$vy{MtMn+DhNXw(E*LwR0;`3MWdoB#rByie{q{#8&W^I{u6u(Q<&d#U1Oh$%BuJr zxjv9CiNjiEN66jAi<=hRVB?Ls)G6L&351S1&(GGEvQc5Li^8zXdFKU4Fc_my`H+1S zrAd0Xv=NN;(D_hrq>BiN9pnP2@hCaHRVABAi<6GR$aIT%lwx{^8EDPYx}eHdQZ{%NLIkXLmr+F5<$vsjFq+*imq) zr&nw1s1JlnMc1iU&;~A5PL|;*Me^EQimK%fYGjw(YHqR9s$0YYTuW~uAyY+{gB(AB z#ZXW3lpr_e;ycw2qMTy<2k?@$AE`Fdc1=++o};O3$`{*q3S8BSPmRz?dVH6`x3`oz z>ak7ef{`;RcF~LV7aax|A2Nr}7x$2ua0>Lr^l}TDUkunjqM;!K0y}Uya26N!g08cI zuf815jS))!fkMI&w|$FyfxEL?ut>!%tiuluXe1~jRJpZmvYRT%pMtt)I<8S_7gi4y zZ`Pht^xO+yFt*r9!Z{CwU(_ciWSkNvr&Z5s%Br8Dd&miP0QqP$96;>;pWEh^aQRw|{PZ$NH`6s5y3A3E;B{-{kos3zCa!O|&6$Oat5+G=HJ8r7 zfcbiRJgg1G6~;TLY6mvC9>$z9O+MT9>V?#`CL*3?50SI4sCh9YX32LKOFx?w2f#Vo zuFyZ{_Ag!a`&mhDyy$FX0+#ig+q><(=R#WTG@Cjymr-=HFcGO4WOemEGxl=KIN%C4 z3h;IjbOYw$2&H@35I2+?v%>%EYNOk8u#*NyUbL&?V_6~&o- zJ+6!H7yFeL7xMWi`uzJa$y(#ZIM?&>o07Ed28Ji!8;8As6W)1*KNXpjbt*5_?&PJ= zy#y0~48cXcGA4mj$m&N_b+X!PwACgsJoPdsa1&;5#u+ zH!oF5i5*Y~rZsEEx=KVU2J&_vI!XXzgTa7JLd8s=3Ff)WM>0H!R<;fzqdKy%G*GQ1 zqoSsR#MsW_=6*5r-2Syq^Gn@kiojN#q6xY7domsFCS}Q`FRD#ZXls-dqpDmMj7WkPxW{1 z#gUz=L@rFoC15rJT|#K3QY?%=wpbZ9lb94_Rh;c-MnB$ZC#4{D1pEb>v}-1^ew?G% zehgm!m08ZHX2vYMioq*p2yWUA(A;$<&_Pah9QN6|^!J@7qF{$BHAWOq`z5fdx1!ex zmnf;0+-%;>JV469y7>&lyoY69F5du|wES!^y|}zV_R>P8e)Hij-Bo%;c7sp-2$)32F)$Urst-D_6msZH5ezeo%k7n7Z;IkZKsetF4IjI z6E*9zhCssGZV`?mw+75qfSm$OKQ>Wg|nkt3oe}2`H3GeM2Zz;nfwVO$(R40X*QYSY5=xp za*?=M&oFdOFlndj;UEjLQl+#I#ijW?VEZg;Vc&CAfR7C4NaT!&UA*;`k`ILYrEJ(* zusSs{1E(N0drJ4d7@EqP=%h!`l8S5xC$?dTlRN#}{r1Lm+5;}}8&2Xc)XJUB(!*@|Q50?+!) zKEzT&jq{dd?Q$_WUY5`gG$VkgDK24Vz3>P1rF7k3(h1Odkm4e3D#8RCD&1OvQw*;$ z^cJxa0;8Csj?jcuB=mBAN_qAq+D{|wTCJNP%yI>UWyK?mLP{hJ=G!kYe_+n`=t^RW z#@X3q$3e)Jq-tV_@76P@zlpsktI3h$U03q2MvG1GI)h@ijl6(>4h7Dt9}8;V*#LMO z)-4xNH14(Vb*=rby7dII{D?)7;(m#PuN;>LhV3EQI;HkWFtXI`G8K>gg{|YrAuBq@ z+&|Ero`r?I))b?O4#()z(+`;sS^Dd;4L_cw_2AMKy2`_9uFB6UCHMdhIczpl`VP)= zDiBe#1RRlV0HZ=$V2#$@nLtC71zkuYN+Gc_)*xV%bHC1>bl-=-khUq%gp55vVhS%# zRsFFc^P7Z~q!FWfv>+pTKrPcf1fXhuDJsXKjGMLn2*XjOkUqi5Bz+TIUZXn}O@$TJ zDZIQi^yYXbYdVlxmj?jA2~yLoFydy;E!|Fmgoyi@C=WtcymZl+LWBEt0Xi@$%qhYL zGC{c#-C)gwqTCB1e!(a@DP6n|_BP7cK+m}gk4z~tOaUb(H_*2+VYaJLjQH%p;Mth+00U%kR6M|N>eQmy5=u?B^Eadz9CD79{ zF~J2Nw|vj9Tr5E>u^mAtp1!`_N=8xquhx3tt^S6Inqhog*QtoqHZ>*z$xSH!Lcpqu z26HfRJjh=O6m>~vnQO4NW&>PLbR(>^qK)NzdW>`f8GN%xG?taIH|@3I(JYyDv||oe zJgw#T9qp<1Pohy^wMnizB!(z$KH5&gXq*`CKJV_e^VqZ!+CwIzU&;Dqyc~_ydhfJ1 zMs;l~s;I&w4IZJaWIyrIdD4weqrWc8;01p+#9q2?-)iy0dhPmssKK}IqSxeogD&)t zyEFcr&`PHHe5E~a`ffk;bFqIRaaSJfda)e!V)=dYdHA_vsj~~Yg;J$QP(PClzJj1n zUqhim)>pEcLl<~!@d{BcPz7Cm)hU}}y3e2FMdD-8Ugx%1j!S~n2m;FLx;0LWwRg!E zx*kocS=C;t2`$By<0|sct{S8I>G`%6(Jp6Tl=}b4FbwQUu@@^U^maR3cACP^N>)vz zG$I32;b_gCv55?d<2sfV++EX>n6WG{&{g7iC=@Z3KesWX$Xxb(8CwMC|$$izPKYVmD?wGjj$Cd<1;VnqX zWk^ynL#x%&Mg57LD+%UT`X=nZ>7JT3_B2oO<|!za>}13wfuqQ8FFI5aE=~V6TP`i3 zBv_MY#7-?psFEp3W>vokvNg|8wUtl=RkHq?UN3#MN~nTktZ|{Sg*4Kl_en(dwZrks z;6KQawv$3JJ-y1ko;6v5T!ieLWWfg_H4Aa%Tm7j4I@kUqDXWnOz`Ix2UF%m8o|Oz@z9ng5%}&c85J4xSkbL&vqbg~4d!uofyAkLMivfPcdmBO`a@kf;h9j#uoUR<;Q=g&5FE>ZH0xI(dWyw z*j?aOj^zD=ckx&XQ^<9Ri~S8M+{wCv?>(>1mUN4B${A+3cM@{`Ik#iIngSrhX(6?V z#hn3Edr4_FaH1dh%p{1UX89}{jr{%m#Au(sSsVSEXC`W(9=C!SUs3C0 zhHBBc5A<$`@MB~DhAC&M8pBmKzFvMUN~03DW>9P?iwOiVLWkQaohOvRts?J}$+es7 zO;|37+}U@4hzwl8#Ho@b3*9l<-v1LUU}%2e7X^o-q^Obk1fsf;6n0?ttJg{b`p$xC z&$f2LzMTO;|8e>Yq)mvkFWnLN!Z5Ws?S%c1s8J^@obyNFRyXB_J7GIE_cti+1~fyV z!E8bqUNaTzZmK|GQ>nS})XAuaTsnKxyZ_*Xkxb26DSX+o(in69+%9yApt4RsWYtu< zzuwP@Y;wk2FfnmUXn`AB+Z5Qw`YzdK{oA z57!atArBHv)hoMsi!vm)%Q=)rQf}8moANp$(8MWByi}K%99@ouo6Y)euUd?%iI`CO z|GI`Y(ei{HjV>rz;z10(o`#n$zOk~X&dncMJmOu;{?pCF&l)edT=4>~9;ta|`qhE& zO9n3w4S21o2xS;|z&2(JXrHALn=_Dig#_sZnS2227)rr=IeEPRH7?+hN*o&;X@cU7 zQdlkB1}v{t7Ky!mD+$8AS)uG;(wkMmcNF133OC)J7{aWw2LC%&;1Zc>-BF#$19LX~ zSx)sRw8^F2=w$YhES1Yr0zG0}jyr8M25yXvKh8l`{1dje%YkE5>4nGC*V2^aV#+hE zFv!6)?qv5FK|~jAzM8eiFM_psfE<-)lmn?2WH=`p{CgHuMdAd<-G z%!Dh_Ic*f{*Q~pAdd4WewKj6U4JZ;f9)uAAxcB3DgMtbs6P0qH%CC>0*(b4xrIjyH z>aZafOoQ-~>B*-ON(!l>N3q`$ypO!g=aWA-XUAkb6IKO7wg4G>{jS=5VkomH$eO>m zJ-ui*B#dj};g?<2w++jQu_!%$Oj{kog}3< z3%4a^pPI4+FVIi;)m#zJP_?yN)7kc@w-C?Vj`fhB+-4&XvfUC83tRK-^7@{2q7uT? zl!jk{0l2@d6s>stSaO)yJ(QBZ!Z35aBUE>j6Sl;r;&6g<9rmDsCp$zdKl$wvoH2L14Dysijwm1+ zm3(>9m8lu%Cq^KxRzd1^vnB}7dsLpg>r}_nGTayUe-2VOGh`s?lltlm1y`NCkS-98 z^Bne$#RB#dHfNe_e)TM;%j`u41o8ehDTMVRTWC>uZ&1X#-Wg2KU981}d2!_DjN7xf ztSX7-`Cm8SluykJx-L6oAJL6C04RW(2*H@aNv0WLv();$p>kaL$%ni)1OBHku5CY?+JpQ=OY%k9&Q@woN`3+slG1ROq!x1E$U=o!wj_el(c$nt+ z!KL)@uBhq4#%!4wXX)sP1aPwszAx$seoO=F^FEuMi#5j^gr(~+#GO*?X^Tq&*z#F% zPVKvp9-$gdrUg&DLe$U$mMODdinkguP}gGr>5yg{|N3xj(WfS43>YteysURuqgOfb z%_Vd?Qt)dM9vdBj8&)qvpu{m+buWO8DotrMPg@(x$?^<++&jd;V<`D{aqh)TVcVHq z*Z9&>BacgH2SO?vbl8yt0?`LFHzIB97jU8Ld^466dsAVu>A4TA0YWPr=bZt>JA$;J z|9Ks##G9;CLWR|i`e)5lnTSv+?N|Su9krXPZ=D~P+u*{=mHPPxkReQ6%xbgKX6%*^m-g%+WW8a*_Cxhrexa$J3o>M5ky@(E#!WSAcVB@ZV@o(eK? zI>6Pbpt`GMd87|w7+Hu5hSah-`lfrN*96$h!FmP7mKi`-={X3OTaXzb*$5Fw)$-pP zs%QFVO(Ilod`{$RL+v6o!ER+Z3{K&+2(!!~{t0w|pN_Ohm@1_*E{D*_8c1!vnF(@j zVsVdQXd<53ryxO=!W?%e5ti|5y?6DnxTTm~3h_}-!4s4}hpf~K%Y_Ci%InF|$w95z z^1^Bm4gS4Qs3p@zt1{1pt_L%P5G~d4{hy-TZTcPz^-y>r1ttc}rS{JjW zFIBDN2hHz+hh=RXi{}*>r|r_O;)77>H0eZ|;o2pAUgdAf&o@5fUI-NUi(Ga3LilJl zVIzAGfes|0iI6JgD94j*1R``AeLXerqD*0R{7^Vz#)&J;5Sn9%C;@9w&Tv1`6)G`p z9k@q0aGNhQQ14znWOEJ~lOL=lGX0NBz2IiDe;MagXlQ8sM+Og~_|($3KOgGx`I0k4 zo^j+~`)kgM`VI%nECTHP=ZgCkRBM@C7n@pw;S`TorO!lF5CnT(Q8EEQv^aS@0=d{; zA%hpv95C@S_mqNHal7n3!@i75ldczC(gxYRM?aDwpm|$!}ceoV39R$t}#sT70bP^20d*gYFNeR!O&u1E|X$mW|71-n{h!Jp5M< zNnGiR4!qzVoHk@%)q#(n7}b_mg(DLvBN#=Wsxqyj{S48Q)BHzO0l>41)UJIwL!r?_ zB*654r^U|o$*Vy%XyZ5^Kt~_qZN*T7p=|APCZ!Z;US2SbR`^MlxddH{lMMT00Pwk~ ztRh&8SF(;Z8*3ORQ288izNZ$GVe7|4dMGDb_Kc_wQ2aew{(jMNnGQ*j(9Dqyg+ZWS zmNw7rlXby4+~^{R-inlCCxK?m%~L^X5k3V&t$4-vuaQ&u9if_h1ExBAt)}1)v*%%9 zwz$RR-FXr<6=K}=v55Q|a;|}(Fu=20ci>GT$SMo#lH@G1@$ezSz#m!tekCHJ%;T~+ zQ|^T!Ht;d3T^}5AWU0egpBkz}o$fox90#H+lB+qX|41m@kXC%_jDXY`8KzrxoB4P6 zR$4^kr?MB^RCp`k)ZyShBn+z!)kWCZJ3>fT|4)g|1qqSwC=l$-&1KH;QRR1uz=@!+ zZmH?9lA5yARpbK@=^8)WpD*f}TW3@r3Rc@7a#KAVD6W~DUk<4sYXlMAVV7>>#f1O6 zf@~1!6%iE^rM&F$3BgCUu8Nn2>Jki-FFL?Jc{3Qfb6h=f>K2Uq#uy?uM{+hn>Tg;5 zv_Rw=C&2MVA;||CSXYoq$79HC=(sV!JNLvNH1PYcfUvgE%<=Y&Bm_!a%JSaYW|dZ7 zDqd^C)2$cg)92M}I?P&f6OH`{lPI<8&$R?@3CCJ}Gz)5q&ge(#=s2#|_*+-lb@l{n zl>DU(3&o>0Zv@>z5UsdQub&W+*1`ER9QnDExX)rZIZT=4hSzlNjgLo-v|N=*JzS}4 zG{bzBevT*1L$G|LX2gwHQEBg>!zval^9iw9|J0=s?Z-+74R~hQH#?j0Yj&-9DOfWRxjs*R`PKVj+H&FTeoX8Eb1pnbQ(7L9eXzl z^vgPf_o`PULnX|Pe<`Y##cI~QY6GlNsXs6v0k;FD6p6EfT}+hB1$KSM@KkWwf2fy| zy1R*i_||qGxP8RNit$L~wMLd$x91ac>e3vdlr5NsBFZ%m9HQdpdaWZMBwU={ zi;cQo^1H0t#z3uk7@)TFP`&c`lN)lj+@b=)+0usuCtM8xM<$odfPO*5l3HK604X5& z)Gf;uAdE-irQ~>K#IVzC9ikI89|ueUa5SMj*urG_N=tOlII$@kHR-;Mer5JhN>RwH_wC=3EUFca!@9?OmQMees)9ik_ zyM8LgX*R3s*ww2T&lQSuj-@JaV?Aro(7>*~(omFMy}y&#Zl=KoZ+9}ztEY}p@T1@- zWKuM6l(oVmM(Pk)p(>5KPtg9oFbYZfcZlhanPK?lo&TXgd_Yn?cS`D!HtUcV`@taY zvNuNE=;+Wc9ae^eY=wJm=-d(pLrKokTU(nX#{EV?rSHq^Evx}Y%zJg;o1Pd__9mpu zuGpl3Wde(&y(SQ0#(kyiI)*=EklKG|Lj8g^(O)$@C<35KS3qySE)GN6+TnR9Rci-7 z&9tuj1#ZG`Mg`J&;UGbUC+Q+;4&)}K$4)L>MOXCmKe{6!cJU^JNT_S~e3-P7)%}hv zeYB9RER>kxhF0dS5u4#*&)FQVNQ5Il7TwY1^8OE6-q+abaQM6s7Z+FpmsZ;iO!3s`_B*kAUoix zeeWUev#Zh(3X5HfUHL{J14`Zn(r7k^qgZ}+{|a|wE}||}3j^OSH&UTCjlFEr^+vLw z8*DbF+s;aL>4&z&1-626=_T}9#~mMF=%$=aMwEBPVu)o4#Q7Cqjc7cH>|EcpIJbH% zEEV33^VAFqy|&hHmz0-1VLn=db0wG2#KdS}*`TfamC;YEw(tf;DdMaJ1Hm^{30u6{ z#sMH=d*=>Ob>9#y|LXui2^EN|qq8&DTsz1(9vJ|$7EOpPWZ5-cX*GNYd^z5&w?1ca z=#!d*qarF=RXSn8qPnzEXrMbwHvo1_HcC$(mor0v6e9Iu-A{Q*8PDQ&NH<==M}3*< zh`YxZiiv|mK(s3^NcNKWTPZ6>Js`~T<4of)m#yREJ<)0ebGO-#drGa6HRQ<1I`6f1 z6F?SC?w*M?ms}$Z;%s^HChEpJfu*L(zafy$e;S z_txG9<~ukRHzK`jIKQ8fg}8fVpQ&*T11n1iwUQD$a%N03n<*vGBKlqVNAS5U8s!6-8Y#z?*} zsXZM>2M%&qjG7d8XuO6~kpj;}WHb;CfEs*QSs|7KTDX?xRp5DG!w%@%>UXicDHs7c z%X9b9Eccpp|9MeoUwasQ%3VwXNo5rsko`Ve%6TsR>;*|sa91_FHE6ZiIeiUS#Qs$U zfLbTaPih*REB?*2+`cGyBa3&|lBDN3sK?&sS)0rH`wQp1jbx_v3F>nba9Gm>BJ&eU zhB#g%D_&UR?VFO~8^BnL2+KEBR238A%rsTP>iMg}2t7B-t_y&$z+?E&MxX#uK(4=S zct{S(Z%{(VOo4s&=N^hATM)m_d#(h$<+Ku+TxWhNuS)6f`Bek>X9^N;V>BqMVHrKF zRS`?WB(YE7kV*Hifvd?_W$3v8*5=^5P4<7-Ay2x($T8Lspcpv1asW`@piu|yzc&+y zH8T$?<$_SQU}7J1e#D3Awb5TnvUQ)k;&(=2aP&8)A@mq%)GCV~-zniBEyN=`WefEG z2G^sVrrN8q7P1OZ@hVjUyw%T7w*{i;bXghuRNX`e968>F#b%A^$2YoW#vapN__lf@ zA}EM6uWxmVH4wem-K*oKLV@%*b|Ld|k=+%?$?r^WAo2jQz%*$uf42qg+OppYy3ZD( zd~T)l{K^cH@qe8f>~3tH222UC!lcN9+_(kcoBD5+1fS4+4E~iYZ0&3gZTR2D9)fc8 zhmLl58*ZmUb|g!6xw)CESF{|2zUZ=Qb<-tU07K__FyH?;mx@-BYhu;i5Qbl$R@Oxj zkPF=n@jPl6pET(=T7-QPa6nA2cV*jWst~@9hLKX~m(nKsPChL+yzhEb3WTwkH$%my z2$ja@2nQFeI4TENQ8bxWN~7z+7t1m-@aooq)$Aj4Rz$D)qc@)}#VzC5a`Q_KrSL?j z6m~VKzFr4rXs!c~_B1Nyfdw+B3A;rp=Tnkf;`=2{Zm2bbtpUc~!|8P0I}-m{1_X1d z>CSqQ;Ddikx9+TH&zLhX-^a%UL{%5H!vM&~zsTgQF(`=SjWWDOL>Je#2C1R&yP%>j z)I5U@@)RaV@fjE5cUG?Nrxt?fQO zuqhl_jv7CH9~1^TZa!O@O6&7FCXx4A14Z;UZ#_&s9+w7@wFS`jqSa))a+6SpQ8}@Y zNZZLVS}P}KL)CKkS%yj2eE<(=A$zS;9W7ywQy3OLEe}7*)(;_!n5X;r=KNN{(4*Rm zv)imaBM-%-us)O;CT9_e&SF(n1wbJ_p*5o6`)$LsU~2)MYuZzuH|bYfWYQWY-U5In z_WahAX}>9Rb0JEj=Ltk~s%|?7T>eaIGa(JEtjW)qpiF5yT-VowY8vI~hmHn<{!=en zQIA$k)@KQm2;%Jl z!wu>ptm^-*QDo&_8s<6wq3%$}7JyE! z**Y-#B|jo-In5^33J*l#vYv^}(C8`MZmF94pX5_i%AA|y%F&o0T{-lJI-xB*!6Aa) zDmDA?VvG~ecR$q7ht5FGj+0jim#yX4tbA%~s|{~Q=h5@jYs6V;!8=w`B|>4>!9ImX zr`bsQ-*)kjOU0Is>7t}?*t7g=kTC!HqullNk4}hR6cDoaC(mxza%D1GcRa-SIDOZp z^HQ0%bUq?3F^uy>UKa`K*91(M3j`|T6_(5sN7zp$#rDCxs|^7g%^@)NOxo;2YSta@ zJ@+KW1*mnN)kEwRtgm)Hy+;tOmH96t z1n;W(4zq2bCSZwC=sc|jun`yham=N4e4G^Qw+ z-lx@n%s!h)S(B{G5peJ9D`w0q1q$7zpGIq6`G}|X?O&;VaSAOrrYYZh9yJS+n!?!h zu^euTDa`0(dXbYY!1AZ~9y68JM>=_oISy9t#;BH@o5!251nBSqEwoQ{&NSjw5)~6bQj=St-#eQ0Rf4C@~hfO%vrw zg8no?Gaw@dce^O9c5-*6zB^4l8~_relqqAtZA=BFF@Vbnag$D7XMb1LfMMPO{`thx!!JsCQ`o2xM|M`m;=|ix zO|do0P=*`H>9xJ((Y;@ZIl<#S06q=-_DCdFnfl68%ykq0qJiEL>u~0*Lams;TJ}$< zfNF=fwn905w9b-$yqIKe9mGn>+$h%AmM7@3^!DqVG)lgZd%wl~^^0Zuv|j0x%#7i! zlfPn2qMpp$dGMDYpk(W&?P>8hp)Zkyl`L!8+!MnObXXX$YKTZfE>Ft_pF6Kkl#u0G z8r(CCrr9GA#q}T(3VJx4%aAS6?a9UM;>_uGD)GCYOB61h2Jw}B#pGdnE=p+Y9mOc5 z{UKIdbDd$P3f^n@zuEowT3sk?7>kyTyGZ`ke-VXZZq^_ACr#zwn&0Di@Gj7p%rA>S3rLgv(}M?E4)GW&`fQbjD8X!9mvKcT$=H zI}2i|qvZ~96;9er?F69u{$2Zw7?=MD$k?SWk54XQo9#Y0d~XbJA8Z(Fx!D}Ny@Y>R ztLsxTLG}jmak^5+;`u>A>o7L}UEV8X1D5+rC1*#+w<&$(?G%}IWd5=>EwZNMmi@|R zwtB9W=t+9=S{*ucQ7G)zcPzdZ2W_|ovRR+z&41xq2A^`TuxZ$@!54BOLGcmsIe=}q zWOELYkn<}v9e@ruyBVk)HOE3v!VIMi+YXnq$1Z%@$LQ?d-Ky{Zd}x4n0VXm=oMzPw zI?$zE?10^9t~u!Rg9`!%v(+T{M)LtH@%o%vDzrx^t&4X7GTqfd!9|I6&y0oZkhgpo zRs3hT^|CcfqrwiYmcCQ*-;ri&$kwzK_EM)>AQf|NwLT%|fYK~!;IS`0)4CdAdPoKq zyxRsBfC`{LHmZ@Fpm<`Am#QZdig<3am~}YHWVUc&&L)E==Jo=6vX^;k3x!}5{SwDZ}~X19t&o*`uOf@chAf_~jaB&Mne8W_AL1@($}eS z1MxK`{h=AtK1m^=VmC^YzpahjGj)H>t(t%eR^jAdk!%fpWS zAKkdR;X57Xa@?!8l>xaZ-N&fPXum*kCJqy(E1Lzu*=$g@=!_B2uZ)VliJO(8p{6Tk6ji4aeETF6)(mThmU&x6=#v&opbQGM(ja=DkEJ=jF zy^he>O`z5gjuV=oUFroHe->ebyp1;XWaD_`^=S>sE0LB7t;oi0HFD7yd$ar$`i)e4 zU#PRkhd04>8e#)aC55;ey*!9l3AoJk@lp}~qJ6_%T@RjBc33|)9>AzJjb z7k4`c*qC!E>kBlK7YB|6XN$V-Mq{)_1GB$BZwW9RFBE)(dDx)YJn-4yj|?vZ{j`)| zoyCrbEbfd%v<0pwbDf8j0yKc*Qe&xFuL zu8D?jDPID%+qC;n9Mpv=TfV^2$8m<1ZI{n~dIRjxj5>EL!Rur)Jl|0i;wTWK|K=^h zI8ff6B|$7hHee;6#d2((3)~G_01G=hJzOfg;@lMW^lDMJ8-4Y}(Vo!-IoEzZ zIhWaq_X{rQfbYthtyHW3cxV-%^m>PW%&okW(KLWrY{H#}y6tMZSEz*1#Dele9sm7q zP_6=?d=wSa4Y$eD$CwqOrlla;hP@APeWP2WxxKCcG;+4tqkWW+V}WG|GdF0)I-1-~ z3Xmc5Ad=mL6*E(mEnP>q;{s^ktSj+(>im_za?FA*DQ4*eYO!ik&d)mVsFddvmG*cl1v|5N-ArfXgGk&=8x#}C^xy^$X$cEUenh%k%~mMh zH7fbbM#5WL6XVjNcl=qCR(rJS?zMoAJv~XJ+|4!GwC9C9wDzo$@|+puLs`KY`;kPQ zDb#(TagH+W$sATG``~V%Bm3@G+*9 zrnjrulg5-J;wl6w)AN@$e9hJH*F~83h3_<1sau*}Ly+kJT+W-Aa~Cqe3zZL62ilh@ zW_p2{Iu&5vBrTnb*aOYA-*+`?>4s1n2l$Qc95%L))p~PkTF(;O%$DH4q3QoUCD&JK z9y4W{(q$I=M@1{UH%j)kpKOW3v-~F9lRxECbGj-OEhDp>;Y-Kj1))Z8SPyyGK{PBi~qr`j74-{)+V~VfLh9*{Y!@PN&m}x=W zN*7U1I2<>~WfGDO$N-^uL935Sy;wC*YJFdHYHf)r+r>R=U)P{Tth4A8{C_l^wf)sT zN3w_z`GcCyeyAGzrs~VXP^Ti2d9(1+BGtgPBLWm_@1l`tuykbs##?F$*l_o551)pH_s&TGQor}Jwh)z-7EwEZz~)FNi>$F3-MoyN(*6!hcn-L-eGX& zMa9-qJ;uX)18>84fOB@mNYum?m0-_FM~4&N)0hJK_y=>Xzadcb+?w?(nclqNwg2Qj zjxI0IrCoWFPuc?2B6M$+hiN<8xp5E_lwBFM>Lk4`rSZ-YIEboO7AaOZNoCw;EOnOD zi{lWMnuphsaLM_4qwW}Q_Eratk!0D%2hm;~1FD@@A>tl;+jtTij@W}2uN>F$WB`ND z;J%;D!E381+v6M+`*CTF+QbloXQjNTEe022y9L-nILGQ@Q898R7}QYYghOQo9|gs> z5NE$!3oo-P=OdbJpZEQ<;@yVJtC8=lBx%{)q3KJ6l{UOfAmYlUy2$^-RQYF48@r_(+7Oq~GvX`!u!cO1I1Dc(2P)H< zhRM%0@i+dnv|iGn&6ST03dLYBi^QGAldYF3i0?T&2mJyy%X}DPvs}y_7 zv#Ozn#`s(?&>(`%Qnqt^<^wsArVC<6g+%mxkmtEPwcPEXw_8?}i2nMphde{3L>zQ^ z7Izz2@9&_?DK|1lggXzZp53?;5H+ZngQ>DKDY7%IRQv;DBr*m@9*fA#OI|RZ%{pDvA}nyck;H)R6H&1#pJk$* z+IO#5-jDitVZXe*Wh*{f_Xz4&h$MFyHhJUn?7-mB8~dy#ybysF|1&_*`!NA|1AjSi z%*BETT-GJZecahmE;aRYZdCr3G!~P!y`A;3v~$0Z)}gcjS6&&~2yf(Ag0W^TeMe-6 zy8LG9+!wUN;G(VHmB{8PHE}IO8ltke_8Mof>Pb6b(~Zp90ubw`Xnf z+X?xHKc7K%qav&DBOG8xcUmc@76Ch#PZ08k9=k;7=0;WybJM${e*W3Kg95=@03W?% zv+=(!gsGgX@vN9)!Q3o>Q2U4aAV~e2e#xtUS=M{_CuPsdZsti{2&nY7X*`9;yDDKD z#Z(^1p?M=FOPM8@{erm8YA-ESy?F4no>J4+z3nfY%;<|^=C8%^pmAGPj!yy@W>)=gWrm!gAs@DNI+iABAA=wg>x}%Dflh1C=|fp}wSzU>v;+ zFyryKho(kF_o#>DC4Bv{nzv*{tSNIY($9ODb&IJ7{LCm@`M-sTvvK!MRwcuS%We)}TG1Ujd|yCppp2E@$5p;R6l zqJoW&!YAMMW!ZZ=j{m?m^lthU^hUY(ba=^z8vglXCm=Sp(~n#8rT8gq=0HNGu|XW_ zb1_~Vc`J3>d5<#Iy@mPV#|re;#yOB8q9e(=!SnCs>!9(4qlOlfB{bHPEx@e&QFyvm z<9z}k5)#F63N!}tx7UxG25MAQLoN_+j_fo2_!IxM_!#8k;P;xc46PH0TXlqxR_;&BLh?E!q6qE|-k_U)bnmKy>^|^wPqeS) zEMK}iN+>?UjE?FEj#uj?)Jx@MaKPp8F59hFgnye{vjV__AiEM6D5sfFBIXIT5iB98k{s6a65AP^CyCO7^@ZeLPi_eSTw-fG zj6JYY{l&gh>k0-CQ@s=aUsm1GlEM?Ulb*GE#x3n0%n#MM%WPVU+<%+**30IZFAZOp z=hw_Z?hdO*U?;>y3br92(&r!dKc(I-lmV#N;I6ZynGRu9S9`_N)pDW@gyGF+?jXo? zGUwTjqPMRka>CF+;DP~sGvd+<$7@Mqmx6W z0E-^kAJ{Epw}S6`dVQAxb3QToAR06IHs%Hid6oiTdfME?PRP0mW$YZQWSA@Msarrk zZrUQ7K}>5Yl#9#EliI0LsC?iGZl*!#56?D|E)_B3rTZs#@A4BWZqxUV82WBsZ^I7n zVnmHo-u=OlHO)b(O9==UTVN5%Yi|NImx~%GtbcfP>tCd?QBa+l`@H33*)%t#AG^+U zi-#+Kku8%*czeZJ?ynfN^D(1xf0FRW`A84%ojJ4ZD-|<3cMTq#>@AA{G305ZWHCSJ zM8@{tZyVz@5Q_l&04_7S7$P?OoFIETLFdoKaI{M?#AC9;CLVz!uNbNiea%J?m9x9_ zJ8b~)$!GU)ibimXkMO;Z9sH5#e{qVC9D$`aCvfYuYW`ZULuk>uA}XU7H6ppW(nVb{ zlaU^-!5A?WmG{D7*8<0}df5(|rLW%?qY+{g(hKyv?ShJ`OsR+608$ZV_*C6(_2txu zEy3^{Pp<~cjhA>&r`K2Dgx~pU>6BY4UxpC|3?{`H>x^GMp!WQ<#IjftfAHo?_+LuV zVZ$ehC(vjW3B!JC@|kr4W~#CYpMJ| zhlEwoOS-e4-{Z!R$<22ZW~&nPDbhOvhN|BY@OaICo3|QoOvMOy1M9bD#F-?poL&TF z5#z4bk05Q7sRVZ0?+Du$ zLr7H&$?5(=ae44H(}4!N_q9^lbXEVgktf2FD8Hb_0Yz^|f!W}e5(lzhGgk6!U{3Oo z?u{NzFy~tglH)hNw}+?T00or~H)(cK{I>W(<|Sh{X!60OCm|-++#x#$A0(a}H8ZPB zcpe6?#DrerQO+On%nS!X^e}O6>@34kS7^2s9DsM;i~=Meyt8Nq^CPL)OxRsKrB3p0Q|8bl~RXgh?;@2&SmU(f?K^WY<5#I zq(Uga1XyuL?WO)4WHbV&AnuqWS09#&x+N&<*M4U7;e*QXB-$(f2iZvh6_OkprbP^n z88$~q(vdmzK`5kFf|J_8y{zp3nh@E`3YQ!6t3L_;6>Zq4!egvUU|I!Z>>)r+xinDy zTG@T9MZ3miNs2Z6kyEeMQ+kI~73C~*wJ&F7gp0g{>%rvft7x%^prnBFtqb%+WN*3! zOu)Kw4~*K*L0vQNczkoufIbFIg&VznUi7dKLL(akxKw=2AcYovo|<)pbt7ek7|&Uv{mHLD z7qbqI)NarIoX*ax`SvPlPMms?@GsS%hx=~sP2TJr;QquzjS6-`bFz(k-%yZ?_ek~S z2n*hjr4*c?lRs@CDJy}_!iTIS!UE4%jNfzo2`^H%;Of>1?Tg0kGeMjqopG zft}t>Nzw$#+4jwowjXZSjpb-ZR*%+uh*B`Fd?7aEr#tGV3+F2d}xKn`^ zb!;G$Y=EqaM)V6b$c`@s>sq2cKt$;}G4Wqo*vH@u5ofTjW_j7}Jld}1G_bLktV0qBNtuM^WzHqZ6vHh?&OQE`81y`^ugm}4(;rLd_ zV6XL@XVXXAIzVy-1OaaFd+)xJ15m$Y2VSPiV5yNK$Kr?b?LD_M;p*l}BUu{HqMs8$ zlgIU<65kdVpH1*1;_+*{kXB`Eq%k>vRNuXuzHw+U7QX*J+Zx9y%!iF;NOeU#ALFH! z%hn|&So*Hf*6~H#hvu`AQ66A-U-+61x)#)mk4lZKleY@zlzo zxA_yA!0^TS)f~)sT)uF9Gdf&2?reitEe^=tlq$UUZlg@+97Y?nZ>L z_IXraO9z;W6; zq#!M1%%Mj+1>kZSlx|xmvngRRNC^5UHmLg`7y34MKDAF>v=MiS1Y;)XbWoYZHypZ| zlx99&DwSG2kFVRHdJxp|%<-lxEX?^uT;NI0LsoprGF%;jotndxQe{^OGfE*;@T(_( z1=7UvDD_jVJ(1m#6>YC6A}-lrvo|^hsoH5O`Qs}N+Uj*)j(^JbL8ge6J`-vY9Opeo z9+`x*fm%e#^FuM|V5R@h{gIQFIYWh@(%M(d?R81O8@Aq}@Uu!BuGb~uF^&2;xEQs@ zK7^{KdYI2fm732IZdz?oRPpqu>t+*D{*DJhG&BN!oR#0Da(+_fZE>H zy7*!Rby2Z^7(p0F@E@mz)@R57sM&K(PJ>TKNgR9$i;}jfPrp8evZ+bRJ8QWHBgD9& zrz5Bj%v;T0WEw}aE%=8^P^o6NNLNKrdC-fZK(#|T_@2SLCc(nmm|D^nIp^uDV>vo} z@)>bzE>T~nn~~~ie^e>AWu!O9a%4f!x5Sm-4MiPy%u%0hP~#TYJ;3V#G@STnYaiO^ z0@Mqu$+J;UVK78}?(nG_+0XiHS}f{~tp8n|BeeKe1zNmU+*U12_Pcz2#uocqE%VSu z6ApNs!nk@1w?A7*=-CDRS%i>^IX?`lzK82leu=*R`mi+u#sQ)`JFvhrK~QEoQ5H<* zJ}??#oLWak-fNV|8vP@9umX+y9nasUm_x7a&jEjw>Amj)n>Z!vCtiW|qP&890e6BldGO{G_a|-R)dTF`N?0AwOq6m1ooT=kH_(-Fg&J(eZWN45aNs0KRG+$2H=(zySJ@-tV{HT1V3MYcYi=^#f6*-dPQMkdGDjB_Q>7 z+G@|;(S{YVd-DMjO6{tpn+wFDHbjz;X`nQ!W;k5e+ad8E5nr6(gFtAnoE&_BZn`Pe z3_2VKN1c@rrtz%Y{P`#8-l6J~qK=KdZ^Pa?7b)*)B13Bd$^stJ^TqwSL((qO8lRAnzBGJjw**RYK?35E z^-v`b_xjP)Lq`|ot|A%ey}D5!0&z;}T98|Z&_r4BsW=s4<%<(ws~TpjFmidBvU3G0 z26%r$lqW^B3@!}kRMA=vKa0M|)SDmk#YeY6*10Q~t0StkgF#(nl#VrjbT*uFuhH7Cxg%XV zr3hUF)boJN)!!IkACd$(T{8|r#>K4n8q z(>GE7Z10PXMRybbyFw`5IjozE!eVv}0wjjpB}^YQl_)TzK(P0vD*+0{lWwp9H1ARe zH5Y8i3V#3CEU2TA$Rpd>YxKlqlt^*#DxE}w2!NZ9lP40_yw)L3ulxM~Qe#HtJx1rwa0t*QN=NgotA|vW z0!du^I1F3EO4*oW%mohzMfcr37jVglw_!Cvu35CHw7oSi`RrTP_qe5^Ln+_K80*If z6M{{;ehCb%8Hnm$iq+ZNY{ikru+x2P$*o?@fK7OH>LGN*x`RnY9XFj zom^Nr(MLw86i9fGrI{hULq!12%1e{wUgx<*PQI%CpIfaFC;nUfn#UShni9lQ;tX6$ zXmZRvw-xa$?>`7W$Z-NP*0iJC163Qh9Iixb+n(e1P4;fr(>+$(PCdijI@=^x3&| zSdu#i(H9&Xc)3bjg9sU3D`wInpoWT`&9h5k0RWYN2%#Hh|AE|8dehsOd&u! z7trqkELyvb(^1qs#SX}M78;K*OrZx4%Z|Uk5di~H?k4G+u#D}+Z7Sybjo38t?A$Gapqz$hK~!- zHnQYqci^E6P2*##3-nT=q(S7D9eW;IG$~<3cwj$-0z&Yh?U@MkAVvX_z{1bvJiasr zlyqV;1Y5RZ;x4d4XR?5nslRjI?F<~A#3XB-$?*s|!ZbFV}2 zwc+0n!SGL^$?@P1!XONfrJ+{LoEn#l`7Ldk(M7b2PA(+U;P73IBR&lc;d!PUaJce* zX&?_IwX2&SOF}U!w z1U0D;Eu>A<7|L&(amUL~4XeL|H~yXoD=39wQUcT6MNGM^Ga`+NaFl8t2t&!v1J$!< z4_M)l$QIK0F~tm3PefY52jN*NLnMLOZnhn zdSA**vNeE_NP>M`F6czXCFr7#{1PB^s5|%pJF0o*ri8Fvvac97`Tps@QzBfG z)l`?id7ldJ4)te}Jg`*;Kbqoq)z8INmU6gF69Re3F{~Cm>BkIM*KO5I`>kRZ!k|vb zCS%_`IauCVYSV&|n)t1IXRHv~&H3%$0T&-dCLjX= z9MTD%0x;tIL~_vIimuXZ_td%B!3ry&z~T2X34WkPg!bz`T$SC^x()Bq!It`tzi;&U zw!A9uMHI7jU4F)?*;$>jcs?zj(?M`}>;Oo$?R?#2IE>$J9ZQ6=TQtMOP7Au$Mrt%v2Uuj>ZGK3f^c zP#w7-c0xa%h_-Y}g8|V0@Xfp3*@znLpa{H{h7%qcPT>Ya*feQ5v+Gzkxz zi8T^68?4OR$+BfatQ=$i@e2~{8Qhc=+aatmS&lskAYi7wtrb;lFO-20G70g)958!2 zKjZwTj%BCM9LSG8*xwUYjV#Y=rP687hIliG8NxsSK8dO2{XB=8e%^CD~utcy57-MP*Q&Wg0Od@qP%Z1yNqLFdV~=AqzA4;BS&Z8&?2Z+(l) zn{N}g@v7KPHA{C@u{td*-?TNynZu0NvBx}Li(c-tVIoiqq9u>s_me6qM68lm9XarK z%A*0AKiKIDZ@Qc%e|Zx-1Es2~s%c@8#oG_e8^xP>N?*%Jv}GmKKn}*4y_aNu;i-h{ zZpJFNP=6ZSnwvM_-Me7I%5tM&P}&vQ-$^SMIJCWk1?beh_qh=(79&2ymqiBAOEBY~ z2IUOBd<1w_MUwvL9l*}yy_t2lq+PAtzi`Ozd^WvRS0gRd7+;20^R|q@g;gh7+)36W zcMQr?XmNL*Jl z!8fri27Ee}e#Vs0Aa>C0p+egQ-KbKbrGjghAs5>Vs1~_3(YAS{9(S#)*LhV1%(aO_0 zo6~0RV7rur7X@HHl^2#aKVfj0&3{QYUj=?()Dch&qj;!q)4x~TPHBMCy6jaA$2c1X z{4rno5K#spY{g^J>czAEfhhg1`nSW;f$J-b?FWL?fd#`KzzWIuRjR-7>-Q}e8BP1n zs-waZyWdr@^_!Kx{BnE8tq2l*r%4u4RC4b;ix57?glb~%qPPLQy-*_4x=ZEB9CU}( z%*86wpE*xxx>g0ilj5tIrqt21PD2z(r)2Br`fKvrGrS5Buy)n}`*f>kN|oIeQT;D% zCDcW-O}eRw9_7sMpQ3)xH{&j8$bcMPoJr7$uV zQLzPzKK!ao_k#mMDuGl&5p?r7hMiE?s&mu1Vu~{3hbvqq)i2`kFeAo9=+`yK8y=5G znE&;Dl$ZX*QPWUCpqZWAUcqt;V0N6j*z!lzfFfH!Gi1BYUH%ba<<6h|cSzJj^040` zBaT=KfS!=LR}IVGES%zJf+)_8fPfb&~wnN><>&g2zIB1%jmb@G+Pm2*3bz zRfp>1P6?!5uO!U;B`sMgqz1}Yc10P}?B*YX$K8jla4K)+UTg}%)kNr9b2yy)lw4lK z^DNl#AbW>GF@%LZ^^}Siz&NT=OMoXAJDt878k^*uhEHh*BPjPV1fo`dPuF#mw-x^b{! zlg+2Ukpf`&?xGW`r!IjxCa1th|jA~`ToTnxR$KVS5UGxbTkq~mm})*4Xa=z(0!P5P3IV93x`;|l>wisPoq4s=vGK0 zLP_r6&-G&?{acnlZ3hnw_Vk@F9!1-9?a)7F?Ss9Cw!iE*0>F(^mbg{Ce}m(@cVQ+G zL3rm(wf36qhpb2*7ysdw9@*k$30zUI1N&~3*_BpxZCN!|`mX>=EDNuW;HlxomA^&G zjh^KrACBP(r?_R=kzca>i22S9z^)G-;ws2pmWq_Y|JTzUApEqM=(45#tNnh+1E<*R z+L1}iZy?{b=HAXr_LY#)T=xQaS;x7Z8S*XiNpo=JVJXSDfj>qu4`9uiKiB#ssiX_6 zB`sGpyG_KZ*X7pm$m!loVgcyKZbn&^>^iWlkSs9*2}-}=+MB6rYEMOzZ-#5~$+vj- zjFP)r#bRdXdzj`4`bQe%ur8G5pdg&@Isd|xBU{d3s+S4sb9~)OIoqBo#($(6*Y*GS%$C3}=6GWBUM0@x0Igi~Dw(p;YaTY+>HU@Ttt-eGA@;%w`@k0m?8Kez-VFa?~cAsvj!q5fjp^Pw) z{WQei@p1-0z27u*7rM`QjC&uq!CU?^0!i%e^& zlT5;kY6P#?+bu3t-lz>dNpX8ujE*5Gs*|vg63$weE5|cMSrNC*YiS1Q$NakMz{iaj zWLF)KM^)m?Pe|?nj9zfR;`Q+3yEO>{3RIt$QS*Z}gu%`V+r8=XY6E|ALt12_KhwcE zNBIVPMBIx5ReeLFOgY}Pk@Km5DOcvRQTAwTOuoC*^xFGUY&fg;ji*R3l3~Y=O~zlX zCjh<10hL$W7V~+HlczA`D#4o@p2jD7=1Fvf?0OD1{GRB>cNn>>WesNc`E6al2cOmG zcW*DU7dee(EAYG9j2cv;3UN;`6~xnr>R5P`DWn*Ks`()|Xa7&z?3F&Zts|*hhN}{X zFaK$l9aImw(11s+5HNqH;%=vtl_??}Dd7uMe(P~k&=1TSEvCI4K22=W1X8mk)&u<4 ztM=$H3@pNK`8LrkzC`z^FQ2+&`LRnwAu+H3jMo8!_0Ilj02}nfJWcmO-!gtCgTu9S z216M^2Rh28lo}yeLt0wMvaEvpHAu%Rzk+7%?K7IwMKD zX$#jDEGc)f6rFph+phV%$zX6Yor#od{(PZzlFZ90DJMVK;MS*cFV*FHBP@Hb(eQyd zvBQ8lH7E2ynQMC!838nxoOIRV#Rb5GV^@gRU_^?jWQSVf&nL4=DdYiorDUN zn@EGUkr!}*;Z6OxV~B=o`k8qGmQ`f(6Tw4YB0L7c?8YJ<-FEUs8D4HAD78&mWUC7P%up}!6t>s0Gur|zh|^LdVvlZ zlTx{-eUB$|dapgFDd|P622XG-5t6Pb8NN?WP{N@uDS9~uQPstoUm|0cH`BFbpoM6W zC*1p6vb%EKIS6S;)Fj}Pa`XHJa{y7!)Kp7s*j~UnO)kx6H8|=ilR`Uh-@uV zxpR7KI^9B5qy;oRP>vcP=yFx~5L>Lvl0T*finSRh!?i@@Wsg)(hOz2w8!>!xPA{|M1AEYnN4kU z0EDXe#Lfb03LB$ZEd!9aH;fxHpz}#BcEAuVBQZ+6v4He-YQP(p>&FIN2M@NB!)DpUj=%A z$$zcbkqYYe>%FmJLo)ZHN_`;izjhr5+(%C+gf1(;meYF)bz}w}`l` zj9{XvgkVY-BpX=#>QRw2BObr^YflcF2%RRIhdFE@of|JG`eELpkc_e&2hK(>vkZ8C zoK!Y=cU$K5Mx`cycWQAG-37kCC-N(n(({(Q?*2eSXtJr&aBte;q_&K2|e9>&CG0iXw_7(0y)wqxYT0*SWM1VI7zjpoOV_?z3Ao2&q52}if2%zx0kK=p>{}vC!i0cFzqwB&a<}CE zqBoqMX1421&+*j1YOsK_lYHs@m0;Sv0PXj>pUrx`CoTgc+gY1qg3_3)`W&G#EX7$1P zYc%x((@1Qa7m;|eCT7V&5-*``6E#AbQx-sCeC^g-9ec|vb-0>vo)M`RSj!{Ys)JWG z08VSj5t@WgtMQQAZZCgi)^SNmW_|r9*H_E2FKeulM#LXXPFg@0xPB}R0VuSx=tgZ` zVabs_spX5+_U=}^upsHCq!Q5wQGbmr5lp~3u;<%Py{BE=$22c0buoz6*-f-GKHtp% z=6gjJ1qwQ&KAG@pve`-`s}B#Dn4A%#AhCmzs4O?1!!eyx-Oy1EhCQKrTNFtj{9i}K zfnoqLKWti}D>72?p9Qfp8;L$Ot#_hyi=H%1Vf=7(08c=$zYxfFcT+55nTKdQZsbE5 zC#s@87#FRt`h9@sunO8^OuJ3jRtL>_CtOuXQ z+!;JPZ3P58@-Q@_LTR#2)>->JR&CQ9M8)9U0;KafgteRJ-=AxDa)V*MHLggsKE?IUrJ(v)JA zE-wfY9VgovIWA_4%65_{@zOXg4LwRpS)`rNa7Cn>C&Ir$^(xz3w|D3LivGW&XA4?T z%x#?g5LRkQT~2{T#}aGL*LQA%1o~x<^_*Ev?$~Zx!?lcE8*d;jxfkyl8PyW$2*6T3 z6HM|O2#a7 zaf5&Dz5jwg5$itoBfGF@yjlvBur3o6g$v#*4ozh*Qv;DjyZa4m_eIPu?RA+w`lOiH zq|+bT!y~UeGGH20(G}_P#0??yt+c!JW)vm0V!5Xjv?CHkE^#Bsfd5vU`O!;5VvXSL zWHO`16yL;8hDCcE%GKqEOCNUBkm8ka79M@q7<+0*t_vR~W_SS48`#1pkyjHZ&S-fW z5l6ER-n_Isn$*{4J(skl1A8$Cgv(1{cSxoGWr+Au9+|VXap{6%Pq+cKpbhxC;nv4E zr~jyr<1NTcp%E{<^>x>~;tU*9>2#y?Zdc7TO+2uL;Fxs$_C-a%cy?(cXm8$wCpZh$)^J zohSW5r_J2D>gDQ6_HwbouEiSa8`z+v%VYzRsf=nGA=0dy`Ll(q!w51KgEeI*VsWh7Ud z9tduV{kN?;U}*F-zUF1kq|UiarFOKc*X9Y(``R|Tv zB_fB$15T7`RzhoC@xRWjgxVu4Q|R#LD-0ae^$g~flZFF^b?_UQjmZ6vFuo5)c#5Hz z1}%qx5=Qo`HHh>u>+^`ZQ$w(~?CouKn5)-Ee#}Xbbk6RFzNo&rhXA{)QFi~`=GnBU z4(olR2z356Mg1y=E{xKZ*HET(`+m`PB$6rT^YUVL^b&`{^j3eR=0a^qqTt*ae6?{v z%+OEj!UmX9DOW20sE3_-zt ztrGnb*4+8TN?LSKby%Fa6x3HfV#G`Z(QS2I?DWxa*xV7EvB0sWv^WGd0!48H@B5ed z`wAzy-T)81ASx2BoL6nAL|9rl|9Vq?adjP`ZPpxXg}=C^ueyJ8=z|?rkmdIP&ktLz z7jS+Z{P?Y=*Bm9_nKd5X*4~mRkB|b7!A!N5*u*^vHgs8y==ALF58k3qz83lGa@jjd z=%KLb3WGHSOcrISbhx4Xs8YI~-&K6QMANer`2i@h=0KC7(=J}(IM+@a za=NQ2{K1I9h4ab*cqC5~b@QfjxC3 zi`fLb7z4Y z*Eu4x+6yEtM0`SKa{izpKc8H!|CnRuQJDTYe-y$-OUnm!ekql@U>+PF01!juU{_WHRG zNkJ14>0eF^i{v~3Uo~1y0%J*WoG0D-8JtWPwFSavy2cG3-6 zei>D9!1KGnZlS8-^i_TU88wN3U5HE=`aN;?tc|dNxTFF~%RMjQE-6eMIN9wW2Y@4fiPKeYmd7zIz zZn(YMEtH7Xa7Qq@fLsubO$8|WZFdmpsy6Q)cfripPvMY7=Qob#A==E6uaVwj4OOd1g4ER_3Iz5tEBEEv&0!0WYTz zWvFX5;T=ehZKgw&_k~~uv+^+B7Pe{Sr%fCqJxPWnIi#0%^h%0L;>XVZMDY;O4j1#J z4Xk)@n%BzGThh)mY15gp#n);7a{~_;wxrdE1^)msr3BfMzA*wGhyc8!Ef@Gc8&jP{xPdnT2-EtOYuLcqEz zL!lh2eXdtOhhcjv_B~pOT1y?Q&X!Wm@t*}@ z7&gdB_6qiI%8z{@LhO)}9RqZ2Bh8L8FQ5>rQu1sGL&23-kg2E{zupe4&)dzb=myrIn7XCehX+cN&__m#*0#w%J%6$hvO+fHaopEz~qpwH%J(hm1-C$ybEmm(qgLC#b+?yDk zR=Q6=w{H3dyipi#r#LBL2o#2sp34FbxZmb5H|lxk>^+3(o4TZ3d~l^J%~$X`JDo3Y zN#C!GNjRbpZLmxsq3q%y#bgsPOuG!`cb)J5XTWOqb2v_g zSBNx4i6#-cX2;U=taS&pnhDto79RCnAOU(}>-|TQlpjxV>=3_dURS>B92P;-_+KGz zA?o+B1FoLfY`V5+-$40MLg2Q?QsGQ#5j6#qbSp&nTXsBM`3et6$T)?1_1?p1U5VzV z##iM!Udts`)DDYO^V3i;!!34&l$0p%9}ckJ6($Q`x8yE}r|^ffSsP#o54&=UtrXH@ zb^C*ZQuoE9?G*D8{z2zY2PX1AJoHo%&3`^Ju1wLgzhbAERND&E<|KHeVCN$}Mxq40 za)lb9{mI>YaGaRoiP7@%j%jlv1p@H>b99I2Q+2EfsLLX7>wQSO#j|N9LbR{g?jH*{ zU-eRK{V$MUa1VjYsBvu_O$77?8yCY^T);s`XSIn5ADPl$-s@gbo6^YBI?iN?p^f#%q3! z0N@763w+T!lOe(&%AjDNV^P^ooJc5oWJHi@iex~YsUGm#^uAt%D^9%HM(Pb6Zyx^l zAMoDJQSaXp8s~4ne8^Q}@H1^PEoix3REW!y^e`{#?umWE$ zQdY#Q#SicJ;^6pqL;ef@>z>~@nXJ~w@PLRjj>Lc!m?IdO^;agEwb`JCp9=vMA;$nk zGIP?9J+Lz92@1nqp+r`+J?+m}CrEl=mo4p!qpp>~%0W#iyRhKIw%ylstI2&9;G}&= z7P&`o93+mXHM0XlJm7K&mA0v7d~oBJo)6~=r2?md+@V8)GeL_tJ<}@(@x6(u@)K;! zx(47dO4b{9KPL6t`uSa6 zI`?vv1rg^zX4ff^ zU}L5@Y{wCUNJ&|-C^AI$!&j}k^*AEZ?__bnp8nJPoSxonQWdpaJ|Q6eM@CN7FAz?R z++~Uof#ne6#Z^~~=WGX%2&Rf0DB%cjOnX|cI(UY8*=TEO=7oHqMo&I{gJxXxqxjfW zZf1zo9|URyM{CmO78|e4|AMltgfD+Pf#~Sur!5Ny&e=`+$;51L{k>_lt-l-fb2aQ0 zyTNj{U-ywUiZtIE z=dS;)R4vxS@HX+N%#$1Mu*a7E1x1#~N+u^~gSY9MEj69PlR!IBeM}$_;5@ldUI}-5 zVyPYu_BMzWIiwt6ZLDSGo6F4@Xgh>vvRFq2Vrh_Cm>wSELT|DN>iu(0W zBgDkheCn6ViPI1JU!ucV86*OfDwEDUcq~_RK3WB@UfA~6Nw>ZGJ`KzKsKcj-2X3<9 zmm7>fNWnvsh6V?+(^uUFazXbwazcYZBHX0RfYEc+=-NA`(MfZ0(HfIdlnc^?%$-_xgj|EG8KKI}k=b&DVDcw{<{EYe=*p z?yM7u`t?n|E>ny{8`JQmmnG>2i|09uUrj{gEwD|8g~Vn;2@J=SzSo`%joH@8cxP7}!mhF2DTy+(ZZ_CpH?;eM^ zT*9m|41sZI5EI?zD%W@6|GXT8{sM&a2Csw&=D>!~0#`$ebmN6h>(=Ii-@4#+2kLp)oGN)`I5ErSk@8Lk5H_;M=K3th^B1R0 z4%7OCq)QnvpS44yb}Y|jrIWw<;r!($Y3g0MDoOw%z+1*S2s-=XBc}}~0XXUJaUpQK zn{R8${o$w~YRdT?T|-kg0b9SDQ_D@tE-nY_>K*j_F6ze;k~rvpvPJcC%2lSsxo$nj z)+};H+-iv~W(3^7b|pGYYYNxN z^P|v_7v-)zX0)b-KcCcr(Mm9-h`x&{e|9$`Mr#Up+N|w7SbM2nS&nJczB$Ky0u$qo z{&arQ76w-Wu8`^=s4=dRi3m0Y4`WxAxzG)j>E7jGWxt~AmFeEu?X7i(@3`y~(#%-k zdk5xiHuOxYWT?poFKsN`0rWZWADiKfmd4!S!|TYnE|iDSi(Cz? zy+`q9{gQr_andy{m9wTBQJzTOJvDdWbm43Nj1(IXd-Y0HX zxLTkM#3r&EnF9gr_KdJ3CM$AD(!(L0oknQSg|yaUAXob)PvCjcl?^C|l1a?Zx00GU z6}j=prfyC|B;fg)0C>gSYIq5FUZyZ_fo|o2D?o@z`r4Zp5^eBi0nZJ$#G@QZ=-R{L z%+biezXI-0b(q36nS+B5_w2-?HJrLklI*qQ1Z^>>sJ{J6w$}NPSRzB1VDAk>#4B+yy$M}@OOyh)^?5KdE;O$i((V7DI0U!sJwKc5x^d1?@ z%K<@n>SNWf#5-rks)6)91kOiMEEoH}I>3Bm+w}q8Ex%`HSEjV#yn!8(w9NvL52!hJ zig5kDO{#{OA(WT;n7i6Msj^E_;V^A#GW7#<)b*C;#Nj z0lRCs&HtjQ<~U#coLTD}CRDWRgd>$@J`@D8k(U>6+L|ZEIlAv{F>HGvROJR7>DJWL zXMBdGHs3w_F97A5T*pcR?#jd9#p0$IIJ21mn-Dt)aZ6})Y=)#C3$TDdlcDDEy&5PZ z3Jr*DYo~_`b&l8h{H>Y9S$@*TJd+fhFK;!z$F0ucq_ZSL4gQotiGN{-a@iu8!wrBd zbs5pR+>DbCIu>+l(y_AQG^!RYn!0NSAA#8<)z2Y)e*U+|?*bP(NQxWy>dijG9H(#7x+p4byAn$KE)1$D#;`rylA+7k;wS{e6^1`! zo^$areXgiQ?*SIMf&4`N30yKzx?ENt@sm)ZaHS7F^{b&Up)2${f-vmAdo$-w zJPVsp?$X91LVbo0d6+>DxCe4ZyX%Mlr4x5xuH-Wu%+IqjyJ7OZZdMMQm;$_4)L;CnNB@F$q-BBDyd;o0$v!=8Gs^( zl#;(Lyw7G1de6W=+0;4cHXVPzPh+EjHIHjCP8%;4{-}CYEIq@1U{Co~=gX?ITutdt z(o2l15Dem=`Zu^|0wUdP219jm`eg&)BBw%V-cGL*GI>)h48TS%7Ncnah`Gw2VmB6D4g_$38}hMC-( z+z`IpnCr_=HTm3`ScGC;P503&=rr0mrL9FT%vi($jyIkwGDQLdGyeh?!4R21U?JPY zW~Sn*&O0vrr2WWm-`irsN4_4!=l(Y?#I`Y3BEIu{&SBfwp|rPjl2~e1K9`LGf?Z@t z4){~KWS97MIjl{qD#P<(W(ZCy57Z!BX)JCNhdOX&{EDe4DK@6Wq`-d@>K1I5&zcfk zflHiMgVQ!5l2>fMSGq9f>pT&qB-63m;DI^0oi^&(Q z)e=s2P`NJGfrvqcym}Cwp4`jz;W@>uult_rPF@Uk#GYu`_94i+J?Qrh9Z7c zEGO@GDiuH{7FXI|VHy`AkPWXzIVmQ5HZ0W8{REcpjAd0m){~Mk=@;0p_n>oIJ2uQj z*hs5`0dacTK_1`#O*aQVMC@A5X0leS%bEsl_&O6ifUitlGDKW)I!*5N9z~%NA|+?$ zR_a|Tr1q#B0JnDkH+ZLg=7ZUWVC!owv=1t^Iz~c@L_Uw*R^LF*Nz4c;-fhR}Nk!P+ z=%+}SD20*-A8aE&%7sFHC@Nw>5CL>^&Mb>$0cI_2a+>P9xP~SL%%n&WO6aI_fM#`g z80Re#rP_ND2&4K^z>qi0Yv`BfFz7j@xBKuJ3b6UB{ndp9U46$K-DrS0k`kNX8SZTC z>7`+Hnwq(-@W+$nc}DeSu(*DHsYoPP1rV%J=vXFRTK{P=HWGJ|DT*fnoc)jKfHgu~ z!yF0S1cPLU`;-cA#2{?6ULSa#2?Z#I&?&%bIOTj0KxgpGF_H%V0y#-~5XXlBcP_E- zeUn5)aMG<|hWX2$JJL7tiI<%z${Bj?qP%>3bB%*yhTyc@4V&Sz$QaRzUOCwcsO^3T zgY>9-V(`m)mo2Jsw#jM$0iXbH*bAX3?+~gVaki6RihvTniu(2-u1C2d7SF5VpivKr zKNN!K;CWeAi83~AgZ!sBo}OoeJsJk_jit`bdf~j;>GnZ#7Jlkj zC0*ggwK|&4r|i6Bpr`=CK}5X~=4rH#Y_DSu04F(;Gma92>d51`9{Yy~!E6`<7Q~fa zfM%7B6GP_;TlLszDv-MuRe4c@dwhYR#gz?0NYd4*Ea-98s#;DR)m^;qbHLVq4ITmv z*UeD|hXniM%KLqeL*e)AbEdGWgYx&}6`e66B~2>-?wy)-B=u0oX+|oDsCs-m`0ddH zX9=PfBNkweLjOsB32Tzqe^ZDCi=hCt{<7|?Kl9woeq4dhYf6z$d(fDDR@G(iD!D`$ z{6cDNpn${L=BSq$(seuV*qT}w!^WO(x_yz;4v(UnjNi68AP{}9<>_$xgdIX|7Bb}y z?fedO;IO>+S>(;<7L$t*hS(_RyD{=z2o-+Bkls?ZZ~%7Gjfn1&h^>0la>6Ivt7`08 zf(*#V0JYVGRqU9nzszT2ZI2?N1GeP%TCFsYR)fgV=I3wwd6#=*bJvenSqfLp8-H3m z50r3_#l|AFoeIW~Tl*qHW8f^1r-U-wnSw6!twTs4^7gR=UT zX#?MkFbajf4IFhU=WMc5w+OT<@%i>D{qk+1-__P*OWKT&w;$&q+y>*0gC~Wkl`Z~# zlj&~ednk4)KZ#`86ZeaX{fa6xV66_A#FJ9>Z@eX!y)Yh2vi+kkb&Fnk#Tu(7KEYWt z!+PY+%HSYGZi2}R0+%gBB~tw-=z zjJC`wiHzZvy!;w-(-D1$y#L!tdU6#ZCG+CN61EQV&>3(*HyF4?Kc&Q$3e5zX&|*m} z=LmurSckUDH=cjtB~oLoIUfMC_kTIRzfzSQ!zgk9mxsE3Op?C-%jIWclpu?*NY#g( z--{M)RL8A$kXEgovojcob`!9P(_f)QL*MhnCS>eJFN5vOrs=M01BkDF2HL&@}c0R1noToxtA!7iF@)U?92G~SY&`|bx;^T@~BaO1k{@VCy z&kgwmd|j97T)!@HM;+OyIw^&in-i3lJ@|c|z%rX!Hwls4JW>IJQqS+8$MG%h(G?Pn z%efBQ<=%k!zmW6*GOP3&dl&2%6kMmZzM~fhiR%sFq&OtIGDjjwD8oI%NBxNW3HU-Y z8kfP-CW0iV=cca}E^CC+6BCIv!d8TK#y#cezwjvb>1{k;mUShe?sSVyU?Lb_-Q`1c z7Te#x4H{fjhd#`YT5*C+R{dx~7H75$IbAHc4KPW4n_?1kppzHbm^j_YE573hv-A7a za^r{KaJ$+P@a1s5nKYdul>@N zfHgBrLO%qvAlB)p0%%4~xwE^7Cr94|6?{n$2ze8f|ISlbI!T9G22VaK`~f%owtT42 zPCLj2$tA3to2K*G_Hm_Vn;z9v=GS!dD2d_F`L&vXlOn!ICR9tr)!k^lSC(q+x*m@2t3Cg7b;V$F|LZ55=AXf4L^DNk;SaH z*GQ~j5HCKW^wNQxj~Cz(27zW(&jh)Ynp9xaO;jlb=<;lZ+g&>)`EM3cZ^jf+BqCMp z=NK=x@$i9#5~zAAdYcrDwaPO6UB~8tIJ8Z<4WZK!5_JXyVB!V)h~NLEO)A`1ZK0hx zm&ZL@8aJC){GBA&j|0ptrA(fkH2eB-S= ziJrx)IS^w%Z^l95BP}tuNE@!lWLYGPDEC@S@OXP`^XhJa?~z^m;xAy4 zZX9pV>|7%HR#@jcu+1*GD8uA=3_B?ZBb4L)sBR~4j|LKcbT=-!y9%AlC9V=)};nuj* zW-^6_+%x%)Z5XD-CY9-hFwPt$%v9(1a4aqct31W|yL1bS@cfiC|+OW%6$ z2@U^OovUJUZgdBHA!I0?@92^sU@LK zXlX-kO?uS>cJ&8C!dYmje(pn%^21xuI6VtT?sCx0j8Hav(4pkWl+{@&S7JK1WlbT= z5{l-6J7v8L*}>J3Ps=2)!ct!agbuTy2eRiS2ianWgUaw`k8e}!>uYsBSM$zjO0*HF zx!SUMCKXoXC}VwE85DZTj%3~a?*X?uG@^Njw)IVhXlgFwZbel^*_6tIfTBTEfRq-W zNHa9Af!l2~3OzDoN^r6zMw_ug=R>tMP+=~n#{%qMxBZKNy%i!g=CWR|I9P(Hg1=E! zQtt8$<-gm{Gc?n|6>Ig~_bPQ=nO)%r-=6l}^>MecT5OH_=z)M}`j4TNSML5=?%n&+ z0DZ07!*&8zBF5p4W3^ZtO;=hqsebcMHpdzb1kYq;aaMB)<5vLs^L&W}RTn`Mqm>O1 z0lHMRYt_AZjg|0$!ot{AkUG;_X;+c@)wj1jyj^*Q0f*{YDD+YMop-o zy_1<#v86)h$RxThm-ELu5CTQY+l-@ra~g4}jwfx>gY(=VEm&kT>%mlwho?DgX3mk9 z7qnyWGCfwK=49oZ6P#R{4eqppbbWUwHnP185|&dUR@u^eYIV1E&rsr3)^Q)+?##kP zJt4FW2thxt)xpWB{i-ymjdgmGrOSfjQ!dra0y9KO1ZppAWujwh+ zHS`&E+maq2k>1-a6cB=2dSp?PEDrGCg~@*M-qdKVS36cU1GnAM6MPXfTZw^!(S zHF{v_H2rD8>~$ksfpZpOBv|>rmYezXUOpoq8dYuLGCVb9gJ^ujD-|XHW?poBb_viF zu(HQ?YL^+)B4kb6d4A`+xeS4hE`RxGUJ(b3S4OnWSUzgg^dpXs^)HI;a*;SUS@30E zW7t9!m|~cr;j%CQbHjybiSg~B6{gjV99Jwm-4ky1^y$4-PD-EnO(&OP5C0)&{*OjJ zw+nGofIb~#bWGJFw}4I-c&6#mvO7>D7;4ZsIGKHk z)E4JIgNs5e4Q>0uT>4#>I`+K^KqIXXD8X}s+1o10x zr3Zjd%Mh|j#Q3c~X_|m4>AN~LkW(`~b>Fk8>ED<#<`^C%UxfR4pse*v3DkbC;s7dujK~Ia*4Ew6Wsh)&GFUrC1;{4v_9lvkwpT zvr!-_kZq;?$s|-S0k6FL^~$^q{9SHMMj2Cf{)&XZ_ocsL=>z&B;rF-#K6@w(LaF|= zQ-fJtoPmtn=@p>75|3nr?bm&rbUfuhO&SYXWUUpSZPMg7vZKOv)yqb4IE4&6r_&)SV{0E6C$~(s>rx?(2FyJ zz#Nd*TA9Ejkt}O!kp<_Lvpag)bLRUdiTYq3c#{P+MQ=*EIEvFY6l@~Vx?z0QgauOe zpcrgUnb=!M51ldlB76R^tcw8{#%CM{`~A|vhRK1CwWz`zv*Gv)Pjr<%&#t9M^d{vY&+tEp-y)*D{kSJ4w7=% zdg4}P_B@{!$^iJ(Q}pi3QkF)77s5cji;2j#a;~A|K-yegIZM1yUMNe23nZTnlZ7@C z(iNnT{_MO~F5RdylucJwohM6b|15ou{Yc@FrTr zF4KwxfgSPpNRJ=)sCs-ka0RD8aQ84^Wv?{D;|ta2pcta|t+8?ODwt-_IZLc*kA+_g zPmp-GLcxt>Wp}ji*6qX!3{6E>DaH5WS-N$adsL`v#1@a13V3NEOL$8zWFcEq31m8- zH>MSndpQfoaAW9ODOlOAJ|>*p%?ZoGyj)>MG_7%Y&TkL(35x8fI&|h-Rax!%69&TGlpB8zfoXm>@%uLE zPA{`XxrL^)X8_!Vx0d9}PL9VVeXTFzrH)4Irc*z^FaU8G(+|W>z_Sx4fzxYf73}QO zj5cU@^nn`|kYo;%dv?YUz7S;6W~KC7R~f3ty<3C96|Me@8YzZN`&Vjy?jADQn0qk|;>(=HjDLJ6DU^$!cj%BC6u z@1sSbCCP|~ix;Rk(Bi(MLllA&>rSuF6{WB3k9I65{dS#w%O8YEQq9G-*Iv;{=6yck z(GQ_FeN!wQF4&j^o(Ia)lO?n-XVbp2w*GO?0KyioBd}?%0E7ivNhEUSGO;F$>oG}l z!NBlZ9;(K`In{f;rFeRyQJt^FZyF5kxo%T8iCQh2kB|VKek}-Lf1v6)JSdcxPyqYa z_kC|B$S4kHFZ4%033Zu`wBTK!Z4c&W#$0@P)gyKCCCT_!rk!v%jB{?%$hDk0EoHLn-1!JGP4Y*PR1O?#W$=IOOuu zK~w_$1ve(V71m|>Q;1MJV;ypUXX|#|GMeTN0gTQ79IEEV?3fXn2p-b*_ru`Q9;*&7b&OI@V8 zE-eWw?p%@1@FXBo-)u{b(6c5*N$9o0M6N<|(zsR0$->&f%=v3tsGX8?#G|HCN-S-y z>{i=7ef5a*mb+p>EY}9pBzW{?^WtgU$@a*GY$-HyS%e1R(YIrU=`YAQp=4;1+F9b&z#loDm{4`AN5PiVFep(;+ zaGX3Ke=jqyR}i}KCvzn-Cyp$%eqNb`uVj2}vMj1aYREeciDecIBtg-JLt)tbWst&r z>kfxx1m(3^h>~Ro+(`E=Vdn3M*nw+jDGjd-0Rk&XdLty^JXL9MAlL}!05u(jOdL+V zCx}rWUtdjqDCK`4pdDNZo8pfefJ!)B0(G-j`gpJ(@UcXcn(^oh)?(XFi7JMs6-sU8 z9Mg%-M%MD=DBOQ$ekaZ>W|#`|YtC0T4lWX`bUXA(m|xbH{7FKB_CC;Dz0x{Z2>9X7 zB!KX$q%je8WO*IGD$(??SVYHxbV_alG3U;slf#UK7=x-!pY-`iqa)5JWFz~vAWS2? zRuE8zFC8xzd9+Um0lTXquI28Jv{W#fIsbC&M1l7;3vNuaoU3A5CKLK=fDF;u;aEpl zo_xvZlAhB|OwExq2yK&Y$!83X9HlaCz;!QJ8 z?6`$q0Esc5xdSZLkTyJhrR$!7Xv^*|!9p8)zqMR80>G*xpJNPEMgnU?^U0(FIL|M3 zu`QuyDuJLjvc}XmY=q%4rTWX4mz-_ybA8T9d3-qS&D2yrrP{&#n(8N9<+|%g88Ktd zMy39CIggB3%DVz9X2i@_VG0c?29oF8t|R>LHY>RcmPZYZbFa{fa2S*zx$7vGGH1@4 zUHy5l(Cn`q1EjaQqS!f&BtRcjt$*?2EU487%0wioBjsiy0p{Bm#RChu_3fNs^sB`u zrXC`PjGQ!JhG=)Qa(tC$NzW{Jaq@%!PS&ND+_@}9HbzHUnoAa_bs+@4a=O4%1`i1f zCq|arqlBe9KSNIC#D*O)!2x+XX0;xOIE(ZW0*(*ZS@nw&02L1LD0;_yF~smG2}atc zFqUus`+1VyBGVof!N;}UE9KT@Dv{)QsR`i~TtRCd7MRsxj0Lmp-56mLr~}zhBNSXl z(p(W9Ol^?_evw9*>VV;i=;>QCjgkSXU@>LB)?!MY3dMh==BbfQE9A|2MkmAWDt!(EsZp8KvH0i14FK7pSW{`v@R$(8^~^}#Rd zWK}lATu^oYb!z-7IrcQkRCRo2`to<&CG2C<1XEvxd!j@FC3^gCSLzii^gw(n8)rp5 zbYYf9g2T@h;z#wGVTsIz4pmV}{up$w37HifJcrc4ED{xIivg>PJc?qO$ z%o8t#&pkd|p+Vza2m*Y(4gZo?1Q}jPp|9{823Km-n#1@0QZ5%^o6u)YHp@P3*|y1B z?7s0A5&+Hhj+WZ%UnlCGJig$9O<_A;skK=k91fAo!~X&3Ygth_4v&uSn(CaCdS1WRCfvyeTnIR6JK@^66-dw3F) z2*^9inWM^ma{QQEPS#PCbezl8;uhTL+IyjUs{&Lc<^$D53Ozw3f(37TzIA0pPnAdnQe|jIvcche=+c1GcwX)K(z9#MMDC#jJk{TYvUM)d90NS961WBN|5cDiB)%1{$cnGM z8ing7ps*8PH@YO%fy#`;W6O_k@ywt`w*ifH#Z#OU#h!hbpUVzP8I!8lxVw3Hw?C!} zr0fmWxt|qT?%-uI0oy1O%pDmK3UKjlk%rnPlvn+A*S0!pSM51*Vd(9*>d+qHBB-?? zLyB(MLol*g@k*O3wCs4&v`%9Y*dUTCaCzJKg6=w=LD;6umEH&H6NJI@wyr^8dD0>F zTz0-#-I>x2#DaMCGgd?p{VF4AW3((gZ$km6zgcs`R=2D|NJ$o}*v zH%k!SEDIX|-}DeLc^$|V0gbreymoN5bbkNX<>l92 z(hTBNXZd7w<0%bgVRX{levSC}qx8BRRHU_dRh-)(m77C$LOy6U5-JwG4I!_QcFFi8?vU;z@Xn;~7p z1vQz|w}`=^_3vfEz&BECxyyFN$Y`b>Ui$3W?79Q*E?+SOq6QCO)I|%-RQKY>@6+N8 zYR*&9e3GP+xxi41NwCsLZLz(=vzy(~99}yezYc=&NFQ`A{c${;={4NP;&}IOy`#3J z_VlcPO_18Tjkr$xN;KJY&6)EX%*At&F00z>L=+=X*U*pb{yBQ$4BWp`^Zkwi7TnEA z6!|!87`%5=V_N(D$E*TY2JOs1p~g>*9@P^g6`n(WYq@;`Xb0T~8mnSNkeZ9Oc&rPGWIUIk=9}!iOShL)8hHxfB%PPrqa95qnK}E# zCf{zyE#k!+zvfqLa=QX{*8)GYidt(lvo+e0iC&fSyj-K?5kdEYk^VVzf!d(h56+wN zP5(NaMn;P}15wihU3`_A&lsKKHrhqK`l z9bZX#epZb30Pij%@p*#K|HLu?p4THo_2-G_EHPR3gz*NSb-!p=WWqML4hs}x=fP&& z>*(3SPSI?oY&AZvh}={mnQFy$XqpOSJ@}RjaJ6gd9@RH7WVWf6*!v2JgN{$+`9lG5xCXLfXW7IH z4G%TNyEZk?R1WOElUFp&gVzIKr7J$HwAaVLMeOO#yoTIhBpljN$1J$^i&b<1W3{=^ zmdY&4-mV7}B{Q|RwO`<$&tX)97Yvfaeu>vK!;mU=q5cAR5UrNqx4eX<+IcmpZ3_q_UZ&#mF0aI&c`Vz92N&qE<3 z>mZo?e*p!A$ciZutsK`c1b3CvWRC2dN}M0Qu5M3v`<6Un*Bf@Yvs7715j*sGn&Do( zK{@?g!Rx!suHm)!m{e!EX*L|W!_ypRJo1&WyZ%}I^}cs_4s&mwhaEYP6*}Y|O!IF*cs8hIAR850OZ1j`3vppm5lVfd?O|9c`8AT>B^r zPqP;35Ed#eA=;|J*YH2$IGipE&<~=+>75}aXQ<2@blOD9&N&dLma7X-cwJ-N7ztaO z*6QbiBG4UJVe14uPanKxos_7}2;#T-!bg)y#kQ=@Qrw~00m8w1Ek7qI>N3-sGQkY* z-oE)K>nUx>LeS4bvVbO1wsUpaIQXnY>rML3)XLkF(SL`oSpTVK6B)LP68d`~Z8Sa0 zfLrFU*s-3>(yyWO&T`-NY#%+5pZCETnh3mX8|~B}51CG;zv)~Kc5TCIdn#xwtf}%J zoVhx(*8-%!O1n$ZzGsm%a>u+0JSqdE|eu$21j#_2hz`{@bX52_8~8+T_U z^)zz<#u|%=_TH+;^F9HGE0?eC^rBBBwk0h>!!&_UaQAC4z z{lTuI={Q3g)6QkD!L4kF`pVd6W1OU^6MPEBiW@{let(4D&}r7dK{?P6Uq=qAbG!#R ztVZ^J1J=`}3fjI>forr-TY}Kr4Gw*+R!(#D?3f*!AV@$=0h?G4+_rpi;|G3_`H@=w`shj~OUa8xI0&WNNwz;xQw9C);JxS*H zVBr;ET;yHywYfVQ^vwUTizu>YUPm<3`2&7k>dq%EW>ehWUZ!gjxNG*%#HKU1pI_cl zlDi^Cc=Cyd_$t7d~aG!dy)z_1fpxNYmdqOS*46%mE#ydOy*OM|E>?&9}UekZa! z0y~Zv2*O(V{|kypy(Pm1Fbvd^KX1-`{7!VE_mCUdO}c9}k!7+|*G_$7_mHsoqCr8= ziG&&ZpcKOUdq>9l3M=rJHdr3on@Aw0myD;|scsF)<=!&`DYpbUFDmsK_3X52f=ic~iHN zzmLhp5K_TEoh(riIvEYsveV#m92xn#8I$sW=rN$ry7R`ZuI@6b6V$P^A?G!Z&lM8b zMlUU^k?^OL^~}l_NU?+}DpO>42p|)az6-}1@JXigb;*aVeN8vCn1~TWgDFW}y>R@U zpwD{0!-&FM6IZ_O0qprI-#}a%{iu`x9%WgC+Caen8l%iC_Db_ypp*MdL;Yw)Jl#@1 z+Ffy$71vpBA*TLk4=P2Vh*(2?&y<75zJH{B5Hmj!B@6!smdPrcc&d43Iq`{Fcj#P) zB_i=*F!BiSdz<4^ju648*tTfH`}dGZvt-;54PrS14aoVZoHNm0#ijPA6<=&rB`Sge z+YYJoj9dobJ&}Xzzg9SEZGLvaBE zUYK68sWZ{gzxRa`Eyg^+5u+?{g(b&`6-MNpqtu}&$ero0-g6<&LEOHrpgP9DIl(@& z6!~CV?&du{9#S^^cAxkput%wV1-7?=)0!+XvVkU}w`HyGS#pX(C8y0U=sz&3`VHt$ z*vj`D7Zt~-zjPcaq!@QmpBi=ka4PfH(U0Id^uEM0&cpPoq_Sp5|zCXWpMG} zT~%CMur;xc&OiViapIzub1%@2PMvF)jeHJX?--Y@pwo-LW;2*0$u-KCuvW(FmM1jt ze4`PaZPAGBL_Q~9e^kgM9vsC1=nS4DE8lRex&n%dc04}u0P460vD?&CJb(dDkcv&U zgN)_frf)f7-j2D9`O}3bik<$RrBs(D2In5QN^fxpqJF~moFb=Z>-%Ia#?!TAVmdqN z3g*5`vQ&2UJ%gRpOV=m z)Cw1$gJSr13Wqjw8e6Wr)f^1_CEM0+Xj~AoW)he{Dt~YT!x@bizK-WFkvJ4n)b*{=r zW%j*?OX@UVeqe;<{_-MW{Vaw~>N29^?0Ibq0|1?7aokUfk8CtULq#Ofgag)~MO7f- zr8bh`{l2f&13HBER#XCh;Mo;Ql-1=b1Rqqz)-HmC_d&W7Z|+d|`K(M^b79DDUy5-7 zU_Gn8hgwzHd!RylMffia&~WpM(pE9fWc&MHFrOj*BFbBGukdr}jMPL1-`px>Q=04s zh&-UeN$8;BD*@LBNp`e)OJ$8HYo6YhToibHy77f7v2Q8@rB!jG@w9fbv?I(xFWj{T zB3&ceA_zHqPbVnv#`jPlS;!jq!i7*g?On59czC@kNafUp3O2p4xh2dpT2a~U)-sXu zZkwwPj)q`J&BFa7Adva8#KIBtdM-aMs;a(0Xn(G2QhU19igGB96ivSy7sjbMV}NYf z4cCnnbweP^kUKkzR}K*wY3;bpTR;E{t*_p0z`C$9sO5K;O%9h%NkNu7k`9+Z%=B-Z z4BE90U`v(_PFT)}o0q^C;n0rjfclLcJAh`7n8R3R1{k829g~*wQ2$+N>ZXMnB!YRl zc{jfe{Jj2#9Bp3VjF|l`7rfpYlq*V&T3fmuGrzWq@){q>{lwuZn$?$hHl1{#4Z1PL z{jzJ4&m^snd3kVe06j^9)*T(JL=S*i!-~BwHPF|iXA&K9t!lnwZfD#1FvMV{66M%i zrzf04lv~7}Z8_LJzwklY%srifZyGsS4!6xon9Y+&X>E(M0VhjvK#L!L`3HVJVA#+D z*<)jH_R194I=RXhZ++bds`#LO3LSgz5Z|(f9+*eDpaMbLo4!N0*obAif$>ji+JQus zUm0oGbnJk>fKQi1{8Mc!z?`+x{1(w$5{?2|(Jx;e&u1Rv@Dem4(ePJ(Dy9avh{$Zo zb_o#G9FZV)Pk7}=WS<1!C`n*2C?Bp4c<1ywmXaRa5QeII07)}ow_iLugiL#Nt2UmG z*j}kz=GoVk2u=dr`i7Ie@R{9eDY268mqBETf)>^=?WMZpJMKVW&Qo7H=*L-1Gb_G4 zWdyffn)5VppE}n^C~noUkQ3Q>E)-UbOt{00@$W4tc&zEMChPxA9%1<2tmshtT%#0U z<~qX+>*lm06s(=}y;vxP%MOcS{X0K8Gd!uawDpcf2eXLzK_IOhVFP1}Bdx)?E4Cm> z0ktbuUc9U8@|EO5wj2H*i%w3j1H<4wRUj38f}hYN^|*(|(Sz&3{E?^-5z_g!MIoW8 zaS1;YR0|oEQYG`aLti3Sx&X4G$G-AAPSOk3^7z=nbWS*u!vn6B3Bpk&aa6g?ruhQI zp1Tg87dzckE=8?IRuX`wvUhp-rDe1i41PnN*EFiUbW?mbv^Q-n?ce47i`B>;k$xEl zgbS_jFVJmq7p@^sT3SL;g*V+K(+uj|4$(ES5uFX@huzhB*HLw|e?2uOc+<s&U~Q6&lh2AQgoy3&}=OBFmr;!{;jvkR?E1CBy6 z$E=cY$a5)foOONQ?EWbZ^s;>PG90obTy*FyxFFR?vfXJhevx67zumL$&Z@9V_Z4}P zmV0F*6_$7loi?D=!q>m8z*ZButy(v-(9qk{5m#E-ohqeP>r+nCVRa1o4s00B@(bfZE|(|{7$@>3C*!m}O*-O! z+kN|{fI~|%k(LQa1t?OlAMJq%Y79s-tO`gA|<2y~f zuxs$14m}dbAz7w(NCLa*8F%N{m+Jx-7+-i&r?Q(Nt-WT#Tm*2R9 zA+ctlnn&bQ=N5`fn6P;r;Z@2-#WB>Ul{4OCZB8rlz(Yg4D5>>J;~HQRHRce)ui zB!~Cg$mV5R;bD)^W{&8H4iIH+1qWz%M`(dX27Ujt|nQu zdYtfG3#Py?1sz8<%lg zay#^EFXD?-hQls%-1uGSzo^sE%m|5b#|$3w-UD`c@h3XS%GR4wWS_6k(s@% zdIn7=>oY>(O{tVQvSdhvbs@%Fg2RM%iKqNBP#Ip+UGj6HuJF@}%atNu?7Sw@Kwynj zA7)s8#cj_}om!Z3lrv;rV% zmAcm^vzFhZzV;Ln=MvDcxq4A6uGgVfr4uwCYsImr;h+*%Cq`jCriznQ25pl#t&`wI zr!b($_;}*m&Yg26=ojHFK@kv(3|rs2H5f4mJ-r=m2-%?Cp`McHN`4ux;njB@_~vpi zx-5@cv)m_pBr(`5^z2&VJPu8`nxhQenZl)t$5uGijj{&4wHw3f%A>Fk1_))IzN8wK z<6`}0k(nZqb*LQ=jrbpkIH4_NOeBQNczso%&rCwd^G4JBN*#m*dLjqhdJGYM&k#ic z?glWp$NPdb79-z78|NZiprF{Oy;jho~`Z9jEguVn8-2tJyxw2zQ_dpKwhF-93j54`0 zTroz>rX2z?OqP5dCx`S2*$%%hW_d-Hs8lv4G*SwMMN3~+xAn1ojFtw(XRvu(b_ z;bPe|n|%!krM#<-;0H1DTMV4-g&g=a;A}J)@xr{(Bvnxt!cvb+e!>DWtKBN~nnQDl zM_RYmkL*Ix+dyA}c^9ynSAA21`I6zLtlS54Cqd<~Cf5d=xd|e<2I`O8IKfM1jE zcg23QGtJS8qzpnJ;Li`**aw7sa2(PkP9*}aCsX(WprMdPvtXR#9n#WRhgat-Wy;D7!N_k1uIjfCG9LVj=O9I-`~KR z`uyksZ^fs)@ZL2cUz(Z(kG>1H-t<3+uFxCSM~F|c5j5wQ?>*Xs&M$E%;9s@6tSnHf z{`-g&*j59C=#(nK7P*L~0Ik?7`EltMqo-M6_q;%yUwy@UR92QE9g-Wu_>T%2&=>WD zac{Ve%GppeEGYALFDRW(0-d@k3uYpoHYt)SEeOu$V8|xFSvtp4mA!El)TgpN+V~f%)Lt zsJB_-N`cF$6-6RdtAeon-$d1P$0}3&_ z*sHbkA6Xy-x-H*2%=0I?eSHfEd=Iy`a4alO{koEquc~Bp60RNNWhF4%_M~rRwLlPioFr`wk5tlF*x>2*DU@Cn14H(2s4);F`f%K zWTNO%FgO|Q>P-BWGEjkXf3`Mw)vMf!(H~l5SGn!ZQ9^$z$y{VN!R6X|xBLM{*isMJ z*0!Q!f)_$+*h>Nle9qBWA+w93%Me7d*>80!8Yy%dxML*g$VILSiZ+L3d{tAKh1IJE z^*VK`t06W0p?n2kVkJpJHq9QoHLNWzu$VxUv~$s_4-iz4FA}!`!iM^-I%S+WqMLgm z`=nD<&j+qsp3~%mX8P@SR#K(+v|gxoJ^gNIOo*NS$8u7y)xI9XeN!;RBNRu#Bg&AS z9iKJ0rAW$YI!cgw{Mjjd3m%k@rc9KzGLZiHFA^?kfgTm&pF6@Qrd^JS4xC{j)kg5V zVWwpN;MdAUjdehCBm`w5%?kHT_g`bqu z(rBein7j{B_DdurG$IUk)cx*9F>#{TPB0CV029DL6ag1daAKl(&*D1g7TtfLpI|Hs zg8nf_fhHSGv(3bM>0bvrGby`~DU_0w=|Hw%xgS@HrjFXSsuJXUrvy(PPS4|k&?^7k zqXFVZAny9tY|AV+_X8J9V8!?fm~TSo=v48YL>e#}r052lw1OdV8BIp@>2I?84?Q}9 zeCvVf8`@~k3Ibb7+FTlTrjIzUrI4MIegPpU{Nj16L;>zTq%1u66}Tv8y+Mbag%U(C z0bd<98C|S9x;Cl*KAmK3d88sMbLs?HHy7`b+KuY>(Ls>1qZW1taW6Jlw>tU3*I4-z zG23~u6?Yg5`iE_iNxj9bUY%l2gqg)r$qb-tF*dSe(+m1C*Mu_cQ9au(6XE)8ugNEN znYz*axVx^Pkqm$#NlTwjcSFy{%NM87NhL{hz-?jPKv-VTbul{BAkLe_QGgM2!Og9j&s?_(O& z9f=<>w==5eQV*9boIiHKQDzrG>qsf6-~KCVx9_t>ItZw^vtwO1NkIr=AUI)O^DF|( z1^>*>tJtjbX#B0&6~os66rw6+-E}ob(yTqkM7?XD{p33Sg&nT4rk^K4(anW3RG* zU)RMf_H*;jWdV)zJ`S>2yNE|Ek~3`jzJmsCOFWyB9fz+Ay3HHU|K=&~j?z%ZJQQ5w zm7xmJekgUnyzibiFHR28QY|pDbHw6r^j+bpFGM#N)tYiDDzryCKDvE!X%6nH?47mK9gzM`;Fx|*GCT71BBNo?_Oef?3l|iDNO%R(c4>QYXpizd6Td#)3a$_ zj6>A(TS~Cs@G$d2IVO}S`W4v@Qg?%qH_Lypqg2zsQwvVh*?$6N>5_X!-~~)v;5RFu zljd88Wlein@mDWNylOM++ilQfxy0%a`dqMHgo+{|xH-8F>Ky;D>x0m&32HtE0a*+S$$18yINIq6v61#2X0$i^l<1^t=!R2tkm@-f64V|IEDxg>n=el&14WH zhGhK`yu@=;;FCi27DD6aLW?*{^sx7;iQg;&uI5B~jawcsJGnSSdcXJ7aV@V*%;WZ} z?k1W_5EGHH?fnTHT0qY=j)}vb8rk&D&dkZ5f|;b12d`{HJ-{x z4cP>6e}Zl*B>`N(dW6_UKF20%ObJ&qi&m3M?ZEvFOJxI#9+=1#hH5-}CMyO)FnfzF zUhy$f{4mrKrEX-Vo?+(bt`6KGTIwuZ6o9)Iw4LI}gZUI0Vh2PPlm-#3C{^- zNB$~on#Ue})-U~?V^+}ut0RQ-%g3?)(ZiXFt08->R`uZka9M9StEYsW zU*icMb)=(=Ez%W%BByLFPC~W0MDJ;>$PeoCB(HlNH{M2t0fQ4y1;JU%zm$>;=DqaC z33~gs5#HR;r_woF{q!_UMrX5wB0dhO+MRagm5tYf^%2UExk|{rv!N}YU6Kv-A4i6n zW#dtgMIhsZ<_>Kg-n^^~)p4eq>Zs`Bk=m1TQ8Tsi4QdLxKJx_@O)q|-K~2KM)U0jW zqTL%uMzE=Va14+-TaR!Y34VhUb8`B%o?kqZBk`pSi*2(-%Y=+H>vh^~yB$19ctaY- zm(7zoPDz>3`RjX!CCUzCKTamdEkv=)QOI!bmHo@Hq>%Y}YjSaJppY!q`6|O9#{Ent z@-a+Z1JD}I2E0w@nB|?JejU=V%AOW>0K?CK2L@^|lV;Km@!4YB{^+3ks;n#2cI}c3 z@&_~+V6F&T#I9>?=H#sXvrYJ|q5|>lPj1sRWS#b0+iNER>W%$ZQ{lp`KbKow>8_Ov zZcj#P=6n+nZqXyce&}k2JUR$mc?Uy*mUF}UWc6tm_2$z zZ54HW1u4PSvG^9`B%&QMMRMUz^YON!bEmMq`(uleIR-<82N6p9EPM7aau~nk*K+zp zVLpQk-ZyOZENY+n_bd~u;`MwLWbQe=FAhZcP*zhMQv9C3qSYury|SBTemx%PuEXbG z4v;Nr82_GqfI-p((!Pl1*ekDmaY1Tc z_-J=>$H8db@g^Qlr~#JU4LpYS@}e%yAL%Z;NpW3|=})c=^b5klJiig|Z(>FEQZzLU;P(ADVP12}Bz4#1Otw>>!D%p9fYKHsi zZe6-57A9ZO+Hr9@Fr7dKFms4;k+omo!{>3MTSBV=AJVF$)j%lp1=2+YI$_$Qt&Gsn z3!O7{W%6?|w%)o&(zP=~FOMh|WDlO{Y>%IWkDyRlLC-WL%pdkBjUcusI4CKbN^ZMk z2%r&+XX%f0Cg3r{Hx%EaZ7;bxDeCDj205B5Vs8ZJAMU6j!4ji@m{W5!gUe+9*;}+V zC{8Vb=XU2H?g>AOs@DjkfjeK5*F}DlDh{b@T=bXIm;4O;gK~NnDd3}CE29DkTo56@mT3$UK{+NSns6paS|5sQ_A7O_RWxEPLH92-aLEzYaEw)ZSC=ZP5S zwV-?SH)z_ax&$?#M^d1OY)pH6*toK=p=s&YT9avD9FVg*xti?7a-+7zB4ZO`-o?n{3R zxGoNGn|>ft&m&Bv@nco)F>kU}l^pEAL=${x`zT5z`BwVlJPu&Ae8mqpre=SB33)BY zH7TQmksLmUQ2y=s3&3HLMWIOihhnM1MhCDv0Z}xD!8+!`5+`=>F7u&pVN;#K0<%q! zLUMvf&+Hd6({|0?RXxmOzVRju#an9K=gW(p>Wh`HsIOjG_6GY`l>Xn) zi029nY+8*wSVo-kneJika?Y7=dHM;*ZN z*Ard2=}+yc1w7xp;a9}3_+W7fEzfvmg9|tA1V*n4AIZvm82Y_!67B?g$&em;Z{hthU1~yl|Fr2*L)jd)r0@rO|O@Z3l$*u7FqB~xs#Tu zi(bI>qm#}%y5GBn49a4et6BE`sO|elpws7g#_~y0USa&7ME<|GX>xZg6=$*i$j_6% zR99amz{|9U|HSusr5GT1@WAsUWzx_S=(LYI)Jba3^wx+WqM*8Dz(7TO^Ka4Wpv>=) zr^UEDjr>F|ZRY4~0n@a%)EO9`y3-iraX0I#no(LdD3pQ0U&ZnA~+q~C-98h zg#sYAGApR{oGqgite*f*TA92oXQs7l?cZw&0o+wnH-55gs_*Y)$Jx0f7*5!Az8y4R zRinAaU)L=_Z0=(w#Nna|lS!j;01>Rf4Y5?-CMQ0h_t0$-z2(*|a+w+DIIj(raSc8U zMGp;!XH>>na&`O>#1&Ubm$`?1p0LA^yOYrP?zEYW5~5gJ_!Dd!(D=9NSa__QGoVUT z>Hce6T}@sY)FG4{K}5l5%V5y(Q5|QfnHDM6gY#v^H4AME`EPseBPsMQ$m z3w7#kVjawc2hoVNDJh6L0qNU4j_O=(%rEuX6%P=b%DH^m55duVX3010e{!Fcpa^Rm z00cLALOP&no0Bc_TrAxMn(G5yxkTAQ*3^cu9trI;>SClcU|mep^0~2Akpv`I6Q7Z` zqrSUci!}M{4D$hO`e8@N?YjwL9gE>a5(pxalf=;y)dKAlQYJ1A_8#yXeBn`kY(C5} zc@$}i3|s&b78r4k(7-hp)MT*M2FM{?$*Tr=L%!L zwJPP8L-Xf9`QT+!CqdW+c(`prS^m$*m`$^Lu?6Zp)=v{kO?a}Tg| z2;QJrttV?KY?4lH)p82O;at#`ZL2(y)-A*rL;?kmA<1$cLo4y*`IsR9%%qyITG~)- zkS7OrrK)74DeGsZM=8_47faK|BGU=v1IX!$^ZJdPX82vZ{SOmVIf)8vNe{HvqSgqy zJZ<;fmC>$)Ce0Vow<&2s)Jnek=)-{4BXRFDu=>nZo@%5g!yuFoomilxVerL6f9BdZbmOCCuWZ{S@r7ddb|GL86~3fwO8+ZD7JYr1)5H z{zsn_9r-|np-vEC(s!aWizaXiUT)=J z>Wl@{i?gR>NkEYAD@OnOYOF_>ush#Z>oB}X=kJrum%M-(v{-({Xj(d*I_6TM#Ec-2 z-;|C2O{irKrd?ghkA)CoAyBFo7_P@9H_+0dH}}K2MBlD(nKA-%VqD`gT8?a~q$qNh zqryLij%ki<0?*C~%FN+wV-BgwuBtGkeXV#B!CO?!$TUk=y$A|;Yv{@s&B1BmHWP%( z#FyfB{-z2aD;SR?Q~^20I&{Z3p$_@puJ0Yc1AY>)z(a;~7XQnbX9v5hI$jMdEnqQ2 z$gi0GMb_L+_~BFo=^QuK`!OKpFygxu=Bdg7rqJgWOP z`KEw^G(R~(&c-z(ycr%W%h?t@ zS_0%4Nn0>|A#wzg`mNWhCpJ2NB|`dDEZkuZ1=@qF5A51Z21|POU;mkNF~SppEVNj@ zJNAMllI-g`qemO=%ToPjd7p&f#X2GE&kfeeJV%MO)e6qae(3gc&b^jmcdk`x8I-Nkst$(g2VXvzc1+iD+)7xigTtLn&dA8VzVrj=AxSve+Eo5r( zolV~&WU`ERLFF32yGsDR9ssA~xNfUtZ3qcW#wh&EpQsJEhF_J`;uTC1dO1)WN7w4$ z*>Nhg+<_ZPx;DECWy$njs3_3XME%1GD*~L|CmK#>$D1!sy`&4P{DX#>({R2wLyDfEXwc(Rasqo0x>kF7V8SNu zT|KMm_MdT~nGC6_oY5LqH)q`Fop1C%Cm=kW%;= zJtShC&|A5bM31=7B50}wm05|jCm(P2xrTm*&kk=SMWHO)u*;E20A?!d6DA37#DG>D zhEZQHqB&HQD0uF#^%vbE6iNhcUbmhg{V5#{O2Mp?#s@Zcnl$RK$jj=>xYz>5qE@^* zm4YV*Cg3q;C?{bruPFl+3j5?aAST%VKI419{ zm~mT;&i{i<8Hi!afLOk!X0Dc|l2O81LaGJ#dUeB)>xN*+Eu5j@(&1T zeQDdrtOtIoSM-v*)1;xg+>?w0tIB0v;Ys_gyFly-RaRk$a}m--u5NjqnuOmr^tW*1 zKoJ*lA83s%7A9zmAB^MP%vt4i{yz?Nb|ioBoKZRJPj_@jdCkkT+9C|~A&fWSmV~jw zx_rwz?}i?FnT%8cbaA&cx7Or}e{T>Ft(0y~jFbfo`gZT#IW9>_o2hFgeCy6EESCQz zk-DClkB+LKq;dTl&d(SQrr2NPO0#9{M3YPpBF*U$kjM3s4HH)56}FdN0K@1RAH%_9 zc-$etUAcN>^vL^7M)^ut&f+_b{c`+mC3_(Z=xRq%m1O&F^tU~Ff^D3)G+RtY(Bq^$ zzY3P8aX)r8BO(2=vrh`rj7R6i?ZJJ&Jb7YQc40(`x6c7~9$ZsVGwOLYEcD3VC*FhS zhg-Vurq;S}3FBFG4TIIoDfjdN2R(}CO|e^nSJP8mxsU^o@)`gD8JxUqlRB9e;Hm$8 z3p4MtqEs8YJN-aL;F;ir*zqR01P0+AQ*GeMsEC^$dk^)6bG{Orh3&RN!!->YzqoP> z9K4bk#iLEv6M~)pw{~#hX%NKgPe7#%v2pJD@tJ1BR)^=;WA0`47IC)DrCwOHM~4M*X#g!$6hHQRRwOupjbpquDL zq5~I#HnXR*Bn9I%AsK@H9^Bb9?t~{(oAEPqggp2Gc3dm3R>+(s*3U?BxOHAd#YSeY zUxl+Vr*B@d5C6wEf8c{`;Kh-Dt4>pdf6J;oPHS90p+ld`^!jY-<(je*_S3VQEP=D{ z%9Hw4#4VnV*+*h~2$xYi=-f-~np4PTvGcA>UPOQ(O5=bbi*7#U*~# z+>pqT+U%KfJk6-jwes zzILhq8N7z)@prc@W^95WLDi1#E7w>LSDw`K-%dVV7yadW&wjK|rv&rQ6*pNGKV}5= z6y`!aOSg^Zo1lSxLo`qKKe%r{i;NTn=X+QbzsB{X6@md|P7peDwRSZ!b4?gyy>C|0 z;YvYFU?@0Yvqr4qvuWPFe~5>IyC0g3p{Pdr%cx#KH6&0^7oxqHW&mKByj_7-!m^)n zP{L=l7n*wHt~RDuh&oJdac1k0`~G;i*Rm)1ABEg9XA2(y3#%g;Qr$lSnYbKBMXzjG zAl~0a%b{9Arcb8W0(BUUsPj^<)yZ9*pt+Ukdo61vyj) zjmr0QLJ!<0gx^U<$xMavr}HiIMQzqMmt41)SZXi%W%;H+l?ClI8T5!qORMt7GLola zHKGSwk88i1NauPE2;A(*ykW;~XlY#D3nEt{?r*330hE`ix zrT?o0_g4VJ&|aQ3-Ul|mj@^-x742WNT1s36>1y{akJKjjEGNeZL&c>N>8kmQiY9?~ z|Eo^NP-{^Zzi`15cX~hcfRVpr@ad-n`T9zOY9srVbuDBPlgb6+xhzU)I$}Dnoaz-x zp=mO{dZwiA+|PiJ1pGjiQrsjelza)__z+hnW0F>-OFR*(|W5?h_Db%|0)!1n+>(lR4G_U{M9Zb@cYwN4s#M z@S(^Fjya9IsAgSDU6_Nv`@6-c=q}MQ<5sl0X)63{Ckw_90;H0@R|j^Xb2A~(){+## z%gM1mvp-VQX(tKe*f0~w!chOqiR?zX6$RVh{t-KD1%)OLX78yK0JVy6yi%tPtLV~o zvB;Bzpt%y-Y-xxvq{CG>(fzXt7F>O z3^`vkUsXTuch^u&tlJL!w8{hfRO~ui|Gl6YCpl0HT_f?BQ$wuOLR1tBmB{9RlOm|{ z;wqebknO0s&z|SgW|(jtP@UR$YWWq{oLWg;)ES>bF8)z0f}_Vci*m&8ihOk@c>%X@fxfX1;v}lYnHkr&eeB>XDY4>@5b^q6S1Ji` z`6SJ$?OyyeIh#{u;hU{5*&a&C? z)kUFYoyCfK5)|`G z;8@wqymlJLit1pteYf}N_W^!SkwelT)!8iofGp`?Vt-r8Bculz{edN>A$#t|$7-V# zoi!>&TB-6<^*SKGv@+(Dr5TS=c#`*B3fByMpq~3OT@CRgZkhQaw&iKL=ePUs2(%?3 z#^e8*^Ts1w#zM1Vic1H7B|87hN;TUZW9rYP-^*;n&Blt4X(rrmoNl(&`Y4W25!cX_RF zH4ZAql!?ygDR5eO+%}&8!C#*7pf-TEs)k?TQMbxvBE%%9eQXkFBVj^p-%`&TfGW2l zkY6>39GaTc;L)w|AxxuVp=xQ+mQOn2pQ-)pvjrjqJ0G?Dkw)Bwgl;RO{orN5~t*;%_AV&U03UzxLX%JP_ z``FouP*pm7U$UvZk=hW^6P%lOkMvjp%b1&c4WHKHtvecDJPX9IOrakXl#?skRaRrY zNItF(Nf(t{mgpD$=rLdPuE;(+{qu!tt-pLfh-~y22+msKebuc%G%7;zH?FV@OpsK@ zCMIH&<|mvy+@JV zO`g#mT6enp4Bq6RlCaRalbJK=>1}vMgfCSa7;gh~T=*PBg0`zq7g1h=oQtIy+~0h) zS^ox>Lf7JFNa>0(W!JurffTfZ#$*HUe%`=rbbsEjk`4!xfB6ER<59AKf3o(vQz^eD z!TvTTNY)H}7~=cB5PJ+89TAVXTLRtq|3h1r{$YdN8=GZdQLc=H3VmB=^i@Q8d5g+0 zC|N-B^1Q?=*)C|M`>nWC>4Y-?kFdsw8oq{a_C3zo&EGWhLnu%>cC!0#fCopuFJe>K z-~dNh=GSY2XKBGm%&uqkj=^^ng6~vehs*_uA;j&Bmh0)tM&rI|5eXdH(MLV4NYt$VQL#i5)^$c&j=>sJjXpHQv14pkuj zIIK3Fk@`{%pcoO6>&n}`4#T8TT(ELLlontDz--`mmlrKkNU{%cvhF_g?;Aw3%^3$x zeh$9EbvbN^&7ce)#UIne3aos|(h^T*5>W6#xYmT3ZSh{>N&WrK z&2MOy^xfmqC@g_y{w9WbTYFUdmzMzMwWKg5^~q#SGHa02RbqkurMsqTN0{XR(}9z7 zt;e?qI0!>uh7XuZR7*F~iz4OKyPI#8GlI^76E_@Gi;MqQm4|jr08etP)So_Otah`x z?`s0}uTH+O`3&1aS5v|J?SQ54QoeaZFJwDA&i53YzLMx=ZsNkOS)b}|%Vz?r!?Nb( zGnybz^6&|_DH>BIyMJ!9kkm!wlPYRhja=D|_&fK*DcxaA_hk-CtCD4{zf{UsG>8sA zT0k4m_l-#o1-+%RTcR(%V9bcaSoN2tR)wFi(j0d&xtoOfXErF2f~13wj2aE?$i~2c zW&+R52s4gLVM^NXldL=eanYNUh~P1pSs@2opdy~zc1yNtXT4t7?~bfE z6fk#XN7BLPCm{3ke=KV}yFQVGlTLnFY5`Ab-d`m9{Haym7yMxJd%iZ&o+EUxD@n~c zsnL5pbGsZ7BMr9jU#!bI7A6Le_gvngG3Cgy2+&OnEH>lE+_Pxeu|t|9zFFx75vUGi zh#BMB!$S2H?_p>aHm9Y{`xx|b;Cf7_Nw8^04aaNE+etr9fhrERtgtPVtcI;RUNQdZ zBO6}HFU}12v$zcs17l}D9=Q)tD>R-si%LC0xQ&k%%+ z_1%nk<9!Jcsdq>}9yvmX}vE5j}!c@V7BZzQzy1a=jN|B%0M> za+MB>%0*uaqU@xZy<1#N_Rgb}jAFUVe=DoJL3K(&bS}4Aiu(r`kr);K5e;B(JdIZi zVCp;$=y7>T992cwAse9MY~$T2F(0sQhfd;5-oytDn;6O{L%3R42jg3F1GrjM$V!k! z`)s@)SPt{$m||qGL)J_A3<({?%sM>ipxh@x*2m}lnVz`ah zFB@O*sBg4o#0r_4a(EW?Q~uY^_uGZak3$9Z&Gmf}QL)B6*V-RDPsH9fzNKiUDV`x^ zaqdD@%`Gic>AQ-)#YJWcZ+>sBYcxC}?Hkm`=mV|`7@9~&GNKYXF@!_n7_^b1sG~vZ zO@a5bNzAt8#bgbay5F`6i4PI7@|CUx`Ozn!^{&NOI5c2yA86E(RX{jqqzorFc9_ip zx9to5)&St{OuXO*m!`wW*;j;vOjKRe3RE1UiNNE3;%Xvi4S14+4qybd{7^Dqcv#Tc zZd`)VmW859O0pH|0V_jkdnYT2?^EZ&_=A2ny3ZwY{Be78gogSAPDzFUQuIVWd$*o) z?i+s@b(W$9ZOP;gr_bN4u6ty+-HSDh=PO);lN6%>6prInxT9~M6{mtRrQRJPZYTFK zpK-93CA4(kxLv`7Sg(q0cjX%Aqhxs6a^DGXUY=P07k$aDP$qa~&Ys;#fmR#3OL%y; zew+I|W0Odd0|j8vRasdpbs#IVE|}3@l0w<7X2J;kilsk1>N1RKBf$Ye&!ryZvf;Yf zSC!qoq7x#*Qi3Oc<5k))U;x%kxzsuXZwvn+Eq2~6KQ+WGA=*6lDE}K#KX&LijLahf zvf*X&Zetito8Zd3ho8xncv(%}Ft>v^GWAX;qhdl$yoqyhr1ji2E-b~9YVfGB{+>|y z50S2G`RgD)4f2VD@z;jA>#7QviJ?C zQ&lh8)>`KaoS!__@+a{)L^$gXA>qHFyx(A#Ay~1zcaJ~If-oQS%d1c-dm=t_+kYFx zTMPD#(dJ^#IhAX!@~33WH_J(GxOWdngaHEQU$pk3k+j!7R`Dm;+f^>4SErbb()nV6 zR%q|4iRK1D!bLDh?elS9K;9KGRl>j|PX&M&?aP&4FZBGoE;v}$cQQMMpQZc}0$fBw zvfS+nwR=H^G7yXC$r!@fZ0wNgdB9d>4DXt6eZtV@^CD|VO48-mtslp4bt4$GQCo0} z(;kEu+%{l8BhIA4pHYFHktiGKLF}Tk{s0Yv-g=x%E6Zo#HYon*D3mO$ub0T86roVf zwsD^LsQ17&NoBkzC=8j-I+I-<>wE;}D`&BP8WZ&s$Vk#X$Fm$|d4RcKO`>Y~q$3-W z({Ux=u?t}`3_j&KJ*s2u<8`>cOYhGgF;RTq@F13k`!|x%@YxN3-;ZLgt3B|HTH72l$(%nP)N>ot25p`@}!aMS~*H)2X*_cjiJAzAPP7P(!N&@P)Mmf~H(Y zW3j-Dr#ZK&%ia|r<1)ZbwbEs6ga2d4qSdk!oY2^v9hCKbju5|+eOI#4jXt3J>0bd} zysF8A!;_EvNlA}xNu)=dtd^}!)(U8#)Yx*v2`!$!_zLpf5?59NZh1KX9mx&# zU|4c72Z7upD5|qgJYOY`5wSMm#>p%87op1a4-pg^pnO&JC$o~*nz09GJ zfk1|00SiZkl75~du+)UNUQQkZ(9nBF>t1QaPSX-Ne^QR;@;FW;QHCXB)a0;^YLFUYHrjstzb2Zfrw;!W-(bCJ7MT}(Hd7|pU(g3~i& zB_l5T+Y6H*Oh8#coAR&0%E4){B5pU2nGQm>Z_!%Vao5cpYQ)vUcW?@Q{B?=uaThR& zfEz29Klr!txu|2p^*1SlHUE4#|J#_@j*+X@m~1spCnVUGskO`omsUO$>>MoRQ=xNd ziJ_lFz-nCZVWy`hiO0nh<6(m1FGHVM!&9x+B5NS>5SN;l1fgFL*ZsfR$cUabG$;8a z`bBFe@3#)V^dl5;MY&V-Ac(%uFK=g?HJ3i0*NKM+!`dCT{6YhVi8j@ymk;>nv8r-Q z1P1d^-@Z4|kk{3KxpP9#D80m6JrO=1(&@Y6&4fL+G?V;0-8!NVTA>?zfVYMxO=Frn zK3QnM8m(JF9wJT`DVceWVqW}y4(Qnhthu;BEY9It`r}?~l<3GT{^|?zB@)$Wxlfvm z3zsBrKkZ$e)FyR`TiNHw5!MPTK+t%=V5>~K#>#E=i#6fU%wuOp$+$$qkC{aFJuK)3 z;6^itA=;8i^S&XmSfH*Uuo*7N6;v)Wij!3hMPpIko-g28C``c?jziwGe@UZbtk-M} zz|{Hl7`VCs&nG7IIA7N{1FD1J^Gs-Xikkd{9y@d3(V(p9w?e&FFG!22id?p0pYD7w zNA?||1$+BL*wUg`Qgu0>D$5rqVw(>b1!uFQWHKxUa3`1r{Sij|eZy$~&gI<{@@V}H z++K=Sm5(z|5YGqj+~xdTf%xiIxN5Q47X1BKiXoEBGF=SUw^#|bCZraNBeZe z2iBGt5=+=qjcZ(;PP(l(&ex9@yXZSY=SBtF_O>(Ra|1j1aA7=>*PHjSDQGbN{U;e* z+HBQg1L8OVZnC9d5U(`60}ziS1=COKFK6q#U0aTy$fH_N=`8;S=<4=`=IAL*y1UnU zjf9DHpIb4h1_6ugaz`%5aeU=-6z^u@koL--Ud3)iRoV~?o#iqT{<4K_K)ZRYJ4VFa zmDMh(fqafuEdPi4zA1LkLEl*B2iN)fXm3*7(4YAHH-J|PzIX{!$E+1*{s#1r*}~ zk7WOflA{o{O|bwGIDDRnuJ)P8|2RN(;X#ZuwS{AyzhIQ~#q-(GI9&C!Fhz%&NIjyt zhCsVP+T#m&SIp?By!0%0hq^VP$A>e>u_dp$aZ1=Z`jbp!bq~u4VPvaPjMKXu?PmE* zkmq|OnDF;D<7S7d1#ZWt636avevE(PaRO*@(^IVFiM#nsol=%1{86f-f(1K+Np0n; zu8$BHpz#{L_pe9-)Wl-asIc1es`=ZCY2nmL!% zhl*i(Up!7Rz7qKes9wn=iCB>%kyAdIZhK`qoiV({?~ify6ItHE$cCG^8sHRGLAMxaq%6U_qM~0YaxmTvz{+imuix~D2Ys_7q9!G z4Tg=;^2e1rT_p`;w71~xUc?c$5Pj5N6Je>Bd2BsS|7273C{*#Qna#;5Rs3_Dmp8X~ z&Bzf4t%V5UpTGsxV&K(_yc(+HdyXMe38~lWq{81w7{5sIQ(VW$+frJ77fKml()B%t zOGwR#OEZ++Qvlh8;eX{Lz!>WBDvBKVkMQE%zj0=Cv&M-AattTY+;9sHg)&bWO5ia*tn zKnWsOgNgpWnO(O4#H8c9eEgKAM}h`BhA$XAw_aR~y{x zvf0oeDq|TY@7h$az0tV8OszQrzV#+M6=l8YsNhqI_jDpcWHyUZ0RDW1nVt5Q(}FjY zP@z7V&JoA<2gc{~AkQvSOvo*;SfN(}u>ZC=X@A|jPR4bZlsT0nvFdk6ktfBSGWZPX zhbp^S5R<5lPN%JNv+_D5A<0&

KqHjNNhhRL*&e5)rFe2$YaRd`=YyU zRzCA~uX#ymC@<3pHeiN{127}?Uvg&Q64-fg8??q0Ah;K9U-4UB)Zi1Q&f?5p{fKr{ z;B3lVCW)p;Df*f(&;&_VPnbeym*Bsh{(d8aV%b5+Cu1i=;X!9&35Z#}{dGCgQ3QTa zrNeFM&9)?S2m|2R)K5Ff(LI8DfV&?GX^9u|m`*o~+1U|>` zL*U+v)KB8}9eIW&y4P4rA)6$$&nuM8I7b3VK_q+Cet z0hPWCMsujlPY?sZkr}zc&-9P+xv#3vEBnXULTURK7-!;rjB>KV%^q?TO$oAeb>&-% zkx%fh#`OX448pz|X+K+cSDB-zQ$kj(Cr`P6peoiZ#Fx(YMs5cY8Qw`{VZvI7nFLvh zig1j*8BT~TL-~X$D^rHFVw!d17N7jigDv09`cqk6p#RiAx z$^jk5LZnP_w+n#e>oFF1s5bsm1VDl;&0-Z^H;jrI)@UiA`9yg+W-jUx272K4FDGaO zy7F{aY;N>*lHEeQdvpP%&C@4^x72_1t)mDxdmLPaUp&H#m^BrP>)iwM*X_0!0cAjJOxrQ{uHK8bKY{iYVQZ zx$xN%50ilafauwXmfc?2=l?4&fjn;&khCWrT_kmy+YDna^x-V)*tM7l{%bRHS~x@% z=|O!wXUaq$R&H_q;7^a)-IC-(Th-Nop%CV)Vv)(P@(fWZlWClh)13ijzdh9%7CHST zDW8517TWDc6g0?@*Nbr^8CnVuH1^kX<0#ms!G7(`ioO)BEWC}HfaT; z%MQWaTh}DX-bM_^F9ION(jq&(t*vK{T^FIhdKeKNLL2J9Zr+e$8X~R|V;JSfGWyW= zO>1G?!Y}537I4CUEzGNVuTlxX&wBO4W*Vu${G`&K~vgMC!IZ+GC1e(CJ4rE5b2Sqq=`)-I;u8J@rH52o|~)TQ4qk?!ZX zR!33~>`Uv+fr_FGjk0>X$M>Jo>S}mPY~bbQ7utx7f#q} zdJPCq0HrqSn2|sW79^U7$jh1r2@Aj%qxRRli;GnD(C*n|2Qee(GE7OCb?3ksN>-VM zYpRr}nZa6R(hE1k2Gv^Ru|2{3i|g(+qXs*6I}(lTCU}1NOeX;P`x0v0GPmq!iS9$n z@d|{oFVZDePI(?bs*O{{96}9eT!~XyI!8#_G`>mms@>HLZ%CBvYQlZNc_|&ASN7q7 z*rmrtilq^Zw@h#rLI5(iSN_lWkNw()uHUi}yDge7rOiTRxs62%QKK&4;Y}%c$I_(b^sl!ip0~|c18+*UUxfdXL>j_obpb{L(l%JeBD6`U6G(z| zO_`mus^zYB-S34S=#IwvZM9K$5k}%BA@X@zn?Xv9W{xS$iq8-FjY>dtn&B=kpAUQ{ znR>LENdfDYrINaqT>VZ;;Dx}3{C;jfI;rIz@OpZA+iF`E3&Z(Ap+)xU_3`@)y`qKT zv>U>g|6bZzgn`I{qUduYo7WH9P(tfRvy-!5?!@;BYxs4vqiTSj?$Pr533Q7MY7rL6jzQS_dzvYQ}9T|?6Z7ACU zn5Fh(n`aWy3dqFR8D^yt)DUzlB(+d#?dYF8UK7%{FN+7E^;xeR6_s#=rrNyo~wa2SXlZzRnKvVsY|`J$V*+CM)qxx z$~)(_7TPXgt{iWH_mYim^4wcxgzdEgA5oC`rK>0I@MIUu8^(UV;K!Kttw>YJj2%?v z!Kh6fL*#<&G3kcEFNT)q7gR79reo;5arHVT%!cVOO~pX9L;XKz_2TcLMf+CEgO>j) z0l~bQ>f+{Y9DMAVsB@B%05%Z$4<{i0NI5(NxHP#^%kEC`3KG_IG~!aDMs2Q_`E1cT zjrbpm3~f3I*mcZ^q!_u52XrzT|ALQ{>8_I}CJmP};7#8dRpYbxRB;@dvIA#0nS}qd z5I{K%xpr|vwgY-kR#y`KIFPOQ;Ij}X<{9+$lX2JH|G1{Aaz;?;A`}IVQ_MUpt$*nO zdwf0)5SYzL3pQHT##+YGgZ0x-b~v2h#ykETR&=x)w|(OkSyQxjUhru-s|FBOI(sIAJBYn4n=oHPH z{m>g_Dk=$?;P$eenV#Rv{qCaDd;EEh8mdDie zuTk!WSo^vbu#1xmSK>F?2pCgX0WFOQ@;u2w;_#rL@e$hasMhF$!b?Hn>^3dk_1ywP zb-dqt8BS@o{fuuP8c?dSoA4kVM)24W@|n!cQ}r%{|G>7GgAV(&Jc8J-K)Xog39cz! z#EGn78jpWN3?9&1dHzDG?`m5q-ZDN6N=V?u(Yo1Rdb=__nwa^46H4q>www#8-@2Ag z*E!~k5EWv0(PlvOPIYkZZS1W{J6COSX-PDh`g|yzV}x^Z!`aZKmyvcdImq5(8Vxz87uaMlJP*YX)zW80 zxtJoYR|AErkZeo^j;H+$!T;Ptk{@^HyPXVz>UKi*1+#1%D+?G<7|{)Y#1vvBz#R8^ z(*fE_-ff+{nQGTNw*PL$8)%?bKB&`si>)+pB4A7Zm*~qMr*^LwJYuWCc7Hh)ecL5(3SW2| zX`xla-~O@Pg~Dp$xU5vIM-Hzxo2&}%%(O#xu~Z1}>?cWVtVWa{G%<~2`|gKIAf1o$ zi7OJ^4$G7+0A8^_swBYlu8GuaG_NNo$=mVEvOYt5VLGs)ZfY?DsHnb0>)cWZc|^(v z5+6ZvBbX@W$W`hdd8Ql1mJDmqd7|$RN5Jo#hNW{q5#2<`$F?x1N#(V;Prc2Y7b72zNP!KM8FJF>y-aS{kZ~1 zor=pW9e>7SZbz@ho{|+EoKa>=@~M4ii2ndQW20oQr_UKqHfe>q_X?o;n}oPQZxI}~ zWdhmEbq;$62Scm}n@}ldI@~?bJ)mul^t1ZoUe=@=BXXl4=j&|ZZipFSY~Q9XjwG4x z?gJSOnZef-Zr;7sw?O^*;m#`h=+KDn6p=!}hZJ=n&m|q<78D{|Bcxa4tgn1y_}oe* z5Wf;-q?X>&bpwxHRg%>yz9MU86Uy0&gb6c5$)l%2%|nLke2zzRq74pZ%l>x>Gqei; zik-cO=9TgFfRabSGLRmK24OW4+2p`}bb7!uy8EXvOtben-Rz6SO;)&2O^b8sx}$-` z>t=~G_TZF`7(*fyboFTyvVRa?E~m!8t!xWs zUH^Wa=?3PkOx=##3Yjpc5C@rvyPKy)htCFi$)LQwD~yfcKHHa-l)WQtH64>tuejZ~ zX8E`#wc&id<{))1)vLnHER2^9g_Mqj(%#Ri&Ddmj0k4oeY^OUHb{4s?@m9eexJrM`n9Is~rAOQ1QI_@&vZneEH5tB~ zsOCkMLJem(t}jZ2YTo-s;rg*)3%mc?1=w1XNVr|A5ngemRAx6zPJB!e4=v%mq^fbxX2H=ssavhNhOHAvw_9he~=YR3^A{AP_W&UzT{tm4sQT@Wh5 zF~^Yrvt1xYP0wo$b8mb;cg6YZtg07lq3Q3vus5rhf@9n*wMdONc$>+?Z}89nTFvUE z8+pr(+O1@K_5O&eoV=J>&26r58-7Jb{UpXl=&H;$7=6;9r2WMaC#*&4;y~e)=F3(o zCm%i@-?_tMg8BPYW>1sJV5vd4+0-wil>@gv05NTT^sAOif z!_FCrMr~X+Z6Mde5Ro{zE|cG0OBaLs%1o9DFcZ(kDWB*`!P~+v{lNikox*GvAxa1F zQ=1Iy95hvGq*2bb3-y1on{SAI7q0lFIK_SCK4#QAj96tHkO^kLx#b9)xaD}}<#W|0 zB|C~N*_IVhIB=llRpJK6_SeDZyQF-%)3Ec=i2m2@EHCJ?-ZtqXRfqUtNM-9>&&G8O zH!4@P$6Jcp=V>5cX^p(ab3%exR(nzWGkH6+3iS~uQ!->^a56W=#J~&QKbqwi4=}Xy zY+twxRDd=sadVrq5|INS%$ZV|Slm5)0oVdvpG|V9D93P_DIRizdd&YNgRJP{TS7nd z&eg6S>25R4R&1(8(`EqvUpu)#PVnR1i4%0z0{C*lMYJ#TRipTw>>Qiq|L+4~zyjF0 zs8GeCYq`$5jellx`#M6ies|BuVE9+6!D`sFHBE&VJfBXt_t8JFd(UIzVCF&^ZkdtP zOvfJrVlAFKAhtzGN&2F}|GCC?02!+lkDwPPcZF)XdC2f%06M$kC0nVp)yBhbV9nJ) zyE%dlNJxxUkEQg|v|JbMlu~#`wIwciws2FHhsUVMb?j!JjuV~urJe;|&~uw3?vmHo z&V|e-aTh=5#HDv%5>^k!4hIoyN7oEx<{g~3ScltH5awi{2jQr9);8=>mHy%^y#@qN zObGLyA}WvN0MPeF;s=~9I@1}Stvvs9$L2Rp|`5!fu@Hb=s_~{Z??ZjZiWWbhjMDKYNV2vVGDqvClP3?-fc(*XP0#i z>kB=(TJhzWx3tr}%N4p~h29)V__$ZPrJXKM@*!Do{PGuurW@}QLPKu3E-5vmRmK1f z|5T`M5i82d`~W_}6ttW>1;LhTc=P10pu@BJDCu?AzT+QI;)dtn&x?JqyT(WccQ?WW zU43oNN*FSjzko{KnRPheQrIkJ2NmQ}*3lr!&TorYsgKx>Yvxj98ZgSGXM0B%t6Tgg zU7=A^%wm6DFNh`-^`0lqiBy@eN<@QV%`lP0fwlw-hN{DVG&iB9yo4R{@o~xq%JpNT z3^Cd3t(6=SHBS$_$5ji>VY4fs10YbiOfN)RX<{dK&t3e}D^wcY88)>)eA!lXskz1U zBEJla6is`^EY-W8;}E!p?9h2mLCOFHywWlC&+uP^;5u|PO!5S`kw$GI&_C!s*B=g( zDs5GPqGZ2Q2KY?jrVzu+1^TDZa@e77!S|ydsiWZYJLU2j0n~|enyBP7iKG85&z@jD z|4$CocA4`%aOhR9=)H$yqM`q~09613hR8DuI3VORYFad+OA90UUhh-yn{dA&W^&7K`soGmXR;YqgHJLCt=oVPD1)S%B8VmK7H^wOz-s3p z;>`habzY4Q>w7HyFJM~OvF?w3Cn!|BDK$twXIby?^OmUT72)^z9_Nw+X~jbX)|ce{ zo?##6f$VPcS!--N`wZ>9S5D&ZwKFAJahO*4?Jyy{nJZj3s21)dS6%aUtO`|{(RyGfHNC@B$s?asZ***6LY9@w!O)6s!Q zuNF3IYNqr;!qCvL2)8tbrLM-7?4Qs^*=53`wY>!a5{!9ea_Zd_-7@!~XHc|emdj+H z*1uQT5F>ib>derpgQ}$&u4!Bug7B1_{+f{w2@RFte^82_yLziD`8s3LZm3BuNfjET zpwex!=xNHIV@TJ>UA2`$;K9K=4pt#ez*#u-ET}20Zva54ux&W=3 zl-dLLPiBEhgn8ez@e3WjcP$h6R@rmD8u_5+OXY{EMlkg8e3oobHPGRyjt6YBxcM!- zMX4M?Aa9OO1`*4h$PltzZd|O3X?za4ytLqB4{Rxv=Oxo`b53l(oV}Ek$e&x|MVO_} z`$+P)0lpf0WyPRp6z{U_c^xzH9P*)@B|oNkl&Zr?t8MKW(>;tl72ty5?OxTcby z@?I6Gl3I#9$1J!%loz@~m6IbKe1OGQ$8W*3k>f-?!F;OQy~g3WEOwbHlin5r-X^lJ z0mqG?-VbIWCN%0N0g0gbSy|7|>dp1533ObX#hf9HQv@GbflhXU%hj|nTh6z`@B46} zMhA{zda;gB_4KF`;k<|ZCadi(V)K|zejXN*t|ShAEeq47%12teqm`%uv=L)k+4sN9 zA|5~0I{JVDHq-G?yoTv4Q2cgfHkb7uXYzI3H6fU=mNKVKu*j76J4<+g_Rn|tI3)3J z#lJgE?9A+cNMJynkbN}H*;eA^b@7R7)woy%I7yF(ie{NplyNvdBn$ z98*&PpmUX3WjIE**bj4C`XC|99e8P<*djm?K9m*4 zlYj}#Qkt~E=aciq+-+)U@<+0 z)KN zsU0p(r|2$7*AIc=367`kwxDpmEaoD=5UZrC_kSWM5amROwNS>8FZLDrs=*~km@P2v z@K_cd!tbl*+g`#O++l1{DtmGUZO6;RWuf+OkF0I@emOID-(G*k(+W6f8^Xzi{?y5e z9sN-bINU`tZ$(t@9+~2!e7ix zoEIGljl{P6Fjjam@opRJ>zHXZ&-#gxF3cA$2t4}jZ|cAY;I&9sN5&o(g@C0BCuipB z+dcu4hoF7OHv!wejsc)c5D4c=xkZ)`T6fdRsH-2`9xT`jZvu2OSz?1j3@z&4=jnu? z$no4VUB49#u(7*d1Aby=AqEH4XRmSALN`25@kYrKS-&8u_Q%rajhyvd?c1O)T?D>J zh5^nS%PY^!2HM~(a3&1^0ax*=sxFO??Q2&5A*Dr64;alwY#Ho)$$>FloQJ4pl6Qv} zg~>@-1ZA+sUEwHH7CH$pP0^7G_IQ%=6twJnZtx!<>piUd>e7qFh{1URWdjlKFG_`N z7n2ZVmHTgwHr&1R5lgugLSZd-mb9#Y6yxxqICovwizvm!gKKO79anFsM=9H zTYjEL>-sK@3Xk(V_A6CBancoTqxPx96zH*j{sukmV`5@7AO|0P02Vfn#EfO^B3L`_ z@m1TM5m@c+odtil&pWLJ<-N0MqSDhlh(v8znP_%m4#O^G<-)Ko$<)H7?Hx*!symQe z?Du243SDgy*VxSWGzZ={gaRrik8)#FNekYlKEP^#3=s^cOwRJWNYHHPXaHXa`z4Zl z_32V=Ga#Pjw(&rAA@17~4f7Og zm@J?lOcCP8HQI4_IXHWUTm$0hOo|38em zpVaB1XdP_-a(!IW+vI=1+V&jeuMsTjrAlMX6`*$v2^B+bq!>FKaF4Dup01eDQvMYu zLio~P_1s{5BuJYnEl?f*hyvt?E$=5vG-8vsMS14A#=~^x^2ts9vN?Q<4Hm9$CsRRg zfdx{B?r?d$Pso;5i8!;v2Rn=PL@p@Li*%0%aeV3FSXu-q#1QXsmoPixs59@k0Kk?Q zm#MPSQa*3~?xKFop)8S*>j54jns*EYE>kQG$3Xx|+t3)-kX^tG5(ZeqAW)C(46FAH zi&RW1FGr<CMF0DjNFr|}{B_<&&~D#DESrQ&oYRAbH~VxG zb=*-8DBQj@3lBd!tV1{4m8eBubXV(X?XRN4l}{v!Vv}}u9bDg#FwW1e2YPz(0Wt)^s7pr?V>@P zP~^jP8jKSo$7_;Zm*(vy5~=dHaCcYztmqfpRgIU0s}(c)B^9Sa;@w1`Mc8gam+ww- zr!d2&(+==hhW?Q$+bnB_tutb@5t;+E7!}{NO)K+Jl9p2M%o8UPwmJm5<<^D4^rUK! zGQN#xXa}bZw(;lVmkV9~4KWax`};-ybhR#ln0h+UlD4{*g#Pg<--RzqIs~Gf_GR(# ze%0lysCp%7je4^u8(QmGfdGVP`mht`W>Ve%PqbW#m4CQdvw~RbevYI2oy`o1S;}tn zF|DPrsL_Eu(=Z7h+Y{$tqjz$vO3?|J(|PoVXvD{zSB{x$~;iyhmWZc2(xoRuVMIe$$i;cA@J zJm@Kd%KJrM-e_Ccb#6Xe&?W0k;|(EMu8si3K-~-oJ~a*++y&)+Je8zQ;rCAqIPXlt zClHaB=;)XNKtJ^VD-&tFvXQd#xee44{X7g2B#l_0FfhlUw7zS#ZJ}$6gcg=ak2uw) z?00C~MJI8_^<1EQzw8A}Hm#N?XkIl|v1frI;d3 zf>$#7B6GvSM~CAR9}|RNiY@zC9fa959!PsNgXO?M1&vN6Ug$E$K?RPPU>-*ANA$&AQ|nFMrm%Vx<3f|l4Jd%g%9bl1VJ4jOyBtJM*iPlrGQcb{pYb5Y=uwUToUo(!7*&vow+C&OPQZ<+V6wG3EDRNEkcB_?_~rEf?vytBqPqL+8cqj3PDBfNQ;jtV zG*h-@3<#ciIHUsY!U_65m=-s{sbl{HoEv+&krop)GFDp;k$of@XF%0=xw?`P;G#{F zKPmS$*|sucH5n64tuz_RSF&i@JTt3~wOP+MLxjh&1qQ<-d*>0UTS8nZfM6#GbhFor z5cGYJVJ?nnVmZlpe_`@wGdlEmQ#2i(5rScnW+hRo1l!3dk(kA0XT38^;4qOs&&o>$ zn+N)C0tSJ9w4OR*;_yb=*N>Z*YFH;fr}xlax{{4ME{?$Q;Q6Ur?+XKyZIKj`<2Vli zP-A+7-y7!Qu`RITyJZC7V@;9^dRKGqrTdq9C8WCu%bWzycY_%Wg6^BsQ>#iN_u6&G za1qVwM6}|filas!i$U<+aMcw_Sa}vtx~I2o7e^y!Cl4c41611<_#Xphd`|<9h;jao-r{Cn;cG6!Xe!HvHBOERry83xQ04mVsZX5GRXB@q9xif2 zTn}s?l4R$+QQkXPw8YexyBdPt-PEx>gdsbChiKzW)!IQB_4L7mYD_+KF|CsWsT z6u;QL35u0quI7qLhEw_iW@gxuIz)&eWMPGFVQn0V5w8c@AU|0+#9CSi--&7IXaTVh zTNc@h<=`6mc)Zj^rQ8oouYAS+NsFJ@Q#yS~)^Wa?%L4?)T#Ij%EjLk%SF*cl#>>o< z_6P6QF@m3E^i5Y;$K-hj=6iGABLk99#(g4;LcwAFVSaH^0t3KWKzMgZ7MSkX1zJ}jepRcRlvOmsIUPS#)HM~M0 zKNtnqw5)P)=W$CHOQHDnpA-O2?u;tRT%PT=m3?#%W>u1YxK8@V5a1DzvYNfBQd9W8 zWelP&3iV9uA!AHruWIQ2PesxawiKIt{PCTIqUe+D+zp;%oJPaQpbiRp!RcMSoCRGs zBE0aE#MjaFE9dp+K0>%2sSy2?kI9O<;y+vCJV&$UYK&Vbjm*=H=~8G%LSVosJ6N|yrbQl0UZ?WTswgyLXb*6S`w-=;7SWu& zpq>_;vy@)o?4F=KawtT9iVupP8sp$n->>*kdB6VyMA&9U{)Ki{ct>wzq3)P|EWmp$o=vVyULp5qQ{e%29SoKV66PcN z!vL&gP7lzEpV{X$O`J`TFvPPX1v{{+V#^8=1BMgj7WZ=HNmGc1nUJV)SJ!y+stPKP z=H+hYdm)l+y7wkJ^=0+J`nT7P8#6TNZekoc(?BXE3iC$!NX!{plG2@P zx%C1*SiHe<#0N>bD=qvFq#*QXzLhF;!ZRqvxh0rOCb)`!8biuz?H8Ou0%>bvvm|FE zhe_M6Dk|PR455OX%(CrSA>o>_LT4Ny2M=1f>>Qamj(Zyzs28@BPr=xG8~^HCvMsnG z)>Nuc!gg#ikhzR_cXIXWXdr9qKr&zKTN}&fs*eSZmL_{b^7KGRoL>L1a{PYJ6gcP zFwf(A8lW>Gnl35-ECw01+D31~SluJkskmidd8()EwH}W(WtwntaBrkqsM`?HQG4`5 zh*I>e)7a1$sJ<&vVTVG^gI6{mhbvOkwB>6X3z*Em#@dcZ=OSK72H zg9@G7KH1|(8|0CJVBJR=PJDnRl9=7Tg~hOx*iy36M8Dcsi}on7<(sWq{Hym!R__)` zF>KyyR21<$JtC{HtFO!~jTwOTs~kCBO;?IwmG+O?WKb%GlYoR$=-mc2VsbwES^GgX zZ5Ku;r7^VN*TiUX!*k}ScIj;ku(t>bOuow@aL_1*hIghr#Bt!99)9%^CqUD_OF}!i z@s{i);D^k`mtB;9>&wRy_QP;x6d#e(2J8!Is4KmZvIV{)+LxqHZ z(Nu&pl_tiG2-HEBC;?D?9dZg#yCoz7ABi!Mv&A`W!BeR*i90i#k+b_VJj^bfl~b3y zWxnN|4LHZsgq?P5D8oG-W|dl0D9UpN)|m$wd#kq}4-01(gyE>|w5>hWQtmD(r)4K< zFqhE-T%J{?={r}fe^;A!`GMGGF{4Jq(>x2>G!$80GPRpN15vyq(Kn?@o~b#}$~bI| z`TX-Q3?n*^nb!mz{K|c+7$FpW`)UTrY-FM(6%q)8tdp6Vhvm1xJ_kvQ&I-$zkQnBTxd0*1geOyY=J3|yvLfulZ3N`<|4L_o1rnANAfpug#QVo>Jq z(2wP{P&YyGo<8?K67u(avR?$Xl-;`-d`@-$rn%3lc;cG?prWX^Zt`%0pcm3+)+2Bc zGl2mYI8`Ni@~vYo(z${`uH7yP`TY5ioaUu^&{BQY;)5R#@I#wznHr_~)p$TvL3r7F zI@$bUo)qb4dQr06t3w~syUFhCm7D~{2lRcRrmJ!C{3Xp5ptiOZ^pLa+1pUo^EG9j7#+L7 zsq+G8qdWC>dl{x}Lns-0LUKZyU6_*ahBQjM1vOCrM%DT z5-PH=errp|>_{~tV*;Q?cHcy;{a=KRSySoE|37rVp<1t*T5qW+sSXi`M80$@O8#^B z9MXK?RI(lJibFdP9IiF2Y&>d_*Y1c%#Hg?5vJ^osV%%4SDwIi{xKT8vN%S{a(ml@|i5{J;?38{kufgb+~pwZSxghgUsyV*&uJz zoG8S$QO66FP5-geDi&I##(lZilDZE0f@@1o6wGqS>wSw!yJ(X$tuCVO@n}|Zrl~_8 z%XC*%U3DH=;GwbF5sHRSdo!4}mPzL=omU?_2b+2YiksKt1;9_48n?FanNl2q=QEu< zdB*o&;=!jeSK$XA;>XeX$r6e$u%3oIAwupwFT6paS;;_32_KOnHkT25M%8Ka^*G#! zZ^1yq#9dAL{S+#NTiADh6PwVyGMpN?N~(RfWyCrb#93QY5lAtP8fu7#Ee-J zny)m+^4$6(SGaC5t1#VDq(`h!2SIR-(1DoR zf`%%&`kzX~ux9u|Z>VFK12hwxQ{GDq7(nDwurZ;h+Y`DYc(`3A`#aLgge`xZ_ z)xU<|z*J|5I!~={I=1PRDbW{ny?Y9`YGyN}qR#432jBDc%>zgfS&A8Q6QQ>uNT_(z zOb)%`IU%_%s6F%EtHoL$POqN)`c@GzuHd*%aq`Gq(=3P-UD_ss8iKlhogI8}I1cs# zs47h3WZMnqc+BlJ6z`Q?Eb-5?mCaw9sZZUkhPoWqx8-_yNvjgVAP#NiutJH*Im5yh zVTvn%0wfspy`41l+UfWXj8GzfTJzU!Z(s%Ai!9WfH>`p*OeYVLm_(T(T*JQR7@9B5 zn1etWBdBBs;srQb@uAvViv@T6{auVbSmlN=LC2MH^!W>%1&yxT4v-cgMD4EAcx~`* zU1vRRxany^y*|fyn-ViEl(|SxzVPzoX!q53ikl@Cf1CP4Kx6)FXSMwA0g%R5O>;h} z4mK!VfjJpL|MV`SorJJ*>}FdB487x__QX}#Ow~W3oL|OJmn&A{)?bgfZdk}EDgzLr?sRG zdS72CX}lSb+3Aza@XoOLd(KFkyA?@{9IQw5@=HjE-~vktbgj;x9KKemOqvb(uIT`mth`bnR$=rn+K-ZG4e9x+SinZFnrZZ*U3q^>GpF(=aR}GHoeY^t8In+2WG6K-e3N1&9=?|O zPz^ba+;xvJlP-7ljX-Fcae&^CgR|LvS&oO;R>a_TikwD;JNUy2@Iu^RCQ#t?9>^4r zvc#wT>=m3dhVXQ*qui>+`c$DGs^78de`rb$RM*w*8Tccu-d?=lqjJ+Zzgm6CdSG54 z8(By*rL-J@>9_#qERL_L?rnKx{6c) zUK57a6uU`6yML6Wd7O6S*zk3E_lgW6L&s4URrHQFIRHxp?1uNS2qpWXh(qifWeZb5 zWyTB9DDt6{rk^@t>@5|brRMmlAS7Emc)#%s#hi~ics2&H922`>1(|&VlS%O;T@&Pz zts~sBtz!<|vUccuBF#SThQ3VKRDo;%5d&icf4_aSvD>CBm@SwZv&XDa6}*T(hnQyP@?Rv9BL|WDmB7KiY)tmUal6LW z5bjkF1}CSrrMtx0Zor;OPQvPz)&h@`XuFZKvR3VLz4B=gpke|bu6ZLEZF^kb4Dm0M z*D9%LS&_v3sDeL!RX-fN-OL2)o~|j3xMKJOtk9(a>XFogdvDlClaHMtUI$qtQSx55 z32AcblM4m&JXL-58LEscpeWXcvtBtSZQ%A9X<=b8-&Tk02RF<4zBdmXuk-mqVYSPK z>%^(TW<0sn{=y(8$2$C(jOOOywPB}45zORyt$z|)=+ z8oj(WGGR6Z!nhX7Jjzpb{rjHSDH8hO-6>6ri3)oawS_Z*C!ykSp91M9tQVW`@hH*O zkPNSW%fpdlv$+hivj+@dei(j1ij@SU-p240Aw1W?Ys~GE0VboCJSss_j)ZD>q`}wE2v_qn@6;_9SpF(>)VwEPC^Sd*;KrSK zi9xQXlZ#~aUo-qUwfY`~aJd;SPj)g6n{lE_n*B|yb!KX-0=6ntpiDB^uvED-5O!%M zeRRCny90QZLl~SevXHn>{EjUZ&w7j*W z+abVm{O0*VI};{u&}qty1Xtw?OaM#K;?bA2`SKaM>1ot$L@vr;+l#53y?H{ximgFf z!E?Y^Y)FHUk(N=i-1|#IP>?<6BgpZqT(K6UxjJx5WG3chMR$30ar?IN!~$fiB+`<9 zY20v>^*V2EMbgDx`dMG!L5bW#2gasQ+BHZ*G`iJN8*Ut**lT&ANDZAm%x@vnIcwqD z>6j1>MOyLq;m0xB|C!7mSWAk{s`@U@o~$=2U4m#XzC?#UciR*M`nMQ+w^?ePfPBrs zUVML_;O}cf5JCkr(XdWMR6Dvn7j~S>f4l~W?$E}4GR=&`AP+Fl^V;lp&{o(lg%8D~ z1_ZTSwJgoau$?>mL`1l|P?iG3Br!%3qz}R1cOXS2rqii|HelNNi7rKB&B}eRIC+M= zhMAGl=u)WwtQQ(Zn|Rbob$`5$BEqaX?VUEzmSNihpBgg374A=Ukr9=pVZ=!T(ZN1a zS6n)ztB)BkM$lN(j1l$BOjM^^_+${3WRSa;eZdBT`x$bKHPGh}(u2$_{64_Rem&YM=K%qqH6MF!)!>At|gj5WLKJ$f6Ac zwTlU&fbl;nih8m$Gm-fWRz9hv>jU|(f6om)i-DE`cP8|px;-H9Nkg60gOPkY6?@}+r(}zilCt`b$IdWO)&fU98bN5+eX>LLOq9TX)jyx3u4*Vi1UgQ}L zm3{`F&pHpF3p-JG zE%ent?ldIWFSVk&bC-5#n8OmVS5{&Q5%5243%a+dDkWb=-1-p%J>6G#Qz0}C6$Mu) zTl4#JO0m%7id3y}N!?(21oGB@_^~~5`28PlXN^~h9HF8C0weYLzP`)`iqzcJ|DoG? z%PF`yYvH*D=isf#ABXYITi6V$*sZfp>}6zgf*-1bs7+aP`Vne(56q>r)Bq?>Q$EC#VltEivGA=wqY+s_Q?FM0&Ll zk8wP>c+m$3Iiy;E4^b8UIu10C#y!Q_O@G=qZYikFtZY#%xDXpl(p#ZTemi%nuXF%= zR;}{)aFgQBV`!ZTjL(VQ5;|iNb9sibR6`cmTW%@WmOC;s!=G&YUibIj zyNXQ)8tW7w@>6IRE9)oW=TX4VNZ49W*;f@a4@b7%*ip}0IiTS zEmTg9E;g%!Wt(cb0m4P&8gNhGt}MuYYtG1WZmR0x93qdT3Rsoq%CCv^%Ai53e){s? zO`QmzW>8tMN9|(BBiVplC%&fJAq=?(`4}2)y{`KUp6M==f;t8;3YC#cvj$rjQ7ro0 z^056a(n645qk?w{>Ov<8tSeQEwWCv|bI=1Z*-UAFF{s z%1<|_`>ERRn?LcqH$RBH^yzMBwmn-n+i@s1OS?1G`+Fosq#pydSASC%CwXpoY$@#V z8Ok#CP8Ose_6|bp(}YO{`Hb;~_Q_Zh+5ksFjgL$<9w1rNf+!NI2i!-^!Y-)Tb8{~2 zvR?rb#(gux>qo1purPz{EX*o<-=@VWjBtd`%C zMo;&^T-`a+ouj2K`0vF`$9q?21E|u#iA8ss@Fqp{TFh==*ACuJ6zd&Jr-dWu<&*68 zdJp63CW5Q~L2SQ5wMqzaV;FwPYzU?-lSY~8A4^l&oEvQb8SQG3bl3Cu;TELaF?5%f3IKVC9tr~gQFWxIIqC)qwus8K^G?qg*3+Xd< zjstuHR8Zt}}4Ee_(~vxfELz*;|c3->k!$%i3j;gg8ZP|4N4?7_Q{p+I7p{CLYn>jgFYQY9x<2uM$&SR z%Nah2sELRT;Lg~HYq?f>j(2&hYN$|ulGO(;bUtFQu#&%p(?=>`F}S|iQz>~`TTy5w zR7C3h0AAEg)_XcjRS%jiF@~PpPKK&Pzz=+UNa=kar*4~txj@Xl>(?AerW-SyKS6nuH_(>m>IYz!%gBV z{aqS)I6E-gLyR^E&<`t=1N)Ch6UCkAYJfi=3O0UCFFsE(5`g(Q>B~Mbrs5+8Zu$I5 zgzHuJ550_VK%eQmYRCYG@~`v?HdG7{jbY~&PR zt2d^Ohc|;L!EA5n-#rlgENB3H1IcAIEw#UH3rJ$9ikE^TNHs_1;6lp#_xIMxDaYq&j8ObI7TZGMiTtgn#GVZL^gLnYCJbv zN9EyxI7KCAlU~Kr4yFK%Y|bm9uo=u4ce#hH({=3YTkEWtL%%3(Wp;W***=bk)*K~r zQ|Phl#w6PC>9#_c*_TS{!_3ODigyGd0{$sdPS45~d9k}q*T7v8*iPjeP8cz0OJ%oU zzpU6T+osIKK^d8@+U`!cbXzQE8ja19^7=poD5@8J!>@|5?Mf?d?cM_E>`WQVTF|I9 z&OE)_8?p=h_&yLDW5H6Xy0CMIG57oRqMA5jb{*m|T?=V9&EpW|v*%s2X z3%VxOnI#MRr`Kr2lA#!F|1D8UN=ymA$Xr%3+|dv*(CyoHOP2+a)p(1OL=Z=H)FZA9 zu;Jfr93We;UGE3b%oDx5yP1Wla)ze8%5oRk26AO*zBHzmKc3#>enkD6b8A)JY&jG& zc6iy%`u6g386E!k_(ca|Ij0y$(amO61OH?PAHS83tIlE6abAq`_5cN{2YziE!ON^w znxVZ$SGqoW^e&&D+++_qbsVkQ1e1rUcDn~ZsC$}5LJOz{Rh8I#q$$MUZS`1N&keOq z5qQW@1fT@e^_Dt*tOs2330;T>MLfiBBSbkUS9}tr>6^)Do2lY3Ln|{gN=JOpE>|*m z12yH1ou?Rz{66xP$MiH9W>E0YlUZ4TVS`M0?j2q)B zs{O+0mvjU7cE!!~u&jG@@rS}$RCRYP_WS4bmc^Ne?U6@f5RTxuOq6h#BGApLMo!hu z%VIzGWR4ykgaW}TQ=-q^4hShI#TjiLSdCaCf^mWw%XV6q!+4ae+*!a?H%od5`Lt`X zw4J{?+W_GyFKgqqGD`^tn?*hhClt6a)yG^ARPyHKCS__|AwnSDSSAoVggu}e2Ahy6 zYWf_nERORU|8~@b=Br7XBae_rcKoO+pX5c>;{Kf&TN2$RKjq-$OWkITTEqs{kA4RV zGE8)kCKRGSFF(J$3j0PX?F8YvK5k)3_=J69|8UL60I0gV?-V4W_Dfizr_($gxWC0_ zf({O%+l6n`hU|@&R!ar0z3XAGYJuE;iRhRXz(M3q#dJlrYpSC~)@%wpGdZb+On9di zkK@c|A`Nk$9&W_y`$dJJ0SP6U7lTD>t1e3j8ME#xLrYuUi0aSoGDuoDlJwCW*%80V zEIGPC9|75L{6EUSwqLCe0NKlRa=m2ps1i0D4iae_LcIU@x(3eYR-B&l5rHbh#LSF^gXGT1y{lKbX(6kGtoqo+(G*IC|^%nz#qV* zq~;#RJ@P#5$gjPl_* zFcXrCXdJ|*bP}aWzO9YPycrBE!inW{5ZDdma*tH4tAJrjo0W+s+WAQ!;5p&8fD8_XyI8)_B978ICHi5#A=b`8?iGR2gXbGJfL(eF5$0t8p-31^jo zO*TUT`VA;Ne=rd$aK0|v`sdPUZ{6PMLO)|$$L!&lc;`BlpPnVuG?O{Nn*iiuLWR#` zICcRv&O&ZC-g@;~tK0fmqU}vp5dLGAM}9yFBh(U3#1o(xD*Mik1xSt z34R^(7XNQyk`Vc&LVF`UWpcvyYPDf2q3D%+Gabe745(8sY&Rk$Xf<db=Q7J)jAlE1_oi$5DSo=a3pBRT`&zkXO*ak5<5CiK z3JdP5+!?(oYbL~rsDTruf=fI5K7|OPp>vUz!Pa-Jm|r!ZxBx!G;A&!r_F6K+5S z>Y5p%h!7~_Uvw<^DP<2b;4_lBD>9XAc{3VI?T>pIdnltvEHcaltb7hAX|0ZbxCbSuccG*Hp#%HGRfQ9$NoI8)Z2hdmh^@;d#&ZO;4Bh$r0AiUhE>Uj@+R zr~=d3c{18XGrnD{H(v8<2RM6bZ*KdJ=d*M$7&Hnz1YQ0vfO8M8iRZ~Fz;x&IWS#tK z$SF|(o&XV!&aFsApC%T&Zpg>)VU%9>Mm#eZ9{cB*2WpoW&?@pqZs!N`%5>@!ygQ!J zJFUdoaW%SlXWQw%a>sY~5ndJy7+TU30_=L$s$ktYJ+T*Ix%mX`ZPwVbip0m<*AwE~ zuTkx{)Wdan#2M$oWyATL=2xs?SLg?y2qHcSaQ(-d8Y9CYFc4T&V>?fxERW~L$4U_z=k}5_V^=$bMV+A z$^Yma9{^F=>xLV2^XZ2Sf{DEFwB^zJ|Dd|AVIcC@28pG@fkC;$2qN{Ta8rR!<>C=L*eha#jqboYdeMH?G# zHOw`J46CLXj(ofSe)(K?x41xA&T1R5{|!a`U&y((9O4KXZNWkb>xD~}`(^hRb%#OJ znB^kv1-M=d&;BZNoqP^?zcFGvtLL*IvhmtScg&mEqN5;dT?a7;u4N|qWYKO^XU!&* zPnRROd`}Q=t()hMy{q@xhKZ4cr%xV0gfW=#ytxTV0cj9A)DnpFX88_wQC&!!2n}nL zhA4qk1PaW)_w8-G>kKz6d}tzI$ayw>V{J4594mA`yjyu7-~e`{XefXk-H z2MboKydR_ACxW}mA63_w1`CkPg>`;#|1VCc|7OiPjp~|cdhB%+TN$GW+&uGbE<1IM z^-va|xZmP|4+%v6jh*73HLa<7b%~(bJK+pl1tdNwg?5~dhzhj%{9Aa;gM_dV$h(6w zJkbn$dVzmxdSrpYNGWy6gk!?C_C!?23`4f9%}tHbXf5$jDR>yTT zQ2{%-dt*TE?@Z0t?|v+v#_LBn4x&fET!{|Dy0?ea37X7yl_^jur?i0e*l4HqmF{Ru zP2e4Q7-5`fpGVSt99;b;U9Kz5?sBZyo{Z|HBGES0Nmp%!rR6Zm6k+zdO)PnGaP8OC zNlAj_y(cX;EZLJXKXWqgJ4n7g=dVrXjGDYsH&(n>nA~({ynUE#Mfj(4@Ztk8lnECf zzcM9(_+i2&Ah{ff(y?G^Iv_|m*m-+fgG#!~0GoLsr##j2j(6+X35oqc!GWa5;C3qf zY`5jcFT#|1{wwMqELOTR^sRk=gaIzN!zq9gcf=TpY8bA+AZCLAo@WJy-#44gmK6M| z#>w5)X&#PKdj!EPCHJ!pk(v0*48CaytLHx~IaK5k^`k1QSnR2X zwXF7G^?dK@G-*ZcbpUs>95{#nxtbRsvHeSj{Ldfr(o8E@g=C?6f^3B*#*71?0CP52 zgu#ozcc26b#%5Y-xAz<7!h6o_#?+2k!ZhEi-ZVDVYEBeClmDY@<8O=;k3t1o^!M1^ zNCmY!z^2FA*a9KFfXCJ@h?`wCOk5$RLr{%f?jFO~HF<$9Fj(WqvcZZ)Exl4_Rlq)#1B*@+ z^T2Ks70@lF+Kj!AJfAv9GvJ~G^bp@aYhjmt`BnwCvG15KEkv`af!`2Z6+H$4u-rnu zF|&EyRAWZkKAG3rt2gR1Cy4STZJd84ZuI3uag;2sdeb-!KhANpGzj*XxlVyKq*k*^ z1ZD3`RLM#`T$=JcF+>*keO|CV-1wD)Z#CS0m7lWIp-An-*{=Nb4_4H`zJ;S|w8R_U z{LM_M3c$BF%!>;Y?PwiHpi;LN^|h(#BGuET?OwH-O^OyL-oLQ4o?S>1_)~oY~Sn2nBSyFY#G5d%(#ei3B*e{gb<^z|5ZPNx zrLarf)JBYX97FSZmEniu_U$krB=mrQMCHky;Xw2usGg{H3BEwYek=1ggI^sa_P1eX z4q^uu5Syhh8jP4(7<4VF6h*eDwO)*WxPx~zXoyVBD?*%EOseO`Ag!(Rd*Zo8wkg!o zoq9rs^~LDHixS2kl81%)W-*fP{@I8q)En~x2rF}k-tqc@FHGF0oK@2Y@nI(%t7{3H zfiUl=90ZlK)0N6B6``Xn;_s;`6T~~MS(4cq^(6y%Ognsl0oPv2sKNct2t~oY93;qu z42dS);xDO$8xMG-Z7uM#swz3)zPNQ8Y`r^tCnUKO!LHoK#VTEt?-nA8U^tz7ab!D z5KMnm$*s@@cv@v{%yn5o^;1#+5*BV$v(~&4)VvTaif7`u;pT3CdjiiCn)cB2&-Pgm zj0na<*l64{iobztMLI%i?pFi(jfn+E{=z@|e`_HsLNS9*u1BxhQW1dx*-+J|Q&t)V zz;IBG*Ai)=;uZum3tm!v0Y0H)B+>7Yf7bx{52w@!0Z^Mvh*((^#9|fI?#Tcstl415(o!E@TWuea}9KqMN zTvBw|PYC!UUlALAe5H7koB1a*sAp_`vzjnr-IO>j6c1E;gKqYWRAv?#X$a7??$hhC z)b|Zo%VB4bF$CjZcXdNCb1;pBV9Kv*Xo$mbiupnd9vokrnV=M|HFDA)7IJRXml&iM z!8zp1V}vbS-0qwA^3YYmDjCP1G7#kDS2$GMYJc2e_vWp9&a7mJuN@NhA5#+~G}D+W zDY_-dEUnmo4Y$pBeQ>iNY*i=Jank*@O02LaJubHZnyBzuTCX051FzqB#$*oL8z~Ya=HUBV0M$EVw~y3EM8C?;KxBu-YJ|5fF#>sOL!p8vm-)4_)W(BM2R_e14xQ_`VlMqs0|rw}hek+bT1^2QTG^P#kmW(7 zTf>8TPq~`~je(X0du_N>u!Tws35^x@9(hW~{O52JY>LS7;lyC5%r7553|IbGqXh2+ zsXSS*HojmMsjX!3`(EUl>yA^gi(J(OMuS9$r!8|q8R(}i_b#Yw1*hnutCnwIRi^l% zWZ3!yN$$=?a~4ArN#FddNSYV~erpp0YLVnM*ZnA-Bq+Zhv6u%v5>kHN63FOL%aRz4 z=L5$3SNR|xHLQd?9r9O}+OApxd?o?zn^^=2UwmqJiX_mG8D`!P>aB061d<=vzfN`% zi(0>#Ms6>QIw%0(nm?y`JN7tp#@q*69YJft&*w6&T0g@moEGR|VQ-%=hp{(~5S=zY z`^|wEtQMhOLm4`zsT6=G>#0=;nPz~Gl*l*%j0a!B_Zl~yT*VB7#;Rw&W}BGflOEqR z-wR9NuT{n9=jUTqy4HcJMA_+&GG?wQD?3LUnTSg;=hy>P0gJ^(wAshuWr8&_^g*Kl z3C2+%+WVrJ$J|%N*vcyghZ_obxu!wauag?Gk^OUj{ZyekbPaajPiaL?fu>|IeD!=~ zRC3Cc!z&?5(5hsr$?nt-YuQNL1_>eMMZIn zeU$(CZ4s?C_|R};+DMjfjPT2pjoixb6gHuRH}bG-(?9WG0rG3~yV|w2XP#wdo!3wu zs_kBAs|AduAa|(G(G>bM!-k+Vy!DVF1~Z{sx6Jv$zl%}|ayd>{T{43tyU@8{j5Jk9 z_^SZJ*%0Mg>Cttl$mPc8z$HO#xi^3o6F}?&AP&z&e`+H*#a=tRi;zI+VHbtE!nOhN&$E1IYrkk+ zs$=jZrCEZRhZofI2ZuA>RSkaWXzOh>krlc((w$ZDXWn)Z% z$nrPdd;IqWiE4h3*rH;V|Gl=EMojZh!?@17ow$8vT7#$hK)8_R61Lq&oCotbH#{Pg zxB6~)`+-)lSuED$KUHd-lo%xK|!heo7yt}??Ig6cm_mGJn9 zl&C(v0!BXowwxADCN+b`_0Sp3wE9qtgR!;X+I``_#pTiPtfyoz-L__ykp$8ZeG&il zC+_C91^TakfCo9@)m4i&tKaRK*pHqwYgywRvUY>!P4q0;^~EJS?oZTBkKYbBhe-1y zy+!4{6GWjN@!lH?H@}W6J3gB9u(^ZWu^mfYb&d6$6#fBu#`w;*6_{^2fX$l8p#6Ov$hGHKw zNEDvbd>Q;e2yEg(e10U3W;G!)$#s0 z?XcNi$)^i};P$6eU?+^7yY;D$WC&oSAR6>xmiv2ud(7gTEug9Q5ml8G79b_g=6hL0 zSYtK%4+p(ItdH+=9LGqxTYr8VJCtQxE;`&+F+j)sN(jyl2YC92`j1I`>c=Tp-Y$ZxV)!qG%dm^U_O7XSgOk1fr?g z`1%Rfb}BwB0pMlh$*m$Y%-q}*pA2tNwU^vR2ZjuTbiKVU!$e#1+x&P1bK1r+KEenl zF!GPk?sAO$>$#2kLclEXXClG_oiV6H$!#xcMfypC0*l7>K#2jYr=yuy?qpqE*J%&u z^?yF#i0j2d$_CP=)D&j)-KdH!IZ^`wl!Zi-!5=HXt?n?dHwuJY^#YAG zc+|DvYqfBTR=6oX0^D$&BY>|bc1694Zpfj!w~&G0vk}#^S7|5k%GA;P7|53vIcNPT z&vSrb<1i3IqOtc|qAc-I<&-ezojO`R@fQJWS<>_tgq$My5j@QVD8!b@K-t4s{8&Or z>cmM=HgepoeEUy*d7NLDr{2qGl>ir%G)`#x-FHBiDR#RHKMOYDu-;3gcMLZb3AM96 z+3U!4Bcd<~{8IN63k|e)V*kJE6Zmv;SmxL)>*~?8#k1}>8YYVA&SlF^1w9H;gA-t( zQg!*aajVuQ9;ka3u&d1%CsNHNkA2>DF~Z~WT!V+rRqA7Yy7YE z20sER(fFU9TQv}3A(B;glEV8PuK@6p>wSid1PGkFCD%`{=2O<@uKCoXpbVP znE?ic_R+Lrwy{Q}mV#6s7mnG;YV1X6c(8^R!3qCg_e`gz9GBA{OK;9>@TbyH8WM2L z$e|s5OZ4&Lj8-n!0bwXocb8!HdZUNy zy6}q(*Ymf{K_Pp3{UcCLr@U~iP)9HNiEYJ3oMjt|A3*IulE8eCCU@Ovq(EjgrU3M^ zSI4b%q1pKC@p6F+a;x=wLgG9IX9VH~U-Pa71%=K$#Ne=@n?i0ti@~pLsMvaOZRNUd zK7w=fpcI8Y4GRVdey&n8QtFi#LS?lhJIPnRHL#_3!7auTG-VuczW59Qh=e^6v6||= zm>Md*tqo}%9%H%Sm6CDUAi{X@rKCB*tyEG!kAztEOV>pQ!<;wh24`IX^H9qGukyN) z7*e-|c9K0Uh4ZE#yKCSgxve*8@@TUsA2aUU0ghe^*%c9J3E!X?DJP{lNOsH=b(B?< z+PWJq5tBbTw}dJTJR%YAuTGIElepNY?r0iRHb%s=v5&kP2EZ<_Mz5Fi^RwPSrUz4@ z4Glq6P^S$iS=Yr(_Ya*D66NMm+7|`iNgQ6^#0A*sD7p*PKjZ_>=CLpK!&R|hJTCSx zxtS@|RY$gAZd>udSoh69(O)bW!ShtUGzWBEa<_UU}(q6S0h@=P(g9Hph zi#^@`#vc7RLz*G1co85biHTI~Hr8JAmf8J2@cX}l3i4??X^1QL2(I?or!7tFt>;$C zz`$zf*`B5nt3=VvS*1{gefa?N@6W(1Q@_c`M5kStY+xBbZ`Q#zZjO$8(05&_Q@5`+ z-mW?(d42M>&MH7qM_wd(r|n%lF^aIvjuFcW*?F20>aA`1Qki2AJ(&lNH&AXnX>F@q z;N>dt*;6D!3VJPBb6jZp7zL%C3kO>9;@l!7qvP>dUb++(_u{2}$6Q|6CE?1dxT7IC z;S``uL9}Lw%EXbv4UUP88!6qftHngOwb3fq`J;X4Wp2hmj_-z-2b7*rScWh^^d#Q3 zfPB;7f1l3@^(t_sdYRzw0FUN5NagfYPaH$&#U=jS+An_+47!V!K>At{`fWSRi5#L^ zL-wlu56#L|3+Se|$I8vI7e@Q!@dFeXa>HsAKFA)SdfB-9X2h9^UyKJy%~Brs;)6FT zPwV$bvQ@y`=_@54BNRQRk9=WP+usxrKj<+-@O)~wN)enYHpO=m3?8H`hjuS+oaQt@K`x*O%p!mYsi zKu>c3M>4QO!P9Ru*3BN}-u#RT`}fQ#Doe4y^^*|rd#;3}43Xl~TZ`1EFT zLFT|Pd>9Qe*AUB#dF|V5&64#Sres6FTLRwC+6dy}OoWXd_TTlhEL#?DjPxmY9ojLnhf%yQ?_^iu)X{#u;4}Yry;MK;$=^~0wX^`F5i{Qx!HiT=3>74j~Y^g zZ#7O(7CY0758^zBVr8?p?KmPygBl?<s;LI=$)0Uzov1q1W;^!)ZsEn;QiWWks+xzlSE6Nn0VtC44`c)<2JW>v)Q2_54rtQ?_{&N~AGi zWUmB5x~aYqrDK@qe(9x6C)qikM=hL@v7Dr8^yzmNHd(p_`KtWHuiK&Kpb0CPQG_0# z)e+SDke_!qKn-Pm1&R>{AbV@VkR_|xeEwVXmlGfm#5_}-pO(5RvGOhWLl958bd?>{ zqs!Y=WE7iWp_EC0fwM zqS-mpnQ{mBJWU$gno0?LxNL#vF@Io`hU_G3tzFyTc@grka_g%L3?uK9S6?&-LssP{ zu_(uA2zY7bIWYn zkI~eABjoAyIJO)4G6- z1qt6i3pG$4pcv>8zEe7nB`Ca7Uhda$b!Q02Z`fNl z$(dyk!tiEn>lS$S$NL44?_jZqyHzKwkWHRAdm9lAo^JGM6j(`+WMtQKbZOUTNra2>`k2CeRidmxY0ee@|&aAC8r~aI+y(-*Ot^LjtxiOh>gyi>7PW8 zERrf-1dL>i#DTymlaD+-5IE&RU&liyvwKIY50Z+|G)#ru*#9O~A#06Gtv7yO>Sf$N zLjfwUeGkTAPP%A!L!qE#lyQ29(4Wkus_SI>$(CejbCRcj)RZWoTU>viv!ZT>=GBGv z;64^y4aafsY9jU(XK^r=b`mjR$-cdEA{ zeI3HRWs9cGW?fN#wv0`T9o%+^uMHOY-Y(#!olx^Kuu|(lm&t~Bu0^TMF5D&6@?hNs z6^@9Llcf;pBPq%9pzkj7Gs%jchs^EA?{uwF%Db3VaiKtW!8&03Rx7+|)FU#zVSbY8 z3sUy}hF|yUK#LA>_;VW*@E^)jW7%r-Q2%p%au_#yWt_U!#!taiO+H@tgw|Z$3L0Q^ zLd9^b0yIEGR6E#Pgx1_=6E;1NFVieiTF~yj4_-xb*3uLSu>fPTl~#8sA11c*nK?HS ztN`4UNp_*6eF#3G^-O!lhXJIVAZ#ysJzGa_uF3evLuSyBGQGdWtcH+_wsn{}K6DNC zx=S!hH2IfqbN0tvN2F8gQS(~K-A;ukKCUl1GTn|(&Vf*YZIoaTJH_-mSR?BDL$z54 z+4)7~>}nVMRqA`k-l>ffN_clWH|npL7@#3vnEuR=UW=@NsU35AaBhpw4`LHH9|%HP;O*p3CB(J@A&Z4ox|3 zMq5$1lOz_ygM^4WQUaGKcwW$s*sZ?Q?-LC*TGm_?UC_4+x4-V$nB-g;$$LzT=Q1lYcUKWSvlu1NOr(xSlWe^fNSLW!095- zhfvSySgiq%F{*YizNrM4o}ZryWoeOwJQ>tzI$6VfuBa02!2 zgmkyU6jDwQ=9=y{6Yht=wM3#WUQb@y@_dsFGX(CJPH(_~9M*XTl(c6QYow|U&ibdS zj=P?VY0VHY{l@yiBz-m}b}h)j3IGuDxXS(}zc;47B3bO)y1~?$k=9Nsb+DfIw&q@B z+Ay<*I49CtMv)fkNOW<{QY|rtsh_}}#mR2F)Ph#M*=ABYmz>$)4ijZ-7f+7u5^yRo z#&<&P{DBZ8ii8B0bQzanuw&>WL1{*Vt{U7xG5bsb4%91_#>m3KW-BS&lH_>&Z+==W zvjP;LDbe{)4g?gm*=_Cd`*ZfvW*pSa0fqfU7q=(z6E3M(Ac&K+DHHDW>j@ZIJ&&>6 z2$X6&ZnW>|BGJ0nXY@~!O#rG&y;echvRAb7oCY$5vCE9{#skpvsA>r0>T$CwQ4mSq zYM54g>ICrm&xJ_XD*fShOBA8w2M^BS;@J*Pe7IvtQYyvp0W7J>TEZiIn~{9G()}Nt zI(WvtKHDy*IcX{oA_n7Iz9QlGC&xGnF#S^vtl8*3UM6XLNRDM~f|(dKZ=ahC$)U>n znm0K+!*iwdlZ9rxuU|)_$!*{mfnZ~$tG{vGofVCQ{8uQ}+?{)N{OX!@DYZ2h1`QX+ zvx?JXsCT2*vx0!ZG^7PAfiAa#qI&~Ot&#X?xMT_QUkWeFU4~TM>L%WN@F2TWE<`Ri z&#V;hxg01V*w-n5No30CC9qm!nW=l#LarAL%vVR zB?Se`xTuNAKaUoI%r1-#vsR~gM{$b%IeVNQFz(ds5Af`#3Q9bzI?@}e$Zh!e9&2d2 zb}-gcl--;P`_zN^ey%Y$B1>d8(_8gP^B71OETy&3`xC&m?}(_;ynUz4i**1dtjP9k zm&LK^mg>Cfgo8`N$M6%T<+x(omce$9OOdditjzdvD8~)W}qy6%F2U)-p;VH`N`iR>E?4{(%yeXNq?1 zuOiAL?9y9t=-R!w7xcLMk7dLhVfX&`8+rq1uQuS8>ccuRBFrfZjpKQF{5(LD+WY!e z*}gLt?~;?*W4?Fd&}dK-YhNEVnA&D9{T`aDw<(f(-dp;mel8fFgTmURjGr9=ANUHl z;1yBUzr@qXGr@_|Ha)nWc@;-OydgxsUSxq@y8@ECWj)0J62CENHP{fVTriGnuTI#2(3(rIzOykMh+`ePOXEeF1c^47oR6vSWW%YIr`cu_`7B zcs}EK+c+RdR+mZZdb#ApQNpFRtO*Z?k)YRYBp!iY>%tE$??JH6S}N?P@fyHRXcY8k zJd_IvBaL#{;5+P=pKS$l%@}C-&0WfoX%zq=>hHe zYDAF7ewD*Uk?$VW!Es#6Izkeb9p$Y}i-8{U&U}zz5&R9e^JtYKtiJkwQL@CVyl|4< zcFSLk%FZZWa_9Lf?sUL*v6&5;kVEhlrcxn$?EF7V&1Us^8@m?7?mvJTb!+U9-I_aBk;rbeW#EgDrbK=r3#S*Q*YCTlH&j zu*$N>_E;0`{i%?<#g|UxTmn;O%kv`s7izI~XaZ78J-cs9Q+3dKI0S_1d%tT`BIGC< zzuOH$!UuTLo1+QxAwI(rz+3qcP{I5=dT1ou-S(WQ^vqW^VhX`eK%e!_=r ztl=|;&E)T>|7bcX2P{f*gKUT=VTj8De(q;KTrEnqApSVGVfo9B_=D>*R)G3zp)p7O zszQ>x+dIk+1XJ27@>Ef^M~B$GBCp6Nf4-)u{oxf<7AbQR8()F`q8+hc#{J9+^r!ggqBn>NQc+0>`Pgo z5D9(?{^F5|8{sS+7`OI*#sLLJNm!s{0Ep+4rHV_c_Hyhhf4z|0@MQImS-`tn062CJ z1-C$rS~^~jBK4CgU9qtL_fsAf2$#MQ|MJPquS#OCpG^X zrS#Ia4~uj?YHe!@rQoLnd_ogy-%FyS#&QE$C+l`mV9nO|e>A4A3Eua|cngS{RbqK} zyJz%JWrnEWgOa2qAc)so9qoNo#>uvx!>Qizwg%5ZLW_#RjeF!H5+OQ+*~J#eOad83 zsjZB%daq3)ASQm}fEcMyKUk~)12D>K*Z~d4wr~F_{S%0)y-@jjbP9(sg1<5s_UdWJ zQn|TLir(+rcZlBgt#%FM^t&t6CB6QP^b{ue9haF*Cra|QH$*hUVl7{4J83pRM7KC& zpQ4H^qvdsM>pu1xJ7knu_v!1?@g5c}8o%`smEy_7t2SmR3BKqde{m^~GfYtHd{^VC zIu@sbDKdCNNGI!dHtor9dt(4z5I+e9gU}hJHK&%LLE+A(9JfY%X$!58Y`Os~Yh1R? zaa5(^L*i8}W_s!rFz*l|AyKWMkX4k#8!yu zOT{p%FPuOB!!L2=AiwjkmUiG|Uj1d0wb|sE#JQSz^+{zAdx80gHNG6X?vXVP`hhs4 ze^rJ{CdS!u7<@cq5zLa7sWVj@rEzezB&%*Q_?G!&v)O+CqWGapm93lo<1Y@izuH!L z@=N)2o!xLZ$jpT&teE;7OKw4e9t3^R-&jtE-dN9R80;IdV>xueG+%zIK+CZ0g^c!2DP$ zbVEYMyCEpTL)vh8XAV${!Mtpi7|Y`<)s57kN!ZPOf__)_WH4Hf8|JJ+O^i9P8}F&z z9y$=Pp>o{zOcUH*{bOA9)>^r+HUdf8hNf$>FU?HFp@$XzLRB3l<V zG|*DBx}H|nYW+E}k6?M0hDyGj3Hv{z>Rcy4{P0%v>9mJCgeYkc-~Wvb5`2|fj<^pQ zj&nA`^`enPm6T|&?x4T=JsBWkH}ERc8ktbcLN}< z(R_N$aJ2&K#@2%HRZ&GCeTju8G*=1cvU)UMA1PxoQpFBNj~wDxpyS?a)GWTKhnv=J zC0=ayZ;gJ)pt~&S)J+#9;89lo{{P0AM91^sa`3*zw;N4h)>dAurC$^K`Sd z|1-_92tr=N{#}|cNA{0}r!7{@tJhx%?|r$6T;4YaC7TOj74AI8M)0YCzRo{6^(bL* z0^)Ej52DOXB+I*Y6|}=5e48dE3aI{4AP;EXwS~Nwq37CDTc`Yogv9GL=3?yln4cBb zWu$>`k_Dc}Q!q$B5Vw&TaORAt=^a>4q9oA{+gB1jv zAosq!T$^2?sKlV4O1OUGOcapSoMBK5qvJ$L%$kHjA;AKmnhmA^BT`?l5{VYy1QMHs zKNIoiIfHz+s@rY1cmK&AejD%pj-ZmH@KTE2bJfp)Z{O0i)(=M6%)p#+z;L2#?pgef zVY<{st3ei|WYS$gfucCAMs%F*{YOzI4aZO0vuEEU3D19YYb~87q9rilmr-3p0Sd|$ zfQissao>Q;0c`ndKJOPKP2Di)Q#Awz&unS}VoX8CgSEkcGJ3lx#BH%-*@-R1qye>G z0NR$X3~&vIYqiueYZ%QhUFb9efMi+TuF?-MJ9;TemdZt@A21k(9)J(jp)5d|13i7SCMQC z?>-E!K|yLcGDeUA=2M4f!IU7LYsyy6`~fK|$+06Xyn zRWAb#GQ}AsTf5LQHAco~G*&?lewmW!C_xokivFr^jVQbHFe6KejT7Q(RIez^t9y}y zL{F`o7Tdi=ro52vh~FxjY!%x+`K7M}{A9!S03d`L9x50CGe|f1kC>;&RuNfDbE+ir5g+Xq7fsF!Mc9b)1bkK(jw0B>h(M0Uv2B;iq07dpv z-}ef%V|Q)^fUr+MaC293oTqwH0J=!ku|{;Fm> z-!m)bMS{qaTh5q}*$I_tO%ZM3`6)q5_?#C-sc~|j&Y>)jv&eP5deoVn zVEUz$hvKAnj)fUeln|udG3hPz)~Yd6G9#%nIw}41pFvi=BSm zJVjf{jvi@*i9(x2urlY*Fwjl3L1#;Q-ScLK1p5F%v)w>CixfZNLNZxrc5TTEc92y= zOxc><+xvS3{d)?HZA9H7+~avf1{uWRw*uQyXxDI0Qn+&fdm7|7(H*sA=w2S<)<-=4 z`#TgC+{()62rZ;cj4c_TN>2nOGs>XK%Q2fapEm3bfU=`5JYWQkKfD6T#Ntv#5Z$zNf*JXn=W0;UCWb zHP?_-k64n~4%>rlMX$0FB{26MSxKJC^*`edd~z?C*rQE;zF-&d-8*IiFKv;Z^ef28 z-3pKE2#(BweXb1X?(I|n-$2D&}1;Rrp6Oy2Ym0C0Xiang5LRJVA#qI ztF9@Mh(qOZ0A%WxPdGc?vb*}Xq9P{!f>QC>$?h{i*)2I+o+oYQ$n}Pwy#O|~4n*Ob zFBZ#~(jW9(O=buX4@38k+u4pmcb?|k7u}sn+F`TLF>n6(Zzw#0#piqzokhYG#5gl8 zI@&N05^RDNkf=_GA1}R%5g0?#wC(^Ih9Z8_Y$;Dh{{5Q^xA<`?!5I6opZ+grxRjlG zNZ_ii@Vi5Qw`%`OB{H9MbA?jY82ca81*FZ)6YAOY`%Qw-OJLkgBjy4CSY5FYJqZbD z1F?I*RelWN9gSt8RadJLTUiT6-q#%qN{Ds>h$PjByi?9D)`iSKSf$)?m$m9>6 zm!wkIS*^RlVvK%zDJwu7jes8nLghvDUz?1kabRvJ^1j4M-&a!(o9y~&Udkov2vj+g zAp8M01BH7-u+~Wb160YFvDHWxSJWxW9R-KNG4Aa)oQKIImjJ-CRg{Tx2#?(zNwl;c zbpL7pY`gvr6GlWvSp&ZRd%D74?#Z*;=7oswh|uDT25ixdh}#ROmtGckZx4VQ88Z5e z$DtIOy# z{2X4bo@2PPD-yV0hleo~%bxb>BMsN#kA<+Daj>ik#KUzwQv#i$_zU$tpkr<}AUf~Y ztOl8p6>h8z}Ny6L3-u>|1_CGM>6jFmYWoD{Yx?{Rl=h89DT_8a!0%Erzz9{gWz6QmmW;clEd>DN+{VUn5#4V-LWfM>xkLCzjI$ z6g-X=kN4s(z}|!GAqUpLP-RZx^HtXrABU0c zt7f_V-O7ExYPO=7TpU!v+$;rg%Sv0~85IsuyKyP%TCTaw9>4XJwX@L>Ksx%9*%RL} zK;d^IqvO4hd7X7dDf$6(?db^(B%daCB%zHR(Mq~aPYml?8RQ-J%OPm7+0dxkvj&~Q z35<$-cP)|RO8G^QJO1i*UG6LUjrearOArd!tt;|Lnol*7YIBAQ9*rZ>_C=n%Z9p@( zrWi1WA6HVYfpOtE7eY1ZMd;kJp)sI5D%Gs6x%>xqVHP(l3Rc1dw1BS zgg)m6ZyX-YYNs2Zrxs&1fH0ON3I~q)T7@ZMwBaeV)DIlLbkpX_S+9CqOZT;qem)D`#uf5pCCo(3H}Lf zfCB)4q}#Mz2Q3V9jZ02HUGFAjHkh1YqfCBa4v)gdxjO70v(pF#_c-lo)1PspCXKvc zAL7}cH{EKs+1Mye0PFx+;=(UgTv=R#8Tw!Yd|l&0ZV?PT$PB%!=&!4!4+*{)$3^Ql zCZ3BclT@U1lY8n7e)W;%*dL5$XgI#30zLd{92>f)%K zR}9(l6Z*!GDTO4)vLRwdqJF#Yv{>SolgOIsr5=E-X>+(Ow&76gv1{|O-l6p^kfIq9 zcQ^O;aE?rF%r_#LB<#EY@xWqA1iBuGH!YY6{deE;`|3;N4zQj!^W`32+c%-|i za&R+UJqOiStx_8KKLuYpk%j~{7{zJCe4$S$^NzyR?GF%MEnsXkMeSulst8~N#|nR_ zF!;RyfL86ZbxA+*?$U*9;M|j(ky2eHc+*?6RcP}{kw&S{gI9$9OG;A>`Fx0g;!YbV^{GAn{XS(SrL^Cca4Bf8gI zzki$r+NmG?iVa`H1z9{To1v(YJE3~EF#fJuL^$4qmM3%@lUB9&Y0cjDyg31{`tuax0|_CI9mnV2 zk%EcfDZ%Zsvs2TZf||mNy}QD{yk_wU4W6dXrM=(-H%A2c>g78<>0`V7R@I$2nNj@1BfhVmrY~|{=l_Z z>J>I$;4NNtiViVpj&;B#a6hBfd#r(Abc+4LTUU&Il5t;gyR!U0L(9>4%@5vW-2ZOJ zcNznkH`|AQapw$rB_T#w(Cb9p24TNEd2$J7mGuLLO<61TSa@Q6thp+9;wS$y$;Jww zxObsvaC&;Ge(qLYAlH9Ge-(y&(MbXRL^vOTsG%>)OK_nI5eV^j52G@qTiW58UAp;2 zcD|zS2`5-B5>78=D6iZ#Rk%uHHE8q?27Ly`Z1umkk((T9x0pzn1y+7*;dIr7A7n_G z?K|pbw6#jtf2|T_cu`kGXRVlCn;IOJMR5O5l4~}oT~o(}Mceo`IuplDjCw-VX zzg-}BC5lv9k?<IgUdC%%Pp66i={bO{X0zhv5r!LL|{eDfH`Ln08x%V{>?}E(lazczKb1?B}9$cN>9GO`0lcV{#b ze|x}Q)$4PFHhIcVe(0x{J_r2rWTh@1s9ZL%AsL3{&ElXL{jQW|=EYp;ad^5h}*LaE< zHGpv;khhF7%~{kVd!hvEFJ~d|$VvOEz`&^;?_m4J+GJdiJ^wX4M~B|?75p-h`My{k z3j4f27;I{WZr!c|SM~4^k5B(!tZ33j-zh@HrBzF*rtM5FmkWf6PPR&8o28Q$yxfVb zNQ4~O-#O+_ogS79j|6xczla*Eq^NKGgUT8J|J28xjcgK()PPK^KvAeK$xCMwS|9+u zo%pR{Ztrk4%kq0xO8M&X{h)QsA)rFjP%U5qH`(8_0+S??K6i$EQ4a*`CA~zH7*peD z9ur4Jb63^2p-N%+3wpyoEO}USd_uV4aKLy-UVPr zow|h#&KD(Lwt2I%oWa!rj$o3TfMSg;AwPbJ4f*bfTa&acUD@7)0WPQPUpDYV;XeLr ze|0)7+l`ZbuiNyUFXhIw2wZdu)I;QG6f6|jaMe2IUMFoip1H0hgRHdTZkgU8rTAEO zZhLKjxFI}GLuWqGMVO;BPD$=4Skb(d{jf|;x3e3zR3nfyYD0VUhbGMpvOI~DWu4Zb z6IWs$Et|D}DGRT@X<_e6I$|p&F22ToP?i2~+I#k=yxw;0grz}w>xjcQ8bB$7VS`B zk2pp^zUy#^S@iufdKf`Djeo}wt+!@xnDrx7%FwKu_i2{CG3XL%72VWQyn!sCqXyhX z0(L%0h1jHW`*voL|9pt+mc2GN!(E@Q&AorMwy;u%r-ymS^A z^*o6!XW%hoB&1*BrOOCOCrAz#P=pKrZFZ^HQ;rL7Zie2s?KddTcA+bBlWxn4{ljO- z*|1J%4xMwa>a}GUlrx-NYY;eWWO&^6S9JYSuD`=e16Sn?=&3AgOva>=F6Uyq2aXpMWzvbLOueYqiyhx8c+;oy;HX)d zsMc}qi|1^0P6|l1h4QK>3yga+61oJU=5(>ykFsT zL%=q@1O76CB^`9njuhS+m%@N3(yU2ZywUQ8y5nqd7pqUz^YDQJ&*gVZ>;MinnVoy1 zz%1qiex`>os<-jk6iN3E$4QM5|!ke)nvvNS^QwNa)6VdXSUIB^8RY;?Ljrh8P0|qwPvxn zFX+~T>P{4YTQX{;v=kmR9)%1->y^C{Y2d$fHBXUM#+{F}U|o;}?!%cCTjl7O9fWDqXtcIKFf0fh= zeRa+&Q@ZH4_!R^hSwnvry>=*1Z2<> zlG+Oj8nqF`tlXX(tTJiZ1AAy@2y+?tR<}Hf!1VP9dx7wTPBcxL~m)@ z5iHO{FFY#vgUa2he{)A`&R7F9qZTvh9y25`CKZ!S>Lt5LoX)KKC@0l3&KpP!8LB;k za8^i5m~5c+p18#Uxn_${=duSSM*js9wp7C+E9PiX!-V|0F&eJMDvc5Q0?eFT|4i;a z%p~ZGme7et=azw6a^BiEENS0d-)q{Q)sglB+Y!I}SJ!mK6ptS*uIZ5G38_JW3(6iK z+D7fVUY{#&jws=5%4B=j;`57sCP{hJ4Q7(k$%p`Hu`uG_H;DORN0k}M+d;V(ZFw`F z%UT0MEbRwpsWxN*Bs&4r>B!W_9j%|Ve+m|@-{WbBXtl<(B7Y+8zx^|yK&(0wUQRI* zl=bRPN{ual42cxro3kv*fMw4`e}Ze{^=W2<@5hLpHaG>pn<}<1dTUg`Q(4evX)U&8 zO4?Ru=Y{@BiCYd&4BrXs(jPy@D;%Pcb=F?7jE0!JVA}mwz1%fi;#~GVZ!I_m#(z@T z^C!G>YD8Q0MM2eM7LVXa`3Z?Sg0O_|&N#6K4yqu}r~C=$)!1s*BXDoLJOJ3qy`28H zc~zHD8CGH@a?>g$$iZnH4E@Fp5hr42LO4`uKE+4~goS@NSu`mldKNU!Yl7-Lmv%vv zJ=PIh{VC#vUWei5!H9<3nWYU1MVt_KJ1ge$Ii|R&0V~**@nr z83!F?UN^&C6){J7tfabMP7I)=w_g4(H&Y@4wRAkkI>g}%1FoA{p-}k6|9jK28lTF! zIa4SLs9g7$uc58@!2$n8H0L%p)EvPnDEW2At3i6$65M4XSd^*LCg+)ZUN+oxBk&3&L>8mf>`f?bA4w@e6%yalqhq6!QB#Ebo zLM!V>t;v{+a$G|z7Kbt2*cNP$Y1Uxzr@(AEWf;k9?WIN%>YuH2lNs>ZPm$awY~e&~ zi;ai^iM{@Q6DRwy!WTJr*QzQ~JYdAnwec>QZR)E2o{IJGZxR`VKF@15POlyPD^LXNp{%=(1yXaH{G8ALHw76z4w(sWD*WhJX6VFnzq7o?WNfQH#ej{icYL zdj{)X0Z-&wmwI%=jb4l7PGrsKhWHOXo`H?_kJ%IIf@TM!q~fuFppyKrIIeitrZ0%2 znkq#Am2d2)RrjjWG8-M<;G-$ZI=Ds}qP&M5fwcacK5@=U6&U zT)E`8_Uwiv`NKkw=i)LGXnyi|Ae`Q-Od?q10dggJ#EPm?&g{yyt)p_py=`XRfoyAa zn4;|Yu2}RFxg?$rN$=Q6jBf`dTMx3li`9;T_TtDP8lNW#RgOCI%@T*5p(5Uv?1G%V z($9b~!jBkPM+cTB!GV|$z!tKPy-xcP=?59mkqtVb%c=3uEW&g7e?KgAKY7o>z>zu7 zi~n462WQWlvlOWKjBP#Z)IlA;&){RrBoD0s^x4!%Ltp(}l*teOA)Emg1~J3Sio1d@ zH4>~&Be11@BJ2$bspedbj;>Fdzt(!H+E{*}VG#bT?xd?PS+>+A?8ufSAw?G^rBEoW znt1#Vi&P-^pfGtfZ8w5%)P^4IsILKl{Cvh`{FV2b(IvPYk4L2#<|yGOf=(I;m*3_$ z6Uh+nw%i`3at9gxrp(CBDCjOg{t7`|(Fd5xTdzF6pd>zBih^!;%+An6Uk|A{JD$x_ z?OPUpq)J~m5K`7*WRlh1D$-8U*4ba~%}<`r1SOf>K!rHi4lo%*Fhm-0||2e5- zRD0Fq!G)7c1DgYnOT1scQAPT@@vOu;y;s9ec$yIq`*MbZV5IpDjhRLKtGVzqn3}hD zyG$I9QJ$&_V=F7Km113{CS0z7%&a0mv))xgl(O@M>#A26my}w1KS$2~I+^9`g1Y)1 z@$Ay_H_$;xAJ|X)Z*(aKOR3)e6xF&dK2?C;Swn_k2a_>kNG5hX1jARee@};s6)>#m zQy_3BBbvwQ!ecikWs!_Hn}vI^>i&q8Ivl;x@E+)UOk79u06#1CWoBTzywfAmP0v=S zToYMkPPLB(mXqjx4EofV+v@4Sv&#yt{jhkHIT(KapY)bEuNV$Ehk=((Yo=t2n;GpptTnUkjN27&>G)1O9tPNPZvwjZGH0{2>ZD+-#nRgoT)y$h#I&tCG zq1`?1K!x#|WTbR!fZll?3Y*kx!&2-Ot8+vi?oX#5p(f4|vcq9pAp;0|_~_{nm;J79 zi>$U9M9C!<1-x)0B?OHoCH4;4ykH#L4kxA+SL*^@FaKG{Sev$aN=KF8$JB(X_vy<{q2-eTGLW!oK~Ct(og8)P zi2VcuO@VY}Mm$ND-0jFv)-;1*KZRiM!(8uCy@g7IM$65pQzigKd0jQGi<5=Ro#R3a zu+2o9*)Z+}X6z&8@l~5I=Khaw$xjRQq2e~3KU2Ru3O(z<@)%FN13@Jx{VEYnu%IiW z?UXI9>h*_NBkKeiF0O@wD-R{JSg=w%B}BB)(YEio(JJlC7O#iy(wP2Zz)kefeh!c4 zibp6hWa}Z^_u6toR>olo!Z6(imhkm)VxJy{$wI9WTJV(EM z;^!9BI&lARNI)}shLq=M2h2$HtcIpzhlzE}G*Wd?3LHI!N*B??uq^6A)xKIm*kyVN z4+59|2!2k_=fN+O5M)h&MP4LsIPpqd_XhDYanmIA@BI-IA;ay_*IY1!&nQ+Ea zs>>{fVYqkZj&Ff_#Gp5KDdOF>`XAic@AP=>yD$HBRKy|z_Nz7!SNz6#Pk{nVRB?Hk z=v>s{VIRWH5?ZE2Vb_3Brm#zQM5owy5&{5NN>eZQeuXP zR3mpdxxiRzV0~h2#ax2%T%2`<({rDlI+E#h3POa&?i;`&!w#)HSu$H<$U_jg(le zS9bG71Pd7CA4VV^eoPfJ}e?m6%f=XokuL!c7%rPEV&^{ z&t(D9&df~NZ@*uoO0U-8O;)+!b8)!abVkTPE9J@F@6!r#(tn-17J=4Ww{CiV1o zgPc~Zr3r~Bm|4`?T+wz`(?QMBxgc2sw-VdJcPF(Mcdh^?md{+2szIEAVA(mwxQaU+n6oWv928nDDdoHY=gbdA^tv{TeQMNVRd3f1Xc`t*f(^$47%Z!l5n(IR zK3n56NXLhLg^b{X85sNm6AM8pMjARX^wz!1pT! z{KmPa_`jTLNJLhB&*-h%87}LmRP7meKuwMW@)^X*u4sO3ia1$G z(bP}eI&Zy1voKZdi&Z}tpF+gJzZi9B0Q3slfxCs884E5+o?HSdi54$Am2EJM!( z%hIia)L1MTdPNx|g!%}b^-~aQ)xs-LE3)&BVfuNUD6BYN#}tc-dzE!IA3h7|?;rTN z9GPsCs%oSH_(hpO%-2q=nZf#tR32Hr#DzAlsq5J#2xs}vRjsh7h=D^5lEY+Vc)XG; z^*SJ#%mv|UvKIpa5K|z!$q7-L1T7915O>}6o#UHy(6I*SS6SR}fLv!TWa@(QawD8a zC604TzTGDZR~qdsg4dS@m;Q-QMRa$A%3c8%aMN%hF7#%9@Z|4}GzHn6l6+@zmy-Xa zLcGslUk~Anm|L}#<;?Qtszy7K$~rCSthY{#F{mn)8ln;=Wg2PVrKg8P%|KW{+0-f&soz*VlRNj>#;1FRz^XKm0(cS~2TPW6P z38Avh|0wDrpUbvrWXZ^ykr#r}YtKDZoN_jm5Pp7THnQK-UYotLeT!nCj`vH{(Oq*< zLD+pgaHEaeC_J3ZGb>SMLaDRWmAFFh}wkGu7zD#WV-%#u*;X zQi2wzW13_nMNYhs5pJMR^Aqq@6_$y0?3|LxpsvXV0~FNm4w}tg+6)_Q$D%l0aA>!Y zSB#SS9IV`3bM{Gx10i`A0C-J9(<$kzN3kqyiQ6q_w07Kmj+~*eYYVCc1=K%4dNL%| zcx+MiX+gBv>fIoZ)s7}OEzj*1Yu^4ABL5)FtnLDw`k?|PNstcYUhs}=a+@(Uxru?$ z4J}p#*KDt4X#pdu->j+zRu)+iGd4w%^c7dkrBt_pO(PL~m5@*z^n5(P&;SF-F$V(F zy171<3z1K!mRYq;Q`v!7oG8v@=S3N|>F0@@|Cp<$$E=~5lLuez;RpugAi=Y&5Hlz* zM22Gj72uYCngK{h{PSW#LAl?q)^FiP=O5RjwRs-&i5YUsxECqsAkNSZiWxD{v z-+|Xj-{>)&{|G)o7iArFgMQ2|_j%q)t%0Z8p-wzEGU-|t4E{?Q=-SSEz|GsXAd~B1l&Et; z6%WWFnH+r>nF(Xj*6!3rasndR0WP?Vp{Qirv z*M&s)wI;@N)b3=dz#Ke7Zb9?frR!|wy~P1`P)@z~Lq3)~o~P7WN>0Bnd`a?ZGcm#n zt?RybHDBtJIUyUK*aYrlW4;mCe%eudnNoNiPV@hWrBKk1 z1TjY`by$!wRMH2R{`FsQmk}o4v%vX!(tyJotQL!o=NmSoodG3}$xofQgPJle1>;0x zlwnjaD&f9T)TPAS^@?<o-+<6n?Rz_ose3TWAqo zCx<~!p-lnfQ_l2{LzQXJoLfcAEBU{Z5Tk83=FF~smEDeAr#TB#PyZK_=bi|X2No5y zc_q&{w>K2?qAc;l3CqVq@YN7VquU{>Y!h5j2}7@PjBZ~4I&UN>qlEHcGzbuQ_mDZ%Vo2D}Cc6-*2 z74H(KNoU}%QJvdVp-Nm?4p66yJy$v@Dx%|J=nR^OcUF09(S=nBD>stAyhVdFXAARA ze4~CWP1zGuKQU)^(t;RBO7IwM!g#>dDD#2}BKfZLjQc}Q07E|8a3zZ(%TRxvc_V;{ z2t3~Zu>H#63MP(CufAFCwEWl3FTpFqVJtsf0g~;-xin0^#x9w{qQiBcn;GLFlPRt) zeO-*9tzf9gZ9$aGmOYKq(uVdC=z{ zAQ!_Casf->&!FK|KTtY(@7Dc17t1P}&GZ~k9Zxf!J$eTC%1|wTEY^!qMadBX8nh}g zD#zKhWXzx6W(E{L;T%f@KRP#?z+O>I}k zs?h@5sNQ&HD0$v!Q+uBxFd(q{V9RMhV8%)?(xg%0LOHG5k>OxUE$mdx=qs@q6CrqyedZurS?ZP1HSKdTgSODPUkAUQ zEj5+i<`ZYMfM92wcZd^w#pezu8#q)STD@dB_$O}}n{b^xy8yR@6X4SS|Ao`8WtIp} ztmenohv3;in4C3CwSgkg&;JbkCd1fuv9b)|gij?cFEm4p9k}3!rRw;3wtqz+XAZix zc??U)Gt{gteHGCyfXLm!)MrID;e6lfLUFYf3T=YBR)EGtD(8Bd{)^zj%b^^LSk>h! zRnC7Ek?>{x(#>WG`Rm88-Pg8GiHMFye232h_B{QqGLjV5OKF8cQtjD%XD4&h9nX4v zIUr1wOCrs2j~Zl0>P^AY>EsmBZn~M+2=%^ z3o-8(4vQZifo_PRthrcC=`A}x*ua!e#7Vahl9ON`&6{4GL_|C5U7{m492;k-258vr z0l!KeC8;8WL2eYx0)*RP$=VMGAW}8$o9OV~$!oh4x1Qn-_pO(^AYb^LYZ~0oay0Dm zJuPl|ziMr60QwNunsDR#(l<7jQ^3c2a=ie?6#_frSCR)8s|6^TxJx6J7zh##S5Kfb z$9EvJ{kRb(tz*yI180vtl6QxC4=V@U znsI&+X-`+CHytz`^XY9>M%tM89zi=mL$A`e*H_fzNRh>k4Reo;lSyAJs+^ze-`&&M z>`XL(X9youRkHJ$a+t-sJXzb-x}^FcUgw!pkvk^o1YSUGv<#N&OZpiRF=1Qk#GnBWcpfM+hgi0#lMSL}>jv(V=*=&?4CD-@cuXytsZULzK<@@=muhxbiY z=IDg#F>!>JnL(HCeAlE2~rWA`Q0Vu2VP?gqGKgqq1w>(xXWXBI)v-wvcKx2Hf zn=e-02#MLns1*s%F3*0$2o~CD){m=LX5iXyita5F5;Cuarj%*b+I-2wS0y7@mJTMh zd!rX45(+7wnZ~wlAnNW3bFM)E%aXF-JZ3BP10A-Rsgg ziQ-Hz)vLRRCZtD07gzG@gyJVEqN3goQcIsvUipfYfJODzCx$ozuk$cuSK6(jDXeg- zpWxxK-XdyiQy7O4I`W7xzhVeihYx* zim1=OWgin?#XFcn_rKb4qZ2}W;`ODd!6^4qt z@Z&h5(8af+^4Fx`NtBZC_t(-lbydzirz;m_h2tQ;coy^bbCxj`*WP8*wWgU?;8)=# z3rM4(k7h3B<-AwXaggn6#3)DmgK3JL5)kWwO(5fVe#7HlHm|Mbdi=v~0VpvnS&bWS z&%#?}DSImocKv5z^WF3cr(qj#)-4N|e(d@L%@goF2YPNch@g=iR1W7Z0&l}lGtYE< zD;m>KALa$Eb6FE0j}8Qa#uy^@MS?UQbYhj`nOh-*-r=*5O5jRGXDW}yuw;LT=d|%a zHtdiF*z=Sf?@Ncxk65ahDz+IO;nhH45h*MRs1VE0Mq7wT!KCRBLn9d|jw7?_D2@fY zEYkj$Uq3n1BVKbfw%mE7>Sn`SF}us8*1W#0TmQja^}Jc;S5pF8QpbHk7Ux~=G-+^s zbhPHYaPB=)s{sFsD1382$PU;BY_DeywzS5QUI6L&Gv*d(zV=|OQ5dEhd+G48Bf4;3 zc`-~Nd?8r`Bkt1w(x16bYP81&McbBZulmd4F&F)D$cyWo5?i)l z@GM%}(n>eP7_krY<`AgvR7dN^u&-JG>07E9Jyc$%2AWbZzAMt_KHqMnxV@*b!#2${ zeH77y+5qzZ43YVTivHbtz`VbjhDY!qyVV!rNGo{q=Y*&qF?9|HX zjbJ!t8PYMxR!>8FH5*d=HNUSke~&E3!aY+}?IA5YhQdg20A=Ax$b_ozWMJYM zzWKt4E_`CI()LRs@Lsi+Izh>IrU|eKzxU}&EST`U_CiO`J2<4bnF5Q6wCsZ4*xz`8 zD@sdh>V`?y;8wf>*hLhRoRNYyGknu8fA>w!KGx+Kmj%gh<6Mzl>d+YjGNbV*i93jYoK|^ z+HJc8@82lm8DeXu_<>@Y%>@Kh8B;yI!4tI`qox?0;;J-M2T=$KemDxlqY_iY4yCO= z@myYdV0BAI6vn^60{ge4yQ<)CNJ?i~G~MzcKG2;UYfbhI#_N7Fj$_tYNw2CVh$ou!ClbFu<05W~N+O(>>GXc|`(^>v zbmA=ASHQoO7MMa-)HDHLIh${Aj}LL2w$0o!u}<2xv$^=`N9))otq*8Nqy=U^x@ybp z$SG%EQr@a6F2rjX__0y-sw#wN*J#%lsP6T5{Re8465@D~1*ZVOh+y_FxLaYbs!2#( zY+8$$akzP_;sof65YY_F1&Pr>2PGa@qn2=+#D=r9JLgk{6U)7jdKNk@fA&8YKt$&% zfI#1gD!OX1d^jUrg&U64OtKPCKeKO1;v!=J*bX2>%WuMgh^kB!n=xiZYXsyZ z4f$p+t5yUbGJ#KVz==M*tiv?pm)V|=A%EI+tT*!?(K1|AnndWL4msuC3Y5d+-Mvgv z4ls3pgh7OadM5^^{tLK&x^Wx_XZyvEA3!c;M%vd#VzZvT?!0O%JGH?(3{7@FsM{Ypr-R`sLob!C8|QoO2ER( z0Bjj(9t1liQg*;Dtls969X)iBOIzp79flpqP;a(8uDuiTmnyN{Ng(Hy9;&H~eCa>$ zu!`6+u)cbUp)QsmMcXHM7rX%t=?R2U-UyGrh-M<_I|nt~quptj(rZoBTdI$o(oUsZ z{B&(FYOpCRbSS{1;-0oTNFA3aKc>x-1uSd@BWoLAF3D1oFc5}4yV-Yx4=hOn{LwO( zL)42KCLa0QaLiUrdF^$z#qO{mKasB>cTmBTLR)?tJ}P_ALcDNounHJ5FkXJ`yDPT6{u>U-{7gHH1HOO;g{_%TdxLTg$`tQhbDi7!&_ zQ-*ZO)Pis`PshTF)+JP9w;07F^XH0lB7{C7ffZ`>W$lD+Dq{gX=`acwuBZxymR55t zs571~Ay^GNpoKEJX=eaQK(@c#T&5~DlhWG@M?jX$=FDnLSXNx(Q=dzduw@x)-UA6p zpSh-~&$^qIcc$R?sWp!`LXUqMolDQhZ;yhIIgLfix*Al@NMc}fGmaH@`g2y#~brt6Ha@q&JB@}*l9>)Y5bQnSnpZF zsY4HXizg8FTCd%LC5`}_eYrxp&A{o?z^p}eVp*}gWiDA@l74H@3h)BUm|~xIa|Kd+ z6y<rKJp8HC&ICklayA38(${L>oLae z6-z#B1UJICxF%xRnT$kG-z$`UUY&r4yk|Qhs53Y1lz6TJ!9x?e2+B z31Dv$aXJ+c@s^Bny3Fr=^BUA4X*uAt{)0fG%s$NCbcyxCobUx)G{J!R zF`VV%`E^KlBV2BAcdG-AVgW?A#Dq*pn9pR=9Oa4h{*=-uLzLmI(a-w1!lLfPLgff{ zp(s}DYCw`MV9Z!cp{t28&5XvC#&$yD-6lO*IqW&hM{Pq76?PWc@vhPWV^C z&$k~9nG!)P-W{1?=J-2T9b@)qOs;4{v2_1XAXZm#skbK^`Op?bhHOF2E>{)vsm+$9 zTPi92f_JU`^})cD&0WDxxU`*m_)2^nKJJYlyTVoBDyk6uU!|mppZ?f^o~>I3%S(Xg zuQLWVeP3fRC?Ulf1TxI^(gr3LLkMciNz&cL!*RiPPAH-O zBikkf`d7;7$73QOgtWF2R57IHx~Oc;JB9|lvxM#^j0ecZ*VE?Rp1hg%BRMhZaGCtJ0=mlGRb!tCo%# z4~g(gfnui~1u!L$(VYDIEfyS~4E$}B;rwCiG(R(9B<16M84$Cx8MO5wIjgTzK@{_uz*MQwV1)P?>d{VpM%iFld@UZ80Aghls~K-#B#qe| zMsZ6&WPf&LL@!@<34z5~y+jp^DfhFYR7l`pP3icdzVRz!A5Q!Kl`L^2X;d~z1mS;m z5b_sOBTKWwDe}NHX=Ug;Ibf4x$mXA*@cyJ&@b`w!OAiy9-C6~2EUC6Z)FWuU=tYgv z_}+553=mk+5F@kWRs5KH05x2Ggfx`j^CcbS=Oh2vV*weQS;afv~<3aGORw}S- zBBpS|=sv74L+AWTf5>vMHO^iF3CT_Ihe$DI))QqdR6C70rY@);xpNZXP%V0oxZ2T) zKG4oHTR@GgIalFbrbM7jbwPk*<#L?}T*WIq9cBuVuJ)!@79Obplvibu=ey)DzC9H& z`=hkgcjM$YShwAEUx7?dPF)ihpR}1Izb8s_3k9`XI%_RfeSOHf(`kKQRAtleZxq7o ze_CgnyIOL!OlYHi6t_wN{9V5dE%gw4hDIua4?eUVV{7spR(1E)e7tb@D=X(xOf6_F z;$2MKyFQRD5s)U{DqTAr(_tWv%n_I%H-r^pt|}rpM0~nI+@=O?Y9ET%x8$Jx1$r%omJc?{6$vc@Q_`ATIp?*1EFRF zB6SmY!^9_yc6;0+*#BN{PK)VX0r!6gujxupgFXt^gVMJ8YkToLDz?boBTqt*O;KHx1G$+&=g_>1rmUmD?|SCiglDNJMitWH3P7Y|E?M`Mb|2 zYDI;^6PKUHS|d%JTFKeIN$uhZJ;Sog6DD+W4Xv5o!$6g-*_=Uq6d=vW$J~by_%~TE z1YRU=o_%}jtCxxp91ho6C`!{8{Fp)Y{4)N&#+zqxSDb$q&tZ_gwMf}0#Ko&fRyMzZ zT%})&(zOKov)t(t|jik;7C~Nqeu|^#$Bp@?GAuw ziLM6e&&N+OrDOL30;1TSBaBl%T2M15@Bv7BST8UH`XoG~$Xk=p>mx6-h)&jGptb~V zXsh{ZXRT zdjU2hP4b|sB^KHsF}^=GxfSi(e}ZK3XvcnFwhy$(l7@cLp94i6?zN=%Y1Y{K2Q*rx zewteDAppd;!)Ie>hh&0$w}k1X{yHOj)7vK|;K{*C>d@0IV@;2xWK!M#dbIPl7|lLu zhdemvBoRnH5cFVuVbAQnNkOw;{U1>z|1{>8fsoCUmU^XEzAh!3;(~!jo)-)!;?GH< zb0+Vy2l^-#ev9kf;{!6?$XSmP8|+4(xY96a(7kfSWgFL{k~>UI(g91d^?}Q|V9$8~ zG78=}%KOrza9g1g*K`f!>b4MdrLE)YJ;6n2luUX$<{WYF)f$-#yky~3h&T&*kWhx< z&YbQZJkTs6r*9IensNm;sUds7^FLnbIoJA~qhMSV=_)e*ZVb<&i(kt{>&;5*jl>Ly z#83XBNLoHrxP?~{YIGa3KHU*pu4_a!9!P_Gv0q1(w?-)T)Ln0Z=mMU~KYVE4$vW(} zrrQxd&!lY`mWb&Xr{kMXotl!-y*K%hdq8=U{S7F%@zhgT1`U|@Y zLr*6GDmB!taF$vX-(W?^J*t3sR^VXNG61#sCP3i({yPyoN(Cd*EF!C?1`QBbi~m&p zJ@&5Ug`?ye!n-6D+)^)Krdf-HpW!^|MITWO6TgTKrUZ-G8miz*64mDGf`jft1-ai? z>}Bm$ZR854ZC9^!=D%=Pj5x_E%{s~5Rmz25RP5Tc9dB!;J*C@j3$Rh+dYt!C7*YL7)G#$z(Q zR}>WG;jM^B&fbF9%jSHbL^!R(G1JP{8?~sFBS`Jp^7fuMW9^qwxGTeeiOm#G6HJ5A zLnfF9qqa62x}|PERlvkBMwOMVx$IDk6e=}(9wPGVLuaNDzn&%u1F-IgE%f%yJdZSk zZQuP-ljceNOzZ9>5Jwvf3EOw!J1b_;lIk^E#PGL{etsMgKH!e|)$!tIbVZkrlF&vR zHBx`|Kw$MNq7P~gC5q6?>gZ!7zKDu#Nv`KJpMcvcJK0qyka@z!gh|g{Q}cx5iF?1H zP@1NTjg&LwIS1}i0=PF#0Px(He4W5lziJet+<(MXzZ|sBn3WOTtEX}Nywooeo`Z3WjBg&+EJ&N~ z>d%$P8PTk7q6r4I@k?*`2i*N}XBc4c@4GApXw9hrjmNb=`qhOM9vUzEd~j2JSCOqq2d($yiT zc9^O2T>N>%Wzgo+u-+}GG8}^oK>G{Hq#pJl+M9G87(Q~0G#j_5;bqp)w^kNpV?Jyv z4n(!|ZmvpW9=zwsFz;1hav-#jdXYf>UEunHa`z7+plwi(q%KK6)hF-gX^jH12OBfb ziRJN)z`Ze13Ug;?N24`jQ3PD|VmJo5J_v3`)xwXRDR==yZj9n?p+f})O4~M|wgnxm z9%B0?Z?3CR2M8m|JbATd3VY|1@Wkx%4j73Q#(6&3KEE=K$*9F*BwiKeuhL!nZu^td zX;(#Js8RF5^)h`2X`G&^@-!%%D3^%_O zD)Tp7x;Svd{V1uSiW0^BaqLly9-Oy6t!H~gNMGk?9$aihO`Vp zv+`aegyQQsS&B>dE3_V(iy)R}xCt^eyAsLK_1v6?|8d~Fu=X=;AGw+Y8HY2qCTH;J z&%LKG&ZbJ1diZ0gE|DOJpk>Zz@nVuxt#2XagXy-?8iU&{T95=IgNDfejR{rfidCEb z^+k!qo(=^IeY=jt-ceQ^j`gFGo_67QlFtvnz_Nv=BUt^`lCw1@Z+I2Re-w zYwL)svxsi=5vgpGdwjdy+x{UXE`$qRC*YbB;^RAF)RnB`Ig0IgC+d9lPW1{tDXz;_ zh%D1Gd#wBMGZi@LhfBCQS(MNu^}Pv9q(PCB3pO*A^Orr`Ma|90GMs)xqWdN0e3{BA zk6S1KUyv;QSMK!H71_^W{lAXNc)d!v?oM)NZMz#kN@g{@Qks~%=9BXOH0O9Po!HBT z$KS2E+<}bx#z>~1y(>%U;-IQ7$b9zS*bN}gHlq?XkX_N0mhGwa6hB<18+9XuF)r5^ zfpp2JH$ixaG_SKCCC&bR!vedgylAQ21LG}EnD>F;!Kek!y9hyRuIlxP>m`2gpB~;D zPT&gh?kK8`mCx!^fn6ZnihZS@)ZKM@lvLE}KfMQo7ga&*6`G6wma27fJ901kgv`J8 z@NLV|zIW^5$7(Z9$UZvM!jqQTrl;&L_YcX0bYw>vip|p$5CAQN%ZQomFH&3%sVW25 zud-)&KNKVd%Yr(B+lH=E>UJUR(FPsRXslg#&ydIbz71Q>vJ@3KlLdpqsYTJtj*wEZ zLu;rz57qD7=4Bhv{|mp4Cq)o)f47B5(F%eZgw8%2khFM$8$rN@@U(9Y-*PZ64(_gm zyJ9keK)L~Lq;|V$fc6zUgFhU%<_66OCDG*2My@+TmjEkZzIk)wk=2;TSMQwYwMqy% zuLJrJrT^I8dLfkXha~IuZZ#?0_?;*KvtXC(1O9n^1dX1X)Ry3En7U7DQ;3h|_}oG$ z%|MY#&95yq3+yOM00by4vo)5ICMUe7Z*jPVJq{i13omn4C~2S-+o>^!BvwQHp)??ssL_%?{Z15GdDM?R7MD z6)pFQ!L85SifYKoI0r4PfPn*sl3r79EfI@@w2Y#+{x_7GuF&h9WAS0a9@Dt&HNx*` zwKm{|i&>kP4)BN*LsKCL@4J(Vkw+@3ED3}1=m9y>Xoj2Bmw-+ z3}SKEH2*16+DPDMray8;Ms1MS2`D&l1-it-C#{s}3Ok}in;n<2+%WX5(*;_C!8#3= zln^Suv@!6VWvN$-LUqXMalTkHKPUwK3xZSVVq@ER!BSL^L*kH26uPOu9>PH;%R-_# ze7__Y=3QfwC40+frE)Vq?-;vw0~IZOXgxlIQKksDn#$)v;%#4q2V^a#<6qc;`C}R> zc*aeRDP8}Aj%OBbHY{2T7B+z#vHwSBWcL2Uf@No?AcfT(({3))=w~WL!2}!p3%2*h z_DZBv5G&r%AfiKmxs)>N)RR?t%Or=Lhyp*%3gzExC%3I~smV07q3`&=cN&0m7>Iy2bUsN~AW5Um z1YGZ~-B)KlefAIpXrdLl&VM`7%b}tyLvGX?nqWumZ0uNK8*7E)`tz8_C2-g8!C-Ex zpk=EblW{!ww^X5kLX z`SWkX(!V-Kl+8-sfAW3)L>RWN}>6PBGi^meg+5B;??rM%eYIC*YJXw%~ljnI5(pTN`rA z>DK>I;wa=<9Z~~#B(P~@S^9cagr2A7k`SlwD7EDrw9B|gE_fDMvIXeKiV-BMZTd$g z03xEq&5z-EEJO-Bg2JK%mh;Dt@$=RR!m@BKH&n*ho`o8cTWUb?F%G)$wNZnMV*j(v z+gq?gE=1`h%Oe%58!p3;b}>5E-X98+@On}};#i*0EPIV0exTO+MDGNvs$PX%mwDmR zgMf>fRu(&`_u-6F705|&GW=N@fyNBnUT?krBX((3d};6>eWk|CplXM=hH`uNi{T|X zK{D)+l7>S3??s-or4NN~brHv(nI#c>AY4bvFl74o-9bCwm_j!=IHd-FD>7Ckh$1rJ zCqgF`JY^iCF5>g4kU~o2Vt#8qLWlRnlpu>_gY-dOPw04G#eJxyo|W9bOmb7q(fYc6 zN|0Jl4tkddl$h1XO)6`H>$(_$ohxGKSu^c)7xwm>go-OJhqPUnk`_yoMiWxQ>$X(h3*za;Wb#?Qd_m~3I#fn% zh-O(RsNDFB)TYq*#4fmCqs|jJ*!+yN$?zyDv(~4+jg_*y8`k+pvm;#h5xW%(7k${R zjd6)t74&G_dxxRo%gmj-7Ege*IM#?y*$iYch)aa_P*6C5({1vu3I7- z!sL?{`8Ae60VcawisUm8sw#XsOkIp*2ex3Md@tp~t{| zl7Xp~u zHCEp~&8QmeV@rNw7)76`7Ug#Mq;CX(W@Qf?mP}p~|7*;>`U^EaLKP4^SZ1Lao_-d{ z8)a=zg-CXGf6($oIQV(cSjLr3&k`C>;$%aJ7gY=u0NJMs(>$z)zbXWnx9qvtPOU;I zk%}31zb*E&`_ca%%zGUC&Mn->e$k)7d6`v^YESKWy4hIh8)pK~lAXYQad<`(QfQ2J z$XuB$L8P-84)SYWfn%9n_h=M|!<{42QvrSvDdnFB%+3?GS4fpiu{H8ykc$2M&sY>u zUt#9a`gRdcsu_SuiRgH`Xz-g?9(hbuTniq?y85Y-lWo0JVBsda>x$_dZDgwmVmqqF zg>Z9JyjP7Zb3y>(+WAgHTy15AR0@(!2^a zB;T!M7@T9L=OsQlz_KhW=%jqM`fNag>c^xrGMgvgU8?b$<*iO(uySoxiFbEu^rrTW zXfk`0U?;6Exh7t~P$}iJIv-)d#d~|gL_zkwI9kfe;)6zm?gC^=MX z<2kJf@MJ&G#jqu9U}rr3PVabZ6&2{u)DMzSQnhI~XnJNnNTsjTbL+sqX^z$BAe(}# z5BYGQ*&yOa4rqIM3)A^1)wDrRYdu+L-fe0zT0VevVu1f;Cp3AfeCYH}{Nj-_I|8kC zIo*bSat`W<8~x-8`tH#4*9P;$jB3nQz*>Ls(*Xcj89iYI_11=ZV4PG2iZ6@KUQOR|yka%i3Iyd{990je^#9IWo6wD}$e^ z!{EGcS0 zqNjSl88bo)xSxjX9irj)yI@|=R1G)^2r{c%2bn9AJJ>M~9wuO`9i{e-#E%7grW$D> zWmHf_bVrCtZcoA{Zfo#C$NBE+%TdE#>%z1`ZlQA)k8o+YB49J}`CcqCI#Gqg3Ip(z z%8kW}4S4FtQM=&;{6Vt!j@Ul!bviVPlR?Mq8pL$AYuclvr&vP@GZ>0gEO_ zgUfiQCwtx{gQvG8Twl0lcQ@LTL3dK^NLZ4!#u0ZSOR8lUt6tGH;;$7gBS-@5)S`tR zQB7|_A7uMD7((g6i@3KZ9-}y?%bx0~(Bhze zGRq;HT)o1J5e8B^Kt0tL(|)}d4HYB)kfS8yB5LmiTHl)WGgjPxwRNeN>^qb(%=?tB zv9JpcyyW;&;)9zPKX)bMm-Hn9=ak^Mi3huO5iWW-69||X;=vf*>@O5Gu4k96wuJ2@ zudLlwxq)L;0ypjK{wjpa*yr^b=)EeNNwwkIR)Mvo;B|iQDQ0_xKNSvHI>V zCv<<5C0I2;v+VC093v)h2-;vuqFL(}T*RO$GJT~qbt*sQrclsGj!?@nrbaY6@<*5! zVow1R&#a_Fb=ZQmmSc9wBdIaKk|S@b^Spq>?VIPvzvRFlONMBsSNB=WSeGq zjN>ib>edha#g<7IH92)nF|m6d>vUoUrVk+rcIXyy#hs8+;^4Ku5fh+!7vYs%W>6 zpA-yNb_A_1_EkC9o*X%yu+kk9b}|a?SNqgD*ez$s?&qEKpxTDI8A1Tr367|7di@QR z2hkXJpU^5A$*0FFli_Bnrgnc6mlZ_+OuEM)nZr-v0*I5eGQk1&Qw>j}(+E-qMQ6w= z#*Mx7sfipFN1WVy0LZh)dytc#ZJ+}m*w3J#(Pj*Z2quV$bl z;W#eC_}D}e3qq-9e^`#I;!PF4-m>u;<**EtUZe8-X`Wzvr}wsPOgDlP`I@v3SYK`>(}$$iXKgGDmA0- zy^|#mO`ualqV#d-i-|WuPu)0!k%4bpCNVvFY_ZKo|HYNDC}dMGqWMJLk0ox}Wg5{+ zqW+TVeETu)HTJR!MV!*F+ut+jq3+SU+%3y)H20{QcTUpR&snE{!B|CiKMZkW?{n*u zL89N4iz>WGs)Qgm~kx!M-}SLzU0EUS>`J;OKJ`wd3_Z+2H@FT=A<-w>xCP8?%YVB6-U zQ@Mb?i;W@mTa%Iw*8f@KhLpTG?klf2j+iHW+G*huN7B2QhMt!;`t6L73DI-%(4io~ z?SU>Dus8BvJ$F9Lu9lD=vaO054e3BJ?!jjCVkI>bMZjt1T2WGd{SPfDh&?-$F=)nk zF(Ou>_pgky<3M5rN&ezb*pquc!n<|WPv00!Tfh2Bz-8~mP)6Rkz=Y_ST1+32NFQWU zgY?{tG$e0{1effv`XV;f-3keMy4eLstFCxnw`dpXnbTfcUQBRU;!=fxZ$?;t?Fp8P zCM*|5gbEz%+~2dma6{7#slxLJd`3LlcDo`o#%}-&o2uCpI0Vx!(sbH;CiLqWu40+4 zEi-#Jq&B9zv4nzJhJdd3S`Cw+6f~UqG{-7Em<~1@Zhg&{$C8-*?qT2Y5!eXNnY0S; zp~FC2eJONx?MocqiU4T}!6H_&p>=QemDR6HIaLxKeDc~+_qGyPM!G{iv>BL*CGxtaT6R@ZFmcmeA4=1 zA{zdt>+CI$MPoT`gOKK8vGXiM)~E6x8+@YStwD5yJuOb5p%C=GbK#ibfo$e0p%6YNf@b3&ix>Y|PKO$eMBBWe&>UEvMxCRyTLccm04F(FY}kUU*n zSbvWDyoNus;%h=2+Kn_+n`afdMmYx2tBpEb5Dm<@Xb?X z60qE2=}J@;HDL84Q%g=^)QF2%3iUacSCXWkT+L?3Q{J1Ug6`*9kHTZ8qvA&jG#8}- zKM$&P3KT`R<~l{!MZBE87TFOTI)P(8DaZ$$So%IDvm7_(VB>mzAFT!HOd;3ah`Tw; zPbqCgXN>|r=?N;WrA{gIy}zDeacd43ynyaGR}`v&$Vuiofe>=whre^soJ!t*R@Q(v zh%q_RPsrJ(=P5GU8cYzm&1Mu^9}E$PZsi4rej65rO%urq6)Z*W2uggvLoDsQNoy%Z2KIS-qJNNxT;~TCk3ouNNztefZs8$N2~bT zR{ zu4l$wtV*co4V1VNm}%YAym_-IYFvVK05HJDy26%pJ=H*FF2<4H{2;Ly*eza1Gv&xz z=uV34pR>z#)rJc;M^O+$CdgL0j72M}pRL1TlkjxX>P#~YCtyYYG0~EOYZ2cMHmXH9 zdWOmDMz*)+3%%Yb@QYZvf6#zIJ7*wSlPX5s`s2^3QZWE6kZik2$ON>OJ0o^?mMU^y zu};cd^Mzh$6`aRQ4+Z4#>~}RlJ~SZ?aNE_z>2|2v^|up;MC?hAH2JEC=J@2~#=9u7 z9Qhd!uJ!{e3uhb9#JO`HM>F8sDyu>W#ZuROr%S4RyI2QD`zt4ITivZ!iAp=nPIg3p zO~ccHM3D`w%R;DvOAb}IfH?Gq&p&u4fVp@h07S)e$VxTwdWUuhqj^ydNgB+D!{rg< zV|!HRmtMD{Q|AH#ssmED&I@ZAdgfZ+cYZhy(q6^{nq&>y4(_%2nppEf&kD@L!2Bt^ zz`Z;d8XyIRBTve7t~qO6VwY_+1;;9+uR+P2fuK~0F5jvil}C7UX5+gj>=5#z)mH)? z63-BQY3R@WrTGxxm+Y5Jp_o=;9kpm1$weP~{p- z%uPjO1U(hIgWhop5-*>H%w1}(t;}itXq37{^o(FLSbw83$XO%o_ZE}pUevyrFwi8$ zMJWRxkdlu~xT9sas_4z%@MOFe#zu(5Ph;JLG7zrnM-YXeKB=|G-uush8FZeU<)&lPClc0xPf=*qnOn z^ZPjm-c)&vHljP>yNKs0%*9I36R$ngt(Ga=Jx^`wdJUXqGkTBplHR|LURAXa;nAso zJ_?zh{=q^i8w}J8+e*ew4b(r@D9yjvi^8Mxh69&txE{QqrR^1B5aBkyq05+q>}mhs zZ)_1|z#t$1;+Rn;6p9OJ3v8z3tX{~>ah-<0T7pr!f8nW{X2D(pEe3W_z`QdV{wK$e z?;_`4&--B}_qpl$NE@UE3Y5jF%?-`=xOT6*^QwxZA2bvyK=UvKecDE6K?3*fQhIJE zB^vQ4Js>X!xRqyiwqYPWp@jHXzrjG6SWxqfu?9zF}E)RvcR%>q{FV!8aFWY4hw2it@@U`e?Jw94D+vq z80`R<#!Br5V-fS7aNott_XU}UB5@a4?G058B}<2jp)tQ_kgv|($H`!;2h{|*C=RW& z204=~isZ^sf6mSDFn4ZNLc>}L9!#Ya6e~gVrfX1v9kAHG28Xlh&*(6E4z0KphN;ri zjBDJK>!WY1Wtv4T*$W~2=2b4Pf~MvSjBA1!A0FuRa+q#lL0}e}#Vh$j5t0v>ythaX z0hZaCkU8X*qpCGG1+~RiyW`Wgq%S-OOF`VmYGt{gi?$`a9*wr~sWZO1etVP5VSAx% zJ~k49CMxsGT}w{eN++dUQ*dex$J$aw=-fr4Wy~^aq7I|)5R+9qH`KI*uF~_>fb6+AI9aa zVYNkwxoD+h6(*~UR)##l_A(OGymWbnm;K|$V{=q`>H@;Ue_V`8I+^hyy4{XOwG;gi7)BB!4Z$WuK6Jng2BfIwxGHT~rtyt3orbC|S;YhObod$7C za=k?u)zdPWMjHjKljM2RUyV%Xtvjp~b33TX!SoQuILH)TU|%%KqJks{Iz@1#7`^zo z^`1et5vr~)j;+|Q&~)nOgyK*EqB-Cr&5Caky6+K zbTH|Yo9;qy)gvjSl;atfl3bOn2nqWz;hD&rIcTYe1Z+zGhmRT5FFmruVaZuL{`(_vzs(g0oMTd7HjY-n~alSI2r?DnTk2AC1?kCVG6KkpW< zXAFNVw&&~EeG9^6aD~RFpKa3Nv(&pjXb_z+K8pvMDM!PB={yq!#rtt%o?KLP1YwfD6P<0Jay05^0`C@J|jw3 zzA|vSor`9e7<+H-F$AT1%FfHa;2M5Q^B^c>){U9hC>9;h?abmXIAk^6lL^oeg&Fx< zyoTR+ca=UPq;wQqVclI@2j9=f$6}9%3N#zlNb>4B`;eol>^;u;%V^7zPF&;_@`KQ2 zX#1@?C&q#5aR$!8vXjemi#0`K$dDc5cm{iZllsx{_Q+RpX@4aIqJ z&L)!bV0S?UEsj1bAqG>)w8TrN+NDgHh6j>}T%`n~d02HUL6L3or~!zbVZTjUWL&01 zIlcG)RJ=j=XC0Fih#mxUa`8>6=6NKc0%Z37s2o@KN@L&PCo|W`Su+d$sr+2+cT5c(nyL55F_OQsROYXL>Ypbnb$s1}W7YoWP z4Sb*Sq_U~F`Qn$NntqkNqzaqTx)=Hip}(ITLYcm^9MgOo3M%gFKfp0=cfJnBeJHFsvbJ^& z{tI7tg;kj(ds7Wwc!Vt1+A78zbUE!Kh?G&@9jTBW+(9uC*buw@GWgrF9}C`8?Im}-`pTc3kb6p?AfI7MR0V&b5&D{(DF@oVkd=%JeTbL{r1%ZYLMmM zM-0>*-jth3(Y;3lzg1B%z%d?Wqy*jqNT!w(Y=V5TwS%<-)6`j*DepFononx}#b{N* zA4M+XmvwKRi{RGMZWW|iVk66EuESn9PHjO{J?>Ysp%OLY;paac$Dvlo^Da zczLbPtQ(y{)N#ucyJ0o4@uR|LXO*puX4+(S5WtoY{F+kuJ*C6{`)Zuw-}E&ij&R}J zImQ|mFHgwvwgTKVYwCPci<3-Jd=uz?y~!!2j6JB|8n^b^Ik@-PcZ zvZ__%J5XvzTRl~=jTWHT)(xsdP-}R)asE3N9sN$a%`!BEfX|S+XNlxtiM-8OuATKH zFx; zsaP1wt(LMf^OUG$k&lrbtYm^Az70YXyLt431>GT15k?y+kz?00<2`mc)f`LYwq2_U4LtX)FK13td2=H% z(U%9kARvgGBK0=#5vhMndxJ|1nzKv1s^`O^lgloWGN}ZgMih8;!04n89@5@F-Xt!r zu(&?$y?I%cAZapDr2Idq%A;MMQDjJ= ztw2MT9gl4wg7$+DafZZl_!!&l9fq!L4yGzn*c5N3w9QDxJ4k6yhKjWRU0(l?#f7Kp z&iHQ&2MF}I=jztX*4}0bp2WzV$$%^3uVu(+{F7C0F2QtA(~Ey+^>oCX zX7e&Ck2$Z7HpD~d**`E|DWu>9U&#Pxz}hI$My~gpMN~UPxM8(h&@>KXK8*!pBTpm3 zZGxN-wAj_EFi=J()la9ty-X~nhNUqKnQuW*T%Y!hw?!0J>If!gCS*?3qA>!w^lAiH zF6JGhZg9ac0x-4p5?r;FiD~fb&Dxe=nczu4m(rEV)2ZBAek$M4A$9p=|8R5f0YT{y z2)ZH0qJv-E-x$Bx#^6Bnt6Y7P7_$Azg_qAQTlG-joiwlb&taoR`|{uViV8U{7;>iB-86F514Ft z)kPjaJ%Am~G=>f%cNSh(wdBmjze@U%uJ3slBZHTva7emRMZs%`ty^N{R6eS`L~`jU zCzG?xnb3_dr@fD!TXG0VL7C^#7%j5+McY2U_BCOOT$`-gM> zcJTmfLG~pWq+3=!E-4VPfy~cd(B@_J$!k9gmE;7UL}ad6#8&w^FxJ$zpOzdgmF0c+ z{x!q;ZAlnU=^1Kt` z8XYPC6R;tXy4#>Db}1E~F3-fe9~$ocU)89E( zKXM|!lOy+~A+W&03iEAiO!M5SzrSV?&76o`BrNqA zl~FTwA>XmrghzheHxc1NzGR#X{5E0eN2u9E`*)diWN*yeNd6FN;76hI%#D!GZNYb%{;RKATEaZkoO_Id;5{qnhMgA zZ2FD*-mgSuKjQbq$mu-DZk_1u5Mr=dMZR#@hNx1O^iB5Br$@u~pzCpSA6^-XItd0DNt{pXc(3ppWOggCr15EB>Tg^?k(hRrtHzb-^oUr}BsFIQ+tJ z+F|(3Btb0YsLlz#ebmwb@0yPFhP!p1OCHlg7K9p}XvZ5dsAlAK@#;sy6jeG=VO=BTulGcQh;~D&{7KUK zqRG)t)xag?zD5Z51VDc8yx>X|Y7JB~*E8V18EixiUCBckAVJD~UR&xKQVYz*zA)v^ zkSlA4OFY*Vo?NJpj&apY!V=Du8T0g5W8UlMvu2qXwd)Z1m>u*50WE1+ft?@;4>H%z z0g|#?5vi+XOPdgQ!wQy51xN7D09eHR+f4MK@cPLt;5=Fz0DKiQ%*FdAo};%g>8*D8AC$UtpfjoN%- zu{lMBm&R8#F99TN?=5aC*n^QtrSMdc6NZ!Tx9ED6C_<(vfIWI$6R7_C#;v1;cr)Ie zewR|oT0fBCM`-cAi3k3Hw4njN^@_X?Tud}DQyC-M-R+pga(FmwF8#4!ONRxgw`5D( z4{oZOl7vWS+!C_P+As1Lc8R}1jMR~ZD=Xu>TKhqFo+R1(g|SHSgIagv2~x3mP)Lfw zix9`4nmmzmX>WFo=IggDcY=LR_>N`isWiBas{=~&J`uyzy=AI_$_{%FcD7oG4SfUd zGs$fsx4>9kd@(<=4X3!bDNBw-`zrEfGDG?4N|j1;U2m_VITkix(NT>+-2YKnY~q zy<+FauuErLcca7IqtkGWR7T81g@B@BNmdP3$wY;(jAe%?ObQ^XoF=-sJeXna3N@=O)7jfAAK@dJ zfgJDs7Y3l10JbhDH#!8c9Cf7WfZSn3)>K#S2Z;eT5c8aJSt6~~1z%*->O<6(oLI^l z{W7aVqoMDB<+mJ0%kF?~cXC7P14=q?UFI5?1y0W}j_lEao2`UD0r77!PpP*%{4ilzdZA28p7#@ zw28KNN-%lFY8veO#^`9sZYRZbZQa*(ThNaG{Lw$T*f7E#d3KNHs5)M^BuXbn zmaTkBD7Jz`{9IloyrLnrh?@<1rlqjxQSJ({Ix-4hC=u1_-QKA3Ob#_dx9n;!$)Eo( zWnOXt?KaV)*}d2kKphnf2ZVYAjur4xvLbY)uq?C z6RpsMj9dDr1%HvO=y*t3jzRWg%uQXZ-4O2g($6r-(p`xeZi?C{^F+RV0to+yTBz^A zc@3o&@E{bqTy}%1NQ$h$(*8PjdMrF9SMfs&v4BVt)v`XDZp~4^iO^z8$$Juka(zfp z$%FqH*=9+d3@f8@Xa`8-F@^|42NrhPfu4xyYOXdz0iD}(`_+l0ze^dKEQfdgV7T+n zaOF|btBS?rdUiC4h>1@EPg))%5%+!C)HPnmGf1@|oIKMKHn1MGSEfC?QdDy8LM;81 zyp&*)NQB9c>)J3Du__aoL%ys?*NA4IcRMzu;|#%gs)pLJ#ftIcV-U8fgc#eb#x&c^ zq#RGH6uU4zD@Xp^v#q$inmMmw?3Z_gY7Ij_1RYk5e4BLp0%VYqgeAz!72Xqz%_krR z7_%IO1MwfBT;j+uW@EnLI7z*91g|E}mpduhT%r_okI@UT4*%zSP1P?m<7(F<{Tr1? zYMTked@-tJ4<0aWz0B@5hEvL=N-|Nr3)Yq7gf*~^P_@emi1|<&dkL`?|9H0Cv}UeC zI%ZX&n{!@$vWm+FgFS%bPkkPRL}CX7SWOX!9_q8FPXeJ~P?v`$m#If|YzKN?`F-Cm zKa5H`?NSC(V-AD-xl4Nk%yzhx&%JmE%m`+veeb0@wbG^v@>`PU?`)az(g}T`+2yWM z68R5sL~hcFQqYv3X#T8CF@IR!^89KL>R9 z_iB5y7_*a@Qxw^MB~u6NwJOhZm)xw((Je(dWorvuy!{ zrcbp{u63AXmOw%`Dt!^R$9>O}W<-HhGr9*vq$kY_+DSazsD{EA;m?(^ID26-^{^5> z2^nQv`ON!y<3cJ2#N2-lC@^S;-PhBgs=3@;T3G80O<(sb8!?_jW(lK-05d?$zh_8> zOtEKzjPp`wVvfIwks*ILm!;WZK9D6O2-!NZF`(9UznVZ1mC6^Khaa{_z-qmtA91yK#msVpu4pBOfPQR4qQ zRcVBXfBATcu;PCoCJ?LGD+}WuOrusqGk$v7H4!LEs>yWpJA0;2H)*`?(U)NjHr-rJ z!-Zhp=UYVHqSfcEvDkuNKEIbeyR78Dp^>{qFP0TiK_iV^R)Y3S;>@$7`tF_|P$7U>Uv7ULR3cn6f_%kGfe zb?zqKVx*o#k9z~{4|*((K70cr!S4o9$C@GTL`sw4yd#Uu zHf{;dyJSXY5}3>oPd!*ocb&+B#Hzf5QxM;<_{{t&&qG8S{QPH zqfqHgsd1(HA^_HAGl)V{M7fISe~9bNBl&O>(Kfh+(qJGhO075TZE!dkb{YN9(;#b8 z^}sbwBT^!yH187aBg*lSdPDkrOB?#Im48ZZBbK-*bGfz4c~+;E*p7f%!>w9aLC1w$ z`U1hsWyIJQWdS^3Yt-VOe;$?r_tL@XMt)Ltk~I{b)w%ie?N@J?LT})14s0t=G|TxqI&#on$x)xdrCQpkN)T$+X@u*x8 z8%Ljf`B9iZj|&@(i2VhDj?4IBl91XsnLR!Sp9xu3s!*eCou&&Fyqj3PS+O2_td%q~ z7#T2?v|@6NvE+ATY=_=ruGlQ@L9<2SDSY3Mv*IbUIAeqJ7QHU@2%|MWatW1J9y;k` zuy^C!Z(U|E-$z@VZ;PY3XeB;)O275Qq5VK9!wG34WZUz`*9Z29Libv;>4DoyEkG15`a(r;dds#x>pjng?9NeDz9v>9dDQ&hExiSEB{= zjdVy#kS+bilo4;Ac?fAx4z{YO@(xRx$8 zL#SB>FlNAhpBTeC_a%K2ooQa>qm7CFVqpvJ1WKE721od*&{rtP83r}y5HtdZIc<$U zfrG}rFP!&749J6Sagfrx#v1ZKwv}9GC~&eC4%hsRg5JKp3om1E+kVN&x6zm zo34O2dm_hX)>W%#{7!sh&pIc_2rfZzqv*(Ogr&Pv)GS-V`nZD}t`0`5$pVCl<{&SX z8LA+0>SVDpE#YjF9gRQ?*}YClo2euBv?Zz=I9>5v*>KD#n5ldJxZf+_zlY1n<937} zoeU+fXPVk$MU%P1OP1ye7nfI-as)`kb5zxk*9a7Rx<)+%k(M_RMsllI_tkwECxC_@ z)dAGTG`n4+GUdAF;UwT`ScUS7&}C#v=#}qslhV_s(A`Uz-?_<{ND290rbz{T?g%Ep zs-T&g6(Kwn7NR01^%7crHk|jEv_5*SOvPRhdkAhR6YVRX;oiYv@hRB@6NV;UU&d`i zHTyM#Dj=%iVb)+4m`KAv^yFibY3%kQ6CREBptPI3#cy%`Q7aotE@SyBmeP-r%g*Kp zw+<8V^qRn8%+02I4olf_q~lw2KYDz~)5e(WOd%31{k{P08=+{EcG||DP<}$)(Z6{Q zpob#`iUbM2kq2als*zeh59P?ypEllpO*~?MUQ!Xov_Ij?!^sw-VXxOTVV;Q{jL@74 z@H2_<*(0P8F1As?dFpd_Qt;}jFhfdG@_Lk{W{1`2FvGAeJ_fk_CY8LWJj?{bSnm9} z<^Kb~#Fy}#l1Vlf9F<(ABUr||$E5^t0K%dUiH@zz*IsFFSWS<7s2BU1M6{`IUTC=_ z{|h9R3&1a zHbuWGS9N(K>5nO`j(LTqdM$z5#8Qu5NY-|!ZoA`>m{V%7>Lci)kqik3O3#Y%!&JNo zxX@vx`v0}pDT$2MhXk&!&dL9g@_|(5J`Q3fU2aZCvS+ooXON?Yx=Pq=XbC?#3)qxC zmjLrvC1Hh36UEU=`M$g$!kH`2Qs9iLSf0B?BzdEy$l-XpFg{ zgv|{NskhKYo@vzA9^@2|I%JGIUr{9UL7ROOldqD7bj3}IbULojW7qAE5|K)MIuCZ^ zY0Y1&(L7D;k7bjD6*v#FI@FmN+6(+44Bbu32J3v)c{AGzs7f{d|DYeyZeOhxOGV;_ z5@}MWDag}Cs|t#Leh{mX((0Zm)5~k{zH;|=5QLWk(yXB?`X?Na`WM$#ICbAO<3qYQ{J#@6x%k+up}T{_!k z%Wf8ed_n@X2mvT}W`X_AA{k+=IUMa$IoL1J=sCPrb7cazL3SUBAwGH+pjp!|ZN^s^ z+C4r19etgLkHKVb;le0^`g(xvjU`d z&onyn>xjpdZv5@LDP3^raVp0A{3Ct>9Ir=PzcAg{{Y$ws1*dg7X2BG)MHdNspq|4x zza(QMggm@+DE$XawLpJ#iK%fb=_t34m3$B%%!)|Hv(G?=={s8QM{LqYAZ6qa6Wx;P z=cUwBeBA{CEQ!k{u}~6+{QZ#QX)6ZN;H*j+sw?%qJhBr`#=U)$+u1LN#7kT*@*sp3 z(b?1ye9psk%z*HG8JJtGDn9!kRr^PeC)>JpLer;psyl=ifV}GeSkoXP^VCsrcjXdO zRK8aVH2usy$4?^~Sg*f`{zo+!U(nV`Tv(#Yd**EqYQw|}8u!H7Su6x#I|tj|1K}r zB&(^ML#W8LbMnbH909!m|HMLO*g+1=d ztFWH4u1SSY{hfcW&!fNyVIuW4fk%QR8~2JqJdVH>XXHt0VEZnjBHbgsQ$!c11#<5@ zy0tEi9yTWa>Hocobq?jFy=4F%n}yZZA_QlOM`K1R5=93{2l<@xRj<20j+6WfI}CC41;TauW%B z!jHderfERv{v$OUe?b{djP1ThMI~sH!yqCaOPsClkA^k>=OAU-)7EBeP;$SYDpmc0d!2svjR()p9xg>cd_0`WUm1U9eA2)~cWfYx4wl}!wo2F5*|Q4wE&%)1;!h51 zmSHGQR!rT)-8!-X`{&3^a?SL7bja-Y>HM`~heooAXHGikbF~kc-}klcOs>{vaRJi_ zX>O^_L}kS8jh2E#X?Q{8!OJbn3bt*F;-Z>q5O4VGj>Vi{H#wT@4IcoBNZ4z=*4hqA zj4g*4UCaiVzD4z-9PZDo$F*$i7CsJrt+!vlfO1)Je*^c-ZAjp@YfHs5?_(q8!7e9k zrT5b82x2$T#C~ZU%Uu=@k&t@+Td={6wO5Vx9#FqK)=zB5OH~kYu!YQg&NS}Q@bG4L z!z{#@;(eRNfs zOg7gJm)M;cf;qr-595}O<4N>-*zoUogWq25Ok4Qqucr(cB`lmR<2LJGHXa13HRo4? zT|%K%$+}SU5RaUkPjShR2c-=g``qvQVOdVt7?X66IznX^HfVs^n_h@_SR`>gFTGZ; z{cK6luR=Jx!+`m}Dv=TK&*_4dg;m(<7kOOV>Kt)fKEGv?LDkw^@x9Zl+Uf+?7#?`u z-k;}sh*3XD>&U$)J$!U5#)zUo<6c1EjOtd`NQg-0*h;oNs9-M8MyRUyj5D8&P&D!& z|3-~A^N(AoWS8w0D$Drs31|kj^xd(;!Pbi00SkkU1<|4mCK6;{`J0 z2#mbc65)N)yn8BdAOK{9PSC8oQhPT5iR%&VLZdE^`lcGh5CUc9ZDbkAu#>A{pk80V zbTX&gnc__^?iLE?`*9$daB;stcgJ0JQxDAei;1mC`rTqtLa|N`x=$(Lxx~@pUBu#7 zCL*P>Fr}*yrdemRF*Uaxp*C;jry{sqfYi%*Q7u+!H-ersUvHz$7CjxL3tKhebZb^i zBZBb>`}+<)XS)aYxMywET^457Ad824^U|S%8qXQ_mZI#i^8XF&b$vwx)s4&q#6Twl zTrxNW{5ZCRqL4k!^m%;M9}gHW!|Cf+I239XzcgSNC7X~_@~L-Ti8ayELO5mdIayOG zY7-dS+n%)0=2P^qPNSvGD@JhN@o=vKJS0k)siSp-zaq*zK&7S=R&u@Pas)jm7J8K+ zjQ5aL(@HfYuYJ$6g2ApAFJm0TO52&;<4Cj4*l7X~oqqYh;ZE$3K`;;n!4f9uo>F#8!;S2B~>7tM$=1T0`Iuw&X{k zD_tS6U!8W2;S?_v^p7K7*nK4)Tg()PT3U;Y_Al?or;cx!A3%X>6+V+KM8>6cb@^si z%AI+fWY1)?++3%{TiwE`cw7j{TkdQ4+$d@>+?I9b`5Z|RUCIv{*{<^ZJ=MrdPc1RK z#{j&uRhqb{A`b%>f3zjps_+jAT2<``7@%^wGa2`hn5Z~|lvN`to1)Jq5tpS~fU&!^15D4panK&Zla$bvF4+o0UWB3c!*OQwfI&c;10;3bFPK zPJz!*PL{mar~;_G_B*5G7LBp3jr7Sbskb(0&1MmH+25)@fn8&&> zk1+?@S*3o^->ae5v47hha{u>8L*SnixTZ@9^A^fM!AIYzvs6V8$;2V$6h?I&|Y)F(z>MEkua91^@R}m6+ zoXvSHFQ={Bq#Gv}tBJ2m zFzUjIc%YiY^R4fwKNLtOtwi=ElD)rKCuMp4={eAtHLCzpfb7S#4fDJ?zc+hZZLB!P z@MrXO4>nuW2VSDJt7}Yw`LvA|b$n{NVGm=QGalQkzlhQV8@jO&oI65k3lWSEUXOhQ zmQUeWNQ-J{JpyP0xGm#$1=7RoWYQe+57iofz)Z?+Z8kfv2NOT~ zKhV3u#ExBa8J2yfvBUvxKzWklqOiBZmwH~5-+xhKNX+c%Jrm|UnIi4h z_xIn#O2GY~$}9(3w(SfI3+Ef2M-!L5$gQWf_?+^@gV7wODP?tUp})Wqe?(<8rE=Z6 zD}JB@_M>k?p6}kf%&EH9oMTNTqLr1w-gk+%VAJ{@36k#5$bY4;*0#Q)>9l=V<;hq} zP;4fC6%YG3hr_`v7{g-lOj{t%l5Xvn_8dL!j!I{4it#h^*Gh-oxJ>bIsgsd@gtET@ zeIG(Nz%S(y@vydK#e~XHZR7{9pi_sGb|U1w3O~u;?^z9i*Za}4g)g z34e6`0E+r3Y%WxmFgsZX-_kpE%{y@mI%&cAFX)J;`ywdWK$yP^9g z2s@tOMXp%YLx-nOFc-A|!^0Kn&4k9?CqRdsi|4s2+cKh3CaPk$o$f&;2BX*N4nWfN zLBzVgVSfvPL^9I!Gvx*7^}1Bb8styBMFw!fWz*=>s|nI-#3=U*z3yLVugX;d?wB9+ zR8|4pM49?~%tVi4;wmvKkGv8!cTA+_&7j$gOvFJ0%Mz)fNSv2uH~fR0H=e)n*4$|@ zCJi)s89aN+X;5|9UEigKH~M81;DdQgikA@LWLbY2gawi29tSn1-6fxUSh5PG!+Lml^@fTT9k-}^t)frYiaI?~q>8F9>LAB{O5Ejl$ z-sl1BOFJ2n&);1 z7w<$(Va@D~D#>&*j~8VL8(VQSZ|V^TPiZ0^s<;)`TvC=k0=!ETLS_Py#Qd7dL(miK zkH{Y*=S)L_-feV6bwFSO_D@TLEf<(SN$=(K!>lt@%?-8~Ym!LQei%XamwIY@sT9Ja zj7&EBJg;Y!w4_Wg-&9hX|5U0pJo{Dv2iozQ7QVPBPPg+T8g_F=rxLgs`_`tdn6a_R!djdBrE z6MXf74e)A<)fm{G&z=?V!vUx?EB|%-iIGEzQrZei#*FbM=vzE|dQrm8mArE?Oysp} z&T8m2ZRT$lenS{jXm2M!(bU+>lRledOO6oF?GI`>yBH#(JG4eGGVZF{aa&X_+2{r~ zv8ZUu|@-gG2|gPO!bn-i$?sj)A>m~d_n{lx9oqTShlVQ?%-l9YP?e$k;;_jqGl zp}wuNw;cdBNf$|)gT6oTS_1|`oZff+Xb>iKlmTm8`bTijjQWCyP$#yOB+ax`d@@%0 zP#SZ}XKqCbx9Pn)M0J)F_ul(QvkS~z{?2*Q-?}3#uO+z16dcP6nOL?#BH%N}9JYGo z8D>*JhDbTGkDPj{{NQ$#y7N7nX-}k25_D2$)jm=r4a}0cizu%E@eGYRdkx!z@-bGz zr7nu{@H6GX_W>oeK*NR2ELDq)s4XBU^5&1e8hP){z z7t3gI%w<()$&;cag%-3!hFcqLu5?;I3Jp3u-p9f%`jWYe%VqoX$g`Vq0LDfUnY zSevJa!ZF2m)YvBEW$%H+t6|vsa;Xh!u&pfp4i)AQZQ|UUb>rSz@*R5t{ViO^RbnAY z;I*V4(b=HDP)NV*!#foD9~O18W;ST{NOcl!#@$m7Ia*Rp?h^i%VkSvKI+gmB=9n&N z(DDT<3jSugPJJ`$U?`BDgob$v=Ka1?9{81~)zNmEY+1zVJ}I0^l)s3J-KcX#m%IgE zlZPCouxr~p{d0@%<^_kuV`(eg|8Bk{>+`sYBHf3AIg-eVz=8Lm_z6ir!9)oLD|);Q=Fu5J3;#K6ep(lyj046L&eTMiwIe?9+tc&A+jjJ1LA2G>m=e zJRg2Z0b^NL*5Pe3S&qoY{{|1OBy@pYT8i!;kPj&P3@Wj3ja-I1xx&Z@{0U=BEp(Sc zF>45&O{=$1_nm8G$Kl8pd$VJEK)qvFNPDRWlEPWK{i!}v+dQ0Y8p13Zlv*wVmT^Vki08o zpSZ2ILOwI6!FmJO)#A$5kf+{;K%}K>{%gg^*alN(mu0RL+o~%@%#*?KYe)c^(gza< z7N*tC!zDH{E|aQkGmJyrefhXAA6%oHx9320B;xRromgt2PA=5~A%pF0kW*+w3Z^+z zmKgV1{5Z&tTqM;sqz_}|RH*$6a{X(x^T$?sH7$gPFlCIG7K>h%Gy&x09@&f95Gj10 z?&CJDL9E|+vTiHBv4;~4(D??O6JdaKi*$q+eZrXItJ?U|WTxfW_&0}uJ16mF> z)yl+Ffl)J$(N^#Sjbgkt`r7(X=S^x9g?>+fma7wyuMl@CZ2JAn{854A`*Ov+~~Td?@4fXBU|e(`9>pLO4+Uj;LX_XhTey9 zno0^BL{DTT0#OlA9wcS4G9!@2{rVL5gvAT(KM9`QxD;l=*AJ_UZE8IRwSOdv?ii@` zb~J(B71^!#?)UB^mXkck4WaJ$$M2g@(pm*Mvn(u}9mOy1X48#=Q=?k$Gku#WuzU7Csn`&oi zTL$n7Zy@scqpiMX$`QbMp+8c}l)EVztwT@CPfTNon|699)(6}kJ8;?D0T2w$6&nY^ zyN(2;awk5;m`-&D`FK4kUyM?_oCn@&lQO=Vde~ow33A*fl&4wUFav>LzS=tW z=%HD-Fn(YBdPC6kUY7>@0R;6i|E z0qx8M;ojQqx~OTo?@>8-+z{MSXB6Rwee<0jB1;(ZBE&qk;{ilsyMHN z3$25=PBa7@_CG8doD^e%3-wR2`?wy8$sHqwBt9(9YmU{ssZJ5Bk(w@5E)1f+g%s}j z<*qC9dLYd{>YIri4;Ua4=O4-FI2=f`4KWC08Nd_tIbOFV2ARPrJ~~iF<@lF({KU;+ zCH`(x5zLT=jP$2^7Nu8s3Q?Zow{689C>cCdBCSLr9Pd|CL;!$^&?iT=DHDs8^V_7s z4Vzj|#hi#56vMEAt5%%<=ZZ2&Z)2fqvYb5XLJF%cG;H1!bOXGJ<^xuLk*8sj$!UkL zSJL~|bC?dv^t;O=yy6#~wQDAcE;bu;pd4qW<-MbUX6k)s6@J6WKvppBpcHvpp-=CQ z!7>nE+xrVi%p+9gI_(}?YLr)G7#eQq z@vvpmB)C$^G;Ef^z*m5b7t#{Hv;(|^!b^=dM`(9+K0(Jjno;C};GqjN;HWu$SPVmN z#!Cp7%wN@VyVNAb?HZ(pG2|8Dk({gB$0Cs79u}y|9h1yj)5$AXaRGca5i6O_kA(tz zxvaaTPfpEldl(W&{&;T+G+^($_%n2}%-NLeyz5$rgO;s$+dFmTpGE zR+p-cCEVh7hIG@?CuM8RB#GA#w^@SsT*rsgKVda)YVd9-7V-oBTv1ReFOQq<^L(z_ zUMgm=`K0Bzd+!x`jYtEf$zP~Gp>H&W_2I2XwLPnKRM@M~8(oL8KvMhss;7id6)rpC z=B@!TGAY_Jrm{-UyEcQX!)T|7n?RQPe3dem|5Or7^Df}TqLYEIdF2;9Pe!?&M;{P>m5A#c+OE9h*Q37#W< zWdxQHp7$ESABcZ{wNh@215{6K=NbmKN#4+-ZFyWs=6d1vLN?8umM8AaylOrnHPZ6C*E=Q`$T z@&?hv=MVIA*tw6KYgf={xnF^px@IayduE^C4T zH(vQe{(5GEiZ47WY8XxVH$>CWEi?P0a%|HFD(R*)1oa-L+0pgx8trYog51oY_76jB z*!Xr`v}Uswl%Rr0$)BF1rh^lZC}CTRw!`VVgCRB-3LN~n$_{bRzE}X)%4&|nL2t)c z8t)a@m`SfRqx(aJw(B-4R9fpcM(~ixk6d&+s`hIrv#@YyX`0~M0v{KR z0CWGKWl=69v>yKg1&k5MtZ8wo`$}O0S~Kg_GaER`=4uY8)1sx+CK@QjC^#K+tq3tQ zkDr`s=pt8JPp+@619zv@r4MYaYoG8RM<#M{o_N2s$4)~@d?-k1^v0H93XZ%gwdd-o zY8P+#=jsnL8n3P6aviGj*&c7cK*9Wa5sE7TZ@Xfxzb~l}e>n~SRg^V3Pefw7jHM~NY5;q0 zQq$+tRw&u8@9Rsi7J*KBvb}C4;aLR`w6425GH$U#sgKvP_6fLs$wEXlcbw(YwhO%o z$<`6XEPVpfpA(%N%c*T`B^(-i@<)1-$`TGozj7v~<=*I5z2bDm^|Fv7X~8&+2q;L&x92^ll!HN5tOUx9d!rq zi?O3WgIq`hw*jj9V}JAYDz;_fQSRn=g>f$${R`5p#U<08^-uUO+o60-Uf;Q*(f+dtQToP9CwvyHWn6cjl{Z?OMaAA6<%9lQ>_FJA0R z-)!-`vf}&XJX3BYOklQv<5xa3p4+eEmtxkkjYMyIIX;97De)cf)BgBKJ3->K1!y+s zVdl>c3sI{ZBaiBU;g{twCl1>yl~i)*3~@`uCj!4AHd?LWewm~OThT9+JN`15-iN7& z^;f?EGQ5Q|LXcY^i^QQWF7|Zb5Ww8aZr~+11H!pbbw9+5?yXh#>A8=(#xU^;U_chR zu%57jn^I*EB&f(GD#SC(i1x@=YcPtw2dNQyOTvJd()8nbiRfFbH~FD5U3vMa_ZB_g zKDC>P<<||_a{DI;MLNk8SgCZd_Y#!4e#Q-<22SpELx|%m!qT-i51nUzLz<(U@9AEg z8cE$46jpNyzPx(O@1eht<4K`Rt#*gyEmbd5u){XIBieDf4+!siy)xL4A3TQ-xq>ZL z2|?MXN77pc9}G#e3Am1N$4mWO6wWtc47{^sG8(9rB})87(uUFS>2wc5w7+Fy`x|(1 z7$H%~Ma;ic^R1QXSngnc>a|F)z8GvCYIL!_K@{!kN&nc>TZ8@d4-qkvt+@An ze;+b3j(Lq&7*TpSoS7h!yXc93YzLDvcm)Sb`_vIjBvT$kBB!i(u;%mxOZ`R1!ONIg z_nJjH{;VlUh)dIlc2nRk)R@UMN;(l6%$z_w!HBbTx4>omh2ASs+kCY%c8hG0FY5gu zuD70P>rIS1u;J_coGgLT2E%I3#^BVF77C+}5C(le*xgyyd#2ranH0CMt!5>YAEMqV zsP0?Q4(D>L)*puGXne)XsgVpRpA_c9$|{|J-LK4#x*>LNxW6Rm3n(Q&SPXvS|I`rH;!fUkj@KVB^*{|jf+d5!fYOrIr>gC`N)q|3&Mf9-g z`$aO>vw(mKm#cI;Gy;}Poy%{wBCyT$lE2Ca874hhMFZ#ZL!hUO_F0or2ko2I5l`#} zYOOJ#%r-4MKqye-;nsBT6_J|$$<0%TI6dWyeH*Sv@C{GWx<6#JH=iU5@obDz2s|Am z=p!0499 z?QRYj{+y93smG_=b=rsEp2{F3%!+kAZ~iJq;#3PD@;GrXgT_{-n`vjmMX}mJ^delA ziITr1vMF06-tx-agsI(q$%AkrUxtJ^1@NVkuf8Xt{b01OUn6VXP(1cF{l#dV(1V29 zU@s}9t{e(Soz7a=bknFuUOnYC?J9v!SZA|!lFs}I?Z2Muq@BdW*I{R^9+n*Z@jxb< zLCN{O1cC8hiNI}tFZ@7ObZq^ZDv64SNt_$Py6vL*PLyW5-y{JK z6U|Q|kz5NVa40+L1#Dwcj52coM&IB-&imshe4H$N4MyfRTc?aa3;I(=qr8&k2~OAE zj~+>_?MXc#^cZ(cuQ5CnN)sP0K%5V<5q!-fow~+BqN`L02H(FFv&vvX6?CGq)a920 zg3{)K0jSHYGifVqx|SgK(6;k08~OUE2=SA1lgx!tGWsd=#5Z2=34gX(Zwmbusw<;nU>$Hf(R zt{yr7dgg^BJo^NCBUh{#(pgyec*4KKyxbWdP05NdLE+PkWG9Zk9i#5ei68=D|C!^$ z3J`50os`eMIPEgPigeo-bf?njHH;2N9&qhg)iY8o8JF4@r?^(anCBtmWm9Ice>0rF zNDwh|Y;AX09w5nb%fG?=FBJl)axWh2JSW?tkLj)VhjECdTQN_cU`N8n=q~Hl}PV+Q8cKaQB9bqPjS>1SL{+`-N!q>4BJla?A=vx+rMb_r$>cg6S zuQB7cOT)Mg{cP3ZUXO69NkQUQimOwfCPZhzeAU!quy5VY%T`)X!-x+Gmp&na^5f<| z0<^s&bIj8yG~cGmBnD0}n3(Zg2N)?8#gE(gRHxv=k$J1|)-QcgL$uPk=+V1qog)0* z*donZEb@F6&GH_=5mbr;hie{`3aPTJKGO^FYql^895fr?JU)fd`mf7kOdW%96Eq7ms)r0DnsCz zNiDTI3+kiFp3cIAV@*Jn zMa31!N@k$qqo)EViKc!c!T}7zZ~I2Xm+w}Fflks@q~zZH2LOw~a4PlPpf#=|A8{Ct z4}u|Vajn{D9z(3eR>aK5as7TYAi}BXr{~D6w~Mm70;v%@T)KutgU9=^0m)Cds(yXJ zTG!>)!Pa6|k}qneM=~_ORLoQY=d>wxsm1a8k(JI)+q!}VV%~A4)$zA*P?Rv4pLjN# z6eUlYjZ+nvi5rlri?H4Rb?IclYRROaV^M?(Hsa`#B`6WS?K9R;a{&8|O)%17;D{+0 zH1x4ZJh6u0iSXAQPT|s;nj=yv`b0>9dtDYw$d^+a`2~G8vit6BE}~ozlp>0;6JM8@d@SN0r(P-7FbBpN;8@K*(oB|aMS1e^TXd!bB@2dJ7Lkqx zX#RP+ubp|qktl9=F{yLqFq>MzvP1La2cLCb+WdgK?iLmL1AT_3sd00p?g67dNleNa zNqaSC>KeacRZs6f)Yy|$sizh1V*N>St=7>KQ5!Qa<@ya!svds~wKKoC1#jx=jAxtjmnKIS`` z+Hd@fW&w9Fvmbq^9KloBCVtX2R2QQyXHFHU2KW{*f=GbOzeHg|yLtB>8}UZH+uyqK$?H3OFA zx)h6ChFJ~2mTW;;3mOsdwkESHpN`=7afeKBVHLg`B%dX5W2jl{1iS2<2a-#P4H8ru z$W962ujfwSGuTSp{;e#YVTWYyNQg5ckE2EXGG%?<4nmpHxZ2^1WpV0@7xb)!JrY=v zwqlq{EpFd1+xQrJSH!;@rZ~|$so|0ZFELhf9942dxQwl}tvV?#IE{6KxgR@(3NKz_ zMr@-K`)&DUTuADm4Q9S@@!$`#q`6Z^I56}3#nJykCQCBkQso|W?vn|-H zge$D@;%@{bTGDH^{4!GD&{Ecn`?SbXEziMOy9%Rf=}J6~4h_}()RN;{4#{m;z6y!bO|0-sjWaPQu(F z?6IwypDRA>%gP5F9)&~RSMDqYsKeA|8ga?&+7BasWqxiB?+AJxuuk1QvQHpE_p%l_ z)3~M`-eZI#L@kOBY?G5ScBI|31JFMUMi^xm>&9&*CbfJdcZZ^C$NY=3Lqg^%`D3JL z;PATvU#3PdPsO@ecY8xg$*Hq>(F-Z)`gR#L@hPpn5G&O%W_{6uY{2Oc>oy^tlz!~Z zT|uy5;5o{Fy0p^5txC-*Xbz;3`!QJE|)ne-w^7a!MZID!Am1kb#-c4M`j)< z>PTMe?_?WIi$M-47HrIjn@Jv9SWPb)kP&63rw%hv&6 zS0}@Rw5`2V63r1hNlPz=L)aePq9EIFZ@we7wS9psl4L4a3S|{;D@(NMv6RI!i#BTC zcF(9TMLzo~sCk_evgY@2p+Hu)86N-Ng{GsRR17GCgHP@A0EKjhllUvP0g}-S*Ca&J zoNWbs-110zLl%lfj4qk6A-qOKYmrLZ0`KN9x59KPc%A zqw)bzXYi^lT_08o{)MHfr zeOB3mMh2+NY2{TToRZc?{|bdq!~^b6tL8RLrg)QdAB!=HCTDWNsh0MhmNu7Bpil8H*J=;9JFHOuieHxGBI&nP0TJyMVedyIZCM^m zh@W*D-{+n|mrvk~#$Ul zLkwnn^}vfoX)hLa+%HK(t695LdvDLDJ$JL?gJVdcvsPfRK@Yn1gC|jyQa&+GzTAY% z!v+}^uGjJx*sLeQ)k+(UY(<OmXku^zBv(NinNuaNfxo?M0y~)gK2E@w@w!+nV zCv_5lZ^5ZAr(k%$b!)tBO3KDD%_5(P7XRL1m?J)#Ua&dBlyh*sPihY1gDr=L(FOW2 ziiF$y@@wgtf;}p=$#gZM40c5)T5D-Ue0_%h%G~@`2jPFj96hwJ zC}KuUf%E#F!fvI&d@)F$v^Dt!k7;BHqv8gXO`yr z1BRPZcMpnM0fMjd0<{U4{H5!$*k&?1mn@O8?M*YVE>!Y_twBnvdLXoUBH;x-}smI@ZvQv)$z(#RDiANf4`D$cyy@FbIdTS93%wrK`o2 zTzlJ84dl`dIhV;eO>WkrBOj{_1vmnTEv)L~RAkHXGKvq$%-;u%k22fok=edF0@yy> zpg3S)yf?VKlmBW~i-=BTg?WvIky599KIHuA?j4$7zCQwaOQzbKA=^C$9C05@sXm(2 zfOqBLPhpuiYmNki83!k`)m>n&Saezz5Imptnh}w@RL1o|9$?_MmiVPeop}!?RE#be z-y(5($M|BWFYB~mtf&w+RE_2%OVyCxMX9L?E(yv1eP`j7@Xf_lCS$G+$ZqgXV%U!4 z&WC{K{`kEqkdyjRL%=yP17HTLy829K-_{2Xj4OyV7|&5dzlcGqd_k;*FIvNyu09I|2%Yf;oA%6wu=^$u}_}R`ekX(U5ffu z{C=>^t`WNaE@?;6!jQa6gPnvGAm}zf<>;7jYY{3luWy zd4IH>Hx?j{k$-*t?J}Alz7BDUBc}95kFA{PKbBePJ~f1<^BV{v-*@B$KBL!~W-88` z?v<8W1zu7;b?D-G9)$&{bhAX7M~wz1@VUJ3N$qs6CZ)AU&b_#WX{7HL6>=&aA^WDl-!L@9X-OHcA#&m*1KE@cIlMp7BkK;KpxdNs4BMovrEsWPap6Adl#sJ5@pnUuvMgV&FKJbh71|#^06w0 z51_e`e>k{+TJN}nmd5uS3XHfTU7x6q`Z{s4%c^Ow`?Jc1=VZD#WWgNT5I6Y2^3pEH zDrvj9?Wg)uI+PME>J(F7MkUK$1tTZN*_Iv1aByG|{Xsn>GaH|tQc34*WM)?_s8e62 zQjwNAxt3^n!K2RWrbzX33!b}tej|F zOc!i~;&fNJwhX+HlY`zAps4#ppr@xzB70_O#G6MU&2| z@Xsalst}^G%uRo%?nj;}%jP@HNHr0R&(WD;)P@wIR?$8LWq_hdCMP=JH!6p1hq>p+AL`)7hDykvI`x{pq@fY z05m|$zg(JqCEO={79^Qy@TtHRo*G^=n%>ySgS62ui-sY-I5h0<=CKNH5G&?L%^p|+ zB~LM*Qy6X32F{ysW@f%CPhFG;jg;KcGWxcnSWZ&7YixyMt($l3&(#!pA89i0azIgFKRM}z}ZuuzC9nZv&xMxSA` zV`PNgRs#3x#NmM&WYL(vO%&xN< z1)o7z;_Z-wiklc3C;Fwx6d0IR+aPCY@Zm2a%+o4@B7F#fDO0HQG)bB#-B(l=-U~-}w~QGnK=94=7ks^XFAUm$cPc3XZ>*@{o|K04$8b(lL{r0X4#%Do ztUu12otH);QED+j-Acpf+=xGUICqf5l;{w5)9=rVV3E7U7L@ZXz=0FotZ^dVSzSqU zkmQ^ytga}#|4|e_xSaySFar)?&DV)ZGcA>(IIc~PbvkO;tE`VH3!SRYv#sK6eIN0R zwv!pTm|vRD_N@>#bCespL#?SvEW<7u3){8HJm(>XWB%VpMqSn00)3$|zENwjDP-UA z8A{5?=KXHVgfoSDHjl+wrXNU3aXB=+_(R3I?w!)FX>&VCn5ynDamTscMYWzS$xx!%A|?RC^w5G=aL%?@}{#z17W*#h=!&~ zT`|F-KT{q)S2&x6$T!41$wwYKde*%IP_L%%VO<<_JzpFUhz?JTsPw;=e=S< zTxiW6L9gm;lyDzGvyuwEfzq-Iqo&D-$)QbTwT6RI8+cz*n1L3QF8zbQKd=Lvvs_AL42Hp`N>+u%e)w{(6~XFygf8zEhh7c2wdr&3!~93wY+X1FF11udc1I z$;k|K@S%Rs%K!O*d@ex#yl9{-Nj1 zj2Z%kRO*$dh4GPalrgr4^xp>~>E~Zti#7K40Qib8pZm~)DrL|&U4BADO`?GeZ1zxj z`S{_;J9m>JX?y4!HKJt^@rfSRHFAM$NO z7xm>0@ug%rbyBs(i8yb;1O}UY@VhJbLWY4!)yg+xuiSS?M5B?TI-uH4{(%Yw$9KD} zaSj{P?~$&YZWshkXer+pU+mh@Iz9M?9uk;_#}S*sJai>>HV73!~-mgFOjklubM(fD)3WJ7iA{4!9|+5)~5{5YM`y zyM*0HN&l@AFJ){Yj}9n(b3NN2@tgwvcC}Kt!-1o1Q8pFW9)(#N?S(BUf6t(tmy1Bj z|NdK+t8&jzy+RT_mp6ZQTH_=$?g6U-*php5JygZ>U*L02?sx(9KgCIPMh(t~@|t0( zh3=-K4)lLEkWg7KN5eKP%s89LGZ`Ewoi?xu<+Fd{cNT; z6$t^zQHpkEx3}@9#LsADLT4TQrlD@gVib1eA94HZke%7FV5r>Y#VOgt?NfU)stF1n z)$3U4dO(SxjYJq-1%+YQPwv#tzj%11jNO9;&KyV-f#~58wf5GSuGwq5@0l9Tvh2lg zluW~4Ga+gKc9oqnRyxjG*>uPWlrmjzeks_A^WbYA9+rd0ao>~bMkkjON4P|cDWv=K z_hc|4$p-qD=LrkPylcbr5u8WVt!2j}byvFoTmU2ngZNEaSYhSpGkN`_LDRVvKJ8AW z6nG1G^&nx7ePvFtPm^G`2>4Hu1z;;)w&#PEssguA6_@Mc)*54@M1}g5Sl%&ijr0?| z<5iGtr2Ub3iM2JE^t#`219$?C2NC-9!vVIni8hzqf3GD9rstpp@QiH#&2q0^cRzd_ zTg`K;@BkP-lw#|s-v?ir8_?sx=Lu`kLd*#d8LhNBe`Q0MUzud+=`089|{3$d@2z!}7hFmJwp}=8StJ!gZ#4 z=xbDf5uPYrCpwkjQ;#WPvV*|+8e_`wt|KJym46XFHBY_e8uxAu7YRNIgFcl~FQqkF ziWfUQ%Xy>dqQeVmcEe|ZwnepkhENV&KZ2njp#zMt)Rb;Cdze|l;&Q)*8Pl&9tqn|w z{2>cD{M0UxA~pQ}cJh~{nGacOdRaOODr+mw{|(SG+)^2;@PelH4bV2Rp2NRSmjr@V ze}qV4FF4C$D)O$aEGFu;kN0a9qUA&BXJZC%#cl3;-{+Ya^Ig=P6%Hi^FngKhCFK-+ zu+(eN~sgH|{`S#P8 zn3HJ|LHq|~GbCcdrDMV}C|C^`5O5~PJidkU{J(P*zeHz4oNT`tQdyMeT(-i#V^BKD zOqAd)jv*Xu94L#ytUbY&UVxaZ(kM7?-DGf_$a~XREx#Gdp{(N*=oDf3!H}12TldVf zf2L0fDQXqsvgeN^6FcwL4vHKr4+ojW8=J3z5mqwC6_&Ghq!Z_T&c?*=h)=}G#)ci; ze;9f(kq|p_(S^;QoRPiXUq}lk<=g`;oq53Ce8~=XaGS+jImhHT=Pd?m9 zgc@VpBY=5OV05wVIB-L#mUMN{mEQk+9LA58{hhtCY2!PzVXvWqQC!m}AKe*X-2n)h zxRW6Kn&~vQ4l8@$Ezs7%XW0y+6T2x#7jy4& zsG|8-7U8C^AXq>^g?do^-hcSV!X|Z(th{0=_FC<>;8Z74)7PeJ?j=z0rCH(>Q;o&h z?WBuZ)PUk1i?S`yMHsYj9capQ9eY^~2R@hSpiAt|@6R4p^N)v)~z^&`oR zFD1F1N!jH*9`CtK-;hVs-k4?X)SyPozu1WvIKe7F6N(+c3QbC66TEvpeh@?|_#6xX9#|OYdFH>^V!U+&2#jr%bvd*8hPyjDV}zm_bEnrb_Vf4k@MX|&cvJ8pkf;}B|#I@ zXpfpN&??8-L3H6a+4#PA!Ob7oX_O3ZhCPMWn;ID{e-{$(nn#E&h*FT=cfJX5G_nve zbi-gA$0pAF`A=U51`q6G+RU6;juj%JlDV*_BvZUs`1r+0y0Ew7apl zW=kz|?L&R^pr~uP8M01w1~Jj!00kPs)8>I|@ai@e192gpx_{dQ$0Fy0bU4-P#LC9H zH9E-C8%xo?Nc4mrV%8=rRJ0Y9gZCo0vm@OE%y(aIa-6R}+XdWk9`!H!z2-m>W| zVBEWuvfZp^(L@+l-x6(t@U99$h=Jv_MAgo@;c+e)$}+G6zQ_9hE+RBwF#}u7iWylO zkLt3>gcRjmHhZ6Usx2d%HY*r>9E_61&4Uy0b0s8Z{&wSYzI zepjvA3UGJoZ7BFTC0hct@XaWkl&XpM{6tyu2ClY+qQEI$bl3AnS!$L#DM`fkIC`ZN zWTc^QEN7y=O#2SSA9)5pQa@|k@KQGz#6$n*Y6HvL6Asc1X9!VNaxQV?jvN3&s;R1w zz~0NOSbEwd5)2%{b(I8DN9PxcgHoe**2XMAoj*#VcaxqYs5_O4-t2INa6ftH541GZ z;fnU&k*(qLUu{c~_LPEL^{E%+tB~;H14R{sK+NIXlx3Exho5X47%_?8ei{?uRiXqp zhOK5^+C(|+09E~bRuU!cMu*v7q$sKNqr&YKv9L2KnF7NKIBMt(A#w*BP}eg@@)e&@ zmA3`%j>Xofn+I$DneqJ}v9Y2R2ieZBM=@oG4>9^YM~6!7%2@hS(+0!fL38qaCpQZh zBPdPjgL4M%23h8|#&cJ{lyz*y_Pe21TrS^jO}-5oQLLlr_8EbQPVaHHUWDEB(-R2} z8k91?5G*!DEcmT2t}oonUXZcSHb1AS3hr|>GU6ggGRoCPiWb=JBj7HKVIWM6k-?9! zOLpKvkp?hHwC?QDq#-)s=ui>W-3Ne!>MI_*2|Xb5E64P^rx2F0b^t)1CBXXo!_@7F zJu)dw=?g(=(C}p?bVD=r(x6ywsdb zUu~bLzhi0@&tU@W0{V&I!~;^0^yML{a`ymS;&U1^)#z2nO~k0{ME@&Wt^Dxj&>VmW z#_K+!^~J5?G&CGN5X&Sjhf*1#vV9Jubons_p9hulpfJL^T^Vx>8HPyJbOPE&yEGSZfj!5*p> z)=v{e*D+O+Bg(UF*?H|DIo5r}YG}&{{0D-%ELS2+{`pbFB^mUR&+VvCSJejv5?qn; zG?KvA)Au?a;vyF~4Kc`Ql;RpF8P?hSd|xi|H2yT-I(P1qKX^cpXyU^jG>8~ipy+2# zKD}ZR-5BQFAm|U&=rI2NS7b8Vr>W_dn-!w24Ip6aTl9Ilf&R_S&vfe|F|N2XdGYe> zs>yH~rIwv1#xb`XYG;T*2m~`44IdEfzkD~=KN5vXySda=pUIANdy4jW2@CC@u7X#p zw(m;=$yB(+YBY48&py&l{-<6KNhoeq3;+Ae)|cFfQ!lnrQ^gjzv66sUmbsy8WI1}6 zi@X{dqG0Y|NM1mZs@@-MmIFEi-w`V|-m5}N56a7#6UaH^Vr$EiKUmL-zyQK|j$jCV zrf}@)!>Kr2yGaXOAZTs>JrY*$NBXC%!JvhEiP})Ub^5EP8`l252-uxZxMV9{Sdnh~ zKTn)cN^%wL;Q$hwE|5~^#Lnsvp;?O4ze1eSV!8*MB4>05?v=!Dxd}Wvg5dtoutJ2u z%aoYyHS*4PJ^K#q?a|7lx1>Xk!J4ynz|4wvzpAa69M)Bm_WLj zr<^bKi1;w_y>3)CRHSVywn%$qLqZD;4BNhXeK+#!uFTT_2_N{3Jbb2@sN+l}t7A=6 z!=ZP|xN3+_BY?t!A}~Ix$|ypCY>NLAadcC`cMaC;q@H^R90o5I;le@@kj)}tRd&r7 zCP4Ha(rA9@)TD~Aa>k34_H)EfmoaA>dseX@2MmtNzXo|>QydqYZ2z>b4^lzCDk!p< zuMkkh1>F{wwp-G)bwKqq^G3>E5M~;1hP96jLqAi2P#XezdW;EkZ zd@^BCm9rl+ulD@X?8b|JM6B(Ez7iJH>)a8D6SzL8D|a41*?~4ZKYc?|AWJ5ap zPAh79+h$`lR^0b#Z=FQaEuABAwLt;&f^GY@4Yf}oc`d_r7SgsGQ3ZI z>Tu$1NCl}F8R;4RBZA|z*W0SkE!WP??{rFRK~)MylyehPzN++U0IX#j3{_vZ6bOTZ zmpD&!8Gb^xlQ53xk~_{uX#?Ww4*thqZV6es!Aeh48C~|NIkx>F-|(hb9_j%>fJ^#~ zH3f>-^E^KvR%0{*iQrIuaN4zO()_crLusj{5HxE$Y1<)2Hb{Sm07@9#p!xP|6El`f z>BQc{7q5><`#zMup)lmRQjLh1w|~A_)7Oc{BMM!~PX8$5{MX43YzLyMNRF!n2j*?0 zk|(c1HVxnC+!2hkTZzWjP>LbLnxDZ9sJb=8F!J*nlpgnH{(P7(VMqpElmB{wal#qX~bJX?v9 zk;AI7)2a%NxHqh`NNnOQah;mlR-qTSN1@lt|mrKhQFp;MH}r7qB==U$-y8fPh%Zl_&cB0}l1JW4#58^YYjm ze(O|Gh##mTSp>67-qeq3S}DjqNPuev*{&adZ7CWM97#!;c(f*KC*YMRB4C0@y=AYn1?%m8_7z`E7Cn%)`M+I_%eU6Qqn1+?P?<7) z&A9yHCHY^*dwyy4aDIY3V+^XT4P#Kx4ON$?k}NrV3;29UjbC>)1|Z}2P6i-K%u_&g z8}-HQ?+1)db!$ns=~S8yZ8GSmMbm~lI>rI{%EhX~_00k~3e`Q=agfz{DOzeQ)@i3U zErf|4Kw)q;hZ$`Gyv23W7$7x83pE=(F|mp{Q~0nuqU~)VZ9*Q*@o@8u??#n8=`j_C zv60U6o*{XhGwX@qfjxG4D6tj~xC!1_3}yQ;Df+HZtPCCQE6~^ul72ozR8JLUK}xC| z@W3*#K~9?da&N^XZ?QBcA+DJAKP)8>DuX3*kWMl86z4`Z_KGKs4?oU(@B_nx|I3=> zU{ZOYAQ6z!Nk<+g1H;UOkno$rRrc=n&51ksXmL-NQ!6VKA93K;qHdsBZdg?PT+r&` zJ$fv)DgC*c#tE-WFWP%?G6jCG#5+zFkOcO4>!>WN8Ifp*lrfHERD#tot!Edh_|A)| zS{lhRvzr?|K~qV-@5)Xp)g(&5UA*4T93%%cRw}jS-yDw(-L{;)k%Bj)n%!;uz0;A; zPLKJ0g*GeQXR%_xvhixJ3NCj_4{ygrQQ(wfTR32JPKjL#hA2{B! zY9iA;W94o%p*aH8jrVq&0(-DEI4ywiSz+RET)%v2B>#ZNYyB!OC}Y(CA{f~q7bV82 zeTrLS!nWKcKfEOn?jJ~9X{;33A=0&YHaq$Hm}UzuwMW?3OO@)xH8TcDr~u_XAm_}4 zZ4!ojBxjgJeL50S2W>vGDVXK4v%Ns9KRn<1s9n!rDk8++>gry}+;w+Em$Y9%DNqZ<@6U{iSN}fLO02TZ!~Xprs=1-IQPp(`04SJeJwM;ds~F> z|9&hi^a{Y5N7LtvE7u*@0>pI%v}{gl4XPGS5;VTi z1z7|*#M^3Wjh0`smN_;t1N%lUAkz|i!}z*4s1B(n#gx2Mf10W{|3+H+8#HJp32fG%)4<5% z$)lp;eAe~1@f8QDZAe8lsb_Y0IgkVKR45bg z2!YXz6#K)`+G61RfYduJRRj?BRM%hcje8=!USKuN+N>yJV6(f9&PK(v&B1IzKpQO! z`Klkk)p!d>OdK&U{s>wrc;jY*+qZk^g7MHup5K|^f-Q`BzYUYs5YDh*FCC*Vq@-x~ z7<)4fTo?Y7UFh@+whbwJvN6rZ2CD*;?}#?9Qh;x{+w?(zT@JN)L%6TYMhz7eISN*J zfO+2w#X{Z;rqDop3R0MHA3rA75pR2njleuk_kn$iZtQGasJ?V9+qIOaYs6RiG%G7v zF2@f6cL0WSg9jiigkwQa&sqyKG(O!g&ilk*S0Xy=L&o=m7QbDBA6-4g+qIKk0Q#Dz zkehw(6&~$NCIKdb*V2jjK#lf&J-CjI9=*DQe#ifaS;0fP_?iOOgrn2d2VNoibtzBW zqw=`UWe&Ue<(ot^_;-I{bC5RjlS7NiXFvkf{)Lxq1qtVjo22J{NE#TL4&+uLa`Lj0 zm`%WLK&^6jT`LVA5gwU!sp?s~IJ~+Co5z^WO(Ku9=X|DaY$n46Ey#<6cVJEogyti|{b8h=R@r`rT^MGbz5NF1T5CYAVX zzNXo>yY6PcrU_>vnR(seg83!bl{e}5KDe>P{(WZEg^7Gaahv`Knw*23e53t`VUN!N z=rNtX^|~6mSOndi>-BU`$U`(Eb?9Sqh2EKeclFjMRn%-l=8oc_2WI zG9(CcAVbR%nh?P{j@V#%&jN%$EFb}@dB$+}cLlg_SPjgRF{I5^uf!c;7M)hTD(URQ z>i2jNYFJP-S`*}HpGLxJ!~Q+uQ5^&tj&U^HhO3QtOcBLZ8@nYl`(H@AuaZ}cDjR5> z%Lg;*n+DVmY>^;5(=&HAL1v5H{ipD5#L@)_?ROvsTQAv*#Ultk>n=pYPxrqi7}Un~ z`4GcNHyrpvx+{&w!z3J}&SFvJ{F9zuM~sGfIt;N(8IGa%?1(&XOeHeTSzx6(?^e#8AC+$`yiwCG zX27sF5dbh{cxq!WJWv4l`s{zP^&oa=Uep1(Y^%U~90S=%MX$?~Yhlz-&w#SNbMM*~+xrgA4EtF<7@*$tR=uW(XLb*{P}-TS z*aqn@Ms0U=V8*$neb-TTd$U9)8{M)l?uvAM8sT4?tdg#~Coa>$T{pD0Qs2!(TePJJ zJ(p8%W3n@hAGxS8YBNEHDYMejmv{|OXc*;cv=i7%LS?&}9UX@!*C2*xs*C{pZ?dbT z#ZCs;$gEXt!8W=zonB#7HSW7JU&;K3pid8nxxbTvJwTOXUQ>k80S~ylSdgIr-OWK* zW3p?+Y`}?-BQw-Sx6QouBzuC(sn+@TNo{uWXm3&@<73ZCz7aH)q$Z)hU%t(#rDM$C*X0-_G58EWVE+iVttE26Koq1=@8a^U2&xhDcF8UhmgIHN?0_QT`KHld$SvA<*k{Jli$qU zpz|1Zl}OuQlCY(oI1fB?g)8?$=GkgnrwUwJvJh$It++q+NNoCglW&C8*(+v3oilrq zX!p4t2}gO2Cc-XZV@T+~3(XfGOG+7)`#+uips$;nRu-1noiUK*WP(FgcYgY1-9gO; z4dN=V@pj8Tc-2?5jteum&A*%S?h=nd8zLQi7=|79E{rfiORUdR1Dt{HTOHf3rXoHk zqKarYc^q1Gs;Eoz@+4Tm7~W~IKpm-?nMkkLWJP3Rmp6rUjQ`Ki&dT56!Zmhc*Z%Ce zXLit5!!+a$;lE;EB}g!TEH20wT?r`u^pAFGLCSsme9r8N=RZYBnIq22B8vjmS6_q8 zx0!LZ5DHng@{|&!h_RH5WoAUu%y5%Q^_flXg&hB`+Oy2XKU(*1+uMmFC0upMx`aO` z1<}?Mky@XjU7{p(jLFJe7+5I-=be(c9lW9FvEq%Guu9^3z0eT^+1pCn)TaO5sIw!4 zl*u<#4xDAfGUy=tafoEJI;qZ=kSVd&@Hjqb$+o`PdE?ubn94PHrDUWj79q7FDg3yT zRE9P?>WS9``9?YT|Et}NnOsER4F$jaMLa=Y@-r3oBeVM~9A`6VChU*s@=*1drPkXc zotj6$o`q2^`Vg%ts=;K>P*`u1%(5uU@zz>7ZLAsP*w8~b=+%M;<>oq%)rD7Jq!mei z6j#ByTqRnH%*$TBj$no9rq|}2oz5ds*xD317$vlK#ev^~53m9^cmV549q9}oeDNS0 z19ewsMH73`@It>~-USGsaZM|=cfY7h*vCrOycxgMO8ox~h40uHg-nNg=#9VuYMK0f zRe&-LLWv1ZE)}2KHPih;K{e@F~ zysMXLk_ORi#nkv75w>xhT^mSbxs>?wxz4ruL^ZNwbDg7cyDU%iP(lR1lGyP^X66cj zWk?-ya=mgWmY(}G;0)T@DYSgf#$r!KEA%>WHeDj$xeFSKLPNIeZZ)Nw%I}OeC4+|O z{?J1Qlk)BByOP`6?LDJy2ls#;zENdo*#U=x@C4SK}Gyt*BxEFR>i{ zTPlD8?ZUMiQ|lw6Jf{sk56LAw)IwQ|z4>Gl%7!Q!;6l-g$*|L}_?q)$k0Z{-T^x}z zY#SxnH{>c_6|ODM67uquW@?zm_E`RwPYAd_Xsmzk;pMxW9QUB%AeO8 zcB4`LW+0?TXK<0x4MbixA6c!*|h$m0D)8G`_(cBLPPr>k|AZJUYD0N407e% zwmQcR&;!Aq{asfZelSbdZG?p9V=tlU@vFWwL0f&6_)2YJY1`|{DXxxs7H8$%g-|6&y_F8_|@+hzc zC8!I;(y%~skf*3rJ{a(T_lQ#P@Du)nq<4kAe{wdTuS^6iZ7bWs>%y=*BLqVKUHX9(4^|EjE$_{O>u@`BXRB2csHALf0VHapFtsl>xW{Kgxg;)}b8-BMgr zcqfyTn&hFZ#Ff5BVcFbtuT9HT8ROMbpz>EjTMI2V+r{PkYe8khwT0+Z-FQ}pEkW2a zY2yu&jekNfM}{#QI?8?o6xt4BAuDr2{I}H=NKlS_nZdC0Z&9!2q*lpaPybL_E=8f) zY1)VasYh)5^1Cii;N|Eu_^GN%OiY5U>H~d7+{aX4(M4MX0Ws{yTQXI*!sS-;HWD`0 zD$cBYAXDtx&^nMYDag>;NcaIIeZmLJyeazX{p;-@gl3qF`boxHlwNmBKu<<(hcKU7 z<;u-{M!>C*y;E~B+19+Sw_j2>T!1-^?AiiMB;PjwQnI}yH~y{dyev@PXa|xXyZ!8q zmoa!msJrT!u!J3onc+FEQyG(S>9=P-$@Jh!1z4iwJh{IC`z^+s?Ea(__> z8~0)6j+)DiPU0D%+kCVj9_VZVftZI8d$^#clTN{6H$b;wPMg#MOpF)pH0nb9u4)5@ zWeYD0jwU}dtE9h|SQj_q}J;U1nc@ZS>jjRkjbZ$IdpWf+{C1u>9ukz|1e4~bNOZ@SX?6Z7en)Zgk3`22uAzSGsCUR+$TPGGJe6OQj zDi0VkcG@D^IxzZ<%bipPu3wIh6Fs6mgt-M9 zb%h@cFIJ4$KpCVD^CH3q^*WYEM(d$v95NvH-6T0DQ7=+a8Vs21Z0A=|0mw3YT4|r&Lx%wM z$#S*{6FjH(~o@b!X|Zk@rH^IPF>K6SoAOuU?dha zYV5Z#`EEDqrQVJ*QuOShX9Rj=alZNuR1QfEoRNoOt~5A2#8c8SF2u}~nw9M`{Ji`H z^bc*cS6?94S;JI>-xn8L+4LD}zg+8|=zVBF$%>8mh3U-#L{~!g91t>knL!gjLR>jW zRx(oGg~cw_E&(WYPHUG@#@e5>2nag%{1Pe#C4dyQ8j*E9!Alo}rtybt#J0gUvF*51 z_0}MOl;7rVO*pHfD7wOF+Rb>E;T)ciWY`oB5Bd13?xEQvWVn)4D@<_w+*uZn98UEh z9OTDoJKG3mQ&j{#s!x}pK=NZ*t!G>(AwU25HTP1pYtl&PNcv1F}TOGE8zQ|66-uE6NbP^M^vSyO!^JRqFd+VBkJie%=mqw;p?ZRzETzqe>O@ur z!jg6l03Um(X_ntUJIz2oc7Sk^ePF6PrkL;+IB%Ns+FZ3zVRNd35VwFxm4qp^HF+ku zba;M3@>TL&4Y$brxJ4`d{piT@y>nerZcsy-l4=eqv1J_?ytm3ZQjwoCObZM~UJp`| z<@~K92K;_zq&QIJ61PmMcj$?_c(mJZ=l!uAt1pLRos z$i~lzzqpT+shr4cBhlc%s!394Ax0z?ky!(f>^Ke=snl&`V*i4G0m=4yUya=`OxIcK z@A!Q8s*o)>00?3)x{zG)#H)`9X5zi$>`HfZH-#_xgB33MRGpr-*+w#@*M}wbe%Mh) zgm#8{MOx*80vCQd;iPEUmpvu=Mlzd8uZL}?Z}wDp8*z0{Z^fvh@FYLlWp=t94d?Vp zqXp`J26i@6g+R?g#`}m?$K}G18^8jRPLC6{836|aL?|$zwKCzs8D^<6fsN_Yr%D$ z$G`^I8gM}OTMp~5cFur~WI8j8VJ{nBYMyhwhhkv>nws$WN*w zO=aX|Ahj~s-i})}@RQ3Xyeau?+qjYQe4u?U$%t2Glb;;J&SNYsMg{@*4T2tg?J!a{ z-xC4(XAH4>`vqlA!wRx{eSG81!!akJ;j^zUjO!$}G2@HIhC`ipACyP4;-|J2L)Zs3 zvNf>U7RKhtu&$fkV&FAH;8(5za(|azg4zfBsUuH!!FPFx^d?`1<&j&RMUD*+qNV3f zJV^!UBvAgR(9s7>#C1eGrT#8LBZ7LxKaCxNzV0BX>5}iN>cgLBm?=3HHWC6R18}2k zjUpB9o0$#!FdR`4`-y+N5S>21H_QRi>pedZfAe)oI5l(n6I;~$NkBGir}yr4QrX&k z&gHmw37!_FxidwECRcSTf(j@=mI>-?wfG&frniN5f+iFnbIPo!?pIycl;{z-b_OjO z0L5&bJ+kc`UY!c0Kk2h>eO6N1oJ`>D+B4azWGKYBSzX41y%wf+lWUksrB#4Q>*g&6e2%=2%c`5) zamfd-*}Ts$WI9zA z+nV!48FXNP#>4-v2i>3AYg&1@qczJ3qx`eO6>sMzZ>DPC&cSdUHm)ZDc5WQVSQT%N z)Deoo`(^EeTU6`E=(w zad<^Th!R7*UE(T${8-GtQ5@f(QE`98FHaog)2>-KXj*TT{TcMU9r{+k*vI>)1kdi=o!?55h4#z@zsNLWLlOY(zKG$X(gmL}N zUI9-PigpC;)uIwVv9Zs^|I=fh%bna`Tc#6cFg6~zr%l`Qv%fZB!_58SC$4d_{OyzU z5`kBB*GlD-z`{;jaS8ryW?XcLrDOQA) zh~>5^Y@exqyiCa&^1cCcIz}5;@*5GfNm|eIRZYsoK-L5usU_HwHfV~*R%rX8wzv)g zX$mosd)B=AD(HsQi!A*O?q>cS>r%rpTd$A1#LI4zs?>yR4Q^WzEh6He(X_T^4@H0H zmQqssY&yO4@nZ~~W$bVJGqLT@rqj%(O_$Gq7TjoFkY5>LESN>z^*u`xmV(05yT^M3 zV_o1eBh1SQ!Zb*+60onM=Vw)YdXM-XxO}njA=;-V_aD6~oG7l@VivDOaayX3TvC#p za)2Ev$s@yPer+%&qf$f~;rKpj+Cmk`r7i4w^osW_Qred+DT+H!Gi$lMR^cxNhP_w0 z8#F1h5{H>g-HbrarlQxva;(K0=$h}i{9ggGfcxmVAhebm;tJ0!LM^U42y+L|FsO_T zXZhr=C*(yot#Dc|{f|eVKL|xhXo_7`E(m7?Y5H(Mz>1UGGDi|czf+;drv&uX$YTFH ze)*Y_9!B+p@};47;2Js)ikyhl*_9xV85S*2K`$vSP+qZm!#IXoa#e~AQQ{%md=Umg zZ|n@2)iC!OUn9|24YDlRgK=ne^gla)*Sc zR$3$=@DTC4P;1{@0D1qd4%-{uy~Yxte;q$#z#vvp+{iOoD7E4#s@&}@(H4mLUMKYX zVxeD=8wNdu(K$rAm9rQ_UA?(LB^W_a<&x=a93~kx z?j4Sxb9>}qCHyf@D4k|o1nZ32|N1%HFA#}js7MQEwDNcUxYtN`^cL}Cay77=aNe#7 ztgr|v@-h|XmE=M+$jW4K_0Lx!czCnaI|1#{s?p*t-(gi&f%y!UOV&ya&Y{`&?~4hfE1Hx-R4`l+22lWpm=e+vpKnGT zZPe-WVTtLk_siopOVn*1Vw3yBUz9{w&Xk0E`7xbi{%V~Y%l)c&l!CF$G5Lnn#ho?g zR2XOZ1fFeoVu$|kT2%GxeAV<8W{=@#uEh{WV5v7HSq{_(AGcuiO~kkn1$ANu z4-U&XA@7lt%V?i`edXrHi%z`> z%+Lie+g?t{SZzrg$x*q%f3WGGGZW-jadx5b#RemB5XAe~;9Mc=mq6Ll2wBn0CC_0s z+~IMh0K5v>`gzHD(3G-nr}5>B*+UD%ru+-*v_@B2i+^2vh-CR{ zdyRAkLJSgWvDZpEu+>`%3^m|#i>SUVfm+jnIO*}P{Bzg3iZJ%;*roW^x@^2ZZUf;W ze$hM&L1OR?Uj0vtOD{)5b^rt2&bGHyNlw|pWKoLcEF%m?R-S#!kWMIXz&)Lui!9eI z+Rmu)lJYmD=YQ2Ke6hV}lIeb7BYw|k|{q!YqOU47NjGQ);84}^gLe_buL+F&?gio4*3!JGVeK|BOMzf znFpzuVaSKD4A7wHYYkiS*munKakieyF~{`Y^jA=!)I_G+&M*HHSrn1&xhcEgRPpH~ zI;VaSt!YZTQ6(!JMbH3t&Yu&x-i% z*?(VwIw?G{)mwQlPC4f!T9=-di(Ox4+>x(9!d6d$NGKD!QaW~s)`R9R+kdV(Mp@E1 zMKtTdC|a(s-FA4w{8=*KB-mDSZg@w)!!t;lU!fUq(Q|WqCALa%Tk)^D2#2-+$N{bp z0UVwQf9@Fcs$S%Y6nFxs9R>j9H|e=Pla5fdbW~OpFqX^eGwv}Z(}=-~Bq!`gxeDfF zeRe5X6=q?lYg%*rN0(k1Yvg7CymPy2J^JD5FG&yUSf;})paB#DFl&9m!H7c=buzQT zv#$E=yDo~#N)j|%nj4?-Y_qoWFRECsC%#Z7)yIq#Gp?35GzlWDBA;zb5*qt@rU5F^ zB~(i?VjmroSXZGWfIlTF%IImqEK>M|oWu70S4s>9!Y(Gxgk<`FB#hUA$5AbR;Uz!K zG@>mG$6LS#!^a~}Kh2LZ80qdv{1cpH(ODXlB6P%FKpGc5w@ryz-qw$O1037uM^%@f zQeEr}WM-hRI$)8yT)-EE}^qB+HU(A_{5S)Rp7 zx{#}|eA42P$MCc{f0GV;5XmR2edALZ!+n!tfE2-4!Nqd*i17x-5v~9*^le>+e&uzb zEuNcoqfHJDA4Hf^ejc(XT>m(D#+oyiw3<-#4-K=fdTQwZ4rNIazhNLukp9mpF$kJB z9?T88#N+ed*vrmV(Z#Cg1qw38)RGKTLWX$67$-z)CfrC==V1(wsa~DeJm=9}lL9>D zft1|}SOU>2R*l5XC0Pb5Hn-^j0Q3Pyp#AP`kMLfb?vaBCA3qzQ3^?^jF)da!`BRKm zqnJXU%)!Fz6&x01h2dYS!w(Pw=kep?wGOiJ#p5*r6Tp`^W+!cOSiac^AYfFsbcBAr zG=DI%!nwqOM7gCI>d`+CtIr0`f)$lLq;SX-X&sAl%D|*dF~Hv~KRFDLJhrwSHC}x6 zGJ`4w8F!Ks%%QEG%K5h;KQu;c|Ra! z0k!50L@SF4_ENl&&Ud>r5Pp=GV%`-!Oe#X1IbSM!ACU-`Ssa4w9*!h`6}l1ElpVh# zRHPhnTv~K<=68O1qmrFu71(EWU8}fV2EF9t%PVl&C=MeZ{|)N`Mq3D#yj2!1^ETqG zhJl7Ag0LsXS)+6uXx>;0O=2f0Og{uYoddu{5%iwhArM<>6S_0O`VrGj7`7Ol!ky4a zu3I3q+@_&nEdj_2H}tylIQl8)Qr#)Cr_G&OH=?NbJr+SLJ8i-1I5vIG_n9fhTB8s8 z!9;Hi5b46+HOqdGbP${jun7USikuQbt9TZ3Gw0NIHyDxIiDUE$SXvU!v*F5S>}Uc6 z$z=@u9v0`W$Tmj4?73eEtKKYkrbQ{r&~ z<_Hrx^dvW)-(^uOBBrBt>TNgX|IM9b;~~*DV+suU3!wxm5N%&#W$0z_d{n?^!5||{ zicPq@2IuL>A?l!wkY`E9t`#{m%_LY5@NzOn5V+Yfgsuf>?N&~;Xe$el~))%>v1E#DJTt>Dcd_kNVermH!rRHm|m#Y%% zFQ{r61jBQ#yrX6g2vB)-6k!a77A~Dp0HpgfoSpO1AEN(lfe~^q|5rssLK*hLwJLwo z^#|@z%h&t=Ja@RgX`Px=O0-y}Mg@;M?f9E63GB)tS(&NYOJ$^+D;k(WmaJxgFy)HsZ*Z{V5}SF}1lM0%TaN|$i8Oj2C$BJMG0_}Z!~*&)f; z@*o&(Lpec0lr>-OuMaDUgQEz>x4*(xmc8bvJ9-GN#7~Iki;X$cxQT9*D-`jU^qK!n zmo}=Y5>!5O*&5Y31e8DD-%L_~&-jq#{l7U_$_>R zK2Y(=c4Ii4Qgr)CJ&8(BSue0ieTi32T(}djk>SPDTbbas{rM^E%?>ED!Yc>)b@bP(rv{hGRX+Ff&o-FHlwoPU9Z^7&DYz~HjZceEOnj%8@oRA)yWrP)hd9*{k9g++m42l=ilFV;VRuX7s`U5v`X-8|ybS*0M$=PMsMHmqawM z-BW0(ix-W5km@_t=Zy3#@o{%GlG6}+xlbh#g!050#Ql@KcKRmL9dI z&D^qfcs%kh63wEqa>cFqBI~};3`!qrB0LmBCsl2O*hR}n-}!3}$St+-ImPB8uCasstu zq-S@JmuP!Vr0_am;**NJW)#1P7r`Ylwh_d=BxnG%w6=!Mhmu?XyagaNXHCY~Kjp3M z;s*sFM*aEod*6z$xlUIQLL!kO=c0S015mn#&ln4f;uEt5K$Mt4MLe2x>fpN-I^5X5 zqAX~9MCgSh2pgm9AF@Nm4qu>Z5{0WDfvEgo#+;^+pEHG_ObIy>0p)ifBOo*JQXZce zZ)T2F#w!QUO;Bqd>bwhMTJ)1Y2uabw)kn@&C}G`6ddy}!Vb-dx>r*X5mj{)iuysrE zwWi>hXTVI^%`x_;y^oGP+2q88O~*AZry;Rs-Qgp318Sb`iRW16k2 z`}Oj6?h5=>(#yEc{Yz%;Q^`O%usX-g0pw^mEG>)X3PjJaK}MIi3r)YQmAlp=PZv9c zN#`XhMki#j;ePtq!EcCeLEzuqiaT&v?G?_dSaClhPqatFu0G|PI`V@My;q_bK?igr zIk>==DIerl?&OFD)*$Ow0wd_Y4&%3+d4hzYBH9VfHm9or+MAZCZof%bF*G2@??K<_ z2gIXEi$wuFYk88y$K!GCz^+g}Kw#~j0H-<_z-oAefvXuGQGyC9Z2hm~23kz{5+(YN^Q}U-G=2lL5v|qAc3YS+-Z;qxp!)NH9<^hRi{;E{)*s#pe30?JSNhu z8g26qdb2c}UXOPknX?G5jHJSTSe+T7l0gD=q&(MTXc6sT53K(*HaL!X@7GS-O`Uw>(Kz^vMN+I*HFvA1v%xSSy z$8mm{cDt#$NR1SSg-X5lDOM_gKp5){Oj>Y-eM_kBe0* zQXK8h0>A>6c?N=57y&HB3o>$IRyRQjoCQb89zZPhG?^|kQ>M&G0*Ujeq`eaaelag2 zj+KqzKjZM(Umz_zxouTN%>4w&VvE2x0mmHv)Xy^>THH2Oyq~4+^siuSV+p;DF(adu z0@~;;BCO{BkvYV$w3p}-q&|`~?eJMEwYcyBdNc(L&FRk26CHK2bvFd@!Fm0Sfu1wc zHvz}?bQ=Ovbo;d=WLHl(?Ne$qnJNDpV>VzB3y`nziYoqufWB#`0xG8RY}rpGd`a|s z4a{GXkA;@?0JSffe%V;!Bm!;BHYTVp5wMnd_VVj>6fFCr$XVrcSNhLM(KSHr-Ye2r zK-y!)JH>T@sjhfh&aw`i7Mk*(WanvBEzm1}7>J0g0z1#f0b;s+x_VX>>r5<;5#84? zYj6;FP$2x!KK0WPe{6w5Jw&x%V)ewwsrm=r$mZn{`?lN}WEy2#vcG&?QFIP^7%8uj=$eFO-pZuyV@!8au%Lr^6n}rn^Ar;O&C6lT*Eg`~CP*SQg zPm*2aZY}m}z~Bm#XU;Vy4_LTMIW@g~7T}Vl*Ogb`Lj9a5FLYW~8+dXar&FfcO17jd zuOqLj@(tNbjlPQPIjQMAri^6?87tfO!`&CWanPXY3|iuIM32FC*9u)3`9m#RK-9^N zB3jW29N@EJ*BJQd;e4%qB=U`i7|>NfXz~}y>9Qv23`IVok*&@&!hXbBUX!-79`= "3.0.0") S3method(vctrs::vec_ptype2, sir.sir) #' @rawNamespace if(getRversion() >= "3.0.0") S3method(vctrs::vec_ptype2, character.sir) #' @rawNamespace if(getRversion() >= "3.0.0") S3method(vctrs::vec_cast, character.sir) +#' @rawNamespace if(getRversion() >= "3.0.0") S3method(vctrs::vec_cast, factor.sir) #' @rawNamespace if(getRversion() >= "3.0.0") S3method(vctrs::vec_cast, sir.character) +#' @rawNamespace if(getRversion() >= "3.0.0") S3method(vctrs::vec_cast, sir.factor) #' @rawNamespace if(getRversion() >= "3.0.0") S3method(vctrs::vec_cast, sir.sir) # S3: amr_selector ---- @@ -257,6 +259,12 @@ vec_cast.sir.sir <- function(x, to, ...) { vec_cast.character.sir <- function(x, to, ...) { as.character(x) } +vec_cast.factor.sir <- function(x, to, ...) { + factor(as.sir(x)) +} vec_cast.sir.character <- function(x, to, ...) { as.sir(x) } +vec_cast.sir.factor <- function(x, to, ...) { + as.sir(x) +} diff --git a/data-raw/_reproduction_scripts/reproduction_of_clinical_breakpoints.R b/data-raw/_reproduction_scripts/reproduction_of_clinical_breakpoints.R index 1d0aaf131..652c9a925 100644 --- a/data-raw/_reproduction_scripts/reproduction_of_clinical_breakpoints.R +++ b/data-raw/_reproduction_scripts/reproduction_of_clinical_breakpoints.R @@ -503,70 +503,9 @@ dim(breakpoints_new) dim(clinical_breakpoints) -# Correct anaerobic bacteria in EUCAST ---- +# Retrieve >= EUCAST 2019 directly from EUCAST ---- -eucast_anaerobe_corrections <- tibble::tribble( - ~guideline, ~type, ~host, ~method, ~site, ~mo, ~rank_index, ~ab, ~ref_tbl, ~disk_dose, ~breakpoint_S, ~breakpoint_R, ~uti, ~is_SDD, - - # Prevotella spp. - "EUCAST 2025", "human", "human", "MIC", NA, as.mo("Prevotella"), 3, as.ab("AMP"), "Prevotella", NA, 0.5, 0.5, FALSE, FALSE, - "EUCAST 2025", "human", "human", "DISK", NA, as.mo("Prevotella"), 3, as.ab("AMP"), "Prevotella", "2 mcg", 25, 25, FALSE, FALSE, - "EUCAST 2025", "human", "human", "DISK", NA, as.mo("Prevotella"), 3, as.ab("SAM"), "Prevotella", "10/10 mcg", 33, 33, FALSE, FALSE, - "EUCAST 2025", "human", "human", "MIC", NA, as.mo("Prevotella"), 3, as.ab("AMX"), "Prevotella", NA, 0.25, 0.25, FALSE, FALSE, - "EUCAST 2025", "human", "human", "DISK", NA, as.mo("Prevotella"), 3, as.ab("AMC"), "Prevotella", "2/1 mcg", 24, 24, FALSE, FALSE, - "EUCAST 2025", "human", "human", "MIC", NA, as.mo("Prevotella"), 3, as.ab("ETP"), "Prevotella", NA, 0.5, 0.5, FALSE, FALSE, - "EUCAST 2025", "human", "human", "DISK", NA, as.mo("Prevotella"), 3, as.ab("ETP"), "Prevotella", "10 mcg", 29, 29, FALSE, FALSE, - "EUCAST 2025", "human", "human", "MIC", NA, as.mo("Prevotella"), 3, as.ab("IPM"), "Prevotella", NA, 0.125, 0.125, FALSE, FALSE, - "EUCAST 2025", "human", "human", "DISK", NA, as.mo("Prevotella"), 3, as.ab("IPM"), "Prevotella", "10 mcg", 35, 35, FALSE, FALSE, - - # Fusobacterium necrophorum - "EUCAST 2025", "human", "human", "MIC", NA, as.mo("Fusobacterium necrophorum"), 2, as.ab("AMP"), "F. necrophorum", NA, 0.5, 0.5, FALSE, FALSE, - "EUCAST 2025", "human", "human", "DISK", NA, as.mo("Fusobacterium necrophorum"), 2, as.ab("AMP"), "F. necrophorum", "2 mcg", 27, 27, FALSE, FALSE, - "EUCAST 2025", "human", "human", "MIC", NA, as.mo("Fusobacterium necrophorum"), 2, as.ab("SAM"), "F. necrophorum", NA, 0.5, 0.5, FALSE, FALSE, - "EUCAST 2025", "human", "human", "DISK", NA, as.mo("Fusobacterium necrophorum"), 2, as.ab("SAM"), "F. necrophorum", "10/10 mcg", 33, 33, FALSE, FALSE, - "EUCAST 2025", "human", "human", "MIC", NA, as.mo("Fusobacterium necrophorum"), 2, as.ab("AMX"), "F. necrophorum", NA, 0.5, 0.5, FALSE, FALSE, - "EUCAST 2025", "human", "human", "MIC", NA, as.mo("Fusobacterium necrophorum"), 2, as.ab("AMC"), "F. necrophorum", NA, 0.5, 0.5, FALSE, FALSE, - "EUCAST 2025", "human", "human", "DISK", NA, as.mo("Fusobacterium necrophorum"), 2, as.ab("AMC"), "F. necrophorum", "2/1 mcg", 23, 23, FALSE, FALSE, - "EUCAST 2025", "human", "human", "MIC", NA, as.mo("Fusobacterium necrophorum"), 2, as.ab("ETP"), "F. necrophorum", NA, 0.06, 0.06, FALSE, FALSE, - "EUCAST 2025", "human", "human", "DISK", NA, as.mo("Fusobacterium necrophorum"), 2, as.ab("ETP"), "F. necrophorum", "10 mcg", 35, 35, FALSE, FALSE, - "EUCAST 2025", "human", "human", "MIC", NA, as.mo("Fusobacterium necrophorum"), 2, as.ab("IPM"), "F. necrophorum", NA, 0.125, 0.125, FALSE, FALSE, - "EUCAST 2025", "human", "human", "DISK", NA, as.mo("Fusobacterium necrophorum"), 2, as.ab("IPM"), "F. necrophorum", "10 mcg", 36, 36, FALSE, FALSE, - - # Clostridium perfringens - "EUCAST 2025", "human", "human", "MIC", NA, as.mo("Clostridium perfringens"), 2, as.ab("AMP"), "C. perfringens", NA, 0.25, 0.25, FALSE, FALSE, - "EUCAST 2025", "human", "human", "DISK", NA, as.mo("Clostridium perfringens"), 2, as.ab("AMP"), "C. perfringens", "2 mcg", 23, 23, FALSE, FALSE, - "EUCAST 2025", "human", "human", "MIC", NA, as.mo("Clostridium perfringens"), 2, as.ab("SAM"), "C. perfringens", NA, 0.25, 0.25, FALSE, FALSE, - "EUCAST 2025", "human", "human", "DISK", NA, as.mo("Clostridium perfringens"), 2, as.ab("SAM"), "C. perfringens", "10/10 mcg", 27, 27, FALSE, FALSE, - "EUCAST 2025", "human", "human", "MIC", NA, as.mo("Clostridium perfringens"), 2, as.ab("AMX"), "C. perfringens", NA, 0.25, 0.25, FALSE, FALSE, - "EUCAST 2025", "human", "human", "MIC", NA, as.mo("Clostridium perfringens"), 2, as.ab("AMC"), "C. perfringens", NA, 0.25, 0.25, FALSE, FALSE, - "EUCAST 2025", "human", "human", "DISK", NA, as.mo("Clostridium perfringens"), 2, as.ab("AMC"), "C. perfringens", "2/1 mcg", 23, 23, FALSE, FALSE, - "EUCAST 2025", "human", "human", "MIC", NA, as.mo("Clostridium perfringens"), 2, as.ab("ETP"), "C. perfringens", NA, 0.5, 0.5, FALSE, FALSE, - "EUCAST 2025", "human", "human", "DISK", NA, as.mo("Clostridium perfringens"), 2, as.ab("ETP"), "C. perfringens", "10 mcg", 24, 24, FALSE, FALSE, - "EUCAST 2025", "human", "human", "MIC", NA, as.mo("Clostridium perfringens"), 2, as.ab("IPM"), "C. perfringens", NA, 0.5, 0.5, FALSE, FALSE, - "EUCAST 2025", "human", "human", "DISK", NA, as.mo("Clostridium perfringens"), 2, as.ab("IPM"), "C. perfringens", "10 mcg", 25, 25, FALSE, FALSE, - - # Cutibacterium acnes - "EUCAST 2025", "human", "human", "MIC", NA, as.mo("Cutibacterium acnes"), 2, as.ab("AMP"), "C. acnes", NA, 0.25, 0.25, FALSE, FALSE, - "EUCAST 2025", "human", "human", "DISK", NA, as.mo("Cutibacterium acnes"), 2, as.ab("AMP"), "C. acnes", "2 mcg", 23, 23, FALSE, FALSE, - "EUCAST 2025", "human", "human", "DISK", NA, as.mo("Cutibacterium acnes"), 2, as.ab("SAM"), "C. acnes", "10/10 mcg", 33, 33, FALSE, FALSE, - "EUCAST 2025", "human", "human", "MIC", NA, as.mo("Cutibacterium acnes"), 2, as.ab("AMX"), "C. acnes", NA, 0.25, 0.25, FALSE, FALSE, - "EUCAST 2025", "human", "human", "DISK", NA, as.mo("Cutibacterium acnes"), 2, as.ab("AMC"), "C. acnes", "2/1 mcg", 24, 24, FALSE, FALSE, - "EUCAST 2025", "human", "human", "DISK", NA, as.mo("Cutibacterium acnes"), 2, as.ab("CTX"), "C. acnes", "5 mcg", 26, 26, FALSE, FALSE, - "EUCAST 2025", "human", "human", "MIC", NA, as.mo("Cutibacterium acnes"), 2, as.ab("CRO"), "C. acnes", NA, 0.06, 0.06, FALSE, FALSE, - "EUCAST 2025", "human", "human", "DISK", NA, as.mo("Cutibacterium acnes"), 2, as.ab("CRO"), "C. acnes", "30 mcg", 33, 33, FALSE, FALSE, - "EUCAST 2025", "human", "human", "MIC", NA, as.mo("Cutibacterium acnes"), 2, as.ab("ETP"), "C. acnes", NA, 0.25, 0.25, FALSE, FALSE, - "EUCAST 2025", "human", "human", "DISK", NA, as.mo("Cutibacterium acnes"), 2, as.ab("ETP"), "C. acnes", "10 mcg", 28, 28, FALSE, FALSE, - "EUCAST 2025", "human", "human", "MIC", NA, as.mo("Cutibacterium acnes"), 2, as.ab("IPM"), "C. acnes", NA, 0.03, 0.03, FALSE, FALSE, - "EUCAST 2025", "human", "human", "DISK", NA, as.mo("Cutibacterium acnes"), 2, as.ab("IPM"), "C. acnes", "10 mcg", 39, 39, FALSE, FALSE, - "EUCAST 2025", "human", "human", "MIC", NA, as.mo("Cutibacterium acnes"), 2, as.ab("LNZ"), "C. acnes", NA, 2, 2, FALSE, FALSE, - "EUCAST 2025", "human", "human", "DISK", NA, as.mo("Cutibacterium acnes"), 2, as.ab("LNZ"), "C. acnes", "10 mcg", 34, 34, FALSE, FALSE -) - -breakpoints_new <- clinical_breakpoints |> - bind_rows(eucast_anaerobe_corrections) |> - bind_rows(eucast_anaerobe_corrections |> mutate(guideline = "EUCAST 2026")) |> - bind_rows(eucast_anaerobe_corrections |> mutate(guideline = "EUCAST 2023")) |> - bind_rows(eucast_anaerobe_corrections |> mutate(guideline = "EUCAST 2024")) +source("data-raw/_reproduction_scripts/reproduction_of_clinical_breakpoints_eucast.R") # SAVE TO PACKAGE ---- diff --git a/data-raw/_reproduction_scripts/reproduction_of_clinical_breakpoints_eucast.R b/data-raw/_reproduction_scripts/reproduction_of_clinical_breakpoints_eucast.R index fb040b221..d79facb61 100644 --- a/data-raw/_reproduction_scripts/reproduction_of_clinical_breakpoints_eucast.R +++ b/data-raw/_reproduction_scripts/reproduction_of_clinical_breakpoints_eucast.R @@ -351,15 +351,24 @@ get_cell <- function(df, r, c) { } parse_bp <- function(txt) { - if (is.na(txt) || txt == "") return(NA_real_) + if (is.na(txt) || txt == "") return(NA_character_) t <- trimws(txt) - # if (toupper(t) %in% c("NOTE", "IE", "IP", "NA", "-")) return(NA_real_) - if (toupper(t) %in% c("NA", "-")) return(NA_real_) - t <- gsub("^\\((.+)\\)$", "\\1", t) - # suppressWarnings(as.numeric(t)) + if (toupper(t) %in% c("NA", "-")) return(NA_character_) + # Parenthesised values like "(2)" are screening breakpoints. They are + # preserved as-is in the raw file (e.g. "(2)") so they remain + # distinguishable from clinical breakpoints. The cleanup section + # later strips the parentheses for numeric conversion and filters + # screening rows out of the clean clinical_breakpoints table. t } +is_screening_bp <- function(txt) { + # A breakpoint cell value wrapped in parentheses, e.g. "(2)" or "(0.5)", + # is a screening breakpoint in EUCAST terminology (present since v12). + if (is.na(txt) || txt == "") return(FALSE) + grepl("^\\(.+\\)$", trimws(txt)) +} + format_disk_dose <- function(dose) { if (is.na(dose) || dose == "") return(NA_character_) d <- trimws(dose) @@ -715,6 +724,7 @@ parse_sheet <- function(xlsx_path, sheet_name) { disk_dose = NA_character_, breakpoint_S = s_val, breakpoint_R = r_val, + is_screening = is_screening_bp(mic_s$base) || is_screening_bp(mic_r$base), note = mic_note ) } @@ -738,6 +748,7 @@ parse_sheet <- function(xlsx_path, sheet_name) { disk_dose = format_disk_dose(disk_dose_cell$base), breakpoint_S = s_val, breakpoint_R = r_val, + is_screening = is_screening_bp(disk_s$base) || is_screening_bp(disk_r$base), note = disk_note ) } @@ -844,6 +855,7 @@ parse_topical_sheet <- function(xlsx_path) { ab = ab_name, disk_dose = NA_character_, breakpoint_S = mic_val, breakpoint_R = mic_val, + is_screening = is_screening_bp(mic_cell$base), note = mic_note ) } @@ -864,6 +876,7 @@ parse_topical_sheet <- function(xlsx_path) { ab = ab_name, disk_dose = ab_dose, breakpoint_S = disk_val, breakpoint_R = disk_val, + is_screening = is_screening_bp(disk_cell$base), note = disk_note ) } @@ -1027,6 +1040,7 @@ parse_yeast_sheet <- function(xlsx_path, sheet_name) { disk_dose = NA_character_, breakpoint_S = s_val, breakpoint_R = r_val, + is_screening = is_screening_bp(s_cell$base) || is_screening_bp(r_cell$base), note = note_text ) } @@ -1169,6 +1183,56 @@ strip_mo_exceptions <- function(x) { trimws(sub("\\s*\\(?(except|other than)\\b.*$", "", x, ignore.case = TRUE, perl = TRUE)) } +# Occasionally, split_agent_organism() fails to separate an organism +# restriction from the antibiotic name in column A -- typically when +# the cell has no rich-text formatting at all (plain text, no bold/non- +# bold boundary to split on), leaving the full string in `ab` while `mo` +# carries only the sheet's default organism. The observed cases all +# follow a pattern of "DrugName, organism-restriction", where the text +# after the comma is recognisably an organism (genus-like capitalised +# word, or "other than" / "except" phrasing) rather than a drug-name +# continuation. For example, EUCAST 2024 Enterococcus sheet: +# ab = "Vancomycin, enterococci other than E. casseliflavus and E. gallinarum" +# This function detects such cases and returns a two-column tibble +# (ab_clean, mo_from_ab) that the pipeline uses to correct both columns. +split_organism_from_ab <- function(ab, mo) { + # Only act on ab values that contain a bare comma (i.e. not inside + # parentheses, which are route/indication qualifiers like "(endocarditis, + # in combination with...)" that are part of the drug name). + # Strip parenthetical content first to test for a bare comma. + ab_no_parens <- gsub("\\([^)]*\\)", "", ab) + has_bare_comma <- grepl(",", ab_no_parens) + + ab_clean <- ab + mo_from_ab <- rep(NA_character_, length(ab)) + + for (i in which(has_bare_comma)) { + # Split at the first bare comma (outside parentheses) + # Simple approach: find the first comma in ab_no_parens, use its + # position to split the original ab string + comma_pos <- regexpr(",", ab_no_parens[i]) + if (comma_pos < 1) next + before <- trimws(substr(ab[i], 1, comma_pos - 1)) + after <- trimws(substr(ab[i], comma_pos + 1, nchar(ab[i]))) + if (!nzchar(after)) next + + # The part after the comma must look like an organism restriction, + # not a drug-name continuation. Heuristic: starts with a genus-like + # capitalised word (3+ letters), or starts with "other" / "except", + # or contains known taxonomic suffixes (cocci, bacill, etc.) + is_organism <- grepl( + "^(other\\b|except\\b|[a-z]*cocc|[a-z]*bacill|[A-Z][a-z]{2,}\\b)", + after, ignore.case = FALSE, perl = TRUE + ) + if (!is_organism) next + + ab_clean[i] <- before + mo_from_ab[i] <- after + } + + tibble(ab_clean = ab_clean, mo_from_ab = mo_from_ab) +} + # Whole-cell variant of the above, used before any list-splitting is # attempted. Only strips a trailing except/other-than clause when it is NOT # wrapped in parentheses attached to a single list member -- e.g. @@ -1379,6 +1443,26 @@ split_mo_list_one <- function(s, sheet_genus_fallback) { breakpoints_eucast <- breakpoints_eucast_raw |> filter(!breakpoint_S %in% c("NOTE", "IE", "IP", "NA", "-"), !breakpoint_R %in% c("NOTE", "IE", "IP", "NA", "-")) |> + # Screening breakpoints (parenthesised values like "(2)") are kept in + # breakpoints_eucast_raw but excluded from the clinical_breakpoints table: + # they are screening cut-offs, not interpretive breakpoints for clinical + # reporting. The is_screening flag was set during parsing. + filter(!is_screening) + +# Occasionally, split_agent_organism() could not separate an organism +# restriction from the drug name (see split_organism_from_ab comment). +# Detect and fix those before mo resolution, so the organism restriction +# is processed alongside the regular mo text. +ab_mo_fix <- split_organism_from_ab(breakpoints_eucast$ab, breakpoints_eucast$mo) +fixed_rows <- !is.na(ab_mo_fix$mo_from_ab) +if (any(fixed_rows)) { + message("NOTE: ", sum(fixed_rows), " row(s) had an organism restriction embedded in the ab column; ", + "splitting into ab + mo (e.g. '", breakpoints_eucast$ab[which(fixed_rows)[1]], "').") + breakpoints_eucast$ab[fixed_rows] <- ab_mo_fix$ab_clean[fixed_rows] + breakpoints_eucast$mo[fixed_rows] <- ab_mo_fix$mo_from_ab[fixed_rows] +} + +breakpoints_eucast <- breakpoints_eucast |> mutate( mo_text = strip_mo_exceptions_wholecell(mo), mo_text = resolve_other_x(mo_text, sheet), @@ -1465,12 +1549,15 @@ if (nrow(ab_previously_coerced_eucast) > 0) { breakpoints_eucast <- breakpoints_eucast |> mutate( - breakpoint_S = as.numeric(breakpoint_S), - breakpoint_R = as.numeric(breakpoint_R), + # Strip any residual parentheses before numeric conversion (defensive: + # is_screening rows are already filtered out above, but a missed edge + # case would otherwise introduce silent NAs via as.numeric()). + breakpoint_S = as.numeric(gsub("^\\((.+)\\)$", "\\1", breakpoint_S)), + breakpoint_R = as.numeric(gsub("^\\((.+)\\)$", "\\1", breakpoint_R)), uti = qualifier %like_case% "UTI", is_SDD = FALSE # EUCAST has no "susceptible, dose dependent" category (CLSI-only concept) ) |> - select(-mo_text, -qualifier) |> + select(-mo_text, -qualifier, -is_screening) |> # Greek symbols and EM dash symbols are not allowed by CRAN, so replace them with ASCII: mutate(disk_dose = disk_dose %>% gsub("\u03bc", "mc", ., fixed = TRUE) %>% # this is 'mu', \u03bc @@ -1512,7 +1599,34 @@ breakpoints_eucast <- breakpoints_eucast |> distinct(guideline, type, host, ab, mo, method, site, breakpoint_S, .keep_all = TRUE) |> select(guideline, type, host, method, site, mo, rank_index, ab, ref_tbl, disk_dose, breakpoint_S, breakpoint_R, uti, is_SDD, note) |> - arrange(desc(guideline), mo, ab, type, host, method) + mutate( + rank_index = case_when( + is.na(mo_rank(mo, keep_synonyms = TRUE)) ~ 6, # for UNKNOWN, B_GRAMN, B_ANAER, B_ANAER-NEG, etc. + mo_rank(mo, keep_synonyms = TRUE) %like% "(infra|sub)" ~ 1, + mo_rank(mo, keep_synonyms = TRUE) == "species" ~ 2, + mo_rank(mo, keep_synonyms = TRUE) == "species group" ~ 2.5, + mo_rank(mo, keep_synonyms = TRUE) == "genus" ~ 3, + mo_rank(mo, keep_synonyms = TRUE) == "family" ~ 4, + mo_rank(mo, keep_synonyms = TRUE) == "order" ~ 5, + TRUE ~ 6 + ), + uti = ifelse(is.na(site), FALSE, site %like% ".*(UTI|urinary|urine).*") + ) breakpoints_eucast %>% count(guideline) -glimpse(breakpoints_eucast) + +saveRDS(breakpoints_eucast_raw, "data-raw/breakpoints_eucast_raw.rds") + +message(paste0(c("Finished. Now add to the package by running:\n\n", + "clinical_breakpoints <- clinical_breakpoints |>", + " filter(guideline %like% \"CLSI\" | type != \"human\" | guideline %like% \"2010|2011|2012|2013|2014|2015|2016|2017|2018\") |>", + " bind_rows(breakpoints_eucast) |>", + " arrange(desc(guideline), mo, ab, type, method) |>", + " filter(!(is.na(breakpoint_S) & is.na(breakpoint_R)) & !is.na(mo) & !is.na(ab)) |>", + " distinct(guideline, type, host, ab, mo, method, site, breakpoint_S, .keep_all = TRUE) |>", + " dataset_UTF8_to_ASCII()", + "", + "usethis::use_data(clinical_breakpoints, overwrite = TRUE, compress = \"xz\", version = 2)", + "rm(clinical_breakpoints)", + "devtools::load_all(\".\")"), + collapse = "\n")) diff --git a/data-raw/_reproduction_scripts/reproduction_of_intrinsic_resistant.R b/data-raw/_reproduction_scripts/reproduction_of_intrinsic_resistant.R index 7de386bd3..d89f38be6 100644 --- a/data-raw/_reproduction_scripts/reproduction_of_intrinsic_resistant.R +++ b/data-raw/_reproduction_scripts/reproduction_of_intrinsic_resistant.R @@ -38,7 +38,7 @@ for (i in seq_len(nrow(antimicrobials))) { int_resis <- interpretive_rules(int_resis, interpretive_rules_df = subset( AMR:::INTERPRETIVE_RULES_DF, - is.na(have_these_values) & reference.rule_group == "Expected phenotypes" & reference.version == 1.2 + reference.rule_group %like% "Expected.* Phenotypes" ), overwrite = TRUE, info = FALSE diff --git a/data-raw/breakpoints_eucast.csv b/data-raw/breakpoints_eucast.csv new file mode 100644 index 000000000..6cefa295d --- /dev/null +++ b/data-raw/breakpoints_eucast.csv @@ -0,0 +1,7664 @@ +"","guideline","type","host","method","site","mo","rank_index","ab","ref_tbl","disk_dose","breakpoint_S","breakpoint_R","uti","is_SDD","note" +"1","EUCAST 2026","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"MEM","A.xylosoxidans (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",26,20,FALSE,FALSE,NA +"2","EUCAST 2026","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"MEM","A.xylosoxidans (file: Clinical Breakpoint Tables v. 16.1)",NA,1,4,FALSE,FALSE,NA +"3","EUCAST 2026","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"SXT","A.xylosoxidans (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",26,26,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"4","EUCAST 2026","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"SXT","A.xylosoxidans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5","EUCAST 2026","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"TZP","A.xylosoxidans (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",26,26,FALSE,FALSE,NA +"6","EUCAST 2026","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"TZP","A.xylosoxidans (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"7","EUCAST 2026","human","human","DISK","systemic infections","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",19,19,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"8","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",19,19,FALSE,FALSE,NA +"9","EUCAST 2026","human","human","MIC","systemic infections","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"10","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,NA +"11","EUCAST 2026","human","human","DISK",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,21,FALSE,FALSE,NA +"12","EUCAST 2026","human","human","DISK","Topical","B_ACNTB",3,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",21,21,FALSE,FALSE,NA +"13","EUCAST 2026","human","human","MIC",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,1,FALSE,FALSE,NA +"14","EUCAST 2026","human","human","MIC","Topical","B_ACNTB",3,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"15","EUCAST 2026","human","human","MIC",NA,"B_ACNTB",3,"COL","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)." +"16","EUCAST 2026","human","human","MIC","Topical","B_ACNTB",3,"COL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"17","EUCAST 2026","human","human","DISK",NA,"B_ACNTB",3,"DOR","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",50,22,FALSE,FALSE,NA +"18","EUCAST 2026","human","human","MIC",NA,"B_ACNTB",3,"DOR","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,2,FALSE,FALSE,NA +"19","EUCAST 2026","human","human","DISK","systemic infections","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",17,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"20","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",17,17,FALSE,FALSE,NA +"21","EUCAST 2026","human","human","DISK","Topical","B_ACNTB",3,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",17,17,FALSE,FALSE,NA +"22","EUCAST 2026","human","human","MIC","systemic infections","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"23","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA +"24","EUCAST 2026","human","human","MIC","Topical","B_ACNTB",3,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA +"25","EUCAST 2026","human","human","DISK",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",24,21,FALSE,FALSE,NA +"26","EUCAST 2026","human","human","MIC",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)",NA,2,4,FALSE,FALSE,NA +"27","EUCAST 2026","human","human","DISK",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",23,20,FALSE,FALSE,NA +"28","EUCAST 2026","human","human","DISK","Topical","B_ACNTB",3,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",23,23,FALSE,FALSE,NA +"29","EUCAST 2026","human","human","MIC",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,1,FALSE,FALSE,NA +"30","EUCAST 2026","human","human","MIC","Topical","B_ACNTB",3,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"31","EUCAST 2026","human","human","DISK","indications other than meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",21,15,FALSE,FALSE,NA +"32","EUCAST 2026","human","human","DISK","meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",21,21,FALSE,FALSE,NA +"33","EUCAST 2026","human","human","MIC","indications other than meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)",NA,2,8,FALSE,FALSE,NA +"34","EUCAST 2026","human","human","MIC","meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"35","EUCAST 2026","human","human","MIC","Topical","B_ACNTB",3,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"36","EUCAST 2026","human","human","DISK",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",16,16,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"37","EUCAST 2026","human","human","MIC",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"38","EUCAST 2026","human","human","DISK","systemic infections","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",17,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"39","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",17,17,FALSE,FALSE,NA +"40","EUCAST 2026","human","human","DISK","Topical","B_ACNTB",3,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",17,17,FALSE,FALSE,NA +"41","EUCAST 2026","human","human","MIC","systemic infections","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"42","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA +"43","EUCAST 2026","human","human","MIC","Topical","B_ACNTB",3,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA +"44","EUCAST 2026","human","human","DISK",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",26,26,FALSE,FALSE,NA +"45","EUCAST 2026","human","human","MIC",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"46","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note" +"47","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,TRUE,FALSE,NA +"48","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility." +"49","EUCAST 2026","human","human","DISK",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",31,31,FALSE,FALSE,NA +"50","EUCAST 2026","human","human","MIC",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"51","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","100 mcg",16,16,TRUE,FALSE,NA +"52","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,16,16,TRUE,FALSE,NA +"53","EUCAST 2026","human","human","DISK","screen only","B_AERCC_SNGN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance." +"54","EUCAST 2026","human","human","DISK",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","1 unit",21,21,FALSE,FALSE,NA +"55","EUCAST 2026","human","human","MIC",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA +"56","EUCAST 2026","human","human","DISK",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",25,25,FALSE,FALSE,NA +"57","EUCAST 2026","human","human","MIC",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA +"58","EUCAST 2026","human","human","DISK",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method." +"59","EUCAST 2026","human","human","MIC",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"60","EUCAST 2026","human","human","DISK",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",26,26,FALSE,FALSE,NA +"61","EUCAST 2026","human","human","MIC",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"62","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note" +"63","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,TRUE,FALSE,NA +"64","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility." +"65","EUCAST 2026","human","human","DISK",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",31,31,FALSE,FALSE,NA +"66","EUCAST 2026","human","human","MIC",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"67","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","100 mcg",16,16,TRUE,FALSE,NA +"68","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,16,16,TRUE,FALSE,NA +"69","EUCAST 2026","human","human","DISK","screen only","B_AERCC_URIN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance." +"70","EUCAST 2026","human","human","DISK",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","1 unit",21,21,FALSE,FALSE,NA +"71","EUCAST 2026","human","human","MIC",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA +"72","EUCAST 2026","human","human","DISK",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",25,25,FALSE,FALSE,NA +"73","EUCAST 2026","human","human","MIC",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA +"74","EUCAST 2026","human","human","DISK",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method." +"75","EUCAST 2026","human","human","MIC",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"76","EUCAST 2026","human","human","DISK",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",29,26,FALSE,FALSE,NA +"77","EUCAST 2026","human","human","MIC",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 16.1)",NA,1,4,FALSE,FALSE,NA +"78","EUCAST 2026","human","human","DISK",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",24,21,FALSE,FALSE,NA +"79","EUCAST 2026","human","human","MIC",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 16.1)",NA,1,4,FALSE,FALSE,NA +"80","EUCAST 2026","human","human","DISK",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",27,24,FALSE,FALSE,NA +"81","EUCAST 2026","human","human","MIC",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.5,FALSE,FALSE,NA +"82","EUCAST 2026","human","human","DISK",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",27,24,FALSE,FALSE,NA +"83","EUCAST 2026","human","human","MIC",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 16.1)",NA,1,4,FALSE,FALSE,NA +"84","EUCAST 2026","human","human","DISK",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",27,24,FALSE,FALSE,NA +"85","EUCAST 2026","human","human","MIC",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,1,FALSE,FALSE,NA +"86","EUCAST 2026","human","human","DISK",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",16,16,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"87","EUCAST 2026","human","human","MIC",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"88","EUCAST 2026","human","human","DISK",NA,"B_BCLLS",3,"CIP","Bacillus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,23,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"89","EUCAST 2026","human","human","MIC",NA,"B_BCLLS",3,"CIP","Bacillus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,0.5,FALSE,FALSE,NA +"90","EUCAST 2026","human","human","DISK",NA,"B_BCLLS",3,"CLI","Bacillus (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",17,17,FALSE,FALSE,NA +"91","EUCAST 2026","human","human","MIC",NA,"B_BCLLS",3,"CLI","Bacillus (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"92","EUCAST 2026","human","human","DISK",NA,"B_BCLLS",3,"ERY","Bacillus (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",24,24,FALSE,FALSE,NA +"93","EUCAST 2026","human","human","MIC",NA,"B_BCLLS",3,"ERY","Bacillus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"94","EUCAST 2026","human","human","DISK",NA,"B_BCLLS",3,"IPM","Bacillus (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",30,30,FALSE,FALSE,NA +"95","EUCAST 2026","human","human","MIC",NA,"B_BCLLS",3,"IPM","Bacillus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"96","EUCAST 2026","human","human","DISK",NA,"B_BCLLS",3,"LNZ","Bacillus (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",22,22,FALSE,FALSE,NA +"97","EUCAST 2026","human","human","MIC",NA,"B_BCLLS",3,"LNZ","Bacillus (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"98","EUCAST 2026","human","human","DISK",NA,"B_BCLLS",3,"LVX","Bacillus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,23,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"99","EUCAST 2026","human","human","MIC",NA,"B_BCLLS",3,"LVX","Bacillus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,1,FALSE,FALSE,NA +"100","EUCAST 2026","human","human","DISK",NA,"B_BCLLS",3,"MEM","Bacillus (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",25,25,FALSE,FALSE,NA +"101","EUCAST 2026","human","human","MIC",NA,"B_BCLLS",3,"MEM","Bacillus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"102","EUCAST 2026","human","human","DISK","screen only","B_BCLLS",3,"NOR","Bacillus (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",21,21,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin." +"103","EUCAST 2026","human","human","DISK",NA,"B_BCLLS",3,"VAN","Bacillus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",10,10,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method." +"104","EUCAST 2026","human","human","MIC",NA,"B_BCLLS",3,"VAN","Bacillus (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"105","EUCAST 2026","human","human","MIC",NA,"B_BCLLS_ANTH",2,"AMX","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant." +"106","EUCAST 2026","human","human","DISK",NA,"B_BCLLS_ANTH",2,"CIP","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,24,FALSE,FALSE,NA +"107","EUCAST 2026","human","human","MIC",NA,"B_BCLLS_ANTH",2,"CIP","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,0.25,FALSE,FALSE,NA +"108","EUCAST 2026","human","human","DISK",NA,"B_BCLLS_ANTH",2,"CLI","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",17,17,FALSE,FALSE,NA +"109","EUCAST 2026","human","human","MIC",NA,"B_BCLLS_ANTH",2,"CLI","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"110","EUCAST 2026","human","human","MIC",NA,"B_BCLLS_ANTH",2,"DOX","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant." +"111","EUCAST 2026","human","human","DISK",NA,"B_BCLLS_ANTH",2,"LNZ","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",20,20,FALSE,FALSE,NA +"112","EUCAST 2026","human","human","MIC",NA,"B_BCLLS_ANTH",2,"LNZ","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"113","EUCAST 2026","human","human","DISK",NA,"B_BCLLS_ANTH",2,"LVX","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,23,FALSE,FALSE,NA +"114","EUCAST 2026","human","human","MIC",NA,"B_BCLLS_ANTH",2,"LVX","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,0.5,FALSE,FALSE,NA +"115","EUCAST 2026","human","human","DISK",NA,"B_BCLLS_ANTH",2,"PEN","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)","1 unit",50,18,FALSE,FALSE,NA +"116","EUCAST 2026","human","human","MIC",NA,"B_BCLLS_ANTH",2,"PEN","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,0.5,FALSE,FALSE,NA +"117","EUCAST 2026","human","human","DISK",NA,"B_BCLLS_ANTH",2,"RIF","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",12,12,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"118","EUCAST 2026","human","human","MIC",NA,"B_BCLLS_ANTH",2,"RIF","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"119","EUCAST 2026","human","human","DISK",NA,"B_BCLLS_ANTH",2,"TCY","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",26,26,FALSE,FALSE,NA +"120","EUCAST 2026","human","human","MIC",NA,"B_BCLLS_ANTH",2,"TCY","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA +"121","EUCAST 2026","human","human","DISK",NA,"B_BCLLS_ANTH",2,"VAN","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",10,10,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"122","EUCAST 2026","human","human","MIC",NA,"B_BCLLS_ANTH",2,"VAN","B.anthracis (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"123","EUCAST 2026","human","human","DISK",NA,"B_BCTRD",3,"AMC","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",14,14,FALSE,FALSE,NA +"124","EUCAST 2026","human","human","MIC",NA,"B_BCTRD",3,"AMC","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"125","EUCAST 2026","human","human","DISK",NA,"B_BCTRD",3,"CLI","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",10,10,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading." +"126","EUCAST 2026","human","human","MIC",NA,"B_BCTRD",3,"CLI","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"127","EUCAST 2026","human","human","DISK",NA,"B_BCTRD",3,"ETP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",23,23,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"128","EUCAST 2026","human","human","MIC",NA,"B_BCTRD",3,"ETP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"129","EUCAST 2026","human","human","DISK",NA,"B_BCTRD",3,"IPM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",29,29,FALSE,FALSE,NA +"130","EUCAST 2026","human","human","MIC",NA,"B_BCTRD",3,"IPM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"131","EUCAST 2026","human","human","DISK",NA,"B_BCTRD",3,"MEM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",28,28,FALSE,FALSE,NA +"132","EUCAST 2026","human","human","MIC",NA,"B_BCTRD",3,"MEM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"133","EUCAST 2026","human","human","DISK",NA,"B_BCTRD",3,"MTR","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",25,25,FALSE,FALSE,"[C] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result." +"134","EUCAST 2026","human","human","MIC",NA,"B_BCTRD",3,"MTR","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[6] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result." +"135","EUCAST 2026","human","human","DISK",NA,"B_BCTRD",3,"SAM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",25,25,FALSE,FALSE,NA +"136","EUCAST 2026","human","human","MIC",NA,"B_BCTRD",3,"SAM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L." +"137","EUCAST 2026","human","human","DISK",NA,"B_BCTRD",3,"TZP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",24,24,FALSE,FALSE,"[3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam." +"138","EUCAST 2026","human","human","MIC",NA,"B_BCTRD",3,"TZP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam." +"139","EUCAST 2026","human","human","DISK",NA,"B_BRCLL_MLTN",2,"CIP","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,27,FALSE,FALSE,NA +"140","EUCAST 2026","human","human","MIC",NA,"B_BRCLL_MLTN",2,"CIP","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,1,FALSE,FALSE,NA +"141","EUCAST 2026","human","human","DISK","meningitis","B_BRCLL_MLTN",2,"CRO","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",30,30,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"142","EUCAST 2026","human","human","MIC","meningitis","B_BRCLL_MLTN",2,"CRO","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"143","EUCAST 2026","human","human","MIC",NA,"B_BRCLL_MLTN",2,"DOX","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant." +"144","EUCAST 2026","human","human","DISK",NA,"B_BRCLL_MLTN",2,"GEN","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",23,23,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"145","EUCAST 2026","human","human","MIC",NA,"B_BRCLL_MLTN",2,"GEN","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"146","EUCAST 2026","human","human","DISK",NA,"B_BRCLL_MLTN",2,"LVX","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,28,FALSE,FALSE,NA +"147","EUCAST 2026","human","human","MIC",NA,"B_BRCLL_MLTN",2,"LVX","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,1,FALSE,FALSE,NA +"148","EUCAST 2026","human","human","DISK",NA,"B_BRCLL_MLTN",2,"RIF","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",20,20,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading." +"149","EUCAST 2026","human","human","MIC",NA,"B_BRCLL_MLTN",2,"RIF","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"150","EUCAST 2026","human","human","DISK",NA,"B_BRCLL_MLTN",2,"STR1","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"151","EUCAST 2026","human","human","MIC",NA,"B_BRCLL_MLTN",2,"STR1","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"152","EUCAST 2026","human","human","DISK",NA,"B_BRCLL_MLTN",2,"SXT","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",29,29,FALSE,FALSE,"[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone. | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"153","EUCAST 2026","human","human","MIC",NA,"B_BRCLL_MLTN",2,"SXT","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"154","EUCAST 2026","human","human","DISK",NA,"B_BRCLL_MLTN",2,"TCY","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",42,42,FALSE,FALSE,NA +"155","EUCAST 2026","human","human","MIC",NA,"B_BRCLL_MLTN",2,"TCY","B.melitensis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"156","EUCAST 2026","human","human","DISK",NA,"B_BRKHL_PSDM",2,"AMC","B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)","20/10 mcg",50,22,FALSE,FALSE,NA +"157","EUCAST 2026","human","human","MIC",NA,"B_BRKHL_PSDM",2,"AMC","B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,8,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"158","EUCAST 2026","human","human","DISK",NA,"B_BRKHL_PSDM",2,"CAZ","B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",50,18,FALSE,FALSE,NA +"159","EUCAST 2026","human","human","MIC",NA,"B_BRKHL_PSDM",2,"CAZ","B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,8,FALSE,FALSE,NA +"160","EUCAST 2026","human","human","DISK",NA,"B_BRKHL_PSDM",2,"CHL","B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,22,FALSE,FALSE,NA +"161","EUCAST 2026","human","human","MIC",NA,"B_BRKHL_PSDM",2,"CHL","B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,8,FALSE,FALSE,NA +"162","EUCAST 2026","human","human","MIC",NA,"B_BRKHL_PSDM",2,"DOX","B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,2,FALSE,FALSE,NA +"163","EUCAST 2026","human","human","DISK",NA,"B_BRKHL_PSDM",2,"IPM","B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",29,29,FALSE,FALSE,NA +"164","EUCAST 2026","human","human","MIC",NA,"B_BRKHL_PSDM",2,"IPM","B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"165","EUCAST 2026","human","human","DISK",NA,"B_BRKHL_PSDM",2,"MEM","B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",24,24,FALSE,FALSE,NA +"166","EUCAST 2026","human","human","MIC",NA,"B_BRKHL_PSDM",2,"MEM","B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"167","EUCAST 2026","human","human","DISK",NA,"B_BRKHL_PSDM",2,"SXT","B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",50,17,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"168","EUCAST 2026","human","human","MIC",NA,"B_BRKHL_PSDM",2,"SXT","B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"169","EUCAST 2026","human","human","DISK","screen only","B_BRKHL_PSDM",2,"TCY","B.pseudomallei (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",23,23,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline." +"170","EUCAST 2026","human","human","DISK",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,26,FALSE,FALSE,NA +"171","EUCAST 2026","human","human","MIC",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,0.5,FALSE,FALSE,NA +"172","EUCAST 2026","human","human","DISK",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",18,18,FALSE,FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin." +"173","EUCAST 2026","human","human","MIC",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin." +"174","EUCAST 2026","human","human","DISK",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",30,30,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from tetracycline." +"175","EUCAST 2026","human","human","MIC",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Susceptibility to doxycycline can be inferred from tetracycline." +"176","EUCAST 2026","human","human","DISK",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,26,FALSE,FALSE,NA +"177","EUCAST 2026","human","human","MIC",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,0.5,FALSE,FALSE,NA +"178","EUCAST 2026","human","human","DISK",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",20,20,FALSE,FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin." +"179","EUCAST 2026","human","human","MIC",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin." +"180","EUCAST 2026","human","human","DISK",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",30,30,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from tetracycline." +"181","EUCAST 2026","human","human","MIC",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Susceptibility to doxycycline can be inferred from tetracycline." +"182","EUCAST 2026","human","human","MIC",NA,"B_CRDDS_DFFC",2,"FDX","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes." +"183","EUCAST 2026","human","human","MIC",NA,"B_CRDDS_DFFC",2,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes. | [2] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result." +"184","EUCAST 2026","human","human","MIC",NA,"B_CRDDS_DFFC",2,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes." +"185","EUCAST 2026","human","human","DISK",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,25,FALSE,FALSE,NA +"186","EUCAST 2026","human","human","MIC",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,1,FALSE,FALSE,NA +"187","EUCAST 2026","human","human","DISK",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",20,20,FALSE,FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing." +"188","EUCAST 2026","human","human","MIC",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing." +"189","EUCAST 2026","human","human","DISK",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",25,25,FALSE,FALSE,NA +"190","EUCAST 2026","human","human","MIC",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"191","EUCAST 2026","human","human","DISK",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",25,25,FALSE,FALSE,NA +"192","EUCAST 2026","human","human","MIC",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"193","EUCAST 2026","human","human","DISK",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)","1 unit",50,12,FALSE,FALSE,NA +"194","EUCAST 2026","human","human","MIC",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,1,FALSE,FALSE,NA +"195","EUCAST 2026","human","human","DISK",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",30,30,FALSE,FALSE,NA +"196","EUCAST 2026","human","human","MIC",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA +"197","EUCAST 2026","human","human","DISK",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",24,24,FALSE,FALSE,NA +"198","EUCAST 2026","human","human","MIC",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"199","EUCAST 2026","human","human","DISK",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method." +"200","EUCAST 2026","human","human","MIC",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"201","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_DPHT",2,"AMX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant." +"202","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_DPHT",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,24,FALSE,FALSE,NA +"203","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_DPHT",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,0.5,FALSE,FALSE,NA +"204","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_DPHT",2,"CLI","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",15,15,FALSE,FALSE,"[1] Wild-type C. ulcerans is less susceptible to clindamycin." +"205","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_DPHT",2,"CLI","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Wild-type C. ulcerans is less susceptible to clindamycin." +"206","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_DPHT",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,15,FALSE,FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant." +"207","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_DPHT",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,2,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant." +"208","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_DPHT",2,"DOX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant." +"209","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_DPHT",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",24,24,FALSE,FALSE,NA +"210","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_DPHT",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA +"211","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_DPHT",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",25,25,FALSE,FALSE,NA +"212","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_DPHT",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"213","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_DPHT",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",24,24,FALSE,FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant." +"214","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_DPHT",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant." +"215","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_DPHT",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","1 unit",50,12,FALSE,FALSE,NA +"216","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_DPHT",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,1,FALSE,FALSE,NA +"217","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_DPHT",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",24,24,FALSE,FALSE,NA +"218","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_DPHT",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA +"219","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_DPHT",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"220","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_DPHT",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"221","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_DPHT",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",24,24,FALSE,FALSE,NA +"222","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_DPHT",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"223","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_ULCR",2,"AMX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant." +"224","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_ULCR",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,24,FALSE,FALSE,NA +"225","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_ULCR",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,0.5,FALSE,FALSE,NA +"226","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_ULCR",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,15,FALSE,FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant." +"227","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_ULCR",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,2,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant." +"228","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_ULCR",2,"DOX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant." +"229","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_ULCR",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",24,24,FALSE,FALSE,NA +"230","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_ULCR",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA +"231","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_ULCR",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",25,25,FALSE,FALSE,NA +"232","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_ULCR",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"233","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_ULCR",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",24,24,FALSE,FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant." +"234","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_ULCR",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant." +"235","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_ULCR",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","1 unit",50,12,FALSE,FALSE,NA +"236","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_ULCR",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,1,FALSE,FALSE,NA +"237","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_ULCR",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",24,24,FALSE,FALSE,NA +"238","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_ULCR",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA +"239","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_ULCR",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"240","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_ULCR",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"241","EUCAST 2026","human","human","DISK",NA,"B_CRYNB_ULCR",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",24,24,FALSE,FALSE,NA +"242","EUCAST 2026","human","human","MIC",NA,"B_CRYNB_ULCR",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"243","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed." +"244","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed." +"245","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed." +"246","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"AMX","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed." +"247","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",26,26,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading." +"248","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"249","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"CRO","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test." +"250","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"CRO","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [3] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test." +"251","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"CTX","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",26,26,FALSE,FALSE,"[C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test." +"252","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",28,28,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed." +"253","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed." +"254","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",39,39,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed." +"255","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"LNZ","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",34,34,FALSE,FALSE,NA +"256","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"LNZ","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"257","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",28,28,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed." +"258","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed." +"259","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","1 unit",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed." +"260","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed." +"261","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",NA,33,FALSE,FALSE,NA +"262","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",27,27,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed." +"263","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",22,22,FALSE,FALSE,NA +"264","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"265","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_AVDM",2,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"266","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_AVDM",2,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"267","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_AVDM",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"268","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_AVDM",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"269","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_AVDM",2,"AMX","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"270","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_AVDM",2,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",33,33,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading." +"271","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_AVDM",2,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA +"272","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_AVDM",2,"CRO","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",30,30,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test." +"273","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_AVDM",2,"CRO","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [5] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test." +"274","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_AVDM",2,"CTX","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",24,24,FALSE,FALSE,"[C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test." +"275","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_AVDM",2,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",28,28,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"276","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_AVDM",2,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"277","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_AVDM",2,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",39,39,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"278","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_AVDM",2,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"279","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_AVDM",2,"LNZ","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",28,28,FALSE,FALSE,NA +"280","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_AVDM",2,"LNZ","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"281","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_AVDM",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",29,29,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"282","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_AVDM",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"283","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_AVDM",2,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","1 unit",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"284","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_AVDM",2,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"285","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_AVDM",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",32,32,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"286","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_AVDM",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L." +"287","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_AVDM",2,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",28,28,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"288","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_AVDM",2,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"289","EUCAST 2026","human","human","DISK",NA,"B_CTBCTR_AVDM",2,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",19,19,FALSE,FALSE,NA +"290","EUCAST 2026","human","human","MIC",NA,"B_CTBCTR_AVDM",2,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"291","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_CTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"292","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_CTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination." +"293","EUCAST 2026","human","human","DISK",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method." +"294","EUCAST 2026","human","human","MIC",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/." +"295","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_INNC",2,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",19,19,FALSE,FALSE,NA +"296","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_INNC",2,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"297","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_INNC",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",21,21,FALSE,FALSE,NA +"298","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_INNC",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"299","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_INNC",2,"AMX","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"300","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_INNC",2,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",17,17,FALSE,FALSE,"[B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading." +"301","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_INNC",2,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"302","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_INNC",2,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",19,19,FALSE,FALSE,"[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result." +"303","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_INNC",2,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result." +"304","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_INNC",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",28,28,FALSE,FALSE,NA +"305","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_INNC",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L." +"306","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_INNC",2,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",24,24,FALSE,FALSE,NA +"307","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_INNC",2,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"308","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_PRFR",2,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"309","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_PRFR",2,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"310","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_PRFR",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"311","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_PRFR",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"312","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_PRFR",2,"AMX","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"313","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_PRFR",2,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",19,19,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading." +"314","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_PRFR",2,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"315","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_PRFR",2,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"316","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_PRFR",2,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"317","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_PRFR",2,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"318","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_PRFR",2,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"319","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_PRFR",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"320","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_PRFR",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"321","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_PRFR",2,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",16,16,FALSE,FALSE,"[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result." +"322","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_PRFR",2,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result." +"323","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_PRFR",2,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","1 unit",15,15,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"324","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_PRFR",2,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"325","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_PRFR",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",27,27,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"326","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_PRFR",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L." +"327","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_PRFR",2,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"328","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_PRFR",2,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"329","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_PRFR",2,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",12,12,FALSE,FALSE,NA +"330","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_PRFR",2,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"331","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_RMSM",2,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",21,21,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"332","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_RMSM",2,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"333","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_RMSM",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",20,20,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"334","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_RMSM",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"335","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_RMSM",2,"AMX","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"336","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_RMSM",2,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",26,26,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"337","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_RMSM",2,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"338","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_RMSM",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",22,22,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"339","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_RMSM",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"340","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_RMSM",2,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",21,21,FALSE,FALSE,"[C] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result." +"341","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_RMSM",2,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result." +"342","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_RMSM",2,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","1 unit",21,21,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"343","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_RMSM",2,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"344","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_RMSM",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",26,26,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"345","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_RMSM",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L." +"346","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_RMSM",2,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",28,28,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"347","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_RMSM",2,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"348","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_SPTC",2,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"349","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_SPTC",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"350","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_SPTC",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"351","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_SPTC",2,"AMX","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"352","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_SPTC",2,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",24,24,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading." +"353","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_SPTC",2,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"354","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_SPTC",2,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",26,26,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"355","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_SPTC",2,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"356","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_SPTC",2,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",31,31,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"357","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_SPTC",2,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"358","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_SPTC",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",29,29,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"359","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_SPTC",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"360","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_SPTC",2,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",21,21,FALSE,FALSE,"[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result." +"361","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_SPTC",2,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result." +"362","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_SPTC",2,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","1 unit",21,21,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"363","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_SPTC",2,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"364","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_SPTC",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",29,29,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"365","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_SPTC",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L." +"366","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_SPTC",2,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"367","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_SPTC",2,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"368","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_SPTC",2,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",14,14,FALSE,FALSE,NA +"369","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_SPTC",2,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA +"370","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_TRTM",2,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",15,15,FALSE,FALSE,NA +"371","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_TRTM",2,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"372","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_TRTM",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",12,12,FALSE,FALSE,NA +"373","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_TRTM",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA +"374","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_TRTM",2,"AMX","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"375","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_TRTM",2,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",28,28,FALSE,FALSE,NA +"376","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_TRTM",2,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"377","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_TRTM",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",24,24,FALSE,FALSE,NA +"378","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_TRTM",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"379","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_TRTM",2,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",20,20,FALSE,FALSE,"[B] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result." +"380","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_TRTM",2,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[3] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result." +"381","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_TRTM",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",22,22,FALSE,FALSE,NA +"382","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_TRTM",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L." +"383","EUCAST 2026","human","human","DISK",NA,"B_CTRDM_TRTM",2,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",13,13,FALSE,FALSE,NA +"384","EUCAST 2026","human","human","MIC",NA,"B_CTRDM_TRTM",2,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA +"385","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_ENTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"386","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_ENTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination." +"387","EUCAST 2026","human","human","DISK",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",10,10,FALSE,FALSE,"[A] For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test." +"388","EUCAST 2026","human","human","MIC",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA +"389","EUCAST 2026","human","human","MIC",NA,"B_ENTRC",3,"AMX","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[1] Susceptibility can be inferred from ampicillin." +"390","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"AMX","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,TRUE,FALSE,"[1] Susceptibility can be inferred from ampicillin." +"391","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"392","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,TRUE,FALSE,NA +"393","EUCAST 2026","human","human","DISK",NA,"B_ENTRC",3,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","20 mcg",22,22,FALSE,FALSE,NA +"394","EUCAST 2026","human","human","MIC",NA,"B_ENTRC",3,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"395","EUCAST 2026","human","human","DISK",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",20,20,FALSE,FALSE,NA +"396","EUCAST 2026","human","human","MIC",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA +"397","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"398","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,TRUE,FALSE,NA +"399","EUCAST 2026","human","human","DISK","screen only","B_ENTRC",3,"NOR","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",12,12,FALSE,FALSE,"[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B." +"400","EUCAST 2026","human","human","DISK",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",16,16,FALSE,FALSE,NA +"401","EUCAST 2026","human","human","MIC",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"402","EUCAST 2026","human","human","DISK",NA,"B_ENTRC",3,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",20,20,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"403","EUCAST 2026","human","human","MIC",NA,"B_ENTRC",3,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"404","EUCAST 2026","human","human","DISK",NA,"B_ENTRC",3,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",15,15,FALSE,FALSE,NA +"405","EUCAST 2026","human","human","MIC",NA,"B_ENTRC",3,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA +"406","EUCAST 2026","human","human","DISK",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",22,22,FALSE,FALSE,NA +"407","EUCAST 2026","human","human","MIC",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"408","EUCAST 2026","human","human","DISK",NA,"B_ENTRC_FACM",2,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",12,12,FALSE,FALSE,"[A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation." +"409","EUCAST 2026","human","human","MIC",NA,"B_ENTRC_FACM",2,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA +"410","EUCAST 2026","human","human","MIC","other indications","B_ENTRC_FCLS",2,"AMX","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,4,FALSE,FALSE,"[3] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"411","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_ENTRC_FCLS",2,"GEP","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,TRUE,FALSE,NA +"412","EUCAST 2026","human","human","DISK",NA,"B_ENTRC_FCLS",2,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",50,21,FALSE,FALSE,NA +"413","EUCAST 2026","human","human","MIC",NA,"B_ENTRC_FCLS",2,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,4,FALSE,FALSE,NA +"414","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","100 mcg",15,15,TRUE,FALSE,NA +"415","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,64,64,TRUE,FALSE,NA +"416","EUCAST 2026","human","human","DISK",NA,"B_ENTRC_FCLS",2,"PIP","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,18,FALSE,FALSE,NA +"417","EUCAST 2026","human","human","MIC",NA,"B_ENTRC_FCLS",2,"PIP","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,16,FALSE,FALSE,NA +"418","EUCAST 2026","human","human","DISK",NA,"B_ENTRC_FCLS",2,"TZP","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",50,18,FALSE,FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare." +"419","EUCAST 2026","human","human","MIC",NA,"B_ENTRC_FCLS",2,"TZP","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,16,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare." +"420","EUCAST 2026","human","human","DISK",NA,"B_ENTRC_FCLS",2,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",12,12,FALSE,FALSE,"[A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation." +"421","EUCAST 2026","human","human","MIC",NA,"B_ENTRC_FCLS",2,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA +"422","EUCAST 2026","human","human","DISK",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,19,FALSE,FALSE,NA +"423","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",19,19,TRUE,FALSE,NA +"424","EUCAST 2026","human","human","MIC",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,8,FALSE,FALSE,NA +"425","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,TRUE,FALSE,NA +"426","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_ESCHR_COLI",2,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,20,FALSE,FALSE,"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin." +"427","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,4,FALSE,FALSE,"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin." +"428","EUCAST 2026","human","human","MIC",NA,"B_ESCHR_COLI",2,"DFX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA +"429","EUCAST 2026","human","human","DISK",NA,"B_ESCHR_COLI",2,"ERV","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","20 mcg",17,17,FALSE,FALSE,NA +"430","EUCAST 2026","human","human","MIC",NA,"B_ESCHR_COLI",2,"ERV","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"431","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","200 mcg",24,24,FALSE,FALSE,"[D] Ignore isolated colonies within the inhibition zone (see pictures below)." +"432","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","200 mcg",24,24,TRUE,FALSE,"[D] Ignore isolated colonies within the inhibition zone (see pictures below)." +"433","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems." +"434","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,TRUE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems." +"435","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"GEP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,TRUE,FALSE,NA +"436","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"437","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination." +"438","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","100 mcg",11,11,TRUE,FALSE,NA +"439","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,64,64,TRUE,FALSE,NA +"440","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",15,15,TRUE,FALSE,NA +"441","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,16,16,TRUE,FALSE,NA +"442","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_ESCHR_COLI",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,17,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"443","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,16,FALSE,FALSE,NA +"444","EUCAST 2026","human","human","DISK",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method." +"445","EUCAST 2026","human","human","MIC",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/." +"446","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",15,15,TRUE,FALSE,NA +"447","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,TRUE,FALSE,NA +"448","EUCAST 2026","human","human","DISK",NA,"B_FNGLD",3,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",21,21,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"449","EUCAST 2026","human","human","MIC",NA,"B_FNGLD",3,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.." +"450","EUCAST 2026","human","human","DISK",NA,"B_FNGLD",3,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",21,21,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"451","EUCAST 2026","human","human","MIC",NA,"B_FNGLD",3,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"452","EUCAST 2026","human","human","MIC",NA,"B_FNGLD",3,"AMX","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"453","EUCAST 2026","human","human","DISK",NA,"B_FNGLD",3,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",23,23,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown." +"454","EUCAST 2026","human","human","MIC",NA,"B_FNGLD",3,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown." +"455","EUCAST 2026","human","human","DISK",NA,"B_FNGLD",3,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",29,29,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"456","EUCAST 2026","human","human","MIC",NA,"B_FNGLD",3,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"457","EUCAST 2026","human","human","DISK",NA,"B_FNGLD",3,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",34,34,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"458","EUCAST 2026","human","human","MIC",NA,"B_FNGLD",3,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"459","EUCAST 2026","human","human","DISK",NA,"B_FNGLD",3,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",31,31,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"460","EUCAST 2026","human","human","MIC",NA,"B_FNGLD",3,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"461","EUCAST 2026","human","human","DISK",NA,"B_FNGLD",3,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",25,25,FALSE,FALSE,"[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result." +"462","EUCAST 2026","human","human","MIC",NA,"B_FNGLD",3,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[6] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result." +"463","EUCAST 2026","human","human","DISK",NA,"B_FNGLD",3,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","1 unit",20,20,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"464","EUCAST 2026","human","human","MIC",NA,"B_FNGLD",3,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"465","EUCAST 2026","human","human","DISK",NA,"B_FNGLD",3,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",27,27,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"466","EUCAST 2026","human","human","MIC",NA,"B_FNGLD",3,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L." +"467","EUCAST 2026","human","human","DISK",NA,"B_FNGLD",3,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",30,30,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"468","EUCAST 2026","human","human","MIC",NA,"B_FNGLD",3,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"469","EUCAST 2026","human","human","DISK",NA,"B_FNGLD",3,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",20,20,FALSE,FALSE,NA +"470","EUCAST 2026","human","human","MIC",NA,"B_FNGLD",3,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"471","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCLT",2,"AMC","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"472","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCLT",2,"AMP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",27,27,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"473","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCLT",2,"AMP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"474","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCLT",2,"AMX","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"475","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCLT",2,"CLI","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",30,30,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading." +"476","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCLT",2,"CLI","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"477","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCLT",2,"ETP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"478","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCLT",2,"ETP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"479","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCLT",2,"IPM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",36,36,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"480","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCLT",2,"IPM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"481","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCLT",2,"MEM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"482","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCLT",2,"MEM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"483","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCLT",2,"MTR","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",30,30,FALSE,FALSE,"[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result." +"484","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCLT",2,"MTR","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[6] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result." +"485","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCLT",2,"PEN","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","1 unit",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"486","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCLT",2,"PEN","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"487","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCLT",2,"SAM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"488","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCLT",2,"SAM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L." +"489","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCLT",2,"TZP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"490","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"AMC","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"491","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"AMC","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"492","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"AMP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",27,27,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"493","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"AMP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"494","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"AMX","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"495","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"CLI","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",30,30,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading." +"496","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"CLI","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"497","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"ETP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"498","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"ETP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"499","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"IPM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",36,36,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"500","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"IPM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"501","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"MEM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"502","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"MEM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"503","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"MTR","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",30,30,FALSE,FALSE,"[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result." +"504","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"MTR","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[6] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result." +"505","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"PEN","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","1 unit",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"506","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"PEN","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"507","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"SAM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"508","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"SAM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L." +"509","EUCAST 2026","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"TZP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"510","EUCAST 2026","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"TZP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"511","EUCAST 2026","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"AMX","H.pylori (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA +"512","EUCAST 2026","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"CLR","H.pylori (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"513","EUCAST 2026","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"LVX","H.pylori (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"514","EUCAST 2026","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"MTR","H.pylori (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,NA +"515","EUCAST 2026","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"RIF","H.pylori (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"516","EUCAST 2026","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"TCY","H.pylori (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"517","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",15,15,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"518","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",50,15,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"519","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"520","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,2,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"521","EUCAST 2026","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",18,18,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase." +"522","EUCAST 2026","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase." +"523","EUCAST 2026","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"AMX","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase." +"524","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMX","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,2,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase." +"525","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"526","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA +"527","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",28,28,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages." +"528","EUCAST 2026","human","human","DISK","Topical","B_HMPHL_INFL",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",28,28,FALSE,FALSE,NA +"529","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages." +"530","EUCAST 2026","human","human","MIC","Topical","B_HMPHL_INFL",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"531","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",32,32,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"532","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.03,0.03,FALSE,FALSE,NA +"533","EUCAST 2026","human","human","MIC","Topical","B_HMPHL_INFL",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA +"534","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"535","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"536","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPT","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.03,0.03,FALSE,FALSE,NA +"537","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",32,32,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"538","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA +"539","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",25,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"540","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"541","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"542","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA +"543","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",27,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"544","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"545","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,1,2,FALSE,FALSE,NA +"546","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,1,FALSE,FALSE,NA +"547","EUCAST 2026","human","human","DISK","pneumonia","B_HMPHL_INFL",2,"CZT","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","30/10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [3] See table of dosages for dosing for different indications." +"548","EUCAST 2026","human","human","MIC","pneumonia","B_HMPHL_INFL",2,"CZT","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[3] See table of dosages for dosing for different indications." +"549","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"DOR","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"550","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"DOR","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"551","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"DOX","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"552","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"553","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"554","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",28,28,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"555","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"556","EUCAST 2026","human","human","MIC","Topical","B_HMPHL_INFL",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA +"557","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"558","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"559","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"560","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA +"561","EUCAST 2026","human","human","MIC","Topical","B_HMPHL_INFL",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA +"562","EUCAST 2026","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"563","EUCAST 2026","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"564","EUCAST 2026","human","human","MIC","meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"565","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"566","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA +"567","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",24,24,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"568","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"569","EUCAST 2026","human","human","DISK","screen only","B_HMPHL_INFL",2,"NAL","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",23,23,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"570","EUCAST 2026","human","human","DISK","Topical","B_HMPHL_INFL",2,"NAL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",23,23,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)." +"571","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"572","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA +"573","EUCAST 2026","human","human","MIC","Topical","B_HMPHL_INFL",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA +"574","EUCAST 2026","human","human","DISK","screen only","B_HMPHL_INFL",2,"PEN","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","1 unit",12,12,FALSE,FALSE,"[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"575","EUCAST 2026","human","human","DISK","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",18,18,FALSE,FALSE,NA +"576","EUCAST 2026","human","human","MIC","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"577","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"SAM","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [5] Susceptibility can be inferred from amoxicillin-clavulanic acid iv." +"578","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"579","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"580","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",25,25,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"581","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"582","EUCAST 2026","human","human","MIC","Topical","B_HMPHL_INFL",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,NA +"583","EUCAST 2026","human","human","DISK",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"584","EUCAST 2026","human","human","MIC",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"585","EUCAST 2026","human","human","DISK",NA,"B_KGLLA_KING",2,"AMC","K.kingae (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",22,22,FALSE,FALSE,NA +"586","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"AMP","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility." +"587","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"AMX","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility." +"588","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"AZM","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility." +"589","EUCAST 2026","human","human","DISK",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",28,28,FALSE,FALSE,NA +"590","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA +"591","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"CLR","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility." +"592","EUCAST 2026","human","human","DISK",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",30,30,FALSE,FALSE,NA +"593","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA +"594","EUCAST 2026","human","human","DISK",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",27,27,FALSE,FALSE,NA +"595","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA +"596","EUCAST 2026","human","human","DISK",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",29,29,FALSE,FALSE,NA +"597","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"598","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"DOX","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant." +"599","EUCAST 2026","human","human","DISK",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",20,20,FALSE,FALSE,NA +"600","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"601","EUCAST 2026","human","human","DISK",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",28,28,FALSE,FALSE,NA +"602","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA +"603","EUCAST 2026","human","human","DISK",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",30,30,FALSE,FALSE,NA +"604","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.03,0.03,FALSE,FALSE,NA +"605","EUCAST 2026","human","human","DISK",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 16.1)","1 unit",25,25,FALSE,FALSE,NA +"606","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.03,0.03,FALSE,FALSE,NA +"607","EUCAST 2026","human","human","DISK",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",20,20,FALSE,FALSE,NA +"608","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"609","EUCAST 2026","human","human","DISK",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",28,28,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"610","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"611","EUCAST 2026","human","human","DISK",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",28,28,FALSE,FALSE,NA +"612","EUCAST 2026","human","human","MIC",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"613","EUCAST 2026","human","human","DISK",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,19,FALSE,FALSE,NA +"614","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",19,19,TRUE,FALSE,NA +"615","EUCAST 2026","human","human","MIC",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,8,FALSE,FALSE,NA +"616","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,TRUE,FALSE,NA +"617","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_KLBSL",3,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,20,FALSE,FALSE,"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin." +"618","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_KLBSL",3,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,4,FALSE,FALSE,"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin." +"619","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"620","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination." +"621","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_KLBSL",3,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,17,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"622","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_KLBSL",3,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,16,FALSE,FALSE,NA +"623","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",15,15,TRUE,FALSE,NA +"624","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,TRUE,FALSE,NA +"625","EUCAST 2026","human","human","DISK","all indications","B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",16,16,FALSE,FALSE,NA +"626","EUCAST 2026","human","human","MIC","all indications","B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"627","EUCAST 2026","human","human","DISK","indications other than meningitis","B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",25,25,FALSE,FALSE,NA +"628","EUCAST 2026","human","human","MIC","indications other than meningitis","B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"629","EUCAST 2026","human","human","DISK","all indications","B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",26,26,FALSE,FALSE,NA +"630","EUCAST 2026","human","human","MIC","all indications","B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"631","EUCAST 2026","human","human","DISK","indications other than meningitis","B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)","1 unit",13,13,FALSE,FALSE,NA +"632","EUCAST 2026","human","human","MIC","indications other than meningitis","B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"633","EUCAST 2026","human","human","DISK","all indications","B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",29,29,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"634","EUCAST 2026","human","human","MIC","all indications","B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"635","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",19,19,FALSE,FALSE,NA +"636","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"637","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AZM","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"638","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",21,21,FALSE,FALSE,NA +"639","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"640","EUCAST 2026","human","human","DISK","Topical","B_MRXLL_CTRR",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",31,31,FALSE,FALSE,NA +"641","EUCAST 2026","human","human","MIC","Topical","B_MRXLL_CTRR",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"642","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",31,31,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"643","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA +"644","EUCAST 2026","human","human","MIC","Topical","B_MRXLL_CTRR",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA +"645","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CLR","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"646","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",24,21,FALSE,FALSE,NA +"647","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,1,2,FALSE,FALSE,NA +"648","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",20,17,FALSE,FALSE,NA +"649","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,1,2,FALSE,FALSE,NA +"650","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",21,18,FALSE,FALSE,NA +"651","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,21,FALSE,FALSE,NA +"652","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,4,8,FALSE,FALSE,NA +"653","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,4,FALSE,FALSE,NA +"654","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"DOR","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",30,30,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"655","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"DOR","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"656","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"DOX","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"657","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",23,23,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"658","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"659","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",29,29,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"660","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"661","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",20,20,FALSE,FALSE,NA +"662","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA +"663","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",29,29,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"664","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"665","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",29,29,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"666","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA +"667","EUCAST 2026","human","human","MIC","Topical","B_MRXLL_CTRR",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA +"668","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",33,33,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"669","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"670","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",26,26,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"671","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"672","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",25,25,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"673","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"674","EUCAST 2026","human","human","DISK","screen only","B_MRXLL_CTRR",2,"NAL","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",23,23,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"675","EUCAST 2026","human","human","DISK","Topical","B_MRXLL_CTRR",2,"NAL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",23,23,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)." +"676","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"677","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"678","EUCAST 2026","human","human","MIC","Topical","B_MRXLL_CTRR",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"679","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"RXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"680","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SAM","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid." +"681","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",15,15,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"682","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"683","EUCAST 2026","human","human","DISK",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",26,26,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"684","EUCAST 2026","human","human","MIC",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"685","EUCAST 2026","human","human","MIC",NA,"B_MYCBC_TBRC",2,"BDQ","M.tuberculosis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] For bedaquiline, breakpoints were determined using the EUCAST reference method." +"686","EUCAST 2026","human","human","MIC",NA,"B_MYCBC_TBRC",2,"DLM","M.tuberculosis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[2] For delamanid and pretomanid, breakpoints were not determined with the EUCAST reference method. Therefore they are provisional and might change according to the results of future studies with the EUCAST reference method for MIC determination. +3.The provisional breakpoint was determined according to MIC data determined with the agar dilution and the agar proportion methods." +"687","EUCAST 2026","human","human","MIC",NA,"B_NESSR_GNRR",2,"CFM","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA +"688","EUCAST 2026","human","human","MIC",NA,"B_NESSR_GNRR",2,"CIP","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.03,0.06,FALSE,FALSE,NA +"689","EUCAST 2026","human","human","MIC",NA,"B_NESSR_GNRR",2,"CRO","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA +"690","EUCAST 2026","human","human","MIC",NA,"B_NESSR_GNRR",2,"CTX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA +"691","EUCAST 2026","human","human","MIC",NA,"B_NESSR_GNRR",2,"OFX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.25,FALSE,FALSE,NA +"692","EUCAST 2026","human","human","MIC","surrogate agent","B_NESSR_GNRR",2,"PEN","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,1,FALSE,FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)." +"693","EUCAST 2026","human","human","MIC",NA,"B_NESSR_GNRR",2,"SPT","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)",NA,64,64,FALSE,FALSE,NA +"694","EUCAST 2026","human","human","MIC",NA,"B_NESSR_GNRR",2,"TCY","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"695","EUCAST 2026","human","human","MIC","indications other than meningitis","B_NESSR_MNNG",2,"AMP","N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,1,FALSE,FALSE,NA +"696","EUCAST 2026","human","human","MIC","indications other than meningitis","B_NESSR_MNNG",2,"AMX","N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,1,FALSE,FALSE,NA +"697","EUCAST 2026","human","human","MIC","meningitis","B_NESSR_MNNG",2,"CHL","N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages." +"698","EUCAST 2026","human","human","MIC","all indications, including meningitis and prophylaxis","B_NESSR_MNNG",2,"CIP","N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.016,0.016,FALSE,FALSE,NA +"699","EUCAST 2026","human","human","MIC","all indications including prophylaxis","B_NESSR_MNNG",2,"CRO","N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"700","EUCAST 2026","human","human","MIC","all indications","B_NESSR_MNNG",2,"CTX","N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"701","EUCAST 2026","human","human","MIC","all indications","B_NESSR_MNNG",2,"MEM","N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only." +"702","EUCAST 2026","human","human","MIC","prophylaxis only","B_NESSR_MNNG",2,"MNO","N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections." +"703","EUCAST 2026","human","human","MIC","all indications","B_NESSR_MNNG",2,"PEN","N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"704","EUCAST 2026","human","human","MIC","prophylaxis only","B_NESSR_MNNG",2,"RIF","N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"705","EUCAST 2026","human","human","MIC","screen only","B_NESSR_MNNG",2,"TCY","N.meningitidis (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections." +"706","EUCAST 2026","human","human","DISK",NA,"B_PPTNP",3,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"707","EUCAST 2026","human","human","DISK",NA,"B_PPTNP",3,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",21,21,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"708","EUCAST 2026","human","human","MIC",NA,"B_PPTNP",3,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"709","EUCAST 2026","human","human","MIC",NA,"B_PPTNP",3,"AMX","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"710","EUCAST 2026","human","human","DISK",NA,"B_PPTNP",3,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",15,15,FALSE,FALSE,"[C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown." +"711","EUCAST 2026","human","human","MIC",NA,"B_PPTNP",3,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown." +"712","EUCAST 2026","human","human","DISK",NA,"B_PPTNP",3,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",32,32,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"713","EUCAST 2026","human","human","MIC",NA,"B_PPTNP",3,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.03,0.03,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"714","EUCAST 2026","human","human","DISK",NA,"B_PPTNP",3,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",37,37,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"715","EUCAST 2026","human","human","MIC",NA,"B_PPTNP",3,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"716","EUCAST 2026","human","human","DISK",NA,"B_PPTNP",3,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"717","EUCAST 2026","human","human","MIC",NA,"B_PPTNP",3,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"718","EUCAST 2026","human","human","DISK",NA,"B_PPTNP",3,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",19,19,FALSE,FALSE,"[E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result." +"719","EUCAST 2026","human","human","MIC",NA,"B_PPTNP",3,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result." +"720","EUCAST 2026","human","human","DISK",NA,"B_PPTNP",3,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","1 unit",18,18,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"721","EUCAST 2026","human","human","MIC",NA,"B_PPTNP",3,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"722","EUCAST 2026","human","human","DISK",NA,"B_PPTNP",3,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",29,29,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"723","EUCAST 2026","human","human","DISK",NA,"B_PPTNP",3,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",36,36,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"724","EUCAST 2026","human","human","DISK",NA,"B_PPTNP",3,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",21,21,FALSE,FALSE,NA +"725","EUCAST 2026","human","human","MIC",NA,"B_PPTNP",3,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"726","EUCAST 2026","human","human","DISK",NA,"B_PPTST_ANRB",2,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",22,22,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"727","EUCAST 2026","human","human","MIC",NA,"B_PPTST_ANRB",2,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.." +"728","EUCAST 2026","human","human","DISK",NA,"B_PPTST_ANRB",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"729","EUCAST 2026","human","human","MIC",NA,"B_PPTST_ANRB",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"730","EUCAST 2026","human","human","MIC",NA,"B_PPTST_ANRB",2,"AMX","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"731","EUCAST 2026","human","human","DISK",NA,"B_PPTST_ANRB",2,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",17,17,FALSE,FALSE,"[C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown." +"732","EUCAST 2026","human","human","MIC",NA,"B_PPTST_ANRB",2,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[6] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown." +"733","EUCAST 2026","human","human","DISK",NA,"B_PPTST_ANRB",2,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",27,27,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"734","EUCAST 2026","human","human","MIC",NA,"B_PPTST_ANRB",2,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"735","EUCAST 2026","human","human","DISK",NA,"B_PPTST_ANRB",2,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",36,36,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"736","EUCAST 2026","human","human","MIC",NA,"B_PPTST_ANRB",2,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"737","EUCAST 2026","human","human","DISK",NA,"B_PPTST_ANRB",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",30,30,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"738","EUCAST 2026","human","human","MIC",NA,"B_PPTST_ANRB",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"739","EUCAST 2026","human","human","DISK",NA,"B_PPTST_ANRB",2,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",22,22,FALSE,FALSE,"[E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result." +"740","EUCAST 2026","human","human","MIC",NA,"B_PPTST_ANRB",2,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[7] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result." +"741","EUCAST 2026","human","human","DISK",NA,"B_PPTST_ANRB",2,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","1 unit",20,20,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"742","EUCAST 2026","human","human","MIC",NA,"B_PPTST_ANRB",2,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"743","EUCAST 2026","human","human","DISK",NA,"B_PPTST_ANRB",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",31,31,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"744","EUCAST 2026","human","human","MIC",NA,"B_PPTST_ANRB",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L." +"745","EUCAST 2026","human","human","DISK",NA,"B_PPTST_ANRB",2,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",32,32,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"746","EUCAST 2026","human","human","MIC",NA,"B_PPTST_ANRB",2,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"747","EUCAST 2026","human","human","DISK",NA,"B_PPTST_ANRB",2,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",15,15,FALSE,FALSE,NA +"748","EUCAST 2026","human","human","MIC",NA,"B_PPTST_ANRB",2,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"749","EUCAST 2026","human","human","DISK",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,19,FALSE,FALSE,NA +"750","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",19,19,TRUE,FALSE,NA +"751","EUCAST 2026","human","human","MIC",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,8,FALSE,FALSE,NA +"752","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,TRUE,FALSE,NA +"753","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_PROTS_MRBL",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"754","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_PROTS_MRBL",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination." +"755","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_PROTS_MRBL",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,17,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"756","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_PROTS_MRBL",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,16,FALSE,FALSE,NA +"757","EUCAST 2026","human","human","DISK",NA,"B_PRVMN_MICR",2,"AMC","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",28,28,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"758","EUCAST 2026","human","human","DISK",NA,"B_PRVMN_MICR",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",29,29,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"759","EUCAST 2026","human","human","MIC",NA,"B_PRVMN_MICR",2,"AMP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"760","EUCAST 2026","human","human","MIC",NA,"B_PRVMN_MICR",2,"AMX","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"761","EUCAST 2026","human","human","DISK",NA,"B_PRVMN_MICR",2,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",18,18,FALSE,FALSE,"[C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown." +"762","EUCAST 2026","human","human","MIC",NA,"B_PRVMN_MICR",2,"CLI","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown." +"763","EUCAST 2026","human","human","DISK",NA,"B_PRVMN_MICR",2,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"764","EUCAST 2026","human","human","MIC",NA,"B_PRVMN_MICR",2,"ETP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"765","EUCAST 2026","human","human","DISK",NA,"B_PRVMN_MICR",2,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",40,40,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"766","EUCAST 2026","human","human","MIC",NA,"B_PRVMN_MICR",2,"IPM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"767","EUCAST 2026","human","human","DISK",NA,"B_PRVMN_MICR",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",36,36,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"768","EUCAST 2026","human","human","MIC",NA,"B_PRVMN_MICR",2,"MEM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"769","EUCAST 2026","human","human","DISK",NA,"B_PRVMN_MICR",2,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",28,28,FALSE,FALSE,"[E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result." +"770","EUCAST 2026","human","human","MIC",NA,"B_PRVMN_MICR",2,"MTR","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result." +"771","EUCAST 2026","human","human","DISK",NA,"B_PRVMN_MICR",2,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","1 unit",31,31,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"772","EUCAST 2026","human","human","MIC",NA,"B_PRVMN_MICR",2,"PEN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,0.03,0.03,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"773","EUCAST 2026","human","human","DISK",NA,"B_PRVMN_MICR",2,"SAM","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",36,36,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"774","EUCAST 2026","human","human","DISK",NA,"B_PRVMN_MICR",2,"TZP","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"775","EUCAST 2026","human","human","DISK",NA,"B_PRVMN_MICR",2,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",19,19,FALSE,FALSE,NA +"776","EUCAST 2026","human","human","MIC",NA,"B_PRVMN_MICR",2,"VAN","Anaerobic bacteria_G-positive (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"777","EUCAST 2026","human","human","DISK",NA,"B_PRVTL",3,"AMC","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"778","EUCAST 2026","human","human","DISK",NA,"B_PRVTL",3,"AMP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"779","EUCAST 2026","human","human","MIC",NA,"B_PRVTL",3,"AMP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"780","EUCAST 2026","human","human","MIC",NA,"B_PRVTL",3,"AMX","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"781","EUCAST 2026","human","human","DISK",NA,"B_PRVTL",3,"CLI","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",31,31,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading." +"782","EUCAST 2026","human","human","MIC",NA,"B_PRVTL",3,"CLI","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"783","EUCAST 2026","human","human","DISK",NA,"B_PRVTL",3,"ETP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",29,29,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"784","EUCAST 2026","human","human","MIC",NA,"B_PRVTL",3,"ETP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"785","EUCAST 2026","human","human","DISK",NA,"B_PRVTL",3,"IPM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"786","EUCAST 2026","human","human","MIC",NA,"B_PRVTL",3,"IPM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"787","EUCAST 2026","human","human","DISK",NA,"B_PRVTL",3,"MEM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",34,34,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"788","EUCAST 2026","human","human","MIC",NA,"B_PRVTL",3,"MEM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"789","EUCAST 2026","human","human","DISK",NA,"B_PRVTL",3,"MTR","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",22,22,FALSE,FALSE,"[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result." +"790","EUCAST 2026","human","human","MIC",NA,"B_PRVTL",3,"MTR","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[3] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result." +"791","EUCAST 2026","human","human","DISK",NA,"B_PRVTL",3,"PEN","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","1 unit",20,20,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"792","EUCAST 2026","human","human","MIC",NA,"B_PRVTL",3,"PEN","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"793","EUCAST 2026","human","human","DISK",NA,"B_PRVTL",3,"SAM","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"794","EUCAST 2026","human","human","DISK",NA,"B_PRVTL",3,"TZP","Anaerobic bacteria_G-negative (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",26,26,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"795","EUCAST 2026","human","human","DISK","systemic infections","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"796","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",15,15,FALSE,FALSE,NA +"797","EUCAST 2026","human","human","MIC","systemic infections","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,16,16,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"798","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,16,16,FALSE,FALSE,NA +"799","EUCAST 2026","human","human","DISK",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,18,FALSE,FALSE,NA +"800","EUCAST 2026","human","human","MIC",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,16,FALSE,FALSE,NA +"801","EUCAST 2026","human","human","DISK",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",50,17,FALSE,FALSE,NA +"802","EUCAST 2026","human","human","MIC",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,8,FALSE,FALSE,NA +"803","EUCAST 2026","human","human","DISK",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,26,FALSE,FALSE,NA +"804","EUCAST 2026","human","human","MIC",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,0.5,FALSE,FALSE,NA +"805","EUCAST 2026","human","human","MIC",NA,"B_PSDMN",3,"COL","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)." +"806","EUCAST 2026","human","human","DISK",NA,"B_PSDMN",3,"DOR","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",50,22,FALSE,FALSE,NA +"807","EUCAST 2026","human","human","MIC",NA,"B_PSDMN",3,"DOR","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,2,FALSE,FALSE,NA +"808","EUCAST 2026","human","human","DISK",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,21,FALSE,FALSE,NA +"809","EUCAST 2026","human","human","MIC",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,8,FALSE,FALSE,NA +"810","EUCAST 2026","human","human","DISK",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",50,20,FALSE,FALSE,NA +"811","EUCAST 2026","human","human","MIC",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,4,FALSE,FALSE,NA +"812","EUCAST 2026","human","human","DISK",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,18,FALSE,FALSE,NA +"813","EUCAST 2026","human","human","MIC",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,2,FALSE,FALSE,NA +"814","EUCAST 2026","human","human","DISK","indications other than meningitis","B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",24,18,FALSE,FALSE,NA +"815","EUCAST 2026","human","human","MIC","indications other than meningitis","B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,2,8,FALSE,FALSE,NA +"816","EUCAST 2026","human","human","DISK",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,18,FALSE,FALSE,NA +"817","EUCAST 2026","human","human","MIC",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,16,FALSE,FALSE,NA +"818","EUCAST 2026","human","human","DISK",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","75/10 mcg",50,18,FALSE,FALSE,NA +"819","EUCAST 2026","human","human","MIC",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,16,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"820","EUCAST 2026","human","human","DISK","systemic infections","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"821","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",18,18,FALSE,FALSE,NA +"822","EUCAST 2026","human","human","MIC","systemic infections","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"823","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"824","EUCAST 2026","human","human","DISK",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",50,18,FALSE,FALSE,NA +"825","EUCAST 2026","human","human","MIC",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,16,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"826","EUCAST 2026","human","human","DISK","Topical","B_PSDMN_AERG",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",26,26,FALSE,FALSE,NA +"827","EUCAST 2026","human","human","MIC","Topical","B_PSDMN_AERG",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"828","EUCAST 2026","human","human","MIC","Topical","B_PSDMN_AERG",2,"COL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA +"829","EUCAST 2026","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","10/4 mcg",17,17,FALSE,FALSE,NA +"830","EUCAST 2026","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L." +"831","EUCAST 2026","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","30/10 mcg",23,23,FALSE,FALSE,"[4] See table of dosages for dosing for different indications." +"832","EUCAST 2026","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [4] See table of dosages for dosing for different indications." +"833","EUCAST 2026","human","human","DISK",NA,"B_PSDMN_AERG",2,"FDC","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",22,22,FALSE,FALSE,NA +"834","EUCAST 2026","human","human","MIC",NA,"B_PSDMN_AERG",2,"FDC","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[2] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/." +"835","EUCAST 2026","human","human","DISK","Topical","B_PSDMN_AERG",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",15,15,FALSE,FALSE,NA +"836","EUCAST 2026","human","human","MIC","Topical","B_PSDMN_AERG",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,NA +"837","EUCAST 2026","human","human","DISK",NA,"B_PSDMN_AERG",2,"IMR","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","10/25 mcg",22,22,FALSE,FALSE,NA +"838","EUCAST 2026","human","human","MIC",NA,"B_PSDMN_AERG",2,"IMR","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L." +"839","EUCAST 2026","human","human","DISK","Topical","B_PSDMN_AERG",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",18,18,FALSE,FALSE,NA +"840","EUCAST 2026","human","human","MIC","Topical","B_PSDMN_AERG",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"841","EUCAST 2026","human","human","DISK","indications other than meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",20,14,FALSE,FALSE,NA +"842","EUCAST 2026","human","human","DISK","meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",20,20,FALSE,FALSE,NA +"843","EUCAST 2026","human","human","MIC","indications other than meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,2,8,FALSE,FALSE,NA +"844","EUCAST 2026","human","human","MIC","meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"845","EUCAST 2026","human","human","DISK",NA,"B_PSDMN_AERG",2,"MEV","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)","20/10 mcg",14,14,FALSE,FALSE,NA +"846","EUCAST 2026","human","human","MIC",NA,"B_PSDMN_AERG",2,"MEV","Pseudomonas (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L." +"847","EUCAST 2026","human","human","MIC","Topical","B_PSDMN_AERG",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"848","EUCAST 2026","human","human","DISK","Topical","B_PSDMN_AERG",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",18,18,FALSE,FALSE,NA +"849","EUCAST 2026","human","human","MIC","Topical","B_PSDMN_AERG",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"850","EUCAST 2026","human","human","DISK",NA,"B_PSTRL",3,"AMC","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)","2/1 mcg",15,15,FALSE,FALSE,NA +"851","EUCAST 2026","human","human","MIC",NA,"B_PSTRL",3,"AMC","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"852","EUCAST 2026","human","human","MIC",NA,"B_PSTRL",3,"AMP","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"853","EUCAST 2026","human","human","MIC",NA,"B_PSTRL",3,"AMX","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"854","EUCAST 2026","human","human","DISK",NA,"B_PSTRL",3,"CIP","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B." +"855","EUCAST 2026","human","human","MIC",NA,"B_PSTRL",3,"CIP","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA +"856","EUCAST 2026","human","human","DISK",NA,"B_PSTRL",3,"CTX","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",26,26,FALSE,FALSE,NA +"857","EUCAST 2026","human","human","MIC",NA,"B_PSTRL",3,"CTX","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)",NA,0.03,0.03,FALSE,FALSE,NA +"858","EUCAST 2026","human","human","MIC",NA,"B_PSTRL",3,"DOX","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"859","EUCAST 2026","human","human","DISK",NA,"B_PSTRL",3,"LVX","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B." +"860","EUCAST 2026","human","human","MIC",NA,"B_PSTRL",3,"LVX","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA +"861","EUCAST 2026","human","human","DISK","screen only","B_PSTRL",3,"NAL","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",23,23,FALSE,FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"862","EUCAST 2026","human","human","DISK",NA,"B_PSTRL",3,"PEN","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)","1 unit",17,17,FALSE,FALSE,NA +"863","EUCAST 2026","human","human","MIC",NA,"B_PSTRL",3,"PEN","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"864","EUCAST 2026","human","human","DISK",NA,"B_PSTRL",3,"SXT","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"865","EUCAST 2026","human","human","MIC",NA,"B_PSTRL",3,"SXT","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"866","EUCAST 2026","human","human","DISK","screen only","B_PSTRL",3,"TCY","Pasteurella (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",24,24,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test." +"867","EUCAST 2026","human","human","DISK",NA,"B_SERRT",3,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",50,15,FALSE,FALSE,"[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"868","EUCAST 2026","human","human","MIC",NA,"B_SERRT",3,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,2,FALSE,FALSE,"[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"869","EUCAST 2026","human","human","MIC",NA,"B_SLMNL",3,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species." +"870","EUCAST 2026","human","human","DISK",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",50,16,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"871","EUCAST 2026","human","human","MIC",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,2,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"872","EUCAST 2026","human","human","MIC",NA,"B_STPHY",3,"AZM","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"873","EUCAST 2026","human","human","DISK",NA,"B_STPHY",3,"CLI","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",22,22,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy""." +"874","EUCAST 2026","human","human","MIC",NA,"B_STPHY",3,"CLI","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy""." +"875","EUCAST 2026","human","human","MIC",NA,"B_STPHY",3,"CLR","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"876","EUCAST 2026","human","human","MIC",NA,"B_STPHY",3,"DAL","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems." +"877","EUCAST 2026","human","human","MIC",NA,"B_STPHY",3,"DOX","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"878","EUCAST 2026","human","human","DISK",NA,"B_STPHY",3,"ERY","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",21,21,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"879","EUCAST 2026","human","human","MIC",NA,"B_STPHY",3,"ERY","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"880","EUCAST 2026","human","human","DISK",NA,"B_STPHY",3,"FUS","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",24,24,FALSE,FALSE,NA +"881","EUCAST 2026","human","human","MIC",NA,"B_STPHY",3,"FUS","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"882","EUCAST 2026","human","human","DISK",NA,"B_STPHY",3,"LNZ","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",21,21,FALSE,FALSE,NA +"883","EUCAST 2026","human","human","MIC",NA,"B_STPHY",3,"LNZ","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA +"884","EUCAST 2026","human","human","DISK",NA,"B_STPHY",3,"MNO","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",23,23,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"885","EUCAST 2026","human","human","MIC",NA,"B_STPHY",3,"MNO","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"886","EUCAST 2026","human","human","DISK","screen only","B_STPHY",3,"NOR","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",17,17,FALSE,FALSE,"[D] | [D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"887","EUCAST 2026","human","human","DISK",NA,"B_STPHY",3,"QDA","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",21,21,FALSE,FALSE,NA +"888","EUCAST 2026","human","human","MIC",NA,"B_STPHY",3,"QDA","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"889","EUCAST 2026","human","human","MIC",NA,"B_STPHY",3,"RXT","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"890","EUCAST 2026","human","human","DISK",NA,"B_STPHY",3,"SXT","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",24,24,FALSE,FALSE,"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"891","EUCAST 2026","human","human","MIC",NA,"B_STPHY",3,"SXT","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"892","EUCAST 2026","human","human","DISK",NA,"B_STPHY",3,"TCY","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",22,22,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"893","EUCAST 2026","human","human","MIC",NA,"B_STPHY",3,"TCY","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"894","EUCAST 2026","human","human","DISK",NA,"B_STPHY",3,"TGC","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",19,19,FALSE,FALSE,"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"895","EUCAST 2026","human","human","MIC",NA,"B_STPHY",3,"TGC","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"896","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_STPHY",3,"TMP","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",19,19,TRUE,FALSE,NA +"897","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_STPHY",3,"TMP","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,TRUE,FALSE,NA +"898","EUCAST 2026","human","human","DISK",NA,"B_STPHY",3,"TZD","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",20,20,FALSE,FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid." +"899","EUCAST 2026","human","human","MIC",NA,"B_STPHY",3,"TZD","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid." +"900","EUCAST 2026","human","human","DISK",NA,"B_STPHY_AURS",2,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"901","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,16,16,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"902","EUCAST 2026","human","human","DISK",NA,"B_STPHY_AURS",2,"BPR","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",17,17,FALSE,FALSE,"[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing." +"903","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"BPR","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[9] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing." +"904","EUCAST 2026","human","human","DISK","Topical","B_STPHY_AURS",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",18,18,FALSE,FALSE,NA +"905","EUCAST 2026","human","human","MIC","Topical","B_STPHY_AURS",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,16,16,FALSE,FALSE,NA +"906","EUCAST 2026","human","human","DISK",NA,"B_STPHY_AURS",2,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"907","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,2,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"908","EUCAST 2026","human","human","MIC","Topical","B_STPHY_AURS",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"909","EUCAST 2026","human","human","DISK","indications other than pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",20,17,FALSE,FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing." +"910","EUCAST 2026","human","human","DISK","pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",20,20,FALSE,FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing." +"911","EUCAST 2026","human","human","MIC","indications other than pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,1,2,FALSE,FALSE,"[7] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing." +"912","EUCAST 2026","human","human","MIC","pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[7] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing." +"913","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"DAP","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"914","EUCAST 2026","human","human","MIC","community-acquired pneumonia","B_STPHY_AURS",2,"DFX","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.016,0.016,FALSE,FALSE,NA +"915","EUCAST 2026","human","human","MIC","skin and skin structure infections","B_STPHY_AURS",2,"DFX","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"916","EUCAST 2026","human","human","DISK",NA,"B_STPHY_AURS",2,"ERV","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","20 mcg",20,20,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test." +"917","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"ERV","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"918","EUCAST 2026","human","human","DISK","screen only","B_STPHY_AURS",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",22,22,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant." +"919","EUCAST 2026","human","human","DISK","Topical","B_STPHY_AURS",2,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",23,23,FALSE,FALSE,NA +"920","EUCAST 2026","human","human","MIC","Topical","B_STPHY_AURS",2,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"921","EUCAST 2026","human","human","DISK",NA,"B_STPHY_AURS",2,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"922","EUCAST 2026","human","human","DISK","Topical","B_STPHY_AURS",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",18,18,FALSE,FALSE,NA +"923","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"924","EUCAST 2026","human","human","MIC","Topical","B_STPHY_AURS",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"925","EUCAST 2026","human","human","DISK",NA,"B_STPHY_AURS",2,"LMU","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",23,23,FALSE,FALSE,NA +"926","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"LMU","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"927","EUCAST 2026","human","human","DISK",NA,"B_STPHY_AURS",2,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,22,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"928","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,1,FALSE,FALSE,NA +"929","EUCAST 2026","human","human","MIC","Topical","B_STPHY_AURS",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"930","EUCAST 2026","human","human","DISK",NA,"B_STPHY_AURS",2,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",25,25,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | [3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents." +"931","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents." +"932","EUCAST 2026","human","human","DISK","Topical","B_STPHY_AURS",2,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","200 mcg",30,30,FALSE,FALSE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used." +"933","EUCAST 2026","human","human","MIC","Topical","B_STPHY_AURS",2,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used." +"934","EUCAST 2026","human","human","DISK","Topical","B_STPHY_AURS",2,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",14,14,FALSE,FALSE,NA +"935","EUCAST 2026","human","human","MIC","Topical","B_STPHY_AURS",2,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"936","EUCAST 2026","human","human","DISK","Topical","B_STPHY_AURS",2,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",17,17,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)." +"937","EUCAST 2026","human","human","MIC","Topical","B_STPHY_AURS",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"938","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"ORI","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems." +"939","EUCAST 2026","human","human","DISK",NA,"B_STPHY_AURS",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","1 unit",26,26,FALSE,FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase." +"940","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins." +"941","EUCAST 2026","human","human","DISK",NA,"B_STPHY_AURS",2,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",26,26,FALSE,FALSE,NA +"942","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA +"943","EUCAST 2026","human","human","MIC","Topical","B_STPHY_AURS",2,"RTP","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"944","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"TEC","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"945","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"TLV","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems." +"946","EUCAST 2026","human","human","DISK",NA,"B_STPHY_AURS",2,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"947","EUCAST 2026","human","human","DISK","Topical","B_STPHY_AURS",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",18,18,FALSE,FALSE,NA +"948","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"949","EUCAST 2026","human","human","MIC","Topical","B_STPHY_AURS",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"950","EUCAST 2026","human","human","MIC",NA,"B_STPHY_AURS",2,"VAN","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"951","EUCAST 2026","human","human","DISK","screen only","B_STPHY_CGLN",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans." +"952","EUCAST 2026","human","human","DISK",NA,"B_STPHY_CONS",2.5,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"953","EUCAST 2026","human","human","MIC",NA,"B_STPHY_CONS",2.5,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,16,16,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"954","EUCAST 2026","human","human","DISK",NA,"B_STPHY_CONS",2.5,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,22,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"955","EUCAST 2026","human","human","MIC",NA,"B_STPHY_CONS",2.5,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,2,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"956","EUCAST 2026","human","human","DISK","screen only","B_STPHY_CONS",2.5,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",22,22,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant." +"957","EUCAST 2026","human","human","DISK",NA,"B_STPHY_CONS",2.5,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",22,22,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"958","EUCAST 2026","human","human","MIC",NA,"B_STPHY_CONS",2.5,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"959","EUCAST 2026","human","human","DISK",NA,"B_STPHY_CONS",2.5,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,24,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"960","EUCAST 2026","human","human","MIC",NA,"B_STPHY_CONS",2.5,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,1,FALSE,FALSE,NA +"961","EUCAST 2026","human","human","DISK",NA,"B_STPHY_CONS",2.5,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",28,28,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | [3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents." +"962","EUCAST 2026","human","human","MIC",NA,"B_STPHY_CONS",2.5,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents." +"963","EUCAST 2026","human","human","DISK",NA,"B_STPHY_CONS",2.5,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",30,30,FALSE,FALSE,NA +"964","EUCAST 2026","human","human","MIC",NA,"B_STPHY_CONS",2.5,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA +"965","EUCAST 2026","human","human","MIC",NA,"B_STPHY_CONS",2.5,"TEC","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA +"966","EUCAST 2026","human","human","DISK",NA,"B_STPHY_CONS",2.5,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",20,20,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"967","EUCAST 2026","human","human","MIC",NA,"B_STPHY_CONS",2.5,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"968","EUCAST 2026","human","human","MIC",NA,"B_STPHY_CONS",2.5,"VAN","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA +"969","EUCAST 2026","human","human","DISK","screen only","B_STPHY_EPDR",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",27,27,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant." +"970","EUCAST 2026","human","human","DISK","screen only","B_STPHY_INTR",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans." +"971","EUCAST 2026","human","human","DISK","screen only","B_STPHY_LGDN",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",27,27,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant." +"972","EUCAST 2026","human","human","DISK",NA,"B_STPHY_LGDN",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","1 unit",26,26,FALSE,FALSE,NA +"973","EUCAST 2026","human","human","MIC",NA,"B_STPHY_LGDN",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA +"974","EUCAST 2026","human","human","DISK","screen only","B_STPHY_PSDN",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans." +"975","EUCAST 2026","human","human","DISK","screen only","B_STPHY_SCHL",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans." +"976","EUCAST 2026","human","human","DISK",NA,"B_STPHY_SPRP",2,"AMP","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",18,18,FALSE,FALSE,"[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)." +"977","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_STPHY_SPRP",2,"GEP","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,TRUE,FALSE,NA +"978","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_STPHY_SPRP",2,"NIT","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)","100 mcg",13,13,TRUE,FALSE,NA +"979","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_STPHY_SPRP",2,"NIT","Staphylococcus (file: Clinical Breakpoint Tables v. 16.1)",NA,64,64,TRUE,FALSE,NA +"980","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"AZM","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and" +"981","EUCAST 2026","human","human","DISK","Topical","B_STRPT_ABCG",2.5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",21,21,FALSE,FALSE,NA +"982","EUCAST 2026","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,NA +"983","EUCAST 2026","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"984","EUCAST 2026","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",17,17,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known." +"985","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known." +"986","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and" +"987","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"988","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAP","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"989","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.03,0.03,FALSE,FALSE,NA +"990","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DOX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"991","EUCAST 2026","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",21,21,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and" +"992","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and" +"993","EUCAST 2026","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,32,32,FALSE,FALSE,NA +"994","EUCAST 2026","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",19,19,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"995","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"996","EUCAST 2026","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,17,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"997","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,2,FALSE,FALSE,NA +"998","EUCAST 2026","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"999","EUCAST 2026","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",19,19,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"1000","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"1001","EUCAST 2026","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",23,23,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"1002","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"1003","EUCAST 2026","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"1004","EUCAST 2026","human","human","DISK","screen only","B_STRPT_ABCG",2.5,"NOR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",12,12,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"1005","EUCAST 2026","human","human","DISK","Topical","B_STRPT_ABCG",2.5,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",12,12,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)." +"1006","EUCAST 2026","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA +"1007","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ORI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"1008","EUCAST 2026","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","1 unit",23,23,FALSE,FALSE,NA +"1009","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.03,0.03,FALSE,FALSE,NA +"1010","EUCAST 2026","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",21,21,FALSE,FALSE,NA +"1011","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"1012","EUCAST 2026","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"RTP","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA +"1013","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and" +"1014","EUCAST 2026","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",16,16,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1015","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1016","EUCAST 2026","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",23,23,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"1017","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"1018","EUCAST 2026","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"1019","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"1020","EUCAST 2026","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",19,19,FALSE,FALSE,"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"1021","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"1022","EUCAST 2026","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TZD","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",18,18,FALSE,FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"1023","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TZD","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"1024","EUCAST 2026","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",13,13,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"1025","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"1026","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"DAL","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"1027","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"DFX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.03,0.03,FALSE,FALSE,NA +"1028","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"ORI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"1029","EUCAST 2026","human","human","DISK",NA,"B_STRPT_ANGN_ANGN",1,"TZD","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",18,18,FALSE,FALSE,NA +"1030","EUCAST 2026","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"TZD","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"1031","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","100 mcg",15,15,TRUE,FALSE,NA +"1032","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,64,64,TRUE,FALSE,NA +"1033","EUCAST 2026","human","human","DISK",NA,"B_STRPT_GRPB",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)","1 unit",18,18,FALSE,FALSE,NA +"1034","EUCAST 2026","human","human","MIC",NA,"B_STRPT_GRPB",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA +"1035","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMC","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,1,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit." +"1036","EUCAST 2026","human","human","DISK","indications other than endocarditis and meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",22,19,FALSE,FALSE,NA +"1037","EUCAST 2026","human","human","MIC","indications other than endocarditis and meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,1,FALSE,FALSE,NA +"1038","EUCAST 2026","human","human","MIC","endocarditis and meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA +"1039","EUCAST 2026","human","human","MIC","endocarditis and meningitis","B_STRPT_PNMN",2,"AMX","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA +"1040","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMX","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,1,FALSE,FALSE,NA +"1041","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"AZM","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"1042","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"BPR","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"1043","EUCAST 2026","human","human","DISK",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",50,28,FALSE,FALSE,NA +"1044","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,0.5,FALSE,FALSE,NA +"1045","EUCAST 2026","human","human","DISK","Topical","B_STRPT_PNMN",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",21,21,FALSE,FALSE,NA +"1046","EUCAST 2026","human","human","MIC","Topical","B_STRPT_PNMN",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,NA +"1047","EUCAST 2026","human","human","MIC","Topical","B_STRPT_PNMN",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA +"1048","EUCAST 2026","human","human","DISK",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",19,19,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"1049","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"1050","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLR","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"1051","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPD","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"1052","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPT","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"1053","EUCAST 2026","human","human","MIC","indications other than endocarditis and meningitis","B_STRPT_PNMN",2,"CRO","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,2,FALSE,FALSE,NA +"1054","EUCAST 2026","human","human","MIC","endocarditis and meningitis","B_STRPT_PNMN",2,"CRO","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"1055","EUCAST 2026","human","human","MIC","indications other than endocarditis and meningitis","B_STRPT_PNMN",2,"CTX","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,2,FALSE,FALSE,NA +"1056","EUCAST 2026","human","human","MIC","endocarditis and meningitis","B_STRPT_PNMN",2,"CTX","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"1057","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,1,FALSE,FALSE,NA +"1058","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"1059","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"DOR","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"1060","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"DOX","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"1061","EUCAST 2026","human","human","DISK",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",22,22,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"1062","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"1063","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"ETP","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"1064","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"FEP","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,1,2,FALSE,FALSE,NA +"1065","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"IPM","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"1066","EUCAST 2026","human","human","DISK",NA,"B_STRPT_PNMN",2,"LMU","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",12,12,FALSE,FALSE,NA +"1067","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"LMU","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"1068","EUCAST 2026","human","human","DISK",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",22,22,FALSE,FALSE,NA +"1069","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"1070","EUCAST 2026","human","human","DISK",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",50,16,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"1071","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,2,FALSE,FALSE,NA +"1072","EUCAST 2026","human","human","MIC","Topical","B_STRPT_PNMN",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"1073","EUCAST 2026","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"1074","EUCAST 2026","human","human","MIC","meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"1075","EUCAST 2026","human","human","DISK",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",22,22,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"1076","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"1077","EUCAST 2026","human","human","DISK",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",24,24,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"1078","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"1079","EUCAST 2026","human","human","DISK","screen only","B_STRPT_PNMN",2,"NOR","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",10,10,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"1080","EUCAST 2026","human","human","DISK","Topical","B_STRPT_PNMN",2,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",10,10,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)." +"1081","EUCAST 2026","human","human","MIC","Topical","B_STRPT_PNMN",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA +"1082","EUCAST 2026","human","human","DISK","screen only","B_STRPT_PNMN",2,"OXA","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","1 mcg",20,20,FALSE,FALSE,"[D] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below." +"1083","EUCAST 2026","human","human","MIC","indications other than endocarditis and meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,1,FALSE,FALSE,NA +"1084","EUCAST 2026","human","human","MIC","endocarditis and meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.06,0.06,FALSE,FALSE,NA +"1085","EUCAST 2026","human","human","DISK",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",22,22,FALSE,FALSE,NA +"1086","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA +"1087","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"RXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"1088","EUCAST 2026","human","human","DISK",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",15,15,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1089","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1090","EUCAST 2026","human","human","DISK",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",25,25,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"1091","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"1092","EUCAST 2026","human","human","DISK",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"1093","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"1094","EUCAST 2026","human","human","DISK",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"1095","EUCAST 2026","human","human","MIC",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"1096","EUCAST 2026","human","human","DISK","indications other than endocarditis","B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",21,15,FALSE,FALSE,NA +"1097","EUCAST 2026","human","human","DISK","endocarditis","B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",21,21,FALSE,FALSE,NA +"1098","EUCAST 2026","human","human","MIC","indications other than endocarditis","B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,2,FALSE,FALSE,NA +"1099","EUCAST 2026","human","human","MIC","endocarditis","B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"1100","EUCAST 2026","human","human","MIC","indications other than endocarditis","B_STRPT_VIRI",2.5,"AMX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,2,FALSE,FALSE,NA +"1101","EUCAST 2026","human","human","MIC","endocarditis","B_STRPT_VIRI",2.5,"AMX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"1102","EUCAST 2026","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)","2 mcg",19,19,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"1103","EUCAST 2026","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"1104","EUCAST 2026","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",27,27,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins." +"1105","EUCAST 2026","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"1106","EUCAST 2026","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",23,23,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins." +"1107","EUCAST 2026","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"1108","EUCAST 2026","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",26,26,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins." +"1109","EUCAST 2026","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"1110","EUCAST 2026","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"DOR","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"1111","EUCAST 2026","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"ERV","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)","20 mcg",17,17,FALSE,FALSE,NA +"1112","EUCAST 2026","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ERV","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA +"1113","EUCAST 2026","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ETP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"1114","EUCAST 2026","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",25,25,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins." +"1115","EUCAST 2026","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"1116","EUCAST 2026","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"IMR","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit." +"1117","EUCAST 2026","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"IPM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"1118","EUCAST 2026","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"MEM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"1119","EUCAST 2026","human","human","DISK","screen only","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)","1 unit",21,21,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"1120","EUCAST 2026","human","human","DISK","indications other than endocarditis","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)","1 unit",21,12,FALSE,FALSE,NA +"1121","EUCAST 2026","human","human","DISK","endocarditis","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)","1 unit",21,21,FALSE,FALSE,NA +"1122","EUCAST 2026","human","human","DISK","endocarditis, in combination with other antimicrobial treatment","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)","1 unit",12,12,FALSE,FALSE,"[B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1123","EUCAST 2026","human","human","MIC","screen only","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"1124","EUCAST 2026","human","human","MIC","indications other than endocarditis","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,1,FALSE,FALSE,NA +"1125","EUCAST 2026","human","human","MIC","endocarditis","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"1126","EUCAST 2026","human","human","MIC","endocarditis, in combination with other antimicrobial treatment","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1127","EUCAST 2026","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",16,16,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"1128","EUCAST 2026","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"1129","EUCAST 2026","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"1130","EUCAST 2026","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"1131","EUCAST 2026","human","human","DISK",NA,"B_VIBRI",3,"AZM","Vibrio (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",16,16,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test." +"1132","EUCAST 2026","human","human","MIC",NA,"B_VIBRI",3,"AZM","Vibrio (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,NA +"1133","EUCAST 2026","human","human","DISK",NA,"B_VIBRI",3,"CAZ","Vibrio (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",22,22,FALSE,FALSE,NA +"1134","EUCAST 2026","human","human","MIC",NA,"B_VIBRI",3,"CAZ","Vibrio (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"1135","EUCAST 2026","human","human","DISK",NA,"B_VIBRI",3,"CIP","Vibrio (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",23,23,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test." +"1136","EUCAST 2026","human","human","MIC",NA,"B_VIBRI",3,"CIP","Vibrio (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"1137","EUCAST 2026","human","human","DISK",NA,"B_VIBRI",3,"CTX","Vibrio (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",21,21,FALSE,FALSE,NA +"1138","EUCAST 2026","human","human","MIC",NA,"B_VIBRI",3,"CTX","Vibrio (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"1139","EUCAST 2026","human","human","MIC",NA,"B_VIBRI",3,"DOX","Vibrio (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"1140","EUCAST 2026","human","human","DISK","screen only","B_VIBRI",3,"ERY","Vibrio (file: Clinical Breakpoint Tables v. 16.1)","15 mcg",12,12,FALSE,FALSE,"[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test." +"1141","EUCAST 2026","human","human","DISK",NA,"B_VIBRI",3,"LVX","Vibrio (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",23,23,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test." +"1142","EUCAST 2026","human","human","MIC",NA,"B_VIBRI",3,"LVX","Vibrio (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"1143","EUCAST 2026","human","human","DISK",NA,"B_VIBRI",3,"MEM","Vibrio (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",24,24,FALSE,FALSE,NA +"1144","EUCAST 2026","human","human","MIC",NA,"B_VIBRI",3,"MEM","Vibrio (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"1145","EUCAST 2026","human","human","DISK","screen only","B_VIBRI",3,"PEF","Vibrio (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",22,22,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test." +"1146","EUCAST 2026","human","human","DISK",NA,"B_VIBRI",3,"SXT","Vibrio (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",21,21,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1147","EUCAST 2026","human","human","MIC",NA,"B_VIBRI",3,"SXT","Vibrio (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1148","EUCAST 2026","human","human","DISK","screen only","B_VIBRI",3,"TCY","Vibrio (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",20,20,FALSE,FALSE,"[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test." +"1149","EUCAST 2026","human","human","DISK",NA,"B_VIBRI",3,"TZP","Vibrio (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",26,26,FALSE,FALSE,NA +"1150","EUCAST 2026","human","human","MIC",NA,"B_VIBRI",3,"TZP","Vibrio (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"1151","EUCAST 2026","human","human","DISK",NA,"B_[FAM]_MORGNLLC",4,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",50,19,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem." +"1152","EUCAST 2026","human","human","MIC",NA,"B_[FAM]_MORGNLLC",4,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,4,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem." +"1153","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","20/10 mcg",19,19,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"1154","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","20/10 mcg",50,19,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"1155","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","20/10 mcg",16,16,TRUE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"1156","EUCAST 2026","human","human","DISK","other indications","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","20/10 mcg",50,19,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"1157","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"1158","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"1159","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,32,32,TRUE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"1160","EUCAST 2026","human","human","MIC","other indications","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,8,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"1161","EUCAST 2026","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1162","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",18,18,FALSE,FALSE,NA +"1163","EUCAST 2026","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1164","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,NA +"1165","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",14,14,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"1166","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",14,14,TRUE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"1167","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"1168","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,TRUE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"1169","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"1170","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,8,FALSE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"1171","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,TRUE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"1172","EUCAST 2026","human","human","MIC","other indications","B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.001,8,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"1173","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",26,21,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes." +"1174","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,1,4,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes." +"1175","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AZA","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30/20 mcg",25,25,FALSE,FALSE,NA +"1176","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AZA","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L." +"1177","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",23,23,FALSE,FALSE,NA +"1178","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"1179","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",22,19,FALSE,FALSE,NA +"1180","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,1,4,FALSE,FALSE,NA +"1181","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",17,17,TRUE,FALSE,NA +"1182","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,TRUE,FALSE,NA +"1183","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",12,12,TRUE,FALSE,NA +"1184","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,16,16,TRUE,FALSE,NA +"1185","EUCAST 2026","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",17,17,FALSE,FALSE,NA +"1186","EUCAST 2026","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,16,16,FALSE,FALSE,NA +"1187","EUCAST 2026","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",25,22,FALSE,FALSE,NA +"1188","EUCAST 2026","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.5,FALSE,FALSE,NA +"1189","EUCAST 2026","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,"[2] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test." +"1190","EUCAST 2026","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,0.125,0.125,FALSE,FALSE,NA +"1191","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"COL","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)." +"1192","EUCAST 2026","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"COL","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"1193","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",21,21,TRUE,FALSE,NA +"1194","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,TRUE,FALSE,NA +"1195","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",23,23,FALSE,FALSE,NA +"1196","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"1197","EUCAST 2026","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",27,24,FALSE,FALSE,NA +"1198","EUCAST 2026","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",27,27,FALSE,FALSE,NA +"1199","EUCAST 2026","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,1,2,FALSE,FALSE,NA +"1200","EUCAST 2026","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"1201","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",23,23,FALSE,FALSE,NA +"1202","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"1203","EUCAST 2026","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",20,17,FALSE,FALSE,NA +"1204","EUCAST 2026","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",20,20,FALSE,FALSE,NA +"1205","EUCAST 2026","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,1,2,FALSE,FALSE,NA +"1206","EUCAST 2026","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,1,1,FALSE,FALSE,NA +"1207","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10/4 mcg",13,13,FALSE,FALSE,NA +"1208","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L." +"1209","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30/10 mcg",22,22,FALSE,FALSE,"[7] See table of dosages for dosing for different indications." +"1210","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[8] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [7] See table of dosages for dosing for different indications." +"1211","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"DOR","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",24,21,FALSE,FALSE,NA +"1212","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"DOR","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,1,2,FALSE,FALSE,NA +"1213","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",23,23,FALSE,FALSE,NA +"1214","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,NA +"1215","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FDC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",23,23,FALSE,FALSE,NA +"1216","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FDC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[4] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/." +"1217","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",27,24,FALSE,FALSE,NA +"1218","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,1,4,FALSE,FALSE,NA +"1219","EUCAST 2026","human","human","DISK","screen only","B_[ORD]_ENTRBCTR",5,"FOX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",19,19,FALSE,FALSE,"[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type." +"1220","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FPE","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30/20 mcg",22,22,FALSE,FALSE,NA +"1221","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FPE","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,4,4,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of enmetazobactam is fixed at 8 mg/L." +"1222","EUCAST 2026","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",17,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1223","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",17,17,FALSE,FALSE,NA +"1224","EUCAST 2026","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",17,17,FALSE,FALSE,NA +"1225","EUCAST 2026","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1226","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"1227","EUCAST 2026","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"1228","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"IMR","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10/25 mcg",22,22,FALSE,FALSE,NA +"1229","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"IMR","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L." +"1230","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",22,19,FALSE,FALSE,NA +"1231","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,2,4,FALSE,FALSE,NA +"1232","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",14,14,TRUE,FALSE,NA +"1233","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,16,16,TRUE,FALSE,NA +"1234","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",23,19,FALSE,FALSE,NA +"1235","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,1,FALSE,FALSE,NA +"1236","EUCAST 2026","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"1237","EUCAST 2026","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",22,16,FALSE,FALSE,NA +"1238","EUCAST 2026","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",22,22,FALSE,FALSE,NA +"1239","EUCAST 2026","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,2,8,FALSE,FALSE,NA +"1240","EUCAST 2026","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"1241","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"MEV","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","20/10 mcg",20,20,FALSE,FALSE,NA +"1242","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MEV","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L." +"1243","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",22,22,FALSE,FALSE,"[3] Fluoroquinolone breakpoints are available for other agents." +"1244","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,"[3] Fluoroquinolone breakpoints are available for other agents." +"1245","EUCAST 2026","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",12,12,FALSE,FALSE,NA +"1246","EUCAST 2026","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,NA +"1247","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",24,24,TRUE,FALSE,NA +"1248","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,TRUE,FALSE,NA +"1249","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",24,22,FALSE,FALSE,NA +"1250","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.5,FALSE,FALSE,NA +"1251","EUCAST 2026","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,0.25,0.25,FALSE,FALSE,NA +"1252","EUCAST 2026","human","human","DISK","screen only","B_[ORD]_ENTRBCTR",5,"PEF","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",24,24,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp." +"1253","EUCAST 2026","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"PEF","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","5 mcg",24,24,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)." +"1254","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30 mcg",20,20,FALSE,FALSE,NA +"1255","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,NA +"1256","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",14,14,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"1257","EUCAST 2026","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10/10 mcg",14,14,TRUE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"1258","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"1259","EUCAST 2026","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,TRUE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"1260","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","1.25/23.75 mcg",15,15,FALSE,FALSE,"[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1261","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,0.5,0.5,FALSE,FALSE,"[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1262","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","75/10 mcg",23,20,FALSE,FALSE,NA +"1263","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,16,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"1264","EUCAST 2026","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",16,16,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1265","EUCAST 2026","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",16,16,FALSE,FALSE,NA +"1266","EUCAST 2026","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 16.1)","10 mcg",16,16,FALSE,FALSE,NA +"1267","EUCAST 2026","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1268","EUCAST 2026","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"1269","EUCAST 2026","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 16.1)",NA,2,2,FALSE,FALSE,NA +"1270","EUCAST 2026","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)","30/6 mcg",20,20,FALSE,FALSE,NA +"1271","EUCAST 2026","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 16.1)",NA,8,8,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"1272","EUCAST 2026","human","human","MIC",NA,"F_ASPRG_FLAVS",2,"ISV","6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,NA +"1273","EUCAST 2026","human","human","MIC",NA,"F_ASPRG_FLAVS",2,"ITR","6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,"[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2 mg/L) is ensured via TDM." +"1274","EUCAST 2026","human","human","MIC",NA,"F_ASPRG_MGTS",2,"AMB","6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,NA +"1275","EUCAST 2026","human","human","MIC",NA,"F_ASPRG_MGTS",2,"ISV","6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,NA +"1276","EUCAST 2026","human","human","MIC",NA,"F_ASPRG_MGTS",2,"ITR","6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,"[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2 mg/L) is ensured via TDM." +"1277","EUCAST 2026","human","human","MIC",NA,"F_ASPRG_MGTS",2,"POS","6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.125,0.125,FALSE,FALSE,NA +"1278","EUCAST 2026","human","human","MIC",NA,"F_ASPRG_MGTS",2,"VOR","6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,"[6] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), voriconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2-3 mg/L) is ensured via TDM." +"1279","EUCAST 2026","human","human","MIC",NA,"F_ASPRG_NDLN",2,"ISV","6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.5,0.5,FALSE,FALSE,NA +"1280","EUCAST 2026","human","human","MIC",NA,"F_ASPRG_NDLN",2,"ITR","6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,"[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2 mg/L) is ensured via TDM." +"1281","EUCAST 2026","human","human","MIC",NA,"F_ASPRG_NDLN",2,"VOR","6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,"[6] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), voriconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2-3 mg/L) is ensured via TDM." +"1282","EUCAST 2026","human","human","MIC",NA,"F_ASPRG_NIGR",2,"AMB","6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,NA +"1283","EUCAST 2026","human","human","MIC",NA,"F_ASPRG_TERRS",2,"ISV","6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,NA +"1284","EUCAST 2026","human","human","MIC",NA,"F_ASPRG_TERRS",2,"ITR","6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,"[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2 mg/L) is ensured via TDM." +"1285","EUCAST 2026","human","human","MIC",NA,"F_ASPRG_TERRS",2,"POS","6. Aspergillus (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.125,0.125,FALSE,FALSE,NA +"1286","EUCAST 2026","human","human","MIC",NA,"F_CANDD_ALBC",2,"AMB","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,NA +"1287","EUCAST 2026","human","human","MIC",NA,"F_CANDD_ALBC",2,"ANI","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.016,0.016,FALSE,FALSE,NA +"1288","EUCAST 2026","human","human","MIC",NA,"F_CANDD_ALBC",2,"FLU","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,2,4,FALSE,FALSE,NA +"1289","EUCAST 2026","human","human","MIC",NA,"F_CANDD_ALBC",2,"ITR","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.06,0.06,FALSE,FALSE,NA +"1290","EUCAST 2026","human","human","MIC",NA,"F_CANDD_ALBC",2,"MIF","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.03,0.03,FALSE,FALSE,NA +"1291","EUCAST 2026","human","human","MIC",NA,"F_CANDD_ALBC",2,"POS","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.06,0.06,FALSE,FALSE,NA +"1292","EUCAST 2026","human","human","MIC",NA,"F_CANDD_ALBC",2,"RZF","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.008,0.008,FALSE,FALSE,"[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method." +"1293","EUCAST 2026","human","human","MIC",NA,"F_CANDD_ALBC",2,"VOR","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.06,0.25,FALSE,FALSE,"[8] Strains with MIC values above the S/I breakpoint are rare or not yet reported. The identification and antifungal susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant. A clinical response of 76% was achieved in infections caused by the species listed below when MICs were lower than or equal to the epidemiological cut-offs. Therefore, wild type populations of C. albicans, C. dubliniensis, C. parapsilosis and C. tropicalis are considered susceptible." +"1294","EUCAST 2026","human","human","MIC",NA,"F_CANDD_DBLN",2,"AMB","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,NA +"1295","EUCAST 2026","human","human","MIC",NA,"F_CANDD_DBLN",2,"ANI","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.03,0.03,FALSE,FALSE,NA +"1296","EUCAST 2026","human","human","MIC",NA,"F_CANDD_DBLN",2,"FLU","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,2,4,FALSE,FALSE,NA +"1297","EUCAST 2026","human","human","MIC",NA,"F_CANDD_DBLN",2,"ITR","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.06,0.06,FALSE,FALSE,NA +"1298","EUCAST 2026","human","human","MIC",NA,"F_CANDD_DBLN",2,"MIF","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.06,0.06,FALSE,FALSE,NA +"1299","EUCAST 2026","human","human","MIC",NA,"F_CANDD_DBLN",2,"POS","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.06,0.06,FALSE,FALSE,NA +"1300","EUCAST 2026","human","human","MIC",NA,"F_CANDD_DBLN",2,"RZF","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.016,0.016,FALSE,FALSE,"[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method." +"1301","EUCAST 2026","human","human","MIC",NA,"F_CANDD_DBLN",2,"VOR","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.06,0.25,FALSE,FALSE,"[8] Strains with MIC values above the S/I breakpoint are rare or not yet reported. The identification and antifungal susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant. A clinical response of 76% was achieved in infections caused by the species listed below when MICs were lower than or equal to the epidemiological cut-offs. Therefore, wild type populations of C. albicans, C. dubliniensis, C. parapsilosis and C. tropicalis are considered susceptible." +"1302","EUCAST 2026","human","human","MIC",NA,"F_CANDD_PRPS",2,"AMB","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,NA +"1303","EUCAST 2026","human","human","MIC",NA,"F_CANDD_PRPS",2,"ANI","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,4,4,FALSE,FALSE,NA +"1304","EUCAST 2026","human","human","MIC",NA,"F_CANDD_PRPS",2,"FLU","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,2,4,FALSE,FALSE,NA +"1305","EUCAST 2026","human","human","MIC",NA,"F_CANDD_PRPS",2,"ITR","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.125,0.125,FALSE,FALSE,NA +"1306","EUCAST 2026","human","human","MIC",NA,"F_CANDD_PRPS",2,"MIF","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,4,4,FALSE,FALSE,NA +"1307","EUCAST 2026","human","human","MIC",NA,"F_CANDD_PRPS",2,"POS","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.06,0.06,FALSE,FALSE,NA +"1308","EUCAST 2026","human","human","MIC",NA,"F_CANDD_PRPS",2,"RZF","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,4,4,FALSE,FALSE,"[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method." +"1309","EUCAST 2026","human","human","MIC",NA,"F_CANDD_PRPS",2,"VOR","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.125,0.25,FALSE,FALSE,NA +"1310","EUCAST 2026","human","human","MIC",NA,"F_CANDD_TRPC",2,"AMB","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,NA +"1311","EUCAST 2026","human","human","MIC",NA,"F_CANDD_TRPC",2,"ANI","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.06,0.06,FALSE,FALSE,NA +"1312","EUCAST 2026","human","human","MIC",NA,"F_CANDD_TRPC",2,"FLU","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,2,4,FALSE,FALSE,NA +"1313","EUCAST 2026","human","human","MIC",NA,"F_CANDD_TRPC",2,"ITR","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.125,0.125,FALSE,FALSE,NA +"1314","EUCAST 2026","human","human","MIC",NA,"F_CANDD_TRPC",2,"MIF","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.06,0.06,FALSE,FALSE,NA +"1315","EUCAST 2026","human","human","MIC",NA,"F_CANDD_TRPC",2,"POS","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.06,0.06,FALSE,FALSE,NA +"1316","EUCAST 2026","human","human","MIC",NA,"F_CANDD_TRPC",2,"RZF","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.03,0.03,FALSE,FALSE,"[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method." +"1317","EUCAST 2026","human","human","MIC",NA,"F_CANDD_TRPC",2,"VOR","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.125,0.25,FALSE,FALSE,"[8] Strains with MIC values above the S/I breakpoint are rare or not yet reported. The identification and antifungal susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant. A clinical response of 76% was achieved in infections caused by the species listed below when MICs were lower than or equal to the epidemiological cut-offs. Therefore, wild type populations of C. albicans, C. dubliniensis, C. parapsilosis and C. tropicalis are considered susceptible." +"1318","EUCAST 2026","human","human","MIC",NA,"F_CNDDZ_AURS",2,"AMB","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.001,2,FALSE,FALSE,"[1] The entire C. auris wild-type population is in the I category. The Susceptible category (≤0.001 mg/L) is simply to avoid missclassification of any WT strains as ""S"" strains." +"1319","EUCAST 2026","human","human","MIC",NA,"F_CNDDZ_AURS",2,"ANI","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.25,0.25,FALSE,FALSE,NA +"1320","EUCAST 2026","human","human","MIC",NA,"F_CNDDZ_AURS",2,"MIF","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.25,0.25,FALSE,FALSE,NA +"1321","EUCAST 2026","human","human","MIC",NA,"F_CRYPT_NFRM",2,"AMB","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,NA +"1322","EUCAST 2026","human","human","MIC",NA,"F_NKSMY_BRTS",2,"AMB","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,NA +"1323","EUCAST 2026","human","human","MIC",NA,"F_NKSMY_BRTS",2,"ANI","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.06,0.06,FALSE,FALSE,NA +"1324","EUCAST 2026","human","human","MIC",NA,"F_NKSMY_BRTS",2,"FLU","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.001,16,FALSE,FALSE,"[4] The entire C. glabrata wild-type population is in the I category. MICs against C. glabrata should be interpreted as resistant when above 16 mg/L. Susceptible category (≤0.001 mg/L) is simply to avoid missclassification of any wild-typestrains as ""S"" strains." +"1325","EUCAST 2026","human","human","MIC",NA,"F_NKSMY_BRTS",2,"MIF","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.06,0.06,FALSE,FALSE,NA +"1326","EUCAST 2026","human","human","MIC",NA,"F_NKSMY_BRTS",2,"RZF","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.016,0.016,FALSE,FALSE,"[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method." +"1327","EUCAST 2026","human","human","MIC",NA,"F_PICHI_KDRV",2,"AMB","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,1,1,FALSE,FALSE,NA +"1328","EUCAST 2026","human","human","MIC",NA,"F_PICHI_KDRV",2,"ANI","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.06,0.06,FALSE,FALSE,NA +"1329","EUCAST 2026","human","human","MIC",NA,"F_PICHI_KDRV",2,"RZF","5. Yeast (file: Antifungal Clinical Breakpoint Table v. 12.1)",NA,0.03,0.03,FALSE,FALSE,"[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method." +"1330","EUCAST 2025","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"MEM","A.xylosoxidans (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",26,20,FALSE,FALSE,NA +"1331","EUCAST 2025","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"MEM","A.xylosoxidans (file: Clinical Breakpoint Tables v. 15.0)",NA,1,4,FALSE,FALSE,NA +"1332","EUCAST 2025","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"SXT","A.xylosoxidans (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",26,26,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1333","EUCAST 2025","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"SXT","A.xylosoxidans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1334","EUCAST 2025","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"TZP","A.xylosoxidans (file: Clinical Breakpoint Tables v. 15.0)","30/6 mcg",26,26,FALSE,FALSE,NA +"1335","EUCAST 2025","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"TZP","A.xylosoxidans (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"1336","EUCAST 2025","human","human","DISK","systemic infections","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",19,19,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1337","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",19,19,FALSE,FALSE,NA +"1338","EUCAST 2025","human","human","MIC","systemic infections","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1339","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,NA +"1340","EUCAST 2025","human","human","DISK",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,21,FALSE,FALSE,NA +"1341","EUCAST 2025","human","human","DISK","Topical","B_ACNTB",3,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",21,21,FALSE,FALSE,NA +"1342","EUCAST 2025","human","human","MIC",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,1,FALSE,FALSE,NA +"1343","EUCAST 2025","human","human","MIC","Topical","B_ACNTB",3,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"1344","EUCAST 2025","human","human","MIC",NA,"B_ACNTB",3,"COL","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)." +"1345","EUCAST 2025","human","human","MIC","Topical","B_ACNTB",3,"COL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"1346","EUCAST 2025","human","human","DISK",NA,"B_ACNTB",3,"DOR","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",50,22,FALSE,FALSE,NA +"1347","EUCAST 2025","human","human","MIC",NA,"B_ACNTB",3,"DOR","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,2,FALSE,FALSE,NA +"1348","EUCAST 2025","human","human","DISK","systemic infections","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",17,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1349","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",17,17,FALSE,FALSE,NA +"1350","EUCAST 2025","human","human","DISK","Topical","B_ACNTB",3,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",17,17,FALSE,FALSE,NA +"1351","EUCAST 2025","human","human","MIC","systemic infections","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1352","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA +"1353","EUCAST 2025","human","human","MIC","Topical","B_ACNTB",3,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA +"1354","EUCAST 2025","human","human","DISK",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",24,21,FALSE,FALSE,NA +"1355","EUCAST 2025","human","human","MIC",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)",NA,2,4,FALSE,FALSE,NA +"1356","EUCAST 2025","human","human","DISK",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",23,20,FALSE,FALSE,NA +"1357","EUCAST 2025","human","human","DISK","Topical","B_ACNTB",3,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",23,23,FALSE,FALSE,NA +"1358","EUCAST 2025","human","human","MIC",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,1,FALSE,FALSE,NA +"1359","EUCAST 2025","human","human","MIC","Topical","B_ACNTB",3,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"1360","EUCAST 2025","human","human","DISK","indications other than meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",21,15,FALSE,FALSE,NA +"1361","EUCAST 2025","human","human","DISK","meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",21,21,FALSE,FALSE,NA +"1362","EUCAST 2025","human","human","MIC","indications other than meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)",NA,2,8,FALSE,FALSE,NA +"1363","EUCAST 2025","human","human","MIC","meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"1364","EUCAST 2025","human","human","MIC","Topical","B_ACNTB",3,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"1365","EUCAST 2025","human","human","DISK",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",14,11,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1366","EUCAST 2025","human","human","MIC",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)",NA,2,4,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1367","EUCAST 2025","human","human","DISK","systemic infections","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",17,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1368","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",17,17,FALSE,FALSE,NA +"1369","EUCAST 2025","human","human","DISK","Topical","B_ACNTB",3,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",17,17,FALSE,FALSE,NA +"1370","EUCAST 2025","human","human","MIC","systemic infections","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1371","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA +"1372","EUCAST 2025","human","human","MIC","Topical","B_ACNTB",3,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA +"1373","EUCAST 2025","human","human","DISK",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",26,26,FALSE,FALSE,NA +"1374","EUCAST 2025","human","human","MIC",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"1375","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note" +"1376","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,TRUE,FALSE,NA +"1377","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility." +"1378","EUCAST 2025","human","human","DISK",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",31,31,FALSE,FALSE,NA +"1379","EUCAST 2025","human","human","MIC",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"1380","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","100 mcg",16,16,TRUE,FALSE,NA +"1381","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,16,16,TRUE,FALSE,NA +"1382","EUCAST 2025","human","human","DISK","screen only","B_AERCC_SNGN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance." +"1383","EUCAST 2025","human","human","DISK",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","1 unit",21,21,FALSE,FALSE,NA +"1384","EUCAST 2025","human","human","MIC",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA +"1385","EUCAST 2025","human","human","DISK",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",25,25,FALSE,FALSE,NA +"1386","EUCAST 2025","human","human","MIC",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA +"1387","EUCAST 2025","human","human","DISK",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method." +"1388","EUCAST 2025","human","human","MIC",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"1389","EUCAST 2025","human","human","DISK",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",26,26,FALSE,FALSE,NA +"1390","EUCAST 2025","human","human","MIC",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"1391","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note" +"1392","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,TRUE,FALSE,NA +"1393","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility." +"1394","EUCAST 2025","human","human","DISK",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",31,31,FALSE,FALSE,NA +"1395","EUCAST 2025","human","human","MIC",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"1396","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","100 mcg",16,16,TRUE,FALSE,NA +"1397","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,16,16,TRUE,FALSE,NA +"1398","EUCAST 2025","human","human","DISK","screen only","B_AERCC_URIN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance." +"1399","EUCAST 2025","human","human","DISK",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","1 unit",21,21,FALSE,FALSE,NA +"1400","EUCAST 2025","human","human","MIC",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA +"1401","EUCAST 2025","human","human","DISK",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",25,25,FALSE,FALSE,NA +"1402","EUCAST 2025","human","human","MIC",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA +"1403","EUCAST 2025","human","human","DISK",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method." +"1404","EUCAST 2025","human","human","MIC",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"1405","EUCAST 2025","human","human","DISK",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",29,26,FALSE,FALSE,NA +"1406","EUCAST 2025","human","human","MIC",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 15.0)",NA,1,4,FALSE,FALSE,NA +"1407","EUCAST 2025","human","human","DISK",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",24,21,FALSE,FALSE,NA +"1408","EUCAST 2025","human","human","MIC",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 15.0)",NA,1,4,FALSE,FALSE,NA +"1409","EUCAST 2025","human","human","DISK",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",27,24,FALSE,FALSE,NA +"1410","EUCAST 2025","human","human","MIC",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.5,FALSE,FALSE,NA +"1411","EUCAST 2025","human","human","DISK",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",27,24,FALSE,FALSE,NA +"1412","EUCAST 2025","human","human","MIC",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 15.0)",NA,1,4,FALSE,FALSE,NA +"1413","EUCAST 2025","human","human","DISK",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",27,24,FALSE,FALSE,NA +"1414","EUCAST 2025","human","human","MIC",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,1,FALSE,FALSE,NA +"1415","EUCAST 2025","human","human","DISK",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",19,16,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1416","EUCAST 2025","human","human","MIC",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 15.0)",NA,2,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1417","EUCAST 2025","human","human","DISK",NA,"B_BCLLS",3,"CIP","Bacillus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,23,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"1418","EUCAST 2025","human","human","MIC",NA,"B_BCLLS",3,"CIP","Bacillus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,0.5,FALSE,FALSE,NA +"1419","EUCAST 2025","human","human","DISK",NA,"B_BCLLS",3,"CLI","Bacillus (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",17,17,FALSE,FALSE,NA +"1420","EUCAST 2025","human","human","MIC",NA,"B_BCLLS",3,"CLI","Bacillus (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"1421","EUCAST 2025","human","human","DISK",NA,"B_BCLLS",3,"ERY","Bacillus (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",24,24,FALSE,FALSE,NA +"1422","EUCAST 2025","human","human","MIC",NA,"B_BCLLS",3,"ERY","Bacillus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"1423","EUCAST 2025","human","human","DISK",NA,"B_BCLLS",3,"IPM","Bacillus (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",30,30,FALSE,FALSE,NA +"1424","EUCAST 2025","human","human","MIC",NA,"B_BCLLS",3,"IPM","Bacillus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"1425","EUCAST 2025","human","human","DISK",NA,"B_BCLLS",3,"LNZ","Bacillus (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",22,22,FALSE,FALSE,NA +"1426","EUCAST 2025","human","human","MIC",NA,"B_BCLLS",3,"LNZ","Bacillus (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"1427","EUCAST 2025","human","human","DISK",NA,"B_BCLLS",3,"LVX","Bacillus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,23,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"1428","EUCAST 2025","human","human","MIC",NA,"B_BCLLS",3,"LVX","Bacillus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,1,FALSE,FALSE,NA +"1429","EUCAST 2025","human","human","DISK",NA,"B_BCLLS",3,"MEM","Bacillus (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",25,25,FALSE,FALSE,NA +"1430","EUCAST 2025","human","human","MIC",NA,"B_BCLLS",3,"MEM","Bacillus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"1431","EUCAST 2025","human","human","DISK","screen only","B_BCLLS",3,"NOR","Bacillus (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",21,21,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin." +"1432","EUCAST 2025","human","human","DISK",NA,"B_BCLLS",3,"VAN","Bacillus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",10,10,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method." +"1433","EUCAST 2025","human","human","MIC",NA,"B_BCLLS",3,"VAN","Bacillus (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"1434","EUCAST 2025","human","human","MIC",NA,"B_BCLLS_ANTH",2,"AMX","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant." +"1435","EUCAST 2025","human","human","DISK",NA,"B_BCLLS_ANTH",2,"CIP","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,24,FALSE,FALSE,NA +"1436","EUCAST 2025","human","human","MIC",NA,"B_BCLLS_ANTH",2,"CIP","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,0.25,FALSE,FALSE,NA +"1437","EUCAST 2025","human","human","DISK",NA,"B_BCLLS_ANTH",2,"CLI","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",17,17,FALSE,FALSE,NA +"1438","EUCAST 2025","human","human","MIC",NA,"B_BCLLS_ANTH",2,"CLI","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"1439","EUCAST 2025","human","human","MIC",NA,"B_BCLLS_ANTH",2,"DOX","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant." +"1440","EUCAST 2025","human","human","DISK",NA,"B_BCLLS_ANTH",2,"LNZ","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",20,20,FALSE,FALSE,NA +"1441","EUCAST 2025","human","human","MIC",NA,"B_BCLLS_ANTH",2,"LNZ","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"1442","EUCAST 2025","human","human","DISK",NA,"B_BCLLS_ANTH",2,"LVX","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,23,FALSE,FALSE,NA +"1443","EUCAST 2025","human","human","MIC",NA,"B_BCLLS_ANTH",2,"LVX","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,0.5,FALSE,FALSE,NA +"1444","EUCAST 2025","human","human","DISK",NA,"B_BCLLS_ANTH",2,"PEN","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)","1 unit",50,18,FALSE,FALSE,NA +"1445","EUCAST 2025","human","human","MIC",NA,"B_BCLLS_ANTH",2,"PEN","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,0.5,FALSE,FALSE,NA +"1446","EUCAST 2025","human","human","DISK",NA,"B_BCLLS_ANTH",2,"RIF","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",12,12,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1447","EUCAST 2025","human","human","MIC",NA,"B_BCLLS_ANTH",2,"RIF","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1448","EUCAST 2025","human","human","DISK",NA,"B_BCLLS_ANTH",2,"TCY","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",26,26,FALSE,FALSE,NA +"1449","EUCAST 2025","human","human","MIC",NA,"B_BCLLS_ANTH",2,"TCY","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA +"1450","EUCAST 2025","human","human","DISK",NA,"B_BCLLS_ANTH",2,"VAN","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",10,10,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1451","EUCAST 2025","human","human","MIC",NA,"B_BCLLS_ANTH",2,"VAN","B.anthracis (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1452","EUCAST 2025","human","human","DISK",NA,"B_BCTRD",3,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","2/1 mcg",14,14,FALSE,FALSE,NA +"1453","EUCAST 2025","human","human","MIC",NA,"B_BCTRD",3,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"1454","EUCAST 2025","human","human","DISK",NA,"B_BCTRD",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",10,10,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading." +"1455","EUCAST 2025","human","human","MIC",NA,"B_BCTRD",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,"[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1456","EUCAST 2025","human","human","DISK",NA,"B_BCTRD",3,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",23,23,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1457","EUCAST 2025","human","human","MIC",NA,"B_BCTRD",3,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1458","EUCAST 2025","human","human","DISK",NA,"B_BCTRD",3,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",29,29,FALSE,FALSE,NA +"1459","EUCAST 2025","human","human","MIC",NA,"B_BCTRD",3,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"1460","EUCAST 2025","human","human","DISK",NA,"B_BCTRD",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",28,28,FALSE,FALSE,NA +"1461","EUCAST 2025","human","human","MIC",NA,"B_BCTRD",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"1462","EUCAST 2025","human","human","DISK",NA,"B_BCTRD",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",25,25,FALSE,FALSE,NA +"1463","EUCAST 2025","human","human","MIC",NA,"B_BCTRD",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA +"1464","EUCAST 2025","human","human","DISK",NA,"B_BCTRD",3,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10/10 mcg",25,25,FALSE,FALSE,NA +"1465","EUCAST 2025","human","human","MIC",NA,"B_BCTRD",3,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L." +"1466","EUCAST 2025","human","human","DISK",NA,"B_BCTRD",3,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","30/6 mcg",24,24,FALSE,FALSE,"[3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam." +"1467","EUCAST 2025","human","human","MIC",NA,"B_BCTRD",3,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam." +"1468","EUCAST 2025","human","human","DISK",NA,"B_BRCLL_MLTN",2,"CIP","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,27,FALSE,FALSE,NA +"1469","EUCAST 2025","human","human","MIC",NA,"B_BRCLL_MLTN",2,"CIP","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,1,FALSE,FALSE,NA +"1470","EUCAST 2025","human","human","DISK","meningitis","B_BRCLL_MLTN",2,"CRO","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",30,30,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1471","EUCAST 2025","human","human","MIC","meningitis","B_BRCLL_MLTN",2,"CRO","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1472","EUCAST 2025","human","human","MIC",NA,"B_BRCLL_MLTN",2,"DOX","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant." +"1473","EUCAST 2025","human","human","DISK",NA,"B_BRCLL_MLTN",2,"GEN","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",23,23,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1474","EUCAST 2025","human","human","MIC",NA,"B_BRCLL_MLTN",2,"GEN","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1475","EUCAST 2025","human","human","DISK",NA,"B_BRCLL_MLTN",2,"LVX","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,28,FALSE,FALSE,NA +"1476","EUCAST 2025","human","human","MIC",NA,"B_BRCLL_MLTN",2,"LVX","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,1,FALSE,FALSE,NA +"1477","EUCAST 2025","human","human","DISK",NA,"B_BRCLL_MLTN",2,"RIF","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",20,20,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading." +"1478","EUCAST 2025","human","human","MIC",NA,"B_BRCLL_MLTN",2,"RIF","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1479","EUCAST 2025","human","human","DISK",NA,"B_BRCLL_MLTN",2,"STR1","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1480","EUCAST 2025","human","human","MIC",NA,"B_BRCLL_MLTN",2,"STR1","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1481","EUCAST 2025","human","human","DISK",NA,"B_BRCLL_MLTN",2,"SXT","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",29,29,FALSE,FALSE,"[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone. | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1482","EUCAST 2025","human","human","MIC",NA,"B_BRCLL_MLTN",2,"SXT","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1483","EUCAST 2025","human","human","DISK",NA,"B_BRCLL_MLTN",2,"TCY","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",42,42,FALSE,FALSE,NA +"1484","EUCAST 2025","human","human","MIC",NA,"B_BRCLL_MLTN",2,"TCY","B.melitensis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"1485","EUCAST 2025","human","human","DISK",NA,"B_BRKHL_PSDM",2,"AMC","B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)","20/10 mcg",50,22,FALSE,FALSE,NA +"1486","EUCAST 2025","human","human","MIC",NA,"B_BRKHL_PSDM",2,"AMC","B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,8,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"1487","EUCAST 2025","human","human","DISK",NA,"B_BRKHL_PSDM",2,"CAZ","B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",50,18,FALSE,FALSE,NA +"1488","EUCAST 2025","human","human","MIC",NA,"B_BRKHL_PSDM",2,"CAZ","B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,8,FALSE,FALSE,NA +"1489","EUCAST 2025","human","human","DISK",NA,"B_BRKHL_PSDM",2,"CHL","B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,22,FALSE,FALSE,NA +"1490","EUCAST 2025","human","human","MIC",NA,"B_BRKHL_PSDM",2,"CHL","B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,8,FALSE,FALSE,NA +"1491","EUCAST 2025","human","human","MIC",NA,"B_BRKHL_PSDM",2,"DOX","B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,2,FALSE,FALSE,NA +"1492","EUCAST 2025","human","human","DISK",NA,"B_BRKHL_PSDM",2,"IPM","B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",29,29,FALSE,FALSE,NA +"1493","EUCAST 2025","human","human","MIC",NA,"B_BRKHL_PSDM",2,"IPM","B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"1494","EUCAST 2025","human","human","DISK",NA,"B_BRKHL_PSDM",2,"MEM","B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",24,24,FALSE,FALSE,NA +"1495","EUCAST 2025","human","human","MIC",NA,"B_BRKHL_PSDM",2,"MEM","B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"1496","EUCAST 2025","human","human","DISK",NA,"B_BRKHL_PSDM",2,"SXT","B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",50,17,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1497","EUCAST 2025","human","human","MIC",NA,"B_BRKHL_PSDM",2,"SXT","B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1498","EUCAST 2025","human","human","DISK","screen only","B_BRKHL_PSDM",2,"TCY","B.pseudomallei (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",23,23,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline." +"1499","EUCAST 2025","human","human","DISK",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,26,FALSE,FALSE,NA +"1500","EUCAST 2025","human","human","MIC",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,0.5,FALSE,FALSE,NA +"1501","EUCAST 2025","human","human","DISK",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",24,24,FALSE,FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin." +"1502","EUCAST 2025","human","human","MIC",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin." +"1503","EUCAST 2025","human","human","DISK",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",30,30,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from tetracycline." +"1504","EUCAST 2025","human","human","MIC",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] Susceptibility to doxycycline can be inferred from tetracycline." +"1505","EUCAST 2025","human","human","DISK",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,26,FALSE,FALSE,NA +"1506","EUCAST 2025","human","human","MIC",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,0.5,FALSE,FALSE,NA +"1507","EUCAST 2025","human","human","DISK",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",20,20,FALSE,FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin." +"1508","EUCAST 2025","human","human","MIC",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin." +"1509","EUCAST 2025","human","human","DISK",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",30,30,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from tetracycline." +"1510","EUCAST 2025","human","human","MIC",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] Susceptibility to doxycycline can be inferred from tetracycline." +"1511","EUCAST 2025","human","human","MIC",NA,"B_CRDDS_DFFC",2,"FDX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes." +"1512","EUCAST 2025","human","human","MIC",NA,"B_CRDDS_DFFC",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes." +"1513","EUCAST 2025","human","human","MIC",NA,"B_CRDDS_DFFC",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes." +"1514","EUCAST 2025","human","human","DISK",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,25,FALSE,FALSE,NA +"1515","EUCAST 2025","human","human","MIC",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,1,FALSE,FALSE,NA +"1516","EUCAST 2025","human","human","DISK",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",20,20,FALSE,FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing." +"1517","EUCAST 2025","human","human","MIC",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing." +"1518","EUCAST 2025","human","human","DISK",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",25,25,FALSE,FALSE,NA +"1519","EUCAST 2025","human","human","MIC",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"1520","EUCAST 2025","human","human","DISK",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",25,25,FALSE,FALSE,NA +"1521","EUCAST 2025","human","human","MIC",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"1522","EUCAST 2025","human","human","DISK",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)","1 unit",50,12,FALSE,FALSE,NA +"1523","EUCAST 2025","human","human","MIC",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,1,FALSE,FALSE,NA +"1524","EUCAST 2025","human","human","DISK",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",30,30,FALSE,FALSE,NA +"1525","EUCAST 2025","human","human","MIC",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA +"1526","EUCAST 2025","human","human","DISK",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",24,24,FALSE,FALSE,NA +"1527","EUCAST 2025","human","human","MIC",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"1528","EUCAST 2025","human","human","DISK",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method." +"1529","EUCAST 2025","human","human","MIC",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"1530","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_DPHT",2,"AMX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant." +"1531","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_DPHT",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,24,FALSE,FALSE,NA +"1532","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_DPHT",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,0.5,FALSE,FALSE,NA +"1533","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_DPHT",2,"CLI","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",15,15,FALSE,FALSE,"[1] Wild-type C. ulcerans is less susceptible to clindamycin." +"1534","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_DPHT",2,"CLI","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Wild-type C. ulcerans is less susceptible to clindamycin." +"1535","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_DPHT",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,15,FALSE,FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant." +"1536","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_DPHT",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,2,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant." +"1537","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_DPHT",2,"DOX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant." +"1538","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_DPHT",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",24,24,FALSE,FALSE,NA +"1539","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_DPHT",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA +"1540","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_DPHT",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",25,25,FALSE,FALSE,NA +"1541","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_DPHT",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"1542","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_DPHT",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",24,24,FALSE,FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant." +"1543","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_DPHT",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant." +"1544","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_DPHT",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","1 unit",50,12,FALSE,FALSE,NA +"1545","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_DPHT",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,1,FALSE,FALSE,NA +"1546","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_DPHT",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",24,24,FALSE,FALSE,NA +"1547","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_DPHT",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA +"1548","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_DPHT",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1549","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_DPHT",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1550","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_DPHT",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",24,24,FALSE,FALSE,NA +"1551","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_DPHT",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"1552","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_ULCR",2,"AMX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant." +"1553","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_ULCR",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,24,FALSE,FALSE,NA +"1554","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_ULCR",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,0.5,FALSE,FALSE,NA +"1555","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_ULCR",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,15,FALSE,FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant." +"1556","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_ULCR",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,2,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant." +"1557","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_ULCR",2,"DOX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant." +"1558","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_ULCR",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",24,24,FALSE,FALSE,NA +"1559","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_ULCR",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA +"1560","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_ULCR",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",25,25,FALSE,FALSE,NA +"1561","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_ULCR",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"1562","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_ULCR",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",24,24,FALSE,FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant." +"1563","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_ULCR",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant." +"1564","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_ULCR",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","1 unit",50,12,FALSE,FALSE,NA +"1565","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_ULCR",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,1,FALSE,FALSE,NA +"1566","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_ULCR",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",24,24,FALSE,FALSE,NA +"1567","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_ULCR",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA +"1568","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_ULCR",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1569","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_ULCR",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1570","EUCAST 2025","human","human","DISK",NA,"B_CRYNB_ULCR",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",24,24,FALSE,FALSE,NA +"1571","EUCAST 2025","human","human","MIC",NA,"B_CRYNB_ULCR",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"1572","EUCAST 2025","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","2/1 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1573","EUCAST 2025","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1574","EUCAST 2025","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1575","EUCAST 2025","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"AMX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1576","EUCAST 2025","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",26,26,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading." +"1577","EUCAST 2025","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"1578","EUCAST 2025","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"CRO","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test." +"1579","EUCAST 2025","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"CRO","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1580","EUCAST 2025","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"CTX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",26,26,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test." +"1581","EUCAST 2025","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",28,28,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1582","EUCAST 2025","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1583","EUCAST 2025","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",39,39,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1584","EUCAST 2025","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.03,0.03,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1585","EUCAST 2025","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"LNZ","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",34,34,FALSE,FALSE,NA +"1586","EUCAST 2025","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"LNZ","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"1587","EUCAST 2025","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",28,28,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1588","EUCAST 2025","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1589","EUCAST 2025","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","1 unit",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1590","EUCAST 2025","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1591","EUCAST 2025","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10/10 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1592","EUCAST 2025","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","30/6 mcg",27,27,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1593","EUCAST 2025","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",22,22,FALSE,FALSE,NA +"1594","EUCAST 2025","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"1595","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_CTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"1596","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_CTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination." +"1597","EUCAST 2025","human","human","DISK",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method." +"1598","EUCAST 2025","human","human","MIC",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/." +"1599","EUCAST 2025","human","human","DISK",NA,"B_CTRDM_PRFR",2,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","2/1 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1600","EUCAST 2025","human","human","MIC",NA,"B_CTRDM_PRFR",2,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"1601","EUCAST 2025","human","human","DISK",NA,"B_CTRDM_PRFR",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1602","EUCAST 2025","human","human","MIC",NA,"B_CTRDM_PRFR",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1603","EUCAST 2025","human","human","MIC",NA,"B_CTRDM_PRFR",2,"AMX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1604","EUCAST 2025","human","human","DISK",NA,"B_CTRDM_PRFR",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",19,19,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading." +"1605","EUCAST 2025","human","human","MIC",NA,"B_CTRDM_PRFR",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"1606","EUCAST 2025","human","human","DISK",NA,"B_CTRDM_PRFR",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1607","EUCAST 2025","human","human","MIC",NA,"B_CTRDM_PRFR",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1608","EUCAST 2025","human","human","DISK",NA,"B_CTRDM_PRFR",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1609","EUCAST 2025","human","human","MIC",NA,"B_CTRDM_PRFR",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1610","EUCAST 2025","human","human","DISK",NA,"B_CTRDM_PRFR",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1611","EUCAST 2025","human","human","MIC",NA,"B_CTRDM_PRFR",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1612","EUCAST 2025","human","human","DISK",NA,"B_CTRDM_PRFR",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",16,16,FALSE,FALSE,NA +"1613","EUCAST 2025","human","human","MIC",NA,"B_CTRDM_PRFR",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA +"1614","EUCAST 2025","human","human","DISK",NA,"B_CTRDM_PRFR",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","1 unit",15,15,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1615","EUCAST 2025","human","human","MIC",NA,"B_CTRDM_PRFR",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1616","EUCAST 2025","human","human","DISK",NA,"B_CTRDM_PRFR",2,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10/10 mcg",27,27,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1617","EUCAST 2025","human","human","MIC",NA,"B_CTRDM_PRFR",2,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L." +"1618","EUCAST 2025","human","human","DISK",NA,"B_CTRDM_PRFR",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","30/6 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1619","EUCAST 2025","human","human","MIC",NA,"B_CTRDM_PRFR",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"1620","EUCAST 2025","human","human","DISK",NA,"B_CTRDM_PRFR",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",12,12,FALSE,FALSE,NA +"1621","EUCAST 2025","human","human","MIC",NA,"B_CTRDM_PRFR",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"1622","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_ENTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"1623","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_ENTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination." +"1624","EUCAST 2025","human","human","DISK",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",10,10,FALSE,FALSE,"[A] For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test." +"1625","EUCAST 2025","human","human","MIC",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA +"1626","EUCAST 2025","human","human","MIC",NA,"B_ENTRC",3,"AMX","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,"[1] Susceptibility can be inferred from ampicillin." +"1627","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"AMX","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,TRUE,FALSE,"[1] Susceptibility can be inferred from ampicillin." +"1628","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"1629","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,TRUE,FALSE,NA +"1630","EUCAST 2025","human","human","DISK",NA,"B_ENTRC",3,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","20 mcg",22,22,FALSE,FALSE,NA +"1631","EUCAST 2025","human","human","MIC",NA,"B_ENTRC",3,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"1632","EUCAST 2025","human","human","DISK",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",20,20,FALSE,FALSE,NA +"1633","EUCAST 2025","human","human","MIC",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA +"1634","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"1635","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,TRUE,FALSE,NA +"1636","EUCAST 2025","human","human","DISK","screen only","B_ENTRC",3,"NOR","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",12,12,FALSE,FALSE,"[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B." +"1637","EUCAST 2025","human","human","DISK",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",16,16,FALSE,FALSE,NA +"1638","EUCAST 2025","human","human","MIC",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"1639","EUCAST 2025","human","human","DISK",NA,"B_ENTRC",3,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",20,20,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"1640","EUCAST 2025","human","human","MIC",NA,"B_ENTRC",3,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"1641","EUCAST 2025","human","human","DISK",NA,"B_ENTRC",3,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",15,15,FALSE,FALSE,NA +"1642","EUCAST 2025","human","human","MIC",NA,"B_ENTRC",3,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA +"1643","EUCAST 2025","human","human","DISK",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",22,22,FALSE,FALSE,NA +"1644","EUCAST 2025","human","human","MIC",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"1645","EUCAST 2025","human","human","DISK",NA,"B_ENTRC_FACM",2,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",12,12,FALSE,FALSE,"[A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation." +"1646","EUCAST 2025","human","human","MIC",NA,"B_ENTRC_FACM",2,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA +"1647","EUCAST 2025","human","human","MIC","other indications","B_ENTRC_FCLS",2,"AMX","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,4,FALSE,FALSE,"[3] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1648","EUCAST 2025","human","human","DISK",NA,"B_ENTRC_FCLS",2,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",50,21,FALSE,FALSE,NA +"1649","EUCAST 2025","human","human","MIC",NA,"B_ENTRC_FCLS",2,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,4,FALSE,FALSE,NA +"1650","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","100 mcg",15,15,TRUE,FALSE,NA +"1651","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,64,64,TRUE,FALSE,NA +"1652","EUCAST 2025","human","human","DISK",NA,"B_ENTRC_FCLS",2,"PIP","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,18,FALSE,FALSE,NA +"1653","EUCAST 2025","human","human","MIC",NA,"B_ENTRC_FCLS",2,"PIP","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,16,FALSE,FALSE,NA +"1654","EUCAST 2025","human","human","DISK",NA,"B_ENTRC_FCLS",2,"TZP","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","30/6 mcg",50,18,FALSE,FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare." +"1655","EUCAST 2025","human","human","MIC",NA,"B_ENTRC_FCLS",2,"TZP","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,16,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare." +"1656","EUCAST 2025","human","human","DISK",NA,"B_ENTRC_FCLS",2,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",12,12,FALSE,FALSE,"[A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation." +"1657","EUCAST 2025","human","human","MIC",NA,"B_ENTRC_FCLS",2,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA +"1658","EUCAST 2025","human","human","DISK",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,19,FALSE,FALSE,NA +"1659","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",19,19,TRUE,FALSE,NA +"1660","EUCAST 2025","human","human","MIC",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,8,FALSE,FALSE,NA +"1661","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,TRUE,FALSE,NA +"1662","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_ESCHR_COLI",2,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,20,FALSE,FALSE,"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin." +"1663","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,4,FALSE,FALSE,"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin." +"1664","EUCAST 2025","human","human","MIC",NA,"B_ESCHR_COLI",2,"DFX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA +"1665","EUCAST 2025","human","human","DISK",NA,"B_ESCHR_COLI",2,"ERV","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","20 mcg",17,17,FALSE,FALSE,NA +"1666","EUCAST 2025","human","human","MIC",NA,"B_ESCHR_COLI",2,"ERV","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"1667","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","200 mcg",24,24,FALSE,FALSE,"[D] Ignore isolated colonies within the inhibition zone (see pictures below)." +"1668","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","200 mcg",24,24,TRUE,FALSE,"[D] Ignore isolated colonies within the inhibition zone (see pictures below)." +"1669","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems." +"1670","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,TRUE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems." +"1671","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"1672","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination." +"1673","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","100 mcg",11,11,TRUE,FALSE,NA +"1674","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,64,64,TRUE,FALSE,NA +"1675","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",15,15,TRUE,FALSE,NA +"1676","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,16,16,TRUE,FALSE,NA +"1677","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_ESCHR_COLI",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,17,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"1678","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,16,FALSE,FALSE,NA +"1679","EUCAST 2025","human","human","DISK",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method." +"1680","EUCAST 2025","human","human","MIC",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/." +"1681","EUCAST 2025","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","2/1 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1682","EUCAST 2025","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"1683","EUCAST 2025","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",27,27,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1684","EUCAST 2025","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1685","EUCAST 2025","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"AMX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1686","EUCAST 2025","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",30,30,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading." +"1687","EUCAST 2025","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"1688","EUCAST 2025","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1689","EUCAST 2025","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1690","EUCAST 2025","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",36,36,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1691","EUCAST 2025","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1692","EUCAST 2025","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1693","EUCAST 2025","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.03,0.03,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1694","EUCAST 2025","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",30,30,FALSE,FALSE,NA +"1695","EUCAST 2025","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"1696","EUCAST 2025","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","1 unit",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1697","EUCAST 2025","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1698","EUCAST 2025","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10/10 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1699","EUCAST 2025","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L." +"1700","EUCAST 2025","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","30/6 mcg",32,32,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1701","EUCAST 2025","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"1702","EUCAST 2025","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"AMX","H.pylori (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA +"1703","EUCAST 2025","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"CLR","H.pylori (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"1704","EUCAST 2025","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"LVX","H.pylori (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"1705","EUCAST 2025","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"MTR","H.pylori (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,NA +"1706","EUCAST 2025","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"RIF","H.pylori (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"1707","EUCAST 2025","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"TCY","H.pylori (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"1708","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","2/1 mcg",15,15,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"1709","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","2/1 mcg",50,15,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"1710","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"1711","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,2,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"1712","EUCAST 2025","human","human","DISK","indications other than endocarditis and meningitis","B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",18,18,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase." +"1713","EUCAST 2025","human","human","MIC","indications other than endocarditis and meningitis","B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase." +"1714","EUCAST 2025","human","human","MIC","indications other than endocarditis and meningitis","B_HMPHL_INFL",2,"AMX","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase." +"1715","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMX","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,2,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase." +"1716","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"1717","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA +"1718","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",28,28,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages." +"1719","EUCAST 2025","human","human","DISK","Topical","B_HMPHL_INFL",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",28,28,FALSE,FALSE,NA +"1720","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages." +"1721","EUCAST 2025","human","human","MIC","Topical","B_HMPHL_INFL",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"1722","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",32,32,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"1723","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.03,0.03,FALSE,FALSE,NA +"1724","EUCAST 2025","human","human","MIC","Topical","B_HMPHL_INFL",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA +"1725","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"1726","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"1727","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPT","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.03,0.03,FALSE,FALSE,NA +"1728","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",32,32,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"1729","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA +"1730","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",25,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"1731","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"1732","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"1733","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA +"1734","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",27,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"1735","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"1736","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,1,2,FALSE,FALSE,NA +"1737","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,1,FALSE,FALSE,NA +"1738","EUCAST 2025","human","human","DISK","pneumonia","B_HMPHL_INFL",2,"CZT","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","30/10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [3] See table of dosages for dosing for different indications." +"1739","EUCAST 2025","human","human","MIC","pneumonia","B_HMPHL_INFL",2,"CZT","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[3] See table of dosages for dosing for different indications." +"1740","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"DOR","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"1741","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"DOR","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"1742","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"DOX","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"1743","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"1744","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"1745","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",28,28,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"1746","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"1747","EUCAST 2025","human","human","MIC","Topical","B_HMPHL_INFL",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA +"1748","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"1749","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"1750","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"1751","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA +"1752","EUCAST 2025","human","human","MIC","Topical","B_HMPHL_INFL",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA +"1753","EUCAST 2025","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"1754","EUCAST 2025","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"1755","EUCAST 2025","human","human","MIC","meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"1756","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"1757","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA +"1758","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",24,24,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"1759","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"1760","EUCAST 2025","human","human","DISK","screen only","B_HMPHL_INFL",2,"NAL","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",23,23,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"1761","EUCAST 2025","human","human","DISK","Topical","B_HMPHL_INFL",2,"NAL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",23,23,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)." +"1762","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"1763","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA +"1764","EUCAST 2025","human","human","MIC","Topical","B_HMPHL_INFL",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA +"1765","EUCAST 2025","human","human","DISK","screen only","B_HMPHL_INFL",2,"PEN","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","1 unit",12,12,FALSE,FALSE,"[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"1766","EUCAST 2025","human","human","DISK","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",18,18,FALSE,FALSE,NA +"1767","EUCAST 2025","human","human","MIC","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"1768","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"SAM","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv." +"1769","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",23,20,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1770","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,1,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1771","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",25,25,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"1772","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"1773","EUCAST 2025","human","human","MIC","Topical","B_HMPHL_INFL",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,NA +"1774","EUCAST 2025","human","human","DISK",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)","30/6 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"1775","EUCAST 2025","human","human","MIC",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"1776","EUCAST 2025","human","human","DISK",NA,"B_KGLLA_KING",2,"AMC","K.kingae (file: Clinical Breakpoint Tables v. 15.0)","2/1 mcg",22,22,FALSE,FALSE,NA +"1777","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"AMP","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility." +"1778","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"AMX","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility." +"1779","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"AZM","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility." +"1780","EUCAST 2025","human","human","DISK",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",28,28,FALSE,FALSE,NA +"1781","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA +"1782","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"CLR","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility." +"1783","EUCAST 2025","human","human","DISK",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",30,30,FALSE,FALSE,NA +"1784","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA +"1785","EUCAST 2025","human","human","DISK",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",27,27,FALSE,FALSE,NA +"1786","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA +"1787","EUCAST 2025","human","human","DISK",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",29,29,FALSE,FALSE,NA +"1788","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"1789","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"DOX","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant." +"1790","EUCAST 2025","human","human","DISK",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",20,20,FALSE,FALSE,NA +"1791","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"1792","EUCAST 2025","human","human","DISK",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",28,28,FALSE,FALSE,NA +"1793","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA +"1794","EUCAST 2025","human","human","DISK",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",30,30,FALSE,FALSE,NA +"1795","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.03,0.03,FALSE,FALSE,NA +"1796","EUCAST 2025","human","human","DISK",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 15.0)","1 unit",25,25,FALSE,FALSE,NA +"1797","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.03,0.03,FALSE,FALSE,NA +"1798","EUCAST 2025","human","human","DISK",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",20,20,FALSE,FALSE,NA +"1799","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"1800","EUCAST 2025","human","human","DISK",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",28,28,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1801","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1802","EUCAST 2025","human","human","DISK",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",28,28,FALSE,FALSE,NA +"1803","EUCAST 2025","human","human","MIC",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"1804","EUCAST 2025","human","human","DISK",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,19,FALSE,FALSE,NA +"1805","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",19,19,TRUE,FALSE,NA +"1806","EUCAST 2025","human","human","MIC",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,8,FALSE,FALSE,NA +"1807","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,TRUE,FALSE,NA +"1808","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_KLBSL",3,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,20,FALSE,FALSE,"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin." +"1809","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_KLBSL",3,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,4,FALSE,FALSE,"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin." +"1810","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"1811","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination." +"1812","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_KLBSL",3,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,17,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"1813","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_KLBSL",3,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,16,FALSE,FALSE,NA +"1814","EUCAST 2025","human","human","DISK","all indications","B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",16,16,FALSE,FALSE,NA +"1815","EUCAST 2025","human","human","MIC","all indications","B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"1816","EUCAST 2025","human","human","DISK","indications other than meningitis","B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",25,25,FALSE,FALSE,NA +"1817","EUCAST 2025","human","human","MIC","indications other than meningitis","B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"1818","EUCAST 2025","human","human","DISK","all indications","B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",26,26,FALSE,FALSE,NA +"1819","EUCAST 2025","human","human","MIC","all indications","B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"1820","EUCAST 2025","human","human","DISK","indications other than meningitis","B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)","1 unit",13,13,FALSE,FALSE,NA +"1821","EUCAST 2025","human","human","MIC","indications other than meningitis","B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"1822","EUCAST 2025","human","human","DISK","all indications","B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",29,29,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1823","EUCAST 2025","human","human","MIC","all indications","B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1824","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","2/1 mcg",19,19,FALSE,FALSE,NA +"1825","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"1826","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AZM","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"1827","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",21,21,FALSE,FALSE,NA +"1828","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"1829","EUCAST 2025","human","human","DISK","Topical","B_MRXLL_CTRR",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",31,31,FALSE,FALSE,NA +"1830","EUCAST 2025","human","human","MIC","Topical","B_MRXLL_CTRR",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"1831","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",31,31,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"1832","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA +"1833","EUCAST 2025","human","human","MIC","Topical","B_MRXLL_CTRR",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA +"1834","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CLR","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"1835","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",24,21,FALSE,FALSE,NA +"1836","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,1,2,FALSE,FALSE,NA +"1837","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",20,17,FALSE,FALSE,NA +"1838","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,1,2,FALSE,FALSE,NA +"1839","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",21,18,FALSE,FALSE,NA +"1840","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,21,FALSE,FALSE,NA +"1841","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,4,8,FALSE,FALSE,NA +"1842","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,4,FALSE,FALSE,NA +"1843","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"DOR","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",30,30,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"1844","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"DOR","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"1845","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"DOX","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"1846","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",23,23,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"1847","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"1848","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",29,29,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"1849","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"1850","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",20,20,FALSE,FALSE,NA +"1851","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA +"1852","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",29,29,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"1853","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"1854","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",29,29,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"1855","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA +"1856","EUCAST 2025","human","human","MIC","Topical","B_MRXLL_CTRR",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA +"1857","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",33,33,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"1858","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"1859","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",26,26,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"1860","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"1861","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",25,25,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"1862","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"1863","EUCAST 2025","human","human","DISK","screen only","B_MRXLL_CTRR",2,"NAL","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",23,23,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"1864","EUCAST 2025","human","human","DISK","Topical","B_MRXLL_CTRR",2,"NAL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",23,23,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)." +"1865","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"1866","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"1867","EUCAST 2025","human","human","MIC","Topical","B_MRXLL_CTRR",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"1868","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"RXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"1869","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SAM","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid." +"1870","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",18,15,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1871","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,1,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1872","EUCAST 2025","human","human","DISK",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",26,26,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"1873","EUCAST 2025","human","human","MIC",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"1874","EUCAST 2025","human","human","MIC",NA,"B_MYCBC_TBRC",2,"BDQ","M.tuberculosis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination." +"1875","EUCAST 2025","human","human","MIC",NA,"B_MYCBC_TBRC",2,"DLM","M.tuberculosis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination." +"1876","EUCAST 2025","human","human","MIC",NA,"B_NESSR_GNRR",2,"CFM","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA +"1877","EUCAST 2025","human","human","MIC",NA,"B_NESSR_GNRR",2,"CIP","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.03,0.06,FALSE,FALSE,NA +"1878","EUCAST 2025","human","human","MIC",NA,"B_NESSR_GNRR",2,"CRO","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA +"1879","EUCAST 2025","human","human","MIC",NA,"B_NESSR_GNRR",2,"CTX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA +"1880","EUCAST 2025","human","human","MIC",NA,"B_NESSR_GNRR",2,"OFX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.25,FALSE,FALSE,NA +"1881","EUCAST 2025","human","human","MIC","surrogate agent","B_NESSR_GNRR",2,"PEN","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,1,FALSE,FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)." +"1882","EUCAST 2025","human","human","MIC",NA,"B_NESSR_GNRR",2,"SPT","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)",NA,64,64,FALSE,FALSE,NA +"1883","EUCAST 2025","human","human","MIC",NA,"B_NESSR_GNRR",2,"TCY","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"1884","EUCAST 2025","human","human","MIC","indications other than meningitis","B_NESSR_MNNG",2,"AMP","N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,1,FALSE,FALSE,NA +"1885","EUCAST 2025","human","human","MIC","indications other than meningitis","B_NESSR_MNNG",2,"AMX","N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,1,FALSE,FALSE,NA +"1886","EUCAST 2025","human","human","MIC","meningitis","B_NESSR_MNNG",2,"CHL","N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages." +"1887","EUCAST 2025","human","human","MIC","all indications, including meningitis and prophylaxis","B_NESSR_MNNG",2,"CIP","N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.016,0.016,FALSE,FALSE,NA +"1888","EUCAST 2025","human","human","MIC","all indications including prophylaxis","B_NESSR_MNNG",2,"CRO","N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"1889","EUCAST 2025","human","human","MIC","all indications","B_NESSR_MNNG",2,"CTX","N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"1890","EUCAST 2025","human","human","MIC","all indications","B_NESSR_MNNG",2,"MEM","N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only." +"1891","EUCAST 2025","human","human","MIC","prophylaxis only","B_NESSR_MNNG",2,"MNO","N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections." +"1892","EUCAST 2025","human","human","MIC","all indications","B_NESSR_MNNG",2,"PEN","N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"1893","EUCAST 2025","human","human","MIC","prophylaxis only","B_NESSR_MNNG",2,"RIF","N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"1894","EUCAST 2025","human","human","MIC","screen only","B_NESSR_MNNG",2,"TCY","N.meningitidis (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections." +"1895","EUCAST 2025","human","human","DISK",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,19,FALSE,FALSE,NA +"1896","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",19,19,TRUE,FALSE,NA +"1897","EUCAST 2025","human","human","MIC",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,8,FALSE,FALSE,NA +"1898","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,TRUE,FALSE,NA +"1899","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_PROTS_MRBL",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"1900","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_PROTS_MRBL",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination." +"1901","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_PROTS_MRBL",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,17,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"1902","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_PROTS_MRBL",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,16,FALSE,FALSE,NA +"1903","EUCAST 2025","human","human","DISK",NA,"B_PRVTL",3,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","2/1 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1904","EUCAST 2025","human","human","DISK",NA,"B_PRVTL",3,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1905","EUCAST 2025","human","human","MIC",NA,"B_PRVTL",3,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1906","EUCAST 2025","human","human","MIC",NA,"B_PRVTL",3,"AMX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1907","EUCAST 2025","human","human","DISK",NA,"B_PRVTL",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",31,31,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading." +"1908","EUCAST 2025","human","human","MIC",NA,"B_PRVTL",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"1909","EUCAST 2025","human","human","DISK",NA,"B_PRVTL",3,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",29,29,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1910","EUCAST 2025","human","human","MIC",NA,"B_PRVTL",3,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1911","EUCAST 2025","human","human","DISK",NA,"B_PRVTL",3,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1912","EUCAST 2025","human","human","MIC",NA,"B_PRVTL",3,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1913","EUCAST 2025","human","human","DISK",NA,"B_PRVTL",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",34,34,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1914","EUCAST 2025","human","human","MIC",NA,"B_PRVTL",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1915","EUCAST 2025","human","human","DISK",NA,"B_PRVTL",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",22,22,FALSE,FALSE,NA +"1916","EUCAST 2025","human","human","MIC",NA,"B_PRVTL",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA +"1917","EUCAST 2025","human","human","DISK",NA,"B_PRVTL",3,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","1 unit",20,20,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1918","EUCAST 2025","human","human","MIC",NA,"B_PRVTL",3,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1919","EUCAST 2025","human","human","DISK",NA,"B_PRVTL",3,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","10/10 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1920","EUCAST 2025","human","human","DISK",NA,"B_PRVTL",3,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 15.0)","30/6 mcg",26,26,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"1921","EUCAST 2025","human","human","DISK","systemic infections","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1922","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",15,15,FALSE,FALSE,NA +"1923","EUCAST 2025","human","human","MIC","systemic infections","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,16,16,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1924","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,16,16,FALSE,FALSE,NA +"1925","EUCAST 2025","human","human","DISK",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,18,FALSE,FALSE,NA +"1926","EUCAST 2025","human","human","MIC",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,16,FALSE,FALSE,NA +"1927","EUCAST 2025","human","human","DISK",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",50,17,FALSE,FALSE,NA +"1928","EUCAST 2025","human","human","MIC",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,8,FALSE,FALSE,NA +"1929","EUCAST 2025","human","human","DISK",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,26,FALSE,FALSE,NA +"1930","EUCAST 2025","human","human","MIC",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,0.5,FALSE,FALSE,NA +"1931","EUCAST 2025","human","human","MIC",NA,"B_PSDMN",3,"COL","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)." +"1932","EUCAST 2025","human","human","DISK",NA,"B_PSDMN",3,"DOR","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",50,22,FALSE,FALSE,NA +"1933","EUCAST 2025","human","human","MIC",NA,"B_PSDMN",3,"DOR","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,2,FALSE,FALSE,NA +"1934","EUCAST 2025","human","human","DISK",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,21,FALSE,FALSE,NA +"1935","EUCAST 2025","human","human","MIC",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,8,FALSE,FALSE,NA +"1936","EUCAST 2025","human","human","DISK",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",50,20,FALSE,FALSE,NA +"1937","EUCAST 2025","human","human","MIC",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,4,FALSE,FALSE,NA +"1938","EUCAST 2025","human","human","DISK",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,18,FALSE,FALSE,NA +"1939","EUCAST 2025","human","human","MIC",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,2,FALSE,FALSE,NA +"1940","EUCAST 2025","human","human","DISK","indications other than meningitis","B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",24,18,FALSE,FALSE,NA +"1941","EUCAST 2025","human","human","MIC","indications other than meningitis","B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,2,8,FALSE,FALSE,NA +"1942","EUCAST 2025","human","human","DISK",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,18,FALSE,FALSE,NA +"1943","EUCAST 2025","human","human","MIC",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,16,FALSE,FALSE,NA +"1944","EUCAST 2025","human","human","DISK",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","75/10 mcg",50,18,FALSE,FALSE,NA +"1945","EUCAST 2025","human","human","MIC",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,16,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"1946","EUCAST 2025","human","human","DISK","systemic infections","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1947","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",18,18,FALSE,FALSE,NA +"1948","EUCAST 2025","human","human","MIC","systemic infections","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"1949","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"1950","EUCAST 2025","human","human","DISK",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","30/6 mcg",50,18,FALSE,FALSE,NA +"1951","EUCAST 2025","human","human","MIC",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,16,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"1952","EUCAST 2025","human","human","DISK","Topical","B_PSDMN_AERG",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",26,26,FALSE,FALSE,NA +"1953","EUCAST 2025","human","human","MIC","Topical","B_PSDMN_AERG",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"1954","EUCAST 2025","human","human","MIC","Topical","B_PSDMN_AERG",2,"COL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA +"1955","EUCAST 2025","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","10/4 mcg",17,17,FALSE,FALSE,NA +"1956","EUCAST 2025","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L." +"1957","EUCAST 2025","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","30/10 mcg",23,23,FALSE,FALSE,"[4] See table of dosages for dosing for different indications." +"1958","EUCAST 2025","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [4] See table of dosages for dosing for different indications." +"1959","EUCAST 2025","human","human","DISK",NA,"B_PSDMN_AERG",2,"FDC","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",22,22,FALSE,FALSE,NA +"1960","EUCAST 2025","human","human","MIC",NA,"B_PSDMN_AERG",2,"FDC","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[2] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/." +"1961","EUCAST 2025","human","human","DISK","Topical","B_PSDMN_AERG",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",15,15,FALSE,FALSE,NA +"1962","EUCAST 2025","human","human","MIC","Topical","B_PSDMN_AERG",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,NA +"1963","EUCAST 2025","human","human","DISK",NA,"B_PSDMN_AERG",2,"IMR","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","10/25 mcg",22,22,FALSE,FALSE,NA +"1964","EUCAST 2025","human","human","MIC",NA,"B_PSDMN_AERG",2,"IMR","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L." +"1965","EUCAST 2025","human","human","DISK","Topical","B_PSDMN_AERG",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",18,18,FALSE,FALSE,NA +"1966","EUCAST 2025","human","human","MIC","Topical","B_PSDMN_AERG",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"1967","EUCAST 2025","human","human","DISK","indications other than meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",20,14,FALSE,FALSE,NA +"1968","EUCAST 2025","human","human","DISK","meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",20,20,FALSE,FALSE,NA +"1969","EUCAST 2025","human","human","MIC","indications other than meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,2,8,FALSE,FALSE,NA +"1970","EUCAST 2025","human","human","MIC","meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"1971","EUCAST 2025","human","human","DISK",NA,"B_PSDMN_AERG",2,"MEV","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)","20/10 mcg",14,14,FALSE,FALSE,NA +"1972","EUCAST 2025","human","human","MIC",NA,"B_PSDMN_AERG",2,"MEV","Pseudomonas (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L." +"1973","EUCAST 2025","human","human","MIC","Topical","B_PSDMN_AERG",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"1974","EUCAST 2025","human","human","DISK","Topical","B_PSDMN_AERG",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",18,18,FALSE,FALSE,NA +"1975","EUCAST 2025","human","human","MIC","Topical","B_PSDMN_AERG",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"1976","EUCAST 2025","human","human","DISK",NA,"B_PSTRL",3,"AMC","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)","2/1 mcg",15,15,FALSE,FALSE,NA +"1977","EUCAST 2025","human","human","MIC",NA,"B_PSTRL",3,"AMC","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"1978","EUCAST 2025","human","human","MIC",NA,"B_PSTRL",3,"AMP","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"1979","EUCAST 2025","human","human","MIC",NA,"B_PSTRL",3,"AMX","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"1980","EUCAST 2025","human","human","DISK",NA,"B_PSTRL",3,"CIP","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B." +"1981","EUCAST 2025","human","human","MIC",NA,"B_PSTRL",3,"CIP","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA +"1982","EUCAST 2025","human","human","DISK",NA,"B_PSTRL",3,"CTX","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",26,26,FALSE,FALSE,NA +"1983","EUCAST 2025","human","human","MIC",NA,"B_PSTRL",3,"CTX","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)",NA,0.03,0.03,FALSE,FALSE,NA +"1984","EUCAST 2025","human","human","MIC",NA,"B_PSTRL",3,"DOX","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"1985","EUCAST 2025","human","human","DISK",NA,"B_PSTRL",3,"LVX","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B." +"1986","EUCAST 2025","human","human","MIC",NA,"B_PSTRL",3,"LVX","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA +"1987","EUCAST 2025","human","human","DISK","screen only","B_PSTRL",3,"NAL","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",23,23,FALSE,FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"1988","EUCAST 2025","human","human","DISK",NA,"B_PSTRL",3,"PEN","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)","1 unit",17,17,FALSE,FALSE,NA +"1989","EUCAST 2025","human","human","MIC",NA,"B_PSTRL",3,"PEN","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"1990","EUCAST 2025","human","human","DISK",NA,"B_PSTRL",3,"SXT","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1991","EUCAST 2025","human","human","MIC",NA,"B_PSTRL",3,"SXT","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1992","EUCAST 2025","human","human","DISK","screen only","B_PSTRL",3,"TCY","Pasteurella (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",24,24,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test." +"1993","EUCAST 2025","human","human","MIC",NA,"B_SLMNL",3,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species." +"1994","EUCAST 2025","human","human","DISK",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",50,16,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1995","EUCAST 2025","human","human","MIC",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,2,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"1996","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"AZM","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"1997","EUCAST 2025","human","human","DISK",NA,"B_STPHY",3,"CLI","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",22,22,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy""." +"1998","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"CLI","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy""." +"1999","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"CLR","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"2000","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"DAL","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems." +"2001","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"DAP","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2002","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"DOX","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"2003","EUCAST 2025","human","human","DISK",NA,"B_STPHY",3,"ERY","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",21,21,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"2004","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"ERY","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"2005","EUCAST 2025","human","human","DISK",NA,"B_STPHY",3,"FUS","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",24,24,FALSE,FALSE,NA +"2006","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"FUS","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"2007","EUCAST 2025","human","human","DISK",NA,"B_STPHY",3,"LNZ","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",21,21,FALSE,FALSE,NA +"2008","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"LNZ","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA +"2009","EUCAST 2025","human","human","DISK",NA,"B_STPHY",3,"MNO","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",23,23,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"2010","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"MNO","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"2011","EUCAST 2025","human","human","DISK","screen only","B_STPHY",3,"NOR","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",17,17,FALSE,FALSE,"[D] | [D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"2012","EUCAST 2025","human","human","DISK",NA,"B_STPHY",3,"QDA","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",21,21,FALSE,FALSE,NA +"2013","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"QDA","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"2014","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"RXT","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"2015","EUCAST 2025","human","human","DISK",NA,"B_STPHY",3,"SXT","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",17,14,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2016","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"SXT","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,2,4,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2017","EUCAST 2025","human","human","DISK",NA,"B_STPHY",3,"TCY","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",22,22,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"2018","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"TCY","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"2019","EUCAST 2025","human","human","DISK",NA,"B_STPHY",3,"TGC","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",19,19,FALSE,FALSE,"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2020","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"TGC","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2021","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_STPHY",3,"TMP","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",14,14,TRUE,FALSE,NA +"2022","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_STPHY",3,"TMP","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,TRUE,FALSE,NA +"2023","EUCAST 2025","human","human","DISK",NA,"B_STPHY",3,"TZD","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",20,20,FALSE,FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid." +"2024","EUCAST 2025","human","human","MIC",NA,"B_STPHY",3,"TZD","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid." +"2025","EUCAST 2025","human","human","DISK",NA,"B_STPHY_AURS",2,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2026","EUCAST 2025","human","human","MIC",NA,"B_STPHY_AURS",2,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,16,16,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2027","EUCAST 2025","human","human","DISK",NA,"B_STPHY_AURS",2,"BPR","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",17,17,FALSE,FALSE,"[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing." +"2028","EUCAST 2025","human","human","MIC",NA,"B_STPHY_AURS",2,"BPR","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[9] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing." +"2029","EUCAST 2025","human","human","DISK","Topical","B_STPHY_AURS",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",18,18,FALSE,FALSE,NA +"2030","EUCAST 2025","human","human","MIC","Topical","B_STPHY_AURS",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,16,16,FALSE,FALSE,NA +"2031","EUCAST 2025","human","human","DISK",NA,"B_STPHY_AURS",2,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"2032","EUCAST 2025","human","human","MIC",NA,"B_STPHY_AURS",2,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,2,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2033","EUCAST 2025","human","human","MIC","Topical","B_STPHY_AURS",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"2034","EUCAST 2025","human","human","DISK","indications other than pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",20,17,FALSE,FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing." +"2035","EUCAST 2025","human","human","DISK","pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",20,20,FALSE,FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing." +"2036","EUCAST 2025","human","human","MIC","indications other than pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,1,2,FALSE,FALSE,"[7] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing." +"2037","EUCAST 2025","human","human","MIC","pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[7] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing." +"2038","EUCAST 2025","human","human","MIC","community-acquired pneumonia","B_STPHY_AURS",2,"DFX","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.016,0.016,FALSE,FALSE,NA +"2039","EUCAST 2025","human","human","MIC","skin and skin structure infections","B_STPHY_AURS",2,"DFX","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2040","EUCAST 2025","human","human","DISK",NA,"B_STPHY_AURS",2,"ERV","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","20 mcg",20,20,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test." +"2041","EUCAST 2025","human","human","MIC",NA,"B_STPHY_AURS",2,"ERV","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2042","EUCAST 2025","human","human","DISK","screen only","B_STPHY_AURS",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",22,22,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant." +"2043","EUCAST 2025","human","human","DISK","Topical","B_STPHY_AURS",2,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",23,23,FALSE,FALSE,NA +"2044","EUCAST 2025","human","human","MIC","Topical","B_STPHY_AURS",2,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2045","EUCAST 2025","human","human","DISK",NA,"B_STPHY_AURS",2,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2046","EUCAST 2025","human","human","DISK","Topical","B_STPHY_AURS",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",18,18,FALSE,FALSE,NA +"2047","EUCAST 2025","human","human","MIC",NA,"B_STPHY_AURS",2,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2048","EUCAST 2025","human","human","MIC","Topical","B_STPHY_AURS",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"2049","EUCAST 2025","human","human","DISK",NA,"B_STPHY_AURS",2,"LMU","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",23,23,FALSE,FALSE,NA +"2050","EUCAST 2025","human","human","MIC",NA,"B_STPHY_AURS",2,"LMU","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2051","EUCAST 2025","human","human","DISK",NA,"B_STPHY_AURS",2,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,22,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"2052","EUCAST 2025","human","human","MIC",NA,"B_STPHY_AURS",2,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,1,FALSE,FALSE,NA +"2053","EUCAST 2025","human","human","MIC","Topical","B_STPHY_AURS",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"2054","EUCAST 2025","human","human","DISK",NA,"B_STPHY_AURS",2,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",25,25,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | [3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents." +"2055","EUCAST 2025","human","human","MIC",NA,"B_STPHY_AURS",2,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents." +"2056","EUCAST 2025","human","human","DISK","Topical","B_STPHY_AURS",2,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","200 mcg",30,30,FALSE,FALSE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used." +"2057","EUCAST 2025","human","human","MIC","Topical","B_STPHY_AURS",2,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used." +"2058","EUCAST 2025","human","human","DISK","Topical","B_STPHY_AURS",2,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",14,14,FALSE,FALSE,NA +"2059","EUCAST 2025","human","human","MIC","Topical","B_STPHY_AURS",2,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"2060","EUCAST 2025","human","human","DISK","Topical","B_STPHY_AURS",2,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",17,17,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)." +"2061","EUCAST 2025","human","human","MIC","Topical","B_STPHY_AURS",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"2062","EUCAST 2025","human","human","MIC",NA,"B_STPHY_AURS",2,"ORI","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems." +"2063","EUCAST 2025","human","human","DISK",NA,"B_STPHY_AURS",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","1 unit",26,26,FALSE,FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase." +"2064","EUCAST 2025","human","human","MIC",NA,"B_STPHY_AURS",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins." +"2065","EUCAST 2025","human","human","DISK",NA,"B_STPHY_AURS",2,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",26,26,FALSE,FALSE,NA +"2066","EUCAST 2025","human","human","MIC",NA,"B_STPHY_AURS",2,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA +"2067","EUCAST 2025","human","human","MIC","Topical","B_STPHY_AURS",2,"RTP","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2068","EUCAST 2025","human","human","MIC",NA,"B_STPHY_AURS",2,"TEC","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"2069","EUCAST 2025","human","human","MIC",NA,"B_STPHY_AURS",2,"TLV","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems." +"2070","EUCAST 2025","human","human","DISK",NA,"B_STPHY_AURS",2,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2071","EUCAST 2025","human","human","DISK","Topical","B_STPHY_AURS",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",18,18,FALSE,FALSE,NA +"2072","EUCAST 2025","human","human","MIC",NA,"B_STPHY_AURS",2,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2073","EUCAST 2025","human","human","MIC","Topical","B_STPHY_AURS",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"2074","EUCAST 2025","human","human","MIC",NA,"B_STPHY_AURS",2,"VAN","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"2075","EUCAST 2025","human","human","DISK","screen only","B_STPHY_CGLN",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans." +"2076","EUCAST 2025","human","human","DISK",NA,"B_STPHY_CONS",2.5,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2077","EUCAST 2025","human","human","MIC",NA,"B_STPHY_CONS",2.5,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,16,16,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2078","EUCAST 2025","human","human","DISK",NA,"B_STPHY_CONS",2.5,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,22,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"2079","EUCAST 2025","human","human","MIC",NA,"B_STPHY_CONS",2.5,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,2,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2080","EUCAST 2025","human","human","DISK","screen only","B_STPHY_CONS",2.5,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",22,22,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant." +"2081","EUCAST 2025","human","human","DISK",NA,"B_STPHY_CONS",2.5,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",22,22,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2082","EUCAST 2025","human","human","MIC",NA,"B_STPHY_CONS",2.5,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2083","EUCAST 2025","human","human","DISK",NA,"B_STPHY_CONS",2.5,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,24,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"2084","EUCAST 2025","human","human","MIC",NA,"B_STPHY_CONS",2.5,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,1,FALSE,FALSE,NA +"2085","EUCAST 2025","human","human","DISK",NA,"B_STPHY_CONS",2.5,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",28,28,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | [3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents." +"2086","EUCAST 2025","human","human","MIC",NA,"B_STPHY_CONS",2.5,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents." +"2087","EUCAST 2025","human","human","DISK",NA,"B_STPHY_CONS",2.5,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",30,30,FALSE,FALSE,NA +"2088","EUCAST 2025","human","human","MIC",NA,"B_STPHY_CONS",2.5,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA +"2089","EUCAST 2025","human","human","MIC",NA,"B_STPHY_CONS",2.5,"TEC","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA +"2090","EUCAST 2025","human","human","DISK",NA,"B_STPHY_CONS",2.5,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",20,20,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2091","EUCAST 2025","human","human","MIC",NA,"B_STPHY_CONS",2.5,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2092","EUCAST 2025","human","human","MIC",NA,"B_STPHY_CONS",2.5,"VAN","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA +"2093","EUCAST 2025","human","human","DISK","screen only","B_STPHY_EPDR",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",27,27,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant." +"2094","EUCAST 2025","human","human","DISK","screen only","B_STPHY_INTR",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans." +"2095","EUCAST 2025","human","human","DISK","screen only","B_STPHY_LGDN",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",27,27,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant." +"2096","EUCAST 2025","human","human","DISK",NA,"B_STPHY_LGDN",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","1 unit",26,26,FALSE,FALSE,NA +"2097","EUCAST 2025","human","human","MIC",NA,"B_STPHY_LGDN",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA +"2098","EUCAST 2025","human","human","DISK","screen only","B_STPHY_PSDN",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans." +"2099","EUCAST 2025","human","human","DISK","screen only","B_STPHY_SCHL",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans." +"2100","EUCAST 2025","human","human","DISK",NA,"B_STPHY_SPRP",2,"AMP","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",18,18,FALSE,FALSE,"[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)." +"2101","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_STPHY_SPRP",2,"NIT","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)","100 mcg",13,13,TRUE,FALSE,NA +"2102","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_STPHY_SPRP",2,"NIT","Staphylococcus (file: Clinical Breakpoint Tables v. 15.0)",NA,64,64,TRUE,FALSE,NA +"2103","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"AZM","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and" +"2104","EUCAST 2025","human","human","DISK","Topical","B_STRPT_ABCG",2.5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",21,21,FALSE,FALSE,NA +"2105","EUCAST 2025","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,NA +"2106","EUCAST 2025","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"2107","EUCAST 2025","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",17,17,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known." +"2108","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known." +"2109","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and" +"2110","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2111","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAP","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2112","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.03,0.03,FALSE,FALSE,NA +"2113","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DOX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"2114","EUCAST 2025","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",21,21,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and" +"2115","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and" +"2116","EUCAST 2025","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,32,32,FALSE,FALSE,NA +"2117","EUCAST 2025","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",19,19,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2118","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2119","EUCAST 2025","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,17,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"2120","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,2,FALSE,FALSE,NA +"2121","EUCAST 2025","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"2122","EUCAST 2025","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",19,19,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"2123","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2124","EUCAST 2025","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",23,23,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"2125","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"2126","EUCAST 2025","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2127","EUCAST 2025","human","human","DISK","screen only","B_STRPT_ABCG",2.5,"NOR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",12,12,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"2128","EUCAST 2025","human","human","DISK","Topical","B_STRPT_ABCG",2.5,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",12,12,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)." +"2129","EUCAST 2025","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA +"2130","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ORI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2131","EUCAST 2025","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","1 unit",23,23,FALSE,FALSE,NA +"2132","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.03,0.03,FALSE,FALSE,NA +"2133","EUCAST 2025","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",21,21,FALSE,FALSE,NA +"2134","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2135","EUCAST 2025","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"RTP","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA +"2136","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and" +"2137","EUCAST 2025","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",18,15,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2138","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,1,2,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2139","EUCAST 2025","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",23,23,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"2140","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"2141","EUCAST 2025","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2142","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2143","EUCAST 2025","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",19,19,FALSE,FALSE,"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2144","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2145","EUCAST 2025","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TZD","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",18,18,FALSE,FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2146","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TZD","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2147","EUCAST 2025","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",13,13,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2148","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2149","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"DAL","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2150","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"DFX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.03,0.03,FALSE,FALSE,NA +"2151","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"ORI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2152","EUCAST 2025","human","human","DISK",NA,"B_STRPT_ANGN_ANGN",1,"TZD","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",18,18,FALSE,FALSE,NA +"2153","EUCAST 2025","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"TZD","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2154","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","100 mcg",15,15,TRUE,FALSE,NA +"2155","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,64,64,TRUE,FALSE,NA +"2156","EUCAST 2025","human","human","DISK",NA,"B_STRPT_GRPB",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)","1 unit",18,18,FALSE,FALSE,NA +"2157","EUCAST 2025","human","human","MIC",NA,"B_STRPT_GRPB",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA +"2158","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMC","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,1,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit." +"2159","EUCAST 2025","human","human","DISK","indications other than endocarditis and meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",22,19,FALSE,FALSE,NA +"2160","EUCAST 2025","human","human","MIC","indications other than endocarditis and meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,1,FALSE,FALSE,NA +"2161","EUCAST 2025","human","human","MIC","endocarditis and meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2162","EUCAST 2025","human","human","MIC","endocarditis and meningitis","B_STRPT_PNMN",2,"AMX","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2163","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMX","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,1,FALSE,FALSE,NA +"2164","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"AZM","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"2165","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"BPR","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2166","EUCAST 2025","human","human","DISK",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",50,28,FALSE,FALSE,NA +"2167","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,0.5,FALSE,FALSE,NA +"2168","EUCAST 2025","human","human","DISK","Topical","B_STRPT_PNMN",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",21,21,FALSE,FALSE,NA +"2169","EUCAST 2025","human","human","MIC","Topical","B_STRPT_PNMN",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,NA +"2170","EUCAST 2025","human","human","MIC","Topical","B_STRPT_PNMN",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA +"2171","EUCAST 2025","human","human","DISK",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",19,19,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"2172","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"2173","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLR","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"2174","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPD","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2175","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPT","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2176","EUCAST 2025","human","human","MIC","indications other than endocarditis and meningitis","B_STRPT_PNMN",2,"CRO","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,2,FALSE,FALSE,NA +"2177","EUCAST 2025","human","human","MIC","endocarditis and meningitis","B_STRPT_PNMN",2,"CRO","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2178","EUCAST 2025","human","human","MIC","indications other than endocarditis and meningitis","B_STRPT_PNMN",2,"CTX","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,2,FALSE,FALSE,NA +"2179","EUCAST 2025","human","human","MIC","endocarditis and meningitis","B_STRPT_PNMN",2,"CTX","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2180","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,1,FALSE,FALSE,NA +"2181","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2182","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"DOR","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"2183","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"DOX","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"2184","EUCAST 2025","human","human","DISK",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",22,22,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"2185","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"2186","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"ETP","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2187","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"FEP","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,1,2,FALSE,FALSE,NA +"2188","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"IPM","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"2189","EUCAST 2025","human","human","DISK",NA,"B_STRPT_PNMN",2,"LMU","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",12,12,FALSE,FALSE,NA +"2190","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"LMU","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2191","EUCAST 2025","human","human","DISK",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",22,22,FALSE,FALSE,NA +"2192","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"2193","EUCAST 2025","human","human","DISK",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",50,16,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"2194","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,2,FALSE,FALSE,NA +"2195","EUCAST 2025","human","human","MIC","Topical","B_STRPT_PNMN",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"2196","EUCAST 2025","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"2197","EUCAST 2025","human","human","MIC","meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2198","EUCAST 2025","human","human","DISK",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",22,22,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"2199","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2200","EUCAST 2025","human","human","DISK",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",24,24,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"2201","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"2202","EUCAST 2025","human","human","DISK","screen only","B_STRPT_PNMN",2,"NOR","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",10,10,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"2203","EUCAST 2025","human","human","DISK","Topical","B_STRPT_PNMN",2,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",10,10,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)." +"2204","EUCAST 2025","human","human","MIC","Topical","B_STRPT_PNMN",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA +"2205","EUCAST 2025","human","human","DISK","screen only","B_STRPT_PNMN",2,"OXA","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","1 mcg",20,20,FALSE,FALSE,"[D] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below." +"2206","EUCAST 2025","human","human","MIC","indications other than endocarditis and meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,1,FALSE,FALSE,NA +"2207","EUCAST 2025","human","human","MIC","endocarditis and meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.06,0.06,FALSE,FALSE,NA +"2208","EUCAST 2025","human","human","DISK",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",22,22,FALSE,FALSE,NA +"2209","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA +"2210","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"RXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"2211","EUCAST 2025","human","human","DISK",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",13,10,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2212","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,1,2,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2213","EUCAST 2025","human","human","DISK",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",25,25,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"2214","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"2215","EUCAST 2025","human","human","DISK",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2216","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2217","EUCAST 2025","human","human","DISK",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2218","EUCAST 2025","human","human","MIC",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2219","EUCAST 2025","human","human","DISK","indications other than endocarditis","B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",21,15,FALSE,FALSE,NA +"2220","EUCAST 2025","human","human","DISK","endocarditis","B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",21,21,FALSE,FALSE,NA +"2221","EUCAST 2025","human","human","MIC","indications other than endocarditis","B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,2,FALSE,FALSE,NA +"2222","EUCAST 2025","human","human","MIC","endocarditis","B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2223","EUCAST 2025","human","human","MIC","indications other than endocarditis","B_STRPT_VIRI",2.5,"AMX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,2,FALSE,FALSE,NA +"2224","EUCAST 2025","human","human","MIC","endocarditis","B_STRPT_VIRI",2.5,"AMX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2225","EUCAST 2025","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)","2 mcg",19,19,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"2226","EUCAST 2025","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"2227","EUCAST 2025","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",27,27,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins." +"2228","EUCAST 2025","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2229","EUCAST 2025","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",23,23,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins." +"2230","EUCAST 2025","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2231","EUCAST 2025","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",26,26,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins." +"2232","EUCAST 2025","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2233","EUCAST 2025","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"DOR","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"2234","EUCAST 2025","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"ERV","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)","20 mcg",17,17,FALSE,FALSE,NA +"2235","EUCAST 2025","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ERV","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA +"2236","EUCAST 2025","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ETP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2237","EUCAST 2025","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",25,25,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins." +"2238","EUCAST 2025","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2239","EUCAST 2025","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"IMR","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit." +"2240","EUCAST 2025","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"IPM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"2241","EUCAST 2025","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"MEM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"2242","EUCAST 2025","human","human","DISK","screen only","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)","1 unit",21,21,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"2243","EUCAST 2025","human","human","DISK","indications other than endocarditis","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)","1 unit",21,12,FALSE,FALSE,NA +"2244","EUCAST 2025","human","human","DISK","endocarditis","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,21,21,FALSE,FALSE,NA +"2245","EUCAST 2025","human","human","DISK","endocarditis, in combination with other antimicrobial treatment","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,12,12,FALSE,FALSE,"[B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2246","EUCAST 2025","human","human","MIC","screen only","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"2247","EUCAST 2025","human","human","MIC","indications other than endocarditis","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,1,FALSE,FALSE,NA +"2248","EUCAST 2025","human","human","MIC","endocarditis","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2249","EUCAST 2025","human","human","MIC","endocarditis, in combination with other antimicrobial treatment","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2250","EUCAST 2025","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",16,16,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2251","EUCAST 2025","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2252","EUCAST 2025","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2253","EUCAST 2025","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2254","EUCAST 2025","human","human","DISK",NA,"B_VIBRI",3,"AZM","Vibrio (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",16,16,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test." +"2255","EUCAST 2025","human","human","MIC",NA,"B_VIBRI",3,"AZM","Vibrio (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,NA +"2256","EUCAST 2025","human","human","DISK",NA,"B_VIBRI",3,"CAZ","Vibrio (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",22,22,FALSE,FALSE,NA +"2257","EUCAST 2025","human","human","MIC",NA,"B_VIBRI",3,"CAZ","Vibrio (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"2258","EUCAST 2025","human","human","DISK",NA,"B_VIBRI",3,"CIP","Vibrio (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",23,23,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test." +"2259","EUCAST 2025","human","human","MIC",NA,"B_VIBRI",3,"CIP","Vibrio (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2260","EUCAST 2025","human","human","DISK",NA,"B_VIBRI",3,"CTX","Vibrio (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",21,21,FALSE,FALSE,NA +"2261","EUCAST 2025","human","human","MIC",NA,"B_VIBRI",3,"CTX","Vibrio (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2262","EUCAST 2025","human","human","MIC",NA,"B_VIBRI",3,"DOX","Vibrio (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2263","EUCAST 2025","human","human","DISK","screen only","B_VIBRI",3,"ERY","Vibrio (file: Clinical Breakpoint Tables v. 15.0)","15 mcg",12,12,FALSE,FALSE,"[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test." +"2264","EUCAST 2025","human","human","DISK",NA,"B_VIBRI",3,"LVX","Vibrio (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",23,23,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test." +"2265","EUCAST 2025","human","human","MIC",NA,"B_VIBRI",3,"LVX","Vibrio (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2266","EUCAST 2025","human","human","DISK",NA,"B_VIBRI",3,"MEM","Vibrio (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",24,24,FALSE,FALSE,NA +"2267","EUCAST 2025","human","human","MIC",NA,"B_VIBRI",3,"MEM","Vibrio (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2268","EUCAST 2025","human","human","DISK","screen only","B_VIBRI",3,"PEF","Vibrio (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",22,22,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test." +"2269","EUCAST 2025","human","human","DISK",NA,"B_VIBRI",3,"SXT","Vibrio (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",21,21,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2270","EUCAST 2025","human","human","MIC",NA,"B_VIBRI",3,"SXT","Vibrio (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2271","EUCAST 2025","human","human","DISK","screen only","B_VIBRI",3,"TCY","Vibrio (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",20,20,FALSE,FALSE,"[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test." +"2272","EUCAST 2025","human","human","DISK",NA,"B_VIBRI",3,"TZP","Vibrio (file: Clinical Breakpoint Tables v. 15.0)","30/6 mcg",26,26,FALSE,FALSE,NA +"2273","EUCAST 2025","human","human","MIC",NA,"B_VIBRI",3,"TZP","Vibrio (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"2274","EUCAST 2025","human","human","DISK",NA,"B_[FAM]_MORGNLLC",4,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",50,19,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem." +"2275","EUCAST 2025","human","human","MIC",NA,"B_[FAM]_MORGNLLC",4,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,4,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem." +"2276","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","20/10 mcg",19,19,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"2277","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","20/10 mcg",50,19,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"2278","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","20/10 mcg",16,16,TRUE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"2279","EUCAST 2025","human","human","DISK","other indications","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","20/10 mcg",50,19,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"2280","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"2281","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"2282","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,32,32,TRUE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"2283","EUCAST 2025","human","human","MIC","other indications","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,8,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"2284","EUCAST 2025","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2285","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",18,18,FALSE,FALSE,NA +"2286","EUCAST 2025","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2287","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,NA +"2288","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",14,14,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"2289","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",14,14,TRUE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"2290","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"2291","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,TRUE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"2292","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"2293","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,8,FALSE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"2294","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,TRUE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"2295","EUCAST 2025","human","human","MIC","other indications","B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.001,8,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"2296","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",26,21,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes." +"2297","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,1,4,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes." +"2298","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AZA","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30/20 mcg",25,25,FALSE,FALSE,NA +"2299","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AZA","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L." +"2300","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",23,23,FALSE,FALSE,NA +"2301","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2302","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",22,19,FALSE,FALSE,NA +"2303","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,1,4,FALSE,FALSE,NA +"2304","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",17,17,TRUE,FALSE,NA +"2305","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,TRUE,FALSE,NA +"2306","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",12,12,TRUE,FALSE,NA +"2307","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,16,16,TRUE,FALSE,NA +"2308","EUCAST 2025","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",17,17,FALSE,FALSE,NA +"2309","EUCAST 2025","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,16,16,FALSE,FALSE,NA +"2310","EUCAST 2025","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",25,22,FALSE,FALSE,NA +"2311","EUCAST 2025","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.5,FALSE,FALSE,NA +"2312","EUCAST 2025","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,"[2] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test." +"2313","EUCAST 2025","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,0.125,0.125,FALSE,FALSE,NA +"2314","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"COL","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)." +"2315","EUCAST 2025","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"COL","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"2316","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",21,21,TRUE,FALSE,NA +"2317","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,TRUE,FALSE,NA +"2318","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",23,23,FALSE,FALSE,NA +"2319","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2320","EUCAST 2025","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",27,24,FALSE,FALSE,NA +"2321","EUCAST 2025","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",27,27,FALSE,FALSE,NA +"2322","EUCAST 2025","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,1,2,FALSE,FALSE,NA +"2323","EUCAST 2025","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"2324","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",23,23,FALSE,FALSE,NA +"2325","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"2326","EUCAST 2025","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",20,17,FALSE,FALSE,NA +"2327","EUCAST 2025","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",20,20,FALSE,FALSE,NA +"2328","EUCAST 2025","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,1,2,FALSE,FALSE,NA +"2329","EUCAST 2025","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,1,1,FALSE,FALSE,NA +"2330","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10/4 mcg",13,13,FALSE,FALSE,NA +"2331","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L." +"2332","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30/10 mcg",22,22,FALSE,FALSE,"[7] See table of dosages for dosing for different indications." +"2333","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[8] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [7] See table of dosages for dosing for different indications." +"2334","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"DOR","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",24,21,FALSE,FALSE,NA +"2335","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"DOR","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,1,2,FALSE,FALSE,NA +"2336","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",23,23,FALSE,FALSE,NA +"2337","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2338","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FDC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",23,23,FALSE,FALSE,NA +"2339","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FDC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[4] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/." +"2340","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",27,24,FALSE,FALSE,NA +"2341","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,1,4,FALSE,FALSE,NA +"2342","EUCAST 2025","human","human","DISK","screen only","B_[ORD]_ENTRBCTR",5,"FOX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",19,19,FALSE,FALSE,"[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type." +"2343","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FPE","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30/20 mcg",22,22,FALSE,FALSE,NA +"2344","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FPE","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of enmetazobactam is fixed at 8 mg/L." +"2345","EUCAST 2025","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",17,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2346","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",17,17,FALSE,FALSE,NA +"2347","EUCAST 2025","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",17,17,FALSE,FALSE,NA +"2348","EUCAST 2025","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2349","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"2350","EUCAST 2025","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"2351","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"IMR","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10/25 mcg",22,22,FALSE,FALSE,NA +"2352","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"IMR","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L." +"2353","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",22,19,FALSE,FALSE,NA +"2354","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,2,4,FALSE,FALSE,NA +"2355","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",14,14,TRUE,FALSE,NA +"2356","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,16,16,TRUE,FALSE,NA +"2357","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",23,19,FALSE,FALSE,NA +"2358","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,1,FALSE,FALSE,NA +"2359","EUCAST 2025","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2360","EUCAST 2025","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",22,16,FALSE,FALSE,NA +"2361","EUCAST 2025","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",22,22,FALSE,FALSE,NA +"2362","EUCAST 2025","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,2,8,FALSE,FALSE,NA +"2363","EUCAST 2025","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"2364","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"MEV","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","20/10 mcg",20,20,FALSE,FALSE,NA +"2365","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MEV","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L." +"2366","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",22,22,FALSE,FALSE,"[3] Fluoroquinolone breakpoints are available for other agents." +"2367","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,"[3] Fluoroquinolone breakpoints are available for other agents." +"2368","EUCAST 2025","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",12,12,FALSE,FALSE,NA +"2369","EUCAST 2025","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,NA +"2370","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",24,24,TRUE,FALSE,NA +"2371","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.5,0.5,TRUE,FALSE,NA +"2372","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",24,22,FALSE,FALSE,NA +"2373","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.5,FALSE,FALSE,NA +"2374","EUCAST 2025","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2375","EUCAST 2025","human","human","DISK","screen only","B_[ORD]_ENTRBCTR",5,"PEF","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",24,24,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp." +"2376","EUCAST 2025","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"PEF","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",24,24,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)." +"2377","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30 mcg",20,20,FALSE,FALSE,NA +"2378","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,NA +"2379","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10/10 mcg",14,14,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"2380","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10/10 mcg",14,14,TRUE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"2381","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"2382","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,TRUE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"2383","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","1.25/23.75 mcg",14,11,FALSE,FALSE,"[7] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2384","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,2,4,FALSE,FALSE,"[7] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2385","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","75/10 mcg",23,20,FALSE,FALSE,NA +"2386","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,16,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"2387","EUCAST 2025","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","5 mcg",15,15,TRUE,FALSE,NA +"2388","EUCAST 2025","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,4,4,TRUE,FALSE,NA +"2389","EUCAST 2025","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",16,16,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2390","EUCAST 2025","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",16,16,FALSE,FALSE,NA +"2391","EUCAST 2025","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 15.0)","10 mcg",16,16,FALSE,FALSE,NA +"2392","EUCAST 2025","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2393","EUCAST 2025","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"2394","EUCAST 2025","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 15.0)",NA,2,2,FALSE,FALSE,NA +"2395","EUCAST 2025","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)","30/6 mcg",20,20,FALSE,FALSE,NA +"2396","EUCAST 2025","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 15.0)",NA,8,8,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"2397","EUCAST 2024","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"MEM","A.xylosoxidans (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",26,20,FALSE,FALSE,NA +"2398","EUCAST 2024","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"MEM","A.xylosoxidans (file: Clinical Breakpoint Tables v. 14.0)",NA,1,4,FALSE,FALSE,NA +"2399","EUCAST 2024","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"SXT","A.xylosoxidans (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",26,26,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2400","EUCAST 2024","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"SXT","A.xylosoxidans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2401","EUCAST 2024","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"TZP","A.xylosoxidans (file: Clinical Breakpoint Tables v. 14.0)","30/6 mcg",26,26,FALSE,FALSE,NA +"2402","EUCAST 2024","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"TZP","A.xylosoxidans (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"2403","EUCAST 2024","human","human","DISK","systemic infections","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",19,19,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2404","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",19,19,FALSE,FALSE,NA +"2405","EUCAST 2024","human","human","MIC","systemic infections","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2406","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,NA +"2407","EUCAST 2024","human","human","DISK",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,21,FALSE,FALSE,NA +"2408","EUCAST 2024","human","human","DISK","Topical","B_ACNTB",3,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",21,21,FALSE,FALSE,NA +"2409","EUCAST 2024","human","human","MIC",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,1,FALSE,FALSE,NA +"2410","EUCAST 2024","human","human","MIC","Topical","B_ACNTB",3,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"2411","EUCAST 2024","human","human","MIC",NA,"B_ACNTB",3,"COL","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)." +"2412","EUCAST 2024","human","human","MIC","Topical","B_ACNTB",3,"COL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"2413","EUCAST 2024","human","human","DISK",NA,"B_ACNTB",3,"DOR","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",50,22,FALSE,FALSE,NA +"2414","EUCAST 2024","human","human","MIC",NA,"B_ACNTB",3,"DOR","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,2,FALSE,FALSE,NA +"2415","EUCAST 2024","human","human","DISK","systemic infections","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",17,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2416","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",17,17,FALSE,FALSE,NA +"2417","EUCAST 2024","human","human","DISK","Topical","B_ACNTB",3,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",17,17,FALSE,FALSE,NA +"2418","EUCAST 2024","human","human","MIC","systemic infections","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2419","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA +"2420","EUCAST 2024","human","human","MIC","Topical","B_ACNTB",3,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA +"2421","EUCAST 2024","human","human","DISK",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",24,21,FALSE,FALSE,NA +"2422","EUCAST 2024","human","human","MIC",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)",NA,2,4,FALSE,FALSE,NA +"2423","EUCAST 2024","human","human","DISK",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",23,20,FALSE,FALSE,NA +"2424","EUCAST 2024","human","human","DISK","Topical","B_ACNTB",3,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",23,23,FALSE,FALSE,NA +"2425","EUCAST 2024","human","human","MIC",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,1,FALSE,FALSE,NA +"2426","EUCAST 2024","human","human","MIC","Topical","B_ACNTB",3,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2427","EUCAST 2024","human","human","DISK","indications other than meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",21,15,FALSE,FALSE,NA +"2428","EUCAST 2024","human","human","DISK","meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",21,21,FALSE,FALSE,NA +"2429","EUCAST 2024","human","human","MIC","indications other than meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)",NA,2,8,FALSE,FALSE,NA +"2430","EUCAST 2024","human","human","MIC","meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"2431","EUCAST 2024","human","human","MIC","Topical","B_ACNTB",3,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"2432","EUCAST 2024","human","human","DISK",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",14,11,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2433","EUCAST 2024","human","human","MIC",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)",NA,2,4,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2434","EUCAST 2024","human","human","DISK","systemic infections","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",17,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2435","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",17,17,FALSE,FALSE,NA +"2436","EUCAST 2024","human","human","DISK","Topical","B_ACNTB",3,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",17,17,FALSE,FALSE,NA +"2437","EUCAST 2024","human","human","MIC","systemic infections","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2438","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA +"2439","EUCAST 2024","human","human","MIC","Topical","B_ACNTB",3,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA +"2440","EUCAST 2024","human","human","DISK",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",26,26,FALSE,FALSE,NA +"2441","EUCAST 2024","human","human","MIC",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2442","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note" +"2443","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,TRUE,FALSE,NA +"2444","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility." +"2445","EUCAST 2024","human","human","DISK",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",31,31,FALSE,FALSE,NA +"2446","EUCAST 2024","human","human","MIC",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2447","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","100 mcg",16,16,TRUE,FALSE,NA +"2448","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,16,16,TRUE,FALSE,NA +"2449","EUCAST 2024","human","human","DISK","screen only","B_AERCC_SNGN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance." +"2450","EUCAST 2024","human","human","DISK",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","1 unit",21,21,FALSE,FALSE,NA +"2451","EUCAST 2024","human","human","MIC",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA +"2452","EUCAST 2024","human","human","DISK",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",25,25,FALSE,FALSE,NA +"2453","EUCAST 2024","human","human","MIC",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA +"2454","EUCAST 2024","human","human","DISK",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method." +"2455","EUCAST 2024","human","human","MIC",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"2456","EUCAST 2024","human","human","DISK",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",26,26,FALSE,FALSE,NA +"2457","EUCAST 2024","human","human","MIC",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2458","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note" +"2459","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,TRUE,FALSE,NA +"2460","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility." +"2461","EUCAST 2024","human","human","DISK",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",31,31,FALSE,FALSE,NA +"2462","EUCAST 2024","human","human","MIC",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2463","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","100 mcg",16,16,TRUE,FALSE,NA +"2464","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,16,16,TRUE,FALSE,NA +"2465","EUCAST 2024","human","human","DISK","screen only","B_AERCC_URIN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance." +"2466","EUCAST 2024","human","human","DISK",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","1 unit",21,21,FALSE,FALSE,NA +"2467","EUCAST 2024","human","human","MIC",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA +"2468","EUCAST 2024","human","human","DISK",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",25,25,FALSE,FALSE,NA +"2469","EUCAST 2024","human","human","MIC",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA +"2470","EUCAST 2024","human","human","DISK",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method." +"2471","EUCAST 2024","human","human","MIC",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"2472","EUCAST 2024","human","human","DISK",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",29,26,FALSE,FALSE,NA +"2473","EUCAST 2024","human","human","MIC",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 14.0)",NA,1,4,FALSE,FALSE,NA +"2474","EUCAST 2024","human","human","DISK",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",24,21,FALSE,FALSE,NA +"2475","EUCAST 2024","human","human","MIC",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 14.0)",NA,1,4,FALSE,FALSE,NA +"2476","EUCAST 2024","human","human","DISK",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",27,24,FALSE,FALSE,NA +"2477","EUCAST 2024","human","human","MIC",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.5,FALSE,FALSE,NA +"2478","EUCAST 2024","human","human","DISK",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",27,24,FALSE,FALSE,NA +"2479","EUCAST 2024","human","human","MIC",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 14.0)",NA,1,4,FALSE,FALSE,NA +"2480","EUCAST 2024","human","human","DISK",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",27,24,FALSE,FALSE,NA +"2481","EUCAST 2024","human","human","MIC",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,1,FALSE,FALSE,NA +"2482","EUCAST 2024","human","human","DISK",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",19,16,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2483","EUCAST 2024","human","human","MIC",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 14.0)",NA,2,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2484","EUCAST 2024","human","human","DISK",NA,"B_BCLLS",3,"CIP","Bacillus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,23,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"2485","EUCAST 2024","human","human","MIC",NA,"B_BCLLS",3,"CIP","Bacillus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,0.5,FALSE,FALSE,NA +"2486","EUCAST 2024","human","human","DISK",NA,"B_BCLLS",3,"CLI","Bacillus (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",17,17,FALSE,FALSE,NA +"2487","EUCAST 2024","human","human","MIC",NA,"B_BCLLS",3,"CLI","Bacillus (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"2488","EUCAST 2024","human","human","DISK",NA,"B_BCLLS",3,"ERY","Bacillus (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",24,24,FALSE,FALSE,NA +"2489","EUCAST 2024","human","human","MIC",NA,"B_BCLLS",3,"ERY","Bacillus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2490","EUCAST 2024","human","human","DISK",NA,"B_BCLLS",3,"IPM","Bacillus (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",30,30,FALSE,FALSE,NA +"2491","EUCAST 2024","human","human","MIC",NA,"B_BCLLS",3,"IPM","Bacillus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2492","EUCAST 2024","human","human","DISK",NA,"B_BCLLS",3,"LNZ","Bacillus (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",22,22,FALSE,FALSE,NA +"2493","EUCAST 2024","human","human","MIC",NA,"B_BCLLS",3,"LNZ","Bacillus (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"2494","EUCAST 2024","human","human","DISK",NA,"B_BCLLS",3,"LVX","Bacillus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,23,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"2495","EUCAST 2024","human","human","MIC",NA,"B_BCLLS",3,"LVX","Bacillus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,1,FALSE,FALSE,NA +"2496","EUCAST 2024","human","human","DISK",NA,"B_BCLLS",3,"MEM","Bacillus (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",25,25,FALSE,FALSE,NA +"2497","EUCAST 2024","human","human","MIC",NA,"B_BCLLS",3,"MEM","Bacillus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2498","EUCAST 2024","human","human","DISK","screen only","B_BCLLS",3,"NOR","Bacillus (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",21,21,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin." +"2499","EUCAST 2024","human","human","DISK",NA,"B_BCLLS",3,"VAN","Bacillus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",10,10,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method." +"2500","EUCAST 2024","human","human","MIC",NA,"B_BCLLS",3,"VAN","Bacillus (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"2501","EUCAST 2024","human","human","MIC",NA,"B_BCLLS_ANTH",2,"AMX","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant." +"2502","EUCAST 2024","human","human","DISK",NA,"B_BCLLS_ANTH",2,"CIP","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,24,FALSE,FALSE,NA +"2503","EUCAST 2024","human","human","MIC",NA,"B_BCLLS_ANTH",2,"CIP","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,0.25,FALSE,FALSE,NA +"2504","EUCAST 2024","human","human","DISK",NA,"B_BCLLS_ANTH",2,"CLI","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",17,17,FALSE,FALSE,NA +"2505","EUCAST 2024","human","human","MIC",NA,"B_BCLLS_ANTH",2,"CLI","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"2506","EUCAST 2024","human","human","MIC",NA,"B_BCLLS_ANTH",2,"DOX","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant." +"2507","EUCAST 2024","human","human","DISK",NA,"B_BCLLS_ANTH",2,"LNZ","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",20,20,FALSE,FALSE,NA +"2508","EUCAST 2024","human","human","MIC",NA,"B_BCLLS_ANTH",2,"LNZ","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"2509","EUCAST 2024","human","human","DISK",NA,"B_BCLLS_ANTH",2,"LVX","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,23,FALSE,FALSE,NA +"2510","EUCAST 2024","human","human","MIC",NA,"B_BCLLS_ANTH",2,"LVX","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,0.5,FALSE,FALSE,NA +"2511","EUCAST 2024","human","human","DISK",NA,"B_BCLLS_ANTH",2,"PEN","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)","1 unit",50,18,FALSE,FALSE,NA +"2512","EUCAST 2024","human","human","MIC",NA,"B_BCLLS_ANTH",2,"PEN","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,0.5,FALSE,FALSE,NA +"2513","EUCAST 2024","human","human","DISK",NA,"B_BCLLS_ANTH",2,"RIF","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",12,12,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2514","EUCAST 2024","human","human","MIC",NA,"B_BCLLS_ANTH",2,"RIF","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2515","EUCAST 2024","human","human","DISK",NA,"B_BCLLS_ANTH",2,"TCY","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",26,26,FALSE,FALSE,NA +"2516","EUCAST 2024","human","human","MIC",NA,"B_BCLLS_ANTH",2,"TCY","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA +"2517","EUCAST 2024","human","human","DISK",NA,"B_BCLLS_ANTH",2,"VAN","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",10,10,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2518","EUCAST 2024","human","human","MIC",NA,"B_BCLLS_ANTH",2,"VAN","B.anthracis (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2519","EUCAST 2024","human","human","DISK",NA,"B_BCTRD",3,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","2/1 mcg",14,14,FALSE,FALSE,NA +"2520","EUCAST 2024","human","human","MIC",NA,"B_BCTRD",3,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"2521","EUCAST 2024","human","human","DISK",NA,"B_BCTRD",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",10,10,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading." +"2522","EUCAST 2024","human","human","MIC",NA,"B_BCTRD",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,"[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2523","EUCAST 2024","human","human","DISK",NA,"B_BCTRD",3,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",23,23,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2524","EUCAST 2024","human","human","MIC",NA,"B_BCTRD",3,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2525","EUCAST 2024","human","human","DISK",NA,"B_BCTRD",3,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",29,29,FALSE,FALSE,NA +"2526","EUCAST 2024","human","human","MIC",NA,"B_BCTRD",3,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"2527","EUCAST 2024","human","human","DISK",NA,"B_BCTRD",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",28,28,FALSE,FALSE,NA +"2528","EUCAST 2024","human","human","MIC",NA,"B_BCTRD",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"2529","EUCAST 2024","human","human","DISK",NA,"B_BCTRD",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",25,25,FALSE,FALSE,NA +"2530","EUCAST 2024","human","human","MIC",NA,"B_BCTRD",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA +"2531","EUCAST 2024","human","human","DISK",NA,"B_BCTRD",3,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10/10 mcg",25,25,FALSE,FALSE,NA +"2532","EUCAST 2024","human","human","MIC",NA,"B_BCTRD",3,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L." +"2533","EUCAST 2024","human","human","DISK",NA,"B_BCTRD",3,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","30/6 mcg",24,24,FALSE,FALSE,NA +"2534","EUCAST 2024","human","human","MIC",NA,"B_BCTRD",3,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"2535","EUCAST 2024","human","human","DISK",NA,"B_BRCLL_MLTN",2,"CIP","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,27,FALSE,FALSE,NA +"2536","EUCAST 2024","human","human","MIC",NA,"B_BRCLL_MLTN",2,"CIP","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,1,FALSE,FALSE,NA +"2537","EUCAST 2024","human","human","DISK","meningitis","B_BRCLL_MLTN",2,"CRO","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",30,30,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2538","EUCAST 2024","human","human","MIC","meningitis","B_BRCLL_MLTN",2,"CRO","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2539","EUCAST 2024","human","human","MIC",NA,"B_BRCLL_MLTN",2,"DOX","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant." +"2540","EUCAST 2024","human","human","DISK",NA,"B_BRCLL_MLTN",2,"GEN","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",23,23,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2541","EUCAST 2024","human","human","MIC",NA,"B_BRCLL_MLTN",2,"GEN","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2542","EUCAST 2024","human","human","DISK",NA,"B_BRCLL_MLTN",2,"LVX","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,28,FALSE,FALSE,NA +"2543","EUCAST 2024","human","human","MIC",NA,"B_BRCLL_MLTN",2,"LVX","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,1,FALSE,FALSE,NA +"2544","EUCAST 2024","human","human","DISK",NA,"B_BRCLL_MLTN",2,"RIF","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",20,20,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading." +"2545","EUCAST 2024","human","human","MIC",NA,"B_BRCLL_MLTN",2,"RIF","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2546","EUCAST 2024","human","human","DISK",NA,"B_BRCLL_MLTN",2,"STR1","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2547","EUCAST 2024","human","human","MIC",NA,"B_BRCLL_MLTN",2,"STR1","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2548","EUCAST 2024","human","human","DISK",NA,"B_BRCLL_MLTN",2,"SXT","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",29,29,FALSE,FALSE,"[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone. | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2549","EUCAST 2024","human","human","MIC",NA,"B_BRCLL_MLTN",2,"SXT","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2550","EUCAST 2024","human","human","DISK",NA,"B_BRCLL_MLTN",2,"TCY","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",42,42,FALSE,FALSE,NA +"2551","EUCAST 2024","human","human","MIC",NA,"B_BRCLL_MLTN",2,"TCY","B.melitensis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2552","EUCAST 2024","human","human","DISK",NA,"B_BRKHL_PSDM",2,"AMC","B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)","20/10 mcg",50,22,FALSE,FALSE,NA +"2553","EUCAST 2024","human","human","MIC",NA,"B_BRKHL_PSDM",2,"AMC","B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,8,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"2554","EUCAST 2024","human","human","DISK",NA,"B_BRKHL_PSDM",2,"CAZ","B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",50,18,FALSE,FALSE,NA +"2555","EUCAST 2024","human","human","MIC",NA,"B_BRKHL_PSDM",2,"CAZ","B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,8,FALSE,FALSE,NA +"2556","EUCAST 2024","human","human","DISK",NA,"B_BRKHL_PSDM",2,"CHL","B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",50,22,FALSE,FALSE,NA +"2557","EUCAST 2024","human","human","MIC",NA,"B_BRKHL_PSDM",2,"CHL","B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,8,FALSE,FALSE,NA +"2558","EUCAST 2024","human","human","MIC",NA,"B_BRKHL_PSDM",2,"DOX","B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,2,FALSE,FALSE,NA +"2559","EUCAST 2024","human","human","DISK",NA,"B_BRKHL_PSDM",2,"IPM","B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",29,29,FALSE,FALSE,NA +"2560","EUCAST 2024","human","human","MIC",NA,"B_BRKHL_PSDM",2,"IPM","B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"2561","EUCAST 2024","human","human","DISK",NA,"B_BRKHL_PSDM",2,"MEM","B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",24,24,FALSE,FALSE,NA +"2562","EUCAST 2024","human","human","MIC",NA,"B_BRKHL_PSDM",2,"MEM","B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"2563","EUCAST 2024","human","human","DISK",NA,"B_BRKHL_PSDM",2,"SXT","B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",50,17,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2564","EUCAST 2024","human","human","MIC",NA,"B_BRKHL_PSDM",2,"SXT","B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2565","EUCAST 2024","human","human","DISK","screen only","B_BRKHL_PSDM",2,"TCY","B.pseudomallei (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",23,23,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline." +"2566","EUCAST 2024","human","human","DISK",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,26,FALSE,FALSE,NA +"2567","EUCAST 2024","human","human","MIC",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,0.5,FALSE,FALSE,NA +"2568","EUCAST 2024","human","human","DISK",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",24,24,FALSE,FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin." +"2569","EUCAST 2024","human","human","MIC",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin." +"2570","EUCAST 2024","human","human","DISK",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",30,30,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from tetracycline." +"2571","EUCAST 2024","human","human","MIC",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Susceptibility to doxycycline can be inferred from tetracycline." +"2572","EUCAST 2024","human","human","DISK",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,26,FALSE,FALSE,NA +"2573","EUCAST 2024","human","human","MIC",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,0.5,FALSE,FALSE,NA +"2574","EUCAST 2024","human","human","DISK",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",20,20,FALSE,FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin." +"2575","EUCAST 2024","human","human","MIC",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin." +"2576","EUCAST 2024","human","human","DISK",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",30,30,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from tetracycline." +"2577","EUCAST 2024","human","human","MIC",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Susceptibility to doxycycline can be inferred from tetracycline." +"2578","EUCAST 2024","human","human","MIC",NA,"B_CRDDS_DFFC",2,"FDX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes." +"2579","EUCAST 2024","human","human","MIC",NA,"B_CRDDS_DFFC",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes." +"2580","EUCAST 2024","human","human","MIC",NA,"B_CRDDS_DFFC",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes." +"2581","EUCAST 2024","human","human","DISK",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,25,FALSE,FALSE,NA +"2582","EUCAST 2024","human","human","MIC",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,1,FALSE,FALSE,NA +"2583","EUCAST 2024","human","human","DISK",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",20,20,FALSE,FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing." +"2584","EUCAST 2024","human","human","MIC",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing." +"2585","EUCAST 2024","human","human","DISK",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",25,25,FALSE,FALSE,NA +"2586","EUCAST 2024","human","human","MIC",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"2587","EUCAST 2024","human","human","DISK",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",25,25,FALSE,FALSE,NA +"2588","EUCAST 2024","human","human","MIC",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2589","EUCAST 2024","human","human","DISK",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)","1 unit",50,12,FALSE,FALSE,NA +"2590","EUCAST 2024","human","human","MIC",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,1,FALSE,FALSE,NA +"2591","EUCAST 2024","human","human","DISK",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",30,30,FALSE,FALSE,NA +"2592","EUCAST 2024","human","human","MIC",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA +"2593","EUCAST 2024","human","human","DISK",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",24,24,FALSE,FALSE,NA +"2594","EUCAST 2024","human","human","MIC",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"2595","EUCAST 2024","human","human","DISK",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method." +"2596","EUCAST 2024","human","human","MIC",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"2597","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_DPHT",2,"AMX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant." +"2598","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_DPHT",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,24,FALSE,FALSE,NA +"2599","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_DPHT",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,0.5,FALSE,FALSE,NA +"2600","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_DPHT",2,"CLI","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",15,15,FALSE,FALSE,"[1] Wild-type C. ulcerans is less susceptible to clindamycin." +"2601","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_DPHT",2,"CLI","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Wild-type C. ulcerans is less susceptible to clindamycin." +"2602","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_DPHT",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,15,FALSE,FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant." +"2603","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_DPHT",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,2,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant." +"2604","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_DPHT",2,"DOX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant." +"2605","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_DPHT",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",24,24,FALSE,FALSE,NA +"2606","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_DPHT",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA +"2607","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_DPHT",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",25,25,FALSE,FALSE,NA +"2608","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_DPHT",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"2609","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_DPHT",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",24,24,FALSE,FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant." +"2610","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_DPHT",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant." +"2611","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_DPHT",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","1 unit",50,12,FALSE,FALSE,NA +"2612","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_DPHT",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,1,FALSE,FALSE,NA +"2613","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_DPHT",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",24,24,FALSE,FALSE,NA +"2614","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_DPHT",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA +"2615","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_DPHT",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2616","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_DPHT",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2617","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_DPHT",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",24,24,FALSE,FALSE,NA +"2618","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_DPHT",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"2619","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_ULCR",2,"AMX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant." +"2620","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_ULCR",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,24,FALSE,FALSE,NA +"2621","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_ULCR",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,0.5,FALSE,FALSE,NA +"2622","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_ULCR",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,15,FALSE,FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant." +"2623","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_ULCR",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,2,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant." +"2624","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_ULCR",2,"DOX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant." +"2625","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_ULCR",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",24,24,FALSE,FALSE,NA +"2626","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_ULCR",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA +"2627","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_ULCR",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",25,25,FALSE,FALSE,NA +"2628","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_ULCR",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"2629","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_ULCR",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",24,24,FALSE,FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant." +"2630","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_ULCR",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant." +"2631","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_ULCR",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","1 unit",50,12,FALSE,FALSE,NA +"2632","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_ULCR",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,1,FALSE,FALSE,NA +"2633","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_ULCR",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",24,24,FALSE,FALSE,NA +"2634","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_ULCR",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA +"2635","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_ULCR",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2636","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_ULCR",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2637","EUCAST 2024","human","human","DISK",NA,"B_CRYNB_ULCR",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",24,24,FALSE,FALSE,NA +"2638","EUCAST 2024","human","human","MIC",NA,"B_CRYNB_ULCR",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"2639","EUCAST 2024","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","2/1 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2640","EUCAST 2024","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2641","EUCAST 2024","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2642","EUCAST 2024","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"AMX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2643","EUCAST 2024","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",26,26,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading." +"2644","EUCAST 2024","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2645","EUCAST 2024","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"CRO","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test." +"2646","EUCAST 2024","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"CRO","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2647","EUCAST 2024","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"CTX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",26,26,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test." +"2648","EUCAST 2024","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",28,28,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2649","EUCAST 2024","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2650","EUCAST 2024","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",39,39,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2651","EUCAST 2024","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.03,0.03,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2652","EUCAST 2024","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"LNZ","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",34,34,FALSE,FALSE,NA +"2653","EUCAST 2024","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"LNZ","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"2654","EUCAST 2024","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",28,28,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2655","EUCAST 2024","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2656","EUCAST 2024","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","1 unit",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2657","EUCAST 2024","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2658","EUCAST 2024","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10/10 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2659","EUCAST 2024","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","30/6 mcg",27,27,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2660","EUCAST 2024","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",22,22,FALSE,FALSE,NA +"2661","EUCAST 2024","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"2662","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_CTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"2663","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_CTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination." +"2664","EUCAST 2024","human","human","DISK",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method." +"2665","EUCAST 2024","human","human","MIC",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/." +"2666","EUCAST 2024","human","human","DISK",NA,"B_CTRDM_PRFR",2,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","2/1 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2667","EUCAST 2024","human","human","MIC",NA,"B_CTRDM_PRFR",2,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"2668","EUCAST 2024","human","human","DISK",NA,"B_CTRDM_PRFR",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2669","EUCAST 2024","human","human","MIC",NA,"B_CTRDM_PRFR",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2670","EUCAST 2024","human","human","MIC",NA,"B_CTRDM_PRFR",2,"AMX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2671","EUCAST 2024","human","human","DISK",NA,"B_CTRDM_PRFR",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",19,19,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading." +"2672","EUCAST 2024","human","human","MIC",NA,"B_CTRDM_PRFR",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2673","EUCAST 2024","human","human","DISK",NA,"B_CTRDM_PRFR",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2674","EUCAST 2024","human","human","MIC",NA,"B_CTRDM_PRFR",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2675","EUCAST 2024","human","human","DISK",NA,"B_CTRDM_PRFR",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2676","EUCAST 2024","human","human","MIC",NA,"B_CTRDM_PRFR",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2677","EUCAST 2024","human","human","DISK",NA,"B_CTRDM_PRFR",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2678","EUCAST 2024","human","human","MIC",NA,"B_CTRDM_PRFR",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2679","EUCAST 2024","human","human","DISK",NA,"B_CTRDM_PRFR",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",16,16,FALSE,FALSE,NA +"2680","EUCAST 2024","human","human","MIC",NA,"B_CTRDM_PRFR",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA +"2681","EUCAST 2024","human","human","DISK",NA,"B_CTRDM_PRFR",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","1 unit",15,15,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2682","EUCAST 2024","human","human","MIC",NA,"B_CTRDM_PRFR",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2683","EUCAST 2024","human","human","DISK",NA,"B_CTRDM_PRFR",2,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10/10 mcg",27,27,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2684","EUCAST 2024","human","human","MIC",NA,"B_CTRDM_PRFR",2,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L." +"2685","EUCAST 2024","human","human","DISK",NA,"B_CTRDM_PRFR",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","30/6 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2686","EUCAST 2024","human","human","MIC",NA,"B_CTRDM_PRFR",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"2687","EUCAST 2024","human","human","DISK",NA,"B_CTRDM_PRFR",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",12,12,FALSE,FALSE,NA +"2688","EUCAST 2024","human","human","MIC",NA,"B_CTRDM_PRFR",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"2689","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_ENTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"2690","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_ENTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination." +"2691","EUCAST 2024","human","human","MIC",NA,"B_ENTRC",3,"AMC","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,4,8,FALSE,FALSE,"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only." +"2692","EUCAST 2024","human","human","DISK",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",10,8,FALSE,FALSE,"[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only." +"2693","EUCAST 2024","human","human","MIC",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,4,8,FALSE,FALSE,"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only." +"2694","EUCAST 2024","human","human","MIC",NA,"B_ENTRC",3,"AMX","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,4,8,FALSE,FALSE,"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only." +"2695","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"2696","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,TRUE,FALSE,NA +"2697","EUCAST 2024","human","human","DISK",NA,"B_ENTRC",3,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",50,21,FALSE,FALSE,NA +"2698","EUCAST 2024","human","human","MIC",NA,"B_ENTRC",3,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,4,FALSE,FALSE,NA +"2699","EUCAST 2024","human","human","DISK",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",20,20,FALSE,FALSE,NA +"2700","EUCAST 2024","human","human","MIC",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA +"2701","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"2702","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,TRUE,FALSE,NA +"2703","EUCAST 2024","human","human","DISK","screen only","B_ENTRC",3,"NOR","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",12,12,FALSE,FALSE,"[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B." +"2704","EUCAST 2024","human","human","MIC",NA,"B_ENTRC",3,"SAM","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,4,8,FALSE,FALSE,"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only." +"2705","EUCAST 2024","human","human","DISK",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",16,16,FALSE,FALSE,NA +"2706","EUCAST 2024","human","human","MIC",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"2707","EUCAST 2024","human","human","DISK",NA,"B_ENTRC_FACM",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)","20 mcg",24,24,FALSE,FALSE,NA +"2708","EUCAST 2024","human","human","MIC",NA,"B_ENTRC_FACM",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA +"2709","EUCAST 2024","human","human","DISK",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",22,22,FALSE,FALSE,NA +"2710","EUCAST 2024","human","human","MIC",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"2711","EUCAST 2024","human","human","DISK",NA,"B_ENTRC_FACM",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",22,22,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2712","EUCAST 2024","human","human","MIC",NA,"B_ENTRC_FACM",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2713","EUCAST 2024","human","human","DISK",NA,"B_ENTRC_FCLS",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)","20 mcg",22,22,FALSE,FALSE,NA +"2714","EUCAST 2024","human","human","MIC",NA,"B_ENTRC_FCLS",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA +"2715","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)","100 mcg",15,15,TRUE,FALSE,NA +"2716","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,64,64,TRUE,FALSE,NA +"2717","EUCAST 2024","human","human","DISK",NA,"B_ENTRC_FCLS",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",20,20,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2718","EUCAST 2024","human","human","MIC",NA,"B_ENTRC_FCLS",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2719","EUCAST 2024","human","human","DISK",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",50,19,FALSE,FALSE,NA +"2720","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",19,19,TRUE,FALSE,NA +"2721","EUCAST 2024","human","human","MIC",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,8,FALSE,FALSE,NA +"2722","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,TRUE,FALSE,NA +"2723","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_ESCHR_COLI",2,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",50,20,FALSE,FALSE,"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin." +"2724","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,4,FALSE,FALSE,"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin." +"2725","EUCAST 2024","human","human","MIC",NA,"B_ESCHR_COLI",2,"DFX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA +"2726","EUCAST 2024","human","human","DISK",NA,"B_ESCHR_COLI",2,"ERV","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","20 mcg",17,17,FALSE,FALSE,NA +"2727","EUCAST 2024","human","human","MIC",NA,"B_ESCHR_COLI",2,"ERV","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2728","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","200 mcg",24,24,FALSE,FALSE,"[D] Ignore isolated colonies within the inhibition zone (see pictures below)." +"2729","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","200 mcg",24,24,TRUE,FALSE,"[D] Ignore isolated colonies within the inhibition zone (see pictures below)." +"2730","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems." +"2731","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,TRUE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems." +"2732","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"2733","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination." +"2734","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","100 mcg",11,11,TRUE,FALSE,NA +"2735","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,64,64,TRUE,FALSE,NA +"2736","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",15,15,TRUE,FALSE,NA +"2737","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,16,16,TRUE,FALSE,NA +"2738","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_ESCHR_COLI",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",50,17,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"2739","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,16,FALSE,FALSE,NA +"2740","EUCAST 2024","human","human","DISK",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method." +"2741","EUCAST 2024","human","human","MIC",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/." +"2742","EUCAST 2024","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","2/1 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2743","EUCAST 2024","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"2744","EUCAST 2024","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",27,27,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2745","EUCAST 2024","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2746","EUCAST 2024","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"AMX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2747","EUCAST 2024","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",30,30,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading." +"2748","EUCAST 2024","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2749","EUCAST 2024","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2750","EUCAST 2024","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2751","EUCAST 2024","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",36,36,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2752","EUCAST 2024","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2753","EUCAST 2024","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2754","EUCAST 2024","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.03,0.03,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2755","EUCAST 2024","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",30,30,FALSE,FALSE,NA +"2756","EUCAST 2024","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2757","EUCAST 2024","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","1 unit",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2758","EUCAST 2024","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2759","EUCAST 2024","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10/10 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2760","EUCAST 2024","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L." +"2761","EUCAST 2024","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","30/6 mcg",32,32,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2762","EUCAST 2024","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"2763","EUCAST 2024","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"AMX","H.pylori (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA +"2764","EUCAST 2024","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"CLR","H.pylori (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2765","EUCAST 2024","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"LVX","H.pylori (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"2766","EUCAST 2024","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"MTR","H.pylori (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,NA +"2767","EUCAST 2024","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"RIF","H.pylori (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"2768","EUCAST 2024","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"TCY","H.pylori (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"2769","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","2/1 mcg",15,15,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"2770","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","2/1 mcg",50,15,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"2771","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"2772","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,2,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"2773","EUCAST 2024","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",18,18,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase." +"2774","EUCAST 2024","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase." +"2775","EUCAST 2024","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"AMX","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase." +"2776","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMX","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,2,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase." +"2777","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"2778","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA +"2779","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",28,28,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages." +"2780","EUCAST 2024","human","human","DISK","Topical","B_HMPHL_INFL",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",28,28,FALSE,FALSE,NA +"2781","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages." +"2782","EUCAST 2024","human","human","MIC","Topical","B_HMPHL_INFL",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"2783","EUCAST 2024","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"2784","EUCAST 2024","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA +"2785","EUCAST 2024","human","human","MIC","meningitis","B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.03,0.03,FALSE,FALSE,NA +"2786","EUCAST 2024","human","human","MIC","Topical","B_HMPHL_INFL",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA +"2787","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"2788","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2789","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPT","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.03,0.03,FALSE,FALSE,NA +"2790","EUCAST 2024","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",32,32,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"2791","EUCAST 2024","human","human","DISK","meningitis","B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",32,32,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis." +"2792","EUCAST 2024","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA +"2793","EUCAST 2024","human","human","MIC","meningitis","B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA +"2794","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",25,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"2795","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"2796","EUCAST 2024","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"2797","EUCAST 2024","human","human","DISK","meningitis","B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis." +"2798","EUCAST 2024","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA +"2799","EUCAST 2024","human","human","MIC","meningitis","B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA +"2800","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",27,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"2801","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",50,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"2802","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,1,2,FALSE,FALSE,NA +"2803","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,1,FALSE,FALSE,NA +"2804","EUCAST 2024","human","human","DISK","pneumonia","B_HMPHL_INFL",2,"CZT","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","30/10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] See table of dosages for dosing for different indications." +"2805","EUCAST 2024","human","human","MIC","pneumonia","B_HMPHL_INFL",2,"CZT","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[2] See table of dosages for dosing for different indications." +"2806","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"DOR","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"2807","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"DOR","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"2808","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"DOX","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"2809","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"2810","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2811","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",28,28,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"2812","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2813","EUCAST 2024","human","human","MIC","Topical","B_HMPHL_INFL",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA +"2814","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"2815","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"2816","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"2817","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA +"2818","EUCAST 2024","human","human","MIC","Topical","B_HMPHL_INFL",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA +"2819","EUCAST 2024","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"2820","EUCAST 2024","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"2821","EUCAST 2024","human","human","MIC","meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2822","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"2823","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA +"2824","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",24,24,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"2825","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"2826","EUCAST 2024","human","human","DISK","screen only","B_HMPHL_INFL",2,"NAL","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",23,23,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"2827","EUCAST 2024","human","human","DISK","Topical","B_HMPHL_INFL",2,"NAL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",23,23,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)." +"2828","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"2829","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA +"2830","EUCAST 2024","human","human","MIC","Topical","B_HMPHL_INFL",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA +"2831","EUCAST 2024","human","human","DISK","screen only","B_HMPHL_INFL",2,"PEN","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","1 unit",12,12,FALSE,FALSE,"[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"2832","EUCAST 2024","human","human","DISK","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",18,18,FALSE,FALSE,NA +"2833","EUCAST 2024","human","human","MIC","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"2834","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"SAM","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv." +"2835","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",23,20,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2836","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,1,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2837","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",25,25,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"2838","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"2839","EUCAST 2024","human","human","MIC","Topical","B_HMPHL_INFL",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,NA +"2840","EUCAST 2024","human","human","DISK",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)","30/6 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"2841","EUCAST 2024","human","human","MIC",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"2842","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"AMP","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility." +"2843","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"AMX","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility." +"2844","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"AZM","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility." +"2845","EUCAST 2024","human","human","DISK",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",28,28,FALSE,FALSE,NA +"2846","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA +"2847","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"CLR","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility." +"2848","EUCAST 2024","human","human","DISK",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",30,30,FALSE,FALSE,NA +"2849","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA +"2850","EUCAST 2024","human","human","DISK",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",27,27,FALSE,FALSE,NA +"2851","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA +"2852","EUCAST 2024","human","human","DISK",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",29,29,FALSE,FALSE,NA +"2853","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2854","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"DOX","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant." +"2855","EUCAST 2024","human","human","DISK",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",20,20,FALSE,FALSE,NA +"2856","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2857","EUCAST 2024","human","human","DISK",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",28,28,FALSE,FALSE,NA +"2858","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA +"2859","EUCAST 2024","human","human","DISK",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",30,30,FALSE,FALSE,NA +"2860","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.03,0.03,FALSE,FALSE,NA +"2861","EUCAST 2024","human","human","DISK",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 14.0)","1 unit",25,25,FALSE,FALSE,NA +"2862","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.03,0.03,FALSE,FALSE,NA +"2863","EUCAST 2024","human","human","DISK",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",20,20,FALSE,FALSE,NA +"2864","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2865","EUCAST 2024","human","human","DISK",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",28,28,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2866","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2867","EUCAST 2024","human","human","DISK",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",28,28,FALSE,FALSE,NA +"2868","EUCAST 2024","human","human","MIC",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2869","EUCAST 2024","human","human","DISK",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",50,19,FALSE,FALSE,NA +"2870","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",19,19,TRUE,FALSE,NA +"2871","EUCAST 2024","human","human","MIC",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,8,FALSE,FALSE,NA +"2872","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,TRUE,FALSE,NA +"2873","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_KLBSL",3,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",50,20,FALSE,FALSE,"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin." +"2874","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_KLBSL",3,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,4,FALSE,FALSE,"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin." +"2875","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"2876","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination." +"2877","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_KLBSL",3,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",50,17,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"2878","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_KLBSL",3,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,16,FALSE,FALSE,NA +"2879","EUCAST 2024","human","human","DISK","all indications","B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",16,16,FALSE,FALSE,NA +"2880","EUCAST 2024","human","human","MIC","all indications","B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"2881","EUCAST 2024","human","human","DISK","indications other than meningitis","B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",25,25,FALSE,FALSE,NA +"2882","EUCAST 2024","human","human","MIC","indications other than meningitis","B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"2883","EUCAST 2024","human","human","DISK","all indications","B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",26,26,FALSE,FALSE,NA +"2884","EUCAST 2024","human","human","MIC","all indications","B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2885","EUCAST 2024","human","human","DISK","indications other than meningitis","B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)","1 unit",13,13,FALSE,FALSE,NA +"2886","EUCAST 2024","human","human","MIC","indications other than meningitis","B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"2887","EUCAST 2024","human","human","DISK","all indications","B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",29,29,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2888","EUCAST 2024","human","human","MIC","all indications","B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2889","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","2/1 mcg",19,19,FALSE,FALSE,NA +"2890","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"2891","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AZM","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"2892","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",21,21,FALSE,FALSE,NA +"2893","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2894","EUCAST 2024","human","human","DISK","Topical","B_MRXLL_CTRR",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",31,31,FALSE,FALSE,NA +"2895","EUCAST 2024","human","human","MIC","Topical","B_MRXLL_CTRR",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"2896","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",31,31,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"2897","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA +"2898","EUCAST 2024","human","human","MIC","Topical","B_MRXLL_CTRR",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA +"2899","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CLR","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"2900","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",24,21,FALSE,FALSE,NA +"2901","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,1,2,FALSE,FALSE,NA +"2902","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",20,17,FALSE,FALSE,NA +"2903","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,1,2,FALSE,FALSE,NA +"2904","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",21,18,FALSE,FALSE,NA +"2905","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",50,21,FALSE,FALSE,NA +"2906","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,4,8,FALSE,FALSE,NA +"2907","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,4,FALSE,FALSE,NA +"2908","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"DOR","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",30,30,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2909","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"DOR","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2910","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"DOX","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"2911","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",23,23,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"2912","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2913","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",29,29,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2914","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2915","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",20,20,FALSE,FALSE,NA +"2916","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA +"2917","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",29,29,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2918","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2919","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",29,29,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"2920","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA +"2921","EUCAST 2024","human","human","MIC","Topical","B_MRXLL_CTRR",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA +"2922","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",33,33,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2923","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2924","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",26,26,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"2925","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2926","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",25,25,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"2927","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"2928","EUCAST 2024","human","human","DISK","screen only","B_MRXLL_CTRR",2,"NAL","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",23,23,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"2929","EUCAST 2024","human","human","DISK","Topical","B_MRXLL_CTRR",2,"NAL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",23,23,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)." +"2930","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"2931","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2932","EUCAST 2024","human","human","MIC","Topical","B_MRXLL_CTRR",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2933","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"RXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"2934","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SAM","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid." +"2935","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",18,15,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2936","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,1,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"2937","EUCAST 2024","human","human","DISK",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",26,26,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"2938","EUCAST 2024","human","human","MIC",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"2939","EUCAST 2024","human","human","MIC",NA,"B_MYCBC_TBRC",2,"BDQ","M.tuberculosis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination." +"2940","EUCAST 2024","human","human","MIC",NA,"B_MYCBC_TBRC",2,"DLM","M.tuberculosis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination." +"2941","EUCAST 2024","human","human","MIC",NA,"B_NESSR_GNRR",2,"CFM","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA +"2942","EUCAST 2024","human","human","MIC",NA,"B_NESSR_GNRR",2,"CIP","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.03,0.06,FALSE,FALSE,NA +"2943","EUCAST 2024","human","human","MIC",NA,"B_NESSR_GNRR",2,"CRO","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA +"2944","EUCAST 2024","human","human","MIC",NA,"B_NESSR_GNRR",2,"CTX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA +"2945","EUCAST 2024","human","human","MIC",NA,"B_NESSR_GNRR",2,"OFX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.25,FALSE,FALSE,NA +"2946","EUCAST 2024","human","human","MIC","surrogate agent","B_NESSR_GNRR",2,"PEN","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,1,FALSE,FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)." +"2947","EUCAST 2024","human","human","MIC",NA,"B_NESSR_GNRR",2,"SPT","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)",NA,64,64,FALSE,FALSE,NA +"2948","EUCAST 2024","human","human","MIC",NA,"B_NESSR_GNRR",2,"TCY","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"2949","EUCAST 2024","human","human","MIC","indications other than meningitis","B_NESSR_MNNG",2,"AMP","N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,1,FALSE,FALSE,NA +"2950","EUCAST 2024","human","human","MIC","indications other than meningitis","B_NESSR_MNNG",2,"AMX","N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,1,FALSE,FALSE,NA +"2951","EUCAST 2024","human","human","MIC","meningitis","B_NESSR_MNNG",2,"CHL","N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages." +"2952","EUCAST 2024","human","human","MIC","all indications, including meningitis and prophylaxis","B_NESSR_MNNG",2,"CIP","N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.016,0.016,FALSE,FALSE,NA +"2953","EUCAST 2024","human","human","MIC","all indications including prophylaxis","B_NESSR_MNNG",2,"CRO","N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2954","EUCAST 2024","human","human","MIC","all indications","B_NESSR_MNNG",2,"CTX","N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"2955","EUCAST 2024","human","human","MIC","all indications","B_NESSR_MNNG",2,"MEM","N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only." +"2956","EUCAST 2024","human","human","MIC","prophylaxis only","B_NESSR_MNNG",2,"MNO","N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections." +"2957","EUCAST 2024","human","human","MIC","all indications","B_NESSR_MNNG",2,"PEN","N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2958","EUCAST 2024","human","human","MIC","prophylaxis only","B_NESSR_MNNG",2,"RIF","N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2959","EUCAST 2024","human","human","MIC","screen only","B_NESSR_MNNG",2,"TCY","N.meningitidis (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections." +"2960","EUCAST 2024","human","human","DISK",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",50,19,FALSE,FALSE,NA +"2961","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",19,19,TRUE,FALSE,NA +"2962","EUCAST 2024","human","human","MIC",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,8,FALSE,FALSE,NA +"2963","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,TRUE,FALSE,NA +"2964","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_PROTS_MRBL",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"2965","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_PROTS_MRBL",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination." +"2966","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_PROTS_MRBL",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",50,17,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"2967","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_PROTS_MRBL",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,16,FALSE,FALSE,NA +"2968","EUCAST 2024","human","human","DISK",NA,"B_PRVTL",3,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","2/1 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2969","EUCAST 2024","human","human","DISK",NA,"B_PRVTL",3,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2970","EUCAST 2024","human","human","MIC",NA,"B_PRVTL",3,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2971","EUCAST 2024","human","human","MIC",NA,"B_PRVTL",3,"AMX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2972","EUCAST 2024","human","human","DISK",NA,"B_PRVTL",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",31,31,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading." +"2973","EUCAST 2024","human","human","MIC",NA,"B_PRVTL",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"2974","EUCAST 2024","human","human","DISK",NA,"B_PRVTL",3,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",29,29,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2975","EUCAST 2024","human","human","MIC",NA,"B_PRVTL",3,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2976","EUCAST 2024","human","human","DISK",NA,"B_PRVTL",3,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2977","EUCAST 2024","human","human","MIC",NA,"B_PRVTL",3,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2978","EUCAST 2024","human","human","DISK",NA,"B_PRVTL",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",34,34,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2979","EUCAST 2024","human","human","MIC",NA,"B_PRVTL",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2980","EUCAST 2024","human","human","DISK",NA,"B_PRVTL",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",22,22,FALSE,FALSE,NA +"2981","EUCAST 2024","human","human","MIC",NA,"B_PRVTL",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA +"2982","EUCAST 2024","human","human","DISK",NA,"B_PRVTL",3,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","1 unit",20,20,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2983","EUCAST 2024","human","human","MIC",NA,"B_PRVTL",3,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2984","EUCAST 2024","human","human","DISK",NA,"B_PRVTL",3,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","10/10 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2985","EUCAST 2024","human","human","DISK",NA,"B_PRVTL",3,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 14.0)","30/6 mcg",26,26,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"2986","EUCAST 2024","human","human","DISK","systemic infections","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2987","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",15,15,FALSE,FALSE,NA +"2988","EUCAST 2024","human","human","MIC","systemic infections","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,16,16,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"2989","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,16,16,FALSE,FALSE,NA +"2990","EUCAST 2024","human","human","DISK",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",50,18,FALSE,FALSE,NA +"2991","EUCAST 2024","human","human","MIC",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,16,FALSE,FALSE,NA +"2992","EUCAST 2024","human","human","DISK",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",50,17,FALSE,FALSE,NA +"2993","EUCAST 2024","human","human","MIC",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,8,FALSE,FALSE,NA +"2994","EUCAST 2024","human","human","DISK",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,26,FALSE,FALSE,NA +"2995","EUCAST 2024","human","human","MIC",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,0.5,FALSE,FALSE,NA +"2996","EUCAST 2024","human","human","MIC",NA,"B_PSDMN",3,"COL","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)." +"2997","EUCAST 2024","human","human","DISK",NA,"B_PSDMN",3,"DOR","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",50,22,FALSE,FALSE,NA +"2998","EUCAST 2024","human","human","MIC",NA,"B_PSDMN",3,"DOR","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,2,FALSE,FALSE,NA +"2999","EUCAST 2024","human","human","DISK",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",50,21,FALSE,FALSE,NA +"3000","EUCAST 2024","human","human","MIC",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,8,FALSE,FALSE,NA +"3001","EUCAST 2024","human","human","DISK",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",50,20,FALSE,FALSE,NA +"3002","EUCAST 2024","human","human","MIC",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,4,FALSE,FALSE,NA +"3003","EUCAST 2024","human","human","DISK",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,18,FALSE,FALSE,NA +"3004","EUCAST 2024","human","human","MIC",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,2,FALSE,FALSE,NA +"3005","EUCAST 2024","human","human","DISK","indications other than meningitis","B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",24,18,FALSE,FALSE,NA +"3006","EUCAST 2024","human","human","MIC","indications other than meningitis","B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,2,8,FALSE,FALSE,NA +"3007","EUCAST 2024","human","human","DISK",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",50,18,FALSE,FALSE,NA +"3008","EUCAST 2024","human","human","MIC",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,16,FALSE,FALSE,NA +"3009","EUCAST 2024","human","human","DISK",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","75/10 mcg",50,18,FALSE,FALSE,NA +"3010","EUCAST 2024","human","human","MIC",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,16,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"3011","EUCAST 2024","human","human","DISK","systemic infections","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"3012","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",18,18,FALSE,FALSE,NA +"3013","EUCAST 2024","human","human","MIC","systemic infections","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"3014","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"3015","EUCAST 2024","human","human","DISK",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","30/6 mcg",50,18,FALSE,FALSE,NA +"3016","EUCAST 2024","human","human","MIC",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,16,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"3017","EUCAST 2024","human","human","DISK","Topical","B_PSDMN_AERG",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",26,26,FALSE,FALSE,NA +"3018","EUCAST 2024","human","human","MIC","Topical","B_PSDMN_AERG",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"3019","EUCAST 2024","human","human","MIC","Topical","B_PSDMN_AERG",2,"COL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA +"3020","EUCAST 2024","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","10/4 mcg",17,17,FALSE,FALSE,NA +"3021","EUCAST 2024","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L." +"3022","EUCAST 2024","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","30/10 mcg",23,23,FALSE,FALSE,"[3] See table of dosages for dosing for different indications." +"3023","EUCAST 2024","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] See table of dosages for dosing for different indications." +"3024","EUCAST 2024","human","human","DISK",NA,"B_PSDMN_AERG",2,"FDC","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",22,22,FALSE,FALSE,NA +"3025","EUCAST 2024","human","human","MIC",NA,"B_PSDMN_AERG",2,"FDC","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/." +"3026","EUCAST 2024","human","human","DISK","Topical","B_PSDMN_AERG",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",15,15,FALSE,FALSE,NA +"3027","EUCAST 2024","human","human","MIC","Topical","B_PSDMN_AERG",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,NA +"3028","EUCAST 2024","human","human","DISK",NA,"B_PSDMN_AERG",2,"IMR","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","10/25 mcg",22,22,FALSE,FALSE,NA +"3029","EUCAST 2024","human","human","MIC",NA,"B_PSDMN_AERG",2,"IMR","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L." +"3030","EUCAST 2024","human","human","DISK","Topical","B_PSDMN_AERG",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",18,18,FALSE,FALSE,NA +"3031","EUCAST 2024","human","human","MIC","Topical","B_PSDMN_AERG",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"3032","EUCAST 2024","human","human","DISK","indications other than meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",20,14,FALSE,FALSE,NA +"3033","EUCAST 2024","human","human","DISK","meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",20,20,FALSE,FALSE,NA +"3034","EUCAST 2024","human","human","MIC","indications other than meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,2,8,FALSE,FALSE,NA +"3035","EUCAST 2024","human","human","MIC","meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"3036","EUCAST 2024","human","human","DISK",NA,"B_PSDMN_AERG",2,"MEV","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)","20/10 mcg",14,14,FALSE,FALSE,NA +"3037","EUCAST 2024","human","human","MIC",NA,"B_PSDMN_AERG",2,"MEV","Pseudomonas (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L." +"3038","EUCAST 2024","human","human","MIC","Topical","B_PSDMN_AERG",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"3039","EUCAST 2024","human","human","DISK","Topical","B_PSDMN_AERG",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",18,18,FALSE,FALSE,NA +"3040","EUCAST 2024","human","human","MIC","Topical","B_PSDMN_AERG",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"3041","EUCAST 2024","human","human","DISK",NA,"B_PSTRL",3,"AMC","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)","2/1 mcg",15,15,FALSE,FALSE,NA +"3042","EUCAST 2024","human","human","MIC",NA,"B_PSTRL",3,"AMC","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"3043","EUCAST 2024","human","human","MIC",NA,"B_PSTRL",3,"AMP","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"3044","EUCAST 2024","human","human","MIC",NA,"B_PSTRL",3,"AMX","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"3045","EUCAST 2024","human","human","DISK",NA,"B_PSTRL",3,"CIP","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B." +"3046","EUCAST 2024","human","human","MIC",NA,"B_PSTRL",3,"CIP","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA +"3047","EUCAST 2024","human","human","DISK",NA,"B_PSTRL",3,"CTX","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",26,26,FALSE,FALSE,NA +"3048","EUCAST 2024","human","human","MIC",NA,"B_PSTRL",3,"CTX","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)",NA,0.03,0.03,FALSE,FALSE,NA +"3049","EUCAST 2024","human","human","MIC",NA,"B_PSTRL",3,"DOX","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"3050","EUCAST 2024","human","human","DISK",NA,"B_PSTRL",3,"LVX","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B." +"3051","EUCAST 2024","human","human","MIC",NA,"B_PSTRL",3,"LVX","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA +"3052","EUCAST 2024","human","human","DISK","screen only","B_PSTRL",3,"NAL","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",23,23,FALSE,FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"3053","EUCAST 2024","human","human","DISK",NA,"B_PSTRL",3,"PEN","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)","1 unit",17,17,FALSE,FALSE,NA +"3054","EUCAST 2024","human","human","MIC",NA,"B_PSTRL",3,"PEN","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"3055","EUCAST 2024","human","human","DISK",NA,"B_PSTRL",3,"SXT","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3056","EUCAST 2024","human","human","MIC",NA,"B_PSTRL",3,"SXT","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3057","EUCAST 2024","human","human","DISK","screen only","B_PSTRL",3,"TCY","Pasteurella (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",24,24,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test." +"3058","EUCAST 2024","human","human","MIC",NA,"B_SLMNL",3,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species." +"3059","EUCAST 2024","human","human","DISK",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",50,16,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3060","EUCAST 2024","human","human","MIC",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3061","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"AZM","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"3062","EUCAST 2024","human","human","DISK",NA,"B_STPHY",3,"CLI","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",22,22,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy""." +"3063","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"CLI","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy""." +"3064","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"CLR","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"3065","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"DAL","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] Coagulase-negative staphylococci susceptible to both vancomycin and teicoplanin can be reported susceptible to dalbavancin. | [5] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin." +"3066","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"DAP","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3067","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"DOX","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"3068","EUCAST 2024","human","human","DISK",NA,"B_STPHY",3,"ERY","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",21,21,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"3069","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"ERY","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"3070","EUCAST 2024","human","human","DISK",NA,"B_STPHY",3,"FUS","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",24,24,FALSE,FALSE,NA +"3071","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"FUS","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"3072","EUCAST 2024","human","human","DISK",NA,"B_STPHY",3,"LNZ","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",21,21,FALSE,FALSE,NA +"3073","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"LNZ","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA +"3074","EUCAST 2024","human","human","DISK",NA,"B_STPHY",3,"MNO","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",23,23,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"3075","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"MNO","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"3076","EUCAST 2024","human","human","DISK","screen only","B_STPHY",3,"NOR","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",17,17,FALSE,FALSE,"[D] | [D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"3077","EUCAST 2024","human","human","DISK",NA,"B_STPHY",3,"QDA","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",21,21,FALSE,FALSE,NA +"3078","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"QDA","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"3079","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"RXT","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"3080","EUCAST 2024","human","human","DISK",NA,"B_STPHY",3,"SXT","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",17,14,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3081","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"SXT","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,2,4,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3082","EUCAST 2024","human","human","DISK",NA,"B_STPHY",3,"TCY","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",22,22,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"3083","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"TCY","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"3084","EUCAST 2024","human","human","DISK",NA,"B_STPHY",3,"TGC","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",19,19,FALSE,FALSE,"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3085","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"TGC","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3086","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_STPHY",3,"TMP","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",14,14,TRUE,FALSE,NA +"3087","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_STPHY",3,"TMP","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,TRUE,FALSE,NA +"3088","EUCAST 2024","human","human","DISK",NA,"B_STPHY",3,"TZD","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",20,20,FALSE,FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid." +"3089","EUCAST 2024","human","human","MIC",NA,"B_STPHY",3,"TZD","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid." +"3090","EUCAST 2024","human","human","DISK",NA,"B_STPHY_AURS",2,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"3091","EUCAST 2024","human","human","MIC",NA,"B_STPHY_AURS",2,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,16,16,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"3092","EUCAST 2024","human","human","DISK",NA,"B_STPHY_AURS",2,"BPR","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",17,17,FALSE,FALSE,"[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing." +"3093","EUCAST 2024","human","human","MIC",NA,"B_STPHY_AURS",2,"BPR","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[8] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing." +"3094","EUCAST 2024","human","human","DISK","Topical","B_STPHY_AURS",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",18,18,FALSE,FALSE,NA +"3095","EUCAST 2024","human","human","MIC","Topical","B_STPHY_AURS",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,16,16,FALSE,FALSE,NA +"3096","EUCAST 2024","human","human","DISK",NA,"B_STPHY_AURS",2,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"3097","EUCAST 2024","human","human","MIC",NA,"B_STPHY_AURS",2,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,2,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"3098","EUCAST 2024","human","human","MIC","Topical","B_STPHY_AURS",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"3099","EUCAST 2024","human","human","DISK","indications other than pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",20,17,FALSE,FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing." +"3100","EUCAST 2024","human","human","DISK","pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",20,20,FALSE,FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing." +"3101","EUCAST 2024","human","human","MIC","indications other than pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,1,2,FALSE,FALSE,"[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing." +"3102","EUCAST 2024","human","human","MIC","pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing." +"3103","EUCAST 2024","human","human","MIC","community-acquired pneumonia","B_STPHY_AURS",2,"DFX","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.016,0.016,FALSE,FALSE,NA +"3104","EUCAST 2024","human","human","MIC","skin and skin structure infections","B_STPHY_AURS",2,"DFX","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"3105","EUCAST 2024","human","human","DISK",NA,"B_STPHY_AURS",2,"ERV","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","20 mcg",20,20,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test." +"3106","EUCAST 2024","human","human","MIC",NA,"B_STPHY_AURS",2,"ERV","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"3107","EUCAST 2024","human","human","DISK","screen only","B_STPHY_AURS",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",22,22,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant." +"3108","EUCAST 2024","human","human","DISK","Topical","B_STPHY_AURS",2,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",24,24,FALSE,FALSE,NA +"3109","EUCAST 2024","human","human","MIC","Topical","B_STPHY_AURS",2,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"3110","EUCAST 2024","human","human","DISK",NA,"B_STPHY_AURS",2,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"3111","EUCAST 2024","human","human","DISK","Topical","B_STPHY_AURS",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",18,18,FALSE,FALSE,NA +"3112","EUCAST 2024","human","human","MIC",NA,"B_STPHY_AURS",2,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"3113","EUCAST 2024","human","human","MIC","Topical","B_STPHY_AURS",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"3114","EUCAST 2024","human","human","DISK",NA,"B_STPHY_AURS",2,"LMU","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",23,23,FALSE,FALSE,NA +"3115","EUCAST 2024","human","human","MIC",NA,"B_STPHY_AURS",2,"LMU","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"3116","EUCAST 2024","human","human","DISK",NA,"B_STPHY_AURS",2,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,22,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"3117","EUCAST 2024","human","human","MIC",NA,"B_STPHY_AURS",2,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,1,FALSE,FALSE,NA +"3118","EUCAST 2024","human","human","MIC","Topical","B_STPHY_AURS",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"3119","EUCAST 2024","human","human","DISK",NA,"B_STPHY_AURS",2,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",25,25,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"3120","EUCAST 2024","human","human","MIC",NA,"B_STPHY_AURS",2,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"3121","EUCAST 2024","human","human","DISK","Topical","B_STPHY_AURS",2,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","200 mcg",30,30,FALSE,FALSE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used. +ND = No ECOFF available." +"3122","EUCAST 2024","human","human","MIC","Topical","B_STPHY_AURS",2,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used. +ND = No ECOFF available." +"3123","EUCAST 2024","human","human","DISK","Topical","B_STPHY_AURS",2,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",14,14,FALSE,FALSE,NA +"3124","EUCAST 2024","human","human","MIC","Topical","B_STPHY_AURS",2,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"3125","EUCAST 2024","human","human","DISK","Topical","B_STPHY_AURS",2,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",17,17,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)." +"3126","EUCAST 2024","human","human","MIC","Topical","B_STPHY_AURS",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"3127","EUCAST 2024","human","human","MIC",NA,"B_STPHY_AURS",2,"ORI","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin." +"3128","EUCAST 2024","human","human","DISK",NA,"B_STPHY_AURS",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","1 unit",26,26,FALSE,FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase." +"3129","EUCAST 2024","human","human","MIC",NA,"B_STPHY_AURS",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins." +"3130","EUCAST 2024","human","human","DISK",NA,"B_STPHY_AURS",2,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",26,26,FALSE,FALSE,NA +"3131","EUCAST 2024","human","human","MIC",NA,"B_STPHY_AURS",2,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA +"3132","EUCAST 2024","human","human","MIC","Topical","B_STPHY_AURS",2,"RTP","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"3133","EUCAST 2024","human","human","MIC",NA,"B_STPHY_AURS",2,"TEC","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"3134","EUCAST 2024","human","human","MIC",NA,"B_STPHY_AURS",2,"TLV","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [6] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin." +"3135","EUCAST 2024","human","human","DISK",NA,"B_STPHY_AURS",2,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"3136","EUCAST 2024","human","human","DISK","Topical","B_STPHY_AURS",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",18,18,FALSE,FALSE,NA +"3137","EUCAST 2024","human","human","MIC",NA,"B_STPHY_AURS",2,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"3138","EUCAST 2024","human","human","MIC","Topical","B_STPHY_AURS",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"3139","EUCAST 2024","human","human","MIC",NA,"B_STPHY_AURS",2,"VAN","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"3140","EUCAST 2024","human","human","DISK","screen only","B_STPHY_CGLN",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans." +"3141","EUCAST 2024","human","human","DISK",NA,"B_STPHY_CONS",2.5,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"3142","EUCAST 2024","human","human","MIC",NA,"B_STPHY_CONS",2.5,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,16,16,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"3143","EUCAST 2024","human","human","DISK",NA,"B_STPHY_CONS",2.5,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,22,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"3144","EUCAST 2024","human","human","MIC",NA,"B_STPHY_CONS",2.5,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,2,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"3145","EUCAST 2024","human","human","DISK","screen only","B_STPHY_CONS",2.5,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",22,22,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant." +"3146","EUCAST 2024","human","human","DISK",NA,"B_STPHY_CONS",2.5,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",22,22,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"3147","EUCAST 2024","human","human","MIC",NA,"B_STPHY_CONS",2.5,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"3148","EUCAST 2024","human","human","DISK",NA,"B_STPHY_CONS",2.5,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,24,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"3149","EUCAST 2024","human","human","MIC",NA,"B_STPHY_CONS",2.5,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,1,FALSE,FALSE,NA +"3150","EUCAST 2024","human","human","DISK",NA,"B_STPHY_CONS",2.5,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",28,28,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"3151","EUCAST 2024","human","human","MIC",NA,"B_STPHY_CONS",2.5,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"3152","EUCAST 2024","human","human","DISK",NA,"B_STPHY_CONS",2.5,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",30,30,FALSE,FALSE,NA +"3153","EUCAST 2024","human","human","MIC",NA,"B_STPHY_CONS",2.5,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA +"3154","EUCAST 2024","human","human","MIC",NA,"B_STPHY_CONS",2.5,"TEC","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA +"3155","EUCAST 2024","human","human","DISK",NA,"B_STPHY_CONS",2.5,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",20,20,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"3156","EUCAST 2024","human","human","MIC",NA,"B_STPHY_CONS",2.5,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"3157","EUCAST 2024","human","human","MIC",NA,"B_STPHY_CONS",2.5,"VAN","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA +"3158","EUCAST 2024","human","human","DISK","screen only","B_STPHY_EPDR",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",27,27,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant." +"3159","EUCAST 2024","human","human","DISK","screen only","B_STPHY_INTR",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans." +"3160","EUCAST 2024","human","human","DISK","screen only","B_STPHY_LGDN",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",27,27,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant." +"3161","EUCAST 2024","human","human","DISK",NA,"B_STPHY_LGDN",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","1 unit",26,26,FALSE,FALSE,NA +"3162","EUCAST 2024","human","human","MIC",NA,"B_STPHY_LGDN",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA +"3163","EUCAST 2024","human","human","DISK","screen only","B_STPHY_PSDN",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans." +"3164","EUCAST 2024","human","human","DISK","screen only","B_STPHY_SCHL",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans." +"3165","EUCAST 2024","human","human","DISK",NA,"B_STPHY_SPRP",2,"AMP","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",18,18,FALSE,FALSE,"[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)." +"3166","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_STPHY_SPRP",2,"NIT","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)","100 mcg",13,13,TRUE,FALSE,NA +"3167","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_STPHY_SPRP",2,"NIT","Staphylococcus (file: Clinical Breakpoint Tables v. 14.0)",NA,64,64,TRUE,FALSE,NA +"3168","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"AZM","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and" +"3169","EUCAST 2024","human","human","DISK","Topical","B_STRPT_ABCG",2.5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",21,21,FALSE,FALSE,NA +"3170","EUCAST 2024","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,NA +"3171","EUCAST 2024","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"3172","EUCAST 2024","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",17,17,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known." +"3173","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known." +"3174","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and" +"3175","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3176","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAP","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3177","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.03,0.03,FALSE,FALSE,NA +"3178","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DOX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"3179","EUCAST 2024","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",21,21,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and" +"3180","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and" +"3181","EUCAST 2024","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,32,32,FALSE,FALSE,NA +"3182","EUCAST 2024","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",19,19,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3183","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3184","EUCAST 2024","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,17,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"3185","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,2,FALSE,FALSE,NA +"3186","EUCAST 2024","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"3187","EUCAST 2024","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",19,19,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"3188","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"3189","EUCAST 2024","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",23,23,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"3190","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"3191","EUCAST 2024","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"3192","EUCAST 2024","human","human","DISK","screen only","B_STRPT_ABCG",2.5,"NOR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",12,12,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"3193","EUCAST 2024","human","human","DISK","Topical","B_STRPT_ABCG",2.5,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",12,12,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)." +"3194","EUCAST 2024","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA +"3195","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ORI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3196","EUCAST 2024","human","human","DISK","indications other than meningitis","B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","1 unit",18,18,FALSE,FALSE,NA +"3197","EUCAST 2024","human","human","MIC","indications other than meningitis","B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"3198","EUCAST 2024","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",21,21,FALSE,FALSE,NA +"3199","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA +"3200","EUCAST 2024","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"RTP","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA +"3201","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and" +"3202","EUCAST 2024","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",18,15,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3203","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,1,2,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3204","EUCAST 2024","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",23,23,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"3205","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"3206","EUCAST 2024","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3207","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3208","EUCAST 2024","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",19,19,FALSE,FALSE,"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3209","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3210","EUCAST 2024","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TZD","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",18,18,FALSE,FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3211","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TZD","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3212","EUCAST 2024","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",13,13,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3213","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3214","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"DAL","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3215","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"DFX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,0.03,0.03,FALSE,FALSE,NA +"3216","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"ORI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3217","EUCAST 2024","human","human","DISK",NA,"B_STRPT_ANGN_ANGN",1,"TZD","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",18,18,FALSE,FALSE,NA +"3218","EUCAST 2024","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"TZD","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"3219","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","100 mcg",15,15,TRUE,FALSE,NA +"3220","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,64,64,TRUE,FALSE,NA +"3221","EUCAST 2024","human","human","DISK","meningitis","B_STRPT_GRPB",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)","1 unit",19,19,FALSE,FALSE,NA +"3222","EUCAST 2024","human","human","MIC","meningitis","B_STRPT_GRPB",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA +"3223","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMC","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,1,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit." +"3224","EUCAST 2024","human","human","DISK","indications other than meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",22,19,FALSE,FALSE,NA +"3225","EUCAST 2024","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,1,FALSE,FALSE,NA +"3226","EUCAST 2024","human","human","MIC","meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"3227","EUCAST 2024","human","human","MIC","meningitis","B_STRPT_PNMN",2,"AMX","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"3228","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMX","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,1,FALSE,FALSE,NA +"3229","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"AZM","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"3230","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"BPR","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"3231","EUCAST 2024","human","human","DISK",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",50,28,FALSE,FALSE,NA +"3232","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,0.5,FALSE,FALSE,NA +"3233","EUCAST 2024","human","human","DISK","Topical","B_STRPT_PNMN",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",21,21,FALSE,FALSE,NA +"3234","EUCAST 2024","human","human","MIC","Topical","B_STRPT_PNMN",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,NA +"3235","EUCAST 2024","human","human","MIC","Topical","B_STRPT_PNMN",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA +"3236","EUCAST 2024","human","human","DISK",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",19,19,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"3237","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"3238","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLR","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"3239","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPD","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"3240","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPT","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"3241","EUCAST 2024","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"CRO","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,2,FALSE,FALSE,NA +"3242","EUCAST 2024","human","human","MIC","meningitis","B_STRPT_PNMN",2,"CRO","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"3243","EUCAST 2024","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"CTX","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,2,FALSE,FALSE,NA +"3244","EUCAST 2024","human","human","MIC","meningitis","B_STRPT_PNMN",2,"CTX","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"3245","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,1,FALSE,FALSE,NA +"3246","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"3247","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"DOR","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"3248","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"DOX","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"3249","EUCAST 2024","human","human","DISK",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",22,22,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"3250","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"3251","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"ETP","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"3252","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"FEP","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,1,2,FALSE,FALSE,NA +"3253","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"IPM","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"3254","EUCAST 2024","human","human","DISK",NA,"B_STRPT_PNMN",2,"LMU","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",12,12,FALSE,FALSE,NA +"3255","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"LMU","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"3256","EUCAST 2024","human","human","DISK",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",22,22,FALSE,FALSE,NA +"3257","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"3258","EUCAST 2024","human","human","DISK",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",50,16,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"3259","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,2,FALSE,FALSE,NA +"3260","EUCAST 2024","human","human","MIC","Topical","B_STRPT_PNMN",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"3261","EUCAST 2024","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"3262","EUCAST 2024","human","human","MIC","meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"3263","EUCAST 2024","human","human","DISK",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",22,22,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"3264","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"3265","EUCAST 2024","human","human","DISK",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",24,24,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"3266","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"3267","EUCAST 2024","human","human","DISK","screen only","B_STRPT_PNMN",2,"NOR","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",10,10,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"3268","EUCAST 2024","human","human","DISK","Topical","B_STRPT_PNMN",2,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",10,10,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)." +"3269","EUCAST 2024","human","human","MIC","Topical","B_STRPT_PNMN",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA +"3270","EUCAST 2024","human","human","DISK","screen only","B_STRPT_PNMN",2,"OXA","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","1 mcg",20,20,FALSE,FALSE,"[C] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below." +"3271","EUCAST 2024","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,2,FALSE,FALSE,"[2] For breakpoints and dosing in pneumonia, see table of dosages." +"3272","EUCAST 2024","human","human","MIC","meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.06,0.06,FALSE,FALSE,NA +"3273","EUCAST 2024","human","human","DISK",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",22,22,FALSE,FALSE,NA +"3274","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA +"3275","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"RXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"3276","EUCAST 2024","human","human","DISK",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",13,10,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3277","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,1,2,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3278","EUCAST 2024","human","human","DISK",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",25,25,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"3279","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"3280","EUCAST 2024","human","human","DISK",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3281","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3282","EUCAST 2024","human","human","DISK",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3283","EUCAST 2024","human","human","MIC",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3284","EUCAST 2024","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",21,15,FALSE,FALSE,NA +"3285","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,2,FALSE,FALSE,NA +"3286","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"AMX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,2,FALSE,FALSE,NA +"3287","EUCAST 2024","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)","2 mcg",19,19,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"3288","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"3289","EUCAST 2024","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",27,27,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins." +"3290","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"3291","EUCAST 2024","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",23,23,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins." +"3292","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"3293","EUCAST 2024","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",26,26,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins." +"3294","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"3295","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"DOR","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"3296","EUCAST 2024","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"ERV","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)","20 mcg",17,17,FALSE,FALSE,NA +"3297","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ERV","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA +"3298","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ETP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"3299","EUCAST 2024","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",25,25,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins." +"3300","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"3301","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"IMR","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit." +"3302","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"IPM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"3303","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"MEM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"3304","EUCAST 2024","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)","1 unit",21,12,FALSE,FALSE,NA +"3305","EUCAST 2024","human","human","DISK","screen only","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)","1 unit",21,21,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"3306","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,2,FALSE,FALSE,NA +"3307","EUCAST 2024","human","human","MIC","screen only","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"3308","EUCAST 2024","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",16,16,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3309","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3310","EUCAST 2024","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3311","EUCAST 2024","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3312","EUCAST 2024","human","human","DISK",NA,"B_VIBRI",3,"AZM","Vibrio (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",16,16,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test." +"3313","EUCAST 2024","human","human","MIC",NA,"B_VIBRI",3,"AZM","Vibrio (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,FALSE,FALSE,NA +"3314","EUCAST 2024","human","human","DISK",NA,"B_VIBRI",3,"CAZ","Vibrio (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",22,22,FALSE,FALSE,NA +"3315","EUCAST 2024","human","human","MIC",NA,"B_VIBRI",3,"CAZ","Vibrio (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"3316","EUCAST 2024","human","human","DISK",NA,"B_VIBRI",3,"CIP","Vibrio (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",23,23,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test." +"3317","EUCAST 2024","human","human","MIC",NA,"B_VIBRI",3,"CIP","Vibrio (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"3318","EUCAST 2024","human","human","DISK",NA,"B_VIBRI",3,"CTX","Vibrio (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",21,21,FALSE,FALSE,NA +"3319","EUCAST 2024","human","human","MIC",NA,"B_VIBRI",3,"CTX","Vibrio (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"3320","EUCAST 2024","human","human","MIC",NA,"B_VIBRI",3,"DOX","Vibrio (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"3321","EUCAST 2024","human","human","DISK","screen only","B_VIBRI",3,"ERY","Vibrio (file: Clinical Breakpoint Tables v. 14.0)","15 mcg",12,12,FALSE,FALSE,"[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test." +"3322","EUCAST 2024","human","human","DISK",NA,"B_VIBRI",3,"LVX","Vibrio (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",23,23,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test." +"3323","EUCAST 2024","human","human","MIC",NA,"B_VIBRI",3,"LVX","Vibrio (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"3324","EUCAST 2024","human","human","DISK",NA,"B_VIBRI",3,"MEM","Vibrio (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",24,24,FALSE,FALSE,NA +"3325","EUCAST 2024","human","human","MIC",NA,"B_VIBRI",3,"MEM","Vibrio (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"3326","EUCAST 2024","human","human","DISK","screen only","B_VIBRI",3,"PEF","Vibrio (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",22,22,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test." +"3327","EUCAST 2024","human","human","DISK",NA,"B_VIBRI",3,"SXT","Vibrio (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",21,21,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3328","EUCAST 2024","human","human","MIC",NA,"B_VIBRI",3,"SXT","Vibrio (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3329","EUCAST 2024","human","human","DISK","screen only","B_VIBRI",3,"TCY","Vibrio (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",20,20,FALSE,FALSE,"[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test." +"3330","EUCAST 2024","human","human","DISK",NA,"B_VIBRI",3,"TZP","Vibrio (file: Clinical Breakpoint Tables v. 14.0)","30/6 mcg",26,26,FALSE,FALSE,NA +"3331","EUCAST 2024","human","human","MIC",NA,"B_VIBRI",3,"TZP","Vibrio (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"3332","EUCAST 2024","human","human","DISK",NA,"B_[FAM]_MORGNLLC",4,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",50,19,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem." +"3333","EUCAST 2024","human","human","MIC",NA,"B_[FAM]_MORGNLLC",4,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,4,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem." +"3334","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","20/10 mcg",19,19,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"3335","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","20/10 mcg",50,19,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"3336","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","20/10 mcg",16,16,TRUE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"3337","EUCAST 2024","human","human","DISK","other indications","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","20/10 mcg",19,19,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"3338","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"3339","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"3340","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,32,32,TRUE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"3341","EUCAST 2024","human","human","MIC","other indications","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"3342","EUCAST 2024","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"3343","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",18,18,FALSE,FALSE,NA +"3344","EUCAST 2024","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"3345","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,NA +"3346","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",14,14,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"3347","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",14,14,TRUE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"3348","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"3349","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,TRUE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"3350","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"3351","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.001,8,FALSE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"3352","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,TRUE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"3353","EUCAST 2024","human","human","MIC","other indications","B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"3354","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",26,21,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes." +"3355","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,1,4,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes." +"3356","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",23,23,FALSE,FALSE,NA +"3357","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"3358","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",22,19,FALSE,FALSE,NA +"3359","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,1,4,FALSE,FALSE,NA +"3360","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",17,17,TRUE,FALSE,NA +"3361","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,TRUE,FALSE,NA +"3362","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",12,12,TRUE,FALSE,NA +"3363","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,16,16,TRUE,FALSE,NA +"3364","EUCAST 2024","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",17,17,FALSE,FALSE,NA +"3365","EUCAST 2024","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,16,16,FALSE,FALSE,NA +"3366","EUCAST 2024","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",25,22,FALSE,FALSE,NA +"3367","EUCAST 2024","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.5,FALSE,FALSE,NA +"3368","EUCAST 2024","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,"[2] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test." +"3369","EUCAST 2024","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,0.125,0.125,FALSE,FALSE,NA +"3370","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"COL","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)." +"3371","EUCAST 2024","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"COL","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"3372","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",21,21,TRUE,FALSE,NA +"3373","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,TRUE,FALSE,NA +"3374","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",23,23,FALSE,FALSE,NA +"3375","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"3376","EUCAST 2024","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",25,22,FALSE,FALSE,NA +"3377","EUCAST 2024","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",25,25,FALSE,FALSE,NA +"3378","EUCAST 2024","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,1,2,FALSE,FALSE,NA +"3379","EUCAST 2024","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"3380","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",23,23,FALSE,FALSE,NA +"3381","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"3382","EUCAST 2024","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",20,17,FALSE,FALSE,NA +"3383","EUCAST 2024","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",20,20,FALSE,FALSE,NA +"3384","EUCAST 2024","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,1,2,FALSE,FALSE,NA +"3385","EUCAST 2024","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,1,1,FALSE,FALSE,NA +"3386","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10/4 mcg",13,13,FALSE,FALSE,NA +"3387","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L." +"3388","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30/10 mcg",22,22,FALSE,FALSE,"[6] See table of dosages for dosing for different indications." +"3389","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [6] See table of dosages for dosing for different indications." +"3390","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"DOR","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",24,21,FALSE,FALSE,NA +"3391","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"DOR","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,1,2,FALSE,FALSE,NA +"3392","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",23,23,FALSE,FALSE,NA +"3393","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,FALSE,FALSE,NA +"3394","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FDC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",23,23,FALSE,FALSE,NA +"3395","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FDC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/." +"3396","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",27,24,FALSE,FALSE,NA +"3397","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,1,4,FALSE,FALSE,NA +"3398","EUCAST 2024","human","human","DISK","screen only","B_[ORD]_ENTRBCTR",5,"FOX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",19,19,FALSE,FALSE,"[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type." +"3399","EUCAST 2024","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",17,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"3400","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",17,17,FALSE,FALSE,NA +"3401","EUCAST 2024","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",17,17,FALSE,FALSE,NA +"3402","EUCAST 2024","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"3403","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"3404","EUCAST 2024","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"3405","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"IMR","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10/25 mcg",22,22,FALSE,FALSE,NA +"3406","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"IMR","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L." +"3407","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",22,19,FALSE,FALSE,NA +"3408","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,2,4,FALSE,FALSE,NA +"3409","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",14,14,TRUE,FALSE,NA +"3410","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,16,16,TRUE,FALSE,NA +"3411","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",23,19,FALSE,FALSE,NA +"3412","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,1,FALSE,FALSE,NA +"3413","EUCAST 2024","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"3414","EUCAST 2024","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",22,16,FALSE,FALSE,NA +"3415","EUCAST 2024","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",22,22,FALSE,FALSE,NA +"3416","EUCAST 2024","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,2,8,FALSE,FALSE,NA +"3417","EUCAST 2024","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"3418","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"MEV","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","20/10 mcg",20,20,FALSE,FALSE,NA +"3419","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MEV","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L." +"3420","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",22,22,FALSE,FALSE,"[3] Fluoroquinolone breakpoints are available for other agents." +"3421","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,"[3] Fluoroquinolone breakpoints are available for other agents." +"3422","EUCAST 2024","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",12,12,FALSE,FALSE,NA +"3423","EUCAST 2024","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,NA +"3424","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",24,24,TRUE,FALSE,NA +"3425","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.5,0.5,TRUE,FALSE,NA +"3426","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",24,22,FALSE,FALSE,NA +"3427","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.5,FALSE,FALSE,NA +"3428","EUCAST 2024","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,0.25,0.25,FALSE,FALSE,NA +"3429","EUCAST 2024","human","human","DISK","screen only","B_[ORD]_ENTRBCTR",5,"PEF","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",24,24,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp." +"3430","EUCAST 2024","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"PEF","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",24,24,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)." +"3431","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30 mcg",20,20,FALSE,FALSE,NA +"3432","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,NA +"3433","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10/10 mcg",14,14,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"3434","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10/10 mcg",14,14,TRUE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"3435","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"3436","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,TRUE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"3437","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","1.25/23.75 mcg",14,11,FALSE,FALSE,"[7] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3438","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,2,4,FALSE,FALSE,"[7] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3439","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","75/10 mcg",23,20,FALSE,FALSE,NA +"3440","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,16,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"3441","EUCAST 2024","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","5 mcg",15,15,TRUE,FALSE,NA +"3442","EUCAST 2024","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,4,4,TRUE,FALSE,NA +"3443","EUCAST 2024","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",16,16,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"3444","EUCAST 2024","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",16,16,FALSE,FALSE,NA +"3445","EUCAST 2024","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 14.0)","10 mcg",16,16,FALSE,FALSE,NA +"3446","EUCAST 2024","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"3447","EUCAST 2024","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"3448","EUCAST 2024","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 14.0)",NA,2,2,FALSE,FALSE,NA +"3449","EUCAST 2024","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)","30/6 mcg",20,20,FALSE,FALSE,NA +"3450","EUCAST 2024","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 14.0)",NA,8,8,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"3451","EUCAST 2023","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"MEM","A.xylosoxidans (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",26,20,FALSE,FALSE,NA +"3452","EUCAST 2023","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"MEM","A.xylosoxidans (file: Clinical Breakpoint Tables v. 13.1)",NA,1,4,FALSE,FALSE,NA +"3453","EUCAST 2023","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"SXT","A.xylosoxidans (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",26,26,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3454","EUCAST 2023","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"SXT","A.xylosoxidans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3455","EUCAST 2023","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"TZP","A.xylosoxidans (file: Clinical Breakpoint Tables v. 13.1)","30/6 mcg",26,26,FALSE,FALSE,NA +"3456","EUCAST 2023","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"TZP","A.xylosoxidans (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"3457","EUCAST 2023","human","human","DISK","systemic infections","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",19,19,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"3458","EUCAST 2023","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",19,19,FALSE,FALSE,NA +"3459","EUCAST 2023","human","human","MIC","systemic infections","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"3460","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,NA +"3461","EUCAST 2023","human","human","DISK",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,21,FALSE,FALSE,NA +"3462","EUCAST 2023","human","human","DISK","Topical","B_ACNTB",3,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",21,21,FALSE,FALSE,NA +"3463","EUCAST 2023","human","human","MIC",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,1,FALSE,FALSE,NA +"3464","EUCAST 2023","human","human","MIC","Topical","B_ACNTB",3,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"3465","EUCAST 2023","human","human","MIC",NA,"B_ACNTB",3,"COL","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)." +"3466","EUCAST 2023","human","human","MIC","Topical","B_ACNTB",3,"COL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"3467","EUCAST 2023","human","human","DISK",NA,"B_ACNTB",3,"DOR","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",50,22,FALSE,FALSE,NA +"3468","EUCAST 2023","human","human","MIC",NA,"B_ACNTB",3,"DOR","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,2,FALSE,FALSE,NA +"3469","EUCAST 2023","human","human","DISK","systemic infections","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",17,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"3470","EUCAST 2023","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",17,17,FALSE,FALSE,NA +"3471","EUCAST 2023","human","human","DISK","Topical","B_ACNTB",3,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",17,17,FALSE,FALSE,NA +"3472","EUCAST 2023","human","human","MIC","systemic infections","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"3473","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA +"3474","EUCAST 2023","human","human","MIC","Topical","B_ACNTB",3,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA +"3475","EUCAST 2023","human","human","DISK",NA,"B_ACNTB",3,"IMR","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)","10/25 mcg",24,24,FALSE,FALSE,"[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit." +"3476","EUCAST 2023","human","human","MIC",NA,"B_ACNTB",3,"IMR","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit." +"3477","EUCAST 2023","human","human","DISK",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",24,21,FALSE,FALSE,NA +"3478","EUCAST 2023","human","human","MIC",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)",NA,2,4,FALSE,FALSE,NA +"3479","EUCAST 2023","human","human","DISK",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",23,20,FALSE,FALSE,NA +"3480","EUCAST 2023","human","human","DISK","Topical","B_ACNTB",3,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",23,23,FALSE,FALSE,NA +"3481","EUCAST 2023","human","human","MIC",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,1,FALSE,FALSE,NA +"3482","EUCAST 2023","human","human","MIC","Topical","B_ACNTB",3,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"3483","EUCAST 2023","human","human","DISK","indications other than meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",21,15,FALSE,FALSE,NA +"3484","EUCAST 2023","human","human","DISK","meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",21,21,FALSE,FALSE,NA +"3485","EUCAST 2023","human","human","MIC","indications other than meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)",NA,2,8,FALSE,FALSE,NA +"3486","EUCAST 2023","human","human","MIC","meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"3487","EUCAST 2023","human","human","MIC","Topical","B_ACNTB",3,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"3488","EUCAST 2023","human","human","DISK",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",14,11,FALSE,FALSE,"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3489","EUCAST 2023","human","human","MIC",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)",NA,2,4,FALSE,FALSE,"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3490","EUCAST 2023","human","human","DISK","systemic infections","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",17,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"3491","EUCAST 2023","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",17,17,FALSE,FALSE,NA +"3492","EUCAST 2023","human","human","DISK","Topical","B_ACNTB",3,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",17,17,FALSE,FALSE,NA +"3493","EUCAST 2023","human","human","MIC","systemic infections","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"3494","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA +"3495","EUCAST 2023","human","human","MIC","Topical","B_ACNTB",3,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA +"3496","EUCAST 2023","human","human","DISK",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",26,26,FALSE,FALSE,NA +"3497","EUCAST 2023","human","human","MIC",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"3498","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note" +"3499","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,TRUE,FALSE,NA +"3500","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility." +"3501","EUCAST 2023","human","human","DISK",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",31,31,FALSE,FALSE,NA +"3502","EUCAST 2023","human","human","MIC",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"3503","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","100 mcg",16,16,TRUE,FALSE,NA +"3504","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,16,16,TRUE,FALSE,NA +"3505","EUCAST 2023","human","human","DISK","screen only","B_AERCC_SNGN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance." +"3506","EUCAST 2023","human","human","DISK",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","1 unit",21,21,FALSE,FALSE,NA +"3507","EUCAST 2023","human","human","MIC",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA +"3508","EUCAST 2023","human","human","DISK",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",25,25,FALSE,FALSE,NA +"3509","EUCAST 2023","human","human","MIC",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA +"3510","EUCAST 2023","human","human","DISK",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method." +"3511","EUCAST 2023","human","human","MIC",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"3512","EUCAST 2023","human","human","DISK",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",26,26,FALSE,FALSE,NA +"3513","EUCAST 2023","human","human","MIC",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"3514","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note" +"3515","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,TRUE,FALSE,NA +"3516","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility." +"3517","EUCAST 2023","human","human","DISK",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",31,31,FALSE,FALSE,NA +"3518","EUCAST 2023","human","human","MIC",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"3519","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","100 mcg",16,16,TRUE,FALSE,NA +"3520","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,16,16,TRUE,FALSE,NA +"3521","EUCAST 2023","human","human","DISK","screen only","B_AERCC_URIN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance." +"3522","EUCAST 2023","human","human","DISK",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","1 unit",21,21,FALSE,FALSE,NA +"3523","EUCAST 2023","human","human","MIC",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA +"3524","EUCAST 2023","human","human","DISK",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",25,25,FALSE,FALSE,NA +"3525","EUCAST 2023","human","human","MIC",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA +"3526","EUCAST 2023","human","human","DISK",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method." +"3527","EUCAST 2023","human","human","MIC",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"3528","EUCAST 2023","human","human","DISK",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",29,26,FALSE,FALSE,NA +"3529","EUCAST 2023","human","human","MIC",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 13.1)",NA,1,4,FALSE,FALSE,NA +"3530","EUCAST 2023","human","human","DISK",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",24,21,FALSE,FALSE,NA +"3531","EUCAST 2023","human","human","MIC",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 13.1)",NA,1,4,FALSE,FALSE,NA +"3532","EUCAST 2023","human","human","DISK",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",27,24,FALSE,FALSE,NA +"3533","EUCAST 2023","human","human","MIC",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.5,FALSE,FALSE,NA +"3534","EUCAST 2023","human","human","DISK",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",27,24,FALSE,FALSE,NA +"3535","EUCAST 2023","human","human","MIC",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 13.1)",NA,1,4,FALSE,FALSE,NA +"3536","EUCAST 2023","human","human","DISK",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",27,24,FALSE,FALSE,NA +"3537","EUCAST 2023","human","human","MIC",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,1,FALSE,FALSE,NA +"3538","EUCAST 2023","human","human","DISK",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",19,16,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3539","EUCAST 2023","human","human","MIC",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 13.1)",NA,2,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3540","EUCAST 2023","human","human","DISK",NA,"B_BCLLS",3,"CIP","Bacillus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,23,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"3541","EUCAST 2023","human","human","MIC",NA,"B_BCLLS",3,"CIP","Bacillus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,0.5,FALSE,FALSE,NA +"3542","EUCAST 2023","human","human","DISK",NA,"B_BCLLS",3,"CLI","Bacillus (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",17,17,FALSE,FALSE,NA +"3543","EUCAST 2023","human","human","MIC",NA,"B_BCLLS",3,"CLI","Bacillus (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"3544","EUCAST 2023","human","human","DISK",NA,"B_BCLLS",3,"ERY","Bacillus (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",24,24,FALSE,FALSE,NA +"3545","EUCAST 2023","human","human","MIC",NA,"B_BCLLS",3,"ERY","Bacillus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"3546","EUCAST 2023","human","human","DISK",NA,"B_BCLLS",3,"IPM","Bacillus (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",30,30,FALSE,FALSE,NA +"3547","EUCAST 2023","human","human","MIC",NA,"B_BCLLS",3,"IPM","Bacillus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"3548","EUCAST 2023","human","human","DISK",NA,"B_BCLLS",3,"LNZ","Bacillus (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",22,22,FALSE,FALSE,NA +"3549","EUCAST 2023","human","human","MIC",NA,"B_BCLLS",3,"LNZ","Bacillus (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"3550","EUCAST 2023","human","human","DISK",NA,"B_BCLLS",3,"LVX","Bacillus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,23,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"3551","EUCAST 2023","human","human","MIC",NA,"B_BCLLS",3,"LVX","Bacillus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,1,FALSE,FALSE,NA +"3552","EUCAST 2023","human","human","DISK",NA,"B_BCLLS",3,"MEM","Bacillus (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",25,25,FALSE,FALSE,NA +"3553","EUCAST 2023","human","human","MIC",NA,"B_BCLLS",3,"MEM","Bacillus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"3554","EUCAST 2023","human","human","DISK","screen only","B_BCLLS",3,"NOR","Bacillus (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",21,21,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin." +"3555","EUCAST 2023","human","human","DISK",NA,"B_BCLLS",3,"VAN","Bacillus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",10,10,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method." +"3556","EUCAST 2023","human","human","MIC",NA,"B_BCLLS",3,"VAN","Bacillus (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"3557","EUCAST 2023","human","human","DISK",NA,"B_BCTRD",3,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","2/1 mcg",14,14,FALSE,FALSE,"[1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors." +"3558","EUCAST 2023","human","human","MIC",NA,"B_BCTRD",3,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors." +"3559","EUCAST 2023","human","human","DISK",NA,"B_BCTRD",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",10,10,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading." +"3560","EUCAST 2023","human","human","MIC",NA,"B_BCTRD",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,"[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"3561","EUCAST 2023","human","human","DISK",NA,"B_BCTRD",3,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",23,23,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"3562","EUCAST 2023","human","human","MIC",NA,"B_BCTRD",3,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"3563","EUCAST 2023","human","human","DISK",NA,"B_BCTRD",3,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",29,29,FALSE,FALSE,NA +"3564","EUCAST 2023","human","human","MIC",NA,"B_BCTRD",3,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"3565","EUCAST 2023","human","human","DISK",NA,"B_BCTRD",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",28,28,FALSE,FALSE,NA +"3566","EUCAST 2023","human","human","MIC",NA,"B_BCTRD",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"3567","EUCAST 2023","human","human","DISK",NA,"B_BCTRD",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",25,25,FALSE,FALSE,NA +"3568","EUCAST 2023","human","human","MIC",NA,"B_BCTRD",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA +"3569","EUCAST 2023","human","human","DISK",NA,"B_BCTRD",3,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10/10 mcg",25,25,FALSE,FALSE,"[1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors." +"3570","EUCAST 2023","human","human","MIC",NA,"B_BCTRD",3,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors." +"3571","EUCAST 2023","human","human","DISK",NA,"B_BCTRD",3,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","30/6 mcg",24,24,FALSE,FALSE,NA +"3572","EUCAST 2023","human","human","MIC",NA,"B_BCTRD",3,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"3573","EUCAST 2023","human","human","DISK",NA,"B_BRKHL_PSDM",2,"AMC","B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)","20/10 mcg",50,22,FALSE,FALSE,NA +"3574","EUCAST 2023","human","human","MIC",NA,"B_BRKHL_PSDM",2,"AMC","B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,8,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"3575","EUCAST 2023","human","human","DISK",NA,"B_BRKHL_PSDM",2,"CAZ","B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",50,18,FALSE,FALSE,NA +"3576","EUCAST 2023","human","human","MIC",NA,"B_BRKHL_PSDM",2,"CAZ","B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,8,FALSE,FALSE,NA +"3577","EUCAST 2023","human","human","DISK",NA,"B_BRKHL_PSDM",2,"CHL","B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",50,22,FALSE,FALSE,NA +"3578","EUCAST 2023","human","human","MIC",NA,"B_BRKHL_PSDM",2,"CHL","B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,8,FALSE,FALSE,NA +"3579","EUCAST 2023","human","human","MIC",NA,"B_BRKHL_PSDM",2,"DOX","B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,2,FALSE,FALSE,NA +"3580","EUCAST 2023","human","human","DISK",NA,"B_BRKHL_PSDM",2,"IPM","B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",29,29,FALSE,FALSE,NA +"3581","EUCAST 2023","human","human","MIC",NA,"B_BRKHL_PSDM",2,"IPM","B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"3582","EUCAST 2023","human","human","DISK",NA,"B_BRKHL_PSDM",2,"MEM","B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",24,24,FALSE,FALSE,NA +"3583","EUCAST 2023","human","human","MIC",NA,"B_BRKHL_PSDM",2,"MEM","B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"3584","EUCAST 2023","human","human","DISK",NA,"B_BRKHL_PSDM",2,"SXT","B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",50,17,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3585","EUCAST 2023","human","human","MIC",NA,"B_BRKHL_PSDM",2,"SXT","B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3586","EUCAST 2023","human","human","DISK","screen only","B_BRKHL_PSDM",2,"TCY","B.pseudomallei (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",23,23,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline." +"3587","EUCAST 2023","human","human","DISK",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,26,FALSE,FALSE,NA +"3588","EUCAST 2023","human","human","MIC",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,0.5,FALSE,FALSE,NA +"3589","EUCAST 2023","human","human","DISK",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",24,24,FALSE,FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin." +"3590","EUCAST 2023","human","human","MIC",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin." +"3591","EUCAST 2023","human","human","DISK",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",30,30,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from tetracycline." +"3592","EUCAST 2023","human","human","MIC",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Susceptibility to doxycycline can be inferred from tetracycline." +"3593","EUCAST 2023","human","human","DISK",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,26,FALSE,FALSE,NA +"3594","EUCAST 2023","human","human","MIC",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,0.5,FALSE,FALSE,NA +"3595","EUCAST 2023","human","human","DISK",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",20,20,FALSE,FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin." +"3596","EUCAST 2023","human","human","MIC",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin." +"3597","EUCAST 2023","human","human","DISK",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",30,30,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from tetracycline." +"3598","EUCAST 2023","human","human","MIC",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Susceptibility to doxycycline can be inferred from tetracycline." +"3599","EUCAST 2023","human","human","MIC",NA,"B_CRDDS_DFFC",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes." +"3600","EUCAST 2023","human","human","MIC",NA,"B_CRDDS_DFFC",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes." +"3601","EUCAST 2023","human","human","DISK",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,25,FALSE,FALSE,NA +"3602","EUCAST 2023","human","human","MIC",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,1,FALSE,FALSE,NA +"3603","EUCAST 2023","human","human","DISK",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",20,20,FALSE,FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing." +"3604","EUCAST 2023","human","human","MIC",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing." +"3605","EUCAST 2023","human","human","DISK",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",25,25,FALSE,FALSE,NA +"3606","EUCAST 2023","human","human","MIC",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"3607","EUCAST 2023","human","human","DISK",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",25,25,FALSE,FALSE,NA +"3608","EUCAST 2023","human","human","MIC",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"3609","EUCAST 2023","human","human","DISK",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)","1 unit",29,29,FALSE,FALSE,NA +"3610","EUCAST 2023","human","human","MIC",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA +"3611","EUCAST 2023","human","human","DISK",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",30,30,FALSE,FALSE,NA +"3612","EUCAST 2023","human","human","MIC",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA +"3613","EUCAST 2023","human","human","DISK",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",24,24,FALSE,FALSE,NA +"3614","EUCAST 2023","human","human","MIC",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"3615","EUCAST 2023","human","human","DISK",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method." +"3616","EUCAST 2023","human","human","MIC",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"3617","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_DPHT",2,"AMX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant." +"3618","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_DPHT",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,24,FALSE,FALSE,NA +"3619","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_DPHT",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,0.5,FALSE,FALSE,NA +"3620","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_DPHT",2,"CLI","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",15,15,FALSE,FALSE,"[1] Wild-type C. ulcerans is less susceptible to clindamycin." +"3621","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_DPHT",2,"CLI","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Wild-type C. ulcerans is less susceptible to clindamycin." +"3622","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_DPHT",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,15,FALSE,FALSE,"[A] Susceptibility to cefotaxime can be inferred from benzylpenicillin." +"3623","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_DPHT",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,2,FALSE,FALSE,"[1] Susceptibility to cefotaxime can be inferred from benzylpenicillin." +"3624","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_DPHT",2,"DOX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Susceptibility to doxycycline can be inferred from tetracycline." +"3625","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_DPHT",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",24,24,FALSE,FALSE,NA +"3626","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_DPHT",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA +"3627","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_DPHT",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",25,25,FALSE,FALSE,NA +"3628","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_DPHT",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"3629","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_DPHT",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",24,24,FALSE,FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant." +"3630","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_DPHT",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant." +"3631","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_DPHT",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","1 unit",50,12,FALSE,FALSE,NA +"3632","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_DPHT",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,1,FALSE,FALSE,NA +"3633","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_DPHT",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",24,24,FALSE,FALSE,NA +"3634","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_DPHT",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA +"3635","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_DPHT",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3636","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_DPHT",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3637","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_DPHT",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",24,24,FALSE,FALSE,NA +"3638","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_DPHT",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"3639","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_ULCR",2,"AMX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant." +"3640","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_ULCR",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,24,FALSE,FALSE,NA +"3641","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_ULCR",2,"CIP","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,0.5,FALSE,FALSE,NA +"3642","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_ULCR",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,15,FALSE,FALSE,"[A] Susceptibility to cefotaxime can be inferred from benzylpenicillin." +"3643","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_ULCR",2,"CTX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,2,FALSE,FALSE,"[1] Susceptibility to cefotaxime can be inferred from benzylpenicillin." +"3644","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_ULCR",2,"DOX","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Susceptibility to doxycycline can be inferred from tetracycline." +"3645","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_ULCR",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",24,24,FALSE,FALSE,NA +"3646","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_ULCR",2,"ERY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA +"3647","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_ULCR",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",25,25,FALSE,FALSE,NA +"3648","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_ULCR",2,"LNZ","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"3649","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_ULCR",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",24,24,FALSE,FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant." +"3650","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_ULCR",2,"MEM","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant." +"3651","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_ULCR",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","1 unit",50,12,FALSE,FALSE,NA +"3652","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_ULCR",2,"PEN","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,1,FALSE,FALSE,NA +"3653","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_ULCR",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",24,24,FALSE,FALSE,NA +"3654","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_ULCR",2,"RIF","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA +"3655","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_ULCR",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3656","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_ULCR",2,"SXT","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3657","EUCAST 2023","human","human","DISK",NA,"B_CRYNB_ULCR",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",24,24,FALSE,FALSE,NA +"3658","EUCAST 2023","human","human","MIC",NA,"B_CRYNB_ULCR",2,"TCY","C.diphtheriae_C.ulcerans (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"3659","EUCAST 2023","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","2/1 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3660","EUCAST 2023","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3661","EUCAST 2023","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3662","EUCAST 2023","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"AMX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3663","EUCAST 2023","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",26,26,FALSE,FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading." +"3664","EUCAST 2023","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"3665","EUCAST 2023","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"CRO","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test." +"3666","EUCAST 2023","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"CRO","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3667","EUCAST 2023","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"CTX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",26,26,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test." +"3668","EUCAST 2023","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",28,28,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3669","EUCAST 2023","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3670","EUCAST 2023","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",39,39,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3671","EUCAST 2023","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.03,0.03,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3672","EUCAST 2023","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"LNZ","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",34,34,FALSE,FALSE,NA +"3673","EUCAST 2023","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"LNZ","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"3674","EUCAST 2023","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",28,28,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3675","EUCAST 2023","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3676","EUCAST 2023","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","1 unit",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3677","EUCAST 2023","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3678","EUCAST 2023","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10/10 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3679","EUCAST 2023","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","30/6 mcg",27,27,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3680","EUCAST 2023","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",22,22,FALSE,FALSE,NA +"3681","EUCAST 2023","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"3682","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_CTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"3683","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_CTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination." +"3684","EUCAST 2023","human","human","DISK",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient inSerratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method." +"3685","EUCAST 2023","human","human","MIC",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient inSerratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/." +"3686","EUCAST 2023","human","human","DISK",NA,"B_CTRDM_PRFR",2,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","2/1 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3687","EUCAST 2023","human","human","MIC",NA,"B_CTRDM_PRFR",2,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"3688","EUCAST 2023","human","human","DISK",NA,"B_CTRDM_PRFR",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3689","EUCAST 2023","human","human","MIC",NA,"B_CTRDM_PRFR",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3690","EUCAST 2023","human","human","MIC",NA,"B_CTRDM_PRFR",2,"AMX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3691","EUCAST 2023","human","human","DISK",NA,"B_CTRDM_PRFR",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",19,19,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading." +"3692","EUCAST 2023","human","human","MIC",NA,"B_CTRDM_PRFR",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"3693","EUCAST 2023","human","human","DISK",NA,"B_CTRDM_PRFR",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3694","EUCAST 2023","human","human","MIC",NA,"B_CTRDM_PRFR",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3695","EUCAST 2023","human","human","DISK",NA,"B_CTRDM_PRFR",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3696","EUCAST 2023","human","human","MIC",NA,"B_CTRDM_PRFR",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3697","EUCAST 2023","human","human","DISK",NA,"B_CTRDM_PRFR",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3698","EUCAST 2023","human","human","MIC",NA,"B_CTRDM_PRFR",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3699","EUCAST 2023","human","human","DISK",NA,"B_CTRDM_PRFR",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",16,16,FALSE,FALSE,NA +"3700","EUCAST 2023","human","human","MIC",NA,"B_CTRDM_PRFR",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA +"3701","EUCAST 2023","human","human","DISK",NA,"B_CTRDM_PRFR",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","1 unit",15,15,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3702","EUCAST 2023","human","human","MIC",NA,"B_CTRDM_PRFR",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3703","EUCAST 2023","human","human","DISK",NA,"B_CTRDM_PRFR",2,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10/10 mcg",27,27,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3704","EUCAST 2023","human","human","MIC",NA,"B_CTRDM_PRFR",2,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L." +"3705","EUCAST 2023","human","human","DISK",NA,"B_CTRDM_PRFR",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","30/6 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3706","EUCAST 2023","human","human","MIC",NA,"B_CTRDM_PRFR",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"3707","EUCAST 2023","human","human","DISK",NA,"B_CTRDM_PRFR",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",12,12,FALSE,FALSE,NA +"3708","EUCAST 2023","human","human","MIC",NA,"B_CTRDM_PRFR",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"3709","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_ENTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"3710","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_ENTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination." +"3711","EUCAST 2023","human","human","MIC",NA,"B_ENTRC",3,"AMC","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,4,8,FALSE,FALSE,"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only." +"3712","EUCAST 2023","human","human","DISK",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",10,8,FALSE,FALSE,"[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only." +"3713","EUCAST 2023","human","human","MIC",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,4,8,FALSE,FALSE,"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only." +"3714","EUCAST 2023","human","human","MIC",NA,"B_ENTRC",3,"AMX","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,4,8,FALSE,FALSE,"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only." +"3715","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"3716","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,TRUE,FALSE,NA +"3717","EUCAST 2023","human","human","DISK",NA,"B_ENTRC",3,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",50,21,FALSE,FALSE,NA +"3718","EUCAST 2023","human","human","MIC",NA,"B_ENTRC",3,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,4,FALSE,FALSE,NA +"3719","EUCAST 2023","human","human","DISK",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",20,20,FALSE,FALSE,NA +"3720","EUCAST 2023","human","human","MIC",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA +"3721","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"3722","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,TRUE,FALSE,NA +"3723","EUCAST 2023","human","human","DISK","screen only","B_ENTRC",3,"NOR","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",12,12,FALSE,FALSE,"[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B." +"3724","EUCAST 2023","human","human","MIC",NA,"B_ENTRC",3,"SAM","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,4,8,FALSE,FALSE,"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only." +"3725","EUCAST 2023","human","human","DISK",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",16,16,FALSE,FALSE,NA +"3726","EUCAST 2023","human","human","MIC",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"3727","EUCAST 2023","human","human","DISK",NA,"B_ENTRC",3,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",12,12,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation." +"3728","EUCAST 2023","human","human","MIC",NA,"B_ENTRC",3,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA +"3729","EUCAST 2023","human","human","DISK",NA,"B_ENTRC_FACM",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)","20 mcg",24,24,FALSE,FALSE,NA +"3730","EUCAST 2023","human","human","MIC",NA,"B_ENTRC_FACM",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA +"3731","EUCAST 2023","human","human","DISK",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",22,22,FALSE,FALSE,NA +"3732","EUCAST 2023","human","human","MIC",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"3733","EUCAST 2023","human","human","DISK",NA,"B_ENTRC_FACM",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",22,22,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3734","EUCAST 2023","human","human","MIC",NA,"B_ENTRC_FACM",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3735","EUCAST 2023","human","human","DISK",NA,"B_ENTRC_FCLS",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)","20 mcg",22,22,FALSE,FALSE,NA +"3736","EUCAST 2023","human","human","MIC",NA,"B_ENTRC_FCLS",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA +"3737","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)","100 mcg",15,15,TRUE,FALSE,NA +"3738","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,64,64,TRUE,FALSE,NA +"3739","EUCAST 2023","human","human","DISK",NA,"B_ENTRC_FCLS",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",20,20,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3740","EUCAST 2023","human","human","MIC",NA,"B_ENTRC_FCLS",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3741","EUCAST 2023","human","human","DISK",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",50,19,FALSE,FALSE,NA +"3742","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",19,19,TRUE,FALSE,NA +"3743","EUCAST 2023","human","human","MIC",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,8,FALSE,FALSE,NA +"3744","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,TRUE,FALSE,NA +"3745","EUCAST 2023","human","human","DISK","infections originating from the urinary tract","B_ESCHR_COLI",2,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",50,20,FALSE,FALSE,"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin." +"3746","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,4,FALSE,FALSE,"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin." +"3747","EUCAST 2023","human","human","MIC",NA,"B_ESCHR_COLI",2,"DFX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA +"3748","EUCAST 2023","human","human","DISK",NA,"B_ESCHR_COLI",2,"ERV","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","20 mcg",17,17,FALSE,FALSE,NA +"3749","EUCAST 2023","human","human","MIC",NA,"B_ESCHR_COLI",2,"ERV","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"3750","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","200 mcg",24,24,TRUE,FALSE,"[E] Ignore isolated colonies within the inhibition zone (see pictures below)." +"3751","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,TRUE,FALSE,"[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems." +"3752","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"3753","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination." +"3754","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","100 mcg",11,11,TRUE,FALSE,NA +"3755","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,64,64,TRUE,FALSE,NA +"3756","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",15,15,TRUE,FALSE,NA +"3757","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,16,16,TRUE,FALSE,NA +"3758","EUCAST 2023","human","human","DISK","infections originating from the urinary tract","B_ESCHR_COLI",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",50,17,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"3759","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,16,FALSE,FALSE,NA +"3760","EUCAST 2023","human","human","DISK",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient inSerratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method." +"3761","EUCAST 2023","human","human","MIC",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient inSerratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/." +"3762","EUCAST 2023","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","2/1 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3763","EUCAST 2023","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"3764","EUCAST 2023","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",27,27,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3765","EUCAST 2023","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3766","EUCAST 2023","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"AMX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3767","EUCAST 2023","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",30,30,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading." +"3768","EUCAST 2023","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"3769","EUCAST 2023","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3770","EUCAST 2023","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3771","EUCAST 2023","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",36,36,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3772","EUCAST 2023","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3773","EUCAST 2023","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3774","EUCAST 2023","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.03,0.03,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3775","EUCAST 2023","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",30,30,FALSE,FALSE,NA +"3776","EUCAST 2023","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"3777","EUCAST 2023","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","1 unit",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3778","EUCAST 2023","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3779","EUCAST 2023","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10/10 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3780","EUCAST 2023","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L." +"3781","EUCAST 2023","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","30/6 mcg",32,32,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3782","EUCAST 2023","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"3783","EUCAST 2023","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"AMX","H.pylori (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA +"3784","EUCAST 2023","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"CLR","H.pylori (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"3785","EUCAST 2023","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"LVX","H.pylori (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"3786","EUCAST 2023","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"MTR","H.pylori (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,NA +"3787","EUCAST 2023","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"RIF","H.pylori (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"3788","EUCAST 2023","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"TCY","H.pylori (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"3789","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","2/1 mcg",15,15,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"3790","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","2/1 mcg",50,15,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"3791","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"3792","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,2,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"3793","EUCAST 2023","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",18,18,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase." +"3794","EUCAST 2023","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase." +"3795","EUCAST 2023","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"AMX","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase." +"3796","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMX","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,2,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase." +"3797","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"3798","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA +"3799","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",28,28,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages." +"3800","EUCAST 2023","human","human","DISK","Topical","B_HMPHL_INFL",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",28,28,FALSE,FALSE,NA +"3801","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages." +"3802","EUCAST 2023","human","human","MIC","Topical","B_HMPHL_INFL",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"3803","EUCAST 2023","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"3804","EUCAST 2023","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA +"3805","EUCAST 2023","human","human","MIC","meningitis","B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.03,0.03,FALSE,FALSE,NA +"3806","EUCAST 2023","human","human","MIC","Topical","B_HMPHL_INFL",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA +"3807","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"3808","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"3809","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPT","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.03,0.03,FALSE,FALSE,NA +"3810","EUCAST 2023","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",32,32,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"3811","EUCAST 2023","human","human","DISK","meningitis","B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",32,32,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"3812","EUCAST 2023","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA +"3813","EUCAST 2023","human","human","MIC","meningitis","B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA +"3814","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",25,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"3815","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"3816","EUCAST 2023","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"3817","EUCAST 2023","human","human","DISK","meningitis","B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"3818","EUCAST 2023","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA +"3819","EUCAST 2023","human","human","MIC","meningitis","B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA +"3820","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",27,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"3821","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",50,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"3822","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,1,2,FALSE,FALSE,NA +"3823","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,1,FALSE,FALSE,NA +"3824","EUCAST 2023","human","human","DISK","pneumonia","B_HMPHL_INFL",2,"CZT","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","30/10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] See table of dosages for dosing for different indications." +"3825","EUCAST 2023","human","human","MIC","pneumonia","B_HMPHL_INFL",2,"CZT","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[2] See table of dosages for dosing for different indications." +"3826","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"DOR","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"3827","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"DOR","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"3828","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"DOX","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"3829","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"3830","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"3831","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",28,28,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"3832","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"3833","EUCAST 2023","human","human","MIC","Topical","B_HMPHL_INFL",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA +"3834","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"3835","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"3836","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"3837","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA +"3838","EUCAST 2023","human","human","MIC","Topical","B_HMPHL_INFL",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA +"3839","EUCAST 2023","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"3840","EUCAST 2023","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"3841","EUCAST 2023","human","human","MIC","meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"3842","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"3843","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA +"3844","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",24,24,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"3845","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"3846","EUCAST 2023","human","human","DISK","screen only","B_HMPHL_INFL",2,"NAL","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",23,23,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"3847","EUCAST 2023","human","human","DISK","Topical","B_HMPHL_INFL",2,"NAL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",23,23,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)." +"3848","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"3849","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA +"3850","EUCAST 2023","human","human","MIC","Topical","B_HMPHL_INFL",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA +"3851","EUCAST 2023","human","human","DISK","screen only","B_HMPHL_INFL",2,"PEN","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","1 unit",12,12,FALSE,FALSE,"[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"3852","EUCAST 2023","human","human","DISK","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",18,18,FALSE,FALSE,NA +"3853","EUCAST 2023","human","human","MIC","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"3854","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"SAM","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv." +"3855","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",23,20,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3856","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,1,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3857","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",25,25,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"3858","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"3859","EUCAST 2023","human","human","MIC","Topical","B_HMPHL_INFL",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,NA +"3860","EUCAST 2023","human","human","DISK",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)","30/6 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"3861","EUCAST 2023","human","human","MIC",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"3862","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"AMP","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility." +"3863","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"AMX","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility." +"3864","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"AZM","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility." +"3865","EUCAST 2023","human","human","DISK",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",28,28,FALSE,FALSE,NA +"3866","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA +"3867","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"CLR","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility." +"3868","EUCAST 2023","human","human","DISK",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",30,30,FALSE,FALSE,NA +"3869","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA +"3870","EUCAST 2023","human","human","DISK",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",27,27,FALSE,FALSE,NA +"3871","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA +"3872","EUCAST 2023","human","human","DISK",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",29,29,FALSE,FALSE,NA +"3873","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"3874","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"DOX","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant." +"3875","EUCAST 2023","human","human","DISK",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",20,20,FALSE,FALSE,NA +"3876","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"3877","EUCAST 2023","human","human","DISK",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",28,28,FALSE,FALSE,NA +"3878","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA +"3879","EUCAST 2023","human","human","DISK",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",30,30,FALSE,FALSE,NA +"3880","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.03,0.03,FALSE,FALSE,NA +"3881","EUCAST 2023","human","human","DISK",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 13.1)","1 unit",25,25,FALSE,FALSE,NA +"3882","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.03,0.03,FALSE,FALSE,NA +"3883","EUCAST 2023","human","human","DISK",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",20,20,FALSE,FALSE,NA +"3884","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"3885","EUCAST 2023","human","human","DISK",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",28,28,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3886","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3887","EUCAST 2023","human","human","DISK",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",28,28,FALSE,FALSE,NA +"3888","EUCAST 2023","human","human","MIC",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"3889","EUCAST 2023","human","human","DISK",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",50,19,FALSE,FALSE,NA +"3890","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",19,19,TRUE,FALSE,NA +"3891","EUCAST 2023","human","human","MIC",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,8,FALSE,FALSE,NA +"3892","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,TRUE,FALSE,NA +"3893","EUCAST 2023","human","human","DISK","infections originating from the urinary tract","B_KLBSL",3,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",50,20,FALSE,FALSE,"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin." +"3894","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_KLBSL",3,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,4,FALSE,FALSE,"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin." +"3895","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"3896","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination." +"3897","EUCAST 2023","human","human","DISK","infections originating from the urinary tract","B_KLBSL",3,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",50,17,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"3898","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_KLBSL",3,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,16,FALSE,FALSE,NA +"3899","EUCAST 2023","human","human","DISK","all indications","B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",16,16,FALSE,FALSE,NA +"3900","EUCAST 2023","human","human","MIC","all indications","B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"3901","EUCAST 2023","human","human","DISK","indications other than meningitis","B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",25,25,FALSE,FALSE,NA +"3902","EUCAST 2023","human","human","MIC","indications other than meningitis","B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"3903","EUCAST 2023","human","human","DISK","all indications","B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",26,26,FALSE,FALSE,NA +"3904","EUCAST 2023","human","human","MIC","all indications","B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"3905","EUCAST 2023","human","human","DISK","indications other than meningitis","B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)","1 unit",13,13,FALSE,FALSE,NA +"3906","EUCAST 2023","human","human","MIC","indications other than meningitis","B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"3907","EUCAST 2023","human","human","DISK","all indications","B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",29,29,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3908","EUCAST 2023","human","human","MIC","all indications","B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3909","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","2/1 mcg",19,19,FALSE,FALSE,NA +"3910","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"3911","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AZM","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"3912","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",21,21,FALSE,FALSE,NA +"3913","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"3914","EUCAST 2023","human","human","DISK","Topical","B_MRXLL_CTRR",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",31,31,FALSE,FALSE,NA +"3915","EUCAST 2023","human","human","MIC","Topical","B_MRXLL_CTRR",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"3916","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",31,31,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"3917","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA +"3918","EUCAST 2023","human","human","MIC","Topical","B_MRXLL_CTRR",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA +"3919","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CLR","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"3920","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",24,21,FALSE,FALSE,NA +"3921","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,1,2,FALSE,FALSE,NA +"3922","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",20,17,FALSE,FALSE,NA +"3923","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,1,2,FALSE,FALSE,NA +"3924","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",21,18,FALSE,FALSE,NA +"3925","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",50,21,FALSE,FALSE,NA +"3926","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,4,8,FALSE,FALSE,NA +"3927","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,4,FALSE,FALSE,NA +"3928","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"DOR","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",30,30,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3929","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"DOR","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3930","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"DOX","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"3931","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",23,23,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"3932","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"3933","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",29,29,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3934","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3935","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",20,20,FALSE,FALSE,NA +"3936","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA +"3937","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",29,29,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3938","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3939","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",29,29,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"3940","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA +"3941","EUCAST 2023","human","human","MIC","Topical","B_MRXLL_CTRR",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA +"3942","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",33,33,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3943","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3944","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",26,26,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"3945","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"3946","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",25,25,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"3947","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"3948","EUCAST 2023","human","human","DISK","screen only","B_MRXLL_CTRR",2,"NAL","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",23,23,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"3949","EUCAST 2023","human","human","DISK","Topical","B_MRXLL_CTRR",2,"NAL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",23,23,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)." +"3950","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"3951","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"3952","EUCAST 2023","human","human","MIC","Topical","B_MRXLL_CTRR",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"3953","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"RXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"3954","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SAM","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid." +"3955","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",18,15,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3956","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,1,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"3957","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",26,26,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"3958","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"3959","EUCAST 2023","human","human","DISK",NA,"B_MRXLL_CTRR",2,"TLT","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",23,23,FALSE,FALSE,NA +"3960","EUCAST 2023","human","human","MIC",NA,"B_MRXLL_CTRR",2,"TLT","M.catarrhalis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"3961","EUCAST 2023","human","human","MIC",NA,"B_MYCBC_TBRC",2,"BDQ","M.tuberculosis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Breakpoints were determined on MICs performed on Middlebrook 7H11/7H10 medium. The comparability of tests performed by other media has not been established. There is ongoing work to review breakpoints using the EUCAST reference method (described above)." +"3962","EUCAST 2023","human","human","MIC",NA,"B_MYCBC_TBRC",2,"DLM","M.tuberculosis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA +"3963","EUCAST 2023","human","human","MIC",NA,"B_NESSR_GNRR",2,"CFM","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA +"3964","EUCAST 2023","human","human","MIC",NA,"B_NESSR_GNRR",2,"CIP","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.03,0.06,FALSE,FALSE,NA +"3965","EUCAST 2023","human","human","MIC",NA,"B_NESSR_GNRR",2,"CRO","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA +"3966","EUCAST 2023","human","human","MIC",NA,"B_NESSR_GNRR",2,"CTX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA +"3967","EUCAST 2023","human","human","MIC",NA,"B_NESSR_GNRR",2,"OFX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.25,FALSE,FALSE,NA +"3968","EUCAST 2023","human","human","MIC","surrogate agent","B_NESSR_GNRR",2,"PEN","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,1,FALSE,FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)." +"3969","EUCAST 2023","human","human","MIC",NA,"B_NESSR_GNRR",2,"SPT","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)",NA,64,64,FALSE,FALSE,NA +"3970","EUCAST 2023","human","human","MIC",NA,"B_NESSR_GNRR",2,"TCY","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"3971","EUCAST 2023","human","human","MIC","indications other than meningitis","B_NESSR_MNNG",2,"AMP","N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,1,FALSE,FALSE,NA +"3972","EUCAST 2023","human","human","MIC","indications other than meningitis","B_NESSR_MNNG",2,"AMX","N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,1,FALSE,FALSE,NA +"3973","EUCAST 2023","human","human","MIC","meningitis","B_NESSR_MNNG",2,"CHL","N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages." +"3974","EUCAST 2023","human","human","MIC","all indications, including meningitis and prophylaxis","B_NESSR_MNNG",2,"CIP","N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.016,0.016,FALSE,FALSE,NA +"3975","EUCAST 2023","human","human","MIC","all indications including prophylaxis","B_NESSR_MNNG",2,"CRO","N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3976","EUCAST 2023","human","human","MIC","all indications","B_NESSR_MNNG",2,"CTX","N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"3977","EUCAST 2023","human","human","MIC","all indications","B_NESSR_MNNG",2,"MEM","N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only." +"3978","EUCAST 2023","human","human","MIC","prophylaxis only","B_NESSR_MNNG",2,"MNO","N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections." +"3979","EUCAST 2023","human","human","MIC","all indications","B_NESSR_MNNG",2,"PEN","N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"3980","EUCAST 2023","human","human","MIC","prophylaxis only","B_NESSR_MNNG",2,"RIF","N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"3981","EUCAST 2023","human","human","MIC","screen only","B_NESSR_MNNG",2,"TCY","N.meningitidis (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections." +"3982","EUCAST 2023","human","human","DISK",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",50,19,FALSE,FALSE,NA +"3983","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",19,19,TRUE,FALSE,NA +"3984","EUCAST 2023","human","human","MIC",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,8,FALSE,FALSE,NA +"3985","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,TRUE,FALSE,NA +"3986","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_PROTS_MRBL",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",15,15,TRUE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"3987","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_PROTS_MRBL",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination." +"3988","EUCAST 2023","human","human","DISK","infections originating from the urinary tract","B_PROTS_MRBL",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",50,17,FALSE,FALSE,"[F] Ignore isolated colonies within the inhibition zone." +"3989","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_PROTS_MRBL",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,16,FALSE,FALSE,NA +"3990","EUCAST 2023","human","human","DISK",NA,"B_PRVTL",3,"AMC","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","2/1 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3991","EUCAST 2023","human","human","DISK",NA,"B_PRVTL",3,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3992","EUCAST 2023","human","human","MIC",NA,"B_PRVTL",3,"AMP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3993","EUCAST 2023","human","human","MIC",NA,"B_PRVTL",3,"AMX","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3994","EUCAST 2023","human","human","DISK",NA,"B_PRVTL",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",31,31,FALSE,FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading." +"3995","EUCAST 2023","human","human","MIC",NA,"B_PRVTL",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"3996","EUCAST 2023","human","human","DISK",NA,"B_PRVTL",3,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",29,29,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3997","EUCAST 2023","human","human","MIC",NA,"B_PRVTL",3,"ETP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3998","EUCAST 2023","human","human","DISK",NA,"B_PRVTL",3,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",35,35,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"3999","EUCAST 2023","human","human","MIC",NA,"B_PRVTL",3,"IPM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"4000","EUCAST 2023","human","human","DISK",NA,"B_PRVTL",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",34,34,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"4001","EUCAST 2023","human","human","MIC",NA,"B_PRVTL",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"4002","EUCAST 2023","human","human","DISK",NA,"B_PRVTL",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",22,22,FALSE,FALSE,NA +"4003","EUCAST 2023","human","human","MIC",NA,"B_PRVTL",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA +"4004","EUCAST 2023","human","human","DISK",NA,"B_PRVTL",3,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","1 unit",20,20,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"4005","EUCAST 2023","human","human","MIC",NA,"B_PRVTL",3,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"4006","EUCAST 2023","human","human","DISK",NA,"B_PRVTL",3,"SAM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","10/10 mcg",33,33,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"4007","EUCAST 2023","human","human","DISK",NA,"B_PRVTL",3,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 13.1)","30/6 mcg",26,26,FALSE,FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents." +"4008","EUCAST 2023","human","human","DISK","systemic infections","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"4009","EUCAST 2023","human","human","DISK","infections originating from the urinary tract","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",15,15,FALSE,FALSE,NA +"4010","EUCAST 2023","human","human","MIC","systemic infections","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,16,16,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"4011","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,16,16,FALSE,FALSE,NA +"4012","EUCAST 2023","human","human","DISK",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",50,18,FALSE,FALSE,NA +"4013","EUCAST 2023","human","human","MIC",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,16,FALSE,FALSE,NA +"4014","EUCAST 2023","human","human","DISK",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",50,17,FALSE,FALSE,NA +"4015","EUCAST 2023","human","human","MIC",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,8,FALSE,FALSE,NA +"4016","EUCAST 2023","human","human","DISK",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,26,FALSE,FALSE,NA +"4017","EUCAST 2023","human","human","MIC",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,0.5,FALSE,FALSE,NA +"4018","EUCAST 2023","human","human","MIC",NA,"B_PSDMN",3,"COL","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)." +"4019","EUCAST 2023","human","human","DISK",NA,"B_PSDMN",3,"DOR","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",50,22,FALSE,FALSE,NA +"4020","EUCAST 2023","human","human","MIC",NA,"B_PSDMN",3,"DOR","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,2,FALSE,FALSE,NA +"4021","EUCAST 2023","human","human","DISK",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",50,21,FALSE,FALSE,NA +"4022","EUCAST 2023","human","human","MIC",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,8,FALSE,FALSE,NA +"4023","EUCAST 2023","human","human","DISK",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",50,20,FALSE,FALSE,NA +"4024","EUCAST 2023","human","human","MIC",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,4,FALSE,FALSE,NA +"4025","EUCAST 2023","human","human","DISK",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,18,FALSE,FALSE,NA +"4026","EUCAST 2023","human","human","MIC",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,2,FALSE,FALSE,NA +"4027","EUCAST 2023","human","human","DISK","indications other than meningitis","B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",24,18,FALSE,FALSE,NA +"4028","EUCAST 2023","human","human","MIC","indications other than meningitis","B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,2,8,FALSE,FALSE,NA +"4029","EUCAST 2023","human","human","DISK",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",50,18,FALSE,FALSE,NA +"4030","EUCAST 2023","human","human","MIC",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,16,FALSE,FALSE,NA +"4031","EUCAST 2023","human","human","DISK",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","75/10 mcg",50,18,FALSE,FALSE,NA +"4032","EUCAST 2023","human","human","MIC",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,16,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"4033","EUCAST 2023","human","human","DISK","systemic infections","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"4034","EUCAST 2023","human","human","DISK","infections originating from the urinary tract","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",18,18,FALSE,FALSE,NA +"4035","EUCAST 2023","human","human","MIC","systemic infections","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"4036","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"4037","EUCAST 2023","human","human","DISK",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","30/6 mcg",50,18,FALSE,FALSE,NA +"4038","EUCAST 2023","human","human","MIC",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,16,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"4039","EUCAST 2023","human","human","DISK","Topical","B_PSDMN_AERG",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",26,26,FALSE,FALSE,NA +"4040","EUCAST 2023","human","human","MIC","Topical","B_PSDMN_AERG",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"4041","EUCAST 2023","human","human","MIC","Topical","B_PSDMN_AERG",2,"COL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA +"4042","EUCAST 2023","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","10/4 mcg",17,17,FALSE,FALSE,NA +"4043","EUCAST 2023","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L." +"4044","EUCAST 2023","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","30/10 mcg",23,23,FALSE,FALSE,"[3] See table of dosages for dosing for different indications." +"4045","EUCAST 2023","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] See table of dosages for dosing for different indications." +"4046","EUCAST 2023","human","human","DISK",NA,"B_PSDMN_AERG",2,"FDC","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",22,22,FALSE,FALSE,NA +"4047","EUCAST 2023","human","human","MIC",NA,"B_PSDMN_AERG",2,"FDC","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/." +"4048","EUCAST 2023","human","human","DISK","Topical","B_PSDMN_AERG",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",15,15,FALSE,FALSE,NA +"4049","EUCAST 2023","human","human","MIC","Topical","B_PSDMN_AERG",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,NA +"4050","EUCAST 2023","human","human","DISK",NA,"B_PSDMN_AERG",2,"IMR","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","10/25 mcg",22,22,FALSE,FALSE,NA +"4051","EUCAST 2023","human","human","MIC",NA,"B_PSDMN_AERG",2,"IMR","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L." +"4052","EUCAST 2023","human","human","DISK","Topical","B_PSDMN_AERG",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",18,18,FALSE,FALSE,NA +"4053","EUCAST 2023","human","human","MIC","Topical","B_PSDMN_AERG",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"4054","EUCAST 2023","human","human","DISK","indications other than meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",20,14,FALSE,FALSE,NA +"4055","EUCAST 2023","human","human","DISK","meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",20,20,FALSE,FALSE,NA +"4056","EUCAST 2023","human","human","MIC","indications other than meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,2,8,FALSE,FALSE,NA +"4057","EUCAST 2023","human","human","MIC","meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"4058","EUCAST 2023","human","human","DISK",NA,"B_PSDMN_AERG",2,"MEV","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)","20/10 mcg",14,14,FALSE,FALSE,NA +"4059","EUCAST 2023","human","human","MIC",NA,"B_PSDMN_AERG",2,"MEV","Pseudomonas (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L." +"4060","EUCAST 2023","human","human","MIC","Topical","B_PSDMN_AERG",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"4061","EUCAST 2023","human","human","DISK","Topical","B_PSDMN_AERG",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",18,18,FALSE,FALSE,NA +"4062","EUCAST 2023","human","human","MIC","Topical","B_PSDMN_AERG",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"4063","EUCAST 2023","human","human","DISK",NA,"B_PSTRL",3,"AMC","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)","2/1 mcg",15,15,FALSE,FALSE,NA +"4064","EUCAST 2023","human","human","MIC",NA,"B_PSTRL",3,"AMC","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"4065","EUCAST 2023","human","human","MIC",NA,"B_PSTRL",3,"AMP","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"4066","EUCAST 2023","human","human","MIC",NA,"B_PSTRL",3,"AMX","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"4067","EUCAST 2023","human","human","DISK",NA,"B_PSTRL",3,"CIP","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B." +"4068","EUCAST 2023","human","human","MIC",NA,"B_PSTRL",3,"CIP","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA +"4069","EUCAST 2023","human","human","DISK",NA,"B_PSTRL",3,"CTX","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",26,26,FALSE,FALSE,NA +"4070","EUCAST 2023","human","human","MIC",NA,"B_PSTRL",3,"CTX","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)",NA,0.03,0.03,FALSE,FALSE,NA +"4071","EUCAST 2023","human","human","MIC",NA,"B_PSTRL",3,"DOX","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"4072","EUCAST 2023","human","human","DISK",NA,"B_PSTRL",3,"LVX","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B." +"4073","EUCAST 2023","human","human","MIC",NA,"B_PSTRL",3,"LVX","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA +"4074","EUCAST 2023","human","human","DISK","screen only","B_PSTRL",3,"NAL","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",23,23,FALSE,FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"4075","EUCAST 2023","human","human","DISK",NA,"B_PSTRL",3,"PEN","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)","1 unit",17,17,FALSE,FALSE,NA +"4076","EUCAST 2023","human","human","MIC",NA,"B_PSTRL",3,"PEN","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"4077","EUCAST 2023","human","human","DISK",NA,"B_PSTRL",3,"SXT","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"4078","EUCAST 2023","human","human","MIC",NA,"B_PSTRL",3,"SXT","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"4079","EUCAST 2023","human","human","DISK","screen only","B_PSTRL",3,"TCY","Pasteurella (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",24,24,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test." +"4080","EUCAST 2023","human","human","MIC",NA,"B_SLMNL",3,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species." +"4081","EUCAST 2023","human","human","DISK",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",50,16,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"4082","EUCAST 2023","human","human","MIC",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"4083","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"AZM","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"4084","EUCAST 2023","human","human","DISK",NA,"B_STPHY",3,"CLI","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",22,22,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy""." +"4085","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"CLI","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy""." +"4086","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"CLR","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"4087","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"DAL","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin." +"4088","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"DAP","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4089","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"DOX","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"4090","EUCAST 2023","human","human","DISK",NA,"B_STPHY",3,"ERY","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",21,21,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"4091","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"ERY","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"4092","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"FOS","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,32,32,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). | [3] Breakpoints for fosfomycin iv are currently under review." +"4093","EUCAST 2023","human","human","DISK",NA,"B_STPHY",3,"FUS","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",24,24,FALSE,FALSE,NA +"4094","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"FUS","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"4095","EUCAST 2023","human","human","DISK",NA,"B_STPHY",3,"LNZ","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",21,21,FALSE,FALSE,NA +"4096","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"LNZ","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA +"4097","EUCAST 2023","human","human","DISK",NA,"B_STPHY",3,"MNO","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",23,23,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"4098","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"MNO","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"4099","EUCAST 2023","human","human","DISK","screen only","B_STPHY",3,"NOR","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"4100","EUCAST 2023","human","human","DISK",NA,"B_STPHY",3,"QDA","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",21,21,FALSE,FALSE,NA +"4101","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"QDA","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"4102","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"RXT","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"4103","EUCAST 2023","human","human","DISK",NA,"B_STPHY",3,"SXT","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",17,14,FALSE,FALSE,"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"4104","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"SXT","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,2,4,FALSE,FALSE,"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"4105","EUCAST 2023","human","human","DISK",NA,"B_STPHY",3,"TCY","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",22,22,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"4106","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"TCY","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"4107","EUCAST 2023","human","human","DISK",NA,"B_STPHY",3,"TGC","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",19,19,FALSE,FALSE,"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4108","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"TGC","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4109","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_STPHY",3,"TMP","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",14,14,TRUE,FALSE,NA +"4110","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_STPHY",3,"TMP","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,TRUE,FALSE,NA +"4111","EUCAST 2023","human","human","DISK",NA,"B_STPHY",3,"TZD","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",20,20,FALSE,FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid." +"4112","EUCAST 2023","human","human","MIC",NA,"B_STPHY",3,"TZD","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid." +"4113","EUCAST 2023","human","human","DISK",NA,"B_STPHY_AURS",2,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci." +"4114","EUCAST 2023","human","human","MIC",NA,"B_STPHY_AURS",2,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,16,16,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci." +"4115","EUCAST 2023","human","human","DISK",NA,"B_STPHY_AURS",2,"BPR","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",17,17,FALSE,FALSE,"[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing." +"4116","EUCAST 2023","human","human","MIC",NA,"B_STPHY_AURS",2,"BPR","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[8] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing." +"4117","EUCAST 2023","human","human","DISK","Topical","B_STPHY_AURS",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",18,18,FALSE,FALSE,NA +"4118","EUCAST 2023","human","human","MIC","Topical","B_STPHY_AURS",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,16,16,FALSE,FALSE,NA +"4119","EUCAST 2023","human","human","DISK",NA,"B_STPHY_AURS",2,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,21,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"4120","EUCAST 2023","human","human","MIC",NA,"B_STPHY_AURS",2,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,1,FALSE,FALSE,NA +"4121","EUCAST 2023","human","human","MIC","Topical","B_STPHY_AURS",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"4122","EUCAST 2023","human","human","DISK","indications other than pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",20,17,FALSE,FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing." +"4123","EUCAST 2023","human","human","DISK","pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",20,20,FALSE,FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing." +"4124","EUCAST 2023","human","human","MIC","indications other than pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,1,2,FALSE,FALSE,"[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing." +"4125","EUCAST 2023","human","human","MIC","pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing." +"4126","EUCAST 2023","human","human","MIC","community-acquired pneumonia","B_STPHY_AURS",2,"DFX","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.016,0.016,FALSE,FALSE,NA +"4127","EUCAST 2023","human","human","MIC","skin and skin structure infections","B_STPHY_AURS",2,"DFX","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"4128","EUCAST 2023","human","human","DISK",NA,"B_STPHY_AURS",2,"ERV","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","20 mcg",20,20,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test." +"4129","EUCAST 2023","human","human","MIC",NA,"B_STPHY_AURS",2,"ERV","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"4130","EUCAST 2023","human","human","DISK","screen only","B_STPHY_AURS",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",22,22,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant." +"4131","EUCAST 2023","human","human","DISK","Topical","B_STPHY_AURS",2,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",24,24,FALSE,FALSE,NA +"4132","EUCAST 2023","human","human","MIC","Topical","B_STPHY_AURS",2,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"4133","EUCAST 2023","human","human","DISK",NA,"B_STPHY_AURS",2,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"4134","EUCAST 2023","human","human","DISK","Topical","B_STPHY_AURS",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",18,18,FALSE,FALSE,NA +"4135","EUCAST 2023","human","human","MIC",NA,"B_STPHY_AURS",2,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"4136","EUCAST 2023","human","human","MIC","Topical","B_STPHY_AURS",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"4137","EUCAST 2023","human","human","DISK",NA,"B_STPHY_AURS",2,"LMU","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",23,23,FALSE,FALSE,NA +"4138","EUCAST 2023","human","human","MIC",NA,"B_STPHY_AURS",2,"LMU","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"4139","EUCAST 2023","human","human","DISK",NA,"B_STPHY_AURS",2,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,22,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"4140","EUCAST 2023","human","human","MIC",NA,"B_STPHY_AURS",2,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,1,FALSE,FALSE,NA +"4141","EUCAST 2023","human","human","MIC","Topical","B_STPHY_AURS",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"4142","EUCAST 2023","human","human","DISK",NA,"B_STPHY_AURS",2,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",25,25,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"4143","EUCAST 2023","human","human","MIC",NA,"B_STPHY_AURS",2,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"4144","EUCAST 2023","human","human","DISK","Topical","B_STPHY_AURS",2,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","200 mcg",30,30,FALSE,FALSE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +ND = No ECOFF available." +"4145","EUCAST 2023","human","human","MIC","Topical","B_STPHY_AURS",2,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +ND = No ECOFF available." +"4146","EUCAST 2023","human","human","DISK","Topical","B_STPHY_AURS",2,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",14,14,FALSE,FALSE,NA +"4147","EUCAST 2023","human","human","MIC","Topical","B_STPHY_AURS",2,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"4148","EUCAST 2023","human","human","DISK","Topical","B_STPHY_AURS",2,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",17,17,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)." +"4149","EUCAST 2023","human","human","MIC","Topical","B_STPHY_AURS",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"4150","EUCAST 2023","human","human","MIC",NA,"B_STPHY_AURS",2,"ORI","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin." +"4151","EUCAST 2023","human","human","DISK",NA,"B_STPHY_AURS",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","1 unit",26,26,FALSE,FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase." +"4152","EUCAST 2023","human","human","MIC",NA,"B_STPHY_AURS",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins." +"4153","EUCAST 2023","human","human","DISK",NA,"B_STPHY_AURS",2,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",26,26,FALSE,FALSE,NA +"4154","EUCAST 2023","human","human","MIC",NA,"B_STPHY_AURS",2,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA +"4155","EUCAST 2023","human","human","MIC","Topical","B_STPHY_AURS",2,"RTP","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"4156","EUCAST 2023","human","human","MIC",NA,"B_STPHY_AURS",2,"TEC","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"4157","EUCAST 2023","human","human","MIC",NA,"B_STPHY_AURS",2,"TLV","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin." +"4158","EUCAST 2023","human","human","DISK",NA,"B_STPHY_AURS",2,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"4159","EUCAST 2023","human","human","DISK","Topical","B_STPHY_AURS",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",18,18,FALSE,FALSE,NA +"4160","EUCAST 2023","human","human","MIC",NA,"B_STPHY_AURS",2,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"4161","EUCAST 2023","human","human","MIC","Topical","B_STPHY_AURS",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"4162","EUCAST 2023","human","human","MIC",NA,"B_STPHY_AURS",2,"VAN","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"4163","EUCAST 2023","human","human","DISK","screen only","B_STPHY_CGLN",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans." +"4164","EUCAST 2023","human","human","DISK",NA,"B_STPHY_CONS",2.5,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci." +"4165","EUCAST 2023","human","human","MIC",NA,"B_STPHY_CONS",2.5,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,16,16,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci." +"4166","EUCAST 2023","human","human","DISK",NA,"B_STPHY_CONS",2.5,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,24,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"4167","EUCAST 2023","human","human","MIC",NA,"B_STPHY_CONS",2.5,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,1,FALSE,FALSE,NA +"4168","EUCAST 2023","human","human","DISK","screen only","B_STPHY_CONS",2.5,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",22,22,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant." +"4169","EUCAST 2023","human","human","DISK",NA,"B_STPHY_CONS",2.5,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",22,22,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"4170","EUCAST 2023","human","human","MIC",NA,"B_STPHY_CONS",2.5,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"4171","EUCAST 2023","human","human","DISK",NA,"B_STPHY_CONS",2.5,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,24,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"4172","EUCAST 2023","human","human","MIC",NA,"B_STPHY_CONS",2.5,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,1,FALSE,FALSE,NA +"4173","EUCAST 2023","human","human","DISK",NA,"B_STPHY_CONS",2.5,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",28,28,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"4174","EUCAST 2023","human","human","MIC",NA,"B_STPHY_CONS",2.5,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"4175","EUCAST 2023","human","human","DISK",NA,"B_STPHY_CONS",2.5,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",30,30,FALSE,FALSE,NA +"4176","EUCAST 2023","human","human","MIC",NA,"B_STPHY_CONS",2.5,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA +"4177","EUCAST 2023","human","human","MIC",NA,"B_STPHY_CONS",2.5,"TEC","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA +"4178","EUCAST 2023","human","human","DISK",NA,"B_STPHY_CONS",2.5,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",20,20,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"4179","EUCAST 2023","human","human","MIC",NA,"B_STPHY_CONS",2.5,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"4180","EUCAST 2023","human","human","MIC",NA,"B_STPHY_CONS",2.5,"VAN","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA +"4181","EUCAST 2023","human","human","DISK","screen only","B_STPHY_EPDR",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",27,27,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant." +"4182","EUCAST 2023","human","human","DISK","screen only","B_STPHY_LGDN",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",27,27,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant." +"4183","EUCAST 2023","human","human","DISK",NA,"B_STPHY_LGDN",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","1 unit",26,26,FALSE,FALSE,NA +"4184","EUCAST 2023","human","human","MIC",NA,"B_STPHY_LGDN",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA +"4185","EUCAST 2023","human","human","DISK","screen only","B_STPHY_PSDN",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans." +"4186","EUCAST 2023","human","human","DISK","screen only","B_STPHY_SCHL",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans." +"4187","EUCAST 2023","human","human","DISK",NA,"B_STPHY_SPRP",2,"AMP","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",18,18,FALSE,FALSE,"[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)." +"4188","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_STPHY_SPRP",2,"NIT","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)","100 mcg",13,13,TRUE,FALSE,NA +"4189","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_STPHY_SPRP",2,"NIT","Staphylococcus (file: Clinical Breakpoint Tables v. 13.1)",NA,64,64,TRUE,FALSE,NA +"4190","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"AZM","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and" +"4191","EUCAST 2023","human","human","DISK","Topical","B_STRPT_ABCG",2.5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",21,21,FALSE,FALSE,NA +"4192","EUCAST 2023","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,NA +"4193","EUCAST 2023","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"4194","EUCAST 2023","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",17,17,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known." +"4195","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known." +"4196","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and" +"4197","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4198","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAP","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4199","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.03,0.03,FALSE,FALSE,NA +"4200","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DOX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"4201","EUCAST 2023","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",21,21,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and" +"4202","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and" +"4203","EUCAST 2023","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,32,32,FALSE,FALSE,NA +"4204","EUCAST 2023","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",19,19,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4205","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4206","EUCAST 2023","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,17,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"4207","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,2,FALSE,FALSE,NA +"4208","EUCAST 2023","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"4209","EUCAST 2023","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",19,19,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"4210","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"4211","EUCAST 2023","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",23,23,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"4212","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"4213","EUCAST 2023","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"4214","EUCAST 2023","human","human","DISK","screen only","B_STRPT_ABCG",2.5,"NOR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",12,12,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"4215","EUCAST 2023","human","human","DISK","Topical","B_STRPT_ABCG",2.5,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",12,12,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)." +"4216","EUCAST 2023","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA +"4217","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ORI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4218","EUCAST 2023","human","human","DISK","indications other than meningitis","B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","1 unit",18,18,FALSE,FALSE,NA +"4219","EUCAST 2023","human","human","MIC","indications other than meningitis","B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"4220","EUCAST 2023","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",21,21,FALSE,FALSE,NA +"4221","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA +"4222","EUCAST 2023","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"RTP","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA +"4223","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and" +"4224","EUCAST 2023","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",18,15,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"4225","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,1,2,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"4226","EUCAST 2023","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",23,23,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"4227","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"4228","EUCAST 2023","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4229","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4230","EUCAST 2023","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",19,19,FALSE,FALSE,"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4231","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4232","EUCAST 2023","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TLT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",20,20,FALSE,FALSE,NA +"4233","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TLT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"4234","EUCAST 2023","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TZD","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",18,18,FALSE,FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4235","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TZD","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4236","EUCAST 2023","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",13,13,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4237","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4238","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"DAL","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4239","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"DFX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,0.03,0.03,FALSE,FALSE,NA +"4240","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"ORI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4241","EUCAST 2023","human","human","DISK",NA,"B_STRPT_ANGN_ANGN",1,"TZD","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",18,18,FALSE,FALSE,NA +"4242","EUCAST 2023","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"TZD","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"4243","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","100 mcg",15,15,TRUE,FALSE,NA +"4244","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,64,64,TRUE,FALSE,NA +"4245","EUCAST 2023","human","human","DISK","meningitis","B_STRPT_GRPB",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)","1 unit",19,19,FALSE,FALSE,NA +"4246","EUCAST 2023","human","human","MIC","meningitis","B_STRPT_GRPB",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA +"4247","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_STRPT_GRPB",2.5,"TMP","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,TRUE,FALSE,"[3] Breakpoints for trimethoprim are currently under review." +"4248","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMC","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,1,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit." +"4249","EUCAST 2023","human","human","DISK","indications other than meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",22,19,FALSE,FALSE,NA +"4250","EUCAST 2023","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,1,FALSE,FALSE,NA +"4251","EUCAST 2023","human","human","MIC","meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"4252","EUCAST 2023","human","human","MIC","meningitis","B_STRPT_PNMN",2,"AMX","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"4253","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMX","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,1,FALSE,FALSE,NA +"4254","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"AZM","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"4255","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"BPR","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"4256","EUCAST 2023","human","human","DISK",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",50,28,FALSE,FALSE,NA +"4257","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,0.5,FALSE,FALSE,NA +"4258","EUCAST 2023","human","human","DISK","Topical","B_STRPT_PNMN",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",21,21,FALSE,FALSE,NA +"4259","EUCAST 2023","human","human","MIC","Topical","B_STRPT_PNMN",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,NA +"4260","EUCAST 2023","human","human","MIC","Topical","B_STRPT_PNMN",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA +"4261","EUCAST 2023","human","human","DISK",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",19,19,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"4262","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"4263","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLR","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"4264","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPD","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"4265","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPT","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"4266","EUCAST 2023","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"CRO","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,2,FALSE,FALSE,NA +"4267","EUCAST 2023","human","human","MIC","meningitis","B_STRPT_PNMN",2,"CRO","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"4268","EUCAST 2023","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"CTX","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,2,FALSE,FALSE,NA +"4269","EUCAST 2023","human","human","MIC","meningitis","B_STRPT_PNMN",2,"CTX","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"4270","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,1,FALSE,FALSE,NA +"4271","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"4272","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"DOR","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"4273","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"DOX","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"4274","EUCAST 2023","human","human","DISK",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",22,22,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"4275","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"4276","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"ETP","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"4277","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"FEP","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,1,2,FALSE,FALSE,NA +"4278","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"IPM","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"4279","EUCAST 2023","human","human","DISK",NA,"B_STRPT_PNMN",2,"LMU","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",12,12,FALSE,FALSE,NA +"4280","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"LMU","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"4281","EUCAST 2023","human","human","DISK",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",22,22,FALSE,FALSE,NA +"4282","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"4283","EUCAST 2023","human","human","DISK",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",50,16,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"4284","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,2,FALSE,FALSE,NA +"4285","EUCAST 2023","human","human","MIC","Topical","B_STRPT_PNMN",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"4286","EUCAST 2023","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"4287","EUCAST 2023","human","human","MIC","meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"4288","EUCAST 2023","human","human","DISK",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",22,22,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"4289","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"4290","EUCAST 2023","human","human","DISK",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",24,24,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"4291","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"4292","EUCAST 2023","human","human","DISK","screen only","B_STRPT_PNMN",2,"NOR","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",10,10,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"4293","EUCAST 2023","human","human","DISK","Topical","B_STRPT_PNMN",2,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",10,10,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)." +"4294","EUCAST 2023","human","human","MIC","Topical","B_STRPT_PNMN",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA +"4295","EUCAST 2023","human","human","DISK","screen only","B_STRPT_PNMN",2,"OXA","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","1 mcg",20,20,FALSE,FALSE,"[C] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below." +"4296","EUCAST 2023","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,2,FALSE,FALSE,"[2] For breakpoints and dosing in pneumonia, see table of dosages." +"4297","EUCAST 2023","human","human","MIC","meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.06,0.06,FALSE,FALSE,NA +"4298","EUCAST 2023","human","human","DISK",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",22,22,FALSE,FALSE,NA +"4299","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA +"4300","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"RXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"4301","EUCAST 2023","human","human","DISK",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",13,10,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"4302","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,1,2,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"4303","EUCAST 2023","human","human","DISK",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",25,25,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"4304","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant." +"4305","EUCAST 2023","human","human","DISK",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4306","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4307","EUCAST 2023","human","human","DISK",NA,"B_STRPT_PNMN",2,"TLT","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",23,23,FALSE,FALSE,NA +"4308","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"TLT","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"4309","EUCAST 2023","human","human","DISK",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4310","EUCAST 2023","human","human","MIC",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4311","EUCAST 2023","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",21,15,FALSE,FALSE,NA +"4312","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,2,FALSE,FALSE,NA +"4313","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"AMX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,2,FALSE,FALSE,NA +"4314","EUCAST 2023","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)","2 mcg",19,19,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"4315","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"4316","EUCAST 2023","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",27,27,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins." +"4317","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"4318","EUCAST 2023","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",23,23,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins." +"4319","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"4320","EUCAST 2023","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",26,26,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins." +"4321","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"4322","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"DOR","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"4323","EUCAST 2023","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"ERV","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)","20 mcg",17,17,FALSE,FALSE,NA +"4324","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ERV","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA +"4325","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ETP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"4326","EUCAST 2023","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",25,25,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins." +"4327","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"4328","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"IMR","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit." +"4329","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"IPM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"4330","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"MEM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"4331","EUCAST 2023","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)","1 unit",21,12,FALSE,FALSE,NA +"4332","EUCAST 2023","human","human","DISK","screen only","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)","1 unit",21,21,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"4333","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,2,FALSE,FALSE,NA +"4334","EUCAST 2023","human","human","MIC","screen only","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"4335","EUCAST 2023","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",16,16,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4336","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4337","EUCAST 2023","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4338","EUCAST 2023","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4339","EUCAST 2023","human","human","DISK",NA,"B_VIBRI",3,"AZM","Vibrio (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",16,16,FALSE,FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test." +"4340","EUCAST 2023","human","human","MIC",NA,"B_VIBRI",3,"AZM","Vibrio (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,FALSE,FALSE,NA +"4341","EUCAST 2023","human","human","DISK",NA,"B_VIBRI",3,"CAZ","Vibrio (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",22,22,FALSE,FALSE,NA +"4342","EUCAST 2023","human","human","MIC",NA,"B_VIBRI",3,"CAZ","Vibrio (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"4343","EUCAST 2023","human","human","DISK",NA,"B_VIBRI",3,"CIP","Vibrio (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",23,23,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test." +"4344","EUCAST 2023","human","human","MIC",NA,"B_VIBRI",3,"CIP","Vibrio (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"4345","EUCAST 2023","human","human","DISK",NA,"B_VIBRI",3,"CTX","Vibrio (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",21,21,FALSE,FALSE,NA +"4346","EUCAST 2023","human","human","MIC",NA,"B_VIBRI",3,"CTX","Vibrio (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"4347","EUCAST 2023","human","human","MIC",NA,"B_VIBRI",3,"DOX","Vibrio (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"4348","EUCAST 2023","human","human","DISK","screen only","B_VIBRI",3,"ERY","Vibrio (file: Clinical Breakpoint Tables v. 13.1)","15 mcg",12,12,FALSE,FALSE,"[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test." +"4349","EUCAST 2023","human","human","DISK",NA,"B_VIBRI",3,"LVX","Vibrio (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",23,23,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test." +"4350","EUCAST 2023","human","human","MIC",NA,"B_VIBRI",3,"LVX","Vibrio (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"4351","EUCAST 2023","human","human","DISK",NA,"B_VIBRI",3,"MEM","Vibrio (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",24,24,FALSE,FALSE,NA +"4352","EUCAST 2023","human","human","MIC",NA,"B_VIBRI",3,"MEM","Vibrio (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"4353","EUCAST 2023","human","human","DISK","screen only","B_VIBRI",3,"PEF","Vibrio (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",22,22,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test." +"4354","EUCAST 2023","human","human","DISK",NA,"B_VIBRI",3,"SXT","Vibrio (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",21,21,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"4355","EUCAST 2023","human","human","MIC",NA,"B_VIBRI",3,"SXT","Vibrio (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"4356","EUCAST 2023","human","human","DISK","screen only","B_VIBRI",3,"TCY","Vibrio (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",20,20,FALSE,FALSE,"[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test." +"4357","EUCAST 2023","human","human","DISK",NA,"B_VIBRI",3,"TZP","Vibrio (file: Clinical Breakpoint Tables v. 13.1)","30/6 mcg",26,26,FALSE,FALSE,NA +"4358","EUCAST 2023","human","human","MIC",NA,"B_VIBRI",3,"TZP","Vibrio (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"4359","EUCAST 2023","human","human","DISK",NA,"B_[FAM]_MORGNLLC",4,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",50,19,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem." +"4360","EUCAST 2023","human","human","MIC",NA,"B_[FAM]_MORGNLLC",4,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,4,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem." +"4361","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","20/10 mcg",19,19,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"4362","EUCAST 2023","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","20/10 mcg",50,19,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"4363","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","20/10 mcg",16,16,TRUE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"4364","EUCAST 2023","human","human","DISK","other indications","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","20/10 mcg",19,19,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"4365","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"4366","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"4367","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,32,32,TRUE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"4368","EUCAST 2023","human","human","MIC","other indications","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"4369","EUCAST 2023","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"4370","EUCAST 2023","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",18,18,FALSE,FALSE,NA +"4371","EUCAST 2023","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"4372","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,NA +"4373","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",14,14,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"4374","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",14,14,TRUE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"4375","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"4376","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,TRUE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"4377","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"4378","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.001,8,FALSE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"4379","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,TRUE,FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"4380","EUCAST 2023","human","human","MIC","other indications","B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"4381","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",26,21,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes." +"4382","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,1,4,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes." +"4383","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",23,23,FALSE,FALSE,NA +"4384","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"4385","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",22,19,FALSE,FALSE,NA +"4386","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,1,4,FALSE,FALSE,NA +"4387","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",17,17,TRUE,FALSE,NA +"4388","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,TRUE,FALSE,NA +"4389","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",12,12,TRUE,FALSE,NA +"4390","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,16,16,TRUE,FALSE,NA +"4391","EUCAST 2023","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",17,17,FALSE,FALSE,NA +"4392","EUCAST 2023","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,16,16,FALSE,FALSE,NA +"4393","EUCAST 2023","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",25,22,FALSE,FALSE,NA +"4394","EUCAST 2023","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.5,FALSE,FALSE,NA +"4395","EUCAST 2023","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,"[2] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test." +"4396","EUCAST 2023","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.125,0.125,FALSE,FALSE,NA +"4397","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"COL","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)." +"4398","EUCAST 2023","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"COL","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"4399","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",21,21,TRUE,FALSE,NA +"4400","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,TRUE,FALSE,NA +"4401","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",23,23,FALSE,FALSE,NA +"4402","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"4403","EUCAST 2023","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",25,22,FALSE,FALSE,NA +"4404","EUCAST 2023","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",25,25,FALSE,FALSE,NA +"4405","EUCAST 2023","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,1,2,FALSE,FALSE,NA +"4406","EUCAST 2023","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"4407","EUCAST 2023","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",23,23,FALSE,FALSE,NA +"4408","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"4409","EUCAST 2023","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",20,17,FALSE,FALSE,NA +"4410","EUCAST 2023","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",20,20,FALSE,FALSE,NA +"4411","EUCAST 2023","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,1,2,FALSE,FALSE,NA +"4412","EUCAST 2023","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,1,1,FALSE,FALSE,NA +"4413","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10/4 mcg",13,13,FALSE,FALSE,NA +"4414","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L." +"4415","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30/10 mcg",22,22,FALSE,FALSE,"[6] See table of dosages for dosing for different indications." +"4416","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [6] See table of dosages for dosing for different indications." +"4417","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"DOR","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",24,21,FALSE,FALSE,NA +"4418","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"DOR","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,1,2,FALSE,FALSE,NA +"4419","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",25,25,FALSE,FALSE,NA +"4420","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,FALSE,FALSE,NA +"4421","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FDC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",22,22,FALSE,FALSE,NA +"4422","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FDC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/." +"4423","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",27,24,FALSE,FALSE,NA +"4424","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,1,4,FALSE,FALSE,NA +"4425","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","200 mcg",21,21,FALSE,FALSE,"[D] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [E] Ignore isolated colonies within the inhibition zone (see pictures below). | [4] Breakpoints for fosfomycin iv are currently under review." +"4426","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,32,32,FALSE,FALSE,"[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [4] Breakpoints for fosfomycin iv are currently under review." +"4427","EUCAST 2023","human","human","DISK","screen only","B_[ORD]_ENTRBCTR",5,"FOX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",19,19,FALSE,FALSE,"[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type." +"4428","EUCAST 2023","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",17,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"4429","EUCAST 2023","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",17,17,FALSE,FALSE,NA +"4430","EUCAST 2023","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",17,17,FALSE,FALSE,NA +"4431","EUCAST 2023","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"4432","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"4433","EUCAST 2023","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"4434","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"IMR","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10/25 mcg",22,22,FALSE,FALSE,NA +"4435","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"IMR","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L." +"4436","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",22,19,FALSE,FALSE,NA +"4437","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,2,4,FALSE,FALSE,NA +"4438","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",14,14,TRUE,FALSE,NA +"4439","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,16,16,TRUE,FALSE,NA +"4440","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",23,19,FALSE,FALSE,NA +"4441","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,1,FALSE,FALSE,NA +"4442","EUCAST 2023","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"4443","EUCAST 2023","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",22,16,FALSE,FALSE,NA +"4444","EUCAST 2023","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",22,22,FALSE,FALSE,NA +"4445","EUCAST 2023","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,2,8,FALSE,FALSE,NA +"4446","EUCAST 2023","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"4447","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"MEV","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","20/10 mcg",20,20,FALSE,FALSE,NA +"4448","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MEV","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L." +"4449","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",22,22,FALSE,FALSE,NA +"4450","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"4451","EUCAST 2023","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",12,12,FALSE,FALSE,NA +"4452","EUCAST 2023","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,NA +"4453","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",24,24,TRUE,FALSE,NA +"4454","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.5,0.5,TRUE,FALSE,NA +"4455","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",24,22,FALSE,FALSE,NA +"4456","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.5,FALSE,FALSE,NA +"4457","EUCAST 2023","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,0.25,0.25,FALSE,FALSE,NA +"4458","EUCAST 2023","human","human","DISK","screen only","B_[ORD]_ENTRBCTR",5,"PEF","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",24,24,FALSE,FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp." +"4459","EUCAST 2023","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"PEF","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",24,24,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)." +"4460","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30 mcg",20,20,FALSE,FALSE,NA +"4461","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,NA +"4462","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10/10 mcg",14,14,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"4463","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10/10 mcg",14,14,TRUE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"4464","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"4465","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,TRUE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/." +"4466","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","1.25/23.75 mcg",14,11,FALSE,FALSE,"[6] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"4467","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,2,4,FALSE,FALSE,"[6] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"4468","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","75/10 mcg",23,20,FALSE,FALSE,NA +"4469","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,16,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"4470","EUCAST 2023","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","5 mcg",15,15,TRUE,FALSE,NA +"4471","EUCAST 2023","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,4,4,TRUE,FALSE,NA +"4472","EUCAST 2023","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",16,16,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"4473","EUCAST 2023","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",16,16,FALSE,FALSE,NA +"4474","EUCAST 2023","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 13.1)","10 mcg",16,16,FALSE,FALSE,NA +"4475","EUCAST 2023","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"4476","EUCAST 2023","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"4477","EUCAST 2023","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 13.1)",NA,2,2,FALSE,FALSE,NA +"4478","EUCAST 2023","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)","30/6 mcg",20,20,FALSE,FALSE,NA +"4479","EUCAST 2023","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 13.1)",NA,8,8,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"4480","EUCAST 2022","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"MEM","A.xylosoxidans (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",26,20,FALSE,FALSE,NA +"4481","EUCAST 2022","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"MEM","A.xylosoxidans (file: Clinical Breakpoint Tables v. 12.0)",NA,1,4,FALSE,FALSE,NA +"4482","EUCAST 2022","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"SXT","A.xylosoxidans (file: Clinical Breakpoint Tables v. 12.0)","1.25/23.75 mcg",26,26,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"4483","EUCAST 2022","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"SXT","A.xylosoxidans (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"4484","EUCAST 2022","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"TZP","A.xylosoxidans (file: Clinical Breakpoint Tables v. 12.0)","30/6 mcg",26,26,FALSE,FALSE,NA +"4485","EUCAST 2022","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"TZP","A.xylosoxidans (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"4486","EUCAST 2022","human","human","DISK","systemic infections","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",19,19,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"4487","EUCAST 2022","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",19,19,FALSE,FALSE,NA +"4488","EUCAST 2022","human","human","MIC","systemic infections","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"4489","EUCAST 2022","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,NA +"4490","EUCAST 2022","human","human","DISK",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",50,21,FALSE,FALSE,NA +"4491","EUCAST 2022","human","human","DISK","Topical","B_ACNTB",3,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",21,21,FALSE,FALSE,NA +"4492","EUCAST 2022","human","human","MIC",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,1,FALSE,FALSE,NA +"4493","EUCAST 2022","human","human","MIC","Topical","B_ACNTB",3,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA +"4494","EUCAST 2022","human","human","MIC",NA,"B_ACNTB",3,"COL","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)." +"4495","EUCAST 2022","human","human","MIC","Topical","B_ACNTB",3,"COL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"4496","EUCAST 2022","human","human","DISK",NA,"B_ACNTB",3,"DOR","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",50,22,FALSE,FALSE,NA +"4497","EUCAST 2022","human","human","MIC",NA,"B_ACNTB",3,"DOR","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,2,FALSE,FALSE,NA +"4498","EUCAST 2022","human","human","DISK","systemic infections","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",17,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"4499","EUCAST 2022","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",17,17,FALSE,FALSE,NA +"4500","EUCAST 2022","human","human","DISK","Topical","B_ACNTB",3,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",17,17,FALSE,FALSE,NA +"4501","EUCAST 2022","human","human","MIC","systemic infections","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"4502","EUCAST 2022","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA +"4503","EUCAST 2022","human","human","MIC","Topical","B_ACNTB",3,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA +"4504","EUCAST 2022","human","human","DISK",NA,"B_ACNTB",3,"IMR","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)","10/25 mcg",24,24,FALSE,FALSE,"[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit." +"4505","EUCAST 2022","human","human","MIC",NA,"B_ACNTB",3,"IMR","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit." +"4506","EUCAST 2022","human","human","DISK",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",24,21,FALSE,FALSE,NA +"4507","EUCAST 2022","human","human","MIC",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)",NA,2,4,FALSE,FALSE,NA +"4508","EUCAST 2022","human","human","DISK",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",23,20,FALSE,FALSE,NA +"4509","EUCAST 2022","human","human","DISK","Topical","B_ACNTB",3,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",23,23,FALSE,FALSE,NA +"4510","EUCAST 2022","human","human","MIC",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,1,FALSE,FALSE,NA +"4511","EUCAST 2022","human","human","MIC","Topical","B_ACNTB",3,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"4512","EUCAST 2022","human","human","DISK","indications other than meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",21,15,FALSE,FALSE,NA +"4513","EUCAST 2022","human","human","DISK","meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",21,21,FALSE,FALSE,NA +"4514","EUCAST 2022","human","human","MIC","indications other than meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)",NA,2,8,FALSE,FALSE,NA +"4515","EUCAST 2022","human","human","MIC","meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"4516","EUCAST 2022","human","human","MIC","Topical","B_ACNTB",3,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA +"4517","EUCAST 2022","human","human","DISK",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)","1.25/23.75 mcg",14,11,FALSE,FALSE,"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"4518","EUCAST 2022","human","human","MIC",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)",NA,2,4,FALSE,FALSE,"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"4519","EUCAST 2022","human","human","DISK","systemic infections","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",17,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"4520","EUCAST 2022","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",17,17,FALSE,FALSE,NA +"4521","EUCAST 2022","human","human","DISK","Topical","B_ACNTB",3,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",17,17,FALSE,FALSE,NA +"4522","EUCAST 2022","human","human","MIC","systemic infections","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"4523","EUCAST 2022","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA +"4524","EUCAST 2022","human","human","MIC","Topical","B_ACNTB",3,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA +"4525","EUCAST 2022","human","human","DISK",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",26,26,FALSE,FALSE,NA +"4526","EUCAST 2022","human","human","MIC",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"4527","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note" +"4528","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,TRUE,FALSE,NA +"4529","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility." +"4530","EUCAST 2022","human","human","DISK",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",31,31,FALSE,FALSE,NA +"4531","EUCAST 2022","human","human","MIC",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"4532","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","100 mcg",16,16,TRUE,FALSE,NA +"4533","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,16,16,TRUE,FALSE,NA +"4534","EUCAST 2022","human","human","DISK","screen only","B_AERCC_SNGN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance." +"4535","EUCAST 2022","human","human","DISK",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","1 unit",21,21,FALSE,FALSE,NA +"4536","EUCAST 2022","human","human","MIC",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"4537","EUCAST 2022","human","human","DISK",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",25,25,FALSE,FALSE,NA +"4538","EUCAST 2022","human","human","MIC",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"4539","EUCAST 2022","human","human","DISK",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method." +"4540","EUCAST 2022","human","human","MIC",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA +"4541","EUCAST 2022","human","human","DISK",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",26,26,FALSE,FALSE,NA +"4542","EUCAST 2022","human","human","MIC",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"4543","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note" +"4544","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,TRUE,FALSE,NA +"4545","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility." +"4546","EUCAST 2022","human","human","DISK",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",31,31,FALSE,FALSE,NA +"4547","EUCAST 2022","human","human","MIC",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"4548","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","100 mcg",16,16,TRUE,FALSE,NA +"4549","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,16,16,TRUE,FALSE,NA +"4550","EUCAST 2022","human","human","DISK","screen only","B_AERCC_URIN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance." +"4551","EUCAST 2022","human","human","DISK",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","1 unit",21,21,FALSE,FALSE,NA +"4552","EUCAST 2022","human","human","MIC",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"4553","EUCAST 2022","human","human","DISK",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",25,25,FALSE,FALSE,NA +"4554","EUCAST 2022","human","human","MIC",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"4555","EUCAST 2022","human","human","DISK",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method." +"4556","EUCAST 2022","human","human","MIC",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA +"4557","EUCAST 2022","human","human","DISK",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",29,26,FALSE,FALSE,NA +"4558","EUCAST 2022","human","human","MIC",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 12.0)",NA,1,4,FALSE,FALSE,NA +"4559","EUCAST 2022","human","human","DISK",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",24,21,FALSE,FALSE,NA +"4560","EUCAST 2022","human","human","MIC",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 12.0)",NA,1,4,FALSE,FALSE,NA +"4561","EUCAST 2022","human","human","DISK",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",27,24,FALSE,FALSE,NA +"4562","EUCAST 2022","human","human","MIC",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,NA +"4563","EUCAST 2022","human","human","DISK",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",27,24,FALSE,FALSE,NA +"4564","EUCAST 2022","human","human","MIC",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 12.0)",NA,1,4,FALSE,FALSE,NA +"4565","EUCAST 2022","human","human","DISK",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",27,24,FALSE,FALSE,NA +"4566","EUCAST 2022","human","human","MIC",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,1,FALSE,FALSE,NA +"4567","EUCAST 2022","human","human","DISK",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 12.0)","1.25/23.75 mcg",19,16,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"4568","EUCAST 2022","human","human","MIC",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 12.0)",NA,2,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"4569","EUCAST 2022","human","human","DISK",NA,"B_BCLLS",3,"CIP","Bacillus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",50,23,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"4570","EUCAST 2022","human","human","MIC",NA,"B_BCLLS",3,"CIP","Bacillus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,0.5,FALSE,FALSE,NA +"4571","EUCAST 2022","human","human","DISK",NA,"B_BCLLS",3,"CLI","Bacillus (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",17,17,FALSE,FALSE,NA +"4572","EUCAST 2022","human","human","MIC",NA,"B_BCLLS",3,"CLI","Bacillus (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA +"4573","EUCAST 2022","human","human","DISK",NA,"B_BCLLS",3,"ERY","Bacillus (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",24,24,FALSE,FALSE,NA +"4574","EUCAST 2022","human","human","MIC",NA,"B_BCLLS",3,"ERY","Bacillus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"4575","EUCAST 2022","human","human","DISK",NA,"B_BCLLS",3,"IPM","Bacillus (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",30,30,FALSE,FALSE,NA +"4576","EUCAST 2022","human","human","MIC",NA,"B_BCLLS",3,"IPM","Bacillus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"4577","EUCAST 2022","human","human","DISK",NA,"B_BCLLS",3,"LNZ","Bacillus (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",22,22,FALSE,FALSE,NA +"4578","EUCAST 2022","human","human","MIC",NA,"B_BCLLS",3,"LNZ","Bacillus (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"4579","EUCAST 2022","human","human","DISK",NA,"B_BCLLS",3,"LVX","Bacillus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",50,23,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"4580","EUCAST 2022","human","human","MIC",NA,"B_BCLLS",3,"LVX","Bacillus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,1,FALSE,FALSE,NA +"4581","EUCAST 2022","human","human","DISK",NA,"B_BCLLS",3,"MEM","Bacillus (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",25,25,FALSE,FALSE,NA +"4582","EUCAST 2022","human","human","MIC",NA,"B_BCLLS",3,"MEM","Bacillus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"4583","EUCAST 2022","human","human","DISK","screen only","B_BCLLS",3,"NOR","Bacillus (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",21,21,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin." +"4584","EUCAST 2022","human","human","DISK",NA,"B_BCLLS",3,"VAN","Bacillus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",10,10,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method." +"4585","EUCAST 2022","human","human","MIC",NA,"B_BCLLS",3,"VAN","Bacillus (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"4586","EUCAST 2022","human","human","DISK",NA,"B_BCTRD",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",10,10,FALSE,FALSE,"[B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading." +"4587","EUCAST 2022","human","human","MIC",NA,"B_BCTRD",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"4588","EUCAST 2022","human","human","DISK",NA,"B_BCTRD",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",28,28,FALSE,FALSE,"[A] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene." +"4589","EUCAST 2022","human","human","MIC",NA,"B_BCTRD",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[2] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene." +"4590","EUCAST 2022","human","human","DISK",NA,"B_BCTRD",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",25,25,FALSE,FALSE,NA +"4591","EUCAST 2022","human","human","MIC",NA,"B_BCTRD",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA +"4592","EUCAST 2022","human","human","DISK",NA,"B_BCTRD",3,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","30/6 mcg",20,20,FALSE,FALSE,NA +"4593","EUCAST 2022","human","human","MIC",NA,"B_BCTRD",3,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"4594","EUCAST 2022","human","human","DISK",NA,"B_BRKHL_PSDM",2,"AMC","B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)","20/10 mcg",50,22,FALSE,FALSE,NA +"4595","EUCAST 2022","human","human","MIC",NA,"B_BRKHL_PSDM",2,"AMC","B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,8,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"4596","EUCAST 2022","human","human","DISK",NA,"B_BRKHL_PSDM",2,"CAZ","B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",50,18,FALSE,FALSE,NA +"4597","EUCAST 2022","human","human","MIC",NA,"B_BRKHL_PSDM",2,"CAZ","B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,8,FALSE,FALSE,NA +"4598","EUCAST 2022","human","human","DISK",NA,"B_BRKHL_PSDM",2,"CHL","B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",50,22,FALSE,FALSE,NA +"4599","EUCAST 2022","human","human","MIC",NA,"B_BRKHL_PSDM",2,"CHL","B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,8,FALSE,FALSE,NA +"4600","EUCAST 2022","human","human","MIC",NA,"B_BRKHL_PSDM",2,"DOX","B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,2,FALSE,FALSE,NA +"4601","EUCAST 2022","human","human","DISK",NA,"B_BRKHL_PSDM",2,"IPM","B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",29,29,FALSE,FALSE,NA +"4602","EUCAST 2022","human","human","MIC",NA,"B_BRKHL_PSDM",2,"IPM","B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"4603","EUCAST 2022","human","human","DISK",NA,"B_BRKHL_PSDM",2,"MEM","B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",24,24,FALSE,FALSE,NA +"4604","EUCAST 2022","human","human","MIC",NA,"B_BRKHL_PSDM",2,"MEM","B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"4605","EUCAST 2022","human","human","DISK",NA,"B_BRKHL_PSDM",2,"SXT","B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)","1.25/23.75 mcg",50,17,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"4606","EUCAST 2022","human","human","MIC",NA,"B_BRKHL_PSDM",2,"SXT","B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"4607","EUCAST 2022","human","human","DISK","screen only","B_BRKHL_PSDM",2,"TCY","B.pseudomallei (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",23,23,FALSE,FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline." +"4608","EUCAST 2022","human","human","DISK",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",50,26,FALSE,FALSE,NA +"4609","EUCAST 2022","human","human","MIC",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,0.5,FALSE,FALSE,NA +"4610","EUCAST 2022","human","human","DISK",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",24,24,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin." +"4611","EUCAST 2022","human","human","MIC",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin." +"4612","EUCAST 2022","human","human","DISK",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",30,30,FALSE,FALSE,"[A] Tetracycline can be used to determine susceptibility to doxycycline." +"4613","EUCAST 2022","human","human","MIC",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to determine susceptibility to doxycycline." +"4614","EUCAST 2022","human","human","DISK",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",50,26,FALSE,FALSE,NA +"4615","EUCAST 2022","human","human","MIC",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,0.5,FALSE,FALSE,NA +"4616","EUCAST 2022","human","human","DISK",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",20,20,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin." +"4617","EUCAST 2022","human","human","MIC",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin." +"4618","EUCAST 2022","human","human","DISK",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",30,30,FALSE,FALSE,"[A] Tetracycline can be used to determine susceptibility to doxycycline." +"4619","EUCAST 2022","human","human","MIC",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to determine susceptibility to doxycycline." +"4620","EUCAST 2022","human","human","MIC",NA,"B_CRDDS_DFFC",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes." +"4621","EUCAST 2022","human","human","MIC",NA,"B_CRDDS_DFFC",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes." +"4622","EUCAST 2022","human","human","DISK",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",50,25,FALSE,FALSE,NA +"4623","EUCAST 2022","human","human","MIC",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,1,FALSE,FALSE,NA +"4624","EUCAST 2022","human","human","DISK",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",20,20,FALSE,FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing." +"4625","EUCAST 2022","human","human","MIC",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing." +"4626","EUCAST 2022","human","human","DISK",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",25,25,FALSE,FALSE,NA +"4627","EUCAST 2022","human","human","MIC",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"4628","EUCAST 2022","human","human","DISK",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",25,25,FALSE,FALSE,NA +"4629","EUCAST 2022","human","human","MIC",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"4630","EUCAST 2022","human","human","DISK",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)","1 unit",29,29,FALSE,FALSE,NA +"4631","EUCAST 2022","human","human","MIC",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"4632","EUCAST 2022","human","human","DISK",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",30,25,FALSE,FALSE,NA +"4633","EUCAST 2022","human","human","MIC",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.5,FALSE,FALSE,NA +"4634","EUCAST 2022","human","human","DISK",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",24,24,FALSE,FALSE,NA +"4635","EUCAST 2022","human","human","MIC",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"4636","EUCAST 2022","human","human","DISK",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method." +"4637","EUCAST 2022","human","human","MIC",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"4638","EUCAST 2022","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",26,26,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading." +"4639","EUCAST 2022","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"4640","EUCAST 2022","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",28,28,FALSE,FALSE,NA +"4641","EUCAST 2022","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"4642","EUCAST 2022","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","1 unit",24,24,FALSE,FALSE,NA +"4643","EUCAST 2022","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA +"4644","EUCAST 2022","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","30/6 mcg",27,27,FALSE,FALSE,NA +"4645","EUCAST 2022","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"4646","EUCAST 2022","human","human","DISK",NA,"B_CTBCTR_ACNS",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",22,22,FALSE,FALSE,NA +"4647","EUCAST 2022","human","human","MIC",NA,"B_CTBCTR_ACNS",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"4648","EUCAST 2022","human","human","DISK",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method." +"4649","EUCAST 2022","human","human","MIC",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/." +"4650","EUCAST 2022","human","human","DISK",NA,"B_CTRDM_PRFR",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",19,19,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading." +"4651","EUCAST 2022","human","human","MIC",NA,"B_CTRDM_PRFR",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"4652","EUCAST 2022","human","human","DISK",NA,"B_CTRDM_PRFR",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",25,25,FALSE,FALSE,NA +"4653","EUCAST 2022","human","human","MIC",NA,"B_CTRDM_PRFR",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"4654","EUCAST 2022","human","human","DISK",NA,"B_CTRDM_PRFR",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",16,16,FALSE,FALSE,NA +"4655","EUCAST 2022","human","human","MIC",NA,"B_CTRDM_PRFR",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA +"4656","EUCAST 2022","human","human","DISK",NA,"B_CTRDM_PRFR",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","1 unit",15,15,FALSE,FALSE,NA +"4657","EUCAST 2022","human","human","MIC",NA,"B_CTRDM_PRFR",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"4658","EUCAST 2022","human","human","DISK",NA,"B_CTRDM_PRFR",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","30/6 mcg",24,24,FALSE,FALSE,NA +"4659","EUCAST 2022","human","human","MIC",NA,"B_CTRDM_PRFR",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"4660","EUCAST 2022","human","human","DISK",NA,"B_CTRDM_PRFR",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",12,12,FALSE,FALSE,NA +"4661","EUCAST 2022","human","human","MIC",NA,"B_CTRDM_PRFR",2,"VAN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"4662","EUCAST 2022","human","human","MIC",NA,"B_ENTRC",3,"AMC","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,4,8,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only." +"4663","EUCAST 2022","human","human","DISK",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",10,8,FALSE,FALSE,"[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only." +"4664","EUCAST 2022","human","human","MIC",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,4,8,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only." +"4665","EUCAST 2022","human","human","MIC",NA,"B_ENTRC",3,"AMX","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,4,8,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only." +"4666","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"4667","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,TRUE,FALSE,NA +"4668","EUCAST 2022","human","human","DISK",NA,"B_ENTRC",3,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",50,21,FALSE,FALSE,NA +"4669","EUCAST 2022","human","human","MIC",NA,"B_ENTRC",3,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,4,FALSE,FALSE,NA +"4670","EUCAST 2022","human","human","DISK",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",20,20,FALSE,FALSE,NA +"4671","EUCAST 2022","human","human","MIC",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA +"4672","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"4673","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,TRUE,FALSE,NA +"4674","EUCAST 2022","human","human","DISK","screen only","B_ENTRC",3,"NOR","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",12,12,FALSE,FALSE,"[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B." +"4675","EUCAST 2022","human","human","MIC",NA,"B_ENTRC",3,"SAM","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,4,8,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only." +"4676","EUCAST 2022","human","human","DISK",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",16,16,FALSE,FALSE,NA +"4677","EUCAST 2022","human","human","MIC",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"4678","EUCAST 2022","human","human","DISK",NA,"B_ENTRC",3,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",12,12,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation." +"4679","EUCAST 2022","human","human","MIC",NA,"B_ENTRC",3,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA +"4680","EUCAST 2022","human","human","DISK",NA,"B_ENTRC_FACM",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)","20 mcg",24,24,FALSE,FALSE,NA +"4681","EUCAST 2022","human","human","MIC",NA,"B_ENTRC_FACM",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"4682","EUCAST 2022","human","human","DISK",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",22,20,FALSE,FALSE,NA +"4683","EUCAST 2022","human","human","MIC",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,1,4,FALSE,FALSE,NA +"4684","EUCAST 2022","human","human","DISK",NA,"B_ENTRC_FACM",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",22,22,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4685","EUCAST 2022","human","human","MIC",NA,"B_ENTRC_FACM",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4686","EUCAST 2022","human","human","DISK",NA,"B_ENTRC_FCLS",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)","20 mcg",22,22,FALSE,FALSE,NA +"4687","EUCAST 2022","human","human","MIC",NA,"B_ENTRC_FCLS",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"4688","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)","100 mcg",15,15,TRUE,FALSE,NA +"4689","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,64,64,TRUE,FALSE,NA +"4690","EUCAST 2022","human","human","DISK",NA,"B_ENTRC_FCLS",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",20,20,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4691","EUCAST 2022","human","human","MIC",NA,"B_ENTRC_FCLS",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4692","EUCAST 2022","human","human","DISK",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",50,19,FALSE,FALSE,NA +"4693","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",19,19,TRUE,FALSE,NA +"4694","EUCAST 2022","human","human","MIC",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,8,FALSE,FALSE,NA +"4695","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,TRUE,FALSE,NA +"4696","EUCAST 2022","human","human","DISK","infections originating from the urinary tract","B_ESCHR_COLI",2,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",50,20,FALSE,FALSE,"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin." +"4697","EUCAST 2022","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,4,FALSE,FALSE,"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin." +"4698","EUCAST 2022","human","human","MIC",NA,"B_ESCHR_COLI",2,"DFX","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"4699","EUCAST 2022","human","human","DISK",NA,"B_ESCHR_COLI",2,"ERV","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","20 mcg",17,17,FALSE,FALSE,NA +"4700","EUCAST 2022","human","human","MIC",NA,"B_ESCHR_COLI",2,"ERV","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"4701","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","200 mcg",24,24,TRUE,FALSE,"[D] Ignore isolated colonies within the inhibition zone (see pictures below)." +"4702","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,TRUE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems." +"4703","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","100 mcg",11,11,TRUE,FALSE,NA +"4704","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,64,64,TRUE,FALSE,NA +"4705","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",15,15,TRUE,FALSE,NA +"4706","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,16,16,TRUE,FALSE,NA +"4707","EUCAST 2022","human","human","DISK","infections originating from the urinary tract","B_ESCHR_COLI",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",50,17,FALSE,FALSE,"[C] Ignore isolated colonies within the inhibition zone." +"4708","EUCAST 2022","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,16,FALSE,FALSE,NA +"4709","EUCAST 2022","human","human","DISK",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method." +"4710","EUCAST 2022","human","human","MIC",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/." +"4711","EUCAST 2022","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",30,30,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading." +"4712","EUCAST 2022","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"4713","EUCAST 2022","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",35,35,FALSE,FALSE,NA +"4714","EUCAST 2022","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.03,0.03,FALSE,FALSE,NA +"4715","EUCAST 2022","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",30,30,FALSE,FALSE,NA +"4716","EUCAST 2022","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"4717","EUCAST 2022","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","1 unit",25,25,FALSE,FALSE,NA +"4718","EUCAST 2022","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA +"4719","EUCAST 2022","human","human","DISK",NA,"B_FSBCTR_NCRP",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","30/6 mcg",32,32,FALSE,FALSE,NA +"4720","EUCAST 2022","human","human","MIC",NA,"B_FSBCTR_NCRP",2,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"4721","EUCAST 2022","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"AMX","H.pylori (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"4722","EUCAST 2022","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"CLR","H.pylori (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,NA +"4723","EUCAST 2022","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"LVX","H.pylori (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA +"4724","EUCAST 2022","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"MTR","H.pylori (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,NA +"4725","EUCAST 2022","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"RIF","H.pylori (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA +"4726","EUCAST 2022","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"TCY","H.pylori (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA +"4727","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","2/1 mcg",15,15,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"4728","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","2/1 mcg",50,15,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"4729","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"4730","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,2,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"4731","EUCAST 2022","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",18,18,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase." +"4732","EUCAST 2022","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase." +"4733","EUCAST 2022","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"AMX","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase." +"4734","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMX","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,2,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase." +"4735","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"4736","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"4737","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",28,28,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages." +"4738","EUCAST 2022","human","human","DISK","Topical","B_HMPHL_INFL",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",28,28,FALSE,FALSE,NA +"4739","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages." +"4740","EUCAST 2022","human","human","MIC","Topical","B_HMPHL_INFL",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"4741","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"4742","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA +"4743","EUCAST 2022","human","human","MIC","Topical","B_HMPHL_INFL",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA +"4744","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"4745","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"4746","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPT","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.03,0.03,FALSE,FALSE,NA +"4747","EUCAST 2022","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",32,32,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"4748","EUCAST 2022","human","human","DISK","meningitis","B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",32,32,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC." +"4749","EUCAST 2022","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"4750","EUCAST 2022","human","human","MIC","meningitis","B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"4751","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",25,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"4752","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA +"4753","EUCAST 2022","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"4754","EUCAST 2022","human","human","DISK","meningitis","B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC." +"4755","EUCAST 2022","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"4756","EUCAST 2022","human","human","MIC","meningitis","B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"4757","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",27,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"4758","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",50,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"4759","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,NA +"4760","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,1,FALSE,FALSE,NA +"4761","EUCAST 2022","human","human","DISK","pneumonia","B_HMPHL_INFL",2,"CZT","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","30/10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] See table of dosages for dosing for different indications." +"4762","EUCAST 2022","human","human","MIC","pneumonia","B_HMPHL_INFL",2,"CZT","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[2] See table of dosages for dosing for different indications." +"4763","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"DOR","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"4764","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"DOR","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA +"4765","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"DOX","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"4766","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"4767","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"4768","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",28,28,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"4769","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"4770","EUCAST 2022","human","human","MIC","Topical","B_HMPHL_INFL",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA +"4771","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"4772","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"4773","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"4774","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA +"4775","EUCAST 2022","human","human","MIC","Topical","B_HMPHL_INFL",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA +"4776","EUCAST 2022","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"4777","EUCAST 2022","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"4778","EUCAST 2022","human","human","MIC","meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"4779","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"4780","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"4781","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",24,24,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"4782","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"4783","EUCAST 2022","human","human","DISK","screen only","B_HMPHL_INFL",2,"NAL","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",23,23,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"4784","EUCAST 2022","human","human","DISK","Topical","B_HMPHL_INFL",2,"NAL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",23,23,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)." +"4785","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"4786","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA +"4787","EUCAST 2022","human","human","MIC","Topical","B_HMPHL_INFL",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA +"4788","EUCAST 2022","human","human","DISK","screen only","B_HMPHL_INFL",2,"PEN","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","1 unit",12,NA,FALSE,FALSE,"[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"4789","EUCAST 2022","human","human","DISK","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",18,18,FALSE,FALSE,NA +"4790","EUCAST 2022","human","human","MIC","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA +"4791","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"SAM","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv." +"4792","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","1.25/23.75 mcg",23,20,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"4793","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,1,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"4794","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",25,25,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"4795","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"4796","EUCAST 2022","human","human","MIC","Topical","B_HMPHL_INFL",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,NA +"4797","EUCAST 2022","human","human","DISK",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)","30/6 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"4798","EUCAST 2022","human","human","MIC",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"4799","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"AMP","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility." +"4800","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"AMX","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility." +"4801","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"AZM","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility." +"4802","EUCAST 2022","human","human","DISK",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",28,28,FALSE,FALSE,NA +"4803","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA +"4804","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"CLR","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility." +"4805","EUCAST 2022","human","human","DISK",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",30,30,FALSE,FALSE,NA +"4806","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA +"4807","EUCAST 2022","human","human","DISK",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",27,27,FALSE,FALSE,NA +"4808","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"4809","EUCAST 2022","human","human","DISK",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",29,29,FALSE,FALSE,NA +"4810","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"4811","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"DOX","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant." +"4812","EUCAST 2022","human","human","DISK",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",20,20,FALSE,FALSE,NA +"4813","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"4814","EUCAST 2022","human","human","DISK",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",28,28,FALSE,FALSE,NA +"4815","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"4816","EUCAST 2022","human","human","DISK",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",30,30,FALSE,FALSE,NA +"4817","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.03,0.03,FALSE,FALSE,NA +"4818","EUCAST 2022","human","human","DISK",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 12.0)","1 unit",25,25,FALSE,FALSE,NA +"4819","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.03,0.03,FALSE,FALSE,NA +"4820","EUCAST 2022","human","human","DISK",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",20,20,FALSE,FALSE,NA +"4821","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"4822","EUCAST 2022","human","human","DISK",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 12.0)","1.25/23.75 mcg",28,28,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"4823","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"4824","EUCAST 2022","human","human","DISK",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",28,28,FALSE,FALSE,NA +"4825","EUCAST 2022","human","human","MIC",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"4826","EUCAST 2022","human","human","DISK",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",50,19,FALSE,FALSE,NA +"4827","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",19,19,TRUE,FALSE,NA +"4828","EUCAST 2022","human","human","MIC",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,8,FALSE,FALSE,NA +"4829","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,TRUE,FALSE,NA +"4830","EUCAST 2022","human","human","DISK","infections originating from the urinary tract","B_KLBSL",3,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",50,20,FALSE,FALSE,"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin." +"4831","EUCAST 2022","human","human","MIC","infections originating from the urinary tract","B_KLBSL",3,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,4,FALSE,FALSE,"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin." +"4832","EUCAST 2022","human","human","DISK","infections originating from the urinary tract","B_KLBSL",3,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",50,17,FALSE,FALSE,"[C] Ignore isolated colonies within the inhibition zone." +"4833","EUCAST 2022","human","human","MIC","infections originating from the urinary tract","B_KLBSL",3,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,16,FALSE,FALSE,NA +"4834","EUCAST 2022","human","human","DISK","all indications","B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",16,16,FALSE,FALSE,NA +"4835","EUCAST 2022","human","human","MIC","all indications","B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA +"4836","EUCAST 2022","human","human","DISK","indications other than meningitis","B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",25,25,FALSE,FALSE,NA +"4837","EUCAST 2022","human","human","MIC","indications other than meningitis","B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA +"4838","EUCAST 2022","human","human","DISK","all indications","B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",26,26,FALSE,FALSE,NA +"4839","EUCAST 2022","human","human","MIC","all indications","B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"4840","EUCAST 2022","human","human","DISK","indications other than meningitis","B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 12.0)","1 unit",13,13,FALSE,FALSE,NA +"4841","EUCAST 2022","human","human","MIC","indications other than meningitis","B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA +"4842","EUCAST 2022","human","human","DISK","all indications","B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 12.0)","1.25/23.75 mcg",29,29,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"4843","EUCAST 2022","human","human","MIC","all indications","B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"4844","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","2/1 mcg",19,19,FALSE,FALSE,NA +"4845","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"4846","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AZM","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"4847","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",21,18,FALSE,FALSE,NA +"4848","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,1,FALSE,FALSE,NA +"4849","EUCAST 2022","human","human","DISK","Topical","B_MRXLL_CTRR",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",31,31,FALSE,FALSE,NA +"4850","EUCAST 2022","human","human","MIC","Topical","B_MRXLL_CTRR",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"4851","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",31,31,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"4852","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"4853","EUCAST 2022","human","human","MIC","Topical","B_MRXLL_CTRR",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"4854","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CLR","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"4855","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",24,21,FALSE,FALSE,NA +"4856","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,NA +"4857","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",20,17,FALSE,FALSE,NA +"4858","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,NA +"4859","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",21,18,FALSE,FALSE,NA +"4860","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",50,21,FALSE,FALSE,NA +"4861","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,4,8,FALSE,FALSE,NA +"4862","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,4,FALSE,FALSE,NA +"4863","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"DOR","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",30,30,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4864","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"DOR","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4865","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"DOX","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"4866","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",23,20,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"4867","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,NA +"4868","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",29,29,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4869","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4870","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",20,20,FALSE,FALSE,NA +"4871","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA +"4872","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",29,29,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4873","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4874","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",29,29,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"4875","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"4876","EUCAST 2022","human","human","MIC","Topical","B_MRXLL_CTRR",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"4877","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",33,33,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4878","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4879","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",26,26,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"4880","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"4881","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",25,25,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"4882","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"4883","EUCAST 2022","human","human","DISK","screen only","B_MRXLL_CTRR",2,"NAL","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",23,23,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"4884","EUCAST 2022","human","human","DISK","Topical","B_MRXLL_CTRR",2,"NAL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",23,23,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)." +"4885","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"4886","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"4887","EUCAST 2022","human","human","MIC","Topical","B_MRXLL_CTRR",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"4888","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"RXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,1,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"4889","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SAM","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid." +"4890","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","1.25/23.75 mcg",18,15,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"4891","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,1,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"4892","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",26,26,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"4893","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant." +"4894","EUCAST 2022","human","human","DISK",NA,"B_MRXLL_CTRR",2,"TLT","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",23,20,FALSE,FALSE,NA +"4895","EUCAST 2022","human","human","MIC",NA,"B_MRXLL_CTRR",2,"TLT","M.catarrhalis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,NA +"4896","EUCAST 2022","human","human","MIC",NA,"B_MYCBC_TBRC",2,"BDQ","M.tuberculosis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Breakpoints were determined on MICs performed on Middlebrook 7H11/7H10 medium. The comparability of tests performed by other media has not been established. There is ongoing work to review breakpoints using the EUCAST reference method (described above)." +"4897","EUCAST 2022","human","human","MIC",NA,"B_MYCBC_TBRC",2,"DLM","M.tuberculosis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA +"4898","EUCAST 2022","human","human","MIC",NA,"B_NESSR_GNRR",2,"CFM","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"4899","EUCAST 2022","human","human","MIC",NA,"B_NESSR_GNRR",2,"CIP","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.03,0.06,FALSE,FALSE,NA +"4900","EUCAST 2022","human","human","MIC",NA,"B_NESSR_GNRR",2,"CRO","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"4901","EUCAST 2022","human","human","MIC",NA,"B_NESSR_GNRR",2,"CTX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"4902","EUCAST 2022","human","human","MIC",NA,"B_NESSR_GNRR",2,"OFX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.25,FALSE,FALSE,NA +"4903","EUCAST 2022","human","human","MIC","surrogate agent","B_NESSR_GNRR",2,"PEN","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,1,FALSE,FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)." +"4904","EUCAST 2022","human","human","MIC",NA,"B_NESSR_GNRR",2,"SPT","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)",NA,64,64,FALSE,FALSE,NA +"4905","EUCAST 2022","human","human","MIC",NA,"B_NESSR_GNRR",2,"TCY","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,1,FALSE,FALSE,NA +"4906","EUCAST 2022","human","human","MIC","indications other than meningitis","B_NESSR_MNNG",2,"AMP","N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,1,FALSE,FALSE,NA +"4907","EUCAST 2022","human","human","MIC","indications other than meningitis","B_NESSR_MNNG",2,"AMX","N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,1,FALSE,FALSE,NA +"4908","EUCAST 2022","human","human","MIC","meningitis","B_NESSR_MNNG",2,"CHL","N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages." +"4909","EUCAST 2022","human","human","MIC","prophylaxis only","B_NESSR_MNNG",2,"CIP","N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.03,0.03,FALSE,FALSE,NA +"4910","EUCAST 2022","human","human","MIC","all indications including prophylaxis","B_NESSR_MNNG",2,"CRO","N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4911","EUCAST 2022","human","human","MIC","all indications","B_NESSR_MNNG",2,"CTX","N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"4912","EUCAST 2022","human","human","MIC","all indications","B_NESSR_MNNG",2,"MEM","N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. 3.The addition of the beta-lactamase inhibitor does not add clinical benefit." +"4913","EUCAST 2022","human","human","MIC","prophylaxis only","B_NESSR_MNNG",2,"MNO","N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections." +"4914","EUCAST 2022","human","human","MIC","all indications","B_NESSR_MNNG",2,"PEN","N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"4915","EUCAST 2022","human","human","MIC","prophylaxis only","B_NESSR_MNNG",2,"RIF","N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"4916","EUCAST 2022","human","human","MIC","screen only","B_NESSR_MNNG",2,"TCY","N.meningitidis (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections." +"4917","EUCAST 2022","human","human","DISK",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",50,19,FALSE,FALSE,NA +"4918","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",19,19,TRUE,FALSE,NA +"4919","EUCAST 2022","human","human","MIC",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,8,FALSE,FALSE,NA +"4920","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,TRUE,FALSE,NA +"4921","EUCAST 2022","human","human","DISK","infections originating from the urinary tract","B_PROTS_MRBL",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",50,17,FALSE,FALSE,"[C] Ignore isolated colonies within the inhibition zone." +"4922","EUCAST 2022","human","human","MIC","infections originating from the urinary tract","B_PROTS_MRBL",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,16,FALSE,FALSE,NA +"4923","EUCAST 2022","human","human","DISK",NA,"B_PRVTL",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",31,31,FALSE,FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading." +"4924","EUCAST 2022","human","human","MIC",NA,"B_PRVTL",3,"CLI","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"4925","EUCAST 2022","human","human","DISK",NA,"B_PRVTL",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",34,34,FALSE,FALSE,NA +"4926","EUCAST 2022","human","human","MIC",NA,"B_PRVTL",3,"MEM","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"4927","EUCAST 2022","human","human","DISK",NA,"B_PRVTL",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",22,22,FALSE,FALSE,NA +"4928","EUCAST 2022","human","human","MIC",NA,"B_PRVTL",3,"MTR","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA +"4929","EUCAST 2022","human","human","DISK",NA,"B_PRVTL",3,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","1 unit",20,20,FALSE,FALSE,NA +"4930","EUCAST 2022","human","human","MIC",NA,"B_PRVTL",3,"PEN","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"4931","EUCAST 2022","human","human","DISK",NA,"B_PRVTL",3,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)","30/6 mcg",26,26,FALSE,FALSE,NA +"4932","EUCAST 2022","human","human","MIC",NA,"B_PRVTL",3,"TZP","Anaerobic bacteria (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"4933","EUCAST 2022","human","human","DISK","systemic infections","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"4934","EUCAST 2022","human","human","DISK","infections originating from the urinary tract","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",15,15,FALSE,FALSE,NA +"4935","EUCAST 2022","human","human","MIC","systemic infections","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,16,16,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"4936","EUCAST 2022","human","human","MIC","infections originating from the urinary tract","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,16,16,FALSE,FALSE,NA +"4937","EUCAST 2022","human","human","DISK",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",50,18,FALSE,FALSE,NA +"4938","EUCAST 2022","human","human","MIC",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,16,FALSE,FALSE,NA +"4939","EUCAST 2022","human","human","DISK",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",50,17,FALSE,FALSE,NA +"4940","EUCAST 2022","human","human","MIC",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,8,FALSE,FALSE,NA +"4941","EUCAST 2022","human","human","DISK",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",50,26,FALSE,FALSE,NA +"4942","EUCAST 2022","human","human","MIC",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,0.5,FALSE,FALSE,NA +"4943","EUCAST 2022","human","human","MIC",NA,"B_PSDMN",3,"COL","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)." +"4944","EUCAST 2022","human","human","DISK",NA,"B_PSDMN",3,"DOR","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",50,22,FALSE,FALSE,NA +"4945","EUCAST 2022","human","human","MIC",NA,"B_PSDMN",3,"DOR","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,2,FALSE,FALSE,NA +"4946","EUCAST 2022","human","human","DISK",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",50,21,FALSE,FALSE,NA +"4947","EUCAST 2022","human","human","MIC",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,8,FALSE,FALSE,NA +"4948","EUCAST 2022","human","human","DISK",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",50,20,FALSE,FALSE,NA +"4949","EUCAST 2022","human","human","MIC",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,4,FALSE,FALSE,NA +"4950","EUCAST 2022","human","human","DISK",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",50,18,FALSE,FALSE,NA +"4951","EUCAST 2022","human","human","MIC",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,2,FALSE,FALSE,NA +"4952","EUCAST 2022","human","human","DISK","indications other than meningitis","B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",24,18,FALSE,FALSE,NA +"4953","EUCAST 2022","human","human","MIC","indications other than meningitis","B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,2,8,FALSE,FALSE,NA +"4954","EUCAST 2022","human","human","DISK",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",50,18,FALSE,FALSE,NA +"4955","EUCAST 2022","human","human","MIC",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,16,FALSE,FALSE,NA +"4956","EUCAST 2022","human","human","DISK",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","75/10 mcg",50,18,FALSE,FALSE,NA +"4957","EUCAST 2022","human","human","MIC",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,16,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"4958","EUCAST 2022","human","human","DISK",NA,"B_PSDMN",3,"TIC","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","75 mcg",50,18,FALSE,FALSE,NA +"4959","EUCAST 2022","human","human","MIC",NA,"B_PSDMN",3,"TIC","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,16,FALSE,FALSE,NA +"4960","EUCAST 2022","human","human","DISK","systemic infections","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"4961","EUCAST 2022","human","human","DISK","infections originating from the urinary tract","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",18,18,FALSE,FALSE,NA +"4962","EUCAST 2022","human","human","MIC","systemic infections","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"4963","EUCAST 2022","human","human","MIC","infections originating from the urinary tract","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"4964","EUCAST 2022","human","human","DISK",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","30/6 mcg",50,18,FALSE,FALSE,NA +"4965","EUCAST 2022","human","human","MIC",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,16,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"4966","EUCAST 2022","human","human","DISK","Topical","B_PSDMN_AERG",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",26,26,FALSE,FALSE,NA +"4967","EUCAST 2022","human","human","MIC","Topical","B_PSDMN_AERG",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"4968","EUCAST 2022","human","human","MIC","Topical","B_PSDMN_AERG",2,"COL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA +"4969","EUCAST 2022","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","10/4 mcg",17,17,FALSE,FALSE,NA +"4970","EUCAST 2022","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L." +"4971","EUCAST 2022","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","30/10 mcg",23,23,FALSE,FALSE,"[3] See table of dosages for dosing for different indications." +"4972","EUCAST 2022","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] See table of dosages for dosing for different indications." +"4973","EUCAST 2022","human","human","DISK",NA,"B_PSDMN_AERG",2,"FDC","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",22,22,FALSE,FALSE,NA +"4974","EUCAST 2022","human","human","MIC",NA,"B_PSDMN_AERG",2,"FDC","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/." +"4975","EUCAST 2022","human","human","DISK","Topical","B_PSDMN_AERG",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",15,15,FALSE,FALSE,NA +"4976","EUCAST 2022","human","human","MIC","Topical","B_PSDMN_AERG",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,NA +"4977","EUCAST 2022","human","human","DISK",NA,"B_PSDMN_AERG",2,"IMR","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","10/25 mcg",22,22,FALSE,FALSE,NA +"4978","EUCAST 2022","human","human","MIC",NA,"B_PSDMN_AERG",2,"IMR","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L." +"4979","EUCAST 2022","human","human","DISK","Topical","B_PSDMN_AERG",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",18,18,FALSE,FALSE,NA +"4980","EUCAST 2022","human","human","MIC","Topical","B_PSDMN_AERG",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"4981","EUCAST 2022","human","human","DISK","indications other than meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",20,14,FALSE,FALSE,NA +"4982","EUCAST 2022","human","human","DISK","meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",20,20,FALSE,FALSE,NA +"4983","EUCAST 2022","human","human","MIC","indications other than meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,2,8,FALSE,FALSE,NA +"4984","EUCAST 2022","human","human","MIC","meningitis","B_PSDMN_AERG",2,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"4985","EUCAST 2022","human","human","DISK",NA,"B_PSDMN_AERG",2,"MEV","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)","20/10 mcg",14,14,FALSE,FALSE,NA +"4986","EUCAST 2022","human","human","MIC",NA,"B_PSDMN_AERG",2,"MEV","Pseudomonas (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L." +"4987","EUCAST 2022","human","human","MIC","Topical","B_PSDMN_AERG",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"4988","EUCAST 2022","human","human","DISK","Topical","B_PSDMN_AERG",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",18,18,FALSE,FALSE,NA +"4989","EUCAST 2022","human","human","MIC","Topical","B_PSDMN_AERG",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"4990","EUCAST 2022","human","human","DISK",NA,"B_PSTRL_MLTC",2,"AMC","P.multocida (file: Clinical Breakpoint Tables v. 12.0)","2/1 mcg",15,15,FALSE,FALSE,NA +"4991","EUCAST 2022","human","human","MIC",NA,"B_PSTRL_MLTC",2,"AMC","P.multocida (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"4992","EUCAST 2022","human","human","MIC",NA,"B_PSTRL_MLTC",2,"AMP","P.multocida (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA +"4993","EUCAST 2022","human","human","MIC",NA,"B_PSTRL_MLTC",2,"AMX","P.multocida (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA +"4994","EUCAST 2022","human","human","DISK",NA,"B_PSTRL_MLTC",2,"CIP","P.multocida (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B." +"4995","EUCAST 2022","human","human","MIC",NA,"B_PSTRL_MLTC",2,"CIP","P.multocida (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA +"4996","EUCAST 2022","human","human","DISK",NA,"B_PSTRL_MLTC",2,"CTX","P.multocida (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",26,26,FALSE,FALSE,NA +"4997","EUCAST 2022","human","human","MIC",NA,"B_PSTRL_MLTC",2,"CTX","P.multocida (file: Clinical Breakpoint Tables v. 12.0)",NA,0.03,0.03,FALSE,FALSE,NA +"4998","EUCAST 2022","human","human","MIC",NA,"B_PSTRL_MLTC",2,"DOX","P.multocida (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA +"4999","EUCAST 2022","human","human","DISK",NA,"B_PSTRL_MLTC",2,"LVX","P.multocida (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B." +"5000","EUCAST 2022","human","human","MIC",NA,"B_PSTRL_MLTC",2,"LVX","P.multocida (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA +"5001","EUCAST 2022","human","human","DISK","screen only","B_PSTRL_MLTC",2,"NAL","P.multocida (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",23,23,FALSE,FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"5002","EUCAST 2022","human","human","DISK",NA,"B_PSTRL_MLTC",2,"PEN","P.multocida (file: Clinical Breakpoint Tables v. 12.0)","1 unit",17,17,FALSE,FALSE,NA +"5003","EUCAST 2022","human","human","MIC",NA,"B_PSTRL_MLTC",2,"PEN","P.multocida (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5004","EUCAST 2022","human","human","DISK",NA,"B_PSTRL_MLTC",2,"SXT","P.multocida (file: Clinical Breakpoint Tables v. 12.0)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5005","EUCAST 2022","human","human","MIC",NA,"B_PSTRL_MLTC",2,"SXT","P.multocida (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5006","EUCAST 2022","human","human","DISK","screen only","B_PSTRL_MLTC",2,"TCY","P.multocida (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",24,24,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test." +"5007","EUCAST 2022","human","human","MIC",NA,"B_SLMNL",3,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species." +"5008","EUCAST 2022","human","human","DISK","screen only","B_SLMNL",3,"PEF","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",24,24,FALSE,FALSE,"[2/C] The pefloxacin 5 µg breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp. | [B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from the pefloxacin disk diffusion screening test. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species." +"5009","EUCAST 2022","human","human","DISK",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 12.0)","1.25/23.75 mcg",50,16,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5010","EUCAST 2022","human","human","MIC",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5011","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"AZM","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"5012","EUCAST 2022","human","human","DISK",NA,"B_STPHY",3,"CHL","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",18,18,FALSE,FALSE,"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages." +"5013","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"CHL","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages." +"5014","EUCAST 2022","human","human","DISK",NA,"B_STPHY",3,"CLI","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",22,22,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy""." +"5015","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"CLI","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy""." +"5016","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"CLR","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"5017","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"DAL","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin." +"5018","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"DAP","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[3] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5019","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"DOX","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"5020","EUCAST 2022","human","human","DISK",NA,"B_STPHY",3,"ERY","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",21,18,FALSE,FALSE,NA +"5021","EUCAST 2022","human","human","DISK","screen only","B_STPHY",3,"ERY","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",21,21,FALSE,FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"5022","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"ERY","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,NA +"5023","EUCAST 2022","human","human","MIC","screen only","B_STPHY",3,"ERY","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"5024","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"FOS","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,32,32,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems." +"5025","EUCAST 2022","human","human","DISK",NA,"B_STPHY",3,"FUS","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",24,24,FALSE,FALSE,NA +"5026","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"FUS","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA +"5027","EUCAST 2022","human","human","DISK",NA,"B_STPHY",3,"LNZ","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",21,21,FALSE,FALSE,NA +"5028","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"LNZ","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA +"5029","EUCAST 2022","human","human","DISK",NA,"B_STPHY",3,"MNO","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",23,23,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"5030","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"MNO","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"5031","EUCAST 2022","human","human","DISK","screen only","B_STPHY",3,"NOR","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"5032","EUCAST 2022","human","human","DISK",NA,"B_STPHY",3,"QDA","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",21,18,FALSE,FALSE,NA +"5033","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"QDA","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,NA +"5034","EUCAST 2022","human","human","DISK",NA,"B_STPHY",3,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",26,26,FALSE,FALSE,NA +"5035","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA +"5036","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"RXT","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"5037","EUCAST 2022","human","human","DISK",NA,"B_STPHY",3,"SXT","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","1.25/23.75 mcg",17,14,FALSE,FALSE,"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5038","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"SXT","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,2,4,FALSE,FALSE,"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5039","EUCAST 2022","human","human","DISK",NA,"B_STPHY",3,"TCY","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",22,19,FALSE,FALSE,NA +"5040","EUCAST 2022","human","human","DISK","screen only","B_STPHY",3,"TCY","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",22,22,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"5041","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"TCY","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,NA +"5042","EUCAST 2022","human","human","MIC","screen only","B_STPHY",3,"TCY","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"5043","EUCAST 2022","human","human","DISK",NA,"B_STPHY",3,"TGC","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",19,19,FALSE,FALSE,"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5044","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"TGC","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5045","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_STPHY",3,"TMP","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",14,14,TRUE,FALSE,NA +"5046","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_STPHY",3,"TMP","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,TRUE,FALSE,NA +"5047","EUCAST 2022","human","human","DISK",NA,"B_STPHY",3,"TZD","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",20,20,FALSE,FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid." +"5048","EUCAST 2022","human","human","MIC",NA,"B_STPHY",3,"TZD","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid." +"5049","EUCAST 2022","human","human","DISK",NA,"B_STPHY_AURS",2,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci." +"5050","EUCAST 2022","human","human","MIC",NA,"B_STPHY_AURS",2,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,16,16,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci." +"5051","EUCAST 2022","human","human","DISK",NA,"B_STPHY_AURS",2,"BPR","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",17,17,FALSE,FALSE,"[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing." +"5052","EUCAST 2022","human","human","MIC",NA,"B_STPHY_AURS",2,"BPR","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[8] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing." +"5053","EUCAST 2022","human","human","DISK","Topical","B_STPHY_AURS",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",18,18,FALSE,FALSE,NA +"5054","EUCAST 2022","human","human","MIC","Topical","B_STPHY_AURS",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,16,16,FALSE,FALSE,NA +"5055","EUCAST 2022","human","human","DISK",NA,"B_STPHY_AURS",2,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",50,21,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"5056","EUCAST 2022","human","human","MIC",NA,"B_STPHY_AURS",2,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,1,FALSE,FALSE,NA +"5057","EUCAST 2022","human","human","MIC","Topical","B_STPHY_AURS",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA +"5058","EUCAST 2022","human","human","DISK","indications other than pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",20,17,FALSE,FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing." +"5059","EUCAST 2022","human","human","DISK","pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",20,20,FALSE,FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing." +"5060","EUCAST 2022","human","human","MIC","indications other than pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,"[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing." +"5061","EUCAST 2022","human","human","MIC","pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing." +"5062","EUCAST 2022","human","human","MIC","community-acquired pneumonia","B_STPHY_AURS",2,"DFX","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.016,0.016,FALSE,FALSE,NA +"5063","EUCAST 2022","human","human","MIC","skin and skin structure infections","B_STPHY_AURS",2,"DFX","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5064","EUCAST 2022","human","human","DISK",NA,"B_STPHY_AURS",2,"ERV","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","20 mcg",20,20,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test." +"5065","EUCAST 2022","human","human","MIC",NA,"B_STPHY_AURS",2,"ERV","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5066","EUCAST 2022","human","human","DISK","screen only","B_STPHY_AURS",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",22,22,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm." +"5067","EUCAST 2022","human","human","DISK","Topical","B_STPHY_AURS",2,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",24,24,FALSE,FALSE,NA +"5068","EUCAST 2022","human","human","MIC","Topical","B_STPHY_AURS",2,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5069","EUCAST 2022","human","human","DISK",NA,"B_STPHY_AURS",2,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"5070","EUCAST 2022","human","human","DISK","Topical","B_STPHY_AURS",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",18,18,FALSE,FALSE,NA +"5071","EUCAST 2022","human","human","MIC",NA,"B_STPHY_AURS",2,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"5072","EUCAST 2022","human","human","MIC","Topical","B_STPHY_AURS",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"5073","EUCAST 2022","human","human","DISK",NA,"B_STPHY_AURS",2,"LMU","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",23,23,FALSE,FALSE,NA +"5074","EUCAST 2022","human","human","MIC",NA,"B_STPHY_AURS",2,"LMU","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5075","EUCAST 2022","human","human","DISK",NA,"B_STPHY_AURS",2,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",50,22,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"5076","EUCAST 2022","human","human","MIC",NA,"B_STPHY_AURS",2,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,1,FALSE,FALSE,NA +"5077","EUCAST 2022","human","human","MIC","Topical","B_STPHY_AURS",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5078","EUCAST 2022","human","human","DISK",NA,"B_STPHY_AURS",2,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",25,25,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"5079","EUCAST 2022","human","human","MIC",NA,"B_STPHY_AURS",2,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5080","EUCAST 2022","human","human","DISK","Topical","B_STPHY_AURS",2,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","200 mcg",30,30,FALSE,FALSE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +ND = No ECOFF available." +"5081","EUCAST 2022","human","human","MIC","Topical","B_STPHY_AURS",2,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +ND = No ECOFF available." +"5082","EUCAST 2022","human","human","DISK","Topical","B_STPHY_AURS",2,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",14,14,FALSE,FALSE,NA +"5083","EUCAST 2022","human","human","MIC","Topical","B_STPHY_AURS",2,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA +"5084","EUCAST 2022","human","human","DISK","Topical","B_STPHY_AURS",2,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",17,17,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)." +"5085","EUCAST 2022","human","human","MIC","Topical","B_STPHY_AURS",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA +"5086","EUCAST 2022","human","human","MIC",NA,"B_STPHY_AURS",2,"ORI","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin." +"5087","EUCAST 2022","human","human","DISK",NA,"B_STPHY_AURS",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","1 unit",26,26,FALSE,FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase." +"5088","EUCAST 2022","human","human","MIC",NA,"B_STPHY_AURS",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins." +"5089","EUCAST 2022","human","human","MIC","Topical","B_STPHY_AURS",2,"RTP","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5090","EUCAST 2022","human","human","MIC",NA,"B_STPHY_AURS",2,"TEC","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"5091","EUCAST 2022","human","human","MIC",NA,"B_STPHY_AURS",2,"TLV","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin." +"5092","EUCAST 2022","human","human","DISK",NA,"B_STPHY_AURS",2,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"5093","EUCAST 2022","human","human","DISK","Topical","B_STPHY_AURS",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",18,18,FALSE,FALSE,NA +"5094","EUCAST 2022","human","human","MIC",NA,"B_STPHY_AURS",2,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"5095","EUCAST 2022","human","human","MIC","Topical","B_STPHY_AURS",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"5096","EUCAST 2022","human","human","MIC",NA,"B_STPHY_AURS",2,"VAN","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"5097","EUCAST 2022","human","human","DISK","screen only","B_STPHY_CGLN",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans." +"5098","EUCAST 2022","human","human","DISK",NA,"B_STPHY_CONS",2.5,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",15,15,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci." +"5099","EUCAST 2022","human","human","MIC",NA,"B_STPHY_CONS",2.5,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,16,16,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci." +"5100","EUCAST 2022","human","human","DISK",NA,"B_STPHY_CONS",2.5,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",50,24,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"5101","EUCAST 2022","human","human","MIC",NA,"B_STPHY_CONS",2.5,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,1,FALSE,FALSE,NA +"5102","EUCAST 2022","human","human","DISK","screen only","B_STPHY_CONS",2.5,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",22,22,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm." +"5103","EUCAST 2022","human","human","DISK",NA,"B_STPHY_CONS",2.5,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",22,22,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"5104","EUCAST 2022","human","human","MIC",NA,"B_STPHY_CONS",2.5,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"5105","EUCAST 2022","human","human","DISK",NA,"B_STPHY_CONS",2.5,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",50,24,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"5106","EUCAST 2022","human","human","MIC",NA,"B_STPHY_CONS",2.5,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,1,FALSE,FALSE,NA +"5107","EUCAST 2022","human","human","DISK",NA,"B_STPHY_CONS",2.5,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",28,28,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"5108","EUCAST 2022","human","human","MIC",NA,"B_STPHY_CONS",2.5,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5109","EUCAST 2022","human","human","MIC",NA,"B_STPHY_CONS",2.5,"TEC","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA +"5110","EUCAST 2022","human","human","DISK",NA,"B_STPHY_CONS",2.5,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",20,20,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"5111","EUCAST 2022","human","human","MIC",NA,"B_STPHY_CONS",2.5,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"5112","EUCAST 2022","human","human","MIC",NA,"B_STPHY_CONS",2.5,"VAN","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA +"5113","EUCAST 2022","human","human","DISK","screen only","B_STPHY_EPDR",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",27,27,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm." +"5114","EUCAST 2022","human","human","DISK","screen only","B_STPHY_LGDN",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",27,27,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm." +"5115","EUCAST 2022","human","human","DISK",NA,"B_STPHY_LGDN",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","1 unit",26,26,FALSE,FALSE,NA +"5116","EUCAST 2022","human","human","MIC",NA,"B_STPHY_LGDN",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"5117","EUCAST 2022","human","human","DISK","screen only","B_STPHY_PSDN",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans." +"5118","EUCAST 2022","human","human","DISK","screen only","B_STPHY_SCHL",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans." +"5119","EUCAST 2022","human","human","DISK",NA,"B_STPHY_SPRP",2,"AMP","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",18,18,FALSE,FALSE,"[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor)." +"5120","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_STPHY_SPRP",2,"NIT","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)","100 mcg",13,13,TRUE,FALSE,NA +"5121","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_STPHY_SPRP",2,"NIT","Staphylococcus (file: Clinical Breakpoint Tables v. 12.0)",NA,64,64,TRUE,FALSE,NA +"5122","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"AZM","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"5123","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"CHL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",19,19,FALSE,FALSE,"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages." +"5124","EUCAST 2022","human","human","DISK","Topical","B_STRPT_ABCG",2.5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",21,21,FALSE,FALSE,NA +"5125","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CHL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages." +"5126","EUCAST 2022","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,NA +"5127","EUCAST 2022","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"5128","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",17,17,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known." +"5129","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known." +"5130","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"5131","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5132","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAP","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[3] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5133","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.03,0.03,FALSE,FALSE,NA +"5134","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DOX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"5135","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",21,18,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"5136","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"5137","EUCAST 2022","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,32,32,FALSE,FALSE,NA +"5138","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",19,19,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5139","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5140","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",50,17,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"5141","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,2,FALSE,FALSE,NA +"5142","EUCAST 2022","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"5143","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",19,19,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"5144","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5145","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",23,23,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"5146","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"5147","EUCAST 2022","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5148","EUCAST 2022","human","human","DISK","screen only","B_STRPT_ABCG",2.5,"NOR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",12,12,FALSE,FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"5149","EUCAST 2022","human","human","DISK","Topical","B_STRPT_ABCG",2.5,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",12,12,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)." +"5150","EUCAST 2022","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA +"5151","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ORI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5152","EUCAST 2022","human","human","DISK","indications other than meningitis","B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","1 unit",18,18,FALSE,FALSE,NA +"5153","EUCAST 2022","human","human","MIC","indications other than meningitis","B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5154","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",21,21,FALSE,FALSE,NA +"5155","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA +"5156","EUCAST 2022","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"RTP","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"5157","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,1,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"5158","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","1.25/23.75 mcg",18,15,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5159","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5160","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",23,20,FALSE,FALSE,NA +"5161","EUCAST 2022","human","human","DISK","screen only","B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",23,23,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"5162","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,NA +"5163","EUCAST 2022","human","human","MIC","screen only","B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"5164","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5165","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5166","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",19,19,FALSE,FALSE,"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5167","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5168","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TLT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",20,17,FALSE,FALSE,NA +"5169","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TLT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,NA +"5170","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TZD","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",18,18,FALSE,FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5171","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TZD","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5172","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",13,13,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5173","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5174","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"DAL","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5175","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"DFX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,0.03,0.03,FALSE,FALSE,NA +"5176","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"ORI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5177","EUCAST 2022","human","human","DISK",NA,"B_STRPT_ANGN_ANGN",1,"TZD","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",18,18,FALSE,FALSE,NA +"5178","EUCAST 2022","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"TZD","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5179","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","100 mcg",15,15,TRUE,FALSE,NA +"5180","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,64,64,TRUE,FALSE,NA +"5181","EUCAST 2022","human","human","DISK","meningitis","B_STRPT_GRPB",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)","1 unit",19,19,FALSE,FALSE,NA +"5182","EUCAST 2022","human","human","MIC","meningitis","B_STRPT_GRPB",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"5183","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_STRPT_GRPB",2.5,"TMP","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,TRUE,FALSE,NA +"5184","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMC","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,1,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit." +"5185","EUCAST 2022","human","human","DISK","indications other than meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",22,19,FALSE,FALSE,NA +"5186","EUCAST 2022","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,1,FALSE,FALSE,NA +"5187","EUCAST 2022","human","human","MIC","meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5188","EUCAST 2022","human","human","MIC","meningitis","B_STRPT_PNMN",2,"AMX","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5189","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMX","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,1,FALSE,FALSE,NA +"5190","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"AZM","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"5191","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"BPR","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5192","EUCAST 2022","human","human","DISK",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",50,28,FALSE,FALSE,NA +"5193","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,0.5,FALSE,FALSE,NA +"5194","EUCAST 2022","human","human","DISK",NA,"B_STRPT_PNMN",2,"CHL","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",21,21,FALSE,FALSE,"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review.For chloramphenicol treatment in meningitis, see table of dosages." +"5195","EUCAST 2022","human","human","DISK","Topical","B_STRPT_PNMN",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",21,21,FALSE,FALSE,NA +"5196","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"CHL","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review.For chloramphenicol treatment in meningitis, see table of dosages." +"5197","EUCAST 2022","human","human","MIC","Topical","B_STRPT_PNMN",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,NA +"5198","EUCAST 2022","human","human","MIC","Topical","B_STRPT_PNMN",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA +"5199","EUCAST 2022","human","human","DISK",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",19,19,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"5200","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"5201","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLR","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"5202","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPD","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,NA +"5203","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPT","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5204","EUCAST 2022","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"CRO","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,2,FALSE,FALSE,NA +"5205","EUCAST 2022","human","human","MIC","meningitis","B_STRPT_PNMN",2,"CRO","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5206","EUCAST 2022","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"CTX","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,2,FALSE,FALSE,NA +"5207","EUCAST 2022","human","human","MIC","meningitis","B_STRPT_PNMN",2,"CTX","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5208","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,1,FALSE,FALSE,NA +"5209","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,NA +"5210","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"DOR","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA +"5211","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"DOX","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"5212","EUCAST 2022","human","human","DISK",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",22,19,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"5213","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"5214","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"ETP","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5215","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"FEP","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,NA +"5216","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"IPM","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"5217","EUCAST 2022","human","human","DISK",NA,"B_STRPT_PNMN",2,"LMU","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",12,12,FALSE,FALSE,NA +"5218","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"LMU","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5219","EUCAST 2022","human","human","DISK",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",22,22,FALSE,FALSE,NA +"5220","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"5221","EUCAST 2022","human","human","DISK",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",50,16,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"5222","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,2,FALSE,FALSE,NA +"5223","EUCAST 2022","human","human","MIC","Topical","B_STRPT_PNMN",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"5224","EUCAST 2022","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"5225","EUCAST 2022","human","human","MIC","meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5226","EUCAST 2022","human","human","DISK",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",22,22,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"5227","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5228","EUCAST 2022","human","human","DISK",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",24,24,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"5229","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"5230","EUCAST 2022","human","human","DISK","screen only","B_STRPT_PNMN",2,"NOR","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",10,10,FALSE,FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"5231","EUCAST 2022","human","human","DISK","Topical","B_STRPT_PNMN",2,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",10,10,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)." +"5232","EUCAST 2022","human","human","MIC","Topical","B_STRPT_PNMN",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA +"5233","EUCAST 2022","human","human","DISK","screen only","B_STRPT_PNMN",2,"OXA","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","1 mcg",20,NA,FALSE,FALSE,"[D] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below." +"5234","EUCAST 2022","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,2,FALSE,FALSE,"[2] For breakpoints and dosing in pneumonia, see table of dosages." +"5235","EUCAST 2022","human","human","MIC","meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.06,0.06,FALSE,FALSE,NA +"5236","EUCAST 2022","human","human","DISK",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",22,22,FALSE,FALSE,NA +"5237","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"5238","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"RXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,1,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"5239","EUCAST 2022","human","human","DISK",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","1.25/23.75 mcg",13,10,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5240","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5241","EUCAST 2022","human","human","DISK",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",25,22,FALSE,FALSE,NA +"5242","EUCAST 2022","human","human","DISK","screen only","B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",25,25,FALSE,FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"5243","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,NA +"5244","EUCAST 2022","human","human","MIC","screen only","B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"5245","EUCAST 2022","human","human","DISK",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5246","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5247","EUCAST 2022","human","human","DISK",NA,"B_STRPT_PNMN",2,"TLT","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",23,20,FALSE,FALSE,NA +"5248","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"TLT","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,NA +"5249","EUCAST 2022","human","human","DISK",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5250","EUCAST 2022","human","human","MIC",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5251","EUCAST 2022","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",21,15,FALSE,FALSE,NA +"5252","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,2,FALSE,FALSE,NA +"5253","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"AMX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,2,FALSE,FALSE,NA +"5254","EUCAST 2022","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)","2 mcg",19,19,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"5255","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"5256","EUCAST 2022","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",27,27,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins." +"5257","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5258","EUCAST 2022","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",23,23,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins." +"5259","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5260","EUCAST 2022","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",26,26,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins." +"5261","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5262","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"DOR","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA +"5263","EUCAST 2022","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"ERV","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)","20 mcg",17,17,FALSE,FALSE,NA +"5264","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ERV","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"5265","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ETP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5266","EUCAST 2022","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",25,25,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins." +"5267","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5268","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"IMR","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit." +"5269","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"IPM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"5270","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"MEM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"5271","EUCAST 2022","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)","1 unit",18,12,FALSE,FALSE,NA +"5272","EUCAST 2022","human","human","DISK","screen only","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)","1 unit",18,18,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"5273","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,2,FALSE,FALSE,NA +"5274","EUCAST 2022","human","human","MIC","screen only","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant." +"5275","EUCAST 2022","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",16,16,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5276","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5277","EUCAST 2022","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5278","EUCAST 2022","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5279","EUCAST 2022","human","human","DISK",NA,"B_VIBRI",3,"AZM","Vibrio (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",16,16,FALSE,FALSE,"[A] Susceptibility to azithromycin can be inferred from the erythromycin disk diffusion screening test." +"5280","EUCAST 2022","human","human","MIC",NA,"B_VIBRI",3,"AZM","Vibrio (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,FALSE,FALSE,NA +"5281","EUCAST 2022","human","human","DISK",NA,"B_VIBRI",3,"CAZ","Vibrio (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",22,22,FALSE,FALSE,NA +"5282","EUCAST 2022","human","human","MIC",NA,"B_VIBRI",3,"CAZ","Vibrio (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA +"5283","EUCAST 2022","human","human","DISK",NA,"B_VIBRI",3,"CIP","Vibrio (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",23,23,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test." +"5284","EUCAST 2022","human","human","MIC",NA,"B_VIBRI",3,"CIP","Vibrio (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5285","EUCAST 2022","human","human","DISK",NA,"B_VIBRI",3,"CTX","Vibrio (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",21,21,FALSE,FALSE,NA +"5286","EUCAST 2022","human","human","MIC",NA,"B_VIBRI",3,"CTX","Vibrio (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5287","EUCAST 2022","human","human","MIC",NA,"B_VIBRI",3,"DOX","Vibrio (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5288","EUCAST 2022","human","human","DISK","screen only","B_VIBRI",3,"ERY","Vibrio (file: Clinical Breakpoint Tables v. 12.0)","15 mcg",12,12,FALSE,FALSE,"[A] Susceptibility to azithromycin can be inferred from the erythromycin disk diffusion screening test." +"5289","EUCAST 2022","human","human","DISK",NA,"B_VIBRI",3,"LVX","Vibrio (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",23,23,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test." +"5290","EUCAST 2022","human","human","MIC",NA,"B_VIBRI",3,"LVX","Vibrio (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5291","EUCAST 2022","human","human","DISK",NA,"B_VIBRI",3,"MEM","Vibrio (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",24,24,FALSE,FALSE,NA +"5292","EUCAST 2022","human","human","MIC",NA,"B_VIBRI",3,"MEM","Vibrio (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5293","EUCAST 2022","human","human","DISK","screen only","B_VIBRI",3,"PEF","Vibrio (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",20,20,FALSE,FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test." +"5294","EUCAST 2022","human","human","DISK",NA,"B_VIBRI",3,"SXT","Vibrio (file: Clinical Breakpoint Tables v. 12.0)","1.25/23.75 mcg",18,18,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5295","EUCAST 2022","human","human","MIC",NA,"B_VIBRI",3,"SXT","Vibrio (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5296","EUCAST 2022","human","human","DISK","screen only","B_VIBRI",3,"TCY","Vibrio (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",20,20,FALSE,FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test." +"5297","EUCAST 2022","human","human","DISK",NA,"B_VIBRI",3,"TZP","Vibrio (file: Clinical Breakpoint Tables v. 12.0)","30/6 mcg",26,26,FALSE,FALSE,NA +"5298","EUCAST 2022","human","human","MIC",NA,"B_VIBRI",3,"TZP","Vibrio (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"5299","EUCAST 2022","human","human","DISK",NA,"B_[FAM]_MORGNLLC",4,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",50,19,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem." +"5300","EUCAST 2022","human","human","MIC",NA,"B_[FAM]_MORGNLLC",4,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.001,4,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem." +"5301","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","20/10 mcg",19,19,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review." +"5302","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","20/10 mcg",16,16,TRUE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars." +"5303","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review." +"5304","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,32,32,TRUE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"5305","EUCAST 2022","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",18,18,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"5306","EUCAST 2022","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",18,18,FALSE,FALSE,NA +"5307","EUCAST 2022","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"5308","EUCAST 2022","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,NA +"5309","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",14,14,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review." +"5310","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review." +"5311","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review." +"5312","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",26,21,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes." +"5313","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,1,4,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes." +"5314","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",23,23,FALSE,FALSE,NA +"5315","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5316","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",22,19,FALSE,FALSE,NA +"5317","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,1,4,FALSE,FALSE,NA +"5318","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",17,17,TRUE,FALSE,NA +"5319","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,TRUE,FALSE,NA +"5320","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",12,12,TRUE,FALSE,NA +"5321","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,16,16,TRUE,FALSE,NA +"5322","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CHL","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",17,17,FALSE,FALSE,"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages." +"5323","EUCAST 2022","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",17,17,FALSE,FALSE,NA +"5324","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CHL","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages." +"5325","EUCAST 2022","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,16,16,FALSE,FALSE,NA +"5326","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",25,22,FALSE,FALSE,NA +"5327","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,NA +"5328","EUCAST 2022","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.125,0.125,FALSE,FALSE,NA +"5329","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"COL","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)." +"5330","EUCAST 2022","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"COL","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"5331","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",21,21,TRUE,FALSE,NA +"5332","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,TRUE,FALSE,NA +"5333","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",23,23,FALSE,FALSE,NA +"5334","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5335","EUCAST 2022","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",25,22,FALSE,FALSE,NA +"5336","EUCAST 2022","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",25,25,FALSE,FALSE,NA +"5337","EUCAST 2022","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,NA +"5338","EUCAST 2022","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA +"5339","EUCAST 2022","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",23,23,FALSE,FALSE,NA +"5340","EUCAST 2022","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA +"5341","EUCAST 2022","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",20,17,FALSE,FALSE,NA +"5342","EUCAST 2022","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",20,20,FALSE,FALSE,NA +"5343","EUCAST 2022","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,NA +"5344","EUCAST 2022","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,1,1,FALSE,FALSE,NA +"5345","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10/4 mcg",13,13,FALSE,FALSE,NA +"5346","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L." +"5347","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30/10 mcg",22,22,FALSE,FALSE,"[6] See table of dosages for dosing for different indications." +"5348","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [6] See table of dosages for dosing for different indications." +"5349","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"DOR","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",24,21,FALSE,FALSE,NA +"5350","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"DOR","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,1,2,FALSE,FALSE,NA +"5351","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",25,25,FALSE,FALSE,NA +"5352","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5353","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FDC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",22,22,FALSE,FALSE,NA +"5354","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FDC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/." +"5355","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",27,24,FALSE,FALSE,NA +"5356","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,1,4,FALSE,FALSE,NA +"5357","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","200 mcg",21,21,FALSE,FALSE,"[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below)." +"5358","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,32,32,FALSE,FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems." +"5359","EUCAST 2022","human","human","DISK","screen only","B_[ORD]_ENTRBCTR",5,"FOX","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",19,19,FALSE,FALSE,"[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type." +"5360","EUCAST 2022","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",17,17,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"5361","EUCAST 2022","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",17,17,FALSE,FALSE,NA +"5362","EUCAST 2022","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",17,17,FALSE,FALSE,NA +"5363","EUCAST 2022","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"5364","EUCAST 2022","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"5365","EUCAST 2022","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"5366","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"IMR","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10/25 mcg",22,22,FALSE,FALSE,NA +"5367","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"IMR","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L." +"5368","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",22,19,FALSE,FALSE,NA +"5369","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,2,4,FALSE,FALSE,NA +"5370","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",14,14,TRUE,FALSE,NA +"5371","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,16,16,TRUE,FALSE,NA +"5372","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",23,19,FALSE,FALSE,NA +"5373","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,1,FALSE,FALSE,NA +"5374","EUCAST 2022","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5375","EUCAST 2022","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",22,16,FALSE,FALSE,NA +"5376","EUCAST 2022","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",22,22,FALSE,FALSE,NA +"5377","EUCAST 2022","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,2,8,FALSE,FALSE,NA +"5378","EUCAST 2022","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"5379","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"MEV","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","20/10 mcg",20,20,FALSE,FALSE,NA +"5380","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MEV","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L." +"5381","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",22,22,FALSE,FALSE,NA +"5382","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5383","EUCAST 2022","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",12,12,FALSE,FALSE,NA +"5384","EUCAST 2022","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,NA +"5385","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",22,22,TRUE,FALSE,NA +"5386","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.5,0.5,TRUE,FALSE,NA +"5387","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",24,22,FALSE,FALSE,NA +"5388","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.5,FALSE,FALSE,NA +"5389","EUCAST 2022","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5390","EUCAST 2022","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"PEF","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",24,24,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis)." +"5391","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30 mcg",20,20,FALSE,FALSE,NA +"5392","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,NA +"5393","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10/10 mcg",14,14,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review." +"5394","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review." +"5395","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","1.25/23.75 mcg",14,11,FALSE,FALSE,"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5396","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,2,4,FALSE,FALSE,"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5397","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","75/10 mcg",23,20,FALSE,FALSE,NA +"5398","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,16,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"5399","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TIC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","75 mcg",23,20,FALSE,FALSE,NA +"5400","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TIC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,16,FALSE,FALSE,NA +"5401","EUCAST 2022","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","5 mcg",15,15,TRUE,FALSE,NA +"5402","EUCAST 2022","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,4,4,TRUE,FALSE,NA +"5403","EUCAST 2022","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",16,16,FALSE,FALSE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"5404","EUCAST 2022","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",16,16,FALSE,FALSE,NA +"5405","EUCAST 2022","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",16,16,FALSE,FALSE,NA +"5406","EUCAST 2022","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/." +"5407","EUCAST 2022","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"5408","EUCAST 2022","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 12.0)",NA,2,2,FALSE,FALSE,NA +"5409","EUCAST 2022","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","30/6 mcg",20,20,FALSE,FALSE,NA +"5410","EUCAST 2022","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"5411","EUCAST 2022","human","human","DISK","uncomplicated UTI only","UNKNOWN",6,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)","10 mcg",15,15,TRUE,FALSE,"[C] Ignore isolated colonies within the inhibition zone." +"5412","EUCAST 2022","human","human","MIC","uncomplicated UTI only","UNKNOWN",6,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 12.0)",NA,8,8,TRUE,FALSE,"[5] Agar dilution is the reference method for mecillinam MIC determination." +"5413","EUCAST 2021","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"MEM","A.xylosoxidans (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",26,20,FALSE,FALSE,NA +"5414","EUCAST 2021","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"MEM","A.xylosoxidans (file: Clinical Breakpoint Tables v. 11.0)",NA,1,4,FALSE,FALSE,NA +"5415","EUCAST 2021","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"SXT","A.xylosoxidans (file: Clinical Breakpoint Tables v. 11.0)","1.25/23.75 mcg",26,26,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5416","EUCAST 2021","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"SXT","A.xylosoxidans (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5417","EUCAST 2021","human","human","DISK",NA,"B_ACHRMB_XYLS",2,"TZP","A.xylosoxidans (file: Clinical Breakpoint Tables v. 11.0)","30/6 mcg",26,26,FALSE,FALSE,NA +"5418","EUCAST 2021","human","human","MIC",NA,"B_ACHRMB_XYLS",2,"TZP","A.xylosoxidans (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"5419","EUCAST 2021","human","human","DISK","systemic infections","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",19,19,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"5420","EUCAST 2021","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",19,19,FALSE,FALSE,NA +"5421","EUCAST 2021","human","human","MIC","systemic infections","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"5422","EUCAST 2021","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,NA +"5423","EUCAST 2021","human","human","DISK",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",50,21,FALSE,FALSE,NA +"5424","EUCAST 2021","human","human","DISK","Topical","B_ACNTB",3,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",21,21,FALSE,FALSE,NA +"5425","EUCAST 2021","human","human","MIC",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,1,FALSE,FALSE,NA +"5426","EUCAST 2021","human","human","MIC","Topical","B_ACNTB",3,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA +"5427","EUCAST 2021","human","human","MIC",NA,"B_ACNTB",3,"COL","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)." +"5428","EUCAST 2021","human","human","MIC","Topical","B_ACNTB",3,"COL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"5429","EUCAST 2021","human","human","DISK",NA,"B_ACNTB",3,"DOR","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",50,22,FALSE,FALSE,NA +"5430","EUCAST 2021","human","human","MIC",NA,"B_ACNTB",3,"DOR","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,2,FALSE,FALSE,NA +"5431","EUCAST 2021","human","human","DISK","systemic infections","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",17,17,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"5432","EUCAST 2021","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",17,17,FALSE,FALSE,NA +"5433","EUCAST 2021","human","human","DISK","Topical","B_ACNTB",3,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",17,17,FALSE,FALSE,NA +"5434","EUCAST 2021","human","human","MIC","systemic infections","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"5435","EUCAST 2021","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA +"5436","EUCAST 2021","human","human","MIC","Topical","B_ACNTB",3,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA +"5437","EUCAST 2021","human","human","DISK",NA,"B_ACNTB",3,"IMR","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)","10/25 mcg",24,24,FALSE,FALSE,"[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit." +"5438","EUCAST 2021","human","human","MIC",NA,"B_ACNTB",3,"IMR","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit." +"5439","EUCAST 2021","human","human","DISK",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",24,21,FALSE,FALSE,NA +"5440","EUCAST 2021","human","human","MIC",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)",NA,2,4,FALSE,FALSE,NA +"5441","EUCAST 2021","human","human","DISK",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",23,20,FALSE,FALSE,NA +"5442","EUCAST 2021","human","human","DISK","Topical","B_ACNTB",3,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",23,23,FALSE,FALSE,NA +"5443","EUCAST 2021","human","human","MIC",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,1,FALSE,FALSE,NA +"5444","EUCAST 2021","human","human","MIC","Topical","B_ACNTB",3,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5445","EUCAST 2021","human","human","DISK","indications other than meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",21,15,FALSE,FALSE,NA +"5446","EUCAST 2021","human","human","DISK","meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",21,21,FALSE,FALSE,NA +"5447","EUCAST 2021","human","human","MIC","indications other than meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)",NA,2,8,FALSE,FALSE,NA +"5448","EUCAST 2021","human","human","MIC","meningitis","B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"5449","EUCAST 2021","human","human","MIC","Topical","B_ACNTB",3,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA +"5450","EUCAST 2021","human","human","DISK",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)","1.25/23.75 mcg",14,11,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5451","EUCAST 2021","human","human","MIC",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)",NA,2,4,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5452","EUCAST 2021","human","human","DISK","systemic infections","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",17,17,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"5453","EUCAST 2021","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",17,17,FALSE,FALSE,NA +"5454","EUCAST 2021","human","human","DISK","Topical","B_ACNTB",3,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",17,17,FALSE,FALSE,NA +"5455","EUCAST 2021","human","human","MIC","systemic infections","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"5456","EUCAST 2021","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA +"5457","EUCAST 2021","human","human","MIC","Topical","B_ACNTB",3,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA +"5458","EUCAST 2021","human","human","DISK",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",26,26,FALSE,FALSE,NA +"5459","EUCAST 2021","human","human","MIC",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5460","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note" +"5461","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,TRUE,FALSE,NA +"5462","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility." +"5463","EUCAST 2021","human","human","DISK",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",31,31,FALSE,FALSE,NA +"5464","EUCAST 2021","human","human","MIC",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5465","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","100 mcg",16,16,TRUE,FALSE,NA +"5466","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,16,16,TRUE,FALSE,NA +"5467","EUCAST 2021","human","human","DISK","screen only","B_AERCC_SNGN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance." +"5468","EUCAST 2021","human","human","DISK",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","1 unit",21,21,FALSE,FALSE,NA +"5469","EUCAST 2021","human","human","MIC",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA +"5470","EUCAST 2021","human","human","DISK",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",25,25,FALSE,FALSE,NA +"5471","EUCAST 2021","human","human","MIC",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA +"5472","EUCAST 2021","human","human","DISK",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method." +"5473","EUCAST 2021","human","human","MIC",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA +"5474","EUCAST 2021","human","human","DISK",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",26,26,FALSE,FALSE,NA +"5475","EUCAST 2021","human","human","MIC",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5476","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note" +"5477","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,TRUE,FALSE,NA +"5478","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility." +"5479","EUCAST 2021","human","human","DISK",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",31,31,FALSE,FALSE,NA +"5480","EUCAST 2021","human","human","MIC",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5481","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","100 mcg",16,16,TRUE,FALSE,NA +"5482","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,16,16,TRUE,FALSE,NA +"5483","EUCAST 2021","human","human","DISK","screen only","B_AERCC_URIN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance." +"5484","EUCAST 2021","human","human","DISK",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","1 unit",21,21,FALSE,FALSE,NA +"5485","EUCAST 2021","human","human","MIC",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA +"5486","EUCAST 2021","human","human","DISK",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",25,25,FALSE,FALSE,NA +"5487","EUCAST 2021","human","human","MIC",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA +"5488","EUCAST 2021","human","human","DISK",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method." +"5489","EUCAST 2021","human","human","MIC",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA +"5490","EUCAST 2021","human","human","DISK",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",29,26,FALSE,FALSE,NA +"5491","EUCAST 2021","human","human","MIC",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 11.0)",NA,1,4,FALSE,FALSE,NA +"5492","EUCAST 2021","human","human","DISK",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",24,21,FALSE,FALSE,NA +"5493","EUCAST 2021","human","human","MIC",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 11.0)",NA,1,4,FALSE,FALSE,NA +"5494","EUCAST 2021","human","human","DISK",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",27,24,FALSE,FALSE,NA +"5495","EUCAST 2021","human","human","MIC",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,NA +"5496","EUCAST 2021","human","human","DISK",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",27,24,FALSE,FALSE,NA +"5497","EUCAST 2021","human","human","MIC",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 11.0)",NA,1,4,FALSE,FALSE,NA +"5498","EUCAST 2021","human","human","DISK",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",27,24,FALSE,FALSE,NA +"5499","EUCAST 2021","human","human","MIC",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,1,FALSE,FALSE,NA +"5500","EUCAST 2021","human","human","DISK",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 11.0)","1.25/23.75 mcg",19,16,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5501","EUCAST 2021","human","human","MIC",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 11.0)",NA,2,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5502","EUCAST 2021","human","human","DISK",NA,"B_BCLLS",3,"CIP","Bacillus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",50,23,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"5503","EUCAST 2021","human","human","MIC",NA,"B_BCLLS",3,"CIP","Bacillus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,0.5,FALSE,FALSE,NA +"5504","EUCAST 2021","human","human","DISK",NA,"B_BCLLS",3,"CLI","Bacillus (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",17,17,FALSE,FALSE,NA +"5505","EUCAST 2021","human","human","MIC",NA,"B_BCLLS",3,"CLI","Bacillus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA +"5506","EUCAST 2021","human","human","DISK",NA,"B_BCLLS",3,"ERY","Bacillus (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",24,24,FALSE,FALSE,NA +"5507","EUCAST 2021","human","human","MIC",NA,"B_BCLLS",3,"ERY","Bacillus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5508","EUCAST 2021","human","human","DISK",NA,"B_BCLLS",3,"IPM","Bacillus (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",30,30,FALSE,FALSE,NA +"5509","EUCAST 2021","human","human","MIC",NA,"B_BCLLS",3,"IPM","Bacillus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5510","EUCAST 2021","human","human","DISK",NA,"B_BCLLS",3,"LNZ","Bacillus (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",22,22,FALSE,FALSE,NA +"5511","EUCAST 2021","human","human","MIC",NA,"B_BCLLS",3,"LNZ","Bacillus (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"5512","EUCAST 2021","human","human","DISK",NA,"B_BCLLS",3,"LVX","Bacillus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",50,23,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"5513","EUCAST 2021","human","human","MIC",NA,"B_BCLLS",3,"LVX","Bacillus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,1,FALSE,FALSE,NA +"5514","EUCAST 2021","human","human","DISK",NA,"B_BCLLS",3,"MEM","Bacillus (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",25,25,FALSE,FALSE,NA +"5515","EUCAST 2021","human","human","MIC",NA,"B_BCLLS",3,"MEM","Bacillus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5516","EUCAST 2021","human","human","DISK","screen only","B_BCLLS",3,"NOR","Bacillus (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",21,21,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as resistant to norfloxacin can be reported resistant to ciprofloxacin and levofloxacin." +"5517","EUCAST 2021","human","human","DISK",NA,"B_BCLLS",3,"VAN","Bacillus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",10,10,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method." +"5518","EUCAST 2021","human","human","MIC",NA,"B_BCLLS",3,"VAN","Bacillus (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"5519","EUCAST 2021","human","human","DISK",NA,"B_BRKHL_PSDM",2,"AMC","B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)","20/10 mcg",50,22,FALSE,FALSE,NA +"5520","EUCAST 2021","human","human","MIC",NA,"B_BRKHL_PSDM",2,"AMC","B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,8,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"5521","EUCAST 2021","human","human","DISK",NA,"B_BRKHL_PSDM",2,"CAZ","B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",50,18,FALSE,FALSE,NA +"5522","EUCAST 2021","human","human","MIC",NA,"B_BRKHL_PSDM",2,"CAZ","B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,8,FALSE,FALSE,NA +"5523","EUCAST 2021","human","human","DISK",NA,"B_BRKHL_PSDM",2,"CHL","B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,22,FALSE,FALSE,NA +"5524","EUCAST 2021","human","human","MIC",NA,"B_BRKHL_PSDM",2,"CHL","B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,8,FALSE,FALSE,NA +"5525","EUCAST 2021","human","human","MIC",NA,"B_BRKHL_PSDM",2,"DOX","B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,2,FALSE,FALSE,NA +"5526","EUCAST 2021","human","human","DISK",NA,"B_BRKHL_PSDM",2,"IPM","B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",29,29,FALSE,FALSE,NA +"5527","EUCAST 2021","human","human","MIC",NA,"B_BRKHL_PSDM",2,"IPM","B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"5528","EUCAST 2021","human","human","DISK",NA,"B_BRKHL_PSDM",2,"MEM","B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",24,24,FALSE,FALSE,NA +"5529","EUCAST 2021","human","human","MIC",NA,"B_BRKHL_PSDM",2,"MEM","B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"5530","EUCAST 2021","human","human","DISK",NA,"B_BRKHL_PSDM",2,"SXT","B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)","1.25/23.75 mcg",50,17,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5531","EUCAST 2021","human","human","MIC",NA,"B_BRKHL_PSDM",2,"SXT","B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5532","EUCAST 2021","human","human","DISK","screen only","B_BRKHL_PSDM",2,"TCY","B.pseudomallei (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,23,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline disk diffusion screen test." +"5533","EUCAST 2021","human","human","DISK",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",50,26,FALSE,FALSE,NA +"5534","EUCAST 2021","human","human","MIC",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,0.5,FALSE,FALSE,NA +"5535","EUCAST 2021","human","human","DISK",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",24,24,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin." +"5536","EUCAST 2021","human","human","MIC",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin." +"5537","EUCAST 2021","human","human","DISK",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",30,30,FALSE,FALSE,"[A] Tetracycline can be used to determine susceptibility to doxycycline." +"5538","EUCAST 2021","human","human","MIC",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to determine susceptibility to doxycycline." +"5539","EUCAST 2021","human","human","DISK",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",50,26,FALSE,FALSE,NA +"5540","EUCAST 2021","human","human","MIC",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,0.5,FALSE,FALSE,NA +"5541","EUCAST 2021","human","human","DISK",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",20,20,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin." +"5542","EUCAST 2021","human","human","MIC",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin." +"5543","EUCAST 2021","human","human","DISK",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",30,30,FALSE,FALSE,"[A] Tetracycline can be used to determine susceptibility to doxycycline." +"5544","EUCAST 2021","human","human","MIC",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to determine susceptibility to doxycycline." +"5545","EUCAST 2021","human","human","MIC",NA,"B_CRDDS_DFFC",2,"MTR","C.difficile (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[5] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with metronidazole. There are no conclusive clinical data regarding the relation between MICs and outcomes." +"5546","EUCAST 2021","human","human","MIC",NA,"B_CRDDS_DFFC",2,"VAN","C.difficile (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with vancomycin. There are no conclusive clinical data regarding the relation between MICs and outcomes." +"5547","EUCAST 2021","human","human","DISK",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",50,25,FALSE,FALSE,NA +"5548","EUCAST 2021","human","human","MIC",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,1,FALSE,FALSE,NA +"5549","EUCAST 2021","human","human","DISK",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",20,20,FALSE,FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing." +"5550","EUCAST 2021","human","human","MIC",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing." +"5551","EUCAST 2021","human","human","DISK",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",25,25,FALSE,FALSE,NA +"5552","EUCAST 2021","human","human","MIC",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"5553","EUCAST 2021","human","human","DISK",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",25,25,FALSE,FALSE,NA +"5554","EUCAST 2021","human","human","MIC",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5555","EUCAST 2021","human","human","DISK",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)","1 unit",29,29,FALSE,FALSE,NA +"5556","EUCAST 2021","human","human","MIC",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA +"5557","EUCAST 2021","human","human","DISK",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",30,25,FALSE,FALSE,NA +"5558","EUCAST 2021","human","human","MIC",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.5,FALSE,FALSE,NA +"5559","EUCAST 2021","human","human","DISK",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",24,24,FALSE,FALSE,NA +"5560","EUCAST 2021","human","human","MIC",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"5561","EUCAST 2021","human","human","DISK",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method." +"5562","EUCAST 2021","human","human","MIC",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"5563","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_CTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",15,15,TRUE,FALSE,"[C] Ignore isolated colonies within the inhibition zone." +"5564","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_CTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,TRUE,FALSE,"[5] Agar dilution is the reference method for mecillinam MIC determination." +"5565","EUCAST 2021","human","human","DISK",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method." +"5566","EUCAST 2021","human","human","MIC",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/." +"5567","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_ENTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",15,15,TRUE,FALSE,"[C] Ignore isolated colonies within the inhibition zone." +"5568","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_ENTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,TRUE,FALSE,"[5] Agar dilution is the reference method for mecillinam MIC determination." +"5569","EUCAST 2021","human","human","MIC",NA,"B_ENTRC",3,"AMC","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,4,8,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only." +"5570","EUCAST 2021","human","human","DISK",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",10,8,FALSE,FALSE,"[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only." +"5571","EUCAST 2021","human","human","MIC",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,4,8,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only." +"5572","EUCAST 2021","human","human","MIC",NA,"B_ENTRC",3,"AMX","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,4,8,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only." +"5573","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"5574","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,TRUE,FALSE,NA +"5575","EUCAST 2021","human","human","DISK",NA,"B_ENTRC",3,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",50,21,FALSE,FALSE,NA +"5576","EUCAST 2021","human","human","MIC",NA,"B_ENTRC",3,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,4,FALSE,FALSE,NA +"5577","EUCAST 2021","human","human","DISK",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",20,20,FALSE,FALSE,NA +"5578","EUCAST 2021","human","human","MIC",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA +"5579","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"5580","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,TRUE,FALSE,NA +"5581","EUCAST 2021","human","human","DISK","screen only","B_ENTRC",3,"NOR","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",12,12,FALSE,FALSE,"[C] | [C] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility. For moxifloxacin, see comment 1/B." +"5582","EUCAST 2021","human","human","MIC",NA,"B_ENTRC",3,"SAM","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,4,8,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only." +"5583","EUCAST 2021","human","human","DISK",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",16,16,FALSE,FALSE,NA +"5584","EUCAST 2021","human","human","MIC",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"5585","EUCAST 2021","human","human","DISK",NA,"B_ENTRC",3,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",12,12,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation." +"5586","EUCAST 2021","human","human","MIC",NA,"B_ENTRC",3,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA +"5587","EUCAST 2021","human","human","DISK",NA,"B_ENTRC_FACM",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)","20 mcg",24,24,FALSE,FALSE,NA +"5588","EUCAST 2021","human","human","MIC",NA,"B_ENTRC_FACM",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA +"5589","EUCAST 2021","human","human","DISK",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",22,20,FALSE,FALSE,NA +"5590","EUCAST 2021","human","human","MIC",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,4,FALSE,FALSE,NA +"5591","EUCAST 2021","human","human","DISK",NA,"B_ENTRC_FACM",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",22,22,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5592","EUCAST 2021","human","human","MIC",NA,"B_ENTRC_FACM",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5593","EUCAST 2021","human","human","DISK",NA,"B_ENTRC_FCLS",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)","20 mcg",22,22,FALSE,FALSE,NA +"5594","EUCAST 2021","human","human","MIC",NA,"B_ENTRC_FCLS",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA +"5595","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)","100 mcg",15,15,TRUE,FALSE,NA +"5596","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,64,64,TRUE,FALSE,NA +"5597","EUCAST 2021","human","human","DISK",NA,"B_ENTRC_FCLS",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",20,20,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5598","EUCAST 2021","human","human","MIC",NA,"B_ENTRC_FCLS",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5599","EUCAST 2021","human","human","DISK",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,19,FALSE,FALSE,NA +"5600","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",19,19,TRUE,FALSE,NA +"5601","EUCAST 2021","human","human","MIC",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,8,FALSE,FALSE,NA +"5602","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,TRUE,FALSE,NA +"5603","EUCAST 2021","human","human","DISK","infections originating from the urinary tract","B_ESCHR_COLI",2,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,20,FALSE,FALSE,"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin." +"5604","EUCAST 2021","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,4,FALSE,FALSE,"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin." +"5605","EUCAST 2021","human","human","MIC",NA,"B_ESCHR_COLI",2,"DFX","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA +"5606","EUCAST 2021","human","human","DISK",NA,"B_ESCHR_COLI",2,"ERV","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","20 mcg",17,17,FALSE,FALSE,NA +"5607","EUCAST 2021","human","human","MIC",NA,"B_ESCHR_COLI",2,"ERV","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5608","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","200 mcg",24,24,TRUE,FALSE,"[D] Ignore isolated colonies within the inhibition zone (see pictures below)." +"5609","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,TRUE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems." +"5610","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",15,15,TRUE,FALSE,"[C] Ignore isolated colonies within the inhibition zone." +"5611","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,TRUE,FALSE,"[5] Agar dilution is the reference method for mecillinam MIC determination." +"5612","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","100 mcg",11,11,TRUE,FALSE,NA +"5613","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,64,64,TRUE,FALSE,NA +"5614","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",15,15,TRUE,FALSE,NA +"5615","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,16,16,TRUE,FALSE,NA +"5616","EUCAST 2021","human","human","DISK","infections originating from the urinary tract","B_ESCHR_COLI",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,17,FALSE,FALSE,"[C] Ignore isolated colonies within the inhibition zone." +"5617","EUCAST 2021","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,16,FALSE,FALSE,NA +"5618","EUCAST 2021","human","human","DISK",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method." +"5619","EUCAST 2021","human","human","MIC",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/." +"5620","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"AMC","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,4,8,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"5621","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"AMP","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,2,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin." +"5622","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"AMX","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,2,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin." +"5623","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"CHL","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,NA +"5624","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"CLI","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA +"5625","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"DOR","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA +"5626","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"ETP","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5627","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"IMR","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit." +"5628","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"IPM","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,2,4,FALSE,FALSE,NA +"5629","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"MEM","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,2,8,FALSE,FALSE,NA +"5630","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"MTR","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA +"5631","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"PEN","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin." +"5632","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"PIP","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,16,16,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin." +"5633","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"SAM","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,4,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L." +"5634","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"TCC","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,8,16,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"5635","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"TIC","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,16,16,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin." +"5636","EUCAST 2021","human","human","MIC",NA,"B_GRAMN",6,"TZP","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 11.0)",NA,8,16,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"5637","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"AMC","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,4,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"5638","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"AMP","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,4,8,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin." +"5639","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"AMX","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,4,8,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin." +"5640","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"CHL","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,NA +"5641","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"CLI","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA +"5642","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"DOR","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA +"5643","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"ETP","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5644","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"IMR","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit." +"5645","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"IPM","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,2,4,FALSE,FALSE,NA +"5646","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"MEM","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,2,8,FALSE,FALSE,NA +"5647","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"MTR","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA +"5648","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"PEN","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin." +"5649","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"PIP","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,8,16,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin." +"5650","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"SAM","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,4,8,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L." +"5651","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"TCC","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,8,16,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"5652","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"TIC","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,8,16,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin." +"5653","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"TZP","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,8,16,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"5654","EUCAST 2021","human","human","MIC",NA,"B_GRAMP",6,"VAN","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"5655","EUCAST 2021","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"AMX","H.pylori (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA +"5656","EUCAST 2021","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"CLR","H.pylori (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,NA +"5657","EUCAST 2021","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"LVX","H.pylori (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA +"5658","EUCAST 2021","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"MTR","H.pylori (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,NA +"5659","EUCAST 2021","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"RIF","H.pylori (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA +"5660","EUCAST 2021","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"TCY","H.pylori (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA +"5661","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","2/1 mcg",15,15,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"5662","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","2/1 mcg",50,15,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"5663","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"5664","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,2,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"5665","EUCAST 2021","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",18,18,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase." +"5666","EUCAST 2021","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase." +"5667","EUCAST 2021","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"AMX","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase." +"5668","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMX","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,2,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase." +"5669","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"5670","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA +"5671","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",28,28,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages." +"5672","EUCAST 2021","human","human","DISK","Topical","B_HMPHL_INFL",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",28,28,FALSE,FALSE,NA +"5673","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages." +"5674","EUCAST 2021","human","human","MIC","Topical","B_HMPHL_INFL",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"5675","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"5676","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.06,FALSE,FALSE,NA +"5677","EUCAST 2021","human","human","MIC","Topical","B_HMPHL_INFL",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.06,FALSE,FALSE,NA +"5678","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"5679","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5680","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPT","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.03,0.03,FALSE,FALSE,NA +"5681","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",32,32,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [4] The breakpoints also apply to meningitis." +"5682","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,"[4] The breakpoints also apply to meningitis." +"5683","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",25,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"5684","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA +"5685","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [4] The breakpoints also apply to meningitis." +"5686","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,"[4] The breakpoints also apply to meningitis." +"5687","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",27,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"5688","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"5689","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,NA +"5690","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,1,FALSE,FALSE,NA +"5691","EUCAST 2021","human","human","DISK","pneumonia","B_HMPHL_INFL",2,"CZT","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","30/10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] See table of dosages for dosing for different indications." +"5692","EUCAST 2021","human","human","MIC","pneumonia","B_HMPHL_INFL",2,"CZT","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[2] See table of dosages for dosing for different indications." +"5693","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"DOR","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",23,23,FALSE,FALSE,"[1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"5694","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"DOR","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[1] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below." +"5695","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"DOX","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"5696","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"5697","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5698","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",28,28,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"5699","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5700","EUCAST 2021","human","human","MIC","Topical","B_HMPHL_INFL",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA +"5701","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"5702","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"5703","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"5704","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.06,FALSE,FALSE,NA +"5705","EUCAST 2021","human","human","MIC","Topical","B_HMPHL_INFL",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.06,FALSE,FALSE,NA +"5706","EUCAST 2021","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"5707","EUCAST 2021","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"5708","EUCAST 2021","human","human","MIC","meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5709","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"5710","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA +"5711","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"5712","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"5713","EUCAST 2021","human","human","DISK","screen only","B_HMPHL_INFL",2,"NAL","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",23,NA,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent." +"5714","EUCAST 2021","human","human","DISK","Topical","B_HMPHL_INFL",2,"NAL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",23,23,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)." +"5715","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"5716","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.06,FALSE,FALSE,NA +"5717","EUCAST 2021","human","human","MIC","Topical","B_HMPHL_INFL",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.06,FALSE,FALSE,NA +"5718","EUCAST 2021","human","human","DISK","screen only","B_HMPHL_INFL",2,"PEN","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","1 unit",12,NA,FALSE,FALSE,"[1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"5719","EUCAST 2021","human","human","DISK","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",18,18,FALSE,FALSE,NA +"5720","EUCAST 2021","human","human","MIC","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA +"5721","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"SAM","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv." +"5722","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","1.25/23.75 mcg",23,20,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5723","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,1,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5724","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",25,22,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"5725","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"5726","EUCAST 2021","human","human","MIC","Topical","B_HMPHL_INFL",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,NA +"5727","EUCAST 2021","human","human","DISK",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)","30/6 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"5728","EUCAST 2021","human","human","MIC",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"5729","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"AMP","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.06,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility." +"5730","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"AMX","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility." +"5731","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"AZM","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility." +"5732","EUCAST 2021","human","human","DISK",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",28,28,FALSE,FALSE,NA +"5733","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.06,FALSE,FALSE,NA +"5734","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"CLR","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility." +"5735","EUCAST 2021","human","human","DISK",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",30,30,FALSE,FALSE,NA +"5736","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.06,FALSE,FALSE,NA +"5737","EUCAST 2021","human","human","DISK",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",27,27,FALSE,FALSE,NA +"5738","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA +"5739","EUCAST 2021","human","human","DISK",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",29,29,FALSE,FALSE,NA +"5740","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5741","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"DOX","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"5742","EUCAST 2021","human","human","DISK",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",20,20,FALSE,FALSE,NA +"5743","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5744","EUCAST 2021","human","human","DISK",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",28,28,FALSE,FALSE,NA +"5745","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA +"5746","EUCAST 2021","human","human","DISK",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",30,30,FALSE,FALSE,NA +"5747","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.03,0.03,FALSE,FALSE,NA +"5748","EUCAST 2021","human","human","DISK",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 11.0)","1 unit",25,25,FALSE,FALSE,NA +"5749","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.03,0.03,FALSE,FALSE,NA +"5750","EUCAST 2021","human","human","DISK",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",20,20,FALSE,FALSE,NA +"5751","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5752","EUCAST 2021","human","human","DISK",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 11.0)","1.25/23.75 mcg",28,28,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5753","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5754","EUCAST 2021","human","human","DISK",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",28,28,FALSE,FALSE,NA +"5755","EUCAST 2021","human","human","MIC",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5756","EUCAST 2021","human","human","DISK",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,19,FALSE,FALSE,NA +"5757","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",19,19,TRUE,FALSE,NA +"5758","EUCAST 2021","human","human","MIC",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,8,FALSE,FALSE,NA +"5759","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,TRUE,FALSE,NA +"5760","EUCAST 2021","human","human","DISK","infections originating from the urinary tract","B_KLBSL",3,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,20,FALSE,FALSE,"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin." +"5761","EUCAST 2021","human","human","MIC","infections originating from the urinary tract","B_KLBSL",3,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,4,FALSE,FALSE,"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin." +"5762","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",15,15,TRUE,FALSE,"[C] Ignore isolated colonies within the inhibition zone." +"5763","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,TRUE,FALSE,"[5] Agar dilution is the reference method for mecillinam MIC determination." +"5764","EUCAST 2021","human","human","DISK","infections originating from the urinary tract","B_KLBSL",3,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,17,FALSE,FALSE,"[C] Ignore isolated colonies within the inhibition zone." +"5765","EUCAST 2021","human","human","MIC","infections originating from the urinary tract","B_KLBSL",3,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,16,FALSE,FALSE,NA +"5766","EUCAST 2021","human","human","DISK",NA,"B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",16,16,FALSE,FALSE,NA +"5767","EUCAST 2021","human","human","MIC",NA,"B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA +"5768","EUCAST 2021","human","human","DISK",NA,"B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",25,25,FALSE,FALSE,NA +"5769","EUCAST 2021","human","human","MIC",NA,"B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA +"5770","EUCAST 2021","human","human","DISK",NA,"B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",26,26,FALSE,FALSE,NA +"5771","EUCAST 2021","human","human","MIC",NA,"B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5772","EUCAST 2021","human","human","DISK","indications other than meningitis","B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 11.0)","1 unit",13,13,FALSE,FALSE,NA +"5773","EUCAST 2021","human","human","MIC","indications other than meningitis","B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA +"5774","EUCAST 2021","human","human","DISK",NA,"B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 11.0)","1.25/23.75 mcg",29,29,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5775","EUCAST 2021","human","human","MIC",NA,"B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5776","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","2/1 mcg",19,19,FALSE,FALSE,NA +"5777","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"5778","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AZM","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"5779","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",21,18,FALSE,FALSE,NA +"5780","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,1,FALSE,FALSE,NA +"5781","EUCAST 2021","human","human","DISK","Topical","B_MRXLL_CTRR",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",31,31,FALSE,FALSE,NA +"5782","EUCAST 2021","human","human","MIC","Topical","B_MRXLL_CTRR",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"5783","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",31,31,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"5784","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA +"5785","EUCAST 2021","human","human","MIC","Topical","B_MRXLL_CTRR",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA +"5786","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CLR","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"5787","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",24,21,FALSE,FALSE,NA +"5788","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,NA +"5789","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",20,17,FALSE,FALSE,NA +"5790","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,NA +"5791","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",21,18,FALSE,FALSE,NA +"5792","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,21,FALSE,FALSE,NA +"5793","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,4,8,FALSE,FALSE,NA +"5794","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,4,FALSE,FALSE,NA +"5795","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"DOR","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",30,30,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5796","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"DOR","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5797","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"DOX","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"5798","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",23,20,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"5799","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,NA +"5800","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",29,29,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5801","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5802","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",20,20,FALSE,FALSE,NA +"5803","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA +"5804","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",29,29,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5805","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5806","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",29,29,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"5807","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA +"5808","EUCAST 2021","human","human","MIC","Topical","B_MRXLL_CTRR",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA +"5809","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",33,33,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5810","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5811","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",26,26,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"5812","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5813","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"5814","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"5815","EUCAST 2021","human","human","DISK","screen only","B_MRXLL_CTRR",2,"NAL","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",23,NA,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent." +"5816","EUCAST 2021","human","human","DISK","Topical","B_MRXLL_CTRR",2,"NAL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",23,23,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)." +"5817","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"5818","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5819","EUCAST 2021","human","human","MIC","Topical","B_MRXLL_CTRR",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5820","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"RXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,1,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"5821","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SAM","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid." +"5822","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","1.25/23.75 mcg",18,15,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5823","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,1,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5824","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",28,25,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"5825","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"5826","EUCAST 2021","human","human","DISK",NA,"B_MRXLL_CTRR",2,"TLT","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",23,20,FALSE,FALSE,NA +"5827","EUCAST 2021","human","human","MIC",NA,"B_MRXLL_CTRR",2,"TLT","M.catarrhalis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,NA +"5828","EUCAST 2021","human","human","MIC",NA,"B_MYCBC_TBRC",2,"BDQ","M.tuberculosis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Breakpoints were determined on MICs performed on Middlebrook 7H11/7H10 medium. The comparability of tests performed by other media has not been established. There is ongoing work to review breakpoints using the EUCAST reference method (described above)." +"5829","EUCAST 2021","human","human","MIC",NA,"B_MYCBC_TBRC",2,"DLM","M.tuberculosis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.06,FALSE,FALSE,NA +"5830","EUCAST 2021","human","human","MIC",NA,"B_NESSR_GNRR",2,"CFM","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA +"5831","EUCAST 2021","human","human","MIC",NA,"B_NESSR_GNRR",2,"CIP","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.03,0.06,FALSE,FALSE,NA +"5832","EUCAST 2021","human","human","MIC",NA,"B_NESSR_GNRR",2,"CRO","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA +"5833","EUCAST 2021","human","human","MIC",NA,"B_NESSR_GNRR",2,"CTX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA +"5834","EUCAST 2021","human","human","MIC",NA,"B_NESSR_GNRR",2,"OFX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.25,FALSE,FALSE,NA +"5835","EUCAST 2021","human","human","MIC","surrogate agent","B_NESSR_GNRR",2,"PEN","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,1,FALSE,FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)." +"5836","EUCAST 2021","human","human","MIC",NA,"B_NESSR_GNRR",2,"SPT","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)",NA,64,64,FALSE,FALSE,NA +"5837","EUCAST 2021","human","human","MIC",NA,"B_NESSR_GNRR",2,"TCY","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,1,FALSE,FALSE,NA +"5838","EUCAST 2021","human","human","MIC","indications other than meningitis","B_NESSR_MNNG",2,"AMP","N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,1,FALSE,FALSE,NA +"5839","EUCAST 2021","human","human","MIC","indications other than meningitis","B_NESSR_MNNG",2,"AMX","N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,1,FALSE,FALSE,NA +"5840","EUCAST 2021","human","human","MIC","meningitis","B_NESSR_MNNG",2,"CHL","N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages." +"5841","EUCAST 2021","human","human","MIC",NA,"B_NESSR_MNNG",2,"CIP","N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.03,0.03,FALSE,FALSE,"[1] Breakpoints apply only to use in the prophylaxis of meningococcal disease." +"5842","EUCAST 2021","human","human","MIC",NA,"B_NESSR_MNNG",2,"CRO","N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5843","EUCAST 2021","human","human","MIC",NA,"B_NESSR_MNNG",2,"CTX","N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5844","EUCAST 2021","human","human","MIC","meningitis","B_NESSR_MNNG",2,"MEM","N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections." +"5845","EUCAST 2021","human","human","MIC",NA,"B_NESSR_MNNG",2,"MNO","N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections." +"5846","EUCAST 2021","human","human","MIC",NA,"B_NESSR_MNNG",2,"PEN","N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5847","EUCAST 2021","human","human","MIC",NA,"B_NESSR_MNNG",2,"RIF","N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,"[2] For prophylaxis of meningitis only (refer to national guidelines)." +"5848","EUCAST 2021","human","human","MIC",NA,"B_NESSR_MNNG",2,"TCY","N.meningitidis (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections." +"5849","EUCAST 2021","human","human","DISK",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,19,FALSE,FALSE,NA +"5850","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",19,19,TRUE,FALSE,NA +"5851","EUCAST 2021","human","human","MIC",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,8,FALSE,FALSE,NA +"5852","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,TRUE,FALSE,NA +"5853","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_PROTS_MRBL",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",15,15,TRUE,FALSE,"[C] Ignore isolated colonies within the inhibition zone." +"5854","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_PROTS_MRBL",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,TRUE,FALSE,"[5] Agar dilution is the reference method for mecillinam MIC determination." +"5855","EUCAST 2021","human","human","DISK","infections originating from the urinary tract","B_PROTS_MRBL",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,17,FALSE,FALSE,"[C] Ignore isolated colonies within the inhibition zone." +"5856","EUCAST 2021","human","human","MIC","infections originating from the urinary tract","B_PROTS_MRBL",2,"TEM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,16,FALSE,FALSE,NA +"5857","EUCAST 2021","human","human","DISK","systemic infections","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",15,15,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"5858","EUCAST 2021","human","human","DISK","infections originating from the urinary tract","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",15,15,FALSE,FALSE,NA +"5859","EUCAST 2021","human","human","MIC","systemic infections","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,16,16,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"5860","EUCAST 2021","human","human","MIC","infections originating from the urinary tract","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,16,16,FALSE,FALSE,NA +"5861","EUCAST 2021","human","human","DISK",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,18,FALSE,FALSE,NA +"5862","EUCAST 2021","human","human","MIC",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,16,FALSE,FALSE,NA +"5863","EUCAST 2021","human","human","DISK",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",50,17,FALSE,FALSE,NA +"5864","EUCAST 2021","human","human","MIC",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,8,FALSE,FALSE,NA +"5865","EUCAST 2021","human","human","DISK",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",50,26,FALSE,FALSE,NA +"5866","EUCAST 2021","human","human","MIC",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,0.5,FALSE,FALSE,NA +"5867","EUCAST 2021","human","human","MIC",NA,"B_PSDMN",3,"COL","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)." +"5868","EUCAST 2021","human","human","DISK",NA,"B_PSDMN",3,"DOR","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",50,22,FALSE,FALSE,NA +"5869","EUCAST 2021","human","human","MIC",NA,"B_PSDMN",3,"DOR","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,2,FALSE,FALSE,NA +"5870","EUCAST 2021","human","human","DISK",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,21,FALSE,FALSE,NA +"5871","EUCAST 2021","human","human","MIC",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,8,FALSE,FALSE,NA +"5872","EUCAST 2021","human","human","DISK",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",50,20,FALSE,FALSE,NA +"5873","EUCAST 2021","human","human","MIC",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,4,FALSE,FALSE,NA +"5874","EUCAST 2021","human","human","DISK",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",50,22,FALSE,FALSE,NA +"5875","EUCAST 2021","human","human","MIC",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,1,FALSE,FALSE,NA +"5876","EUCAST 2021","human","human","DISK","indications other than meningitis","B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",24,18,FALSE,FALSE,NA +"5877","EUCAST 2021","human","human","DISK","meningitis","B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",24,24,FALSE,FALSE,NA +"5878","EUCAST 2021","human","human","MIC","indications other than meningitis","B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,2,8,FALSE,FALSE,NA +"5879","EUCAST 2021","human","human","MIC","meningitis","B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"5880","EUCAST 2021","human","human","DISK",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,18,FALSE,FALSE,NA +"5881","EUCAST 2021","human","human","MIC",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,16,FALSE,FALSE,NA +"5882","EUCAST 2021","human","human","DISK",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","75/10 mcg",50,18,FALSE,FALSE,NA +"5883","EUCAST 2021","human","human","MIC",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,16,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"5884","EUCAST 2021","human","human","DISK",NA,"B_PSDMN",3,"TIC","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","75 mcg",50,18,FALSE,FALSE,NA +"5885","EUCAST 2021","human","human","MIC",NA,"B_PSDMN",3,"TIC","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,16,FALSE,FALSE,NA +"5886","EUCAST 2021","human","human","DISK","systemic infections","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",18,18,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"5887","EUCAST 2021","human","human","DISK","infections originating from the urinary tract","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",18,18,FALSE,FALSE,NA +"5888","EUCAST 2021","human","human","MIC","systemic infections","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"5889","EUCAST 2021","human","human","MIC","infections originating from the urinary tract","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"5890","EUCAST 2021","human","human","DISK",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","30/6 mcg",50,18,FALSE,FALSE,NA +"5891","EUCAST 2021","human","human","MIC",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,16,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"5892","EUCAST 2021","human","human","DISK","Topical","B_PSDMN_AERG",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",26,26,FALSE,FALSE,NA +"5893","EUCAST 2021","human","human","MIC","Topical","B_PSDMN_AERG",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5894","EUCAST 2021","human","human","MIC","Topical","B_PSDMN_AERG",2,"COL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA +"5895","EUCAST 2021","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","10/4 mcg",17,17,FALSE,FALSE,NA +"5896","EUCAST 2021","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L." +"5897","EUCAST 2021","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","30/10 mcg",23,23,FALSE,FALSE,"[3] See table of dosages for dosing for different indications." +"5898","EUCAST 2021","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] See table of dosages for dosing for different indications." +"5899","EUCAST 2021","human","human","DISK",NA,"B_PSDMN_AERG",2,"FDC","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",22,22,FALSE,FALSE,NA +"5900","EUCAST 2021","human","human","MIC",NA,"B_PSDMN_AERG",2,"FDC","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/." +"5901","EUCAST 2021","human","human","DISK","Topical","B_PSDMN_AERG",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",15,15,FALSE,FALSE,NA +"5902","EUCAST 2021","human","human","MIC","Topical","B_PSDMN_AERG",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,NA +"5903","EUCAST 2021","human","human","DISK",NA,"B_PSDMN_AERG",2,"IMR","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)","10/25 mcg",22,22,FALSE,FALSE,NA +"5904","EUCAST 2021","human","human","MIC",NA,"B_PSDMN_AERG",2,"IMR","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L." +"5905","EUCAST 2021","human","human","DISK","Topical","B_PSDMN_AERG",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",20,20,FALSE,FALSE,NA +"5906","EUCAST 2021","human","human","MIC","Topical","B_PSDMN_AERG",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"5907","EUCAST 2021","human","human","MIC",NA,"B_PSDMN_AERG",2,"MEV","Pseudomonas (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L." +"5908","EUCAST 2021","human","human","MIC","Topical","B_PSDMN_AERG",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"5909","EUCAST 2021","human","human","DISK","Topical","B_PSDMN_AERG",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",18,18,FALSE,FALSE,NA +"5910","EUCAST 2021","human","human","MIC","Topical","B_PSDMN_AERG",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"5911","EUCAST 2021","human","human","DISK",NA,"B_PSTRL_MLTC",2,"AMC","P.multocida (file: Clinical Breakpoint Tables v. 11.0)","2/1 mcg",15,15,FALSE,FALSE,NA +"5912","EUCAST 2021","human","human","MIC",NA,"B_PSTRL_MLTC",2,"AMC","P.multocida (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"5913","EUCAST 2021","human","human","MIC",NA,"B_PSTRL_MLTC",2,"AMP","P.multocida (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA +"5914","EUCAST 2021","human","human","MIC",NA,"B_PSTRL_MLTC",2,"AMX","P.multocida (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA +"5915","EUCAST 2021","human","human","DISK",NA,"B_PSTRL_MLTC",2,"CIP","P.multocida (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B." +"5916","EUCAST 2021","human","human","MIC",NA,"B_PSTRL_MLTC",2,"CIP","P.multocida (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.06,FALSE,FALSE,NA +"5917","EUCAST 2021","human","human","DISK",NA,"B_PSTRL_MLTC",2,"CTX","P.multocida (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",26,26,FALSE,FALSE,NA +"5918","EUCAST 2021","human","human","MIC",NA,"B_PSTRL_MLTC",2,"CTX","P.multocida (file: Clinical Breakpoint Tables v. 11.0)",NA,0.03,0.03,FALSE,FALSE,NA +"5919","EUCAST 2021","human","human","MIC",NA,"B_PSTRL_MLTC",2,"DOX","P.multocida (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA +"5920","EUCAST 2021","human","human","DISK",NA,"B_PSTRL_MLTC",2,"LVX","P.multocida (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B." +"5921","EUCAST 2021","human","human","MIC",NA,"B_PSTRL_MLTC",2,"LVX","P.multocida (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.06,FALSE,FALSE,NA +"5922","EUCAST 2021","human","human","DISK","screen only","B_PSTRL_MLTC",2,"NAL","P.multocida (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",23,NA,FALSE,FALSE,"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent." +"5923","EUCAST 2021","human","human","DISK",NA,"B_PSTRL_MLTC",2,"PEN","P.multocida (file: Clinical Breakpoint Tables v. 11.0)","1 unit",17,17,FALSE,FALSE,NA +"5924","EUCAST 2021","human","human","MIC",NA,"B_PSTRL_MLTC",2,"PEN","P.multocida (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5925","EUCAST 2021","human","human","DISK",NA,"B_PSTRL_MLTC",2,"SXT","P.multocida (file: Clinical Breakpoint Tables v. 11.0)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5926","EUCAST 2021","human","human","MIC",NA,"B_PSTRL_MLTC",2,"SXT","P.multocida (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5927","EUCAST 2021","human","human","DISK","screen only","B_PSTRL_MLTC",2,"TCY","P.multocida (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",24,24,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test." +"5928","EUCAST 2021","human","human","MIC",NA,"B_SLMNL",3,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.06,FALSE,FALSE,"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species." +"5929","EUCAST 2021","human","human","DISK","screen only","B_SLMNL",3,"PEF","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",24,24,FALSE,FALSE,"[2/C] The pefloxacin 5 µg breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp. | [B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species." +"5930","EUCAST 2021","human","human","DISK",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 11.0)","1.25/23.75 mcg",50,16,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5931","EUCAST 2021","human","human","MIC",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5932","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"AZM","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"5933","EUCAST 2021","human","human","DISK",NA,"B_STPHY",3,"CHL","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",18,18,FALSE,FALSE,NA +"5934","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"CHL","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,NA +"5935","EUCAST 2021","human","human","DISK",NA,"B_STPHY",3,"CLI","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",22,19,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy""." +"5936","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"CLI","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy""." +"5937","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"CLR","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"5938","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"DAL","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5939","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"DAP","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5940","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"DOX","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"5941","EUCAST 2021","human","human","DISK",NA,"B_STPHY",3,"ERY","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",21,18,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"5942","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"ERY","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"5943","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"FOS","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,32,32,FALSE,FALSE,"[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems." +"5944","EUCAST 2021","human","human","DISK",NA,"B_STPHY",3,"FUS","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",24,24,FALSE,FALSE,NA +"5945","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"FUS","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA +"5946","EUCAST 2021","human","human","DISK",NA,"B_STPHY",3,"LNZ","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",21,21,FALSE,FALSE,NA +"5947","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"LNZ","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA +"5948","EUCAST 2021","human","human","DISK",NA,"B_STPHY",3,"MNO","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"5949","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"MNO","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"5950","EUCAST 2021","human","human","DISK","screen only","B_STPHY",3,"NOR","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",17,NA,FALSE,FALSE,"[C] | [C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin, levofloxacin and ofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents." +"5951","EUCAST 2021","human","human","DISK",NA,"B_STPHY",3,"QDA","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",21,18,FALSE,FALSE,NA +"5952","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"QDA","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,NA +"5953","EUCAST 2021","human","human","DISK",NA,"B_STPHY",3,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",26,23,FALSE,FALSE,NA +"5954","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"RIF","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.5,FALSE,FALSE,NA +"5955","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"RXT","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"5956","EUCAST 2021","human","human","DISK",NA,"B_STPHY",3,"SXT","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","1.25/23.75 mcg",17,14,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5957","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"SXT","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,2,4,FALSE,FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"5958","EUCAST 2021","human","human","DISK",NA,"B_STPHY",3,"TCY","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",22,19,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"5959","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"TCY","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"5960","EUCAST 2021","human","human","DISK",NA,"B_STPHY",3,"TGC","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",19,19,FALSE,FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5961","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"TGC","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"5962","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_STPHY",3,"TMP","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",14,14,TRUE,FALSE,NA +"5963","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_STPHY",3,"TMP","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,TRUE,FALSE,NA +"5964","EUCAST 2021","human","human","DISK",NA,"B_STPHY",3,"TZD","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",21,21,FALSE,FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid." +"5965","EUCAST 2021","human","human","MIC",NA,"B_STPHY",3,"TZD","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid." +"5966","EUCAST 2021","human","human","DISK",NA,"B_STPHY_AURS",2,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",18,18,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci." +"5967","EUCAST 2021","human","human","MIC",NA,"B_STPHY_AURS",2,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci." +"5968","EUCAST 2021","human","human","DISK",NA,"B_STPHY_AURS",2,"BPR","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",17,17,FALSE,FALSE,"[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing." +"5969","EUCAST 2021","human","human","MIC",NA,"B_STPHY_AURS",2,"BPR","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[8] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing." +"5970","EUCAST 2021","human","human","DISK","Topical","B_STPHY_AURS",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",18,18,FALSE,FALSE,NA +"5971","EUCAST 2021","human","human","MIC","Topical","B_STPHY_AURS",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,16,16,FALSE,FALSE,NA +"5972","EUCAST 2021","human","human","DISK",NA,"B_STPHY_AURS",2,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",50,21,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"5973","EUCAST 2021","human","human","MIC",NA,"B_STPHY_AURS",2,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,1,FALSE,FALSE,NA +"5974","EUCAST 2021","human","human","MIC","Topical","B_STPHY_AURS",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA +"5975","EUCAST 2021","human","human","DISK","indications other than pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",20,17,FALSE,FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing." +"5976","EUCAST 2021","human","human","DISK","pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",20,20,FALSE,FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing." +"5977","EUCAST 2021","human","human","MIC","indications other than pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing." +"5978","EUCAST 2021","human","human","MIC","pneumonia","B_STPHY_AURS",2,"CPT","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing." +"5979","EUCAST 2021","human","human","MIC",NA,"B_STPHY_AURS",2,"DFX","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5980","EUCAST 2021","human","human","DISK",NA,"B_STPHY_AURS",2,"ERV","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","20 mcg",20,20,FALSE,FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test." +"5981","EUCAST 2021","human","human","MIC",NA,"B_STPHY_AURS",2,"ERV","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5982","EUCAST 2021","human","human","DISK","screen only","B_STPHY_AURS",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",22,22,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm." +"5983","EUCAST 2021","human","human","DISK","Topical","B_STPHY_AURS",2,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",24,24,FALSE,FALSE,NA +"5984","EUCAST 2021","human","human","MIC","Topical","B_STPHY_AURS",2,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5985","EUCAST 2021","human","human","DISK",NA,"B_STPHY_AURS",2,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",18,18,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"5986","EUCAST 2021","human","human","DISK","Topical","B_STPHY_AURS",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",18,18,FALSE,FALSE,NA +"5987","EUCAST 2021","human","human","MIC",NA,"B_STPHY_AURS",2,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"5988","EUCAST 2021","human","human","MIC","Topical","B_STPHY_AURS",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"5989","EUCAST 2021","human","human","DISK",NA,"B_STPHY_AURS",2,"LMU","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",23,23,FALSE,FALSE,NA +"5990","EUCAST 2021","human","human","MIC",NA,"B_STPHY_AURS",2,"LMU","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5991","EUCAST 2021","human","human","DISK",NA,"B_STPHY_AURS",2,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",50,22,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"5992","EUCAST 2021","human","human","MIC",NA,"B_STPHY_AURS",2,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,1,FALSE,FALSE,NA +"5993","EUCAST 2021","human","human","MIC","Topical","B_STPHY_AURS",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"5994","EUCAST 2021","human","human","DISK",NA,"B_STPHY_AURS",2,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",25,25,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"5995","EUCAST 2021","human","human","MIC",NA,"B_STPHY_AURS",2,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA +"5996","EUCAST 2021","human","human","DISK","Topical","B_STPHY_AURS",2,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","200 mcg",30,30,FALSE,FALSE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +ND = No ECOFF available." +"5997","EUCAST 2021","human","human","MIC","Topical","B_STPHY_AURS",2,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +ND = No ECOFF available." +"5998","EUCAST 2021","human","human","DISK","Topical","B_STPHY_AURS",2,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",14,14,FALSE,FALSE,NA +"5999","EUCAST 2021","human","human","MIC","Topical","B_STPHY_AURS",2,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA +"6000","EUCAST 2021","human","human","DISK","Topical","B_STPHY_AURS",2,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",17,17,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)." +"6001","EUCAST 2021","human","human","MIC","Topical","B_STPHY_AURS",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA +"6002","EUCAST 2021","human","human","MIC",NA,"B_STPHY_AURS",2,"ORI","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6003","EUCAST 2021","human","human","DISK",NA,"B_STPHY_AURS",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","1 unit",26,26,FALSE,FALSE,"[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase." +"6004","EUCAST 2021","human","human","MIC",NA,"B_STPHY_AURS",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins." +"6005","EUCAST 2021","human","human","MIC","Topical","B_STPHY_AURS",2,"RTP","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6006","EUCAST 2021","human","human","MIC",NA,"B_STPHY_AURS",2,"TEC","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6007","EUCAST 2021","human","human","MIC",NA,"B_STPHY_AURS",2,"TLV","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6008","EUCAST 2021","human","human","DISK",NA,"B_STPHY_AURS",2,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",18,18,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"6009","EUCAST 2021","human","human","DISK","Topical","B_STPHY_AURS",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",18,18,FALSE,FALSE,NA +"6010","EUCAST 2021","human","human","MIC",NA,"B_STPHY_AURS",2,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"6011","EUCAST 2021","human","human","MIC","Topical","B_STPHY_AURS",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"6012","EUCAST 2021","human","human","MIC",NA,"B_STPHY_AURS",2,"VAN","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6013","EUCAST 2021","human","human","DISK",NA,"B_STPHY_CONS",2.5,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",22,22,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci." +"6014","EUCAST 2021","human","human","MIC",NA,"B_STPHY_CONS",2.5,"AMK","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci." +"6015","EUCAST 2021","human","human","DISK",NA,"B_STPHY_CONS",2.5,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",50,24,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"6016","EUCAST 2021","human","human","MIC",NA,"B_STPHY_CONS",2.5,"CIP","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,1,FALSE,FALSE,NA +"6017","EUCAST 2021","human","human","DISK","screen only","B_STPHY_CONS",2.5,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",22,22,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm." +"6018","EUCAST 2021","human","human","DISK",NA,"B_STPHY_CONS",2.5,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",22,22,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"6019","EUCAST 2021","human","human","MIC",NA,"B_STPHY_CONS",2.5,"GEN","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"6020","EUCAST 2021","human","human","DISK",NA,"B_STPHY_CONS",2.5,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",50,24,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"6021","EUCAST 2021","human","human","MIC",NA,"B_STPHY_CONS",2.5,"LVX","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,1,FALSE,FALSE,NA +"6022","EUCAST 2021","human","human","DISK",NA,"B_STPHY_CONS",2.5,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",28,28,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"6023","EUCAST 2021","human","human","MIC",NA,"B_STPHY_CONS",2.5,"MFX","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA +"6024","EUCAST 2021","human","human","MIC",NA,"B_STPHY_CONS",2.5,"TEC","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA +"6025","EUCAST 2021","human","human","DISK",NA,"B_STPHY_CONS",2.5,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",22,22,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"6026","EUCAST 2021","human","human","MIC",NA,"B_STPHY_CONS",2.5,"TOB","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"6027","EUCAST 2021","human","human","MIC",NA,"B_STPHY_CONS",2.5,"VAN","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6028","EUCAST 2021","human","human","DISK","screen only","B_STPHY_EPDR",2,"FOX","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",25,25,FALSE,FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm." +"6029","EUCAST 2021","human","human","DISK",NA,"B_STPHY_LGDN",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","1 unit",26,26,FALSE,FALSE,NA +"6030","EUCAST 2021","human","human","MIC",NA,"B_STPHY_LGDN",2,"PEN","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA +"6031","EUCAST 2021","human","human","DISK","screen only","B_STPHY_PSDN",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius and S. schleiferi." +"6032","EUCAST 2021","human","human","DISK","screen only","B_STPHY_SCHL",2,"OXA","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","1 mcg",20,20,FALSE,FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius and S. schleiferi." +"6033","EUCAST 2021","human","human","DISK",NA,"B_STPHY_SPRP",2,"AMP","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",18,18,FALSE,FALSE,"[C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L." +"6034","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_STPHY_SPRP",2,"NIT","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)","100 mcg",13,13,TRUE,FALSE,NA +"6035","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_STPHY_SPRP",2,"NIT","Staphylococcus (file: Clinical Breakpoint Tables v. 11.0)",NA,64,64,TRUE,FALSE,NA +"6036","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"AZM","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"6037","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"CHL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",19,19,FALSE,FALSE,NA +"6038","EUCAST 2021","human","human","DISK","Topical","B_STRPT_ABCG",2.5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",21,21,FALSE,FALSE,NA +"6039","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CHL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,NA +"6040","EUCAST 2021","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,NA +"6041","EUCAST 2021","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"6042","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",17,17,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known." +"6043","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known." +"6044","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"6045","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6046","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAP","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6047","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.03,0.03,FALSE,FALSE,NA +"6048","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DOX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"6049","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",21,18,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"6050","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"6051","EUCAST 2021","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,32,32,FALSE,FALSE,NA +"6052","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",19,19,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6053","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6054","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",50,17,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"6055","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,2,FALSE,FALSE,NA +"6056","EUCAST 2021","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"6057","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",19,19,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"6058","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6059","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"6060","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"6061","EUCAST 2021","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6062","EUCAST 2021","human","human","DISK","screen only","B_STRPT_ABCG",2.5,"NOR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",12,NA,FALSE,FALSE,"[C] | [C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents." +"6063","EUCAST 2021","human","human","DISK","Topical","B_STRPT_ABCG",2.5,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",12,12,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)." +"6064","EUCAST 2021","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA +"6065","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ORI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6066","EUCAST 2021","human","human","DISK","indications other than meningitis","B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","1 unit",18,18,FALSE,FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6067","EUCAST 2021","human","human","MIC","indications other than meningitis","B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6068","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",21,15,FALSE,FALSE,NA +"6069","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.5,FALSE,FALSE,NA +"6070","EUCAST 2021","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"RTP","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA +"6071","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,1,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"6072","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","1.25/23.75 mcg",18,15,FALSE,FALSE,"[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"6073","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"6074","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",23,20,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"6075","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"6076","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6077","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6078","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",19,19,FALSE,FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6079","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6080","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TLT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",20,17,FALSE,FALSE,NA +"6081","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TLT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,NA +"6082","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TZD","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",18,18,FALSE,FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6083","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TZD","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6084","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",13,13,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6085","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6086","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"DAL","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6087","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"DFX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,0.03,0.03,FALSE,FALSE,NA +"6088","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"ORI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6089","EUCAST 2021","human","human","DISK",NA,"B_STRPT_ANGN_ANGN",1,"TZD","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",18,18,FALSE,FALSE,NA +"6090","EUCAST 2021","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"TZD","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6091","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","100 mcg",15,15,TRUE,FALSE,NA +"6092","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,64,64,TRUE,FALSE,NA +"6093","EUCAST 2021","human","human","DISK","meningitis","B_STRPT_GRPB",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)","1 unit",19,19,FALSE,FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6094","EUCAST 2021","human","human","MIC","meningitis","B_STRPT_GRPB",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6095","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_STRPT_GRPB",2.5,"TMP","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,TRUE,FALSE,NA +"6096","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMC","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,1,FALSE,FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit." +"6097","EUCAST 2021","human","human","DISK","indications other than meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",22,16,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below." +"6098","EUCAST 2021","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,2,FALSE,FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below." +"6099","EUCAST 2021","human","human","MIC","meningitis","B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below." +"6100","EUCAST 2021","human","human","MIC","meningitis","B_STRPT_PNMN",2,"AMX","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below." +"6101","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMX","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,1,FALSE,FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below." +"6102","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"AZM","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"6103","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"BPR","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6104","EUCAST 2021","human","human","DISK",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",50,28,FALSE,FALSE,NA +"6105","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,0.5,FALSE,FALSE,NA +"6106","EUCAST 2021","human","human","DISK",NA,"B_STRPT_PNMN",2,"CHL","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",21,21,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages." +"6107","EUCAST 2021","human","human","DISK","Topical","B_STRPT_PNMN",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",21,21,FALSE,FALSE,NA +"6108","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"CHL","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages." +"6109","EUCAST 2021","human","human","MIC","Topical","B_STRPT_PNMN",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,NA +"6110","EUCAST 2021","human","human","MIC","Topical","B_STRPT_PNMN",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA +"6111","EUCAST 2021","human","human","DISK",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",19,19,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"6112","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"6113","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLR","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"6114","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPD","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,NA +"6115","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPT","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA +"6116","EUCAST 2021","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"CRO","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,2,FALSE,FALSE,NA +"6117","EUCAST 2021","human","human","MIC","meningitis","B_STRPT_PNMN",2,"CRO","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6118","EUCAST 2021","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"CTX","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,2,FALSE,FALSE,NA +"6119","EUCAST 2021","human","human","MIC","meningitis","B_STRPT_PNMN",2,"CTX","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6120","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,1,FALSE,FALSE,NA +"6121","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,NA +"6122","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"DOR","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA +"6123","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"DOX","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"6124","EUCAST 2021","human","human","DISK",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",22,19,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"6125","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"6126","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"ETP","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6127","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"FEP","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,NA +"6128","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"IPM","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"6129","EUCAST 2021","human","human","DISK",NA,"B_STRPT_PNMN",2,"LMU","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",12,12,FALSE,FALSE,NA +"6130","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"LMU","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6131","EUCAST 2021","human","human","DISK",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",22,22,FALSE,FALSE,NA +"6132","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"6133","EUCAST 2021","human","human","DISK",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",50,16,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"6134","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,2,FALSE,FALSE,NA +"6135","EUCAST 2021","human","human","MIC","Topical","B_STRPT_PNMN",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"6136","EUCAST 2021","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"6137","EUCAST 2021","human","human","MIC","meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA +"6138","EUCAST 2021","human","human","DISK",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",22,22,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"6139","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6140","EUCAST 2021","human","human","DISK",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"6141","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"6142","EUCAST 2021","human","human","DISK","screen only","B_STRPT_PNMN",2,"NOR","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",10,NA,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents." +"6143","EUCAST 2021","human","human","DISK","Topical","B_STRPT_PNMN",2,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",10,10,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)." +"6144","EUCAST 2021","human","human","MIC","Topical","B_STRPT_PNMN",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,FALSE,FALSE,NA +"6145","EUCAST 2021","human","human","DISK","screen only","B_STRPT_PNMN",2,"OXA","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","1 mcg",20,NA,FALSE,FALSE,"[E] For interpretation of the oxacillin disk screen, see flow chart below." +"6146","EUCAST 2021","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,2,FALSE,FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [2] For breakpoints and dosing in pneumonia, see table of dosages." +"6147","EUCAST 2021","human","human","MIC","meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.06,0.06,FALSE,FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below." +"6148","EUCAST 2021","human","human","DISK",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",22,17,FALSE,FALSE,NA +"6149","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.5,FALSE,FALSE,NA +"6150","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"RXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,1,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"6151","EUCAST 2021","human","human","DISK",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","1.25/23.75 mcg",13,10,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"6152","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"6153","EUCAST 2021","human","human","DISK",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",25,22,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"6154","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"6155","EUCAST 2021","human","human","DISK",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6156","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6157","EUCAST 2021","human","human","DISK",NA,"B_STRPT_PNMN",2,"TLT","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","15 mcg",23,20,FALSE,FALSE,NA +"6158","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"TLT","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,NA +"6159","EUCAST 2021","human","human","DISK",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6160","EUCAST 2021","human","human","MIC",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6161","EUCAST 2021","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",21,15,FALSE,FALSE,NA +"6162","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,2,FALSE,FALSE,NA +"6163","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"AMX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,2,FALSE,FALSE,NA +"6164","EUCAST 2021","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)","2 mcg",19,19,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"6165","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"6166","EUCAST 2021","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",27,27,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins." +"6167","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6168","EUCAST 2021","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",23,23,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins." +"6169","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6170","EUCAST 2021","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",26,26,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins." +"6171","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6172","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"DOR","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA +"6173","EUCAST 2021","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"ERV","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)","20 mcg",17,17,FALSE,FALSE,NA +"6174","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ERV","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA +"6175","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ETP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6176","EUCAST 2021","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",25,25,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins." +"6177","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6178","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"IMR","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit." +"6179","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"IPM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"6180","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"MEM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"6181","EUCAST 2021","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)","1 unit",18,12,FALSE,FALSE,NA +"6182","EUCAST 2021","human","human","DISK","screen only","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)","1 unit",18,NA,FALSE,FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents." +"6183","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,2,FALSE,FALSE,NA +"6184","EUCAST 2021","human","human","MIC","screen only","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,NA,FALSE,FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents." +"6185","EUCAST 2021","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",16,16,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6186","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6187","EUCAST 2021","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6188","EUCAST 2021","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6189","EUCAST 2021","human","human","DISK",NA,"B_[FAM]_MORGNLLC",4,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",50,19,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem." +"6190","EUCAST 2021","human","human","MIC",NA,"B_[FAM]_MORGNLLC",4,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.001,4,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem." +"6191","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","20/10 mcg",19,19,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review." +"6192","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","20/10 mcg",16,16,TRUE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars." +"6193","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review." +"6194","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,32,32,TRUE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"6195","EUCAST 2021","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",18,18,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"6196","EUCAST 2021","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",18,18,FALSE,FALSE,NA +"6197","EUCAST 2021","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"6198","EUCAST 2021","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,NA +"6199","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",14,14,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review." +"6200","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,"[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review." +"6201","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,"[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review." +"6202","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",26,21,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes." +"6203","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,1,4,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes." +"6204","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",23,23,FALSE,FALSE,NA +"6205","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA +"6206","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",22,19,FALSE,FALSE,NA +"6207","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,1,4,FALSE,FALSE,NA +"6208","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",17,17,TRUE,FALSE,NA +"6209","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,TRUE,FALSE,NA +"6210","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",12,12,TRUE,FALSE,NA +"6211","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,16,16,TRUE,FALSE,NA +"6212","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CHL","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",17,17,FALSE,FALSE,NA +"6213","EUCAST 2021","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",17,17,FALSE,FALSE,NA +"6214","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CHL","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,NA +"6215","EUCAST 2021","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,16,16,FALSE,FALSE,NA +"6216","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",25,22,FALSE,FALSE,NA +"6217","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,NA +"6218","EUCAST 2021","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.125,0.125,FALSE,FALSE,NA +"6219","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"COL","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)." +"6220","EUCAST 2021","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"COL","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"6221","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",21,21,TRUE,FALSE,NA +"6222","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,TRUE,FALSE,NA +"6223","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",23,23,FALSE,FALSE,NA +"6224","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6225","EUCAST 2021","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",25,22,FALSE,FALSE,NA +"6226","EUCAST 2021","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",25,25,FALSE,FALSE,NA +"6227","EUCAST 2021","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,NA +"6228","EUCAST 2021","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA +"6229","EUCAST 2021","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",23,23,FALSE,FALSE,NA +"6230","EUCAST 2021","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA +"6231","EUCAST 2021","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",20,17,FALSE,FALSE,NA +"6232","EUCAST 2021","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",20,20,FALSE,FALSE,NA +"6233","EUCAST 2021","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,NA +"6234","EUCAST 2021","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,1,1,FALSE,FALSE,NA +"6235","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10/4 mcg",13,13,FALSE,FALSE,NA +"6236","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L." +"6237","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30/10 mcg",22,22,FALSE,FALSE,"[6] See table of dosages for dosing for different indications." +"6238","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [6] See table of dosages for dosing for different indications." +"6239","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"DOR","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",24,21,FALSE,FALSE,NA +"6240","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"DOR","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,1,2,FALSE,FALSE,NA +"6241","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",25,25,FALSE,FALSE,NA +"6242","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6243","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FDC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",22,22,FALSE,FALSE,NA +"6244","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FDC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/." +"6245","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",27,24,FALSE,FALSE,NA +"6246","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,1,4,FALSE,FALSE,NA +"6247","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","200 mcg",21,21,FALSE,FALSE,"[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below)." +"6248","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,32,32,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems." +"6249","EUCAST 2021","human","human","DISK","screen only","B_[ORD]_ENTRBCTR",5,"FOX","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",19,19,FALSE,FALSE,"[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type." +"6250","EUCAST 2021","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",17,17,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"6251","EUCAST 2021","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",17,17,FALSE,FALSE,NA +"6252","EUCAST 2021","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",17,17,FALSE,FALSE,NA +"6253","EUCAST 2021","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"6254","EUCAST 2021","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"6255","EUCAST 2021","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"6256","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"IMR","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10/25 mcg",22,22,FALSE,FALSE,NA +"6257","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"IMR","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L." +"6258","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",22,19,FALSE,FALSE,NA +"6259","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,2,4,FALSE,FALSE,NA +"6260","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",14,14,TRUE,FALSE,NA +"6261","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,16,16,TRUE,FALSE,NA +"6262","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",23,19,FALSE,FALSE,NA +"6263","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,1,FALSE,FALSE,NA +"6264","EUCAST 2021","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA +"6265","EUCAST 2021","human","human","DISK","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",22,16,FALSE,FALSE,NA +"6266","EUCAST 2021","human","human","DISK","meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",22,22,FALSE,FALSE,NA +"6267","EUCAST 2021","human","human","MIC","indications other than meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,2,8,FALSE,FALSE,NA +"6268","EUCAST 2021","human","human","MIC","meningitis","B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"6269","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MEV","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L." +"6270","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",22,22,FALSE,FALSE,NA +"6271","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA +"6272","EUCAST 2021","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",12,12,FALSE,FALSE,NA +"6273","EUCAST 2021","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,NA +"6274","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",22,22,TRUE,FALSE,NA +"6275","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.5,0.5,TRUE,FALSE,NA +"6276","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",24,22,FALSE,FALSE,NA +"6277","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.5,FALSE,FALSE,NA +"6278","EUCAST 2021","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,0.25,0.25,FALSE,FALSE,NA +"6279","EUCAST 2021","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"PEF","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",24,24,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)." +"6280","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30 mcg",20,20,FALSE,FALSE,NA +"6281","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,NA +"6282","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10/10 mcg",14,14,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review." +"6283","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review." +"6284","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","1.25/23.75 mcg",14,11,FALSE,FALSE,"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"6285","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,2,4,FALSE,FALSE,"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"6286","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","75/10 mcg",23,20,FALSE,FALSE,NA +"6287","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,16,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"6288","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TIC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","75 mcg",23,20,FALSE,FALSE,NA +"6289","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TIC","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,16,FALSE,FALSE,NA +"6290","EUCAST 2021","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","5 mcg",15,15,TRUE,FALSE,NA +"6291","EUCAST 2021","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,4,4,TRUE,FALSE,NA +"6292","EUCAST 2021","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",16,16,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"6293","EUCAST 2021","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",16,16,FALSE,FALSE,NA +"6294","EUCAST 2021","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 11.0)","10 mcg",16,16,FALSE,FALSE,NA +"6295","EUCAST 2021","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"6296","EUCAST 2021","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"6297","EUCAST 2021","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 11.0)",NA,2,2,FALSE,FALSE,NA +"6298","EUCAST 2021","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)","30/6 mcg",20,20,FALSE,FALSE,NA +"6299","EUCAST 2021","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 11.0)",NA,8,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"6300","EUCAST 2020","human","human","DISK","systemic infections","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",19,19,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"6301","EUCAST 2020","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",19,19,FALSE,FALSE,NA +"6302","EUCAST 2020","human","human","MIC","systemic infections","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"6303","EUCAST 2020","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,NA +"6304","EUCAST 2020","human","human","DISK",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",50,21,FALSE,FALSE,NA +"6305","EUCAST 2020","human","human","DISK","Topical","B_ACNTB",3,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",21,21,FALSE,FALSE,NA +"6306","EUCAST 2020","human","human","MIC",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,1,FALSE,FALSE,NA +"6307","EUCAST 2020","human","human","MIC","Topical","B_ACNTB",3,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA +"6308","EUCAST 2020","human","human","MIC",NA,"B_ACNTB",3,"COL","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)." +"6309","EUCAST 2020","human","human","MIC","Topical","B_ACNTB",3,"COL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"6310","EUCAST 2020","human","human","DISK","systemic infections","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",17,17,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"6311","EUCAST 2020","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",17,17,FALSE,FALSE,NA +"6312","EUCAST 2020","human","human","DISK","Topical","B_ACNTB",3,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",17,17,FALSE,FALSE,NA +"6313","EUCAST 2020","human","human","MIC","systemic infections","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"6314","EUCAST 2020","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA +"6315","EUCAST 2020","human","human","MIC","Topical","B_ACNTB",3,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA +"6316","EUCAST 2020","human","human","MIC",NA,"B_ACNTB",3,"IMR","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L." +"6317","EUCAST 2020","human","human","DISK",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",24,21,FALSE,FALSE,NA +"6318","EUCAST 2020","human","human","MIC",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)",NA,2,4,FALSE,FALSE,NA +"6319","EUCAST 2020","human","human","DISK",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",23,20,FALSE,FALSE,NA +"6320","EUCAST 2020","human","human","DISK","Topical","B_ACNTB",3,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",23,23,FALSE,FALSE,NA +"6321","EUCAST 2020","human","human","MIC",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,1,FALSE,FALSE,NA +"6322","EUCAST 2020","human","human","MIC","Topical","B_ACNTB",3,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6323","EUCAST 2020","human","human","DISK",NA,"B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",21,15,FALSE,FALSE,NA +"6324","EUCAST 2020","human","human","MIC",NA,"B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)",NA,2,8,FALSE,FALSE,NA +"6325","EUCAST 2020","human","human","MIC","Topical","B_ACNTB",3,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA +"6326","EUCAST 2020","human","human","DISK",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)","1.25/23.75 mcg",14,11,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"6327","EUCAST 2020","human","human","MIC",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)",NA,2,4,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"6328","EUCAST 2020","human","human","DISK","systemic infections","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",17,17,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"6329","EUCAST 2020","human","human","DISK","infections originating from the urinary tract","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",17,17,FALSE,FALSE,NA +"6330","EUCAST 2020","human","human","DISK","Topical","B_ACNTB",3,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",17,17,FALSE,FALSE,NA +"6331","EUCAST 2020","human","human","MIC","systemic infections","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"6332","EUCAST 2020","human","human","MIC","infections originating from the urinary tract","B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA +"6333","EUCAST 2020","human","human","MIC","Topical","B_ACNTB",3,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA +"6334","EUCAST 2020","human","human","DISK",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","2 mcg",26,26,FALSE,FALSE,NA +"6335","EUCAST 2020","human","human","MIC",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA +"6336","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note" +"6337","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,TRUE,FALSE,NA +"6338","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility." +"6339","EUCAST 2020","human","human","DISK",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",31,31,FALSE,FALSE,NA +"6340","EUCAST 2020","human","human","MIC",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA +"6341","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","100 mcg",16,16,TRUE,FALSE,NA +"6342","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,16,16,TRUE,FALSE,NA +"6343","EUCAST 2020","human","human","DISK","screen only","B_AERCC_SNGN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance." +"6344","EUCAST 2020","human","human","DISK",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","1 unit",21,21,FALSE,FALSE,NA +"6345","EUCAST 2020","human","human","MIC",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA +"6346","EUCAST 2020","human","human","DISK",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",25,25,FALSE,FALSE,NA +"6347","EUCAST 2020","human","human","MIC",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA +"6348","EUCAST 2020","human","human","DISK",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method." +"6349","EUCAST 2020","human","human","MIC",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA +"6350","EUCAST 2020","human","human","DISK",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","2 mcg",26,26,FALSE,FALSE,NA +"6351","EUCAST 2020","human","human","MIC",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA +"6352","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note" +"6353","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,TRUE,FALSE,NA +"6354","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility." +"6355","EUCAST 2020","human","human","DISK",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",31,31,FALSE,FALSE,NA +"6356","EUCAST 2020","human","human","MIC",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA +"6357","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","100 mcg",16,16,TRUE,FALSE,NA +"6358","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,16,16,TRUE,FALSE,NA +"6359","EUCAST 2020","human","human","DISK","screen only","B_AERCC_URIN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance." +"6360","EUCAST 2020","human","human","DISK",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","1 unit",21,21,FALSE,FALSE,NA +"6361","EUCAST 2020","human","human","MIC",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA +"6362","EUCAST 2020","human","human","DISK",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",25,25,FALSE,FALSE,NA +"6363","EUCAST 2020","human","human","MIC",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA +"6364","EUCAST 2020","human","human","DISK",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method." +"6365","EUCAST 2020","human","human","MIC",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA +"6366","EUCAST 2020","human","human","DISK",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",29,26,FALSE,FALSE,NA +"6367","EUCAST 2020","human","human","MIC",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 10.0)",NA,1,4,FALSE,FALSE,NA +"6368","EUCAST 2020","human","human","DISK",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",24,21,FALSE,FALSE,NA +"6369","EUCAST 2020","human","human","MIC",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 10.0)",NA,1,4,FALSE,FALSE,NA +"6370","EUCAST 2020","human","human","DISK",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",27,24,FALSE,FALSE,NA +"6371","EUCAST 2020","human","human","MIC",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,NA +"6372","EUCAST 2020","human","human","DISK",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",27,24,FALSE,FALSE,NA +"6373","EUCAST 2020","human","human","MIC",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 10.0)",NA,1,4,FALSE,FALSE,NA +"6374","EUCAST 2020","human","human","DISK",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",27,24,FALSE,FALSE,NA +"6375","EUCAST 2020","human","human","MIC",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,1,FALSE,FALSE,NA +"6376","EUCAST 2020","human","human","DISK",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 10.0)","1.25/23.75 mcg",19,16,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"6377","EUCAST 2020","human","human","MIC",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 10.0)",NA,2,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"6378","EUCAST 2020","human","human","DISK",NA,"B_BRKHL_PSDM",2,"AMC","B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)","20/10 mcg",50,22,FALSE,FALSE,NA +"6379","EUCAST 2020","human","human","MIC",NA,"B_BRKHL_PSDM",2,"AMC","B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,8,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"6380","EUCAST 2020","human","human","DISK",NA,"B_BRKHL_PSDM",2,"CAZ","B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",50,18,FALSE,FALSE,NA +"6381","EUCAST 2020","human","human","MIC",NA,"B_BRKHL_PSDM",2,"CAZ","B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,8,FALSE,FALSE,NA +"6382","EUCAST 2020","human","human","DISK",NA,"B_BRKHL_PSDM",2,"CHL","B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",50,22,FALSE,FALSE,NA +"6383","EUCAST 2020","human","human","MIC",NA,"B_BRKHL_PSDM",2,"CHL","B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,8,FALSE,FALSE,NA +"6384","EUCAST 2020","human","human","MIC",NA,"B_BRKHL_PSDM",2,"DOX","B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,2,FALSE,FALSE,NA +"6385","EUCAST 2020","human","human","DISK",NA,"B_BRKHL_PSDM",2,"IPM","B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",29,29,FALSE,FALSE,NA +"6386","EUCAST 2020","human","human","MIC",NA,"B_BRKHL_PSDM",2,"IPM","B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"6387","EUCAST 2020","human","human","DISK",NA,"B_BRKHL_PSDM",2,"MEM","B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",24,24,FALSE,FALSE,NA +"6388","EUCAST 2020","human","human","MIC",NA,"B_BRKHL_PSDM",2,"MEM","B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"6389","EUCAST 2020","human","human","DISK",NA,"B_BRKHL_PSDM",2,"SXT","B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)","1.25/23.75 mcg",50,17,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"6390","EUCAST 2020","human","human","MIC",NA,"B_BRKHL_PSDM",2,"SXT","B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"6391","EUCAST 2020","human","human","DISK","screen only","B_BRKHL_PSDM",2,"TCY","B.pseudomallei (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",50,23,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline disk diffusion screen test." +"6392","EUCAST 2020","human","human","DISK",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",26,26,FALSE,FALSE,NA +"6393","EUCAST 2020","human","human","MIC",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6394","EUCAST 2020","human","human","DISK",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",24,24,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin." +"6395","EUCAST 2020","human","human","MIC",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin." +"6396","EUCAST 2020","human","human","DISK",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",30,30,FALSE,FALSE,"[A] Tetracycline can be used to determine susceptibility to doxycycline." +"6397","EUCAST 2020","human","human","MIC",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to determine susceptibility to doxycycline." +"6398","EUCAST 2020","human","human","DISK",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",26,26,FALSE,FALSE,NA +"6399","EUCAST 2020","human","human","MIC",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6400","EUCAST 2020","human","human","DISK",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",20,20,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin." +"6401","EUCAST 2020","human","human","MIC",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin." +"6402","EUCAST 2020","human","human","DISK",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",30,30,FALSE,FALSE,"[A] Tetracycline can be used to determine susceptibility to doxycycline." +"6403","EUCAST 2020","human","human","MIC",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to determine susceptibility to doxycycline." +"6404","EUCAST 2020","human","human","MIC",NA,"B_CRDDS_DFFC",2,"MTR","C.difficile (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[5] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with metronidazole. There are no conclusive clinical data regarding the relation between MICs and outcomes." +"6405","EUCAST 2020","human","human","MIC",NA,"B_CRDDS_DFFC",2,"VAN","C.difficile (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with vancomycin. There are no conclusive clinical data regarding the relation between MICs and outcomes." +"6406","EUCAST 2020","human","human","DISK",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",25,25,FALSE,FALSE,NA +"6407","EUCAST 2020","human","human","MIC",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA +"6408","EUCAST 2020","human","human","DISK",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)","2 mcg",20,20,FALSE,FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing." +"6409","EUCAST 2020","human","human","MIC",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing." +"6410","EUCAST 2020","human","human","DISK",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",25,25,FALSE,FALSE,NA +"6411","EUCAST 2020","human","human","MIC",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"6412","EUCAST 2020","human","human","DISK",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",25,25,FALSE,FALSE,NA +"6413","EUCAST 2020","human","human","MIC",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6414","EUCAST 2020","human","human","DISK",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)","1 unit",29,29,FALSE,FALSE,NA +"6415","EUCAST 2020","human","human","MIC",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA +"6416","EUCAST 2020","human","human","DISK",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",30,25,FALSE,FALSE,NA +"6417","EUCAST 2020","human","human","MIC",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.5,FALSE,FALSE,NA +"6418","EUCAST 2020","human","human","DISK",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",24,24,FALSE,FALSE,NA +"6419","EUCAST 2020","human","human","MIC",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"6420","EUCAST 2020","human","human","DISK",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method." +"6421","EUCAST 2020","human","human","MIC",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"6422","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_CTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",15,15,TRUE,FALSE,"[D] Ignore isolated colonies within the inhibition zone." +"6423","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_CTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination." +"6424","EUCAST 2020","human","human","DISK",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method." +"6425","EUCAST 2020","human","human","MIC",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/." +"6426","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_ENTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",15,15,TRUE,FALSE,"[D] Ignore isolated colonies within the inhibition zone." +"6427","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_ENTRBC",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination." +"6428","EUCAST 2020","human","human","MIC",NA,"B_ENTRC",3,"AMC","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,4,8,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only." +"6429","EUCAST 2020","human","human","DISK",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)","2 mcg",10,8,FALSE,FALSE,"[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only." +"6430","EUCAST 2020","human","human","MIC",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,4,8,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only." +"6431","EUCAST 2020","human","human","MIC",NA,"B_ENTRC",3,"AMX","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,4,8,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only." +"6432","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"6433","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,TRUE,FALSE,NA +"6434","EUCAST 2020","human","human","DISK",NA,"B_ENTRC",3,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",50,21,FALSE,FALSE,NA +"6435","EUCAST 2020","human","human","MIC",NA,"B_ENTRC",3,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,4,FALSE,FALSE,NA +"6436","EUCAST 2020","human","human","DISK",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",20,20,FALSE,FALSE,NA +"6437","EUCAST 2020","human","human","MIC",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA +"6438","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"6439","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,TRUE,FALSE,NA +"6440","EUCAST 2020","human","human","DISK","screen only","B_ENTRC",3,"NOR","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",12,12,FALSE,FALSE,"[B] | [B] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility." +"6441","EUCAST 2020","human","human","MIC",NA,"B_ENTRC",3,"SAM","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,4,8,FALSE,FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only." +"6442","EUCAST 2020","human","human","DISK",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",16,16,FALSE,FALSE,NA +"6443","EUCAST 2020","human","human","MIC",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"6444","EUCAST 2020","human","human","DISK",NA,"B_ENTRC",3,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",12,12,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation." +"6445","EUCAST 2020","human","human","MIC",NA,"B_ENTRC",3,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA +"6446","EUCAST 2020","human","human","DISK",NA,"B_ENTRC_FACM",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)","20 mcg",24,24,FALSE,FALSE,NA +"6447","EUCAST 2020","human","human","MIC",NA,"B_ENTRC_FACM",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA +"6448","EUCAST 2020","human","human","DISK",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",22,20,FALSE,FALSE,NA +"6449","EUCAST 2020","human","human","MIC",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,1,4,FALSE,FALSE,NA +"6450","EUCAST 2020","human","human","DISK",NA,"B_ENTRC_FACM",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",22,22,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6451","EUCAST 2020","human","human","MIC",NA,"B_ENTRC_FACM",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6452","EUCAST 2020","human","human","DISK",NA,"B_ENTRC_FCLS",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)","20 mcg",22,22,FALSE,FALSE,NA +"6453","EUCAST 2020","human","human","MIC",NA,"B_ENTRC_FCLS",2,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA +"6454","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)","100 mcg",15,15,TRUE,FALSE,NA +"6455","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,64,64,TRUE,FALSE,NA +"6456","EUCAST 2020","human","human","DISK",NA,"B_ENTRC_FCLS",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",20,20,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6457","EUCAST 2020","human","human","MIC",NA,"B_ENTRC_FCLS",2,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6458","EUCAST 2020","human","human","DISK",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",50,19,FALSE,FALSE,NA +"6459","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",19,19,TRUE,FALSE,NA +"6460","EUCAST 2020","human","human","MIC",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,8,FALSE,FALSE,NA +"6461","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,TRUE,FALSE,NA +"6462","EUCAST 2020","human","human","MIC","infections originating from the urinary tract","B_ESCHR_COLI",2,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,4,FALSE,FALSE,NA +"6463","EUCAST 2020","human","human","MIC",NA,"B_ESCHR_COLI",2,"DFX","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA +"6464","EUCAST 2020","human","human","DISK",NA,"B_ESCHR_COLI",2,"ERV","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","20 mcg",17,17,FALSE,FALSE,NA +"6465","EUCAST 2020","human","human","MIC",NA,"B_ESCHR_COLI",2,"ERV","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6466","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",15,15,TRUE,FALSE,"[D] Ignore isolated colonies within the inhibition zone." +"6467","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination." +"6468","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","100 mcg",11,11,TRUE,FALSE,NA +"6469","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,64,64,TRUE,FALSE,NA +"6470","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",15,15,TRUE,FALSE,NA +"6471","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,16,16,TRUE,FALSE,NA +"6472","EUCAST 2020","human","human","DISK",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method." +"6473","EUCAST 2020","human","human","MIC",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/." +"6474","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"AMC","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,4,8,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"6475","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"AMP","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,2,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin." +"6476","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"AMX","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,2,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin." +"6477","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"CHL","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,NA +"6478","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"CLI","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA +"6479","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"ETP","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6480","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"IMR","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L." +"6481","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"IPM","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,2,4,FALSE,FALSE,NA +"6482","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"MEM","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,2,8,FALSE,FALSE,NA +"6483","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"MTR","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA +"6484","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"PEN","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin." +"6485","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"PIP","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,16,16,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin." +"6486","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"SAM","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,4,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L." +"6487","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"TCC","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,8,16,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"6488","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"TIC","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,16,16,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin." +"6489","EUCAST 2020","human","human","MIC",NA,"B_GRAMN",6,"TZP","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 10.0)",NA,8,16,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"6490","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"AMC","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,4,8,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"6491","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"AMP","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,4,8,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin." +"6492","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"AMX","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,4,8,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin." +"6493","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"CHL","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,NA +"6494","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"CLI","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA +"6495","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"ETP","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6496","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"IMR","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L." +"6497","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"IPM","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,2,4,FALSE,FALSE,NA +"6498","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"MEM","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,2,8,FALSE,FALSE,NA +"6499","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"MTR","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA +"6500","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"PEN","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin." +"6501","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"PIP","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,8,16,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin." +"6502","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"SAM","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,4,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L." +"6503","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"TCC","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,8,16,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"6504","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"TIC","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,8,16,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin." +"6505","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"TZP","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,8,16,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"6506","EUCAST 2020","human","human","MIC",NA,"B_GRAMP",6,"VAN","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"6507","EUCAST 2020","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"AMX","H.pylori (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA +"6508","EUCAST 2020","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"CLR","H.pylori (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,NA +"6509","EUCAST 2020","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"LVX","H.pylori (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA +"6510","EUCAST 2020","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"MTR","H.pylori (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,NA +"6511","EUCAST 2020","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"RIF","H.pylori (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA +"6512","EUCAST 2020","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"TCY","H.pylori (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA +"6513","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","2/1 mcg",15,15,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"6514","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","2/1 mcg",50,15,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"6515","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"6516","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,2,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"6517","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","2 mcg",18,18,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase." +"6518","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase." +"6519","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMX","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase." +"6520","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMX","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,2,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase." +"6521","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"6522","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA +"6523","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",28,28,FALSE,FALSE,NA +"6524","EUCAST 2020","human","human","DISK","Topical","B_HMPHL_INFL",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",28,28,FALSE,FALSE,NA +"6525","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"6526","EUCAST 2020","human","human","MIC","Topical","B_HMPHL_INFL",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"6527","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"6528","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.06,FALSE,FALSE,NA +"6529","EUCAST 2020","human","human","MIC","Topical","B_HMPHL_INFL",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.06,FALSE,FALSE,NA +"6530","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"6531","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA +"6532","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPT","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.03,0.03,FALSE,FALSE,NA +"6533","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",32,32,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"6534","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA +"6535","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",25,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"6536","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA +"6537","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"6538","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA +"6539","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",27,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"6540","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",50,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"6541","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,NA +"6542","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,1,FALSE,FALSE,NA +"6543","EUCAST 2020","human","human","MIC","pneumonia","B_HMPHL_INFL",2,"CZT","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,"[2] See table of dosages for dosing for different indications." +"6544","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"DOX","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"6545","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"6546","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6547","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",28,28,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"6548","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA +"6549","EUCAST 2020","human","human","MIC","Topical","B_HMPHL_INFL",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA +"6550","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"6551","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"6552","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"6553","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.06,FALSE,FALSE,NA +"6554","EUCAST 2020","human","human","MIC","Topical","B_HMPHL_INFL",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.06,FALSE,FALSE,NA +"6555","EUCAST 2020","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"6556","EUCAST 2020","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"6557","EUCAST 2020","human","human","MIC","meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA +"6558","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"6559","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA +"6560","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"6561","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"6562","EUCAST 2020","human","human","DISK","screen only","B_HMPHL_INFL",2,"NAL","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",23,NA,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent." +"6563","EUCAST 2020","human","human","DISK","Topical","B_HMPHL_INFL",2,"NAL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",23,23,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)." +"6564","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"6565","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.06,FALSE,FALSE,NA +"6566","EUCAST 2020","human","human","MIC","Topical","B_HMPHL_INFL",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.06,FALSE,FALSE,NA +"6567","EUCAST 2020","human","human","DISK","screen only","B_HMPHL_INFL",2,"PEN","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","1 unit",12,NA,FALSE,FALSE,"[1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"6568","EUCAST 2020","human","human","DISK","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",18,18,FALSE,FALSE,NA +"6569","EUCAST 2020","human","human","MIC","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA +"6570","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"SAM","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid." +"6571","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","1.25/23.75 mcg",23,20,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"6572","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,1,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"6573","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",25,22,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"6574","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"6575","EUCAST 2020","human","human","MIC","Topical","B_HMPHL_INFL",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,NA +"6576","EUCAST 2020","human","human","DISK",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)","30/6 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below." +"6577","EUCAST 2020","human","human","MIC",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"6578","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"AMP","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.06,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility." +"6579","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"AMX","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility." +"6580","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"AZM","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility." +"6581","EUCAST 2020","human","human","DISK",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",28,28,FALSE,FALSE,NA +"6582","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.06,FALSE,FALSE,NA +"6583","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"CLR","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility." +"6584","EUCAST 2020","human","human","DISK",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",30,30,FALSE,FALSE,NA +"6585","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.06,FALSE,FALSE,NA +"6586","EUCAST 2020","human","human","DISK",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",27,27,FALSE,FALSE,NA +"6587","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA +"6588","EUCAST 2020","human","human","DISK",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",29,29,FALSE,FALSE,NA +"6589","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6590","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"DOX","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"6591","EUCAST 2020","human","human","DISK",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",20,20,FALSE,FALSE,NA +"6592","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6593","EUCAST 2020","human","human","DISK",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",28,28,FALSE,FALSE,NA +"6594","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA +"6595","EUCAST 2020","human","human","DISK",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",30,30,FALSE,FALSE,NA +"6596","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.03,0.03,FALSE,FALSE,NA +"6597","EUCAST 2020","human","human","DISK",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 10.0)","1 unit",25,25,FALSE,FALSE,NA +"6598","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.03,0.03,FALSE,FALSE,NA +"6599","EUCAST 2020","human","human","DISK",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",20,20,FALSE,FALSE,NA +"6600","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6601","EUCAST 2020","human","human","DISK",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 10.0)","1.25/23.75 mcg",28,28,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"6602","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"6603","EUCAST 2020","human","human","DISK",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",28,28,FALSE,FALSE,NA +"6604","EUCAST 2020","human","human","MIC",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6605","EUCAST 2020","human","human","DISK",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",50,19,FALSE,FALSE,NA +"6606","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",19,19,TRUE,FALSE,NA +"6607","EUCAST 2020","human","human","MIC",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,8,FALSE,FALSE,NA +"6608","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,TRUE,FALSE,NA +"6609","EUCAST 2020","human","human","MIC","infections originating from the urinary tract","B_KLBSL",3,"CZO","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,4,FALSE,FALSE,NA +"6610","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",15,15,TRUE,FALSE,"[D] Ignore isolated colonies within the inhibition zone." +"6611","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination." +"6612","EUCAST 2020","human","human","DISK",NA,"B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 10.0)","2 mcg",16,16,FALSE,FALSE,NA +"6613","EUCAST 2020","human","human","MIC",NA,"B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA +"6614","EUCAST 2020","human","human","DISK",NA,"B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",25,25,FALSE,FALSE,NA +"6615","EUCAST 2020","human","human","MIC",NA,"B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA +"6616","EUCAST 2020","human","human","DISK",NA,"B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",26,26,FALSE,FALSE,NA +"6617","EUCAST 2020","human","human","MIC",NA,"B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA +"6618","EUCAST 2020","human","human","DISK",NA,"B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 10.0)","1 unit",13,13,FALSE,FALSE,NA +"6619","EUCAST 2020","human","human","MIC",NA,"B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA +"6620","EUCAST 2020","human","human","DISK",NA,"B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 10.0)","1.25/23.75 mcg",29,29,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"6621","EUCAST 2020","human","human","MIC",NA,"B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"6622","EUCAST 2020","human","human","DISK",NA,"B_MRGNL_MRGN",2,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",50,17,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem." +"6623","EUCAST 2020","human","human","MIC",NA,"B_MRGNL_MRGN",2,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,4,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem." +"6624","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","2/1 mcg",19,19,FALSE,FALSE,NA +"6625","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"6626","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AZM","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"6627","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",21,18,FALSE,FALSE,NA +"6628","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,1,FALSE,FALSE,NA +"6629","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CHL","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",30,30,FALSE,FALSE,"[A] Breakpoints relate to topical use only." +"6630","EUCAST 2020","human","human","DISK","Topical","B_MRXLL_CTRR",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",30,30,FALSE,FALSE,NA +"6631","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CHL","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Breakpoints relate to topical use only." +"6632","EUCAST 2020","human","human","MIC","Topical","B_MRXLL_CTRR",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"6633","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",31,31,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"6634","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA +"6635","EUCAST 2020","human","human","MIC","Topical","B_MRXLL_CTRR",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA +"6636","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CLR","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"6637","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",24,21,FALSE,FALSE,NA +"6638","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,NA +"6639","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",20,17,FALSE,FALSE,NA +"6640","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,NA +"6641","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",21,18,FALSE,FALSE,NA +"6642","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",50,21,FALSE,FALSE,NA +"6643","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,4,8,FALSE,FALSE,NA +"6644","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,4,FALSE,FALSE,NA +"6645","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"DOX","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"6646","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",23,20,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"6647","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,NA +"6648","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",29,29,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6649","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6650","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",20,20,FALSE,FALSE,NA +"6651","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA +"6652","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",29,29,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6653","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6654","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",29,29,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"6655","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA +"6656","EUCAST 2020","human","human","MIC","Topical","B_MRXLL_CTRR",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA +"6657","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",33,33,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6658","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6659","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",26,26,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"6660","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA +"6661","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",25,25,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"6662","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"6663","EUCAST 2020","human","human","DISK","screen only","B_MRXLL_CTRR",2,"NAL","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",23,NA,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent." +"6664","EUCAST 2020","human","human","DISK","Topical","B_MRXLL_CTRR",2,"NAL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",23,23,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)." +"6665","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"6666","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA +"6667","EUCAST 2020","human","human","MIC","Topical","B_MRXLL_CTRR",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA +"6668","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"RXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,1,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"6669","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SAM","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid." +"6670","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","1.25/23.75 mcg",18,15,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"6671","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,1,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"6672","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",28,25,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"6673","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"6674","EUCAST 2020","human","human","DISK",NA,"B_MRXLL_CTRR",2,"TLT","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",23,20,FALSE,FALSE,NA +"6675","EUCAST 2020","human","human","MIC",NA,"B_MRXLL_CTRR",2,"TLT","M.catarrhalis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,NA +"6676","EUCAST 2020","human","human","MIC",NA,"B_MYCBC_TBRC",2,"BDQ","M.tuberculosis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Breakpoints were determined on MICs performed on Middlebrook 7H11/7H10 medium. The comparability of tests performed by other media has not been established. There is ongoing work to review breakpoints using the EUCAST reference method (described above)." +"6677","EUCAST 2020","human","human","MIC",NA,"B_MYCBC_TBRC",2,"DLM","M.tuberculosis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.06,FALSE,FALSE,NA +"6678","EUCAST 2020","human","human","MIC",NA,"B_NESSR_GNRR",2,"CFM","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA +"6679","EUCAST 2020","human","human","MIC",NA,"B_NESSR_GNRR",2,"CIP","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.03,0.06,FALSE,FALSE,NA +"6680","EUCAST 2020","human","human","MIC",NA,"B_NESSR_GNRR",2,"CRO","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA +"6681","EUCAST 2020","human","human","MIC",NA,"B_NESSR_GNRR",2,"CTX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA +"6682","EUCAST 2020","human","human","MIC",NA,"B_NESSR_GNRR",2,"OFX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.25,FALSE,FALSE,NA +"6683","EUCAST 2020","human","human","MIC","surrogate agent","B_NESSR_GNRR",2,"PEN","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,1,FALSE,FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility)." +"6684","EUCAST 2020","human","human","MIC",NA,"B_NESSR_GNRR",2,"SPT","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)",NA,64,64,FALSE,FALSE,NA +"6685","EUCAST 2020","human","human","MIC",NA,"B_NESSR_GNRR",2,"TCY","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,1,FALSE,FALSE,NA +"6686","EUCAST 2020","human","human","MIC",NA,"B_NESSR_MNNG",2,"AMP","N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,1,FALSE,FALSE,NA +"6687","EUCAST 2020","human","human","MIC",NA,"B_NESSR_MNNG",2,"AMX","N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,1,FALSE,FALSE,NA +"6688","EUCAST 2020","human","human","MIC","meningitis","B_NESSR_MNNG",2,"CHL","N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] See table of dosages." +"6689","EUCAST 2020","human","human","MIC",NA,"B_NESSR_MNNG",2,"CIP","N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.03,0.03,FALSE,FALSE,"[1] Breakpoints apply only to use in the prophylaxis of meningococcal disease." +"6690","EUCAST 2020","human","human","MIC",NA,"B_NESSR_MNNG",2,"CRO","N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6691","EUCAST 2020","human","human","MIC",NA,"B_NESSR_MNNG",2,"CTX","N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6692","EUCAST 2020","human","human","MIC","meningitis","B_NESSR_MNNG",2,"MEM","N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6693","EUCAST 2020","human","human","MIC",NA,"B_NESSR_MNNG",2,"MNO","N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections." +"6694","EUCAST 2020","human","human","MIC",NA,"B_NESSR_MNNG",2,"PEN","N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.25,FALSE,FALSE,NA +"6695","EUCAST 2020","human","human","MIC",NA,"B_NESSR_MNNG",2,"RIF","N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,"[2] For prophylaxis of meningitis only (refer to national guidelines)." +"6696","EUCAST 2020","human","human","MIC",NA,"B_NESSR_MNNG",2,"TCY","N.meningitidis (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections." +"6697","EUCAST 2020","human","human","DISK",NA,"B_PROTS",3,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",50,17,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem." +"6698","EUCAST 2020","human","human","MIC",NA,"B_PROTS",3,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,4,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem." +"6699","EUCAST 2020","human","human","DISK",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",50,19,FALSE,FALSE,NA +"6700","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",19,19,TRUE,FALSE,NA +"6701","EUCAST 2020","human","human","MIC",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,8,FALSE,FALSE,NA +"6702","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,TRUE,FALSE,NA +"6703","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_PROTS_MRBL",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",15,15,TRUE,FALSE,"[D] Ignore isolated colonies within the inhibition zone." +"6704","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_PROTS_MRBL",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination." +"6705","EUCAST 2020","human","human","DISK",NA,"B_PRVDN",3,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",50,17,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem." +"6706","EUCAST 2020","human","human","MIC",NA,"B_PRVDN",3,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,4,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem." +"6707","EUCAST 2020","human","human","DISK","systemic infections","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",15,15,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"6708","EUCAST 2020","human","human","DISK","infections originating from the urinary tract","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",15,15,FALSE,FALSE,NA +"6709","EUCAST 2020","human","human","MIC","systemic infections","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,16,16,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"6710","EUCAST 2020","human","human","MIC","infections originating from the urinary tract","B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,16,16,FALSE,FALSE,NA +"6711","EUCAST 2020","human","human","DISK",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",50,18,FALSE,FALSE,NA +"6712","EUCAST 2020","human","human","MIC",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,16,FALSE,FALSE,NA +"6713","EUCAST 2020","human","human","DISK",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",50,17,FALSE,FALSE,NA +"6714","EUCAST 2020","human","human","MIC",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,8,FALSE,FALSE,NA +"6715","EUCAST 2020","human","human","DISK",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",50,26,FALSE,FALSE,NA +"6716","EUCAST 2020","human","human","MIC",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,0.5,FALSE,FALSE,NA +"6717","EUCAST 2020","human","human","MIC",NA,"B_PSDMN",3,"COL","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)." +"6718","EUCAST 2020","human","human","DISK",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",50,21,FALSE,FALSE,NA +"6719","EUCAST 2020","human","human","MIC",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,8,FALSE,FALSE,NA +"6720","EUCAST 2020","human","human","DISK",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",50,20,FALSE,FALSE,NA +"6721","EUCAST 2020","human","human","MIC",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,4,FALSE,FALSE,NA +"6722","EUCAST 2020","human","human","DISK",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",50,22,FALSE,FALSE,NA +"6723","EUCAST 2020","human","human","MIC",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,1,FALSE,FALSE,NA +"6724","EUCAST 2020","human","human","DISK",NA,"B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",24,18,FALSE,FALSE,NA +"6725","EUCAST 2020","human","human","MIC",NA,"B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,2,8,FALSE,FALSE,NA +"6726","EUCAST 2020","human","human","DISK",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",50,18,FALSE,FALSE,NA +"6727","EUCAST 2020","human","human","MIC",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,16,FALSE,FALSE,NA +"6728","EUCAST 2020","human","human","DISK",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","75/10 mcg",50,18,FALSE,FALSE,NA +"6729","EUCAST 2020","human","human","MIC",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,16,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"6730","EUCAST 2020","human","human","DISK",NA,"B_PSDMN",3,"TIC","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","75 mcg",50,18,FALSE,FALSE,NA +"6731","EUCAST 2020","human","human","MIC",NA,"B_PSDMN",3,"TIC","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,16,FALSE,FALSE,NA +"6732","EUCAST 2020","human","human","DISK","systemic infections","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",18,18,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"6733","EUCAST 2020","human","human","DISK","infections originating from the urinary tract","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",18,18,FALSE,FALSE,NA +"6734","EUCAST 2020","human","human","MIC","systemic infections","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"6735","EUCAST 2020","human","human","MIC","infections originating from the urinary tract","B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"6736","EUCAST 2020","human","human","DISK",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","30/6 mcg",50,18,FALSE,FALSE,NA +"6737","EUCAST 2020","human","human","MIC",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,16,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"6738","EUCAST 2020","human","human","DISK","Topical","B_PSDMN_AERG",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",25,25,FALSE,FALSE,NA +"6739","EUCAST 2020","human","human","MIC","Topical","B_PSDMN_AERG",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6740","EUCAST 2020","human","human","MIC","Topical","B_PSDMN_AERG",2,"COL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA +"6741","EUCAST 2020","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","10/4 mcg",17,17,FALSE,FALSE,NA +"6742","EUCAST 2020","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L." +"6743","EUCAST 2020","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)","30/10 mcg",24,24,FALSE,FALSE,"[2] See table of dosages for dosing for different indications." +"6744","EUCAST 2020","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [2] See table of dosages for dosing for different indications." +"6745","EUCAST 2020","human","human","DISK","Topical","B_PSDMN_AERG",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",15,15,FALSE,FALSE,NA +"6746","EUCAST 2020","human","human","MIC","Topical","B_PSDMN_AERG",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,NA +"6747","EUCAST 2020","human","human","MIC",NA,"B_PSDMN_AERG",2,"IMR","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L." +"6748","EUCAST 2020","human","human","DISK","Topical","B_PSDMN_AERG",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",20,20,FALSE,FALSE,NA +"6749","EUCAST 2020","human","human","MIC","Topical","B_PSDMN_AERG",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"6750","EUCAST 2020","human","human","MIC",NA,"B_PSDMN_AERG",2,"MEV","Pseudomonas (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L." +"6751","EUCAST 2020","human","human","MIC","Topical","B_PSDMN_AERG",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"6752","EUCAST 2020","human","human","DISK","Topical","B_PSDMN_AERG",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",16,16,FALSE,FALSE,NA +"6753","EUCAST 2020","human","human","MIC","Topical","B_PSDMN_AERG",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"6754","EUCAST 2020","human","human","DISK",NA,"B_PSTRL_MLTC",2,"AMC","P.multocida (file: Clinical Breakpoint Tables v. 10.0)","2/1 mcg",15,15,FALSE,FALSE,NA +"6755","EUCAST 2020","human","human","MIC",NA,"B_PSTRL_MLTC",2,"AMC","P.multocida (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"6756","EUCAST 2020","human","human","MIC",NA,"B_PSTRL_MLTC",2,"AMP","P.multocida (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA +"6757","EUCAST 2020","human","human","MIC",NA,"B_PSTRL_MLTC",2,"AMX","P.multocida (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA +"6758","EUCAST 2020","human","human","DISK",NA,"B_PSTRL_MLTC",2,"CIP","P.multocida (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B." +"6759","EUCAST 2020","human","human","MIC",NA,"B_PSTRL_MLTC",2,"CIP","P.multocida (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.06,FALSE,FALSE,NA +"6760","EUCAST 2020","human","human","DISK",NA,"B_PSTRL_MLTC",2,"CTX","P.multocida (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",26,26,FALSE,FALSE,NA +"6761","EUCAST 2020","human","human","MIC",NA,"B_PSTRL_MLTC",2,"CTX","P.multocida (file: Clinical Breakpoint Tables v. 10.0)",NA,0.03,0.03,FALSE,FALSE,NA +"6762","EUCAST 2020","human","human","MIC",NA,"B_PSTRL_MLTC",2,"DOX","P.multocida (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA +"6763","EUCAST 2020","human","human","DISK",NA,"B_PSTRL_MLTC",2,"LVX","P.multocida (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B." +"6764","EUCAST 2020","human","human","MIC",NA,"B_PSTRL_MLTC",2,"LVX","P.multocida (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.06,FALSE,FALSE,NA +"6765","EUCAST 2020","human","human","DISK","screen only","B_PSTRL_MLTC",2,"NAL","P.multocida (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",23,NA,FALSE,FALSE,"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent." +"6766","EUCAST 2020","human","human","DISK",NA,"B_PSTRL_MLTC",2,"PEN","P.multocida (file: Clinical Breakpoint Tables v. 10.0)","1 unit",17,17,FALSE,FALSE,NA +"6767","EUCAST 2020","human","human","MIC",NA,"B_PSTRL_MLTC",2,"PEN","P.multocida (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6768","EUCAST 2020","human","human","DISK",NA,"B_PSTRL_MLTC",2,"SXT","P.multocida (file: Clinical Breakpoint Tables v. 10.0)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"6769","EUCAST 2020","human","human","MIC",NA,"B_PSTRL_MLTC",2,"SXT","P.multocida (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"6770","EUCAST 2020","human","human","DISK","screen only","B_PSTRL_MLTC",2,"TCY","P.multocida (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",24,24,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test." +"6771","EUCAST 2020","human","human","MIC",NA,"B_SLMNL",3,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.06,FALSE,FALSE,"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species." +"6772","EUCAST 2020","human","human","DISK","screen only","B_SLMNL",3,"PEF","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",24,24,FALSE,FALSE,"[2/C] The pefloxacin 5 µg breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp. | [B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species." +"6773","EUCAST 2020","human","human","DISK",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 10.0)","1.25/23.75 mcg",50,16,FALSE,FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"6774","EUCAST 2020","human","human","MIC",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"6775","EUCAST 2020","human","human","DISK","Topical","B_STPHY_AURS",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",18,18,FALSE,FALSE,NA +"6776","EUCAST 2020","human","human","MIC","Topical","B_STPHY_AURS",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,16,16,FALSE,FALSE,NA +"6777","EUCAST 2020","human","human","MIC","Topical","B_STPHY_AURS",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA +"6778","EUCAST 2020","human","human","DISK","Topical","B_STPHY_AURS",2,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",24,24,FALSE,FALSE,NA +"6779","EUCAST 2020","human","human","MIC","Topical","B_STPHY_AURS",2,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6780","EUCAST 2020","human","human","DISK","Topical","B_STPHY_AURS",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",18,18,FALSE,FALSE,NA +"6781","EUCAST 2020","human","human","MIC","Topical","B_STPHY_AURS",2,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"6782","EUCAST 2020","human","human","MIC","Topical","B_STPHY_AURS",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6783","EUCAST 2020","human","human","DISK","Topical","B_STPHY_AURS",2,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","200 mcg",30,30,FALSE,FALSE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +ND = No ECOFF available." +"6784","EUCAST 2020","human","human","MIC","Topical","B_STPHY_AURS",2,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +ND = No ECOFF available." +"6785","EUCAST 2020","human","human","DISK","Topical","B_STPHY_AURS",2,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",14,14,FALSE,FALSE,NA +"6786","EUCAST 2020","human","human","MIC","Topical","B_STPHY_AURS",2,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA +"6787","EUCAST 2020","human","human","DISK","Topical","B_STPHY_AURS",2,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",17,17,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)." +"6788","EUCAST 2020","human","human","MIC","Topical","B_STPHY_AURS",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA +"6789","EUCAST 2020","human","human","MIC","Topical","B_STPHY_AURS",2,"RTP","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6790","EUCAST 2020","human","human","DISK","Topical","B_STPHY_AURS",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",18,18,FALSE,FALSE,NA +"6791","EUCAST 2020","human","human","MIC","Topical","B_STPHY_AURS",2,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"6792","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"AZM","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"6793","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"CHL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",19,19,FALSE,FALSE,NA +"6794","EUCAST 2020","human","human","DISK","Topical","B_STRPT_ABCG",2.5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",21,21,FALSE,FALSE,NA +"6795","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CHL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,NA +"6796","EUCAST 2020","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,NA +"6797","EUCAST 2020","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"6798","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","2 mcg",17,17,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known." +"6799","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known." +"6800","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"6801","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6802","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAP","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6803","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.03,0.03,FALSE,FALSE,NA +"6804","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DOX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"6805","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",21,18,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"6806","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"6807","EUCAST 2020","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"FUS","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,32,32,FALSE,FALSE,NA +"6808","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",19,19,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6809","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6810","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",50,17,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"6811","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,2,FALSE,FALSE,NA +"6812","EUCAST 2020","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"6813","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",19,19,FALSE,FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"6814","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6815","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",23,23,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"6816","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"6817","EUCAST 2020","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"MUP","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6818","EUCAST 2020","human","human","DISK","screen only","B_STRPT_ABCG",2.5,"NOR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",12,NA,FALSE,FALSE,"[C] | [C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents." +"6819","EUCAST 2020","human","human","DISK","Topical","B_STRPT_ABCG",2.5,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",12,12,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)." +"6820","EUCAST 2020","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA +"6821","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ORI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6822","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","1 unit",18,18,FALSE,FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6823","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6824","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",21,15,FALSE,FALSE,NA +"6825","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.5,FALSE,FALSE,NA +"6826","EUCAST 2020","human","human","MIC","Topical","B_STRPT_ABCG",2.5,"RTP","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA +"6827","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,1,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"6828","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","1.25/23.75 mcg",18,15,FALSE,FALSE,"[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"6829","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,"[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"6830","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",23,20,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"6831","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"6832","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6833","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6834","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",19,19,FALSE,FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6835","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6836","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TLT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",20,17,FALSE,FALSE,NA +"6837","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TLT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,NA +"6838","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TZD","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","2 mcg",18,18,FALSE,FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6839","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TZD","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6840","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",13,13,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6841","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6842","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"DAL","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6843","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"DFX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,0.03,0.03,FALSE,FALSE,NA +"6844","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"ORI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6845","EUCAST 2020","human","human","DISK",NA,"B_STRPT_ANGN_ANGN",1,"TZD","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)","2 mcg",18,18,FALSE,FALSE,NA +"6846","EUCAST 2020","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"TZD","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA +"6847","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)","100 mcg",15,15,TRUE,FALSE,NA +"6848","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,64,64,TRUE,FALSE,NA +"6849","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_STRPT_GRPB",2.5,"TMP","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,TRUE,FALSE,NA +"6850","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMC","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,1,FALSE,FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit." +"6851","EUCAST 2020","human","human","DISK",NA,"B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","2 mcg",22,16,FALSE,FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below." +"6852","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,2,FALSE,FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below." +"6853","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMX","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,1,FALSE,FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below." +"6854","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"AZM","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"6855","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"BPR","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6856","EUCAST 2020","human","human","DISK",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",50,28,FALSE,FALSE,NA +"6857","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,0.5,FALSE,FALSE,NA +"6858","EUCAST 2020","human","human","DISK",NA,"B_STRPT_PNMN",2,"CHL","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",21,21,FALSE,FALSE,NA +"6859","EUCAST 2020","human","human","DISK","Topical","B_STRPT_PNMN",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",21,21,FALSE,FALSE,NA +"6860","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"CHL","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,NA +"6861","EUCAST 2020","human","human","MIC","Topical","B_STRPT_PNMN",2,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,NA +"6862","EUCAST 2020","human","human","MIC","Topical","B_STRPT_PNMN",2,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA +"6863","EUCAST 2020","human","human","DISK",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","2 mcg",19,19,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"6864","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"6865","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLR","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"6866","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPD","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,NA +"6867","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPT","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA +"6868","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"CRO","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,2,FALSE,FALSE,NA +"6869","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"CTX","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,2,FALSE,FALSE,NA +"6870","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,1,FALSE,FALSE,NA +"6871","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,NA +"6872","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"DOX","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"6873","EUCAST 2020","human","human","DISK",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",22,19,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"6874","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"6875","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"ETP","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6876","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"FEP","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,NA +"6877","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"IPM","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"6878","EUCAST 2020","human","human","DISK",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",22,22,FALSE,FALSE,NA +"6879","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"6880","EUCAST 2020","human","human","DISK",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",50,16,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"6881","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.001,2,FALSE,FALSE,NA +"6882","EUCAST 2020","human","human","MIC","Topical","B_STRPT_PNMN",2,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"6883","EUCAST 2020","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"6884","EUCAST 2020","human","human","MIC","meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA +"6885","EUCAST 2020","human","human","DISK",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",22,22,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"6886","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6887","EUCAST 2020","human","human","DISK",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",24,24,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"6888","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"6889","EUCAST 2020","human","human","DISK","screen only","B_STRPT_PNMN",2,"NOR","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",10,NA,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents." +"6890","EUCAST 2020","human","human","DISK","Topical","B_STRPT_PNMN",2,"NOR","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",10,10,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)." +"6891","EUCAST 2020","human","human","MIC","Topical","B_STRPT_PNMN",2,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,FALSE,FALSE,NA +"6892","EUCAST 2020","human","human","DISK","screen only","B_STRPT_PNMN",2,"OXA","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","1 mcg",20,NA,FALSE,FALSE,"[D] For interpretation of the oxacillin disk screen, see flow chart below." +"6893","EUCAST 2020","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,2,FALSE,FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] For breakpoints and dosing in pneumonia, see table of dosages." +"6894","EUCAST 2020","human","human","MIC","meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.06,0.06,FALSE,FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below." +"6895","EUCAST 2020","human","human","DISK",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",22,17,FALSE,FALSE,NA +"6896","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.5,FALSE,FALSE,NA +"6897","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"RXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,1,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"6898","EUCAST 2020","human","human","DISK",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","1.25/23.75 mcg",13,10,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"6899","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"6900","EUCAST 2020","human","human","DISK",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",25,22,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"6901","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"6902","EUCAST 2020","human","human","DISK",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6903","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6904","EUCAST 2020","human","human","DISK",NA,"B_STRPT_PNMN",2,"TLT","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","15 mcg",23,20,FALSE,FALSE,NA +"6905","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"TLT","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,NA +"6906","EUCAST 2020","human","human","DISK",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6907","EUCAST 2020","human","human","MIC",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6908","EUCAST 2020","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)","2 mcg",21,15,FALSE,FALSE,NA +"6909","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,2,FALSE,FALSE,NA +"6910","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"AMX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,2,FALSE,FALSE,NA +"6911","EUCAST 2020","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)","2 mcg",19,19,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"6912","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"6913","EUCAST 2020","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",27,27,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins." +"6914","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6915","EUCAST 2020","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",23,23,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins." +"6916","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6917","EUCAST 2020","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",26,26,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins." +"6918","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6919","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CZO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6920","EUCAST 2020","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"ERV","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)","20 mcg",17,17,FALSE,FALSE,NA +"6921","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ERV","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA +"6922","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ETP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6923","EUCAST 2020","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",25,25,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins." +"6924","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6925","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"IMR","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L." +"6926","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"IPM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"6927","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"MEM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"6928","EUCAST 2020","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)","1 unit",18,12,FALSE,FALSE,NA +"6929","EUCAST 2020","human","human","DISK","screen only","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)","1 unit",18,NA,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents." +"6930","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,2,FALSE,FALSE,NA +"6931","EUCAST 2020","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",16,16,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6932","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6933","EUCAST 2020","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6934","EUCAST 2020","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"6935","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","20/10 mcg",19,19,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review." +"6936","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","20/10 mcg",16,16,TRUE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars." +"6937","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review." +"6938","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,32,32,TRUE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"6939","EUCAST 2020","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",18,18,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"6940","EUCAST 2020","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",18,18,FALSE,FALSE,NA +"6941","EUCAST 2020","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"6942","EUCAST 2020","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,NA +"6943","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",14,14,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review." +"6944","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,"[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review." +"6945","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,"[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review." +"6946","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",26,21,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes." +"6947","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,1,4,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes." +"6948","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",23,23,FALSE,FALSE,NA +"6949","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA +"6950","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",22,19,FALSE,FALSE,NA +"6951","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,1,4,FALSE,FALSE,NA +"6952","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",17,17,TRUE,FALSE,NA +"6953","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,TRUE,FALSE,NA +"6954","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",12,12,TRUE,FALSE,NA +"6955","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,16,16,TRUE,FALSE,NA +"6956","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CHL","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",17,17,FALSE,FALSE,NA +"6957","EUCAST 2020","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",17,17,FALSE,FALSE,NA +"6958","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CHL","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,NA +"6959","EUCAST 2020","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"CHL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,16,16,FALSE,FALSE,NA +"6960","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",25,22,FALSE,FALSE,NA +"6961","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,NA +"6962","EUCAST 2020","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"CIP","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.125,0.125,FALSE,FALSE,NA +"6963","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"COL","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)." +"6964","EUCAST 2020","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"COL","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"6965","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",21,21,TRUE,FALSE,NA +"6966","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,TRUE,FALSE,NA +"6967","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",23,23,FALSE,FALSE,NA +"6968","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6969","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",25,22,FALSE,FALSE,NA +"6970","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,NA +"6971","EUCAST 2020","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",23,23,FALSE,FALSE,NA +"6972","EUCAST 2020","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,1,1,FALSE,FALSE,NA +"6973","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",20,17,FALSE,FALSE,NA +"6974","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,1,2,FALSE,FALSE,NA +"6975","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10/4 mcg",13,13,FALSE,FALSE,NA +"6976","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L." +"6977","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30/10 mcg",22,22,FALSE,FALSE,"[4] See table of dosages for dosing for different indications." +"6978","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [4] See table of dosages for dosing for different indications." +"6979","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",25,25,FALSE,FALSE,NA +"6980","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,FALSE,FALSE,NA +"6981","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",27,24,FALSE,FALSE,NA +"6982","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,1,4,FALSE,FALSE,NA +"6983","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","200 mcg",24,24,FALSE,FALSE,"[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below)." +"6984","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","200 mcg",24,24,TRUE,FALSE,"[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below)." +"6985","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,32,32,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems." +"6986","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,32,32,TRUE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems." +"6987","EUCAST 2020","human","human","DISK","screen only","B_[ORD]_ENTRBCTR",5,"FOX","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",19,19,FALSE,FALSE,"[2] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type." +"6988","EUCAST 2020","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",17,17,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"6989","EUCAST 2020","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",17,17,FALSE,FALSE,NA +"6990","EUCAST 2020","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",17,17,FALSE,FALSE,NA +"6991","EUCAST 2020","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"6992","EUCAST 2020","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"6993","EUCAST 2020","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"GEN","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"6994","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"IMR","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L." +"6995","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",22,17,FALSE,FALSE,NA +"6996","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,2,4,FALSE,FALSE,NA +"6997","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",14,14,TRUE,FALSE,NA +"6998","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,16,16,TRUE,FALSE,NA +"6999","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",23,19,FALSE,FALSE,NA +"7000","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,1,FALSE,FALSE,NA +"7001","EUCAST 2020","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"LVX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA +"7002","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",22,16,FALSE,FALSE,NA +"7003","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,2,8,FALSE,FALSE,NA +"7004","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MEV","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L." +"7005","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",22,22,FALSE,FALSE,NA +"7006","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA +"7007","EUCAST 2020","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",12,12,FALSE,FALSE,NA +"7008","EUCAST 2020","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"NEO","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,NA +"7009","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",22,22,TRUE,FALSE,NA +"7010","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.5,0.5,TRUE,FALSE,NA +"7011","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",24,22,FALSE,FALSE,NA +"7012","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.5,FALSE,FALSE,NA +"7013","EUCAST 2020","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"OFX","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,0.25,0.25,FALSE,FALSE,NA +"7014","EUCAST 2020","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"PEF","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",24,24,FALSE,FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis)." +"7015","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30 mcg",20,17,FALSE,FALSE,NA +"7016","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,16,FALSE,FALSE,NA +"7017","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10/10 mcg",14,14,FALSE,FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review." +"7018","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review." +"7019","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","1.25/23.75 mcg",14,11,FALSE,FALSE,"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"7020","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,2,4,FALSE,FALSE,"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"7021","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","75/10 mcg",23,20,FALSE,FALSE,NA +"7022","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,16,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"7023","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TIC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","75 mcg",23,20,FALSE,FALSE,NA +"7024","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TIC","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,16,FALSE,FALSE,NA +"7025","EUCAST 2020","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","5 mcg",15,15,TRUE,FALSE,NA +"7026","EUCAST 2020","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,4,4,TRUE,FALSE,NA +"7027","EUCAST 2020","human","human","DISK","systemic infections","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",17,17,FALSE,FALSE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"7028","EUCAST 2020","human","human","DISK","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",17,17,FALSE,FALSE,NA +"7029","EUCAST 2020","human","human","DISK","Topical","B_[ORD]_ENTRBCTR",5,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 10.0)","10 mcg",16,16,FALSE,FALSE,NA +"7030","EUCAST 2020","human","human","MIC","systemic infections","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/." +"7031","EUCAST 2020","human","human","MIC","infections originating from the urinary tract","B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"7032","EUCAST 2020","human","human","MIC","Topical","B_[ORD]_ENTRBCTR",5,"TOB","Topical agents (file: Clinical Breakpoint Tables v. 10.0)",NA,2,2,FALSE,FALSE,NA +"7033","EUCAST 2020","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)","30/6 mcg",20,17,FALSE,FALSE,NA +"7034","EUCAST 2020","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 10.0)",NA,8,16,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"7035","EUCAST 2019","human","human","DISK",NA,"B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",19,17,FALSE,FALSE,NA +"7036","EUCAST 2019","human","human","MIC",NA,"B_ACNTB",3,"AMK","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)",NA,8,16,FALSE,FALSE,NA +"7037","EUCAST 2019","human","human","DISK",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",50,21,FALSE,FALSE,NA +"7038","EUCAST 2019","human","human","MIC",NA,"B_ACNTB",3,"CIP","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,1,FALSE,FALSE,NA +"7039","EUCAST 2019","human","human","MIC",NA,"B_ACNTB",3,"COL","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)." +"7040","EUCAST 2019","human","human","DISK",NA,"B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",17,17,FALSE,FALSE,NA +"7041","EUCAST 2019","human","human","MIC",NA,"B_ACNTB",3,"GEN","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,NA +"7042","EUCAST 2019","human","human","DISK",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",24,21,FALSE,FALSE,NA +"7043","EUCAST 2019","human","human","MIC",NA,"B_ACNTB",3,"IPM","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)",NA,2,4,FALSE,FALSE,NA +"7044","EUCAST 2019","human","human","DISK",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",23,20,FALSE,FALSE,NA +"7045","EUCAST 2019","human","human","MIC",NA,"B_ACNTB",3,"LVX","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,FALSE,FALSE,NA +"7046","EUCAST 2019","human","human","DISK",NA,"B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",21,15,FALSE,FALSE,NA +"7047","EUCAST 2019","human","human","MIC",NA,"B_ACNTB",3,"MEM","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)",NA,2,8,FALSE,FALSE,NA +"7048","EUCAST 2019","human","human","DISK",NA,"B_ACNTB",3,"NET","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",16,16,FALSE,FALSE,NA +"7049","EUCAST 2019","human","human","MIC",NA,"B_ACNTB",3,"NET","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,NA +"7050","EUCAST 2019","human","human","DISK",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)","1.25/23.75 mcg",14,11,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"7051","EUCAST 2019","human","human","MIC",NA,"B_ACNTB",3,"SXT","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)",NA,2,4,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"7052","EUCAST 2019","human","human","DISK",NA,"B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",17,17,FALSE,FALSE,NA +"7053","EUCAST 2019","human","human","MIC",NA,"B_ACNTB",3,"TOB","Acinetobacter (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,NA +"7054","EUCAST 2019","human","human","DISK",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","2 mcg",26,26,FALSE,FALSE,NA +"7055","EUCAST 2019","human","human","MIC",NA,"B_AERCC_SNGN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,NA +"7056","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note" +"7057","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,TRUE,FALSE,NA +"7058","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility." +"7059","EUCAST 2019","human","human","DISK",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",31,31,FALSE,FALSE,NA +"7060","EUCAST 2019","human","human","MIC",NA,"B_AERCC_SNGN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,NA +"7061","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","100 mcg",16,16,TRUE,FALSE,NA +"7062","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_AERCC_SNGN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,16,16,TRUE,FALSE,NA +"7063","EUCAST 2019","human","human","DISK","screen","B_AERCC_SNGN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance." +"7064","EUCAST 2019","human","human","DISK",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","1 unit",21,21,FALSE,FALSE,NA +"7065","EUCAST 2019","human","human","MIC",NA,"B_AERCC_SNGN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA +"7066","EUCAST 2019","human","human","DISK",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",25,25,FALSE,FALSE,NA +"7067","EUCAST 2019","human","human","MIC",NA,"B_AERCC_SNGN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA +"7068","EUCAST 2019","human","human","DISK",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method." +"7069","EUCAST 2019","human","human","MIC",NA,"B_AERCC_SNGN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,NA +"7070","EUCAST 2019","human","human","DISK",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","2 mcg",26,26,FALSE,FALSE,NA +"7071","EUCAST 2019","human","human","MIC",NA,"B_AERCC_URIN",2,"AMP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,NA +"7072","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",21,21,TRUE,FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note" +"7073","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"CIP","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,TRUE,FALSE,NA +"7074","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"LVX","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,TRUE,FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility." +"7075","EUCAST 2019","human","human","DISK",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",31,31,FALSE,FALSE,NA +"7076","EUCAST 2019","human","human","MIC",NA,"B_AERCC_URIN",2,"MEM","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,NA +"7077","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","100 mcg",16,16,TRUE,FALSE,NA +"7078","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_AERCC_URIN",2,"NIT","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,16,16,TRUE,FALSE,NA +"7079","EUCAST 2019","human","human","DISK","screen","B_AERCC_URIN",2,"NOR","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",17,17,FALSE,FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance." +"7080","EUCAST 2019","human","human","DISK",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","1 unit",21,21,FALSE,FALSE,NA +"7081","EUCAST 2019","human","human","MIC",NA,"B_AERCC_URIN",2,"PEN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA +"7082","EUCAST 2019","human","human","DISK",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",25,25,FALSE,FALSE,NA +"7083","EUCAST 2019","human","human","MIC",NA,"B_AERCC_URIN",2,"RIF","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA +"7084","EUCAST 2019","human","human","DISK",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method." +"7085","EUCAST 2019","human","human","MIC",NA,"B_AERCC_URIN",2,"VAN","A.sanguinicola_A.urinae (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,NA +"7086","EUCAST 2019","human","human","DISK",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",29,26,FALSE,FALSE,NA +"7087","EUCAST 2019","human","human","MIC",NA,"B_AERMN",3,"ATM","Aeromonas (file: Clinical Breakpoint Tables v. 9.0)",NA,1,4,FALSE,FALSE,NA +"7088","EUCAST 2019","human","human","DISK",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",24,21,FALSE,FALSE,NA +"7089","EUCAST 2019","human","human","MIC",NA,"B_AERMN",3,"CAZ","Aeromonas (file: Clinical Breakpoint Tables v. 9.0)",NA,1,4,FALSE,FALSE,NA +"7090","EUCAST 2019","human","human","DISK",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",27,24,FALSE,FALSE,NA +"7091","EUCAST 2019","human","human","MIC",NA,"B_AERMN",3,"CIP","Aeromonas (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,NA +"7092","EUCAST 2019","human","human","DISK",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",27,24,FALSE,FALSE,NA +"7093","EUCAST 2019","human","human","MIC",NA,"B_AERMN",3,"FEP","Aeromonas (file: Clinical Breakpoint Tables v. 9.0)",NA,1,4,FALSE,FALSE,NA +"7094","EUCAST 2019","human","human","DISK",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",27,24,FALSE,FALSE,NA +"7095","EUCAST 2019","human","human","MIC",NA,"B_AERMN",3,"LVX","Aeromonas (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,FALSE,FALSE,NA +"7096","EUCAST 2019","human","human","DISK",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 9.0)","1.25/23.75 mcg",19,16,FALSE,FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"7097","EUCAST 2019","human","human","MIC",NA,"B_AERMN",3,"SXT","Aeromonas (file: Clinical Breakpoint Tables v. 9.0)",NA,2,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"7098","EUCAST 2019","human","human","DISK",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",26,26,FALSE,FALSE,NA +"7099","EUCAST 2019","human","human","MIC",NA,"B_CMPYL_COLI",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA +"7100","EUCAST 2019","human","human","DISK",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)","15 mcg",24,24,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin." +"7101","EUCAST 2019","human","human","MIC",NA,"B_CMPYL_COLI",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin." +"7102","EUCAST 2019","human","human","DISK",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",30,30,FALSE,FALSE,"[A] Tetracycline can be used to determine susceptibility to doxycycline." +"7103","EUCAST 2019","human","human","MIC",NA,"B_CMPYL_COLI",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to determine susceptibility to doxycycline." +"7104","EUCAST 2019","human","human","DISK",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",26,26,FALSE,FALSE,NA +"7105","EUCAST 2019","human","human","MIC",NA,"B_CMPYL_JEJN",2,"CIP","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA +"7106","EUCAST 2019","human","human","DISK",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)","15 mcg",20,20,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin." +"7107","EUCAST 2019","human","human","MIC",NA,"B_CMPYL_JEJN",2,"ERY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin." +"7108","EUCAST 2019","human","human","DISK",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",30,30,FALSE,FALSE,"[A] Tetracycline can be used to determine susceptibility to doxycycline." +"7109","EUCAST 2019","human","human","MIC",NA,"B_CMPYL_JEJN",2,"TCY","C.jejuni_C.coli (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[1] Tetracycline can be used to determine susceptibility to doxycycline." +"7110","EUCAST 2019","human","human","MIC",NA,"B_CRDDS_DFFC",2,"MTR","C.difficile (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[5] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with metronidazole. There are no conclusive clinical data regarding the relation between MICs and outcomes." +"7111","EUCAST 2019","human","human","MIC",NA,"B_CRDDS_DFFC",2,"VAN","C.difficile (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with vancomycin. There are no conclusive clinical data regarding the relation between MICs and outcomes." +"7112","EUCAST 2019","human","human","DISK",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",25,25,FALSE,FALSE,NA +"7113","EUCAST 2019","human","human","MIC",NA,"B_CRYNB",3,"CIP","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,NA +"7114","EUCAST 2019","human","human","DISK",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)","2 mcg",20,20,FALSE,FALSE,NA +"7115","EUCAST 2019","human","human","MIC",NA,"B_CRYNB",3,"CLI","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA +"7116","EUCAST 2019","human","human","DISK",NA,"B_CRYNB",3,"GEN","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",23,23,FALSE,FALSE,NA +"7117","EUCAST 2019","human","human","MIC",NA,"B_CRYNB",3,"GEN","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,NA +"7118","EUCAST 2019","human","human","DISK",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",25,25,FALSE,FALSE,NA +"7119","EUCAST 2019","human","human","MIC",NA,"B_CRYNB",3,"LNZ","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,NA +"7120","EUCAST 2019","human","human","DISK",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",25,25,FALSE,FALSE,NA +"7121","EUCAST 2019","human","human","MIC",NA,"B_CRYNB",3,"MFX","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA +"7122","EUCAST 2019","human","human","DISK",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)","1 unit",29,29,FALSE,FALSE,NA +"7123","EUCAST 2019","human","human","MIC",NA,"B_CRYNB",3,"PEN","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA +"7124","EUCAST 2019","human","human","DISK",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",30,25,FALSE,FALSE,NA +"7125","EUCAST 2019","human","human","MIC",NA,"B_CRYNB",3,"RIF","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.5,FALSE,FALSE,NA +"7126","EUCAST 2019","human","human","DISK",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",24,24,FALSE,FALSE,NA +"7127","EUCAST 2019","human","human","MIC",NA,"B_CRYNB",3,"TCY","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,NA +"7128","EUCAST 2019","human","human","DISK",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method." +"7129","EUCAST 2019","human","human","MIC",NA,"B_CRYNB",3,"VAN","Corynebacterium (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,NA +"7130","EUCAST 2019","human","human","DISK",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [B] Zone diameter breakpoints validated for E. coli only. For C.koseri, use an MIC method." +"7131","EUCAST 2019","human","human","MIC",NA,"B_CTRBC_KOSR",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/." +"7132","EUCAST 2019","human","human","MIC",NA,"B_ENTRC",3,"AMC","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)",NA,4,8,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin." +"7133","EUCAST 2019","human","human","DISK",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)","2 mcg",10,8,FALSE,FALSE,NA +"7134","EUCAST 2019","human","human","MIC",NA,"B_ENTRC",3,"AMP","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)",NA,4,8,FALSE,FALSE,NA +"7135","EUCAST 2019","human","human","MIC",NA,"B_ENTRC",3,"AMX","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)",NA,4,8,FALSE,FALSE,"[3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin." +"7136","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"7137","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"CIP","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,TRUE,FALSE,NA +"7138","EUCAST 2019","human","human","MIC",NA,"B_ENTRC",3,"ERV","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA +"7139","EUCAST 2019","human","human","DISK",NA,"B_ENTRC",3,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",21,18,FALSE,FALSE,NA +"7140","EUCAST 2019","human","human","MIC",NA,"B_ENTRC",3,"IPM","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)",NA,4,8,FALSE,FALSE,NA +"7141","EUCAST 2019","human","human","DISK",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",19,19,FALSE,FALSE,NA +"7142","EUCAST 2019","human","human","MIC",NA,"B_ENTRC",3,"LNZ","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,NA +"7143","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",15,15,TRUE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"7144","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_ENTRC",3,"LVX","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,TRUE,FALSE,NA +"7145","EUCAST 2019","human","human","DISK","screen","B_ENTRC",3,"NOR","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",12,12,FALSE,FALSE,"[B] | [B] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility." +"7146","EUCAST 2019","human","human","MIC",NA,"B_ENTRC",3,"SAM","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)",NA,4,8,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin." +"7147","EUCAST 2019","human","human","DISK",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",16,16,FALSE,FALSE,NA +"7148","EUCAST 2019","human","human","MIC",NA,"B_ENTRC",3,"TEC","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,NA +"7149","EUCAST 2019","human","human","DISK",NA,"B_ENTRC",3,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)","15 mcg",18,18,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7150","EUCAST 2019","human","human","MIC",NA,"B_ENTRC",3,"TGC","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7151","EUCAST 2019","human","human","DISK",NA,"B_ENTRC",3,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",12,12,FALSE,FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation." +"7152","EUCAST 2019","human","human","MIC",NA,"B_ENTRC",3,"VAN","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,NA +"7153","EUCAST 2019","human","human","DISK",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)","15 mcg",22,20,FALSE,FALSE,NA +"7154","EUCAST 2019","human","human","MIC",NA,"B_ENTRC_FACM",2,"QDA","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)",NA,1,4,FALSE,FALSE,NA +"7155","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)","100 mcg",15,15,TRUE,FALSE,NA +"7156","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_ENTRC_FCLS",2,"NIT","Enterococcus (file: Clinical Breakpoint Tables v. 9.0)",NA,64,64,TRUE,FALSE,NA +"7157","EUCAST 2019","human","human","DISK",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",19,19,FALSE,FALSE,NA +"7158","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",19,19,TRUE,FALSE,NA +"7159","EUCAST 2019","human","human","MIC",NA,"B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,NA +"7160","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,TRUE,FALSE,NA +"7161","EUCAST 2019","human","human","MIC",NA,"B_ESCHR_COLI",2,"ERV","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA +"7162","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",15,15,TRUE,FALSE,"[D] Ignore isolated colonies within the inhibition zone for E. coli." +"7163","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination." +"7164","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","100 mcg",11,11,TRUE,FALSE,NA +"7165","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NIT","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,64,64,TRUE,FALSE,NA +"7166","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",15,15,TRUE,FALSE,NA +"7167","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_ESCHR_COLI",2,"NTR","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,16,16,TRUE,FALSE,NA +"7168","EUCAST 2019","human","human","DISK",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","15 mcg",18,18,FALSE,FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [B] Zone diameter breakpoints validated for E. coli only. For C.koseri, use an MIC method." +"7169","EUCAST 2019","human","human","MIC",NA,"B_ESCHR_COLI",2,"TGC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/." +"7170","EUCAST 2019","human","human","MIC",NA,"B_GRAMN",6,"AMC","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)",NA,4,8,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"7171","EUCAST 2019","human","human","MIC",NA,"B_GRAMN",6,"AMP","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,2,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin." +"7172","EUCAST 2019","human","human","MIC",NA,"B_GRAMN",6,"AMX","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,2,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin." +"7173","EUCAST 2019","human","human","MIC",NA,"B_GRAMN",6,"CHL","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,NA +"7174","EUCAST 2019","human","human","MIC",NA,"B_GRAMN",6,"CLI","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,NA +"7175","EUCAST 2019","human","human","MIC",NA,"B_GRAMN",6,"ETP","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA +"7176","EUCAST 2019","human","human","MIC",NA,"B_GRAMN",6,"IPM","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)",NA,2,4,FALSE,FALSE,NA +"7177","EUCAST 2019","human","human","MIC",NA,"B_GRAMN",6,"MEM","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)",NA,2,8,FALSE,FALSE,NA +"7178","EUCAST 2019","human","human","MIC",NA,"B_GRAMN",6,"MTR","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,NA +"7179","EUCAST 2019","human","human","MIC",NA,"B_GRAMN",6,"PEN","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin." +"7180","EUCAST 2019","human","human","MIC",NA,"B_GRAMN",6,"PIP","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)",NA,16,16,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin." +"7181","EUCAST 2019","human","human","MIC",NA,"B_GRAMN",6,"SAM","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)",NA,4,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L." +"7182","EUCAST 2019","human","human","MIC",NA,"B_GRAMN",6,"TCC","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)",NA,8,16,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"7183","EUCAST 2019","human","human","MIC",NA,"B_GRAMN",6,"TIC","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)",NA,16,16,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin." +"7184","EUCAST 2019","human","human","MIC",NA,"B_GRAMN",6,"TZP","Anaerobes, Gramnegative (file: Clinical Breakpoint Tables v. 9.0)",NA,8,16,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"7185","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"AMC","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,4,8,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"7186","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"AMP","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,4,8,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin." +"7187","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"AMX","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,4,8,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin." +"7188","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"CHL","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,NA +"7189","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"CLI","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,NA +"7190","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"ETP","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA +"7191","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"IPM","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,2,4,FALSE,FALSE,NA +"7192","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"MEM","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,2,8,FALSE,FALSE,NA +"7193","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"MTR","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,NA +"7194","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"PEN","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin." +"7195","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"PIP","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,8,16,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin." +"7196","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"SAM","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,4,8,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L." +"7197","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"TCC","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,8,16,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"7198","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"TIC","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,8,16,FALSE,FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin." +"7199","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"TZP","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,8,16,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"7200","EUCAST 2019","human","human","MIC",NA,"B_GRAMP",6,"VAN","Anaerobes, Grampositive (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,NA +"7201","EUCAST 2019","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"AMX","H.pylori (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility." +"7202","EUCAST 2019","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"CLR","H.pylori (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility." +"7203","EUCAST 2019","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"LVX","H.pylori (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility." +"7204","EUCAST 2019","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"MTR","H.pylori (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility." +"7205","EUCAST 2019","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"RIF","H.pylori (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility." +"7206","EUCAST 2019","human","human","MIC",NA,"B_HLCBCT_PYLR",2,"TCY","H.pylori (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility." +"7207","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","2/1 mcg",15,15,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation." +"7208","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMC","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"7209","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","2 mcg",16,16,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase." +"7210","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMP","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase." +"7211","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"AMX","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase." +"7212","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation." +"7213","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"CFM","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA +"7214","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",28,28,FALSE,FALSE,NA +"7215","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"CHL","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,NA +"7216","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"7217","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"CIP","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.06,FALSE,FALSE,NA +"7218","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",26,26,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm)." +"7219","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPD","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,NA +"7220","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"CPT","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.03,0.03,FALSE,FALSE,NA +"7221","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",32,32,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation." +"7222","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"CRO","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA +"7223","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",25,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation." +"7224","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"CTB","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,NA +"7225","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation." +"7226","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"CTX","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA +"7227","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",27,25,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation." +"7228","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",50,27,FALSE,FALSE,NA +"7229","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,NA +"7230","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"CXM","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,1,FALSE,FALSE,NA +"7231","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"DOX","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"7232","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",23,23,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis)." +"7233","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"ETP","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Not for meningitis (meropenem is the only carbapenem used for meningitis)." +"7234","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",28,28,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm)." +"7235","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"FEP","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,NA +"7236","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm). | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis)." +"7237","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"IPM","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[2] Not for meningitis (meropenem is the only carbapenem used for meningitis)." +"7238","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"7239","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"LVX","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.06,FALSE,FALSE,NA +"7240","EUCAST 2019","human","human","DISK","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",20,20,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis)." +"7241","EUCAST 2019","human","human","MIC","indications other than meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[2] Not for meningitis (meropenem is the only carbapenem used for meningitis)." +"7242","EUCAST 2019","human","human","MIC","meningitis","B_HMPHL_INFL",2,"MEM","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,"[3] Meropenem is the only carbapenem used for meningitis." +"7243","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"7244","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"MFX","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA +"7245","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",24,21,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"7246","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"MNO","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"7247","EUCAST 2019","human","human","DISK","screen","B_HMPHL_INFL",2,"NAL","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",23,NA,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent." +"7248","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",30,30,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"7249","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"OFX","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.06,FALSE,FALSE,NA +"7250","EUCAST 2019","human","human","DISK","screen","B_HMPHL_INFL",2,"PEN","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","1 unit",12,NA,FALSE,FALSE,"[1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation." +"7251","EUCAST 2019","human","human","DISK","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",18,18,FALSE,FALSE,NA +"7252","EUCAST 2019","human","human","MIC","for prophylaxis only","B_HMPHL_INFL",2,"RIF","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,NA +"7253","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"SAM","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid." +"7254","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","1.25/23.75 mcg",23,20,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"7255","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"SXT","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"7256","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",25,22,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"7257","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"TCY","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"7258","EUCAST 2019","human","human","DISK",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)","30/6 mcg",27,27,FALSE,FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation." +"7259","EUCAST 2019","human","human","MIC",NA,"B_HMPHL_INFL",2,"TZP","H.influenzae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"7260","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"AMP","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.06,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility." +"7261","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"AMX","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility." +"7262","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"AZM","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility." +"7263","EUCAST 2019","human","human","DISK",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",28,28,FALSE,FALSE,NA +"7264","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"CIP","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.06,FALSE,FALSE,NA +"7265","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"CLR","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility." +"7266","EUCAST 2019","human","human","DISK",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",30,30,FALSE,FALSE,NA +"7267","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"CRO","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.06,FALSE,FALSE,NA +"7268","EUCAST 2019","human","human","DISK",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",27,27,FALSE,FALSE,NA +"7269","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"CTX","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA +"7270","EUCAST 2019","human","human","DISK",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",29,29,FALSE,FALSE,NA +"7271","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"CXM","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA +"7272","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"DOX","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"7273","EUCAST 2019","human","human","DISK",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 9.0)","15 mcg",20,20,FALSE,FALSE,NA +"7274","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"ERY","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA +"7275","EUCAST 2019","human","human","DISK",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",28,28,FALSE,FALSE,NA +"7276","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"LVX","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA +"7277","EUCAST 2019","human","human","DISK",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",30,30,FALSE,FALSE,NA +"7278","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"MEM","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.03,0.03,FALSE,FALSE,NA +"7279","EUCAST 2019","human","human","DISK",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 9.0)","1 unit",25,25,FALSE,FALSE,NA +"7280","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"PEN","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.03,0.03,FALSE,FALSE,NA +"7281","EUCAST 2019","human","human","DISK",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",20,20,FALSE,FALSE,NA +"7282","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"RIF","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA +"7283","EUCAST 2019","human","human","DISK",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 9.0)","1.25/23.75 mcg",28,28,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"7284","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"SXT","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"7285","EUCAST 2019","human","human","DISK",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",28,28,FALSE,FALSE,NA +"7286","EUCAST 2019","human","human","MIC",NA,"B_KGLLA_KING",2,"TCY","K.kingae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA +"7287","EUCAST 2019","human","human","DISK",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",19,19,FALSE,FALSE,NA +"7288","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",19,19,TRUE,FALSE,NA +"7289","EUCAST 2019","human","human","MIC",NA,"B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,NA +"7290","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,TRUE,FALSE,NA +"7291","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_KLBSL",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",15,15,TRUE,FALSE,"[D] Ignore isolated colonies within the inhibition zone for E. coli." +"7292","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_KLBSL",3,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination." +"7293","EUCAST 2019","human","human","DISK",NA,"B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 9.0)","2 mcg",16,16,FALSE,FALSE,NA +"7294","EUCAST 2019","human","human","MIC",NA,"B_LISTR_MNCY",2,"AMP","L.monocytogenes (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,NA +"7295","EUCAST 2019","human","human","DISK",NA,"B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 9.0)","15 mcg",25,25,FALSE,FALSE,NA +"7296","EUCAST 2019","human","human","MIC",NA,"B_LISTR_MNCY",2,"ERY","L.monocytogenes (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,NA +"7297","EUCAST 2019","human","human","DISK",NA,"B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",26,26,FALSE,FALSE,NA +"7298","EUCAST 2019","human","human","MIC",NA,"B_LISTR_MNCY",2,"MEM","L.monocytogenes (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,NA +"7299","EUCAST 2019","human","human","DISK",NA,"B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 9.0)","1 unit",13,13,FALSE,FALSE,NA +"7300","EUCAST 2019","human","human","MIC",NA,"B_LISTR_MNCY",2,"PEN","L.monocytogenes (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,NA +"7301","EUCAST 2019","human","human","DISK",NA,"B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 9.0)","1.25/23.75 mcg",29,29,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"7302","EUCAST 2019","human","human","MIC",NA,"B_LISTR_MNCY",2,"SXT","L.monocytogenes (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.06,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"7303","EUCAST 2019","human","human","DISK",NA,"B_MRGNL_MRGN",2,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",50,17,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem." +"7304","EUCAST 2019","human","human","MIC",NA,"B_MRGNL_MRGN",2,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,4,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem." +"7305","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","2/1 mcg",19,19,FALSE,FALSE,NA +"7306","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AMC","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"7307","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"AZM","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"7308","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",21,18,FALSE,FALSE,NA +"7309","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CFM","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,FALSE,FALSE,NA +"7310","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CHL","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",30,30,FALSE,FALSE,"[A] Breakpoints relate to topical use only." +"7311","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CHL","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[1] Breakpoints relate to topical use only." +"7312","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",31,31,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"7313","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CIP","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA +"7314","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CLR","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"7315","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",24,21,FALSE,FALSE,NA +"7316","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CRO","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,NA +"7317","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",20,17,FALSE,FALSE,NA +"7318","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CTX","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,NA +"7319","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",21,18,FALSE,FALSE,NA +"7320","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",50,21,FALSE,FALSE,NA +"7321","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,4,8,FALSE,FALSE,NA +"7322","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"CXM","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,4,FALSE,FALSE,NA +"7323","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"DOX","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"7324","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","15 mcg",23,20,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"7325","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ERY","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,NA +"7326","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",29,29,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7327","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"ETP","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7328","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",20,20,FALSE,FALSE,NA +"7329","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"FEP","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,NA +"7330","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",29,29,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7331","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"IPM","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7332","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",29,29,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"7333","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"LVX","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA +"7334","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",33,33,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7335","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MEM","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7336","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",26,26,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"7337","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,NA +"7338","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",25,22,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"7339","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"MNO","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"7340","EUCAST 2019","human","human","DISK","screen","B_MRXLL_CTRR",2,"NAL","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",23,NA,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent." +"7341","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",28,28,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"7342","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"OFX","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,NA +"7343","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"RXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"7344","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SAM","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid." +"7345","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","1.25/23.75 mcg",18,15,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"7346","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"SXT","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,FALSE,FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"7347","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",28,25,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"7348","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"TCY","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"7349","EUCAST 2019","human","human","DISK",NA,"B_MRXLL_CTRR",2,"TLT","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)","15 mcg",23,20,FALSE,FALSE,NA +"7350","EUCAST 2019","human","human","MIC",NA,"B_MRXLL_CTRR",2,"TLT","M.catarrhalis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,NA +"7351","EUCAST 2019","human","human","MIC",NA,"B_MYCBC_TBRC",2,"BDQ","M.tuberculosis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Breakpointss apply only to tests performed on Middlebrook 7H11/7H10 medium. Comparability of tests performed by other media has not been established." +"7352","EUCAST 2019","human","human","MIC",NA,"B_MYCBC_TBRC",2,"DLM","M.tuberculosis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.06,FALSE,FALSE,NA +"7353","EUCAST 2019","human","human","MIC",NA,"B_NESSR_GNRR",2,"CFM","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA +"7354","EUCAST 2019","human","human","MIC",NA,"B_NESSR_GNRR",2,"CIP","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.03,0.06,FALSE,FALSE,NA +"7355","EUCAST 2019","human","human","MIC",NA,"B_NESSR_GNRR",2,"CRO","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA +"7356","EUCAST 2019","human","human","MIC",NA,"B_NESSR_GNRR",2,"CTX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA +"7357","EUCAST 2019","human","human","MIC",NA,"B_NESSR_GNRR",2,"OFX","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.25,FALSE,FALSE,NA +"7358","EUCAST 2019","human","human","MIC",NA,"B_NESSR_GNRR",2,"PEN","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,1,FALSE,FALSE,"[1] Always test for beta-lactamase. If positive, report resistant to benzylpenicillin, ampicillin and amoxicillin. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. The susceptibility of beta-lactamase negative isolates to ampicillin and amoxicillin can be inferred from benzylpenicillin." +"7359","EUCAST 2019","human","human","MIC",NA,"B_NESSR_GNRR",2,"SPT","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)",NA,64,64,FALSE,FALSE,NA +"7360","EUCAST 2019","human","human","MIC",NA,"B_NESSR_GNRR",2,"TCY","N.gonorrhoeae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,FALSE,FALSE,NA +"7361","EUCAST 2019","human","human","MIC",NA,"B_NESSR_MNNG",2,"AMP","N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,1,FALSE,FALSE,NA +"7362","EUCAST 2019","human","human","MIC",NA,"B_NESSR_MNNG",2,"AMX","N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,1,FALSE,FALSE,NA +"7363","EUCAST 2019","human","human","MIC",NA,"B_NESSR_MNNG",2,"CHL","N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,NA +"7364","EUCAST 2019","human","human","MIC",NA,"B_NESSR_MNNG",2,"CIP","N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.03,0.03,FALSE,FALSE,"[1] Breakpoints apply only to use in the prophylaxis of meningococcal disease." +"7365","EUCAST 2019","human","human","MIC",NA,"B_NESSR_MNNG",2,"CRO","N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7366","EUCAST 2019","human","human","MIC",NA,"B_NESSR_MNNG",2,"CTX","N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7367","EUCAST 2019","human","human","MIC","meningitis","B_NESSR_MNNG",2,"MEM","N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7368","EUCAST 2019","human","human","MIC",NA,"B_NESSR_MNNG",2,"MNO","N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections." +"7369","EUCAST 2019","human","human","MIC",NA,"B_NESSR_MNNG",2,"PEN","N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.25,FALSE,FALSE,NA +"7370","EUCAST 2019","human","human","MIC",NA,"B_NESSR_MNNG",2,"RIF","N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,"[1] For prophylaxis of meningitis only (refer to national guidelines)." +"7371","EUCAST 2019","human","human","MIC",NA,"B_NESSR_MNNG",2,"TCY","N.meningitidis (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections." +"7372","EUCAST 2019","human","human","DISK",NA,"B_PROTS",3,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",50,17,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem." +"7373","EUCAST 2019","human","human","MIC",NA,"B_PROTS",3,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,4,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem." +"7374","EUCAST 2019","human","human","DISK",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",19,19,FALSE,FALSE,NA +"7375","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",19,19,TRUE,FALSE,NA +"7376","EUCAST 2019","human","human","MIC",NA,"B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,NA +"7377","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_PROTS_MRBL",2,"CXM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,TRUE,FALSE,NA +"7378","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_PROTS_MRBL",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",15,15,TRUE,FALSE,"[D] Ignore isolated colonies within the inhibition zone for E. coli." +"7379","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_PROTS_MRBL",2,"MEC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,TRUE,FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination." +"7380","EUCAST 2019","human","human","DISK",NA,"B_PRVDN",3,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",50,17,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem." +"7381","EUCAST 2019","human","human","MIC",NA,"B_PRVDN",3,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,4,FALSE,FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem." +"7382","EUCAST 2019","human","human","DISK",NA,"B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",18,15,FALSE,FALSE,NA +"7383","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"AMK","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,8,16,FALSE,FALSE,NA +"7384","EUCAST 2019","human","human","DISK",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",18,18,FALSE,FALSE,NA +"7385","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"ATM","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,16,16,FALSE,FALSE,NA +"7386","EUCAST 2019","human","human","DISK",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",17,17,FALSE,FALSE,NA +"7387","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"CAZ","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,NA +"7388","EUCAST 2019","human","human","DISK",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",26,26,FALSE,FALSE,NA +"7389","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"CIP","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA +"7390","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"COL","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)." +"7391","EUCAST 2019","human","human","DISK",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",21,21,FALSE,FALSE,NA +"7392","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"FEP","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,NA +"7393","EUCAST 2019","human","human","DISK",NA,"B_PSDMN",3,"GEN","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",15,15,FALSE,FALSE,NA +"7394","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"GEN","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,NA +"7395","EUCAST 2019","human","human","DISK",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",20,20,FALSE,FALSE,NA +"7396","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"IPM","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,NA +"7397","EUCAST 2019","human","human","DISK",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",22,22,FALSE,FALSE,NA +"7398","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"LVX","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,NA +"7399","EUCAST 2019","human","human","DISK",NA,"B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",24,18,FALSE,FALSE,NA +"7400","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"MEM","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,2,8,FALSE,FALSE,NA +"7401","EUCAST 2019","human","human","DISK",NA,"B_PSDMN",3,"NET","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",12,12,FALSE,FALSE,NA +"7402","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"NET","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,NA +"7403","EUCAST 2019","human","human","DISK",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",18,18,FALSE,FALSE,NA +"7404","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"PIP","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,16,16,FALSE,FALSE,NA +"7405","EUCAST 2019","human","human","DISK",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","75/10 mcg",18,18,FALSE,FALSE,NA +"7406","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"TCC","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,16,16,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"7407","EUCAST 2019","human","human","DISK",NA,"B_PSDMN",3,"TIC","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","75 mcg",18,18,FALSE,FALSE,NA +"7408","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"TIC","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,16,16,FALSE,FALSE,NA +"7409","EUCAST 2019","human","human","DISK",NA,"B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",16,16,FALSE,FALSE,NA +"7410","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"TOB","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,NA +"7411","EUCAST 2019","human","human","DISK",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","30/6 mcg",18,18,FALSE,FALSE,NA +"7412","EUCAST 2019","human","human","MIC",NA,"B_PSDMN",3,"TZP","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,16,16,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"7413","EUCAST 2019","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","10/4 mcg",17,17,FALSE,FALSE,NA +"7414","EUCAST 2019","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZA","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L." +"7415","EUCAST 2019","human","human","DISK",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)","30/10 mcg",24,24,FALSE,FALSE,NA +"7416","EUCAST 2019","human","human","MIC",NA,"B_PSDMN_AERG",2,"CZT","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,"[2] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"7417","EUCAST 2019","human","human","MIC",NA,"B_PSDMN_AERG",2,"MEV","Pseudomonas (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L." +"7418","EUCAST 2019","human","human","DISK",NA,"B_PSTRL_MLTC",2,"AMC","P.multocida (file: Clinical Breakpoint Tables v. 9.0)","2/1 mcg",15,15,FALSE,FALSE,NA +"7419","EUCAST 2019","human","human","MIC",NA,"B_PSTRL_MLTC",2,"AMC","P.multocida (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"7420","EUCAST 2019","human","human","MIC",NA,"B_PSTRL_MLTC",2,"AMP","P.multocida (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,NA +"7421","EUCAST 2019","human","human","MIC",NA,"B_PSTRL_MLTC",2,"AMX","P.multocida (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,NA +"7422","EUCAST 2019","human","human","DISK",NA,"B_PSTRL_MLTC",2,"CIP","P.multocida (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B." +"7423","EUCAST 2019","human","human","MIC",NA,"B_PSTRL_MLTC",2,"CIP","P.multocida (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.06,FALSE,FALSE,NA +"7424","EUCAST 2019","human","human","DISK",NA,"B_PSTRL_MLTC",2,"CTX","P.multocida (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",26,26,FALSE,FALSE,NA +"7425","EUCAST 2019","human","human","MIC",NA,"B_PSTRL_MLTC",2,"CTX","P.multocida (file: Clinical Breakpoint Tables v. 9.0)",NA,0.03,0.03,FALSE,FALSE,NA +"7426","EUCAST 2019","human","human","MIC",NA,"B_PSTRL_MLTC",2,"DOX","P.multocida (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,NA +"7427","EUCAST 2019","human","human","DISK",NA,"B_PSTRL_MLTC",2,"LVX","P.multocida (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",27,27,FALSE,FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B." +"7428","EUCAST 2019","human","human","MIC",NA,"B_PSTRL_MLTC",2,"LVX","P.multocida (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.06,FALSE,FALSE,NA +"7429","EUCAST 2019","human","human","DISK","screen","B_PSTRL_MLTC",2,"NAL","P.multocida (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",23,NA,FALSE,FALSE,"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent." +"7430","EUCAST 2019","human","human","DISK",NA,"B_PSTRL_MLTC",2,"PEN","P.multocida (file: Clinical Breakpoint Tables v. 9.0)","1 unit",17,17,FALSE,FALSE,NA +"7431","EUCAST 2019","human","human","MIC",NA,"B_PSTRL_MLTC",2,"PEN","P.multocida (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA +"7432","EUCAST 2019","human","human","DISK",NA,"B_PSTRL_MLTC",2,"SXT","P.multocida (file: Clinical Breakpoint Tables v. 9.0)","1.25/23.75 mcg",23,23,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"7433","EUCAST 2019","human","human","MIC",NA,"B_PSTRL_MLTC",2,"SXT","P.multocida (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"7434","EUCAST 2019","human","human","DISK","screen","B_PSTRL_MLTC",2,"TCY","P.multocida (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",24,24,FALSE,FALSE,"[A] Susceptibility inferred from tetracycline screen test." +"7435","EUCAST 2019","human","human","MIC",NA,"B_SLMNL",3,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.06,FALSE,FALSE,"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species." +"7436","EUCAST 2019","human","human","DISK","screen","B_SLMNL",3,"PEF","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",24,24,FALSE,FALSE,"[B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species." +"7437","EUCAST 2019","human","human","DISK",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 9.0)","1.25/23.75 mcg",16,16,FALSE,FALSE,"[A] Isolates showing any sign of inhibition zone ≥ 16 mm should be reported susceptible and growth within the inhibition zone should be ignored. The density of growth within the zone may vary from a fine haze to substantial growth (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"7438","EUCAST 2019","human","human","MIC",NA,"B_STNTR_MLTP",2,"SXT","S.maltophilia (file: Clinical Breakpoint Tables v. 9.0)",NA,4,4,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"7439","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"AZM","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"7440","EUCAST 2019","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"CHL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",19,19,FALSE,FALSE,NA +"7441","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CHL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,NA +"7442","EUCAST 2019","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","2 mcg",17,17,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known." +"7443","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known." +"7444","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"CLR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"7445","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAL","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7446","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DAP","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7447","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"DOX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"7448","EUCAST 2019","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","15 mcg",21,18,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"7449","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ERY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"7450","EUCAST 2019","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",19,16,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7451","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LNZ","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,2,4,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7452","EUCAST 2019","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",17,17,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"7453","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"LVX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,NA +"7454","EUCAST 2019","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",19,19,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"7455","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MFX","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA +"7456","EUCAST 2019","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",23,20,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"7457","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"MNO","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"7458","EUCAST 2019","human","human","DISK","screen","B_STRPT_ABCG",2.5,"NOR","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",12,NA,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to levofloxacin and moxifloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents." +"7459","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"ORI","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7460","EUCAST 2019","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","1 unit",18,18,FALSE,FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7461","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"PEN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7462","EUCAST 2019","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",21,15,FALSE,FALSE,NA +"7463","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RIF","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.5,FALSE,FALSE,NA +"7464","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"RXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"7465","EUCAST 2019","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","1.25/23.75 mcg",18,15,FALSE,FALSE,"[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"7466","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"SXT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,"[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"7467","EUCAST 2019","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",23,20,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"7468","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TCY","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"7469","EUCAST 2019","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7470","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TEC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7471","EUCAST 2019","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","15 mcg",19,19,FALSE,FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7472","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TGC","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7473","EUCAST 2019","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"TLT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","15 mcg",20,17,FALSE,FALSE,NA +"7474","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TLT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,NA +"7475","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"TZD","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7476","EUCAST 2019","human","human","DISK",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",13,13,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7477","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ABCG",2.5,"VAN","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7478","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"DAL","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7479","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"ORI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7480","EUCAST 2019","human","human","MIC",NA,"B_STRPT_ANGN_ANGN",1,"TZD","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,NA +"7481","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)","100 mcg",15,15,TRUE,FALSE,NA +"7482","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_STRPT_GRPB",2.5,"NIT","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,64,64,TRUE,FALSE,NA +"7483","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_STRPT_GRPB",2.5,"TMP","Streptococcus A,B,C,G (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,TRUE,FALSE,NA +"7484","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMC","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,FALSE,FALSE,"[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"7485","EUCAST 2019","human","human","DISK",NA,"B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","2 mcg",22,16,FALSE,FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation." +"7486","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMP","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,2,FALSE,FALSE,"[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation." +"7487","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"AMX","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,FALSE,FALSE,"[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation." +"7488","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"AZM","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"7489","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"BPR","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA +"7490","EUCAST 2019","human","human","DISK",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",50,28,FALSE,FALSE,NA +"7491","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"CEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.03,0.5,FALSE,FALSE,NA +"7492","EUCAST 2019","human","human","DISK",NA,"B_STRPT_PNMN",2,"CHL","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",21,21,FALSE,FALSE,NA +"7493","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"CHL","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,NA +"7494","EUCAST 2019","human","human","DISK",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","2 mcg",19,19,FALSE,FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"7495","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLI","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"7496","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"CLR","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"7497","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPD","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,NA +"7498","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"CPT","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,NA +"7499","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"CRO","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,2,FALSE,FALSE,NA +"7500","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"CTX","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,2,FALSE,FALSE,NA +"7501","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,FALSE,FALSE,NA +"7502","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"CXM","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,NA +"7503","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"DOX","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"7504","EUCAST 2019","human","human","DISK",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","15 mcg",22,19,FALSE,FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"7505","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"ERY","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"7506","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"ETP","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,"[2] Not for meningitis (meropenem is the only carbapenem used for meningitis)." +"7507","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"FEP","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,NA +"7508","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"IPM","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[2] Not for meningitis (meropenem is the only carbapenem used for meningitis)." +"7509","EUCAST 2019","human","human","DISK",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",22,19,FALSE,FALSE,NA +"7510","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"LNZ","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,2,4,FALSE,FALSE,NA +"7511","EUCAST 2019","human","human","DISK",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",16,16,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"7512","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"LVX","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,NA +"7513","EUCAST 2019","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[2] Not for meningitis (meropenem is the only carbapenem used for meningitis)." +"7514","EUCAST 2019","human","human","MIC","meningitis","B_STRPT_PNMN",2,"MEM","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,"[3] Meropenem is the only carbapenem used for meningitis." +"7515","EUCAST 2019","human","human","DISK",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",22,22,FALSE,FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note" +"7516","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"MFX","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA +"7517","EUCAST 2019","human","human","DISK",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",24,21,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"7518","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"MNO","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"7519","EUCAST 2019","human","human","DISK","screen","B_STRPT_PNMN",2,"NOR","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",10,NA,FALSE,FALSE,"[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to levofloxacin and moxifloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents." +"7520","EUCAST 2019","human","human","DISK","screen","B_STRPT_PNMN",2,"OXA","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","1 mcg",20,NA,FALSE,FALSE,"[D] For interpretation of the oxacillin disk screen, see flow chart below." +"7521","EUCAST 2019","human","human","MIC","indications other than meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,2,FALSE,FALSE,"[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [3] For breakpoints and dosing in pneumonia, see table of dosages." +"7522","EUCAST 2019","human","human","MIC","meningitis","B_STRPT_PNMN",2,"PEN","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.06,FALSE,FALSE,"[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation." +"7523","EUCAST 2019","human","human","DISK",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",22,17,FALSE,FALSE,NA +"7524","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"RIF","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.06,0.5,FALSE,FALSE,NA +"7525","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"RXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,FALSE,FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin." +"7526","EUCAST 2019","human","human","DISK",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","1.25/23.75 mcg",13,10,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"7527","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"SXT","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"7528","EUCAST 2019","human","human","DISK",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",25,22,FALSE,FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"7529","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"TCY","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required." +"7530","EUCAST 2019","human","human","DISK",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",17,17,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7531","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"TEC","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7532","EUCAST 2019","human","human","DISK",NA,"B_STRPT_PNMN",2,"TLT","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","15 mcg",23,20,FALSE,FALSE,NA +"7533","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"TLT","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,NA +"7534","EUCAST 2019","human","human","DISK",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",16,16,FALSE,FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7535","EUCAST 2019","human","human","MIC",NA,"B_STRPT_PNMN",2,"VAN","S.pneumoniae (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7536","EUCAST 2019","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)","2 mcg",21,15,FALSE,FALSE,NA +"7537","EUCAST 2019","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"AMP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,2,FALSE,FALSE,NA +"7538","EUCAST 2019","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"AMX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,2,FALSE,FALSE,NA +"7539","EUCAST 2019","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)","2 mcg",19,19,FALSE,FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"7540","EUCAST 2019","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CLI","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant." +"7541","EUCAST 2019","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",27,27,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins." +"7542","EUCAST 2019","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CRO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA +"7543","EUCAST 2019","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",23,23,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins." +"7544","EUCAST 2019","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CTX","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA +"7545","EUCAST 2019","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",26,26,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins." +"7546","EUCAST 2019","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CXM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA +"7547","EUCAST 2019","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"CZO","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA +"7548","EUCAST 2019","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ERV","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,0.125,0.125,FALSE,FALSE,NA +"7549","EUCAST 2019","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"ETP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA +"7550","EUCAST 2019","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",25,25,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins." +"7551","EUCAST 2019","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"FEP","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA +"7552","EUCAST 2019","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"IPM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,NA +"7553","EUCAST 2019","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"MEM","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,NA +"7554","EUCAST 2019","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)","1 unit",18,12,FALSE,FALSE,NA +"7555","EUCAST 2019","human","human","DISK","screen","B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)","1 unit",18,NA,FALSE,FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents." +"7556","EUCAST 2019","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"PEN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,2,FALSE,FALSE,NA +"7557","EUCAST 2019","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",16,16,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7558","EUCAST 2019","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"TEC","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7559","EUCAST 2019","human","human","DISK",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",15,15,FALSE,FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7560","EUCAST 2019","human","human","MIC",NA,"B_STRPT_VIRI",2.5,"VAN","Viridans group streptococci (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory." +"7561","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","20/10 mcg",19,19,FALSE,FALSE,"[A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars." +"7562","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","20/10 mcg",16,16,TRUE,FALSE,"[A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars." +"7563","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,"[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"7564","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"AMC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,32,32,TRUE,FALSE,"[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"7565","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",18,15,FALSE,FALSE,NA +"7566","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMK","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,16,FALSE,FALSE,NA +"7567","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",14,14,FALSE,FALSE,"[A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars." +"7568","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMP","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,"[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm." +"7569","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"AMX","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,"[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm." +"7570","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",26,21,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes." +"7571","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ATM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,1,4,FALSE,FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes." +"7572","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",23,23,FALSE,FALSE,NA +"7573","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"BPR","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,NA +"7574","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",22,19,FALSE,FALSE,NA +"7575","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CAZ","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,1,4,FALSE,FALSE,NA +"7576","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",17,17,TRUE,FALSE,NA +"7577","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,TRUE,FALSE,NA +"7578","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",12,12,TRUE,FALSE,NA +"7579","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CFR","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,16,16,TRUE,FALSE,NA +"7580","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CHL","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",17,17,FALSE,FALSE,NA +"7581","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CHL","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,NA +"7582","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",25,22,FALSE,FALSE,NA +"7583","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CIP","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,NA +"7584","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"COL","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,2,2,FALSE,FALSE,"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive)." +"7585","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",21,21,TRUE,FALSE,NA +"7586","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"CPD","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,TRUE,FALSE,NA +"7587","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",23,23,FALSE,FALSE,NA +"7588","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CPT","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA +"7589","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",25,22,FALSE,FALSE,NA +"7590","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CRO","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,NA +"7591","EUCAST 2019","human","human","DISK","UTI only","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",23,23,TRUE,FALSE,NA +"7592","EUCAST 2019","human","human","MIC","UTI only","B_[ORD]_ENTRBCTR",5,"CTB","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,TRUE,FALSE,NA +"7593","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",20,17,FALSE,FALSE,NA +"7594","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CTX","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,1,2,FALSE,FALSE,NA +"7595","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10/4 mcg",13,13,FALSE,FALSE,NA +"7596","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZA","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L." +"7597","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30/10 mcg",23,23,FALSE,FALSE,NA +"7598","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"CZT","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,1,1,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." +"7599","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",25,25,FALSE,FALSE,NA +"7600","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"ETP","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,0.5,FALSE,FALSE,NA +"7601","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",27,24,FALSE,FALSE,NA +"7602","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FEP","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,1,4,FALSE,FALSE,NA +"7603","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","200 mcg",24,24,FALSE,FALSE,"[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below)." +"7604","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","200 mcg",24,24,TRUE,FALSE,"[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below)." +"7605","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,32,32,FALSE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems." +"7606","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"FOS","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,32,32,TRUE,FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems." +"7607","EUCAST 2019","human","human","DISK","screen","B_[ORD]_ENTRBCTR",5,"FOX","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",19,19,FALSE,FALSE,"[2] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type." +"7608","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",17,14,FALSE,FALSE,NA +"7609","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"GEN","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,2,4,FALSE,FALSE,NA +"7610","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",22,17,FALSE,FALSE,NA +"7611","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"IPM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,2,4,FALSE,FALSE,NA +"7612","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",14,14,TRUE,FALSE,NA +"7613","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"LEX","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,16,16,TRUE,FALSE,NA +"7614","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",23,19,FALSE,FALSE,NA +"7615","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"LVX","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,FALSE,FALSE,NA +"7616","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",22,16,FALSE,FALSE,NA +"7617","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MEM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,2,8,FALSE,FALSE,NA +"7618","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MEV","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L." +"7619","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",22,22,FALSE,FALSE,NA +"7620","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"MFX","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.25,FALSE,FALSE,NA +"7621","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"NET","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",15,12,FALSE,FALSE,NA +"7622","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"NET","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,2,4,FALSE,FALSE,NA +"7623","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",22,19,TRUE,FALSE,NA +"7624","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"NOR","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,0.5,1,TRUE,FALSE,NA +"7625","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",24,22,FALSE,FALSE,NA +"7626","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"OFX","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,0.25,0.5,FALSE,FALSE,NA +"7627","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30 mcg",20,17,FALSE,FALSE,NA +"7628","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"PIP","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,16,FALSE,FALSE,NA +"7629","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10/10 mcg",14,14,FALSE,FALSE,"[A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars." +"7630","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SAM","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,8,FALSE,FALSE,"[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L." +"7631","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","1.25/23.75 mcg",14,11,FALSE,FALSE,"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"7632","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"SXT","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,2,4,FALSE,FALSE,"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration." +"7633","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","75/10 mcg",23,20,FALSE,FALSE,NA +"7634","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TCC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,16,FALSE,FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L." +"7635","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TIC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","75 mcg",23,20,FALSE,FALSE,NA +"7636","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TIC","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,16,FALSE,FALSE,NA +"7637","EUCAST 2019","human","human","DISK","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","5 mcg",18,15,TRUE,FALSE,NA +"7638","EUCAST 2019","human","human","MIC","uncomplicated UTI only","B_[ORD]_ENTRBCTR",5,"TMP","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,2,4,TRUE,FALSE,NA +"7639","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","10 mcg",17,14,FALSE,FALSE,NA +"7640","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TOB","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,2,4,FALSE,FALSE,NA +"7641","EUCAST 2019","human","human","DISK",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)","30/6 mcg",20,17,FALSE,FALSE,NA +"7642","EUCAST 2019","human","human","MIC",NA,"B_[ORD]_ENTRBCTR",5,"TZP","Enterobacterales (file: Clinical Breakpoint Tables v. 9.0)",NA,8,16,FALSE,FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L." diff --git a/data-raw/breakpoints_eucast_raw.csv b/data-raw/breakpoints_eucast_raw.csv index e87a88ac5..f31ffb4aa 100644 --- a/data-raw/breakpoints_eucast_raw.csv +++ b/data-raw/breakpoints_eucast_raw.csv @@ -1,12592 +1,12592 @@ -"guideline","version","file_desc","type","host","method","site","mo","rank_index","ab","disk_dose","breakpoint_S","breakpoint_R","note","sheet" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin",NA,"8","8","[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +"guideline","version","file_desc","type","host","method","site","mo","rank_index","ab","disk_dose","breakpoint_S","breakpoint_R","is_screening","note","sheet" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin",NA,"8","8",FALSE,"[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin","10 mcg","14","14","[A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin","10 mcg","14","14",FALSE,"[A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam",NA,"8","8","[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam",NA,"8","8",FALSE,"[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","10/10 mcg","14","14","[A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","10/10 mcg","14","14",FALSE,"[A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin",NA,"8","8","[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin",NA,"8","8",FALSE,"[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin","/ mcg","Note","Note","[C] Susceptibility inferred from ampicillin.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid",NA,"8","8","[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin","/ mcg","Note","Note",FALSE,"[C] Susceptibility inferred from ampicillin.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid",NA,"8","8",FALSE,"[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","20/10 mcg","19","19","[A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","20/10 mcg","19","19",FALSE,"[A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)",NA,"32","32","[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)",NA,"32","32",FALSE,"[1] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","20/10 mcg","16","16","[A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","20/10 mcg","16","16",FALSE,"[A] Wild type Enterobacterales are categorised as susceptible to aminopenicillins. Some countries prefer to categorise wild-type isolates of E. coli and P. mirabilis as ""Susceptible, increased exposure"". When this is the case, use the MIC breakpoint S ≤ 0.5 mg/L and the corresponding zone diameter breakpoint S ≥ 50 mm. | [B] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","16",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","17",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","16","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","17",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin",NA,"8","16",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin","75 mcg","23","20",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin",NA,"Note","Note","[5] Breakpoints still under consideration.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin",NA,"Note","Note","[5] Breakpoints still under consideration.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Mecillinam (uncomplicated UTI only)",NA,"8","8","[6] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Mecillinam (uncomplicated UTI only)","10 mcg","15","15","[D] Ignore isolated colonies within the inhibition zone for E. coli.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime",NA,"1","2",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime","5 mcg","20","17",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen)","30 mcg","19","19","[2] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)","10 mcg","21","21",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8","[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (UTI only)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (UTI only)","30 mcg","23","23",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"1","1","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","23","23",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone",NA,"1","2",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone","30 mcg","25","22",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"8","8",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","19","19",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","25","25",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem",NA,"2","4",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem","10 mcg","22","17",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Morganella morganii,Proteus spp. and Providencia spp.",NA,"Imipenem",NA,"0.125","4","[2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Morganella morganii,Proteus spp. and Providencia spp.",NA,"Imipenem","10 mcg","50","17","[2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem",NA,"2","8",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem","10 mcg","22","16",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8","[3] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","IP mcg","IP","IP",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin","5 mcg","25","22",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06","[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note","[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Salmonella spp.",NA,"Pefloxacin (screen)","5 mcg","24","24","[B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","5 mcg","22","22",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","1",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","22","19",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin",NA,"8","16",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin","30 mcg","18","15",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin",NA,"2","4",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin","10 mcg","17","14",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"2","4",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin","10 mcg","15","12",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin",NA,"2","4",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin","10 mcg","17","14",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. coli",NA,"Eravacycline","IP mcg","IP","IP",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18","[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [B] Zone diameter breakpoints validated for E. coli only. For C.koseri, use an MIC method.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"8","8",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"2","2","[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv",NA,"32","32","[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","200 mcg","24","24","[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral (uncomplicated UTI only)",NA,"32","32","[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral (uncomplicated UTI only)","200 mcg","24","24","[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)",NA,"2","4",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","18","15",NA,"Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"16","16",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","18","18",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"16","16","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","18","18",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin",NA,"16","16",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin","75 mcg","18","18",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"16","16","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","18","18",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"8","8",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","21","21",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"8","8",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","17","17",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8","[1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4","[2] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","24","24",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"4","4",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","20","20",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem",NA,"2","8",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem","10 mcg","24","18",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8","[1] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","IP mcg","IP","IP",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"16","16",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","18","18",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.5","0.5",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","26","26",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"1","1",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","22","22",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin",NA,"8","16",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin","30 mcg","18","15",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin",NA,"4","4",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin","10 mcg","15","15",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"4","4",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin","10 mcg","12","12",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin",NA,"4","4",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin","10 mcg","16","16",NA,"Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"2","2","[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"4","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","16","16","[A] Isolates showing any sign of inhibition zone ≥ 16 mm should be reported susceptible and growth within the inhibition zone should be ignored. The density of growth within the zone may vary from a fine haze to substantial growth (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem",NA,"2","8",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem","10 mcg","21","15",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.06","1",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin",NA,"8","16",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin","30 mcg","19","17",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"4","4",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin","10 mcg","16","16",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"2","2","[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin",NA,"4","8",NA,"Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","2 mcg","10","8",NA,"Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"4","8","[4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"4","8","[3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem",NA,"4","8",NA,"Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","10 mcg","21","18",NA,"Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen)","10 mcg","12","12","[B] | [B] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility.","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","16",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","17",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","16",FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","17",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin",NA,"8","16",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin","75 mcg","23","20",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16",FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin",NA,"Note","Note",FALSE,"[5] Breakpoints still under consideration.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin",NA,"Note","Note",FALSE,"[5] Breakpoints still under consideration.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Mecillinam (uncomplicated UTI only)",NA,"8","8",FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Mecillinam (uncomplicated UTI only)","10 mcg","15","15",FALSE,"[D] Ignore isolated colonies within the inhibition zone for E. coli.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime",NA,"1","2",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime","5 mcg","20","17",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen)","30 mcg","19","19",FALSE,"[2] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)","10 mcg","21","21",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8",FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (UTI only)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (UTI only)","30 mcg","23","23",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"1","1",FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","23","23",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone",NA,"1","2",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone","30 mcg","25","22",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"8","8",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","19","19",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","25","25",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem",NA,"2","4",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem","10 mcg","22","17",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Morganella morganii,Proteus spp. and Providencia spp.",NA,"Imipenem",NA,"0.125","4",FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Morganella morganii,Proteus spp. and Providencia spp.",NA,"Imipenem","10 mcg","50","17",FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii,Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem",NA,"2","8",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem","10 mcg","22","16",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8",FALSE,"[3] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","IP mcg","IP","IP",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4",FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21",FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin",NA,"0.25","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin","5 mcg","25","22",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note",FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Salmonella spp.",NA,"Pefloxacin (screen)","5 mcg","24","24",FALSE,"[B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin",NA,"0.25","0.25",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","5 mcg","22","22",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","1",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","22","19",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin",NA,"8","16",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin","30 mcg","18","15",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin",NA,"2","4",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin","10 mcg","17","14",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"2","4",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin","10 mcg","15","12",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin",NA,"2","4",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin","10 mcg","17","14",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. coli",NA,"Eravacycline","IP mcg","IP","IP",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5",FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18",FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [B] Zone diameter breakpoints validated for E. coli only. For C.koseri, use an MIC method.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"8","8",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"2","2",FALSE,"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note",FALSE,"[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv",NA,"32","32",FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","200 mcg","24","24",FALSE,"[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral (uncomplicated UTI only)",NA,"32","32",FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral (uncomplicated UTI only)","200 mcg","24","24",FALSE,"[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)",NA,"2","4",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","18","15",FALSE,NA,"Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4",FALSE,"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11",FALSE,"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"16","16",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","18","18",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"16","16",FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","18","18",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin",NA,"16","16",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin","75 mcg","18","18",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"16","16",FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","18","18",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"8","8",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","21","21",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"8","8",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","17","17",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8",FALSE,"[1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4",FALSE,"[2] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","24","24",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"4","4",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","20","20",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem",NA,"2","8",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem","10 mcg","24","18",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8",FALSE,"[1] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","IP mcg","IP","IP",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"16","16",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","18","18",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.5","0.5",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","26","26",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"1","1",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","22","22",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin",NA,"8","16",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin","30 mcg","18","15",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin",NA,"4","4",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin","10 mcg","15","15",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"4","4",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin","10 mcg","12","12",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin",NA,"4","4",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin","10 mcg","16","16",FALSE,NA,"Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"2","2",FALSE,"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note",FALSE,"[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"4","4",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","16","16",FALSE,"[A] Isolates showing any sign of inhibition zone ≥ 16 mm should be reported susceptible and growth within the inhibition zone should be ignored. The density of growth within the zone may vary from a fine haze to substantial growth (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem",NA,"2","8",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem","10 mcg","21","15",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.06","1",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin",NA,"8","16",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin","30 mcg","19","17",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"4","4",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin","10 mcg","16","16",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"2","2",FALSE,"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note",FALSE,"[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin",NA,"4","8",FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","2 mcg","10","8",FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"4","8",FALSE,"[4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"4","8",FALSE,"[3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"4","8",FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note",FALSE,"[3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note",FALSE,"[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[3] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[3/A] Susceptibility to ampicillin, amoxicillin and piperacillin with and without beta-lactamase inhibitor can be inferred from ampicillin.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem",NA,"4","8",FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","10 mcg","21","18",FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen)","10 mcg","12","12",FALSE,"[B] | [B] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note",FALSE,"[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","30 mcg","Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","30 mcg","Note","Note",FALSE,"[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note",FALSE,"[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)",NA,"Note","Note","[3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)",NA,"Note","Note",FALSE,"[3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","300 mcg","Note","Note","[B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","300 mcg","Note","Note",FALSE,"[B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note",FALSE,"[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",NA,"Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",NA,"Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin",NA,"4","4",NA,"Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","5 mcg","12","12","[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","4",NA,"Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","20",NA,"Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline","IP mcg","IP","IP",NA,"Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline","15 mcg","18","18","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","19","19",NA,"Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see http://www.eucast.org/guidance_documents/.","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see http://www.eucast.org/guidance_documents/.","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[2] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note","[A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note","[2] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note","[A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin",NA,"0.25","0.25","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin","1 unit","18","18","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | [2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | [2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","17","17","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen)","10 mcg","12","Note","[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to levofloxacin and moxifloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","18","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin",NA,"0.25","0.5",NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","15 mcg","20","17",NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","1","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","20","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","20","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","4","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","16","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5","[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"Note","Note","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. For isolates resistant to linezolid, perform an MIC test. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","19","19",NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.06","0.5",NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","15",NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"2","2",NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","IP","IP",NA,"Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.06","2","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [3] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [3] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"0.06","0.06","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin",NA,"0.5","2","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin","2 mcg","22","16","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv",NA,"Note","Note","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen)","1 mcg","20","Note","[D] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.03","0.5",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime",NA,"0.5","2",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.5",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone",NA,"0.5","2",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.5",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5","[2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2","[2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2","[2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)",NA,"0.25","0.25","[3] Meropenem is the only carbapenem used for meningitis.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)",NA,"Note","Note","[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] For use in meningitis determine the meropenem MIC. | [3] Meropenem is the only carbapenem used for meningitis.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"2","2",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","16","16","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen)","10 mcg","10","Note","[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to levofloxacin and moxifloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","19","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin",NA,"0.25","0.5",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","15 mcg","23","20",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","1","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","21","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","22","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","4",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","19",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"8","8",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.06","0.5",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","17",NA,"S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","13","10","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin",NA,"0.25","2",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","1 unit","18","12",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen)","1 unit","18","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin",NA,"0.5","2",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","2 mcg","21","15",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"0.5","2",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin","30 mcg","IP","IP",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19","[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","IP mcg","IP","IP",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.25","0.25",NA,"Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid",NA,"Note","Note","[A] Perform an MIC test.","Viridans group streptococci" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen)","1 unit","12","Note","[1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin",NA,"1","1","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin","2 mcg","16","16","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1","[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","10/10 mcg","Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [C] Susceptibility can be inferred from amoxicillin-clavulanic acid.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv",NA,"2","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [D] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"2","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [D] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"2","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","15","15","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25","[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm).","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm).","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.125","1",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5","[2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2","[2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm). | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2","[2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)",NA,"0.25","0.25","[3] Meropenem is the only carbapenem used for meningitis.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)",NA,"Note","Note","[C] For use in meningitis determine the meropenem MIC value. | [3] Meropenem is the only carbapenem used for meningitis.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen)","30 mcg","23","Note","[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","21","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","22","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",NA,"H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","20","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","1",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","18",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.125","4",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen)","30 mcg","23","Note","[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.5",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","20","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin",NA,"0.25","0.5",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","15 mcg","23","20",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","22","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","28","25","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"2","2","[1] Breakpoints relate to topical use only.","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","30 mcg","30","30","[A] Breakpoints relate to topical use only.","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin",NA,"0.06","1","[1] Always test for beta-lactamase. If positive, report resistant to benzylpenicillin, ampicillin and amoxicillin. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. The susceptibility of beta-lactamase negative isolates to ampicillin and amoxicillin can be inferred from benzylpenicillin.","N.gonorrhoeae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note","[1] Always test for beta-lactamase. If positive, report resistant to benzylpenicillin, ampicillin and amoxicillin. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. The susceptibility of beta-lactamase negative isolates to ampicillin and amoxicillin can be inferred from benzylpenicillin.","N.gonorrhoeae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note","[1] Always test for beta-lactamase. If positive, report resistant to benzylpenicillin, ampicillin and amoxicillin. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. The susceptibility of beta-lactamase negative isolates to ampicillin and amoxicillin can be inferred from benzylpenicillin.","N.gonorrhoeae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Always test for beta-lactamase. If positive, report resistant to benzylpenicillin, ampicillin and amoxicillin. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. The susceptibility of beta-lactamase negative isolates to ampicillin and amoxicillin can be inferred from benzylpenicillin.","N.gonorrhoeae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",NA,"N.gonorrhoeae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"N.gonorrhoeae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"N.gonorrhoeae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",NA,"N.gonorrhoeae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",NA,"N.gonorrhoeae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note","[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","1",NA,"N.gonorrhoeae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",NA,"N.gonorrhoeae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin",NA,"0.06","0.25",NA,"N.meningitidis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin",NA,"0.125","1",NA,"N.meningitidis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin",NA,"0.125","1",NA,"N.meningitidis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime",NA,"0.125","0.125","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone",NA,"0.125","0.125","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem(meningitis)",NA,"0.25","0.25","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin",NA,"0.03","0.03","[1] Breakpoints apply only to use in the prophylaxis of meningococcal disease.","N.meningitidis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline",NA,"1","2","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline",NA,"1","2","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol",NA,"2","2",NA,"N.meningitidis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin",NA,"0.25","0.25","[1] For prophylaxis of meningitis only (refer to national guidelines).","N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","5 mcg","12","12",FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","4",FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","20",FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline",NA,"0.125","0.125",FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline","IP mcg","IP","IP",FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline",NA,"0.25","0.25",FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline","15 mcg","18","18",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","19","19",FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE",FALSE,"[1] For more information, see http://www.eucast.org/guidance_documents/.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE",FALSE,"[1] For more information, see http://www.eucast.org/guidance_documents/.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note",FALSE,"[2] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note",FALSE,"[A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note",FALSE,"[2] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note",FALSE,"[A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin",NA,"0.25","0.25",FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin","1 unit","18","18",FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | [2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility. | [2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","17","17",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen)","10 mcg","12","Note",FALSE,"[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to levofloxacin and moxifloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","18",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","1",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin",NA,"0.25","0.5",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","15 mcg","20","17",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17",FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","2",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","1",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","20",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","2",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","20",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125",FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19",FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","4",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","16",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5",FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"Note","Note",FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. For isolates resistant to linezolid, perform an MIC test. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","19","19",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1",FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note",FALSE,"[A] Use an MIC method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.06","0.5",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","15",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"2","2",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","IP","IP",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2",FALSE,"[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15",FALSE,"[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.06","2",FALSE,"[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [3] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [3] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"0.06","0.06",FALSE,"[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin",NA,"0.5","2",FALSE,"[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin","2 mcg","22","16",FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv",NA,"Note","Note",FALSE,"[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv",NA,"Note","Note",FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1",FALSE,"[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note",FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note",FALSE,"[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note",FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1",FALSE,"[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note",FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note",FALSE,"[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [4] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[1] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen)","1 mcg","20","Note",FALSE,"[D] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.03","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note",FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime",NA,"0.5","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note",FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone",NA,"0.5","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone",NA,"Note","Note",FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5",FALSE,"[2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note",FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2",FALSE,"[2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note",FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",FALSE,"[2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)",NA,"0.25","0.25",FALSE,"[3] Meropenem is the only carbapenem used for meningitis.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥20 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing. When the screen is positive (inhibition zone <20 mm), see flow chart below for interpretation. | [B] For use in meningitis determine the meropenem MIC. | [3] Meropenem is the only carbapenem used for meningitis.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"2","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","16","16",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen)","10 mcg","10","Note",FALSE,"[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to levofloxacin and moxifloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17",FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16",FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","19",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","1",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin",NA,"0.25","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","15 mcg","23","20",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19",FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","2",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","1",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","21",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","2",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","22",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","4",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","19",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"8","8",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.06","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","17",FALSE,NA,"S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","13","10",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin",NA,"0.25","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","1 unit","18","12",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen)","1 unit","18","Note",FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin",NA,"0.5","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","2 mcg","21","15",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"0.5","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note",FALSE,"[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin","30 mcg","IP","IP",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25",FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23",FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27",FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26",FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note",FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note",FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note",FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19",FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","IP mcg","IP","IP",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.25","0.25",FALSE,NA,"Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid",NA,"Note","Note",FALSE,"[A] Perform an MIC test.","Viridans group streptococci" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen)","1 unit","12","Note",FALSE,"[1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin",NA,"1","1",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin","2 mcg","16","16",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1",FALSE,"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","10/10 mcg","Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [C] Susceptibility can be inferred from amoxicillin-clavulanic acid.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv",NA,"2","2",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [D] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"2","2",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [D] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2",FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"2","2",FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","15","15",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25",FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm).","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","5 mcg","27","27",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm).","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","30 mcg","32","32",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.125","1",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5",FALSE,"[2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2",FALSE,"[2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [B] ATU relevant only if the benzylpenicillin 1 unit disk screen is positive (inhibition zone <12 mm). | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",FALSE,"[2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all beta-lactam agents for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below for interpretation. | [2] Not for meningitis (meropenem is the only carbapenem used for meningitis).","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)",NA,"0.25","0.25",FALSE,"[3] Meropenem is the only carbapenem used for meningitis.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)",NA,"Note","Note",FALSE,"[C] For use in meningitis determine the meropenem MIC value. | [3] Meropenem is the only carbapenem used for meningitis.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","5 mcg","30","30",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen)","30 mcg","23","Note",FALSE,"[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","2",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","2",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","21",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"1","2",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","22",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",FALSE,NA,"H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","20",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1",FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1",FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","1",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","18",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.125","4",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen)","30 mcg","23","Note",FALSE,"[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.5",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","20",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","1",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin",NA,"0.25","0.5",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","15 mcg","23","20",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","2",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","2",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","22",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"1","2",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","28","25",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"2","2",FALSE,"[1] Breakpoints relate to topical use only.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","30 mcg","30","30",FALSE,"[A] Breakpoints relate to topical use only.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin",NA,"0.06","1",FALSE,"[1] Always test for beta-lactamase. If positive, report resistant to benzylpenicillin, ampicillin and amoxicillin. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. The susceptibility of beta-lactamase negative isolates to ampicillin and amoxicillin can be inferred from benzylpenicillin.","N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note",FALSE,"[1] Always test for beta-lactamase. If positive, report resistant to benzylpenicillin, ampicillin and amoxicillin. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. The susceptibility of beta-lactamase negative isolates to ampicillin and amoxicillin can be inferred from benzylpenicillin.","N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[1] Always test for beta-lactamase. If positive, report resistant to benzylpenicillin, ampicillin and amoxicillin. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. The susceptibility of beta-lactamase negative isolates to ampicillin and amoxicillin can be inferred from benzylpenicillin.","N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] Always test for beta-lactamase. If positive, report resistant to benzylpenicillin, ampicillin and amoxicillin. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase. The susceptibility of beta-lactamase negative isolates to ampicillin and amoxicillin can be inferred from benzylpenicillin.","N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","1",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin",NA,"0.06","0.25",FALSE,NA,"N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin",NA,"0.125","1",FALSE,NA,"N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin",NA,"0.125","1",FALSE,NA,"N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime",NA,"0.125","0.125",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone",NA,"0.125","0.125",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem(meningitis)",NA,"0.25","0.25",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin",NA,"0.03","0.03",FALSE,"[1] Breakpoints apply only to use in the prophylaxis of meningococcal disease.","N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline",NA,"1","2",FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline",NA,"1","2",FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol",NA,"2","2",FALSE,NA,"N.meningitidis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin",NA,"0.25","0.25",FALSE,"[1] For prophylaxis of meningitis only (refer to national guidelines).","N.meningitidis" "EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Benzylpenicillin",NA,"0.25","0.5","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Benzylpenicillin",NA,"0.25","0.5",FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" "EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ampicillin",NA,"4","8","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Ampicillin",NA,"4","8",FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" "EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ampicillin-sulbactam",NA,"4","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Ampicillin-sulbactam",NA,"4","8",FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobes, Grampositive" "EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Amoxicillin",NA,"4","8","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Amoxicillin",NA,"4","8",FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" "EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Amoxicillin-clavulanic acid",NA,"4","8",FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Grampositive" "EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Piperacillin",NA,"8","16","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Piperacillin",NA,"8","16",FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" "EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Piperacillin-tazobactam",NA,"8","16","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Piperacillin-tazobactam",NA,"8","16",FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobes, Grampositive" "EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ticarcillin",NA,"8","16","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Ticarcillin",NA,"8","16",FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" "EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Ticarcillin-clavulanic acid",NA,"8","16",FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Grampositive" "EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Cefoxitin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ertapenem",NA,"0.5","0.5",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Imipenem",NA,"2","4",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Imipenem",NA,"2","4",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Meropenem",NA,"2","8",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Meropenem",NA,"2","8",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Moxifloxacin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Moxifloxacin",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Dalbavancin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Oritavancin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Teicoplanin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Teicoplanin",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Telavancin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Vancomycin",NA,"2","2",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Erythromycin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Erythromycin",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Clindamycin",NA,"4","4",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Clindamycin",NA,"4","4",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Doxycycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Doxycycline",NA,"Note","Note",FALSE,"[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" "EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Eravacycline",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Minocycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Minocycline",NA,"Note","Note",FALSE,"[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" "EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Tetracycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Tetracycline",NA,"Note","Note",FALSE,"[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" "EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Tigecycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Tigecycline",NA,"Note","Note",FALSE,"[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" "EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Chloramphenicol",NA,"8","8",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Chloramphenicol",NA,"8","8",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Metronidazole",NA,"4","4",NA,"Anaerobes, Grampositive" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with vancomycin. There are no conclusive clinical data regarding the relation between MICs and outcomes.","C.difficile" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IE","IE","[4] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distribution between studies.","C.difficile" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2","[5] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with metronidazole. There are no conclusive clinical data regarding the relation between MICs and outcomes.","C.difficile" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Benzylpenicillin",NA,"0.25","0.5","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin",NA,"0.5","2","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin-sulbactam",NA,"4","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobes, Gramnegative" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin",NA,"0.5","2","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Gramnegative" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin",NA,"16","16","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin-tazobactam",NA,"8","16","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobes, Gramnegative" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin",NA,"16","16","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Gramnegative" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Anaerobes, Gramnegative" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Cefoxitin",NA,"IE","IE",NA,"Anaerobes, Gramnegative" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Anaerobes, Gramnegative" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ertapenem",NA,"0.5","0.5",NA,"Anaerobes, Gramnegative" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem",NA,"2","4",NA,"Anaerobes, Gramnegative" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem",NA,"2","8",NA,"Anaerobes, Gramnegative" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Anaerobes, Gramnegative" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Moxifloxacin",NA,"IE","IE",NA,"Anaerobes, Gramnegative" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Erythromycin",NA,"IE","IE",NA,"Anaerobes, Gramnegative" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Clindamycin",NA,"4","4",NA,"Anaerobes, Gramnegative" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Doxycycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Eravacycline",NA,"IE","IE",NA,"Anaerobes, Gramnegative" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Minocycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tetracycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tigecycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Chloramphenicol",NA,"8","8",NA,"Anaerobes, Gramnegative" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Metronidazole",NA,"4","4",NA,"Anaerobes, Gramnegative" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin",NA,"0.125","0.125","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility.","H.pylori" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility.","H.pylori" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.5","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility.","H.pylori" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility.","H.pylori" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility.","H.pylori" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility.","H.pylori" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin",NA,"1","1",NA,"L.monocytogenes" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin","1 unit","13","13",NA,"L.monocytogenes" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin",NA,"1","1",NA,"L.monocytogenes" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin","2 mcg","16","16",NA,"L.monocytogenes" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem",NA,"0.25","0.25",NA,"L.monocytogenes" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem","10 mcg","26","26",NA,"L.monocytogenes" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin",NA,"1","1",NA,"L.monocytogenes" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin","15 mcg","25","25",NA,"L.monocytogenes" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole",NA,"0.06","0.06","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","29","29","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Benzylpenicillin",NA,"0.5","0.5",NA,"P.multocida" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Benzylpenicillin","1 unit","17","17",NA,"P.multocida" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"1","1",NA,"P.multocida" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"1","1",NA,"P.multocida" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",NA,"P.multocida" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Cefotaxime",NA,"0.03","0.03",NA,"P.multocida" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Cefotaxime","5 mcg","26","26",NA,"P.multocida" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"P.multocida" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ciprofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Levofloxacin",NA,"0.06","0.06",NA,"P.multocida" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Levofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Nalidixic acid (screen)","30 mcg","23","Note","[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","P.multocida" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"1","1",NA,"P.multocida" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility inferred from tetracycline screen test.","P.multocida" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Tetracycline (screen)","30 mcg","24","24","[A] Susceptibility inferred from tetracycline screen test.","P.multocida" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin",NA,"0.5","0.5",NA,"C.jejuni_C.coli" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","5 mcg","26","26",NA,"C.jejuni_C.coli" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","24","24","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note","[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","30 mcg","30","30","[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Corynebacterium" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","1 unit","29","29",NA,"Corynebacterium" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Ciprofloxacin",NA,"1","1",NA,"Corynebacterium" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","5 mcg","25","25",NA,"Corynebacterium" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Corynebacterium" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Moxifloxacin","5 mcg","25","25",NA,"Corynebacterium" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Gentamicin",NA,"1","1",NA,"Corynebacterium" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Gentamicin","10 mcg","23","23",NA,"Corynebacterium" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Vancomycin",NA,"2","2",NA,"Corynebacterium" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Vancomycin","5 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Erythromycin",NA,"IP","IP",NA,"Corynebacterium" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Erythromycin","15 mcg","IP","IP",NA,"Corynebacterium" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Clindamycin",NA,"0.5","0.5",NA,"Corynebacterium" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Clindamycin","2 mcg","20","20",NA,"Corynebacterium" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Tetracycline",NA,"2","2",NA,"Corynebacterium" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Tetracycline","30 mcg","24","24",NA,"Corynebacterium" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Linezolid",NA,"2","2",NA,"Corynebacterium" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Linezolid","10 mcg","25","25",NA,"Corynebacterium" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Rifampicin",NA,"0.06","0.5",NA,"Corynebacterium" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Rifampicin","5 mcg","30","25",NA,"Corynebacterium" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","1 unit","21","21",NA,"A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","2 mcg","26","26",NA,"A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note","[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","10 mcg","31","31",NA,"A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",NA,"A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21","[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2","[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","Note","Note","[B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Norfloxacin (screen)","10 mcg","17","17","[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin",NA,"1","1",NA,"A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",NA,"A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",NA,"A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","5 mcg","25","25",NA,"A.sanguinicola_A.urinae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",NA,"K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",NA,"K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[3] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",NA,"K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",NA,"K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",NA,"K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",NA,"K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",NA,"K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",NA,"K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",NA,"K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",NA,"K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",NA,"K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",NA,"K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",NA,"K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",NA,"K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",NA,"Aeromonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",NA,"Aeromonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",NA,"Aeromonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",NA,"Aeromonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",NA,"Aeromonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",NA,"Aeromonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Aeromonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",NA,"Aeromonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Aeromonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",NA,"Aeromonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","19","16","[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06",NA,"M.tuberculosis" -"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25","[1] Breakpointss apply only to tests performed on Middlebrook 7H11/7H10 medium. Comparability of tests performed by other media has not been established.","M.tuberculosis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin",NA,"8","8","[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin",NA,"8","8","[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid",NA,"8","8","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","20/10 mcg","19","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)",NA,"32","32","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","20/10 mcg","16","16","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","16",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","17",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","16","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","17",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin",NA,"8","16",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin","75 mcg","23","20",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin",NA,"Note","Note","[5] Breakpoints still under consideration.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin",NA,"Note","Note","[C] Breakpoints still under consideration.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (uncomplicated UTI only)",NA,"8","8","[6] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (uncomplicated UTI only)","10 mcg","15","15","[D] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli, and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)",NA,"0.001","4",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli, and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)","IP mcg","IP","IP",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime",NA,"1","2",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime","5 mcg","20","17",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","30 mcg","19","19","[2] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)","10 mcg","21","21",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8","[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","30 mcg","23","23",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"2","2","[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [4] See table of dosages for dosing for different indications.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","22","22","[4] See table of dosages for dosing for different indications.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone",NA,"1","2",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone","30 mcg","25","22",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"0.001","8",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","50","19",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","25","25",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem",NA,"2","4",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem","10 mcg","22","17",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Morganella morganii,Proteus spp. and Providencia spp.",NA,"Imipenem",NA,"0.001","4","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Morganella morganii,Proteus spp. and Providencia spp.",NA,"Imipenem","10 mcg","50","17","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales except Morganella spp.",NA,"Imipenem-relebactam",NA,"2","2","[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales except Morganella spp.",NA,"Imipenem-relebactam","IP mcg","IP","IP",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem",NA,"2","8",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem","10 mcg","22","16",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8","[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","IP mcg","IP","IP",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin","5 mcg","25","22",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06","[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note","[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Salmonella spp.",NA,"Pefloxacin (screen only)","5 mcg","24","24","[2/C] The pefloxacin 5 µg breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp. | [B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli",NA,"Delafloxacin",NA,"0.125","0.125",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli",NA,"Delafloxacin",NA,"Note","Note","[D] A disk diffusion test is not yet developed. Perform an MIC test.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","5 mcg","22","22",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","0.5",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","22","22",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","30 mcg","18","18","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","18","18",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)",NA,"2","2","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","10 mcg","17","17","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli",NA,"Eravacycline","20 mcg","17","17",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18","[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"8","8",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"2","2","[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv",NA,"32","32","[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","200 mcg","24","24","[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral (uncomplicated UTI only)",NA,"32","32","[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral (uncomplicated UTI only)","200 mcg","24","24","[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","15","15",NA,"Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"0.001","16",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"0.001","16","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin",NA,"0.001","16",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin","75 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"0.001","16","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"0.001","8",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","50","21",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"0.001","8",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","50","17",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8","[1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4","[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [2] See table of dosages for dosing for different indications.","Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","24","24","[2] See table of dosages for dosing for different indications.","Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"0.001","4",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","50","20",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"P. aeruginosa",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"P. aeruginosa",NA,"Imipenem-relebactam","IP mcg","IP","IP",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem",NA,"2","8",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem","10 mcg","24","18",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","IP mcg","IP","IP",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"0.001","16",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","50","26",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"0.001","1",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","50","22",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)",NA,"16","16","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","30 mcg","15","15","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"16","16",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","15","15",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","10 mcg","18","18","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","18","18",NA,"Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"2","2","[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","16","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","IP mcg","IP","IP",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem",NA,"2","8",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem","10 mcg","21","15",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","30 mcg","19","19","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","19","19",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)",NA,"4","4","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)",NA,"4","4","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","10 mcg","17","17","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"2","2","[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","2 mcg","10","8","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem",NA,"0.001","4",NA,"Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","10 mcg","50","21",NA,"Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","12","12","[B] | [B] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +except Clostridioides difficile",NA,"Metronidazole",NA,"4","4",FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2",FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with vancomycin. There are no conclusive clinical data regarding the relation between MICs and outcomes.","C.difficile" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IE","IE",FALSE,"[4] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distribution between studies.","C.difficile" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2",FALSE,"[5] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with metronidazole. There are no conclusive clinical data regarding the relation between MICs and outcomes.","C.difficile" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Benzylpenicillin",NA,"0.25","0.5",FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin",NA,"0.5","2",FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin-sulbactam",NA,"4","8",FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin",NA,"0.5","2",FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin-clavulanic acid",NA,"4","8",FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin",NA,"16","16",FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin-tazobactam",NA,"8","16",FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin",NA,"16","16",FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin-clavulanic acid",NA,"8","16",FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem",NA,"2","4",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem",NA,"2","8",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Moxifloxacin",NA,"IE","IE",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Erythromycin",NA,"IE","IE",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Clindamycin",NA,"4","4",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Doxycycline",NA,"Note","Note",FALSE,"[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Minocycline",NA,"Note","Note",FALSE,"[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tetracycline",NA,"Note","Note",FALSE,"[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tigecycline",NA,"Note","Note",FALSE,"[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Chloramphenicol",NA,"8","8",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Metronidazole",NA,"4","4",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin",NA,"0.125","0.125",FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility.","H.pylori" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1",FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility.","H.pylori" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.5",FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility.","H.pylori" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1",FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility.","H.pylori" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8",FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility.","H.pylori" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1",FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs), which distinguish wild-type isolates from those with reduced susceptibility.","H.pylori" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin",NA,"1","1",FALSE,NA,"L.monocytogenes" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin","1 unit","13","13",FALSE,NA,"L.monocytogenes" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin",NA,"1","1",FALSE,NA,"L.monocytogenes" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin","2 mcg","16","16",FALSE,NA,"L.monocytogenes" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem",NA,"0.25","0.25",FALSE,NA,"L.monocytogenes" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem","10 mcg","26","26",FALSE,NA,"L.monocytogenes" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin",NA,"1","1",FALSE,NA,"L.monocytogenes" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin","15 mcg","25","25",FALSE,NA,"L.monocytogenes" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole",NA,"0.06","0.06",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","29","29",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Benzylpenicillin",NA,"0.5","0.5",FALSE,NA,"P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Benzylpenicillin","1 unit","17","17",FALSE,NA,"P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"1","1",FALSE,NA,"P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"1","1",FALSE,NA,"P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid",NA,"1","1",FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",FALSE,NA,"P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Cefotaxime",NA,"0.03","0.03",FALSE,NA,"P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Cefotaxime","5 mcg","26","26",FALSE,NA,"P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,NA,"P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ciprofloxacin","5 mcg","27","27",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Levofloxacin",NA,"0.06","0.06",FALSE,NA,"P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Levofloxacin","5 mcg","27","27",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Nalidixic acid (screen)","30 mcg","23","Note",FALSE,"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"1","1",FALSE,NA,"P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Tetracycline (screen)","30 mcg","24","24",FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin",NA,"0.5","0.5",FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","5 mcg","26","26",FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","24","24",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note",FALSE,"[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Tetracycline",NA,"2","2",FALSE,"[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","30 mcg","30","30",FALSE,"[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Benzylpenicillin",NA,"0.125","0.125",FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","1 unit","29","29",FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Ciprofloxacin",NA,"1","1",FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","5 mcg","25","25",FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Moxifloxacin",NA,"0.5","0.5",FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Moxifloxacin","5 mcg","25","25",FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Gentamicin",NA,"1","1",FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Gentamicin","10 mcg","23","23",FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Vancomycin","5 mcg","17","17",FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Erythromycin",NA,"IP","IP",FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Erythromycin","15 mcg","IP","IP",FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Clindamycin",NA,"0.5","0.5",FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Clindamycin","2 mcg","20","20",FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Tetracycline",NA,"2","2",FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Tetracycline","30 mcg","24","24",FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Linezolid",NA,"2","2",FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Linezolid","10 mcg","25","25",FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Rifampicin",NA,"0.06","0.5",FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Rifampicin","5 mcg","30","25",FALSE,NA,"Corynebacterium" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","1 unit","21","21",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin",NA,"0.25","0.25",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","2 mcg","26","26",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem",NA,"0.25","0.25",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","10 mcg","31","31",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21",FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2",FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","Note","Note",FALSE,"[B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Norfloxacin (screen)","10 mcg","17","17",FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin",NA,"1","1",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","5 mcg","16","16",FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin",NA,"0.125","0.125",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","5 mcg","25","25",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06",FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125",FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[3] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25",FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5",FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",FALSE,NA,"K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",FALSE,NA,"Aeromonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",FALSE,NA,"Aeromonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",FALSE,NA,"Aeromonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",FALSE,NA,"Aeromonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",FALSE,NA,"Aeromonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",FALSE,NA,"Aeromonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",FALSE,NA,"Aeromonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",FALSE,NA,"Aeromonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",FALSE,NA,"Aeromonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",FALSE,NA,"Aeromonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","19","16",FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06",FALSE,NA,"M.tuberculosis" +"EUCAST 2019","9.0","Clinical Breakpoint Tables v. 9.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25",FALSE,"[1] Breakpointss apply only to tests performed on Middlebrook 7H11/7H10 medium. Comparability of tests performed by other media has not been established.","M.tuberculosis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin",NA,"8","8",FALSE,"[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin","10 mcg","14","14",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam",NA,"8","8",FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","10/10 mcg","14","14",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin",NA,"8","8",FALSE,"[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin","/ mcg","Note","Note",FALSE,"[B] Susceptibility inferred from ampicillin. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid",NA,"8","8",FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","20/10 mcg","19","19",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. Breakpoints for oral administration are relevant for uncomplicated urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)",NA,"32","32",FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","20/10 mcg","16","16",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","16",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","17",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","16",FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","17",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin",NA,"8","16",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin","75 mcg","23","20",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16",FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Temocillin",NA,"Note","Note",FALSE,"[5] Breakpoints still under consideration.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Temocillin",NA,"Note","Note",FALSE,"[C] Breakpoints still under consideration.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (uncomplicated UTI only)",NA,"8","8",FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (uncomplicated UTI only)","10 mcg","15","15",FALSE,"[D] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli, and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)",NA,"0.001","4",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli, and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)","IP mcg","IP","IP",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime",NA,"1","2",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime","5 mcg","20","17",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","30 mcg","19","19",FALSE,"[2] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)","10 mcg","21","21",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8",FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","30 mcg","23","23",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"2","2",FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [4] See table of dosages for dosing for different indications.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","22","22",FALSE,"[4] See table of dosages for dosing for different indications.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone",NA,"1","2",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone","30 mcg","25","22",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"0.001","8",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","50","19",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","25","25",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Imipenem",NA,"2","4",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Imipenem","10 mcg","22","17",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Morganella morganii,Proteus spp. and Providencia spp.",NA,"Imipenem",NA,"0.001","4",FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Morganella morganii,Proteus spp. and Providencia spp.",NA,"Imipenem","10 mcg","50","17",FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales except Morganella spp.",NA,"Imipenem-relebactam",NA,"2","2",FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales except Morganella spp.",NA,"Imipenem-relebactam","IP mcg","IP","IP",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem",NA,"2","8",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem","10 mcg","22","16",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8",FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","IP mcg","IP","IP",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4",FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21",FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin",NA,"0.25","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin","5 mcg","25","22",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note",FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Salmonella spp.",NA,"Pefloxacin (screen only)","5 mcg","24","24",FALSE,"[2/C] The pefloxacin 5 µg breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp. | [B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli",NA,"Delafloxacin",NA,"0.125","0.125",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli",NA,"Delafloxacin",NA,"Note","Note",FALSE,"[D] A disk diffusion test is not yet developed. Perform an MIC test.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin",NA,"0.25","0.25",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","5 mcg","22","22",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","22","22",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)",NA,"(8)","(8)",TRUE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","30 mcg","(18)","(18)",TRUE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","18","18",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)",NA,"(2)","(2)",TRUE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","10 mcg","(17)","(17)",TRUE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)",NA,"2","2",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)",NA,"(2)","(2)",TRUE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","10 mcg","(17)","(17)",TRUE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli",NA,"Eravacycline","20 mcg","17","17",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5",FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18",FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"8","8",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"2","2",FALSE,"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note",FALSE,"[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv",NA,"32","32",FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","200 mcg","24","24",FALSE,"[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin oral (uncomplicated UTI only)",NA,"32","32",FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin oral (uncomplicated UTI only)","200 mcg","24","24",FALSE,"[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","15","15",FALSE,NA,"Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4",FALSE,"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11",FALSE,"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"0.001","16",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"0.001","16",FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin",NA,"0.001","16",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin","75 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"0.001","16",FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"0.001","8",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","50","21",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"0.001","8",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","50","17",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8",FALSE,"[1] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4",FALSE,"[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [2] See table of dosages for dosing for different indications.","Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","24","24",FALSE,"[2] See table of dosages for dosing for different indications.","Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"0.001","4",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","50","20",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"P. aeruginosa",NA,"Imipenem-relebactam",NA,"2","2",FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"P. aeruginosa",NA,"Imipenem-relebactam","IP mcg","IP","IP",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem",NA,"2","8",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem","10 mcg","24","18",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8",FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","IP mcg","IP","IP",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"0.001","16",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.001","0.5",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","50","26",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"0.001","1",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","50","22",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)",NA,"(16)","(16)",TRUE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","30 mcg","(15)","(15)",TRUE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"16","16",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","15","15",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)",NA,"(2)","(2)",TRUE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","10 mcg","(18)","(18)",TRUE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","18","18",FALSE,NA,"Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"2","2",FALSE,"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note",FALSE,"[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","16",FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"2","2",FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","IP mcg","IP","IP",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem",NA,"2","8",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem","10 mcg","21","15",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.001","1",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)",NA,"(8)","(8)",TRUE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","30 mcg","(19)","(19)",TRUE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","19","19",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)",NA,"(4)","(4)",TRUE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","10 mcg","(17)","(17)",TRUE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"4","4",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)",NA,"(4)","(4)",TRUE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","10 mcg","(17)","(17)",TRUE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"4","4",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"2","2",FALSE,"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note",FALSE,"[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin",NA,"4","8",FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","2 mcg","10","8",FALSE,"[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"4","8",FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"4","8",FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"4","8",FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. Oral administration is relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note",FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem",NA,"0.001","4",FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","10 mcg","50","21",FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","12","12",FALSE,"[B] | [B] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note",FALSE,"[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","30 mcg","Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","30 mcg","Note","Note",FALSE,"[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note",FALSE,"[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)",NA,"Note","Note","[3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)",NA,"Note","Note",FALSE,"[3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","300 mcg","Note","Note","[B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","300 mcg","Note","Note",FALSE,"[B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note",FALSE,"[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",NA,"Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",NA,"Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin",NA,"4","4",NA,"Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","5 mcg","12","12","[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","4",NA,"Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","20",NA,"Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. faecalis",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. faecalis",NA,"Eravacycline","20 mcg","22","22",NA,"Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. faecium",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. faecium",NA,"Eravacycline","20 mcg","24","24",NA,"Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. faecalis",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. faecalis",NA,"Tigecycline","15 mcg","20","20","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. faecium",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. faecium",NA,"Tigecycline","15 mcg","22","22","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","20","20",NA,"Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see http://www.eucast.org/guidance_documents/.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see http://www.eucast.org/guidance_documents/.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[2] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note","[A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note","[2] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note","[A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin",NA,"0.25","0.25","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin","1 unit","18","18","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test is not yet developed. Perform an MIC test.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"0.001","2",NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","50","17","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","Note","[C] | [C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","18","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin",NA,"0.25","0.5",NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","15 mcg","20","17",NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","23","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","20","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","19","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5","[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","2 mcg","18","18","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","19","19",NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.06","0.5",NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","15",NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"2","2",NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","IP","IP",NA,"Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.06","2","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"0.06","0.06","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin",NA,"0.5","2","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin","2 mcg","22","16","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm. | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","1 mcg","20","Note","[D] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.001","0.5",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime",NA,"0.5","2",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.5",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone",NA,"0.5","2",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.5",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/B] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)",NA,"0.25","0.25",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] For use in meningitis determine the meropenem MIC.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/B] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"0.001","2",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","50","16","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","Note","[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","19","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin",NA,"0.25","0.5",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","15 mcg","23","20",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","24","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","22","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","2",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","22",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"8","8",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.125","0.5",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","17",NA,"S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","13","10","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin",NA,"0.25","2",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","1 unit","18","12",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","1 unit","18","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin",NA,"0.5","2",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","2 mcg","21","15",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"0.5","2",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin","30 mcg","IP","IP",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","IP mcg","IP","IP",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note","[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"S. anginosus group",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"S. anginosus group",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test is not yet developed. Perform an MIC test.","Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19","[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","20 mcg","17","17",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.25","0.25",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid","2 mcg","18","18",NA,"Viridans group streptococci" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","1 unit","12","Note","[1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin",NA,"1","1","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin","2 mcg","18","18","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1","[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","10/10 mcg","Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv",NA,"2","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"0.001","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.001","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","50","15","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25","[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)",NA,"0.5","0.5","[2] See table of dosages for dosing for different indications.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","IP mcg","IP","IP","[2] See table of dosages for dosing for different indications.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.001","1",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)",NA,"0.25","0.25",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC for meropenem.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","Note","[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","1","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","24","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","22","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",NA,"H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","20","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","1",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","18",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.001","4",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","Note","[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.5",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","20","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin",NA,"0.25","0.5",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","15 mcg","23","20",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","1","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","25","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","28","25","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"2","2","[1] Breakpoints relate to topical use only.","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","30 mcg","30","30","[A] Breakpoints relate to topical use only.","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)",NA,"0.06","1","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",NA,"N.gonorrhoeae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"N.gonorrhoeae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"N.gonorrhoeae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",NA,"N.gonorrhoeae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",NA,"N.gonorrhoeae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note","[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","1",NA,"N.gonorrhoeae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",NA,"N.gonorrhoeae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin",NA,"0.06","0.25",NA,"N.meningitidis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin",NA,"0.125","1",NA,"N.meningitidis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin",NA,"0.125","1",NA,"N.meningitidis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime",NA,"0.125","0.125","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone",NA,"0.125","0.125","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (meningitis)",NA,"0.25","0.25","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin",NA,"0.03","0.03","[1] Breakpoints apply only to use in the prophylaxis of meningococcal disease.","N.meningitidis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)",NA,"2","2","[1] See table of dosages.","N.meningitidis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin",NA,"0.25","0.25","[2] For prophylaxis of meningitis only (refer to national guidelines).","N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","5 mcg","12","12",FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","4",FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","20",FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. faecalis",NA,"Eravacycline",NA,"0.125","0.125",FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. faecalis",NA,"Eravacycline","20 mcg","22","22",FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. faecium",NA,"Eravacycline",NA,"0.125","0.125",FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. faecium",NA,"Eravacycline","20 mcg","24","24",FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. faecalis",NA,"Tigecycline",NA,"0.25","0.25",FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. faecalis",NA,"Tigecycline","15 mcg","20","20",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. faecium",NA,"Tigecycline",NA,"0.25","0.25",FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. faecium",NA,"Tigecycline","15 mcg","22","22",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","20","20",FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE",FALSE,"[1] For more information, see http://www.eucast.org/guidance_documents/.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE",FALSE,"[1] For more information, see http://www.eucast.org/guidance_documents/.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note",FALSE,"[2] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note",FALSE,"[A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note",FALSE,"[2] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note",FALSE,"[A] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin",NA,"0.25","0.25",FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin","1 unit","18","18",FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,"[2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,"[2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2/B] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2/B] Streptococcus groups A, B, C and G do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"0.03","0.03",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"Note","Note",FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"0.001","2",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","50","17",FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19",FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","Note",FALSE,"[C] | [C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","18",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","1",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin",NA,"0.25","0.5",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","15 mcg","20","17",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17",FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","2",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","23",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","2",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","20",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125",FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19",FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","2",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","19",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5",FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","2 mcg","18","18",FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","19","19",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1",FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note",FALSE,"[A] Use an MIC method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.06","0.5",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","15",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"2","2",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","IP","IP",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2",FALSE,"[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15",FALSE,"[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.06","2",FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"0.06","0.06",FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin",NA,"0.5","2",FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin","2 mcg","22","16",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1",FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1",FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm. | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter).","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (MIC or zone diameter). | [4] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","1 mcg","20","Note",FALSE,"[D] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.001","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime",NA,"0.5","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone",NA,"0.5","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[3] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[3/B] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)",NA,"0.25","0.25",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] For use in meningitis determine the meropenem MIC.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[3] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[3/B] Streptococcus pneumoniae do not produce beta-lactamase. The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"0.001","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","50","16",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","Note",FALSE,"[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17",FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16",FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","19",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","1",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin",NA,"0.25","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","15 mcg","23","20",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19",FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","2",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","24",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","2",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","22",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","22",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"8","8",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.125","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","17",FALSE,NA,"S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","13","10",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin",NA,"0.25","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","1 unit","18","12",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","1 unit","18","Note",FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin",NA,"0.5","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","2 mcg","21","15",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"0.5","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note",FALSE,"[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as susceptible can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as non-susceptible should be tested for susceptibility to individual agents. | [B] For isolates susceptible to benzylpenicillin, susceptibility can be inferred from benzylpenicillin or ampicillin. For isolates resistant to benzylpenicillin, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin","30 mcg","IP","IP",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25",FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23",FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27",FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26",FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note",FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note",FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"2","2",FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam","IP mcg","IP","IP",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note",FALSE,"[A] Benzylpenicillin 1 unit can be used to screen for beta-lactam resistance in viridans group streptococci. See Note A on penicillins.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"S. anginosus group",NA,"Delafloxacin",NA,"0.03","0.03",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"S. anginosus group",NA,"Delafloxacin",NA,"Note","Note",FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19",FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","20 mcg","17","17",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.25","0.25",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid","2 mcg","18","18",FALSE,NA,"Viridans group streptococci" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","1 unit","12","Note",FALSE,"[1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin",NA,"1","1",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin","2 mcg","18","18",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1",FALSE,"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","10/10 mcg","Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv",NA,"2","2",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"0.001","2",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2",FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.001","2",FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","50","15",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25",FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","5 mcg","27","27",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)",NA,"0.5","0.5",FALSE,"[2] See table of dosages for dosing for different indications.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","IP mcg","IP","IP",FALSE,"[2] See table of dosages for dosing for different indications.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","30 mcg","32","32",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.001","1",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)",NA,"0.25","0.25",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC for meropenem.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","5 mcg","30","30",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","Note",FALSE,"[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","2",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","1",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","24",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"1","2",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","22",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",FALSE,NA,"H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","20",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1",FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1",FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","1",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","18",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.001","4",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","Note",FALSE,"[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.5",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","20",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","1",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin",NA,"0.25","0.5",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","15 mcg","23","20",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","2",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","1",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","25",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"1","2",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","28","25",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"2","2",FALSE,"[1] Breakpoints relate to topical use only.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol","30 mcg","30","30",FALSE,"[A] Breakpoints relate to topical use only.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)",NA,"0.06","1",FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note",FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","1",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin",NA,"0.06","0.25",FALSE,NA,"N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin",NA,"0.125","1",FALSE,NA,"N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin",NA,"0.125","1",FALSE,NA,"N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime",NA,"0.125","0.125",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone",NA,"0.125","0.125",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (meningitis)",NA,"0.25","0.25",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin",NA,"0.03","0.03",FALSE,"[1] Breakpoints apply only to use in the prophylaxis of meningococcal disease.","N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline",NA,"2","2",FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)",NA,"2","2",FALSE,"[1] See table of dosages.","N.meningitidis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin",NA,"0.25","0.25",FALSE,"[2] For prophylaxis of meningitis only (refer to national guidelines).","N.meningitidis" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Benzylpenicillin",NA,"0.25","0.5","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Benzylpenicillin",NA,"0.25","0.5",FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ampicillin",NA,"4","8","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Ampicillin",NA,"4","8",FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ampicillin-sulbactam",NA,"4","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Ampicillin-sulbactam",NA,"4","8",FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobes, Grampositive" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Amoxicillin",NA,"4","8","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Amoxicillin",NA,"4","8",FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Amoxicillin-clavulanic acid",NA,"4","8",FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Grampositive" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Piperacillin",NA,"8","16","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Piperacillin",NA,"8","16",FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Piperacillin-tazobactam",NA,"8","16","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Piperacillin-tazobactam",NA,"8","16",FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobes, Grampositive" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ticarcillin",NA,"8","16","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Ticarcillin",NA,"8","16",FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Ticarcillin-clavulanic acid",NA,"8","16",FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Grampositive" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Cefoxitin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ertapenem",NA,"0.5","0.5",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Imipenem",NA,"2","4",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Imipenem",NA,"2","4",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Imipenem-relebactam",NA,"2","2",FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Anaerobes, Grampositive" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Meropenem",NA,"2","8",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Meropenem",NA,"2","8",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Moxifloxacin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Moxifloxacin",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Dalbavancin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Oritavancin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Teicoplanin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Teicoplanin",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Telavancin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Vancomycin",NA,"2","2",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Erythromycin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Erythromycin",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Clindamycin",NA,"4","4",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Clindamycin",NA,"4","4",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Doxycycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Doxycycline",NA,"Note","Note",FALSE,"[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Eravacycline",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Minocycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Minocycline",NA,"Note","Note",FALSE,"[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Tetracycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Tetracycline",NA,"Note","Note",FALSE,"[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Tigecycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Tigecycline",NA,"Note","Note",FALSE,"[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Chloramphenicol",NA,"8","8",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Chloramphenicol",NA,"8","8",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Metronidazole",NA,"4","4",NA,"Anaerobes, Grampositive" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with vancomycin. There are no conclusive clinical data regarding the relation between MICs and outcomes.","C.difficile" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IE","IE","[4] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distribution between studies.","C.difficile" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2","[5] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with metronidazole. There are no conclusive clinical data regarding the relation between MICs and outcomes.","C.difficile" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Benzylpenicillin",NA,"0.25","0.5","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin",NA,"0.5","2","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin-sulbactam",NA,"4","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobes, Gramnegative" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin",NA,"0.5","2","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Gramnegative" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin",NA,"16","16","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin-tazobactam",NA,"8","16","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobes, Gramnegative" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin",NA,"16","16","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Gramnegative" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Anaerobes, Gramnegative" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Cefoxitin",NA,"IE","IE",NA,"Anaerobes, Gramnegative" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Anaerobes, Gramnegative" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ertapenem",NA,"0.5","0.5",NA,"Anaerobes, Gramnegative" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem",NA,"2","4",NA,"Anaerobes, Gramnegative" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Anaerobes, Gramnegative" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem",NA,"2","8",NA,"Anaerobes, Gramnegative" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"Anaerobes, Gramnegative" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Moxifloxacin",NA,"IE","IE",NA,"Anaerobes, Gramnegative" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Erythromycin",NA,"IE","IE",NA,"Anaerobes, Gramnegative" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Clindamycin",NA,"4","4",NA,"Anaerobes, Gramnegative" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Doxycycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Eravacycline",NA,"IE","IE",NA,"Anaerobes, Gramnegative" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Minocycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tetracycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tigecycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Chloramphenicol",NA,"8","8",NA,"Anaerobes, Gramnegative" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Metronidazole",NA,"4","4",NA,"Anaerobes, Gramnegative" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral",NA,"0.125","0.125",NA,"H.pylori" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1",NA,"H.pylori" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.5",NA,"H.pylori" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1",NA,"H.pylori" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8",NA,"H.pylori" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1",NA,"H.pylori" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin",NA,"1","1",NA,"L.monocytogenes" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin","1 unit","13","13",NA,"L.monocytogenes" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv",NA,"1","1",NA,"L.monocytogenes" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv","2 mcg","16","16",NA,"L.monocytogenes" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem",NA,"0.25","0.25",NA,"L.monocytogenes" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem","10 mcg","26","26",NA,"L.monocytogenes" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin",NA,"1","1",NA,"L.monocytogenes" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin","15 mcg","25","25",NA,"L.monocytogenes" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole",NA,"0.06","0.06","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","29","29","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Benzylpenicillin",NA,"0.5","0.5",NA,"P.multocida" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Benzylpenicillin","1 unit","17","17",NA,"P.multocida" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"1","1",NA,"P.multocida" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"1","1",NA,"P.multocida" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",NA,"P.multocida" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Cefotaxime",NA,"0.03","0.03",NA,"P.multocida" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Cefotaxime","5 mcg","26","26",NA,"P.multocida" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"P.multocida" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ciprofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Levofloxacin",NA,"0.06","0.06",NA,"P.multocida" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Levofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Nalidixic acid (screen only)","30 mcg","23","Note","[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","P.multocida" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"1","1",NA,"P.multocida" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility inferred from tetracycline screen test.","P.multocida" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Tetracycline (screen only)","30 mcg","24","24","[A] Susceptibility inferred from tetracycline screen test.","P.multocida" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin",NA,"0.5","0.5",NA,"C.jejuni_C.coli" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","5 mcg","26","26",NA,"C.jejuni_C.coli" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","24","24","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note","[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","30 mcg","30","30","[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Corynebacterium" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","1 unit","29","29",NA,"Corynebacterium" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Ciprofloxacin",NA,"1","1",NA,"Corynebacterium" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","5 mcg","25","25",NA,"Corynebacterium" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Corynebacterium" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Moxifloxacin","5 mcg","25","25",NA,"Corynebacterium" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Vancomycin",NA,"2","2",NA,"Corynebacterium" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Vancomycin","5 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Erythromycin",NA,"IP","IP",NA,"Corynebacterium" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Erythromycin","15 mcg","IP","IP",NA,"Corynebacterium" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Clindamycin","2 mcg","20","20","[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Tetracycline",NA,"2","2",NA,"Corynebacterium" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Tetracycline","30 mcg","24","24",NA,"Corynebacterium" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Linezolid",NA,"2","2",NA,"Corynebacterium" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Linezolid","10 mcg","25","25",NA,"Corynebacterium" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Rifampicin",NA,"0.06","0.5",NA,"Corynebacterium" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Rifampicin","5 mcg","30","25",NA,"Corynebacterium" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","1 unit","21","21",NA,"A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","2 mcg","26","26",NA,"A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note","[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","10 mcg","31","31",NA,"A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",NA,"A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21","[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2","[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","Note","Note","[B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Norfloxacin (screen only)","10 mcg","17","17","[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin",NA,"1","1",NA,"A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",NA,"A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",NA,"A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","5 mcg","25","25",NA,"A.sanguinicola_A.urinae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",NA,"K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",NA,"K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[3] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",NA,"K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",NA,"K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",NA,"K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",NA,"K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",NA,"K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",NA,"K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",NA,"K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",NA,"K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",NA,"K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",NA,"K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",NA,"K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",NA,"K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",NA,"Aeromonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",NA,"Aeromonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",NA,"Aeromonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",NA,"Aeromonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",NA,"Aeromonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",NA,"Aeromonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Aeromonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",NA,"Aeromonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Aeromonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",NA,"Aeromonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","19","16","[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid",NA,"0.001","8","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","20/10 mcg","50","22",NA,"B.pseudomallei" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime",NA,"0.001","8",NA,"B.pseudomallei" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","10 mcg","50","18",NA,"B.pseudomallei" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem",NA,"2","2",NA,"B.pseudomallei" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","10 mcg","29","29",NA,"B.pseudomallei" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem",NA,"2","2",NA,"B.pseudomallei" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","10 mcg","24","24",NA,"B.pseudomallei" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"0.001","2",NA,"B.pseudomallei" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","30 mcg","50","23","[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol",NA,"0.001","8",NA,"B.pseudomallei" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","30 mcg","50","22",NA,"B.pseudomallei" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","17","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06",NA,"M.tuberculosis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25","[1] Breakpoints were determined on MICs performed on Middlebrook 7H11/7H10 medium. The comparability of tests performed by other media has not been established. There is ongoing work to review breakpoints using the EUCAST reference method (described above).","M.tuberculosis" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin",NA,"2","2",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","10 mcg","16","16",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)",NA,"8","8",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","10 mcg","12","12",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin",NA,"8","8",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","10 mcg","15","15",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","10 mcg","16","16",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","5 mcg","25","25",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","5 mcg","20","20",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","5 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","30 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)",NA,"4","4",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","21","21",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","23",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","5 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","30 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin",NA,"2","2",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","10 mcg","18","18",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","10 mcg","17","17","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","30 mcg","18","18",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","10 mcg","24","24",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)",NA,"1","1",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","10 mcg","14","14",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin",NA,"1","1","[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +except Clostridioides difficile",NA,"Metronidazole",NA,"4","4",FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2",FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with vancomycin. There are no conclusive clinical data regarding the relation between MICs and outcomes.","C.difficile" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IE","IE",FALSE,"[4] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distribution between studies.","C.difficile" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2",FALSE,"[5] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with metronidazole. There are no conclusive clinical data regarding the relation between MICs and outcomes.","C.difficile" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Benzylpenicillin",NA,"0.25","0.5",FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin",NA,"0.5","2",FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin-sulbactam",NA,"4","8",FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin",NA,"0.5","2",FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin-clavulanic acid",NA,"4","8",FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin",NA,"16","16",FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin-tazobactam",NA,"8","16",FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin",NA,"16","16",FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin-clavulanic acid",NA,"8","16",FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem",NA,"2","4",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem-relebactam",NA,"2","2",FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem",NA,"2","8",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Moxifloxacin",NA,"IE","IE",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Erythromycin",NA,"IE","IE",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Clindamycin",NA,"4","4",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Doxycycline",NA,"Note","Note",FALSE,"[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Minocycline",NA,"Note","Note",FALSE,"[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tetracycline",NA,"Note","Note",FALSE,"[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tigecycline",NA,"Note","Note",FALSE,"[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Chloramphenicol",NA,"8","8",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Metronidazole",NA,"4","4",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral",NA,"0.125","0.125",FALSE,NA,"H.pylori" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1",FALSE,NA,"H.pylori" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.5",FALSE,NA,"H.pylori" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1",FALSE,NA,"H.pylori" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8",FALSE,NA,"H.pylori" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1",FALSE,NA,"H.pylori" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin",NA,"1","1",FALSE,NA,"L.monocytogenes" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin","1 unit","13","13",FALSE,NA,"L.monocytogenes" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv",NA,"1","1",FALSE,NA,"L.monocytogenes" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv","2 mcg","16","16",FALSE,NA,"L.monocytogenes" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem",NA,"0.25","0.25",FALSE,NA,"L.monocytogenes" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem","10 mcg","26","26",FALSE,NA,"L.monocytogenes" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin",NA,"1","1",FALSE,NA,"L.monocytogenes" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin","15 mcg","25","25",FALSE,NA,"L.monocytogenes" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole",NA,"0.06","0.06",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","29","29",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Benzylpenicillin",NA,"0.5","0.5",FALSE,NA,"P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Benzylpenicillin","1 unit","17","17",FALSE,NA,"P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"1","1",FALSE,NA,"P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"1","1",FALSE,NA,"P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid",NA,"1","1",FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",FALSE,NA,"P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Cefotaxime",NA,"0.03","0.03",FALSE,NA,"P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Cefotaxime","5 mcg","26","26",FALSE,NA,"P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,NA,"P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ciprofloxacin","5 mcg","27","27",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Levofloxacin",NA,"0.06","0.06",FALSE,NA,"P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Levofloxacin","5 mcg","27","27",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Nalidixic acid (screen only)","30 mcg","23","Note",FALSE,"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"1","1",FALSE,NA,"P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Tetracycline (screen only)","30 mcg","24","24",FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin",NA,"0.5","0.5",FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","5 mcg","26","26",FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","24","24",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note",FALSE,"[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Tetracycline",NA,"2","2",FALSE,"[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","30 mcg","30","30",FALSE,"[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Benzylpenicillin",NA,"0.125","0.125",FALSE,NA,"Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","1 unit","29","29",FALSE,NA,"Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Ciprofloxacin",NA,"1","1",FALSE,NA,"Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","5 mcg","25","25",FALSE,NA,"Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Moxifloxacin",NA,"0.5","0.5",FALSE,NA,"Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Moxifloxacin","5 mcg","25","25",FALSE,NA,"Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Vancomycin","5 mcg","17","17",FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Erythromycin",NA,"IP","IP",FALSE,NA,"Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Erythromycin","15 mcg","IP","IP",FALSE,NA,"Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Clindamycin","2 mcg","20","20",FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Tetracycline",NA,"2","2",FALSE,NA,"Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Tetracycline","30 mcg","24","24",FALSE,NA,"Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Linezolid",NA,"2","2",FALSE,NA,"Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Linezolid","10 mcg","25","25",FALSE,NA,"Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Rifampicin",NA,"0.06","0.5",FALSE,NA,"Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Rifampicin","5 mcg","30","25",FALSE,NA,"Corynebacterium" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","1 unit","21","21",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin",NA,"0.25","0.25",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","2 mcg","26","26",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem",NA,"0.25","0.25",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","10 mcg","31","31",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21",FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2",FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","Note","Note",FALSE,"[B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Norfloxacin (screen only)","10 mcg","17","17",FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin",NA,"1","1",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","5 mcg","16","16",FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin",NA,"0.125","0.125",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","5 mcg","25","25",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06",FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125",FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[3] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25",FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5",FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",FALSE,NA,"K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",FALSE,NA,"Aeromonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",FALSE,NA,"Aeromonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",FALSE,NA,"Aeromonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",FALSE,NA,"Aeromonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",FALSE,NA,"Aeromonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",FALSE,NA,"Aeromonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",FALSE,NA,"Aeromonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",FALSE,NA,"Aeromonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",FALSE,NA,"Aeromonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",FALSE,NA,"Aeromonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","19","16",FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid",NA,"0.001","8",FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","20/10 mcg","50","22",FALSE,NA,"B.pseudomallei" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime",NA,"0.001","8",FALSE,NA,"B.pseudomallei" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","10 mcg","50","18",FALSE,NA,"B.pseudomallei" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem",NA,"2","2",FALSE,NA,"B.pseudomallei" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","10 mcg","29","29",FALSE,NA,"B.pseudomallei" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem",NA,"2","2",FALSE,NA,"B.pseudomallei" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","10 mcg","24","24",FALSE,NA,"B.pseudomallei" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"0.001","2",FALSE,NA,"B.pseudomallei" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","30 mcg","50","23",FALSE,"[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol",NA,"0.001","8",FALSE,NA,"B.pseudomallei" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","30 mcg","50","22",FALSE,NA,"B.pseudomallei" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","17",FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06",FALSE,NA,"M.tuberculosis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25",FALSE,"[1] Breakpoints were determined on MICs performed on Middlebrook 7H11/7H10 medium. The comparability of tests performed by other media has not been established. There is ongoing work to review breakpoints using the EUCAST reference method (described above).","M.tuberculosis" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","10 mcg","17","17",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","10 mcg","16","16",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin",NA,"0.125","0.125",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin",NA,"0.25","0.25",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.25",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol",NA,"16","16",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","10 mcg","12","12",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","10 mcg","15","15",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","10 mcg","16","16",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","5 mcg","25","25",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","5 mcg","20","20",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","5 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","30 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin (framycetin)",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","21","21",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","23",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","5 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","30 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","10 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","10 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","10 mcg","17","17",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol",NA,"16","16",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","30 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","10 mcg","24","24",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","10 mcg","14","14",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin",NA,"1","1",FALSE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. ND = No ECOFF available.","Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","200 mcg","30","30","[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","200 mcg","30","30",FALSE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. ND = No ECOFF available.","Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Retapamulin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin",NA,"4","4",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"32","32",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","200 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"0.125","0.125",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin",NA,"4","4",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin",NA,"8","8",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","30 mcg","28","28",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","30 mcg","30","30",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin",NA,"8","8","[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin",NA,"8","8","[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid",NA,"8","8","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","20/10 mcg","19","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)",NA,"32","32","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","20/10 mcg","16","16","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","8",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","20",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","8","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","20",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin",NA,"8","16",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin","75 mcg","23","20",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)",NA,"0.001","16",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)","30 mcg","50","17","[C] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)",NA,"8","8","[5] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)","10 mcg","15","15","[C] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli, and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)",NA,"0.001","4","[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli, and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)","30 mcg","50","20","[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol",NA,"2","2","[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","30 mcg","22","22",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","5 mcg","20","17",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","5 mcg","20","20",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","30 mcg","19","19","[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)","10 mcg","21","21",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8","[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","30 mcg","23","23",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"2","2","[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [6] See table of dosages for dosing for different indications.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","22","22","[6] See table of dosages for dosing for different indications.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","25","22",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","30 mcg","25","25",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"0.001","8",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","50","19",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem",NA,"1","2",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","10 mcg","24","21",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","25","25",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem",NA,"2","4",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem","10 mcg","22","19",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Morganellaceae",NA,"Imipenem",NA,"0.001","4","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Morganellaceae",NA,"Imipenem","10 mcg","50","19","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam",NA,"2","2","[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","10 mcg","22","16",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","10 mcg","22","22",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8","[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","IP mcg","IP","IP",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin","5 mcg","25","22",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06","[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note","[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Salmonella spp.",NA,"Pefloxacin (screen only)","5 mcg","24","24","[2/C] The pefloxacin 5 µg breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp. | [B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli",NA,"Delafloxacin",NA,"0.125","0.125",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli",NA,"Delafloxacin",NA,"Note","Note","[D] A disk diffusion test is not yet developed. Perform an MIC test.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","5 mcg","22","22",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","0.5",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","22","22",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","30 mcg","18","18","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","18","18",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)",NA,"2","2","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","10 mcg","16","16","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","16","16",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli",NA,"Eravacycline","20 mcg","17","17",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18","[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"8","8",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"2","2","[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv",NA,"32","32","[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","200 mcg","21","21","[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)",NA,"8","8","[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)","200 mcg","24","24","[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","15","15",NA,"Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"0.001","16",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"0.001","16","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin",NA,"0.001","16",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin","75 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"0.001","16","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"0.001","8",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","50","21",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"P. aeruginosa",NA,"Cefiderocol",NA,"2","2","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/.","Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"P. aeruginosa",NA,"Cefiderocol","30 mcg","22","22",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"0.001","8",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","50","17",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] See table of dosages for dosing for different indications.","Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","23","23","[3] See table of dosages for dosing for different indications.","Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem",NA,"0.001","2",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","10 mcg","50","22",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"0.001","4",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","50","20",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"P. aeruginosa",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"P. aeruginosa",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis)","10 mcg","24","18",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis)","10 mcg","24","24",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","IP mcg","IP","IP",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"0.001","16",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","50","26",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"0.001","1",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","50","22",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)",NA,"16","16","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","30 mcg","15","15","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"16","16",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","15","15",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","10 mcg","18","18","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","18","18",NA,"Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"2","2","[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"IE","IE","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/.","S.maltophilia" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"Note","Note","[A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","16","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"IE","IE","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/.","Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"Note","Note","[A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem",NA,"0.001","2",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","10 mcg","50","22",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","10/25 mcg","24","24","[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","10 mcg","21","15",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","10 mcg","21","21",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","30 mcg","19","19","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","19","19",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)",NA,"4","4","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)",NA,"4","4","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","10 mcg","17","17","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"2","2","[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Benzylpenicillin",NA,"0.125","0.125","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Benzylpenicillin","1 unit","26","26","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. lugdunensis",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. lugdunensis",NA,"Benzylpenicillin","1 unit","26","26",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. saprophyticus",NA,"Ampicillin",NA,"Note","Note","[2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. aureus",NA,"Retapamulin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","21","21",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"32","32",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","200 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"0.125","0.125",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin",NA,"0.06","0.06",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin",NA,"0.06","0.06",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","30 mcg","28","28",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","H. influenzae",NA,"Neomycin (framycetin)",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","H. influenzae",NA,"Neomycin (framycetin)","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","30 mcg","30","30",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin (framycetin)",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2020","10.0","Clinical Breakpoint Tables v. 10.0","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin",NA,"8","8",FALSE,"[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin","10 mcg","14","14",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam",NA,"8","8",FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","10/10 mcg","14","14",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin",NA,"8","8",FALSE,"[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin","/ mcg","Note","Note",FALSE,"[B] Susceptibility inferred from ampicillin. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid",NA,"8","8",FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","20/10 mcg","19","19",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)",NA,"32","32",FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","20/10 mcg","16","16",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","8",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","20",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","8",FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","20",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin",NA,"8","16",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin","75 mcg","23","20",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16",FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)",NA,"0.001","16",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)","30 mcg","50","17",FALSE,"[C] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)",NA,"8","8",FALSE,"[5] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)","10 mcg","15","15",FALSE,"[C] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli, and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)",NA,"0.001","4",FALSE,"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli, and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)","30 mcg","50","20",FALSE,"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol",NA,"2","2",FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","30 mcg","22","22",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)",NA,"1","2",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","5 mcg","20","17",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","5 mcg","20","20",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)",NA,"Note","Note",FALSE,"[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","30 mcg","19","19",FALSE,"[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)","10 mcg","21","21",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8",FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","30 mcg","23","23",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"2","2",FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [6] See table of dosages for dosing for different indications.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","22","22",FALSE,"[6] See table of dosages for dosing for different indications.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)",NA,"1","2",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","25","22",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","30 mcg","25","25",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"0.001","8",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","50","19",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem",NA,"1","2",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","10 mcg","24","21",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","25","25",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem",NA,"2","4",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem","10 mcg","22","19",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Morganellaceae",NA,"Imipenem",NA,"0.001","4",FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Morganellaceae",NA,"Imipenem","10 mcg","50","19",FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam",NA,"2","2",FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam","10/25 mcg","22","22",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)",NA,"2","8",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","10 mcg","22","16",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)",NA,"2","2",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","10 mcg","22","22",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8",FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","IP mcg","IP","IP",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4",FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21",FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin",NA,"0.25","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin","5 mcg","25","22",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note",FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Salmonella spp.",NA,"Pefloxacin (screen only)","5 mcg","24","24",FALSE,"[2/C] The pefloxacin 5 µg breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp. | [B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from pefloxacin disk diffusion susceptibility. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli",NA,"Delafloxacin",NA,"0.125","0.125",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli",NA,"Delafloxacin",NA,"Note","Note",FALSE,"[D] A disk diffusion test is not yet developed. Perform an MIC test.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin",NA,"0.25","0.25",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","5 mcg","22","22",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","22","22",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)",NA,"(8)","(8)",TRUE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","30 mcg","(18)","(18)",TRUE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","18","18",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)",NA,"(2)","(2)",TRUE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","10 mcg","(17)","(17)",TRUE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)",NA,"2","2",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)",NA,"(2)","(2)",TRUE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","10 mcg","(16)","(16)",TRUE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","16","16",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli",NA,"Eravacycline","20 mcg","17","17",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5",FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18",FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see http://www.eucast.org/guidance_documents/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"8","8",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"2","2",FALSE,"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note",FALSE,"[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv",NA,"32","32",FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","200 mcg","21","21",FALSE,"[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)",NA,"8","8",FALSE,"[2] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)","200 mcg","24","24",FALSE,"[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","15","15",FALSE,NA,"Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4",FALSE,"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11",FALSE,"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"0.001","16",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"0.001","16",FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin",NA,"0.001","16",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin","75 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"0.001","16",FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"0.001","8",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","50","21",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"P. aeruginosa",NA,"Cefiderocol",NA,"2","2",FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/.","Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"P. aeruginosa",NA,"Cefiderocol","30 mcg","22","22",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"0.001","8",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","50","17",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8",FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4",FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] See table of dosages for dosing for different indications.","Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","23","23",FALSE,"[3] See table of dosages for dosing for different indications.","Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem",NA,"0.001","2",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","10 mcg","50","22",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"0.001","4",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","50","20",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"P. aeruginosa",NA,"Imipenem-relebactam",NA,"2","2",FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"P. aeruginosa",NA,"Imipenem-relebactam","10/25 mcg","22","22",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis)",NA,"2","8",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (indications other than meningitis)","10 mcg","24","18",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis)",NA,"2","2",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Meropenem (meningitis)","10 mcg","24","24",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8",FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","IP mcg","IP","IP",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"0.001","16",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.001","0.5",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","50","26",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"0.001","1",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","50","22",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)",NA,"(16)","(16)",TRUE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","30 mcg","(15)","(15)",TRUE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"16","16",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","15","15",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)",NA,"(2)","(2)",TRUE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","10 mcg","(18)","(18)",TRUE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","18","18",FALSE,NA,"Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"2","2",FALSE,"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note",FALSE,"[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"IE","IE",FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/.","S.maltophilia" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"Note","Note",FALSE,"[A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","16",FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"IE","IE",FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"Note","Note",FALSE,"[A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem",NA,"0.001","2",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","10 mcg","50","22",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"2","2",FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","10/25 mcg","24","24",FALSE,"[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)",NA,"2","8",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","10 mcg","21","15",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)",NA,"2","2",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","10 mcg","21","21",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.001","1",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)",NA,"(8)","(8)",TRUE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","30 mcg","(19)","(19)",TRUE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","19","19",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)",NA,"(4)","(4)",TRUE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","10 mcg","(17)","(17)",TRUE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"4","4",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)",NA,"(4)","(4)",TRUE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","10 mcg","(17)","(17)",TRUE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"4","4",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"2","2",FALSE,"[1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note",FALSE,"[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Benzylpenicillin",NA,"0.125","0.125",FALSE,"[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Benzylpenicillin","1 unit","26","26",FALSE,"[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp, then report resistant. If not sharp, then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. lugdunensis",NA,"Benzylpenicillin",NA,"0.125","0.125",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. lugdunensis",NA,"Benzylpenicillin","1 unit","26","26",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Benzylpenicillin",NA,"Note","Note",FALSE,"[2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Benzylpenicillin",NA,"Note","Note",FALSE,"[C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. saprophyticus",NA,"Ampicillin",NA,"Note","Note",FALSE,"[2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. saprophyticus",NA,"Ampicillin","2 mcg","18","18","[C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. saprophyticus",NA,"Ampicillin","2 mcg","18","18",FALSE,"[C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note",FALSE,"[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor). 4.S. aureus,S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. pseudintermedius and S. schleiferi",NA,"Oxacillin (screen only)","1 mcg","20","20","[E] For screening for methicillin resistance in S. pseudintermedius and S. schleiferi.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin",NA,"Note","Note",FALSE,"[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin",NA,"Note","Note",FALSE,"[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. pseudintermedius and S. schleiferi",NA,"Oxacillin (screen only)","1 mcg","20","20",FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius and S. schleiferi.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note",FALSE,"[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note",FALSE,"[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note",FALSE,"[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note",FALSE,"[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note",FALSE,"[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note",FALSE,"[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note",FALSE,"[1] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note",FALSE,"[A] Most S. aureusare penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most coagulase-negative staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in coagulase-negative staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. 3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. 3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. 3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. 3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus and coagulase-negative staphylococci other than S. epidermidis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus and coagulase-negative staphylococci other than S. epidermidis",NA,"Cefoxitin (screen only)","30 mcg","22","22","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. epidermidis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. epidermidis",NA,"Cefoxitin (screen only)","30 mcg","25","25","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. pseudintermedius and S. schleiferi",NA,"Cefoxitin (screen only)",NA,"Note","Note","[5] In S. pseudintermedius and S. schleiferi the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. pseudintermedius and S. schleiferi",NA,"Cefoxitin (screen only)",NA,"Note","Note","[C] In S. pseudintermedius and S. schleiferi the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline(indications other than pneumonia)",NA,"1","2","[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline(indications other than pneumonia)","5 mcg","20","17","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (pneumonia)",NA,"1","1","[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (pneumonia)","5 mcg","20","20","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Ceftobiprole",NA,"2","2","[8] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Ceftobiprole","5 mcg","17","17","[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus and coagulase-negative staphylococci other than S. epidermidis",NA,"Cefoxitin (screen only)",NA,"Note","Note",FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus and coagulase-negative staphylococci other than S. epidermidis",NA,"Cefoxitin (screen only)","30 mcg","22","22",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. epidermidis",NA,"Cefoxitin (screen only)",NA,"Note","Note",FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. epidermidis",NA,"Cefoxitin (screen only)","30 mcg","25","25",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. pseudintermedius and S. schleiferi",NA,"Cefoxitin (screen only)",NA,"Note","Note",FALSE,"[5] In S. pseudintermedius and S. schleiferi the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. pseudintermedius and S. schleiferi",NA,"Cefoxitin (screen only)",NA,"Note","Note",FALSE,"[C] In S. pseudintermedius and S. schleiferi the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline(indications other than pneumonia)",NA,"1","2",FALSE,"[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline(indications other than pneumonia)","5 mcg","20","17",FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (pneumonia)",NA,"1","1",FALSE,"[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (pneumonia)","5 mcg","20","20",FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Ceftobiprole",NA,"2","2",FALSE,"[8] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Ceftobiprole","5 mcg","17","17",FALSE,"[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. 3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. 3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Ciprofloxacin","5 mcg","50","21","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin","5 mcg","50","24","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin",NA,"0.25","0.25",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin",NA,"Note","Note","[B] A disk diffusion test is not yet developed. Perform an MIC test.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Levofloxacin","5 mcg","50","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin","5 mcg","50","24","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Moxifloxacin","5 mcg","25","25","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin","5 mcg","28","28","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","17","Note","[C] | [C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin, levofloxacin and ofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[2] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Amikacin",NA,"8","8","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Amikacin","30 mcg","18","18","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Amikacin",NA,"8","8","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Amikacin","30 mcg","22","22","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Gentamicin",NA,"1","1","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Gentamicin","10 mcg","18","18","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Gentamicin",NA,"1","1","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Gentamicin","10 mcg","22","22","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Tobramycin",NA,"1","1","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Tobramycin","10 mcg","18","18","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Tobramycin",NA,"1","1","[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Tobramycin","10 mcg","22","22","[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Oritavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Teicoplanin",NA,"2","2","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"4","4",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"MRSA",NA,"Telavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"MRSA",NA,"Telavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Vancomycin",NA,"2","2","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"4","4","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"1","2","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"1","2","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin",NA,"1","2","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","15 mcg","21","18","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"1","2","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telithromycin",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telithromycin",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin",NA,"0.25","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","2 mcg","22","19","[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin",NA,"1","2",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","15 mcg","21","18",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Eravacycline",NA,"0.25","0.25",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Eravacycline","20 mcg","20","20","[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","30 mcg","23","23","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","30 mcg","22","19","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline",NA,"0.5","0.5","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","15 mcg","19","19","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","10 mcg","21","21",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid",NA,"0.5","0.5","[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","2 mcg","21","21","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"8","8",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","30 mcg","18","18",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"32","32","[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[A] Use an MIC method.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid",NA,"1","1",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","10 mcg","24","24",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Lefamulin",NA,"0.25","0.25",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Lefamulin","5 mcg","23","23",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","13","13",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin",NA,"0.06","0.5",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin","5 mcg","26","23",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","14","14",NA,"Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","17","14","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","2 mcg","10","8","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem",NA,"0.001","4",NA,"Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","10 mcg","50","21",NA,"Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[1] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[B] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C] | [C] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility. For moxifloxacin, see comment 1/B.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Ciprofloxacin",NA,"0.001","1",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Ciprofloxacin","5 mcg","50","21",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin",NA,"0.001","1",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin","5 mcg","50","24",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin",NA,"0.25","0.25",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin",NA,"Note","Note",FALSE,"[B] A disk diffusion test is not yet developed. Perform an MIC test.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Levofloxacin",NA,"0.001","1",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Levofloxacin","5 mcg","50","22",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin",NA,"0.001","1",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin","5 mcg","50","24",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Moxifloxacin",NA,"0.25","0.25",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Moxifloxacin","5 mcg","25","25",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin",NA,"0.25","0.25",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin","5 mcg","28","28",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","17","Note",FALSE,"[C] | [C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin, levofloxacin and ofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note",FALSE,"[2] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note",FALSE,"[D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Amikacin",NA,"(8)","(8)",TRUE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Amikacin","30 mcg","(18)","(18)",TRUE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Amikacin",NA,"(8)","(8)",TRUE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Amikacin","30 mcg","(22)","(22)",TRUE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Gentamicin",NA,"(1)","(1)",TRUE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Gentamicin","10 mcg","(18)","(18)",TRUE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Gentamicin",NA,"(1)","(1)",TRUE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Gentamicin","10 mcg","(22)","(22)",TRUE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Tobramycin",NA,"(1)","(1)",TRUE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Tobramycin","10 mcg","(18)","(18)",TRUE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Tobramycin",NA,"(1)","(1)",TRUE,"[1] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Tobramycin","10 mcg","(22)","(22)",TRUE,"[A] For systemic infections, aminoglycosides must be used in combination with other active therapy. In this circumstance, the breakpoint/ECOFF in brackets can be used to distinguish between organisms with and without acquired resistance mechanisms. For isolates without resistance mechanisms, include a comment in the report: “Aminoglycosides are often given in combination with other agents, either to support the activity of the aminoglycoside or to broaden the spectrum of therapy. In systemic infections, the aminoglycoside must be supported by other active therapy."" For more information, see http://www.eucast.org/guidance_documents/.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"0.125","0.125",FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Oritavancin",NA,"0.125","0.125",FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Oritavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Teicoplanin",NA,"2","2",FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Teicoplanin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"4","4",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"MRSA",NA,"Telavancin",NA,"0.125","0.125",FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"MRSA",NA,"Telavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Vancomycin",NA,"2","2",FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Vancomycin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"4","4",FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"1","2",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"1","2",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin",NA,"1","2",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","15 mcg","21","18",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"1","2",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telithromycin",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telithromycin",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin",NA,"0.25","0.5",FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","2 mcg","22","19",FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin",NA,"1","2",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","15 mcg","21","18",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"1","2",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Eravacycline",NA,"0.25","0.25",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Eravacycline","20 mcg","20","20",FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","30 mcg","23","23",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline",NA,"1","2",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","30 mcg","22","19",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline",NA,"0.5","0.5",FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","15 mcg","19","19",FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid",NA,"4","4",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","10 mcg","21","21",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","2 mcg","21","21",FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"8","8",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","30 mcg","18","18",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"1","1",FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"Note","Note",FALSE,"[A] Use an MIC method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"32","32",FALSE,"[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[A] Use an MIC method.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid",NA,"1","1",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","10 mcg","24","24",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. aureus",NA,"Lefamulin",NA,"0.25","0.25",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. aureus",NA,"Lefamulin","5 mcg","23","23",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","13","13",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin",NA,"0.06","0.5",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin","5 mcg","26","23",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","14","14",FALSE,NA,"Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4",FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","17","14",FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin",NA,"4","8",FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","2 mcg","10","8",FALSE,"[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"4","8",FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"4","8",FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"4","8",FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note",FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem",NA,"0.001","4",FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","10 mcg","50","21",FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note",FALSE,"[1] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note",FALSE,"[B] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","12","12",FALSE,"[C] | [C] Susceptibility of ciprofloxacin and levofloxacin can be inferred from the norfloxacin susceptibility. For moxifloxacin, see comment 1/B.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note",FALSE,"[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","30 mcg","Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","30 mcg","Note","Note",FALSE,"[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note",FALSE,"[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)",NA,"Note","Note","[3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)",NA,"Note","Note",FALSE,"[3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","300 mcg","Note","Note","[B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","300 mcg","Note","Note",FALSE,"[B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note",FALSE,"[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",NA,"Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",NA,"Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin",NA,"4","4",NA,"Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","5 mcg","12","12","[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","4",NA,"Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","20",NA,"Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. faecalis",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. faecalis",NA,"Eravacycline","20 mcg","22","22",NA,"Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. faecium",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. faecium",NA,"Eravacycline","20 mcg","24","24",NA,"Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. faecalis",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. faecalis",NA,"Tigecycline","15 mcg","20","20","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. faecium",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. faecium",NA,"Tigecycline","15 mcg","22","22","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","20","20",NA,"Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see http://www.eucast.org/guidance_documents/.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see http://www.eucast.org/guidance_documents/.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[2] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[3] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note","[B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note","[3] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [4] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note","[B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [4] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.25","0.25","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","18","18","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)",NA,"0.125","0.125","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)","1 unit","19","19","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test is not yet developed. Perform an MIC test.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"0.001","2",NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","50","17","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","Note","[C] | [C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","18","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin",NA,"0.25","0.5",NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","15 mcg","20","17",NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","23","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","20","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19","[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","19","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5","[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","2 mcg","18","18","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","19","19",NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.06","0.5",NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","15",NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"2","2",NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","IP","IP",NA,"Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.06","2","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"0.06","0.06","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)",NA,"0.5","2","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","2 mcg","22","16","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"0.5","0.5","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"0.5","0.5","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [D] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [D] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","1 mcg","20","Note","[E] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.001","0.5",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"0.5","2",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.5",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"0.5","2",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.5",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"1","1",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)",NA,"0.25","0.25",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC for meropenem.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"0.001","2",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","50","16","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","Note","[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","19","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin",NA,"0.25","0.5",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","15 mcg","23","20",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","24","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","22","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","2",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","22",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"8","8","[1] For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","30 mcg","21","21","[1] For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","5 mcg","12","12",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.125","0.5",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","17",NA,"S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","13","10","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin",NA,"0.25","2",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","1 unit","18","12",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)",NA,"0.25","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","1 unit","18","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin",NA,"0.5","2",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","2 mcg","21","15",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"0.5","2",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem",NA,"1","1",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. anginosus group",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. anginosus group",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test is not yet developed. Perform an MIC test.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[1] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci .The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[B] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci .The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19","[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","20 mcg","17","17",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid","2 mcg","18","18",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[1] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[A] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","1 unit","12","Note","[1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)",NA,"1","1","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","2 mcg","18","18","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1","[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","10/10 mcg","Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"2","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"0.001","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.001","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","50","15","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25","[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime",NA,"0.125","0.125","[4] The breakpoints also apply to meningitis.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [4] The breakpoints also apply to meningitis.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)",NA,"0.5","0.5","[2] See table of dosages for dosing for different indications.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","30/10 mcg","23","23","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] See table of dosages for dosing for different indications.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone",NA,"0.125","0.125","[4] The breakpoints also apply to meningitis.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [4] The breakpoints also apply to meningitis.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.001","1",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem",NA,"1","1","[1] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","10 mcg","23","23","[1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)",NA,"0.25","0.25",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC for meropenem.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","Note","[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","1","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","24","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","22","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",NA,"H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","20","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","1",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","18",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.001","4",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem",NA,"1","1","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","10 mcg","30","30","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","Note","[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.5",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","20","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin",NA,"0.25","0.5",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","15 mcg","23","20",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","1","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","25","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"1","2","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","28","25","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[1] For topical use of chloramphenicol, see tables of topical agents.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[A] For topical use of chloramphenicol, see tables of topical agents.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)",NA,"0.06","1","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",NA,"N.gonorrhoeae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"N.gonorrhoeae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"N.gonorrhoeae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",NA,"N.gonorrhoeae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",NA,"N.gonorrhoeae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note","[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","1",NA,"N.gonorrhoeae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",NA,"N.gonorrhoeae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin",NA,"0.25","0.25",NA,"N.meningitidis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime",NA,"0.125","0.125","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone",NA,"0.125","0.125","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections.","N.meningitidis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections.","N.meningitidis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections. | [3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections.","N.meningitidis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (meningitis)",NA,"0.25","0.25","[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections.","N.meningitidis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections. | [3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin",NA,"0.03","0.03","[1] Breakpoints apply only to use in the prophylaxis of meningococcal disease.","N.meningitidis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","N.meningitidis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin",NA,"0.25","0.25","[2] For prophylaxis of meningitis only (refer to national guidelines).","N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","5 mcg","12","12",FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","4",FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","20",FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. faecalis",NA,"Eravacycline",NA,"0.125","0.125",FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. faecalis",NA,"Eravacycline","20 mcg","22","22",FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. faecium",NA,"Eravacycline",NA,"0.125","0.125",FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. faecium",NA,"Eravacycline","20 mcg","24","24",FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. faecalis",NA,"Tigecycline",NA,"0.25","0.25",FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. faecalis",NA,"Tigecycline","15 mcg","20","20",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. faecium",NA,"Tigecycline",NA,"0.25","0.25",FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. faecium",NA,"Tigecycline","15 mcg","22","22",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","20","20",FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE",FALSE,"[1] For more information, see http://www.eucast.org/guidance_documents/.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE",FALSE,"[1] For more information, see http://www.eucast.org/guidance_documents/.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note",FALSE,"[2] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note",FALSE,"[A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note",FALSE,"[3] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note",FALSE,"[B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note",FALSE,"[3] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [4] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note",FALSE,"[B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [4] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.25","0.25",FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","18","18",FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)",NA,"0.125","0.125",FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)","1 unit","19","19",FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"0.03","0.03",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"Note","Note",FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"0.001","2",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","50","17",FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19",FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","Note",FALSE,"[C] | [C] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","18",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","1",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin",NA,"0.25","0.5",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","15 mcg","20","17",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17",FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","2",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","23",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","2",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","20",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125",FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19",FALSE,"[2] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","2",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","19",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5",FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","2 mcg","18","18",FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","19","19",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1",FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note",FALSE,"[A] Use an MIC method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.06","0.5",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","15",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"2","2",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","IP","IP",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2",FALSE,"[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15",FALSE,"[3] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.06","2",FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"0.06","0.06",FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)",NA,"0.5","2",FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","2 mcg","22","16",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"0.5","0.5",FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"0.5","0.5",FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1",FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [D] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1",FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [D] Perform an MIC or infer susceptibility from the ampicillin 2 µg disk diffusion test with ampicillin breakpoints S≥22, R<19 mm. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","1 mcg","20","Note",FALSE,"[E] For interpretation of the oxacillin disk screen, see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.001","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"0.5","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"0.5","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"1","1",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)",NA,"0.25","0.25",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem(meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk screen test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] For isolates with oxacillin inhibition zone <20 mm, or benzylpenicillin MIC >0.06 mg/L, determine the MIC for meropenem.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"0.001","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","50","16",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","Note",FALSE,"[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as non-susceptible should be tested for susceptibility to individual agents.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17",FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16",FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","19",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","1",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin",NA,"0.25","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","15 mcg","23","20",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19",FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","2",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","24",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","2",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","22",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","22",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"8","8",FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","5 mcg","12","12",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.125","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","17",FALSE,NA,"S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","13","10",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin",NA,"0.25","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","1 unit","18","12",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)",NA,"0.25","Note",FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","1 unit","18","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin",NA,"0.5","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","2 mcg","21","15",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"0.5","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note",FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem",NA,"1","1",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"2","2",FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. anginosus group",NA,"Delafloxacin",NA,"0.03","0.03",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. anginosus group",NA,"Delafloxacin",NA,"Note","Note",FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note",FALSE,"[1] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci .The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note",FALSE,"[B] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci .The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19",FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","20 mcg","17","17",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid","2 mcg","18","18",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note",FALSE,"[1] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note",FALSE,"[A] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","1 unit","12","Note",FALSE,"[1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)",NA,"1","1",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","2 mcg","18","18",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1",FALSE,"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam","10/10 mcg","Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"2","2",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"0.001","2",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2",FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.001","2",FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","50","15",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25",FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime",NA,"0.125","0.125",FALSE,"[4] The breakpoints also apply to meningitis.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","5 mcg","27","27",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [4] The breakpoints also apply to meningitis.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)",NA,"0.5","0.5",FALSE,"[2] See table of dosages for dosing for different indications.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","30/10 mcg","23","23",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] See table of dosages for dosing for different indications.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone",NA,"0.125","0.125",FALSE,"[4] The breakpoints also apply to meningitis.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","30 mcg","32","32",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [4] The breakpoints also apply to meningitis.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.001","1",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem",NA,"1","1",FALSE,"[1] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","10 mcg","23","23",FALSE,"[1/A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)",NA,"0.25","0.25",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem(meningitis)",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk screen test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC for meropenem.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","5 mcg","30","30",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","Note",FALSE,"[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","2",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","1",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","24",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"1","2",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","22",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2",FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28",FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",FALSE,NA,"H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","20",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1",FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1",FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","1",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","18",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.001","4",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem",NA,"1","1",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","10 mcg","30","30",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","Note",FALSE,"[B] | [B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.5",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","20",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","1",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin",NA,"0.25","0.5",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","15 mcg","23","20",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","2",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","1",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","25",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"1","2",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","28","25",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline and minocycline, but some resistant to tetracycline may be susceptible to minocycline and/or doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note",FALSE,"[1] For topical use of chloramphenicol, see tables of topical agents.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note",FALSE,"[A] For topical use of chloramphenicol, see tables of topical agents.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)",NA,"0.06","1",FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note",FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","1",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin",NA,"0.25","0.25",FALSE,NA,"N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)",NA,"0.125","1",FALSE,NA,"N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)",NA,"0.125","1",FALSE,NA,"N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime",NA,"0.125","0.125",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone",NA,"0.125","0.125",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem",NA,"Note","Note",FALSE,"[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections.","N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem",NA,"Note","Note",FALSE,"[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections.","N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections. | [3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note",FALSE,"[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections.","N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (meningitis)",NA,"0.25","0.25",FALSE,"[1] Non-susceptible isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections.","N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. The meningitis breakpoint can be used to categorise meropenem for other serious infections. | [3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin",NA,"0.03","0.03",FALSE,"[1] Breakpoints apply only to use in the prophylaxis of meningococcal disease.","N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline",NA,"2","2",FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)",NA,"2","2",FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages.","N.meningitidis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin",NA,"0.25","0.25",FALSE,"[2] For prophylaxis of meningitis only (refer to national guidelines).","N.meningitidis" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Benzylpenicillin",NA,"0.25","0.5","[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Benzylpenicillin",NA,"0.25","0.5",FALSE,"[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ampicillin",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Ampicillin",NA,"4","8",FALSE,"[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ampicillin-sulbactam",NA,"4","8","[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Ampicillin-sulbactam",NA,"4","8",FALSE,"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Amoxicillin",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Amoxicillin",NA,"4","8",FALSE,"[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Amoxicillin-clavulanic acid",NA,"4","8",FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Piperacillin",NA,"8","16","[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Piperacillin",NA,"8","16",FALSE,"[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Piperacillin-tazobactam",NA,"8","16","[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Piperacillin-tazobactam",NA,"8","16",FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ticarcillin",NA,"8","16","[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Ticarcillin",NA,"8","16",FALSE,"[2] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Ticarcillin-clavulanic acid",NA,"8","16",FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Cefiderocol",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Cefoxitin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Doripenem",NA,"1","1",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Doripenem",NA,"1","1",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Ertapenem",NA,"0.5","0.5",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Imipenem",NA,"2","4",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Imipenem",NA,"2","4",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Imipenem-relebactam",NA,"2","2",FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Meropenem",NA,"2","8",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Meropenem",NA,"2","8",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Moxifloxacin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Moxifloxacin",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Dalbavancin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Oritavancin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Teicoplanin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Teicoplanin",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Telavancin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Vancomycin",NA,"2","2",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Erythromycin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Erythromycin",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Clindamycin",NA,"4","4",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Clindamycin",NA,"4","4",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Doxycycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Doxycycline",NA,"Note","Note",FALSE,"[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Eravacycline",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Minocycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Minocycline",NA,"Note","Note",FALSE,"[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Tetracycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Tetracycline",NA,"Note","Note",FALSE,"[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Tigecycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Tigecycline",NA,"Note","Note",FALSE,"[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Chloramphenicol",NA,"8","8",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Chloramphenicol",NA,"8","8",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Lefamulin",NA,"IE","IE",NA,"Anaerobes, Grampositive" +except Clostridioides difficile",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"Anaerobes, Grampositive" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-positive anaerobes -except Clostridioides difficile",NA,"Metronidazole",NA,"4","4",NA,"Anaerobes, Grampositive" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with vancomycin. There are no conclusive clinical data regarding the relation between MICs and outcomes.","C.difficile" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IE","IE","[4] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distribution between studies.","C.difficile" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2","[5] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with metronidazole. There are no conclusive clinical data regarding the relation between MICs and outcomes.","C.difficile" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Benzylpenicillin",NA,"0.25","0.5","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin",NA,"0.5","2","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin-sulbactam",NA,"4","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobes, Gramnegative" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin",NA,"0.5","2","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Gramnegative" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin",NA,"16","16","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin-tazobactam",NA,"8","16","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobes, Gramnegative" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin",NA,"16","16","[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Gramnegative" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Anaerobes, Gramnegative" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Cefoxitin",NA,"IE","IE",NA,"Anaerobes, Gramnegative" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"Anaerobes, Gramnegative" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Doripenem",NA,"1","1",NA,"Anaerobes, Gramnegative" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ertapenem",NA,"0.5","0.5",NA,"Anaerobes, Gramnegative" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem",NA,"2","4",NA,"Anaerobes, Gramnegative" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Anaerobes, Gramnegative" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem",NA,"2","8",NA,"Anaerobes, Gramnegative" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Anaerobes, Gramnegative" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Moxifloxacin",NA,"IE","IE",NA,"Anaerobes, Gramnegative" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Erythromycin",NA,"IE","IE",NA,"Anaerobes, Gramnegative" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Clindamycin",NA,"4","4",NA,"Anaerobes, Gramnegative" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Doxycycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Eravacycline",NA,"IE","IE",NA,"Anaerobes, Gramnegative" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Minocycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tetracycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tigecycline",NA,"Note","Note","[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Chloramphenicol",NA,"8","8",NA,"Anaerobes, Gramnegative" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Metronidazole",NA,"4","4",NA,"Anaerobes, Gramnegative" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral",NA,"0.125","0.125",NA,"H.pylori" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1",NA,"H.pylori" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.5",NA,"H.pylori" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1",NA,"H.pylori" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8",NA,"H.pylori" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1",NA,"H.pylori" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","13","13",NA,"L.monocytogenes" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv",NA,"1","1",NA,"L.monocytogenes" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv","2 mcg","16","16",NA,"L.monocytogenes" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem",NA,"0.25","0.25",NA,"L.monocytogenes" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem","10 mcg","26","26",NA,"L.monocytogenes" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin",NA,"1","1",NA,"L.monocytogenes" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin","15 mcg","25","25",NA,"L.monocytogenes" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole",NA,"0.06","0.06","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","29","29","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Benzylpenicillin",NA,"0.5","0.5",NA,"P.multocida" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Benzylpenicillin","1 unit","17","17",NA,"P.multocida" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"1","1",NA,"P.multocida" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"1","1",NA,"P.multocida" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",NA,"P.multocida" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Cefotaxime",NA,"0.03","0.03",NA,"P.multocida" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Cefotaxime","5 mcg","26","26",NA,"P.multocida" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"P.multocida" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ciprofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Levofloxacin",NA,"0.06","0.06",NA,"P.multocida" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Levofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Nalidixic acid (screen only)","30 mcg","23","Note","[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","P.multocida" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"1","1",NA,"P.multocida" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility inferred from tetracycline screen test.","P.multocida" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Tetracycline (screen only)","30 mcg","24","24","[A] Susceptibility inferred from tetracycline screen test.","P.multocida" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"C.jejuni_C.coli" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","5 mcg","50","26",NA,"C.jejuni_C.coli" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","24","24","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note","[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","30 mcg","30","30","[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Corynebacterium" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","1 unit","29","29",NA,"Corynebacterium" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Corynebacterium" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","5 mcg","50","25",NA,"Corynebacterium" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Corynebacterium" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Moxifloxacin","5 mcg","25","25",NA,"Corynebacterium" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Vancomycin",NA,"2","2",NA,"Corynebacterium" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Vancomycin","5 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Erythromycin",NA,"IP","IP",NA,"Corynebacterium" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Erythromycin","15 mcg","IP","IP",NA,"Corynebacterium" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Clindamycin","2 mcg","20","20","[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Tetracycline",NA,"2","2",NA,"Corynebacterium" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Tetracycline","30 mcg","24","24",NA,"Corynebacterium" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Linezolid",NA,"2","2",NA,"Corynebacterium" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Linezolid","10 mcg","25","25",NA,"Corynebacterium" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Rifampicin",NA,"0.06","0.5",NA,"Corynebacterium" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Rifampicin","5 mcg","30","25",NA,"Corynebacterium" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","1 unit","21","21",NA,"A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","2 mcg","26","26",NA,"A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note","[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","10 mcg","31","31",NA,"A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",NA,"A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21","[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2","[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","Note","Note","[B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Norfloxacin (screen only)","10 mcg","17","17","[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin",NA,"1","1",NA,"A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",NA,"A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",NA,"A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","5 mcg","25","25",NA,"A.sanguinicola_A.urinae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",NA,"K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",NA,"K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[3] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",NA,"K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",NA,"K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",NA,"K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",NA,"K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",NA,"K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",NA,"K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",NA,"K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",NA,"K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",NA,"K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",NA,"K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",NA,"K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",NA,"K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",NA,"Aeromonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",NA,"Aeromonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",NA,"Aeromonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",NA,"Aeromonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",NA,"Aeromonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",NA,"Aeromonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Aeromonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",NA,"Aeromonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Aeromonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",NA,"Aeromonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","19","16","[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam",NA,"4","4","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"A.xylosoxidans" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem",NA,"1","4",NA,"A.xylosoxidans" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","10 mcg","26","20",NA,"A.xylosoxidans" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","26","26","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" +except Clostridioides difficile",NA,"Metronidazole",NA,"4","4",FALSE,NA,"Anaerobes, Grampositive" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2",FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with vancomycin. There are no conclusive clinical data regarding the relation between MICs and outcomes.","C.difficile" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IE","IE",FALSE,"[4] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distribution between studies.","C.difficile" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2",FALSE,"[5] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections with metronidazole. There are no conclusive clinical data regarding the relation between MICs and outcomes.","C.difficile" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Benzylpenicillin",NA,"0.25","0.5",FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin",NA,"0.5","2",FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ampicillin-sulbactam",NA,"4","8",FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin",NA,"0.5","2",FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Amoxicillin-clavulanic acid",NA,"4","8",FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin",NA,"16","16",FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Piperacillin-tazobactam",NA,"8","16",FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin",NA,"16","16",FALSE,"[1] Susceptibility to ampicillin, amoxicillin, piperacillin and ticarcillin can be inferred from susceptibility to benzylpenicillin.","Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ticarcillin-clavulanic acid",NA,"8","16",FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Doripenem",NA,"1","1",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem",NA,"2","4",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Imipenem-relebactam",NA,"2","2",FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem",NA,"2","8",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Moxifloxacin",NA,"IE","IE",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Erythromycin",NA,"IE","IE",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Clindamycin",NA,"4","4",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Doxycycline",NA,"Note","Note",FALSE,"[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Minocycline",NA,"Note","Note",FALSE,"[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tetracycline",NA,"Note","Note",FALSE,"[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Tigecycline",NA,"Note","Note",FALSE,"[1] For anaerobic bacteria there is clinical evidence of activity in mixed intra-abdominal infections, but no correlation between MIC values, PK-PD data and clinical outcome. Therefore no breakpoints for susceptibility testing are given.","Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Chloramphenicol",NA,"8","8",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Gram-negative anaerobes",NA,"Metronidazole",NA,"4","4",FALSE,NA,"Anaerobes, Gramnegative" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral",NA,"0.125","0.125",FALSE,NA,"H.pylori" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1",FALSE,NA,"H.pylori" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.5",FALSE,NA,"H.pylori" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1",FALSE,NA,"H.pylori" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8",FALSE,NA,"H.pylori" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1",FALSE,NA,"H.pylori" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)",NA,"1","1",FALSE,NA,"L.monocytogenes" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","13","13",FALSE,NA,"L.monocytogenes" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",FALSE,NA,"L.monocytogenes" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",FALSE,NA,"L.monocytogenes" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv",NA,"1","1",FALSE,NA,"L.monocytogenes" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv","2 mcg","16","16",FALSE,NA,"L.monocytogenes" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem",NA,"0.25","0.25",FALSE,NA,"L.monocytogenes" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem","10 mcg","26","26",FALSE,NA,"L.monocytogenes" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin",NA,"1","1",FALSE,NA,"L.monocytogenes" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin","15 mcg","25","25",FALSE,NA,"L.monocytogenes" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole",NA,"0.06","0.06",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","29","29",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Benzylpenicillin",NA,"0.5","0.5",FALSE,NA,"P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Benzylpenicillin","1 unit","17","17",FALSE,NA,"P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"1","1",FALSE,NA,"P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"1","1",FALSE,NA,"P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid",NA,"1","1",FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",FALSE,NA,"P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Cefotaxime",NA,"0.03","0.03",FALSE,NA,"P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Cefotaxime","5 mcg","26","26",FALSE,NA,"P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,NA,"P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ciprofloxacin","5 mcg","27","27",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Levofloxacin",NA,"0.06","0.06",FALSE,NA,"P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Levofloxacin","5 mcg","27","27",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Nalidixic acid (screen only)","30 mcg","23","Note",FALSE,"[B] Isolates categorised as susceptible to nalidixic acid can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as non-susceptible may have fluoroquinolone resistance and should be tested against the appropriate agent.","P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"1","1",FALSE,NA,"P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Tetracycline (screen only)","30 mcg","24","24",FALSE,"[A] Susceptibility inferred from tetracycline screen test.","P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin",NA,"0.001","0.5",FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","5 mcg","50","26",FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","24","24",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note",FALSE,"[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Tetracycline",NA,"2","2",FALSE,"[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","30 mcg","30","30",FALSE,"[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Benzylpenicillin",NA,"0.125","0.125",FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","1 unit","29","29",FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Ciprofloxacin",NA,"0.001","1",FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","5 mcg","50","25",FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Moxifloxacin",NA,"0.5","0.5",FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Moxifloxacin","5 mcg","25","25",FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Vancomycin","5 mcg","17","17",FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Erythromycin",NA,"IP","IP",FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Erythromycin","15 mcg","IP","IP",FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Clindamycin","2 mcg","20","20",FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Tetracycline",NA,"2","2",FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Tetracycline","30 mcg","24","24",FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Linezolid",NA,"2","2",FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Linezolid","10 mcg","25","25",FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Rifampicin",NA,"0.06","0.5",FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Rifampicin","5 mcg","30","25",FALSE,NA,"Corynebacterium" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","1 unit","21","21",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin",NA,"0.25","0.25",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","2 mcg","26","26",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem",NA,"0.25","0.25",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","10 mcg","31","31",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21",FALSE,"[A] Susceptibility can be inferred from norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2",FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","Note","Note",FALSE,"[B] Susceptibility can be inferred from ciprofloxacin or norfloxacin susceptibility. See Note","A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Norfloxacin (screen only)","10 mcg","17","17",FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin",NA,"1","1",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","5 mcg","16","16",FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin",NA,"0.125","0.125",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","5 mcg","25","25",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06",FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125",FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[3] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25",FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5",FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Isolates susceptible to tetracycline are also susceptible to doxycycline, but some resistant to tetracycline may be susceptible to doxycycline. An MIC method should be used to test doxycycline susceptibility of tetracycline resistant isolates if required.","K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",FALSE,NA,"K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",FALSE,NA,"Aeromonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",FALSE,NA,"Aeromonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",FALSE,NA,"Aeromonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",FALSE,NA,"Aeromonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",FALSE,NA,"Aeromonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",FALSE,NA,"Aeromonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",FALSE,NA,"Aeromonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",FALSE,NA,"Aeromonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",FALSE,NA,"Aeromonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",FALSE,NA,"Aeromonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","19","16",FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam",NA,"4","4",FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",FALSE,NA,"A.xylosoxidans" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem",NA,"1","4",FALSE,NA,"A.xylosoxidans" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","10 mcg","26","20",FALSE,NA,"A.xylosoxidans" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","26","26",FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Imipenem",NA,"0.5","0.5",NA,"Bacillus" +except B. anthracis",NA,"Imipenem",NA,"0.5","0.5",FALSE,NA,"Bacillus" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Imipenem","10 mcg","30","30",NA,"Bacillus" +except B. anthracis",NA,"Imipenem","10 mcg","30","30",FALSE,NA,"Bacillus" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Meropenem",NA,"0.25","0.25",NA,"Bacillus" +except B. anthracis",NA,"Meropenem",NA,"0.25","0.25",FALSE,NA,"Bacillus" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Meropenem","10 mcg","25","25",NA,"Bacillus" +except B. anthracis",NA,"Meropenem","10 mcg","25","25",FALSE,NA,"Bacillus" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Bacillus" +except B. anthracis",NA,"Ciprofloxacin",NA,"0.001","0.5",FALSE,NA,"Bacillus" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Ciprofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +except B. anthracis",NA,"Ciprofloxacin","5 mcg","50","23",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Levofloxacin",NA,"0.001","1",NA,"Bacillus" +except B. anthracis",NA,"Levofloxacin",NA,"0.001","1",FALSE,NA,"Bacillus" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Levofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +except B. anthracis",NA,"Levofloxacin","5 mcg","50","23",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Norfloxacin (screen only)","10 mcg","21","21","[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as resistant to norfloxacin can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" +except B. anthracis",NA,"Norfloxacin (screen only)","10 mcg","21","21",FALSE,"[B] | [B] Isolates categorised as susceptible to norfloxacin can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as resistant to norfloxacin can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Vancomycin",NA,"2","2",NA,"Bacillus" +except B. anthracis",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Bacillus" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Vancomycin","5 mcg","10","10","[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" +except B. anthracis",NA,"Vancomycin","5 mcg","10","10",FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Erythromycin",NA,"0.5","0.5",NA,"Bacillus" +except B. anthracis",NA,"Erythromycin",NA,"0.5","0.5",FALSE,NA,"Bacillus" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Erythromycin","15 mcg","24","24",NA,"Bacillus" +except B. anthracis",NA,"Erythromycin","15 mcg","24","24",FALSE,NA,"Bacillus" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Clindamycin",NA,"1","1",NA,"Bacillus" +except B. anthracis",NA,"Clindamycin",NA,"1","1",FALSE,NA,"Bacillus" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Clindamycin","2 mcg","17","17",NA,"Bacillus" +except B. anthracis",NA,"Clindamycin","2 mcg","17","17",FALSE,NA,"Bacillus" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Linezolid",NA,"2","2",NA,"Bacillus" +except B. anthracis",NA,"Linezolid",NA,"2","2",FALSE,NA,"Bacillus" "EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Linezolid","10 mcg","22","22",NA,"Bacillus" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid",NA,"0.001","8","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","20/10 mcg","50","22",NA,"B.pseudomallei" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime",NA,"0.001","8",NA,"B.pseudomallei" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","10 mcg","50","18",NA,"B.pseudomallei" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem",NA,"2","2",NA,"B.pseudomallei" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","10 mcg","29","29",NA,"B.pseudomallei" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem",NA,"2","2",NA,"B.pseudomallei" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","10 mcg","24","24",NA,"B.pseudomallei" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"0.001","2",NA,"B.pseudomallei" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","30 mcg","50","23","[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol",NA,"0.001","8",NA,"B.pseudomallei" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","30 mcg","50","22",NA,"B.pseudomallei" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","17","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25","[1] Breakpoints were determined on MICs performed on Middlebrook 7H11/7H10 medium. The comparability of tests performed by other media has not been established. There is ongoing work to review breakpoints using the EUCAST reference method (described above).","M.tuberculosis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06",NA,"M.tuberculosis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Pretomanid",NA,"IE","IE","[2] MIC data have been generated with MGIT system and not with the EUCAST reference method. Therefore, it has not been possible to set an ECOFF, nor calibrate MGIT MIC values against the reference method. Consequently, EUCAST cannot endorse the tentative breakpoint set by EMA based on the MGIT method. Breakpoints are pending MIC data with the reference method.","M.tuberculosis" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin",NA,"2","2",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","10 mcg","16","16",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)",NA,"8","8",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","10 mcg","12","12",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin",NA,"8","8",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","10 mcg","15","15",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","5 mcg","26","26",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","5 mcg","20","20",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","5 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","30 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)",NA,"4","4",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","21","21",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","23",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","5 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","30 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin",NA,"2","2",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","10 mcg","18","18",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","10 mcg","17","17","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","30 mcg","18","18",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","10 mcg","24","24",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)",NA,"1","1",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","10 mcg","14","14",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin",NA,"1","1","[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +except B. anthracis",NA,"Linezolid","10 mcg","22","22",FALSE,NA,"Bacillus" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid",NA,"0.001","8",FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","20/10 mcg","50","22",FALSE,NA,"B.pseudomallei" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime",NA,"0.001","8",FALSE,NA,"B.pseudomallei" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","10 mcg","50","18",FALSE,NA,"B.pseudomallei" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem",NA,"2","2",FALSE,NA,"B.pseudomallei" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","10 mcg","29","29",FALSE,NA,"B.pseudomallei" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem",NA,"2","2",FALSE,NA,"B.pseudomallei" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","10 mcg","24","24",FALSE,NA,"B.pseudomallei" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"0.001","2",FALSE,NA,"B.pseudomallei" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","30 mcg","50","23",FALSE,"[A] Susceptibility inferred from tetracycline disk diffusion screen test.","B.pseudomallei" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol",NA,"0.001","8",FALSE,NA,"B.pseudomallei" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","30 mcg","50","22",FALSE,NA,"B.pseudomallei" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","17",FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25",FALSE,"[1] Breakpoints were determined on MICs performed on Middlebrook 7H11/7H10 medium. The comparability of tests performed by other media has not been established. There is ongoing work to review breakpoints using the EUCAST reference method (described above).","M.tuberculosis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06",FALSE,NA,"M.tuberculosis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Pretomanid",NA,"IE","IE",FALSE,"[2] MIC data have been generated with MGIT system and not with the EUCAST reference method. Therefore, it has not been possible to set an ECOFF, nor calibrate MGIT MIC values against the reference method. Consequently, EUCAST cannot endorse the tentative breakpoint set by EMA based on the MGIT method. Breakpoints are pending MIC data with the reference method.","M.tuberculosis" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","10 mcg","17","17",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","10 mcg","16","16",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin",NA,"0.125","0.125",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin",NA,"0.25","0.25",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.25",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol",NA,"16","16",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","10 mcg","12","12",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","10 mcg","15","15",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","10 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","5 mcg","26","26",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","5 mcg","20","20",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","5 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","30 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin (framycetin)",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","21","21",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","23",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","5 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","30 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","10 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","10 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","10 mcg","17","17",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol",NA,"16","16",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","30 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","10 mcg","24","24",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","10 mcg","14","14",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin",NA,"1","1",FALSE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. ND = No ECOFF available.","Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","200 mcg","30","30","[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","200 mcg","30","30",FALSE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. ND = No ECOFF available.","Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Retapamulin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin",NA,"4","4",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"32","32",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","200 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"0.125","0.125",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin",NA,"4","4",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin",NA,"8","8",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","30 mcg","28","28",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","30 mcg","31","31",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin",NA,"8","8","[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin",NA,"8","8","[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid",NA,"8","8","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","20/10 mcg","19","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)",NA,"32","32","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","20/10 mcg","16","16","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","8",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","20",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","8","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","20",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin",NA,"8","16",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin","75 mcg","23","20",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)",NA,"0.001","16",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)","30 mcg","50","17","[C] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli, Citrobacter spp. Klebsiella spp.,  Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)",NA,"8","8","[5] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli, Citrobacter spp. Klebsiella spp.,  Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)","10 mcg","15","15","[C] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli, and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)",NA,"0.001","4","[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli, and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)","30 mcg","50","20","[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol",NA,"2","2","[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","30 mcg","22","22",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","5 mcg","20","17",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","5 mcg","20","20",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","30 mcg","19","19","[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)","10 mcg","21","21",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8","[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","30 mcg","23","23",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"2","2","[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [6] See table of dosages for dosing for different indications.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","22","22","[6] See table of dosages for dosing for different indications.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","25","22",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","30 mcg","25","25",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"0.001","8",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","50","19",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem",NA,"1","2",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","10 mcg","24","21",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","25","25",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem",NA,"2","4",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem","10 mcg","22","19",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Morganellaceae",NA,"Imipenem",NA,"0.001","4","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Morganellaceae",NA,"Imipenem","10 mcg","50","19","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam",NA,"2","2","[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","10 mcg","22","16",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","10 mcg","22","22",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8","[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","20/10 mcg","20","20",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin","5 mcg","25","22",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06","[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note","[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Salmonella spp.",NA,"Pefloxacin (screen only)","5 mcg","24","24","[2/C] The pefloxacin 5 µg breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp. | [B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from the pefloxacin disk diffusion screening test. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli",NA,"Delafloxacin",NA,"0.125","0.125",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli",NA,"Delafloxacin",NA,"Note","Note","[D] A disk diffusion test is not yet developed. Perform an MIC test.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","5 mcg","22","22",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","0.5",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","22","22",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","30 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","18","18",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","10 mcg","16","16","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","16","16",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli",NA,"Eravacycline","20 mcg","17","17",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18","[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"8","8","[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17","[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"2","2","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv",NA,"32","32","[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","200 mcg","21","21","[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)",NA,"8","8","[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)","200 mcg","24","24","[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","15","15",NA,"Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"0.001","16",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"0.001","16","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin",NA,"0.001","16",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin","75 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"0.001","16","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"0.001","8",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","50","21",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"P. aeruginosa",NA,"Cefiderocol",NA,"2","2","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"P. aeruginosa",NA,"Cefiderocol","30 mcg","22","22",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"0.001","8",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","50","17",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] See table of dosages for dosing for different indications.","Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","23","23","[3] See table of dosages for dosing for different indications.","Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem",NA,"0.001","2",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","10 mcg","50","22",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"0.001","4",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","50","20",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"P. aeruginosa",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"P. aeruginosa",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)","10 mcg","20","14",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)",NA,"2","8",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)","10 mcg","24","18",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (meningitis)","10 mcg","20","20",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","20/10 mcg","14","14",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"0.001","16",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","50","26",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"0.001","2",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"16","16",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","15","15",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","18","18",NA,"Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"4","4","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"IE","IE","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","S.maltophilia" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"Note","Note","[A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","16","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"IE","IE","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"Note","Note","[A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem",NA,"0.001","2",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","10 mcg","50","22",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","10/25 mcg","24","24","[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","10 mcg","21","15",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","10 mcg","21","21",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","30 mcg","19","19","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","19","19",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"2","2","[2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Benzylpenicillin",NA,"0.125","0.125","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Benzylpenicillin","1 unit","26","26","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. lugdunensis",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. lugdunensis",NA,"Benzylpenicillin","1 unit","26","26",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. saprophyticus",NA,"Ampicillin",NA,"Note","Note","[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. saprophyticus",NA,"Ampicillin","2 mcg","18","18","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. pseudinter-medius, S. schleiferi and S. coagulans",NA,"Oxacillin (screen only)","1 mcg","20","20","[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. aureus",NA,"Retapamulin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","21","21",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"32","32",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","200 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"0.125","0.125",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin",NA,"0.06","0.06",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin",NA,"0.06","0.06",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","30 mcg","28","28",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","H. influenzae",NA,"Neomycin (framycetin)",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","H. influenzae",NA,"Neomycin (framycetin)","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H.influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","30 mcg","31","31",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin (framycetin)",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2021","11.0","Clinical Breakpoint Tables v. 11.0","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin",NA,"8","8",FALSE,"[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin","10 mcg","14","14",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam",NA,"8","8",FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam","10/10 mcg","14","14",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin",NA,"8","8",FALSE,"[1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin","/ mcg","Note","Note",FALSE,"[B] Susceptibility inferred from ampicillin. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid",NA,"8","8",FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid","20/10 mcg","19","19",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] Aminopenicillin breakpoints in Enterobacterales are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only. Breakpoints for other infections are under review.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)",NA,"32","32",FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid (uncomplicated UTI only)","20/10 mcg","16","16",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","8",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","20",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","8",FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","20",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin",NA,"8","16",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin","75 mcg","23","20",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16",FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)",NA,"0.001","16",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)","30 mcg","50","17",FALSE,"[C] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli, Citrobacter spp. Klebsiella spp.,  Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)",NA,"8","8",FALSE,"[5] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli, Citrobacter spp. Klebsiella spp.,  Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)","10 mcg","15","15",FALSE,"[C] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli, and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)",NA,"0.001","4",FALSE,"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli, and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)","30 mcg","50","20",FALSE,"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol",NA,"2","2",FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","30 mcg","22","22",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)",NA,"1","2",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","5 mcg","20","17",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","5 mcg","20","20",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)",NA,"Note","Note",FALSE,"[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","30 mcg","19","19",FALSE,"[4] The cefoxitin ECOFF (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)","10 mcg","21","21",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8",FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","30 mcg","23","23",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"2","2",FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [6] See table of dosages for dosing for different indications.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","22","22",FALSE,"[6] See table of dosages for dosing for different indications.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)",NA,"1","2",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","25","22",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","30 mcg","25","25",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"0.001","8",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","50","19",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem",NA,"1","2",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","10 mcg","24","21",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","25","25",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem",NA,"2","4",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem","10 mcg","22","19",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Morganellaceae",NA,"Imipenem",NA,"0.001","4",FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Morganellaceae",NA,"Imipenem","10 mcg","50","19",FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam",NA,"2","2",FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam","10/25 mcg","22","22",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)",NA,"2","8",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","10 mcg","22","16",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)",NA,"2","2",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","10 mcg","22","22",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8",FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","20/10 mcg","20","20",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4",FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21",FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin",NA,"0.25","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin","5 mcg","25","22",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note",FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. To screen for ciprofloxacin resistance in Salmonella spp., use the pefloxacin 5 µg disk. See Note | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Salmonella spp.",NA,"Pefloxacin (screen only)","5 mcg","24","24",FALSE,"[2/C] The pefloxacin 5 µg breakpoint used to screen for clinical fluoroquinolone resistance in Salmonella spp., can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp. | [B] | [B] Susceptibility of Salmonella spp. to ciprofloxacin can be inferred from the pefloxacin disk diffusion screening test. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli",NA,"Delafloxacin",NA,"0.125","0.125",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli",NA,"Delafloxacin",NA,"Note","Note",FALSE,"[D] A disk diffusion test is not yet developed. Perform an MIC test.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin",NA,"0.25","0.25",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","5 mcg","22","22",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","22","22",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)",NA,"(8)","(8)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","30 mcg","(18)","(18)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","18","18",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","10 mcg","(17)","(17)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)",NA,"2","2",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","10 mcg","(16)","(16)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","16","16",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli",NA,"Eravacycline","20 mcg","17","17",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5",FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18",FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"8","8",FALSE,"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",FALSE,"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"(2)","(2)",TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note",FALSE,"[A] Use an MIC method (broth microdilution only). | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv",NA,"32","32",FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","200 mcg","21","21",FALSE,"[C] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)",NA,"8","8",FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)","200 mcg","24","24",FALSE,"[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","15","15",FALSE,NA,"Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4",FALSE,"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11",FALSE,"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"0.001","16",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"0.001","16",FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin",NA,"0.001","16",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin","75 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"0.001","16",FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"0.001","8",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","50","21",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"P. aeruginosa",NA,"Cefiderocol",NA,"2","2",FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"P. aeruginosa",NA,"Cefiderocol","30 mcg","22","22",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"0.001","8",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","50","17",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8",FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4",FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] See table of dosages for dosing for different indications.","Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","23","23",FALSE,"[3] See table of dosages for dosing for different indications.","Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem",NA,"0.001","2",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","10 mcg","50","22",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"0.001","4",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","50","20",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"P. aeruginosa",NA,"Imipenem-relebactam",NA,"2","2",FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"P. aeruginosa",NA,"Imipenem-relebactam","10/25 mcg","22","22",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)",NA,"2","8",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)","10 mcg","20","14",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)",NA,"2","8",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)","10 mcg","24","18",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (meningitis)",NA,"2","2",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (meningitis)","10 mcg","20","20",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8",FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","20/10 mcg","14","14",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"0.001","16",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.001","0.5",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","50","26",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"0.001","2",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)",NA,"(16)","(16)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","30 mcg","(15)","(15)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"16","16",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","15","15",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","10 mcg","(18)","(18)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","18","18",FALSE,NA,"Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"(4)","(4)",TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note",FALSE,"[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"IE","IE",FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","S.maltophilia" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"Note","Note",FALSE,"[A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","16",FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"IE","IE",FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"Note","Note",FALSE,"[A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem",NA,"0.001","2",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","10 mcg","50","22",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"2","2",FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","10/25 mcg","24","24",FALSE,"[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)",NA,"2","8",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","10 mcg","21","15",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)",NA,"2","2",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","10 mcg","21","21",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.001","1",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)",NA,"(8)","(8)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","30 mcg","(19)","(19)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","19","19",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)",NA,"(4)","(4)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","10 mcg","(17)","(17)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"4","4",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)",NA,"(4)","(4)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","10 mcg","(17)","(17)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"4","4",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"(2)","(2)",TRUE,"[2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note",FALSE,"[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4",FALSE,"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11",FALSE,"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Benzylpenicillin",NA,"0.125","0.125",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Benzylpenicillin","1 unit","26","26",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. lugdunensis",NA,"Benzylpenicillin",NA,"0.125","0.125",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. lugdunensis",NA,"Benzylpenicillin","1 unit","26","26",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note",FALSE,"[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note",FALSE,"[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. saprophyticus",NA,"Ampicillin",NA,"Note","Note",FALSE,"[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. saprophyticus",NA,"Ampicillin","2 mcg","18","18",FALSE,"[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. pseudinter-medius, S. schleiferi and S. coagulans",NA,"Oxacillin (screen only)","1 mcg","20","20",FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. 3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. 3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. 3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. 3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","22","22","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. epidermidis and S.lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. epidermidis and S.lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","27","27","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. pseudintermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note","[5] In S. pseudintermedius,S. schleiferiand S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. pseudintermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note","[C] In S. pseudintermedius,S. schleiferiand S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)",NA,"1","2","[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)","5 mcg","20","17","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (pneumonia)",NA,"1","1","[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (pneumonia)","5 mcg","20","20","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Ceftobiprole",NA,"2","2","[8] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Ceftobiprole","5 mcg","17","17","[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note",FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","22","22",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. epidermidis and S.lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note",FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. epidermidis and S.lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","27","27",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. pseudintermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note",FALSE,"[5] In S. pseudintermedius,S. schleiferiand S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. pseudintermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note",FALSE,"[C] In S. pseudintermedius,S. schleiferiand S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)",NA,"1","2",FALSE,"[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)","5 mcg","20","17",FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (pneumonia)",NA,"1","1",FALSE,"[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (pneumonia)","5 mcg","20","20",FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Ceftobiprole",NA,"2","2",FALSE,"[8] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Ceftobiprole","5 mcg","17","17",FALSE,"[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. 3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. 3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Ciprofloxacin","5 mcg","50","21","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin","5 mcg","50","24","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"0.016","0.016",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"Note","Note","[B] A disk diffusion test is not yet developed. Perform an MIC test.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"0.25","0.25",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"Note","Note","[B] A disk diffusion test is not yet developed. Perform an MIC test.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Levofloxacin","5 mcg","50","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin","5 mcg","50","24","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Moxifloxacin","5 mcg","25","25","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin","5 mcg","28","28","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","17","17","[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[2] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Amikacin",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Amikacin","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Amikacin",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Amikacin","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Gentamicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Gentamicin","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Gentamicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Gentamicin","10 mcg","22","22","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Tobramycin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Tobramycin","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Tobramycin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Tobramycin","10 mcg","20","20","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Oritavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Teicoplanin",NA,"2","2",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"4","4",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"MRSA",NA,"Telavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"MRSA",NA,"Telavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Vancomycin",NA,"2","2",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"4","4",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"2","2","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"1","2","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin",NA,"1","2",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","15 mcg","21","18",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin (screen only)",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin (screen only)","15 mcg","21","21","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"1","2","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telithromycin",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telithromycin",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin",NA,"0.25","0.25","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","2 mcg","22","22","[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin",NA,"1","2",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","15 mcg","21","18",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"1","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Eravacycline",NA,"0.25","0.25",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Eravacycline","20 mcg","20","20","[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline",NA,"1","2",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","30 mcg","22","19",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline (screen only)",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline (screen only)","30 mcg","22","22","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline",NA,"0.5","0.5","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","15 mcg","19","19","[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","10 mcg","21","21",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid",NA,"0.5","0.5","[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","2 mcg","20","20","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"8","8","[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","30 mcg","18","18","[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"1","1","[3] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"32","32","[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[A] Use an MIC method.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid",NA,"1","1",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","10 mcg","24","24",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Lefamulin",NA,"0.25","0.25",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Lefamulin","5 mcg","23","23",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","13","13",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin",NA,"0.06","0.06",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin","5 mcg","26","26",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","14","14",NA,"Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","17","14","[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","2 mcg","10","8","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem",NA,"0.001","4",NA,"Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","10 mcg","50","21",NA,"Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[1] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[B] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Ciprofloxacin",NA,"0.001","1",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Ciprofloxacin","5 mcg","50","21",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin",NA,"0.001","1",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin","5 mcg","50","24",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"0.016","0.016",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"Note","Note",FALSE,"[B] A disk diffusion test is not yet developed. Perform an MIC test.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"0.25","0.25",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"Note","Note",FALSE,"[B] A disk diffusion test is not yet developed. Perform an MIC test.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Levofloxacin",NA,"0.001","1",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Levofloxacin","5 mcg","50","22",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin",NA,"0.001","1",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin","5 mcg","50","24",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Moxifloxacin",NA,"0.25","0.25",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Moxifloxacin","5 mcg","25","25",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin",NA,"0.25","0.25",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin","5 mcg","28","28",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","17","17",FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note",FALSE,"[2] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note",FALSE,"[D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Amikacin",NA,"(16)","(16)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Amikacin","30 mcg","(15)","(15)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Amikacin",NA,"(16)","(16)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Amikacin","30 mcg","(15)","(15)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Gentamicin",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Gentamicin","10 mcg","(18)","(18)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Gentamicin",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Gentamicin","10 mcg","(22)","(22)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Tobramycin",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Tobramycin","10 mcg","(18)","(18)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Tobramycin",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Tobramycin","10 mcg","(20)","(20)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"0.125","0.125",FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Oritavancin",NA,"0.125","0.125",FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Oritavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Teicoplanin",NA,"2","2",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Teicoplanin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"4","4",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"MRSA",NA,"Telavancin",NA,"0.125","0.125",FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"MRSA",NA,"Telavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Vancomycin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"4","4",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"2","2",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"1","2",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin",NA,"1","2",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","15 mcg","21","18",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin (screen only)",NA,"1","1",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin (screen only)","15 mcg","21","21",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"1","2",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as screen negative can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telithromycin",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telithromycin",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin",NA,"0.25","0.25",FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","2 mcg","22","22",FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin",NA,"1","2",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","15 mcg","21","18",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"1","2",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Eravacycline",NA,"0.25","0.25",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Eravacycline","20 mcg","20","20",FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline",NA,"0.5","0.5",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","30 mcg","23","23",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline",NA,"1","2",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","30 mcg","22","19",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline (screen only)",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline (screen only)","30 mcg","22","22",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline",NA,"0.5","0.5",FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","15 mcg","19","19",FALSE,"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid",NA,"4","4",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","10 mcg","21","21",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","2 mcg","20","20",FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"8","8",FALSE,"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol","30 mcg","18","18",FALSE,"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"1","1",FALSE,"[3] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"Note","Note",FALSE,"[A] Use an MIC method. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"32","32",FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[A] Use an MIC method.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid",NA,"1","1",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","10 mcg","24","24",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. aureus",NA,"Lefamulin",NA,"0.25","0.25",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. aureus",NA,"Lefamulin","5 mcg","23","23",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","13","13",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Rifampicin",NA,"0.06","0.06",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Rifampicin","5 mcg","26","26",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","14","14",FALSE,NA,"Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4",FALSE,"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","17","14",FALSE,"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin",NA,"4","8",FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","2 mcg","10","8",FALSE,"[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"4","8",FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"4","8",FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"4","8",FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note",FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[2] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] Susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) can be inferred from ampicillin. Ampicillin resistance is uncommon in E. faecalis (confirm with MIC) but common in E. faecium.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem",NA,"0.001","4",FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","10 mcg","50","21",FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note",FALSE,"[1] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note",FALSE,"[B] There are no clinical breakpoints for Enterococcus spp. and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by Enterococcus spp. The norfloxacin disk diffusion test or the moxifloxacin MIC ECOFF (1 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","12","12",FALSE,"[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note",FALSE,"[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","30 mcg","Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","30 mcg","Note","Note",FALSE,"[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note",FALSE,"[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)",NA,"Note","Note","[3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)",NA,"Note","Note",FALSE,"[3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","300 mcg","Note","Note","[B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","300 mcg","Note","Note",FALSE,"[B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note",FALSE,"[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",NA,"Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",NA,"Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin",NA,"4","4",NA,"Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","5 mcg","12","12","[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","4",NA,"Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","20",NA,"Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. faecalis",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. faecalis",NA,"Eravacycline","20 mcg","22","22",NA,"Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. faecium",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. faecium",NA,"Eravacycline","20 mcg","24","24",NA,"Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. faecalis",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. faecalis",NA,"Tigecycline","15 mcg","20","20","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. faecium",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. faecium",NA,"Tigecycline","15 mcg","22","22","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","20","20",NA,"Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[2] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[3] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note","[B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note","[3] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [4] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note","[B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [4] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.25","0.25",NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","18","18",NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)",NA,"0.125","0.125",NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)","1 unit","19","19",NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","5 mcg","12","12",FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","4",FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","20",FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. faecalis",NA,"Eravacycline",NA,"0.125","0.125",FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. faecalis",NA,"Eravacycline","20 mcg","22","22",FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. faecium",NA,"Eravacycline",NA,"0.125","0.125",FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. faecium",NA,"Eravacycline","20 mcg","24","24",FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. faecalis",NA,"Tigecycline",NA,"0.25","0.25",FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. faecalis",NA,"Tigecycline","15 mcg","20","20",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. faecium",NA,"Tigecycline",NA,"0.25","0.25",FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. faecium",NA,"Tigecycline","15 mcg","22","22",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","20","20",FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE",FALSE,"[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE",FALSE,"[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note",FALSE,"[2] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note",FALSE,"[A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note",FALSE,"[3] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note",FALSE,"[B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note",FALSE,"[3] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [4] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note",FALSE,"[B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [4] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.25","0.25",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","18","18",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)",NA,"0.125","0.125",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)","1 unit","19","19",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test is not yet developed. Perform an MIC test.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"0.001","2",NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","50","17","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","18","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin",NA,"0.25","0.5",NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","15 mcg","20","17",NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","2",NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","20",NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline (screen only)",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline (screen only)","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19","[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","19","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5","[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","2 mcg","18","18","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8","[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","19","19","[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1","[3] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.06","0.06",NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","21",NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"2","2",NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","IP","IP",NA,"Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.06","2","[2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"0.06","0.06",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)",NA,"0.5","1",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","2 mcg","22","19",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"0.03","0.03",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"Note","Note",FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"0.001","2",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","50","17",FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19",FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12",FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","18",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","1",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin",NA,"0.25","0.5",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","15 mcg","20","17",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17",FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","2",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","0.5",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","23",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","2",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","20",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline (screen only)",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline (screen only)","30 mcg","23","23",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125",FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19",FALSE,"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","19",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5",FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","2 mcg","18","18",FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",FALSE,"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","19","19",FALSE,"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review. For chloramphenicol treatment in meningitis, see table of dosages.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1",FALSE,"[3] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note",FALSE,"[A] Use an MIC method. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.06","0.06",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","21",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"2","2",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","IP","IP",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2",FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15",FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.06","2",FALSE,"[2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"0.06","0.06",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)",NA,"0.5","1",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","2 mcg","22","19",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing. .","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing. .","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","1 mcg","20","Note","[D] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.001","0.5",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"0.5","2",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.5",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"0.5","2",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.5",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"1","1",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"0.001","2",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","50","16","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10","[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","19","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin",NA,"0.25","0.5",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","15 mcg","23","20",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","24","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","2",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","22",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline (screen only)",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline (screen only)","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","2",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","22",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"8","8","[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review.For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","30 mcg","21","21","[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review.For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","5 mcg","12","12",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.125","0.125",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","22",NA,"S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","13","10","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin",NA,"0.25","2",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","1 unit","18","12",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)",NA,"0.25","0.25","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","1 unit","18","18","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin",NA,"0.5","2",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","2 mcg","21","15",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"0.5","2",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem",NA,"1","1",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. anginosus group",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. anginosus group",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test is not yet developed. Perform an MIC test.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[1] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[B] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19","[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","20 mcg","17","17",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid","2 mcg","18","18",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[1] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[A] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","1 unit","12","Note","[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)",NA,"1","1","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","2 mcg","18","18","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1","[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"2","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"0.001","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.001","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","50","15","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25","[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)",NA,"0.5","0.5","[2] See table of dosages for dosing for different indications.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","30/10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] See table of dosages for dosing for different indications.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.001","1",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem",NA,"1","1",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC for meropenem.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","24","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",NA,"H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","20","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","1",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","18",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.001","4",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem",NA,"1","1","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","10 mcg","30","30","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.5","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.5",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","20","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","1","[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin",NA,"0.25","0.5",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","15 mcg","23","20",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","26","26","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[1] For topical use of chloramphenicol, see tables of topical agents.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[A] For topical use of chloramphenicol, see tables of topical agents.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)",NA,"0.06","1","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",NA,"N.gonorrhoeae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"N.gonorrhoeae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"N.gonorrhoeae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",NA,"N.gonorrhoeae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",NA,"N.gonorrhoeae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note","[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","1",NA,"N.gonorrhoeae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",NA,"N.gonorrhoeae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)",NA,"0.25","0.25",NA,"N.meningitidis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)",NA,"0.125","0.125","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)",NA,"0.125","0.125","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. 3.The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. 3.The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. 3.The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note",NA,"N.meningitidis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)",NA,"0.25","0.25","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. 3.The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. 3.The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (prophylaxis only)",NA,"0.03","0.03",NA,"N.meningitidis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)",NA,"1","1","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)",NA,"2","2","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","N.meningitidis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)",NA,"0.25","0.25",NA,"N.meningitidis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam",NA,"8","8","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","30/6 mcg","20","20",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"B. thetaiotaomicron",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"B. thetaiotaomicron",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem",NA,"1","1","[2] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene.","Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","10 mcg","28","28","[A] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene.","Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin",NA,"4","4","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","2 mcg","10","10","[B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","5 mcg","25","25",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","1 unit","20","20",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem",NA,"0.25","0.25",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","10 mcg","34","34",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","2 mcg","31","31","[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","5 mcg","22","22",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin",NA,"0.06","0.06",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","1 unit","25","25",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","30/6 mcg","32","32",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Meropenem",NA,"0.03","0.03",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Meropenem","10 mcg","35","35",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Clindamycin","2 mcg","30","30","[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Metronidazole",NA,"0.5","0.5",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Metronidazole","5 mcg","30","30",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin",NA,"0.5","0.5",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","1 unit","15","15",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","30/6 mcg","24","24",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem",NA,"0.125","0.125",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","10 mcg","25","25",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","5 mcg","12","12",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","2 mcg","19","19","[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","5 mcg","16","16",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin",NA,"0.06","0.06",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","1 unit","24","24",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam",NA,"0.25","0.25","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","30/6 mcg","27","27",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem",NA,"0.125","0.125",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","10 mcg","28","28",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","5 mcg","22","22",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","2 mcg","26","26","[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"IP","IP",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IE","IE","[2] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distributions between studies.","Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IE","IE",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"IP","IP",NA,"Anaerobic bacteria" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral",NA,"0.125","0.125",NA,"H.pylori" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1",NA,"H.pylori" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.5",NA,"H.pylori" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1",NA,"H.pylori" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8",NA,"H.pylori" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1",NA,"H.pylori" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","13","13",NA,"L.monocytogenes" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)",NA,"1","1",NA,"L.monocytogenes" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","2 mcg","16","16",NA,"L.monocytogenes" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)",NA,"0.25","0.25",NA,"L.monocytogenes" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","10 mcg","26","26",NA,"L.monocytogenes" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","15 mcg","25","25",NA,"L.monocytogenes" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)",NA,"0.06","0.06","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","1.25/23.75 mcg","29","29","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Benzylpenicillin",NA,"0.5","0.5",NA,"P.multocida" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Benzylpenicillin","1 unit","17","17",NA,"P.multocida" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"1","1",NA,"P.multocida" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"1","1",NA,"P.multocida" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",NA,"P.multocida" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Cefotaxime",NA,"0.03","0.03",NA,"P.multocida" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Cefotaxime","5 mcg","26","26",NA,"P.multocida" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"P.multocida" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ciprofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Levofloxacin",NA,"0.06","0.06",NA,"P.multocida" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Levofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","P.multocida" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"1","1",NA,"P.multocida" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","P.multocida" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Tetracycline (screen only)","30 mcg","24","24","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","P.multocida" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"C.jejuni_C.coli" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","5 mcg","50","26",NA,"C.jejuni_C.coli" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8","[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","24","24","[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note","[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","30 mcg","30","30","[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Corynebacterium" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","1 unit","29","29",NA,"Corynebacterium" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Corynebacterium" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","5 mcg","50","25",NA,"Corynebacterium" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Corynebacterium" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Moxifloxacin","5 mcg","25","25",NA,"Corynebacterium" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Vancomycin",NA,"2","2",NA,"Corynebacterium" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Vancomycin","5 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Erythromycin",NA,"IP","IP",NA,"Corynebacterium" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Erythromycin","15 mcg","IP","IP",NA,"Corynebacterium" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Clindamycin","2 mcg","20","20","[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Tetracycline",NA,"2","2",NA,"Corynebacterium" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Tetracycline","30 mcg","24","24",NA,"Corynebacterium" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Linezolid",NA,"2","2",NA,"Corynebacterium" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Linezolid","10 mcg","25","25",NA,"Corynebacterium" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Rifampicin",NA,"0.06","0.5",NA,"Corynebacterium" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Rifampicin","5 mcg","30","25",NA,"Corynebacterium" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","1 unit","21","21",NA,"A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","2 mcg","26","26",NA,"A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note","[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","10 mcg","31","31",NA,"A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",NA,"A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21","[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2","[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"Note","Note","[B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Norfloxacin (screen only)","10 mcg","17","17","[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin",NA,"1","1",NA,"A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",NA,"A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",NA,"A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","5 mcg","25","25",NA,"A.sanguinicola_A.urinae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",NA,"K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",NA,"K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[3] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",NA,"K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",NA,"K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",NA,"K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",NA,"K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",NA,"K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",NA,"K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",NA,"K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",NA,"K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",NA,"K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",NA,"K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",NA,"K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",NA,"K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",NA,"Aeromonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",NA,"Aeromonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",NA,"Aeromonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",NA,"Aeromonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",NA,"Aeromonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",NA,"Aeromonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Aeromonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",NA,"Aeromonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Aeromonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",NA,"Aeromonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","19","16","[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam",NA,"4","4","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"A.xylosoxidans" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem",NA,"1","4",NA,"A.xylosoxidans" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","10 mcg","26","20",NA,"A.xylosoxidans" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","26","26","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam",NA,"1","1","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"Vibrio" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime",NA,"0.25","0.25",NA,"Vibrio" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","5 mcg","21","21",NA,"Vibrio" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",NA,"Vibrio" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",NA,"Vibrio" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime",NA,"1","1",NA,"Vibrio" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","10 mcg","22","22",NA,"Vibrio" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem",NA,"0.5","0.5",NA,"Vibrio" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","10 mcg","24","24",NA,"Vibrio" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin",NA,"0.25","0.25",NA,"Vibrio" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","5 mcg","23","23","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Vibrio" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","5 mcg","23","23","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","5 mcg","20","20","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin",NA,"4","4",NA,"Vibrio" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","15 mcg","16","16","[A] Susceptibility to azithromycin can be inferred from the erythromycin disk diffusion screening test.","Vibrio" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","15 mcg","12","12","[A] Susceptibility to azithromycin can be inferred from the erythromycin disk diffusion screening test.","Vibrio" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline",NA,"0.5","0.5",NA,"Vibrio" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Vibrio" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","30 mcg","20","20","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Vibrio" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","18","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1",FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","1 mcg","20","Note",FALSE,"[D] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.001","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"0.5","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"0.5","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"1","1",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin inhibition zone ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] For isolates with an oxacillin 1 µg zone <9 mm, determine the MIC. For isolates with an oxacillin zone ≥9 mm, report susceptible without further testing.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"0.001","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","50","16",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10",FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17",FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16",FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","19",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","1",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin",NA,"0.25","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","15 mcg","23","20",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19",FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","2",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","0.5",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","24",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","22",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline (screen only)",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline (screen only)","30 mcg","25","25",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as screen negative can be reported susceptible to doxycycline and minocycline. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","22",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"8","8",FALSE,"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review.For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",FALSE,"[1] The clinical efficacy of chloramphenicol in meningitis has been questioned and breakpoints are currently under review.For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","5 mcg","12","12",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.125","0.125",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","22",FALSE,NA,"S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","13","10",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin",NA,"0.25","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","1 unit","18","12",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)",NA,"0.25","0.25",FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","1 unit","18","18",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin",NA,"0.5","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","2 mcg","21","15",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"0.5","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note",FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates (inhibition zone ≥18 mm or MIC ≤0.25 mg/L), susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates (inhibition zone <18 mm or MIC >0.25 mg/L), susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem",NA,"1","1",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"2","2",FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. anginosus group",NA,"Delafloxacin",NA,"0.03","0.03",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. anginosus group",NA,"Delafloxacin",NA,"Note","Note",FALSE,"[A] A disk diffusion test is not yet developed. Perform an MIC test.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note",FALSE,"[1] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note",FALSE,"[B] There are no clinical breakpoints for viridans group streptococci and moxifloxacin, but moxifloxacin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The moxifloxacin MIC ECOFF (0.5 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19",FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","20 mcg","17","17",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid","2 mcg","18","18",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note",FALSE,"[1] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note",FALSE,"[A] There are no clinical breakpoints for viridans group streptococci and rifampicin, but rifampicin has been used for oral step-down treatment of endocarditis caused by viridans group streptococci. The rifampicin MIC ECOFF (0.125 mg/L) can be used to screen for resistance mechanisms. When screen negative, the isolate should be reported “wild type” or “devoid rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","1 unit","12","Note",FALSE,"[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)",NA,"1","1",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","2 mcg","18","18",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1",FALSE,"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"2","2",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"0.001","2",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2",FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.001","2",FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","50","15",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25",FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","5 mcg","27","27",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","5 mcg","27","27",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)",NA,"0.5","0.5",FALSE,"[2] See table of dosages for dosing for different indications.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","30/10 mcg","23","23",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] See table of dosages for dosing for different indications.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","32","32",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","30 mcg","32","32",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.001","1",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem",NA,"1","1",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","10 mcg","23","23",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (inhibition zone ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (inhibition zone <12 mm), see flow chart below. | [D] For benzylpenicillin 1 unit disk screen positive isolates (inhibition zone <12 mm), determine the MIC for meropenem.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","5 mcg","30","30",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23",FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","2",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","24",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"2","2",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","25",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2",FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28",FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",FALSE,NA,"H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","20",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1",FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1",FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","1",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","18",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.001","4",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem",NA,"1","1",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","10 mcg","30","30",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23",FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.5",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.5",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","20",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","1",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin, clarithromycin and roxithromycin.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin",NA,"0.25","0.5",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","15 mcg","23","20",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","2",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","25",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"2","2",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","26","26",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note",FALSE,"[1] For topical use of chloramphenicol, see tables of topical agents.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note",FALSE,"[A] For topical use of chloramphenicol, see tables of topical agents.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)",NA,"0.06","1",FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note",FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","1",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)",NA,"0.25","0.25",FALSE,NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)",NA,"0.125","1",FALSE,NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)",NA,"0.125","1",FALSE,NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)",NA,"0.125","0.125",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)",NA,"0.125","0.125",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem",NA,"Note","Note",FALSE,"[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. 3.The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem",NA,"Note","Note",FALSE,"[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. 3.The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. 3.The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note",FALSE,NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)",NA,"0.25","0.25",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. 3.The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. 3.The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (prophylaxis only)",NA,"0.03","0.03",FALSE,NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)",NA,"1","1",FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)",NA,"2","2",FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)",NA,"2","2",FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages.","N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)",NA,"0.25","0.25",FALSE,NA,"N.meningitidis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam",NA,"8","8",FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","30/6 mcg","20","20",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"B. thetaiotaomicron",NA,"Piperacillin-tazobactam",NA,"IE","IE",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"B. thetaiotaomicron",NA,"Piperacillin-tazobactam",NA,"IE","IE",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem",NA,"1","1",FALSE,"[2] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","10 mcg","28","28",FALSE,"[A] The meropenem zone diameter breakpoint will detect all cfiA gene mediated carbapenem resistance in Bacteroides fragilis. Some isolates with an MIC of 1 mg/L may harbour the cfiA gene.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin",NA,"(4)","(4)",TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","2 mcg","(10)","(10)",TRUE,"[B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole",NA,"4","4",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","5 mcg","25","25",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","1 unit","20","20",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam",NA,"0.5","0.5",FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem",NA,"0.25","0.25",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","10 mcg","34","34",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin",NA,"0.25","0.25",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","2 mcg","31","31",FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole",NA,"4","4",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","5 mcg","22","22",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin",NA,"0.06","0.06",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","1 unit","25","25",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam",NA,"0.5","0.5",FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","30/6 mcg","32","32",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Meropenem",NA,"0.03","0.03",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Meropenem","10 mcg","35","35",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Clindamycin",NA,"0.25","0.25",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Clindamycin","2 mcg","30","30",FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Metronidazole",NA,"0.5","0.5",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Metronidazole","5 mcg","30","30",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin",NA,"0.5","0.5",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","1 unit","15","15",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam",NA,"0.5","0.5",FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","30/6 mcg","24","24",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem",NA,"0.125","0.125",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","10 mcg","25","25",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","5 mcg","12","12",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin",NA,"0.25","0.25",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","2 mcg","19","19",FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole",NA,"4","4",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","5 mcg","16","16",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin",NA,"0.06","0.06",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","1 unit","24","24",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam",NA,"0.25","0.25",FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","30/6 mcg","27","27",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem",NA,"0.125","0.125",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","10 mcg","28","28",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","5 mcg","22","22",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin",NA,"0.25","0.25",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","2 mcg","26","26",FALSE,"[A] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2",FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"IP","IP",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IE","IE",FALSE,"[2] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distributions between studies.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IE","IE",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2",FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"IP","IP",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral",NA,"0.125","0.125",FALSE,NA,"H.pylori" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1",FALSE,NA,"H.pylori" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.5",FALSE,NA,"H.pylori" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1",FALSE,NA,"H.pylori" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8",FALSE,NA,"H.pylori" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1",FALSE,NA,"H.pylori" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)",NA,"1","1",FALSE,NA,"L.monocytogenes" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","13","13",FALSE,NA,"L.monocytogenes" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",FALSE,NA,"L.monocytogenes" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",FALSE,NA,"L.monocytogenes" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)",NA,"1","1",FALSE,NA,"L.monocytogenes" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","2 mcg","16","16",FALSE,NA,"L.monocytogenes" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)",NA,"0.25","0.25",FALSE,NA,"L.monocytogenes" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","10 mcg","26","26",FALSE,NA,"L.monocytogenes" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)",NA,"1","1",FALSE,NA,"L.monocytogenes" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","15 mcg","25","25",FALSE,NA,"L.monocytogenes" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)",NA,"0.06","0.06",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","1.25/23.75 mcg","29","29",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Benzylpenicillin",NA,"0.5","0.5",FALSE,NA,"P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Benzylpenicillin","1 unit","17","17",FALSE,NA,"P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"1","1",FALSE,NA,"P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ampicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"1","1",FALSE,NA,"P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid",NA,"1","1",FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",FALSE,NA,"P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Cefotaxime",NA,"0.03","0.03",FALSE,NA,"P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Cefotaxime","5 mcg","26","26",FALSE,NA,"P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,NA,"P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Ciprofloxacin","5 mcg","27","27",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Levofloxacin",NA,"0.06","0.06",FALSE,NA,"P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Levofloxacin","5 mcg","27","27",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Nalidixic acid (screen only)","30 mcg","23","23",FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"1","1",FALSE,NA,"P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Tetracycline (screen only)","30 mcg","24","24",FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Pasteurella multocida",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","P.multocida" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin",NA,"0.001","0.5",FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Ciprofloxacin","5 mcg","50","26",FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8",FALSE,"[1] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","24","24",FALSE,"[A] Erythromycin can be used to determine susceptibility to azithromycin and clarithromycin.","C.jejuni_C.coli" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note",FALSE,"[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Campylobacter jejuni and coli",NA,"Tetracycline",NA,"2","2",FALSE,"[1] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Campylobacter jejuni and coli",NA,"Tetracycline","30 mcg","30","30",FALSE,"[A] Tetracycline can be used to determine susceptibility to doxycycline.","C.jejuni_C.coli" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Benzylpenicillin",NA,"0.125","0.125",FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Benzylpenicillin","1 unit","29","29",FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Ciprofloxacin",NA,"0.001","1",FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Ciprofloxacin","5 mcg","50","25",FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Moxifloxacin",NA,"0.5","0.5",FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Moxifloxacin","5 mcg","25","25",FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Vancomycin","5 mcg","17","17",FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Erythromycin",NA,"IP","IP",FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Erythromycin","15 mcg","IP","IP",FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Clindamycin","2 mcg","20","20",FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacteria. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Tetracycline",NA,"2","2",FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Tetracycline","30 mcg","24","24",FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Linezolid",NA,"2","2",FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Linezolid","10 mcg","25","25",FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Corynebacterium spp.",NA,"Rifampicin",NA,"0.06","0.5",FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Corynebacterium spp.",NA,"Rifampicin","5 mcg","30","25",FALSE,NA,"Corynebacterium" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Benzylpenicillin","1 unit","21","21",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin",NA,"0.25","0.25",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ampicillin","2 mcg","26","26",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem",NA,"0.25","0.25",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Meropenem","10 mcg","31","31",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21",FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2",FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"Note","Note",FALSE,"[B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Norfloxacin (screen only)","10 mcg","17","17",FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin",NA,"1","1",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Vancomycin","5 mcg","16","16",FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin",NA,"0.125","0.125",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aerococcus sanguinicola and urinae",NA,"Rifampicin","5 mcg","25","25",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06",FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125",FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[3] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25",FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5",FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",FALSE,NA,"K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",FALSE,NA,"Aeromonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",FALSE,NA,"Aeromonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",FALSE,NA,"Aeromonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",FALSE,NA,"Aeromonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",FALSE,NA,"Aeromonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",FALSE,NA,"Aeromonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",FALSE,NA,"Aeromonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",FALSE,NA,"Aeromonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",FALSE,NA,"Aeromonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",FALSE,NA,"Aeromonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","19","16",FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam",NA,"4","4",FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",FALSE,NA,"A.xylosoxidans" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem",NA,"1","4",FALSE,NA,"A.xylosoxidans" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","10 mcg","26","20",FALSE,NA,"A.xylosoxidans" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","26","26",FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam",NA,"1","1",FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",FALSE,NA,"Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime",NA,"0.25","0.25",FALSE,NA,"Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","5 mcg","21","21",FALSE,NA,"Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",FALSE,NA,"Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",FALSE,NA,"Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime",NA,"1","1",FALSE,NA,"Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","10 mcg","22","22",FALSE,NA,"Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem",NA,"0.5","0.5",FALSE,NA,"Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","10 mcg","24","24",FALSE,NA,"Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin",NA,"0.25","0.25",FALSE,NA,"Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","5 mcg","23","23",FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin",NA,"0.25","0.25",FALSE,NA,"Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","5 mcg","23","23",FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","5 mcg","20","20",FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin",NA,"4","4",FALSE,NA,"Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","15 mcg","16","16",FALSE,"[A] Susceptibility to azithromycin can be inferred from the erythromycin disk diffusion screening test.","Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","15 mcg","12","12",FALSE,"[A] Susceptibility to azithromycin can be inferred from the erythromycin disk diffusion screening test.","Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline",NA,"0.5","0.5",FALSE,NA,"Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","30 mcg","20","20",FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","18",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio" "EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Imipenem",NA,"0.5","0.5",NA,"Bacillus" +except B. anthracis",NA,"Imipenem",NA,"0.5","0.5",FALSE,NA,"Bacillus" "EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Imipenem","10 mcg","30","30",NA,"Bacillus" +except B. anthracis",NA,"Imipenem","10 mcg","30","30",FALSE,NA,"Bacillus" "EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Meropenem",NA,"0.25","0.25",NA,"Bacillus" +except B. anthracis",NA,"Meropenem",NA,"0.25","0.25",FALSE,NA,"Bacillus" "EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Meropenem","10 mcg","25","25",NA,"Bacillus" +except B. anthracis",NA,"Meropenem","10 mcg","25","25",FALSE,NA,"Bacillus" "EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Bacillus" +except B. anthracis",NA,"Ciprofloxacin",NA,"0.001","0.5",FALSE,NA,"Bacillus" "EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Ciprofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +except B. anthracis",NA,"Ciprofloxacin","5 mcg","50","23",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" "EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Levofloxacin",NA,"0.001","1",NA,"Bacillus" +except B. anthracis",NA,"Levofloxacin",NA,"0.001","1",FALSE,NA,"Bacillus" "EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Levofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +except B. anthracis",NA,"Levofloxacin","5 mcg","50","23",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" "EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Norfloxacin (screen only)","10 mcg","21","21","[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" +except B. anthracis",NA,"Norfloxacin (screen only)","10 mcg","21","21",FALSE,"[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" "EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Vancomycin",NA,"2","2",NA,"Bacillus" +except B. anthracis",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Bacillus" "EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Vancomycin","5 mcg","10","10","[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" +except B. anthracis",NA,"Vancomycin","5 mcg","10","10",FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" "EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Erythromycin",NA,"0.5","0.5",NA,"Bacillus" +except B. anthracis",NA,"Erythromycin",NA,"0.5","0.5",FALSE,NA,"Bacillus" "EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Erythromycin","15 mcg","24","24",NA,"Bacillus" +except B. anthracis",NA,"Erythromycin","15 mcg","24","24",FALSE,NA,"Bacillus" "EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Clindamycin",NA,"1","1",NA,"Bacillus" +except B. anthracis",NA,"Clindamycin",NA,"1","1",FALSE,NA,"Bacillus" "EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Clindamycin","2 mcg","17","17",NA,"Bacillus" +except B. anthracis",NA,"Clindamycin","2 mcg","17","17",FALSE,NA,"Bacillus" "EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Linezolid",NA,"2","2",NA,"Bacillus" +except B. anthracis",NA,"Linezolid",NA,"2","2",FALSE,NA,"Bacillus" "EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Linezolid","10 mcg","22","22",NA,"Bacillus" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid",NA,"0.001","8","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","20/10 mcg","50","22",NA,"B.pseudomallei" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime",NA,"0.001","8",NA,"B.pseudomallei" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","10 mcg","50","18",NA,"B.pseudomallei" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem",NA,"2","2",NA,"B.pseudomallei" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","10 mcg","29","29",NA,"B.pseudomallei" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem",NA,"2","2",NA,"B.pseudomallei" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","10 mcg","24","24",NA,"B.pseudomallei" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"0.001","2",NA,"B.pseudomallei" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"Note","Note","[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","30 mcg","23","23","[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol",NA,"0.001","8",NA,"B.pseudomallei" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","30 mcg","50","22",NA,"B.pseudomallei" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","17","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25","[1] Breakpoints were determined on MICs performed on Middlebrook 7H11/7H10 medium. The comparability of tests performed by other media has not been established. There is ongoing work to review breakpoints using the EUCAST reference method (described above).","M.tuberculosis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06",NA,"M.tuberculosis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Pretomanid",NA,"IE","IE","[2] MIC data have been generated with MGIT system and not with the EUCAST reference method. Therefore, it has not been possible to set an ECOFF, nor calibrate MGIT MIC values against the reference method. Consequently, EUCAST cannot endorse the tentative breakpoint set by EMA based on the MGIT method. Breakpoints are pending MIC data with the reference method.","M.tuberculosis" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin",NA,"2","2",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","10 mcg","16","16",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)",NA,"8","8",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","10 mcg","12","12",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin",NA,"8","8",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","10 mcg","15","15",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","5 mcg","26","26",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","5 mcg","18","18",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","5 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","30 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)",NA,"4","4",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","21","21",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","23",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","5 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","30 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin",NA,"2","2",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","10 mcg","18","18",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","10 mcg","17","17","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","30 mcg","18","18",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","10 mcg","24","24",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)",NA,"1","1",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","10 mcg","14","14",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin",NA,"1","1","[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +except B. anthracis",NA,"Linezolid","10 mcg","22","22",FALSE,NA,"Bacillus" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid",NA,"0.001","8",FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","20/10 mcg","50","22",FALSE,NA,"B.pseudomallei" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime",NA,"0.001","8",FALSE,NA,"B.pseudomallei" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","10 mcg","50","18",FALSE,NA,"B.pseudomallei" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem",NA,"2","2",FALSE,NA,"B.pseudomallei" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","10 mcg","29","29",FALSE,NA,"B.pseudomallei" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem",NA,"2","2",FALSE,NA,"B.pseudomallei" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","10 mcg","24","24",FALSE,NA,"B.pseudomallei" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"0.001","2",FALSE,NA,"B.pseudomallei" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","30 mcg","23","23",FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol",NA,"0.001","8",FALSE,NA,"B.pseudomallei" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","30 mcg","50","22",FALSE,NA,"B.pseudomallei" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","17",FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25",FALSE,"[1] Breakpoints were determined on MICs performed on Middlebrook 7H11/7H10 medium. The comparability of tests performed by other media has not been established. There is ongoing work to review breakpoints using the EUCAST reference method (described above).","M.tuberculosis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06",FALSE,NA,"M.tuberculosis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Pretomanid",NA,"IE","IE",FALSE,"[2] MIC data have been generated with MGIT system and not with the EUCAST reference method. Therefore, it has not been possible to set an ECOFF, nor calibrate MGIT MIC values against the reference method. Consequently, EUCAST cannot endorse the tentative breakpoint set by EMA based on the MGIT method. Breakpoints are pending MIC data with the reference method.","M.tuberculosis" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","10 mcg","17","17",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","10 mcg","16","16",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin",NA,"0.125","0.125",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin",NA,"0.25","0.25",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.25",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol",NA,"16","16",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","10 mcg","12","12",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","10 mcg","15","15",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","10 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","5 mcg","26","26",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","5 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","5 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","30 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin (framycetin)",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","21","21",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","23",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","5 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","30 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","10 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","10 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","10 mcg","17","17",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol",NA,"16","16",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","30 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","10 mcg","24","24",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","10 mcg","14","14",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin",NA,"1","1",FALSE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. ND = No ECOFF available.","Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","200 mcg","30","30","[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","200 mcg","30","30",FALSE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. ND = No ECOFF available.","Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Retapamulin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin",NA,"4","4",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"32","32",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","200 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"0.125","0.125",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin",NA,"4","4",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin",NA,"8","8",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","30 mcg","28","28",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","30 mcg","31","31",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Amphotericin B",NA,"1","1",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Amphotericin B",NA,"0.001","2","[1] The entire C. auris wild-type population is in the I category. The Susceptible category (≤0.001 mg/L) is simply to avoid missclassification of any WT strains as ""S"" strains.","5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Amphotericin B",NA,"1","1",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Amphotericin B",NA,"1","1",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Amphotericin B",NA,"1","1",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Amphotericin B",NA,"1","1",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Amphotericin B",NA,"1","1",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Amphotericin B",NA,"IE","IE",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Cryptococcus neoformans",NA,"Amphotericin B",NA,"1","1",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Anidulafungin",NA,"0.016","0.016",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Anidulafungin",NA,"0.25","0.25",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Anidulafungin",NA,"0.03","0.03",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Anidulafungin",NA,"0.06","0.06",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Anidulafungin",NA,"0.06","0.06",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Anidulafungin",NA,"4","4",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Anidulafungin",NA,"0.06","0.06",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Anidulafungin",NA,"IE","IE",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Caspofungin",NA,"Note","Note","[2] Isolates that are susceptible to anidulafungin as well as micafungin should be considered susceptible to caspofungin, until caspofungin breakpoints have been established. EUCAST breakpoints have not yet been established for caspofungin, due to significant inter-laboratory variation in MIC ranges for caspofungin.","5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Caspofungin",NA,"IE","IE",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Caspofungin",NA,"IE","IE",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Caspofungin",NA,"Note","Note","[2] Isolates that are susceptible to anidulafungin as well as micafungin should be considered susceptible to caspofungin, until caspofungin breakpoints have been established. EUCAST breakpoints have not yet been established for caspofungin, due to significant inter-laboratory variation in MIC ranges for caspofungin.","5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Caspofungin",NA,"Note","Note","[2] Isolates that are susceptible to anidulafungin as well as micafungin should be considered susceptible to caspofungin, until caspofungin breakpoints have been established. EUCAST breakpoints have not yet been established for caspofungin, due to significant inter-laboratory variation in MIC ranges for caspofungin.","5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Caspofungin",NA,"Note","Note","[2] Isolates that are susceptible to anidulafungin as well as micafungin should be considered susceptible to caspofungin, until caspofungin breakpoints have been established. EUCAST breakpoints have not yet been established for caspofungin, due to significant inter-laboratory variation in MIC ranges for caspofungin.","5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Caspofungin",NA,"Note","Note","[2] Isolates that are susceptible to anidulafungin as well as micafungin should be considered susceptible to caspofungin, until caspofungin breakpoints have been established. EUCAST breakpoints have not yet been established for caspofungin, due to significant inter-laboratory variation in MIC ranges for caspofungin.","5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Caspofungin",NA,"IE","IE",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Fluconazole",NA,"2","4",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Fluconazole",NA,"Note","Note","[3] The fluconazole susceptibility of the earliest C. auris strains (likely representing the wild-type, e.g.CBS10913) was low (4 mg/L, determined in-house by EUCAST), and C. auris isolates with low azole MICs are still reported, particularly from South America. However, most C. auris isolates exhibit fluconazole MIC values >16 mg/L and harbour acquired resistance mechanisms. Due to the paucity of true wild-type, non-outbreak isolates, a fluconazole ECOFF cannot be established. Clinical data on isolates with lower MICs (≤ 16 mg/L) are very limited. Therefore, EUCAST has insufficient data to support fluconazole therapy for C. auris, even when the MIC is low.","5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Fluconazole",NA,"2","4",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Fluconazole",NA,"0.001","16","[4] The entire C. glabrata wild-type population is in the I category. MICs against C. glabrata should be interpreted as resistant when above 16 mg/L. Susceptible category (≤0.001 mg/L) is simply to avoid missclassification of any wild-typestrains as ""S"" strains.","5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Fluconazole",NA,"2","4",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Fluconazole",NA,"2","4",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Fluconazole",NA,"IE","IE","[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Cryptococcus neoformans",NA,"Fluconazole",NA,"IE","IE",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Isavuconazole",NA,"IE","IE",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Isavuconazole",NA,"IE","IE",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Isavuconazole",NA,"IE","IE",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Isavuconazole",NA,"IE","IE",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Isavuconazole",NA,"IE","IE",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Isavuconazole",NA,"IE","IE",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Isavuconazole",NA,"IE","IE",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Isavuconazole",NA,"IE","IE",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Cryptococcus neoformans",NA,"Isavuconazole",NA,"IE","IE",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Itraconazole",NA,"0.06","0.06",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Itraconazole",NA,"IE","IE",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Itraconazole",NA,"0.06","0.06",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Itraconazole",NA,"IE","IE","[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Itraconazole",NA,"IE","IE","[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Itraconazole",NA,"0.125","0.125",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Itraconazole",NA,"0.125","0.125",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Itraconazole",NA,"IE","IE","[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Cryptococcus neoformans",NA,"Itraconazole",NA,"IE","IE",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Micafungin",NA,"0.03","0.03",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Micafungin",NA,"0.25","0.25",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Micafungin",NA,"0.06","0.06",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Micafungin",NA,"0.06","0.06",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Micafungin",NA,"IE","IE","[6] MICs for C. krusei are approximately three two-fold dilution steps higher than those for C. albicans and, similarly, those for C. guilliermondii are approximately eight two-fold dilutions higher. In addition, there were only a small number of cases involving these species in the clinical trials. This means there is insufficient evidence (IE) to indicate whether the wild-type population of these pathogens can be considered susceptible to micafungin.","5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Micafungin",NA,"4","4",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Micafungin",NA,"0.06","0.06",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Micafungin",NA,"IE","IE","[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Posaconazole",NA,"0.06","0.06",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Posaconazole",NA,"IE","IE",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Posaconazole",NA,"0.06","0.06",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Posaconazole",NA,"IE","IE","[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Posaconazole",NA,"IE","IE","[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Posaconazole",NA,"0.06","0.06",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Posaconazole",NA,"0.06","0.06",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Posaconazole",NA,"IE","IE","[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Cryptococcus neoformans",NA,"Posaconazole",NA,"IE","IE",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Rezafungin",NA,"0.008","0.008","[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Rezafungin",NA,"IE","IE","[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Rezafungin",NA,"0.016","0.016","[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Rezafungin",NA,"0.016","0.016","[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Rezafungin",NA,"0.03","0.03","[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Rezafungin",NA,"4","4","[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Rezafungin",NA,"0.03","0.03","[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Rezafungin",NA,"IE","IE","[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Voriconazole",NA,"0.06","0.25","[8] Strains with MIC values above the S/I breakpoint are rare or not yet reported. The identification and antifungal susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant. A clinical response of 76% was achieved in infections caused by the species listed below when MICs were lower than or equal to the epidemiological cut-offs. Therefore, wild type populations of C. albicans, C. dubliniensis, C. parapsilosis and C. tropicalis are considered susceptible.","5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Voriconazole",NA,"IE","IE",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Voriconazole",NA,"0.06","0.25","[8] Strains with MIC values above the S/I breakpoint are rare or not yet reported. The identification and antifungal susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant. A clinical response of 76% was achieved in infections caused by the species listed below when MICs were lower than or equal to the epidemiological cut-offs. Therefore, wild type populations of C. albicans, C. dubliniensis, C. parapsilosis and C. tropicalis are considered susceptible.","5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Voriconazole",NA,"IE","IE","[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Voriconazole",NA,"IE","IE","[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Voriconazole",NA,"0.125","0.25",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Voriconazole",NA,"0.125","0.25","[8] Strains with MIC values above the S/I breakpoint are rare or not yet reported. The identification and antifungal susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant. A clinical response of 76% was achieved in infections caused by the species listed below when MICs were lower than or equal to the epidemiological cut-offs. Therefore, wild type populations of C. albicans, C. dubliniensis, C. parapsilosis and C. tropicalis are considered susceptible.","5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Voriconazole",NA,"IE","IE",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Cryptococcus neoformans",NA,"Voriconazole",NA,"IE","IE",NA,"5. Yeast" -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Amphotericin B",NA,"1","1",NA,"6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Amphotericin B",NA,"1","1",NA,"6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus flavus",NA,"Anidulafungin",NA,"IE","IE",NA,"6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Anidulafungin",NA,"IE","IE",NA,"6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus nidulans",NA,"Anidulafungin",NA,"IE","IE",NA,"6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Anidulafungin",NA,"IE","IE",NA,"6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus terreus",NA,"Anidulafungin",NA,"IE","IE",NA,"6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus flavus",NA,"Caspofungin",NA,"IE","IE",NA,"6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Caspofungin",NA,"IE","IE",NA,"6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus nidulans",NA,"Caspofungin",NA,"IE","IE",NA,"6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Caspofungin",NA,"IE","IE",NA,"6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus terreus",NA,"Caspofungin",NA,"IE","IE",NA,"6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus flavus",NA,"Isavuconazole",NA,"1","1",NA,"6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Isavuconazole",NA,"1","1",NA,"6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus nidulans",NA,"Isavuconazole",NA,"0.5","0.5",NA,"6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Isavuconazole",NA,"IE","IE","[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus.","6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus terreus",NA,"Isavuconazole",NA,"1","1",NA,"6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus flavus",NA,"Itraconazole",NA,"1","1","[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2 mg/L) is ensured via TDM.","6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Itraconazole",NA,"1","1","[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2 mg/L) is ensured via TDM.","6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus nidulans",NA,"Itraconazole",NA,"1","1","[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2 mg/L) is ensured via TDM.","6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Itraconazole",NA,"IE","IE","[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus. | [4] The MIC values for isolates of A. niger and A. versicolor are in general higher than those for A. fumigatus. Whether this translates into a poorer clinical response is unknown.","6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus terreus",NA,"Itraconazole",NA,"1","1","[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2 mg/L) is ensured via TDM.","6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus flavus",NA,"Micafungin",NA,"IE","IE",NA,"6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Micafungin",NA,"IE","IE",NA,"6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus nidulans",NA,"Micafungin",NA,"IE","IE",NA,"6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Micafungin",NA,"IE","IE",NA,"6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus terreus",NA,"Micafungin",NA,"IE","IE",NA,"6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus flavus",NA,"Posaconazole",NA,"IE","IE","[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus.","6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Posaconazole",NA,"0.125","0.125",NA,"6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus nidulans",NA,"Posaconazole",NA,"IE","IE","[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus.","6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Posaconazole",NA,"IE","IE","[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus.","6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus terreus",NA,"Posaconazole",NA,"0.125","0.125",NA,"6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus flavus",NA,"Voriconazole",NA,"IE","IE","[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus.","6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Voriconazole",NA,"1","1","[6] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), voriconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2-3 mg/L) is ensured via TDM.","6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus nidulans",NA,"Voriconazole",NA,"1","1","[6] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), voriconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2-3 mg/L) is ensured via TDM.","6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Voriconazole",NA,"IE","IE","[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus.","6. Aspergillus " -"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus terreus",NA,"Voriconazole",NA,"IE","IE","[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus.","6. Aspergillus " -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin iv",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin iv","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin iv",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin iv","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)",NA,"0.001","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","/ mcg","Note","Note","[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"". | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)",NA,"8","8","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","/ mcg","Note","Note","[D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Infer from ampicillin oral, but the report should explain the meaning of breakpoints in brackets. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv",NA,"8","8","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","20/10 mcg","19","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)",NA,"0.001","8","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","20/10 mcg","50","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"32","32","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","20/10 mcg","16","16","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"8","8","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","20/10 mcg","19","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","8",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","20",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","8","[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","20",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)",NA,"0.001","16",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)","30 mcg","50","17","[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)",NA,"8","8","[6] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)","10 mcg","15","15","[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)",NA,"0.001","4","[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)","30 mcg","50","20","[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol",NA,"2","2","[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","30 mcg","22","22",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","5 mcg","20","17",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","5 mcg","20","20",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","30 mcg","19","19","[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)","10 mcg","21","21",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8","[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","30 mcg","23","23",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"2","2","[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [6] See table of dosages for dosing for different indications.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","22","22","[6] See table of dosages for dosing for different indications.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","25","22",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","30 mcg","25","25",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"0.001","8",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","50","19",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem",NA,"1","2",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","10 mcg","24","21",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","25","25",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem",NA,"2","4",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem","10 mcg","22","19",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Morganellaceae",NA,"Imipenem",NA,"0.001","4","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Morganellaceae",NA,"Imipenem","10 mcg","50","19","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam",NA,"2","2","[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","10 mcg","22","16",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","10 mcg","22","22",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8","[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","20/10 mcg","20","20",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06","[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note","[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)",NA,"0.25","0.5",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","5 mcg","25","22",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"0.125","0.125","[2] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"Note","Note","[2/B] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24","[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli",NA,"Delafloxacin",NA,"0.125","0.125",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli",NA,"Delafloxacin",NA,"Note","Note","[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","5 mcg","22","22",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","0.5",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","24","24",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","30 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","18","18",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","10 mcg","16","16","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","16","16",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli",NA,"Eravacycline","20 mcg","17","17",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient inSerratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18","[A] For other Enterobacterales, the activity of tigecycline varies from insufficient inSerratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note","[1] Efficacy for this order is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note","[A] Efficacy for this order is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"2","2","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note","[B] Use an MIC method (broth microdilution only). | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv",NA,"32","32","[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [4] Breakpoints for fosfomycin iv are currently under review.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","200 mcg","21","21","[D] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [E] Ignore isolated colonies within the inhibition zone (see pictures below). | [4] Breakpoints for fosfomycin iv are currently under review.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)",NA,"8","8","[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)","200 mcg","24","24","[E] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","15","15",NA,"Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[6] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[6] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"0.001","16",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"0.001","16","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"0.001","16","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"0.001","8",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","50","21",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"P. aeruginosa",NA,"Cefiderocol",NA,"2","2","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"P. aeruginosa",NA,"Cefiderocol","30 mcg","22","22",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"0.001","8",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","50","17",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] See table of dosages for dosing for different indications.","Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","23","23","[3] See table of dosages for dosing for different indications.","Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem",NA,"0.001","2",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","10 mcg","50","22",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"0.001","4",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","50","20",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"P. aeruginosa",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"P. aeruginosa",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)","10 mcg","20","14",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)",NA,"2","8",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)","10 mcg","24","18",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (meningitis)","10 mcg","20","20",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","20/10 mcg","14","14",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"0.001","16",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","50","26",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"0.001","2",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"16","16",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","15","15",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","18","18",NA,"Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"4","4","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Fosfomycin iv",NA,"Note","Note","[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). The ECOFF is 256 mg/L.","Pseudomonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"IE","IE","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","S.maltophilia" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"Note","Note","[A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","16","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"IE","IE","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"Note","Note","[A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem",NA,"0.001","2",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","10 mcg","50","22",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","10/25 mcg","24","24","[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","10 mcg","21","15",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","10 mcg","21","21",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","30 mcg","19","19","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","19","19",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"2","2","[2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Benzylpenicillin",NA,"0.125","0.125","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Benzylpenicillin","1 unit","26","26","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. lugdunensis",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. lugdunensis",NA,"Benzylpenicillin","1 unit","26","26",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. saprophyticus",NA,"Ampicillin",NA,"Note","Note","[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. saprophyticus",NA,"Ampicillin","2 mcg","18","18","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. pseudintermedius, S. schleiferi and S. coagulans",NA,"Oxacillin (screen only)","1 mcg","20","20","[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. aureus",NA,"Retapamulin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","21","21",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"32","32",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","200 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"0.125","0.125",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin",NA,"0.06","0.06",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin",NA,"0.06","0.06",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","30 mcg","28","28",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","H. influenzae",NA,"Neomycin (framycetin)",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","H. influenzae",NA,"Neomycin (framycetin)","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for gram positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","30 mcg","31","31",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin (framycetin)",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2022","12.0","Clinical Breakpoint Tables v. 12.0","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Amphotericin B",NA,"1","1",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Amphotericin B",NA,"0.001","2",FALSE,"[1] The entire C. auris wild-type population is in the I category. The Susceptible category (≤0.001 mg/L) is simply to avoid missclassification of any WT strains as ""S"" strains.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Amphotericin B",NA,"1","1",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Amphotericin B",NA,"1","1",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Amphotericin B",NA,"1","1",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Amphotericin B",NA,"1","1",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Amphotericin B",NA,"1","1",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Amphotericin B",NA,"IE","IE",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Cryptococcus neoformans",NA,"Amphotericin B",NA,"1","1",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Anidulafungin",NA,"0.016","0.016",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Anidulafungin",NA,"0.25","0.25",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Anidulafungin",NA,"0.03","0.03",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Anidulafungin",NA,"0.06","0.06",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Anidulafungin",NA,"0.06","0.06",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Anidulafungin",NA,"4","4",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Anidulafungin",NA,"0.06","0.06",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Anidulafungin",NA,"IE","IE",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Caspofungin",NA,"Note","Note",FALSE,"[2] Isolates that are susceptible to anidulafungin as well as micafungin should be considered susceptible to caspofungin, until caspofungin breakpoints have been established. EUCAST breakpoints have not yet been established for caspofungin, due to significant inter-laboratory variation in MIC ranges for caspofungin.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Caspofungin",NA,"IE","IE",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Caspofungin",NA,"IE","IE",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Caspofungin",NA,"Note","Note",FALSE,"[2] Isolates that are susceptible to anidulafungin as well as micafungin should be considered susceptible to caspofungin, until caspofungin breakpoints have been established. EUCAST breakpoints have not yet been established for caspofungin, due to significant inter-laboratory variation in MIC ranges for caspofungin.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Caspofungin",NA,"Note","Note",FALSE,"[2] Isolates that are susceptible to anidulafungin as well as micafungin should be considered susceptible to caspofungin, until caspofungin breakpoints have been established. EUCAST breakpoints have not yet been established for caspofungin, due to significant inter-laboratory variation in MIC ranges for caspofungin.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Caspofungin",NA,"Note","Note",FALSE,"[2] Isolates that are susceptible to anidulafungin as well as micafungin should be considered susceptible to caspofungin, until caspofungin breakpoints have been established. EUCAST breakpoints have not yet been established for caspofungin, due to significant inter-laboratory variation in MIC ranges for caspofungin.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Caspofungin",NA,"Note","Note",FALSE,"[2] Isolates that are susceptible to anidulafungin as well as micafungin should be considered susceptible to caspofungin, until caspofungin breakpoints have been established. EUCAST breakpoints have not yet been established for caspofungin, due to significant inter-laboratory variation in MIC ranges for caspofungin.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Caspofungin",NA,"IE","IE",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Fluconazole",NA,"2","4",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Fluconazole",NA,"Note","Note",FALSE,"[3] The fluconazole susceptibility of the earliest C. auris strains (likely representing the wild-type, e.g.CBS10913) was low (4 mg/L, determined in-house by EUCAST), and C. auris isolates with low azole MICs are still reported, particularly from South America. However, most C. auris isolates exhibit fluconazole MIC values >16 mg/L and harbour acquired resistance mechanisms. Due to the paucity of true wild-type, non-outbreak isolates, a fluconazole ECOFF cannot be established. Clinical data on isolates with lower MICs (≤ 16 mg/L) are very limited. Therefore, EUCAST has insufficient data to support fluconazole therapy for C. auris, even when the MIC is low.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Fluconazole",NA,"2","4",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Fluconazole",NA,"0.001","16",FALSE,"[4] The entire C. glabrata wild-type population is in the I category. MICs against C. glabrata should be interpreted as resistant when above 16 mg/L. Susceptible category (≤0.001 mg/L) is simply to avoid missclassification of any wild-typestrains as ""S"" strains.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Fluconazole",NA,"2","4",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Fluconazole",NA,"2","4",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Fluconazole",NA,"IE","IE",FALSE,"[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Cryptococcus neoformans",NA,"Fluconazole",NA,"IE","IE",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Isavuconazole",NA,"IE","IE",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Isavuconazole",NA,"IE","IE",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Isavuconazole",NA,"IE","IE",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Isavuconazole",NA,"IE","IE",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Isavuconazole",NA,"IE","IE",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Isavuconazole",NA,"IE","IE",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Isavuconazole",NA,"IE","IE",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Isavuconazole",NA,"IE","IE",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Cryptococcus neoformans",NA,"Isavuconazole",NA,"IE","IE",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Itraconazole",NA,"0.06","0.06",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Itraconazole",NA,"IE","IE",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Itraconazole",NA,"0.06","0.06",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Itraconazole",NA,"IE","IE",FALSE,"[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Itraconazole",NA,"IE","IE",FALSE,"[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Itraconazole",NA,"0.125","0.125",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Itraconazole",NA,"0.125","0.125",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Itraconazole",NA,"IE","IE",FALSE,"[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Cryptococcus neoformans",NA,"Itraconazole",NA,"IE","IE",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Micafungin",NA,"0.03","0.03",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Micafungin",NA,"0.25","0.25",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Micafungin",NA,"0.06","0.06",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Micafungin",NA,"0.06","0.06",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Micafungin",NA,"IE","IE",FALSE,"[6] MICs for C. krusei are approximately three two-fold dilution steps higher than those for C. albicans and, similarly, those for C. guilliermondii are approximately eight two-fold dilutions higher. In addition, there were only a small number of cases involving these species in the clinical trials. This means there is insufficient evidence (IE) to indicate whether the wild-type population of these pathogens can be considered susceptible to micafungin.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Micafungin",NA,"4","4",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Micafungin",NA,"0.06","0.06",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Micafungin",NA,"IE","IE",FALSE,"[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Posaconazole",NA,"0.06","0.06",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Posaconazole",NA,"IE","IE",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Posaconazole",NA,"0.06","0.06",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Posaconazole",NA,"IE","IE",FALSE,"[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Posaconazole",NA,"IE","IE",FALSE,"[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Posaconazole",NA,"0.06","0.06",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Posaconazole",NA,"0.06","0.06",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Posaconazole",NA,"IE","IE",FALSE,"[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Cryptococcus neoformans",NA,"Posaconazole",NA,"IE","IE",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Rezafungin",NA,"0.008","0.008",FALSE,"[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Rezafungin",NA,"IE","IE",FALSE,"[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Rezafungin",NA,"0.016","0.016",FALSE,"[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Rezafungin",NA,"0.016","0.016",FALSE,"[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Rezafungin",NA,"0.03","0.03",FALSE,"[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Rezafungin",NA,"4","4",FALSE,"[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Rezafungin",NA,"0.03","0.03",FALSE,"[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Rezafungin",NA,"IE","IE",FALSE,"[7] Breakpoints apply for MICs determined with Tween 20 supplemented medium according to the EUCAST E.Def 7.4 method.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida albicans",NA,"Voriconazole",NA,"0.06","0.25",FALSE,"[8] Strains with MIC values above the S/I breakpoint are rare or not yet reported. The identification and antifungal susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant. A clinical response of 76% was achieved in infections caused by the species listed below when MICs were lower than or equal to the epidemiological cut-offs. Therefore, wild type populations of C. albicans, C. dubliniensis, C. parapsilosis and C. tropicalis are considered susceptible.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida auris",NA,"Voriconazole",NA,"IE","IE",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida dubliniensis",NA,"Voriconazole",NA,"0.06","0.25",FALSE,"[8] Strains with MIC values above the S/I breakpoint are rare or not yet reported. The identification and antifungal susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant. A clinical response of 76% was achieved in infections caused by the species listed below when MICs were lower than or equal to the epidemiological cut-offs. Therefore, wild type populations of C. albicans, C. dubliniensis, C. parapsilosis and C. tropicalis are considered susceptible.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida glabrata",NA,"Voriconazole",NA,"IE","IE",FALSE,"[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida krusei",NA,"Voriconazole",NA,"IE","IE",FALSE,"[5] The ECOFFs for these species are in general higher than for C. albicans.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida parapsilosis",NA,"Voriconazole",NA,"0.125","0.25",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida tropicalis",NA,"Voriconazole",NA,"0.125","0.25",FALSE,"[8] Strains with MIC values above the S/I breakpoint are rare or not yet reported. The identification and antifungal susceptibility tests on any such isolate must be repeated and if the result is confirmed the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for confirmed isolates with MIC above the current resistant breakpoint they should be reported resistant. A clinical response of 76% was achieved in infections caused by the species listed below when MICs were lower than or equal to the epidemiological cut-offs. Therefore, wild type populations of C. albicans, C. dubliniensis, C. parapsilosis and C. tropicalis are considered susceptible.","5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Candida guilliermondii",NA,"Voriconazole",NA,"IE","IE",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Cryptococcus neoformans",NA,"Voriconazole",NA,"IE","IE",FALSE,NA,"5. Yeast" +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Amphotericin B",NA,"1","1",FALSE,NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Amphotericin B",NA,"1","1",FALSE,NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus flavus",NA,"Anidulafungin",NA,"IE","IE",FALSE,NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Anidulafungin",NA,"IE","IE",FALSE,NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus nidulans",NA,"Anidulafungin",NA,"IE","IE",FALSE,NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Anidulafungin",NA,"IE","IE",FALSE,NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus terreus",NA,"Anidulafungin",NA,"IE","IE",FALSE,NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus flavus",NA,"Caspofungin",NA,"IE","IE",FALSE,NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Caspofungin",NA,"IE","IE",FALSE,NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus nidulans",NA,"Caspofungin",NA,"IE","IE",FALSE,NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Caspofungin",NA,"IE","IE",FALSE,NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus terreus",NA,"Caspofungin",NA,"IE","IE",FALSE,NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus flavus",NA,"Isavuconazole",NA,"1","1",FALSE,NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Isavuconazole",NA,"1","1",FALSE,NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus nidulans",NA,"Isavuconazole",NA,"0.5","0.5",FALSE,NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Isavuconazole",NA,"IE","IE",FALSE,"[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus.","6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus terreus",NA,"Isavuconazole",NA,"1","1",FALSE,NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus flavus",NA,"Itraconazole",NA,"1","1",FALSE,"[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2 mg/L) is ensured via TDM.","6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Itraconazole",NA,"1","1",FALSE,"[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2 mg/L) is ensured via TDM.","6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus nidulans",NA,"Itraconazole",NA,"1","1",FALSE,"[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2 mg/L) is ensured via TDM.","6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Itraconazole",NA,"IE","IE",FALSE,"[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus. | [4] The MIC values for isolates of A. niger and A. versicolor are in general higher than those for A. fumigatus. Whether this translates into a poorer clinical response is unknown.","6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus terreus",NA,"Itraconazole",NA,"1","1",FALSE,"[3] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), itraconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2 mg/L) is ensured via TDM.","6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus flavus",NA,"Micafungin",NA,"IE","IE",FALSE,NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Micafungin",NA,"IE","IE",FALSE,NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus nidulans",NA,"Micafungin",NA,"IE","IE",FALSE,NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Micafungin",NA,"IE","IE",FALSE,NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus terreus",NA,"Micafungin",NA,"IE","IE",FALSE,NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus flavus",NA,"Posaconazole",NA,"IE","IE",FALSE,"[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus.","6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Posaconazole",NA,"0.125","0.125",FALSE,NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus nidulans",NA,"Posaconazole",NA,"IE","IE",FALSE,"[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus.","6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Posaconazole",NA,"IE","IE",FALSE,"[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus.","6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus terreus",NA,"Posaconazole",NA,"0.125","0.125",FALSE,NA,"6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus flavus",NA,"Voriconazole",NA,"IE","IE",FALSE,"[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus.","6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus fumigatus",NA,"Voriconazole",NA,"1","1",FALSE,"[6] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), voriconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2-3 mg/L) is ensured via TDM.","6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus nidulans",NA,"Voriconazole",NA,"1","1",FALSE,"[6] For isolates with confirmed MIC 2 mg/L (one dilution above the breakpoint), voriconazole may be considered for treatment of chronic pulmonary aspergillosis when no alternative is available and when sufficient exposure (>2-3 mg/L) is ensured via TDM.","6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus niger",NA,"Voriconazole",NA,"IE","IE",FALSE,"[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus.","6. Aspergillus " +"EUCAST 2026","12.1","Antifungal Clinical Breakpoint Table v. 12.1","human","human","MIC",NA,"Aspergillus terreus",NA,"Voriconazole",NA,"IE","IE",FALSE,"[2] The ECOFFs for these species are in general one two-fold dilution higher than for A. fumigatus.","6. Aspergillus " +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin iv",NA,"8","8",FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin iv","10 mcg","14","14",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)",NA,"8","8",FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","10 mcg","14","14",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv",NA,"8","8",FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","10/10 mcg","14","14",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)",NA,"8","8",FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","10/10 mcg","14","14",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin iv",NA,"8","8",FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin iv","/ mcg","Note","Note",FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)",NA,"0.001","8",FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","/ mcg","Note","Note",FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"". | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"8","8",FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","/ mcg","Note","Note",FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)",NA,"(8)","(8)",TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","/ mcg","Note","Note",FALSE,"[D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Infer from ampicillin oral, but the report should explain the meaning of breakpoints in brackets. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv",NA,"8","8",FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","20/10 mcg","19","19",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)",NA,"0.001","8",FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","20/10 mcg","50","19",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"32","32",FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","20/10 mcg","16","16",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"(8)","(8)",TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","20/10 mcg","(19)","(19)",TRUE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","8",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","20",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","8",FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","20",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16",FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)",NA,"0.001","16",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)","30 mcg","50","17",FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)",NA,"8","8",FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)","10 mcg","15","15",FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)",NA,"0.001","4",FALSE,"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli and Klebsiella spp. (except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)","30 mcg","50","20",FALSE,"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol",NA,"2","2",FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","30 mcg","22","22",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)",NA,"1","2",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","5 mcg","20","17",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","5 mcg","20","20",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)",NA,"Note","Note",FALSE,"[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","30 mcg","19","19",FALSE,"[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)","10 mcg","21","21",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8",FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","30 mcg","23","23",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"2","2",FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [6] See table of dosages for dosing for different indications.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","22","22",FALSE,"[6] See table of dosages for dosing for different indications.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)",NA,"1","2",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","25","22",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","30 mcg","25","25",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"0.001","8",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","50","19",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem",NA,"1","2",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","10 mcg","24","21",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","25","25",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem",NA,"2","4",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem","10 mcg","22","19",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Morganellaceae",NA,"Imipenem",NA,"0.001","4",FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Morganellaceae",NA,"Imipenem","10 mcg","50","19",FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam",NA,"2","2",FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam","10/25 mcg","22","22",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)",NA,"2","8",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","10 mcg","22","16",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)",NA,"2","2",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","10 mcg","22","22",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8",FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","20/10 mcg","20","20",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4",FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21",FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note",FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with low-level ciprofloxacin resistance (MIC >0.06 mg/L). The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)",NA,"0.25","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","5 mcg","25","22",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"0.125","0.125",FALSE,"[2] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"Note","Note",FALSE,"[2/B] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24",FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably detect low-level resistance in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where low-level ciprofloxacin resistance must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli",NA,"Delafloxacin",NA,"0.125","0.125",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli",NA,"Delafloxacin",NA,"Note","Note",FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Moxifloxacin",NA,"0.25","0.25",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Moxifloxacin","5 mcg","22","22",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","24","24",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)",NA,"(8)","(8)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","30 mcg","(18)","(18)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","18","18",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","10 mcg","(17)","(17)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)",NA,"2","2",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","10 mcg","(16)","(16)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","16","16",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli",NA,"Eravacycline","20 mcg","17","17",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5",FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient inSerratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18",FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient inSerratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note",FALSE,"[1] Efficacy for this order is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note",FALSE,"[A] Efficacy for this order is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"(2)","(2)",TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note",FALSE,"[B] Use an MIC method (broth microdilution only). | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Fosfomycin iv",NA,"32","32",FALSE,"[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems. | [4] Breakpoints for fosfomycin iv are currently under review.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Fosfomycin iv","200 mcg","21","21",FALSE,"[D] Zone diameter breakpoints apply to E. coli only. For other Enterobacterales, use an MIC method. | [E] Ignore isolated colonies within the inhibition zone (see pictures below). | [4] Breakpoints for fosfomycin iv are currently under review.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)",NA,"8","8",FALSE,"[5] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)","200 mcg","24","24",FALSE,"[E] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","15","15",FALSE,NA,"Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4",FALSE,"[6] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11",FALSE,"[6] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"0.001","16",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"0.001","16",FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"0.001","16",FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"0.001","8",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","50","21",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"P. aeruginosa",NA,"Cefiderocol",NA,"2","2",FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"P. aeruginosa",NA,"Cefiderocol","30 mcg","22","22",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"0.001","8",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","50","17",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8",FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4",FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] See table of dosages for dosing for different indications.","Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","23","23",FALSE,"[3] See table of dosages for dosing for different indications.","Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem",NA,"0.001","2",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","10 mcg","50","22",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"0.001","4",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","50","20",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"P. aeruginosa",NA,"Imipenem-relebactam",NA,"2","2",FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"P. aeruginosa",NA,"Imipenem-relebactam","10/25 mcg","22","22",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)",NA,"2","8",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)","10 mcg","20","14",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)",NA,"2","8",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)","10 mcg","24","18",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (meningitis)",NA,"2","2",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (meningitis)","10 mcg","20","20",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8",FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","20/10 mcg","14","14",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"0.001","16",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.001","0.5",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","50","26",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"0.001","2",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)",NA,"(16)","(16)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","30 mcg","(15)","(15)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"16","16",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","15","15",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","10 mcg","(18)","(18)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","18","18",FALSE,NA,"Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"(4)","(4)",TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note",FALSE,"[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[3] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). The ECOFF is 256 mg/L.","Pseudomonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"IE","IE",FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","S.maltophilia" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"Note","Note",FALSE,"[A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","16",FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"IE","IE",FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"Note","Note",FALSE,"[A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem",NA,"0.001","2",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","10 mcg","50","22",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"2","2",FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam","10/25 mcg","24","24",FALSE,"[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)",NA,"2","8",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","10 mcg","21","15",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)",NA,"2","2",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","10 mcg","21","21",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.001","1",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)",NA,"(8)","(8)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","30 mcg","(19)","(19)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","19","19",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)",NA,"(4)","(4)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","10 mcg","(17)","(17)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"4","4",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)",NA,"(4)","(4)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","10 mcg","(17)","(17)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"4","4",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"(2)","(2)",TRUE,"[2] For information on how to use breakpoints in brackets, see hhttps://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note",FALSE,"[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4",FALSE,"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11",FALSE,"[3] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Benzylpenicillin",NA,"0.125","0.125",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Benzylpenicillin","1 unit","26","26",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. lugdunensis",NA,"Benzylpenicillin",NA,"0.125","0.125",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. lugdunensis",NA,"Benzylpenicillin","1 unit","26","26",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note",FALSE,"[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note",FALSE,"[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. saprophyticus",NA,"Ampicillin",NA,"Note","Note",FALSE,"[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. saprophyticus",NA,"Ampicillin","2 mcg","18","18",FALSE,"[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. pseudintermedius, S. schleiferi and S. coagulans",NA,"Oxacillin (screen only)","1 mcg","20","20",FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. schleiferi and S. coagulans.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. 3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. 3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. 3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. 3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","22","22","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","27","27","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. pseudintermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note","[5] In S. pseudintermedius,S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. pseudintermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note","[C] In S. pseudintermedius,S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)",NA,"1","2","[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)","5 mcg","20","17","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (pneumonia)",NA,"1","1","[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (pneumonia)","5 mcg","20","20","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Ceftobiprole",NA,"2","2","[8] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Ceftobiprole","5 mcg","17","17","[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note",FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","22","22",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note",FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","27","27",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. pseudintermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note",FALSE,"[5] In S. pseudintermedius,S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. pseudintermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note",FALSE,"[C] In S. pseudintermedius,S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)",NA,"1","2",FALSE,"[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)","5 mcg","20","17",FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (pneumonia)",NA,"1","1",FALSE,"[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (pneumonia)","5 mcg","20","20",FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Ceftobiprole",NA,"2","2",FALSE,"[8] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Ceftobiprole","5 mcg","17","17",FALSE,"[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. 3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F. | [2] See table of dosages. 3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Ciprofloxacin","5 mcg","50","21","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin","5 mcg","50","24","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"0.016","0.016",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"Note","Note","[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"0.25","0.25",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"Note","Note","[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Levofloxacin","5 mcg","50","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin","5 mcg","50","24","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Moxifloxacin","5 mcg","25","25","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin","5 mcg","28","28","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","17","17","[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[2] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Amikacin",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Amikacin","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Amikacin",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Amikacin","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Gentamicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Gentamicin","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Gentamicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Gentamicin","10 mcg","22","22","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Tobramycin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Tobramycin","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Tobramycin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Tobramycin","10 mcg","20","20","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Oritavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Teicoplanin",NA,"2","2",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"4","4",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"MRSA",NA,"Telavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"MRSA",NA,"Telavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Vancomycin",NA,"2","2",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"4","4",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"2","2","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","15 mcg","21","21","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telithromycin",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telithromycin",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin",NA,"0.25","0.25","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","2 mcg","22","22","[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin",NA,"1","1",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","15 mcg","21","21",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Eravacycline",NA,"0.25","0.25",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Eravacycline","20 mcg","20","20","[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","30 mcg","22","22","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline",NA,"0.5","0.5","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","15 mcg","19","19","[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","10 mcg","21","21",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid",NA,"0.5","0.5","[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","2 mcg","20","20","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"32","32","[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). | [3] Breakpoints for fosfomycin iv are currently under review.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[A] Use an MIC method. | [3] Breakpoints for fosfomycin iv are currently under review.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid",NA,"1","1",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","10 mcg","24","24",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Lefamulin",NA,"0.25","0.25",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Lefamulin","5 mcg","23","23",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","13","13",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Rifampicin",NA,"0.06","0.06",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Rifampicin","5 mcg","26","26",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Rifampicin",NA,"0.06","0.06",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Rifampicin","5 mcg","30","30",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","14","14",NA,"Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","17","14","[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin",NA,"4","8","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","2 mcg","10","8","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"4","8","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"4","8","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem",NA,"0.001","4",NA,"Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","10 mcg","50","21",NA,"Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 5/D and 7/F.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Ciprofloxacin",NA,"0.001","1",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Ciprofloxacin","5 mcg","50","21",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin",NA,"0.001","1",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin","5 mcg","50","24",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"0.016","0.016",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"Note","Note",FALSE,"[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"0.25","0.25",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"Note","Note",FALSE,"[B] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Levofloxacin",NA,"0.001","1",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Levofloxacin","5 mcg","50","22",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin",NA,"0.001","1",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin","5 mcg","50","24",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Moxifloxacin",NA,"0.25","0.25",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Moxifloxacin","5 mcg","25","25",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin",NA,"0.25","0.25",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin","5 mcg","28","28",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","17","17",FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note",FALSE,"[2] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note",FALSE,"[D] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Amikacin",NA,"(16)","(16)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Amikacin","30 mcg","(15)","(15)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Amikacin",NA,"(16)","(16)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Amikacin","30 mcg","(15)","(15)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Resistance to amikacin is most reliably determined by testing with kanamycin (MIC >8 mg/L). The corresponding zone diameter for the kanamycin 30 µg disk is R<18 mm for S. aureus and R<22 mm for coagulase-negative staphylococci.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Gentamicin",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Gentamicin","10 mcg","(18)","(18)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Gentamicin",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Gentamicin","10 mcg","(22)","(22)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Tobramycin",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Tobramycin","10 mcg","(18)","(18)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Tobramycin",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Tobramycin","10 mcg","(20)","(20)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"0.125","0.125",FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Oritavancin",NA,"0.125","0.125",FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Oritavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Teicoplanin",NA,"2","2",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Teicoplanin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"4","4",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"MRSA",NA,"Telavancin",NA,"0.125","0.125",FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"MRSA",NA,"Telavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Vancomycin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"4","4",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"2","2",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"1","1",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin",NA,"1","1",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","15 mcg","21","21",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"1","1",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Telithromycin",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Telithromycin",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin",NA,"0.25","0.25",FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","2 mcg","22","22",FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin",NA,"1","1",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","15 mcg","21","21",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Eravacycline",NA,"0.25","0.25",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Eravacycline","20 mcg","20","20",FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline",NA,"0.5","0.5",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","30 mcg","23","23",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","30 mcg","22","22",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline",NA,"0.5","0.5",FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","15 mcg","19","19",FALSE,"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid",NA,"4","4",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","10 mcg","21","21",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","2 mcg","20","20",FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"1","1",FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"Note","Note",FALSE,"[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"32","32",FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). | [3] Breakpoints for fosfomycin iv are currently under review.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[A] Use an MIC method. | [3] Breakpoints for fosfomycin iv are currently under review.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid",NA,"1","1",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","10 mcg","24","24",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Lefamulin",NA,"0.25","0.25",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Lefamulin","5 mcg","23","23",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","13","13",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. aureus",NA,"Rifampicin",NA,"0.06","0.06",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. aureus",NA,"Rifampicin","5 mcg","26","26",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Rifampicin",NA,"0.06","0.06",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Rifampicin","5 mcg","30","30",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","14","14",FALSE,NA,"Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4",FALSE,"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","17","14",FALSE,"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin",NA,"4","8",FALSE,"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","2 mcg","10","8",FALSE,"[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"4","8",FALSE,"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"4","8",FALSE,"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"4","8",FALSE,"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note",FALSE,"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem",NA,"0.001","4",FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","10 mcg","50","21",FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note",FALSE,"[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note",FALSE,"[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","12","12",FALSE,"[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note",FALSE,"[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","30 mcg","Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for high-level aminoglycoside resistance)","30 mcg","Note","Note",FALSE,"[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note",FALSE,"[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)",NA,"Note","Note","[3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)",NA,"Note","Note",FALSE,"[3] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","300 mcg","Note","Note","[B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for high-level streptomycin resistance)","300 mcg","Note","Note",FALSE,"[B] Isolates with high-level gentamicin resistance may not be high-level resistant to streptomycin. Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and low-level intrinsic resistant. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. The isolate is high-level resistant to streptomycin. There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note",FALSE,"[A] Gentamicin can be used to screen for high-level aminoglycoside resistance (HLAR). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin and low-level intrinsic resistant. For other aminoglycosides, this may not be the case. Synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm. The isolate is high-level resistant to gentamicin and other aminoglycosides, except streptomycin which must be tested separately if required (see note 3/B). There will be no synergy with penicillins or glycopeptides.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",NA,"Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",NA,"Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin",NA,"4","4",NA,"Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","5 mcg","12","12","[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","1",NA,"Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","22",NA,"Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. faecalis",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. faecalis",NA,"Eravacycline","20 mcg","22","22",NA,"Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. faecium",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. faecium",NA,"Eravacycline","20 mcg","24","24",NA,"Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. faecalis",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. faecalis",NA,"Tigecycline","15 mcg","20","20","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. faecium",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. faecium",NA,"Tigecycline","15 mcg","22","22","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","20","20",NA,"Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[2] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[3] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note","[B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note","[3] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [4] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note","[B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [4] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.25","0.25",NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","18","18",NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)",NA,"0.125","0.125",NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)","1 unit","19","19",NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"0.001","2",NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","50","17","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","21","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin",NA,"0.25","0.25",NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","15 mcg","20","20",NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19","[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","19","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5","[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","2 mcg","18","18","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.06","0.06",NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","21",NA,"Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"2","2","[3] Breakpoints for trimethoprim are currently under review.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","IP","IP","[3] Breakpoints for trimethoprim are currently under review.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.06","2","[2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"0.06","0.06",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)",NA,"0.5","1",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","2 mcg","22","19",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","1 mcg","20","20","[C] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.001","0.5",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"0.5","2",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"0.5","2",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.25",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"1","1",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"0.001","2",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","50","16","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10","[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","22","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin",NA,"0.25","0.25",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","15 mcg","23","23",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","24","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","2",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","22",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note","[1] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note","[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","5 mcg","12","12",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.125","0.125",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","22",NA,"S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","13","10","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin",NA,"0.25","2",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","1 unit","21","12",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)",NA,"0.25","0.25","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","1 unit","21","21","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin",NA,"0.5","2",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","2 mcg","21","15",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"0.5","2",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem",NA,"1","1",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. anginosus group",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. anginosus group",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19","[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","20 mcg","17","17",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid","2 mcg","18","18",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[1] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","1 unit","12","12","[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)",NA,"1","1","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","2 mcg","18","18","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1","[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"2","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"0.001","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.001","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","50","15","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25","[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)",NA,"0.5","0.5","[2] See table of dosages for dosing for different indications.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","30/10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] See table of dosages for dosing for different indications.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.001","1",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem",NA,"1","1",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)",NA,"0.06","0.06",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)",NA,"0.03","0.03",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)","5 mcg","Note","Note","[B] Susceptibility can be inferred from the nalidixic acid screening test.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[C] | [C] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","24","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",NA,"H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","20","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","0.5",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","21",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.001","4",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem",NA,"1","1","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","10 mcg","30","30","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.25",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","23","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin",NA,"0.25","0.25",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","15 mcg","23","23",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","26","26","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[1] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)",NA,"0.06","1","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",NA,"N.gonorrhoeae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"N.gonorrhoeae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"N.gonorrhoeae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",NA,"N.gonorrhoeae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",NA,"N.gonorrhoeae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note","[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","0.5",NA,"N.gonorrhoeae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",NA,"N.gonorrhoeae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)",NA,"0.25","0.25",NA,"N.meningitidis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)",NA,"0.125","0.125","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)",NA,"0.125","0.125","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)",NA,"0.25","0.25","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (all indications, including meningitis and prophylaxis)",NA,"0.016","0.016",NA,"N.meningitidis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)",NA,"1","1","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)",NA,"2","2","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","N.meningitidis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)",NA,"0.25","0.25",NA,"N.meningitidis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam",NA,"2","2","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","10/10 mcg","25","25","[1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid",NA,"2","2","[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","14","14","[1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam",NA,"2","2","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","30/6 mcg","24","24",NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Ertapenem",NA,"2","2","[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Ertapenem","10 mcg","23","23","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Imipenem",NA,"1","1",NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Imipenem","10 mcg","29","29",NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem",NA,"1","1",NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","10 mcg","28","28",NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin",NA,"4","4","[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","2 mcg","10","10","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","5 mcg","25","25",NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","1 unit","20","20","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin","2 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ertapenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ertapenem","10 mcg","29","29","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Imipenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","10 mcg","34","34","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","2 mcg","31","31","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","5 mcg","22","22",NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","1 unit","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin","2 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","30/6 mcg","32","32","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ertapenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ertapenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Imipenem","10 mcg","36","36","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Meropenem",NA,"0.03","0.03","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Meropenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Clindamycin","2 mcg","30","30","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Metronidazole",NA,"0.5","0.5",NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Metronidazole","5 mcg","30","30",NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","1 unit","15","15","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin","2 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","10/10 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","30/6 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ertapenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ertapenem","10 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Imipenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Imipenem","10 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","10 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","5 mcg","12","12",NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","2 mcg","19","19","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","5 mcg","16","16",NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","1 unit","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin","2 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Cefotaxime","5 mcg","26","26","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ceftriaxone",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ceftriaxone","30 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ertapenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ertapenem","10 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Imipenem",NA,"0.03","0.03","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Imipenem","10 mcg","39","39","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","10 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","5 mcg","22","22",NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","2 mcg","26","26","[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Linezolid",NA,"2","2",NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Linezolid","10 mcg","34","34",NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"IP","IP",NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IE","IE","[2] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distributions between studies.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IE","IE",NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"IP","IP",NA,"Anaerobic bacteria" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral",NA,"0.125","0.125",NA,"H.pylori" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1",NA,"H.pylori" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.25",NA,"H.pylori" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1",NA,"H.pylori" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8",NA,"H.pylori" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1",NA,"H.pylori" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","13","13",NA,"L.monocytogenes" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)",NA,"1","1",NA,"L.monocytogenes" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","2 mcg","16","16",NA,"L.monocytogenes" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)",NA,"0.25","0.25",NA,"L.monocytogenes" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","10 mcg","26","26",NA,"L.monocytogenes" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","15 mcg","25","25",NA,"L.monocytogenes" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)",NA,"0.06","0.06","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","1.25/23.75 mcg","29","29","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5",NA,"Pasteurella" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Benzylpenicillin","1 unit","17","17",NA,"Pasteurella" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"1","1",NA,"Pasteurella" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"1","1",NA,"Pasteurella" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",NA,"Pasteurella" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Cefotaxime",NA,"0.03","0.03",NA,"Pasteurella" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Cefotaxime","5 mcg","26","26",NA,"Pasteurella" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Pasteurella" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Ciprofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Pasteurella" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Levofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Pasteurella" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"1","1",NA,"Pasteurella" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Tetracycline (screen only)","30 mcg","24","24","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"C.jejuni_C.coli" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","5 mcg","50","26",NA,"C.jejuni_C.coli" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","24","24","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note","[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline",NA,"2","2","[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","30 mcg","30","30","[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Corynebacterium" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","29","29",NA,"Corynebacterium" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Corynebacterium" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","25",NA,"Corynebacterium" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Corynebacterium" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","5 mcg","25","25",NA,"Corynebacterium" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin",NA,"2","2",NA,"Corynebacterium" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","5 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","2 mcg","20","20","[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"2","2",NA,"Corynebacterium" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",NA,"Corynebacterium" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",NA,"Corynebacterium" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",NA,"Corynebacterium" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",NA,"Corynebacterium" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","30","30",NA,"Corynebacterium" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.001","1",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","50","12",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"1","1","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime",NA,"0.001","2","[1] Susceptibility to cefotaxime can be inferred from benzylpenicillin.","C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","5 mcg","50","15","[A] Susceptibility to cefotaxime can be inferred from benzylpenicillin.","C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem",NA,"0.25","0.25","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","10 mcg","24","24","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","24",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin",NA,"0.06","0.06",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","15 mcg","24","24",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"C. diphtheriae",NA,"Clindamycin",NA,"0.5","0.5","[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"C. diphtheriae",NA,"Clindamycin","2 mcg","15","15","[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"0.5","0.5","[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"1","1",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","24","24",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","1 unit","21","21",NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","2 mcg","26","26",NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note","[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","10 mcg","31","31",NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21","[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2","[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"Note","Note","[B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Norfloxacin (screen only)","10 mcg","17","17","[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin",NA,"1","1",NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","5 mcg","25","25",NA,"A.sanguinicola_A.urinae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",NA,"K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",NA,"K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[3] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",NA,"K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",NA,"K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",NA,"K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",NA,"K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",NA,"K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",NA,"K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",NA,"K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",NA,"K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",NA,"K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",NA,"K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",NA,"K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",NA,"K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",NA,"Aeromonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",NA,"Aeromonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",NA,"Aeromonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",NA,"Aeromonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",NA,"Aeromonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",NA,"Aeromonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Aeromonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",NA,"Aeromonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Aeromonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",NA,"Aeromonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","19","16","[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam",NA,"4","4","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"A.xylosoxidans" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem",NA,"1","4",NA,"A.xylosoxidans" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","10 mcg","26","20",NA,"A.xylosoxidans" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","26","26","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam",NA,"1","1","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"Vibrio" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime",NA,"0.25","0.25",NA,"Vibrio" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","5 mcg","21","21",NA,"Vibrio" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",NA,"Vibrio" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",NA,"Vibrio" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime",NA,"1","1",NA,"Vibrio" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","10 mcg","22","22",NA,"Vibrio" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem",NA,"0.5","0.5",NA,"Vibrio" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","10 mcg","24","24",NA,"Vibrio" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin",NA,"0.25","0.25",NA,"Vibrio" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","5 mcg","23","23","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Vibrio" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","5 mcg","23","23","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","5 mcg","22","22","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin",NA,"4","4",NA,"Vibrio" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","15 mcg","16","16","[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","15 mcg","12","12","[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline",NA,"0.5","0.5",NA,"Vibrio" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","30 mcg","20","20","[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","21","21","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin","5 mcg","12","12",FALSE,"[A] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","1",FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","22",FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. faecalis",NA,"Eravacycline",NA,"0.125","0.125",FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. faecalis",NA,"Eravacycline","20 mcg","22","22",FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. faecium",NA,"Eravacycline",NA,"0.125","0.125",FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. faecium",NA,"Eravacycline","20 mcg","24","24",FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. faecalis",NA,"Tigecycline",NA,"0.25","0.25",FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. faecalis",NA,"Tigecycline","15 mcg","20","20",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. faecium",NA,"Tigecycline",NA,"0.25","0.25",FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. faecium",NA,"Tigecycline","15 mcg","22","22",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","20","20",FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE",FALSE,"[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE",FALSE,"[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note",FALSE,"[2] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note",FALSE,"[A] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note",FALSE,"[3] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note",FALSE,"[B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note",FALSE,"[3] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [4] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note",FALSE,"[B] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [4] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.25","0.25",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","18","18",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)",NA,"0.125","0.125",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)","1 unit","19","19",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"0.03","0.03",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"Note","Note",FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"0.001","2",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","50","17",FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19",FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12",FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","21",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","0.5",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin",NA,"0.25","0.25",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telithromycin","15 mcg","20","20",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17",FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","0.5",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","23",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","23",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125",FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19",FALSE,"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","19",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5",FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","2 mcg","18","18",FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1",FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note",FALSE,"[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.06","0.06",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","21",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"2","2",FALSE,"[3] Breakpoints for trimethoprim are currently under review.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","IP","IP",FALSE,"[3] Breakpoints for trimethoprim are currently under review.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2",FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15",FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.06","2",FALSE,"[2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"0.06","0.06",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)",NA,"0.5","1",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","2 mcg","22","19",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1",FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","1 mcg","20","20",FALSE,"[C] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.001","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"0.5","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.25",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"0.5","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.25",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"1","1",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"0.001","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","50","16",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10",FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17",FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16",FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","22",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","0.5",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telithromycin",NA,"0.25","0.25",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telithromycin","15 mcg","23","23",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19",FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","0.5",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","24",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","25",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","22",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note",FALSE,"[1] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note",FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","5 mcg","12","12",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.125","0.125",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","22",FALSE,NA,"S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","13","10",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin",NA,"0.25","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","1 unit","21","12",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)",NA,"0.25","0.25",FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","1 unit","21","21",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin",NA,"0.5","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","2 mcg","21","15",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"0.5","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note",FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem",NA,"1","1",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"2","2",FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. anginosus group",NA,"Delafloxacin",NA,"0.03","0.03",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. anginosus group",NA,"Delafloxacin",NA,"Note","Note",FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note",FALSE,"[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note",FALSE,"[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for high-level aminoglycoside resistance)",NA,"Note","Note",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturer's instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Telithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19",FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","20 mcg","17","17",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid","2 mcg","18","18",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note",FALSE,"[1] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note",FALSE,"[A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","1 unit","12","12",FALSE,"[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)",NA,"1","1",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","2 mcg","18","18",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1",FALSE,"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"2","2",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"0.001","2",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2",FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.001","2",FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","50","15",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25",FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","5 mcg","27","27",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","5 mcg","27","27",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)",NA,"0.5","0.5",FALSE,"[2] See table of dosages for dosing for different indications.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","30/10 mcg","23","23",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] See table of dosages for dosing for different indications.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","32","32",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","30 mcg","32","32",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.001","1",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem",NA,"1","1",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","10 mcg","23","23",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)",NA,"0.06","0.06",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)","5 mcg","30","30",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)",NA,"0.03","0.03",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)","5 mcg","Note","Note",FALSE,"[B] Susceptibility can be inferred from the nalidixic acid screening test.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23",FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Telithromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","24",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"2","2",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","25",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2",FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28",FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",FALSE,NA,"H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","20",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1",FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1",FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","0.5",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","21",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.001","4",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem",NA,"1","1",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","10 mcg","30","30",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23",FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.25",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","23",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","0.5",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Telithromycin",NA,"0.25","0.25",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Telithromycin","15 mcg","23","23",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","25",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"2","2",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","26","26",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note",FALSE,"[1] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note",FALSE,"[A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)",NA,"0.06","1",FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note",FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","0.5",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)",NA,"0.25","0.25",FALSE,NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)",NA,"0.125","1",FALSE,NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)",NA,"0.125","1",FALSE,NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)",NA,"0.125","0.125",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)",NA,"0.125","0.125",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem",NA,"Note","Note",FALSE,"[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem",NA,"Note","Note",FALSE,"[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)",NA,"0.25","0.25",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (all indications, including meningitis and prophylaxis)",NA,"0.016","0.016",FALSE,NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)",NA,"1","1",FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)",NA,"2","2",FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)",NA,"2","2",FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages.","N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)",NA,"0.25","0.25",FALSE,NA,"N.meningitidis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam",NA,"2","2",FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","10/10 mcg","25","25",FALSE,"[1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid",NA,"2","2",FALSE,"[3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","14","14",FALSE,"[1] Aminopenicillins without beta-lactamase inhibitors are rarely active against Bacteroides spp. and EUCAST has refrained from setting breakpoints for ampicillin and amoxicillin without inhibitors.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam",NA,"2","2",FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","30/6 mcg","24","24",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Ertapenem",NA,"(2)","(2)",TRUE,"[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Ertapenem","10 mcg","(23)","(23)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Imipenem",NA,"1","1",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Imipenem","10 mcg","29","29",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem",NA,"1","1",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","10 mcg","28","28",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin",NA,"(4)","(4)",TRUE,"[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","2 mcg","(10)","(10)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole",NA,"4","4",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","5 mcg","25","25",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","1 unit","20","20",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin","2 mcg","25","25",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","10/10 mcg","33","33",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ertapenem",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ertapenem","10 mcg","29","29",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Imipenem",NA,"0.125","0.125",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Imipenem","10 mcg","35","35",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","10 mcg","34","34",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin",NA,"0.25","0.25",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","2 mcg","31","31",FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole",NA,"4","4",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","5 mcg","22","22",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin",NA,"0.06","0.06",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","1 unit","25","25",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin","2 mcg","27","27",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam","10/10 mcg","33","33",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","30/6 mcg","32","32",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ertapenem",NA,"0.06","0.06",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ertapenem","10 mcg","35","35",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Imipenem",NA,"0.125","0.125",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Imipenem","10 mcg","36","36",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Meropenem",NA,"0.03","0.03",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Meropenem","10 mcg","35","35",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Clindamycin",NA,"0.25","0.25",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Clindamycin","2 mcg","30","30",FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Metronidazole",NA,"0.5","0.5",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Metronidazole","5 mcg","30","30",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","1 unit","15","15",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin","2 mcg","23","23",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","10/10 mcg","27","27",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","30/6 mcg","24","24",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ertapenem",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ertapenem","10 mcg","24","24",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Imipenem",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Imipenem","10 mcg","25","25",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem",NA,"0.125","0.125",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","10 mcg","25","25",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","5 mcg","12","12",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin",NA,"0.25","0.25",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","2 mcg","19","19",FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole",NA,"4","4",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","5 mcg","16","16",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin",NA,"0.06","0.06",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","1 unit","24","24",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin","2 mcg","23","23",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","10/10 mcg","33","33",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","30/6 mcg","27","27",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Cefotaxime","5 mcg","26","26",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ceftriaxone",NA,"0.06","0.06",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ceftriaxone","30 mcg","33","33",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ertapenem",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ertapenem","10 mcg","28","28",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Imipenem",NA,"0.03","0.03",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Imipenem","10 mcg","39","39",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem",NA,"0.125","0.125",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","10 mcg","28","28",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","5 mcg","22","22",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin",NA,"0.25","0.25",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","2 mcg","26","26",FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Linezolid",NA,"2","2",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Linezolid","10 mcg","34","34",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2",FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"IP","IP",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IE","IE",FALSE,"[2] Fidaxomicin breakpoints and ECOFF have not been set because the available data show major variation in MIC distributions between studies.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IE","IE",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2",FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"IP","IP",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral",NA,"0.125","0.125",FALSE,NA,"H.pylori" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1",FALSE,NA,"H.pylori" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.25",FALSE,NA,"H.pylori" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1",FALSE,NA,"H.pylori" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8",FALSE,NA,"H.pylori" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1",FALSE,NA,"H.pylori" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)",NA,"1","1",FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","13","13",FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)",NA,"1","1",FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","2 mcg","16","16",FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)",NA,"0.25","0.25",FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","10 mcg","26","26",FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)",NA,"1","1",FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","15 mcg","25","25",FALSE,NA,"L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)",NA,"0.06","0.06",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","1.25/23.75 mcg","29","29",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5",FALSE,NA,"Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Benzylpenicillin","1 unit","17","17",FALSE,NA,"Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"1","1",FALSE,NA,"Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"1","1",FALSE,NA,"Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid",NA,"1","1",FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",FALSE,NA,"Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Cefotaxime",NA,"0.03","0.03",FALSE,NA,"Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Cefotaxime","5 mcg","26","26",FALSE,NA,"Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,NA,"Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Ciprofloxacin","5 mcg","27","27",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Levofloxacin",NA,"0.06","0.06",FALSE,NA,"Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Levofloxacin","5 mcg","27","27",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Nalidixic acid (screen only)","30 mcg","23","23",FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"1","1",FALSE,NA,"Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Tetracycline (screen only)","30 mcg","24","24",FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin",NA,"0.001","0.5",FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","5 mcg","50","26",FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note",FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4",FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20",FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8",FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","24","24",FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note",FALSE,"[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline",NA,"2","2",FALSE,"[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","30 mcg","30","30",FALSE,"[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.125","0.125",FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","29","29",FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","1",FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","25",FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin",NA,"0.5","0.5",FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","5 mcg","25","25",FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","5 mcg","17","17",FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","2 mcg","20","20",FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"2","2",FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","30","30",FALSE,NA,"Corynebacterium" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.001","1",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","50","12",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"1","1",FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime",NA,"0.001","2",FALSE,"[1] Susceptibility to cefotaxime can be inferred from benzylpenicillin.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","5 mcg","50","15",FALSE,"[A] Susceptibility to cefotaxime can be inferred from benzylpenicillin.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem",NA,"0.25","0.25",FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","10 mcg","24","24",FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","0.5",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","24",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin",NA,"0.06","0.06",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","15 mcg","24","24",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"C. diphtheriae",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"C. diphtheriae",NA,"Clindamycin","2 mcg","15","15",FALSE,"[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"0.5","0.5",FALSE,"[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"1","1",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","24","24",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","1 unit","21","21",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin",NA,"0.25","0.25",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","2 mcg","26","26",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem",NA,"0.25","0.25",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","10 mcg","31","31",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21",FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2",FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"Note","Note",FALSE,"[B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Norfloxacin (screen only)","10 mcg","17","17",FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin",NA,"1","1",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","5 mcg","16","16",FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin",NA,"0.125","0.125",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","5 mcg","25","25",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06",FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125",FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[3] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25",FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5",FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",FALSE,NA,"K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",FALSE,NA,"Aeromonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",FALSE,NA,"Aeromonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",FALSE,NA,"Aeromonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",FALSE,NA,"Aeromonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",FALSE,NA,"Aeromonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",FALSE,NA,"Aeromonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",FALSE,NA,"Aeromonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",FALSE,NA,"Aeromonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",FALSE,NA,"Aeromonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",FALSE,NA,"Aeromonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","19","16",FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam",NA,"4","4",FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",FALSE,NA,"A.xylosoxidans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem",NA,"1","4",FALSE,NA,"A.xylosoxidans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","10 mcg","26","20",FALSE,NA,"A.xylosoxidans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","26","26",FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam",NA,"1","1",FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",FALSE,NA,"Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime",NA,"0.25","0.25",FALSE,NA,"Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","5 mcg","21","21",FALSE,NA,"Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",FALSE,NA,"Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",FALSE,NA,"Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime",NA,"1","1",FALSE,NA,"Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","10 mcg","22","22",FALSE,NA,"Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem",NA,"0.5","0.5",FALSE,NA,"Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","10 mcg","24","24",FALSE,NA,"Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin",NA,"0.25","0.25",FALSE,NA,"Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","5 mcg","23","23",FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin",NA,"0.25","0.25",FALSE,NA,"Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","5 mcg","23","23",FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","5 mcg","22","22",FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin",NA,"4","4",FALSE,NA,"Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","15 mcg","16","16",FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","15 mcg","12","12",FALSE,"[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline",NA,"0.5","0.5",FALSE,NA,"Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","30 mcg","20","20",FALSE,"[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","21","21",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio" "EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Imipenem",NA,"0.5","0.5",NA,"Bacillus" +except B. anthracis",NA,"Imipenem",NA,"0.5","0.5",FALSE,NA,"Bacillus" "EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Imipenem","10 mcg","30","30",NA,"Bacillus" +except B. anthracis",NA,"Imipenem","10 mcg","30","30",FALSE,NA,"Bacillus" "EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Meropenem",NA,"0.25","0.25",NA,"Bacillus" +except B. anthracis",NA,"Meropenem",NA,"0.25","0.25",FALSE,NA,"Bacillus" "EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Meropenem","10 mcg","25","25",NA,"Bacillus" +except B. anthracis",NA,"Meropenem","10 mcg","25","25",FALSE,NA,"Bacillus" "EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Bacillus" +except B. anthracis",NA,"Ciprofloxacin",NA,"0.001","0.5",FALSE,NA,"Bacillus" "EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Ciprofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +except B. anthracis",NA,"Ciprofloxacin","5 mcg","50","23",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" "EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Levofloxacin",NA,"0.001","1",NA,"Bacillus" +except B. anthracis",NA,"Levofloxacin",NA,"0.001","1",FALSE,NA,"Bacillus" "EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Levofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +except B. anthracis",NA,"Levofloxacin","5 mcg","50","23",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" "EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Norfloxacin (screen only)","10 mcg","21","21","[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" +except B. anthracis",NA,"Norfloxacin (screen only)","10 mcg","21","21",FALSE,"[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" "EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Vancomycin",NA,"2","2",NA,"Bacillus" +except B. anthracis",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Bacillus" "EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Vancomycin","5 mcg","10","10","[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" +except B. anthracis",NA,"Vancomycin","5 mcg","10","10",FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" "EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Erythromycin",NA,"0.5","0.5",NA,"Bacillus" +except B. anthracis",NA,"Erythromycin",NA,"0.5","0.5",FALSE,NA,"Bacillus" "EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Erythromycin","15 mcg","24","24",NA,"Bacillus" +except B. anthracis",NA,"Erythromycin","15 mcg","24","24",FALSE,NA,"Bacillus" "EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Clindamycin",NA,"1","1",NA,"Bacillus" +except B. anthracis",NA,"Clindamycin",NA,"1","1",FALSE,NA,"Bacillus" "EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Clindamycin","2 mcg","17","17",NA,"Bacillus" +except B. anthracis",NA,"Clindamycin","2 mcg","17","17",FALSE,NA,"Bacillus" "EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Linezolid",NA,"2","2",NA,"Bacillus" +except B. anthracis",NA,"Linezolid",NA,"2","2",FALSE,NA,"Bacillus" "EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Linezolid","10 mcg","22","22",NA,"Bacillus" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid",NA,"0.001","8","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","20/10 mcg","50","22",NA,"B.pseudomallei" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime",NA,"0.001","8",NA,"B.pseudomallei" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","10 mcg","50","18",NA,"B.pseudomallei" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem",NA,"2","2",NA,"B.pseudomallei" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","10 mcg","29","29",NA,"B.pseudomallei" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem",NA,"2","2",NA,"B.pseudomallei" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","10 mcg","24","24",NA,"B.pseudomallei" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"0.001","2",NA,"B.pseudomallei" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"Note","Note","[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","30 mcg","23","23","[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol",NA,"0.001","8",NA,"B.pseudomallei" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","30 mcg","50","22",NA,"B.pseudomallei" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","17","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25","[1] Breakpoints were determined on MICs performed on Middlebrook 7H11/7H10 medium. The comparability of tests performed by other media has not been established. There is ongoing work to review breakpoints using the EUCAST reference method (described above).","M.tuberculosis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06",NA,"M.tuberculosis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Pretomanid",NA,"Note","Note","[2] A provisional screen value of ≤2 mg/L can be used for antimicrobial susceptibility testing with Mycobacteria Growth Indicator Tube (MGIT, Becton Dickinson). There are insufficient MIC data with the reference method to set a clinical breakpoint.","M.tuberculosis" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin",NA,"2","2",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","10 mcg","16","16",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)",NA,"8","8",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","10 mcg","12","12",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin",NA,"8","8",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","10 mcg","15","15",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","5 mcg","26","26",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","5 mcg","18","18",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","5 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","30 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)",NA,"4","4",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","21","21",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","23",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","5 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","30 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Gentamicin",NA,"2","2",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","10 mcg","18","18",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","10 mcg","17","17","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","30 mcg","18","18",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","10 mcg","24","24",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)",NA,"1","1",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","10 mcg","14","14",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Mupirocin",NA,"1","1","[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +except B. anthracis",NA,"Linezolid","10 mcg","22","22",FALSE,NA,"Bacillus" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid",NA,"0.001","8",FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","20/10 mcg","50","22",FALSE,NA,"B.pseudomallei" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime",NA,"0.001","8",FALSE,NA,"B.pseudomallei" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","10 mcg","50","18",FALSE,NA,"B.pseudomallei" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem",NA,"2","2",FALSE,NA,"B.pseudomallei" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","10 mcg","29","29",FALSE,NA,"B.pseudomallei" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem",NA,"2","2",FALSE,NA,"B.pseudomallei" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","10 mcg","24","24",FALSE,NA,"B.pseudomallei" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"0.001","2",FALSE,NA,"B.pseudomallei" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","30 mcg","23","23",FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol",NA,"0.001","8",FALSE,NA,"B.pseudomallei" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","30 mcg","50","22",FALSE,NA,"B.pseudomallei" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","17",FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25",FALSE,"[1] Breakpoints were determined on MICs performed on Middlebrook 7H11/7H10 medium. The comparability of tests performed by other media has not been established. There is ongoing work to review breakpoints using the EUCAST reference method (described above).","M.tuberculosis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06",FALSE,NA,"M.tuberculosis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Pretomanid",NA,"Note","Note",FALSE,"[2] A provisional screen value of ≤2 mg/L can be used for antimicrobial susceptibility testing with Mycobacteria Growth Indicator Tube (MGIT, Becton Dickinson). There are insufficient MIC data with the reference method to set a clinical breakpoint.","M.tuberculosis" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","10 mcg","17","17",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","10 mcg","16","16",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin",NA,"0.125","0.125",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin",NA,"0.25","0.25",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.25",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol",NA,"16","16",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","10 mcg","12","12",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","10 mcg","15","15",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","10 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","5 mcg","26","26",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","5 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","5 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","30 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin (framycetin)",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","21","21",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","23",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","5 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","30 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Gentamicin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","10 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Tobramycin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","10 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","10 mcg","17","17",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol",NA,"16","16",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","30 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","10 mcg","24","24",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","10 mcg","14","14",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Mupirocin",NA,"1","1",FALSE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. ND = No ECOFF available.","Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","200 mcg","30","30","[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","200 mcg","30","30",FALSE,"[2] Breakpoints for nasal decontamination S ≤1, R >256 mg/L (S ≥30, R <18 mm for the mupirocin 200 µg disk). Isolates in the I category are associated with short term suppression (useful preoperatively) but, unlike fully susceptible isolates, long term eradication rates are low. ND = No ECOFF available.","Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Retapamulin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Retapamulin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin",NA,"4","4",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"32","32",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","200 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"0.125","0.125",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin",NA,"4","4",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin",NA,"8","8",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","30 mcg","28","28",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","30 mcg","31","31",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin iv",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin iv","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin iv",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin iv","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)",NA,"0.001","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","/ mcg","Note","Note","[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"". | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)",NA,"8","8","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","/ mcg","Note","Note","[D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Infer from ampicillin oral, but the report should explain the meaning of breakpoints in brackets. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv",NA,"8","8","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","20/10 mcg","19","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)",NA,"0.001","8","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","20/10 mcg","50","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"32","32","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","20/10 mcg","16","16","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"8","8","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","20/10 mcg","19","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","8",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","20",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","8","[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","20",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)",NA,"0.001","16",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)","30 mcg","50","17","[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)",NA,"8","8","[6] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)","10 mcg","15","15","[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli and Klebsiella spp.(except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)",NA,"0.001","4","[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli and Klebsiella spp.(except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)","30 mcg","50","20","[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol",NA,"2","2","[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","30 mcg","23","23",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","5 mcg","20","17",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","5 mcg","20","20",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","30 mcg","19","19","[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)","10 mcg","21","21",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8","[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","30 mcg","23","23",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"2","2","[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [6] See table of dosages for dosing for different indications.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","22","22","[6] See table of dosages for dosing for different indications.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","25","22",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","30 mcg","25","25",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"0.001","8",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","50","19",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem",NA,"1","2",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","10 mcg","24","21",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","23","23",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem",NA,"2","4",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem","10 mcg","22","19",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Morganellaceae",NA,"Imipenem",NA,"0.001","4","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Morganellaceae",NA,"Imipenem","10 mcg","50","19","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam",NA,"2","2","[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","10 mcg","22","16",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","10 mcg","22","22",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8","[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","20/10 mcg","20","20",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06","[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note","[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)",NA,"0.25","0.5",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","5 mcg","25","22",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"0.125","0.125","[2] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"Note","Note","[2/B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24","[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli",NA,"Delafloxacin",NA,"0.125","0.125",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli",NA,"Delafloxacin",NA,"Note","Note","[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.",NA,"Moxifloxacin",NA,"0.25","0.25","[3] Fluoroquinolone breakpoints are available for other agents.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.",NA,"Moxifloxacin","5 mcg","22","22","[3] Fluoroquinolone breakpoints are available for other agents.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","0.5",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","24","24",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","30 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","18","18",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","10 mcg","16","16","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","16","16",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli",NA,"Eravacycline","20 mcg","17","17",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18","[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note","[1] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note","[A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"2","2","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note","[B] Use an MIC method (broth microdilution only). | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin iv (infections originating from the urinary tract)",NA,"8","8","[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin iv (infections originating from the urinary tract)","200 mcg","24","24","[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin iv (other indications)",NA,"Note","Note","[5] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin iv (other indications)",NA,"Note","Note","[E] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"other Enterobacterales",NA,"Fosfomycin iv",NA,"Note","Note","[6] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"other Enterobacterales",NA,"Fosfomycin iv",NA,"Note","Note","[F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)",NA,"8","8","[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)","200 mcg","24","24","[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","15","15",NA,"Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[7] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[7] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"0.001","16",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"0.001","16","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"0.001","16","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"0.001","8",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","50","21",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"P. aeruginosa",NA,"Cefiderocol",NA,"2","2","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"P. aeruginosa",NA,"Cefiderocol","30 mcg","22","22",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"0.001","8",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","50","17",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] See table of dosages for dosing for different indications.","Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","23","23","[3] See table of dosages for dosing for different indications.","Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem",NA,"0.001","2",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","10 mcg","50","22",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"0.001","4",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","50","20",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"P. aeruginosa",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"P. aeruginosa",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)","10 mcg","20","14",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)",NA,"2","8",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)","10 mcg","24","18",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (meningitis)","10 mcg","20","20",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","20/10 mcg","14","14",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"0.001","16",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","50","26",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"0.001","2",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"16","16",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","15","15",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","18","18",NA,"Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"4","4","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Fosfomycin iv",NA,"Note","Note","[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Fosfomycin iv",NA,"Note","Note","[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"IE","IE","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","S.maltophilia" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"Note","Note","[A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","16","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"IE","IE","[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"Note","Note","[A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem",NA,"0.001","2",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","10 mcg","50","22",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","10 mcg","21","15",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","10 mcg","21","21",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","30 mcg","19","19","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","19","19",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"2","2","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Fosfomycin iv",NA,"Note","Note","[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Fosfomycin iv",NA,"Note","Note","[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Benzylpenicillin",NA,"0.125","0.125","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Benzylpenicillin","1 unit","26","26","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. lugdunensis",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. lugdunensis",NA,"Benzylpenicillin","1 unit","26","26",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. saprophyticus",NA,"Ampicillin",NA,"Note","Note","[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. saprophyticus",NA,"Ampicillin","2 mcg","18","18","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Oxacillin (screen only)","1 mcg","20","20","[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [2] See table of dosages. +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. aureus",NA,"Retapamulin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. aureus",NA,"Retapamulin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","21","21",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"32","32",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","200 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"0.125","0.125",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin",NA,"0.06","0.06",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin",NA,"0.06","0.06",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","30 mcg","28","28",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","H. influenzae",NA,"Neomycin (framycetin)",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","H. influenzae",NA,"Neomycin (framycetin)","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","30 mcg","31","31",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin (framycetin)",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2023","13.1","Clinical Breakpoint Tables v. 13.1","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin iv",NA,"8","8",FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin iv","10 mcg","14","14",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)",NA,"8","8",FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","10 mcg","14","14",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv",NA,"8","8",FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","10/10 mcg","14","14",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)",NA,"8","8",FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","10/10 mcg","14","14",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin iv",NA,"8","8",FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin iv","/ mcg","Note","Note",FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)",NA,"0.001","8",FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","/ mcg","Note","Note",FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"". | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"8","8",FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","/ mcg","Note","Note",FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)",NA,"(8)","(8)",TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","/ mcg","Note","Note",FALSE,"[D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Infer from ampicillin oral, but the report should explain the meaning of breakpoints in brackets. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv",NA,"8","8",FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","20/10 mcg","19","19",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)",NA,"0.001","8",FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","20/10 mcg","50","19",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"32","32",FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","20/10 mcg","16","16",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"(8)","(8)",TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","20/10 mcg","(19)","(19)",TRUE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","8",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","20",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","8",FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","20",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16",FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)",NA,"0.001","16",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)","30 mcg","50","17",FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)",NA,"8","8",FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)","10 mcg","15","15",FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli and Klebsiella spp.(except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)",NA,"0.001","4",FALSE,"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli and Klebsiella spp.(except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)","30 mcg","50","20",FALSE,"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol",NA,"2","2",FALSE,"[3] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","30 mcg","23","23",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)",NA,"1","2",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","5 mcg","20","17",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","5 mcg","20","20",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)",NA,"Note","Note",FALSE,"[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","30 mcg","19","19",FALSE,"[4] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)","10 mcg","21","21",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8",FALSE,"[5] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","30 mcg","23","23",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"2","2",FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [6] See table of dosages for dosing for different indications.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","22","22",FALSE,"[6] See table of dosages for dosing for different indications.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)",NA,"1","2",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","25","22",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","30 mcg","25","25",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"0.001","8",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","50","19",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem",NA,"1","2",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","10 mcg","24","21",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","23","23",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem",NA,"2","4",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem","10 mcg","22","19",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Morganellaceae",NA,"Imipenem",NA,"0.001","4",FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Morganellaceae",NA,"Imipenem","10 mcg","50","19",FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam",NA,"2","2",FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam","10/25 mcg","22","22",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)",NA,"2","8",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","10 mcg","22","16",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)",NA,"2","2",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","10 mcg","22","22",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8",FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","20/10 mcg","20","20",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4",FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21",FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note",FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)",NA,"0.25","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","5 mcg","25","22",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"0.125","0.125",FALSE,"[2] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"Note","Note",FALSE,"[2/B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24",FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli",NA,"Delafloxacin",NA,"0.125","0.125",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli",NA,"Delafloxacin",NA,"Note","Note",FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.",NA,"Moxifloxacin",NA,"0.25","0.25",FALSE,"[3] Fluoroquinolone breakpoints are available for other agents.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.",NA,"Moxifloxacin","5 mcg","22","22",FALSE,"[3] Fluoroquinolone breakpoints are available for other agents.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","24","24",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)",NA,"(8)","(8)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","30 mcg","(18)","(18)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","18","18",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","10 mcg","(17)","(17)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)",NA,"2","2",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","10 mcg","(16)","(16)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","16","16",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli",NA,"Eravacycline","20 mcg","17","17",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5",FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18",FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note",FALSE,"[1] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note",FALSE,"[A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"(2)","(2)",TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note",FALSE,"[B] Use an MIC method (broth microdilution only). | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin iv (infections originating from the urinary tract)",NA,"8","8",FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin iv (infections originating from the urinary tract)","200 mcg","24","24",FALSE,"[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin iv (other indications)",NA,"Note","Note",FALSE,"[5] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin iv (other indications)",NA,"Note","Note",FALSE,"[E] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"other Enterobacterales",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[6] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"other Enterobacterales",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)",NA,"8","8",FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)","200 mcg","24","24",FALSE,"[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","15","15",FALSE,NA,"Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4",FALSE,"[7] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11",FALSE,"[7] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"0.001","16",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"0.001","16",FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"0.001","16",FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"0.001","8",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","50","21",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"P. aeruginosa",NA,"Cefiderocol",NA,"2","2",FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"P. aeruginosa",NA,"Cefiderocol","30 mcg","22","22",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"0.001","8",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","50","17",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8",FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4",FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] See table of dosages for dosing for different indications.","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","23","23",FALSE,"[3] See table of dosages for dosing for different indications.","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem",NA,"0.001","2",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","10 mcg","50","22",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"0.001","4",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","50","20",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"P. aeruginosa",NA,"Imipenem-relebactam",NA,"2","2",FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"P. aeruginosa",NA,"Imipenem-relebactam","10/25 mcg","22","22",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)",NA,"2","8",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)","10 mcg","20","14",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)",NA,"2","8",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)","10 mcg","24","18",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (meningitis)",NA,"2","2",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (meningitis)","10 mcg","20","20",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8",FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","20/10 mcg","14","14",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"0.001","16",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.001","0.5",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","50","26",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"0.001","2",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)",NA,"(16)","(16)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","30 mcg","(15)","(15)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"16","16",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","15","15",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","10 mcg","(18)","(18)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","18","18",FALSE,NA,"Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"(4)","(4)",TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note",FALSE,"[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"IE","IE",FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","S.maltophilia" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"Note","Note",FALSE,"[A] Zone diameters of ≥20 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","S.maltophilia" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","16",FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"IE","IE",FALSE,"[1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"Note","Note",FALSE,"[A] Zone diameters of ≥17 mm for the cefiderocol 30 µg disk correspond to MIC values below the PK-PD breakpoint of S ≤ 2 mg/L.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem",NA,"0.001","2",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","10 mcg","50","22",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[1] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[1/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)",NA,"2","8",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","10 mcg","21","15",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)",NA,"2","2",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","10 mcg","21","21",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[1] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[1/A] The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.001","1",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)",NA,"(8)","(8)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","30 mcg","(19)","(19)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","19","19",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)",NA,"(4)","(4)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","10 mcg","(17)","(17)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"4","4",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)",NA,"(4)","(4)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","10 mcg","(17)","(17)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"4","4",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"(2)","(2)",TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note",FALSE,"[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4",FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11",FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Benzylpenicillin",NA,"0.125","0.125",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Benzylpenicillin","1 unit","26","26",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. lugdunensis",NA,"Benzylpenicillin",NA,"0.125","0.125",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. lugdunensis",NA,"Benzylpenicillin","1 unit","26","26",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note",FALSE,"[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note",FALSE,"[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. saprophyticus",NA,"Ampicillin",NA,"Note","Note",FALSE,"[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. saprophyticus",NA,"Ampicillin","2 mcg","18","18",FALSE,"[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Oxacillin (screen only)","1 mcg","20","20",FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [2] See table of dosages. 3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [2] See table of dosages. +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [2] See table of dosages. 3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [2] See table of dosages. +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [2] See table of dosages. 3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [2] See table of dosages. +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [2] See table of dosages. 3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","22","22","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","27","27","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note","[5] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note","[C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)",NA,"1","2","[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)","5 mcg","20","17","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (pneumonia)",NA,"1","1","[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (pneumonia)","5 mcg","20","20","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Ceftobiprole",NA,"2","2","[8] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Ceftobiprole","5 mcg","17","17","[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [2] See table of dosages. +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note",FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","22","22",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note",FALSE,"[4] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","27","27",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note",FALSE,"[5] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note",FALSE,"[C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)",NA,"1","2",FALSE,"[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)","5 mcg","20","17",FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (pneumonia)",NA,"1","1",FALSE,"[6] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (pneumonia)","5 mcg","20","20",FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Ceftobiprole",NA,"2","2",FALSE,"[8] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Ceftobiprole","5 mcg","17","17",FALSE,"[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [2] See table of dosages. 3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [2] See table of dosages. +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F. | [2] See table of dosages. 3.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Ciprofloxacin",NA,"0.001","2","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Ciprofloxacin","5 mcg","50","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin",NA,"0.001","2","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin","5 mcg","50","22","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"0.016","0.016",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"Note","Note","[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"0.25","0.25",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"Note","Note","[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Levofloxacin","5 mcg","50","22","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin","5 mcg","50","24","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Moxifloxacin","5 mcg","25","25","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin","5 mcg","28","28","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","17","17","[D] | [D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Amikacin",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Amikacin","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Amikacin",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Amikacin","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Gentamicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Gentamicin","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Gentamicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Gentamicin","10 mcg","22","22","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Tobramycin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Tobramycin","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Tobramycin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Tobramycin","10 mcg","20","20","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] Coagulase-negative staphylococci susceptible to both vancomycin and teicoplanin can be reported susceptible to dalbavancin. | [5] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Oritavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Teicoplanin",NA,"2","2",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"4","4",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"MRSA",NA,"Telavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [6] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"MRSA",NA,"Telavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Vancomycin",NA,"2","2",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"4","4",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"2","2","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","15 mcg","21","21","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin",NA,"0.25","0.25","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","2 mcg","22","22","[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin",NA,"1","1",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","15 mcg","21","21",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Eravacycline",NA,"0.25","0.25",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Eravacycline","20 mcg","20","20","[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","30 mcg","22","22","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline",NA,"0.5","0.5","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","15 mcg","19","19","[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","10 mcg","21","21",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid",NA,"0.5","0.5","[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","2 mcg","20","20","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid",NA,"1","1",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","10 mcg","24","24",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Lefamulin",NA,"0.25","0.25",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Lefamulin","5 mcg","23","23",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","13","13",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Rifampicin",NA,"0.06","0.06",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Rifampicin","5 mcg","26","26",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Rifampicin",NA,"0.06","0.06",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Rifampicin","5 mcg","30","30",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","14","14",NA,"Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","17","14","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin",NA,"4","8","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","2 mcg","10","8","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"4","8","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"4","8","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"4","8","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem",NA,"0.001","4",NA,"Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","10 mcg","50","21",NA,"Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 6/D and 8/F.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Ciprofloxacin",NA,"(0.001)","(2)",TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Ciprofloxacin","5 mcg","(50)","(17)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin",NA,"(0.001)","(2)",TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin","5 mcg","(50)","(22)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"0.016","0.016",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"Note","Note",FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"0.25","0.25",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"Note","Note",FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Levofloxacin",NA,"0.001","1",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Levofloxacin","5 mcg","50","22",FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin",NA,"0.001","1",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin","5 mcg","50","24",FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Moxifloxacin",NA,"0.25","0.25",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Moxifloxacin","5 mcg","25","25",FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin",NA,"0.25","0.25",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin","5 mcg","28","28",FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","17","17",FALSE,"[D] | [D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note",FALSE,"[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note",FALSE,"[E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Amikacin",NA,"(16)","(16)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Amikacin","30 mcg","(15)","(15)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Amikacin",NA,"(16)","(16)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Amikacin","30 mcg","(15)","(15)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Gentamicin",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Gentamicin","10 mcg","(18)","(18)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Gentamicin",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Gentamicin","10 mcg","(22)","(22)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Tobramycin",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Tobramycin","10 mcg","(18)","(18)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Tobramycin",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Tobramycin","10 mcg","(20)","(20)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"0.125","0.125",FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [4] Coagulase-negative staphylococci susceptible to both vancomycin and teicoplanin can be reported susceptible to dalbavancin. | [5] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Oritavancin",NA,"0.125","0.125",FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [5] S. aureus isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Oritavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Teicoplanin",NA,"2","2",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Teicoplanin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"4","4",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"MRSA",NA,"Telavancin",NA,"0.125","0.125",FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [6] MRSA isolates susceptible to vancomycin can be reported susceptible to telavancin.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"MRSA",NA,"Telavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Vancomycin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"4","4",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"2","2",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"1","1",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin",NA,"1","1",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","15 mcg","21","21",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"1","1",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin",NA,"0.25","0.25",FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","2 mcg","22","22",FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin",NA,"1","1",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","15 mcg","21","21",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Eravacycline",NA,"0.25","0.25",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Eravacycline","20 mcg","20","20",FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline",NA,"0.5","0.5",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","30 mcg","23","23",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","30 mcg","22","22",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline",NA,"0.5","0.5",FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","15 mcg","19","19",FALSE,"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid",NA,"4","4",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","10 mcg","21","21",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","2 mcg","20","20",FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"1","1",FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"Note","Note",FALSE,"[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid",NA,"1","1",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","10 mcg","24","24",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Lefamulin",NA,"0.25","0.25",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Lefamulin","5 mcg","23","23",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","13","13",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. aureus",NA,"Rifampicin",NA,"0.06","0.06",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. aureus",NA,"Rifampicin","5 mcg","26","26",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Rifampicin",NA,"0.06","0.06",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Rifampicin","5 mcg","30","30",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","14","14",FALSE,NA,"Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4",FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","17","14",FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin",NA,"4","8",FALSE,"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin","2 mcg","10","8",FALSE,"[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"4","8",FALSE,"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"4","8",FALSE,"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"4","8",FALSE,"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test. | [1] Aminopenicillin breakpoints in enterococci are based on intravenous administration. For oral administration the breakpoints are relevant for urinary tract infections only.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note",FALSE,"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[2] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] In E. faecalis, susceptibility to ampicillin, amoxicillin and piperacillin (with and without beta-lactamase inhibitor) is the expected phenotype, while in E. faecium, resistance is common. Isolates resistant to ampicillin can be reported resistant to ampicillin, amoxicillin and piperacillin (with or without inhibitor). For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem",NA,"0.001","4",FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem","10 mcg","50","21",FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note",FALSE,"[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note",FALSE,"[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus spp. There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","12","12",FALSE,"[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note",FALSE,"[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","30 mcg","Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","30 mcg","Note","Note",FALSE,"[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note",FALSE,"[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note","[3] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing. +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note",FALSE,"[3] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing. Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)","300 mcg","Note","Note","[B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing. +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)","300 mcg","Note","Note",FALSE,"[B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing. Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note",FALSE,"[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",NA,"Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",NA,"Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin, enterococci other than E. casseliflavus and E. gallinarum",NA,"4","4","[1] Vancomycin resistance is the expected phenotype for E. casseliflavus and E. gallinarum and therefore susceptibility testing should not be performed.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin, enterococci other than E. casseliflavus and E. gallinarum","5 mcg","12","12","[A] Vancomycin resistance is the expected phenotype for E. casseliflavus and E. gallinarum and therefore susceptibility testing should not be performed. | [B] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","1",NA,"Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","22",NA,"Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. faecalis",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. faecalis",NA,"Eravacycline","20 mcg","22","22",NA,"Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. faecium",NA,"Eravacycline",NA,"0.125","0.125",NA,"Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. faecium",NA,"Eravacycline","20 mcg","24","24",NA,"Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. faecalis",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. faecalis",NA,"Tigecycline","15 mcg","20","20","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. faecium",NA,"Tigecycline",NA,"0.25","0.25","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. faecium",NA,"Tigecycline","15 mcg","22","22","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","20","20",NA,"Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[2] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[3] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[4] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note","[C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note","[4] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [5] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note","[C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [5] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.25","0.25",NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","18","18",NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)",NA,"0.125","0.125",NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)","1 unit","19","19",NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Vancomycin, enterococci other than E. casseliflavus and E. gallinarum",NA,"4","4",FALSE,"[1] Vancomycin resistance is the expected phenotype for E. casseliflavus and E. gallinarum and therefore susceptibility testing should not be performed.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Vancomycin, enterococci other than E. casseliflavus and E. gallinarum","5 mcg","12","12",FALSE,"[A] Vancomycin resistance is the expected phenotype for E. casseliflavus and E. gallinarum and therefore susceptibility testing should not be performed. | [B] Vancomycin susceptible enterococci exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","1",FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","22",FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. faecalis",NA,"Eravacycline",NA,"0.125","0.125",FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. faecalis",NA,"Eravacycline","20 mcg","22","22",FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. faecium",NA,"Eravacycline",NA,"0.125","0.125",FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. faecium",NA,"Eravacycline","20 mcg","24","24",FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. faecalis",NA,"Tigecycline",NA,"0.25","0.25",FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. faecalis",NA,"Tigecycline","15 mcg","20","20",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. faecium",NA,"Tigecycline",NA,"0.25","0.25",FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. faecium",NA,"Tigecycline","15 mcg","22","22",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","20","20",FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE",FALSE,"[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE",FALSE,"[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[2] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note",FALSE,"[3] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note",FALSE,"[B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note",FALSE,"[4] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note",FALSE,"[C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note",FALSE,"[4] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [5] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note",FALSE,"[C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type for both E. faecalis and E. faecium is 1 mg/L, with a corresponding zone diameter ECOFF of 21 mm for trimethoprim and 23 mm for trimethoprim-sulfamethoxazole. | [5] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.25","0.25",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","18","18",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)",NA,"0.125","0.125",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin (meningitis)","1 unit","19","19",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility (indications other than meningitis) with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, for which therapy with either of these agents is considered inadequate. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"0.001","2",NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","50","17","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","21","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19","[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","19","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5","[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","2 mcg","18","18","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.06","0.06",NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","21",NA,"Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[3] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.06","2","[2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"0.06","0.06",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)",NA,"0.5","1",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","2 mcg","22","19",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","1 mcg","20","20","[C] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.001","0.5",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"0.5","2",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"0.5","2",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.25",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"1","1",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"0.001","2",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","50","16","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10","[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","22","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","24","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","2",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","22",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note","[1] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note","[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","5 mcg","12","12",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.125","0.125",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","22",NA,"S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","13","10","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin",NA,"0.25","2",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","1 unit","21","12",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)",NA,"0.25","0.25","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","1 unit","21","21","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin",NA,"0.5","2",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","2 mcg","21","15",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"0.5","2",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem",NA,"1","1",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. anginosus group",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. anginosus group",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"0.03","0.03",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"Note","Note",FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"0.001","2",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","50","17",FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19",FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12",FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","21",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","0.5",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17",FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","0.5",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","23",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","23",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125",FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19",FALSE,"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","19",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5",FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","2 mcg","18","18",FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1",FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note",FALSE,"[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.06","0.06",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","21",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note",FALSE,"[3] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note",FALSE,"[B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2",FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15",FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"0.06","2",FALSE,"[2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [2] For breakpoints and dosing in pneumonia, see table of dosages.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"0.06","0.06",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)",NA,"0.5","1",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than meningitis)","2 mcg","22","19",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1",FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis).","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [4] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [B] Susceptibility inferred from ampicillin (indications other than meningitis). | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","1 mcg","20","20",FALSE,"[C] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.001","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"0.5","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.25",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"0.5","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.25",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"1","1",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"0.001","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","50","16",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10",FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17",FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16",FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","22",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","0.5",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19",FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","0.5",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","24",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","25",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","22",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note",FALSE,"[1] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note",FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","5 mcg","12","12",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.125","0.125",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","22",FALSE,NA,"S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","13","10",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin",NA,"0.25","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin","1 unit","21","12",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)",NA,"0.25","0.25",FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","1 unit","21","21",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin",NA,"0.5","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin","2 mcg","21","15",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"0.5","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note",FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [3] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [B] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem",NA,"1","1",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"2","2",FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. anginosus group",NA,"Delafloxacin",NA,"0.03","0.03",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. anginosus group",NA,"Delafloxacin",NA,"Note","Note",FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note",FALSE,"[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note",FALSE,"[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19","[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","20 mcg","17","17",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid","2 mcg","18","18",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[1] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","1 unit","12","12","[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)",NA,"1","1","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","2 mcg","18","18","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1","[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"2","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"0.001","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.001","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","50","15","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25","[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)",NA,"0.5","0.5","[2] See table of dosages for dosing for different indications.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","30/10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] See table of dosages for dosing for different indications.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.001","1",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem",NA,"1","1",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)",NA,"0.06","0.06",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)",NA,"0.03","0.03",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)",NA,"Note","Note","[B] Susceptibility can be inferred from the nalidixic acid screening test.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[C] | [C] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","24","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",NA,"H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","20","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","0.5",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","21",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.001","4",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem",NA,"1","1","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","10 mcg","30","30","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.25",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","23","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","26","26","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[1] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)",NA,"0.06","1","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",NA,"N.gonorrhoeae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"N.gonorrhoeae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"N.gonorrhoeae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",NA,"N.gonorrhoeae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",NA,"N.gonorrhoeae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note","[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","0.5",NA,"N.gonorrhoeae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",NA,"N.gonorrhoeae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)",NA,"0.25","0.25",NA,"N.meningitidis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)",NA,"0.125","0.125","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)",NA,"0.125","0.125","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)",NA,"0.25","0.25","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (all indications, including meningitis and prophylaxis)",NA,"0.016","0.016",NA,"N.meningitidis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)",NA,"1","1","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)",NA,"2","2","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","N.meningitidis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)",NA,"0.25","0.25",NA,"N.meningitidis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","10/10 mcg","25","25",NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid",NA,"2","2","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","14","14",NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam",NA,"2","2","[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","30/6 mcg","24","24",NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Ertapenem",NA,"2","2","[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Ertapenem","10 mcg","23","23","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Imipenem",NA,"1","1",NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Imipenem","10 mcg","29","29",NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem",NA,"1","1",NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","10 mcg","28","28",NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin",NA,"4","4","[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","2 mcg","10","10","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","5 mcg","25","25",NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","1 unit","20","20","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin","2 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ertapenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ertapenem","10 mcg","29","29","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Imipenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","10 mcg","34","34","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","2 mcg","31","31","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","5 mcg","22","22",NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","1 unit","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin","2 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","30/6 mcg","32","32","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ertapenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ertapenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Imipenem","10 mcg","36","36","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Meropenem",NA,"0.03","0.03","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Meropenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Clindamycin","2 mcg","30","30","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Metronidazole",NA,"0.5","0.5",NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Metronidazole","5 mcg","30","30",NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","1 unit","15","15","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin","2 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","10/10 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","30/6 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ertapenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ertapenem","10 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Imipenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Imipenem","10 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","10 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","5 mcg","12","12",NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","2 mcg","19","19","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","5 mcg","16","16",NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","1 unit","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin","2 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Cefotaxime","5 mcg","26","26","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ceftriaxone",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ceftriaxone","30 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ertapenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ertapenem","10 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Imipenem",NA,"0.03","0.03","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Imipenem","10 mcg","39","39","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","10 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","5 mcg","22","22",NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","2 mcg","26","26","[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Linezolid",NA,"2","2",NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Linezolid","10 mcg","34","34",NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"IP","IP",NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"0.5","0.5","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IP","IP",NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"IP","IP",NA,"Anaerobic bacteria" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral",NA,"0.125","0.125",NA,"H.pylori" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1",NA,"H.pylori" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.25",NA,"H.pylori" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1",NA,"H.pylori" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8",NA,"H.pylori" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1",NA,"H.pylori" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","13","13",NA,"L.monocytogenes" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)",NA,"1","1",NA,"L.monocytogenes" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","2 mcg","16","16",NA,"L.monocytogenes" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)",NA,"0.25","0.25",NA,"L.monocytogenes" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","10 mcg","26","26",NA,"L.monocytogenes" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","15 mcg","25","25",NA,"L.monocytogenes" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)",NA,"0.06","0.06","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","1.25/23.75 mcg","29","29","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5",NA,"Pasteurella" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Benzylpenicillin","1 unit","17","17",NA,"Pasteurella" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"1","1",NA,"Pasteurella" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"1","1",NA,"Pasteurella" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",NA,"Pasteurella" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Cefotaxime",NA,"0.03","0.03",NA,"Pasteurella" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Cefotaxime","5 mcg","26","26",NA,"Pasteurella" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Pasteurella" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ciprofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Pasteurella" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Levofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Pasteurella" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"1","1",NA,"Pasteurella" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Tetracycline (screen only)","30 mcg","24","24","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"C.jejuni_C.coli" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","5 mcg","50","26",NA,"C.jejuni_C.coli" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","24","24","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note","[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline",NA,"2","2","[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","30 mcg","30","30","[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.001","1",NA,"Corynebacterium" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","50","12",NA,"Corynebacterium" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Corynebacterium" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","25",NA,"Corynebacterium" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Corynebacterium" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","5 mcg","25","25",NA,"Corynebacterium" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin",NA,"2","2",NA,"Corynebacterium" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","5 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","2 mcg","20","20","[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"2","2",NA,"Corynebacterium" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",NA,"Corynebacterium" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",NA,"Corynebacterium" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",NA,"Corynebacterium" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",NA,"Corynebacterium" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","30","30",NA,"Corynebacterium" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.001","1",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","50","12",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"1","1","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime",NA,"0.001","2","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","5 mcg","50","15","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem",NA,"0.25","0.25","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","10 mcg","24","24","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","24",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin",NA,"0.06","0.06",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","15 mcg","24","24",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"C. diphtheriae",NA,"Clindamycin",NA,"0.5","0.5","[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"C. diphtheriae",NA,"Clindamycin","2 mcg","15","15","[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"1","1",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","24","24",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","1 unit","21","21",NA,"A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","2 mcg","26","26",NA,"A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note","[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","10 mcg","31","31",NA,"A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",NA,"A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21","[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2","[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"Note","Note","[B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Norfloxacin (screen only)","10 mcg","17","17","[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin",NA,"1","1",NA,"A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",NA,"A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",NA,"A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","5 mcg","25","25",NA,"A.sanguinicola_A.urinae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",NA,"K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",NA,"K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[3] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",NA,"K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",NA,"K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",NA,"K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",NA,"K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",NA,"K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",NA,"K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",NA,"K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",NA,"K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",NA,"K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",NA,"K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",NA,"K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",NA,"K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",NA,"Aeromonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",NA,"Aeromonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",NA,"Aeromonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",NA,"Aeromonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",NA,"Aeromonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",NA,"Aeromonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Aeromonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",NA,"Aeromonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Aeromonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",NA,"Aeromonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","19","16","[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam",NA,"4","4","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"A.xylosoxidans" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem",NA,"1","4",NA,"A.xylosoxidans" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","10 mcg","26","20",NA,"A.xylosoxidans" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","26","26","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam",NA,"1","1","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"Vibrio" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime",NA,"0.25","0.25",NA,"Vibrio" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","5 mcg","21","21",NA,"Vibrio" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",NA,"Vibrio" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",NA,"Vibrio" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime",NA,"1","1",NA,"Vibrio" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","10 mcg","22","22",NA,"Vibrio" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem",NA,"0.5","0.5",NA,"Vibrio" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","10 mcg","24","24",NA,"Vibrio" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin",NA,"0.25","0.25",NA,"Vibrio" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","5 mcg","23","23","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Vibrio" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","5 mcg","23","23","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","5 mcg","22","22","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin",NA,"4","4",NA,"Vibrio" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","15 mcg","16","16","[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","15 mcg","12","12","[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline",NA,"0.5","0.5",NA,"Vibrio" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","30 mcg","20","20","[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","21","21","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19",FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","20 mcg","17","17",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid","2 mcg","18","18",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note",FALSE,"[1] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note",FALSE,"[A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","1 unit","12","12",FALSE,"[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)",NA,"1","1",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","2 mcg","18","18",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (meningitis)",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1",FALSE,"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"2","2",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"0.001","2",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2",FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.001","2",FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","50","15",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25",FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (indications other than meningitis)","5 mcg","27","27",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime (meningitis)","5 mcg","27","27",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)",NA,"0.5","0.5",FALSE,"[2] See table of dosages for dosing for different indications.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","30/10 mcg","23","23",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] See table of dosages for dosing for different indications.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","32","32",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone (meningitis)","30 mcg","32","32",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.001","1",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem",NA,"1","1",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","10 mcg","23","23",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[3] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[3/E] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)",NA,"0.06","0.06",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (indications other than meningitis)","5 mcg","30","30",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)",NA,"0.03","0.03",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin (meningitis)",NA,"Note","Note",FALSE,"[B] Susceptibility can be inferred from the nalidixic acid screening test.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23",FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L, erythromycin 16 mg/L and telithromycin 8 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","24",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"2","2",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","25",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2",FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28",FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",FALSE,NA,"H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","20",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1",FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1",FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","0.5",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","21",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.001","4",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem",NA,"1","1",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","10 mcg","30","30",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2/A] The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor. Therefore the addition of the beta-lactamase inhibitor does not add clinical benefit.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23",FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.25",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","23",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","0.5",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","25",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"2","2",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","26","26",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note",FALSE,"[1] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note",FALSE,"[A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)",NA,"0.06","1",FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note",FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","0.5",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)",NA,"0.25","0.25",FALSE,NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)",NA,"0.125","1",FALSE,NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)",NA,"0.125","1",FALSE,NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)",NA,"0.125","0.125",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)",NA,"0.125","0.125",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem",NA,"Note","Note",FALSE,"[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem",NA,"Note","Note",FALSE,"[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)",NA,"0.25","0.25",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of the beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (all indications, including meningitis and prophylaxis)",NA,"0.016","0.016",FALSE,NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)",NA,"1","1",FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)",NA,"2","2",FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)",NA,"2","2",FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages.","N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)",NA,"0.25","0.25",FALSE,NA,"N.meningitidis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam",NA,"2","2",FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","10/10 mcg","25","25",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid",NA,"2","2",FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","14","14",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam",NA,"2","2",FALSE,"[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","30/6 mcg","24","24",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Ertapenem",NA,"(2)","(2)",TRUE,"[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Ertapenem","10 mcg","(23)","(23)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Imipenem",NA,"1","1",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Imipenem","10 mcg","29","29",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem",NA,"1","1",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","10 mcg","28","28",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin",NA,"(4)","(4)",TRUE,"[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","2 mcg","(10)","(10)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole",NA,"4","4",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","5 mcg","25","25",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","1 unit","20","20",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin","2 mcg","25","25",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","10/10 mcg","33","33",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ertapenem",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ertapenem","10 mcg","29","29",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Imipenem",NA,"0.125","0.125",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Imipenem","10 mcg","35","35",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","10 mcg","34","34",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin",NA,"0.25","0.25",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","2 mcg","31","31",FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole",NA,"4","4",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","5 mcg","22","22",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin",NA,"0.06","0.06",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","1 unit","25","25",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin","2 mcg","27","27",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam","10/10 mcg","33","33",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","30/6 mcg","32","32",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ertapenem",NA,"0.06","0.06",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ertapenem","10 mcg","35","35",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Imipenem",NA,"0.125","0.125",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Imipenem","10 mcg","36","36",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Meropenem",NA,"0.03","0.03",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Meropenem","10 mcg","35","35",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Clindamycin",NA,"0.25","0.25",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Clindamycin","2 mcg","30","30",FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Metronidazole",NA,"0.5","0.5",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Metronidazole","5 mcg","30","30",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","1 unit","15","15",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin","2 mcg","23","23",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","10/10 mcg","27","27",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","30/6 mcg","24","24",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ertapenem",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ertapenem","10 mcg","24","24",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Imipenem",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Imipenem","10 mcg","25","25",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem",NA,"0.125","0.125",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","10 mcg","25","25",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","5 mcg","12","12",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin",NA,"0.25","0.25",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","2 mcg","19","19",FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole",NA,"4","4",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","5 mcg","16","16",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin",NA,"0.06","0.06",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","1 unit","24","24",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin","2 mcg","23","23",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","10/10 mcg","33","33",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","30/6 mcg","27","27",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Cefotaxime","5 mcg","26","26",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ceftriaxone",NA,"0.06","0.06",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ceftriaxone","30 mcg","33","33",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ertapenem",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ertapenem","10 mcg","28","28",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Imipenem",NA,"0.03","0.03",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Imipenem","10 mcg","39","39",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem",NA,"0.125","0.125",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","10 mcg","28","28",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","5 mcg","22","22",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin",NA,"0.25","0.25",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","2 mcg","26","26",FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Linezolid",NA,"2","2",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Linezolid","10 mcg","34","34",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2",FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"IP","IP",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"0.5","0.5",FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IP","IP",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2",FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"IP","IP",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral",NA,"0.125","0.125",FALSE,NA,"H.pylori" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1",FALSE,NA,"H.pylori" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.25",FALSE,NA,"H.pylori" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1",FALSE,NA,"H.pylori" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8",FALSE,NA,"H.pylori" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1",FALSE,NA,"H.pylori" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)",NA,"1","1",FALSE,NA,"L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","13","13",FALSE,NA,"L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",FALSE,NA,"L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",FALSE,NA,"L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)",NA,"1","1",FALSE,NA,"L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","2 mcg","16","16",FALSE,NA,"L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)",NA,"0.25","0.25",FALSE,NA,"L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","10 mcg","26","26",FALSE,NA,"L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",FALSE,NA,"L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",FALSE,NA,"L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",FALSE,NA,"L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",FALSE,NA,"L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)",NA,"1","1",FALSE,NA,"L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","15 mcg","25","25",FALSE,NA,"L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)",NA,"0.06","0.06",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","1.25/23.75 mcg","29","29",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5",FALSE,NA,"Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Benzylpenicillin","1 unit","17","17",FALSE,NA,"Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"1","1",FALSE,NA,"Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"1","1",FALSE,NA,"Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid",NA,"1","1",FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",FALSE,NA,"Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Cefotaxime",NA,"0.03","0.03",FALSE,NA,"Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Cefotaxime","5 mcg","26","26",FALSE,NA,"Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,NA,"Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ciprofloxacin","5 mcg","27","27",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Levofloxacin",NA,"0.06","0.06",FALSE,NA,"Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Levofloxacin","5 mcg","27","27",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Nalidixic acid (screen only)","30 mcg","23","23",FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"1","1",FALSE,NA,"Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Tetracycline (screen only)","30 mcg","24","24",FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin",NA,"0.001","0.5",FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","5 mcg","50","26",FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note",FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4",FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20",FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8",FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","24","24",FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note",FALSE,"[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline",NA,"2","2",FALSE,"[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","30 mcg","30","30",FALSE,"[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.001","1",FALSE,NA,"Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","50","12",FALSE,NA,"Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","1",FALSE,NA,"Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","25",FALSE,NA,"Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin",NA,"0.5","0.5",FALSE,NA,"Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","5 mcg","25","25",FALSE,NA,"Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","5 mcg","17","17",FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","2 mcg","20","20",FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"2","2",FALSE,NA,"Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",FALSE,NA,"Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",FALSE,NA,"Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",FALSE,NA,"Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",FALSE,NA,"Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","30","30",FALSE,NA,"Corynebacterium" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.001","1",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","50","12",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"1","1",FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime",NA,"0.001","2",FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","5 mcg","50","15",FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem",NA,"0.25","0.25",FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","10 mcg","24","24",FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","0.5",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","24",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin",NA,"0.06","0.06",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","15 mcg","24","24",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"C. diphtheriae",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"C. diphtheriae",NA,"Clindamycin","2 mcg","15","15",FALSE,"[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"1","1",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","24","24",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","1 unit","21","21",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin",NA,"0.25","0.25",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","2 mcg","26","26",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem",NA,"0.25","0.25",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","10 mcg","31","31",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21",FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2",FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"Note","Note",FALSE,"[B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Norfloxacin (screen only)","10 mcg","17","17",FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin",NA,"1","1",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","5 mcg","16","16",FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin",NA,"0.125","0.125",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","5 mcg","25","25",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06",FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125",FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[3] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[B] The intrinsic activity of clavulanic acid in K. kingae is such that the organism is inhibited by 2 mg/L clavulanic acid.Therefore no breakpoints for amoxicillin-clavulanic acid can be given.","K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25",FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5",FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",FALSE,NA,"K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",FALSE,NA,"Aeromonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",FALSE,NA,"Aeromonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",FALSE,NA,"Aeromonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",FALSE,NA,"Aeromonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",FALSE,NA,"Aeromonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",FALSE,NA,"Aeromonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",FALSE,NA,"Aeromonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",FALSE,NA,"Aeromonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",FALSE,NA,"Aeromonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",FALSE,NA,"Aeromonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","19","16",FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam",NA,"4","4",FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",FALSE,NA,"A.xylosoxidans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem",NA,"1","4",FALSE,NA,"A.xylosoxidans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","10 mcg","26","20",FALSE,NA,"A.xylosoxidans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","26","26",FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam",NA,"1","1",FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",FALSE,NA,"Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime",NA,"0.25","0.25",FALSE,NA,"Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","5 mcg","21","21",FALSE,NA,"Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",FALSE,NA,"Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",FALSE,NA,"Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime",NA,"1","1",FALSE,NA,"Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","10 mcg","22","22",FALSE,NA,"Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem",NA,"0.5","0.5",FALSE,NA,"Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","10 mcg","24","24",FALSE,NA,"Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin",NA,"0.25","0.25",FALSE,NA,"Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","5 mcg","23","23",FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin",NA,"0.25","0.25",FALSE,NA,"Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","5 mcg","23","23",FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","5 mcg","22","22",FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin",NA,"4","4",FALSE,NA,"Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","15 mcg","16","16",FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","15 mcg","12","12",FALSE,"[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline",NA,"0.5","0.5",FALSE,NA,"Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","30 mcg","20","20",FALSE,"[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","21","21",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio" "EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Imipenem",NA,"0.5","0.5",NA,"Bacillus" +except B. anthracis",NA,"Imipenem",NA,"0.5","0.5",FALSE,NA,"Bacillus" "EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Imipenem","10 mcg","30","30",NA,"Bacillus" +except B. anthracis",NA,"Imipenem","10 mcg","30","30",FALSE,NA,"Bacillus" "EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Meropenem",NA,"0.25","0.25",NA,"Bacillus" +except B. anthracis",NA,"Meropenem",NA,"0.25","0.25",FALSE,NA,"Bacillus" "EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Meropenem","10 mcg","25","25",NA,"Bacillus" +except B. anthracis",NA,"Meropenem","10 mcg","25","25",FALSE,NA,"Bacillus" "EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Bacillus" +except B. anthracis",NA,"Ciprofloxacin",NA,"0.001","0.5",FALSE,NA,"Bacillus" "EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Ciprofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +except B. anthracis",NA,"Ciprofloxacin","5 mcg","50","23",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" "EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Levofloxacin",NA,"0.001","1",NA,"Bacillus" +except B. anthracis",NA,"Levofloxacin",NA,"0.001","1",FALSE,NA,"Bacillus" "EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Levofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +except B. anthracis",NA,"Levofloxacin","5 mcg","50","23",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" "EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Norfloxacin (screen only)","10 mcg","21","21","[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" +except B. anthracis",NA,"Norfloxacin (screen only)","10 mcg","21","21",FALSE,"[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" "EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Vancomycin",NA,"2","2",NA,"Bacillus" +except B. anthracis",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Bacillus" "EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Vancomycin","5 mcg","10","10","[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" +except B. anthracis",NA,"Vancomycin","5 mcg","10","10",FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" "EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Erythromycin",NA,"0.5","0.5",NA,"Bacillus" +except B. anthracis",NA,"Erythromycin",NA,"0.5","0.5",FALSE,NA,"Bacillus" "EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Erythromycin","15 mcg","24","24",NA,"Bacillus" +except B. anthracis",NA,"Erythromycin","15 mcg","24","24",FALSE,NA,"Bacillus" "EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Clindamycin",NA,"1","1",NA,"Bacillus" +except B. anthracis",NA,"Clindamycin",NA,"1","1",FALSE,NA,"Bacillus" "EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Clindamycin","2 mcg","17","17",NA,"Bacillus" +except B. anthracis",NA,"Clindamycin","2 mcg","17","17",FALSE,NA,"Bacillus" "EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Linezolid",NA,"2","2",NA,"Bacillus" +except B. anthracis",NA,"Linezolid",NA,"2","2",FALSE,NA,"Bacillus" "EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Linezolid","10 mcg","22","22",NA,"Bacillus" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Benzylpenicillin",NA,"0.001","0.5",NA,"B.anthracis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Benzylpenicillin","1 unit","50","18",NA,"B.anthracis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Amoxicillin iv",NA,"0.125","0.125","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Amoxicillin iv",NA,"Note","Note","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Ciprofloxacin",NA,"0.001","0.25",NA,"B.anthracis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Ciprofloxacin","5 mcg","50","24",NA,"B.anthracis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Levofloxacin",NA,"0.001","0.5",NA,"B.anthracis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Levofloxacin","5 mcg","50","23",NA,"B.anthracis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Vancomycin",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Vancomycin","5 mcg","10","10","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Clindamycin",NA,"1","1",NA,"B.anthracis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Clindamycin","2 mcg","17","17",NA,"B.anthracis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Doxycycline",NA,"0.06","0.06","[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Tetracycline",NA,"0.125","0.125",NA,"B.anthracis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Tetracycline","30 mcg","26","26",NA,"B.anthracis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Linezolid",NA,"2","2",NA,"B.anthracis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Linezolid","10 mcg","20","20",NA,"B.anthracis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Rifampicin",NA,"1","1","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Rifampicin","5 mcg","12","12","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)","30 mcg","30","30","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Ciprofloxacin",NA,"0.001","1",NA,"B.melitensis " -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Ciprofloxacin","5 mcg","50","27",NA,"B.melitensis " -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Levofloxacin",NA,"0.001","1",NA,"B.melitensis " -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Levofloxacin","5 mcg","50","28",NA,"B.melitensis " -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Gentamicin",NA,"0.5","0.5","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Gentamicin","10 mcg","23","23","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Streptomycin",NA,"1","1","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Streptomycin","10 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Doxycycline",NA,"0.25","0.25","[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis " -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis " -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Tetracycline",NA,"0.5","0.5",NA,"B.melitensis " -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Tetracycline","30 mcg","42","42",NA,"B.melitensis " -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Rifampicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Rifampicin","5 mcg","20","20","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.","B.melitensis " -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.melitensis " -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","29","29","[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone. | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.melitensis " -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid",NA,"0.001","8","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","20/10 mcg","50","22",NA,"B.pseudomallei" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime",NA,"0.001","8",NA,"B.pseudomallei" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","10 mcg","50","18",NA,"B.pseudomallei" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem",NA,"2","2",NA,"B.pseudomallei" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","10 mcg","29","29",NA,"B.pseudomallei" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem",NA,"2","2",NA,"B.pseudomallei" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","10 mcg","24","24",NA,"B.pseudomallei" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"0.001","2",NA,"B.pseudomallei" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"Note","Note","[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","30 mcg","23","23","[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol",NA,"0.001","8",NA,"B.pseudomallei" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","30 mcg","50","22",NA,"B.pseudomallei" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","17","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25","[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination.","M.tuberculosis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06","[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination.","M.tuberculosis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Pretomanid",NA,"Note","Note","[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination. | [2] A provisional screen value of 2 mg/L is advised according to published MIC data determined with MGIT.","M.tuberculosis" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin",NA,"2","2",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","10 mcg","16","16",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)",NA,"8","8",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","10 mcg","12","12",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin",NA,"8","8",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","10 mcg","15","15",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","5 mcg","26","26",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","5 mcg","18","18",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","5 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","30 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)",NA,"4","4",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","21","21",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","23",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","5 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","30 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin",NA,"2","2",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","10 mcg","18","18",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","10 mcg","17","17","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin",NA,"1","1",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","30 mcg","18","18",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","10 mcg","24","24",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)",NA,"1","1",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","10 mcg","14","14",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin",NA,"1","1","[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used. +except B. anthracis",NA,"Linezolid","10 mcg","22","22",FALSE,NA,"Bacillus" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Benzylpenicillin",NA,"0.001","0.5",FALSE,NA,"B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Benzylpenicillin","1 unit","50","18",FALSE,NA,"B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Amoxicillin iv",NA,"0.125","0.125",FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Amoxicillin iv",NA,"Note","Note",FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Ciprofloxacin",NA,"0.001","0.25",FALSE,NA,"B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Ciprofloxacin","5 mcg","50","24",FALSE,NA,"B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Levofloxacin",NA,"0.001","0.5",FALSE,NA,"B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Levofloxacin","5 mcg","50","23",FALSE,NA,"B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Vancomycin",NA,"(4)","(4)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Vancomycin","5 mcg","(10)","(10)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Clindamycin",NA,"1","1",FALSE,NA,"B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Clindamycin","2 mcg","17","17",FALSE,NA,"B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Doxycycline",NA,"0.06","0.06",FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Tetracycline",NA,"0.125","0.125",FALSE,NA,"B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Tetracycline","30 mcg","26","26",FALSE,NA,"B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Linezolid",NA,"2","2",FALSE,NA,"B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Linezolid","10 mcg","20","20",FALSE,NA,"B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Rifampicin",NA,"(1)","(1)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Rifampicin","5 mcg","(12)","(12)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)","30 mcg","(30)","(30)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Ciprofloxacin",NA,"0.001","1",FALSE,NA,"B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Ciprofloxacin","5 mcg","50","27",FALSE,NA,"B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Levofloxacin",NA,"0.001","1",FALSE,NA,"B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Levofloxacin","5 mcg","50","28",FALSE,NA,"B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Gentamicin",NA,"(0.5)","(0.5)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Gentamicin","10 mcg","(23)","(23)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Streptomycin",NA,"(1)","(1)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Streptomycin","10 mcg","(15)","(15)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Doxycycline",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Tetracycline",NA,"0.5","0.5",FALSE,NA,"B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Tetracycline","30 mcg","42","42",FALSE,NA,"B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Rifampicin",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Rifampicin","5 mcg","(20)","(20)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.","B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","29","29",FALSE,"[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone. | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.melitensis " +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid",NA,"0.001","8",FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","20/10 mcg","50","22",FALSE,NA,"B.pseudomallei" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime",NA,"0.001","8",FALSE,NA,"B.pseudomallei" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","10 mcg","50","18",FALSE,NA,"B.pseudomallei" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem",NA,"2","2",FALSE,NA,"B.pseudomallei" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","10 mcg","29","29",FALSE,NA,"B.pseudomallei" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem",NA,"2","2",FALSE,NA,"B.pseudomallei" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","10 mcg","24","24",FALSE,NA,"B.pseudomallei" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"0.001","2",FALSE,NA,"B.pseudomallei" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","30 mcg","23","23",FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol",NA,"0.001","8",FALSE,NA,"B.pseudomallei" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","30 mcg","50","22",FALSE,NA,"B.pseudomallei" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","17",FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25",FALSE,"[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination.","M.tuberculosis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06",FALSE,"[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination.","M.tuberculosis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Pretomanid",NA,"Note","Note",FALSE,"[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination. | [2] A provisional screen value of 2 mg/L is advised according to published MIC data determined with MGIT.","M.tuberculosis" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","10 mcg","17","17",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","10 mcg","16","16",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin",NA,"0.125","0.125",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin",NA,"0.25","0.25",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.25",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol",NA,"16","16",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","10 mcg","12","12",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","10 mcg","15","15",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","10 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","5 mcg","26","26",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","5 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ofloxacin","5 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Chloramphenicol",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Chloramphenicol","30 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","P. aeruginosa",NA,"Neomycin (framycetin)",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","P. aeruginosa",NA,"Neomycin (framycetin)","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","21","21",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","23",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ofloxacin","5 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Chloramphenicol",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Chloramphenicol","30 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Neomycin (framycetin)","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","10 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","10 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","10 mcg","17","17",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol",NA,"16","16",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","30 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","10 mcg","24","24",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","10 mcg","14","14",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Bacitracin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin",NA,"1","1",FALSE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used. ND = No ECOFF available.","Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","200 mcg","30","30","[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used. +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","200 mcg","30","30",FALSE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used. ND = No ECOFF available.","Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Retapamulin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin",NA,"4","4",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"32","32",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","200 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"0.125","0.125",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin",NA,"4","4",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin",NA,"8","8",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","30 mcg","28","28",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","30 mcg","31","31",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin (framycetin)",NA,"ND","ND",NA,"Topical agents" -"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","10 mcg","ND","ND",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin iv",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin iv","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin iv",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin iv","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)",NA,"0.001","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","/ mcg","Note","Note","[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"". | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)",NA,"0.001","8","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","/ mcg","Note","Note","[D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and ""amoxicillin oral (other indications)"" can be used in high exposure in combination therapy (see Note 3/D). Isolates resistant to ampicillin can be reported resistant. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv",NA,"8","8","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","20/10 mcg","19","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)",NA,"0.001","8","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","20/10 mcg","50","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"32","32","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","20/10 mcg","16","16","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"0.001","8","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","20/10 mcg","50","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","8",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","20",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","8","[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","20",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)",NA,"0.001","16",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)","30 mcg","50","17","[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)",NA,"8","8","[6] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)","10 mcg","15","15","[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli and Klebsiella spp.(except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)",NA,"0.001","4","[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli and Klebsiella spp.(except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)","30 mcg","50","20","[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime-enmetazobactam",NA,"4","4","[3] For susceptibility testing purposes, the concentration of enmetazobactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime-enmetazobactam","30/20 mcg","22","22",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol",NA,"2","2","[4] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","30 mcg","23","23",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","5 mcg","20","17",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","5 mcg","20","20",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)",NA,"Note","Note","[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","30 mcg","19","19","[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)","10 mcg","21","21",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8","[6] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","30 mcg","23","23",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"2","2","[8] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [7] See table of dosages for dosing for different indications.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","22","22","[7] See table of dosages for dosing for different indications.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","27","24",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","30 mcg","27","27",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"0.001","8",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","50","19",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem",NA,"1","2",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","10 mcg","24","21",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","23","23",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem",NA,"2","4",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem","10 mcg","22","19",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Morganellaceae",NA,"Imipenem",NA,"0.001","4","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Morganellaceae",NA,"Imipenem","10 mcg","50","19","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam",NA,"2","2","[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","10 mcg","22","16",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","10 mcg","22","22",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8","[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","20/10 mcg","20","20",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam-avibactam",NA,"4","4","[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam-avibactam","30/20 mcg","25","25",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06","[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note","[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)",NA,"0.25","0.5",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","5 mcg","25","22",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"0.125","0.125","[2] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"Note","Note","[2/B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24","[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli",NA,"Delafloxacin",NA,"0.125","0.125",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli",NA,"Delafloxacin",NA,"Note","Note","[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.",NA,"Moxifloxacin",NA,"0.25","0.25","[3] Fluoroquinolone breakpoints are available for other agents.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.",NA,"Moxifloxacin","5 mcg","22","22","[3] Fluoroquinolone breakpoints are available for other agents.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","0.5",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","24","24",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","30 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","18","18",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","10 mcg","16","16","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","16","16",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Azithromycin",NA,"Note","Note","[1] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 µg disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Azithromycin",NA,"Note","Note","[1/A] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 µg disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms. | [B] When reading azithromycin zone diameters, take growth appearing as a thin inner zone on some batches of Mueller-Hinton agar into account.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli",NA,"Eravacycline","20 mcg","17","17",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18","[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note","[1] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note","[A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"2","2","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note","[B] Use an MIC method (broth microdilution only). | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin iv (infections originating from the urinary tract)",NA,"8","8","[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin iv (infections originating from the urinary tract)","200 mcg","24","24","[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin iv (other indications)",NA,"Note","Note","[5] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin iv (other indications)",NA,"Note","Note","[E] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"other Enterobacterales",NA,"Fosfomycin iv",NA,"Note","Note","[6] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"other Enterobacterales",NA,"Fosfomycin iv",NA,"Note","Note","[F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)",NA,"8","8","[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)","200 mcg","24","24","[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","15","15",NA,"Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[7] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[7] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"0.001","16",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"0.001","16","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"0.001","16","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"0.001","8",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","50","21",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor.","Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[A] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor.","Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"P. aeruginosa",NA,"Cefiderocol",NA,"2","2","[2] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"P. aeruginosa",NA,"Cefiderocol","30 mcg","22","22",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"0.001","8",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","50","17",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8","[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4","[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [4] See table of dosages for dosing for different indications.","Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","23","23","[4] See table of dosages for dosing for different indications.","Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem",NA,"0.001","2",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","10 mcg","50","22",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"0.001","4",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","50","20",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"P. aeruginosa",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"P. aeruginosa",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)","10 mcg","20","14",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)",NA,"2","8",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)","10 mcg","24","18",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (meningitis)","10 mcg","20","20",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","20/10 mcg","14","14",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"0.001","16",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","50","26",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"0.001","2",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"16","16",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","15","15",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","18","18",NA,"Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"4","4","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Fosfomycin iv",NA,"Note","Note","[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Fosfomycin iv",NA,"Note","Note","[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"Note","Note","[2] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥28 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","S.maltophilia" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","30 mcg","Note","Note","[A] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥28 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","S.maltophilia" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"S.maltophilia" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"S.maltophilia" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Ciprofloxacin",NA,"Note","Note","[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms.","S.maltophilia" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Ciprofloxacin",NA,"Note","Note","[A] Disk diffusion criteria are not available.","S.maltophilia" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Levofloxacin",NA,"Note","Note","[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms.","S.maltophilia" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Levofloxacin",NA,"Note","Note","[A] Disk diffusion criteria are not available.","S.maltophilia" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Minocycline",NA,"Note","Note","[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [2] Pertains to intravenous therapy. Oral therapy will lead to insufficient exposure.","S.maltophilia" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Minocycline",NA,"Note","Note","[A] Disk diffusion criteria are not available.","S.maltophilia" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Tigecycline",NA,"Note","Note","[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms.","S.maltophilia" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Tigecycline",NA,"Note","Note","[A] Disk diffusion criteria are not available.","S.maltophilia" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","2","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","16","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"Note","Note","[2] The in vitro activity of cefiderocol against Acinetobacter spp. is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥21 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <17 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol","30 mcg","Note","Note","[A] The in vitro activity of cefiderocol against Acinetobacter spp. is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥21 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <17 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem",NA,"0.001","2",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","10 mcg","50","22",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","10 mcg","21","15",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","10 mcg","21","21",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","30 mcg","19","19","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","19","19",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE","[1] Minocycline has been discussed as alternative therapy in Acinetobacter infections. The “IE” in the table pertains to intravenous therapy only. Oral administration will not accomplish sufficient exposure.","Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"2","2","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Fosfomycin iv",NA,"Note","Note","[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Fosfomycin iv",NA,"Note","Note","[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Benzylpenicillin",NA,"0.125","0.125","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Benzylpenicillin","1 unit","26","26","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. lugdunensis",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. lugdunensis",NA,"Benzylpenicillin","1 unit","26","26",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. saprophyticus",NA,"Ampicillin",NA,"Note","Note","[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. saprophyticus",NA,"Ampicillin","2 mcg","18","18","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Oxacillin (screen only)","1 mcg","20","20","[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit. +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. aureus",NA,"Retapamulin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Fusidic acid",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Fusidic acid","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","S. pneumoniae",NA,"Bacitracin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","21","21",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"32","32",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Bacitracin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin","200 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"0.125","0.125",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Gentamicin","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Tobramycin","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin",NA,"0.06","0.06",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin",NA,"0.06","0.06",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","30 mcg","28","28",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Fusidic acid",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Fusidic acid","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","H. influenzae",NA,"Neomycin (framycetin)",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","H. influenzae",NA,"Neomycin (framycetin)","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Gentamicin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Gentamicin","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Tobramycin",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Tobramycin","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","30 mcg","31","31",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Fusidic acid",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Fusidic acid","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","MIC","Topical","M. catarrhalis",NA,"Neomycin (framycetin)",NA,"ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2024","14.0","Clinical Breakpoint Tables v. 14.0","human","human","DISK","Topical","M. catarrhalis",NA,"Neomycin (framycetin)","10 mcg","ND","ND",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin iv",NA,"8","8",FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin iv","10 mcg","14","14",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)",NA,"8","8",FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","10 mcg","14","14",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv",NA,"8","8",FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","10/10 mcg","14","14",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)",NA,"8","8",FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","10/10 mcg","14","14",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin iv",NA,"8","8",FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin iv","/ mcg","Note","Note",FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)",NA,"0.001","8",FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","/ mcg","Note","Note",FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"". | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"8","8",FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","/ mcg","Note","Note",FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)",NA,"(0.001)","(8)",TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","/ mcg","Note","Note",FALSE,"[D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and ""amoxicillin oral (other indications)"" can be used in high exposure in combination therapy (see Note 3/D). Isolates resistant to ampicillin can be reported resistant. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv",NA,"8","8",FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","20/10 mcg","19","19",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)",NA,"0.001","8",FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","20/10 mcg","50","19",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"32","32",FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","20/10 mcg","16","16",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"(0.001)","(8)",TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","20/10 mcg","(50)","(19)",TRUE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","8",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","20",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","8",FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","20",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16",FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)",NA,"0.001","16",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)","30 mcg","50","17",FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)",NA,"8","8",FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)","10 mcg","15","15",FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli and Klebsiella spp.(except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)",NA,"0.001","4",FALSE,"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli and Klebsiella spp.(except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)","30 mcg","50","20",FALSE,"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime-enmetazobactam",NA,"4","4",FALSE,"[3] For susceptibility testing purposes, the concentration of enmetazobactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime-enmetazobactam","30/20 mcg","22","22",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol",NA,"2","2",FALSE,"[4] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","30 mcg","23","23",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)",NA,"1","2",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","5 mcg","20","17",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","5 mcg","20","20",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)",NA,"Note","Note",FALSE,"[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","30 mcg","19","19",FALSE,"[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)","10 mcg","21","21",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8",FALSE,"[6] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","30 mcg","23","23",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"2","2",FALSE,"[8] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [7] See table of dosages for dosing for different indications.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","22","22",FALSE,"[7] See table of dosages for dosing for different indications.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)",NA,"1","2",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","27","24",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","30 mcg","27","27",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"0.001","8",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","50","19",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem",NA,"1","2",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","10 mcg","24","21",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","23","23",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem",NA,"2","4",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem","10 mcg","22","19",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Morganellaceae",NA,"Imipenem",NA,"0.001","4",FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Morganellaceae",NA,"Imipenem","10 mcg","50","19",FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam",NA,"2","2",FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam","10/25 mcg","22","22",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)",NA,"2","8",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","10 mcg","22","16",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)",NA,"2","2",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","10 mcg","22","22",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8",FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","20/10 mcg","20","20",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4",FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21",FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam-avibactam",NA,"4","4",FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam-avibactam","30/20 mcg","25","25",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note",FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)",NA,"0.25","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","5 mcg","25","22",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"0.125","0.125",FALSE,"[2] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"Note","Note",FALSE,"[2/B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24",FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli",NA,"Delafloxacin",NA,"0.125","0.125",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli",NA,"Delafloxacin",NA,"Note","Note",FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.",NA,"Moxifloxacin",NA,"0.25","0.25",FALSE,"[3] Fluoroquinolone breakpoints are available for other agents.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.",NA,"Moxifloxacin","5 mcg","22","22",FALSE,"[3] Fluoroquinolone breakpoints are available for other agents.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","24","24",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)",NA,"(8)","(8)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","30 mcg","(18)","(18)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","18","18",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","10 mcg","(17)","(17)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)",NA,"2","2",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","10 mcg","(16)","(16)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","16","16",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Azithromycin",NA,"Note","Note",FALSE,"[1] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 µg disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Azithromycin",NA,"Note","Note",FALSE,"[1/A] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 µg disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms. | [B] When reading azithromycin zone diameters, take growth appearing as a thin inner zone on some batches of Mueller-Hinton agar into account.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli",NA,"Eravacycline","20 mcg","17","17",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5",FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18",FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note",FALSE,"[1] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note",FALSE,"[A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"(2)","(2)",TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note",FALSE,"[B] Use an MIC method (broth microdilution only). | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin iv (infections originating from the urinary tract)",NA,"8","8",FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin iv (infections originating from the urinary tract)","200 mcg","24","24",FALSE,"[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin iv (other indications)",NA,"Note","Note",FALSE,"[5] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin iv (other indications)",NA,"Note","Note",FALSE,"[E] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"other Enterobacterales",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[6] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"other Enterobacterales",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)",NA,"8","8",FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)","200 mcg","24","24",FALSE,"[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","15","15",FALSE,NA,"Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4",FALSE,"[7] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterobacterales",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11",FALSE,"[7] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"0.001","16",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"0.001","16",FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"0.001","16",FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"0.001","8",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","50","21",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note",FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note",FALSE,"[A] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"P. aeruginosa",NA,"Cefiderocol",NA,"2","2",FALSE,"[2] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"P. aeruginosa",NA,"Cefiderocol","30 mcg","22","22",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"0.001","8",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","50","17",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8",FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4",FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [4] See table of dosages for dosing for different indications.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","23","23",FALSE,"[4] See table of dosages for dosing for different indications.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem",NA,"0.001","2",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","10 mcg","50","22",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"0.001","4",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","50","20",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"P. aeruginosa",NA,"Imipenem-relebactam",NA,"2","2",FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"P. aeruginosa",NA,"Imipenem-relebactam","10/25 mcg","22","22",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)",NA,"2","8",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)","10 mcg","20","14",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)",NA,"2","8",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)","10 mcg","24","18",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (meningitis)",NA,"2","2",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (meningitis)","10 mcg","20","20",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8",FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","20/10 mcg","14","14",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"0.001","16",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam-avibactam",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam-avibactam",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.001","0.5",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","50","26",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"0.001","2",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)",NA,"(16)","(16)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","30 mcg","(15)","(15)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"16","16",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","15","15",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","10 mcg","(18)","(18)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","18","18",FALSE,NA,"Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"(4)","(4)",TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note",FALSE,"[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pseudomonas spp.",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pseudomonas spp.",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"Note","Note",FALSE,"[2] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥28 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","S.maltophilia" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","30 mcg","Note","Note",FALSE,"[A] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥28 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","S.maltophilia" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Aztreonam-avibactam",NA,"IE","IE",FALSE,NA,"S.maltophilia" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Aztreonam-avibactam",NA,"IE","IE",FALSE,NA,"S.maltophilia" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Ciprofloxacin",NA,"Note","Note",FALSE,"[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms.","S.maltophilia" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Ciprofloxacin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Levofloxacin",NA,"Note","Note",FALSE,"[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms.","S.maltophilia" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Levofloxacin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Minocycline",NA,"Note","Note",FALSE,"[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [2] Pertains to intravenous therapy. Oral therapy will lead to insufficient exposure.","S.maltophilia" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Minocycline",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Tigecycline",NA,"Note","Note",FALSE,"[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms.","S.maltophilia" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Tigecycline",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","2",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","16",FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"Note","Note",FALSE,"[2] The in vitro activity of cefiderocol against Acinetobacter spp. is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥21 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <17 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol","30 mcg","Note","Note",FALSE,"[A] The in vitro activity of cefiderocol against Acinetobacter spp. is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥21 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <17 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem",NA,"0.001","2",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","10 mcg","50","22",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)",NA,"2","8",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","10 mcg","21","15",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)",NA,"2","2",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","10 mcg","21","21",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.001","1",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)",NA,"(8)","(8)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","30 mcg","(19)","(19)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","19","19",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)",NA,"(4)","(4)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","10 mcg","(17)","(17)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"4","4",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)",NA,"(4)","(4)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","10 mcg","(17)","(17)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"4","4",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",FALSE,"[1] Minocycline has been discussed as alternative therapy in Acinetobacter infections. The “IE” in the table pertains to intravenous therapy only. Oral administration will not accomplish sufficient exposure.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"(2)","(2)",TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note",FALSE,"[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4",FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","14","11",FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Benzylpenicillin",NA,"0.125","0.125",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Benzylpenicillin","1 unit","26","26",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. lugdunensis",NA,"Benzylpenicillin",NA,"0.125","0.125",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. lugdunensis",NA,"Benzylpenicillin","1 unit","26","26",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note",FALSE,"[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note",FALSE,"[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. saprophyticus",NA,"Ampicillin",NA,"Note","Note",FALSE,"[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. saprophyticus",NA,"Ampicillin","2 mcg","18","18",FALSE,"[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Oxacillin (screen only)","1 mcg","20","20",FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit. 4.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit. +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit. 4.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","22","22","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","27","27","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note","[6] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note","[C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)",NA,"1","2","[7] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)","5 mcg","20","17","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (pneumonia)",NA,"1","1","[7] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (pneumonia)","5 mcg","20","20","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Ceftobiprole",NA,"2","2","[9] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Ceftobiprole","5 mcg","17","17","[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Ciprofloxacin",NA,"0.001","2","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Ciprofloxacin","5 mcg","50","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin",NA,"0.001","2","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin","5 mcg","50","22","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"0.016","0.016",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"Note","Note","[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"0.25","0.25",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"Note","Note","[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Levofloxacin","5 mcg","50","22","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin","5 mcg","50","24","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Moxifloxacin",NA,"0.25","0.25","[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Moxifloxacin","5 mcg","25","25","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | [3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin",NA,"0.25","0.25","[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin","5 mcg","28","28","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | [3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","17","17","[D] | [D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Amikacin",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Amikacin","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Amikacin",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Amikacin","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Gentamicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Gentamicin","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Gentamicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Gentamicin","10 mcg","22","22","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Tobramycin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Tobramycin","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Tobramycin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Tobramycin","10 mcg","20","20","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"0.25","0.25","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Oritavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Teicoplanin",NA,"2","2",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"4","4",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"MRSA",NA,"Telavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"MRSA",NA,"Telavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Vancomycin",NA,"2","2",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"4","4",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"2","2","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","15 mcg","21","21","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin",NA,"0.25","0.25","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","2 mcg","22","22","[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin",NA,"1","1",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","15 mcg","21","21",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Eravacycline",NA,"0.25","0.25",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Eravacycline","20 mcg","20","20","[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","30 mcg","22","22","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline",NA,"0.5","0.5","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","15 mcg","19","19","[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","10 mcg","21","21",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid",NA,"0.5","0.5","[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","2 mcg","20","20","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid",NA,"1","1",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","10 mcg","24","24",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Lefamulin",NA,"0.25","0.25",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Lefamulin","5 mcg","23","23",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","13","13",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Rifampicin",NA,"0.06","0.06",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Rifampicin","5 mcg","26","26",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Rifampicin",NA,"0.06","0.06",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Rifampicin","5 mcg","30","30",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","14","14",NA,"Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","17","14","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin iv",NA,"4","4",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin iv","2 mcg","10","10","[A] For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam iv",NA,"Note","Note","[1] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam iv",NA,"Note","Note","[B] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin iv",NA,"4","4","[1] Susceptibility can be inferred from ampicillin.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin iv",NA,"Note","Note","[B] Susceptibility can be inferred from ampicillin.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"4","4","[1] Susceptibility can be inferred from ampicillin.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"Note","Note","[B] Susceptibility can be inferred from ampicillin.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecalis",NA,"Amoxicillin oral (other indications)",NA,"0.001","4","[3] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecalis",NA,"Amoxicillin oral (other indications)",NA,"Note","Note","[C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[1] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[B] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"Note","Note","[1] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"Note","Note","[B] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecalis",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"Note","Note","[3] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecalis",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"Note","Note","[C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecalis",NA,"Piperacillin",NA,"0.001","16",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecalis",NA,"Piperacillin","30 mcg","50","18",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecalis",NA,"Piperacillin-tazobactam",NA,"0.001","16","[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecalis",NA,"Piperacillin-tazobactam","30/6 mcg","50","18","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecalis",NA,"Imipenem",NA,"0.001","4",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecalis",NA,"Imipenem","10 mcg","50","21",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused byEnterococcus faecalis There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused byEnterococcus faecalis There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note",FALSE,"[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","22","22",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note",FALSE,"[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","27","27",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note",FALSE,"[6] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note",FALSE,"[C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)",NA,"1","2",FALSE,"[7] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)","5 mcg","20","17",FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (pneumonia)",NA,"1","1",FALSE,"[7] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (pneumonia)","5 mcg","20","20",FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Ceftobiprole",NA,"2","2",FALSE,"[9] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Ceftobiprole","5 mcg","17","17",FALSE,"[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefotaxime and ceftriaxone are reported for methicillin-susceptible staphylococci, these should be reported “Susceptible, increased exposure” (I). Some methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Ciprofloxacin",NA,"(0.001)","(2)",TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Ciprofloxacin","5 mcg","(50)","(17)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin",NA,"(0.001)","(2)",TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin","5 mcg","(50)","(22)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"0.016","0.016",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"Note","Note",FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"0.25","0.25",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"Note","Note",FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Levofloxacin",NA,"0.001","1",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Levofloxacin","5 mcg","50","22",FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin",NA,"0.001","1",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin","5 mcg","50","24",FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Moxifloxacin",NA,"0.25","0.25",FALSE,"[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Moxifloxacin","5 mcg","25","25",FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | [3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin",NA,"0.25","0.25",FALSE,"[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin","5 mcg","28","28",FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | [3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","17","17",FALSE,"[D] | [D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note",FALSE,"[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note",FALSE,"[E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Amikacin",NA,"(16)","(16)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Amikacin","30 mcg","(15)","(15)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Amikacin",NA,"(16)","(16)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Amikacin","30 mcg","(15)","(15)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Gentamicin",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Gentamicin","10 mcg","(18)","(18)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Gentamicin",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Gentamicin","10 mcg","(22)","(22)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Tobramycin",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Tobramycin","10 mcg","(18)","(18)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Tobramycin",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Tobramycin","10 mcg","(20)","(20)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"0.25","0.25",FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Oritavancin",NA,"0.125","0.125",FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Oritavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Teicoplanin",NA,"2","2",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Teicoplanin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"4","4",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"MRSA",NA,"Telavancin",NA,"0.125","0.125",FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"MRSA",NA,"Telavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Vancomycin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"4","4",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"2","2",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"1","1",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin",NA,"1","1",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","15 mcg","21","21",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"1","1",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin",NA,"0.25","0.25",FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","2 mcg","22","22",FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin",NA,"1","1",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","15 mcg","21","21",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Eravacycline",NA,"0.25","0.25",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Eravacycline","20 mcg","20","20",FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline",NA,"0.5","0.5",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","30 mcg","23","23",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","30 mcg","22","22",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline",NA,"0.5","0.5",FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","15 mcg","19","19",FALSE,"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid",NA,"4","4",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","10 mcg","21","21",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","2 mcg","20","20",FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"1","1",FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Daptomycin",NA,"Note","Note",FALSE,"[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid",NA,"1","1",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","10 mcg","24","24",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Lefamulin",NA,"0.25","0.25",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Lefamulin","5 mcg","23","23",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","13","13",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. aureus",NA,"Rifampicin",NA,"0.06","0.06",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. aureus",NA,"Rifampicin","5 mcg","26","26",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Rifampicin",NA,"0.06","0.06",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Rifampicin","5 mcg","30","30",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"4","4",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","14","14",FALSE,NA,"Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4",FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","17","14",FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin iv",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin iv","2 mcg","10","10",FALSE,"[A] For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam iv",NA,"Note","Note",FALSE,"[1] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam iv",NA,"Note","Note",FALSE,"[B] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin iv",NA,"4","4",FALSE,"[1] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin iv",NA,"Note","Note",FALSE,"[B] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"4","4",FALSE,"[1] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"Note","Note",FALSE,"[B] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecalis",NA,"Amoxicillin oral (other indications)",NA,"(0.001)","(4)",TRUE,"[3] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecalis",NA,"Amoxicillin oral (other indications)",NA,"Note","Note",FALSE,"[C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note",FALSE,"[1] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note",FALSE,"[B] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"Note","Note",FALSE,"[1] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"Note","Note",FALSE,"[B] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecalis",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"Note","Note",FALSE,"[3] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecalis",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"Note","Note",FALSE,"[C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecalis",NA,"Piperacillin",NA,"0.001","16",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecalis",NA,"Piperacillin","30 mcg","50","18",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecalis",NA,"Piperacillin-tazobactam",NA,"0.001","16",FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecalis",NA,"Piperacillin-tazobactam","30/6 mcg","50","18",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecalis",NA,"Imipenem",NA,"0.001","4",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecalis",NA,"Imipenem","10 mcg","50","21",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note",FALSE,"[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused byEnterococcus faecalis There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note",FALSE,"[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused byEnterococcus faecalis There are no clinical breakpoints but acquired resistance should be excluded (isolates with MIC >1 mg/L). The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","12","12",FALSE,"[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note",FALSE,"[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","30 mcg","Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","30 mcg","Note","Note",FALSE,"[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note",FALSE,"[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note","[3] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing. +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note",FALSE,"[3] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing. Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)","300 mcg","Note","Note","[B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing. +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)","300 mcg","Note","Note",FALSE,"[B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing. Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note",FALSE,"[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecalis and E. faecium",NA,"Vancomycin",NA,"4","4",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecalis and E. faecium",NA,"Vancomycin","5 mcg","12","12","[A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"other enterococci",NA,"Vancomycin",NA,"4","4",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"other enterococci",NA,"Vancomycin","5 mcg","15","15",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","1",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","22",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline",NA,"0.25","0.25",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline","20 mcg","22","22",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline",NA,"0.5","0.5","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline","15 mcg","20","20","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","20","20",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[2] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[3] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[4] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note","[C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note","[4] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole. | [5] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note","[C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole. | [5] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Benzylpenicillin",NA,"0.03","0.03",NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Benzylpenicillin","1 unit","23","23",NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin","1 unit","18","18",NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"0.001","2",NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","50","17","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","21","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19","[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","19","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5","[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","2 mcg","18","18","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.25","0.25",NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","21",NA,"Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[3] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than endocarditis and meningitis)",NA,"0.06","1",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than endocarditis and meningitis)","1 unit","Note","Note","[A] Read and interpret the benzylpenicillin disk only for isolates with oxacillin 1 µg zone diameters <20 mm. If benzylpenicillin zone ≥14 mm, report benzylpenicillin “susceptible, increased exposure” (I), If zone <14 mm, report benzylpenicillin resistant (R), see flow chart below. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (endocarditis and meningitis)",NA,"0.06","0.06",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (endocarditis and meningitis)",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than endocarditis and meningitis)",NA,"0.5","1",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than endocarditis and meningitis)","2 mcg","22","19",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (endocarditis and meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (endocarditis and meningitis)",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (endocarditis and meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (endocarditis and meningitis)",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","1 mcg","20","20","[D] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oxacillin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cloxacillin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cloxacillin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dicloxacillin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dicloxacillin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Flucloxacillin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Flucloxacillin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.001","0.5",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than endocarditis and meningitis)",NA,"0.5","2",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than endocarditis and meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (endocarditis and meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (endocarditis and meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Noteâ€ť can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than endocarditis and meningitis)",NA,"0.5","2",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than endocarditis and meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (endocarditis and meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (endocarditis and meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.25",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"1","1",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"0.001","2",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","50","16","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10","[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","22","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","24","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","2",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","22",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note","[1] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note","[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","5 mcg","12","12",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.125","0.125",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","22",NA,"S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","13","10","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)",NA,"0.25","0.25","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","1 unit","21","21","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (indications other than endocarditis)",NA,"0.25","1",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (indications other than endocarditis)","1 unit","21","12",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis)",NA,"0.25","0.25",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis)",NA,"21","21",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis, in combination with other antimicrobial treatment)",NA,"1","1","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis, in combination with other antimicrobial treatment)",NA,"12","12","[B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin (indications other than endocarditis)",NA,"0.5","2",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin (indications other than endocarditis)","2 mcg","21","15",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin iv (endocarditis)",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin iv (endocarditis)","2 mcg","21","21",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin (indications other than endocarditis)",NA,"0.5","2",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin (indications other than endocarditis)",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin iv (endocarditis)",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin iv (endocarditis)",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [D] Susceptibility can be inferred from the benzylpenicillin screen test or from ""Ampicillin iv (endocarditis)"".","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Oxacillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Oxacillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cloxacillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cloxacillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Dicloxacillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Dicloxacillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Flucloxacillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Flucloxacillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem",NA,"1","1",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. anginosus group",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. anginosus group",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecalis and E. faecium",NA,"Vancomycin",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecalis and E. faecium",NA,"Vancomycin","5 mcg","12","12",FALSE,"[A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"other enterococci",NA,"Vancomycin",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"other enterococci",NA,"Vancomycin","5 mcg","15","15",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","1",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","22",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline",NA,"0.25","0.25",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline","20 mcg","22","22",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline",NA,"0.5","0.5",FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline","15 mcg","20","20",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","20","20",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE",FALSE,"[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE",FALSE,"[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[2] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note",FALSE,"[3] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note",FALSE,"[B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note",FALSE,"[4] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note",FALSE,"[C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note",FALSE,"[4] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole. | [5] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note",FALSE,"[C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole. | [5] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Benzylpenicillin",NA,"0.03","0.03",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Benzylpenicillin","1 unit","23","23",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin",NA,"0.125","0.125",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin","1 unit","18","18",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy.2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime-enmetazobactam",NA,"Note","Note",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime-enmetazobactam",NA,"Note","Note",FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"0.03","0.03",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"Note","Note",FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"0.001","2",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","50","17",FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19",FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12",FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","21",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","0.5",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17",FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","0.5",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","23",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","23",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125",FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19",FALSE,"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","19",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5",FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","2 mcg","18","18",FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1",FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note",FALSE,"[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.25","0.25",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","21",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note",FALSE,"[3] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note",FALSE,"[B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2",FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15",FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than endocarditis and meningitis)",NA,"0.06","1",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than endocarditis and meningitis)","1 unit","Note","Note",FALSE,"[A] Read and interpret the benzylpenicillin disk only for isolates with oxacillin 1 µg zone diameters <20 mm. If benzylpenicillin zone ≥14 mm, report benzylpenicillin “susceptible, increased exposure” (I), If zone <14 mm, report benzylpenicillin resistant (R), see flow chart below. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (endocarditis and meningitis)",NA,"0.06","0.06",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (endocarditis and meningitis)",NA,"Note","Note",FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than endocarditis and meningitis)",NA,"0.5","1",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin (indications other than endocarditis and meningitis)","2 mcg","22","19",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (endocarditis and meningitis)",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (endocarditis and meningitis)",NA,"Note","Note",FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)",NA,"Note","Note",FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (endocarditis and meningitis)",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (endocarditis and meningitis)",NA,"Note","Note",FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note",FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note",FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1",FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note",FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note",FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","1 mcg","20","20",FALSE,"[D] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oxacillin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cloxacillin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cloxacillin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dicloxacillin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dicloxacillin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Flucloxacillin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Flucloxacillin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.001","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime-enmetazobactam",NA,"Note","Note",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime-enmetazobactam",NA,"Note","Note",FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than endocarditis and meningitis)",NA,"0.5","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than endocarditis and meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (endocarditis and meningitis)",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (endocarditis and meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.25",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than endocarditis and meningitis)",NA,"0.5","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than endocarditis and meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (endocarditis and meningitis)",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (endocarditis and meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.25",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"1","1",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"0.001","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","50","16",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10",FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17",FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16",FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","22",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","0.5",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19",FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","0.5",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","24",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","25",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","22",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note",FALSE,"[1] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note",FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","5 mcg","12","12",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.125","0.125",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","22",FALSE,NA,"S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","2",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","13","10",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)",NA,"0.25","0.25",FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","1 unit","21","21",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (indications other than endocarditis)",NA,"0.25","1",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (indications other than endocarditis)","1 unit","21","12",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis)",NA,"0.25","0.25",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis)",NA,"21","21",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis, in combination with other antimicrobial treatment)",NA,"(1)","(1)",TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis, in combination with other antimicrobial treatment)",NA,"(12)","(12)",TRUE,"[B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin (indications other than endocarditis)",NA,"0.5","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin (indications other than endocarditis)","2 mcg","21","15",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin iv (endocarditis)",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin iv (endocarditis)","2 mcg","21","21",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin (indications other than endocarditis)",NA,"0.5","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin (indications other than endocarditis)",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin iv (endocarditis)",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin iv (endocarditis)",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [D] Susceptibility can be inferred from the benzylpenicillin screen test or from ""Ampicillin iv (endocarditis)"".","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note",FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,"[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,"[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Oxacillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Oxacillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cloxacillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cloxacillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Dicloxacillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Dicloxacillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Flucloxacillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Flucloxacillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime-enmetazobactam",NA,"Note","Note",FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime-enmetazobactam",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem",NA,"1","1",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"2","2",FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. anginosus group",NA,"Delafloxacin",NA,"0.03","0.03",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. anginosus group",NA,"Delafloxacin",NA,"Note","Note",FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note",FALSE,"[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note",FALSE,"[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19","[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","20 mcg","17","17",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE","[1] Linezolid has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >2 mg/L) should be excluded. When excluded, the isolate should be reported “devoid of linezolid resistance mechanisms”, but not as susceptible to linezolid.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid","2 mcg","18","18",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[1] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","1 unit","12","12","[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than endocarditis and meningitis)",NA,"1","1","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than endocarditis and meningitis)","2 mcg","18","18","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin iv (endocarditis and meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin iv (endocarditis and meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1","[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)",NA,"2","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (endocarditis and meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (endocarditis and meningitis)",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"0.001","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.001","2","[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","50","15","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25","[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2/D] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)",NA,"0.5","0.5","[3] See table of dosages for dosing for different indications.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","30/10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [3] See table of dosages for dosing for different indications.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.001","1",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem",NA,"1","1",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin",NA,"0.03","0.03",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","5 mcg","32","32","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","24","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",NA,"H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","20","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","0.5",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","21",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.001","4",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem",NA,"1","1","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","10 mcg","30","30","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.25",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","23","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","26","26","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[1] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)",NA,"0.06","1","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",NA,"N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",NA,"N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",NA,"N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note","[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","0.5",NA,"N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",NA,"N.gonorrhoeae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)",NA,"0.25","0.25",NA,"N.meningitidis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)",NA,"0.125","0.125","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)",NA,"0.125","0.125","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)",NA,"0.25","0.25","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Aztreonam",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (all indications, including meningitis and prophylaxis)",NA,"0.016","0.016",NA,"N.meningitidis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)",NA,"1","1","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)",NA,"2","2","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","N.meningitidis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)",NA,"0.25","0.25",NA,"N.meningitidis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","10/10 mcg","25","25",NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid",NA,"2","2","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","14","14",NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam",NA,"2","2","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","30/6 mcg","24","24","[3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Ertapenem",NA,"2","2","[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Ertapenem","10 mcg","23","23","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Imipenem",NA,"1","1",NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Imipenem","10 mcg","29","29",NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem",NA,"1","1",NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","10 mcg","28","28",NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin",NA,"4","4","[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","2 mcg","10","10","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","5 mcg","25","25",NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","1 unit","20","20","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin","2 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ertapenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ertapenem","10 mcg","29","29","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Imipenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","10 mcg","34","34","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","2 mcg","31","31","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","5 mcg","22","22",NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","1 unit","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin","2 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","30/6 mcg","32","32","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ertapenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ertapenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Imipenem","10 mcg","36","36","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Meropenem",NA,"0.03","0.03","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Meropenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Clindamycin","2 mcg","30","30","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Metronidazole",NA,"0.5","0.5",NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Metronidazole","5 mcg","30","30",NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","1 unit","15","15","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin","2 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","10/10 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","30/6 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ertapenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ertapenem","10 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Imipenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Imipenem","10 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","10 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","5 mcg","12","12",NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","2 mcg","19","19","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole",NA,"4","4",NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","5 mcg","16","16",NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","1 unit","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin","2 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Cefotaxime","5 mcg","26","26","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ceftriaxone",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ceftriaxone","30 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ertapenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ertapenem","10 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Imipenem",NA,"0.03","0.03","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Imipenem","10 mcg","39","39","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","10 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","5 mcg","22","22",NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","2 mcg","26","26","[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Linezolid",NA,"2","2",NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Linezolid","10 mcg","34","34",NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"IP","IP",NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"0.5","0.5","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IP","IP",NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"IP","IP",NA,"Anaerobic bacteria" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral",NA,"0.125","0.125",NA,"H.pylori" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1",NA,"H.pylori" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.25",NA,"H.pylori" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1",NA,"H.pylori" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8",NA,"H.pylori" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1",NA,"H.pylori" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","13","13",NA,"L.monocytogenes" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)",NA,"1","1",NA,"L.monocytogenes" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","2 mcg","16","16",NA,"L.monocytogenes" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)",NA,"0.25","0.25",NA,"L.monocytogenes" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","10 mcg","26","26",NA,"L.monocytogenes" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","15 mcg","25","25",NA,"L.monocytogenes" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)",NA,"0.06","0.06","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","1.25/23.75 mcg","29","29","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5",NA,"Pasteurella" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Benzylpenicillin","1 unit","17","17",NA,"Pasteurella" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"1","1",NA,"Pasteurella" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"1","1",NA,"Pasteurella" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",NA,"Pasteurella" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Cefotaxime",NA,"0.03","0.03",NA,"Pasteurella" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Cefotaxime","5 mcg","26","26",NA,"Pasteurella" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Pasteurella" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ciprofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Pasteurella" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Levofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Pasteurella" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"1","1",NA,"Pasteurella" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Tetracycline (screen only)","30 mcg","24","24","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"C.jejuni_C.coli" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","5 mcg","50","26",NA,"C.jejuni_C.coli" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","24","24","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note","[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline",NA,"2","2","[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","30 mcg","30","30","[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.001","1",NA,"Corynebacterium" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","50","12",NA,"Corynebacterium" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Corynebacterium" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","25",NA,"Corynebacterium" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Corynebacterium" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","5 mcg","25","25",NA,"Corynebacterium" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin",NA,"2","2",NA,"Corynebacterium" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","5 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","2 mcg","20","20","[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"2","2",NA,"Corynebacterium" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",NA,"Corynebacterium" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",NA,"Corynebacterium" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",NA,"Corynebacterium" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",NA,"Corynebacterium" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","30","30",NA,"Corynebacterium" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.001","1",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","50","12",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"1","1","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime",NA,"0.001","2","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","5 mcg","50","15","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem",NA,"0.25","0.25","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","10 mcg","24","24","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","24",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin",NA,"0.06","0.06",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","15 mcg","24","24",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"C. diphtheriae",NA,"Clindamycin",NA,"0.5","0.5","[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"C. diphtheriae",NA,"Clindamycin","2 mcg","15","15","[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"1","1",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","24","24",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","1 unit","21","21",NA,"A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","2 mcg","26","26",NA,"A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note","[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","10 mcg","31","31",NA,"A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",NA,"A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21","[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2","[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"Note","Note","[B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Norfloxacin (screen only)","10 mcg","17","17","[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin",NA,"1","1",NA,"A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",NA,"A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",NA,"A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","5 mcg","25","25",NA,"A.sanguinicola_A.urinae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",NA,"K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",NA,"K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note","[A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note","[A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[3] The in vitro antimicrobial activity of the fixed concentration of 2 mg/L for clavulanic acid is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","2/1 mcg","22","22",NA,"K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",NA,"K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",NA,"K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",NA,"K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",NA,"K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",NA,"K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",NA,"K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",NA,"K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",NA,"K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",NA,"K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",NA,"K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",NA,"K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",NA,"K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",NA,"Aeromonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",NA,"Aeromonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",NA,"Aeromonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",NA,"Aeromonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",NA,"Aeromonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",NA,"Aeromonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Aeromonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",NA,"Aeromonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Aeromonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",NA,"Aeromonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","19","16","[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam",NA,"4","4","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"A.xylosoxidans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Cefiderocol",NA,"Note","Note","[2] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥26 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","A.xylosoxidans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Cefiderocol","30 mcg","Note","Note","[A] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥26 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","A.xylosoxidans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem",NA,"1","4",NA,"A.xylosoxidans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","10 mcg","26","20",NA,"A.xylosoxidans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","26","26","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam",NA,"1","1","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"Vibrio" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime",NA,"0.25","0.25",NA,"Vibrio" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","5 mcg","21","21",NA,"Vibrio" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",NA,"Vibrio" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",NA,"Vibrio" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime",NA,"1","1",NA,"Vibrio" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","10 mcg","22","22",NA,"Vibrio" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem",NA,"0.5","0.5",NA,"Vibrio" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","10 mcg","24","24",NA,"Vibrio" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin",NA,"0.25","0.25",NA,"Vibrio" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","5 mcg","23","23","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Vibrio" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","5 mcg","23","23","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","5 mcg","22","22","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin",NA,"4","4",NA,"Vibrio" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","15 mcg","16","16","[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","15 mcg","12","12","[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline",NA,"0.5","0.5",NA,"Vibrio" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","30 mcg","20","20","[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","21","21","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19",FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","20 mcg","17","17",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",FALSE,"[1] Linezolid has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >2 mg/L) should be excluded. When excluded, the isolate should be reported “devoid of linezolid resistance mechanisms”, but not as susceptible to linezolid.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid","2 mcg","18","18",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note",FALSE,"[1] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note",FALSE,"[A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (isolates with MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","1 unit","12","12",FALSE,"[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than endocarditis and meningitis)",NA,"1","1",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than endocarditis and meningitis)","2 mcg","18","18",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin iv (endocarditis and meningitis)",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin iv (endocarditis and meningitis)",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1",FALSE,"[3] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [4] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)",NA,"2","2",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (endocarditis and meningitis)",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (endocarditis and meningitis)",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"0.001","2",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral.Isolates resistant to ampicillin can be reported resistant to amoxicillin oral. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2",FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.001","2",FALSE,"[5] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","50","15",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25",FALSE,"[6] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime-enmetazobactam",NA,"Note","Note",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime-enmetazobactam",NA,"Note","Note",FALSE,"[2/D] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","5 mcg","27","27",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)",NA,"0.5","0.5",FALSE,"[3] See table of dosages for dosing for different indications.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","30/10 mcg","23","23",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [3] See table of dosages for dosing for different indications.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","30 mcg","32","32",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.001","1",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem",NA,"1","1",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","10 mcg","23","23",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[3] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[3] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam-avibactam",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam-avibactam",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin",NA,"0.03","0.03",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","5 mcg","32","32",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23",FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","24",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"2","2",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","25",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2",FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28",FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",FALSE,NA,"H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","20",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1",FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1",FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime-enmetazobactam",NA,"Note","Note",FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime-enmetazobactam",NA,"Note","Note",FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","0.5",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","21",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.001","4",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem",NA,"1","1",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","10 mcg","30","30",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam-avibactam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam-avibactam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23",FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.25",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","23",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","0.5",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","25",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"2","2",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","26","26",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note",FALSE,"[1] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note",FALSE,"[A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","1",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","18","15",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)",NA,"0.06","1",FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note",FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam-avibactam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","0.5",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)",NA,"0.25","0.25",FALSE,NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)",NA,"0.125","1",FALSE,NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)",NA,"0.125","1",FALSE,NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)",NA,"0.125","0.125",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)",NA,"0.125","0.125",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem",NA,"Note","Note",FALSE,"[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem",NA,"Note","Note",FALSE,"[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)",NA,"0.25","0.25",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Aztreonam-avibactam",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (all indications, including meningitis and prophylaxis)",NA,"0.016","0.016",FALSE,NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)",NA,"1","1",FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)",NA,"2","2",FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)",NA,"2","2",FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages.","N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)",NA,"0.25","0.25",FALSE,NA,"N.meningitidis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam",NA,"2","2",FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","10/10 mcg","25","25",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid",NA,"2","2",FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","14","14",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam",NA,"2","2",FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","30/6 mcg","24","24",FALSE,"[3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Ertapenem",NA,"(2)","(2)",TRUE,"[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Ertapenem","10 mcg","(23)","(23)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Imipenem",NA,"1","1",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Imipenem","10 mcg","29","29",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem",NA,"1","1",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","10 mcg","28","28",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin",NA,"(4)","(4)",TRUE,"[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","2 mcg","(10)","(10)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole",NA,"4","4",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","5 mcg","25","25",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","1 unit","20","20",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin","2 mcg","25","25",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","10/10 mcg","33","33",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Ertapenem",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Ertapenem","10 mcg","29","29",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Imipenem",NA,"0.125","0.125",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Imipenem","10 mcg","35","35",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","10 mcg","34","34",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin",NA,"0.25","0.25",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","2 mcg","31","31",FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole",NA,"4","4",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","5 mcg","22","22",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin",NA,"0.125","0.125",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Benzylpenicillin","1 unit","25","25",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin","2 mcg","27","27",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ampicillin-sulbactam","10/10 mcg","33","33",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Piperacillin-tazobactam","30/6 mcg","32","32",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Ertapenem",NA,"0.06","0.06",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Ertapenem","10 mcg","35","35",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Imipenem",NA,"0.125","0.125",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Imipenem","10 mcg","36","36",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Meropenem",NA,"0.03","0.03",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Meropenem","10 mcg","35","35",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Clindamycin",NA,"0.25","0.25",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Clindamycin","2 mcg","30","30",FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Fusobacterium necrophorum",NA,"Metronidazole",NA,"0.5","0.5",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Fusobacterium necrophorum",NA,"Metronidazole","5 mcg","30","30",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","1 unit","15","15",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin","2 mcg","23","23",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","10/10 mcg","27","27",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","30/6 mcg","24","24",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Ertapenem",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Ertapenem","10 mcg","24","24",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Imipenem",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Imipenem","10 mcg","25","25",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem",NA,"0.125","0.125",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","10 mcg","25","25",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","5 mcg","12","12",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin",NA,"0.25","0.25",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","2 mcg","19","19",FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole",NA,"4","4",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","5 mcg","16","16",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin",NA,"0.06","0.06",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","1 unit","24","24",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin","2 mcg","23","23",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","10/10 mcg","33","33",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] At very low concentrations of ampicillin, amoxicillin and piperacillin when in inhibitor combinations, the in vitro antimicrobial activity of the fixed concentration of inhibitor (2 mg/L for clavulanic acid and 4 mg/L for sulbactam and tazobactam) is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","30/6 mcg","27","27",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Cefotaxime","5 mcg","26","26",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ceftriaxone",NA,"0.06","0.06",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ceftriaxone","30 mcg","33","33",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ertapenem",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ertapenem","10 mcg","28","28",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Imipenem",NA,"0.03","0.03",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Imipenem","10 mcg","39","39",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem",NA,"0.125","0.125",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","10 mcg","28","28",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","5 mcg","22","22",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin",NA,"0.25","0.25",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","2 mcg","26","26",FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Cutibacterium acnes",NA,"Linezolid",NA,"2","2",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Cutibacterium acnes",NA,"Linezolid","10 mcg","34","34",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2",FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"IP","IP",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"0.5","0.5",FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IP","IP",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2",FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"IP","IP",FALSE,NA,"Anaerobic bacteria" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral",NA,"0.125","0.125",FALSE,NA,"H.pylori" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1",FALSE,NA,"H.pylori" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.25",FALSE,NA,"H.pylori" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1",FALSE,NA,"H.pylori" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8",FALSE,NA,"H.pylori" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1",FALSE,NA,"H.pylori" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)",NA,"1","1",FALSE,NA,"L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","13","13",FALSE,NA,"L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",FALSE,NA,"L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",FALSE,NA,"L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)",NA,"1","1",FALSE,NA,"L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","2 mcg","16","16",FALSE,NA,"L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)",NA,"0.25","0.25",FALSE,NA,"L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","10 mcg","26","26",FALSE,NA,"L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",FALSE,NA,"L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",FALSE,NA,"L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",FALSE,NA,"L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",FALSE,NA,"L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)",NA,"1","1",FALSE,NA,"L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","15 mcg","25","25",FALSE,NA,"L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)",NA,"0.06","0.06",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","1.25/23.75 mcg","29","29",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5",FALSE,NA,"Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Benzylpenicillin","1 unit","17","17",FALSE,NA,"Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"1","1",FALSE,NA,"Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"1","1",FALSE,NA,"Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid",NA,"1","1",FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",FALSE,NA,"Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Cefotaxime",NA,"0.03","0.03",FALSE,NA,"Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Cefotaxime","5 mcg","26","26",FALSE,NA,"Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,NA,"Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Ciprofloxacin","5 mcg","27","27",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Levofloxacin",NA,"0.06","0.06",FALSE,NA,"Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Levofloxacin","5 mcg","27","27",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Nalidixic acid (screen only)","30 mcg","23","23",FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"1","1",FALSE,NA,"Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Tetracycline (screen only)","30 mcg","24","24",FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin",NA,"0.001","0.5",FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","5 mcg","50","26",FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note",FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4",FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20",FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8",FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","24","24",FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note",FALSE,"[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline",NA,"2","2",FALSE,"[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","30 mcg","30","30",FALSE,"[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.001","1",FALSE,NA,"Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","50","12",FALSE,NA,"Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","1",FALSE,NA,"Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","25",FALSE,NA,"Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin",NA,"0.5","0.5",FALSE,NA,"Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","5 mcg","25","25",FALSE,NA,"Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","5 mcg","17","17",FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","2 mcg","20","20",FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"2","2",FALSE,NA,"Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",FALSE,NA,"Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",FALSE,NA,"Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",FALSE,NA,"Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",FALSE,NA,"Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","30","30",FALSE,NA,"Corynebacterium" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.001","1",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","50","12",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"1","1",FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime",NA,"0.001","2",FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","5 mcg","50","15",FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem",NA,"0.25","0.25",FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","10 mcg","24","24",FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","0.5",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","24",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin",NA,"0.06","0.06",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","15 mcg","24","24",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"C. diphtheriae",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"C. diphtheriae",NA,"Clindamycin","2 mcg","15","15",FALSE,"[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"1","1",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","24","24",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","1 unit","21","21",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin",NA,"0.25","0.25",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","2 mcg","26","26",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem",NA,"0.25","0.25",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","10 mcg","31","31",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21",FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2",FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"Note","Note",FALSE,"[B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Norfloxacin (screen only)","10 mcg","17","17",FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin",NA,"1","1",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","5 mcg","16","16",FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin",NA,"0.125","0.125",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","5 mcg","25","25",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06",FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note",FALSE,"[A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125",FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[3] The in vitro antimicrobial activity of the fixed concentration of 2 mg/L for clavulanic acid is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","2/1 mcg","22","22",FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25",FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5",FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",FALSE,NA,"K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",FALSE,NA,"Aeromonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",FALSE,NA,"Aeromonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",FALSE,NA,"Aeromonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",FALSE,NA,"Aeromonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",FALSE,NA,"Aeromonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",FALSE,NA,"Aeromonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",FALSE,NA,"Aeromonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",FALSE,NA,"Aeromonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",FALSE,NA,"Aeromonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",FALSE,NA,"Aeromonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"2","4",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","19","16",FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam",NA,"4","4",FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",FALSE,NA,"A.xylosoxidans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Cefiderocol",NA,"Note","Note",FALSE,"[2] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥26 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","A.xylosoxidans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Cefiderocol","30 mcg","Note","Note",FALSE,"[A] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is also animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥26 mm) are mostly devoid of resistance mechanisms. Isolates with MICs 1-2 mg/L have acquired resistance mechanisms which may result in impaired clinical response. Isolates with MIC values >2 mg/L (zone diameter <22 mm) will likely be resistant. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","A.xylosoxidans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem",NA,"1","4",FALSE,NA,"A.xylosoxidans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","10 mcg","26","20",FALSE,NA,"A.xylosoxidans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","26","26",FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam",NA,"1","1",FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",FALSE,NA,"Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime",NA,"0.25","0.25",FALSE,NA,"Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","5 mcg","21","21",FALSE,NA,"Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",FALSE,NA,"Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",FALSE,NA,"Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime",NA,"1","1",FALSE,NA,"Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","10 mcg","22","22",FALSE,NA,"Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem",NA,"0.5","0.5",FALSE,NA,"Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","10 mcg","24","24",FALSE,NA,"Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin",NA,"0.25","0.25",FALSE,NA,"Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","5 mcg","23","23",FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin",NA,"0.25","0.25",FALSE,NA,"Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","5 mcg","23","23",FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","5 mcg","22","22",FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin",NA,"4","4",FALSE,NA,"Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","15 mcg","16","16",FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","15 mcg","12","12",FALSE,"[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline",NA,"0.5","0.5",FALSE,NA,"Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","30 mcg","20","20",FALSE,"[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","21","21",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio" "EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Imipenem",NA,"0.5","0.5",NA,"Bacillus" +except B. anthracis",NA,"Imipenem",NA,"0.5","0.5",FALSE,NA,"Bacillus" "EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Imipenem","10 mcg","30","30",NA,"Bacillus" +except B. anthracis",NA,"Imipenem","10 mcg","30","30",FALSE,NA,"Bacillus" "EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Meropenem",NA,"0.25","0.25",NA,"Bacillus" +except B. anthracis",NA,"Meropenem",NA,"0.25","0.25",FALSE,NA,"Bacillus" "EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Meropenem","10 mcg","25","25",NA,"Bacillus" +except B. anthracis",NA,"Meropenem","10 mcg","25","25",FALSE,NA,"Bacillus" "EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Bacillus" +except B. anthracis",NA,"Ciprofloxacin",NA,"0.001","0.5",FALSE,NA,"Bacillus" "EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Ciprofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +except B. anthracis",NA,"Ciprofloxacin","5 mcg","50","23",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" "EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Levofloxacin",NA,"0.001","1",NA,"Bacillus" +except B. anthracis",NA,"Levofloxacin",NA,"0.001","1",FALSE,NA,"Bacillus" "EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Levofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +except B. anthracis",NA,"Levofloxacin","5 mcg","50","23",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" "EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Norfloxacin (screen only)","10 mcg","21","21","[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" +except B. anthracis",NA,"Norfloxacin (screen only)","10 mcg","21","21",FALSE,"[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" "EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Vancomycin",NA,"2","2",NA,"Bacillus" +except B. anthracis",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Bacillus" "EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Vancomycin","5 mcg","10","10","[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" +except B. anthracis",NA,"Vancomycin","5 mcg","10","10",FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" "EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Erythromycin",NA,"0.5","0.5",NA,"Bacillus" +except B. anthracis",NA,"Erythromycin",NA,"0.5","0.5",FALSE,NA,"Bacillus" "EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Erythromycin","15 mcg","24","24",NA,"Bacillus" +except B. anthracis",NA,"Erythromycin","15 mcg","24","24",FALSE,NA,"Bacillus" "EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Clindamycin",NA,"1","1",NA,"Bacillus" +except B. anthracis",NA,"Clindamycin",NA,"1","1",FALSE,NA,"Bacillus" "EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Clindamycin","2 mcg","17","17",NA,"Bacillus" +except B. anthracis",NA,"Clindamycin","2 mcg","17","17",FALSE,NA,"Bacillus" "EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Linezolid",NA,"2","2",NA,"Bacillus" +except B. anthracis",NA,"Linezolid",NA,"2","2",FALSE,NA,"Bacillus" "EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Linezolid","10 mcg","22","22",NA,"Bacillus" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Benzylpenicillin",NA,"0.001","0.5",NA,"B.anthracis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Benzylpenicillin","1 unit","50","18",NA,"B.anthracis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Amoxicillin iv",NA,"0.125","0.125","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Amoxicillin iv",NA,"Note","Note","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Ciprofloxacin",NA,"0.001","0.25",NA,"B.anthracis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Ciprofloxacin","5 mcg","50","24",NA,"B.anthracis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Levofloxacin",NA,"0.001","0.5",NA,"B.anthracis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Levofloxacin","5 mcg","50","23",NA,"B.anthracis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Vancomycin",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Vancomycin","5 mcg","10","10","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Clindamycin",NA,"1","1",NA,"B.anthracis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Clindamycin","2 mcg","17","17",NA,"B.anthracis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Doxycycline",NA,"0.06","0.06","[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Tetracycline",NA,"0.125","0.125",NA,"B.anthracis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Tetracycline","30 mcg","26","26",NA,"B.anthracis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Linezolid",NA,"2","2",NA,"B.anthracis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Linezolid","10 mcg","20","20",NA,"B.anthracis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Rifampicin",NA,"1","1","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Rifampicin","5 mcg","12","12","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)","30 mcg","30","30","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Ciprofloxacin",NA,"0.001","1",NA,"B.melitensis " -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Ciprofloxacin","5 mcg","50","27",NA,"B.melitensis " -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Levofloxacin",NA,"0.001","1",NA,"B.melitensis " -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Levofloxacin","5 mcg","50","28",NA,"B.melitensis " -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Gentamicin",NA,"0.5","0.5","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Gentamicin","10 mcg","23","23","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Streptomycin",NA,"1","1","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Streptomycin","10 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Doxycycline",NA,"0.25","0.25","[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis " -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis " -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Tetracycline",NA,"0.5","0.5",NA,"B.melitensis " -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Tetracycline","30 mcg","42","42",NA,"B.melitensis " -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Rifampicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Rifampicin","5 mcg","20","20","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.","B.melitensis " -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.melitensis " -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","29","29","[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone. | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.melitensis " -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid",NA,"0.001","8","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","20/10 mcg","50","22",NA,"B.pseudomallei" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime",NA,"0.001","8",NA,"B.pseudomallei" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","10 mcg","50","18",NA,"B.pseudomallei" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem",NA,"2","2",NA,"B.pseudomallei" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","10 mcg","29","29",NA,"B.pseudomallei" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem",NA,"2","2",NA,"B.pseudomallei" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","10 mcg","24","24",NA,"B.pseudomallei" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"0.001","2",NA,"B.pseudomallei" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"Note","Note","[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","30 mcg","23","23","[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol",NA,"0.001","8",NA,"B.pseudomallei" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","30 mcg","50","22",NA,"B.pseudomallei" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","17","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25","[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination.","M.tuberculosis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06","[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination.","M.tuberculosis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Pretomanid",NA,"Note","Note","[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination. | [2] A provisional screen value of 2 mg/L is advised according to published MIC data determined with MGIT.","M.tuberculosis" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin",NA,"2","2",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","10 mcg","16","16",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)",NA,"8","8",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","10 mcg","12","12",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin",NA,"8","8",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","10 mcg","15","15",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","5 mcg","26","26",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","5 mcg","18","18",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)",NA,"4","4",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","21","21",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","23",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin",NA,"2","2",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","10 mcg","18","18",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","10 mcg","17","17","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin",NA,"1","1",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","30 mcg","18","18",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","10 mcg","23","23",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)",NA,"1","1",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","10 mcg","14","14",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin",NA,"1","1","[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.","Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","200 mcg","30","30","[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.","Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin",NA,"4","4",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"32","32",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"0.125","0.125",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin",NA,"4","4",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin",NA,"8","8",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","30 mcg","28","28",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents" -"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","30 mcg","31","31",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin iv",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin iv","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)",NA,"8","8","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","10/10 mcg","14","14","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin iv",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin iv","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)",NA,"0.001","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","/ mcg","Note","Note","[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"". | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"8","8","[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","/ mcg","Note","Note","[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)",NA,"0.001","8","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","/ mcg","Note","Note","[D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and ""amoxicillin oral (other indications)"" can be used in high exposure in combination therapy (see Note 3/D). Isolates resistant to ampicillin can be reported resistant. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv",NA,"8","8","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","20/10 mcg","19","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)",NA,"0.001","8","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","20/10 mcg","50","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"32","32","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","20/10 mcg","16","16","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"0.001","8","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","20/10 mcg","50","19","[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","8",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","20",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","8","[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","20",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)",NA,"0.001","16",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)","30 mcg","50","17","[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)",NA,"8","8","[6] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)","10 mcg","15","15","[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli and Klebsiella spp.(except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)",NA,"0.001","4","[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli and Klebsiella spp.(except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)","30 mcg","50","20","[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime-enmetazobactam",NA,"4","4","[3] For susceptibility testing purposes, the concentration of enmetazobactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime-enmetazobactam","30/20 mcg","22","22",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol",NA,"2","2","[4] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","30 mcg","23","23",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","5 mcg","20","17",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","5 mcg","20","20",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)",NA,"Note","Note","[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","30 mcg","19","19","[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)","10 mcg","21","21",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8","[6] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","30 mcg","23","23",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"2","2","[8] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [7] See table of dosages for dosing for different indications.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","22","22","[7] See table of dosages for dosing for different indications.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)",NA,"1","2",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","27","24",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)",NA,"1","1",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","30 mcg","27","27",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"0.001","8",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","50","19",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem",NA,"1","2",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","10 mcg","24","21",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","23","23",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem",NA,"2","4",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem","10 mcg","22","19",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Morganellaceae",NA,"Imipenem",NA,"0.001","4","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Morganellaceae",NA,"Imipenem","10 mcg","50","19","[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam",NA,"2","2","[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","10 mcg","22","16",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","10 mcg","22","22",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8","[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","20/10 mcg","20","20",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21","[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam-avibactam",NA,"4","4","[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam-avibactam","30/20 mcg","25","25",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06","[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note","[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)",NA,"0.25","0.5",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","5 mcg","25","22",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"0.125","0.125","[2] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"Note","Note","[2/B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24","[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Delafloxacin",NA,"0.125","0.125",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Delafloxacin",NA,"Note","Note","[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.",NA,"Moxifloxacin",NA,"0.25","0.25","[3] Fluoroquinolone breakpoints are available for other agents.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.",NA,"Moxifloxacin","5 mcg","22","22","[3] Fluoroquinolone breakpoints are available for other agents.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","0.5",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","24","24",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","30 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","18","18",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","10 mcg","16","16","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","16","16",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Azithromycin",NA,"Note","Note","[1] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 µg disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Azithromycin",NA,"Note","Note","[1/A] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 µg disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms. | [B] When reading azithromycin zone diameters, take growth appearing as a thin inner zone on some batches of Mueller-Hinton agar into account.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Eravacycline","20 mcg","17","17",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18","[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note","[1] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note","[A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"2","2","[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note","[B] Use an MIC method (broth microdilution only). | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Fosfomycin iv (infections originating from the urinary tract)",NA,"8","8","[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Fosfomycin iv (infections originating from the urinary tract)","200 mcg","24","24","[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Fosfomycin iv (other indications)",NA,"Note","Note","[5] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Fosfomycin iv (other indications)",NA,"Note","Note","[E] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"other Enterobacterales",NA,"Fosfomycin iv",NA,"Note","Note","[6] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"other Enterobacterales",NA,"Fosfomycin iv",NA,"Note","Note","[F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)",NA,"8","8","[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)","200 mcg","24","24","[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Gepotidacin (uncomplicated UTI only)",NA,"8","8",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Gepotidacin (uncomplicated UTI only)",NA,"IP","IP",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli and Klebsiella spp. (except K. aerogenes)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"2","2",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli and Klebsiella spp. (except K. aerogenes)",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","15","15",NA,"Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Proteus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[7] For Proteus spp., there is insufficient clinical evidence of efficacy. The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or trimethoprim 5 µg disk zone diameter <14 mm).","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Proteus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[G] For Proteus spp., there is insufficient clinical evidence of efficacy. The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or trimethoprim 5 µg disk zone diameter <14 mm).","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales except Serratia spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5","[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales except Serratia spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","15","15","[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Serratia spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","2","[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Serratia spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","15","[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"0.001","16",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"0.001","16","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"0.001","16","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"0.001","8",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","50","21",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor.","Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[A] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor.","Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"P. aeruginosa",NA,"Cefiderocol",NA,"2","2","[2] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"P. aeruginosa",NA,"Cefiderocol","30 mcg","22","22",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"0.001","8",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","50","17",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8","[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4","[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [4] See table of dosages for dosing for different indications.","Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","23","23","[4] See table of dosages for dosing for different indications.","Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem",NA,"0.001","2",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","10 mcg","50","22",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"0.001","4",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","50","20",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"P. aeruginosa",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"P. aeruginosa",NA,"Imipenem-relebactam","10/25 mcg","22","22",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)","10 mcg","20","14",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)",NA,"2","8",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)","10 mcg","24","18",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (meningitis)","10 mcg","20","20",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8","[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","20/10 mcg","14","14",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"0.001","16",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","50","26",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"0.001","2",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","50","18",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"16","16",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","15","15",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","18","18",NA,"Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"4","4","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Fosfomycin iv",NA,"Note","Note","[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Fosfomycin iv",NA,"Note","Note","[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"Note","Note","[2] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥28 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","S.maltophilia" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","30 mcg","Note","Note","[A] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥28 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","S.maltophilia" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Aztreonam-avibactam",NA,"IE","IE","[1] The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or aztreonam-avibactam 30-20 µg disk zone diameter <21 mm).","S.maltophilia" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Aztreonam-avibactam",NA,"IE","IE","[A] The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or aztreonam-avibactam 30-20 µg disk zone diameter <21 mm).","S.maltophilia" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Ciprofloxacin",NA,"Note","Note","[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms.","S.maltophilia" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Ciprofloxacin",NA,"Note","Note","[A] Disk diffusion criteria are not available.","S.maltophilia" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Levofloxacin",NA,"Note","Note","[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms.","S.maltophilia" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Levofloxacin",NA,"Note","Note","[A] Disk diffusion criteria are not available.","S.maltophilia" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Minocycline",NA,"Note","Note","[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [2] Pertains to intravenous therapy. Oral therapy will lead to insufficient exposure.","S.maltophilia" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Minocycline",NA,"Note","Note","[A] Disk diffusion criteria are not available.","S.maltophilia" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Tigecycline",NA,"Note","Note","[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms.","S.maltophilia" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Tigecycline",NA,"Note","Note","[A] Disk diffusion criteria are not available.","S.maltophilia" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","2","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","16","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"Note","Note","[2] The in vitro activity of cefiderocol against Acinetobacter baumannii group is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥21 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <17 mm) have acquired resistance mechanisms and are likely to be resistant to this agent. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol","30 mcg","Note","Note","[A] The in vitro activity of cefiderocol against Acinetobacter baumannii group is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥21 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <17 mm) have acquired resistance mechanisms and are likely to be resistant to this agent. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem",NA,"0.001","2",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","10 mcg","50","22",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)",NA,"2","8",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","10 mcg","21","15",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)",NA,"2","2",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","10 mcg","21","21",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)",NA,"8","8","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","30 mcg","19","19","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","19","19",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","10 mcg","17","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"4","4",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE","[1] Minocycline has been discussed as alternative therapy in Acinetobacter infections. The “IE” in the table pertains to intravenous therapy only. Oral administration will not accomplish sufficient exposure.","Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",NA,"Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"2","2","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note","[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Fosfomycin iv",NA,"Note","Note","[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Fosfomycin iv",NA,"Note","Note","[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","16","16","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Benzylpenicillin",NA,"0.125","0.125","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Benzylpenicillin","1 unit","26","26","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. lugdunensis",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. lugdunensis",NA,"Benzylpenicillin","1 unit","26","26",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. saprophyticus",NA,"Ampicillin",NA,"Note","Note","[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. saprophyticus",NA,"Ampicillin","2 mcg","18","18","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Oxacillin (screen only)","1 mcg","20","20","[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note","[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit. +except B. anthracis",NA,"Linezolid","10 mcg","22","22",FALSE,NA,"Bacillus" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Benzylpenicillin",NA,"0.001","0.5",FALSE,NA,"B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Benzylpenicillin","1 unit","50","18",FALSE,NA,"B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Amoxicillin iv",NA,"0.125","0.125",FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Amoxicillin iv",NA,"Note","Note",FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Ciprofloxacin",NA,"0.001","0.25",FALSE,NA,"B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Ciprofloxacin","5 mcg","50","24",FALSE,NA,"B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Levofloxacin",NA,"0.001","0.5",FALSE,NA,"B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Levofloxacin","5 mcg","50","23",FALSE,NA,"B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Vancomycin",NA,"(4)","(4)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Vancomycin","5 mcg","(10)","(10)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Clindamycin",NA,"1","1",FALSE,NA,"B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Clindamycin","2 mcg","17","17",FALSE,NA,"B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Doxycycline",NA,"0.06","0.06",FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Tetracycline",NA,"0.125","0.125",FALSE,NA,"B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Tetracycline","30 mcg","26","26",FALSE,NA,"B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Linezolid",NA,"2","2",FALSE,NA,"B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Linezolid","10 mcg","20","20",FALSE,NA,"B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Bacillus anthracis",NA,"Rifampicin",NA,"(1)","(1)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Bacillus anthracis",NA,"Rifampicin","5 mcg","(12)","(12)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)","30 mcg","(30)","(30)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Ciprofloxacin",NA,"0.001","1",FALSE,NA,"B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Ciprofloxacin","5 mcg","50","27",FALSE,NA,"B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Levofloxacin",NA,"0.001","1",FALSE,NA,"B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Levofloxacin","5 mcg","50","28",FALSE,NA,"B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Gentamicin",NA,"(0.5)","(0.5)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Gentamicin","10 mcg","(23)","(23)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Streptomycin",NA,"(1)","(1)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Streptomycin","10 mcg","(15)","(15)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Doxycycline",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Tetracycline",NA,"0.5","0.5",FALSE,NA,"B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Tetracycline","30 mcg","42","42",FALSE,NA,"B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Rifampicin",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Rifampicin","5 mcg","(20)","(20)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.","B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","29","29",FALSE,"[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone. | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.melitensis " +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid",NA,"0.001","8",FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","20/10 mcg","50","22",FALSE,NA,"B.pseudomallei" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime",NA,"0.001","8",FALSE,NA,"B.pseudomallei" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","10 mcg","50","18",FALSE,NA,"B.pseudomallei" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem",NA,"2","2",FALSE,NA,"B.pseudomallei" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","10 mcg","29","29",FALSE,NA,"B.pseudomallei" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem",NA,"2","2",FALSE,NA,"B.pseudomallei" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","10 mcg","24","24",FALSE,NA,"B.pseudomallei" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"0.001","2",FALSE,NA,"B.pseudomallei" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","30 mcg","23","23",FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol",NA,"0.001","8",FALSE,NA,"B.pseudomallei" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","30 mcg","50","22",FALSE,NA,"B.pseudomallei" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","17",FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25",FALSE,"[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination.","M.tuberculosis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06",FALSE,"[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination.","M.tuberculosis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Pretomanid",NA,"Note","Note",FALSE,"[1] Breakpoints were not determined with the EUCAST reference method. Therefore they are provisory values that might change according to the results on ongoing studies using the EUCAST reference protocol for MIC determination. | [2] A provisional screen value of 2 mg/L is advised according to published MIC data determined with MGIT.","M.tuberculosis" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","10 mcg","17","17",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","10 mcg","16","16",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin",NA,"0.125","0.125",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin",NA,"0.25","0.25",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.25",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol",NA,"16","16",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","10 mcg","12","12",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","10 mcg","15","15",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","10 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","5 mcg","26","26",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","5 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","21","21",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","23",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Gentamicin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","10 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Tobramycin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","10 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","10 mcg","17","17",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol",NA,"16","16",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","30 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","10 mcg","23","23",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","10 mcg","14","14",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Mupirocin",NA,"1","1",FALSE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","200 mcg","30","30",FALSE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. aureus",NA,"Retapamulin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","21","21",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"32","32",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"0.125","0.125",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin",NA,"0.06","0.06",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin",NA,"0.06","0.06",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","30 mcg","28","28",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2025","15.0","Clinical Breakpoint Tables v. 15.0","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","30 mcg","31","31",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin iv",NA,"8","8",FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin iv","10 mcg","14","14",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)",NA,"8","8",FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin oral (uncomplicated UTI only)","10 mcg","14","14",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv",NA,"8","8",FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam iv","10/10 mcg","14","14",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)",NA,"8","8",FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ampicillin-sulbactam oral (uncomplicated UTI only)","10/10 mcg","14","14",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin iv",NA,"8","8",FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin iv","/ mcg","Note","Note",FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)",NA,"0.001","8",FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (infections originating from the urinary tract)","/ mcg","Note","Note",FALSE,"[C] Isolates susceptible to ampicillin (iv or oral) can be reported ""susceptible, increased exposure” (I) to ""amoxicillin oral (infections originating from the urinary tract)"". Isolates resistant to ampicillin (iv or oral) can be reported resistant to ""amoxicillin oral (infections originating from the urinary tract)"". | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"8","8",FALSE,"[1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (uncomplicated UTI only)","/ mcg","Note","Note",FALSE,"[B] Susceptibility inferred from ampicillin (iv or oral). | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)",NA,"(0.001)","(8)",TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin oral (other indications)","/ mcg","Note","Note",FALSE,"[D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [E] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and ""amoxicillin oral (other indications)"" can be used in high exposure in combination therapy (see Note 3/D). Isolates resistant to ampicillin can be reported resistant. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv",NA,"8","8",FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid iv","20/10 mcg","19","19",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)",NA,"0.001","8",FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (infections originating from the urinary tract)","20/10 mcg","50","19",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"32","32",FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)","20/10 mcg","16","16",FALSE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"(0.001)","(8)",TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amoxicillin-clavulanic acid oral (other indications)","20/10 mcg","(50)","(19)",TRUE,"[A] Ignore growth that may appear as a thin inner zone on some batches of Mueller-Hinton agars. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] For information on how to implement the new aminopenicillin breakpoints, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin",NA,"8","8",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin","30 mcg","20","20",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Piperacillin-tazobactam",NA,"8","8",FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Piperacillin-tazobactam","30/6 mcg","20","20",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid",NA,"8","16",FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ticarcillin-clavulanic acid","75/10 mcg","23","20",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)",NA,"0.001","16",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes) and P. mirabilis",NA,"Temocillin (infections originating from the urinary tract)","30 mcg","50","17",FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)",NA,"8","8",FALSE,"[6] Agar dilution is the reference method for mecillinam MIC determination.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli, Citrobacter spp., Klebsiella spp., Raoultella spp., Enterobacter spp. and P. mirabilis",NA,"Mecillinam oral (pivmecillinam) (uncomplicated UTI only)","10 mcg","15","15",FALSE,"[F] Ignore isolated colonies within the inhibition zone.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefaclor (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefadroxil (uncomplicated UTI only)","30 mcg","12","12",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefalexin (uncomplicated UTI only)","30 mcg","14","14",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli and Klebsiella spp.(except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)",NA,"0.001","4",FALSE,"[2] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli and Klebsiella spp.(except K. aerogenes)",NA,"Cefazolin (infections originating from the urinary tract)","30 mcg","50","20",FALSE,"[A] Isolates susceptible to cefadroxil and/or cefalexin can be reported ""susceptible, increased exposure” (I) to cefazolin.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime",NA,"1","4",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime","30 mcg","27","24",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefepime-enmetazobactam",NA,"4","4",FALSE,"[3] For susceptibility testing purposes, the concentration of enmetazobactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefepime-enmetazobactam","30/20 mcg","22","22",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefiderocol",NA,"2","2",FALSE,"[4] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefiderocol","30 mcg","23","23",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefixime (uncomplicated UTI only)","5 mcg","17","17",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)",NA,"1","2",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (indications other than meningitis)","5 mcg","20","17",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefotaxime (meningitis)","5 mcg","20","20",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefoxitin (screen only)",NA,"Note","Note",FALSE,"[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefoxitin (screen only)","30 mcg","19","19",FALSE,"[5] The cefoxitin cut-off value (8 mg/L) has a high sensitivity but poor specificity for identification of AmpC-producing Enterobacterales as this agent is also affected by permeability alterations and some carbapenemases. Classical non-AmpC producers are wild type, whereas plasmid AmpC producers or chromosomal AmpC hyperproducers are non-wild type.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Cefpodoxime (uncomplicated UTI only)","10 mcg","21","21",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftaroline",NA,"0.5","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftaroline","5 mcg","23","23",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime",NA,"1","4",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime","10 mcg","22","19",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftazidime-avibactam",NA,"8","8",FALSE,"[6] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftazidime-avibactam","10/4 mcg","13","13",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftibuten (infections originating from the urinary tract)","30 mcg","23","23",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftobiprole",NA,"0.25","0.25",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftobiprole","5 mcg","23","23",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam",NA,"2","2",FALSE,"[8] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [7] See table of dosages for dosing for different indications.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftolozane-tazobactam","30/10 mcg","22","22",FALSE,"[7] See table of dosages for dosing for different indications.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)",NA,"1","2",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (indications other than meningitis)","30 mcg","27","24",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)",NA,"1","1",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ceftriaxone (meningitis)","30 mcg","27","27",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv",NA,"0.001","8",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime iv","30 mcg","50","19",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)",NA,"8","8",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli, Klebsiella spp. (except K. aerogenes), Raoultella spp. and P. mirabilis",NA,"Cefuroxime oral (uncomplicated UTI only)","30 mcg","19","19",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Doripenem",NA,"1","2",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Doripenem","10 mcg","24","21",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ertapenem","10 mcg","23","23",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem",NA,"2","4",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem","10 mcg","22","19",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Morganellaceae",NA,"Imipenem",NA,"0.001","4",FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Morganellaceae",NA,"Imipenem","10 mcg","50","19",FALSE,"[2] The intrinsically low activity of imipenem against Morganella morganii, Proteus spp. and Providencia spp. requires the high exposure of imipenem.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam",NA,"2","2",FALSE,"[3] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales except Morganellaceae",NA,"Imipenem-relebactam","10/25 mcg","22","22",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)",NA,"2","8",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (indications other than meningitis)","10 mcg","22","16",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem (meningitis)",NA,"2","2",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem (meningitis)","10 mcg","22","22",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Meropenem-vaborbactam",NA,"8","8",FALSE,"[4] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Meropenem-vaborbactam","20/10 mcg","20","20",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam",NA,"1","4",FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam","30 mcg","26","21",FALSE,"[1] The aztreonam breakpoints for Enterobacterales will detect clinically important resistance mechanisms (including ESBL). Some isolates that produce beta-lactamases are susceptible to aztreonam with these breakpoints and should be reported as tested, i.e. the presence or absence of an ESBL does not in itself influence the categorisation of susceptibility. ESBL detection and characterisation are recommended for public health and infection control purposes.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Aztreonam-avibactam",NA,"4","4",FALSE,"[2] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Aztreonam-avibactam","30/20 mcg","25","25",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,"[1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Salmonella spp.",NA,"Ciprofloxacin",NA,"Note","Note",FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [1] There is clinical evidence for ciprofloxacin to indicate a poor response in systemic infections caused by Salmonella spp. with any detectable fluoroquinolone resistance mechanisms. The available data relate mainly to Salmonella Typhi but there are also case reports of poor response with other Salmonella species.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)",NA,"0.25","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (indications other than meningitis)","5 mcg","25","22",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"0.125","0.125",FALSE,"[2] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ciprofloxacin (meningitis)",NA,"Note","Note",FALSE,"[2/B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24",FALSE,"[A] Tests with a ciprofloxacin 5 µg disk will not reliably exclude all fluoroquinolone resistance mechanisms in Salmonella spp. Perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [B] In meningitis, where all fluoroquinolone resistance mechanisms must be excluded, either perform an MIC test, or infer susceptibility from the pefloxacin 5 µg screening test. | [C] The pefloxacin screening test can also be used to detect fluoroquinolone resistance mechanisms in other Enterobacterales such as E. coli, K. pneumoniae and Shigella spp.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Delafloxacin",NA,"0.125","0.125",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Delafloxacin",NA,"Note","Note",FALSE,"[D] A disk diffusion test awaits action from the responsible pharmaceutical company.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Levofloxacin",NA,"0.5","1",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Levofloxacin","5 mcg","23","19",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.",NA,"Moxifloxacin",NA,"0.25","0.25",FALSE,"[3] Fluoroquinolone breakpoints are available for other agents.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales except Morganella morganii, Proteus spp. and Serratia spp.",NA,"Moxifloxacin","5 mcg","22","22",FALSE,"[3] Fluoroquinolone breakpoints are available for other agents.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)",NA,"0.5","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Norfloxacin (uncomplicated UTI only)","10 mcg","24","24",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Ofloxacin","5 mcg","24","22",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (systemic infections)",NA,"(8)","(8)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (systemic infections)","30 mcg","(18)","(18)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","18","18",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (systemic infections)","10 mcg","(17)","(17)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)",NA,"2","2",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (systemic infections)","10 mcg","(16)","(16)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","16","16",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Azithromycin",NA,"Note","Note",FALSE,"[1] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 µg disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Azithromycin",NA,"Note","Note",FALSE,"[1/A] Azithromycin has been used in the treatment of enteric infections, primarily with Salmonella Typhi and Shigella species and although wild type distributions vary somewhat, isolates with MICs above 16 mg/L (azithromycin 15 µg disk zone diameters <12 mm) are likely to have azithromycin resistance mechanisms. | [B] When reading azithromycin zone diameters, take growth appearing as a thin inner zone on some batches of Mueller-Hinton agar into account.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Eravacycline",NA,"0.5","0.5",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Eravacycline","20 mcg","17","17",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli and C. koseri",NA,"Tigecycline",NA,"0.5","0.5",FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [3] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli and C. koseri",NA,"Tigecycline","15 mcg","18","18",FALSE,"[A] For other Enterobacterales, the activity of tigecycline varies from insufficient in Serratia spp., Proteus spp., Morganella morganii and Providencia spp. to variable in other species. For more information, see https://www.eucast.org/eucastguidancedocuments/. | [B] Zone diameter breakpoints validated for E. coli only. For C. koseri, use an MIC method.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note",FALSE,"[1] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Chloramphenicol",NA,"Note","Note",FALSE,"[A] Efficacy for Enterobacterales is uncertain. Screening cut-off values can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >16 mg/L; zone diameter <17 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales",NA,"Colistin",NA,"(2)","(2)",TRUE,"[3] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales",NA,"Colistin",NA,"Note","Note",FALSE,"[B] Use an MIC method (broth microdilution only). | [2] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Fosfomycin iv (infections originating from the urinary tract)",NA,"8","8",FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Fosfomycin iv (infections originating from the urinary tract)","200 mcg","24","24",FALSE,"[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Fosfomycin iv (other indications)",NA,"Note","Note",FALSE,"[5] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Fosfomycin iv (other indications)",NA,"Note","Note",FALSE,"[E] There is currently a lack of clinical evidence to support clinical breakpoints.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"other Enterobacterales",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[6] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"other Enterobacterales",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[F] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy in other Enterobacterales, see https://www.eucast.org/eucastguidancedocuments/.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)",NA,"8","8",FALSE,"[4] Agar dilution is the reference method for fosfomycin. MICs must be determined in the presence of glucose-6-phosphate (25 mg/L in the medium). Follow the manufacturers' instructions for commercial systems.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Fosfomycin oral (uncomplicated UTI only)","200 mcg","24","24",FALSE,"[D] Ignore isolated colonies within the inhibition zone (see pictures below).","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Gepotidacin (uncomplicated UTI only)",NA,"8","8",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Gepotidacin (uncomplicated UTI only)",NA,"IP","IP",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","11","11",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli",NA,"Nitroxoline (uncomplicated UTI only)","30 mcg","15","15",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. coli and Klebsiella spp. (except K. aerogenes)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"2","2",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. coli and Klebsiella spp. (except K. aerogenes)",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","15","15",FALSE,NA,"Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Proteus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note",FALSE,"[7] For Proteus spp., there is insufficient clinical evidence of efficacy. The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or trimethoprim 5 µg disk zone diameter <14 mm).","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Proteus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note",FALSE,"[G] For Proteus spp., there is insufficient clinical evidence of efficacy. The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or trimethoprim 5 µg disk zone diameter <14 mm).","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterobacterales except Serratia spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5",FALSE,"[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterobacterales except Serratia spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","15","15",FALSE,"[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Serratia spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","2",FALSE,"[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Serratia spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","15",FALSE,"[8] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterobacterales" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin",NA,"0.001","16",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin","30 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam",NA,"0.001","16",FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Piperacillin-tazobactam","30/6 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid",NA,"0.001","16",FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ticarcillin-clavulanic acid","75/10 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime",NA,"0.001","8",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime","30 mcg","50","21",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note",FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note",FALSE,"[A] The addition of a beta-lactamase inhibitor does not add clinical benefit.The beta-lactamases produced by the organisms either do not modify the parent cephalosporin or are insufficiently inhibited by the inhibitor.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"P. aeruginosa",NA,"Cefiderocol",NA,"2","2",FALSE,"[2] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"P. aeruginosa",NA,"Cefiderocol","30 mcg","22","22",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftazidime",NA,"0.001","8",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftazidime","10 mcg","50","17",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam",NA,"8","8",FALSE,"[3] For susceptibility testing purposes, the concentration of avibactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftazidime-avibactam","10/4 mcg","17","17",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam",NA,"4","4",FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [4] See table of dosages for dosing for different indications.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"P. aeruginosa",NA,"Ceftolozane-tazobactam","30/10 mcg","23","23",FALSE,"[4] See table of dosages for dosing for different indications.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Doripenem",NA,"0.001","2",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Doripenem","10 mcg","50","22",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Imipenem",NA,"0.001","4",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Imipenem","10 mcg","50","20",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"P. aeruginosa",NA,"Imipenem-relebactam",NA,"2","2",FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"P. aeruginosa",NA,"Imipenem-relebactam","10/25 mcg","22","22",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)",NA,"2","8",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (indications other than meningitis)","10 mcg","20","14",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)",NA,"2","8",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas other than P. aeruginosa",NA,"Meropenem(indications other than meningitis)","10 mcg","24","18",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem (meningitis)",NA,"2","2",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem (meningitis)","10 mcg","20","20",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam",NA,"8","8",FALSE,"[2] For susceptibility testing purposes, the concentration of vaborbactam is fixed at 8 mg/L.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"P. aeruginosa",NA,"Meropenem-vaborbactam","20/10 mcg","14","14",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam",NA,"0.001","16",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam","30 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Aztreonam-avibactam",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Aztreonam-avibactam",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Ciprofloxacin",NA,"0.001","0.5",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Ciprofloxacin","5 mcg","50","26",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Levofloxacin",NA,"0.001","2",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Levofloxacin","5 mcg","50","18",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)",NA,"(16)","(16)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (systemic infections)","30 mcg","(15)","(15)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"16","16",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","15","15",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (systemic infections)",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (systemic infections)","10 mcg","(18)","(18)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"2","2",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","18","18",FALSE,NA,"Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Colistin",NA,"(4)","(4)",TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Colistin",NA,"Note","Note",FALSE,"[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pseudomonas spp.",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pseudomonas spp.",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Pseudomonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol",NA,"Note","Note",FALSE,"[2] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥28 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","S.maltophilia" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Cefiderocol","30 mcg","Note","Note",FALSE,"[A] The in vitro activity of cefiderocol against Stenotrophomonas maltophilia is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥28 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","S.maltophilia" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Aztreonam-avibactam",NA,"IE","IE",FALSE,"[1] The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or aztreonam-avibactam 30-20 µg disk zone diameter <21 mm).","S.maltophilia" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Aztreonam-avibactam",NA,"IE","IE",FALSE,"[A] The ECOFF can be used to exclude acquired resistance mechanisms (presence of resistance indicated by MICs >8 mg/L or aztreonam-avibactam 30-20 µg disk zone diameter <21 mm).","S.maltophilia" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Ciprofloxacin",NA,"Note","Note",FALSE,"[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms.","S.maltophilia" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Ciprofloxacin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Levofloxacin",NA,"Note","Note",FALSE,"[1] Fluoroquinolones have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms.","S.maltophilia" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Levofloxacin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Minocycline",NA,"Note","Note",FALSE,"[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms. | [2] Pertains to intravenous therapy. Oral therapy will lead to insufficient exposure.","S.maltophilia" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Minocycline",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Tigecycline",NA,"Note","Note",FALSE,"[1] Tetracyclines have been used in combination therapy. The ECOFF can be used to exclude acquired resistance mechanisms.","S.maltophilia" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Tigecycline",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria are not available.","S.maltophilia" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","2",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Stenotrophomonas maltophilia",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","16",FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.maltophilia" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Piperacillin-tazobactam",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Cefiderocol",NA,"Note","Note",FALSE,"[2] The in vitro activity of cefiderocol against Acinetobacter baumannii group is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥21 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <17 mm) have acquired resistance mechanisms and are likely to be resistant to this agent. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Cefiderocol","30 mcg","Note","Note",FALSE,"[A] The in vitro activity of cefiderocol against Acinetobacter baumannii group is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥21 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <17 mm) have acquired resistance mechanisms and are likely to be resistant to this agent. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Doripenem",NA,"0.001","2",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Doripenem","10 mcg","50","22",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem",NA,"2","4",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem","10 mcg","24","21",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)",NA,"2","8",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (indications other than meningitis)","10 mcg","21","15",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)",NA,"2","2",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem (meningitis)","10 mcg","21","21",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organisms either do not modify the parent carbapenem or are insufficiently inhibited by the inhibitor.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Ciprofloxacin",NA,"0.001","1",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","50","21",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","1",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","20",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)",NA,"(8)","(8)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (systemic infections)","30 mcg","(19)","(19)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)",NA,"8","8",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Amikacin (infections originating from the urinary tract)","30 mcg","19","19",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)",NA,"(4)","(4)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (systemic infections)","10 mcg","(17)","(17)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)",NA,"4","4",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Gentamicin (infections originating from the urinary tract)","10 mcg","17","17",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)",NA,"(4)","(4)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (systemic infections)","10 mcg","(17)","(17)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)",NA,"4","4",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tobramycin (infections originating from the urinary tract)","10 mcg","17","17",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",FALSE,"[1] Minocycline has been discussed as alternative therapy in Acinetobacter infections. The “IE” in the table pertains to intravenous therapy only. Oral administration will not accomplish sufficient exposure.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Minocycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Colistin",NA,"(2)","(2)",TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Colistin",NA,"Note","Note",FALSE,"[A] Use an MIC method (broth microdilution only). | [1] Colistin MIC determination should be performed with broth microdilution. Quality control must be performed with both a susceptible QC strain (E. coli ATCC 25922 or P. aeruginosa ATCC 27853) and the colistin resistant E. coli NCTC 13846 (mcr-1 positive).","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[3] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5",FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Acinetobacter spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","16","16",FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Acinetobacter" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Benzylpenicillin",NA,"0.125","0.125",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Benzylpenicillin","1 unit","26","26",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [B] For S. aureus, disk diffusion is more reliable than MIC determination for detection of penicillinase producers, provided the zone diameter is measured AND the zone edge for isolates with zone diameters ≥26 mm is closely inspected (see pictures below). Examine the zone edge with transmitted light (plate held up to light). If the zone diameter is <26 mm, then report resistant. If the zone diameter is ≥26 mm AND the zone edge is sharp (no reduction of growth towards zone edge, like a ""cliff""), then report resistant. If not sharp (reduction of growth towards zone edge, like a ""beach""), then report susceptible and if uncertain, then report resistant. Chromogenic cephalosporin-based beta-lactamase tests do not reliably detect staphylococcal penicillinase.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. lugdunensis",NA,"Benzylpenicillin",NA,"0.125","0.125",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. lugdunensis",NA,"Benzylpenicillin","1 unit","26","26",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note",FALSE,"[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"other staphylococci",NA,"Benzylpenicillin",NA,"Note","Note",FALSE,"[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. saprophyticus",NA,"Ampicillin",NA,"Note","Note",FALSE,"[2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. saprophyticus",NA,"Ampicillin","2 mcg","18","18",FALSE,"[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [3] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described. | [D] Ampicillin susceptible S. saprophyticus are mecA-negative and susceptible to ampicillin, amoxicillin and piperacillin (without or with a beta-lactamase inhibitor).","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ticarcillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Oxacillin (screen only)","1 mcg","20","20",FALSE,"[E] For screening for methicillin resistance in S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"other staphylococci",NA,"Oxacillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [4] S. aureus, S. lugdunensis and S. saprophyticus with oxacillin MIC values >2 mg/L are mostly methicillin resistant due to the presence of the mecA or mecC gene. Occasionally oxacillin MIC values are high in S. aureus in absence of mec-gene mediated resistance. These isolates have been called BORSA (borderline oxacillin resistant S. aureus). EUCAST does not recommend systematic screening for BORSA. For coagulase-negative staphylococci other than S. saprophyticus and S. lugdunensis, the oxacillin MIC in methicillin resistant isolates is >0.25 mg/L.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cloxacillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dicloxacillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note",FALSE,"[1] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [2] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Flucloxacillin",NA,"Note","Note",FALSE,"[A] Most S. aureus are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. Isolates that test susceptible to benzylpenicillin and cefoxitin can be reported susceptible to all penicillins. Isolatesthat test resistant to benzylpenicillin but susceptible to cefoxitin are susceptible to β-lactam β-lactamase inhibitor combinations, the isoxazolylpenicillins (oxacillin, cloxacillin, dicloxacillin and flucloxacillin) and nafcillin. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. Isolates that test resistant to cefoxitin are resistant to all penicillins. | [C] Most staphylococci are penicillinase producers and some are methicillin resistant. Either mechanism renders them resistant to benzylpenicillin, phenoxymethylpenicillin, ampicillin, amoxicillin, piperacillin and ticarcillin. No currently available method can reliably detect penicillinase production in all species of staphylococci but methicillin resistance can be detected with cefoxitin as described.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefaclor",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefadroxil",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefalexin",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefazolin",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit. 4.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit. +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefepime-enmetazobactam",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit. 4.S. aureus and S. lugdunensis with cefoxitin MIC values >4 mg/L and S. saprophyticus with cefoxitin MIC values >8 mg/L are methicillin resistant, mostly due to the presence of the mecA or mecC gene. Disk diffusion reliably predicts methicillin resistance.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","22","22","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note","[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","27","27","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note","[6] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note","[C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)",NA,"1","2","[7] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)","5 mcg","20","17","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (pneumonia)",NA,"1","1","[7] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (pneumonia)","5 mcg","20","20","[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Ceftobiprole",NA,"2","2","[9] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Ceftobiprole","5 mcg","17","17","[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note","[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note","[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Ciprofloxacin",NA,"0.001","2","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Ciprofloxacin","5 mcg","50","17","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin",NA,"0.001","2","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin","5 mcg","50","22","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"0.016","0.016",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"Note","Note","[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"0.25","0.25",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"Note","Note","[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Levofloxacin","5 mcg","50","22","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin",NA,"0.001","1",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin","5 mcg","50","24","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Moxifloxacin",NA,"0.25","0.25","[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Moxifloxacin","5 mcg","25","25","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | [3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin",NA,"0.25","0.25","[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin","5 mcg","28","28","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | [3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","17","17","[D] | [D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note","[E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Amikacin",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Amikacin","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Amikacin",NA,"16","16","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Amikacin","30 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Gentamicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Gentamicin","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Gentamicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Gentamicin","10 mcg","22","22","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Tobramycin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Tobramycin","10 mcg","18","18","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Tobramycin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Tobramycin","10 mcg","20","20","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"0.25","0.25","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Oritavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Teicoplanin",NA,"2","2",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"4","4",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"MRSA",NA,"Telavancin",NA,"0.125","0.125","[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"MRSA",NA,"Telavancin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Vancomycin",NA,"2","2",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"4","4",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"Note","Note","[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"2","2","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","15 mcg","21","21","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"1","1","[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin",NA,"0.25","0.25","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","2 mcg","22","22","[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin",NA,"1","1",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","15 mcg","21","21",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Eravacycline",NA,"0.25","0.25",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Eravacycline","20 mcg","20","20","[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","30 mcg","22","22","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline",NA,"0.5","0.5","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","15 mcg","19","19","[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","10 mcg","21","21",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid",NA,"0.5","0.5","[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","2 mcg","20","20","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"other staphylococci",NA,"Daptomycin",NA,"Note","Note","[3] For other staphylococci, the ECOFF can be used to exclude acquired resistance mechanisms, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"other staphylococci",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[4] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid",NA,"1","1",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","10 mcg","24","24",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. saprophyticus",NA,"Gepotidacin (uncomplicated UTI only)",NA,"0.25","0.25",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. saprophyticus",NA,"Gepotidacin (uncomplicated UTI only)",NA,"IP","IP",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Lefamulin",NA,"0.25","0.25",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Lefamulin","5 mcg","23","23",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","13","13",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Rifampicin",NA,"0.06","0.06",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Rifampicin","5 mcg","26","26",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Rifampicin",NA,"0.06","0.06",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Rifampicin","5 mcg","30","30",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"2","2",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","19","19",NA,"Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5","[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","24","24","[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin iv",NA,"4","4",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin iv","2 mcg","10","10","[A] For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam iv",NA,"Note","Note","[1] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam iv",NA,"Note","Note","[B] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin iv",NA,"4","4","[1] Susceptibility can be inferred from ampicillin.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin iv",NA,"Note","Note","[B] Susceptibility can be inferred from ampicillin.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"4","4","[1] Susceptibility can be inferred from ampicillin.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"Note","Note","[B] Susceptibility can be inferred from ampicillin.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis",NA,"Amoxicillin oral (other indications)",NA,"0.001","4","[3] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis",NA,"Amoxicillin oral (other indications)",NA,"Note","Note","[C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[1] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[B] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"Note","Note","[1] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"Note","Note","[B] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"Note","Note","[3] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"Note","Note","[C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis",NA,"Piperacillin",NA,"0.001","16",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis",NA,"Piperacillin","30 mcg","50","18",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis",NA,"Piperacillin-tazobactam",NA,"0.001","16","[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis",NA,"Piperacillin-tazobactam","30/6 mcg","50","18","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis",NA,"Imipenem",NA,"0.001","4",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis",NA,"Imipenem","10 mcg","50","21",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus faecalis There are no clinical breakpoints but acquired resistance (indicated by MIC >1 mg/L) should be excluded. The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note","[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus faecalis There are no clinical breakpoints but acquired resistance (indicated by MIC >1 mg/L) should be excluded. The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note",FALSE,"[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus and coagulase-negative staphylococci except S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","22","22",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)",NA,"Note","Note",FALSE,"[5] For staphylococci other than S. aureus, S. lugdunensis and S. saprophyticus, the cefoxitin MIC is a poorer predictor of methicillin resistance than the disk diffusion test.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. epidermidis and S. lugdunensis",NA,"Cefoxitin (screen only)","30 mcg","27","27",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [B] If coagulase-negative staphylococci are not identified to species level, use zone diameter breakpoints S≥25, R<25 mm, with an ATU of 22-24 mm. For isolates with results inside the ATU: identify species, perform PCR for mecA/mecC or report resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note",FALSE,"[6] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. pseudintermedius, S. intermedius, S. schleiferi and S. coagulans",NA,"Cefoxitin (screen only)",NA,"Note","Note",FALSE,"[C] In S. pseudintermedius,S. intermedius, S. schleiferi and S. coagulans the cefoxitin disk is less predictive for the detection of methicillin resistance than in other staphylococci. Use the oxacillin 1 µg disk with zone diameter breakpoints S≥20, R<20 mm.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)",NA,"1","2",FALSE,"[7] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (indications other than pneumonia)","5 mcg","20","17",FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Ceftaroline (pneumonia)",NA,"1","1",FALSE,"[7] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Ceftaroline (pneumonia)","5 mcg","20","20",FALSE,"[D] Methicillin-susceptible isolates can be reported susceptible to ceftaroline without further testing.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Ceftobiprole",NA,"2","2",FALSE,"[9] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Ceftobiprole","5 mcg","17","17",FALSE,"[F] Methicillin-susceptible isolates can be reported susceptible to ceftobiprole without further testing.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ceftriaxone",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F. | [2] See table of dosages.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to cephalosporins is inferred from the cefoxitin susceptibility except for cefixime, ceftazidime, ceftazidime-avibactam, ceftibuten, cefiderocol and ceftolozane-tazobactam, which do not have breakpoints and should not be used for staphylococcal infections. For agents given orally, care to achieve sufficient exposure at the site of the infection should be exercised. If cefazolin, cefepime, cefotaxime, ceftriaxone or cefuroxime iv are reported for methicillin-susceptible staphylococci, these should be reported “susceptible, increased exposure” (I) - see https://www.eucast.org/eucastguidancedocuments/. Many methicillin-resistant S. aureus are susceptible to ceftaroline and ceftobiprole, see Notes 7/D and 9/F.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doripenem",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ertapenem",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[1] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[A] Susceptibility of staphylococci to carbapenems is inferred from the cefoxitin susceptibility. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Ciprofloxacin",NA,"(0.001)","(2)",TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Ciprofloxacin","5 mcg","(50)","(17)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin",NA,"(0.001)","(2)",TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Ciprofloxacin","5 mcg","(50)","(22)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"0.016","0.016",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (community-acquired pneumonia)",NA,"Note","Note",FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"0.25","0.25",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Delafloxacin (skin and skin structure infections)",NA,"Note","Note",FALSE,"[C] A disk diffusion test awaits action from the responsible pharmaceutical company.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Levofloxacin",NA,"0.001","1",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Levofloxacin","5 mcg","50","22",FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin",NA,"0.001","1",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Levofloxacin","5 mcg","50","24",FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Moxifloxacin",NA,"0.25","0.25",FALSE,"[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Moxifloxacin","5 mcg","25","25",FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | [3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin",NA,"0.25","0.25",FALSE,"[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Moxifloxacin","5 mcg","28","28",FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note | [3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","17","17",FALSE,"[D] | [D] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and ""susceptible increased exposure"" (I) to levofloxacin. For ciprofloxacin, the isolate is without phenotypically detectable resistance mechanisms and can be used in high exposure in combination therapy (see Note 2/A). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note",FALSE,"[3] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Ofloxacin",NA,"Note","Note",FALSE,"[E] Ofloxacin breakpoints for Staphylococcus spp. have been removed since in systemic infections with staphylococci the agent is inferior to other fluoroquinolones. For topical use of ofloxacin, see tables of topical agents.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Amikacin",NA,"(16)","(16)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Amikacin","30 mcg","(15)","(15)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Amikacin",NA,"(16)","(16)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Amikacin","30 mcg","(15)","(15)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Gentamicin",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Gentamicin","10 mcg","(18)","(18)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Gentamicin",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Gentamicin","10 mcg","(22)","(22)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Tobramycin",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Tobramycin","10 mcg","(18)","(18)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Tobramycin",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Tobramycin","10 mcg","(20)","(20)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"0.25","0.25",FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Dalbavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Oritavancin",NA,"0.125","0.125",FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Oritavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Teicoplanin",NA,"2","2",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Teicoplanin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"4","4",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Teicoplanin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"MRSA",NA,"Telavancin",NA,"0.125","0.125",FALSE,"[3] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"MRSA",NA,"Telavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Vancomycin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"4","4",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Vancomycin",NA,"Note","Note",FALSE,"[A] Disk diffusion is unreliable and cannot distinguish between wild-type isolates and those with non-vanA-mediated glycopeptide resistance.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"2","2",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"1","1",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Erythromycin",NA,"1","1",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Erythromycin","15 mcg","21","21",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"1","1",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in staphylococci. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Clindamycin",NA,"0.25","0.25",FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Clindamycin","2 mcg","22","22",FALSE,"[B] Place the erythromycin and clindamycin disks 12-20 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"".","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin",NA,"1","1",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Quinupristin-dalfopristin","15 mcg","21","21",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Eravacycline",NA,"0.25","0.25",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Eravacycline","20 mcg","20","20",FALSE,"[B] For MRSA that test susceptible with disk diffusion, the results should be confirmed with an MIC test.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Minocycline",NA,"0.5","0.5",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Minocycline","30 mcg","23","23",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tetracycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tetracycline","30 mcg","22","22",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tigecycline",NA,"0.5","0.5",FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tigecycline","15 mcg","19","19",FALSE,"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Linezolid",NA,"4","4",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Linezolid","10 mcg","21","21",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Tedizolid",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Tedizolid","2 mcg","20","20",FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Chloramphenicol",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Daptomycin",NA,"1","1",FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Daptomycin",NA,"Note","Note",FALSE,"[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"other staphylococci",NA,"Daptomycin",NA,"Note","Note",FALSE,"[3] For other staphylococci, the ECOFF can be used to exclude acquired resistance mechanisms, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"other staphylococci",NA,"Daptomycin",NA,"Note","Note",FALSE,"[A] Use an MIC method.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[4] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[B] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Fusidic acid",NA,"1","1",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Fusidic acid","10 mcg","24","24",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. saprophyticus",NA,"Gepotidacin (uncomplicated UTI only)",NA,"0.25","0.25",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. saprophyticus",NA,"Gepotidacin (uncomplicated UTI only)",NA,"IP","IP",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Lefamulin",NA,"0.25","0.25",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Lefamulin","5 mcg","23","23",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. saprophyticus",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","13","13",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. saprophyticus",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. aureus",NA,"Rifampicin",NA,"0.06","0.06",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. aureus",NA,"Rifampicin","5 mcg","26","26",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Coagulase-negative staphylococci",NA,"Rifampicin",NA,"0.06","0.06",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Coagulase-negative staphylococci",NA,"Rifampicin","5 mcg","30","30",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"2","2",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","19","19",FALSE,NA,"Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5",FALSE,"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Staphylococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","24","24",FALSE,"[5] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Staphylococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin iv",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin iv","2 mcg","10","10",FALSE,"[A] For E. faecalis that test resistant to ampicillin with disk diffusion, confirm with an MIC test.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam iv",NA,"Note","Note",FALSE,"[1] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ampicillin-sulbactam iv",NA,"Note","Note",FALSE,"[B] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin iv",NA,"4","4",FALSE,"[1] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin iv",NA,"Note","Note",FALSE,"[B] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"4","4",FALSE,"[1] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin oral (uncomplicated UTI only)",NA,"Note","Note",FALSE,"[B] Susceptibility can be inferred from ampicillin.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis",NA,"Amoxicillin oral (other indications)",NA,"(0.001)","(4)",TRUE,"[3] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis",NA,"Amoxicillin oral (other indications)",NA,"Note","Note",FALSE,"[C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note",FALSE,"[1] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note",FALSE,"[B] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"Note","Note",FALSE,"[1] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amoxicillin-clavulanic acid oral (uncomplicated UTI only)",NA,"Note","Note",FALSE,"[B] Susceptibility can be inferred from ampicillin. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"Note","Note",FALSE,"[3] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis",NA,"Amoxicillin-clavulanic acid oral (other indications)",NA,"Note","Note",FALSE,"[C] Isolates susceptible to ampicillin are without phenotypically detectable resistance mechanisms and the specified agents can be used in high exposure in combination therapy (see Note 4/D). Isolates resistant to ampicillin can be reported resistant. | [D] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis",NA,"Piperacillin",NA,"0.001","16",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis",NA,"Piperacillin","30 mcg","50","18",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis",NA,"Piperacillin-tazobactam",NA,"0.001","16",FALSE,"[5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis",NA,"Piperacillin-tazobactam","30/6 mcg","50","18",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. Beta-lactamase producing enterococci are extremely rare.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis",NA,"Imipenem",NA,"0.001","4",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis",NA,"Imipenem","10 mcg","50","21",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","15","15",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Levofloxacin (uncomplicated UTI only)","5 mcg","15","15",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note",FALSE,"[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus faecalis There are no clinical breakpoints but acquired resistance (indicated by MIC >1 mg/L) should be excluded. The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Moxifloxacin",NA,"Note","Note",FALSE,"[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by Enterococcus faecalis There are no clinical breakpoints but acquired resistance (indicated by MIC >1 mg/L) should be excluded. The norfloxacin disk diffusion screen test can be used to exclude resistance mechanisms. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Norfloxacin (screen only)","10 mcg","12","12",FALSE,"[C] | [C] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the norfloxacin disk diffusion screening test. For moxifloxacin, see comment 1/B.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Amikacin",NA,"Note","Note",FALSE,"[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","30 mcg","Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)","30 mcg","Note","Note",FALSE,"[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Netilmicin",NA,"Note","Note",FALSE,"[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note","[3] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing. +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note",FALSE,"[3] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing. Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)","300 mcg","Note","Note","[B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing. +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Streptomycin (test for acquired aminoglycoside-modifying enzyme)","300 mcg","Note","Note",FALSE,"[B] Isolates screening positive with gentamicin for aminoglycoside-modifying enzymes may still exhibit synergy with streptomycin. This can be screened for with streptomycin testing. Negative test: Isolates with streptomycin MIC ≤512 mg/L or a zone diameter ≥14 mm. The isolate is wild type for streptomycin and synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with streptomycin MIC >512 mg/L or a zone diameter <14 mm. Combinations between penicillins or glycopeptides and streptomycin will not be synergistic.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note","[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tobramycin",NA,"Note","Note",FALSE,"[A] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L or a zone diameter ≥8 mm. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. For other aminoglycosides, this may not be the case. Positive test: Isolates with gentamicin MIC >128 mg/L or a zone diameter <8 mm denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic, except streptomycin which must be tested separately if required (see note 3/B).","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis and E. faecium",NA,"Vancomycin",NA,"4","4",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis and E. faecium",NA,"Vancomycin","5 mcg","12","12","[A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"other enterococci",NA,"Vancomycin",NA,"4","4",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"other enterococci",NA,"Vancomycin","5 mcg","15","15",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","1",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","22",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline",NA,"0.25","0.25",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline","20 mcg","22","22",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline",NA,"0.5","0.5","[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline","15 mcg","20","20","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","20","20",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE","[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[2] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note","[A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis",NA,"Gepotidacin (uncomplicated UTI only)",NA,"8","8",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis",NA,"Gepotidacin (uncomplicated UTI only)",NA,"IP","IP",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[3] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note","[B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",NA,"Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[4] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note","[C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note","[4] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole. | [5] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note","[C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole. | [5] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Benzylpenicillin",NA,"0.03","0.03",NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Benzylpenicillin","1 unit","23","23",NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin","1 unit","18","18",NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Teicoplanin",NA,"2","2",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Teicoplanin","30 mcg","16","16",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis and E. faecium",NA,"Vancomycin",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis and E. faecium",NA,"Vancomycin","5 mcg","12","12",FALSE,"[A] Vancomycin susceptible E. faecalis and E. faecium exhibit sharp zone edges and do not exhibit colonies in the inhibition zone. Examine zone edges with transmitted light (plate held up to light). If the zone edge is fuzzy, colonies grow within the zone or if you are uncertain, then perform confirmatory testing with PCR or report resistant (see pictures below) even if the zone diameter is ≥ 12 mm. Isolates must not be reported susceptible before 24 h incubation.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"other enterococci",NA,"Vancomycin",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"other enterococci",NA,"Vancomycin","5 mcg","15","15",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecium",NA,"Quinupristin-dalfopristin",NA,"1","1",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecium",NA,"Quinupristin-dalfopristin","15 mcg","22","22",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Eravacycline",NA,"0.25","0.25",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Eravacycline","20 mcg","22","22",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tigecycline",NA,"0.5","0.5",FALSE,"[2] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tigecycline","15 mcg","20","20",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Linezolid",NA,"4","4",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Linezolid","10 mcg","20","20",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE",FALSE,"[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Daptomycin",NA,"IE","IE",FALSE,"[1] For more information, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[2] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Fosfomycin iv",NA,"Note","Note",FALSE,"[A] Antimicrobial susceptibility testing is discouraged. For information on the use of fosfomycin iv in combination therapy, see https://www.eucast.org/eucastguidancedocuments/.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis",NA,"Gepotidacin (uncomplicated UTI only)",NA,"8","8",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis",NA,"Gepotidacin (uncomplicated UTI only)",NA,"IP","IP",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note",FALSE,"[3] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Lefamulin",NA,"Note","Note",FALSE,"[B] Lefamulin has insufficient activity against E. faecalis. For E. faecium, the ECOFF of 0.5 mg/L can be used to distinguish wild type from non-wild type isolates.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"E. faecalis",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Nitroxoline (uncomplicated UTI only)",NA,"IE","IE",FALSE,NA,"Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note",FALSE,"[4] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim (uncomplicated UTI only)","5 mcg","Note","Note",FALSE,"[C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"Note","Note",FALSE,"[4] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole. | [5] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Enterococcus spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","Note","Note",FALSE,"[C] The activity of trimethoprim and trimethoprim-sulfamethoxazole is uncertain against enterococci, and it is not possible to predict clinical outcome. Isolates with MICs >1 mg/L most likely have resistance mechanisms against trimethoprim and trimethoprim-sulfamethoxazole. For E. faecalis and E. faecium this corresponds to a zone diameter <21 mm for trimethoprim and <23 mm for trimethoprim-sulfamethoxazole. | [5] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Enterococcus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Benzylpenicillin",NA,"0.03","0.03",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Benzylpenicillin","1 unit","23","23",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin",NA,"0.125","0.125",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Benzylpenicillin","1 unit","18","18",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Oxacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Cloxacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Dicloxacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, C and G",NA,"Flucloxacillin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to penicillins is inferred from the benzylpenicillin susceptibility with the exception of phenoxymethylpenicillin and isoxazolylpenicillins for streptococcus group B, where there is insufficient evidence for clinical efficacy. 2.Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note","[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"0.001","2",NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","50","17","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19","[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12","[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","21","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","23","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125","[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19","[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","19","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5","[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","2 mcg","18","18","[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1","[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note","[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.25","0.25",NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","21",NA,"Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[3] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note","[B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","16","16","[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than endocarditis and meningitis)",NA,"0.06","1",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than endocarditis and meningitis)","1 unit","Note","Note","[A] Read and interpret the benzylpenicillin disk only for isolates with oxacillin 1 µg zone diameters <20 mm. If benzylpenicillin zone ≥14 mm, report benzylpenicillin “susceptible, increased exposure” (I), If zone <14 mm, report benzylpenicillin resistant (R), see flow chart below. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (endocarditis and meningitis)",NA,"0.06","0.06",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (endocarditis and meningitis)",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (indications other than endocarditis and meningitis)",NA,"0.5","1",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (indications other than endocarditis and meningitis)","2 mcg","22","19",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (endocarditis and meningitis)",NA,"0.06","0.06",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (endocarditis and meningitis)",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (endocarditis and meningitis)",NA,"0.06","0.06",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (endocarditis and meningitis)",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note","[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","1 mcg","20","20","[D] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oxacillin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cloxacillin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cloxacillin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dicloxacillin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dicloxacillin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Flucloxacillin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Flucloxacillin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.001","0.5",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefadroxil",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefadroxil",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefalexin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefalexin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefazolin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefazolin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than endocarditis and meningitis)",NA,"0.5","2",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than endocarditis and meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (endocarditis and meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (endocarditis and meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than endocarditis and meningitis)",NA,"0.5","2",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than endocarditis and meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (endocarditis and meningitis)",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (endocarditis and meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.25",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"1","1",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"Note","Note","[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"0.001","2",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","50","16","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10","[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","22","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5","[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19","[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","24","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","2",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","22",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note","[1] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note","[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin",NA,"0.5","0.5",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","5 mcg","12","12",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.125","0.125",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","22",NA,"S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","15","15","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)",NA,"0.25","0.25","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","1 unit","21","21","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (indications other than endocarditis)",NA,"0.25","1",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (indications other than endocarditis)","1 unit","21","12",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis)",NA,"0.25","0.25",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis)","1 unit","21","21",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis, in combination with other antimicrobial treatment)",NA,"1","1","[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis, in combination with other antimicrobial treatment)","1 unit","12","12","[B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin (indications other than endocarditis)",NA,"0.5","2",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin (indications other than endocarditis)","2 mcg","21","15",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin iv (endocarditis)",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin iv (endocarditis)","2 mcg","21","21",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin (indications other than endocarditis)",NA,"0.5","2",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin (indications other than endocarditis)",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin iv (endocarditis)",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin iv (endocarditis)",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [D] Susceptibility can be inferred from the benzylpenicillin screen test or from ""Ampicillin iv (endocarditis)"".","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE","[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Oxacillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Oxacillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cloxacillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cloxacillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Dicloxacillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Dicloxacillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Flucloxacillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Flucloxacillin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem",NA,"1","1",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note","[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. anginosus group",NA,"Delafloxacin",NA,"0.03","0.03",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. anginosus group",NA,"Delafloxacin",NA,"Note","Note","[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note","[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefaclor",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefadroxil",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefalexin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefazolin",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime-enmetazobactam",NA,"Note","Note",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefepime-enmetazobactam",NA,"Note","Note",FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftibuten",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ceftriaxone",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to cephalosporins is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doripenem",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Ertapenem",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note",FALSE,"[1] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem",NA,"Note","Note",FALSE,"[A] The susceptibility of streptococcus groups A, B, C and G to carbapenems is inferred from the benzylpenicillin susceptibility.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"0.03","0.03",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Delafloxacin",NA,"Note","Note",FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"0.001","2",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","50","17",FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin",NA,"0.5","0.5",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Moxifloxacin","5 mcg","19","19",FALSE,"[B] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12",FALSE,"[C] | [C] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"0.125","0.125",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Dalbavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"0.25","0.25",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Oritavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Teicoplanin","30 mcg","15","15",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Vancomycin","5 mcg","13","13",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Erythromycin","15 mcg","21","21",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"0.5","0.5",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus groups A, B, C and","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Clindamycin","2 mcg","17","17",FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant and consider adding this comment to the report: ""Clindamycin may still be used for short-term therapy of less serious skin and soft tissue infections as constitutive resistance is unlikely to develop during such therapy"". The clinical importance of inducible clindamycin resistance in combination treatment of severe S. pyogenes infections is not known.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline",NA,"0.5","0.5",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Minocycline","30 mcg","23","23",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tetracycline","30 mcg","23","23",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline",NA,"0.125","0.125",FALSE,"[3] For tigecycline broth microdilution MIC determination, the medium must be prepared fresh on the day of use. | [2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tigecycline","15 mcg","19","19",FALSE,"[2] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Linezolid","10 mcg","19","19",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid",NA,"0.5","0.5",FALSE,"[2] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Tedizolid","2 mcg","18","18",FALSE,"[A] Isolates susceptible to linezolid can be reported susceptible to tedizolid. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"1","1",FALSE,"[2] Daptomycin MICs must be determined in the presence of Ca (50 mg/L in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Daptomycin",NA,"Note","Note",FALSE,"[A] Use an MIC method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"64","64",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","15","15",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin",NA,"0.25","0.25",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Rifampicin","5 mcg","21","21",FALSE,NA,"Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note",FALSE,"[3] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. agalactiae (group B streptococci)",NA,"Trimethoprim (uncomplicated UTI only)",NA,"Note","Note",FALSE,"[B] The activity of trimethoprim is uncertain against S. agalactiae and it is not possible to predict clinical outcome. The ECOFF to categorise isolates as wild type or non-wild type is 2 mg/L.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5",FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus groups A, B, C and G",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","16","16",FALSE,"[4] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Streptococcus A,B,C,G" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than endocarditis and meningitis)",NA,"0.06","1",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (indications other than endocarditis and meningitis)","1 unit","Note","Note",FALSE,"[A] Read and interpret the benzylpenicillin disk only for isolates with oxacillin 1 µg zone diameters <20 mm. If benzylpenicillin zone ≥14 mm, report benzylpenicillin “susceptible, increased exposure” (I), If zone <14 mm, report benzylpenicillin resistant (R), see flow chart below. | [B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (endocarditis and meningitis)",NA,"0.06","0.06",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Benzylpenicillin (endocarditis and meningitis)",NA,"Note","Note",FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (indications other than endocarditis and meningitis)",NA,"0.5","1",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (indications other than endocarditis and meningitis)","2 mcg","22","19",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (endocarditis and meningitis)",NA,"0.06","0.06",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin iv (endocarditis and meningitis)",NA,"Note","Note",FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (indications other than endocarditis and meningitis)",NA,"Note","Note",FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (endocarditis and meningitis)",NA,"0.06","0.06",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin iv (endocarditis and meningitis)",NA,"Note","Note",FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"0.5","1",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin oral",NA,"Note","Note",FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid iv",NA,"Note","Note",FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.5","1",FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Amoxicillin-clavulanic acid oral",NA,"Note","Note",FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin",NA,"Note","Note",FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis).","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [3] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below. | [C] Susceptibility inferred from ampicillin (indications other than endocarditis and meningitis). | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Phenoxymethylpenicillin",NA,"Note","Note",FALSE,"[B] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin (screen only)","1 mcg","20","20",FALSE,"[D] For interpretation of the oxacillin disk screen, see flow chart below. | [1] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oxacillin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oxacillin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cloxacillin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cloxacillin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dicloxacillin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dicloxacillin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Flucloxacillin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Flucloxacillin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefaclor",NA,"0.001","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefaclor","30 mcg","50","28",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefadroxil",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefadroxil",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefalexin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefalexin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefazolin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefazolin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"1","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefepime-enmetazobactam",NA,"Note","Note",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefepime-enmetazobactam",NA,"Note","Note",FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than endocarditis and meningitis)",NA,"0.5","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (indications other than endocarditis and meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (endocarditis and meningitis)",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefotaxime (endocarditis and meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"0.25","0.25",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefpodoxime",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"0.25","0.25",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftobiprole",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than endocarditis and meningitis)",NA,"0.5","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (indications other than endocarditis and meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (endocarditis and meningitis)",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ceftriaxone (endocarditis and meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"0.5","1",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime iv",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"0.25","0.25",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Cefuroxime oral",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"1","1",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doripenem",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Ertapenem",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"2","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (indications other than meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem (meningitis)",NA,"Note","Note",FALSE,"[A] The oxacillin 1 µg disk diffusion screening test or a benzylpenicillin MIC test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (oxacillin zone diameter ≥20 mm, or benzylpenicillin MIC ≤0.06 mg/L) all beta-lactam agents for which clinical breakpoints are available, including those with “Note” can be reported susceptible without further testing, except for cefaclor, which if reported, should be reported as “susceptible, increased exposure” (I). When the screen is positive (oxacillin zone diameter <20 mm, or benzylpenicillin MIC >0.06 mg/L), see flow chart below.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[3/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Levofloxacin",NA,"0.001","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Levofloxacin","5 mcg","50","16",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Moxifloxacin","5 mcg","22","22",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10",FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to moxifloxacin and as ""susceptible increased exposure"" (I) to levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Dalbavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Oritavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Teicoplanin",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Teicoplanin","30 mcg","17","17",FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Vancomycin",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Vancomycin","5 mcg","16","16",FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Erythromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Erythromycin","15 mcg","22","22",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"0.5","0.5",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Streptococcus pneumoniae. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Clindamycin","2 mcg","19","19",FALSE,"[B] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [2] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Minocycline",NA,"0.5","0.5",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Minocycline","30 mcg","24","24",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tetracycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tetracycline","30 mcg","25","25",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Linezolid",NA,"2","2",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Linezolid","10 mcg","22","22",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Tedizolid",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note",FALSE,"[1] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Chloramphenicol",NA,"Note","Note",FALSE,"[1/A] Efficacy for this species is uncertain. ECOFFs can be used to distinguish wild-type isolates from isolates with acquired resistance (presence of resistance indicated by MIC >8 mg/L; zone diameter <21 mm for the chloramphenicol 30 µg disk). For chloramphenicol treatment in meningitis, see table of dosages.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Daptomycin",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Lefamulin",NA,"0.5","0.5",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Lefamulin","5 mcg","12","12",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Rifampicin",NA,"0.125","0.125",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Rifampicin","5 mcg","22","22",FALSE,NA,"S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole",NA,"1","1",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Streptococcus pneumoniae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","15","15",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","S.pneumoniae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)",NA,"0.25","0.25",FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (screen only)","1 unit","21","21",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (indications other than endocarditis)",NA,"0.25","1",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (indications other than endocarditis)","1 unit","21","12",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis)",NA,"0.25","0.25",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis)","1 unit","21","21",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis, in combination with other antimicrobial treatment)",NA,"(1)","(1)",TRUE,"[2] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Benzylpenicillin (endocarditis, in combination with other antimicrobial treatment)","1 unit","(12)","(12)",TRUE,"[B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin (indications other than endocarditis)",NA,"0.5","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin (indications other than endocarditis)","2 mcg","21","15",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin iv (endocarditis)",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin iv (endocarditis)","2 mcg","21","21",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin (indications other than endocarditis)",NA,"0.5","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin (indications other than endocarditis)",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin iv (endocarditis)",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin iv (endocarditis)",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [D] Susceptibility can be inferred from the benzylpenicillin screen test or from ""Ampicillin iv (endocarditis)"".","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note",FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [4] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. Isolates categorised as screen negative can be reported susceptible to beta-lactam agents for which clinical breakpoints are listed (including those with “Note”). Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant. | [C] For benzylpenicillin screen negative isolates, susceptibility can be inferred from benzylpenicillin or ampicillin. For benzylpenicillin screen positive isolates, susceptibility is inferred from ampicillin. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,"[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,"[3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Oxacillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Oxacillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cloxacillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cloxacillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Dicloxacillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Dicloxacillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Flucloxacillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Flucloxacillin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefazolin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime","30 mcg","25","25",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefepime-enmetazobactam",NA,"Note","Note",FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefepime-enmetazobactam",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins. | [1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefotaxime",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefotaxime","5 mcg","23","23",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. anginosus group",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ceftriaxone",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ceftriaxone","30 mcg","27","27",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Cefuroxime iv",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Cefuroxime iv","30 mcg","26","26",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Doripenem",NA,"1","1",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Doripenem",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Ertapenem",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem",NA,"2","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"2","2",FALSE,"[1] For susceptibility testing purposes, the concentration of relebactam is fixed at 4 mg/L. | [2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit. | [A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem",NA,"2","2",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem",NA,"Note","Note",FALSE,"[A] Benzylpenicillin (MIC or disk diffusion) can be used to screen for beta-lactam resistance in viridans group streptococci. See Note 1/A on penicillins.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2/B] The addition of a beta-lactamase inhibitor does not add clinical benefit.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. anginosus group",NA,"Delafloxacin",NA,"0.03","0.03",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. anginosus group",NA,"Delafloxacin",NA,"Note","Note",FALSE,"[A] A disk diffusion test awaits action from the responsible pharmaceutical company.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note",FALSE,"[1] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Moxifloxacin",NA,"Note","Note",FALSE,"[B] Moxifloxacin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.5 mg/L; zone diameter <21 mm for the moxifloxacin 5 µg disk) should be excluded. When acquired resistance has been excluded, the isolate should be reported “devoid of fluoroquinolone resistance mechanisms”, but not as susceptible to moxifloxacin.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Amikacin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Gentamicin (test for acquired aminoglycoside-modifying enzyme)",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Netilmicin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note","[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tobramycin",NA,"Note","Note",FALSE,"[2] Gentamicin can be used to screen for the presence of aminoglycoside-modifying enzymes (high-level aminoglycoside resistance). Negative test: Isolates with gentamicin MIC ≤128 mg/L. The isolate is wild type for gentamicin (i.e. does not contain aminoglycoside-modifying enzymes). Therefore, synergy with penicillins or glycopeptides can be expected if the isolate is susceptible to the penicillin or glycopeptide. Positive test: Isolates with gentamicin MIC >128 mg/L denote presence of aminoglycoside-modifying enzymes. Combinations between penicillins or glycopeptides and aminoglycosides will not be synergistic.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25","[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note","[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15","[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19","[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","20 mcg","17","17",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE","[1] Linezolid has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >2 mg/L) should be excluded. When excluded, the isolate should be reported “devoid of linezolid resistance mechanisms”, but not as susceptible to linezolid.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.5","0.5",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid","2 mcg","18","18",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Daptomycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Daptomycin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",NA,"Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[1] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note","[A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","1 unit","12","12","[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)",NA,"1","1","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","2 mcg","18","18","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin iv (meningitis)",NA,"Note","Note","[3] In meningitis, H. influenzae negative in the benzylpenicillin 1 unit screen (zone diameter ≥12 mm) can be reported susceptible. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin iv (meningitis)",NA,"Note","Note","[C] In meningitis, H. influenzae negative in the benzylpenicillin 1 unit screen (zone diameter ≥12 mm) can be reported susceptible. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1","[4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [5] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"2","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"Note","Note","[3] In meningitis, H. influenzae negative in the benzylpenicillin 1 unit screen (zone diameter ≥12 mm) can be reported susceptible. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"Note","Note","[C] In meningitis, H. influenzae negative in the benzylpenicillin 1 unit screen (zone diameter ≥12 mm) can be reported susceptible. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"0.001","2","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral. Isolates resistant to ampicillin can be reported resistant to amoxicillin oral. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2","[6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.001","2","[6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","50","15","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE","[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25","[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[2/D] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","5 mcg","27","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)",NA,"0.5","0.5","[3] See table of dosages for dosing for different indications.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","30/10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [3] See table of dosages for dosing for different indications.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","30 mcg","32","32","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.001","1",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem",NA,"1","1",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note","[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"Note","Note","[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note","[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin",NA,"0.03","0.03",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","5 mcg","32","32","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note","[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","24","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28","[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",NA,"H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1","[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note","[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime-enmetazobactam",NA,"Note","Note","[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","0.5",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","21",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.001","4",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem",NA,"1","1","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","10 mcg","30","30","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note","[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.25","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.25",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","23","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","0.5","[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note","[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","1","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","25","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"2","2","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","26","26","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[1] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note","[A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",NA,"M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"1","1","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","15","15","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)",NA,"0.06","1","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note","[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",NA,"N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",NA,"N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",NA,"N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",NA,"N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note","[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","0.5",NA,"N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin",NA,"IE","IE",NA,"N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",NA,"N.gonorrhoeae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)",NA,"0.25","0.25",NA,"N.meningitidis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)",NA,"0.125","1",NA,"N.meningitidis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)",NA,"0.125","0.125","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)",NA,"0.125","0.125","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)",NA,"0.25","0.25","[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"Note","Note","[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Aztreonam",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Aztreonam-avibactam",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (all indications, including meningitis and prophylaxis)",NA,"0.016","0.016",NA,"N.meningitidis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)",NA,"1","1","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)",NA,"2","2","[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",NA,"N.meningitidis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)",NA,"2","2","[1] For chloramphenicol treatment in meningitis, see table of dosages.","N.meningitidis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)",NA,"0.25","0.25",NA,"N.meningitidis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam",NA,"2","2","[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","10/10 mcg","25","25",NA,"Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid",NA,"2","2","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","14","14",NA,"Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam",NA,"2","2","[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","30/6 mcg","24","24","[3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Ertapenem",NA,"2","2","[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Ertapenem","10 mcg","23","23","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Imipenem",NA,"1","1",NA,"Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Imipenem","10 mcg","29","29",NA,"Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem",NA,"1","1",NA,"Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","10 mcg","28","28",NA,"Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin",NA,"4","4","[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","2 mcg","10","10","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole",NA,"4","4","[6] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","5 mcg","25","25","[C] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","1 unit","20","20","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin","2 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ertapenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ertapenem","10 mcg","29","29","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Imipenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","10 mcg","34","34","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","2 mcg","31","31","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole",NA,"4","4","[3] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","5 mcg","22","22","[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Benzylpenicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Benzylpenicillin","1 unit","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ampicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ampicillin","2 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ampicillin-sulbactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ampicillin-sulbactam","10/10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Amoxicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"F. necrophorum",NA,"Amoxicillin-clavulanic acid",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"F. necrophorum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"F. nucleatum",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [4] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"F. nucleatum",NA,"Amoxicillin-clavulanic acid",NA,"23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"F. necrophorum",NA,"Piperacillin-tazobactam",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"F. necrophorum",NA,"Piperacillin-tazobactam","30/6 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"F. nucleatum",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent. | [5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"F. nucleatum",NA,"Piperacillin-tazobactam",NA,"35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ertapenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ertapenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Imipenem","10 mcg","36","36","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Meropenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Meropenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Clindamycin","2 mcg","30","30","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Metronidazole",NA,"1","1","[6] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Metronidazole","5 mcg","30","30","[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","1 unit","15","15","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin","2 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","10/10 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","30/6 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ertapenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ertapenem","10 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Imipenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Imipenem","10 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","10 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","5 mcg","12","12",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","2 mcg","19","19","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole",NA,"4","4","[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","5 mcg","16","16","[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Ampicillin",NA,"1","1",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Ampicillin","2 mcg","21","21",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Ampicillin-sulbactam",NA,"1","1","[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Ampicillin-sulbactam","10/10 mcg","28","28",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Amoxicillin",NA,"2","2",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Amoxicillin",NA,"Note","Note","[A] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Amoxicillin-clavulanic acid",NA,"2","2","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Piperacillin-tazobactam",NA,"4","4","[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Piperacillin-tazobactam","30/6 mcg","24","24",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Meropenem",NA,"IE","IE",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Meropenem",NA,"IE","IE",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Clindamycin",NA,"2","2","[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Clindamycin","2 mcg","17","17","[B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Metronidazole",NA,"4","4","[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Metronidazole","5 mcg","19","19","[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Benzylpenicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Benzylpenicillin","1 unit","21","21","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Ampicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Ampicillin","2 mcg","20","20","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Ampicillin-sulbactam",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Ampicillin-sulbactam","10/10 mcg","26","26","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Amoxicillin-clavulanic acid",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","21","21","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Piperacillin-tazobactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Piperacillin-tazobactam","30/6 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Ertapenem",NA,"IE","IE",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Ertapenem",NA,"IE","IE",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Imipenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Imipenem","10 mcg","26","26","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Meropenem",NA,"2","2","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Meropenem","10 mcg","22","22","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Metronidazole",NA,"4","4","[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Metronidazole","5 mcg","21","21","[C] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Benzylpenicillin",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Benzylpenicillin","1 unit","21","21","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Ampicillin",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Ampicillin","2 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Ampicillin-sulbactam",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Ampicillin-sulbactam","10/10 mcg","29","29","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Amoxicillin",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Piperacillin-tazobactam",NA,"2","2","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Piperacillin-tazobactam","30/6 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Ertapenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Ertapenem","10 mcg","26","26","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Imipenem","10 mcg","31","31","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Meropenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Meropenem","10 mcg","29","29","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Vancomycin",NA,"4","4",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Vancomycin","5 mcg","14","14",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Clindamycin",NA,"0.5","0.5",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Clindamycin","2 mcg","24","24","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Metronidazole",NA,"4","4","[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Metronidazole","5 mcg","21","21","[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Ampicillin",NA,"4","4",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Ampicillin","2 mcg","12","12",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Ampicillin-sulbactam",NA,"4","4","[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Ampicillin-sulbactam","10/10 mcg","22","22",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Amoxicillin",NA,"2","2",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Amoxicillin",NA,"Note","Note","[A] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Amoxicillin-clavulanic acid",NA,"2","2","[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Ertapenem",NA,"IE","IE",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Ertapenem",NA,"IE","IE",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Imipenem",NA,"1","1",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Imipenem","10 mcg","28","28",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Meropenem",NA,"1","1",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Meropenem","10 mcg","24","24",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Vancomycin",NA,"4","4",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Vancomycin","5 mcg","13","13",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Metronidazole",NA,"4","4","[3] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Metronidazole","5 mcg","20","20","[B] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","1 unit","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin","2 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","10/10 mcg","33A","33",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","30/6 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Cefotaxime",NA,"Note","Note","[3] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Cefotaxime","5 mcg","26","26","[C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ceftriaxone",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [3] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ceftriaxone","30 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ertapenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ertapenem","10 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Imipenem",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Imipenem","10 mcg","39","39","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","10 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","5 mcg","22","22",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin",NA,"0.25","0.25",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","2 mcg","26","26","[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Linezolid",NA,"2","2",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Linezolid","10 mcg","34","34",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Benzylpenicillin","1 unit","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Ampicillin",NA,"1","1","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Ampicillin","2 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Ampicillin-sulbactam",NA,"1","1","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Ampicillin-sulbactam","10/10 mcg","32","32","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Amoxicillin",NA,"2","2","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Amoxicillin-clavulanic acid",NA,"2","2","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Piperacillin-tazobactam",NA,"4","4","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Piperacillin-tazobactam","30/6 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Cefotaxime",NA,"Note","Note","[5] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Cefotaxime","5 mcg","24","24","[C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Ceftriaxone",NA,"1","1","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [5] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Ceftriaxone","30 mcg","30","30","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Ertapenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Ertapenem","10 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Imipenem","10 mcg","39","39","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Meropenem",NA,"1","1","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Meropenem","10 mcg","29","29","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Vancomycin","5 mcg","19","19",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Clindamycin",NA,"0.125","0.125",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Clindamycin","2 mcg","33","33","[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Linezolid",NA,"2","2",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Linezolid","10 mcg","28","28",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Benzylpenicillin","1 unit","20","20","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Ampicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Ampicillin","2 mcg","21","21","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Ampicillin-sulbactam",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Ampicillin-sulbactam","10/10 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Amoxicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Amoxicillin-clavulanic acid",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L..","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","21","21","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Piperacillin-tazobactam",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Piperacillin-tazobactam","30/6 mcg","30","30","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Ertapenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Ertapenem","10 mcg","29","29","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Imipenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Imipenem","10 mcg","34","34","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Meropenem",NA,"0.25","0.25","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Meropenem","10 mcg","31","31","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Vancomycin",NA,"1","1",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Vancomycin","5 mcg","20","20",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Clindamycin",NA,"0.5","0.5","[5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Clindamycin","2 mcg","23","23","[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Metronidazole",NA,"2","2","[6] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Metronidazole","5 mcg","25","25","[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Benzylpenicillin",NA,"0.03","0.03","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Benzylpenicillin","1 unit","31","31","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Ampicillin",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Ampicillin","2 mcg","29","29","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Ampicillin-sulbactam","10/10 mcg","36","36","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Amoxicillin",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Amoxicillin-clavulanic acid","2/1 mcg","28","28","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Piperacillin-tazobactam","30/6 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Ertapenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Ertapenem","10 mcg","33","33","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Imipenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Imipenem","10 mcg","40","40","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Meropenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Meropenem","10 mcg","36","36","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Vancomycin","5 mcg","19","19",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Clindamycin",NA,"1","1","[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Clindamycin","2 mcg","18","18","[C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Metronidazole",NA,"1","1","[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Metronidazole","5 mcg","28","28","[E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Benzylpenicillin","1 unit","20","20","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Ampicillin",NA,"1","1","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Ampicillin","2 mcg","25","25","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Ampicillin-sulbactam",NA,"1","1","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Ampicillin-sulbactam","10/10 mcg","31","31","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Amoxicillin",NA,"1","1","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L..","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Amoxicillin-clavulanic acid","2/1 mcg","22","22","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Piperacillin-tazobactam",NA,"1","1","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Piperacillin-tazobactam","30/6 mcg","32","32","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Ertapenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Ertapenem","10 mcg","27","27","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Imipenem",NA,"0.125","0.125","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Imipenem","10 mcg","36","36","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Meropenem",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Meropenem","10 mcg","30","30","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Vancomycin",NA,"2","2",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Vancomycin","5 mcg","15","15",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Clindamycin",NA,"1","1","[6] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Clindamycin","2 mcg","17","17","[C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Metronidazole",NA,"2","2","[7] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Metronidazole","5 mcg","22","22","[E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Benzylpenicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Benzylpenicillin","1 unit","18","18","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Ampicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Ampicillin","2 mcg","21","21","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Ampicillin-sulbactam","10/10 mcg","29","29","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Amoxicillin",NA,"0.5","0.5","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Piperacillin-tazobactam","30/6 mcg","36","36","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Ertapenem",NA,"0.03","0.03","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Ertapenem","10 mcg","32","32","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Imipenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Imipenem","10 mcg","37","37","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Meropenem",NA,"0.06","0.06","[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Meropenem","10 mcg","35","35","[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Vancomycin",NA,"0.5","0.5",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Vancomycin","5 mcg","21","21",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Clindamycin",NA,"2","2","[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Clindamycin","2 mcg","15","15","[C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Metronidazole",NA,"4","4","[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Metronidazole","5 mcg","19","19","[E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"IP","IP",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"0.5","0.5","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IP","IP",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2","[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes. | [2] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"IP","IP",NA,"Anaerobic bacteria_G-positive" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral",NA,"0.125","0.125",NA,"H.pylori" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1",NA,"H.pylori" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.25",NA,"H.pylori" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1",NA,"H.pylori" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8",NA,"H.pylori" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1",NA,"H.pylori" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","13","13",NA,"L.monocytogenes" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)",NA,"1","1",NA,"L.monocytogenes" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","2 mcg","16","16",NA,"L.monocytogenes" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)",NA,"0.25","0.25",NA,"L.monocytogenes" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","10 mcg","26","26",NA,"L.monocytogenes" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",NA,"L.monocytogenes" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)",NA,"1","1",NA,"L.monocytogenes" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","15 mcg","25","25",NA,"L.monocytogenes" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)",NA,"0.06","0.06","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","1.25/23.75 mcg","29","29","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5",NA,"Pasteurella" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Benzylpenicillin","1 unit","17","17",NA,"Pasteurella" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"1","1",NA,"Pasteurella" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"1","1",NA,"Pasteurella" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid",NA,"1","1","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",NA,"Pasteurella" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Cefotaxime",NA,"0.03","0.03",NA,"Pasteurella" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Cefotaxime","5 mcg","26","26",NA,"Pasteurella" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Pasteurella" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Ciprofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Pasteurella" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Levofloxacin","5 mcg","27","27","[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Pasteurella" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"1","1",NA,"Pasteurella" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Tetracycline (screen only)","30 mcg","24","24","[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"C.jejuni_C.coli" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","5 mcg","50","26",NA,"C.jejuni_C.coli" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8","[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","18","18","[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note","[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline",NA,"2","2","[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","30 mcg","30","30","[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.001","1",NA,"Corynebacterium" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","50","12",NA,"Corynebacterium" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","1",NA,"Corynebacterium" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","25",NA,"Corynebacterium" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin",NA,"0.5","0.5",NA,"Corynebacterium" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","5 mcg","25","25",NA,"Corynebacterium" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",NA,"Corynebacterium" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin",NA,"2","2",NA,"Corynebacterium" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","5 mcg","17","17","[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin",NA,"0.5","0.5","[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","2 mcg","20","20","[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"2","2",NA,"Corynebacterium" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",NA,"Corynebacterium" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",NA,"Corynebacterium" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",NA,"Corynebacterium" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",NA,"Corynebacterium" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","30","30",NA,"Corynebacterium" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.001","1",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","50","12",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"1","1","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"Note","Note","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime",NA,"0.001","2","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","5 mcg","50","15","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem",NA,"0.25","0.25","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","10 mcg","24","24","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","24",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin",NA,"0.06","0.06",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","15 mcg","24","24",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"C. diphtheriae",NA,"Clindamycin",NA,"0.5","0.5","[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"C. diphtheriae",NA,"Clindamycin","2 mcg","15","15","[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"0.5","0.5","[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"1","1",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","24","24",NA,"C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23","[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","1 unit","21","21",NA,"A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","2 mcg","26","26",NA,"A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note","[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note","[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem",NA,"0.25","0.25",NA,"A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","10 mcg","31","31",NA,"A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",NA,"A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21","[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2","[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"Note","Note","[B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Norfloxacin (screen only)","10 mcg","17","17","[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin",NA,"1","1",NA,"A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","5 mcg","16","16","[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",NA,"A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",NA,"A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin",NA,"0.125","0.125",NA,"A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","5 mcg","25","25",NA,"A.sanguinicola_A.urinae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",NA,"K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",NA,"K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note","[A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125","[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note","[A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note","[3] The in vitro antimicrobial activity of the fixed concentration of 2 mg/L for clavulanic acid is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","2/1 mcg","22","22",NA,"K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",NA,"K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",NA,"K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",NA,"K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",NA,"K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",NA,"K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",NA,"K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",NA,"K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",NA,"K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",NA,"K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",NA,"K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5","[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note","[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",NA,"K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5","[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note","[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",NA,"K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",NA,"K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",NA,"K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",NA,"Aeromonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",NA,"Aeromonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",NA,"Aeromonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",NA,"Aeromonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",NA,"Aeromonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",NA,"Aeromonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",NA,"Aeromonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",NA,"Aeromonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",NA,"Aeromonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",NA,"Aeromonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"1","1","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","16","16","[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam",NA,"4","4","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"A.xylosoxidans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Cefiderocol",NA,"Note","Note","[2] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥26 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","A.xylosoxidans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Cefiderocol","30 mcg","Note","Note","[A] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥26 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","A.xylosoxidans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem",NA,"1","4",NA,"A.xylosoxidans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","10 mcg","26","20",NA,"A.xylosoxidans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","26","26","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam",NA,"1","1","[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",NA,"Vibrio" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime",NA,"0.25","0.25",NA,"Vibrio" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","5 mcg","21","21",NA,"Vibrio" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",NA,"Vibrio" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",NA,"Vibrio" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime",NA,"1","1",NA,"Vibrio" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","10 mcg","22","22",NA,"Vibrio" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem",NA,"0.5","0.5",NA,"Vibrio" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","10 mcg","24","24",NA,"Vibrio" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin",NA,"0.25","0.25",NA,"Vibrio" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","5 mcg","23","23","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Vibrio" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","5 mcg","23","23","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","5 mcg","22","22","[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin",NA,"4","4",NA,"Vibrio" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","15 mcg","16","16","[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","15 mcg","12","12","[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline",NA,"0.5","0.5",NA,"Vibrio" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline",NA,"Note","Note","[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","30 mcg","20","20","[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","21","21","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. anginosus group",NA,"Dalbavancin",NA,"0.125","0.125",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. anginosus group",NA,"Dalbavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. anginosus group",NA,"Oritavancin",NA,"0.25","0.25",FALSE,"[2] MICs must be determined in the presence of polysorbate-80 (0.002% in the medium for broth dilution methods; agar dilution methods have not been validated). Follow the manufacturers' instructions for commercial systems. | [3] Isolates susceptible to vancomycin can be reported susceptible to dalbavancin and oritavancin. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. anginosus group",NA,"Oritavancin",NA,"Note","Note",FALSE,"[A] Disk diffusion criteria have not been defined and an MIC method should be used. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Teicoplanin",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Teicoplanin","30 mcg","16","16",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Telavancin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Vancomycin",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Vancomycin","5 mcg","15","15",FALSE,"[B] Non-wild type isolates were not available when developing the disk diffusion method. | [1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Azithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Clarithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Erythromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Erythromycin","15 mcg","IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Roxithromycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Clindamycin","2 mcg","19","19",FALSE,"[A] Place the erythromycin and clindamycin disks 12-16 mm apart (edge to edge) and look for antagonism (the D phenomenon) to detect inducible clindamycin resistance. | [1] Inducible clindamycin resistance can be detected by antagonism of clindamycin activity by a macrolide agent. If not detected, then report as tested according to the clinical breakpoints. If detected, then report as resistant.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Quinupristin-dalfopristin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Eravacycline",NA,"0.125","0.125",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Eravacycline","20 mcg","17","17",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",FALSE,"[1] Linezolid has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >2 mg/L) should be excluded. When excluded, the isolate should be reported “devoid of linezolid resistance mechanisms”, but not as susceptible to linezolid.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Linezolid",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"S. anginosus group",NA,"Tedizolid",NA,"0.5","0.5",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"S. anginosus group",NA,"Tedizolid","2 mcg","18","18",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Daptomycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Daptomycin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note",FALSE,"[1] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Viridans group streptococci",NA,"Rifampicin",NA,"Note","Note",FALSE,"[A] Rifampicin has been used in oral follow-up treatment of endocarditis caused by viridans group streptococci. There are no clinical breakpoints but acquired resistance (indicated by MIC >0.25 mg/L; zone diameter <21 mm for the rifampicin 5 µg disk) should be excluded. When excluded, the isolate should be reported “devoid of rifampicin resistance mechanisms”, but not as susceptible to rifampicin.","Viridans group streptococci" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Benzylpenicillin (screen only)","1 unit","12","12",FALSE,"[1/A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)",NA,"1","1",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin (indications other than meningitis)","2 mcg","18","18",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin iv (meningitis)",NA,"Note","Note",FALSE,"[3] In meningitis, H. influenzae negative in the benzylpenicillin 1 unit screen (zone diameter ≥12 mm) can be reported susceptible. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin iv (meningitis)",NA,"Note","Note",FALSE,"[C] In meningitis, H. influenzae negative in the benzylpenicillin 1 unit screen (zone diameter ≥12 mm) can be reported susceptible. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"1","1",FALSE,"[4] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [5] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] Susceptibility can be inferred from amoxicillin-clavulanic acid iv.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"2","2",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (indications other than meningitis)",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [E] Susceptibility can be inferred from ampicillin. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"Note","Note",FALSE,"[3] In meningitis, H. influenzae negative in the benzylpenicillin 1 unit screen (zone diameter ≥12 mm) can be reported susceptible. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin iv (meningitis)",NA,"Note","Note",FALSE,"[C] In meningitis, H. influenzae negative in the benzylpenicillin 1 unit screen (zone diameter ≥12 mm) can be reported susceptible. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"0.001","2",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin oral",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [F] Isolates susceptible to ampicillin can be reported ""susceptible, increased exposure” (I) to amoxicillin oral. Isolates resistant to ampicillin can be reported resistant to amoxicillin oral. | [2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv",NA,"2","2",FALSE,"[6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid iv","2/1 mcg","15","15",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral",NA,"0.001","2",FALSE,"[6] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amoxicillin-clavulanic acid oral","2/1 mcg","50","15",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin",NA,"IE","IE",FALSE,"[2] Beta-lactamase positive isolates can be reported resistant to ampicillin, amoxicillin and piperacillin without inhibitors. Tests based on a chromogenic cephalosporin can be used to detect the beta-lactamase.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam",NA,"0.25","0.25",FALSE,"[7] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Piperacillin-tazobactam","30/6 mcg","27","27",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all penicillins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for amoxicillin oral and amoxicillin-clavulanic acid oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Phenoxymethylpenicillin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime",NA,"0.25","0.25",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime","30 mcg","28","28",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefepime-enmetazobactam",NA,"Note","Note",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefepime-enmetazobactam",NA,"Note","Note",FALSE,"[2/D] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefixime",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefixime","5 mcg","26","26",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefotaxime",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefotaxime","5 mcg","27","27",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefpodoxime",NA,"0.25","0.25",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefpodoxime","10 mcg","26","26",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"0.03","0.03",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftaroline",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftibuten",NA,"1","1",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftibuten","30 mcg","25","25",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)",NA,"0.5","0.5",FALSE,"[3] See table of dosages for dosing for different indications.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftolozane-tazobactam (pneumonia)","30/10 mcg","23","23",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below. | [3] See table of dosages for dosing for different indications.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ceftriaxone",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ceftriaxone","30 mcg","32","32",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime iv",NA,"1","2",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime iv","30 mcg","27","25",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Cefuroxime oral",NA,"0.001","1",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Cefuroxime oral","30 mcg","50","27",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all cephalosporins for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing, except for cefuroxime oral, which if reported, should be reported “susceptible, increased exposure” (I). When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doripenem",NA,"1","1",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doripenem","10 mcg","23","23",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ertapenem",NA,"0.5","0.5",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ertapenem","10 mcg","23","23",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem",NA,"2","2",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem","10 mcg","20","20",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[3] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)",NA,"2","2",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (indications other than meningitis)","10 mcg","20","20",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [B] Read the outer edge of zones where an otherwise clear inhibition zone contains an area of growth around the disk, see pictures below.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"0.25","0.25",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem (meningitis)",NA,"Note","Note",FALSE,"[A] The benzylpenicillin 1 unit disk diffusion screening test shall be used to exclude beta-lactam resistance mechanisms. When the screen is negative (zone diameter ≥12 mm) all carbapenems for which clinical breakpoints are available, including those with “Note”, can be reported susceptible without further testing. When the screen is positive (zone diameter <12 mm), see flow chart below. | [D] For benzylpenicillin screen positive isolates (zone <12 mm), determine the MIC in meningitis.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[3] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[3/E] The addition of the beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Aztreonam-avibactam",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Aztreonam-avibactam",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ciprofloxacin",NA,"0.03","0.03",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ciprofloxacin","5 mcg","32","32",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Levofloxacin",NA,"0.06","0.06",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Levofloxacin","5 mcg","30","30",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Moxifloxacin",NA,"0.125","0.125",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Moxifloxacin","5 mcg","28","28",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23",FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Ofloxacin",NA,"0.06","0.06",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Ofloxacin","5 mcg","30","30",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Erythromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[1] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Clinical evidence for the efficacy of macrolides in H. influenzae respiratory infections is conflicting due to high spontaneous cure rates. Should there be a need to test any macrolide against this species, the epidemiological cut-offs (ECOFFs) should be used to detect strains with acquired resistance. The ECOFFs for each agent are: azithromycin 4 mg/L, clarithromycin 32 mg/L and erythromycin 16 mg/L. There are insufficient data available to establish an ECOFF for roxithromycin.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Minocycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Minocycline","30 mcg","24","24",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tetracycline",NA,"2","2",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tetracycline","30 mcg","25","25",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Chloramphenicol",NA,"2","2",FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Chloramphenicol","30 mcg","28","28",FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)",NA,"1","1",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Rifampicin (for prophylaxis only)","5 mcg","18","18",FALSE,NA,"H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Haemophilus influenzae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","H.influenzae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"1","1",FALSE,"[2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L. | [3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid",NA,"1","1",FALSE,"[4] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[3] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[A] Susceptibility can be inferred from amoxicillin-clavulanic acid.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ticarcillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime",NA,"4","4",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime","30 mcg","20","20",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefepime-enmetazobactam",NA,"Note","Note",FALSE,"[1] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefepime-enmetazobactam",NA,"Note","Note",FALSE,"[1/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent cephalosporin or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefixime",NA,"0.5","0.5",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefixime","5 mcg","21","21",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefotaxime",NA,"1","2",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefotaxime","5 mcg","20","17",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefpodoxime",NA,"IP","IP",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefpodoxime","10 mcg","IP","IP",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftaroline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftibuten",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftobiprole",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftolozane-tazobactam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ceftriaxone",NA,"1","2",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ceftriaxone","30 mcg","24","21",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv",NA,"4","8",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime iv","30 mcg","21","18",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral",NA,"0.001","4",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Cefuroxime oral","30 mcg","50","21",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doripenem",NA,"1","1",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doripenem","10 mcg","30","30",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ertapenem",NA,"0.5","0.5",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ertapenem","10 mcg","29","29",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem","10 mcg","29","29",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem",NA,"2","2",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem","10 mcg","33","33",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2/A] The addition of a beta-lactamase inhibitor does not add clinical benefit. The beta-lactamases produced by the organism either do not modify the parent carbapenem or are not affected by the inhibitor.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Aztreonam-avibactam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Aztreonam-avibactam",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ciprofloxacin","5 mcg","31","31",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Levofloxacin","5 mcg","29","29",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Moxifloxacin",NA,"0.25","0.25",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Moxifloxacin","5 mcg","26","26",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23",FALSE,"[B] | [B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin, levofloxacin, moxifloxacin and ofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Ofloxacin","5 mcg","28","28",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Amikacin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Netilmicin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tobramycin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"0.25","0.25",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Erythromycin",NA,"0.25","0.25",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Erythromycin","15 mcg","23","23",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"0.5","0.5",FALSE,"[1] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Roxithromycin",NA,"Note","Note",FALSE,"[A] Erythromycin can be used to screen for macrolide resistance in Moraxella catarrhalis. Isolates categorised as susceptible can be reported susceptible to azithromycin, clarithromycin and roxithromycin. Isolates categorised as resistant should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Minocycline",NA,"1","1",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Minocycline","30 mcg","25","25",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tetracycline",NA,"2","2",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tetracycline","30 mcg","26","26",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible to tetracycline can be reported susceptible to doxycycline and minocycline. Isolates categorised as resistant to tetracycline should be tested for susceptibility to individual agents or reported resistant.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note",FALSE,"[1] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Chloramphenicol",NA,"Note","Note",FALSE,"[A] For topical use of chloramphenicol, see table of topical agents.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Fosfomycin iv",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole",NA,"1","1",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Moraxella catarrhalis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","15","15",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","M.catarrhalis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Benzylpenicillin (surrogate agent)",NA,"0.06","1",FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin",NA,"Note","Note",FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[1] Always test for beta-lactamase (tests based on a chromogenic cephalosporin can be used). If beta-lactamase positive, report resistant to ampicillin and amoxicillin. If beta-lactamase negative, determine the MIC of benzylpenicillin. Infer the susceptibility to ampicillin and amoxicillin from the benzylpenicillin MIC (do not report benzylpenicillin susceptibility).","N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Amoxicillin-clavulanic acid",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Temocillin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefixime",NA,"0.125","0.125",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefotaxime",NA,"0.125","0.125",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Cefoxitin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ceftriaxone",NA,"0.125","0.125",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doripenem",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ertapenem",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Imipenem-relebactam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Meropenem-vaborbactam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Aztreonam-avibactam",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ciprofloxacin",NA,"0.03","0.06",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Moxifloxacin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Ofloxacin",NA,"0.125","0.25",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[1] Azithromycin is always used in conjunction with another effective agent. For testing purposes with the aim of detecting acquired resistance mechanisms, the ECOFF is 1 mg/L.","N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Doxycycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Minocycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tetracycline",NA,"0.5","0.5",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Lefamulin",NA,"IE","IE",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria gonorrhoeae",NA,"Spectinomycin",NA,"64","64",FALSE,NA,"N.gonorrhoeae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Benzylpenicillin (all indications)",NA,"0.25","0.25",FALSE,NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (indications other than meningitis)",NA,"0.125","1",FALSE,NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin (meningitis)",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ampicillin-sulbactam",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (indications other than meningitis)",NA,"0.125","1",FALSE,NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Amoxicillin (meningitis)",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefiderocol",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Cefotaxime (all indications)",NA,"0.125","0.125",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ceftriaxone (all indications including prophylaxis)",NA,"0.125","0.125",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory.","N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Doripenem",NA,"Note","Note",FALSE,"[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ertapenem",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem",NA,"Note","Note",FALSE,"[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Imipenem-relebactam",NA,"Note","Note",FALSE,"[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem (all indications)",NA,"0.25","0.25",FALSE,"[1] Resistant isolates are rare or not yet reported. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed and the isolate sent to a reference laboratory. | [2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only.","N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Meropenem-vaborbactam",NA,"Note","Note",FALSE,"[2] Breakpoints for serious N. meningitidis systemic infections (meningitis with or without septicemia) have been determined for meropenem only. | [3] The addition of a beta-lactamase inhibitor does not add clinical benefit.","N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Aztreonam",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Aztreonam-avibactam",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ciprofloxacin (all indications, including meningitis and prophylaxis)",NA,"0.016","0.016",FALSE,NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Delafloxacin",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Levofloxacin",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Moxifloxacin",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Ofloxacin",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Eravacycline",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Minocycline (prophylaxis only)",NA,"1","1",FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tetracycline (screen only)",NA,"2","2",FALSE,"[1] Tetracycline can be used to predict susceptibility to minocycline for prophylaxis against N. meningitidis infections.","N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Tigecycline",NA,"IE","IE",FALSE,NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Chloramphenicol (meningitis)",NA,"2","2",FALSE,"[1] For chloramphenicol treatment in meningitis, see table of dosages.","N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Neisseria meningitidis",NA,"Rifampicin (prophylaxis only)",NA,"0.25","0.25",FALSE,NA,"N.meningitidis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam",NA,"2","2",FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Ampicillin-sulbactam","10/10 mcg","25","25",FALSE,NA,"Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid",NA,"2","2",FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","14","14",FALSE,NA,"Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam",NA,"2","2",FALSE,"[4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L. | [3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Piperacillin-tazobactam","30/6 mcg","24","24",FALSE,"[3] Isolates susceptible to ampicillin-sulbactam and amoxicillin-clavulanic acid may be resistant to piperacillin-tazobactam.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Ertapenem",NA,"(2)","(2)",TRUE,"[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Ertapenem","10 mcg","(23)","(23)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Imipenem",NA,"1","1",FALSE,NA,"Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Imipenem","10 mcg","29","29",FALSE,NA,"Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Meropenem",NA,"1","1",FALSE,NA,"Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Meropenem","10 mcg","28","28",FALSE,NA,"Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Clindamycin",NA,"(4)","(4)",TRUE,"[5] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Clindamycin","2 mcg","(10)","(10)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacteroides spp.",NA,"Metronidazole",NA,"4","4",FALSE,"[6] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacteroides spp.",NA,"Metronidazole","5 mcg","25","25",FALSE,"[C] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Benzylpenicillin","1 unit","20","20",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin","2 mcg","25","25",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ampicillin-sulbactam","10/10 mcg","33","33",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Ertapenem",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Ertapenem","10 mcg","29","29",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Imipenem",NA,"0.125","0.125",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Imipenem","10 mcg","35","35",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Meropenem",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Meropenem","10 mcg","34","34",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Clindamycin",NA,"0.25","0.25",FALSE,NA,"Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Clindamycin","2 mcg","31","31",FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Prevotella spp.",NA,"Metronidazole",NA,"4","4",FALSE,"[3] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Prevotella spp.",NA,"Metronidazole","5 mcg","22","22",FALSE,"[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Benzylpenicillin",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Benzylpenicillin","1 unit","25","25",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ampicillin",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ampicillin","2 mcg","27","27",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ampicillin-sulbactam",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ampicillin-sulbactam","10/10 mcg","33","33",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Amoxicillin",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"F. necrophorum",NA,"Amoxicillin-clavulanic acid",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"F. necrophorum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"F. nucleatum",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L. | [4] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"F. nucleatum",NA,"Amoxicillin-clavulanic acid",NA,"23","23",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"F. necrophorum",NA,"Piperacillin-tazobactam",NA,"0.125","0.125",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"F. necrophorum",NA,"Piperacillin-tazobactam","30/6 mcg","35","35",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"F. nucleatum",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent. | [5] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"F. nucleatum",NA,"Piperacillin-tazobactam",NA,"35","35",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ertapenem",NA,"0.06","0.06",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Ertapenem","10 mcg","35","35",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Imipenem",NA,"0.125","0.125",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Imipenem","10 mcg","36","36",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Meropenem",NA,"0.06","0.06",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Meropenem","10 mcg","35","35",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Clindamycin",NA,"0.25","0.25",FALSE,NA,"Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Clindamycin","2 mcg","30","30",FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Metronidazole",NA,"1","1",FALSE,"[6] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Fusobacterium necrophorum and Fusobacterium nucleatum",NA,"Metronidazole","5 mcg","30","30",FALSE,"[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-negative" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Benzylpenicillin",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Benzylpenicillin","1 unit","15","15",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin","2 mcg","23","23",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ampicillin-sulbactam","10/10 mcg","27","27",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Piperacillin-tazobactam","30/6 mcg","24","24",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Ertapenem",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Ertapenem","10 mcg","24","24",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Imipenem",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Imipenem","10 mcg","25","25",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Meropenem",NA,"0.125","0.125",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Meropenem","10 mcg","25","25",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Vancomycin","5 mcg","12","12",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Clindamycin",NA,"0.25","0.25",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Clindamycin","2 mcg","19","19",FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium perfringens",NA,"Metronidazole",NA,"4","4",FALSE,"[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium perfringens",NA,"Metronidazole","5 mcg","16","16",FALSE,"[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Ampicillin",NA,"1","1",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Ampicillin","2 mcg","21","21",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Ampicillin-sulbactam",NA,"1","1",FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Ampicillin-sulbactam","10/10 mcg","28","28",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Amoxicillin",NA,"2","2",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Amoxicillin-clavulanic acid",NA,"2","2",FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","19","19",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Piperacillin-tazobactam",NA,"4","4",FALSE,"[3] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Piperacillin-tazobactam","30/6 mcg","24","24",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Meropenem",NA,"IE","IE",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Meropenem",NA,"IE","IE",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Clindamycin",NA,"(2)","(2)",TRUE,"[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Clindamycin","2 mcg","(17)","(17)",TRUE,"[B] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium innocuum",NA,"Metronidazole",NA,"4","4",FALSE,"[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium innocuum",NA,"Metronidazole","5 mcg","19","19",FALSE,"[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Benzylpenicillin",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Benzylpenicillin","1 unit","21","21",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Ampicillin",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Ampicillin","2 mcg","20","20",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Ampicillin-sulbactam",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Ampicillin-sulbactam","10/10 mcg","26","26",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Amoxicillin",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Amoxicillin-clavulanic acid",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","21","21",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Piperacillin-tazobactam",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Piperacillin-tazobactam","30/6 mcg","28","28",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Ertapenem",NA,"IE","IE",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Ertapenem",NA,"IE","IE",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Imipenem",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Imipenem","10 mcg","26","26",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Meropenem",NA,"2","2",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Meropenem","10 mcg","22","22",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium ramosum",NA,"Metronidazole",NA,"4","4",FALSE,"[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium ramosum",NA,"Metronidazole","5 mcg","21","21",FALSE,"[C] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Benzylpenicillin",NA,"0.125","0.125",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Benzylpenicillin","1 unit","21","21",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Ampicillin",NA,"0.125","0.125",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Ampicillin","2 mcg","25","25",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Ampicillin-sulbactam",NA,"0.125","0.125",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Ampicillin-sulbactam","10/10 mcg","29","29",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Amoxicillin",NA,"0.125","0.125",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","25","25",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Piperacillin-tazobactam",NA,"2","2",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Piperacillin-tazobactam","30/6 mcg","23","23",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Ertapenem",NA,"0.06","0.06",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Ertapenem","10 mcg","26","26",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Imipenem",NA,"0.125","0.125",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Imipenem","10 mcg","31","31",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Meropenem",NA,"0.125","0.125",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Meropenem","10 mcg","29","29",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Vancomycin",NA,"4","4",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Vancomycin","5 mcg","14","14",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Clindamycin",NA,"0.5","0.5",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Clindamycin","2 mcg","24","24",FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium septicum",NA,"Metronidazole",NA,"4","4",FALSE,"[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium septicum",NA,"Metronidazole","5 mcg","21","21",FALSE,"[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Ampicillin",NA,"4","4",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Ampicillin","2 mcg","12","12",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Ampicillin-sulbactam",NA,"4","4",FALSE,"[1] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Ampicillin-sulbactam","10/10 mcg","22","22",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Amoxicillin",NA,"2","2",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Amoxicillin-clavulanic acid",NA,"2","2",FALSE,"[2] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Ertapenem",NA,"IE","IE",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Ertapenem",NA,"IE","IE",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Imipenem",NA,"1","1",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Imipenem","10 mcg","28","28",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Meropenem",NA,"1","1",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Meropenem","10 mcg","24","24",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Vancomycin",NA,"4","4",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Vancomycin","5 mcg","13","13",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridium tertium",NA,"Metronidazole",NA,"4","4",FALSE,"[3] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridium tertium",NA,"Metronidazole","5 mcg","20","20",FALSE,"[B] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Benzylpenicillin",NA,"0.125","0.125",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Benzylpenicillin","1 unit","24","24",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin","2 mcg","23","23",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ampicillin-sulbactam","10/10 mcg","33A","33",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Amoxicillin-clavulanic acid","2/1 mcg","24","24",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Piperacillin-tazobactam","30/6 mcg","27","27",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[3] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Cefotaxime","5 mcg","26","26",FALSE,"[C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ceftriaxone",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [3] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ceftriaxone","30 mcg","33","33",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Ertapenem",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Ertapenem","10 mcg","28","28",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Imipenem",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Imipenem","10 mcg","39","39",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Meropenem",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Meropenem","10 mcg","28","28",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. Resistance to beta-lactam agents in C. acnes is rare. The identification and antimicrobial susceptibility test result on any such isolate must be confirmed.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Vancomycin","5 mcg","22","22",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Clindamycin",NA,"0.25","0.25",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Clindamycin","2 mcg","26","26",FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium acnes",NA,"Linezolid",NA,"2","2",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium acnes",NA,"Linezolid","10 mcg","34","34",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Benzylpenicillin",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Benzylpenicillin","1 unit","23","23",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Ampicillin",NA,"1","1",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Ampicillin","2 mcg","23","23",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Ampicillin-sulbactam",NA,"1","1",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Ampicillin-sulbactam","10/10 mcg","32","32",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Amoxicillin",NA,"2","2",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Amoxicillin-clavulanic acid",NA,"2","2",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Piperacillin-tazobactam",NA,"4","4",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Piperacillin-tazobactam","30/6 mcg","28","28",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Cefotaxime",NA,"Note","Note",FALSE,"[5] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Cefotaxime","5 mcg","24","24",FALSE,"[C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Ceftriaxone",NA,"1","1",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [5] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Ceftriaxone","30 mcg","30","30",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [C] Susceptibility to ceftriaxone can be inferred from the cefotaxime disk diffusion test.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Ertapenem",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Ertapenem","10 mcg","28","28",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Imipenem",NA,"0.125","0.125",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Imipenem","10 mcg","39","39",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Meropenem",NA,"1","1",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Meropenem","10 mcg","29","29",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Vancomycin","5 mcg","19","19",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Clindamycin",NA,"0.125","0.125",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Clindamycin","2 mcg","33","33",FALSE,"[D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Cutibacterium avidum",NA,"Linezolid",NA,"2","2",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Cutibacterium avidum",NA,"Linezolid","10 mcg","28","28",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Benzylpenicillin",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Benzylpenicillin","1 unit","20","20",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Ampicillin",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Ampicillin","2 mcg","21","21",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Ampicillin-sulbactam",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Ampicillin-sulbactam","10/10 mcg","27","27",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Amoxicillin",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Amoxicillin-clavulanic acid",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L..","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","21","21",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Piperacillin-tazobactam",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Piperacillin-tazobactam","30/6 mcg","30","30",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Ertapenem",NA,"0.06","0.06",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Ertapenem","10 mcg","29","29",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Imipenem",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Imipenem","10 mcg","34","34",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Meropenem",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Meropenem","10 mcg","31","31",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Vancomycin",NA,"1","1",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Vancomycin","5 mcg","20","20",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Clindamycin","2 mcg","23","23",FALSE,"[C] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Finegoldia spp.",NA,"Metronidazole",NA,"2","2",FALSE,"[6] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Finegoldia spp.",NA,"Metronidazole","5 mcg","25","25",FALSE,"[D] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Benzylpenicillin",NA,"0.03","0.03",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Benzylpenicillin","1 unit","31","31",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Ampicillin",NA,"0.125","0.125",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Ampicillin","2 mcg","29","29",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Ampicillin-sulbactam","10/10 mcg","36","36",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Amoxicillin",NA,"0.125","0.125",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Amoxicillin-clavulanic acid","2/1 mcg","28","28",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Piperacillin-tazobactam","30/6 mcg","33","33",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Ertapenem",NA,"0.06","0.06",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Ertapenem","10 mcg","33","33",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Imipenem",NA,"0.06","0.06",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Imipenem","10 mcg","40","40",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Meropenem",NA,"0.06","0.06",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Meropenem","10 mcg","36","36",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Vancomycin","5 mcg","19","19",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Clindamycin",NA,"(1)","(1)",TRUE,"[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Clindamycin","2 mcg","(18)","(18)",TRUE,"[C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Parvimonas micra",NA,"Metronidazole",NA,"1","1",FALSE,"[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Parvimonas micra",NA,"Metronidazole","5 mcg","28","28",FALSE,"[E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Benzylpenicillin",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Benzylpenicillin","1 unit","20","20",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Ampicillin",NA,"1","1",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Ampicillin","2 mcg","25","25",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Ampicillin-sulbactam",NA,"1","1",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] For susceptibility testing purposes, the concentration of sulbactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Ampicillin-sulbactam","10/10 mcg","31","31",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Amoxicillin",NA,"1","1",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Amoxicillin-clavulanic acid",NA,"1","1",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [3] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L..","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Amoxicillin-clavulanic acid","2/1 mcg","22","22",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Piperacillin-tazobactam",NA,"1","1",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [4] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Piperacillin-tazobactam","30/6 mcg","32","32",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Ertapenem",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Ertapenem","10 mcg","27","27",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Imipenem",NA,"0.125","0.125",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Imipenem","10 mcg","36","36",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Meropenem",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Meropenem","10 mcg","30","30",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Vancomycin","5 mcg","15","15",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Clindamycin",NA,"(1)","(1)",TRUE,"[6] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Clindamycin","2 mcg","(17)","(17)",TRUE,"[C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [5] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptostreptococcus anaerobius",NA,"Metronidazole",NA,"2","2",FALSE,"[7] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptostreptococcus anaerobius",NA,"Metronidazole","5 mcg","22","22",FALSE,"[E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Benzylpenicillin",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Benzylpenicillin","1 unit","18","18",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Ampicillin",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Ampicillin","2 mcg","21","21",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Ampicillin-sulbactam",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Ampicillin-sulbactam","10/10 mcg","29","29",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Amoxicillin",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [B] Susceptibility can be inferred from ampicillin.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","23","23",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Piperacillin-tazobactam",NA,"Note","Note",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents. | [2] The in vitro antimicrobial activity of the fixed concentration of the inhibitor is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Piperacillin-tazobactam","30/6 mcg","36","36",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Ertapenem",NA,"0.03","0.03",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Ertapenem","10 mcg","32","32",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Imipenem",NA,"0.06","0.06",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Imipenem","10 mcg","37","37",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Meropenem",NA,"0.06","0.06",FALSE,"[1] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Meropenem","10 mcg","35","35",FALSE,"[A] Isolates susceptible to benzylpenicillin can be reported susceptible to all beta-lactam agents with breakpoints (including those with Note) without further testing. Isolates resistant to benzylpenicillin should be tested for susceptibility to individual agents.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Vancomycin",NA,"0.5","0.5",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Vancomycin","5 mcg","21","21",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Clindamycin",NA,"(2)","(2)",TRUE,"[4] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Clindamycin","2 mcg","(15)","(15)",TRUE,"[C] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [D] Examine zones carefully for colonies within zones. Colonies should be taken into account when reading. | [3] Inducible clindamycin resistance may occur. This can be detected by antagonism of clindamycin activity by a macrolide agent [erythromycin and clindamycin disks 12-16 mm apart (edge to edge)]. The clinical significance is unknown.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Peptoniphilus spp.",NA,"Metronidazole",NA,"4","4",FALSE,"[5] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Peptoniphilus spp.",NA,"Metronidazole","5 mcg","19","19",FALSE,"[E] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"2","2",FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Vancomycin",NA,"IP","IP",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"0.5","0.5",FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Fidaxomicin",NA,"IP","IP",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"2","2",FALSE,"[1] The breakpoints are based on epidemiological cut-off values (ECOFFs) and apply to oral treatment of C. difficile infections. There are no conclusive clinical data regarding the relation between MICs and outcomes. | [2] Metronidazole resistance is rare, but inadequate anaerobic conditions may lead to false resistance. In case of resistance, confirm sufficient anaerobicity, species identification and antimicrobial susceptibility test result.","Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Clostridioides difficile",NA,"Metronidazole",NA,"IP","IP",FALSE,NA,"Anaerobic bacteria_G-positive" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Amoxicillin oral",NA,"0.125","0.125",FALSE,NA,"H.pylori" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Levofloxacin",NA,"1","1",FALSE,NA,"H.pylori" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Clarithromycin",NA,"0.25","0.25",FALSE,NA,"H.pylori" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Tetracycline",NA,"1","1",FALSE,NA,"H.pylori" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Metronidazole",NA,"8","8",FALSE,NA,"H.pylori" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Helicobacter pylori",NA,"Rifampicin",NA,"1","1",FALSE,NA,"H.pylori" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)",NA,"1","1",FALSE,NA,"L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (indications other than meningitis)","1 unit","13","13",FALSE,NA,"L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",FALSE,NA,"L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Benzylpenicillin (meningitis)",NA,"IE","IE",FALSE,NA,"L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)",NA,"1","1",FALSE,NA,"L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Ampicillin iv (all indications)","2 mcg","16","16",FALSE,NA,"L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)",NA,"0.25","0.25",FALSE,NA,"L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Meropenem (all indications)","10 mcg","26","26",FALSE,NA,"L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",FALSE,NA,"L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Moxifloxacin (meningitis)",NA,"IE","IE",FALSE,NA,"L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",FALSE,NA,"L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Linezolid (meningitis)",NA,"IE","IE",FALSE,NA,"L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)",NA,"1","1",FALSE,NA,"L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Erythromycin (indications other than meningitis)","15 mcg","25","25",FALSE,NA,"L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)",NA,"0.06","0.06",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Listeria monocytogenes",NA,"Trimethoprim-sulfamethoxazole (all indications)","1.25/23.75 mcg","29","29",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","L.monocytogenes" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Benzylpenicillin",NA,"0.5","0.5",FALSE,NA,"Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Benzylpenicillin","1 unit","17","17",FALSE,NA,"Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"1","1",FALSE,NA,"Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Ampicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"1","1",FALSE,NA,"Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from benzylpenicillin susceptibility.","Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid",NA,"1","1",FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Amoxicillin-clavulanic acid","2/1 mcg","15","15",FALSE,NA,"Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Cefotaxime",NA,"0.03","0.03",FALSE,NA,"Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Cefotaxime","5 mcg","26","26",FALSE,NA,"Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,NA,"Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Ciprofloxacin","5 mcg","27","27",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Levofloxacin",NA,"0.06","0.06",FALSE,NA,"Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Levofloxacin","5 mcg","27","27",FALSE,"[A] The nalidixic acid disk diffusion test can be used to screen for fluoroquinolone resistance. See Note B.","Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Nalidixic acid (screen only)","30 mcg","23","23",FALSE,"[B] Isolates categorised as screen negative can be reported susceptible to ciprofloxacin and levofloxacin. Isolates categorised as screen positive should be tested for susceptibility to individual agents or reported resistant.","Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"1","1",FALSE,NA,"Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Tetracycline (screen only)","30 mcg","24","24",FALSE,"[A] Susceptibility to doxycycline can be inferred from the tetracycline disk diffusion screening test.","Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Pasteurella spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Pasteurella" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin",NA,"0.001","0.5",FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Ciprofloxacin","5 mcg","50","26",FALSE,NA,"C.jejuni_C.coli" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note",FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"C. jejuni",NA,"Erythromycin",NA,"4","4",FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"C. jejuni",NA,"Erythromycin","15 mcg","20","20",FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"C. coli",NA,"Erythromycin",NA,"8","8",FALSE,"[1] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"C. coli",NA,"Erythromycin","15 mcg","18","18",FALSE,"[A] Susceptibility to azithromycin and clarithromycin can be inferred from erythromycin.","C.jejuni_C.coli" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note",FALSE,"[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline",NA,"2","2",FALSE,"[1] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Campylobacter jejuni and C. coli",NA,"Tetracycline","30 mcg","30","30",FALSE,"[A] Susceptibility to doxycycline can be inferred from tetracycline.","C.jejuni_C.coli" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.001","1",FALSE,NA,"Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","50","12",FALSE,NA,"Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","1",FALSE,NA,"Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","25",FALSE,NA,"Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin",NA,"0.5","0.5",FALSE,NA,"Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Moxifloxacin","5 mcg","25","25",FALSE,NA,"Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Gentamicin",NA,"IE","IE",FALSE,NA,"Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Vancomycin","5 mcg","17","17",FALSE,"[A] Non-wild typeisolates were not available when developing the disk diffusion method.","Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Clindamycin","2 mcg","20","20",FALSE,"[1] Inducible clindamycin resistance may occur in Corynebacterium spp. This can be detected by antagonism of clindamycin activity by a macrolide agent. The clinical significance is unknown. There is currently no recommendation for testing.","Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"2","2",FALSE,NA,"Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",FALSE,NA,"Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",FALSE,NA,"Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",FALSE,NA,"Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",FALSE,NA,"Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium spp.other than C. diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","30","30",FALSE,NA,"Corynebacterium" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin",NA,"0.001","1",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Benzylpenicillin","1 unit","50","12",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"1","1",FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime",NA,"0.001","2",FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Cefotaxime","5 mcg","50","15",FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported ""susceptible, increased exposure” (I) to cefotaxime. Isolates resistant to benzylpenicillin should be tested for susceptibility to cefotaxime or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem",NA,"0.25","0.25",FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Meropenem","10 mcg","24","24",FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to meropenem. Isolates resistant to benzylpenicillin should be tested for susceptibility to meropenem or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin",NA,"0.001","0.5",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Ciprofloxacin","5 mcg","50","24",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin",NA,"0.06","0.06",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Erythromycin","15 mcg","24","24",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"C. diphtheriae",NA,"Clindamycin",NA,"0.5","0.5",FALSE,"[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"C. diphtheriae",NA,"Clindamycin","2 mcg","15","15",FALSE,"[1] Wild-type C. ulcerans is less susceptible to clindamycin.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"0.5","0.5",FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline",NA,"1","1",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Tetracycline","30 mcg","24","24",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid",NA,"2","2",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Linezolid","10 mcg","25","25",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin",NA,"0.06","0.06",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Rifampicin","5 mcg","24","24",FALSE,NA,"C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.5","0.5",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Corynebacterium diphtheriae and C. ulcerans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","23","23",FALSE,"[1] Trimethoprim-sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","C.diphtheriae_C.ulcerans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin",NA,"0.125","0.125",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Benzylpenicillin","1 unit","21","21",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin",NA,"0.25","0.25",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ampicillin","2 mcg","26","26",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[1] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from ampicillin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem",NA,"0.25","0.25",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Meropenem","10 mcg","31","31",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)",NA,"2","2",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Ciprofloxacin (uncomplicated UTI only)","5 mcg","21","21",FALSE,"[A] Susceptibility can be inferred from the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"2","2",FALSE,"[1] Susceptibility can be inferred from ciprofloxacin susceptibility.","A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Levofloxacin (uncomplicated UTI only)",NA,"Note","Note",FALSE,"[B] Susceptibility can be inferred from the ciprofloxacin susceptibility or the norfloxacin disk diffusion screening test. See Note","A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Norfloxacin (screen only)","10 mcg","17","17",FALSE,"[C] | [C] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance.","A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin",NA,"1","1",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Vancomycin","5 mcg","16","16",FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)",NA,"16","16",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Nitrofurantoin (uncomplicated UTI only)","100 mcg","16","16",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin",NA,"0.125","0.125",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aerococcus sanguinicola and A. urinae",NA,"Rifampicin","5 mcg","25","25",FALSE,NA,"A.sanguinicola_A.urinae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Benzylpenicillin",NA,"0.03","0.03",FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Benzylpenicillin","1 unit","25","25",FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Ampicillin",NA,"0.06","0.06",FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Ampicillin",NA,"Note","Note",FALSE,"[A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin",NA,"0.125","0.125",FALSE,"[2] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin",NA,"Note","Note",FALSE,"[A] Susceptibility can be inferred from benzylpenicillin susceptibility.","K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid",NA,"Note","Note",FALSE,"[3] The in vitro antimicrobial activity of the fixed concentration of 2 mg/L for clavulanic acid is such that artefactually low MIC values may be obtained. Therefore no breakpoints can be given. This does not affect disk diffusion where the concentration of the inhibitor decreases proportionally with the concentration of the agent.","K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Amoxicillin-clavulanic acid","2/1 mcg","22","22",FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Cefotaxime",NA,"0.125","0.125",FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Cefotaxime","5 mcg","27","27",FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Ceftriaxone",NA,"0.06","0.06",FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Ceftriaxone","30 mcg","30","30",FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Cefuroxime iv",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Cefuroxime iv","30 mcg","29","29",FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Meropenem",NA,"0.03","0.03",FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Meropenem","10 mcg","30","30",FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Ciprofloxacin","5 mcg","28","28",FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Levofloxacin",NA,"0.125","0.125",FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Levofloxacin","5 mcg","28","28",FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Azithromycin",NA,"0.25","0.25",FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Azithromycin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Clarithromycin",NA,"0.5","0.5",FALSE,"[1] Susceptibility can be inferred from erythromycin susceptibility.","K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Clarithromycin",NA,"Note","Note",FALSE,"[A] Infer susceptibility from erythromycin susceptibility.","K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Erythromycin",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Erythromycin","15 mcg","20","20",FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Doxycycline",NA,"0.5","0.5",FALSE,"[1] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Tetracycline can be used to screen for resistance in tetracycline agents. Isolates categorised as susceptible can be reported susceptible to doxycycline. Isolates categorised as resistant should be tested for susceptibility to doxycycline or reported resistant.","K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Tetracycline",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Tetracycline","30 mcg","28","28",FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Rifampicin",NA,"0.5","0.5",FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Rifampicin","5 mcg","20","20",FALSE,NA,"K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Kingella kingae",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","28","28",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","K.kingae" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Cefepime",NA,"1","4",FALSE,NA,"Aeromonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Cefepime","30 mcg","27","24",FALSE,NA,"Aeromonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Ceftazidime",NA,"1","4",FALSE,NA,"Aeromonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Ceftazidime","10 mcg","24","21",FALSE,NA,"Aeromonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Aztreonam",NA,"1","4",FALSE,NA,"Aeromonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Aztreonam","30 mcg","29","26",FALSE,NA,"Aeromonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Ciprofloxacin",NA,"0.25","0.5",FALSE,NA,"Aeromonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Ciprofloxacin","5 mcg","27","24",FALSE,NA,"Aeromonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Levofloxacin",NA,"0.5","1",FALSE,NA,"Aeromonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Levofloxacin","5 mcg","27","24",FALSE,NA,"Aeromonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"1","1",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Aeromonas spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","16","16",FALSE,"[A] Read the obvious zone edge and disregard haze or growth within the inhibition zone (see pictures below). | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Aeromonas" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam",NA,"4","4",FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","A.xylosoxidans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",FALSE,NA,"A.xylosoxidans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Cefiderocol",NA,"Note","Note",FALSE,"[2] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥26 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","A.xylosoxidans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Cefiderocol","30 mcg","Note","Note",FALSE,"[A] The in vitro activity of cefiderocol against Achromobacter xylosoxidans is comparable to the activity of the agent against Enterobacterales and there is animal data to suggest efficacy. However, there is insufficient clinical data to determine a clinical breakpoint. Isolates with MIC values ≤0.5 mg/L (zone diameter ≥26 mm) are mostly devoid of resistance mechanisms and are likely to be a target for treatment with this agent. Isolates with MICs 1-2 mg/L have some acquired resistance mechanisms. Little clinical data exists regarding clinical outcome for these isolates, however, they may still be a target for treatment with this agent if there are limited treatment options. Isolates with MIC values >2 mg/L (zone diameter <22 mm) have acquired resistance mechanisms and are likely to be resistant to this agent. | [1] Broth microdilution MIC determination must be performed in iron-depleted Mueller-Hinton broth and specific reading instructions must be followed. For testing conditions and reading instructions, see https://www.eucast.org/eucastguidancedocuments/.","A.xylosoxidans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Meropenem",NA,"1","4",FALSE,NA,"A.xylosoxidans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Meropenem","10 mcg","26","20",FALSE,NA,"A.xylosoxidans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Achromobacter xylosoxidans",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","26","26",FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","A.xylosoxidans" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam",NA,"1","1",FALSE,"[1] For susceptibility testing purposes, the concentration of tazobactam is fixed at 4 mg/L.","Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Piperacillin-tazobactam","30/6 mcg","26","26",FALSE,NA,"Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Cefotaxime",NA,"0.25","0.25",FALSE,NA,"Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Cefotaxime","5 mcg","21","21",FALSE,NA,"Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",FALSE,NA,"Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"V. fluvialis",NA,"Cefotaxime",NA,"IE","IE",FALSE,NA,"Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Ceftazidime",NA,"1","1",FALSE,NA,"Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Ceftazidime","10 mcg","22","22",FALSE,NA,"Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Meropenem",NA,"0.5","0.5",FALSE,NA,"Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Meropenem","10 mcg","24","24",FALSE,NA,"Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Ciprofloxacin",NA,"0.25","0.25",FALSE,NA,"Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Ciprofloxacin","5 mcg","23","23",FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Levofloxacin",NA,"0.25","0.25",FALSE,NA,"Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Levofloxacin","5 mcg","23","23",FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Pefloxacin (screen only)","5 mcg","22","22",FALSE,"[A] Susceptibility to ciprofloxacin and levofloxacin can be inferred from the pefloxacin disk diffusion screening test.","Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Azithromycin",NA,"4","4",FALSE,NA,"Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Azithromycin","15 mcg","16","16",FALSE,"[A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Erythromycin (screen only)","15 mcg","12","12",FALSE,"[1/A] Susceptibility to azithromycin (and erythromycin when azithromycin is not available) is inferred from the erythromycin disk diffusion test.","Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Doxycycline",NA,"0.5","0.5",FALSE,NA,"Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Tetracycline (screen only)","30 mcg","20","20",FALSE,"[1/A] Susceptibility to doxycycline (and tetracycline when doxycycline is not available) is inferred from the tetracycline disk diffusion test.","Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole",NA,"0.25","0.25",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Vibrio spp.",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","21","21",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","Vibrio" "EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Imipenem",NA,"0.5","0.5",NA,"Bacillus" +except B. anthracis",NA,"Imipenem",NA,"0.5","0.5",FALSE,NA,"Bacillus" "EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Imipenem","10 mcg","30","30",NA,"Bacillus" +except B. anthracis",NA,"Imipenem","10 mcg","30","30",FALSE,NA,"Bacillus" "EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Meropenem",NA,"0.25","0.25",NA,"Bacillus" +except B. anthracis",NA,"Meropenem",NA,"0.25","0.25",FALSE,NA,"Bacillus" "EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Meropenem","10 mcg","25","25",NA,"Bacillus" +except B. anthracis",NA,"Meropenem","10 mcg","25","25",FALSE,NA,"Bacillus" "EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Ciprofloxacin",NA,"0.001","0.5",NA,"Bacillus" +except B. anthracis",NA,"Ciprofloxacin",NA,"0.001","0.5",FALSE,NA,"Bacillus" "EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Ciprofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +except B. anthracis",NA,"Ciprofloxacin","5 mcg","50","23",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" "EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Levofloxacin",NA,"0.001","1",NA,"Bacillus" +except B. anthracis",NA,"Levofloxacin",NA,"0.001","1",FALSE,NA,"Bacillus" "EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Levofloxacin","5 mcg","50","23","[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" +except B. anthracis",NA,"Levofloxacin","5 mcg","50","23",FALSE,"[A] The norfloxacin disk diffusion test can be used to screen for fluoroquinolone resistance. See Note","Bacillus" "EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Norfloxacin (screen only)","10 mcg","21","21","[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" +except B. anthracis",NA,"Norfloxacin (screen only)","10 mcg","21","21",FALSE,"[B] | [B] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to ciprofloxacin and levofloxacin. Isolates categorised as screen positive can be reported resistant to ciprofloxacin and levofloxacin.","Bacillus" "EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Vancomycin",NA,"2","2",NA,"Bacillus" +except B. anthracis",NA,"Vancomycin",NA,"2","2",FALSE,NA,"Bacillus" "EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Vancomycin","5 mcg","10","10","[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" +except B. anthracis",NA,"Vancomycin","5 mcg","10","10",FALSE,"[A] Non-wild type isolates were not available when developing the disk diffusion method.","Bacillus" "EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Erythromycin",NA,"0.5","0.5",NA,"Bacillus" +except B. anthracis",NA,"Erythromycin",NA,"0.5","0.5",FALSE,NA,"Bacillus" "EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Erythromycin","15 mcg","24","24",NA,"Bacillus" +except B. anthracis",NA,"Erythromycin","15 mcg","24","24",FALSE,NA,"Bacillus" "EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Clindamycin",NA,"1","1",NA,"Bacillus" +except B. anthracis",NA,"Clindamycin",NA,"1","1",FALSE,NA,"Bacillus" "EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Clindamycin","2 mcg","17","17",NA,"Bacillus" +except B. anthracis",NA,"Clindamycin","2 mcg","17","17",FALSE,NA,"Bacillus" "EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus spp. -except B. anthracis",NA,"Linezolid",NA,"2","2",NA,"Bacillus" +except B. anthracis",NA,"Linezolid",NA,"2","2",FALSE,NA,"Bacillus" "EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus spp. -except B. anthracis",NA,"Linezolid","10 mcg","22","22",NA,"Bacillus" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Benzylpenicillin",NA,"0.001","0.5",NA,"B.anthracis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Benzylpenicillin","1 unit","50","18",NA,"B.anthracis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Amoxicillin iv",NA,"0.125","0.125","[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Amoxicillin iv",NA,"Note","Note","[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Ciprofloxacin",NA,"0.001","0.25",NA,"B.anthracis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Ciprofloxacin","5 mcg","50","24",NA,"B.anthracis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Levofloxacin",NA,"0.001","0.5",NA,"B.anthracis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Levofloxacin","5 mcg","50","23",NA,"B.anthracis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Vancomycin",NA,"4","4","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Vancomycin","5 mcg","10","10","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Clindamycin",NA,"1","1",NA,"B.anthracis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Clindamycin","2 mcg","17","17",NA,"B.anthracis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Doxycycline",NA,"0.06","0.06","[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Tetracycline",NA,"0.125","0.125",NA,"B.anthracis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Tetracycline","30 mcg","26","26",NA,"B.anthracis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Linezolid",NA,"2","2",NA,"B.anthracis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Linezolid","10 mcg","20","20",NA,"B.anthracis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Rifampicin",NA,"1","1","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Rifampicin","5 mcg","12","12","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)","30 mcg","30","30","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Ciprofloxacin",NA,"0.001","1",NA,"B.melitensis " -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Ciprofloxacin","5 mcg","50","27",NA,"B.melitensis " -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Levofloxacin",NA,"0.001","1",NA,"B.melitensis " -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Levofloxacin","5 mcg","50","28",NA,"B.melitensis " -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Gentamicin",NA,"0.5","0.5","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Gentamicin","10 mcg","23","23","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Streptomycin",NA,"1","1","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Streptomycin","10 mcg","15","15","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Doxycycline",NA,"0.25","0.25","[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis " -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Doxycycline",NA,"Note","Note","[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis " -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Tetracycline",NA,"0.5","0.5",NA,"B.melitensis " -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Tetracycline","30 mcg","42","42",NA,"B.melitensis " -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Rifampicin",NA,"2","2","[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Rifampicin","5 mcg","20","20","[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.","B.melitensis " -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125","[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.melitensis " -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","29","29","[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone. | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.melitensis " -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid",NA,"0.001","8","[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","20/10 mcg","50","22",NA,"B.pseudomallei" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime",NA,"0.001","8",NA,"B.pseudomallei" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","10 mcg","50","18",NA,"B.pseudomallei" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem",NA,"2","2",NA,"B.pseudomallei" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","10 mcg","29","29",NA,"B.pseudomallei" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem",NA,"2","2",NA,"B.pseudomallei" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","10 mcg","24","24",NA,"B.pseudomallei" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"0.001","2",NA,"B.pseudomallei" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"Note","Note","[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","30 mcg","23","23","[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol",NA,"0.001","8",NA,"B.pseudomallei" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","30 mcg","50","22",NA,"B.pseudomallei" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4","[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","17","[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25","[1] For bedaquiline, breakpoints were determined using the EUCAST reference method.","M.tuberculosis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06","[2] For delamanid and pretomanid, breakpoints were not determined with the EUCAST reference method. Therefore they are provisional and might change according to the results of future studies with the EUCAST reference method for MIC determination. +except B. anthracis",NA,"Linezolid","10 mcg","22","22",FALSE,NA,"Bacillus" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Benzylpenicillin",NA,"0.001","0.5",FALSE,NA,"B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Benzylpenicillin","1 unit","50","18",FALSE,NA,"B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Amoxicillin iv",NA,"0.125","0.125",FALSE,"[1] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Amoxicillin iv",NA,"Note","Note",FALSE,"[A] Isolates ""susceptible, increased exposure” (I) to benzylpenicillin can be reported susceptible to amoxicillin. Isolates resistant to benzylpenicillin should be tested for susceptibility to amoxicillin or reported resistant.","B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Ciprofloxacin",NA,"0.001","0.25",FALSE,NA,"B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Ciprofloxacin","5 mcg","50","24",FALSE,NA,"B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Levofloxacin",NA,"0.001","0.5",FALSE,NA,"B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Levofloxacin","5 mcg","50","23",FALSE,NA,"B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Vancomycin",NA,"(4)","(4)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Vancomycin","5 mcg","(10)","(10)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Clindamycin",NA,"1","1",FALSE,NA,"B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Clindamycin","2 mcg","17","17",FALSE,NA,"B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Doxycycline",NA,"0.06","0.06",FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Tetracycline",NA,"0.125","0.125",FALSE,NA,"B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Tetracycline","30 mcg","26","26",FALSE,NA,"B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Linezolid",NA,"2","2",FALSE,NA,"B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Linezolid","10 mcg","20","20",FALSE,NA,"B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Bacillus anthracis",NA,"Rifampicin",NA,"(1)","(1)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Bacillus anthracis",NA,"Rifampicin","5 mcg","(12)","(12)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.anthracis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Ceftriaxone (meningitis)","30 mcg","(30)","(30)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Ciprofloxacin",NA,"0.001","1",FALSE,NA,"B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Ciprofloxacin","5 mcg","50","27",FALSE,NA,"B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Levofloxacin",NA,"0.001","1",FALSE,NA,"B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Levofloxacin","5 mcg","50","28",FALSE,NA,"B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Gentamicin",NA,"(0.5)","(0.5)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Gentamicin","10 mcg","(23)","(23)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Streptomycin",NA,"(1)","(1)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Streptomycin","10 mcg","(15)","(15)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Doxycycline",NA,"0.25","0.25",FALSE,"[1] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Isolates susceptible to tetracycline can be reported susceptible to doxycycline. Isolates resistant to tetracycline should be tested for susceptibility to doxycycline or reported resistant.","B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Tetracycline",NA,"0.5","0.5",FALSE,NA,"B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Tetracycline","30 mcg","42","42",FALSE,NA,"B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Rifampicin",NA,"(2)","(2)",TRUE,"[1] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/.","B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Rifampicin","5 mcg","(20)","(20)",TRUE,"[A] For information on how to use breakpoints in brackets, see https://www.eucast.org/eucastguidancedocuments/. | [B] Examine zones carefully for colonies close to the zone edge. Colonies should be taken into account when reading.","B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole",NA,"0.125","0.125",FALSE,"[2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Brucella melitensis",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","29","29",FALSE,"[C] Read the obvious zone edges and disregard haze or faint growth within the inhibition zone. | [2] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.melitensis " +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid",NA,"0.001","8",FALSE,"[1] For susceptibility testing purposes, the concentration of clavulanic acid is fixed at 2 mg/L.","B.pseudomallei" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Amoxicillin-clavulanic acid","20/10 mcg","50","22",FALSE,NA,"B.pseudomallei" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Ceftazidime",NA,"0.001","8",FALSE,NA,"B.pseudomallei" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Ceftazidime","10 mcg","50","18",FALSE,NA,"B.pseudomallei" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Imipenem",NA,"2","2",FALSE,NA,"B.pseudomallei" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Imipenem","10 mcg","29","29",FALSE,NA,"B.pseudomallei" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Meropenem",NA,"2","2",FALSE,NA,"B.pseudomallei" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Meropenem","10 mcg","24","24",FALSE,NA,"B.pseudomallei" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"0.001","2",FALSE,NA,"B.pseudomallei" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Doxycycline",NA,"Note","Note",FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Tetracycline (screen only)","30 mcg","23","23",FALSE,"[A] Isolates categorised as screen negative can be reported ""susceptible increased exposure"" (I) to doxycyline. Isolates categorised as screen positive can be reported resistant to doxycycline.","B.pseudomallei" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol",NA,"0.001","8",FALSE,NA,"B.pseudomallei" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Chloramphenicol","30 mcg","50","22",FALSE,NA,"B.pseudomallei" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole",NA,"0.001","4",FALSE,"[1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK",NA,"Burkholderia pseudomallei",NA,"Trimethoprim-sulfamethoxazole","1.25/23.75 mcg","50","17",FALSE,"[A] There may be growth within the inhibition zone. The density of growth may vary from a fine haze to substantial growth (see pictures below). If any zone edge can be seen, ignore growth within the inhibition zone and read the zone diameter. | [1] Trimethoprim:sulfamethoxazole in the ratio 1:19. Breakpoints are expressed as the trimethoprim concentration.","B.pseudomallei" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Bedaquiline",NA,"0.25","0.25",FALSE,"[1] For bedaquiline, breakpoints were determined using the EUCAST reference method.","M.tuberculosis" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Delamanid",NA,"0.06","0.06",FALSE,"[2] For delamanid and pretomanid, breakpoints were not determined with the EUCAST reference method. Therefore they are provisional and might change according to the results of future studies with the EUCAST reference method for MIC determination. 3.The provisional breakpoint was determined according to MIC data determined with the agar dilution and the agar proportion methods.","M.tuberculosis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Pretomanid",NA,"Note","Note","[2] For delamanid and pretomanid, breakpoints were not determined with the EUCAST reference method. Therefore they are provisional and might change according to the results of future studies with the EUCAST reference method for MIC determination. +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC",NA,"Mycobacterium tuberculosis",NA,"Pretomanid",NA,"Note","Note",FALSE,"[2] For delamanid and pretomanid, breakpoints were not determined with the EUCAST reference method. Therefore they are provisional and might change according to the results of future studies with the EUCAST reference method for MIC determination. 3.The provisional breakpoint was determined according to MIC data determined with the agar dilution and the agar proportion methods. | [4] A provisional screen value of 2 mg/L is advised according to published MIC data determined with MGIT.","M.tuberculosis" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin",NA,"2","2",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","10 mcg","16","16",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin",NA,"0.25","0.25",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin",NA,"Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)",NA,"8","8",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","10 mcg","12","12",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin",NA,"8","8",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","10 mcg","15","15",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","5 mcg","26","26",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","5 mcg","18","18",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)",NA,"4","4",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin",NA,"1","1",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","21","21",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","23",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)",NA,"2","2",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Gentamicin",NA,"2","2",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","10 mcg","18","18",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Tobramycin",NA,"2","2",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","10 mcg","18","18",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","10 mcg","17","17","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin",NA,"1","1",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin",NA,"1","1",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin",NA,"Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol",NA,"16","16",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","30 mcg","18","18",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","10 mcg","23","23",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)",NA,"1","1",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","10 mcg","14","14",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Mupirocin",NA,"1","1","[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.","Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","200 mcg","30","30","[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.","Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Retapamulin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin",NA,"4","4",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"4","4",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","21","21",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"32","32",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin",NA,"0.5","0.5",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"0.125","0.125",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin",NA,"4","4",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin",NA,"8","8",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin",NA,"0.06","0.06",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin",NA,"0.06","0.06",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin",NA,"Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","30 mcg","28","28",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","5 mcg","Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"Note","Note","[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol",NA,"2","2",NA,"Topical agents" -"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","30 mcg","31","31",NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Gentamicin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Gentamicin","10 mcg","17","17",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Tobramycin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Tobramycin","10 mcg","16","16",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Pefloxacin (screen only)","5 mcg","24","24",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Ciprofloxacin",NA,"0.125","0.125",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Levofloxacin",NA,"0.25","0.25",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Ofloxacin",NA,"0.25","0.25",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Ofloxacin",NA,"Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Chloramphenicol",NA,"16","16",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Chloramphenicol","30 mcg","17","17",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Colistin (for polymyxin B)",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Enterobacterales",NA,"Neomycin (framycetin)",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Enterobacterales",NA,"Neomycin (framycetin)","10 mcg","12","12",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Gentamicin",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","P. aeruginosa",NA,"Gentamicin","10 mcg","15","15",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Tobramycin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","P. aeruginosa",NA,"Tobramycin","10 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Ciprofloxacin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","P. aeruginosa",NA,"Ciprofloxacin","5 mcg","26","26",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Levofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","P. aeruginosa",NA,"Levofloxacin","5 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Ofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","P. aeruginosa",NA,"Colistin (for polymyxin B)",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Gentamicin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Gentamicin","10 mcg","17","17",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Tobramycin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Tobramycin","10 mcg","17","17",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ciprofloxacin",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Ciprofloxacin","5 mcg","21","21",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Levofloxacin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Acinetobacter spp.",NA,"Levofloxacin","5 mcg","23","23",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Ofloxacin",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Acinetobacter spp.",NA,"Colistin (for polymyxin B)",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Gentamicin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Gentamicin","10 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Tobramycin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Tobramycin","10 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Norfloxacin (screen only)","10 mcg","17","17",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Ciprofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Levofloxacin",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Ofloxacin",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Ofloxacin",NA,"Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Chloramphenicol",NA,"16","16",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Chloramphenicol","30 mcg","18","18",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Fusidic acid",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Fusidic acid","10 mcg","23","23",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Neomycin (framycetin)",NA,"1","1",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Neomycin (framycetin)","10 mcg","14","14",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Mupirocin",NA,"1","1",FALSE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. aureus",NA,"Mupirocin","200 mcg","30","30",FALSE,"[2] Breakpoints for nasal decolonization in carriers of S. aureus, S ≤1, R >1 mg/L (disk diffusion with mupirocin 200 µg disk S ≥30, R <30 mm). For short term suppression of nasal colonization (usually as a perioperative practice) breakpoints of S ≤256, R >256 mg/L (disk diffusion S ≥18 mm, R <18 mm) can be used.","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. aureus",NA,"Retapamulin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Norfloxacin (screen only)","10 mcg","10","10",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. pneumoniae",NA,"Ciprofloxacin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. pneumoniae",NA,"Levofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Ofloxacin",NA,"Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","S. pneumoniae",NA,"Chloramphenicol",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","S. pneumoniae",NA,"Chloramphenicol","30 mcg","21","21",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Norfloxacin (screen only)","10 mcg","12","12",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Ofloxacin",NA,"Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","Streptococcus groups A, B, C and G",NA,"Chloramphenicol","30 mcg","21","21",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Fusidic acid",NA,"32","32",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Mupirocin",NA,"0.5","0.5",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","Streptococcus groups A, B, C and G",NA,"Retapamulin",NA,"0.125","0.125",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","H. influenzae",NA,"Gentamicin",NA,"4","4",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","H. influenzae",NA,"Tobramycin",NA,"8","8",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","H. influenzae",NA,"Nalidixic acid (screen only)","30 mcg","23","23",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","H. influenzae",NA,"Ciprofloxacin",NA,"0.06","0.06",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","H. influenzae",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","H. influenzae",NA,"Levofloxacin",NA,"0.06","0.06",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","H. influenzae",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","H. influenzae",NA,"Ofloxacin",NA,"0.06","0.06",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","H. influenzae",NA,"Ofloxacin",NA,"Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","H. influenzae",NA,"Chloramphenicol",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","H. influenzae",NA,"Chloramphenicol","30 mcg","28","28",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Nalidixic acid (screen only)","30 mcg","23","23",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","M. catarrhalis",NA,"Ciprofloxacin",NA,"0.125","0.125",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Ciprofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","M. catarrhalis",NA,"Levofloxacin",NA,"0.125","0.125",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Levofloxacin","5 mcg","Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"0.25","0.25",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Ofloxacin",NA,"Note","Note",FALSE,"[1] Screening agent for detection of fluoroquinolone resistance (pefloxacin for Enterobacterales, norfloxacin for Gram-positive organisms and nalidixic acid for H. influenzae and M. catarrhalis).","Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","MIC","Topical","M. catarrhalis",NA,"Chloramphenicol",NA,"2","2",FALSE,NA,"Topical agents" +"EUCAST 2026","16.1","Clinical Breakpoint Tables v. 16.1","human","human","DISK","Topical","M. catarrhalis",NA,"Chloramphenicol","30 mcg","31","31",FALSE,NA,"Topical agents" diff --git a/data-raw/breakpoints_eucast_raw.rds b/data-raw/breakpoints_eucast_raw.rds index 4beed643eedf12f62ec54721caea5921fb531b58..5035d2ef4147129b2bef8329002422d0fecffbe8 100644 GIT binary patch literal 160850 zcmeFY2Ut^E+BU4Bpwd*NHw6WyBfSNcrqTpdq=S^uJA{sifOHWlp#%W|>Agef9TIvA z5Nbm2gbsf|&zW;(<}KgM`+nc`&oygr*4~8dwby!{weNL5_p_l7yn5lh;4UBQWX-;T zp#8PdGi2_kD=SB-d&<6+N>5pgRS~d4Rj0pt9<#a#t9lV(`Z^uwU8BBS3Itx zcj8$s=+8HwJaT$QcM^DqG9fT%cHbQyH9NI`y0$Cgc?zzsuC`is-y(*L9X8WnMNiNl z?U2*!xa#O~UZ3)r1RYzi#kwlu?-qhi4`wmmoIx|xGV~WN{*RR6o5IkGm;YDFD?I!E zm3IH5MvL_3DX#usEk825T_67{B820YFa5tL?OqdC{$Jb|d(TA%d;I^a2LI#De%SrR z_`f;f|J_mK(#lG8UMcojo!SW|CbF7r^e16fh!eD#{_mWOWo^aE2w2ZF2U81Jj+NQ` zBPZZh#((h2zkk2@1;9Vkoxjtl1{zR*K0sPqWaB?E(!bO6nZ+ubRzZyX#Q%`-{(~le z_eSN9L$ZI=G5>kn6B&oq4ga&A`+KGZ`Hj1}axSlEiEHXwL4ub3#kgdeX@?%sE6}=5 zQ|d&gF`5~P3iATqQa<#(dXqu&(~Y}NKmPyVB;ROSW27;enoF<#<24c{x#)kf6Ojhd z5C4ke`p4Z=&eN&?ujb`{+!}wG8--Dw-Ut#nAXX7}MPMhjNla#}LF~WWsjHZ+nr8m> zo}2#(i~cp7bQ(ZiopAnbtN$+0c0#zV>i)Z5{+C1Ue{crMawA3l4f+3D0FU}mUbaJ zQegFX*47i*wT0B0uBy{&=UCLy;tRxQl3|p7qL~Xg)f4V zWfC>T0Kk~1L(d=U zo|Q@dh7|%*E^KjN;IdYoa`e3({q+(P{DKuO$F#ZP4_AV-JJll2ZiW3erVjgUYo_zo zj~z?WpcbCg<7cg3I`3R*e7dZFC}L&1lt;=@C~IXu&XKH$_8O_q*s0Y8TwF`~G1$xV z5#ivJ-by98NFaCf>|^m?AFmOdpRCPTey-|q?uoWSM3ekJ7wlQj-1(OSX zB3E!N?~esiRmCeIAc~pEB!%NJH4zeERKq9)ZUO`&!d`AP(VpU-_g$@d1mZ$NLE(fq zi8Vg<2%LI@d!52bRoCTeZS8ivmzUQe?$0sTis1ag2HEd_`Xt^bP!K_4I%!@OpLhxD z{rO8+>*AgHqoY>P#&UQB(n(A}Fvg7i^P-%_1jK3qN6zC4Zt4d-TubV)Kvd?hUe=V3 zdzk-qFON@g&!)+uu9cm$mEJ00l{!{p}iH7y}P%YYO!%1h0WqD;PIfdfiP{E-q40E^EZ3Hm}Y~ zkou&SkD0SBZTvQSqlBxnS6<0oar=zUm1jTprcXR^&ZaEigR>f2tnqa#Uewm|-G=<^ zR4y#8q(+*Lfy#u3O%oYI*cte?Ls{q9KYtOg?DRvyw~KaT&1 zpv-_3Ew1cG0%~Vfb#+;sbSFbuMch33LmU$eDYgKtw-VXrW7sQ9*Y?( z9Pb>5HC{Zkhr;DEvtY|AzMLmMMVW7XALM-Mt1x5TgM*_Yg8f;qV?WU3QxoqHC;8{gb`TkgGzUsao)MIBTRQsvzQEFP;M8AVrzMh0YRb#=dCzG{0u( zj+3su*i4^9!)*{mgT%~nr*?159>vJ{9UPvhHzv;8Tw(?pWvtx5D`m&61Ci9|$l$8Z zuBAd`pX;<(joXdc*-hgaEQ?qiPC}QQ2HnW~Uko`L5NEg55`EBU>9XkPklH}gMvd@z08fgdZ5$w1G<>}lCzQigl(88Hn97%jo_X~>{x0%kOJQIcSHp9M)ikOBTZs$ucG}q) z5Q!p+g4`2K$GDBAaF#RgmsQdYs?KySG{%I+`(M3&vNsbd{(I%waa41Nk0|y-8F07y z2giPU?A80I9W?u~r4ji88V7FOF;Uq|d~70Iqayw7@q&W0`#wn@)uAb0eFG#e7&SP% z^qQPh$8DpD{P(IfZcTQVX2@+BQArsMS*Retxxz2H(MY2Bvl5xx2OGk_=Zo|Sf|x?q z?X&Wbe#{WsZ8xE98VwRxTT54rb;R7pxFK@ab1`PdOa;i)EfcAy@clkg#msRI>|=ur z598U=wDHp?&IWTA!C}i@Vg+Rhhvh$aPqW>c(Y#Yuk3FWra!O+Q38$IrZI2BSGXvsC zlulX{BhZke=Ds%P=@`Vh?#|;NV!SAAYfU`pb!60PY&~cd*Uz(42Evo)#{_X&boE$k zr0KX+_8_pP#6v9MGTKBkBz&H2VIjQ1N0Dm1|M?M3aM^IP)j={zOLg4ai!G4QTvgvD~Z^Enduw_UPDqDfr$CMCqXr8QZx3 zq|y)Sv1ThI8j+nYAYMFH=Qi8E5TPGa>Nd&llx9s7!9l`F!!mAE73lW@w9z&>sT4O;xKW2k?^fVG z>a5K{=QP=)OdPM@zC*M$u^c{18B1eEL}FAKN`$0USGC3evr1!*Qz(n~9rQ2@0SLP3 zd9=|&|9e%#dSW5$cl-M72Q*B?K4U$XuD1+Jc=gg^4>N(B(7oy3s>)RaR6^%3GiPJ@ z3lI^a(Lw@WaW2`4c6LLoRjwol{qj53`<`28uJ;UtTeVQHSvuA1`STS-G2f%we7Q70 z$-=(jvX91e;x|*gvlcGf{;-v`{(7%ub=XBz1fA|s<_>(Wm_Wnf*84t9VcL(isfpi1 zB~~H7#mde@OQ@2Tsk4g*VW%#_wO%rXHYk5i11@o$Hv^$o8}Na=+bu8qChrN^@fMh0 z6}wk;=ElrBB8n47{kC{pVLTey$|#;uNB-rUsRQOumvX!i;^ssN)zxV!E|{@m6wiD1 zORASY=Mfio=&G8_HhctkRc*HEDRUC!X|I>N`UR}?e(OrISPJ$A&UktVyyX<;0??|Z z@gNcc!s4Ikd*)l9RBDpxvJl!kncO`N^oSg1Q@=LteQwv9h)^LdF;pXF%oxdgFo`^c z$#|Sr!sUU0%{ObpTuJnlc_sU)UEe1+7G(`C6eZPc##?kWO-{aEKWxg##nI0OJYzkS z7u(HUbXt|BAG5!HVofVRHdT!-L!%^dt#6oKBh?pIyckw21Pg@n%yga|fdD&;D^ z5wcFyjf_7Ix>Mssj*>LuGczTY!UPVVrXM=PNgv~r2E4ofBXL?Aulq~TM^%{^A}wuN zXS*%EjKg4&u+J->icUV-ZRu=wxh9C0Wm|*pD{PorHS~UYKV3ZM_R=1b=(%;vlOij1 z+6#})iFanBb6jGkvj`XC78f8|`IvzP=elvBqAAdvY_~fw%+a^{8ee9qq4?w&4HyT` z&#o^nn6am@oHvcddMza$Z#B*>JQF!%>hBKsOKbm1WIfh*G|9=9)pO^A$x%o({N<_q z?Q9nV{e3+M2}UG7_A1Eyy4DJ=_P2625xNq!)R($0VIuA$S~6aC?`+IYW za%Rhj1`;p1IHeDNe1^}T=I2;w70THk7N2BtUT1(fP5U$dRxP-C7>)2alO>qMiIB)R z2~UAzuzv>jK{)*&`eyGGVHTXW2N$uRK)nY&RT-kui52ESl&V-N%<3W12AA7;0>cv( zrD2_RO|&6mMMllt0FgpGOzX7AD*Cq_*?XMJzkC`%4;>KV$XuTa7MR%ii4AxieFoSC zfmu``kM`GsaHAb8=q(EuDrL%CpV5fIu4M94BA{dNz=qqb5RR+yw0{~Dy{pif&sG&^ zdt|mWwB>JcStcuFIVT(f5YpWHeo^t-9ovSOzgiQ}_LF|d3ZzCUqfA9~_*S{t&6ScL z*A1XCl^BC!q6;Lb9PWhEen{LQ`;5fY1>6b4Js~yA#+MC2@h8Qu^Gl_8@v)^+Evs#xr^eQb& zk=^51Da0T(9=!SV$TAP$rt2nLpa3ip_hAw7Za#T8F?|M8%Y9{ws`^PwfD)~(exmT| zO?`|9E4^KXOQ-)zc@NZNw!G#v{xXrrsmP37A2_sXppqzPUIw?w0&2qZ(5dR+7UhNP z`CK<3!j@amiS)=Le{o5-`oF*_mQQ5=2~IUM{XLu_HFNj_PUV$A8xnKNP8QoZM9a%R z&wE?RAm^OO-;K>{MUy16l=|nDunTyD@I7a|fbukOhg5QWc)rl4TXZ0G{>^3^Ppd z*DDd9_qc}M|t~a{NVoOv9h=rQjnU8t8ux$iHrq!;|r-~L#QfA z$ChRD3$?_jZ>9!Q7bAt=M;fS93HK^2Z1RV@3eYcBAj?RekB2;4QWO+8y^pNg-SBiB=o?UnfmEp)b){96R#Rf zf2RBst3Bhl7NNhGZ9>pj(fr>C?N5TTEhb*L3>Izd;f2NfGm6HqbG^ax-9i(1lmtAV zFP|A*!mOBIi)}?8$~m?{yllIiNLok=_N{S3cdv7>!Ha0&_RW}D2c~^(DP%A2$&vez z%j`!qe3!&yWoF;p=1!~_JvE8hB>k6#oS=fI-S?_&AK4l~SlffwA?mAO*7mSs;gG9q zxK%o$U{}ZJ2PoZlD|thinXT7Z3KQKOjfj`S25z2`i|0#Ybe%^mDnoZ(Rhkd9$@;20N$SS*eD-2DroQTEi0|-)tyQN^AqkSVcTL;cu zr{{$OGyuhKZ?{d=GZQ*3&T_f@5%%^uUhU9AGt5{X`|5)#L@iFiQzpaQg*<0HuI}T=Mbz(1jkzF| z#|&WKj50PDx#9B6>3Cx9PQm5bE=6__7kO7Ni$s5&(_O(B&dF#-e7C~Ah{L3B8mnWa zbh?+wF4Wk$>MF8XjTiBX_ zyImquYV?y>DILL^l;dFd4na%E+B}{SAd-eimpbsx5VYp*}ZeMwC}m| zC(?P{;R^8?mS;4y*_t4|MpQqTd*a|*h~3fPv8zK1%IoCxl5~$k5#Eima8~j0V3HQmgwRf~gT=e}Sjcg!a_WS9 z`9&Q^Dsv$^Y7GfjfC!gCFCm9?q&rh{*~zC}FPbX{igB+xIN1H4R8j35%&~}bmQ5S=7IACz<(%>v84XaCp<>aRFtS}kNoeg- zgBa2gH%*SOp;0xnvAY0IYmKSZ7je@A6RBzUFE*KV?0=glkXEWfIt)z_sWGH;Xy3ao1uz) ztDl;ke&IMlY;9K5zBeyZ5n*q|7Y*G%=@v|#C)}01LxU-KP%0o(r}ZDTiC-#(t1I%@ zXXPM`0MC1QxQrGXH;yM`fxJ!LEmp3ht?)ksas~(%$VFxUV<4x;;pGzRbKqp~y|Dhf zLV<;CRY-ywMhf{gr0w+V4jcny}=i{CTfmhpg*)Cs=XZ(fS>i4F^ipO|V zi(U>cQm|BQtorN*GTXt4@IMGezjc}#aL-j$-3QEP60H>Sxax*xh3uUNw0Ipjwph~I zQjD0}*@Ulv$%Bw_{yb&dG)lQy)AY!kL#Xu`c!R1Nh$o201hJU?n6n-86SK=RnK#D< z!p3v0mCdS#Gr9WPUSD(_TcRkd5K!^fw@0S@601-3Ho(gG%-wbOES}7P7+ulKV<6q-s5~tG%i34v93rP10 zH5b<8DQY47X`gD49bh<#f(v_&!e~e8GwT=K&>>H)#<}q@&rAtkthe(F&Uo?d1c~&r zg@UH8!ztyWY5%~0yMTYqfQcAlL`+dcuu`}?pBCE00xozJO ze@HehS9@s^WJ$d2KgV8a9>!0f(6ukhPDlgOG6UcYGgwPqxaPfHN#Hog^(30B5UdIi zl2fm|m__ckI+6G^o2p2y$fDZDdYxr20ZEA2rlm*-$?5}Fj~1CMbD|soJ9v-k6vi_> z_&9y}f5PV5S00@cR&)9as-Z&pVgjR}P{7`9%~lxlboGn^KfO|i!*~#O(Ja==6c~Vf z>sC%bQQWW0^rq=>6m$G5TCc!H>#NT)nVnXRde{7x%JQ$SinWLdFh6qh?v{SRjj_AZ z&D79S@<`>j=ZTjPl}PwUsSA8n*)IVO0y)r|%xId(nM&IGI3xt^*bvVSrCHupbha(Air5|0pugR`hR0g4 zBob5cVTm(&r9M0s-yg8&xUF@QHYQ_?seZI%j9|j*C>RgIXCsOXP@ELvmw{Le zM@|Za&+rw#x<9+-;H+>Vd4Jy;kk2%wAkBC1uG=-n8MQrads}3iw_)kZMiy8o!lE$+ zNc_f1p+U#(hI6avV9`{{LPWx9v%fwBE`#c<;LnH2!#xZhs;o(_;(ehd)CgJm$&-Wd zYzM?S;JD%Pjd_NoewFlZ7Fgz(VN5J%Pj>8Gp zTjFLMV$pTu<{5CMUo+T*aCyM%{`1+9E4PYq!$0yLes^p}F^O(Z=f&$;J!Rgo7(pe( zGTKc(R|z}>43sg(tPPwiyjneNAOEwcA7SWdqMh|K>VJFqH&Op7V9#@xykv=9nvCF! z{*2{=m*19I=0t3bET=WB)D;rv4vHQgy&P4%8)_lI;qUq2Wrd11;`T|DICplw)wsgt zM>flZf6(oIDtLoShrMDgeDsHYv-jW^oBqI-;bbo7LBHwmLI2&vzY6*l>0Z3&go>aK z>uFDy@3qjWbGv#@#?~d&tf_~_tzUJV)bi3fbOLC^X&S*>nj5M1(w^y}6Qnf)mmyCc<_V%Z#UdRClYjwdM}LDWR)#%qVr3|U6~q{duyc1*A{YFu3q;OSPmdRXtSvIiUAArf~Ix1Ko@hpQhT zeu~4)evsC12^mMYlOjI%x*QH90J;83q&~aju<%?R*0X!iCoC8>f+ZVY#ER0$Z+$je zA|s9t#f_wf+~|;Sx=K8CH`}E(bdbKDeN1_a9o}U3j%jo>bTX1~Y!kN9+V<{TPHw!a zww-k?Mc(>a%sU6oS@773ZD-Y9h@ACPNIgcc1gUDAEKB7P9hp?@8O{=a38jahcp(#=% zc^CG6CQdpos(<$jg`?ack-ksSIeZBh&2N@5ylyyhxWfh`QFUNR-@Y45EbDc0Ox(TC7b5!0Gj%C^{5 zPQl1@h>C)hA#p1jbJaV8^gbJhb=NlzJldht2OaM#*Jn{rlZc_T?y8bAxxc9s-ZH<$ zRX1uwFZ3{t^T`H7$+fi7xD~6RTCC2$J|dQIB=!n^O_x`k9>&~bF=V>k^i5Udr>N@q zz`=J2e_D;ljs@{a7EYHn5$9X8cW3jna~8f=RH~{+1vPVsGk_kc=Alo6Jb~WMwY}3`K4|>7fiwa;h_6i$}*AI>cB$n1FoSidp=e?bb|>8y-8jNa_e_;qeFF3v+B% z)e)`G^g6yH-@%{rF7vso28JEh6(+R)U1-WZ0XTMZ{NunlX5iLXjxj?+R+O66>c=-B zgArqw{_3q^Oz22Tc?pNl&VV3~o&d@336kHW*o~Ic%9=c_(;NM|U+(f-UA%&&zAwL- z2W-*`B>*6p*8rMijilIRWa-`|02gKLbA^UUb1!fsSwZkIBX6s`lj-F*CZSX%9aU1?>>DG zy7p7Cm`(nrSTrot<}Q9Z4NQ2;=$a=g>*^w8t68b_ORRP3JQr(k?zFR`c2Rm-JXdrG3#ENtyVl!gwjkP?4PAnb`Dl1n@Io99` zG`qI%e7X|lmL`pv*XrY*VY(sO&uaOz=YA4jKZC9Rn)r?-{`17QRHPt02oc$qqxG4n&?j0Bdu9H0G6I;@f@8Kw3HnY-zgABQ;fdxF zsXc-P_`^94tDIWmiH|%whN(s%eBh}8@!X-+&T&6-nDKn>Ek)p<+k8-0Piw*5?a%86 z)g4a^G`^qb8#V2ps!}EqHDh!2^>%f?OTvYg<#tH7?<08YBBgkk#?8o?)MqWOAS^I5 zJvj&F{wta{A5Y&7$$76OWI<+B-N~9j!_>vRLwrt$k=16#hy&c;Q2Dv&Z>YS`k45E& z?u)y~5An^a#{sh2^M4akm9K~VbEu5b`)gEYT+CWN|Sdaa4`z%DajcM*TZs+y*bB-2d4)?H9Mq3IwK=K z%mU=M+}GphD;W;dqz!FJ5-l`5aPdN?twh(e{Ac$0Q!br}$w!6k<|GPMLI~uQ_rzGL zT<8keuXKix)EavL;uMoKG|!ZXQpaCP#H*R#l!%g>SS8|ZwGg4_#*^8*8+s45W3=}d zEaL=G`)&rXEHjcN&7f*}wf26Iu*x3>ey~XIqkO(1bRo`+*O=?ADB!uKtY*o@y73tH za?dLIRR@6GU#UucerH#;d=zfy9miH37xe|)cP2)7rW9`*ddRn}8uE)5yrn zMSa>-`C|uO20cQdM^+pMjRz9lb1uuo-t5=ocbzb+i8e;+-aqcf-0O#YHm5TMR!n)d zw9o83%h>_Skrh-68$V3g@OvTx%+}UJJBx-pN#8O7x)t{&r!W5K7#Jh&-L{!&FN?v- z&&0E5X*5MD$oQ^vGi?v}?YM;wd)-O^>`|u+cn76mJZJp3>NCm_tQAAPr2JMVn1`f< z@sH{4-_W~s<#b$UILDLCh^y^ptbo_0bNJqThz#S|AVF44x;^PQf48D2;VB)$QuEg7 z%Ww8+RV5FPc3x_qG!`{OvtMqc`zJ52|KZh&a{w1u_>EZW-iMR4{DD|2in_z$Y_3d- zdwjum!0D@s%%XWTSbQJL_=9eNu9?Ip*sr+hl+DlwqlYC}Ez@Y-827ezwU)wWvWe31 zCP?=NTee1~bzisw_?ZT4#o2~QElphYyFdU6wbarAnXaz*^8NBq;$)CP5;Agr^q3{f zALz*IQeMs@Q1erjcA>AgGc5<^%m=^CEWELC#=bpo@02i;0J(G`E*_1p?Y`@W^R>VT zIIC{&8yU&ZJ=fct8X~KCJ4kxW1#iv_)y4`TBBNNU-nCwz3D@>4LhZEDNt;R@ts~fL z(BdV`gXKI_qZ=bex|750eeQkk2H2Ndgm|zDI$vEK{v@)JbD)n=ebLT&GsC1DmR>D< ziTc*PXT@KjGvQ2_r}@mv$ur)H$AH|NRO%1%EE0#yopi&DnT#i#9`Aye>)!46ME@}e z$h+C`D=k>R!4B2hB^7&s%?b{I4&LwL2%IGYy8{c3&y#^GYp#MqytuH|RmwG!ySNaO zT9plIh^b7OgR`gObXgP$Yn)D)$%+&CG~M}H^OE=Ltvq?N{rCIEy5%U-`~<)Cv(-j@ z=QDk__(zSh6qE)e5Zx$OR7_vTPF*$^kBF>{L&bp4bBK%vJ*AP`h!3ly;jiC#5l|Ko z?e8nj<>(7ZyFZ|*t*s;wXAV@zbD;zmjQp+4A_)C`wFyq@{fnOdDe(sB8?*@Mw#!n8 zP@YW3{fytkfL4hMRrsn-Fx~p)3tJ+rOn}Pet!Y{iVEvF?-^{>u(7;#qv`V{@2Sl$e zn4DPiLNs1&E0Kp^hOxu9TcUnxmjmx+FzBzt0MT-xPW10$yBanD>3Q(=kE_i*ZhriR zvpVDfKPY=3MD~4qE$PL3A;{J1dxPG?A)2R7C19Jw+A=%cxIL9Tai0+hRD>c?IGSnu zd;zNOwgA1{P&<3|*^`y#Xm4YtC6r#=<6q_^6GP&8{?EH(hp36Z`s2=(jefe};x-K@DB{AL zgbVOefrP;|C(}S*9!f3k?5PPWWNBKYSu^yRPxY;)9B0&!0$YY{Rl@Pps)^thgIfod zmtO?7xwZ4?ywzuhFy3mVM;2Zhp+QT%yt(M_U__)9MwU#KZuNYz)x}(KQQt$BD?44R zM0r-g$6TDucEY>JAAU7y1{~S|x)-+g44aK>TZiN37|KV2Y8c&8Vci?Zue%vfXMtBn zc(i2h><;7TT%O63h&WME8}}U^F|x-*HqG40<8KaV<%svHdtuC!{*VlFu4K zyp%4xFJf3MOpbLJ<+T- zRe+-rFob^enbI3CRmN{Ryj!=@*9kp0!7Kh_!k{jH^ephhhwW1L1O1wu-0;H&PE92Z zXL8spO}m9WzGVjg!)kuP@C?o!hk zVG}W4(F0Gs^H>8}4z7BS6*4OTz7MF3XkJ_F=-z-jWNESkMxfWS8wyY zO)cKo!smQ{qakmM@({we6~xoR$FaN>XvVk{#`owWvQda$izp5(Rzxrq;~!+MfIB!a z3i+neEADnjeKNgt{uL{dC-BkjsjQ>R@uR4bP&uVfbpD7(i8b~Xob(6vw`RcUY^;>s z*qN5R=YD;bJhk&llv=BqCtoSEozhUN%i?G^O}r5Plc<+##%l`+_@zG<-n^E)wO3Cy z3a;g$2X}1CNmU48T$uS|GQu@=5Zm>%W}7>6#w>nwJ;I`dY3!`Mk=3@R^)Z5>oQ74b z3_LA|BjMlbT77fe42ZXD(Ez$G2PGkGzAMYAt?-XaxaqBZnTGG>9>2j&e>@?m4ir8e zX%%(j|0;g*R89~N5@2t`a(C8ShpHhMLFFdduUy*e?#0-^yrcm$T@j-H` zB&1^gvb4+XXj^A_{M*P>ynu`z2tk+VJfjjaXUFWz%j%gPD^ES=)q}p9wzCZh!h z7h~j!6NfaBnMKwmvl8arPISrqtXy*P*UP;=+9Q=q)tve|1_t};2yiDsOJ$yB16Fft ze*2OMT>^yX3|g=4e%Xz@$2X$r#?f1iuffH4@bq?Yk*>+!ZedAY79^wPQNi0V(BfuA zH}Dvy!y)p;Uo9k#&Jf|^Qc+!&v)h=HU7>u1B|urgC!Sx*CvoAq&S&Ty_d3VjD?1>I z`R$<+fuSAsf@BiTbvfT+hx8J4W+R?HWs8`Tk?d>n2js){k<|-y_L;8T6-^~$sZ}b3 zG|78V-V)&ejsdFKDilUTb|v&S_%#EHX;eTUKUgfQLhHLKfJds5p}kw#m2-m2Ual$8 z>NpCfsChfqzB}Qi6Hgp~3uDNv{q<|Qv67^ec;FKL;;qt}unGvbM@Y1+gSj*)bX;q?sMtrp)6nn3eQ?T>oyAGuW9E;N~<} z*H7g%y*jT!E$fo~id7twDI{hZJYO_W-MEP0@6hsB%eReJ4xal~OY`XseJ08_r=2!t z30Ix5c8dpqh?-*Z+H69+U zx3L5jRgNc5ER^U!SFN0BNx#0bN@bgI2}4oooKer3=~3Wr* z0BMpE6IwZCd|Qg+l9bFC2B;3LvIfZ8Ei`Eg^SxBAnq~?LdU=xwwjPedASPyyvqckU zUPQwg<7G)(g=lxIQbu4xw89da)lUYOG8%-bVjj&lhS+CaVRp2pl9Aw(*HN5l9lzfd zMq^>}LGX(=qfqaxmf)9U$d^=dm4VRvxtU9E%p+YI@V?DwB^YM~SCQp|a)Le{6dImP zE9HOkbT?r$&v#r4;%JH5BnT4euyWexG0RuJ^WbDx<3kQwLsgO_v{65HdSl0UtuXn% zj;djevK#Uy@fSiVil}R|3$9z~E5ekug$WuEA-Sh7CFylC_0JTq)zsG@M`O+ZYifM9>*!YMN<0M zV(RJClP+q%HoyMkB%FY_;adA87OuHfm-{ZNLTlSww}mWim_szG=)kO;pLbqNU`&@w zrcc;~F&m6wA^GXB%iX=+cLmahqpHXA>y4ffrOjHuAX1vTK}wXi{p9Soc8gHt5@qPl z)YXn7$lc=#i`^wbt`I1UW7}c#fZC;a6C=;Mom<@>=sfzxX!Mr)b?g?PoII^S$F6SA z=+@_?Ggxyt#GxwsEva{(G!DP?q4&VRAfR+18@RlvZcxXY%^8_zr?!}?${_I29EfrP z&0hXWn6*<3*L_2hX;7T|VW3L=4dNloK(_V3yA(6;$f{B2u`Q#O8hu6pVTL6m^e}Ru z!UGn(+B})&$>Cz&BertwTdZuLyU=M^9T2v?f95JV8Z!0wSy3v?|-L zGpjgf!ae9$+pqfHyv6vPEcEmCF3oIc7{8fK#k};|8Y?VAb`al%Ep_Oy+@wlAyx$^* zz|v|rJ+!ZK$11yfMCL{44-K)TE{nop&C^r}K$=Gk#|RfpxeV`|WI8lxvjc}eqdu@$ zN|Qn-(2b{c;aR1-e!c#h+np))mZME?ZWqeS{%}&*Pv^}L8{+$$w`(qK@d-EC_+wSk za^taj3C=c0ArHEe^hnu9*euO8qRQMGBzHPL?PRJ-)nMWChy0ec`@$)&keSSy_XJ*b zDE}^Caf!7mCAvJeGRMx+B~lL(*ck_Xr)o{8fDW3KJk0EgHsy^7U}CIc;(Vz@p6Rxe zp|YZ`taNyv<VquN+n?I`M3j8w)8b3Ogd%c1+=C^m7<@@Zh4>o4R zrIs6H7E{D(8o#Dh&n;HXoH&B?$~+$&-ff(T^A`&m8GGh7SV)iGtj|1}@_ORA*MiG} zu`}))bj4Rbxz~vBM+(Z9Uuf~(vXI;*b;*&ecr{fkbp@sPVxCB_w6skLs6WjlK(Q!C zIOs`~3)}XexNx##+@l0YgBEezAl8VJ>uKU;e#V=|8xZMzw%XoL<5Np5RFlW9w)|cT z%{nKjEGGUp1FF<>LtXMQ8>TQ()f`BGLgXmaa+8BsrFbnJ*44Ws5QH!nT(r2spJ|p< z7!u?8Ry~_lCFY^F4$UhKN;rIlFZB&9W{&@bHan?%wY%RD;E7m7ruNhih_S=Yd?0(! zK$Jy7wLW1NvUA0_R30W2D)ljkD&sI`PKaAFO(!G&@uB)`zky*feIvy=7e7qJuIIC_YJf7TpCT`?eSNgP6oTZQKj9iF1|JdVOFBfut?Gr zZ+Cr{JvGioSRbcW#j=Z0WZY=5PSak{2V?@Kj$Pka*9c*v9D0lpoPi(!*!%JE`^dmO$K5TGeiIuMfJ4$oR=1=KUbDOX34&AoiwAE5NVd8bJ$XTe0 zpIKVc?CZhP36>koSnRM^V6Udtm}?c`l}?BiU)(!UE`7M=1QHuOyql>B&zU}!?w?Q@ zOvJ=gMIZmL&6b^Go}Uk+oVp|Mi&flr-G80%GB-Hoo&J&)J32wdz&$=E^JceI?&fv# zDe4O6=mBDVBg~TFP-)(9&4#PkOn$2CPVBrAdY7PbB3I;Ua6hk$;_hLn!|uVnN>7@p zegaFbPO|Eu74n_@>8N3K^qOaEaeT?g$Pd^psefLh<0N2$LM+!|6k@A;2G=9!aE+JM z%dJNfTBX{s(JD;!Vqoy?8Dt->aTRdIj#A1F-{AlavF29>xGcerbm^_PFc)Lrh8`*v zt(h+q$89(P@~b<{P?G|7h+^M1f;ZEV$$RXDe$$?Ik9gf$I_=OnR;%g(Id2!Ji-+*c zv}LkZqDvR0Z<%o?l|7LN6mCU@x{NG)aaoA-qIMpnc9!l3anOtQ8O?zA54`q+#szQW zvHE2S6z?ITBoLG(eNz^_F8-?qR(5X`OqXDD4$T<}Ux!-NT(8YG;6cpTS+#du zjg)*D;vy2dVIl9dv}(KJLsZv@a=RR8?S*mNEh;Lz*+9r`2HHUEZW_LheN~dX1KPF~ zFSO>nzbuR@EKOMoL#VA;qVqw11IArT+^njqLlq}#8-PaZKgR?^I^e`Y< zCEO&vPZd_6+KorxrUWwl|~ouRmk zDc8Q`o-i|k>X6vj_X*uKX+n00p+)^LFrFvM%2)qWQ_t%p-oOxFV_l$)#7;%y3N<1F z=$ofg-PyHGGQ!c}ID+YX*L(PF_sLpvS9R#Y!F4RJdxZX-*YTv~>XK=O_X`;SdQMDv zQ>o-rlG<8x+wfoYH?incFTSdbeAVyaA0YQy$vBd~>)rP_q)tbPDxF-)PTX@giU1np z5NT1)!5eM z6qFK_y8PkX;iHbA{8V@Xe?UfQ|AT;rUB;%nViYMQ7pn6Itse-K$oPeuSmjoPl?9YG z-`!RZj8I+mr?6+jaE+=ztV;?6xzQt|cHD)juYSTA7wmTFZDHWYhEzAhF0tH*eHd7l z;d{qW_xt?R1D%L5*>3mhAM}zga<)67Db<7DO^S}FzEazmS&il^W1vf5@3em1$g1pX zJiW1Fq!~P(YNt;S!giuAg#`QK#Rt-3SEls>c>opBD7Fw(m28jg%R3x=Xu@KnZF@(G z#pZ-Jj2YCP`yz`m!-T3j7GIIvCcW1+?FPqfNx#|`^kW8kL5biDcSbkM$ebFzF{1`0 zEAKqDD|h3YCXV`Um}vp}O1<)W5tlc6JI+2yOX=~m*IE0@jMkYIsmfi_<_iAc$Snr)8App z9sNCDa?MV%e==lwnZIGk!4^R;A6I^565e>>#v2Y_%#eVV@>3$W?wLvy%YQYK*|#fg z(x8Rg8s4S`2?uDGvkM=;vv=T6i1RZU0j!UZ*zr54Uwz)O1iQySZHi+*2jt;4U45{( zlF;Uut})EByZl77!;*X-;|`3x3hKxQ0!pFUhdJ2{$P*t%(~e^6QW`VEIi&UdvCM$< znb-BW1$z<09Qkb4;+NXxU7cA6rS@-1y|+&D+&iFI(@!adxppA;HOE5anGVR8T|9G#IBGeWfNzj%k!~m`|ENLkM!3?CCyW=SK+K+*g(Sii5P2{ z=j$l>6`2`QM?TK@%!yM}?ROP^hCmrSvMak{vAR zEK+jHw)S1u-SWhxdpF8RMbb?ZCThl3QK%Q;_A|)NL8@MW?UYvTI?N z!{{H}^>Z!DYlE}y6mt{4vt2yQ%6T404GNIk@m)Hw0Itf(_F&h;5BtRW zXokU#9IFms6pD6{a)(dMaagiOtmbrNXJV#qG1X{o!Gp7S^@OJSzKg8IGJC{g{yg6` zM5#L>#po@k!XZ-9B5mQD-r4qmFKDo!CqrNuW)@TeGBxNEWPWZ5ZOV2kaY;!YO3-#r zy9kF|UXkRtpJR0Wh6i8g%d(g^6A7SJqK!X!c8--Nj{LD zp6XpiqQTvT@P7MI6FC`QXB$>$%M;(jB=5MWkk1bsEiB1-qb>80UwlE02mYDN@NZ;S z8l?y|U$ZXBO2!xqS)m5C#cRUxS;X{CImKCV18ZO@$^h#(9#2I?Y#bcm8K9^3mE=2? zpGP%!pQbf*5232@yKHyi&%Ws^eb-mA_z*|AE^Ji0<49Y>34)Tv^gpEl<*I5i@ULHS{A?rF6$C_AJEGNz-tT z@3Kf7)`X`(CM0+)0EHf%2Rp#QT*$;APa@&OtM7zjkDQ~91y63f%4Y{%Ycvwzs7hJQ zXL*I*2Fq!dRDvdU{X5*K<;IIn%d^Aa)MhPpe97?A=UUi2h`g|PgSxq65ey6$Xb5Yc zX46tC{G5~ubKcHSc+kRsxhVH_|426tuw4X2lS+GZ~mO6McKoCJs-OWPB1&23pVGsO-* zs~4l_^6OpIGnlt7_U}9yZ|#5a;w4Yv>3DJ5r(z(DB;bCK2+}@mx?_?3e!%kS@iUA7 zrq34}!^wVh(N`;QtI8jI`JgmS2G7^TYHjmnP7G*g733kKZe@dM7YoBVi^$>`GcSP# z9GM=~=?WhW<8D#UeJ68-u1OD~$(0t@MZ z2nFy9<)CX3xi3~H7NH*V#0>g!6I7kepOXFxXB&MIBw#9 ze?D@U15|KKkydU)#Qc~PP*YmU5+IG98H%eM0*4R%e{}tIRFnVz$B(}ZL_tKQK}6|R zS{mu@QDY!AVuS(%NfV@zj?v9FMsDOlMY?07L1{KZVj$@kU+>TReSUeav$O4N*FV>F zo#*|2zdat$=MzRZ$mTgArDFByA?BG%Wwh&H6J#)nL5Q4e(by+j1434U=>$sIh%+DG z@RK0o9$7&K8d(dj@|DBHh~q~yE;1el{uQl$T#6mAx`^ql;xX$m+w5MuQ?QL+e!EdK z1u#1$ef#jEklz(T1+x@zcf-B5S2466A1m;mbeE;mH?ZY#t6U$H2eMsWixe8aS~*`Y zI`d%8YLWE&MFUNHF~P@!RH`AA{WkEl`dEG_kl6;SY~21{TaT%FG6#NAvsLSl%s+-T zva&wtt{`)`mygiz51H7@Vk{6l8K0avvMTy!sIGH%*;);SSedL|@Ft@v7ZBFKA6IAZ#)?;T)|$NjQz|CkyQ z8p`U#aPsGYv}v+mb17u@I74xd7l1&sjez^;{Auo9bm5t{`+)4joX};E=eZ>QUetc4a46*pr-#<~*9j`oMcPIG_&k&!$h1eW14qDTA?+c|OdkA9STL zEgU&#=JpUOzvi|lJ;et69bTU#bscz}mhw=o0h$@rnCpDC#Bo!SG)ujg3(MwBVf*EI zan0BS)r$p*e%rSz;|7RkBNYD)n}6WKu<7_tflW6X8FTEPfnw0^bi|wB8kwJE>Tq!n zng>y)Z2KRQRz$R&q62W`+jyKdMVSxKv%Eseu07P@aMbuVvwMhR4JV@?n@+ z=>Mfox`V%|)8U#Eq@mYf@?*e<*38;z+uG94Gigt{7e3nExb5gM^IBC(&vgZL;n~C4 zIa3W7Zm9*58jox5FW6=d{2$I<9}EZV;gpd_DrSwLkdD*XGS}6ZmxMk0lAJ!YZ%S^S zL&5i(JYQ?tfJsMo$>!d-O-Q#$nJU7PM~4+FC#F$n&LVw}xD=~WKeaR-eja~ZCuy`m z+l#xoenjc*oDelXJg{H$hEcYs(#9_Y#@{4fYCIHy*?2X=-N|_zLPQ&U09MSG)aMwTwRhk5cl#vxiqWXC*(P!hFb?#;akKpxCY4pW zV1g%qL%XHOa(c~KF2}%qXD?Iw_rR=Qg`Mb!l!g`F(7w(5-?mn>Bv!GZZ0eRq2w#&! zvDdiG95R5e4wJNq$bD$ow{ew4?wu0()LBLiOg;dkSUToO=%3oo-8bx#uJ54#lzZHr z6}W4is&qge+~oG~cun8er`ohDIr7e)zB`kI*O=2i?+_L5@GolNUj}?dV0FpGvK`Y| zY8BHmh5>WAxvFbC@{m;~0g?+i2yi#FkTMPhpN#LUK* zSJe*~W^ycdJT_{V?>wEJYMetesjmKc&s?~D+=l8Wket93r*l8O*GeV532tF3mbGVb zOC_%;KGvUQFM!%=X}PxkDG_hc=a5j(nM!`&B7EE2+mC)FmVvO*<=FG-pa_n4U%He%zk zhfOu)*J`AM>a(0k!)9o!8*OytI^G~I}cU~$d3;kh)gN;9*!LLTVbZGxv*q` zlp$L};}e*+;&gP@|KwRPv-O7MOMp>fg#iZ6tXHIdt<2@-9&zm|&a0XqP?zOCD2?0&*W7W;YK<)(7C2I6 zmZ1q^^k7T*ftto}7Hhd0XC}|PYZKjj9!u3dmg3Z~4@~l&>s31jCfCiAs=HssXRpu3 zUFHAmU?N#wCezMmA{S+py$9&Q8qZBso;`O==Jh8pzU?mV%B;dk)e9LBiRK?}{Fr7g zUE8n|yS{1jPMj}jfz-bNAJ^m$0MgK%aSOO*L-Vfs>}2{7WPDZv_nVHdt)8qtqx{}Z z?>q<<83^zh$k;Ae$y2g+L$$e7#Ej!#6FZ~TITpS=w8t{5La3hAtC&9Gg8G27GodVc zrCY9%xCzv9>FXqn9<0_f6Y&&bBJIAQ+bit*%*~t(QG0)EPO_>)SP2VQ0t+Z)Zy6ky z67fy>s$w0)=nqjou8oaYp~tv#$~t27nOt?4)eqdM85mXw)MJmcJlhN$7i*xELy97HjJ2$@k0< zp|DCW04x7jy_YN8T5FOkEt9HK1i7Z>1Gyj1TN9cI%l`=3``=E%){HI#{N#OF79uC> zo_b3a(_V^s=P)e!zhb^mX_>cB_yxJs8sY zvNu}bksz9pj`67zCV=)XX@OAnBn*Q^4!+5g$GO4f$9 zmeoo4BM8nebyOYS`z$r_Fj1yuf|~&2Xkxx{Zlke%+x%~=zH>(H;B5IfR<~=Utp-g$ zo%Rgu$3*TLhqkp5v4_*3`AI3UrD;C|1slg>3Zew;jk}`X12gXLYWJ5P%r zSkb2~jy&$#y{YxjW!x6h{%_nq+I2xiUt)kpPPI_(S>D7bIqdXN!Yxx7@%ri832}qo zXx3XZ2YA_orKdHqkI}Me&y*`>L6zUP`3V)WNu6IG!4w%)+j1+YFL-{OMMnOVNs}c~9p!rej$p$YvE2riwjhXM~ zfm|=_lu4B|U-P=w)STjON!(atw9ts+enKOd_$YFnngL4pZqMMy#%dxu&WW6LIeXIH zZ@zPyeVMr;)J?zQf$O<5Ag6~|*cW|l} zob#CKDN>#OoAY8;yfAs3iwzRu;OvqM>OHoQUXa3|@F%p{aa*>kROEoy=Ag?3I(Y(< z=9UPc-avl?{0J6N-;SS%vtW=hM7~@%k{l~D2L``@+MOaO17#JT{eWF-oe_&~6AFRP z4hHzkhKFR*IH`-3i4bx|HhblqY*#6E+;X3T^}+|g_=qb#=E|4o7yehp8WO1w;$~i3<3=`G6(6?NNvtrpm$EVV$ztNh}n4V z-pM<=w+}W@JP!3PD&fTjB9FAGm{Iof@M#%SnTCeD()XdfJ!VRvFqD%m%NCzFV$C z`NqT0!|muFpEUZz>AJW0c{_EswC|Zyp(TZXzD(v*Ieb#^q(_uW+4wFc*mz~)?wYAs zP`Uc#9%lS{`N_1%s;!>tT>V)8^p)IgKk$ReusmGUR`0K0yC@v`G9i@q0-Y zL;bcsvrKSw`k}4|MnJ~cK_!sEGz$Cy@guY$`{Hf5-qgqBlWNwZexOsIPDB+1&?3-z%a|crBHyC`{ z^RFGxT_klpM^DiVIE4E2sRCOyN;`*9fIXi4lqL~$rH2}7~DM@`5ZuEYCIV$ zOhqYUv2$k^t|M{J6WSdJ@rx(w_8t$&TbO6!@+Zj>mll*RO-5WBt2~I~8qxcxAV(i* zV`ALC=%|N-R>ww>Iu8E}34~sF7Y__;N#Pe z|CWcBdKd^?gX`YG#}*O(W=T7_meGechG#qV*Fi(|sEBzbxmAtpY=ufT@rRBwRyTZw z63zK;87#mIJVfN8`rlVv84C3bSQW=Op{WyQK6x2tmQH9YX0wy9=oEOIx{-l`%AXel z=QqoI1Rab*(H~^vQ|4uMgx)wO?9SVA#;@I`re=5>vdzMmmBr$0{}l4Cn;=`ZVXon6 zGG;0#N;X9|077(tS6t=ZdSN2dofV;8ioFYSU0_cIIB zU%L>U@~>T}dv19N1oZRu?+mj)%vomZ&U>a%Iu5E--Qi!`g6Qx!he^-xs3NHt8wC#4 zx&zfI4^|g#qLgmw)#zS^ewv$3#IC=gem!yM$_X^SQsLu} z(8kHEx%$*-R=&O54#B+SmNJ2NwjIDVx??mU93!?{ccRu#+U-WgYdQ-=ZzCB)g{jrX~i1QMv#}!>R z*a97m6H3ixZA9M*J;cKci>y4JbV_1LcM6`xxc|`H8sv%_;QwEByXcig$0{{qc*mLe zK{4vEHTL|S*ux+sBR&_Xz{^AdiWlrLGY*~4gZj=QZ*JfD18r{;sAnP66^Aw^&bjPgVV zeBJl6u;2m_@fBcVB2XY29+m2tzc;?AsylC3tTpzr$>eY#<0-O2Cwt=Yg_dvY%wNN> zMT=CI_@80G{MRrvzL1`H_8-HbPqJ057&rZoVIU7p0__v#rUH+U_z^U+os6+M)Go^38gjRWaKXIy{meo~2RyS`Wvxfl+<0SbF4Tyo;YHH23h@{^w zFH@*1c8$o1@owumbw2x}zhs=VV_O1d{&In#$sPR3$V@I|QgoEpQbHcAc#?kOH;nZY zAx`9va+h3u=LC+Fg{WQ=f7QMn8*qvOv^T(BNiA*1#y6AFYW6hdVe-pMr#<&_3l0d? z^8ylYE7rEz9OJDiM-_%jSQ)S0Lw_%?oLte3sZu7T+< zn|*`UdrYnLk&QJ+*aQ)4;ctAh;R;c4^wHN_4q_Mjn2Gf4P*>L~Dhkln!vfEsUlv27 zwy@O6Y1y~yO9hr=m>L@;AX!Q67n9CYRQ8TSvnD*v?=)RhJ^*h^a>Ne5p$(Z#&mT1|d^ z*&0qbBraIU_Mn(zclF$Y{EH^$jx7)0Yf#~zot}dy+ibFa^J`;Viqx7VquGRubY@$P zz6XL&n?{ccj_S7NO<>@?lTjTv@A>$L6!Nrzyr7Nz@rm5mIwCaB{6TB82ZHT#@yIQD z6OdqObh>+w1hZKz*kmMld4fR3zhzJNDgh2?gO4Mx(nzGi!NY=m9495`;mt(1QI^*%gBG4I*S5btl*;F~&!4|v%*($JPkXsys7KZ% zay}?Kddl55$^zMn<+lxaB4ey~i7C2Lai`12SO_+y|G$_*>`L)v2_fqrKCA%WT=(1NI(605vr>T0Bq}7ggZuIaDGKMUfI#mUo5;b1 zW}Q%W#e`f;c5YJ&rAtLO)$$GRYmM(_4QC>Z*Rt87gD$%V^pq&dl}Uh?@&v-)yFMESb+=KLT(CPN zj!rYF<_I)2JCV$+#pMMl_%`p@fe>>MsM0d=*)JX}(Z*7}JqEJ7$(3ncdXk2Y%NFk0 z7v+syH7?S;chfRiplHl69v?yM)VWwzqM?`#l!!=;dVb*@8LCZK?U$hn^AOL*_#bNi z$CLyJn)`HltW5tID}R9T@(E^;d4QfFlwaZw+~xY!40-eLSG9DuIi5Co>4)fbdGPb& z6KzuI>yTH59+IjCf1bAK)~y8jy4~Kg;!<35&quu`wWdsoZs55pyFT@2Gn(S6Y)cO> zu?ND?%d7rEt&_d$%EVvd@qPN)o!1g2FAInFdv?7ZwMwXWEyU%dWnOZRAR_}Fv%lPf z=znQRL;&OeZ``9?TY~;x6TiU`NN2f{w?HhZFn|5bs>l*>S-0pAw54gWFm4HDcYEmC z@zPG|I}<4G2^;0^pxfTL7-VFgGV0HHY98?zPdCC6(RCK_!-2M&IFh5Q(f4*c@)bb) z+h67ZydBS8`vUTx9^P0!uA|4^r@yFrm##^S8kA~=czG1V3ysE)hwd(=|6QSe@7^E% zGa;8ZYwO`653?%s4cO)yPzS$15cv;ZQOM$!c4kfU7n%Z=PJ;LkY zb3)m((OVy6^mAld^8<~TgNr^=F1M}4-HG=CDYgcb2~JZ1s5@x5EJw#j(rmIMlfFu2 zlH-g%rxrkM5ufVxUYTzbYjuX$9(V~|5zkb`asw+zn*s{0Ht7Q_wSjr6(WXOWVw&1y z){pw70XqpIxsx^yjh~3%N@z+Sb99_1SyG6(Sw6qTwbYHJRKC8zS0$E<(HJMEnYGwD zKC){*rUkh(BmuI<`S)4$F{@E8!|)b!lJ#(x)Jk0+Z$OHw#|)GhCbR;WvecYI2r)m6 zZE0rI<>6r?&F_xyLIHiB-{SmvN*OW*DOT2C1Y{yccE(&-fzn_BP!=>DT9N-%K=C(j z%g8PDn_nu5+r$yL0zX|T(;li3a&j}FDY@JoK(CUu?zGr7#cMwanK3t$N!Z=w*M-dG z$6e9M&y+7-F)eZ7AU4Y+(RTokll@Z|&lo~=R!xmNL)1!m5W*sk@=e~LdxisJ@4$#gI?*Q+7(U23O}4I>AM$Yy(7Q?qnt3eB?KgZOEn$79}1%? z+T5rgO{y86`aN}e(MwVnJ%w-HLLibRNCL&!`O%!qODXA6Kx}N#(?T=I8AJd z(F(7SbZ(?V3djA9k2hxe2$k3pVCV;9vM2jHG3fr&NlYs2Q}i-E&Jzgir!3m$L_DV}d@VCk-Q^jH zH-@;Z%%0fC{Yberf8!c3BqDwCJvxkcf*&(O9RdEH(#=mt9H*MnBLol2HqAAn)SLKx zKa|hqhKy3B4LWuz;^So`fe;NnD(nqO;Diky<^`o6qR-Alt#}=+Jz}f~0VXZ67@Rc` zNBwYNBu0d!QKpu^!U% zYlYV}>^w!uW4QBY|F0_T``%K zEbz^xI^|C{7(Hn$RnOm^Xs&@z^5u$xg^mc9agVrxTG{jYr}mP0yGR|6zN(aZL2O5w z-nyt;M;{Ky8gp5(uU$abn7&+BNRcBuuy^ssHjx} zdb3U}*H0xfzrf&}M6Ejq=hMLzwf5zc0vRp zARNt1L4A9ePEZAIOjTyNPLX`U)#w|Kp@xctyt*&A5f#Clf^xIVq z5^9|hW9naSx`E%es(YU1Du#B^eI8E7&3c8)OF3OK;Vn9SF-e7i}xWyKMB<{JK% zK@a42Pbi#l-uO`YSJ+^SBj{3N{x(G&i0*}a&j|4Rm)fIY@+VVE?*F;?bQ)|e8OVj_ z13PaTR zq9?ia(yebR^FN|XNlZBsP%vi=-5Of+Ikt`+!r_Y{1`iy=O7qW4Pe$rCii4msWtQmc z7IS*MV%JKJxNlRqtnN}V(oV)~yuEq_4)kcSh?zhKF^=7uitqG&Z`K#K@o{nMN(qg4 zGg-9$gA$tF53`KB7^XVcdSKeDPq(2}xTbL2TUOHxw~`U(c)2u)Zh& zhkQX%$5m!q-<&js7D&+wEsGAOjKar)O=&A-87iR3CZxB|Yd7;;up3!Mq1+W0BCkqQ zGy2p%fu+lW?uZH8w^G0%(()kTW#hx!oRBd_2pKM2@i{$foF<5EMSej3$`i`|stjcI*f_h(Fu3cYvxa5ya2@b| zhw%+NyzQ}Zc_pVuGw0s-0-#r3azMRti^i@s<*1V@TO@wI1_78d+d!AKXL%C1@M-}Q&<55$~4r9 zDGWx29V+tjd%o7)tn}($SnhnseE5>yAw{QEf$zDL3675N>R^`hYYC-K65nLS=uF!v zeBwmP65NNSOd@Lz0QoXKb^5Zl*NA?D!gvCM79R=7rHgjIu8 zx=iDS4b?7rqy%7%i{Yb>lhR)Xp9kEPC2x|xB})!4t|AM+o>{R3?+PL!?+D7$xy?0k zt2BSTIU*>f2WR*CLAR2`Mi*qd$~ob7dES+w_I^h! zWam^k3f}d?yoIQyyJY8kXfBGA87$t?AF!EJzh!0H4Pip&3;Q0nZHOe!_F%uIbmj-4G$Lvhy{IbYZP-~+I>5wN8&Qf1|c3~PeZ`xwun|NhZaD- z6te?6$v9`$F2``&YV^C_wPlU1tT3nke&vrm6@bK#mm7}R5m7^gFiWfYJ&Ol-7@k;B(GF2=>-5V+OWgf8}dYq_i3lWtXAPzmZ#qP=aq8+syOZ_7rH0z{-t z1_?|Ur6(=)QPeF$767xyp;Q({rfg2CO7{czoc(D~Jo9?NA=izU2OYI5N7d;jE#@sR z6{F+#x$3iTH>vZNI1lCnT^#7L*rjQAjp}vid>;EIzjCg-`HA$g$;x!x@aNjaGmer( zq?Ljs{cg|wdjVUqP|XZ*;|n8y&UiMiYsKB3cEyD!oqA2tYc2h^EBTFk7MZ-zW?TyR zn`IQ+jG-S@bOFxyI=W1`T(CDa6$IGrV%JEqj$)Wd0v z2bi=JmaWg1CIMn?yp`u5%U>PbY{mIp$DQV94f+qX_sXkR=E|Cjvw!-hqgmDI?++759r*aqN@YBrzlO$&PPPx z-c_YhFul|Zily|~j86bT-kH?d2YGJe@pQ!q>kZW2ikd^Cb{ofK7@CkTpDEsU;)~#0 z%1<6G22H^`UuZ;HCV5Y>2aO5|q%KL=v(k_qds&+C?MB$pB})A6>UCDljAnr!dks)L zQ#|+LS07X~6ZKhr^$mWZE@R58vI01g@^UPI>>@1;4Cl>)<|pw=y7lkkIfIW^&qFF0 z%78Q98`QH$%u}pr21@J~Ev7gOg~-(4!^qw`<6pF{$yqnX`6_$z^RG5#;8=&tOvbNR zVKqUxVxbjBr-~;2tws4)YHKpN)+M_0+R7PWLb~6P%zBOVDNTE+z>MPMkG}b)-gDi( zspWHxSI<{cj@;Ban7R1a@{T*IALO3{GBTDTmtFWa71VrQeLq(%xG;QnzYnVQ$q$KA zK2XKqH9Vb3qBatS(?Z_lYU=($%oj#YuYclCEd>zGdPpOy9O#5+QBFHmZqZ=OclJv5 z9sWZFUT2+TNL7O1!whmm5BKhz-~nQg>Vl8hy}aKuZ?Ym+(Kotw_}f4d89vA?E}WK5 zhv@NX&p*rhyQL&FU62DUnferltBWRq3FD|CaQLj_i%Rv&ihfa7+k##k^X@~Z%0QK< z4j&R{g#D6{W03MFnjQ?b0fb=YeIo|Xw6sySYKR(YX3D%k@ifWwIA2R`eR~1flXB~o zFKQBSs`8AWK2sGT=#ho=&yva5gLmvF_Rw9_4v9v3y)(9|s}A{GriIL~dPmsuXQ$$+ znJ81Q`!!Pqqw0qGjqG>jDHdYD8*SBpE^u6Se_U3~+;5(CUcCBvyo89n*=wya+6J6j za-HZ@>98qYmP91WVaOWJz~7BmI342ct6!GJBmhhkO6Q}OD}m&XoHXye352|KTePJH5mdrL_O>)fmDFb_G6v7B$yxx9?*KW6{~i7K4PEp+NUVr zOev~LAQr+I5Jf?(jTg1HW6j$!Pj0XnPG5Z;0}>{CcPS?iO3c`bos8P4lXm7a^o(xZkF? zBsFFpRgg3i-tF=Y^twR6;~$GXzUo%E8=1TmnQ>FH$nW3JKE{u4a?k-m+4KR*yCSt0 zv+7jwytSsuvu_KwrON7sc)Q#)4EoJ0x|vKg|RV5Lpc(B5+e)bv|b z5>u{fIEng`{tyGa!m+X%kB*5MQ_u8tZKH>Y{t%Xf8GX!`UFrn;gSsK^Wpd*tm$(<* zhdUsr*-J{_s_dC>q@djhnB6k!9SC(TrG@(Rxt8pq2u??Is6eq7Tw(KBdL5QBt;e_y zJ-}Ak2yZ@d#tO6mU#WV`^&?p>zfceebn{YCd*+KRwfd*`eAxbaY#t=edsJJg4fmPu z9d0bU0>3DMgdtzMv7nP7aeMl_f@=r;hW7dpEy``ErruAgauK4gs55S_ObS7HgD@b% zNLqCQ8@j8Sn8KuCg@sQV%P(3qhY%5xAMB?NH8Z4X`OBCH&LE>zvk4hXG>8G$lv2Em zy-tnxgiiXJ1tcHeM{kc$Ls$Vs;Y=|@qIyM;2CfNk>!VeD;C&x4x4DrC)k21j z?E`j)0Mw)n+ptPuH*5O0_^2Z}b!dvPKvJqtHR)0$g z_X8{mUVZyFuhWld8MR+^osv`ruHp_abNCxNX*_+^=;Tboq>BytFk)Pfpo%Kk5vQ@~ zpHRLS0hu)37%5ZpVmygArc0fEY9a31>o}IM-R%a%w)m{?D-V?{iA8lgxisY2?@rpz zk;nDkFMYd59&3Dhz`FMh?HMjg>$UCu zF5l!~V8KV!q0&N%1nwEzxhoSvc6wx3DnWLr*NA$V%k*b zdtQ7CMHKM+a>k*qy>~EB_;HAs>qlfB- zxFi+oi@RyR zr(2-3^uu;A#pNy|ld{m%n#Rq|2nRW4Ox$6 z=?U1fz*r9zBD`Y56r}%DMV1ZmI}S7^dI1I-Q;{_AkH}4Nl#LvH9h>oNujWa~bvjx2 z7Q#I+-kV#;lwQ{x5JAZ-$@ii|HKoQvQfu4zOHHKAKHnPsXcLqm^18P`&xhM!+=o8o zX+UC=fRDyz&Wj(MH2PbyeB8lJ_CGk^WkaN*(JHqf2q=f%`rZ`Wq;)wcWjf$ zi}zQOxT(^Y_4PbQthBhsI5TS12-~6BSrV==RczQl(Oi(a1L5oRI#m|;x3ul6i&D0g znM&gNFBKp2c#!#(LpA5W50zl5sklMG!oWy2%NGT$#?o;!HM`vFr<{{KeAZpyNuHjI z3tb0Jfb4y!6{przLFI!RYkD8*zq8-MYnYOe5jk+y7Hk{&qwg{&o-6gR=bY;0!>I5b z7W0j9V$eTUaU>-*_|RRqZ;p|odY-F;sIFBmfKDf2sj(1quK++2>NsT<$trlTvd~{H ziaR|Y?XPZ0`wd6O17fKOwQ~i9Ru>LrR_^-x*k%QvzVp=0E?x~XwBxT~cx2#&x?kzz zoD+h#QAh8KE)_4MA6z&4u1{R9`wpdsevU+QxWv`cyZSJXrFufDRkzTJ!P)5*I!H zSd7JB>y%_+p*CyfQQ!UR+w6^1Nl{93`vkcVA2&Az6Yl(1ju__*KZ{hp5{Quu3y3`%q>+@=p3t0}{L-oZ$KCyfo{IG6 zc_s*RV|ixEM~g|98iQ#&N*0T;FPZ8!4;(Ikoxl8aHg;;KcMZW5_U!}iHWKVR=62&y zq$>VhNQ^4XG&32!$gtr zg#O=*?Ozzx7j0tfc(woOd|K1z`4z+KgiN`eX~tDRC=UzsRII7JShr}@I0L)4hg=D3 z4Y}72f9!l#{Ftlle!$+G1K_5KU-eq%mv4cQl5wQO*Q1^tfm*LvBkDN6`)S46eeu(J z%z)7mog@-Gdy(dyp<3Y&L2umCIoF*1$B~hX?R%0Y2Vanp_R?2%c%VQTEm*{tt5Fx- zWs?n$-c*k21J!%xZZ^R1#uQrykk{8H!rkj=gXPVv?g!ix5Yl4^;PmPJJ4i73P>r!HTA4!#1(*~+Ww#3{~ z>lsVe)8bZ1i^Zx+#uZtZu6x%*8D;^1yON-fGk2Y18$_-aK61FeY6h-b@&ESps!5YN z|Ljv@Q`Bazkg=`3J2%>DEYdh;fcA@sWbJbYF+LA)@4RNpyf5pjo0WSpke>RWskc_9`+T>5#hUBuTaqv0YN5*u>=b9t1~K zWMK;K(h=CZ-U3Q*;MDkl(#I0d4t=U}3zJS@wYf>7Z#T#Re<*|8w0J6_qo9||380b+ zjN=2c>x}4Ep-(G61hD>@OP`1gW&Xc!^7}I7=hQJoq|uCnHIIMh?Lyhz$}j8sw>#JM z0|(xYWXGH}UQ_qa(H!KPa8u?9HtM^*$SbJMNfadgIPVNRTi&4^;#JF9I_iu8$6xia)XvCueqQ-Bw^HXihXit^sykuF-zb8fS zLhC3vJlh+Cshcgz`d-#?Lyw@My?m6FMvyD`mlR;5#)eQV`mUuT~7+{6gBfjv0v;%wv&$6@|zPZoJ+`6vDwA5bMg+pp}Tb;khTioa}!z+oFf}WDoO5PadhT|1jKJ3=cH%eLk-z zXXxB&B=Ol8(qGE++54d=f|yuX12;^L_hSQ;2piv*0;O1XxqmEBH@mZ7tiC5@a<#PE zFr(4(9%aTUD6xr7dW>H>L@W$?v!fLW>v>spJDfD26tc8BFcTncRERV5nA5GMNN}d% zH(P`ES+a8H`!amvNT~rAunCN69YdqSm`L5a9^1<$1(gZa`fYx-_TIc>Sy~r05e2dO z9&srWPEpkiP7k|@PMlqv0VWP3tLNawcdiZt7M=hz;|(>f>=oRYx%L6b>EoR4>PdvR zw(kHjM2%chjHWC+Nh7kMcg8d;Yr~Xpq^m>`01_ycr&pU}`2!9Emj;?ti?Sy#d8SC9 z4@}KjmP}YwO}Cx~?3GNHCDtrFKta`m#Op-^#nXG+O>IW_2!bX7$3&prOz`DEm)>iV zD3X%a|2w@G=q-{`8t9{b_{H>L$zF2%W$A#$B;enZ)FnGiZ2~n#QYOqz0)m46T_IJM zzNnz{7wxLLX(z!{O_rRp9>ZHTei8r8IJ*QO)1j>k)?vNnW7qd8N-K^(b&1yJdlZx| zO#WF|1tV@4P|JQh_t54lg|n--_~O24dUAQ;wzB{R!>?$PB0!sqa-pY{H^V8JN_)}a zk257gimbyRVf?xigbZa%nbSeXs|;PVxGMgu6f8U@v`aDNY$??ZEvrT%-lP4}6ub_| zq`4xeop+TXLAmx!#zTxQhoX%Io|jib12(GXE0T;1Nv)qTuKI&d&S#T-C+3kA-IRpKPUu$6=b$qRs2*6We~vO`_L)&0 z$_NPo^L=ymOE>lL%DnX%6s-<^NCyn8or#&1bca!eqAof@$jau+bI<{5ww74$NL10Z z@zYdUq>;ZOL-M3-iN6Gs` zl^d+6>4)>W8^dsq@ZFv$dG4?S(oEdX%@uMV90k}vP|5_A?20+Wp&6^Btr8@$zGj}1u8j8g(UyV2a zXr8FqGV}y7^-)KyOgu>Qd~WRizN~mq2S3tL1NVL?aNAvdQ(aNGS^+ifUAMyM!TEl? z_uhyh{b=kk{=<4*sLD2QU$Tv#d?HNtt!4Bq*`Sa%(O5vTj+dWf#e!Yhy?fILVCX+= z^c#$5n}2W%c1|=aOAxouQXDY1z^Y0WGuOrXlv!oTYd=-kWw_4q6?!Zrre}Ct z8WoqF`?w%%G%Dj3HU|&890|_Oi3MHG)q0{7Pr5}>I!(XLX*LH7HVTj4|W_gN&#yFFK;~Gg)d`L#^oz}Mk_LrkY*+;r$nxRsHly9fs!gX5bxF? z$)jp{WoX)@L>vlyA&JWVkrfu=IQ zcF+6w>aQslkro6?M-vK6bv)0@n6*l}$!@7WqS2D@1L6ReZ>y&jm#2Eaq{=stbp>a_ zZ`kkNi74`1f55w%UN?T1HhV&D;CdKVv|~&(ygNfMneM)&sWjkj^QnBt99%*7yqBVf zY5NY5-*I(*k3eauCaqKWytXpeoz@T3^VmruSQbvr_pYa(GU`FO%L(1J#1=hhnZBbV zi&{lty-!~EthHi2YK{1L`@O7FsYCvT6qG9g2Le=0-(}KksNEVvfX7U>%?@BVpWXUo zmjw2#QI43eT?yAP$vni)AD=5wO3`xpzi*nq;VuZ*NS@9pnUXR@HSQtzFeqdStNx^bPJ9*ztDn%qU?a18ccS2mtp}twiOAC>&+3UDEO*N5RD^ooYtikYd zsB=Xs;@4=fEsnv&!KKhGmQP#L!{vkj6o|KdJVBbDenRrQC5LAnmq|u*p-{OuTIYkP zUO-h|b2qcw_Hg+|O?jnPxx7fy-Z>fOpNV{wCFkYr5c&<8g6VQ#Lcw%~%pO3<9WZ>< z?d zC=_>o7kdFkK<#}nzrf`^tLC&)0I0o9Q@$|F{3)hb7>GW=RcgQz>5P+IAY&DJu1R&W zd?&fZqcv2ZrV~u&P~ULpfL?aYJ>BUS1xJ}JQNIYTd1jDlX0siD92y$cD$(W7;2Y}0 zZ+-AK$#wxE|6?=r%G{5v6SBDN;bazkIFEy z#_2r6_b%~w>Y5~a;X_SjRN3Xy?!0IM z5EaCICXe-x5S8iSONO*WAF_VN>88nMHFASD{Ay32+$JBuI6>d;699{@)gmpHayP%4_{{;)z-Fu`x?*!6^a*k*Wg-;ySoGl8r(gHwzvj&THGn_ zP~2UE77OkWoIK8X_ulc7@!mgKNp{xG%FZ5RuRT9=eP{VZ3u`L=M9V0qxXm6s5;#}~ zXiA-1bM^}zrSYCiWpvb6>rvWm0yCO1HMbO+CV68N&&%=_&o?Gm9r>vAXlZC=sP`Pj z2JwU~>J7&)Z|@2F7TOiKR#$Pd*eve7pV-gLsWYTsPE}h}TC5D2L^yGlKlv7&(N(fx zYNE8(S9u567#FHR(sWuQliS#xWMksaWT$x9aM8g_L?%iB~e|mo=3bT`KI(GPx%*0xMLa25qx(xoRrn zbj#uqwO`&aYn}e^$)H!;G0O3YJaX%u+M8&NYWZS_w6Pb_w)q2^vtb|_$61gWTctklAdY_%WtH7JI=K_RSccrQvOcC@!SYVFwVucX_J!gmF*@Q^^21@tWKcZ zsZy(m37dKS9U!9$rO;PQYh-gjm8>zTCfERn2SovRsYOHneipnRA(@waOEvlJ5~vqbtrKPp*mtL z-bZ|DPCu0s?aW@wvB~xwby?Olej52aa-QRk>}IHfs1_xbb5;X{dEg)4(yTD6W{Gy- zpZlHkj8Ca=jxfD!V^wPd$R*!;-)Mpp&i|IWD!H?Xd!D2&>V(!6 z4Gh|2nl_t5GtG^^Zih2==q;EoAsC8vMOS7_Vs6ZZgE7uw#l-`-Td#j4Vv_2;P<3eN zKcekc2O6>#69hG;ltT9^adT`*QhD*zTg-lF+4U7FL^bC~nKKf^$inDwX&p^XSu97H zG6hmJ^P13y0H6d;yWG3TJ@TUMSoVy#qh8n1x02-S8R`YQ>6`DGIP+bc>&uM=3uqVl z85Cd6x_o3U-QFCoF%zb{bW7;`>oWaId7|!E$M^4__QKwTf-)lBgu2r68&5tmqQuWs zbbgo6x$w68lKtCOX^;6m9-TAzxnyfHA-besU{B~}b`sc$5@J`mHA{CEPE1R`HvkTV zcXB8~n*{Rrk`7aerf}Xit9u(VAPCu2Rde%tBmx;JaBqH`!|A!2&|oDv1i9mTcDuT? zzsV&JhMMeSD7oS68Uf9Fq&tfE8~RA z$YY~?$>DVg%?r(C{p_FjSKgbMt2qSOQu6FD>knXm5xZ4%Nl-c=u$6MqMxaFf>*?#Qi0C6; zQ=u0dSe4FSPeZzy*h#UN0E;}NKMfAY^=Jl*4kw>V2dP+V5*7RFNMLQ#pOu?!!4K2I z$O|o|w4HvjwaIbEM6@&KZffHzxA~N!>kihP_4DDrBtvn;^v%_zCE_|!HF!?J@`mGB z)r^4sShYXUD;np+Ica5jmh}o1e^OHpo+!@7TgkzTp7mhUfoD|Yrw645+*3R+VtKs& za*C-PD>WvTFe{14KDd~-k~wmZH3U$rS<&fC>E~S_ig_v*F<#OVu&d&|#7w@JjWmf1 zS|;FuHJHRjJVgz04>bDB6r0ZF(l*ml#LvAest!jlErO)2`~knKtFpjkkBmhghHVv@ zyV4J)_FhPHI=I8`WkEhtVHp9e9ts{EhHga2{O~8er4)ZytdT^*l1IuhC_aslXTJG2GdpRX?=b;d-GEG`Z_V#RS!w25>SW_@fqo8n}oyIZ0 z#`LM2+s2oh_I$lIo9_;t2_<6M#XhQghx5_0O_gNo2f|NJW`B&pq8UEs^c)Os2Ag1@ zf^IDsXzjFaEY^oywzDcf#%Z$|(@0U}Y$vLe_E~A+)$8UFFUM zS7nc`BAuM3vz-)@dmV@YZ^Bc@Ip-IE#yW|@HMJ_bTjXpipB{9zp)Ufw5}Iq53~8gm zn~6FJsb;b$FPX|-D=sb(=vdE32H;|rTCsEdiY4sLu2oUO(us88v5MN_!&2OzNNp+TAy{XfelOnFu*U(fS9Tl;yr>Dbk-t)4px1H1McgJwo zOFgJDE696N(cC%Far>ATSpvQ7XY|c%8$f~2iC7bwZLHNN<{cS$b%uy}9AH86h+(l6 zzDCph&MpQ(GR>yr6iW^=@=D%O79nG+;&Yc` z;swH(>+6!14F^=8k1UX9n0}z7aZ-Pp9QNYka924uBy!rcr+nm-3>q9Bfh~IDIOP@m zNU45S+TWL=^***(*E%1w&YVDYIldd*OiU$P`Ku^gmxL$Qb*`Gqt;!;miEC#XSfJyo z`o4FXN6enF=@a45A()p5{*}|tpI*AtOVQN^Tv|%6&YVqu{@I95{HFyJfQ@Ij>_AJJ z%+nIFrDaZ%U=%;CYb30nC$Xw2H9rC>kG6`DNUB-Uz5oIM0XDC^;zLSWGJX$u*(WG@ zC;wFQ){<+cDeh^U=Vj7hs2&O5EI(uz3C}BNYWk?9|2ksY26~~XPpamg)|EGG6%5ys z3PxRYnvY`QAKjY@oqkblQaprSSeDsSiHnv+Xkx zR8sx?izF!#w~{1DHPl3~yr6CafyjjY?WXJdcb?gQ$vB(4U&Rgwrltp99V%Z5){~Is z68-P+%DFjFxbVee6K8b7m9+QO)p2M#@Kf}^GTpELN6vdVaz;3M;mWI_>U`TS9DlME z2^r2g|8L)|`A9%@^6z)7Azps3Zm~v?9DNm6bHUsslTGcA(vAOYzyEu*){vdff9(S( z_^9(9_DJTkx%GJaON0_BgLHqKX|(Uqd-GpMez-ygCjY1JUVFBSx7Q`ZB@4vx!OSk- z58^g9BYo3+J(t8yyevBFz3|YNs_cUdA$olJE$ya|8m52x-IpObLMl22noj=k%wmLjJH`a))VdX|Yy zjcaic72SdrH^()WqcVR0UHpI}(y%+JIuoU!-Uo3r+h%x?aFyj*tAp@sps(?KTmU$Q zQ)YIf2$1$v0wB1Tjjc3v&G2>G^|oREkFi%CtSfYRKB9sgNFYbInQ1xLb%79}jU z`nev_dXqf-&F>F<*F&xaJTfX;Fix4L0KM=$6QzR0-9cq`^FOqd2iT{~$br%B;4`^5LSu0TEoCuZ!)(X6FcQkR}k}U2DELXk(BqS5GClI8ZU&*6r8;Xlg88yU` z1H1q7>;V~v&T|OsQ-@q1!F;KymWhY{%7R6kEBN#_`~Rlb&0yB8VXUoTTwTJ3HhP?F z4OB#+oo1UWch@&lCR>&R@Sxm=-BX;;AJsqp$Uk$gmYd-rNQs71sY_&=ygM){{VJIM zb>ALE`X<}=(CRC;=CoK_6o~%lwtK4tZagnPdY483G;o7yaqQ#STg2vcc=kf0JQm zER)O!8QQbmB|v_Z!hKQ5SAgm@3jIrFQ`dD_- zAi~at3wve|mckvw;pT0vAepNNr+kto9iSF~_Ws)*OXH@3{KD_0mGmds=mLZ()hVyL z`jh$Mz?`q7KD-!uyH`_@sJRkwIul3({%FQ{L>L~?(2KXq)$pNJR=Pz-XzZ%>18>tQ z+Tc|wsh&{d*U~fdT1s<~D*1Rg&kS?z=3Xmui&J~C3MKWL(8Sd`BE3RFv%3E`Wdvd# zQ5{igiZTQ^`a8)PtG2>A!mq%NZ0RYUIW;`hOh6bjm1fS18gTQQ=jC{|L4wDMXV+P=r&NL>u~MMSJE*`JM^p7LR4-f7qBvRWdy#GjgaMw6EEx zUB#1>aP%AdFjQDqB40RDpxiQSLBh957@M_ymee3bCoR&lw{1r#0`7nAf7OwZ1r+AG zCmkxLTCZOUU$;xw%k;9_ganrA-*>jHpy&na%)&W2C4#9wdA4UZIl{BO`4U({F^$Gk zVpXl*N_xP@1uo1~T@x+*nW)<4gbev4Co-?axPzizcXnf4=2|7Uq;LzwnXODLZKDWh zO5!tdM&l^9boIF0%fw+4@?ZhV$x4P6H>I0qe-lQtOlYCnExY;)e2lydq_O#ff#l&| zct=V(x#E&B!6;1}Tj-~t;YPPUh8KEp<)9^Np(Cb=b76*B7jjz-J=eLoq~-Lsn`lkU zq7lIN7p2^B9s{*n4YNw#M@s(EGQo=G-md<^d-9t&GUEsB#Xg^?m&AjY9Z0xJ3hWTJ zncxQ#zZ-~r3J*pxOzR>y6X86BGEDhedFTHbTB2+^L`ZD%V~y_Yw>6|2&HK;wowsXA z6|U++yCNjtoiv}EvYox$>DOO3!6%^u^E>;Wg%OANQE)1a)8I^eM8@d%9wWCJcj8A$ zQBfo;@Ue9CUp+YM>UGM5_|`Re2=}%*Mx+o3hgPa_T5}#_2CJ#dV{xi(G7nuVaLGA; zmdG!RVfY$**`Aa$*z?EPE?-^9@gZ&NnIIzLrD{jI9yl%=8h`FG^%QTMHU{znR;bH# zg`qV6RI;z7ST$~B+=6Y-{!z;>ww>#?B%m~xxN9K3qD8F{<8`oodw4TXFeX`WG3~IB zZxPd23JXjhi^=`DyR8DPniwc0FPc9nxR)D-47;DO=5)zFwQ-u8BUq|^E{u-sQqz98%Uz(0tK{) zpQi3_yZF#ouZa=}d~3AQZG~N$pFSwe?h0P6g*WZ3DyMLzg8?IzuRi+=gNTguC zaCE*_apg7;w6Y#1$4A9xwO)><1F^VKl2W133>XmY=7fqh-*cWiw{J3XKKwk@cA2UG zCS_!4iU6DEP8WBqvQ8_Mo{sTD2>StB`#u7nj;{B#?0rL5gXG-(o{7M-PSxfnkX|D!mJ~mqkN6)gWc>vU7+bW(VlXrv?}WpJQxuy!kf5QtS`>O2usw?Zwr~}FNU4%I^%k0yTh+!9B_eeDhn>fat=V+eEX6o{i%u3n zsT?sTNMe87V|`vIt#9zNsOEW5KYHZRy?b6iJ#TxfLa>~Z>Xa|S*{D{HYiG2?-qKgh zBjQNs@@U@Sz9@KPcJ(pnwRZl(SYli+Wm|hJ&1Aa4C&1kjoB#e{-V&-Y#8NK$;R zCe(tDYid>v&)W0qQ617OSoQnnoXpdsOQre4XIJ#b=MszYedr(MVO!Tlh4_jS5Dc=s zYl22x`^wUTW1#3$oFQ=|(Nm$0`++eB2&+Kcn6E`fT9x{i^hEI5&iEMD_SzkY_uK(_ z+Ri8N&cgJ5Sp-bf-(!602kC2QM`8DjDJ|93mwxyonYr6HX7kp!)|&kQQ_3=EV|BeA zcOB+zOkW?K&dQ5Dpb0}u!X6TC$84jh@&lqSKsq&gD?Ix-@g$X*=VQQGC>yivCt$&X zuMZSMbmgKd-P;e6beeP`kXYO_NO8oF%zBWa1y*^jj$$b1e&szL42+*-EZlLu*GXzn z>iy7xU^Sz~Z|h;&TB)htQW`R0FU{;1X6LO~eS@HUbr&gpwi4PO)Wkt%vA+lcSGggp zxNEs#O~J6#g;d++E?Y%A#kwPty8Jp?{VP^|q{irY4;8~%D6}GMPc6_o6OUwqZFp$2 za$W~?t}orE`}FrM-}{pKlu9YB8s(3SR)_A~$ZBog7YW#0Ocq5QxCS3cxEC`CP9)_{ z9Gc|F17mHMD{Kwt+IS$ATM&xyJ~oM2BVSD}7&9=>ec%=t^6B9KK}cS25oY5 zIQ>0Lw_!j{q;u7P19`hY^zG!qS=roFIzK`U%9Av@v^vCvpSN(SAgGd?&g>CAFhXou zr_tcD?61P{GWvG3#Jf;#JTeS4c z+a^Qy5W3+JiDB&k_AhP(0_N*HEHT3JrQ110TxjRA$tpRYt)+>^AVbLqD%xsVW-Qsz zotE68!w$|vrDO~0Kqy@!uXO&P?+ed zidf&j$RTN4V@|nMx8%{U`<~s8c^HC=+m+&zji~))!rFT^Hrjqx~R|yG{RShqi>;p&K zyZX?FvYy9wiem>V1b&)OdwnlIJ3)od_cb9{*ap>Bra*OO8?|J-N@#2}%xsmqXJ ziAY_p_PK#X&9@p@>jvIMK4jFExMJ|INO#q~{-%a2Uz{UZ1{$o1M<^uyHrd0V1K;V0 z4{c*eet|SSd7^C`BQ~gf`0yF_$cEd5T6YGL%te?S+a{+84M#V;_u~Gwg$=3rGaOuGKDjh&byXe4+9GO5&1o)Hl8me zgs?~hZ^QWqxVfYY@^jfPg$)<=`yVtleb$4ke*59D8NWQ;N(85Yt$Auj?}f0x3){d% zhqJ4M5WIEt^6@l-ALXi28vjUF@t*1`P*`7T0%e!|+tKO-4z5cuLxGKnS|n3-R4>^SeHDfst;}|J{e19&EGE=EqjnhFFA_C-bXWe zZ!%H)ZXJ%a$5w1IHJ>I7GTse5O(w1_Wag(S=9y^=@mtAFe2%>X7m zUrL#;c5-A^@?4c;(XEp3(3+N@vUVOITe;OT0%_Ly&UQ)-bzX#Nguay;f*b#7Xp=kc zoL1pG#bTVkRhIWtv+9$S3ND<;-6fmLaytc^`{23ef4fy^qiVPk-zbagzmjQ|12~w> z_bC%Xs38=|bD*<+K|`0lu`iLODLek*Q8@tox!~~lWPZzaT!byp`_V<63;0M18T}Xn z-j97G5az>Xd&1kT2Ppq*1r^JL?t>4egKb6)`@BSj2qcB}PwRBbv&-*RA5QRm~)r!rBCNyY&dKSkxS6`Z0YToBU+c_RC+{*wB+>g2PskI z-@4&Lloia7vys0E++3L2xS4MdEHvM4&)O66wkj;OeEn*Z$P8vyJU*DT!xD8nSz7ph zIX*%Rj-HYLK{tyRQ4u%Yh_B{#J^7rX4;J_qAar>pW|60Aj9v5oEjz>G^Pdcoo&A+@ zDuIKc+=SUZFSnM)&O-ir;KtaQJh`eYl$%Ttdl55p{{|yJ zdlDBDOSzgo&>^m~RcQ?w!@1OnV?^_=r=llRe8AdiUBy{1jSopDr-XqmjbL1PNH`@I zxeY6UCvWVkQCI@sq4%hpCazQj$tv7{EkCXnv4t}994eT~IUUC})Tt@3)kVs-@R^+Z z#JA(oMlnO^+BuK<@ZEhg>A&tz%`qjwWuQVl{z$g51nE zJ@SZ;M#L~d!h5LNZrGw>+l&L5QOS{JLB@a4j-_(s~*Y# zSYDr%t^>ax8CVxO+6n#RemiW$xL@BO0 zqM}hB|4t4q@7tupGpi=j z%cq;9rC|6|ON&)1_N{4G?t2zo<-~C_f+D?x){qOUN7Yn5T*y${7=cPBce;;xdZT_b z$_hQtml*U-9_N6hhQOV98jJCTAL!n$EgYKT-xPPgqOPjX+w?$af^j@LU$aY|XggGP z$u4?cn@y#!p+WJvSPmu1?!f+AsM_5_c_q zXxKD_?<0R_N@#s?EwRK6g4GlzE@Z`zCVCfpKeuvUKd!x_KZ_wZBMQu9DBY>EN_Qo1 z;w}(#56N^ov3KkZSg5OV-lhCVGdHWGth3;D?Lbe>!bVNUo$GeIe~XN_T{^S9huZVJ z)7H9M`l5oz5FX!SXF30aIh9BtX)hEaHDKj5K+YROo49$t`Z&Fx~_)lS1y!^h;h_d13SB5P#h zWwaoZ)uNt~i2my`rOteN?$vuw=6XY15jx4e&XF<;C3)4WPX{ynv}zb*{w)S>w)f8x z3_YEG^qkm)cImH+4NYhf&#Qa5{WThc6LkLoz#!39h3B13^pjpQMRhf1&Eg|&0y)wIuuo+Z z0r=^S6+|?qlD@zX$f_5KWsxRfyR@BGBtTiw3E3j$q8B>ytycZb=1NR`5bzzs}{N1CiR z3SXx*iB^fQ!K>xB8M>I-vGk9C%tY?6lU3k>&tqpaK5Q?PeAIkz{;XAe3P7a?uIj)G z5GH|DV-yvvqs_iA*<(k6zOj#c)BkGv73hV{3(n`YG4u#|0`j&Shes+G9`4!6R zRj1>s$H_s)K&8&jOK;@mb6#<9rCnaYfVHIZ3UJ!z~#PzZ2s#Kz2}D$+HiA6nZaAt z1Y*O~>7fDzD1k2EEcezBkRT z>Me}8vItRgwoJ=*uEr2X>WdC!`!w0Aj-ko!NXKI~0B$aQ*N?sR4~WwE+BzHE;0{4P zH3F3KtZ&OJP*Cfy)wSv%n_3@^W3%TWcoW0#@vy!v8&axBgE77{dmh5S`vTj+%T?og ztJCR9(n$f_FHU0u17F_w^1tK0=1a+?tT9R2xQ;i92KVAOHE5wf3UoF_Lee%6fcXAj_F6u%5lQjAO`0Y* zRUOM*EcXW03$kVci&hI)6A*Q~W0fecD}>)M>PN3;pYM;&<}+4G3i5TSFU4tNAkJPt z*2uZ3rS=!_*B7*;#Pp3x;DJ~Qx7LvlS-FOc&v?Ub%J<$y?c9e+B<`{E$XhZcx&&tZzZ=fJZylv*&e72z>VrL=S_d7nr1=7;2rhC@K+3eWH*$c0bU~T2QBcNkg7DHn9~5AM?~=?6sBWulr*@O#iwT5NuIni?3-N3^N502*rB{w^{Z z74LG-_rr44K`=6A982I!(rZKU!Lqr!yrqTv@M^Plx<_{atX;q2a{?Gvw5vKcmAKrS zW9LEi?XL))da-B&YKO-O$z}USTuUUb?s3S`vXSty`^Xp=e7%>!d^Tnl zdzT2RpN&~w(5yf(4ZX#~?sWTBu_?wXz7OSg&L4uE*YXI@i?`p@{`upway7%PcIOCP zj@esTyo34uj<~Dtx^ywrC&TVDyyTiSs?7In@zCbbE%vo&L1sUm00&moPlIpnU^U`G z@o4KZn!9n5$L!8vJHxKpWaM2aroAmgFdNfXv(}JVVuxvfjkRT=KU=|{hh=DXGmZCe ze~2H4N5Lm1#R%p1k-?NO1<2Xh>W5v!WU)S&)7XPwOHljRsHlsa@AU4LsZQ-E z6K0&ykY~7})}s+#MHFPf!saB}6 z?WzTE6YZSr&3lvR$PI3FX*(8FBpYWE#6G1%$$$F-%EBUW*GH?@b#9E1xzPH0$kH2l zQ(NKWcq9Py!hf8;pw!v7WIY_zO$+}(_$V9RL71U0|LczrQX8y?wr_)$Sz*gv zYcLTT`7Pza2jR$9rDWLWWp#fYmy@%<-cFSL`rYBp^*EnXulf{s&KA?-tBEkwCW*6m z>Jn?rOUkuXXD!9}P zy1Bjq(SM%v2I&J?_7~Co{d`2AtznXnXLoc}S~%9AlyU{T#*a*z4Yb&&&qNDCKipmJ z745!dWd^#ftt@?tWWHLUqr^G;Cb5#i0$630It23A4!TI^BoHrZOdr{^SkYT3&f3+p zT1L3@eG@vJi#*O-T1(%vG&P%OA#vMQ9m#gtK7V!FfsO@;D?Z7~mPiu!*pqyq- zSV52eA-1MnW$jFK#Td({yGh5Pv6R^cm|aohrKwqyYl@c?*>&|zd&5#^TVw-e0Loj0@@E^@r`^T z{i)aaJfJT_{E0W}p)`KX9tk5~TF)Q8%Yf&TQ7`wr ztna^_zoDDe{vh`V4XwcqNDlMqr392$_VA);eeMqLKKEV4aLOTq{Go1=Q+4-S8?xyc z^aUl+Pwf4;2k8DuEj9#|P&2YMc5dD<@lM7D1F-qY3pWDw+qyg!Ed60|EM1P!5{orC z$=U)gK-UEsE5?jX>k|!Rjf9?S+AjYlUG$GKJp9nKUGX*q^*2{<2WNnv@jr-m2+*7# z?C+2NJRQQR;$T{w|w6*MPjecd}>pGTTe!RGNV zCQI7?2~Y!|Ze|Q`vK?VmRjDphj18tRT3AofeG}R1*yLNwHkQuf-c3S)`03Wb&P!?k zl%*KXI=O3G+Xq=k)5I}mO74hzpmnf_98IL#efuJ>e<9G;8WR0%mk(S=Q#VCBS)cF|t?XIv7qx_yQV^N@5nBA~F%pMn*~LBzkUE)7 zE?nH3%xfMDtk!TT>CA~8kJL?ynC$0gmVYdhC?9(%b)XcH6^MNgKhor!N^Fg0f4@Dt z=)%&9$W5N$T3*Ss!M20g$Iafg$Uo`bB>_LPxoOq|TL&r&*S;~_{2Q-|j_DU|-3nI+ z)M(>vK7$N@L{f_W)j`05=Z@@_#VTsYgg&Qx4yUitIV&TW#bBYCN$r)hW{bO zP{P;_>te{<`VAGu8Ek#!lHiWA?uwebGuDHYKz@0@DDSl{i0It3EKos}LH+)?O{lGH zUOztM@hH zBEnqx*kINd#%UdTt1l-=(5Kk>zL`3C#puWxDW7$Zx^MLc$q1Dne$%T^8|cKXK3NbU z;5cY6Tf(y((~{c66P(G#ZM^IFly6JDg@(F#$`mbkZ+a=Jw_8JvEnx!+C-xU z#QiP{7Z}Tk#^)`K{hZPnM#qZng%z?hc%#?Zwk5qjpVgMyPrL_N2%xAZHt<}z=-Qua zzuhYl2eYC_d(cnrHF0UsnO%`#l0dOHErFs2TiuJB63*-HE|hN6{M8x!aRRaF^HJ$C z?Xl?#k?C?7vP!nnO4EAwWXvAH-iXFp4a^U#EQ%CzW~U{7XrXUWIh)+dtHwyVs^4&jd%+#e^dKG^Iok@J5WszrP$(@gbE%9zN^z%>TwZEL% z`{6CDl3VRiamF?8Px{@4KU_^&jhT0SWu@{xaG2!r&bi6iYAEt?{p|#Iy7Z)DQ2Was zU>LduEq-$;=$X>H$l%do=R;%oVg%#wT$W%V3ZLh6>-<$l@)nEzsj3Z%s}(#rjgRBk zC5?nu)+~5tT7-UwMtwj)NV&i;n?ZyeD@e+eGIaGeAnS?44v2QB=Rl(C>$fDCm*_s+dYiUx80b|eJ+AJeh)mK^SbeIl`y$HoF zQXd$2=pUFa+U$1Ul(1k=>9Dmzb~5LDsyH*Me(r+ZsREcF5!Fh-;v2G z9{j!zAUIJh{rwIK)J(sHQWi|(`PQ!e%*wby`xNXRi8oV19!?4Fo6ZH$c7m!JxevSr*qCnkyPsIBE_ZWJ|L9TnYV1$BWtRe_pi?BC-9 zSKjsH(#2)EDR`4QfWN`qjqbaV5>C@{w}jjNTzygetIE?YP8&i))+&9i#dSL$xMh6= zg~sV^c1-c+=ZNnT1$!z2F?FFLsDT!>gbQn=CgJ1GZ=sx@4Z8Q5M;IUBdHBtm+hnMdKiwO(NL{9d<*V5+KL=^Zqb{Y z!?6m|Pyaydj+WYx?Dt*j{0~dcq;1MdK97f@kNDDk0X)eL2mEcy%AQENP8VWZUV~E7 z{&Yf8IP*7ruY595CZZo}*3BgY1BH}F3(iAgzicS4*ikJXQT&M2^*THq`74*shyDs zpte7#nfedJ<_~9P4W9zHH~m7xFVWrk-BiyJ7bMlqlxKZ*GCpaHwj+`Hxy|cA$vAxG za%`4hz=w{KXs_2dxy&K1Y+&|bXm)xQv`=aQws|7j@2meS(QdYVP;bN|i_Yz*lWJpZ z0&*yv*X)G&n;6kX_w-VxtqKT?4#K66;oIl)X57xV2u?fqOht(?JM|Z~{P-pEh>YY82sFJ)g(}{jaFfwyD zX_^|hkaAqv8$UgtjIHJ*0~hFA{tI45AlEX%N)~2|aUA>~-@pm))J31OF{^%rtEU)? zkm?+tuu?{!@ID`Df4n^-_ig7|!Qx(Ci!+Z8t7&wFKhnlE($ADzE(EOI4ydJd=rD_< zWo`sL>3}LLqBjO2R4O0CHfa+Qu)59?zEheQZasl()swd{iVrZigw+SkTKbfdDR54a z^Ao(DN&g#O7jMjWd-ds={A;Zpe0TGqMsIr zvK>|j@~ev?Wx;IzR?2>Yg9F0moC$EMv6Gvmj+CUKK@-9Y$*)6(AdHMS8Z!$Nw?M*5 zdf`}F>4#ygg`Y=T9#HXqilWuL`bBtLo{_6CoyGLEP^-Whw4%GVyoOM-<7|WFg@L?{ z*GOk#FZ-CH^=pxZ-=wb!d@G_1GX$z(Rmap}!{brJ&GvjQ$~AKs=Q;sFWkMDnUc_Ep z>XJTC|K3!Ca1SOwx7M9HCc-F3%LL3Z=<1w+4*f>h!8&U2$ZbJWA5rZ;EW1b142cpN zBG6WJCMN+~V?;P$-|2@xK*U#8r4HC|>f4@BwiK5%^6i#gy_yi8Sf2JntUqK9a!8aA z&qMKX(GwqlQx!AvaC+=30I(+`@OT%2jkFWJ4A%jD?Z{+szs%H&t6-Cc-lW#@qU2m+ zfH^p-REAQ*POJYH%tlE6511`Ub48By!Bdx0=V(iRU&`J3?T2S-*Uwgga~e&6n9u}-F5$o@uwT9#_op~a?p*5#>s(OBV_JK%|Sd*436Y%nX>16w!7>6ezLMxLni?^eJ> z_1NYi>u&ayKCkZFq%pLF-mY8z^4C3D!bXp)vf}9{umLx@=2JENzdlf%{#8@+<{Ieh z<@=yS^it{_C0fE;ofhS5sKW0>Iij}kj3eiyQ&GvPu1mzO4IxEQ8B)R~*^|%npILF}j_9VXq^_ScMRtkRUmXUMr;ezX};&)Ktba@QKqjf-d z#N*~r)qN-?R^~{9MrlouJk7Jlk=0dl)`H56iLGHQ^VRC|R!G-;yOZZe@2Q|X{L9O! zImpQ+k2Ygk2ZeKWJDnTX(!U5gYn9BDG`ycQj2E*)?)*j0(@o8Z>ywiV;8$jOr3}iT zDlWe1Y-{t)gVbdUo?H#xS>lc+3X*75HYOTHe{s7=k0(jZQCFW#+Pf=1WZ8V&gNmGr z>kj$iu!aAJvg6cFgHE%rI|5Ab5+v)}D`bPJ4ic*RYP`9@(7m;5)v%?oOd-qB`_Eo= zyjNu_Wn`h;Rb+Bh&i*1NMA&BZ%9VoeZT{bk{Zq^TW$dH8VgHk{$Lao0#?Fkc_um%&z_)%szlkhfg~N(jFxq zN$+l0^zv<74=IeRqr*Q7fc#lj0G&5X49@>|%pTYJKQKG1Z1=w~JHhXWe_{4T3abB& z*~MzI60>e?CW`;Rm|X=+osb2EBcbibNjHS{d|n#P`^!^V!MiQzB7s-MyqGq<8jDXS|DN_OnMdrObhorzHv7 z9*G4_2f@$v1>3%4E;uqXCY=Ugrg4HGchSh6zum+)xZ|2suZ;;(jZ2b%EUzp>3gI_j z1G=1bPe0qMVrStFuk!<#R4gACS0B|ILysIFcVnDH9|qjIW7cht1{rF$tno_B6z|ao zKhDhcJH5vSrI%IXpU~(qwm=6pXy(&5qx}5dh ziHN{gG_LlSjFvW@#hTGk=*@h^0hOu%R61c8L>(rrNH^ih=ncg%A(g+4s^#TaF2~#3cBNS#&6%dhRs&UYPPb9)iw||5A zecZWQuD+=)@vANMo<-B(d4tQWv!f=ht*6>%b}C8Es-VIo22Mr16hUDoPUXkG8cv*) z#Cpz>Qn^DVEjy3HQRY{=ZtB$^kg2yZ3bR&zo@XU)On`MS|AdA%LsN4adNoPX;1s8k z6M07woBoJ=*vk~|sP_?L$cvqqr*DRXVqnda%64<(QLqnT3j23MEKHoDISD`ex%5CQ z814u3?rDQE=}+r1o`Lb`E4u4MQNz06IX5z!aRC(00YVnteAQ$_V+aWc`L-rI6dMI1 ziGaNaf;_{(D1JY5!~H(F;oUe*K~5@o?(fFNj{j$^5(kPo8xxt!#!6obJQvTO`)g4rXiG{xXQq zyu;0wL4;nLp2q5Kjw_7u-X06A-^}WWq{6?HG^%_m6xC1M3Ec>L1~e)t zfk=gjMo8vvMxMOSRCLa+F+y>t0Wy{;bM+Uqe_BEv2K=nT53NdG3ZkwfUHWSAdk^QL zwnBoKwqHe8p3fUOJ$%Ek=+&<@`|uIvfJL|E-t0@M^yt}2*Yq#N*-_2cL$wi9V5gvs z)WKA$6~P)ZSXW~|rr2@MNb4X!kDnktM{&hQ+*VWAqUxYBUix&3LUd`qGM)%hsm8Dy zy4rv5W$BlB+n=m_P^#M(zxBpxpK7r-7!I;XZyxov8SeA~3i?^FrSiMv6ArORM%cCk z>$9rgIk^$VMT;>d?gAiTETI z_q0s^X;C~{a6HmeIKHB%>cKM_PyrQ&5r*w0{>M}BkHsJdQSQy+0zg{j5IQ$%4mPmV zV|-_eh?vv=#B3UE%uP~C&IhTsy~6Ra;~MU4p6wTS`vtf5HPYS~tBvVKhh#V!#O}aU zZ@*AIlbGLQ#L!q^Jwng`(yI9U@Jr~X%0LtUeMT7%e_5S2W>WQ_^UD0{1ofo(UIeRU zln-O-H}LT)JHml@rNQZbG?u?E2;oaCQM?}_L&9=Poi4)^nS z{|{mB7^F$mg$b6c%Qm}g8(p?-+qP}nwr$&Xmu*{H{e8Q$I~y@GapL~SxcNTkMn=Ao zN6$HUV{)373yv>J7wKE4pAUvnkZJ|lW`RDJHY)3J+{NF5ETUPfFC9o>^6y8)KE+Qz z2A-o=9!qNKsRnc;lKE)VDF$U@L`<}hH{?SwA>oNTN-!LS1$2hIjvX@(g^7_747&fy zvP@k9k=Enhuwz6(>(n2!9ft{M3T*_?z5P!_YRCxBUP%^uhWsJciPYEe>@h0qG;4k- z&Bgs}@&zedq4m@|gyZV_BrfYor=y5=E#pRfCWQ?=x5>!V!|-qM=$xxTW@nWglMu#> z+s4Q#u@J^d@H)YSQ|6|UphU3s54WUOwB?~HwuCIKY*wj-YC zWy6Ixkk71BZ4YV5Oqq&2ySAP8(`tTa_6zNrKdUAa@WthdUQA+JT=QJobbHo_3mv8D zaH?gHmkpE-aL9!$b+EkgT!=@*^HXMO9 z93lPMHXO;Ch+Y)s%mH0jBOH3F{T7rC5ZhFoQ9**A!RBDR{|kwz-D;%%CjCCSt#)nG zuWfm$Q+BQF1t}DiKR=w$|3BasFJ3%N>I+V@)4%+jtwtjZ;p#`MP2dg*u-1Yu;^||a zz6m`V2|PTJFKFk)f)29NAD)Nca+8834gXfb<}c~Y!5I@@EFqN6mq&fNwngRlHK=GH z#YXk8)gu1XW;p2X^G(!&G1Zn_opG%Mte#ebk2&Z|WPVW0Fx_6B7y2}Pp9ES--)k;A z^mS7?Q1G)mS(#-J)FRe?V#|#!4sSN2qj%nyfzLSR6?_ARF|J=5R7nW$li z#s=p{%D@)&Pnyz{L;j~SqtgDxoe2s{KA$6gm|HmiE`@pfJEyBBCW&a`YM{3oa~@UX zTnls1-iQwX7&M9`Cy{nr#K~!8kx9cHPif&W?TqHB;^hz2ztqkzF3BC`5lc4b2K7^@PtTSY;CN z75niPmK`AjgU+(Y>)qi9hHksIvGCs*2cP4=4l~?%+R_%>H}AmU(J{3FfehojX_@vh z07|;v;a?b5g1oqZ^=iqF26SPeS!I2dFb|2t^N&%_8Iilsd2kQs3zL7jHlp3RW98vu z{Q{`nv5jEN>wWWzJK=)VQrtJMnh{P7 z^a~ap1R5y$|FCF|riMDvlqNIkhE+SP&FP!bHCCucXj1&XkOq$$221otZmt8E;N1QH zWJjdP;Y)d;i(l{jbQpM-A7QU_!yCOv53aZtxZRyJuS>_vcUZvrCJ@HdG%#Q8aF|FJ zbLu!+OzusrTggl>Rd%#o`$hj8_$={st*%13>vr3jTnRGSKJB1&JXGy-@itQJ!@BeK zJPegc3}+RgFTl@n*vzS&@s~v-dW|wJRjOIw5>&_d zjDC3)a(Y!A%$%7r(+9fFcq1H1Ohgcy7kOcd6Z+S58lT@#W#!*wg^n$2aAP72Qn%k@XDQ7Nl5-pS(JzEW1y zv|m!WWokjZ(G~7U9m>I{mE?QK9_DTc7_twZ!`WrdO+$e_^!+N##M-`C8on7_In1`aARwd9Tq{zhtb{^Cjrjtir&LmZEq-~x#ytNLI?64z6bq0iGT^2at)m6X?cr$@x za=*z!Gi&kM;vzV*k4xlHoIR+m(c@SHs#=#X1asBh{3+;38zL%*tqE@vt+!@H!vVCI9hVDy75j+gf z$hjyu7m4d7IX9I<{)UCmI+=<31G*1_wSk{vOEpt7H(>-(LRqbBE4!^sw!;WjARy7weB7uOAN z0Hw5T??IP1gh>_8q=C9!8^q%mm(~^Jct5f*-Dw~+Ihzq%aOUnMq4{?S!Dt+vOi%mg zgX#zbfO>dz0hdET-eMeREwz~C)U^9zhNO$4;ajdzjF!69>VeyQ2E(bb_P0nO@*ZHP z@foEgBGO*mL+eB-k^Hk*9@wj7(lCQ516F=GEEDHh>^9)Ig&DZ|oY)g`blF?@LO2pZ zzFu)Xa?AiIU#MW%MTDRUU4k@{p2A^XUa3lHGLH;a{&kpxDmhoW$`K50X#>5R=?-~G zL{$;uw=HNk{K>3VAmyCuJfGtc^bo5ahBPRL(T->%1TfPs)h!^<)5$#5^M}3UH_kFh z*DW)8{}?``AA>1$_mz<*k`M5;-ZzwDI>_H|wrf4+~0 zK;U8x>-NEusfBm=1V#;&Mk-p>)F5U!9W3+`gc6G)rw6<=uML~Q-Q4z46C&Og|G46E z#k@Y>ZV9z4FTB-$N=H1w9{t^_kG?h^-(RuAK7qDBGLWy3qk@u&WlSU6H#Gz29+-#A z=1Ss2#ZhGP8i&|jz4!fIi$JtWdoHVvs{gqtfd#O&M<(0KPD3w&SM(+wYYW* zoflg4k>{(siSU*i>K%9`BW^>XK{Ji|qDah+=BAyeEsqT&--8!#0~HO-F+PB%=cv3| z;WZ8#EJPZBkd1)|0UnkYSS_k|o+PcA1(SLEm}zrG2`N24K;1H64D<2j$n8D;zA*CG zq~;(OC?{_k(L`hJS7XCvNq6$Yky+x)ApN2@@2%NJXZN1s(!YL`&?>x2_2YyJIR)laBLra_HIf-!pbk3wu>xaLPK4ZKHZUbzZ88B zlq?lXMKIH6iNCl@`ct2Ha~4a8sRSgSFNYI#UgcE0?onJAN$*&J-q9U%(X_{?78!Kr zs$8Z##=I7p1HK@~CIB_TkS?sg`SzD9V80rEs|h5|CMUz>V52;KFP>$GS$eA(pYkoA z>_sE=uAW!_d2u9iKyfnqjA$rMe;0aC!hUMS32v@P0IotCqJ~);$Sz`jesh*9 zr5FAW79ws>c3VTS7>g>;@#>Df-m|jI#$y7%qjso-)7t~liG(=j8SBlbLR_i<1{F=L z|7>(gV5bBFVu8fN{nU;3--4I;c#nr+Shx@?aOw6^daX&$#Q1?)BCq{dQR%e5(BMi+ zff|nhXdL&*V1)L>gejG(B)PD#kF4Ftp!FGob5O^Z&reUzJ3Jk=F>c;}7D@a}(IW&` zu~3AmldF6=%JWxlr~xYylBXSnIBal83MIkiR%2q@X7Ud}X$%Quyxf%KQ~?j)B%f{y z3IY;Llp|xd3^lSrNNzerE36$UOhN&eFgeWK2YDPFBrs;>_?GP)#p@;8yv&B`*(Ucq z;0B;;n#LFiffALT>{>+Z)u1Ohii9gvw(OcTNIXBfqLT`6bKK_pGzjB}fL+*DnK}dJ2HTGHYcp4`Rnu#g){>)eFD*i`yx#vdz25&GbEt6JEt*@ zYzqIf!KyB<`%O{%4gGVFBhp)|J(LKptm`Z3o@zLV%>bS9>_}SBEWl>>E;E_?&(w+| zSR!HwkN64v*s&)MI>VrLbD_Z1G>sd5V@mg87rW>(mu{P;RfkryK#_hI9Cv zY~zm`DLwiJ{1yDlHvG0h?mD3_s0g;NRj-@%m~4d!hm((MmE8z*yxy!z9$hDx-Wl=( zd5z%}{r_6{6)AWF0;yZA0ZLKGa4AnZw|i{H=p73~=Jnovg49SGUEFg@c*JmplaL>^wa^ z&B5Rzl`pr;bO+Or&CMKNR_7oZ+f(SCi0 z5-+IHMAFL&o_D1U$4?Mj+4CVxEdAM5 z1oQrM-%?}KBYb&Pbp(Am{(>53Li2h0Y+53qHQ_2;Xr#Hbq~4a6QNkmT6n}BT?N|L9 zKZa7y^J|t=5RF|WJGKgbu-i6x-14L)s|5drn5@+d+a(ll=cmK+INF&6&TPR0n7(0y z$6A-8vYzdBYdQhzN~b%Xj#M7^5CI}gK${L$Wc-592GJY}ZG)h2>FyFC?Z^RzXaR3V zT|}&hs+dn`I}EM~=6MSnH6CN#eE0Xw!HtCm&M^qFB?5tP2q^WtxsX>PQDvFNVW^Z? znqu_fAa%eRPHq1!77Z z2z_+&`ac{RYPet5mjDUyi|+L`bvN*LSJoyfukzMqwVCRe=2}sSV_pv*Y5e8VKwg9-R6l2@z?UZK!rh4U$j z)%1qs#Xz?t3f30GTrZP9RmNlJ6Z8#lTXK?kv^Wu~Mo)?(m+ZHqBdY)n>3DSa6fpWk zB6K1PNuBftcQc$lSq$_62Q;QmN5+4JYztsbeqR-{eEl0oQ5i_&NNzD@35G=c`=;11mX-ZvW5kVGosA+P3S zyUMIg6#>GJf<4$H#MQ4KeKvXh7M20Gq~2sP{EVX|2p^@<@AbQZ07yO+j4(g4pqP?1F*wi`v`9rE#vkqJ~6URETQA3=AnqX;g$5VH19W%aj;p z6@H4zX_146ynB*caMibU(;wYTV(sk>t+AzQ<;W66oDfu5vctF#zVlbs+4vm52cwk* zHmm8EikG*Cb;7|-5Vuz-QexhzM~c5>2}imiEm=2FS+?Q&ITVHls>Q8}gpDf6?$scL z&fp?tS5w0*Hg;v!*oP@x*hlWQHrP%)@KmFZ5Qpd1remLX!nl-;)TCP1SIDesQNc+QZ&j<-=fggqyX#(sDWq;H%Ygw4jm zVSj(_ZtRHxIx-tUU>JMHCy~$d@p%90>L>>(Zl7OjAiFnBFW%yDcRsk-?D{^^khVA> z+3*nRj48wLImg|*EZ|tnR7P?k9E$)6m+WNSdT~mOXm}TT%5O9Y?~!-rU{s>C%i8)o zJ~5iT0B667d+?;Oaf>g$54awx@&2q>kMP+UU#l?+e)By%KDIpGHF#h*4| zLo{;L&zXJj$GZr*TE!8sN4{`FX?_HAW|#X38}~V>bG}@2T4nx4SlfUqV7c#j2g|KV z**HORLh|s$&SfYAKBcdAcc(q~%#1!B#OJ5`43uX*m z)+GYIxkH|a(XyXuBHzzTCfl3aO$pK+_27{?g1m~y)@e?d!pUT;dhtD?bqWXv!=j=! ze?HHi77R8baJ1U#51pvffK#^DV(&Qbqj-&;tPHoiTF{2O8#cdtyt0;=2OFXvt3*Cd zMS11rY7gb{7RM9ObjxttZk5tDQq@*n6O*C+i+&_f7N?>o)K4nqa7Z`=ch0x&T_S~KL-3d8a=Vj+TKj?yc1QxB&JgPQd zACcojtUst>O9S}mFV&)wPQe5=%*2NUM7&KG9*^{;kJ^SWIYM_d047=T-$G=izlFM zk4wok)r*Ww!&bbP`tA(_>HvMe6g-K;MX!2OO4yPJl50dIDHi{LN0Lq9svLn*fyQu+ zgvKM&He)6?^6yc+Qt&LPNYMAe$)oxh0~z~A83N(7ha-{gY*&}a0DopNacBKPY~r0O zq>zOU)Vj0+LTb8|fu6Urh0UEVfo?9V#DYrYI+@?yX944$?SPHwTu3siKEJ|?(LsS`Sk(B1Hz%!rNH%0GqC43PSO$m z(Htosd{)uz&M#}q0H%lX6Dnb~Nm9x=;C@b#J^fvGE}WkOeskhX_O5u-HJ^K3nZ)Le zx5_AUveyIkN-AKpgHq1$G3M&gYoC|zeN z(rHTBY|3*(?ywF?oerzcMRuf#a9t}>0t5#3*{^x8NE_@S8y&t}R-Dg_6pLFmTWb`l zR~vW!Fq_ax)69|cQ?6DHeWMcl+{GnWA_$sXS4YvIlBc5frF~6dLc@&3OF<<@*pE$H z0uh%GhB6tQ69>s={qj8O=OyKw38%}+4;qZv!Rj1|BVPsb(w++KT{~YQ5U{a|8#JIW z>)zIQ&=9YFx(&XE%&kOJKE($xgX?{>JLb1=CJaFbRK!LOEpHtBo;FGRWk_&{tv$+{PO(Hw~ zdy7k10v4wMTc5pA*gh2c&-Yu2<)dN1j4+nx3s$XP*wgAuE)kCtEwbB@h+6DUKQc% zJg*;lMV&Z2B3IJ)WDX3e?X77{Q`}moBIQWol zyr__9ziEFCG_yT+3`U+=;E_;4$;AutJ;(>zW8ub38kq1#`t1uL&sXOkAdzbi#>GSm z`pTb-Z2R%Lg%1d?U|XaUkhKwOagjcSdZzL2Aty+A+TjMtJLI5dFw^E+X_PB1M+u?= zR9@7Y?k|<}*vfY=2hX+f(i26b4OGbVTsGp`IAtOo2zB%XPXbBJCnYn50ZB^8QfaS% zHyVVLCHAtBxnEskFI?MPb1|gPKzyVkAOYTXk_9>aWMz6b>fW#;6eae_cz@ zkO!5+#k{R0p!k+BdZGllcyc22co8tMggDsYyk9&qae)0P?^t|1Uz=mDq1afiCWmZ& zp`k1d8rdsNEMJ>o?m-4h_v>p02jyg9KScYLP?oS1vgwLziaA+t zfi$)d1XEcED2{wnm~hMQGt`XRat8q)IzlsV9tq53CJACQSRNAn$vyMXiBk_=x1QsH z*}Mg&XpPEb07g%K+3vPV{^Zoky`e1TnZx<4Sy7YTnzIIiUrEZKxrn^Y@-xH#Y zKD=jexIna{%1Qabh5DZ!wy!)!_+VwcJdqYc04k@alwdN>ROnZQ%ivFd=JqFKVn?%Z&I z*R2D&3%3AkgwKG7SKx1<2!jLH!+fazU!0tAkao=eKYXYNm-&q#jJw*$+Z7asZs4EN zj>Wwrhnun_@40^Z69iQj*iWrAtwQ~YUPBF~UVqE}3PqU-xX7Xrc#D7zcdiM`s55G&W91#^D0Q} zw-z`VY9NwL*M511Dq^_kv5uI5Kl9&MS-+ zB9LdsW0uY1s=2X2h~YSy1I6UlU6A?fS?Vh5mXz$c>E`;-S0DmAr`}3yn7pip)rxnm z;lP8_yRw#6=pdhiXk~6sppa^zz6(@j>(cnq5k8oi?mWa@>sEHF#!&~-1|AW>h&vBN z?xH+&2X_vUvCLkAnNZ(um;5WF43FuY*uutaem>}vZ z9|eH}*YN-IbO1m*3XcBc>Ig$*vFXhemXYtk)KhuaHaIvtFUPe}>cRyzt@|zA$F}oa z3i*O$K1H{^yv*7UMA%BwhTa3PxGu;}DW&&@F10=ocM=>!A%yS#+BV;vuA-&iQ4PZi z!}6<697YgjaqT`UH}M3S0K2+M?)IV!gxg*V7!D49revkZ>u%_=@opPcXf$jGHs<(| z_8|tGYsbkS>0F@ykt+Iy%`X?%5`*FnwPMQH(Y>6wR%}tjw9)?><3Da09pa;w#x3oH zsPK_Jeu5DZp~2!eNCMdrcco&>bv)Ex!1dro5wa zORk`wc>C-^4A~ZWy=Qx{Pa%rIddVyKl%lq1!%Y?ssg@kZHxlIGhvG25eDVkq!^#25 zS|7s3%8r&V6eJ*0chWE{gl$qBI8necpwMI$AEi|`2_K*#L!S$;C|o9KRy+dy9rt5j zLKE5rmZTSPLRsCcc%cV;XAxTb5ddUhxDUupPcs6LvEIK!4`847LmVqX4+ulZrhO1E zl!I%(Szv0JuPkH}#8x~qVaM2__FsrbexWs_lV{5nbr_jI!sZaO+&sr|n0+G|uH=CU ztYDayz*1)Nu@FBI$mH;N-$+#3LZ|}>Zz^0VQTX-MA#@EQ_uy}AQRNJ!!Q-r->jcsm z(N7(qh(;@2OgMJo8rhm8tl2>IN=U|sC&LC}!XOdI`O`}TN0JY@a4t2DnF9}HrkCmF zOx(wsbCWB;4W>xw(7i*n^-47#uL8x=3Eb4oY0(Z=aURTwqBegs3YjEp3|CzWeP1e* zJKWwgh~W5nN5jcrjl9&UcQM^hT?r{AMjrN>cx*2ohAs}p*;K|q@y2{Bq}iBd(L=#v zwkW;ACbjAT2ihF$(MchqZfLa~*BmE*Gt1uV#mh`viN%2d78%tZJA>WC6b^1;{%6uE zJsAc6VO0DnfE4&kEUBq0T>>+UQDqKsrJR??et_BhuibmZrn86|I<6et3*;$jy^RT` zjY`ii$m;pJP)4r9vOkm@+Rb zatwHiv%n#=MLFp$55|1tWBH9GR%|uEXWp?LauhAw>(StHm~gh9)Kti9!FQAf3Nz;- z8EE!gwuaN+tGF`(r*TAZy*|{;tdq#q43&=?baMN1>U9?V_0-P{5{tz~C z!5naye=^mm_r^PF2N!wu20O~4Z9Y8|-}L^{utho%Xg=ITO-mVpfLL6N*aoiXG!AE) zcQ7Dr03K4IlEZocTmm_^L^@U*$543y5tqDpOqTkFhK&k5>5ZI1ocha3W+fXFI^6(u zTE>B~JkbFxjso5FMH!iL)FV~)iG&5=Ro$g)iN}gW0Uk;lg`y(v@)6Q;Nr}(L(%IQx zhNQpOqp~u@mXx~u#>>?bB;vKpH8I{$&8I_8l3>a%Oh_>;OFqf5K}I`eN53r0lFlvTl~)=93FF7IOrn ze~(OMgBpn_EN23o(a0uaNaW_Bv^w|T1i!a@GM->#Qn1!5=#72V=qXzvms<(dTRZ_1 ztolRc44W{WLxWN^4s)hlCqJQwFYm-E`|>#ZC*GK0>nWcx74jiIE&{%?5V~s=1%ifJ zcyfVrQ%+!}VOGQ>u@V{_rip^3r>R6Sa9lf^=PXNN2Z2TerCS$982s)&5}|#gbfNM1dB5 zk=^mAd0|bG*t{B|rL1l+$o_Fli-T#s-G|oShaMoE@VxDv3k&MO-fOsKV8_0S5}Vr5 zMfYn9a6D_L%$Xh=h7JNq+(ehEMzzO@FLGb>oFh`6?%V+qKpdAox`lH*FcumDKqa$RrJ~y6 z`yt(_4oUYvYb3^kY|y0R+YEgiPRMm!^yCPdEY{=x;*KN=YQhj=*9toBT@oYtkS$>j zGxAs4mg>YBs#S{6_{04+n`dD#?jxTchRXg#9tv$U;3v?6EoOFCRfozJbPKf4SqcxJ z3Dt>|%Vfe59OP^Sm#}c%a|%rt;OD}K|TYmdu z{3*K(nklCo)4}GNGxVlrEF1mE@5#u&iuD?>$cu%`u-ZrL>+Erud2z0hx8n-uy&?1J31#&>W!&a9XGCFW-_NM zy@`aKnF7`yW0>F7;RQ_09OR({aLwoQC^X}YvjK&BEJA3m(5q5U1%onH#!XEQ`l=c5 ziM)WIg_lwh`($P@`*PK0R#|~&=2{o}aZk^ZQRnphm)llvW|4+j{%;|YpI8N7*9=cK z{%;(@XKRk_+7f&I+eY3Sl_)v`$l_eI*(>vt=gU3T{t?3pBW4m=(ZnaDa=0bad>ibR zoFa=GDxyT{!7Myhw!YWnH-}`k7s*Z8>VHCMg_0FFU>p2;J5_&+GDF*}&L>y-EeZ?b zR0@U#&WMolQQ*XWNGEC5`-omf(0iy)>xo4JlZc2#*D!K~VsikFH@t%F0=i*Xt%zzT zTTyMOHrH8dh}_j%8mtZ1M;UE!#HScxO*ESw=sMDIpyNcs3WFB}%=Mk9{$k&HX{*Qw z*2WC|iB*%eQ3;LLY1)|`aiA7MEd-tRJElFWrgQ71NlTI*F&0lq-7XdpGtc)#VBOFuge@pyocfR78N-}vPb07N$;W;+&hD=*U6VTkw#FL|K3ex-f{ePe<;{4e$0w`XS7l zqG+)?B4kWh#2A>+Ffc)AY&9WcWLQK?RVAZB`YbzOS*o265zp(YlT7413$BQ>M-evT zG;pZf#53_GZI}&~$ZIWldBz|AF*4yWS-JAoYweBB^mc8@#0*^m<%J&zEA5LRVNWli`HK~p^vqFWNL;Dpl5BuLK}*k9-f130LmR-zEc$?_beS(4fc{@Iu$4+8eS zf&Etmq&cLy!gX&A&11B&8ngrF(f}VWeZsL0 z7kFDK(8?O~q%3q{fLsO_*EY7dJfQA6<}-2p=LoZ^P+UX6@}%ZYh-n+7Tb~* zSQO6r&6!Qs4JzrEt7Ft7sfU*zWzXSZ7NMrOJCob$mzlv=+cDu*oU~i6W--kDKLnn< z!@zSRtTT5gb8t0vG{|Jl$EEuc(>?QS&s7i%MhKcIXs6tRJcu%vyR?$P-rugQj&1Ea ztSQS1w|ImneGaVp-Vdrbf0jV*+C0zGG5`_$B2 zO*j4!h)9l#@M zF;4=nK>48r(7xka23uik?2rB{X!-fmXb{CVV>9>KGmSq+3=KfSNJy<`^Ti=uq_%-3$Fw1kWBo(MTy>&YPI&D*%Rfvl`$Wjc{lZ^hoX<>)w zBG|QwV;amCAxA_=4;M&-E0{$qkBh8!&|~x?)eV|QECY{J6h4E*e>6xgi(Ir2Fb8Bn z4S}w=0LPGE0QpMyACcf$}grX@cv_9D_S!?`Nc}Uwn%=@B5tY`sOHZ`Yv^jK7C(x zlb!;ATBv$3S}2Kn)*Sm@_zCG*Grvf(zXS%cs===q7%O>d>>LRvx_*VY{D=0x>Pf>VxxQ|du~ z{p}fh2fXiVy6fY1vbGGR<0lw)0|JgMgH){!Y%MjU-(!LUAgu-_>jkovp5YlWGs#8M zTUi-Ge|8Pf9aeo;0MwypxUVF-zd<3~cSf=EpjL^rT+;hno!n_u0ejyke%B|i>h!Xe z`0Bg=g>Fa*!;qwUyzTuZ`<@k;Cb+5{Mhh5lN4eJOq9qZP)XXA)#+%r^D{1 zu7)hY>eEw5t&w3pMWB&k72Oh=1q>@7s&80#9|^tSGpMEi zxpjPPcg)kPPq6@xtEa<(O$Ck77}_{8Bd-5D_UHE<*56w}YeAv@0%?Lb@z~WTB(tg^ zH6|}ik%;(=@wAqaN{cUynx!ikr}I#EWMO~CKItF{D)j3qIj12iaS2|6-Ia`3eDK!c zo5<@*70&v7-sSerF}<723xB>gWSSh2)1P~4(pDN*`rkZ`VIx3O`f z_#}X4*<7H0NR)L{=kS}kK3Am`RBR|vuPJVL2 zHw4^5Mdy?|ZdpFQ8ehIWg=tw|B1m3Ia$?}dRNOFz1=OMlh$h7X^D%J~gla6}vreS4 zNCub?B6BN!31c8(m+nXE#hYyZ=t^W4GX-37;~5}O=d+7Tn`^&iIFn{{88qtCN3pU2 zpO%v>{BZ49etAyTUYN7vz2Om zlWN8cw8ym<-A^k~!)Pc-79v@T=2j{2+;SrnOY?-?t%~X8?Niwkt~`=v{C1icf*A*O zo}1VV1^GjsUj`kFKsW~>08?lMHMHs*o?ViM)lg&o|fU$u{gRGf8YS2TLELcLqYhs z1nC|I1FE;v!Tb|IqTFaVNZ=?4Yd65{hah#Se|Q zWYEXXl21n6;B8Eq8{7C%TuXt!an8E?g%t_pLGfjU+vK5EiITu#(+Mu#q}!N1j1#Bt{7x}Y&JqO4xj$kk@wnBL}6r>?@gtBaE#|?49FZ|Nz=w0Lhz@1cuL2-Rl08`v}B?9AV#;ev7TM4~#x@k5@VY5U>z4VP|m$>Nv24i81j*kV1{S$skpJ(G8 zsA1G*cw@jW6JWe!_S%-``$8a;5cn#A)?4lNvGiUbFSh@>$Ne?H6*q=$f*_ z@*BFCM<+5*CssIzAaQRXtIr@=mW@89@4IlaYV0l`eP+f4c(7*9+^x(sGCa|q_>L-= zDwBmgyI)l{RHS<;Wc2tG%7ualGvS8F&MY691N z#;D|i4ik+@C!U3JOfHRSb=39prOroox0(h8gA`#Yz4^sts98Oo!-&LyM8k}9MtSVC z-@}YbZNbxYjj6Lc(WYAHMz=YzHx-kWfbl_CGKT)WC@AuAtv1*YYJ++^a^JUxdEYS~ ze?m2F>8}B}%`;@1ftZGt2|k`0P&mciaK#a)YeYkc z=m=$lB@2;K6CNZ(`UW&esq+|+rmO+iKplcUE(&s(%KOTp$7Y3%rix?11)3m_qv*4| z&WE`w%!|jC!}=O-D&+aZ4O*3BN{+szY#iz7+cCD??wq(sv7Hnl1^b2!__h}zRhC5W zW`)%WCLFLU+Yu#w%3*HvNWl#zIE6&d#-;%VJNEP^3A?eWmOi-0q#d@uH8q-e*{+;S z?z_=-rQ@>3#67G0#zIecvz!coI!YDPzA8T;Vp=Ygi8vR{IoTIV95g_8^OoU8fMOs^ zJP&E(Q`}0LMCj6vv;2ie!!^r6!3R~@I9_FF;)MH5<+15F=kxu#nH6%*&Sz|6e4SRa z^@TEEK)z$gmB%YTKryKpF8ZuOG*gtP?@dWP~VZEs#1=Et%SMspPZ?NOQp5|0=Zj!Qxsd0 zam$M^d_odITDDJz9TGj1&yJVD%fO}lMf%oCOWxyyFhI6HIAUl=L3l7lxF_x=W%DV) zrffR-{+E{Fk8MKwzD-vUCH> ztOBOQ3hNvSL-2OUpV=B2Mu&S#&a+2dl{`iNQ)OzsW|W;cV+b>X#sWyR_2YoZ5d^E=PP-KJmM0yCD7Qx2mz9b%IUW67Kcx8W?a${jgP0?V`D1a+bDcoE zxzcD0tMbUd#>$#Anq2p7rEpB^O(h6rkMN3nsYJk;C`T;)HOrJ&A|Gt|6UApi?Cj?YUf_~m~O)|6V<5vW^^LQRjSS% zzRE7e^c>)Zcl>9Au6QIrG8+NuAo;x}huHwV2s@;eji~NpNewSE$X2NBdYWG0H;@$z z;5o{y{8^$DJ3pf@%6?oZbV5T*hqEKE-a_BjVR806N7Aea*pZBs4~oVeI#8K@sJf7M zs%zdkSgvR>;(y(EOI0-jtS~pNx{_DWAc^BwnDtr2nxF!Z+Ih?t*Q2YZk-kvZ0yCDv zAgnD(Zf-nzjpSCiG>?GrF$k`4nb zNUYp+7Z}$L_?kMY@HCGUHlHYO6DU;~9S6BX-?SQ)L&r0-h5H#vO~wOx=m{0DUhyh= zlf|@4HHXO-* z7pAVrvPP@X7FB+%!g$-y4UABTx?+kUL2k2K0n@XJrB-Oj(HQaYr)^vPRC>qy>Q{tR zdc#wk#t2sZl+cY&yLG&3O2KNaks)8BwEu~h;duCvpST#lUYx$0dMeoskP{u`V4F-a zy3oyNl%^%hvbwz1#fk!lNTT;oG0ArClvM1pvf+DSvfmVdac=whK3I0Q(0?5y4sdNJOj0>IAb98+-P zNLCoxDPdWQ&`N}^OJK>wr?gf~P;P(_zyxmT9WyuJKE_b6b z%z7RcOi>jKpT%Z7?m9H2V*T4!8TNhaTJ6|N8WVz=iVQ{jwA}Pjg$0-JH*Rl<*|CoPkq(96*S1hm1i5rJs z9mGHLCCz>amh^vJ{}C*mt=+Q%2Ja-_uv8Q(O}Ipad2IPPtP*FQhu$RT!R=bsQzVG$@)x_pkZ!0HI8{Tq%AId3d)wF(U z3|({lmn+D=Iz{d;e{Jb3XyE3WsW5u*|KSSKp#E?L_jAMlZ?2$C_xQnzo#u(R%aH-l zu(VbLdgL{5XuGyF3b3+ zlLHmpIkwOkS>jQu9|w0fJ@Rd$OjkWnC>_#gsArXE%s-+a?hjEAfz9o@AX^?A=O0m! z_4ofE3Tg_yB)VW&Chqv zPh(0-lo#DvA9*zFw)+?%6NeA0aQq0VIMI^OPB0u%0{Fnhe|(^SQGpLLzz6pImk%8H z#|M_0&-^zZco1GPHNoiGhdTS6itl$2;Csfte|+Hf012b2%MeU$8Eu$fS0MSPEHtVi zilfZWl|2$O-q};iaC{TW(Y8U%kYp6td6~RA3*HTOH&wSqUdteDD?M_cl14RnB9MS@ zGs|e}f}7KvUAD}9PvBMXV=c{1ZYu~`D7E{&feJ&6GJgEI{efPfn>?tYYz;tAy0K93 zCBlbVNQ4+yMcLNcpF>>Gu9Vw_&fG4n792Jxf{8o&HgeL;{%S9Sx3L)vEtnx4xYdtg zr=h2;6_TSjEhX9$2hT4*xhrkws|7C
~Vke-Qp359+Foqg5(9TVH)Mzc6A@e?6v zk1R)`BPDEk)m*q0`?X$;2*-!9zy3D_pD0#29$KHvtC0rlDuC3Px!EV zEGzqagDn%*AR%JoXjF^usPdL>Ri6Jf03XIB;qC|_3gP5cMU;Hu!_t57q3%EUkgXN8 zwIRjzX=bKpgpsmS6OTnb3+(Dut3Zy0J<%XEsx$N#-VL)zaSDTSE3H6i0|VFo=KCIH zboMd1g}NHHdu;V@{=*~|xGmE1Nz6S(vqr?b7?ypaRq`=lJKxQL3#Fk#7@7Uw?(Kc~ zO}c@>YQnw=Q(8leyS` z_{3Sr%c^B1)z2zTL3|NNrFhgY0=ce6JOYF(eTuOQXsAPDC;E6~U|(e?@Gr%?u_2$X?)qqh>f;C zAMAQYhA8dr?Y#K>@%ZAvy;3{5puX&70l!RSgfFAuQmzQ{7x=fGpc1AuGX3!eYnpP_ zs5Y){R6Hc8Z_F2doH+dN_z^F~-{C*_anDFR%t6|Q>e%Ds-QaL&o4ksMDxA?dIMkVB z=UVy;Zmus$|M6lx1YAy1^5#=P{fFunCiQ1T3LcAbrK|85PyXU=(`S+yf$om{nCoI^ zvS0N5h@t|L9Qk7@?2N6L%QO-xyF9w1LzmQYa2ZdDCTznh`goo#1=IR1Sk#lv%b@$# z_@r#X?CU}$=n4Cz8|;s9f$yD)DwYS6F&9~QDi>TMFzD49Lf8_qTkk}Jb+4>-2v|9< z((Nw7mpxU(YrYhmcf`qj`0?kDx+p0Ut+a7-n!#4^e0bUhS$UB}r1|!pVCziB5BYHP zJW5k(3>&7q-8QG?i&{o^rjDkD`n-JK|Acv^hgjX!OW09+Nse`pL*_9$C<%7b zMF35!nBLCz-qvmSl`+!~*Rp#4r=M@O0u*8y=blVCvb(MZy@l-{Q_8t2?gyKWLZJTLmVKocg3WUe9rudz zGqmmGt_BPPZsKju%a779&N^hIUNgADYg|-5(nLtPdg5g@Qs(}%5S&AD1XJow=@l>1ECYYaZ{{7bnZP>y4KbLe-N7^8_dw!YPxNzn3#!!C1-H(V}CJ_vHCru!`^(wASf@+A z?-(TwL*BQ$!TZp+K+lp-51tV|!&DUT2*N>pXO5gV$xMnq-Y|XicCmYEsEo4rLu!P~ z$RqMk@-$HMmP1-dsIu!HY~Tj`4SXE?bHWddTsj#9v7#d4u` zWtKXF?pQ>X$Tu~E=AbeFheB_XL|>bBCfJ~`1|-W}?klQjhWnnzj(JkSDi65%-hku1 z#S&f0O8BLm@n&;gM+^-u=-?u^Xe*bFx`ekF&iPY`=0PFS4D9Aa3OXh?fhtEfB9~s& zzeqhyG1E`65E&7ch$Kj?bN0sPY6G6Gs%9bHGc`~o*4de(Z8YCbB2Z}FOiR{EJHr0f zQH!^&%{bp>D_%PVb)HBx-k$!vksoLozKl`65N||T9+Sf)QBaX{e*J?*k%1X@L_V;^ z9Jxh>)rsPpT;LceUJy6KnmkfZ+OKwv;-xxqpbJ62$gX84$xwt-{Xf{LiM@(LQ}pCj zU}2wk&mU2fe9Xc&lvEW2Wv%#639IWx_d-8_BRi7@zfUt4l1RWB)KaI-r)U=M@#5p) zIZYFTmi<-Xkj5Ux{$TeqBaocnv3a&45wz*6fMuK9!mH91P3{+x43kWC|Hj-1NAIVjO7I>4ZQiqQR z$Q%gS(3z#}_(i`PlT4YW3D)Tn#+*>G*ItIVbo+{`ogcDm8EF*}yu;uP9D)TPgbG=X z+C;Gj<%V1l^{DL&lc6~xQ}t@QtfX`HHzJ9Vs>DrH%lXb%6N^XaBujy~M`m^q^&Y?r zRNvtnBuO<|-ZFF&PaRYGE9Y#U{rWSjWF5g$`0SPXq!eAOm3{dT6gZ(2U*p2s66SUwH`EG}tUIp2vinQ?#+tRqV%e ze`{vE&Y#r}BYmFrs0}ePR(cwl4NM z*Nh;HfunOG-pO`9l}0-f|BQ5MN0u*BqInv*x31|j6u;(bMN^sIoOXDvgj9kl6UFtg zm*U{;S=i9Bw%*WE-YNW@(Gw)SPwReOJynWZE0*KXL4f^u@J<{u^?ooxN;lkQO5ZF| zICl=n-8Z<2i`!fC<7%+qz*6`b=96lt*lsf4J>%;r!+TMhXm2#@vL_TCj?;OJlfO)# zTKjR@C@1kKE(-Imj6&UfU3BLjo0Pt+<wy1a9u96gjI-YsmZmQ9RR{RWW z&4GEhw6NHJVX1rcQJja?C7)^EId?ZpXAkjnq9JqBV!X5SR^|2;V(QTue!(HgqgG!9 z)@eXBMQTUcXGCp=0M2t8_s7mMI~eRcJvQos!&EPQ(>^=I2uRHjQ(?c^4*9bvQf(sdE<)y zy&Cu1HV|O&!`?bMVVu&tjKfKVkYa?ALLqq|Aw?Z-mS*%2BuKcb>9XGP<{W0ZdZ@w7 zZ0l_hP)yftxjHz-XBmZn71Np7W7G=bGp6TF1}wDk9Nt6JZ?crG5v&b zh&3a-N$(c4d_(5q{814wmx>~aImPDk+3dlON#akQh~bW&X9>H#WHI645;byabZ&{t zk{m*Z^Mcul{q)XvP_GXyfFYXWfJ>Bm|dncL&(VYwSLo#<#Vjzd+)*?9>1|sJXX;W@js#Do$>@cWqB&;dXaFIs4kQZKCH!-LO1>>tv{H#AI(|3?U9dY36vy6% zQw#1tWtHyfv`g)(MsgfxF(MpSiyA?4EG!|vAeO8YS1a8riJ>nx8kgWWJD*Tc5l@30 zq#9RCY?SH1O!D)zU@U+jsenpMjZ8~QY?S?&K`(^l=hstJ6#oA_wJJ{f1@x2V6!6L{ z8ecCI5mz50Q*m75v10PvpSB@CMz)Zx%57Qiq5p1Lx{rJ+LzVqYoxA3vzWpY&4y?{& z#qe3t2KaJz96WstJR`@xw8>0KtlRxVHo3(P8A@Qb(2~pnD4REFpmdxI@3cr^-DV4{ z9n>De_s*T+I+UGE6`<2w8Sp(YB<5=}!Nyt}e85IQ1gX&sLo8cOL{dbt1Q5(}M=?Vmd>`ZQJWp49 z-KLKDU@mOk8E5;vqpql)1{V+iGMI@SNKn(*;tBZqO!2CU!<8efCxXD@;bn?R&JRkt zKVlPdQ66?5-_4dQ5*0IK3vu55wzGqy0s&uMI6YjZG6bssu0$U%{@A%wJ=sj7I%n#~pRd02(=l&PuvEs-inF=22 zYLAyS9p3ljej6XWr)86N33dB&Y|eFX!Vuj-pbcUyq>9n3Su_6|Y@V4yQqJA%SApfh zE{5yb#}mB9fznNqMg^T$Iz2VWNGj;OWWt2iD;Gmt4p4nqNdh-VwRF*I!YB_zOpy3q zwhwr)(V7&lsKKlvNbycl^eKBTLLJf=)&WCgoeYuOIgcW6!wF-X)g+xnN1|=8EeZ~* z6_@*C+Khzi20aHFS=bT%gR7Ij)*O{XUpXAl(-+m-er;k=vvH(yK25s=JC2^b>`p1- zP?G-q2OE?0?;j77MER2$-O-rz2nbW*@~Xl0x6f@j6hK5;3CvOd+EqFX%F+>@ee+6UqB2bq zpT+i)>~AJ#{PytQl%T?{7W)5@2$FVT{0}0?!`%fTU?SbDI?`0~+$h?lY5=msjyDun z6r^K|+w9e!xR)9p((DtsO-Uj`fpWx(S6G|WW<2$EhhJtOA4HS#N;Bcv#PFCemC3Oh zq=rHhOK!MI=WqASTbi)mbKAu2lqH#>A4_=Qr%Kc2tzcG{OeU`P4Q~GXtC9B*%!PHw z;UP~KPxc3_HqFJ=Odk8*Dhyis80oKNw9zK?FPdpSP~)NfJ4%c23k>?(x$^yYfr%wc zArPCQBp+5lsXwhBTpc=Gn~yo;eIMl_35C0k7ZwM zSIS(Zyv|n`1_oiqpU490s_rqy$^qEc(+ov<#+M+FDFQ?V%~72N?*zl zoTr_<$=`MeF>qz!h_%X7(~ocB4amEx2r~)A7A_X0&_Sd{MTSqDl48hdQ zANO)Zj$*o*y~1yf!xgTN=jiNk0|KliD_fdk*jN}5dcel~YL_)+&Mm`!u>SIMjimKZ*wCHUF9!he=~ zQ&GC%rc^vTBI4DSyVuue*rC-mDyOfYBhSsV$;}^#o6^rkNbm9aNqPdgN6C_Ua*1lr7cRt zEcvk?O_!(lqUpJllk;PjZWi&P8;NKu6uB?HhhN6;yxPEGoo|lP#0EN)T8fwre0W@_ zz!B(o&(w;T{y<_rmEm-kP%NM$i5`ezF~7yC8Wc#{f&}UX{AWv0mabc;3Z1pjpX{Oc zLKD{7w{rGEb11KDJy(2@rHXjc8{S+s$I>`JM7KESID8t3!V!#NZ!ibEFN#5resKtZ zWIWp-jSAQ7ONCeiRm$&ELe@h!<^J_Q&l|Mo!Dx|-0KKO$7STSEQadV}JE-Zv^>6R^ zfVKNh8Zxk6J^3RQHU)LT#v%;$1FVeqU#!i> zA2T)~+jIqLLoUVIYUv5mfm4@#GB7GaWN?>Zy5`zv{K?RR1``J}I%3Eu$DpqLjT>tW zFIf9x)?*E5<*)GRPt?s;q7*gK7eu9gf8><+tnL6icyJUKr(le4mGd zTb@pn0EzD?Jb9R3ph`XfzEgxpbjdq3U?9AgA8?P(otW-~8i+s~3Te~!>+o-)+WU6& zScsY5N`U#2!;kt%Kn^0!{1Um=HTL3

m^Qj>qXBbsGgZTc4}~YFvSK5biW|8QU);=A|~t*jjysa*OmxF1{z# zS9E6?khoy1mC{Znh*)+6!){E7ZdTtJu`R7U<1LsVHF-f5j(yoWFwe--wSU>VaTJ)Y zJ}H2$!?}3*)7iUjO(diLB2fuMiB+|)=#9gr2u~4mt>DQ{XI*++?h-?Oj`_N74%C9T zXO%E|-qg6umoNy5tpmf@8%6Ls>N0oxGIKzJ9e;lNp>qEL)ym8%;c>zoN<4gKH#w|_DR0$#}qvX zL}aHLV9!* z$tIj9asM~3Q&0i$x}*hGnXNT4sWdMDulr+zTLO#9nwRAr)k|To_)t9$4s?42O*KP$ zeH2E6Xg?E2J9BA?g5Kepm^lg8{}avUN(LF>2O$n81(-gG}P z?d^tan>x>vQ2L5|fv9EU{(d!9ZDOS~JeQ4|Z*jS2&uXsmHBI((Q@^c$1xqvTqy2&& z#k@*)%S0*-w`FeCmn;7sp4qo2pR1uv=`WqGD?d`Ipc#kKsZ<|bkQ&j{aYR*b#i>hT zbR<+I%Gs)83*PY;hxv{Z#?!&fXVhj|_Vwz>UnDwXA#0SLZgu`%wiVR(!^U*znVmgv z{-S7Asn5k=aFEat%AS$`_9~G~hG@D;_aHub{Hytom{c%&eSet|(ER5Z^>peSVB|hm1PpbDfcLSLr(Yo_l>#cX@VxD)@F} zrZGl(1Nce57Qr*S2t7RvI7L?gJ8QnkZjI}&zYyHYcLi3VM0k90$D)4O`Ic!lSo?yI z*b#FHV@BVLA7uHmr0=n50;OZ|$)Pv{stKzAU1zre&~*hb2Kag5bvF*O<_Jg6bIrZu zyi?A_a<`en>gwSdtyjIxW{R1-44GjV@c6aO7s|)}6U@0zt70<(-&$dXMdJiP4hecS zAf@q}94;=f%ib8EUT7&kbz-89D-vk+JiGq@935VTnmS{}BEkYyCFX)Tq?v~q zvjl+Ot@ON59wjT1#4!t*D>ufLXx@tL{V{ey9HyL`rt4~I;(m zz^OCXb9KhD-7qDcusCJ<&Wgj3fgyeChkP2>eq6O(G}cPo=hmUiRozV3O7@{KjLW0; zo4+A>!U;3}a8G@^05rBgY$v5p*l6=k5lZAXB3vc2Q&NgI#%ZiuL(rpUmy=TjTA~dz z%_Zrd0)#w+5BOMyvLp;^OgEHk1&GS_EA=R%za_d<%&q>%4M~z4)B9umQH1&eXl`(9 z!Jl9GN}TkqZy^gwAxbY3M=YM;krujF-1(x?qm^!a4lvESu_)jb6!OUT*GLNc$Eyp zYcLiUhC^K~`DHi2P+}SdsH5@=xS~W{iyIu#DoUB7!h}{f8SldeAsf7#j*IEz9HCF} z81AhjUb@DXx}Z)@=}L|N9=lPuz<4D;TN)^PG`?RhN_hxM1?Lma8){8oOxrk3?9Q>7 za0FW(h7^6Gs>_eDPOG-GQuZb1ch@$|xtZy~GZv~Bt!%`?1!Ov!NMsK}$p7GWXb0cV z=fWcZr@%q@kQY*U4W9dTu=>{yo+EqnvLe*VV&UFr(eZuZzOnDERr|E;uRmwHbqLm0 zz;m{(9f7pVrw&WT)koLl>FDccYbE97X9V)bCnj0@=WXlFN0%$$VV>Q9NAE$X%g^>I z#!AZDQ@5)B&o5Y2r$2a{mAnFzzY&JWr<@rjH)4;W(*Ihlq0>sCkwh;VYag1${xRa9 z&rY9BuVochou%7;n?cK1T`Z?9C(QnL|HR-qmGZ9;u@><9@U{|!ol@SoCB7tL(eRzG z=2+50&+U6=-!sctc~e@s%KUg#tP4bBVwHm+kNOWTNiFmN6DyB0#ssKDFQ{znY7^(? z=`bgN#Z#;B?l1FEGL)fY#FQQPs!U5hZl+B*(xUt^iYZ=wUA{4 zCxTM$g(wVGLj{^)toLH9^f=Gg%6OSpf2PebyY(_S;5dY}e~xQ(rtok{(|k0+%%3B1W+(k#Mz&h;$qhIyZwIPtzQ zmJA5H`?b{ae$P(Zp4ttSia}DO{>uZ=oZHvdI?gND3FeD?fIzybvSN?EZQ|r6AihIV zs^v3Sbg2|@^%wIhfs3K&@`1DW%fmaP7!^@x`f8CW4<)#tNKyfI+2lq!G{n=2qZ#Vy zOY*6OI3vJFaLBJ@hEoKt5k@19$7bunZjZk9hr?;#m8C=(GaI`~Jm9gk;w*P>w$ejG zMs84tQ54N(;qtLRJabhDBi*J0vy0gF8Isf$(0{^F+}35BfuQyL{506=>P`a*09_Hr zrj@ZdBCc_)cAn#wl^w#{K?&e4ctWqF(x<_4awNPo1Aatt3+y;7*zM1UM3X6cIBLi| z5yHsCnqfLEx8*S_>cTyIjlkpVX4 zg0?WW)E4im&p^E<`8H!V;ptke#w*sC_Yp5_xgQH?se49AknzmkwUu@3A>&?Rn9np! zM3ZKVcX_vRGfY$vNh~wj)=P>|U>v%B6T*KE0%{{zg|UgO#Gr;l+E98n_-^m~#-`4y zQ|I>=7i@%2e`9L2VXnUjIHaZ7)C5?(Aw~0}hmt;x76Z1uxX?`Ox>#D>nBMEnzfgzR zL-(U}X$$%u@O=)0T@D`CAt`m$<@^-!LNB(sM`|o|46C+V8&2S@vUndcvFUCRq6b1b z@Ap$FQWP(9Ink6~5v6b7894NtK)>W@xJo~5U4 zFxh=ZPp#((U6Du!`HITcS&J5B_T~QSE#+?o+N=jX`r_d0nnS@w3kE{<0jl%NLK;8r zu!0%zgmY<0L!p(-o;O*na`wPQtkV98b*kQUEE51r#YZGDnZj|tVycQ%wOy#?%;S3c z2Mt~%Kh&6hp}{(;s|UbEhZ#;EqA@L}?#h*88&&dBFBq*uv@l!jE@6p0eC=SIoHhxU z8~00qlk#Vbu@hL!#BJh_lNQRGiLCOi2_z*jf9ETfsXnS?e}J@dcD~%LD%=Bm{2FB} zPA03k|li600YW-T=^` z?IyKYInbiOGkkek&ah8cBw(<(*}3>|lcz9kzB9p5rgq$`{ipdiLQq>h{X5yvnOVEG){T@6OeZOy=GD0k^3l(uSPC-WuR2D0R zcuGZs*};Mb+pC}8JIrf{Z$*mm%rw<)0KvcN8xzQMJ1Tz#4I1q`)NQaue}&-!%gOzn z{%Ya73#B8je(rdC&kE50`0Y1b&`XML1>10$Dk6*<|3hbI_`{Qf5y@UjyWQE;N(I>V zftL;121hdzmYBg-NUpv`y@YOge9K;T8RT+l8q0Or1M}!UH9%Jm%m4sBM0+hm_`MKJjN8pnta)oD7$q?a}amFKc znvrV1B#t+8)g#g8MHc%Qm=8*e-l3H`SwP-2O6Iu08&pf*XNx%H$Fso0PX1BJ{>YFS zd-|LX^#zM$iSYlWl1~zaV$d4B&U7a_OdvnMH;wDJsybP-*GOsQOR1q$5l{C=qSKiYpl-jPMe)O$dy@TX!{qgdg?tKNV zcUGaI(NO3g4$vSrIh~X7kO?ULE0f3RB(HkJ8ooB{_}&tlG`5Zf&Mg+R0Inje!9t#S zhlO*6MSY3Itc?HeKdv&?_M4q=DZeQFFMA-gxn23ToBJiVI!jLK4ud-Yob9UPWED9u z*DR}Enn3-G%XIt#XOsT{XAtf$1qtSZc?_2*{@yW#D|Yt71op#`wxR>b=Zh%{DGCez z3aT9HaDsJC{VRy}kYjKA`!TCsgYLt2_K=qZ)y1eaSzTu#zf-5&KHLb>jF?WJ#|fxz zlj8-jF3+;Zo8rw)9aSO_#GHzt9F=@Sf6c2sKIh*)6SoN-K2&GXAe3~+x& zJEV$~2|uC7O5rh^0M#jtNgLv~nQ1!Zp0SMaFE9QyChC}Qgab&cTCkGNl1A4ei6(8)p?*VRUcGX&m^ z{#b&({Yoz?|K^2`TU@`fq?@4Y@tbtll9nBY`cp0^^DEgURAjQOD#y7s|9C9=uG%3q z-us`(G->mueAJy~?9w4S<2iVkb2HH+msv>GHx#+rlpi2z!PUBvgqwZOQc=TAFG1+2 z1W-SZ>ziMsYqEmdvrcQW>YjKuKlBoed6VlyG->onxpsXbXa-S=V0R<(brXce(2H6; zz0r@G+uALM7x@iMkPKl4@;G7yPjXqRhi5`_ zVF-_)Jv4*ag+sHCr%o}vy}})Wc2AB{&`sksjK+n=FYU^tv#o%bzX13ptGq<(Ad#DCYdcix!O4lm2(SKa~{=#3jc+2 z>e0zzbfSjxnTzcE`nNKu_(~)66vW*MZ(`w_ z-6~waDJ~GACITS#)Ia#Q)HFx+S^KUus^IEzU@mt8zo|GcND8NAPq*(9Z`cYx64pUP z0^6;^T6}@%AQH9zP9l^hiwoL^UnL@s?%(s_9B|zijH<2}NU^x{k~!$)baHsM$K5YL z8iGIXRx*y@>Z2`Ww-HT-UDV$3vKd7fM5^FLPR8~f4F;K$82`(ku_=7{v*dsIGfskk z`7?P~wT-&=Y`zV=DF_Gi@i%er6+JI~uQcCm+{sZH$Kq>8gLLL3NX`bOjI_AjPpC25 zq+Q10YmxX&ZgG=n#LG#Ge5FdoD?me*BX^A4I9e+Ulc7Y()7=QuZ0fI@E!dL zkFIUcj(*_y?{U1ZmF_xI_n`1Pc-vG(IL~m+kY?d)i?zx-1H z{HRo<(1SJOEavf;pToJ5EvjrChOrGTS@W`V_mZZv#YRk~PaqRxuN^&zL3~XM;nJHx zd8kyZ19*fId@^uK1nMBPL10ay`&CPDzcVmO90=gmM8#@(wZZa(M+2R4m0-3vO z!cljo2q2!5P}LaJVoe^1bu8q}mOqP>H+9>6fs_^^`}KZ_%7@S#HSf*gr>DQiKVPRV zFE}-)pctwdt97h&p57x8_xnckB7OF}z|d84ZmTd)XYF-f zodEx`(A96)A`&#e_p_)cC=yo0w}Qew1#uOJ;1rE5phnv7RvY3r8H^3mmX9dHGqE{s zHth%rI)#GSuUI#FkZWYjG!k&~y;VSOb(b4q=ko2B4O!2;|8wd6h^P+G4Wv&LAp#=Y zt;Om{gq%`05dG25$imZfSz64#O98y2#p2W!*G8Osw?E#p-xeIomBqTleo52?pdhSp z1j3BPs7gec`@mGB5%7xvw=w2|8SR3K0B-%5{!%1WL;}}`-rui#zI&38F&AY8Su2&< z{4+33tS1Xq%~mgjttu+|-Hi}gdDLM}QNBI$;V&?SJjE$hVFEZBh59)PKC3PQ9i%GK z|M?RI@`E*TF^Z_!2@0l4$SO z$^Ss(y{KxSzw7-u%e6Z$fnam`qGF>fUVii`04hcS{67Y>bU?W4oUjHn z%V4?Ug3jOFZ1tti>oa>A9u{$Y2%SA)nSWpJu*1Y)oHa1qWNRS#LpsY`OkV|b>T(Qe zd#>b={IpFgHMEzL^CbNws_Lk)FIBiD_#UzpY@`Mx$xb{)oQItrv$%!nzMIZG#9 z9)^Yv4D89-5fQ?|yA$y>YH(gA7ffGJj4UR;Dz;1|V?pV+c(K}hJ*n}`QV%EA?(6hm zl(nayxg$bGs9YJmJl80_Y|YR5T8Tu$HIRUZ6U)?m1C8BMXytNI`^r`=1&srYwS<2B zlSm_RAJVH<*+N4M6@4bDT#5k+{pn>OYQ3sLKxk1E>fnX@(6PHVK?fJPLZCRz}0~ z-xw0Y=>c=w4(xll!8~XcGG{*1!_YNOfPcC%T+^d%y-Od<9^|TgLOSqa)Z!>lQ)o@1 zn9=9PO*$m(1ZcVlSg?WGhRp&e?C~SH&cpK4P3g|rUN~iG^_>s=9(Q8=t+t-!ZR+VF zzu2m}TewQ))4Acq);g>VYW!Gco`mlFGqyafJ$$-r>x8O5hj^?xlsjWroa)L{ zi#}y7#|Ymbxny;9X%RhB2nMf(1Skixl|?2nd5=RTWg~pF;;a%V@4Jo~6ePEG=Zg_? z>*xuAa?nWxI_kepgAw{o=xXD6dUad7VQ3AD5P$uzZf#_ecbt1;o=2_>e?Yf3Khrw> z`iDS!sg7<_b0oIs87C*Y!-fJTzwbtEGDMFk$=VR5m5#!!N-3`IsK|l&*aw-muJ|Z| zGxcJmou<~f3KZy|U`idiSWErR^f4sD5b!aRYH0r~tBz2`F)*4V;T!*1L*N4a$>0dcUQ0%I!ojQk8L5NM}k81 zL9IvlvKu~XNEF7*opyV!7bPEuINXaS|#bzzBqLwcXSt*4k!09_RiMmddz=-jEn@)dCae05~}@k{`)&p;U=Ir%oC4B zSbDFOO?_=kGc|&LnWQ|A_A13EbsC_yLgm2~deA6e5QTonk}5Y+U3KD$g~})~WX*tc zo3RgI65YQNX#I?3W^}x{0@Q*64;*$B{Fq@c{dVE76_B8UVOf`5#KF%JJAwW+;w|N$ z5pQSI)k(iIKR)i_dlDXtqfd*CrBr-1k%Yx^V*yPHX50FsBX&tvWoFil)Lv-wXKF*7 zm3$&(%CHN9?8ll3R9JRNIC7xSZIHIIJ>xZnpHz zt_W>uYi#C?7cyOtsUBD1`w_;iMwo;0a=DwF5n*}``o*XN)V^xo%%w<+QH^^ z3zFh9^(ER$)}MXYH;n5w%-%c!#UtV0lu5<)C_8omx$YCUWvv_DBzsqW(n)K=jbJpG zb#Qmqv#}p(!1=@*cgTC@zWLi#W^kmvSZ@brS4~!WLrxsTjTMl2qOVYc41B>}?~#|T zzGtLzcfGE!9UUDwPg67l9D4$uMrd#bv5@w_v-XP9F3aNRorU;%VR1f6ViG))c|kEz z+6pS>0OBPZk|{I-quDK(^>S08pA3#!HgMASPivl9uCe$Zc4`@r;-`NbFT|@&L4R)7 zfIJ8zOvS(&R45^PS>D0;YEG}Bz6KK`+cP2j+knZ+ibS9E3U*`NwYjCv>F9Yy8M9qs z_!yWs8mDUZ!D~~M*;kQ9T%G1487Ys2GC5)2&}Zdx^%L!LF51q! z;~tdCuWF6uS%`%OAy~5^^*!OzOx1RA3rmtER)4}uhb#K|lX9FaY!{acuJOS>N-`K*h_ zY;QsFb*+jVrOh&@jE*qU=WUtmT8S7I;d!`kxzaxgrHSy6_liq@boaDL0%4X)OjPsO z&rvr)(tljCKYc0P zJWV4{CI?@Q3u^@8aL#%uWPGDYs*3hEOLr!glMKBWI+1EI!TIry8U+3?F=b}f->zNk z@_CYCyV$m%SuyQg4UE85I%WP?qdWA(T=MeH2Pa@n6&n}Dkpy8gl}HZ;xdH+3u^EMB zLVge_Vd<^!p7GkNtoJ51`3B$d@r%bTOD^Q`_UzFVlpx&`j=)It6KSSnFnnyGEqFij zQfc(Ik$PkCPHk3{CwXr93%YKMS7=d0n5Yo8MaokkL<7gwxgFs|#$}YkCbBQ) zl%mC_D(NT{M^|%o6(8j@T%@j2Zsjv2RaMjad+ctavVwN;0iU|5nM5zaiWE$+o8?biv}Xc zEKVda0`$V)`?8VGuR!W%gPF9wsPYUA+aPSn9X(5}OB~_KHsZ?qmHpA zCAEd%ONOUkc1Zc&MkjfNjOv~Ukg0BEct2GXX4=_kCSwLRiWkvb+P^I!=J?X%%R4yr$U&SoN4PS{&?w19?(dM8XLolj z>%Bkuy@GxJ1d>wQoQk_j-8Z>afXt5AM(w{UJI)$6A2%-_HD_@gS@y89m)fsTdq%b% z9iql?tl~Oi?eI8y6iSN5Is8b@lT-xvBVj^}VCT}70IxjJ77s{rS?g^c6hvv1!s#}b z%PulZZth;`!LWgs;0{=v7Q-e@zkBDcB+I1&JAmO`hEs|lq%lKOjE0f^&epihA1upJ z>HH{RPQ*((#Fz2X>+1AY(8r{UmB7?|4}sq8g>h0z{jl({R0s9F-$#YN>wDx@!B$_X zq&yWgWVF|4&>mkLs3=Sl8EuyLF*wNEK!+Bn zy4Pfva5|ZcY~fIEM%HYg+w(SbD=5hTX2YNJ^HV9Dd=pCS*YZi@!SzA8oc46$bhWe6 z8W%rQD9~S46S#}x_yavu5pW2D^40ww+k0~>D7+wVl}i<_vf#@LoB#tq=dzyvOCC{n-w_B8*RWy&Um8BD5YpVC3#D= z1IcO5*MvhLLBZHFCK-=eifh<3%k>%tbj7&+3HGH?iCYZ#d^0ZByKGeDghAh!_-e;f z87`Q|z;=tKF~)n1scbx2kCX3G*D>te2pE=<cpR9X|OOj-; zR-vMAgO@p;*Ed+Ruxz@?Cbd5b$gW#&0IO=eb>rm)?(8Przd!?z8b~aBQOPQ!dBRz3 zlXob0jL3YDot8BC-7(*#m-v#$TM=Je$JGU1yEUk@^YtpdF8cJbE9{X30w`-1?Xp3UdvIUoDV zvDa#1ljV33@!Sv~SlB~^ZQfuK4uZu3)b>4DLc>UKHQIXTE5;q8kjO)OEoDGJcZbc8 ziY3l>EK%3*?tt1-e&WtV0lSJ-O?>;BP@2<}xJbZFAF-`p66-d-msZ_GN0xi#Mxe%H ziH++s{Kp2fD!~p&;o`gWX=i89kC^^J7^=IL{5u@Q6ijK8qXJpkU~!(jl!}*cdAt1p zk{hMxYKMNPErXhOv$KmsU_{WvT0+^@TUQy`6bs1@0iS$~P@r&b8o-!@5tc(_677Z49WK_; zGhM|xtH(eaG@g8W?C#Z2sgUtvUlLOkbYmGo)>5T~-GILI`G;FpIQjA_2)(dZaJ_HS z@Vp<8Y;_)-3Psu3dm8h zg1xz(SDaF~gR;gLe<$U7T-f|2mfJr@6^nS{dyn+j!0sLvnYE-{EwBr>f*2c?cNZ}! z-i4$TM4PLbPkN=hFTStZ5->3-;g1)IWk`}|j*g)|M~<4TsI3BftbTt{v&cD>Aiu{N zB~BA~*(A)0s)$oa7zIm^1R_vg`RAG3GcpDRUAv-?yln8OJm#Hb6^%;UP&$JsAhWa( ztlp|v^jDAp=qRzE(k<2ifhY@>-{`KXP65XIxRx=#p1b^tnytUTc{YihEPh^Jcxz|) zOO&=E>W19Y2%0S}%9vc~596T`N(hay@?Ud~{<;{E!02Qk>+7Otah%N0qK%*x*ea(Z zlkvg-g1YQVp<&rSJGRN8poS%&gMp!{Z>&^1xPAI&Q%5wPr2f##?RUX4k?O&geVQQjo>`g^*!g zp~wZA;~H~ynUN6lLm<~Msdx+pO7aK9ru`7y26X>lZwt}LAq*iwS59$r$kP)MLgi+? zQ`2`|)2gh>8K3bRfg4TGz-IJ)8^SQ0w{vZcvPx~gRe)ne?<;XKrCF0?w`+C&zSFH; zzdFH$t`>^YFd1ZL0i9$~>S(XWs9al}36c*&`DD3#6l7l!ci64ya|5OZts70edvo|h z4W`uCiYS1aL2@?K85iYCVu6CUDkZGVf^*Os6l;e5C+oJ6yq%iW9P-LktWTs?0Xr%n>1Ygbzmg-; za(A_!LSoPH38MlzXJZ*u30W=;^S05nK8KimJ5eniqT0V8#8j)jd@|e}d3Ds?W2B0n zGuNYxm6a-`PQ0qTCh%@mKUi`zIk#%}PvV5k6NK3T*52%Gy|yllTqLTKSIH*t%YP}u zN?^f|lu*Z|ucR$V)Ze=Kl)=Jlj4uQ%*RaJ>+t8A5A0{~SsrA=KJ+z=0OJNZ3nhxN6 zv8m8W%;Av%0+HLCiGHc`O1|}Y;9BtP9`JXaOxjdhSqiNZR)QfRjO7DIukr``99g?aP0hT?HB{iQT7x7N zXRq}`zrMx4U{^J;BwyRmzrm=qRsC4b-a6BK!K_*wwY>Tr{*$d(<3_CcNQHm6qWQ>D zQ!`KkU!k0-x$x6+gcHKSH5?uqJguFo;Wpy)%QssI^{RNj*t<_6`ejots?Q8Aliwm- zt1}D^LEiqvNGnrD4B_i3gqV>rBkAPO9Su9{8Kz1VvmTD-s;$3qH#tP`Ka;^NcCJ)c z43h1F*FNM=RpM#s&3RQz;}!0B7xnWY)Nt9`lSZ_EjMogPdY~e~h=a>I6KI$9%DW}2 zLQQ2oJ?=X^87QR&!zIriOBj#@h4eM;sOZNRWk|s4{vHZPY`9==ow@$CrwD4iN+GFH zZ>2*vH|gx~aOaeT-;jx>R(lpw@`@ZG*k@F!e44o>v>VO<_Hr{%tRMA?g7IHiKlarT%R8`jm@be$fxvgGn+?)|>` z_%_*-HW?%1eG=Fw%?4ec`g63(oLRRXI33oy*Ye^s>cEd!&T7EmU|82>~o+hv6QyS9_F%%tl;C z>##|YWyjkPhH}(5EyJt;R!`of={^FS?z8NYsZ8}PQ~UEuA@GHv973y6$Q|`zFYY38 zNNW8;qYxt>1rtd=$Q?`|#{*bCNuL9iMkvKMC8gk>rppT%=^Qjy%gRiS zpvM6R8u(#Ys^iTs;&vM3?!klPM-*@zPES0_w*w6Zs&w-Mmqf9O;7NnT3;cUeK+*}q zQ&c;N;v+;;msMN?pw@kH%A%SiI?OYAR*fj=FBZ*!@FzMwx+N*PsgH67uiv{fHv>rd zZ{d0Q94JJ?V6m zrDRQ+yrEBJQ2NmdRiiLSvC0ih>PxS;*o&~@8mkm@$k9+RKd7>-+>Wwjtr6(wvA7{o zg(qz_N$lclIM~n_j5NW>q=u9m^{?@El)6@zexiV5W5Ux3$>=DoBYAm@v94y1;@HBE zAbmGy-I%R^E9H!TDdl;9QiiFZibu6>MIN#fWT$=#B>-{+RBTc{a;Gj7Q&JOzIpO(c z4uafG&}or;X~NdKc>t<5CU&3ggC@h!@O9bd`M8n217FSC*$APKhdpPvI=;^A=qQec zcuT*GU02Z|$eMgVU343b6}k+AMS%pRs2Y(LDNHSa5#K1* zp*WQMqGBG1eDJww~a9YYUTv2&eAmgun-9-wOh?!N(1UBEoB4|&D^VedHTuf=N7f+F^UnWK$SQs+d6bETJ*||EN?Io3QykV6${$VG?Lf-Y z7u((=6h$Dgj`p>g#!2zi5f0)He@xA&W;{vG_;?m=v|ltP+1ai!NW{9aUhArV+3(^a zL7S!Op?}#hvmMr0Y=kCL!43GAHNEU#onwd~Tg+1BvTAVEKQ&7oK(>(i>p$SGp#hL_ z@BwZtM(zXRS?It&j!XJkrXk+!8=4Cyv33_{Dq2G6AzltU>hL1ClzI{Aa|UmO{XW_+ zu~F``j8^QO+#>CD+81c_g|Uu2R6AVOx^E}e?F1(DD?O^h0&}I7B3@5{Zgdx@pM6DJ zcz$g$g?}8)>_ENd_u=Hv#L{0^`q2+m)0AsdlfE4K&Z6* zl=Q2(M4BM*uL$&rrCZ>`Y&B`bv>*ZUm?fAxvwNLn2#+41 zjTwfjpoV_Ep`8OftVCZeIJq0Po-FPE#v1=;u2eH;x1IOX9+F?24cY^340{s0vlg4O zk7Zx)8yA9Ygyhb=j>=sd8r`96O*igmvHH3X-K3DZeE`irD@L{8`x`lz=cmgW`b=LaXeE^rU z4GT{E&Hyty1d)VU9!Iz=ufVaUuC5>O{N^RyvWBBM#lDbkF<;ON=t0!=T#x-QCx;^o zPWu`BP_a2=zVpmW9N?YAZ2G~Q^HJZ6ppj8at7g=&r6#j|Y4Y6harcHFp3bnhcOM+V zB11ZU7L8$I<_8T6Bl>1n`YBXpH<-IkkuXSLJm5$v=k$V3(=N0e0C6f_vqEw96hif7xZq z@q4!a|Lw9gs+f#XH*`8q$X|B3C5KS#f3nLazYXoDm%p4oh z7iB=H8vlB!=_>|lfEYdFfaqm8n^p-h%-R>Yj-E4NSOCK;2QbWwe;H<1AuU_2pj2dl zVNL@W=0oNpXMkaj0E0Fc{}035(FC;z4=~KX%5($%G0Zgx+(}NJ*aRMA2N}COy%aad4S76(8-_>;k`vUNyz_q)SK?~lzAI1j@wBNh)gJ-i+l;h8dn%6h=_yv;NKp49;Kr^K=DK8XypSu5m)#=VpTm z*cG3p(-#y<+EwRNs9 zRIfIcJ=9pyO63bSDewc-l(QbvZjc~b?&ZLn!`Hf=k+?e*-*s(;yr~2B5;jMv%=5FK z@)nDudyUq7&l#XQ8*Z1Qy>~JU{euEpD{+;pX~`g_c`2LktOx8H7kdh*jUj`svT9!~ zg|aKOQqG@Zk`fz}Dosf5K>M6Hry+mYr*5eR5cQU}l8R}GE)0aE14KZkvnXTpHR#dU zK6$V4qA>->&mBVY2bJvi+M#8GlS;x{439|e!C#be)iawe$IqtY-Z<{9<;Ix29;+o> zh0ay!S@fieB2IRBP+}Zj||lF>C(AnAJ9{BDZS^E_8-{(N_BAN#ssk-TVb) z99(qWf8;-I-?7fL?wS#3CVKO);_zQL7X_k&m)19TNtu!2AVTM;O1OLVGQ5?SX@2^5 zx>H#Q%gBH{#;{5T!;UJd#aQjiprx8SUXAc)tOQR}Jc)x6p2?lWDzq-1 z{0d+|Td1BlDHmV(>3YIS_nYvWfMgN03ng-{Pl>g}aMpt6P>LnK5_(0`Wp;jo zJ2yTf1ZryL#g$UwHvZ9{hm8`|N<$#V%t4yR-K8@^MDGYr|1R0-HN zUF$U$)csYW;H*G<*yKZ?^BfBBG=d2ba-DnU5$Zn1;P*{{WiHW*GE@d==9(00fM(tl z#`;S$-=hLFv;00m&4*^5hx?C&VUz#~$2Q+~lT+pKB zLo>fVY)9b#t(mW_n$)6RNHntz5KW#guCUOZM0(BE*Ob^lCp|h_+gJgW#9Xe0!bp0S zEKmsbHD(;WBYVOBamSSwY0dLDiN!t%caakZ%)US2?ODb5?ljge0nIhw=;|O$v7wkB zLW;p!TQ&O-+IJ@p#e%l1GP<5AQAF^Us%gUtI$5b#+ZLd@)3kNqAVb47K?#~NhRxbcqh1F_DHwXoeI;qZ zAR1MahRO8!PYbSh^YX?ok)=Z0z~=F_Fj7Q-6aQf=R+R;VTH!-{aslPuQ2jza+VEI@ zU(7J3r@s<(+<{g~HV0P=e!4fpc<-GhV-v zE``4&*%}n(KfCu5(jqN$0%i*uONkC)zN{h^l&f}Qw>)Vet5q;OY=kLFCqQQ}8w4F7O)YF|M1oq2y^Hs}94 zFlT6%DVnQ|z;*2~J>UWoDe(y$6${yRVXZ{I+V0B-t3=|Mqaz|WKh zbK--3TU6bhtp8i)dkxmZYY&Uk;sCL#p5WHL8O?Ut?XM*`p1^^(muJ!$6o6)K)j^_v zGV%$H1q{EL*yt=J_dq77BUJ!Cy60Kg@-nWZUTE~jGFb9jq~PBi!u zPUHEW!3(W16QBwnVX2b@rbO{D+bu1HQWACWW4#k3oY0iO^Tw|0WUo z7bUotCPNs)-50^Dof{nd_~XZ`8U2RGwSI<5S|;!zE5zzy3NF!9`&{U?G^3fZMzLG> zVa!&)Z5n!pYVxj>3oNVFA_?Z=G5E3D0NWhR#RmV~!w7?4^AF1=k9;n&W=JyJP-112 zp?PacvxZ_yeVGwI#+X=_t_q4Qm3;YYOv_t8!1z6%$?wdJ`QEk7-i3qA`?`FEcHSl)0Zac zGukY@G!;ss}EF4bTo+x$YiG~4RDKerZ3ZezB6o z1e51f_zS9(**bDpdP5+-F|Q!^aZOjr)T}2Jo<%U_GBkt5M{<`OzZ}y{Gbta!(arS+}D8l(pCtl!#1{(X?X4jEwk;rMiyg z_X94me^ch{(Fnqj0l73RZWO^-2o1->P_#YF-#qemS$WVLvZ$rY)Ps%8_WIg@U?>U{ zAQ(#jcQAC)-0BpXvyn-sR`l7UX#5vO?%g@dE0b`YG~cU0(OZ<)vJZ@T)}<{UWtjB<4dDB$Ly(%gIvk4JMPXm*&W;$%!%#?Qd&e z#uE<-OF(Pc4v?p$Ca~CAh*UCpHu8EYv2MC{yQ$L5; zcm7Tih(B)Dc4+2ZaLpAqngtA5-7$JY!pg_Gy5WhKWesymA77$%TA-VrXfow26OYl1 z$sB<-7+zMTMiW6uofUT`8!WgPP17Q!h?m>fv=Tq)8AgzO|32GWVQJ452Ut`NO0^pf zjtqYMXqDC&{%5O{1CzKACJ!Y}=uULBaHmjbut9iad1;b2Lp&1-b>EW`WFr8Ni&8R@ zSxo7eaNNT`u8LGgP!0%**k$1q#90iL0y$aoh=>4j@mjHJ2t3N7+*RGU?}zRWZbV0L z9_u;?GVh{q)du2Y8gSuRJCp)#^d_kfc}?ngp;fXj1rj{vMvVj!FYVEe`fqxG+tz&R z;;0X>Qu;kMV=;$G3UpROm%>(Gc{jERsDF1UOkRpOE&RVBw9wxWS}S9w&oBWt?x<-t z=e=)+G|XRp0?u`3*WbWsW}#=hZCmZK!rEAQqErk&ck$_?b9%$rAmGX$)nl#$4}q#) z_A(35&j_#NH*;So>+d{-Ry90FvFLF5OM@Z83Fnfkx^tl|bVrq(ickTKy95Sh^f(GB zVxwN=kIJ1 z1PBylqxc#lbP;FK)d!^hdR8vodQ!O95OhU128f(G06GjQ@2nR(x>A_)sS7NdA5Y84 z!pc2<EO=yj8%AJ1ntK>iB75ND?0sfipAOHM4HcZPnj9y8BG~)b-fZ>_Ms32YcQ^Vv8 zdS-1tKtNMdgC{l3W|KARfE=j9MDiAalFl(PFr!cDI(}{27yH)}b*WxxTFj;{u= zXZ~938Fd`&c_5(OqWzG^%2Ydw@F{sqX1-)OMA zP+Y)mmVoqBawI-st5$6GX4duV`R#GCg?JxXI%Xa+Y|IW`@G#wt0|!D z?A?3443xkj9M~!%Uy&y+tgGlJuM%GDcsm}8#C)7`{4V%j`{lt{=ICR<*{7A$lTINJ zr!l!cs-e7vX9mKyky+7lB~7uWnM7F9!jn)rN~N2dav2|B?i0W@C#R(vUwE+hQs>6v zBe%Ph+)nc*Im9$SU$KS8HQ^yADtuH>i6m!ux*^<~-OX5C*S5OVzc*tYYCg<2n&0ly z<(#&Y7@@AZx0H6rk&+j0+Bhh-QW~DNoi=*_R-evp1zfI-hsh05XyJlFo2Fi4!gO>S zzOGiew0~N-D{!YR9ZU(;v&72$l0ESfuZ10~dpQPEixAAF2_D??ihl{$15+EvDG02a z^c!YVDdD##gCW62ftUXPS-y4Q09iU4MmJSOcU@QjrhX%){)!aN(cQC3)`o&g7_2vP z%e-9{P^w{B2PGByZ%S#QjD29;6(^w56xOvvz_V|*)Os0WeQD#5n*j-9{}VkJHWg+! z6|63g6{D{TR=4M>aj(~nGm&wmIAitdqkg9$)768H4yiI?s9OVE`}eFbzx^*0qu37pQB zry>LH;P{imeTV0UJ2(qRB>-|6|Q^4&1|gQoP_&M8aPrstd8^I zdJ@bXtL09m0h?^KjbDAlwpFM;lMysV*jQHq{p$HiSi3|-a$#@&<9J3`U6c@|h;{&96yRXSEJk=|kZ@?RpD(6f#Oxq) zRV+6&mwLhEueZBj8k4raLosM%0clXP)_*n`8ko@d)B!_j$bGhXUtYcu&jnzS(JlkZ zpd5yPGN|T8#&Nn%x~IX%Zy529-!O+yr|(gEsmfp6+t_gUFMZql^Aqa+HV&}=tH#>+((I9#r z`#gKv9QcMY3TL#=PrrdJ%%qoU{kVuuXFo@exrRHwUuc+hh0tsbT23Q8A$6tW)hPDf z_8^qZ^hVmNjZZRBdhfLuRXdlWJE%r@Aih*bXQQ%Q-?S>z&Ii@b-_yz;6a@7NcrZvnn zweuWi^R_D1A7tEdlXErp(q*xTeGEzQ)E^5Lil$r24x>^VFBcaHjGtbRd5 z<}XKGddoT{fBcW5o?!9q)BNS6&Mc@Eadz30k=!A?U?RE@FlY$3E%{LLrG1|4&}Ns7 zWR49=LB4gzPc*nU(M{N^WriM253mS#)%@5+G{jx2@D+yFUx=9Ib*Mg4ge2-ViTkTb2*oR>xR0z4>~6(6Y0ZSf>Q<#uf@RrqXTyFg`x#je_M zx;`45gFUL)Aur|osd>h|YbPpOlLmmVe!vqJgNh97yUwr!94v^dR|6JX09trWV zf$>|*Df{I0^ZuCXM-*Y(g24u<(KdyQ5epPfa1a%uchWZZh>vkd+awD1aLdJa#Zho5zyhCD2ekKhC1H_ z6HHHv4&Sn+U>heJ{OuCMpN@3(M)T8NnGn85n0mAWaov*cv7Q+8C992DqetQ4O>*d> zAY+ReueVa0*5Qp-=NzTnp}V|3vV0DM^)6Ylh0Z$0;C{tJ8t-WZ{IIy1rt3yk`S6EV zPS+^96=v!|I(ZxStt6{Nk*ObAX|EX&H-_vCdDl;8P`fk;UJ!KpuyPpqi8N(*ZT3Qo zVdaF(7!q|(HBa)OS!-XQ3plHEAX!TaAy~K(7)If?j7N$yA|$xe)u-r|Tpm8P-j++0 z?4U%%Ww47IOkrP83kz^4#A0F4<$-*UBSi+~cWx$L9Ocs&18sBzDmBtCyqOgjEv70- zFe-mkb-|kPM1%)e_bH>Q3kDJ*o{|7SRpZLx%N=$f0Z9NPA~p+Oj1_% zbLzo()Ob{RPt+5G%Q}W#l+pOA%xU{z^{xFRwC!^CS^EW`2tERH7BEK~>0|CG;gxht zeM}c~J9G{F6N|BPHvJ9b8tHl#yyM1JS-XtWpc;FuqLyj1v~qhs0p`7&x=$@whoBE% z%6Xhzk6XBnvp!0xQNB>U__s9(yjH(OO%4YwTve|c&TYS z&SsQBOC*h%94RqKvJ+=F^31X0=w&Mo4E_$iWA9)$!Vq3t^OKR8iOnndGPa&AzIhMMz`&?i2+<3ecvB6eMR_zrh@=zdLDqL zml-30I6u(zWq~F)#QH5#CROzk6@xzjO$QWDdV?KTAmyx-P7mR->aY$yZTNV*9BjEu z$2?{{zT8$5`efPFak1%Pc5EYOWDPY8M1|fr(jBdowYWC*oyS?W2H%UTIxV;g{(-d+e^vSqpGHDU@c2QFWT!9y z^@mTZ0A?QhE6PQJ!}cil6@s}(cl#2!B`Z&&Wyw)SOuue*0`&AF>9F1yN||JIH3I=M z=b`3H${8a7Pd^KtUD~Vf0Hy%hRFxr$i1Tr>{C=#6+1~1Un|m?HgZpxUaPhxRosOB-o5-&Ah5_Qp)8eV)>F8ZJ^a-4~xXOU}(70 z!CXSOHp^nNS>x}>=2$K5N|%MYOgbQbwGHS;VHw|G7bsNZ+LYLNuhW$ySMPu=!N(r6 z67AP2Wp2*8>CjE^T93oN$hP|7*I_@*`d-}r?A{RiAkCEjs>SDK&8m>}AXb@ZLI;U7MCQ?M|a91ZA zTRR*LD&aCTtkM`cxko~kAHS}i^gS|i(8AV&oh6!F4JCdLVOY%NU8yS}?LEv*Rbj5P zw##1Qq!$qPtCX=Vg!5x=)~R7*pV7w`wed*kB|KP~>D;JpQjm&LfBaEOHv~ zc_NfU5fs2}5{hiGUdQAaId+JNhRxDndmGJC)>633$+OpHG z@ghSKa4Mw!4P2hv-CO1scAHi_xNYX+3^qC2jJ?Se;{FWy<1@dpdKqjTwKV?8Nk(R- zli^u7)3KnKkI3uFlo$MzkoN9AIoe#N^vr3GetV|X_x3O5FMZ$&0`0gwTptM^w|=e7 z2yHwd3xXJ}o2=_w;AIue{<&xe!_KCP*=_KmDmb|{hjsFh^>dhO^*-OPdUpk5t@!+C zv=v*-$WJMH+j-9pqa@m-a7$>mvt5>>jab*N`4XFpyVUCg1XTOkc55Rfr#G4Y1Q3!j zlzbRpB4a4PT3^30@Q-sBameBuPL@gv!!1D6+yzlP|YTd5SEXkNuiiXxUn*sMvTo&!mR4oW3`;hZr&r z8?;&<l*}Ykztvm8%WRp@v{yf6u7hAN>O7BtFVmKGDRvS z8ArxQAQVhNmg419kL*NT4k3lxd`5GYu(cR&sT+1(e~YAEPfJ}fK~X2~h*Q}UvQCWT z{iX8=)(xrm=P@mj_X_nY>X-}yYorpa^2+(GlVmNCjnc{21efA}fBfmUJVDI83J>s~ z?*Kt~*lATT-65?e$}ub{ymo9h3bEHO8OL?x&zm)H?26=J-HDGMp<~37>rM@$hF({% zd$}340uQ+#>63^76dKpjsCLrBHWwxGwaP7xKc1}s>Evr}#SV5z&l7jw_pN5Z`TbL0 zScFIfVMrpw*!#vIRu7%$K^ytpLcYe|U`f&xW#*&H_q)>}c+ZOJqZ9R~B}+32bnoNOFWHNMg2UY)8{@ktj;-jaAJBlTz~}8R-`-NZqtvlw<13S;I9Asyf8( zc8FAd9MeGblQmUnIOFnIz!eNQUxz4Ze_YaBG2e5`Vr@nqhAcelzoJuah$gmO=n5~i z$$tR-2>a>QL&XQ+MCZJ(g{t)i*#|s~@;|=z$lZ|GIP(?~p*s7@b}0$2nZu0jax^#obV`l4>NBq-Z*JD9?f= z1x_ps;o(Po$nvpPw`4Pxq)^@X`v3w$P%E`Ffr@hmGKJZJJ=}4DrsYPF^mcAz=2G~| zv9i>}PK2|=()aihbf7XVD|(n+vrD0aJZs6+eTnm7)x25^joQPdQc07GONV0g%tUR6()UR&Zi&X|XcMtaE#H%vN-tZ~HtRQb~n9Fw5G$o+>%t zn$M*_eK-;S(QVDQUjpMA;hvIw^dVpr{JlqO)x-uaLvFfkbUZK|rpY=45@;JODV%#E z&n@{4zsx+vQJ^p^;5JaBG!SWZCQ<-IFOL<>$4g_l$FZz1~rt6kkzdlU7%8f7uNn;x{%)4Co+z?ru&_iZJiJr8|-GT z2EIK%DrCeW@;eaO{UNxp!kE+X`q%{(`Ul7*$=GM{&nbp_b>dE}Ye{D^&9YK%K2I&) zZNMbRQ&)NkC`qx0B9FbI`R#7YKqrINW&6p->Mti1(v613>9YjkQRNe3ea}9ppDrxj zC6b$6qtqad)Y}-zm|yM3-|&8EjstcH(&P>dBDDa!1o(_LTtw*XF%){@i!-y|ZO6fI zICM_g=yX>CE85<+D22szVph+K2lu2iAsh1bDjO#SA$a?<3x8NGg~-_-1w2_Ep&OAW@86gjyLa<6-jJeWu^Eo!7KgO8RM(n(oY z&l{V}Yg*A*uBwT-QPT4ntLzUkbwjWgx@!Ys9c_l%DBwQOwQsp7S*yrx#oh_UyK>v2 z)pR2TFo3m!U6+rwg2HS;la=m=Y}K=al9lPPN|Xea>F`48H$^Nek23s;ywgXGOdWs2L92Ux1 zmvcvUjuNF0w|dIzsVA`SgYUPGzb4~gE6xU8au=e6Rc0pV5!c-f2YaNhD{D&cipk_o zjY9^?R*B`7sWM8c`mz+UYORY@9BAB2Bu!K<*6ZkKu+FH@Qm`Z3*qs)htAFZiPLITC zTqbq9*){pSO^h}!FaryV{WvuFxdam8Wv-nac7bW&Fop5Y+`%*>Nslce6g0v2XI0V~ zR+wAX&I9nebioTAcwc0~5^zA!7 z32C?Jy~4LbUY9;~6mUNUx7!t$NU^n5fe~{pF)NQM6C_*iVSC4wzaA-@B=-;do3 z)06c$>Q>y3qdO*62eNILF)zz5IuCkSK^o3D;GXdc1>nKjvVxGpvM6?s26G}mC6?pF zlXK%d>#+{r7#VobA>ix8XHOEp#s88Zr9zY*~rr zo6uw`p^r(6-~fyq0L~hzR$dg!M&1LK4&?tV9W)<3vjJ8D8a62|yOL+Hm!LqnNC5ew z5xn^r>vaLx!y0ED{BV>VRub}5%uiV5jC-Gt#Q)hku%XB-4bt(xKcn@2p8Vxy!loEK zlv4$By(~kR@&0yJ^>Mc0(6Pe^*S!JhWjVuJxBxtiDX19?&q4H748nHbPBsV}mzp#a zLu3wwyD}NjxEKMvwEvz)07y%3WA$6wPu1u1~(9+vd86pfvYB8{EVi7!ENn?Z%41{6pgJ;-ocq)&R} z$W8{Kcser(jLt@9yz)sWWUVkDsg_+KVk`Wr(y;~m{C1c{qf9z4itoo3)NY;s3+M&0 zBTH9sBvs}S_CF(MGuO=8Q+-?LZZ;N+(d09cv{Mt=x zd#O*A2PuATJqkXidG5y#yt)mSzogqkzu>1s%EZw7P2UF!Q2Y*rOg{|lp+OAWc*s1k z(XKzfMv`(4xFOb70o;}n)s{4Ly8N`f9bz1h^T7$sF55<Tg>D-Vx3ljDlAcikoGe!ib@Iw@rDl7U zX!QREygiB-OY+p0%d6~tTmu)lRQ(VnvPeN|Szw>`OMrAdvEf=WWjC+Oj`}S3Oy(*&7Sp)K+T}FgS*;dd8s{;y42nHFYEXUoDVvK;#lE0q-n0Hvl9$&!0E;lrG zBFp&xzvsL&QE|aNKW%0mY+kJtf+Rb}kuY=dRHt6qNLBc-z*o5oAvJ>%0|S6fxm>Sx zi#L7 zf9bRGo89+gS&YR^oP`LMEc-gH;&_{lVJa;^BjJ({msrT~8#5V0CHaJ9<{f}}Nm%o( zi!Tmy^bNESa4GjC3#6-w^yHS;YJ5=WIK4u%b%MK2)ALB}D&ITnu@#fvj{B=pxS=%*b~ zP=}N3$SIOo+eWEwKq90B=Bo@ROhoLDMDi{fMN?n@<9Rhhe|Njj{@m2nRnDL$UBH|H zQi2N@UFM4@$P08WYk%!hDE+3OAfY%f>RcTS%J zRD8r0Ox`bm?ca1tZZH-IXv8HLn1|ltta2EE_wCeOm^KK$P^uBq!y?3CMU$5<9_fIB z?zdFTfP#oWF-1P8$K;5-sbrm><5cZ0+jP|rO19Zs=#y+W<5ltqve0ewQ3a$fk{D}) z4x}5ne&$HQgqb!4kHuIO#<-QwpWC$V zPoS9pcz5aJ#Jd#z{<EAE_(Rm@|%y z??36#!mZ)a)@Y`(YA@91Tb!&rJQ!oBNDqu%(8@hDJdSj?D`!FAIl^SK^cZkAU&v>2 z2pk~BV+AW%zA-`bEmT;M)QSWf4bRXAfmFo#Lb0-><{0sY4VJAGtQ)GCH5GQN%T_uh zqRYU~mPj+5eOZT1EO#xGP@3x2uP@DA2+FQ=m{WS#LNRa(9C@#17424`m+xacVx!vx zOYJTSt0=hjCoCjkAAXbDeF+gI-il760aa|7P81`huQb6dQ=}5nkWHmVwSVaFYsF)2vSsVzkYAsxFYAo0Z>NS> z`(^0(=>i!8ficVcW{p!_L(i3l{E06G3()||w_?`K01%`X$QEFVRa?;Bj$s*x#Ldnfc&5T^Hku3=^LR zq$NYWuC3jludfr%781Nx9@V z4=Y*}?sBVh%*jg8(u_(}Ud7G{_L+qC#xW2Ai8wQ zHl=iwLa(Tit=2EV#_BAu7j0>8)x#RbNldxZjKe~#qsRzWs|UHHQ{~p{`7i(;g&+PhI>rnYU?3jN6ituB{R~G8a5=#+09^J9fmpgCfXJ^k1N= zQP|xR6D|gWEWc|Fld_L!npx2v5F2FZS2-T|)GCaxx3UdrRwl0O&Y-s1NmpUSYcf^^ z#;9pA?(e|%3v(AOM(*3P<(+Q`CIDwMT!wnvh7oZfe_uXOv6X1c?VC(|cvG3CuMY>^ zuzZd6r1C~%Z_-baQNoQoKRZ_*FRwfBu!X8hRo3$iYcnLRr<;|+4m>0f0ld&Vx|=hQ z*wued@NJvEYNehQP5@8)Zr>-#8DwVRLbx>2P+z(DKGbr)_-fRMPs6^c7h-h8a|*I6 zvrXB5HSKky6Z8Y-;nO^lKOFG=w6+xVI5&V6x>V`h_ns;4%-h|49bO1Ll z-G`>ThUXJ%g9<5CiP3pU2-zn;p^Ao+niHF&ND6B+uGG-8jxTsu=PzZ8>|O4D*kEy1}Ee$=-z78Od{<}BdyFeAAdI!OcjymH{68BL8}p%XCF#k*=f3Qh4LQWqkvP{ zyV9Z>^?WfWWXk@05vm)Dtzp6x$dgTuIG;FFukwCGK)Yo7w=1))U`Pi(m#zW?{uRq} z%nwuHxO?)76sIztQsExIMBZVL8jv1 zFD>f+Yc`xr+HYvvEPgVAluV^0V3xL~vABmHFNnYz)&GedQ0!aQ%f>5X7X-_xn^FA=Wyhn(GI z9~g(9wej>Hi{>w+7MR4jv;dXh*y}1v-~2z7V5z?-ehSK8OSUJbD&TzAs3|_d&vjL+(O>}l(}*s z9XPt;Gxh{~9pRl{Z-0x3K#)z1)_n;pfSMua6IR8;A~;$!#B<66Dil(plmK;9f-DD2 zEmb-FbgfL9P!}8cthCzmZK7O378v2;%vxk=kk*LwIN?L(){PscvgeQQwsR$=rqeP$ z(%N8t-}Fo#+725)-q@pQ1;E>|fjQw1hnu9vReRUJZI=JxaL1_sC$l>nUOe>*KA$BG z16smyZ=f|Br{N@dh=%YrLAP{G8wvKal97yABcEGz_HPd4tjnp_T+1DuRM$g~Tllr@ z`E#VD(rT}i8frsfH1HV-#8E3(E{5-!z+XQV`Iog7HAajRrJ#&ox)8`lE2-Ks-7yKt z)(N$_CLJR_GWhjVkfuLu<47z}vdmr8?sKcCgP%5bv)gmOOGzC(sQ7b z2OEBM0F;88GZ%L%qaFM`P4Aa%8`p`2&BWr#yFD)TFWYzsa5?+U2hT;w4Sub%7j2xM zb1{sLe|||p1O>hXR9KuuIkUUgYM-#%C#nM0o%vi9+6g3YG)=uvJNH_ri33&#bGL3a z(WA>r%Ak9Is(S}x3Xxmdcb7o{1z$kJS7~c`ZDX4oU~0|Snt(`bh+swwK}jUUKkfY| z!gb6s6dTFWbQM^Nz=x;4K4^obgW zKE*nhNBG8d)GwF78}F_<{iTr8)Db(+x)!sVgVphcA#Pu$zCcf`UNLU}!hmp4i2ZAg zh^F)g=;$*yelT1n)_EI{GO6hf;I(J0Zx)>{R5vRNy|lL19bn_p>Y&es{uF#WRQ_kk zWKaEf+m*Zf=6gO-SX7K~Nz5A*gfH+6yZ$J`yi_nY-1L2zsj&^2fCE(e0tbNlnfu|- z09+)l3qG3Ay|>}*z=6*Z$Y^BONM!v<&E6OP7iVu7+(x&xZ6;=BW@cu~jvX^IGcz;E z7&9|7GegYG%*-*{F|%Wj^E~Ig^Sx6uf2LNcd$(FrNu?^acK3a)>-igzkQ2<<^7wa+ zeQ6YMJ`^gMC?tWsy%BNc*m0J=JCIfoJ?dRmjpXQC1sbc9$cM~J-cp zwtNGf*2B)P8C>1qt`*scyq5&4*pfI8h2pwfd`|9n-_c5VC!+o1s2aVpR{ECh0-nek+49 z>CPZG+vCE3kbP}t=<9%l;iqDgcoB(&9f{YzbT?KXdg%*0>lZEL7|idxofXMLU=ON^ zFyaRf7wM0ieP;QLLE!lfxftO1%7N+l*Ay&4lKwPXOl9cYuw>NOoZRA#g1c*+a4wm> zyA3T~YvMb9^(ei3C{nlV}wmrZ`0HYSuQRPn$GvI5;!s04Cd zbwWzKY7h3usWNZ?$$NKM0Pd&KXQ54G2*)c|0kiFRQq2-cO^Ku zZ;)q5lE;~;8X{b#(MJ7~(B+-}htO^Pm(b14+6J<=j^Di8X~I!|?*uL0LNEQx=Q2O2 z#(947xdcXb_oa{C9TmR+(7EV6uYysIl9MgJp$=oie1zGrcZ7|*Lpb|OxNv}DB;4>J z9T(y`i#D?=+UD^hJ(2h4fuCtsNSqqzk{*WR>i+s61uIl78VfN`XWypD$y@U{7~h;BS769apl4WiwI`?>*)*K2Y+CSGu~;IC?K|7 z&9k)tk(KaB5dP}V=!`fhuCb7w7>&P2oEnV9P`P&S_U4te@-TI7&C+_jX1K4uvLRJV zjuY8L=RRvG_3`ZdH3b#l!A6II%U6=pO`AxokiV?&IQ5 z;)pbuV9MrC!;*i8p{)9 z%tW&olyZ(59oz!ryGKE_x4Lu%8=H|j+&d)1kF`Z{)4`uSznsnMms?LI@hza}pV+1t zHsuyd^Q8QK^tc{B$0_neW@KYKQ}-s-wLAZkYBD6xP0N-(Zlgfjq(at6MAO~wZWd*= ze87GFVj}x>7N;7Sg;9aO>nVTu_M}&K_PiIEVWUdw3%z`#K9I)O(J?f*@vj-J@||US z=%Nb#3p$GrZk#{#*Cs%b`OjpfKj?`)keE?m)6(|&AV~{RH(+G#%N94xeZQL`%oruT zaIW4@z*=@`pSl0QoX%FTU$p^${`N)x3?U8|eWJHS(VwZJFXjJ5Z%MUKG7B3X^)IFH zk7lAhWth6qz!Owq|8W8<9QTox`R@_@DF$@?aWRQ^AaKphj%5f1+}YsHs|+wLIh5Kw z@c=l(Bx2(X`Gb>|KH=NhG1|A&b{5q2uR(ATXeG>kuKrccNY=*HfS9DbVfP&=74uL<(Nc`2j!tiH@-_DvmlTb9@y_`10$Oa`1(xYh|f< zP-S5w>~vAfsW24QAx)3Kb~GaYZ1A6_CEvB-upe@fvEqZj!s8oNTJg_}Ia@tR8WYJm zF#PP!a}g)=Lm*Nx)k@E2!b-XV=({s_RKx0S8=W+fT+Nv+LtBbvQaU6`DiQQ-l~TQN zA}UWo7iv%Q55qG!Df4~$f*Hq$RK8w@_eGeH_D2+9_FJLv-Y=_rRzY=ab%dK9LF}PP zr9M@IqTbNFZ1SDC!5JjSqVBkywbK!+ebF5>tfN!U8#J8K{Ab}mXxU}wB}kx{N#c z)s)Ep@V6ZkFiQ?y(YCuXq;yoK5bBe{OPTa52_?vQ5m(jTdzKoT-Jga#8xmxHj|qk0 zsj?;N1g*ZZk+Kl7(33R; zXfn0DR`PFEk8UqB$k@5=APW_+Sl0Es!LwN4 z``5wqed$ULEgwi@+d9}@hIDA{1lYsoqE;Bq{)Mf7oWeNv9`WQgiaa;nRQIZ-^gcD& zsCBZklNLsBfm(c2lfm%QiWACPau!3Af6h(x`wc|Q@(Uo<<6L9^(&=l6ita40 ztDT)MPRvE82Xlf-dJ!HK=Mee)H6O=^Tgl`*{pB@BP|rL@n! ziu8Uirhng$hvT^R-p7Z|ozwFu3!%@VLB;BF1kr2l537{1p36M3b`l8SDyBGH+%KU7 zCqaM5_;z5EzAGK7bSKfbf|6D$_+$rQ8&NSkTZV%5<%u9V-Y5NQKUkPxDV$wSZkz2e zOW2oEHtL=Gt$Akgi{3dG;xw}ToNcf>nUruU!XG$jWWU6}4r4stSSHUqgRq51t;7Z7 zb%yj@tiZPesY-6!mrKf7?50XcK}1r>FJxj0vbOZxm4X3t5+%V41I&C5i4ujmq)|72 z4aQ@XO7Mh!cY$g^=>|N#o!}m6r+gH&N1J8Q5`t{e2u7-Ir-vZ5ih3Y0DZ#;&b7&GN*R^#0qr6d%4|HtcX zf8L(uC7Du<-*67YyQBfGLsB;(`qq<|OHT7vuxO=qU2NqpQQO!75U zVsDNDj2vo!el*%|2ByCF(`?L*)#73g+5?a%z2YW+sxCJkB)PcU{Tdm4Th-up8tTMFEjbZ3cgF5hpyAu1)lt^Zb=DNNwj^9qGTd`^}GI-W=B;& zQYO942ayy~XL-Q(2#zzKAdE7A=&dNc`T?=bd)Y(|wnVta(YRv%H1l67*cz=&Vx)=$ zUxghGh7#pJRPgkr+tM#}qc4s92dA!U(VuL6bgzS`5pVcEli;hl-Y zaV^DR5mk~he^)ggH^dM7It)MowT1rjcNOSD1~D>cqw%?SM_tUYhyLr|mEQyeQZf7Mz|ZKO#U@nb`U9IAs2Ng%P$m@y*GkxmWlOnbP`*`V#O7x|Vz%1IWq z7g{D{_cr$fNoOAs#DFEoYTspBRq#b6NRViLZn7MwgJ(HW)Ln- zIMQToLCE{rrZv;Ip~JJH)l+5i9Gl$Gif)T;Dli6GM*FmZD0pljUvaRG{{JfxOif9SlCPXCf+06n`M>i7<4P0zJku+JPYkL_}N9+UjU_ZqgFQU zy(79z#EzTFGr9uqHo_VVMGd;jA`hWJAm%^~sW z8lKzX^K|U3t3N)~chI@6bXVo%s#uSam-7Cc1xUSMt>N=Bt5S)&#lX;^ho3~t(}en< zy__H=sl9fRJk#@;M8zOvDf57f#8^nF@y&wEFkP1e`eBx%P$cmxq$rXo;#h2Gn>gx< z>H#ogc>C=l4_NUzzh>C+ET0P^$)0|L9!K9n}*vLX6Z zipmP%4KzWmkbb%q{fpeC9;yw1s8)$AI_nQTU1D^ienx*(cfK}D!|H}b~|Ca+!nfZTmz&)@Gi+?%bsDC-& zdyD_!fDhpRHwT7xljWgXwnbBY10A9t(D&12 zT=<&0K1}0UY!&@$hHi8y@!wFhx`26&E#S+S0bLJab$~%(gk>X=9Qn9!Ry&9oN@o{` z06w;ZxOP`9VhlmKvK!0e&+D!s3dgW2tn3A^LhAbNAdN2z%E2Gx`~DILX1|DAkANRu ze_opM0cWxINY7|8b^BdORNTi$&O~$t#OaRHn?#R=7tiK7X~A>&P>rPl&VK;uEOBrz z?m;swwr*99iHnMkHGHqX`K)pKIif2av_ChdY|S3&L8g)mg4Lo$2%X3DuP8ETt5hAZ z*F`D$QWNV-Mg8<(@Oxyz=ki2VfhLyM==E(9L4^R8Y-68;^YNl6VD+kQ3dMjF97S zVDeK__cuX>WF4?%9jMRXTDW+u;q5M|M#1G3w=es27PE|g_7gbiv%;!L&KmrOqSjGZoU5t|Zf91>K^UvnJQz`gAV9y@h#6bq~nHJHW zE@G@bS#$};Zjq&`>y9;N*32o^(7#sM3*BW`cpfb`D>R2<{m%7PO7T9}#H!Te)ibbVlz zbGWuW3o#5$dqMrH$;wQR&QA4n z0rUo#Z5zS5uZcUQ;0S2X9*NM=m|BBck4}^RRp?NK`3QaaA!bRxM#8U zwX0?pmx!Olt}>R+>L03(7!>s6V7b6GrtH@CA^OK8=8!FfGbvYR;gswep;iC`Mnv1ZPKYb4V zu+(&PDtt8NvAqImbwehp`)mapL7H3&1s5>{emM(e!DW_mWt1yz#y7l3Ok?Kk(2`zr z$U@7mbO>HrNETq2FKFW|QeZsER8}0$(M?W1iRze7Q3coAI9N4yqq!`S#TiZ3J(J1d zoycCW=$PbkBJCHcy7z>-%_4;p(y(CN z(0LkP6rUMLnK9dpfU)wGfLx&W?kE|Dw|g5ulE9?5Gp_Hgo5$ccx)Q_VI0o;LKxSu_ zQ!4iP*{+(HmM}08CR`Z}2%C$rSce{%*5_aLTv?WZ9EwjttvI^AL|oE)FGQV|czWp; zzozH}yppU@-NOAk=a`9QWanj_@)zKVhGiaptKOqLxwBvZ+8PhyRBeWqeg)zdEpR%I zt+HS-oufn%)Qq7zIFbDJ50#P~IOCHl=L{puuPN4x+Mji_FO*>EaSYkdZ-1XD=-1b> zePoA@BDPDROMMMIj>*jT%<@x2zom=eMbL!Xm*ak9f21z8+6+LsK;ri)#Emkdr;>C?-mc9W2`~! z`r)`ohmvzN}WnV}hMPy@A&VWc;fyzu#L+BDD!b+_MY(+>ob8o`p0 z@)h(v!CL1l@JCwp$q3YR{i?`v>imD}Xm}pRH2sYvqm?F&LJHF>&eCxcB_;rWY7pV5 zUFO|rXrzsd^98|DU`z++KmG&W1QvZM7+r2pZqm$`3~=WGm}P({$$j19g#(7;!*hi39osXYusH(x@q*IC6)=T!zr8 znox7CtZx9%OiZX_TrQ?R5d|R%}zrF89 zWPnWJ^dF!13yol68{ouh_lSgN{qj^F25ePl{bJ1G-p$>C*afD?@Kx{qoaLqn3K2X? z`5~hxaR>DZ`UwmO!k0$={y=!s^gL|jpUu`U--0TaP9|+yX|Rm66gQ?{QYCXpoYA`4 z!HhKYT}gg=x3-^Y@_PB?SK8#$0k3>h;@TQ773LW>;`eV>=(!({3G1AMm4{$;Q*~3* zzkk1}?If69j~1;P5gny?1vK+^wUn+-Q9--HJ$d?=K(S3O zgt>m&DHklNQ_|KS<|w(ir+mHSp+kGv&QU9}lSBS6Gnr_{(<4aoQL$`F>$vmiZK$Bx z^}cWHmPa_W`rx0EZ_lAO^cZL@{+4!xkc2PGa{;eG^()M)^`+%DdHifh&YTdbS-r4+ zHE+^U@(j)1Qd!1s7Gt`iBnu12$ptqgLTWCtQ1%#q?ISC;OzgJdE-b1|;23!TfFS^3 zkvY+pDUiwz-}OA$WB@Uzw2IHboqOah@^rQqpCr*y#e=^VO>o|QJA|vi{c$qFUQdM( z^=`Zpf}4zJMk}jlf}EoU+*-lRy3WH>#~V?b>M7M{Tr%HhW=oDxq#syFLINp{XDhpt6$Qc3A1qtJbd4znexx8vZm8d|=a%kz*LI6%Dy&~^d} zx(&xfQWii94oBs$U8=-vk#E-zBh-ZEz$``%GW2jolxq(@-AqY`wc+l91m46PS=n5M zC*Nrt8Nw=MS5xw2@#p>d@$QG%?SQV@(-|DqZ0C>H9RD8o=I>=*_n<#BX$coqbBwEW`&0ts zss{#bzh!=V|InJ~JGx{lzP+1Bm|s1BAjw5|wIKDMpC6upv5ufBi6oQ6M-ls$*8+&hv9k`E28PFUsWMpUY+hC=gDv%v-k$O)y*qM*_a)}eMAYL znh+-I$O(+cw71>HWrm5yZ<4+JlFnNpqPVzFZ04HCa>!xnl<6oxfA|Zo_?d_na_xG4 zhnqgeHaZpqNl^rf3k;71oOtR(G7s3O|9r$&KrP@-48U)0FTCi%uQt5S{IL0qeO7;K1@b56^&w)IbC^H(d6 zA51;2%&3AsU-1;vm{u&r5EjEMwuKb4H%|JHt>KL{QO!q*T#A&eif<#wk+ z49;LFGOXgDx2~ zm(BlvJi|PNX3jhq#~ef)Ob6@<1VZnily=9!KMU8dKU{vmEv*>Wj_N09cx{C+`F+-x z%M|oV1SCZih}Tc1y7P2Y7LUduKSFt5#e2M#pek5Bv$U&{RvO_C!8zoE6;g8@e$SV$ z|9;++noi%Q_chG-p2X-Al?Yk;(ZUYdT)fiebK287tMCK&zek#^bG$|anpTmFX4g6W z9bD;S`NW8>nO381b{-}pNz?msx0xEROc>u45_=iXJ7;nbAohq1Hi6)qvm%*ajUkF;d!LR+G zoJgp4A}U%1%j#56W@x^w4BgO`V8yDUv(=h}>B}z0a<@b}jh55CC~6kdBRKG*2A{Cu z)PP@?q9wI8vyQ&q7h7?pz6%puk!-p}u3yo>`l^X%hPkm0faT_i<(~${9&Vvh+cKFV z3qwx+-ozHW%jDZXxn5KBNk0!iF~8ro_;&lem5gV^S5mJ5O3uq|DlGQXYdoK22(5+OCG%wDzj zfUz;qDA1nQg2TV?fL>-PB(>mzBYT}SE{*R(g@-6>pcRR(LX;ih#;dQ8b7oHgZ8=q* z1^#~6Zz+XjTqw-^l{BKEGm3~3cM4JL%7_>YkPImC=R>F`g>uV6;toiiVsgfSCeI=} zewu6c#Jjvn!`Ig-@ir)aOPzh#5C3x}Dj~B@f~J9JlHsO>Po4*Szjn)tYT=wVfuR9T z-g0avZmuNUwK>;U-KU-BXycenN>q;V2RGUO}G*lV!q(XhSki&Wiq%sh6OX_gc5 zdFR7w?yGUlrY%I~n1%Z$C`a0;GOrw_JY~a)AYF6p&+l5C%j;TO{^rGfuCm}u{#ktY zOqQ6k&@3Td!^TP4H@>z5mS~2Wwuh?`9o9qQsT*OAPU=?G#yy&>A-pP6Yq*tV3!8QG z=gz@f-f1VzoE^qFb$zE8H_FjTe{J$dI;*A)r;3o?H-`7Q%DA1OT%IBU)0c?Jib(-l zi}SJl6Z)*}W`Jo3&NoEBXG_OyySnZ{fx?DZBhep!fD`YNc#DYKIuk~y%MvW)p^^Aq zP(Juh9AHywI!DxTG9#89G)f8~ItB=-cVtnhO=i<<0M|lxH^T**TfLLa+HZhJNo6a( zgwCRzQNxWNE)Qi&QMRa0M_bMenR!9Qk)~rwH^c1d3Q+@eX%_BsjJ}EB=(5hRNedND zWxAvn=;OJrudo2nP#p6>rl0hdYoEnRDB#J3eHZbABos~8k0oOyh!9jPvQ;CJbZZc|n2+9SO!)C!h!s)xGM> zzx(6)(!EI>jFY@Vo8)!pSbI=v+jBa2GBGHPZOUs!WHWf2xcgGKGWcuCq4Uzl^LY5z zkL~YM?!{JPOgKS7dg;As9liafR33+w8XjUIi~GmLD%WBm8Wtuu=+T((rwLgZ@VM&e zcH7*W{?>mH>2u`HyRpb085n~~Lu-sOeQS#du>T;^qy6^`pNKS8U3KyD#Mf>!88ggK z6uNdR%MNxQ;_*5mf0U`=GPC&(easit zq-_^AiNjt?SSW1b*)RUr;TjAYi0^8*#@`-h*}!FP#khM0J}bj{+1#{ZduE1sWaLBv z;!}0z`ppz}t%mV}I4pxBPPD4aw@u$i8j+fHbMqe96+IC+GU0En#k)sX{(Xjvsw-lkHhOzdNjYh36>@A9J-WQ+w4zUR0$XujX4A>)O}pIGuH&e zK}K$B*Xe`d@L8DOpX^4S!p9>Q&!Ft$$rMG8^)pK!ltGD%mK3tFN+F{kx!Hy?xJj$E zTclVhmO=1=N^K|`20Fne|CRBe@b2{)jEZVg};n$I|(VHEJ(Y%^`0)Ls;%ozhT ze#C9y>vbh%bGO-EjN^6!v@~-;OG?Qcy=y)G>MB)h<5N52S9sBNEsee-nRe^0L(VNY z5nrB^CymOqMLp5q{kLa!t(EF1jsa$UV+A1$cBCY5UU#mI+?Hd5iA+V{a?l^yVp+P> z7(Jg`2l3y|E!!XHRmI0NF&_y+LlZ8NhwjYm1C93cM1M5?4-tzOY}z}-Lp*uO7AbPEq2#OHJe=rcdyRw%tL+z z_+RmttdD0{nZyDUnOxnIdTq$!WYA^ApmyPmOWBV4I7SEp@t`k9C&RJBOM3RVI&aId zx&LVKyRvp=wX-p?3g0f9t{(mNIi2-BI?57TV}5RjVXTA2V+0vq(PAQ(K9PJ(M$ZHk z2U4?pPVT}rBW(Cl)AuLVQY?q9rOvTPpIBS{#w;10Dt+%sq4;Q)kSC78N8p<+s@<7u zeH5H!^R?E#MSrYxQ41qJ0!txjJhI!bQxPB%I!ivF6>ggz9Wtt+oLqf1Ao1174oF5ez;oCydFkiUWH5Cll za~EPztAn;y{c#k9yVJe@WlF+f7!}DQt}=)D*3|EpTnA`$sS*ed$J(l$ zRx=6y(IKEy0T+n#x4Es*T2oW>-02MbU5j*|o&jhkhNIn8z(58kO-stj;OBWsM+;ND ze34Z{3Q;NuA>13wv5bu_4__w;W_AS@_E2=)r|SeY25y8dfdm~=Zv9f9Sdyt5`d zU4M>xzD(zfGuWNN!82vG=nc>IhnDOOjqitb=LFj(PS=4FTi!RKQwkPK$q(v(mfCRD zPagHWZ%$ujBT|PgX!+~n+!Z|G3q89BxQNB4*@a09r8`=j-ifnlqi=({M^t+xBs(d2 z^6}$Yem5BUBoy}`>18jN51G+M^rm!3vt&6VDcPzr>LWExToanjy#ckULGyusXntz7 z!@R@S1a!(fu@&D4W;HBe)o}eG3-{Op#jandg(N~h)o-Vl&}X6$CELieNRd;U_4`>X zWJTVYBb_7akXm?{Sa}fr;O$Mf&auIo!6H*%bsn+$r)w62fm&ujnR25EQC&SPK&oCS z5{1<)QR)`}7vms9cKRIYuo5c`Hqio_lCRvd*d-i4;VpI0F$2P!hSS8^<{t8O9h5|F z?|S2N8uP$FqSwbFEC1dfb1c4k@{7DE)Y6+;(H6yrj(%P}Gd*hzbvKWx>3gVGt7{`; z{s>w;Oz03V$Z)jZzW0R#j|^YapxboXN!C~Ic}fee8xBT7*}#%AQp;)Hi`fu^rrzAl z*)i~R%pZrht+_c@49-3RsxZ`zr=Lx+0NdY6JhgH!6j^#x?21X4TU{o#0;YGecYtDsS!< z@SFERqRJJa5PW$``*Cr7@$^TUUc)p4k6UP!6x zFE`Elj=y3bjwF{4r;3PiRWc805$5^1$NjNs=-n-D^Xd`M#pW)J^8~XSl}8li5`o)E zBv2MS9+e4YQ){SsRZM97PteZ6p_yFiEYa zAVX%;^*;KKH{ck*#p-OOU|A!I>KdDP5?X29)C2$MV~e^k=`TccMmC>hbMeAF)Ci@U zG0(oACgQL>NIrU6(00NtdAyWZ)U5%`T|ZTSdtvUseU8O88Lx9Kgf`I@oeNzjj$Rs+RBG`1 zHZ@MrB$}+pDT*O`FN zFT(l6T#=?)&9mtxp7|(^U42Y4yPTeNzNdPU8GQtehE!zFe|$+9U;oO+ec zMR8!L#H<4hm`+72riD;agPNBwGh(e}1Q-vkWJwSCdgCudxv6VVV(gC|a>`WanKFtn zQao)0Xtha#K~Fu`v%6Gc4S5j<@MyFJNtPvL%>`?W9%FLXT%4y*z|tuK@0B%eDk!6k zn>3|5Pm}j9#hN>yncQ9BifMW|r98|ka#Xz5StP7jDckO|GUTQ%`P{~!?J1Ljct@jK znRof5RDfI&pWSy7dYu(}73_OF+#|8{?mBjqeyqmA=5EiX9u6%Ig=8_& z0n;HStu~na!hQl+D+E^r$FMo#l+h_deQVh zAsx89`ee{{>UPNmpss?XuttEKwxZVr^b$=r&EgPnl+L8mk?^t$%UNuxoN#TFZ03}f z@jjy;VsD-_#a)U?h-8sn!hIufYbzO^T?isMMjq&tWgR-kP?EP_qq-Et%~ie?3A5X# zfEdy1TZ=}n-s9;A^k7R|d27N)&Zdt9_IYXzP+&zaiF+(RJB8H-MJP2KyKDdWvoye< zTsi7%yPapFakUs|?a@qddCAl6*45EIUb5(>BR0ZxGS^Fqa?-%K+3DmpA4*^)B4eg7 z;A1B9ZOymi@_eJ~b*y4abQ`wC?M8S$1N-!{7VP=uc+ZXF)Rh$jFXOvzbO)wSOs9Us zu#AiILY-%%l}n{{c@bE1nWg$qaDeQx9B=&GdW|ijCm^5IT{^=3Q8t}|lga|kRK~F< zA}EaL1S$c8C(@@HhtOyu$ND$ox2Zy#sEp^hS7I&bDdY~7oNykSJEEvIar%0R5dw>; z;=`xLWScJ=rAbR7Ea9C;1`m2k@hIL3>w9HnOQ5rv$=WNUMN z1;`$zznw*bOTihrPR-}oW5P^xVewggGlXtctt8b$S?LFEMXZ4X4isuim`=O+axf&i z!q0njp-+Mg3lV6bb)ZiEup2nn3&^H4orBQ8|)#J19tKk-ya{^zAD2f?B`r)3qJ zTvP5SB1;Ji&f81Hy?hqX_^&WIF&1_dfp>v&R&pVSvRTCT&q%|wUtEnvZlC2hfx%Vi zIlJ9;*lNf>v@lKF^Qg*iMX*g3f>PWui93Z^LrVK1npoDe9RF!?NIVB}3C# zoK^6J|KQ*>tbZ6{oKjb7Qq+|ci@qP7b*;rtzRcNZ^|9E(GyF6r=>xwo^kozS*Z!l@j z(d08*mrY`3##5DOl2yT;{I2+Y){6Ec8ru|`9V6Kp#UQp`Lkw$KbGH73kKCl!APa1B`0JitIhkXY-EybyH!2%);qkiMU%!S zN+{pmBA9KAZ6LS`qyehiXsYXR-7tlQuf}E^@(c>JufkJcyJ{UqkLlf}D&Jd<=}7jK zXKNJ{&Z?`tk+LCU8pGD}3l^^>vc1JO$TiRPxELL1>_s%p&p z@szUd)8hf&Fm53_k0;$yU+5D<59GLum}<68icBEp)bW;A&fn?2EyubG%5S2p55VoX z5l@4^xSUH{Gd^a~pb=Gch>GqlZlRg;jQ+KVFY`-8OZnPn)Lj0K(`AU_V#+;zyYV)C z!l3*0tV~t+O=a;yDuN`6Q8~^e-?2Nc!2l&j9naI}L`*Bm2glm^tq^QYnpVn{1@E@J zDUBtQ0h&pxY@np*`1)y5=QulFtlswauvV0Sbd)a*J1?BfAgD5h64*&>NUR_<2NPa# zT#?L*otLZw&hHY{LR|?`8E~%+enM`a{e9{~s{q=^yn;h*YQ9k(NQdNdnih7(u-uka z8_LBV)Ox48f6S64(VJ?)QziBo!5OJHStwDxA}PiqUfcSp(iLcZ(|jV1LkfyZo#uAd z>4qp9SO-vRuV2L$LKgN$za9QNFE%sMuP?hNizCNol7-&@e6=dMO~?KeY7yy(npiNO zGyo~~)pJV}NM{z5c}AJDRRU**Nvy>NDYb^gr7eHM172JJoE#ni_1@<3t1(zV4HI_h*o6yZp8=iOaD|?&nlv-|Np-p|)6IG%r!DE8#S}C+UA&A~nEJ@aN&Cx$ zY2A&O^+He>-ICV{>WwrcLXmY$eg&Pz2I|RXdCQlSEwsK98eFi&0W3&zRTWlhK2I@y z#0>cT5D8(MR)(igZfOQxZ94oeR3L$lNISw>qk7d6hb~lz&nqL$Jt|hGafPhvA@qFw z?syf){p*i0Y%v1f&C+XZ2z+Z^fU^Y0FX`AmO$dRur2sS>3n6f7wmFJxBrs~Q&p{Dd z;f#33fDlq4(&r#WF;sQcCT5}||7?;Pg0@%Tu%+GitNr~Za z1*iXd-omIS!tu_|zHQ3@}|2cWVO-CZE zU3O_qgD+e^!mqhtepjmI>2{g*h@d$&l!stJ|C*`Th$YTk(_tt3?dAT@Qty5~l@wJN z`)fS;2va!uk>I1KarVgoi!x0)i3V0~g`hevwb5KtG;R(3s$^m#ZC*IfOG!3>8zU4{ zxBKAt+NoC1M4&8m+Q0P)_6IT|vN&y;Pyjt-cmw)VAg{r$!Sra-Lra=49TXb3Gh}mxd%Kf7+-^3K<`;peeN%zh@do=Lz1(i|J={6%B%BHqu~V@!SJhc;$JEv z_9%-ky9QxF4AMSrMm_D?Ezd70UCZU&)f>u^xGY6oOwoE%qsuOPIF7M#C`6bnZ_pP( zO>UhCZK}x$`))gb2JpH_jh!8*Db?h(X&vEZO)zotk%f}{2}2uG%qz2tIZmSa7Jr6y zHy99?AjhG+7bvy3W|BNM9CzG%QU6pvGdV(GSe@VB5p_iPaU*cOiV-zM8p*6#&;9x9 z-99z6o>A@8b5^^d7iHBh8;KJiyk^$zF54j_k~xL%$i6R@ZZeT#yTv)(4ZMw#PUFrE zsnhr#*wGvvilES2OV31y2i( z_Mt008(_0|LI&Jywl|tDu{l7FS$fTnP>HsIuE47R7O8Q|N~s^fYaMXW`x~hJFtEXB z)$?+soFw5S-ygq;F2zK@FI-u8v%X6YXsJuluJF+M$J0Zdu!+G z`#6<+yJeNh5b`{dI0Tisv|q!z>gv|wCINr0Wjexop4tKh9Y%Od6KW0?+;_LwY0cGd zO{O*VJy^J|>-P7%7xhWUl1#zcETUAb;tJaU^glJ)F%YJayzFx`S`irhve0BUuFX@= z5=A8+nM*Ym2t}GAW-1)idKycxUowggqOq$=9B~Hx7Efw1+V2d5F zVc2mrvI5D1G!N;&$?G4L%Ex4Kn>ttitCLdCbK8T`+6skj;#TY1{m@^LAS+#*+pHd)BiDL@YhnbB?G-{c~`@`AT4xfKG>^sVk=> z0;FeZx~-_y@lzPWy;vBGcm#~`DEDQ00<7K0_p^iC`yfodXUe;7=g-T}@&zjEFj7>gAb7coy;Q#>C0Chz;n z2$Cf6Y`f-6_EPsaLaWPS=dX$uVK!Pe3LZuM!BKYD$W3$<&rfku8iRQpfT(P2Y#&eE z&*%eEL<)46YF5;0HM~&@lZH;ijs2x>$rWN>hsFe9=4f|BJk{3~pml7Ifk`hL}0# zn3-h8IA&(Xn3EtHbDx0Zw!wXY=WO*@dCw2u>dXmhrKZJ8ufuQ-QS7oH1Th7v z*w;}Ai$Nw{Ii2i%-l#RkiFVBrKpm zN}40BSJ)Ukm|W5ahn8eRWL+lGT*fgqKUBbu{=L3tXL*viH;uusi@5tdtFngI)-)Q_ zw8ARjOb<;(c!yevzhxqJEaFrMgC;0SLC?BHaFwZxM%E{+uqVm`@o-dh11Gzj$}EVG z>WF+bk<)W*(6%N*;quDw7}|aeGj3QPwTq^+rwv4Q6DKk?W>|@byF>_9Q zuM2STD9ZpYCKR@HmaR9yvv#Gyvz$UnmMJ@YAv4fX-Du3)Yg8+_ucN!*xl`%Ox(G~% z?n$Q(F1cc*^@?lm*&_&8e$r236*oRC;VtN>klOL|VWrMA0RW4Ykb7;zM_&-uIgQzG z^X9|La^2+Y+Tq=$Wo@ z8Qu`!0_#e$!me#vNV(|5KOCrzQ*TG9$rz>v^@Y>>!X+Fj{p8$x%>toH#uerh0pJaN zXM}jvVrW!9M(y>DTPfSwX0m=cBxwU5Cclgp^1N)|Ca|-IMqDu0j4;kcN~?bWm)jF$ zwW?=cH$0vl&^CBl!SG|_ZcXjrPbrwA>h5e*9_Mo>1J64obERP;U z#XgH)32vFjg3QA>862V@Crw5mdRMQGQQWm!5bcYL>mV1XER2#ZO^4cW^=U3A(QG5< zYP0&i?$^`7AXRRN{}BD9_gfoiI~vm7ez0@CNAh4o6xrd)%JO6N@kxAzcaZxc@Uwg| z`o*wKk>DO*B&i7&)Jn;5BgeHPy6o+52M#`0;_K|G;1U^2=lB~))v4K~Y31fI(zI%= z2To>XjOnx-*Wro-<1?qH)V3q1PjZ>ak%`_rGj)0XeOJWr1{oGa)O8{3Cp51(mKlEV zj|D~Mg> zB7E5qBb2Xk2oigHTItYX2t&9IUAYms>buoHVjE&#$FTswL*cWCsy8~?if**XE>!79 zd{t&=m3Fe#oKGzbEQZy-cE4q7%q>==AncSW=@2t>IyCmXwCE-v&*TvGSREL@vq%Nn}(pXQxludSL3bm)2&aFM6) zj`K>6-D5w|90?^6(P00)4RQ7WG}m)Y67?uL8&cFnZ>Y6xxnXc1LGE z%~T?qR1}^8XkXB8pY?zYWMz~_)Ri_0d8H7y&30Tcrjm$A%M&Aaig-z@MKufAX(?{1 zpeMNZ?t2P2ss}SSi|tGz;liegWvDgcw4?U4aiG%7ckH|1A1o^Ii!7hpgtTZkU8Y}W za;S~K5ni>jhQC4_qx0)&xxJm9pPuB$XRx1`=fX~d@~8LmqUT#@CKzxVpC+hoMvA(o zERC4f$9$m_7wRMs&pUeMN?yb)g~tx7zks{+5#blC(jlOH>B<49F;8?mCRA25X51bk zYxI?f+sdZ)hqzISWhRGyPO6L@4n=|?Ci76p&y3T8wb5#+5%0_Sg3V{OQ%?6HtTMoo)fPCTv_e?PKqR1}`J}nm$+GrnGb`iQ39=-DP z-DnfTxbw3P1f z)_B0Y^ON?io5l!!TQ=L+0|}?H^0tIo548=CJ;j#jha5EEq&e#io&j|K^HR^mo=zD? zGouZA*_$`JdsDe)g4hks_V14Vy|jwKhyyZDEGOX>Q&|?)adeVqUpn)|d)x;1*J$F< zcmTrPy2~~k-ZRa8#4MChT(7O|T1;QBk7lY*!v}-Vny<%e$YBmFs&CrK$0azXsc^uY zyx~OYa3=DP_5J4!LcI}5<4vgQtp-an`NS~8wLTHq5_-g&>-nb@P(CxF60M43bJ4v_ zLaH)EWe!K*B;5=wU!;GXNe9{1A2#YGnh4JTnTS-r0>zw92SWOgB<-An6eaBtF;8FX zR+k;d`ygXtjq!<1nS#qZ!W3szkgM*T3tR;|ARZH=vAq|-s4&cBW1DoI(qG0U?ikt= zl;q78zd}tdgWD@fLPSq5+1}NsdN97T!mWxs1}}k)1ewoYh$jG}(@zGQ$>duETt5x2 zlyhQUolxRqLxfR}4IyM#2W4{UO%4zV{Ky9L3w8* zF1qEjZ3SFYg%@;*8_hskLU!6R^H{3KH=5r(`v&+2=w@9!6Et&CE1-iv=j07G;2MppWP zBYQACajRE_cEHsR7v=)2^#k4S;oY#^O%0gVo%nPotFzIX#V5Cw%){7bYU1scwdf$?&vt8LJ18lKYbMPj#gyT^L8DUXe&0nTOiIT zrfH{$2-xz6PCsN64jjGud966%h;$b~7Q1k>dHBW)-aW~~A$^CgW^Z5BrbhH4od{Y- z9n8V?WR-X~#WXFjWE(|7gj+_EYB%f5Enwyuk&3d+3>*iGEUucky9B1IM^B+AFNp zr>UZ@SXb;pnM3#!Q}qet?}ADec(Z#^_7RKxmbD#3SqJiJ*!|qyV8T=LpX3)C$%N4e zhT*7$-dxp*7jz^SJ7d<67{YDwjZC@VHtJRRPY6>l(}HsYZ^z z7&*Mc&B?99gJ8-VhI-E0fYX{8ttD=%%6yLA&8R%z15+uP!6CE97OqcZ9g0{P?DoK+ z57e&J^;4~HCe5BwC&uHIUDx&tEWTstE#wk}f@&huOFao8EAP~HT=kx{O?X1fEN0W% zch5yHRYJ&bcjKQt{dQWiiTPEIT2h1&-; z%gDwhwH^XyO9k~I&`Q`C_8$Nr+0jgZm~jsJRCj5AlIL)LNw+qgUB?LA*?o#%H!@jL zIVZ-RHeD9x^j(H*NAY(dpXM=PnUSQ0b|(u&WilY1*v7k_=$ysf<}uP~C<%wD&5dQS zz|S?KYie5Bt|<$U&_4Z8Sf;NdH12yj&wuQje<~__QnX%yXz*MQq?|H#s5GhS39~** z9esl;hnyb|KCbZSOqwyk2`T04*SFEc70`Gaz}n4EdKKH>n;x6_E7Q*1SYkUoA3Vhf zv!j3z1S*R6#p;?iM*Jk5pggpruY0t7a%!3eCTH z*nt5zS~m?|!XoJkph>_euD2+caG-^0HV(`UpUgUj+#R%G#db4{9K6q9jJC&U)G_l0 zwZ>-&vd}EOM$F%CMU*tds90u0m5k~NpUSw_mvSlj>zMuFHQr+V+T$vhmQ_QcY%=O? z)1cjl<64m=hw{SUG>bh+`q6(nT?e0(^$G9*c7Ka~>S##vl~Gm0Xt>=bsSaP$ZM%95ea-P| zL98;gmt%)xle#pWS`}GMtgCnJoJfs5x?M;nW+=;|l;P|-m9V=oc2!hKzPrn@uCGTE zOU})EwKWI^!x|zRfkwwFu&@<98*vO83v(K7yDe75N{PVLVo10l@6T*cP2g~Bf@pgW7{OGLT0Iw{inyD4aw-$91OJ1y^nu8gzhvqi(PH-S#Rn#P8but zYdMyIuRvI~a9N7yL?9IR_aDvTPvYx`TUK%}p+Dr2XCL`V$0CvD0@l zQj()xB9xt`(7;^6(5j=*sypJScAg?DgMJ2-_Tk0YG3oQLxsvGfNF{EZP&JhPNcTNf z5=!r~1dGrjNyBhNDUI6IA`mxXt;&M>z9Hk!YP#h@)0_GO8F@`#U(b^2$LBlrST-?t zUCVKTxn1IODd9Bwx-IGjFmdcZK`L7sHLFQLAMBf>9GYX}4=G%MF1!sDiROz|?d$3Z z=?0}VknPL7+4{MGCTjWZF7|njD|uaZNHWqU021zg(MK}+0x|CADpjkx&7{|8%vb$7 zgx|dzTfU)Wn=bG#tzmhzm5!B;z)D9D)!rd=fxkoWP$l{T^?wDrgE07Yl80(5?LfNc zJCeuhDy2%LZzY{xW_@1b6eVV6-|egGP!6K@2FYQB=EGItW2pihUIc=kas)mv83`ns z#o!@6CB>H)Dyz5c7O>NENv3?SGEBB$*Ul@5>o`0{iAPvL1q=T3{OL=+gQzJjsv?TC zzdMa1GYs~%!)?M-f#JbPB z?fk{MGYGz^%#JMqFhBX(`{xT}rKMeP;i{=8)r)>MgEh{t3kKDXN1YZ9F3RbQg;uhu zuMwtmxnOw21jfeB?#4=_I?jK6R8Rd=Y8V)Pw**?bmt|nd#UWOMN)1jBOgO6r?~r{n zKl=y4fgvZ<@7>LayD)pr4o$hQJ9!$Kzil3ghEMENTP#56SIX`V4&}t*c}c9ZHoX!@ zrimdoRwK*`vlo+3%5TX;tMiJsK$p{k(Zj6nK9O-H)d;tc3Hqq??8(Gola_igN2Ume|XCdVpDiFS(z`-h^;P^dwhR~5r+jOFwkQWl#S%5RP5WHL@x zb>6YBwtI3hZ$z00%Mr8-8aEUaemEy#y?)>_V(l5Yu=qaEoN>1QFR+ zWyn5}QI2IFDX{L8dQM*V5qiE9M|D-z98&@Gl5o`XFPt)2W2? zJkzV33`FU_q;leGZ^0d~v$~ovOPj8SdTpC3J33x3E;cRd-s>_17V@5ty_no}usAK{ z9f^fD%B<@{6yjgz(f6ccYx3ae<$g7Z6*d)qV0B4um(8JFRG=OE1}%E|)1Vt1A>q@! z^N*mZ#2`nFTo3yhXe#5X>yTi9R4+wY&OI-l{UHgik-aICMK;r>5Szt4d`2bpI%wmb zDj9d{ONopo>2PZn5Uel7=a&xk+!ZTo{&ZpQ_01QEgT)efaefuzrXqzuokKKAfYLWH znEItK`OjEot0XZwn6=4JJfJA3>qND~xI&X+nl!Z&KVoDV=yQmC>CI&7`11tn= zi$G4n%9X%M>Myr%TQMk?&Eqjgl7ztrC5Q7aF10ul7RWi3E1NAinqCK!$*nXE&p`ja zs0MNL5f8o_A!!GHHkv#0%}ed9{m^veiFKL43tvjf8H7MZU) zx!wH0n|~{6-x;WrD53DcGVA1)y%5vNy$EXC2q=Tn@hQhheGW0;PV|Ln0hw#^a=bfM zWm)LA!-*^aw87U`oLkW$&n?xLq}rzD^~5Zr>Q}fNmAjmgfY?|Q|0Us`yV+JI6gpCv zcbSW0lP}1)#cZ!_F)lFS4*QvO%gt-P4@)HedzA;xE z$r7bnFmPt!DX6I*a8s1#i$G;sg^BUO4$%mf!Z89(`oa?R&@S<41e1D8>DQBZo+NwXZ{gN8CiDg~`>gCRuV1%|F(CiS=P*Y`b@=%$8 z@*8DBk3?Xd4=AcU;nU(XmKxGqU6F#(LycUk>(IJjyUZ8;7n}Tu;7ZA`I|$xKC-R&%9}d;R;p*LWaC?w8ylfC$w_Heu(>j2AO3Y9*SrUP=|O_{k3V2@41r6Ac9Q}j|0ChMo3 zd;xeQ=R4G!C%U8ud0%sv#8TJSmlMzLsDZ^&eMZY02C_y4IGNj7Y8f@9hupKH`QM>l zDk~Y93}5cb9xCT0#0{pTVdys(i;XKwKf~<)YP%a}8{YP;zt~0E@4D4b_mXyGqbXGx=x6=vc` zB$xGP_Qu`LmG5KNRsy>?zC_9l*=$T$fs1%%$XIGs#wiTHVtiSCc9T%gp0RHwQ`(L% zg`%sw*HBaYSS>H>2ZmBLnX;2uDDe~5LSvZFLr?#(LHNVz2kI+v5Z*-=74~yPVO5FU2Ri z#W4eIRnL*gfW5YaV%HF5c;#;D5EBXzv%0Qt(Kj~#7=BH!tysplA!Th8I{{@0&Z@RkJ5z9vntNt<&Ff6FGutoudLJz+ghVN?V8#2s7K+?K zG%}8IDe;_u>nbFwu(a6JaBVQZh;73@9Q#p+h6JGlCsD1`klePSd0Trkf{r2n^%TYk zeO$;jBk??S2{~2wJ*H+y@$0eYHlj`Y=c^V&Dy+*&Ivb@}YISj~bW_1S2ig4t#rKx% zTWtoS5hxJEZ)$k6EIH=q*zVoB?oz$HV{z*qtHwR1-iE0|!|WjkWg%!x#ivfkT6^n| zaEvfS+xCarPgWe>=Z`7NWG_dd z<)Km!bqZER)j9=wr`$aiP4(p6YFewnvoM3rOj5S?KGNr}+Yf`9%f_jVw4+}@*gkOf z54QjIpRxU;4kdIDwjXx2iY>S`3kZ>gNm}>^wx4_BDg9IK`=uaRd#!!k5qSA(lh79O zDOs5E58LEztzajlcxA8fxf1nT^6Z2!w}!VGxM*&l4b354wjukM9f z@lQeh!S?1mDNEg z%3AaEa9d6iE#isR>j&C>IjOo?GS!kqYgPSRDw`@d3Zss!%OH#vWI)@9bF-GM*>Is3 ziE?HG3{IL7V+&p2+=)B~c-(QV6$by%!ZjU>4&u`wZm98=7Ve!qEQFLa{`I_hD#iW< zF$;I@T>223!PLKzg8vchk8c2h{Y_lWs`krj<_$H$rBq#g__SZKO^6r$P;?@IEQe*n zPd~^mU$e^KJ3q=&axasooUz!Zy~1h$xIzk2jhKJt-*TlPF5}uED`C+aIi>A*Jravo zh^~BhyyF@rF-2ZSSGANUDp=GQPFgOM)S=8U@o&O2+^PK$!^!E#N&H?ZYfyawST6$m9 zCa;8mmwo0OL{G2?C-GZ0ib$09$&yM}BZrJ<&{Fj%!|>eSZXVFl%vZUPJ^3D_6^T6t zT$ZQ1=}z62zz3BNQme(4aRi+`9mP?F#Z}^9#75PK+R}S*}gE;=bXn5~F=ue+P?t(u=KQ#n_ z;`&UG^xbB)$(Mgn_)&J>a$(>>JJRW>ydhs8p+D1gX19XRKW&sCV_9iC)_%)XKh;&* z=t9QOBKN?+$?qq+Qi}cvjaj0d-)?Q z;$PRMAN{uUtPH9>ZX!smrfPxqqbo-a!H^C4m=3pR(BvM$&6-SmxYE;)mf?6vq#8$Q8k%%0OH{4eR&!92+vy3rYwR z=gZFa8(8e-$-cE4o2iDEz{F2;h=-RP4qQqi*&Pufwwsp3mi7WshU2dG{`L%hJckjK zC6{g<^NBM=vA+|NZCYrz$QWPLiM49Z$(yq%Q4Ls`M*SoW$G3VJT+%jkcQBlTL!X!3 za!N{d&ZdO<6lc^I@XH;~)99kx2P-y9tC2C4$4pxJ}?9dCon_nHrs z(kOxBtDZ0Dw;KV#xY$-=&JwD}AB1wNzvCG8I%R}KFPJ9!e>j3~mZJ~~BTi!mjuB?% z#)9K&FDXTCYx2~5Dm|{H8;QebT=LYY@>(S?GEw&@JkBz|wk*jZjvN2}R$g;?x7Q@` zBcQ@%EkC6i+bu>bQL4UiGo&)zopME1vPD2Bc?-1CNXxWE zmVA2#PdS1qJQqrtkPo~a_KJOutR=iei;Ik%P|0b&=|M?nlSCva0 zyD>?)rVCeF-u1Fl|A|b_{tqK5$gXRey9Tyj_UN`F#+6=XN(re=Z9tAfqEVYs-lK(*SyWpe-dlVV^Jh%2$ zYl=+aNi;iSac2{6|N!VyzsCG z9NR{DR)jEtB!+{L!9Lqrg`AY6$e=bL#`5}QdA((Ktx9bwa5Jr5H}IPP*B^pJ+u`X| zlK-|nVj*3MqlR=h*ig$6N~D5pp%{Pm29=$2xd>|xML3LmYQH-svxJHFOEh6#m?Euf z`a@L{w;(Eg#*ST%(I;F1+o2Jy^|G{Cvz8V^DSN34Ty5_7w~3)QiKF~seY%;MbXm6L zA!%4D+hfdP8oN7`Y-|snC<4((9=PZr>?!tK8pw8impA(8cDnA<1~#VXJIra?YXPPx zycULPD8YOi98#7rYOAIk54E;Zhjv*uTIb-}c#r6mVl$m#9fFB}o081j2Ewrr5SShIP8@ncOD+W~3&ey|c+lS|CU)&25j!>J| zVxnk&?d>V;-8;jV$d z#lYQVUF~7>&4>w?#o%jrR~OwVVofbbm5_uTCR%e95mKx)F4+PZ0besUw3FgX_c9AA zTVk_RQm(bzxu(WoYW7O~r0L94HpE$}{W%Gk^E5%8D|b|($C5w}NaLb>0j!`0RP30# zj&8Nyl?LsBbsp>%dIK}Pv0WDWQnP13t^_vMKdyu^!k*YNNv=hSE@7i)B2h<KuEF%Eyyo7)=UF!BH1gOK;@!hOs&`U%5!dFwGoP(NsP zwS=AI{Zm9*%E{LVQs+QUUyiiiMzdHPt=udM=(=tkS+Cyve#P^$l7)D(GVO>)P zQZTO}tY`Ujb!pv6Da-6Z?)p>0FIWG;fzT`%Zjz5$D_Q|J`V%6HM=lyZD7j_2$M;UL z0fX~Id>0C533rN#hGTT53x0NhVOdN0I+k2&skMz*)({s98~hd(+lk#uMGtSHF6D3k zL9{goAxe2lFfU`RoI9YOsW!4Sl^Ve^3g?OPsOnSd@;+~X>Yus zG|Nu5o^PmLO8c*Vrp1U8^EeH)msR7WKBZpwQL9$WkT*x#OVL?zB2<-`uw2c}`E^^> zD&igRasPN>1kE)efvYK;AiZpbWa<@5>wrdud@4dDr&Z&^*a)=XQV8SC`xCn>BJR@dEMvw@xfnJh!_ zleOmEmkZYBxtu|5ulGBex0kx*2DZNOz!5=ij%@Z)mx(O>p9&9gh<`f|+Jpru+cye% z@|uW!f1G{W`7JGNsWc+M^%?K}EKPZI;Bft^D&_KYCC?|B0NBAY%wvO5m`X&c?4+YB zmNXTA21UijECDTVTAxtYOb(JakenE0qUYCw$rnqVViX9w{_z{+llu%V5rO;$@e_I9 z=B6$$_^R-|%y9r~M8oGwRaU zegx+4O`oRRvl=1Fqman^scZ(|e|Oo9$*IR?T4bKu=T)9Sv)9CG)_UGUGbTFj7M*Wz z{~)E-D&?>{P}X4Pbv&5%d1r9QGEI{OLpo_^mCR}fCw}j%NhDfbc?(^f=ld*KMf-W} zFPBsFeCh}xonBJHUk5>1e;-alpl{a&e}*Vi_Au)nTuOExS|DIZu{zeL4e;&c+u z^ZeB5Reoqxnt=|dFPwvOVxb;lO-o-S7*S;a%)d@GJGv{(N*tqdlA3UZ?y|s5#MKNR zEFB@-H9!ia_iQ&sx)Pp_vbO{DQ&U}d6y&vefgElEb?vAWtkB;R5=^M2Mx}OxFJzLy zL^b4pJKT9736fG7^D^xru{na{pqoW5n-u5LsMmNyFl1Ui5yJ_u?d|H>cFGCQq`NHT zAatAh{a}BOfnlP97~O}7ckODKc>EmCCTBNbY!Y;}O6Ei-ZT8dRQ2ac_++@yQK)cp~ z_@S>2nsj21BlA(-VdM=v(L!hu{rTy$dJ~Z9yI0vjDqaw=jeIDUGCzfpnUaSARf)kM z5FfYzxdiJ!-JpYLI_#2I|0!9Z9*?{t$mtP_n1)Xp8U{9RP{+J3x!9s?CbR|C?|H75 z|z?y0t!#kZ#(`_GzCIDqXgC>}13Z@DDMn7Vbu=B}Q=){B!np+wDViAbB(DdD@of;r^)xgG5x*|g(0A+ znmvW?nWYl8SZ_W2{d>k$q-1kOK}w=hmsm<|K}==rDWc>1_Rh1A*Ko`q*i63_Uv$=PzO`JU{p3G1a~U%s4E zWRPDvfU_KyFZ zc>w6j*_oT|NB82(UJ*9ZkWCt3Ali?-D8*4$%vxb+$T?XmekAz^ZAHQ+m6}E!v5Xft zsl>dAk{2`hA;wYwM6J3!#H9O}K{_-vnb18rCs0^@RQ2C@2MqfE_6|%P?FW?hWbwp| zNhQQ*%6-)@sMS%r8W$Wh<7{!kEUVo@C0Il6reu|^XwG|hj;87R2%C=US0r{ZDwi;G zWHh^0FA*|35^U+QzZZMmGM;AJJSVzqFI}x?DbYBNe2h1?byW?y4w5$KYBzR>h-0v5 zC<<}+_dQ1MS(%56>N6JQ|1BH<4bNa*_R#-Mvbp4sTM9#Hyn)sZv!Rx zFr5g^-^T2t7InJ9TC8w712kG>zy&!`;*P_^?dx6w#AaKs;B9&^zy%X9I2191J6^JI z``VAWW|4x^Xlj~rfwo$PJKJ2rTYj}`I&G>E@C(r4)H_4FmWQ7Dy+!EkM1lq?-zL?A zLrRmD$`eGYZi)u-nqB>|13s3?9nf z&P&)%w@wKcrGRQiH{pCCB}by9#Wtg;Di$A0?0SmhVJ6YQ%O|BOrAtDpv`{u>RD43e zLi*hTSGyeEGziT%A7)xP@bGmym>Ce!N^UZios8Wu+O>}<_Fe;X zfp*|Nvt*f4*xVvHta8Ja$kj$Ev5D+FWd_(Htfr^TCgqUkU&^SOvC$;IH#%tmkBD9jO^7bFG7(%NghTEJhbmr>{t zjMXC2;UMXnU%mToD<`29n>uo}MLD)#JdC6!ZW_9s_`N!1!yt2U|y?sG%3}L6_c;D6^msaIB(WT*Er`1#ubk7oztN@TSxoS zIevJT#~Yif&*~*j*C7THqf~$h2e^~Wd+`uISbgDMT2>~kUojAcNz8+>rE>V~P-YPusg2kI`yxt>dGL!<#w+W#7++Xf(&z~1k9Fet>>*2ruJT5K2 zGL!8)2yN4V=ETItRNtoufVmhxzIZoWPyyyOj91^iC5MNZt?g#sgXu6DL{o_bU*s-D zU2`ED42(nE4DLnXb)^_lj($krJMe-siVM9b!D-Y!;z1JI#$os zk?I&`<|y0I#AbdDaT zD#0|^IWaE~oRJ{*3nogkRJTd1C}Jb!P>d#)M(wv*3Mm%K8pk^(zH3~ZF+fL?YN1(E zv*m!5O#iUuw4UK16>${T<>#R$>dr^en*m#j$C1nnk{uxL*J)y(>3rhKS5GlDkt?&% zAoN9BF>}Kb|11In2L4yErbzSEBOa$-HF~hfi-E9(6KDh*4e>WU6vy<#+Wv+B^5FR=6(uT$DrsD4p z2n?4yrqVL?ptbq*-R69x{|G(p(jc|CYAj3SiE!gUv+E~7#i-61($t23Ru|TCX#xQ~h%%^ohx&1!rgkk&)i>Y^d z&d7pS%xmOietmp)5+Mz^_7>F|3h9idUf(V}n(KXaq5`CQy$oA@-*5-*XmH8VL&#rV zp5iR;J0M-k4ZqlR3N7OjgkQfrLvU{=S2goa8T#-Gj1P4JK!_mA3xoe4jDzLQjPV0~ ztx8hm?tH{ClO4yWG1=clH-&PDyK+lq=vx{|HH#s*DJRtz*X#PF9IefEAnRtRP)q3?K8*QLgEr%?7J?VK zzGHkyF-V$mIhyjR-zALrS>Mo;Dkc%VS}Xm+VenUg0Gucld3kn)nxTcinj;9mWnRm# z{8IU4&JHbi(8L*x{oN{@6fd`IDYr{>TJfricc#c_Z%-nK=!nESMt@Vu!#3(ZT5DBO1%Gg2kmSPu!I0qF zr6g@$dC}l{r`a>fkm94lLU_90I1-N!jY*>JOmLfu@pk} zaATluqs0#v@fOjVPNygwIP~+_+m0#Jaw}AW=WPeQ7JQ)pHa^n*m&@*}t*gw_v~=?+ z@kVoqY`tZ1zHCiC4D74|AE2aLDW_PISc-G7#2&6In~(b4FsDRsuA|``Q7P}Zb=$?a zCLW-4%((~eR=h0U%ikP>`8mjCduD^BVZZVheVq|Zl`bW2+>uy(v4iUjRa?vbm>VRG z(Y8!bZGwjsg&J&blJXjB0p9DA=kbP(Y#d2k571)}S^sNqj9r!+5n$Y27n2fAF`627 zLXn^}JdWW|tv`G|!JI^FDPE=*_f=jx4F{&@W5v3ylf`8fpCMm?|HwZgRo1X85i+^y z41m(!N{ZLHIqc``>+DNcvAG4kgwivu_Q!!B`A3uR4-zsiy4~vyX}l@ zGqt=62eL(@Cb|5 zp1{538W#_bqrp}%xue5Eo5}kLY4PaG(wx?mQSO?3S`c9&IE48;+r+Vdola^L5(!K> zn?h~6a}rmaFpy;NUv>opjz4yVe1Uk7UE#NE6}6fQ`k#n5uzA(iYxrHQQezNZ!{Z2E z`39`!$>mY;l2pZ)!!PZKC`A}XRPj1h!A~HdhM@-4V_;7H`sM;nC3PjWlq&jn8~m2f z3B91+2FS9IXZy#pFyRBm$S!YdBboXS%R&&&khe3y@%wEEXd~3Z>DlB)BO@)Xr0 ziq+M;mt%u{YzHl=5mn2ESAEILz2eP`Nr@EMCd{i~CalMj5*~w>N3A%4cx5kN0xu{u zR1!8&VN|OVs=*6X{#?{zV!-IhqnY$sZZda)z77XJdRbZYXI*5#WXTxsaTHL3mEmY2 zx4ancBkQUyk+j+qZXJc0KlrP1`lM^`DQm)TS#$*U&avh$Ru((DDU~9*<7Pm{RY zG&`d1@81*YQYOd**3I#6u7&-7xE4CwK&}PYX$0}UsQ^qUn!loK7g^2lQu}$3tO6P9 zNIoZnhVg0Oi4{zk!8e;6MKMeRFBwT>k5bcAE19$nN?*`8fV%wpRwN>KamB{-0b6sq z>c=Vtc#{E?ZRlk>kskg4uQ{MTz+n{~F$H!`TY0V_C}}O0uI-#F)jLUpk)5PUpy|ET zlSZ}+&;MX2%hz&p{q^&G!_u|9bURnZ8^Dvjt(z5nmViqXaqO5PbyKvf`gb+&4OhbF zgwKvJe{QzHoqv=za zr}ZJD7+QMMs=)xH=i=AqTpzz6EdG$ZU4qeYAbFa%pM}2#tF`M>Qva|GuK|r;Y;I7O z8|Aj~vBtB`(kVWDJNkkJ7JlynjQv6t^o(CKdDlptUM(4X7=YO^ynOO+eR-5C`hXmL zsF{>bE5WC-M87!hdR1c0w<4hM6rz2^*7S!K5Kkw=@D@72a3fO8~)SaSg+AosKy*>9FTr zIyYOM+4<6PXs4-bmfbDVm%fkNsR&seV+@pBnos+ugt|ltnz+@tzQgLd1H*c`($EJR zPk8KG4~-r<$mjq=rbZnJh?^|B$g9caCKvZWI#Sg8t4d_Dw(p~zg!v~TTujr$;yz!g ztSJ0hDvWhUK{AL;9Z)e;`Kwu@yOeBrU<+LD&jWM)1aPB!L$hgaIPICFYKGk=iU3tc zMkYnHpTPDnOCZK8HdRRQgvEo=aaUjR|JA5Ksq(i`q3C~SR1o-gqe7SJzl;jE8vm_P zA&B}fqkcO3c=d{G%7%?{%4~CxVdS|t-U_KyU9i8T{M*1a@Z%l zmg(D|bi7KTnev03-!Jhx?UeKMEY{R)j?Ddr79T6FwBEkq^tH*{2WiO))c1uDD zP@N`SE8bcj^$^((5?ZU}Eg4bbPb6$V5>k7nP}ueG!zZs8AcJlv3bi&%XT=ECwU z@wa8fL76taS*)emo`kM`VPe|0cl<+zk%qGl%c=|PpbFvsp~AkbU~;Raz;a|kLv9(m z<(j4Nhtn8X5g|V;yN!jvPPsqnioj;OcVH2(sp!YoSayugwaKOh3Z-eGS{ z1%8s8e57D@>k3jspkEXl@ll&PrE@dw4UdzmF#b(AZj@i#s>sT_RvK^Q4#A`RUm9)) z>8%nbrj&i8ytLB>UcszXc&GK56w8Q1cCk_(@!Opywy0IA!q3RZI~O>L3BIYT{z@K9 zSAvax=*VFURR;MHt|^z?fBn>}ynOi=62{-zlU!InB4h-z=L(uiTRs_OB|Kt<8QGVd z@C~#geL50daCQaRH`De)(1dEfjTjv*xjoi?;b&Z@-hQ9>snUWq#D?Es)^%O&pPYU> z0)Q|2Y|!UoyaGkE@UzJBbG_agzFHko=-m*6riiuK3GG&Awn7#1jD&DtU&&S|KW>Oh z&|_XOe%VCWQ8&VxPI7F`0hBi5@I^q^oe7LL?@;T(-e~>avUwZUV~Iq@vo2ymP$J{Q z_+3Da&3*!n_mn~bCS6flybkX$rq@VnC%cHe!_byBNx_rXFtN2Ho)VQF{$G2Ia+VXh zE?@j3bJsw!8S(5kiCWL!Pw%#H?h55JPuii4k!<*{+cKCuUne^5jcx4xA6>efh73rF z_|t1^?5y^O%WIU|iSVy1?9nTWT)XM|^Uz(GU6@R!c{j8)`)89IY6dDH%cqg1h!%0< zr6K}i`byfq55&;SrxVJ%FdWuCbgdUP`6idY9$EBe=QOQL+TRtg!-*hCaA_gO$SWlx zClAN6#d*|UR^HI;RW{t%HG05v>|~^SJSi_8*YTYHh()bJ=4Y&@wf)hhU$Sv?MSASv z%G0z^7OZT!Mz;=3sznuc7})yO<9kHh@o*O7 zeKsbiW*2?R(xW)CtH%%R{9FeO;w5twC@lvHqpV8%M`=XAe(yv?(btKK#&U_T=vQ*a zd=1(CNRPJ6%4hvyMaF#`k~bz^iSO#s_tH!G$pGl%;gT&Mo^IP)s!mC7Fc)605+ z*cUO)7B83$8rSD<=lb{FY=2lfs183e9ca9{sm+|5Umh~UY=vACKpIFNUGudOJz7h^ zHD4>yice&$lANHUG6{~q~ zkd{Lt7r@#L%hG{jX^gA*IUnYX$8&3z#MnLqwDD4kX2BUq$H)O7j4i7 z*+s2JHuBxw?6ycc;l^}xW}u@%!6AQr_T9u;lj%Z*&;hQUff48+SSph)P=DyPt?1p3 z2=))W@T=QuczK-?k}q+3RDhOjbD2;?v}Pg&gc!x)`YUzjO~1)SPjNlHx{MAg?O`;w zLaQD64w!JZ`q~+_YJdRz#NXe+2*OWMwAwL4KyW-Gr6ooj8pLccE{(JL=8Q&;N#lGL zB(7?3;|Op!Q5)IY~w1k0kZud+q@S zWZ|d|o8iR>sCF-nM3pZ*t|_u9thk^XBE0){sh=rFo*6S4jW{R^3T}~-Yfu{!y}--uiVSP#8J^BU9JbRS zk8Jiay0fD+ObFp}sCE$S6J<(zpO$kl5t5&cKg8|msC>!{9XT|o`K|uVxtZHD4*#>4 zpM)bfE_;-Pg2_-!BT1CbOv5~Js=+?c7TYvqvc%zM?swf0Mk)js<&2Gnu|j#D*nlRz ziF~c&}?zDtu0av1(V!m%FyR!xxk! zu;g#$i4OjiE-@zsQk?6qsDiTYI>?TWm75><)00PObVdEknZcu3yAEvHy9$5 z?hOWlwoL6m4F(F1#dm3s1_LVZy}_V)Z!oN3uNBl3jb;_L{$GU7z`qS1_RmO4Tk;ynZaO+@V_t^41O34@{a}s(hq~d1@ysS zFuOBG^_1HG(_n~cx;GeX9u0;7kUtCtv3r9dQtPhWHe|G{7o z%KI-32BEY+4F2y^^4<1>!O$3#@uCdKwRh`KP0(8x`zHAISjE2wGHk#4cp%i-sl$O_p5^5dEGtB8=wRd z41m884F10n3^6|mhFKuNV8tz&#|K>2>XBgR_=8}8`;}m5{)1pJeIyvBfCPi)Bf+pO z+W;gOME@ihx_%N2VTP2fe-I4M?g@suKL`ej|3EMt{*_>G`;A}#Q3etW-aiNi5S0gl z0rH+;@cD&cfd0QvFz~fL5Dc6S)hquTp?~_mK_X<*P~1No)Upb5@8&ee| zZL{7M=2GD8egxTg!L{kwl${wfP_K1?1xWcYz0-cjqTIntAdpXU-czS@E_^eMC!unN zp;U*FAn&u{LkVrNE%H8>_Fd z+QIB<=6KOkBaH=CKJ3#8=}2!#;FDdpmVyP{qyFT6=?2`<)>MZs*4!WVX6u~Y+;+NK z(PVeFid{!;MZY%mrJI@3Ylq|9uh@Ey`EA!MC)oo{E~^^9Z#=1dyj{6zgwmH$NXN9i z5#4^QE?u{;M3!nmVM}V4F=e-vPJ#Kw6O$Mvr#T!+Pqc{YDYrT#US3-x)(f2LI!ceH zi;c0(o_%YLSGsW>rZ@ou$&uLP@R@A%b4D0B-DBZpvQpv=&Moh2zTlgI+M{eOQ5_uS znis{kc7S&-8yp|zcIo0v$9V56N_q&~sUtS1u{cBD*z$aL8e3VP`F??FDK}6(Bs3;f z;(dn){3&l4-e`Y+A7(99;0r-W7soZ}vb&1v5jq9yczOU!%EBp)%X0*Vb>Uc~4(#W` z(<|ZAD7TUtnUZ%hFLkcd@xEUo!bPT_BX2L z5FGQR*g{e~HL%?*H^Z+`7pgTo4#mkUm~LeO-r45OcFG)>@e^jp+jz!Ek@8a7$9=Jj zl-1p-h7b9rHXfR+q|G6ewJ=!S4LvDP;4P`E2HrVxRCLfP=2bCgE$RDv z5FpUV2DJS|)d|hGpDMWZ)H8{zTa%RlHHOSDcI@KERuv;B()Ks&*CT6uG2X*i zd!qY&0}~)F-@dyuCwV^BL3W+f*=0NTaWRH>MyAjXURLBA+q^WpJy^o?T3J(@9)Dji zgjxVsZbZ}ilMZG^Er}|9kNKC$2s;IGV>vRa!9#6Yl{z<+Y#Sb1v%T#vz~5;M3@(@J zH>r)Ph^%p50UzIcSB}rMOV!cd&S+jqo+6#`1^_#s8b7FY*zU;7{gYwvT5qyFUgNO! zt-a+~DYNdWw>LcxoJs)l`2J%)NB~J} zV`@JCz}B}zO87$~P})we=;5ZFp_I6@B=ogz_dd{Q@m~b}sH8lL^eO?m->Nlv zrd*i~aj0Gh6jbhDTa@UsC0cf=a;6s}s0ndv-)I51L_%rmkMie%W~;d?qqG?m{BpDQ z;w1{wih^kyp^LE-kI%Vz|0Ix)mmbE?RzZaBWl3^onIS9eUw%@G`e4kL0jXasoc z$8Rn;IQy3?IvX3_%DhPbZYo@t8xnk{#%nmXCoz{>{Bc2|A@?}Ee6+{eNY!m`t<~6z z{Ryd*xl2@|{_$I$!dju)Wm2yI=^O=n&I&E2^SNO`IV>{ZI0hIsjPdJU?5$Oy z{(H=%-cIAyu$t+!n{>7rfYCIvG?Fd*8QCx(<~Qu(e4TS}-Ad2fY|?6?9y0b(7*Mz( zK)Ra}oHyncW?Aia*D7sf45v~UsGc^cnMxan_Epr9{XFs!10Fdo}~SJoAiz3OUqJ*uahQHrDAmDshU#m9fCYR~@gv z59f@!aF>;>6bUHuE7JHAV3>jfH{Ba<4{E*&OP=q;LZqrR$(vnkhA>PpW%_6aSOG4z zx3RHdW7J^j)-!veE@E}Fu?x#(mfek96RkjCJ+_fd{e4Z66D#*XFXs+!j9ogTptUABc*%`b(+air&}qCP#xBAr>TQdm7BT9*@SZ?6OAycFshzs3Qe&KJ;KLi zD-;)YI2WTAs&}*(Htye18R6;%&2SW|@vk}k=B%j3CuhntS-)|jzA^5S@?;|GOKJTy zjPEm?pq5BP!UTEiZpHDX4pu!m)1Vp#0C4jzN$8jaiVb8JsBW+g+*q2oJB&vez*_{t zug?;iqJUxp>;;4y7;jwL%R4T6d#H|A(|^M}ieGfOfD_U67T zEkqg|cHL}3+IIk4%#oa1oNY{)i2H>yyRpcKMq-Us4SRy)DH>qdxxR3A>6mVJS4kFf zzo;&JExT6e46fqT!3x+0K3JdQlp0MCd+dV^g&8OCDdeUpKxcYvPl&%0wQfFLMx@WvL%Zc!WR0-RYq`V?!d$yON zl9of{z2Bs`UNEnz(jsDsr9T%<8ssVma1qIet{HBk;k|!5NbB5Z zo9jF3B!u*=QdeXf{(-B2gNce&tVky{N6vC>?n%$}V75;-5nbVV*s}PzPg=}ESzzf4 zl*{|D1w~)t6)&R3n4IGuN?^nV>VViRmba5-K0*0o}d8QVCOOmsXffjda2)8&Yw=hgWic7eud>^&lkfC zu`2E7V^k1(5RR;{!3)Ax%VVEQ=4OwfY$>>C>ywKBL+hM2-6I}3q>;JgrokqK z%wKFRcHK@P`53z>1@y%j5I5#sWtSX*KPw?lHs+IlZip`_1BH~RsK@a;hi_gF)2+>j+32h#L+up^K4E{n*jv13V- zQ+CT!1D}e~6H%gajI;t6^ZJ>=@d=eeKFZn?a-_TiJw@6SB+=4jk$J2jR}^16WCf;a zUg<^OQcIiO=UoUg_IUkTw{`e=huabkT8CeiA?V*>72yVcK0=vn?Y4je(hXKon$><- zAvO>gELa5#Qk~svX(%&JurGzq%NSCXk%DF;291g7b7fzW4Dn6%JZJ4WM8&dz2NkR! z(7gKaeC#N+jiI!%D5OhM_Jx>b>pB%umFV>pjyZMNnR&*{YyB~~=9%z#U3+u=n4X$C zoEoN>_ulaf7q|&Kx}Omui@)XGVlg6s6ahlCM4wkC7vL>VGKOvVGPRjgp#k zr>b&o>ieSG(GuNXsfSXSR!e7lp@o#8DsuRW$4m646)Wjtcvvd;(Y+RNP_2x{Uw_`;K|pxc1wG-`5aK{XVBwu#lJ)k35W z3G@w5L`l+#VlC&)(MzUdOgFD+VijA_jyB*+Hcwhn#9`&4ZTRs(ri0}FhV7JmTS1bb-QH*T#g4MDohcyKeb;KE?{BcePfMglC7 zQ3G(1L@B3jDf;seof`gP*HiE>iQ*h%iYa;p8ejFp!wXy6_A(N0eA@{%cEmbQ7?(F) zx(aAN-$tu@&CyxesrKzOV5^o%Zz9VSjx@YMc&R}Jnh_=H`cD=8l;rCKg}KTz)U~4xgCTR%lG%Rp(n1(K&o5eL>EU|7 z36UHo)9F=DH=&bS&;2SnA)p0wPRu@=)qLx;KV!1$I-pFpNgjI}H-2ms%+ep zILnf-%;yYTGqxXq+J55xExxH6bFy=TLakr>YpG26>MK}kSYqS|4CK&>FSFCcEo%*3 z^La@j2cJ!5#=p5aRI#>!)kQximU?a|Fvl($Q$Qo#D#V|oW`X-uzg_r0$e2G zB`ma`I*Y(Uw>LEsYVJ!IFKVPh?k`6%1e;c?&CwGKB-CeWi7=_*z;*}_>Cxe7TttAgl_ zYdfpnD}X7EoI`*VU)s7Kqb|f0T{a|-Zd~^JiVBI*uhXiyCU5REiz{QiR4KhZtd+!A zfEViBatt0~1$?cUr3j-nVaxbxL&JmEYD3(0mxEEU?-q%YWBgT-?-!41JIE=yp)b~5 z)G}jyv@kfsPF+4OLh1}CCuTR`>$5+V8fv*+J+rz&LoVrQvNl#_lFG`wv(TKa3l;IDqPaE**~@f*0X}AqH|bOy)pa{Sy)ih$iizALtAAT%d4X2FkeC{V9E@uxAkHGjNf!#a@7mhh+;uh_h&t+cjY(`2A`dK>n zGhFuTwoYJ|!BN`#@8`I@yqNDhH_ztw%-}}!SDJ0|>CFJd5BBT{6Iws1$CiFxHh=m4HI{eaCCy7Pj~~n?qQH~kx*992uP(F5s_yiCEJd8dEP>noNhWwb z<_R#wxGZ`UwuS}q)?oUX3spzWC3w%K1PUerXO`iUL;$XGf>J)d44b=9Ub-oEoA{FX z?53V!Supg~e%+yPxv?uDf*VPIy@+M|s9x`OB*mBgcmP(Qo$106g70uy;$}p@jhoNW zrk2C&rQXU9kij+7U+o;VNiQ9`%b5toRpacGgL+|%5)SP&V+8M1`;MpYY!%kyaETN> zRHUdrPLzA@mR@!it7TtCFxP?J)Jg)U?HnJs4u7a50q6+({xSW9?Q6o39{-5pEqb^! z2VI3SOWqfyi9capmVEA!JRgmwioFY58s4_H1{>4=(~7 zxDr$Jk;=3QKPm(3JL^l(UU_dBN4KRdiIL+~Swt)8ZC{vt3AS|}!SEgW_L!6r;S#f4 z2g0C=@o@@ZUHr*YEMx1VUQOp5E>U38`zZ=N*<<&T`hv2sGVt%m++o&kfrch02*eM} z%c^%^LY1cY07qr$q3-p%<()<%nTmY5z0{P#H^q^57R}S61n$gNoRhqY<@RkY zUazMt9BKMsz3mQ2(%hO8GD?QZSHn+EpK+-K{i(d*516%SYu6UFXg~WtoQj|z;OEt> zwb!16L(8-&8dxj!0sp1MD;7?h_YsH^c4DS#JRy$Xd*^C^bqj;MN3YS9b=!c|=k!c- zlz@EOFMYKIArUgXf2>8f&RBhZDvEi?WQgXRv+3{hhI4BCQsPXSF1Xats3($uAP`Ni zZ!OsG)9T2el?t;a74!A7P{DBn0!uyZ)p4@%+<`ILn?c;hum1h%2G`v3*9qx5W@Q1* znSHJ2dX(=zRNB!rzPjy;K9_uSf6=tQ@rB_M{xMWo0plFOkQKWJwbfOcU z*hoNN4jros=3!Txj`fLF_7c}Qzr#4*vs2rM+RqBz_KpW15X_TJZJB{$n>C6`03We< zI+{3SQk#Q&xn+GAYw!e@4QlrJ6UGruGY#{zgEA!pK9(XWi_PoGu@_vU8_t7qBVGq? zfj6`cqJ07(I8V+j`?@2TswOrL-?(;aqhp0qSN6l;t-RPPQ%-rd+;(}p6(pUdI!ewk zUcbrc;fop17=QVJ3GMU67vbF;6hHke2N?y6(znGcAA@ns%Hy69eE zQv;N`TeJ0f!_@SR%aCnUG;rRYt#!A_uxy)$P`2rIsBs4Xv;aeHv~umqFzhUfWE{m! z-^-7B9=Q3+)8xu~388H4G7(YpAEnk&tclHy63C_20@l741ir^hj0i5$3A*v851tpH z+JsBq$*x4G$eIe2yyDnQp$*lqtYkG?*W1_@NwLDu;Ye`>-s?>3M9i+s3fXwdy2og` z`x4o9CDiyHY(aj}PcxG4c~T}q5u-0!)k9Uh(nJ*Trtmn1m%M^`hKe^$G4RVLlYI0* z6w#ZHor<#DGDS^5zkrnRmcgU?j zg@As(!K<6x52h_DqA0w;sVQ&06ABg8h33LS)fT-PI)co|Rhb+Vz|?~2N3w2*jf)Yc zJSJE-z)tbXUJh3^{RBh&TrPd)*^|Hok<2BT)~#mvap5``B{&^7}e*5NokpL9FPs1Y7@I_`hK&tu4DGI zwyotRMnimspY&dmDX>F(DTBz#xQAdjaz@AfD)_6ue8|{x=9VhEW}*`vuPQR(<7S9X z7%WFyWG}~o+1=}5ojYwbyJL1y3q~hbn09`XT+HHuk_)R|!QG?e0bK+-*nB6(>7_R?Y{jnlR!j$ztU=#)DnvYitK z1@MLSg%1-fVbW#@d<}An;~!#+y8OQvTl9Ah-TEn`T@-<0OSR4U%1^N+HW42IS@Hwa z2F#Wn=CVb6-Z7lP_**mZGIL9XE^ARg-P-G{S7=F_&(tyH^O#UB?+Qu?^yEcW@8#QB3~Qh;SVC~ zntP0&v{a_aX*zfArWcB#d~Lt$QO5SU6cHjfnXsEwn$_4T&Wi@GHv))7KHX&AN1?d! z|7gkyi#F%Kl%BMjoiJWKMc9E~xR+&7+Z((pi#}o(;?I}?tLUpctt0J300prtB(=9L zsf$5V{y|>qRZLdewc)eo=ILx=d?~@dAIv;5eV{MqvC0) zC)FIyQ^qPv}b!juY8s18qAi2E+i4L6f?4b#;30VKI^ew*AVGT z7Bc6fTalK6@H!g@w6@BEgYP=H(7xtqV!qKmkk51Xj22O|T-IGSv>eZm1&NdGN$+zK zG9LmBeJeasy`uB*Ph{)|GRBvoJYYxyA>F4d2117`&kw#h?$?>`$ z7`m=darjotzltwgT?3B>e7}Wuuaui}w8cKkl~v@A34sDnN1G44f*}Lrquk;Cx`q=` zDB|~-jW7`4Wk}QgwMY}F=JSiJ`Cz@_ad!fkw;-x`gN8^mz-NhhHlAzx=QLp^wdp0& z5rBX~6oYuQ?@>Qh3iAg6M__2e1-pv#W{>h_hvY0Ms4uuFU^_%c`pb@Yd%y&}_bg0Q z6Ix89>EWM&fSYA#dtTyE0WZaC(xjlIUT?s_6)j-Yy;C}X(`cr4f-G8y7H&L>tD0GI zLDhN-3Wa@tn8eXaao>ocV*!VG_7(&Tc)&Rb|2F1Do*L8E0K1?Hrs=YBCfSdRk>}7) z{8j_<%LtYyl*bcNR`sKcoaB9yOw-{zfeA*L(qpi!+#7ddykE_eUa#)}v( z>`Ttqu_srnMb++dVRhR1wTzu;Y5CX}Bl|Tst)UfJ(_pD>?=*^K;s%AtWW(6SwC~0_&sztNGhz_ws2d*#LifW`c`Ge;#-dtTp z(hk$~I5) }EN7q!9Ht$ao3(vj7P(ipW2@ke{IqX_Y6@{^N0Tj*bl|0zAP`&7#>>^q>!rE zIp-Uw8E-MH@hWH%l(`kB^?lO_OL=g&FO#_kMcs%@HO{1xXEbOkTFImKg9njbI{|-P zxC=EVMDTmkiC&z~c=gFsx@l7J4GFd@qRad^*m(?QVpxLw zjK2HR#X_b%%^a>E?RmiiV9j`G(7E5vj<;lRWzbfyrI8MK1N4hjTRo&6x=m4zl0)kdyzMc^mPw_q+(8%AD7ULm7Vm#g=Y z7SwTem~}o|xn&oXbzSBq{OyUJlEfxv=zTm~T(niqG!IUs)uhkUd-m-{zT0}DI~(m4 z1hR&|Z^3t{yPH!9VpNhEdp?V_>L;4YJL$-?OZ|2LaeR>>jJ3H+>=J~Y{^FRH4fQ3P ztQRp{Ad;#DYA(MBu%npxJPz~rHd}1qt zxLit3Z7EGza16-canuT=fSr$p8$1RO)>zw60_ce{sU=zry;xKCSbuHqLh^Fs=z_<5 z@ki!3XlvoSDXiFy#aDW0sC5wcv!-2mzH#s5qv(%l#j82|?KvA@_bpgQqlHEV5B_@( zg25RvrKOb2K|bb%Lgeu;mmN+Y{Qka|@tMhyIsZr>zz;&Zwq$N-@SpkOXJ@XvW{6^} z{|Iu1CJ-*Zoie01(yhb@u3rc8qCkEm57Q@ZD-QOlu-W=)Odv1|U%lvgY_1q(UMjWa zzCj-aM<28mxO+{FocL7LIYiR$W0qzc8h0~rkJR@(T2kB7+SrzPGrS+$xOOJ0aOhjI z*Uc{sVjE&tm2y#X_F4_3TzRnPYR~Veg;a)cr#ATvqsb6@+X}n$bqJ~Z+gPmY?=g7( zsR`NqDDT^#Y1v>E!U&%OW5dw%dP!+E%g(3O^1ATmrVBGC^+rznBN3sI=I@Qrh19 z`_ANL|GhI$+PDgjJ;R9ufRS>)UkNm7dW_kt4)OcG(bcp8fx=#Z_u@Nmin1@EQ(s&k zB7F;v$iDE)fgb91)6x9m)pJgS`*gg){O6#-*BEXutJNd#6(r9AdH;t_tPA4MCDyvgK z&T=vj!SWa~4@Z?y3i^gsMBfI)F|r$v@1_}VHSEIJuly&v@ybF>;qRr zgm-bCzmf6y2(jhuJ~7e&cCn*HfCwJfot=(k71_jByI(n$igoUE7baN!a3u*daOn0V z*|T9)n0SMnN`|zo^)aIG*8hwss*NQ!kBQq`y+A~>8##_Ij}f&YgT0AnYq=zr%6Iz2 z9-AsybN%*oDfu93e|^e%;^ti3b*~B29KC@aBX!-6*KT=5##ck22e_Dd3go3SQWS;T zD?5GU-#^sH-X42iIb%9E;9p~ZiI#`pDZ;!S*;k#H?5cpj&k1&jzlKbx)gK`<^cXTK zKXQLLKmMM>-@V6}iDgN`l!??Wc;mykI{`Xywz*mk5n0q@CiGDe=* zGg^HTz>>eOK>m!Dhc9fVirm&{l^_ZD!kf#McEElPDNxF~_jQR2F{bt;nuo?Y#Qk`2 ze|qY;3nW!};FA2bfj0#FAXtcQo8jMLz2Iu76n8%*K23d_40j`6z;6|=waURttC8%B zCVc?$+a9yu6=+%QomK>}7j4wMjsKQKlEW5cuLQ*ic45<;;-Ms1A|bGO^)Ks^Oh#Z? zGDCVWuvcr&veCvf$44qlcgTYi@a(HCx2E@cie+^;OpQMrdKb;%%N|Jqj1^x8;2<(Z z*m$9EoN5j;n5{#W4Wb4nHsM)Ob&7Gj@FfmhLAD;3;>Kyv!h z1??qq$tfeWtMoI0Ff@%nJ7Q!+l7;+ne#t`Oet%{m zp;?xnSt#je7P>D(%%FZPLjrQ%f^jNsq?kayD=ViSC~;;x=5BO)NAcTU>L#t>)7}p3UFEcJ9#SxrxR+9(Q7=|gs%eBwLUBr zgcjJtJXQ4W7(LJA!oe4o-qP<@gR8w#xoCL(Hkt5pFgOx`;{t20C^Xovk{Wu-4}8#2 zPzh)b{-_)`oYPXu$O7}T_%Bd@t+gMDnh99ocvkSFaRmbUzC@_e`87E~f-O)!mNQz= zkLAqI0Zkw6Zvz@=AF!%v!1^O55@3K=NuMw^Q91tQMH29uY2fFdyurq{*SAr?7vu=ebnLe0*B1_EkbTSi}m}+nV=A!xk5A8;gZU| z$n}ZZ8~bPEoa_u@c`R|hEXt7f96lBjY{KGwb$2HScb#)Fc$YdW>goQ@Bg4}pmsV%d zL0~ABWY>*xw8Mhm%3{0h$+pF(>GbzdaVV>IR-`Q= zo6lV5WE-wiX-ViIuLZgB_4aQCrC(XI9yJ8H)+F)xixf%THOvi!d`W>5IyeExC|?yl zlfXA1s8BdL@vaOh9pJUa7CW>{RY3N%k^y(6_s-ey?u5?}<&Cu`+^D-s338EZKj~<^ Px&s%WJ+4+I69xG{^XV=~ literal 160376 zcmeFZ2V7IzmdCGxfCUf`k&aZQ3ZX~|5osz-KtVdvLJPfzA|Snq2uQzxfbXoK)BU2HhZCpy85 z(us2cOi-67xuT$HUca-f;W2rF$_!IswrrlDCgySgP&tyF|7fTw^Nn={S&Ip~2!jZq znvGs$q@nuLGrSi`1wDFn9N3pDu&|e(gp>pE_LxWCBz?|suZV8CRwi)m%DZxnXQe$H zbn}ufk8(Rkr^29R<&_6Dc#dHT$@F9HpreY)@?m6$`|jKx%wvCfe0+Ru#qDITreqIV z!{r67Ia5vYu$uzbL7&~?@<#_jp#p@v2*h469?0=5KXgs>aP(1y{k|ys>jK?6ud6ri z{A*6KLvm6z{-q`UJ0Ui+z-*t|^a+Q7P4(ES|=J_`qCR{&)f?8Xy&DM!5 z?u~=WB;V7Cd0}58W_GZ|JjE5_se$5o^T{2 z_?Nca-*qiD!P-i7S*hceZWnaR$v|P*Q;=u1JnFz{afk%DKPp152AFE|+&Jxd#{Ky1 zrOQ{a@ov%mPdMSjLVv}f8Nc#pAGJU8IQ}=fW|VyT-k(Cqe4>S> z`<~IV^?eX@ypXD(E6{EM&eBy@DtOc2iyudDncsX!OTQHGs^E=d&{)^Y6`ab1Os_E` z2Vv!_mCg>~x=^Jt{qq-;{6z$m{N{^i^04#xs(_(xmp6W8%^VeDH3Ts_F96z>9$-m% z{&Bg>^}hI+i+}zBQ?H2;VzuBGGtB$9i8Ey*Gl`d)^m#-141k=Q#ypJ_atI!z?jlWe)0CX(=o5( zgsxLgoZmvyu%y?@Grnc>pQdGTVlLA_{%S{AwJvn=viT6+p46~0MM1YbrW&S7G7cwU zSP3vm#g7=KHItLz18X;dAm@rB&@is%z(#VF zayPG_`<8Bllq1G22lTH#T)TN;J{0%7*_Krbel*bC_IUg!E9%Q&PEe{znJq zIJ&x$t0-k*Od(^>Fiqbdqg@R|_u%qxUZ>>87cn2AezTXNY6c#tAAjY*L6{@%h<+k! zUV589={;wpT*gptc;d=+N8uZ|=hd5#{P57ZCG}EhFZ@d1uf0FJ9fTh9E~avOjIrvt zl>9w6&fTq{OLnbKC$up?Er8VR_7VJeuFfw%zyE6C<;A*P zR~g!&oyQof<$OHxEAjiYPa=yG)NVjkhv6ax1Y>SD4hqJUhFqUiyyQ>NE0uC7VH@qN z0b8y$RaeL1P9ApDkerp-%zTYxQ_a&X|4*C@%Ik>79cF+W(|2pB#GYJi4#A@(tablT z(e}cFQRZNucNZJGw1r0G_kYYb`v^<{Q~!wqewsTLX(rS0jPBmW)*g;hVfrWBG{}Q7 zrrqzKznh=N^jDWOQehFFZ!o_9Ogq6>2BSVvUo_5a47lb;4$^(&v=OE`*GT0bBv@p$ z4sAMXKf-OUB_BR&W?@(|Fw#g3H|a?4#hQw>=PpQ3+-UQB6DW+#3E-ZpuNOV8h06R{cv*b*}uP+>!$XUR)W zQJ^4$v?Y;3zX1bXzqZ_|*^)LJ#nT&M9o<7Q>_G*$D>S%17Y&jMi>LrY?t4$&j!zR)S zby5k&m6tQqJ(_wcFRY9R@SmG?ev`-Sd^^V>{Uld9(M+ydvLj|`zcU->M&vlAI6XGZm@-yaWZBea>@rYb`k`C2c4DeAXFiRN-UA=O|N-tpK? zS)|?AmcKn^xCHSt#vg}-z~jCmaL;gpNxUG5w1m*W^EHMKtprktqChGQ5~z(4bl2*^ zX5*^OG8AOpxe<~HAQ@$edL#dt1x;e+Ff&|ki=GMxY-w8i=@aJ0a2G2mtat*8%94)C zfBblu?bQre9cPOjG7rR%E6{dJkW~A-FX)>Y5Z+nU$%tkEFL2f{Ddrz{Bsx#fJq{+s zjn;P3#4QXQil&XFA8>4F03C%`M}_jL9f6XUM}r}T;5;zOf{k?k%Kk3hzIWvaBAoW2=F0z1bf?bQ1W;1bQS zuhPXUB7*z&8++~y2Q2MdQehBFB3eAfZR{TO3IF%w)l##JkX6d=7T+(wI0jNbt|%9P zFmr`P>Clt>VlQttBaC7YSVwit(aogOj-tIko;d*}n?*9{2{{NYHROiBa(8NouHSLb z*r#IEV%B-|vZC{tlZJJyiKW4hcE;9~pS$svxU7S$FtVM=3y)r%BH329eEiK=oSTxc zZG?WOn3wrp_e3SuQeg4hKLqow{B)Iek6ogBDpnfq{-w8FoK+H|(`}!6UbxsWeRp7pVTU|{V>&9}UJ>(a;) z!IC-jCH5@?B*W!Ta~oEKZ@A3v>(WFtI~_i9FH?#)pAvvC+=fo_lMP0~P-0%AB1OOq zIA&CY>~0l}Glt5dfU8S;u6rBh016!aFD6bO;sq(x_}|i8$rCNp>|lL5)3&9+?)W_{ ze%L0Ghqk)}_Qo+J-^1&E2jA>2VH|^zW(>Ds{17}4Ui}lKZMGi{|ve6w6m%#(gv>^p_*jiXX1mwtIA2kD(X>YgXF`fw} z3~mW6X6_AG9&l8-M|qawH&HZv_}oP2;4qt|a@|1b3N7XqL!=Y=tVIT65|Ioov#mFd z!-r?@JVfbqGy2}u^B=DMbPT~k-e_(GQ67?*6^%%w&r-C6I?sl6#K4Qb#W~MzAKTov zJ;@J(Dpna9$s4X&FARGd#`f%U0Ru%E!|Yuo_$VT|q$>g#uBF}c zgxne+HM#s(b7e<<%RQPJ(LIOiR54b8QX(6TBnp2xVAjJN&6SuDcDA{`r=~2$x_rez z^&a{I02)!d)uVTvQy^V#0k_8;kEdj;it)_z(gM%tCBFTOVPU_4BtSM^@doB-1bHe-!n$zTN_Fga)u+pb1dStVev6@fx=W!%*=S;GNj>w8QKVnL0GpM7?pb`0$-%&FRPIc8f@J#FN#XHb!L z7!*TN(RS$f+*P%X&343{`v6pJFO z4{|H9pnA?h2vADREm--dW31IT=5MVf9}=HRI>rn~!b~1}bx3I+?9-W8;KQ_Mw+IPt z4+vVt&6LPd`XzOq!Hy;l*AW|StwJ%wb+@x#;)IxOIR`0RkpzxrSObll-z|!kXl*rW zlR{@&mQSQaXAKTM>7#5@D@>-#YmRaamNBqu2B%MjRbfWXka=m}0tmtcz~oeXOdNA5 zcRAk`jQV_6^qBS7uPHYFWM`KycU53#v?gb&oYKvzmucVI9>J}!hSdTDu<&?#M|v7_ zZ*N^KlS@y9z|&2B6@fn4w~rQ%HcqUpiy%oiJt~jQO`M(OadJmDJU52Iec?jkV~1U= z22(oQ4>ezFpeMemB2E|EI7Q0KKh6Wtp@{a4uBNhX3=gDUnUk16;&>a@?)){rG<`=d z@I}q^E50~x{0?95(`OO4O~nDo_(YvhJ-@q#64mz;`2ZP3VP)IPb(@_g$I&#BG?OhA z{3#S6U!(6#4RIrn!v$d~B@JD0q6q+6i-?amM z!0P@U9$~69@PVB%tNV)%`&Ao@@K}zJpiDLEXg;`KlyH=L-yN@L^Y0YyRTQsj9EDZd zufHm~UdrEJ(pP63@QJuT-2FLODfz;fYu1wcl>BXbVV+#j!sv0d>q#9rY?ZZMt4%qj zg4Ad7$;*fyWxK#M4`m*YTbw|Wzt6E{w!h|>dCwm>cFA;<1S@0)Yk7&OK&!9~OO0z2 zYVuT<@}0e;`s2S|V&fK9v!tZ16U0EGz3^AE79%wF7dOzSz`>F%^$IqNzf5${{TDZT7 zVb@#LZ$dDt>13jCN?ShX)!dzKo+re8eU4GxpM#J{X%1mao>xoi5VP!KUTrClxjD0;b^-r=5IQH(9o-7I^8jZx$Z z$)JOtG*_gd+twUz^FphKp7b4)S5-pj^3Zwxhh4LH<(m%Yb$*MrMb>R@X^0;2Pl+lJYS1)e|N3juLM@Y_yf} zQX3sPqc{sWL<8q7Va@e(*?E+^7os3F(AJ?%F-|@>d*f>oHrxH=v4$O8_k{^h?hBgR zC;U-$a#Bdp9#^7q;?XC&fZh#hHjO$rhQsiCrg4_0-~igL8j+{@DkiV03n7A+Xx&Lq z8}vfP5QPISpW(Mf904%;qGz?-GYd2tMOKKV7c7G#N|n$Ndm zETz#iPIG$i7ZTz~Qdvs^ic92TC-%I5MD^O={qF};#W8TL_glni)S7#&v0X$&rTUu! z(IBq73}@!^3Mpm>rmHf^&48_rg@c*<4p$7N`hq6a0Jf~CBN-%3&cK4wPwjc+&G?*) zwPrL#zeQwAdbXp2yRb_Z>8|%cX02rOEmtItMrg~g9IyDn@w)4>azQkz`JCnwb*%&^^yDx=|-n@)93(+BxD$nxz&=G4f(c2{)C=>-kG* zAy%zXqtA|8nR!Pc!is$>t;MIGZMSqbcW{${71?->ObP*}mV>cSnA1D$&|<)f+@oD5jot6y z*;Xp25)<;lD_^V??3&wghX!SID<_Ar|Fk4+ko$ugy%48ABq?P)4;4X?{*(h|shS<( zCWj!4z%^GM4rZi{{>Vpnx)nb^pgKyR4HST>IKdd&%nRp{JX+mHa%o_CB=kp#A1T!6;G}?NSfJ zldnnd=JIITZB?ZmkXA@Mo?uyh5$c+W1&7ZXWP2GGVpU}2VlACTIRj!w2i&ns&A&&jp+n-^jO4pq zq4ZL%PfDZKE3d4MM5KMWgmd#X?r}Yfjh=d_B5lwm%(P2~yS7R~A%I)IlHDN;y0iLS zvuG}YmJBl}&1zzIJr(kETAkYsFcU5mH*PON9Bg4t*-e8A88n>!z>l&Mo!zZPm$z?O?bOZC6}A0{%!4dU z9^A60)4oagfRKB()vHGBG}136MI(>a$sh3Mj;{OCYHi}{@h65s+Xs#2oU`N$-@iF> zc;M&<1+#gDTjABTcjQqq;}IM1Z+>mTeP$`}aLG{g?EB+4D)^;p7N}zD{q^kivt{?P z3`_LBfk8sY@=Uti)QGG0T!bzi$!cFU4eyqoG2jB6uY$gY4IhQLcC>ABx0K9D+3(GJ zd+ed!ZdIb)F&R)}L%K3c2@sD2WJ_*^eM4i5i?F9sMg41imXi(&LHkn&SGeitt~@nk zaauL{x`w;ts-HND8wxd&H#o#$qkYiy4N3N$KPI%KKPCmEE@Dy(0nePUU%*NuzhEo5^5y|AR$Uwee3jyyl7ylF2S z8=@FFHAg!!s-8@3n_Gz%Eh}>q5Q2@T@c>Q@pJVrn8Kna-5kHyC!OhR$_YCnt!%r^M z@{?O>4bwi~nKbfzY0r#SYALd{68OrJo4*i9$zaEP3AHn?DC>N>Hmj_49`k?sdoe#e zAnLc6e>LTP4LY}r_T5sQ#4U_m?vxOLp4C3$%k``lDPU}Kw&)6Q@qSjsfAra5c9xlb zd$S_KP8pa9fA+~Qx+J=F0)Q+*ce$5J6WpBCeJh%KR9_jLMYZ; z5*IxUx#zq@A@MztFg*fKXuJ0excjqbLr4Y9RIlx_g3cwvT@o^)nXv z{NU@zZ+w0K;&1r+{5QTXGoJI+!(&~b;U{0E|H9Wc!=HSW>(LT={(HU>GW_Igi#p9` ziGP5v*Z#;?kw48>7C)Ny2=V`jubM``5=Y9! zxy}ZEPJMxfACm`j@Z{l1P3rn+89B_nkb6%D3s)5ted-eLrN*^&fQx%Q1Mg=7;-_R4 zcKTJaT6FX0b%L!y*Kl|y5XVbm04`tti^-%{@Gr-os?n`2@$9s==1_~5j$xwvjy3p? zYK~UU(+?`MwMSCh4B~zK=)NxE8osklx@xnuH1?dpJ^0GeL<5@f>`h_1HTt!gS!SHy(Y9zjeay_2qBLzq zD7ces+dFoz)kdoqrcd5m%Yb5jurBbRmrL5dV+w1kkYNn6AYmaeHayLi3|IV(ys78p zeNu%;D$2)@xAynsoy`B0ybWQSXs2m4l9n5;AAQbetgf~M4KaTj*DI;f^8SszFMz+Q zTU1{EX!Mg@huN6kt#-xb7mLAP$eLhAvoCjvq7#9y5rUWqHnmm!_|tW!$MP===BjWcEJqM>xG$U5D8p1qa4!R+c@Gckh3lf!cfh+q` zxa-?ut;{oj1)FeyMH!O zCjP9zY;m=S0UPZG?!v?YFIplk+q!qln1C zYnnunBB(D^>iru7im8Qte1%emv5GPf&|$Pa0KQ0IsOBdv>^wIsk>aT12C!G z8V2EjU!^Y~<@abl^7#Xr@hN{VeVhIwegA;w(!Yo1NT6PuSUA{VI! z&-e1v4!sF-2;vci&mw}tC10W0@BPR}5ETu1E>i-jE8;k7MCDF|>|M_(^Mb&|#jxTa+UCsDvqs8M!_oePAiFnG-N|RWz->wNP-=3&vqiB5TQw zLSKD+6O)aALAehqofFA|!#()7S-Ls$&XW=9!atJ{S=PTMBaZwr$q06Ie6z=b;`F_Z zHxCqJ6%S@CsDx)@Ks?}qkN|t;=5Ymf!v*Sgt(Qv4uo*fJb9{(LiKWN~sKVq=q1=uS zW};~$5B!dgNk{a4pkm7MQ9QGH(C^uSZzJKt&Bf%?dyeax9*x5%+7bBLy~qn(_rtql z(JvUzah-y}wUET0#I=LabB1UQ(0g{Fx$v`2$)wjF*DFRtPsGY3ledVFW1xqaB^0;p zB_a&qEKG4=IBe9PPLJH0j~-qZ+!kLFjmt5^a7wp4movk*T;&fYK|Zw^iP2dJHqH`U zv;pi@^Fl|7m~UKHh3l8TH!uPd*#YS23ieAjjKp|0b7OO?@XnY1}*ng zz5X$kwod)*Z}S!;H7om;XQK|@`rHlALWioZ{rHyM2SQ95Iv@#q{OXAy``=8b$-6<6 z50^ZvHVaKcuym3ql}V(BiT*H~hDm0a^X$&xhMH+(`{^CyGk~u3(5i=azhS)wV#9Yxo_XVUGGUW#1gLO0Y08!!P})kw%!r)+l(z)2!Z4=j~a7Uyle-FKx9wLRGHaUVeFo zXbAIV$1KwA+)KQLbH2dvJD6B=G0YhvICjfIiF_m@W4D$@jXJ>NVztO@dsy?f&2*VV z<|W>AxJck9-9An-JsX0u_(&+0~LpKJS;^|OxY zl3j)}L#$HQv%DG3^m3!w>5ftsy?5+(X4h)izUKke05Q`BC@?sO*6-pyb*3!t{Xoif>f&_!)nZI7fHN^K(Uj|Ari zdGhT9LpN_-S{o$|2fU{fetSGX{H%ksrOFPugX=lYQzBIYmNSyr;ac2*B98V)$??5k zO)hk7`gILag|JgTCcKPU;zB@wXD!h~uN+I~ezJ_`7p#rRlK>V0zpHm`4eHSBXJ5s; zb1@m1cu~XOk2ZGRLtTv`3<|fmw9Lwae2(j++M3$fn?=xf7hLGH)<8&fU+TTW_BK^s5TTS9fv zP^ouG)xzibLf#^l%y^KdwMEBqcYxq}N1@cHtz%1<sO~2$ z=odm~7A!r@Efy@W2=y>lFU+@D$L&*-ahq*p*JwTTNtDQ|N{22^*gB41x!n!#K0J!lMl<$3({sBw>dV`1r8NAPia zu$}yJ=F|MhIw;fkkof$LfXJMr;ljF%iW29EMgU`11^sIT9JUr?Py45NVE*_DBMlKo}zSY*`2z1 zIGpsFMDdmb^PF-!Oj`y8XVApvqWnkmwLBuX2Q#hsX_ zks@p-HN0#|71Ruw&E0$xg4hfP2-|!0No5rUIs@x(W*KSUBSlPvf#AS-A`Y?_^>cIxM@mNtG$^&8~#ZvRQY1?rp~u;9h4B`Q81)%r;FYakE{(np-(B;CP`tYm1}=^j$TDobY>-%w5Ct zHs3pzlMTxTWbujw$zKneLA~VV&c27wduEJlW~v~-cO>uks2yAr%I&nJjZGm25|tVj zoz}yvT?gi(?jmIkwc2!nN9BBh=#1~jqaTUwVw#*!xZI$VK^O!n3;52?_r;J@ymgU= zB9CR?Ny?O((|-s?<|Ze!IqizuDkf&eTZC34Xes6TujS=ix@;u!9W2`LMmB63QzkZN zaIy77S0ApA#y%p8=0TIj#E_hfS`WQ3faSRw6K;P(dhl-Am)lgCUN4Dz0;*IOcse5j z)5K{tXlOF;i0Sg+%BbPxMG}-;XyjrdOIOcW zMYfFV)~afW04 zmtBm-{!62B=2S7-u5^+4IvEf>dnNBm` zz1B^52_S|%)X}2c*U>^gxbUrPmpL*~D}Q2qjd6|RnyHe4t7yu2uFFHdy{7vDJ>F>> zHF0ns!-JQ=kKsOnRmx<8R}*$LJPKbhlEA10DGX7(KrN2ErP!g6G}c$YB;U91eQu)6 zdp9io3k%PzkcoU`CAS#w?H?dJOHx%rvFvA_DSFE zlfWKmLe-dPnt}bkE zS6tBakZ@zt{JvEB=w0883Be6MTpP)>n#bCvU1G*^MDxqc-#S6LuUy8C+tI8UFmebK z^1?l66x85EZ8CxoYvbIOfv*X)N6zBRs+SId`%q-&4k&YAUQP*jrM3=@$X4=QfiTHV zj3}5}RTJMDL{M`?CNASNW34l*^5jd79-1D|arm!=a(&;6j?0-rBq$3KQJJHxR{$IE zM4%u*UNYO%X)bD_(rZSWqR3?16#7`WnyAL5YBi*+DtdyTg7H)r{zALxbv7tDNM>uy z(c-wr3o)V2z!s%OuBbIk{|nNUV}V$3-1_;9fflvWhRYP_pfYIe20e%qoXB_QWHn1q zhwGh-r4MUA|I2E$KSh$kXJs-nfYF0NZ54N~E_ot-I2YqlC7(5|g!K%fa+72|Erbi= zYBC56u8(#=+b37>-QC98_U2#2b%LOutaX=1MLI-ac359o;MQfAHL3KN-Kw@ul8RhA z+c>m=7WOE0GYW0lbfL;#z_pC=7ZjP zSyiKBhyY&*2i06w>e#C=7ceT6MGMjtrc64LOJS3B<@9c)b5?z}3{VXSjYusokxLzo zOeOtl;(FrX;@=g3*@yKKU|bmjt^%Fq_L`-Jhxuto{EzCBKiM>3lj2JJ;%TmgwQzQs z2(>026FD#A(e;2xjx(n^ZGbP>tT$jLEFl1*%@u5LnC8*T1t}T%*55V$qLP=*SUgaA z8D}S>3)yM)_$uy8%puOT0_683OaZf_{QwWgl{%XD^OoXc5)D6rpSNSH?C<_`i3cW`R*_9_okgE0s|vAX81Wnhlgq(V8i*S;%n=!QMJ04HUS{` zUm{uTG}YRiCCXoN3udIA=JKKhGsMCE*#fNz1^Q6{9po^$ls8KIPtRo21vr+=J(yZ?Vyq*UGfbwaDc}KZHTPwqz@= zz*6~i1`TSI+|eY2AE=vHxk%!{H2caZd!D;UHzViSKB}Ws_5sew0C~g*+Rj!rEl8{5 zz-+gRwgki&^Id`y_O*cW2Vm?0c+9qUKYwh`YGk(PM0I0~m-11YQ(I-CD(kDYx#0T4 zuKOQhWV_#psn?6%C>Jb(+SYaX#MElB(?_-PrPf%<65JE%TR2u5t%C#@Y-g@Ys5@pE?I$Tun^*#_`@ul_1^71RUP{%WiK$uu+X#HtbJ(JiBsnkfd+kXK{U zu6w|2`;&Oev5-2bzBpdmSlwl0s~t<$T3Lg$1j(6>XWwRD;!+#_lCR}RR$&-w zIL^_OGFj)|K|1(QHK+7?J|H!IT{A}4O7`+rk(TJq4-u(QewLPC^`VkJVCq1ma}lBg zY_DT2>c7v+smrUmn5UZRNE*tSji7B(VC8r}zUk-=J?T=qC9gcTT+0j&lO1nOp$VxG zRymHNcAO7=aA^8!JbL3<4WXmqyGFbKBBdbdr-x92&6cNeJCC&NQuiE5!Tn6AtH9g6 zODChe9`Q>m*Roxb+wk=LH*z9)0Q;6(k7)D0~d0A;+hg5OIJ$QK7C0fFLXC~H80t}lfvKGup@b9 zVlzOnf`!>rJ4dA5D(W=?V}#N637DzVn_IGYwugaQb$pK!03S$B@}hb4Jo*`b_sghH-#7){e~o#hBIv?V za;v5(>NS%|tW1e|P+^;oN`LZ>IuyPbxp$kIX;=?*E6kR8_u;H9!-g8tjqw(l{L8dg zL}upa+?Z~-!=h~G981C&t4txeB<5Mw7yqFbvp#q@ zCq2$XJ+9Vni_61Sg@iJD(JW*WHOoBa#5b47HYhJC{kg<4uIk3v%N1yrtz^Y%sC68* zbTxIo5k$^zKyiyuCfnZdIjnK1-P@FH>Yztk-()67%_4QSzvtUvw(#^4_6~2JOJu4` za(`Mkna1601@ojzFn*`bk;6+!gl(68cyfE_VzQaDd~j-Nv?=>H1dSk{S`5d|V8Aiy zvYw>1y|r4Yj65`rLW6H}mEq zpZ6b~%{wj3mP>sp#=i*^AM|rQbDEH;Fi=r-e++cEZOK{UKI>M%Um)DIkwp#PKk>ik zA6|J$89N88kRsr-WAo0w!BwvXa;JzM^ja3KK+r)L>tN+ecdtl*3s!+J%4!T&XIt7K3HU+Sf%D#h>#9oxk9_N#zv`k9ym5g zyEJh4E%RIE$QR|A1wNPDvt8i8cD~L)`@!j+8frmi{=xbFJOlwh&YutI-g3!UA;;zK zTx%DCo*m8v&b@sl#2h>ozGwP~My=&Z<_N_Sf9j6w8MVY6Bjw1#cZ8ERj@1;E*~Z1I z9fYTs1=eT_0(Q!1rR>2|BempVCjl#3;}3Cbb|Hfl%vW<7Is7&>jKZ39Y10uaA>|Y^4`%pjyJx(? zBg-NHwCF?HLQ32#4l`Ce>32MiY>b5)cIg{-jc$)KS4Ypw@AA*heCD_3R3OiGSJGwx zuP{BL71`7@>t4@71A^#pFXSA*b6^d$&wLvvOr1YYtsSRKZTHa=;V`B(A62>LLe!Mv zucrthPE^|!G8z_eMgZo<9wuqExbBvi18pLAR$0TUg>$6Lw8PZOD_$-gf@dmt1_z=A z3s>3DRH|LpGbe(1Ro&Fjol_%Rr0~Z!`U{2&gI3Ev=OeHVd72lFR$ZFaf?;>TJFfAs z=D0KB>=kwFV5g3x(izO{N`y@k9w33!Qj>}*x!#_YSM`UFx;4+32@?|F#;?YDviM6U z^lcC2fI?D$*vnf%9bCI$ck2kDVHn$BUFJE&H#v{!Pj5pzslu*x8VTrEr45*oGW#7q zWmZDvHtf04!#g?i?OGUxSZ=D80!KfO>8?rPb0iu<>W9GzfN0CS=385-*%FXDfxh#) zU~B1}irN)nR2JB`Ku3MnXj`JBy-2GB2>WDAd%i;kL>GHWFx@HZ{@saN&kjl5@z zR6I%Z9(+Q|A$dyOhSR0fS1A_tLh`k3v&NpYs@F(}r<>mAHH$OiQ|emF4_JwmR$c&t ziDi7BT*0iP@(=z-nLv&to{Z~m`+j9hun_fO<9ducgOG6a=0T}`?_)DMBAVdiiVzVus@$`W_sc@DYkqMtkU!ooa^fTed_ z+n&KX(l|tX9)5={U*wkHyzKIu;!-7^AkOg(H&>m3y#;eRIzqdx$4k#>14hfNQW)s3 zW!CD^u%aMa3I>=boW=ABgX5gL4_A$kK4Qorwk#eP7L|lw_ zMxQ}cRqi!`p14ucEP#jFnHWmQR>TE%^I%ckjbZi5K|vEatybbJd+2PHOt;GmIxfCB ze7MoJox|P5*(4Q~tT>MY;l7!}SY$5q+4=z#iQ%)Qf}KESsgex7h--gCZJdp)2v-Gy9uQ-tR?eIDp`@ z95H{ZiMtas&o%LhM%pogg@&;*^p!UABc#ZBM#+-F!^ESG%?=ZD{dZn)8N-x_{Ap=` zjfyJeW&*rzKaot4G8R&#Dcqh^!#2L?6vYM`DjQT>jjVjKK$e=V>|s;F+P=%3B+L(1 z&hTMha2|_kl+uLgY8@=d2FD72J)TuCtm)$zhY>D|X&RKaAIyq_qnqCS}JgoYJf2 z-O5}N9E?D=oetFtR3%j18|}#$(pAOQ$jDCebLMn?K5LrESXhcP>sg?=i+zz1e(zh zlymFE$S!0>fy-^GA5Pg$XR|j3X=D0|Dm(!@vs_)$-x~BrR9eN+Z%*0Fs_7?p<;6}f z`Mg-meKE5=5V%LFI5ES)NJFH?Puv*>Z%yZ zniIGq?5$+%=EyzB(DBP!M}o-%7jXfFhi78TnvE{qJCFm+RGBz16_MUT5cdtWwS&wv z3p;9$i>=N$Qa2qtq#7X}QKE#WDNzJzM;ExEOSKk#cQ%X9wE7$>2!wDjyRTA%F$Zm~ zi}y-ZmoYR$iobJ?v8{8jj1;MoZ?}zEF+b1SY}@h%6y8~Z`L7P&^hLQG@0;0d5%_vI zz?BleIvbU*C$!-WWcS{6RwfZjKkkn*C?(IGJ2;~&3XRJ$V(NOr>NuEPSQ#j_BtKy# zR6DDH`)$x;Ck7O3+SCm91kfCjpen205V)_P^7v%0zYfqKm@4g{396YjFvj+bnLETn zI&%1Ycy%bX!c-L-eQ4)g&iNpVHvC09(RE4@BQeaF>1`liX6y)?4lkp*(xS_^h*&E>ZvbFmv#Y}A%eM0NM4X#$- z7_-?!K7CwxKjrnyI65#+RVcYtwH8*qMEkSil^C<}s7#5xqH(PmYk|3yPxd!ZQ5E2^ z3ZCeJ=!2Y9wyqfhYsmEc;B}S;qbBO66WHyimIuN$)$ZU2Pe;m~O^$_tX?L9w!q+D& z9u~9>A4CWgeUYA83vGYb87geoa@&n>Vy%7u^V(52IRm$pUU1(e_lMK2cgKo7Mo4kC z3ci!dw##o*w7!XR*Nwv=tB}~Y7QGUd&{wIV@?!%vkSAc;2Nm+Ab_t!3yBp0=&guoAw7 zP|%z`(p^kHLqbAa$6pH*0t8Nm|L^k z@J_GnND6haqO<;aS-y(rlF{Ml4`jw)g7^?FotX}7nZ_r?_%T_@-*OvXk?k%H3Wph6>@+lv$<;zLs0QEte53;LnXp%iZPIlo`z0sGoMv3Ngl+d7mx3Rzc0JNBINg3m-PM6M+kuRm5?Fp zGj8UWn4ue*eYBg54hrU;aZmgBCY)JT|83f3XQ0reB9jo=`d5q+Xc-UeqQ7%LqG)fd zBYydL=jRWleBHH{MactdmaGq3@&z690WA3fZ1JGcJWJo=$D-!ezS_|lf=hXV3fjdq zw_9a8?P+pJKaB`kj=6TvPg4%{=L~uo=km?5N?d)eq{_2YyoWLtgdiPq5$;Sijd9!l zBk>u%n%+7I&2Nq@v>n7IzKp%g?UIspgx24A_0}b>xs%^j2$i!LhR(I03N#8BjK(FM z>#<3z=6KL=a-$d($#lQYjcHHZhA+fKr`dhki@&oS%)?K{%v2s*oYW(N;gPLs&x0L5z;Y6hm@!YNQ@o` zqk9{pHyV_b7T89NP`VLtAnAkOU);a@xsT^Qp5t>IJGOtf&#v=zp6B~>T?2c|5s!BT zxbFV%8lUa@zi7N>!T->B2k3ukd}SBDrS@;dz0Tq>SH~@1^B@GR=}0`uT4Qsl8x9_r zKMt88*Wf%FnF#Rw(tXf9TJg>%ck0o23Jjs!{R;PESfDfD`ar9g{U%22pzQyWT-H3( zDxr6%all}wEcFu(pL+OeTkh|fEd}`5n}B`hM00Pz&UW&n9CBkv1CD{llSgyGFC&hG z2sQ9?`<5lk5x!N#QG4SLJ}dek3GwM%47gj+3UG&F(uQJNSj$rtxSM$8$(x|Tg?S6p z{q@v*swx@xY%9xYZeD0_*4nP>)(K?h`oSN$y%IFu|1Y_{CdaoQ4y}D#BVe)2<<`;q z!g|)s5_nLWh#a8q^5_sIxmSbPmMwr))OnkP)h|6<+@9oho|{6QOrDuV?+VU1emHB$ z3dEb1)gn2MgIKV^d`42O=!J6?thkSgw4ax-$;fh0Q@`$4FMZo`&d)XNz(+?fC``QX z8eW>sCPhJsqeDpdiP4?&QsI%u9M7uKqFNdc6R|9H5_eczJhJkRT#I?Jem$pvDbm5#e_3{LIj9_aN-)pt`x<(_}d3i9I7 z^!#}W9&Mh;MBcQKQe|}5m&O25nE{|Xys8#(%bEA;TG)J zTJJEDEc3~^)VmoZ`eE>Qgn-KIL6~I*ZgXJJ{0R5md$m-;d&4zC(X4hMexbtaPEq|? z_PkYlEd~4bl@hVn**dOqvh_UIy)0=embUo&>4mU`y#c+zZb#KeO>7ZuLAq-LWre#k zi?qj2_HCBN7qZEZ?Q;EdcYn?nnOBx=2XS+DHe;mPfa87OObobE1KS%t=_uj8wxzE; z;u4-y+o=5jHg3K#%8RQc@S717yzq=JF2)EnVqM_e=imr=eC;rZ++NpoqG zl_`7tPt;0S38;XhP+pPwbwkN)xI0MeplABF(2(gB_pzW#Hn#ZTkqj!>Zn=-(!4U43 z-Rre%XQB7JY)wDRX0qD^Jx|>c8yTWoF_BHQj49iNZp`43atGKfpg(jFB(^JcnqJvwENQ#i=aCAu)K5D=2_{z4PW06wiT*bFdaQVQa zmopOooK=?QSh10Un)d!5x7^N{aYJ3*wdB{lHSDQraL?-{L*qbdQzGwwm*vT(Ke7zA z{Ff{dt>|P+UU*)Z+=y%w;BnE&OfD&s1dd4qy%QrP z)D*qhOC)(F1bF)A3yO#p3GcfspN=*%UPr#^DseN==jr4zl#S8P-Usxx8qC&Lo>|$a zatGWjzUwAtL#N12_GNQaIF@&`@r_AZvYG6mv9EvS^NiHiUB?w)fGa1o1r>ecbqX1J zSX%FGW5AGWvTdbO0+Bs6Vd2$FZb~*Qb(mEda0xcHB@+3LIp&Hy##chpR_F#d#O@ISQff%= zsBV|M^pmh{BHX}~{e>lnxnsVMPhF&jHMyhcHN-Sq+GNX~rl;|3gVo_Wz`R+jrGYLg z^S2XB<{6>!?tEV2@-#bLp70Y3;Q6wC>_fduCRk-4)%JdF0<6rzdvj#rq{kGD{ec9| zVsqx{7Uw)vX8W9eG?hQa7UpdDaftKF;IS6e1Q}Cn_h$hkbeZjk+s@ZhfX+Rvis{7l ze9-OV7;oPdXEFbhHl}rB=#)X2_`rMaM(Q?X#MnG!d;5H6z=oZ|7p(k&ryHO zxr@jDBHWv({~_Gnz5glP{*m^=mC7Hz3w7o;6!b&7zS*GD-Tp(k&FmKzM<$M>`UE&* zNn);d%GYw0a6xYBSUS1=-RJHzRB0+=+%nXo#y2_m@|-P`vqr^_FkHF%Y09Qx%bUEXlO_y9rv1&9mrdof?dX~$=# zSyM=~P-tna3cw{@5qKHE0BvomTLK_*q(?R4+P zQxVLP(#rPa#ru}pNMiM|D9gO%)656QUQ!3;)q43RWXD8>vLoX%?XxR}`BD^A_8Q)h%o74Ns_L^iu^_gcfL%U&;nB z9CA;U^D$48$gLbOLqaTfB&lGU25U|x^vVWOBm769_9DEDnLu!)TCZc{bo_g;$|mE9 z*ZrxUM8q&hydK}bEcS4b*OMA+Gme-PTHA1u(cA`Y^&s@M)Cj_bQh$vK2`m9Ke9gtZYJbw95ZZ541i1pMxT zN$ac%Vw8SwMXh93hO?`NHI#vFrH1{bE16#ICo8k&*~SbU9443ouUQmM=z_z`U2hmF z$E81^O6HF9$jrXmM=vP0e$yaexFx=aJ+*a+^iZ5N`#)L8XF&KTf^ph*i*7(VZTioDvXl>@&)Z5(vOr9V< z_`P^*8=**ElcCc(y+DE_C0JX2B^-agI?wQ9HYe~5JY~4dyE+TFdn(4&ALlq}d)ZY^ zK?D2S1}Wzzjrn_>6Fy1?pY#Q!u!$>g z;}lzguHVc?X6FZ(yr|xXrjZdOuc_8OWK96-2~yOY>i#a2Lbon;)C&swPUV z*B#yyJ!xRa4<3p#UINoSFpbPluUb>N=~tr=)u3rHBujZ@72TL)_Td!n`#pG;Ymf*1 zPnBbxQ`VdtGKR5Ru{vOrAV8Ps{QZt*CwVMl6o~`br2dy@U+jY09lWxU3A7@05)#7oiqS;&(duxYZ{vZ47ZY91UHn-?&b2CVYE4BNPQkV zrIGhkncp8MV#TuKp;SLv5^{05JdOO*;a7Z8?%|q%mED|=AIvRcM`JR*!iHqNOrIXI z<+k>(zGSjYA|>Lvl>x`@MF^USv7Ts?LbPftOvEgG&UDkm$eWnGrY63qBXE!xfB0`D9~>3}4rWZux7*><0+Dv~IGo zcv0*4#;ASfeO%2WqiWRe*{_vkd#x-4;4OobnU1`oPFCOFIHt4P4bf?P3+@RL_<;Y*w?e@v zkKK=>Rwo<}NgF?ueTko_TuOhHqLT&l8O{QgR*XM&n=i!)axpSw31$Xp3 z#v7(0g*;Y`8^AoW-{rHR?XcpDhm}I)h@l*3rUMv|YkFT!S|HLNnJgp)bmp@Pc6K<_ zY6AD+ekC?O3P)^+dK1%C1rQ3Y)9!7r&5eY)yqFVKJS zfQ;@*7M6nSFY&?(TiEqCUg-Rd7iIq)FX+Ml4KEzM#W0`$124EN{@_JCS1v65-*~|_ z|9{~{>)VjQkz4XApBw3L_R{7zedUr(;J5z{{b`t#9Y5p$F$^PyaX^!25TZQvno1|Q zpJnqBv(ZpQyraIZyyEYdL!bvG!_{%hd$@Z$vIZ)fEtj4`xhFU*M>faD?^VOgNvF3d z9eo*Iyf(`y|Ic1dr1c0K6_ofy&JRW zqcKZ#{aN8X`W9VeATStx@w$ufCaKxh`dayF-E$AYo#k76HtK1#$DjMJD@+|$??00G z?)%-*O~*W}*`bku7)jg|ys!oy>?g`Rg`;8ZOf1jS?+P=&8uY^6luzsoR z(*4)C%|%cCasM&9f?0w8a{phEk!SyO|CWt^+<)NT?*Gq>+DY#p_n&23zH<0)_djDq zyxl~vxZ&4s;WoTOAKM*IaiVL-q^IGiBtRbMv&{nU3#FWsY*X>Q)Q1{WAot(@i}{ ziU*HW#K&$hy~xWg%&pgdHZmScBr5(JA+m%wAQG5e=|)ZI_>w)<-QXYFKg)l<`Eym% zBFtxxHi$GtViTcu)je~bTGh~U1BPV01*JZxre3inj~{z`tSqZ&?iaTqNkwq|gA73X zKgbZ!VlRSuWr~bXaz(e&5aRGM9~K_hyk!GqYcjw9{|*M!7pr21n2qx*oi;_oXmD*1 z(B+`|Ar~ef&@Qk7te~VZ<4x1_MTDbXiT!!(Wp6%tQCyE-Dpq`Sn&4ZD&^_6#R z@$^?2b*R&Ji9_EI8E{Hr+D;|Sf+vBl{;ZrHWn)Dkg;}1{6$=`CiNPvQ*R%NHfMEQf zXi@IFTH#()Hqr=D7uhM!y5Gn%WToIAWGR?+=*K z5E5BS+%ZEbqRUMlD18PE#1HM1?^n4RDw&mG@;YMFC5^S7vdUz4BNVfd_Xst?1Ax_L zq{gAkjr8M*s_wGj3qU}RFCoUm+L3w}#9ZW{9Xb5TH)6NnAy!L)e37oh9 z>TW?fRX|Z=NK%O1Kg)_+NE*T@d#)v8eo{ZY1dRE7oF7se`am~48~&Z>(mVll1smD~ zRV3KcPrBXn{H+^4_I}YB4rXcUEDf?@tp^~UO@hvCmIqj zc|zyGX2$mBzj;D5@Nb?tQvB~c!TI&Scw(DM)RNyR_WzeBTHF4?6Kr+=<_Vct@08&` zqlXf?A%;#@t-XwaTNwKmg_-#e?rz$D>H^F3f42A*jInXL6_WboZHyVuE^`U6_~J#T zWFq=#TU9<7I`Wy*NLdgIETjM|Hzy%%Ei~!5tRQ$MB2$mO4j*$4L#V9ntQ88C2a-dl>^xbZr!M5K6R#Sf2;pRzwHXG4iudJVDN!W-qmJ zyqE`yDr%aoTn-EHe*`_ZN~q94KFlV40RSxH& zK5=Rf4W&!Nc!?5MRy?B1_VPH-LnarfG%v>oZfFh(B>jU$X3CK02nt^PY zZ+Os)I<33=>6$+^|8x$%6qr%(>A5Mkf8-lW)fPjH_0Y}Vx}{!|Z6kY@dQV-CaE4B7 zB_Qh>Wy-v{60ce^>m0C^^T$KzSEgFi<3kN%`m4}DJ+Oq*$iE5J^qst`4$PCj+*FTq|NT3h?QKe~lrSe=g#|ncA<_$jkW(uvqKI4{OCo z<{xY(xdSf8(M)PXG=E%Xe zxNmk8SxEiM%^LllA9XeGihs|zd4Z+sEd0VhNw?TI!atJL6PJ9N*ckfj#`4}kK@WXRtg!ENq0h~FTHD|xguIm z3e{q%IBCQ+J_|KHgb@c&z8Pit+75}*eE0mu@`h7N6WrlesXg*Wmm6`;A4J_$4RB|g zmDe-gj?9c&h)6DX+1S#o)PX(t0qM_^CLPnL+W`?%F+98dp`rfU$LED8$~P+MWfKmY z;^y@pfPq<7AS6CJ%Q2j(`5+ ziW&f_04DftLIsuqQ>;aJ*H}(1MgP_C^`)i4Ihh>!Cin*JLpS1V-+BZmQsMZxL>gAK zJ$wiq80i=fpq$RZScBGn^pn5#6W16rpB$dX*+;t}t^C@V0Hgc_gHj1`o6G(6Cw}5z z0EM(cA+TKgAtMivYi}*=3Cb@@`UZc5`C)2~p;-Z>e0M|3oMLy`a1LPm!}^y%hM_v` z5oJbBc~e&+ajl;&Ej}wXWs6nBf{+=Q)G9+P zx>M&*2G&I+Hb%HcWd<9)Y=xk-mt!m7C~X)@0j(Y=#Zh!XUs9)m-0??RZtKV$6FLOU zaIq*o$AI90v?c=27;SZHENHWGn&g&$61I&|E90a0v|33;e@<0XYDozVd6n=HxYR=_IXjnXf~7)k{R%PaP<+Ln-H>{$Sa>;i&B5%-DnY*j8U+| zAA-o_xM5!<(hwMY^98P!7vTonV1Qv8yurWGRaAqHnC!{H9t?W$bP|)s*Qs2DE+pVr z4*r76^tnFi=C&I4+o}e7f?UMw*z4P}*a97r>pyoHGqZAHUV>Q$(1`8BM+F&P97@Hu zuqKvv^=#cB)q0r;oVsN9>`Rv;r(EAov?$Ln)f2N`N6>aT`~~P`t=~4pmK5`{zKIEM z42ZEp8VL|xMsje3Vj2+-(SW^Xo`MqwR^TUz>GUz0)LGiK#e}UY6 zbE6-0T4YVLA!6(ser^+E!A2#5Qx}$4KpH6m|G~GV;jR-jyj<0jBBRs3D73n!3ZuF8Ud=d2CdOF^<))fR zjZrDFCA^*uV$=x)F!mS~Gi4u%7a#qCKIt)dRz}}rwoG5c37ZJiuNxONX(XRWJwY76 z%$R5QUFN<2vMAg2m|HNb62?KQVpST zD9f?o6)L5+U$st{HmMV2$)q(=Fv5U&BeboPN8;1FP7k_;YK~ z0&7=&Rpg65Uo)?H=NHFLW3q^wHzx0-T?M$@z;e4?9|#e|yt5#LpfvN#s%thS@*OZ| zP}fBn!i1}Yx}RTOW(~eV-%Q80`f(B2hAMq(T7$G$*8&G(qJU!5*LnmS6K zp0V4V$-*XCv9|=%;-p4+#ieW6dPDwI-%BF4qs?^_uV!!cZ(_$uyx1#Z%c~ z6nu^&NZ=}DO}oUJpVV9UJLAKHwxy??t~O~7F0lUmgH(2vtA0ehbQLJe`X?L$rokUPAQ6WIfJ=?!?$r#!QO zCv|gm_Nlq*$S|!LxWkI~RK6McMo#Bo|NAsu;>K;G{MXE|4Hbt5jc9Z;CM{RZ4Ftw+ z{(_aKEYC#{eJ{W8h`bu2FELFKuHvYJJo=oIHnM%N>IxgF<07va3rG9jxC3%2FFr7| zFkPrl8xEGlk7W}70~^g# zthVMi!J(w++RUN&lZ@8tsLJL!%)ESC4#j$FF+B7x*lnn)Rfz3&tk}!o_90L<*hCrC z^!MsA;7I~Jb5vpmh79e`0Dxz_+RoJxD*VUdA0q}&g{M~g0f8t@Tv;_9Bp*aDuBYFH ziqmKPm92)pl-Me#xrEOr zg<}#mO=zD+Oq@!ZISsUure7XjmW{mIAo9)UcxL*U2?2wW3rvJESFGKnSXhD&5E1tEKOwh7Up;R;dFq3h<+(V;Kku4qdf15V-5DTV3v zlwjhcTAat-pORSKmw5?qU-L~X-2FLFpGLFhab)g90O)gh{JnyRn0|iVPCMHB+?p*x z!#A8~I)KfOgyh0P59+T7>3GvV7GU>v1U)p-WRye)YF#O;2Qw0qt>{TESiR$~hW)M( zvpI$fisjCbko;b-h&zWRdd8gs37%!DTA9$soFM%?c?m-mno|>~b=-NdgZzxvxQW{7 zr^$AF|BU@@f8^m|C1%5gL>oWlz1uMvCRynNy=oUGFG-nJX>=qeLnjmpCV3KSe{PLz zYh_agSQ-$Hw9hHpBQ+4H?uiEhbW0|x2cXR%lECLoi8r;aae?J3-{WruC>`?%&X6p` zbMMYJup#oj7vt47*}PPZ!o{5H*rwj;wLOC$J=$=8Ts!_jra&QL(i8bsrXU$|E9ZlE zZOdT*X5_ZMzk*~6S*Bl+FQ}LZA(IRJ=jl;CJBGVMB-Sz^s^LVUF5`&C!kqPccV>aW zUCx)P^>wE8<7T51rR>W(tXHjNv^aV9U7`l+&$vHJYt^LjScUqrdp|g71>OuuX0GdC z*wddn^DN3nMP>5Me9;2c?vw(xP@O!Ha}cy@;ju^j|el{&Lg4Ec1ebO3Rh!sf|J1!RwVDLeCN2 z0*2*Ft<9GccI?NqIc@MH`@k{DH{UlZ=g_awRrC z>;D30N2Db{971YTl&pe5*~R>|7LKEyNDxf>G{bfO+z;5 z{rwtHzWhAoss^t+%qR0*Md+NX={NV|c6hC=#L|&#j2VRw<%mT)iRJ?a zR}6a;dC;28)d0xndyi^4m%CVl#{~G&7X@q?A6-B8Fcah1i?cFL7C%f#9r@r(U2k+S zpGoHV`gq#Z?PIafbEk}H+FOYQra5FmRQ7USOyM&2MyR+vbg~k z^)+20fNZ`zA)&%_QMyrn_2Vl;Lhpbv50~lOl)Bgst{@;}Qz?~!O{zcT>L1;XX+KxZm}!~&w#K+zkL2`;PpvJI zc7U65h6!c7nc=w*vjkR4s_5IKh6251A7t2Q@|suo^4wsGi2xOUDGH6&K#1?l#aOv2 z#&r7-*+1AW>e~k^h}5MyqRSETKo4mprwexFjr1u5_J!STqlA^Q8{-e4#Y^lMgHhdX z-kX95{p~xMjrCgMSOa8l|82=`_o5@pDQZw`Kxk!dVji&Gm~On_`uY#5=iP11_Tluu zw`BTkxogSvj+MF>=1Kx?lt|dZ2qLDw)cGqX`aRhi0;QHPGRo7GWFXRD$(3|#pZ>lk z4iXm{-945qB515Y*O~pb3mC<{kpfkounL~wGr(( zDnshz)c;N=Si+c!n-906p-lsOGCsADUuiz1<6a=oJEKu$m-3@$6F@&^&XZNco;?;) zbLx{6@4tOv6n|&()a+S{r%X+1PTl7&LAML7>?^!AJauY@sL_yWn>tSf!Hs}}P=p{`m4 zYC(ro^W{n!XWe_4#7Hb74 z3=#S6OAbzc+iXbShjc(W0zLBAJH&jRuO~H9!P8gL665xaj~+NtQ-g<~wmh}*HvSDO zX$}PchMH^u&xM;4q3-yq2`#{W(KrnN3raE8GSb|k)|~Z$HHPh40y<)b=t_n` zN(jKhP*S}4XM-Zkby>D(Low6b*B>94qenB6%;-~Mc3XyY^o=`+{U99I7NRKx~Q#%5sSZLazc1Tx#m2b`t~=5kWPH7 zr@r{c@m~lRp;>-B8T^PATQ^-zw+G@Z1^VATrjOfYpR?|YV`=1hj)Ni6q(u4YDav0p zV{dmxX<+W(!IelHd?-{JPaEp6RT%2eQBiNg0{BFTKrQx?YeDu;^q67-hpGKx2# zwx8nA$_7Eu1AAcIXYSO;Lkq(nE56LPhciZ1FhlGY_io@w#>;|o(M(L% zkMy#flZ?!bW=~Ll#%&+PoVha0!!!vRC4AQ=^)TI$BH~dJuD}f2tGLK}uhKgsu9e*T zUS?`ZNOXd{7oHlt&iAY>ofC%8qaS(-s>$GWZZ_TGL8JAGYfd?N{w@(y$J;){D>-Xc%5xc zCLv^{jSJKsoR3Ix*vpiP&fxQI3^j~jnR_rWd6qm}n>G|?LPAx?L-PJ1Rb9-Bs0w{> zg?p-pDbP7J!3zxa42}cUT2J$Y6J~-k>-PIHq(jSY;rQM_@A~*i+;p1SSdpZz2cQa7 zO5YE;gTVesd}m}_prO4&?;092HWvxs<^5UVdX@V~G4`rha)ngCI`Znd1eYQ(sYWS5hTN=B^Qqi_*S z@8x+!5U8KT=f3Q+Z8oxcSqR$pdeVWqmg_jVdhN`ygb0$#(Om$gweZ?8gvEEN3xh{bNWk9cIg8 zr0nX)kjk(tob%iFOlJ8S);FdjWkKw5eF1`|$9s^B5WDN{%Rj3B>b=9j=UM)Vw7!XU zMT;iVqfs6CoTfbEBYVpsfWS9)E+!#2bU`X4o4%pzg<5_+< zaD<%zXpp4sMkol>hM4F;I8|+FuPW;@)$f{uCZQ2jw=1vdPLX0;-;`%Q)?Wt8h9^7b zi;rZjjMVYesPqX)2$bavX>Mj2N^fL6bkv%0F5y+Fb z?XQ*G9@p%}#X%?3%c2gIA&mv}>liR37Zow}vIUR&OAmMNscG9VBz$|tj?5`C%IWHQ zzEihA)f#8y&66xOUT8dTxL>ZG%et`~CJQP5JO+zVI5gGv_3cLc%0jR;Z{C(B-HRZ- zt;N`(U)_XZ8KJwq=)z82e)g+J7GmVfS5UdKHhkrqNzsgTeg=I&6nqmeGQU;HBKMQ-UDSQq_Y@$8J%(hK z)WF85)kL}Nb-kANU9pTpEJ5HaRtmmQ-j??i15YWdwyhLIFs%0XM8pX4;EBh5Ryx(& z>eY+-{Q3dMMd^BrTG2AgAIH9bx~INk)v6O>fH(A9Ou6;Fhs!C3Nm3qO ziA=pQ^NZpRdJsY`$S-Ef=xLMW2J^Df?~71YG4Ql`OB#!n;0-w8A~wEi(eq&Vw5Y5p zXSF1x>)&-6(KB2gce^pJPtf8eh4b%J0jdgNtdF69+R&l*3n`L#P+U_-L(eC16=OMd zxNLO9_D}s7TRoF+JIb7x0kTMygLiCk@3eJXa~5u~;oTj=nhP+?G-K%T2P&?^-yes2 z;^Yc&9`F(sl++j5$eX` zOu+kBoz4ba+f|ZxWv#y*vzjIBh2%4MT)w+lKmQT(HY!$O{d4DaCc&ol?|)fS{i^wt zu3Vst=uW@>n(y7wtbPl5JLNCb2iKRsP^RgAQ0TS>bN>(E0}zq9WYNCkPGEJZX?~Hw+6`tHi@6`hDqeCmj5R{x*CY6Q z!DU1CiMrO!*UHJFRWci{N_#ee1oohBu1eM4-W(-Kwa7U5PZ*IU@% zbVj+e=_47xsK@bp=kh=@J%>u+C|rX>!z$gQgI5?5Nny?ppe{Kb#s%T3E~*&{!9IkEFZq)^w--@4s-G^3@)Jf$TxI z0h7<30|rgXyfea^kuh6t0%KMS7aVA_@jio@c8YI{7Y^Y&)>w<~VdY{_m|Sb+PQkQvJ7AwVz=Sopq04n6}2vl3b&6p)I&IOpKD! zT2f|ple7C1qm!gdAz#+)x2+palAoKs{2!f*{qs}Mu)6_~++w!;1z~Z6Ga%?L_0zq| zPuF$gAf#FM<4Ch8q-L&CKh@<}jRW~P9~c>6roZQ?=sP8YQ-Tt6oS*HRocm?ByLDA- zE!i#Dbr#jWfi%3IiX)}AsC}P->g^DZbpTED$+Jvy%ueEMF0 zP@>3@=JF})3H<>H%Wy&>IpqD`&B7~-xm_g!4(M6yHf9mi3o;OD7prt@rdu z-(#RaRe66&6A5b1PJSBk#6hEmm0IMeo?U>|yTrizr*K5>jc&nmLZ5HZ-8V!=k@LB2 zLcjsLeqpa3_>0!wNaAWX4}K1@X~sC5;Y;1dMpomP&&<=We(V<$K|^%b+J3c!QRw|* znr_`}Cd`t$Zpt3Uqcr-g)W5qwO{9A}#^A=jSlrT6IS*<6Y4p5~>=SSZZHlo28`KJl zWv$GqG4P((cbwcV!t%MPl2d|pO0JYeCPYPt^b_Q>vZjnO8hT4)0KCvKzLX^l3Fw9n@Fy=_2`>fJ-NNFHF*82lu>V8Geq5C^@CZw+#JR+)UkQQ&AYwQL9 zye`q;rO2&VqoT-!yMBUa}ZnWGF3J0iT(&u&=KrAnw9^Ism#484rRrW}rP>mM?wjx{-eRW*TzeLt{S zd}T45x{W!7rf&fPd%UNmXX=O=9nw2yxQPX0O|Ei_*sr-K+|DZ2UxLI`_cfnM7SEt1 zt@-R<$Q6~B#8T8DE5G9H@m({aI(=jhuTRr;pE#u1z)CubGK0tY-)tF+i5!$oB4D#l zONTautsg$yJWRYFHyGE-d&U{tb_H=S{rVM50eu?{lXqTv~8Ix87m^wp8Zsk->HoS;7T&Mh;W zIg1*OK7v6`yOTSc%D^&u$IWGE?zLGSlVjbNsQ^ceZ46jYs`J-bQ<}RfaFkyP|J1}t z+sG{MW1gP-<(|%NvoS@J*Yq`E>28Iw z(FkuQ5Ogwb2J+g%Hq-*W>^vYft#$(rd0YVJw~>+Y#b$t3 z5{5>Q1&y8=fH^m(b6N)x5v-En^MFLGQI~&Z`Ljo$VD~z`Ct?Rq4)UVz@rVCL1T9ht+ZD<@eWi{gvYD- z6zMmQxNqT&e%=qvNGgdHD~_$M7Of97B!9gx z@(je5-ga#nYlHEtFbUm`v|~G!_Bn|I##9Od*3ptqHNOqpM+Pzm_$zs*Ap+(S0^}3nd~VT4UT>C&kmR(J+Uv$-0mLkC{)gtZcU%ZrvOn9OKZM zdWqU`9>akhFI2}9KVBe($m)qph8a?ORMMJhCLUID!EEtVi}Uq_H- zj4C}Pw70loWS89|tjcph?S)HJ@Qw_+T-PTBlZHu+E{dDO3v7UM+6X!(eb=ZA$M#B# zXNK-GBO!Uyvb;{|&}pj2Q;LYFCuRi2)C0SEs8kx);y~lC58f56YyjbMfR+)LSQ=FZ z-HKvtCVk1#x%LhazmXrqHzOyms5O)i$>b`bd4$fdoL%;0c?(y3%4<9!v1G<(Q_f_V z)NDsAyMrEhC^B@b>SeOJWpeo~?1h4$e=vE5sj4^aqpBueSHH$}i;LRF^N1do}otaqW>XSjRu+MxU=$3hr z7UcmXV?4Q0p|o8-CBFeZ(ID0ycW_tdU>^780U{{DP@m1HTY_r#f$D4O6cEf@t*crW zMdh9l>UyXtV_%CnWeGa*LxO=mm<7j-<`qebdH~qgs?p{!(?l5KaA=M`#CedzSnu%k zRH3K7l>Ahm)`+=qf|om(uvj*m4Xrwu;#SghdTw!opNs~_S||q*`PGqrU^3V`Z_c!I z_-y7uGbyH7icIiw|Ix}_w48_kz#E8%&gnad2dh`J>mn?~{KASJ7wmy-*EaJL8B8*g z87GH|+CdVq+pF+2n%?2FI6+4a?IDr%Wu zji>02;_ADUWE$xs$t=e;3;YF*;_4Zvrm!Zr>#6|JMT@@n&9Km&S$EOe&G8wk)MA#O z(|?(>2sWKQG2rJD-52wdDyjn1DKKf$YVe(GO3-NZrpqMP9-3;DO44bY-*oo#>K6Cs zFD9MMrRy^cN6N@&u2GrEu~h_sPoT~920a5l`AS!maZ8BHYYA=IV#fO# zo!m-e`&lvL87^u9vn_j?Q?FGf{DaWntP~o%yv@fyfHixtJc#BJDYU_I_s1qI@JWeI zq;SbFSjlHTTo_$Yy^$sCm+n?B+=^Ey*^{zsT3vmC>Wkw`kQL7;*pv8uRuA8X5;P6;R^abDp41KBwNv9Hx;OV zWj&NHkgu=<7i&a#jjL>DjHuxMvBN!Iq=86=`_{ncT+3zq0dk}Hlg~>fS^$-=O3HrH zHme$x$EO_3Oj&L{jNJA$z-mnC@M$&JLhhxFNApH3i=~a5>Nv@wmwz`m$(R}?^WcK7xRJ1aCN^}oX=845uW%d;E z)25=ig3_06@v-HtAs3A)L6D}JPpsdeUwMMxG))9k)=qA)XdBR)cjIJt%^dsrJy^A! zUJG4_K_5bmoe>uNiGwX&tL+kp`StD`PDOSije>at9*|;rDfs>IMehb4(R8WF@)Mi| z_c7ktF#GDb>pesfzlnk2m7rtOugWUdRp~DG*~ZsSRY*|;82`X0t!F3#l3#6pnEy~8 zU#Ad17|kOtx*Y%YCm^k4=2c4yG^^rr+z-Q60BV!{L8yN8T4tZxL~^5(%|Q%)|K^z= zMMG`XfHO{QvkV_2xf4|Ato(oYddr|j zx3^Ds@1|*J+-cn1H8_pCyEkqD8h6;Zy9No3yIbS#?iQeNch?O2|GqP4=FF*6`LOa- zDyiqglT~Zo*S&t1?dXH#M?5r;TvZMrq3nI+ldtQXQ6I$N59i}3EaI7Id)JyYKJri5 zvuK|pKs{6aM!X(d5%9Anw~UNuxdi99AqaV4*e`9}_K&RTkbyOp4Vq(Z0$F^ET|h4> z9i0iUje4^I&`R;=Abq^(Q*Ul)S?#iQ82&=22Ct%}nj3d&$>Yd7aWj4hVyj9s{^;3O zg0dcwZGjIE*d`K@T2%u;4w-GR`HlT%m|7_FxhQ=|0|=~I;|Qx`v_F`P9-_w8Ab?Yq zPs258Sft%lX|G0yl8(;2oMjEFl%5rN5qScxG;B%AXQ3y~DtV^zl?^LQoFhdWGL>d! z&LSG_$!cmE>jku2P~FcydmUmOGvs=L;c1<%hU$*{PW&qv3p<+1K@*sJD5rG-Phs;$0qsO26eU1HRx zrVViaU24gycf>~CmAA#6S73&nxjC3EejJ%5yR+KJdQORtVtK5t;)?E$;px7iYrbgT zl62U00w04S>}~${0lMz9no~t${&-25XuE>dtY}%fS4Ac0BK;I{!Rk-JLM&Vk8#*w6G@2l?Q(+D`C|O~&vO+k7OlC= z>|3`??ph-TJ$Xm^K(z$>U`P7IZ2sdXwyc=>&A=TXWd@|T!}FXP=o9nDmeP_&8m3b+ zag4tu+m-ht(zWwEp3b%)u0HYAL5q==DRbCNVJ^K%TGk?sC{dhSu|WIXUFQrE@^c~P zF0-olziO8BIxssWyB}o}>u603gN4@qtrAK@>5vzb_4v-6Bywa*6cs0o1U;z+-AZ<< zKryWB)8j6&WULFCkr=<#?-DOnobODOFIeaTKJtHOfCIxcMI!FF)MH5=VDeJ z(5h20s}kMnET2KUKuU7H8xK%rKF(||pV)%NLhpKM&viW)*uNnAQ3%U#E10>K%qjp5 zmVTX-#bC@zp}hW3QQ0{(k0F&m7hd~_pozn_9UB?UC^aD z(7PhDr8JDAmX+P`@wVb<{K_`4ElKm=@+Kr3ScN>aF2mUp^5P81F2HtoSkJbyf|pe> ziq+yiB;2D-P&jtQf#g$~e|n&uVL1u(#u|Wpw+Y>13;9XZ2%O{kjr=q%{q2I*_D6d@ zWMsUFQ$|(syZT*RVr##S=s1Uwj`SR`AYrW{EIDRE4%;zOxqtYJ61{mFAcQ@V27BUo z4n~Q7#e4R$U^Y~lOo`q@!CKXL$X2%Y0ZW4wK|?C!P4=DotDOUVh%SZ1lQj+DTArHlvZ% zyQCdNgWAagR+v%EV)Zq{1-_8gr~sRq0`6-?7Q(&M{NA?ZJ8quh-xktz%UI@ea}xo1 z*qSIas*=aeY8b_6Me;I}8-w}741$=WS+GVSNS4ne(izHyAUTIIiG)^yh-Mew^GFkG zHLZHScI=}nBdJx>33e^*){j)H+K-&=e@Z)?A(|!M@WxJT0Sx>8>>UoYQeB?w&NfOF zKw34QBwBM)r5b1R%aUY>dorFIKiwU|oLWlK zn*86&G2c)zpOTvo0KCED>szpi`-V*0!lrmrZp>QWsI{L%V(XbFxy((o?z!jBT zzWNZSs-Y>b#8gi?wv01nXAK*5&~zAP?rA^Qyg%TqcRS%>ucm0spwM^;Y3kl?VKNv` zstY)15)^3OYC)c|JK2ml;5MiG(_*I~d-FX|MUofYfvN4@WnfHe?@QQ5lK3qJLgiBx@vA!%k4u9^NBCs!e9nuurc&(sg z(PBUGa(;p!i0IptkkjBc^H7dQ6%&}vwNh;?WqBbfnq`3B;qyg<<)rkbWvH_aL>TQM z2H2N{6cYwFxa>B8>1{T(>%HmK;C0n$tn{VIe3ViLSIu(2ZBY+ykY%zmVk;Z5{qZ7u ztYGT%BJM@fd{7QC0nK*RklGN~V~}F!;(g!fTi#>L)yhN;>;=-fqyAEcLiWfsI1A5+ z7jx{}>i#l@PMzO_zX_zpJbEZ<{B_gEF>Sme3p5Dre%#(*iOB&g5GEK|R^1f3GlR{& z2AA78$B*XO4W7Oh$wR~oe96Js0xO_z93VZKA^;ES&7S~=7|B%c9n&iubUQHU9H^oX zWveq%b0m73eH?bwYN1FxGr-?&6L?B5y@*uTt$%xBpoWp#jXhe)``+(9^_np5;>?KY zXJa&+bsy~>7_3syr&E8ZVRNL>tLP1l+A+e9+twHZhda1Suqzo@GP2w9O%+T0{aTFm zUEyxeEv3kgl|AQ?Ld`7C80FNs;-i%@;KUwA>MhUj%qoD(pz9v|3Te**je=!LDvUN!qf^jPff;vsMyErbB0BQt^`ewhkJ7(8F{c%j9ASBC1Mo?MznEm z*RO6L2j^Ww-@ivn)J1?oG!_Lg-A5tZQXDfCSzuilkQzICaeZ` zi4e@3Ae#h*S&T#ouEO-yaMpx4zT{v(2og`n+KZ)azg*YVw7SP=kkKNZz$XBfYs$t=#-RcOzq?^xX#3iEN?i zG=MsQG@3ak;ik~aX8#l8tX16EcQZ3g24(P7x8u}!gq5$tzlvRN=!eWPl|?u9=$7;} zRsSFY>pH+LRDS8X(IJYMVmSO)9-~*mp&W{CHn*$LdtC;P5StRA7TM>EQr(B*_Y`#^ z^TBi@&#Jv)>O0C=C%Bj`ueqy2;DmWT|E0LUiPApEI<7eO1eC{xo?|~HPHWW&cR;>m zu>*2cphcw+KHRtvZhfdffs_1I%ZQ!u>j13fu+x7%PLThH!E6mf{oWPZ3S_d9F*c5d zAjNql!tZ+inCHopAQ&NUSRy}C(GV({&0B*KsE;)|%Xnzs|Byj*^Q&YviL`WZ8eJxx zCoda|C<#z6S?n~Lzg` zyn9zQs2L^SiL+co_d$=HQv;EZcyh-9Uw)xDp>l~Yqk1F8Rq>4|%5A230-okFR*2Vl zH;#@!pA&O%6(C{77V%EkFIAcOlOVZzi)Ebwr$rh$bdX$UtRZ|T=7HX~rk}>RJ;E~_c?-vJ0D&^*$B*mf$gTP}}IRKm?t)o{S_f#^@s6lF8H zSF!VNT`y^tqIB7UC=B6PxCz>Nly6QddYT}#C!phnSFG>(Hx4#04AVlh8MBQRd|3r1 ziBa*CdPXtknvuWJMO8#-do%93((*^2{y5ncsR{gi%iQ~m|2`XLraMd9HYqP55wXD9 zDhK?`p|iQPhV^ksXuw{2q>_7=fKjth;AI?Ne^fQ)E#nbMEIIm+1b1hn{~vDko52tN z@zCHhuI!P_bfdzA^6!e3maM7xU%7bFCA2GtW}4|5Cq#aa%O%$Y3M-f#>0$`tTC~0I zrG&O$UdawG-sNmmMGNXZmP8#>^In>gaqGTmwDRXHux{_mj+=T26L^V0$0ABJc~lk zr5#_&?|>XtrS#3?S0_=_;PJJ!7vW(G760vvc~Carj@%3;(Xf6dldx-oZ|Z!(QZiI+ z2e^wG?6c|dFn9|ADNLECxtv)E{Vg~YhJ5O(Ln7&>6r1>ufg8e9b7sfoKm(^{x?&4)z|fYfS@SX(#AvVqAM>s1T;GM8}i zd$QU$mp!^*yGs|rfT`QzsB&wq2sE~M<*E-lpg574%xi2;y=^Q!ej<*9s+JK7qo3u` z-8L`eW06oa_fDjx1ihVD=8pwXxWf!BrU<{UtWO2AKb;mYg6LApNTY-yJ2cuK)Ei+lMz!P*ZHSnWkZdJ#!dLVrf2^Q&KNkopp>>>>ZA|t)9k{ zD>r*|Uo$6>CSLJEwdi_gi|D5Lj$7yTsvmy;TAnvx0ZWYx^O1Tff$~|da_|)5QfwTn z*T=!Y`J03}ps{s3nP(DG{L2d#@VZ+c9AcJtK8x)zt$A1p~MHjO7BH!Epgom1kZ zOkPDh>z@a|%ioAa=t+qEEk1uKb^=(7XQ=A|kjWgAB+kOeN~IlYWbSCumI~Y9K5D7E2q5dA){s(%ze1F(=+KwwgM;^;kItUkk5FIa<))!V6)-yWav{DH18Wo@cL9 za|EmV9XBOZH+EB3NE>Ma$dsHMVi~dhck%vyS0xo!FyQNN158MZg* zl`#S*svc0I)#fnbn)>!V700|7c)~=cTDn}U61KEi1+8yWMx6q=SQ%r`7&Y2bJyl=4|?_>F;e?UNT)>CtZdfrkPaS=95F2 zb%{?sR)aZ{(QPk-9lkp}9&1X0^f-9TvNUZGf*CZ6yX9jlX15*pMIj80Pps~pp1$;w zVv_@f$xX`>A_h4j?1VAt62X1^Q`paW!vJF(|jzo(|!*Q;K*U3U{i0P%Vyg_~ZUUyEkGoED^@#){ePWs>R zut35=nDQx9Ac19J?wUk>GHuVXUISB=OU*_Oo>w&1jC!{;tqDxwl)F}&y+A{SL=^V_HABu2l-w__mixer3-J;L5jy>%!57Nl06Zm z)%Eu6aYS|t=cJnxXpN2I<(cya(}E27i1>BBiQoblV!}2GXfnS=7YT!{vu8MsG_n)u76*(6TgQ3b z8%2~<#Jx>09b>pgv<4>ti?CjmZ7_2NkrF@5IE4*osGK!>#zRJ6xb4e+d|owc4@#ro zMVI2S@TVVC_Fw`HS=^KvA#Tro-JPYw8L)B3$O$!vtC)_Ms6O5EeYqY+c9(!Vatx8| z+^sP5bib+IWq2C3_bIF!d0&-M<#<0bJ46jkm6~Kmnz+P6$CbG;8`=Hb8KB5)&R`1W z#q{Pzi5t*aZ|0OsrOlm;OtqpkV215m>mG{&j^a#ZyjX$S3=^npx2#qOkq7~-N7-%o zx(YrONH#&mg+kVQLlPEYRx<@BB!G0+ue#>mIP`PI-qf4u8!rJ@i;lbA1xAG+fcq(C zvOH^|FzzrxoyTr=6)&S8$)>2Ii;ttP080eOncmQN%EHfMV^BX6U@4L(uyz9j zkV!y7J*}6zH)RmW_1FM?6WdIYLDfBd(%VFM2{1ojHhucK??Y;OkW!J%Yw1(RQ#FC< zc>>EzUOeBgC$V{R*qv_3mv>pA!+GaCb~%K3Fc$LN|7>$K_IhiWFqpZdqQnZ$98D(p z6y0)gYbNGWUdq`fQnd}|@eSRGv3hF;NHOF|xa%RlT{Tkd|IPjhqtump3AfSw&z|3n z2?}bd)bUBY7n`4eJc*BY>Olr#wY+KyhZF}5+qoMvbJ{oF9V?|Q-VTSXNAU1iEjHcC z-N9%tU+rQJzGtM*@x%{$&!;??9s9w*xP3yVVe@6=CR>M8Yh^c817bYnqhgvyDj^Wn zHa^kC_{M!F#1+w|jFC!jr$DbhMTD0l{i13`XD>d_<)sU+xCcpdEUtK4$It0wkdziC*lrutoV$jV`DO{ba&{UJ#NA4+Ml}cM$8%CaiO~H z(Hn@rbPhqtRsl3`>-8l%Y|63&S)h74dha$C14~-oPdyrMzF~OxCw47VklrXU)C1_y z0LsV@CCwUzi|I?6CS2zF2|x<$9)KS}p{DI*a%IAL9aj71F$2o2<>CSCy@E?jy5ccy z*(Gk^Mq6?Q(Enaq6!;}Kv?-N0^UVm*i(3UIwm(6jcRKuG$W@Gsf`KC!{xXaFTiSxh z^kBSVdjIai?`CS3`FGdLgz(fUBaW19&T~~3v)*q$Ex&1(t$g7t5q}In#lyNMb#4uE zOMSX4cE+y3)OS&dEl=aEaraywEY8FP)J$oIYmO(nysRS3F%o{vHKd#qSj3{d8Ep6j zrFxC8n}xyN2E9-+*WV#j?TmzFMp1}i8FSmcx%&-GKi`$+vv6=?=jk_|3a@B|o+C5& z(|3+~Ne?mzu_BB61v-q3u-Wdavn710JIRZ1n(M<$2Rc}`S8dpIfdo+=e!ctdCH_o| zggVeze`|qgmebEXDzHn%)oIid3G|+3ujfW!x-+M~J{Qelt4YB`9sdRgpL?3Hi?Jl+ zqcA;Y%G~j+`Xf zqt^s(us&Q)ZeY)l$KVuhs8*cHVlRCG5hBKj0PRtV!_};#q9UK0&*?L$s3JMfJDAI@ zRt$RY#41duaV0F>F(n!49(b>6H9uf@xk)+3c`>>OtiO`rcvrgmYqL|dr`nQ#lscNY-5DwZ(YSc*A-wa1#{cc?S7doO_%3Gwt1MJbSL)fG%!J`;$TTjwhIF zjbZy{e#Gv#;y?L)Em-KYc%8%cEPABeek~b{fj)J0#*7RplfS1Vho>tY^@j~1TKm7* z-9$$ba8kyqrs2QN4wH>Vxt_mZNHt4=`Hj?DqFn5>Tgefr1dp z#}L}oAZ?X)P<(Lj)B64E#@Huq?YmFQ-s-+C2)T0ZyG3t9adq)6pt(eDp6VFGa@j(* z2X&8@w&}>@PUDnsAw6JP~f>kFAnD`xYv;3oq@ODck}39YLxy@INn^=1WNwE z3}-Iu7M9-0fxKjM*X$2{x`FmzES)Z3w;}9-`W#p@&&F<1CttG=Gic~T@8S@F^7J`5>fPFs}zs^QbqZfLG# zW?a=P2)u8i2`S8ns-_ds$s?4DgZFq%(+aaS4jp1Q?uRgEN|sOQZzme>6S$eYe>OMS&{0B z270TL!J0^GY2mUs$VzVyv!^>AGj+O31;~lRUqO-G`g`gb6v&?r%H?2CtcPuUd`JPK z;Tb|tqe!Yejbi1wKcM4~L5+D&Yah-!xSq(JY1GkYh!8)(Ld}v~XvE1U;0k7qHi2RL zrS~-rx#rXkNzH|Laa6d1(O7bV@=53bOXso34W(WXWqf!)b(4siq)$hN!P#>B zDWtU`x*B10@MOQE&`3Wwe1`v<>2J~Ra{r)BWBgy2go^{l284XegCFw_j|UG`XeH#+%&+=iYmL0|Ps)qI8DMi+8cF0#ouSVseT(M(MM_7I+s360^(W@esEh43 z1Rq?z7u_3^ru#cj+szHr6*oxS0y!zW;Fp>3fn*tMPg^Ava;Fi+RpHRoF;h%|B&X*VHjHjTFEx_gts8 zJvSFjq>$LzR{8L=_#JES->lE1?VEc@k3OrU&%*r@Ks7hc|1C_CF)+aF$$BxGV9cXZ z^WiHPR5E7Gkd-wdY^)pn=MxDlO4 zZ%N?#DTkIt$lPgSHC1t$3|Fc96AxG%ZnJ1>S2X<=+60lzNFR(Wd#ziEqqb#pcsuGD zwGEWkG2=MvxySr9nGk0dD5UERVb6rw#1H}LBO-9=1LIM#JpK0($&yBNT7EwcU0cUt z$S7S6caXRb5y2;;X#>iIW%lJ{E!WE$d}jXGXW;l%>6{g?W!rI{y&QH`HM!Fcb$GvY zy2FIDuM3Jo*Ym77X^N=4Cj!V2X?a=%8h*y(VC1`=AYR#x1!)#0f&b(KpN;_INx2jm zjsb>T<6DgL{ph^AUy_*E{e!9B3qQ`gw_c#vgyldy9=9NxKl~K!E=`6WzDzD>=;4Ng zMTkL!HzO_?hSI8GJeUafCdRfyLg2WKlsL_$JE-@sw2_4CRhK_bf3i)IIF%ko+3BVm zU<@=HvPGYW@W37gfYjC6;rgAR9}a;)xyq7S4c2fUa>?);^Xc$P<#_AaxK;UB@iaUP zvjm30!<)YJz4jtakP6HwVa5q#ld9S;PPt`OJWrml6&c|9pRRmvt9%+-tDsV@M?EjjG(D48 z(CB2YPw+O=2oXj2prc!#LL)5dG*sQz;lljnAG`<4;uFi(P9f^pwt3D)!&(cEc6TE- zoiZN_eSa1IN0!2S^;hE_KkhRu)V%r2Yp< zHTr2i;$#*EiK`PYiDsqn8L4w8b05_d`KC!yN>|cC`HoQ?2%VMz;4#slqBqt9jY__rV&s5~Tx1E< z7D^rbSr)hTz?mfeYDWdxFv-d^g2jRR4;dwvSC~p_^xNO&@?6YQwi7fe7=~BWMVdN< z=mvyrzI5r<^JxS4FF%=Txf|nQ5qVDfirZ>O}1)6MW)!&5^D)VS5#$3#; z$5OPdd$~a2aGw*YRS6r)|AoHIpXNf~I=S$5&ST;v=y&11u4FR>JK)yev*5e!wdAiv z_H(B+wyh!HN9rWGZdOL&r55mZ#rF7RUZ_n5)L^%A7qkmnbtyw>S|F>F-{9r@S*D-cUpX?)7g2v29K z7^atFt#8yUl%|Vi@gI{opNlBev^+MFd(?q3smXpYKZi2vF*m32!#v9;fKXj{h1wC` zv|-ji&P)Q52VSh<><4h@I!WCNp^R3%L+q{ve+}0M7kGwcAz zfL|>ZSx*w|`^l_PzaT5oSj@@McT2)dzu?r-O&Iepd^HEIcN4D#^fSA|3&Jmc5r_MM zzw;B+y#XL@jkSEb9+$4Wc79sw-?+SM!#^)EvSQkD zrBJ3RI|LZy(p#N@y?1&bS$|o%gV{*{vT6B+7L>6&j4iffgfOkGQa;fSAQ}m9Fc{DL z&R{k=ALFpRA#!{P_5DFKz8({v85Hv-D!~V0dU#X{EQmw^hH!YOI$T>U9=bRtZjf?D z>YuMf$^Yudt?fGqRt(&)()mEDxs^SPWjP2bF2JvQq^FSL_lRkw7-u;bzz0y3i&0Dc zKXB^c?FUX(v+g%NJUdII2#L?T&#s^9#6=V=x@ zsJMLk<;+@HAg{KQEpd%-aRVzM#a5N-?W!_JZ;Ll#NlZ$@Rmd$?5ye=kB zNVdr%6Q=?%t6rodUJ&f#JJ5t3oAr)Y#}%w7s@3Kl*E+RZekSDcn%;gIWxG& z>?A#9Npd2NPpjo4WvY=031iCV!pBnP9^LfV*^*;NrhP7&jHZWb6rDN zp}&;`6NY~zX=u8QlpsbH5#=vujbvYGOjY&*BuQElcWK~c-{xF$M zIcVbq)CFTJ>0@0BpwFb-GzR)I4EH;-`f?>;;QOq0k~I@%d2ieXWdgchug74j+YIUosXCu1K1)scE;3_70{jso3k zTWVA-lGpTqFUxCN8)>~;^ycewV`_TKQjlvq%IQ&|&#%u8@=@hKf}^)VN}?ERWDyOe z(oVvZAa3k`pAYt+5hM#Sj`X!_`rG*i%rT28!d!`AE|;j=vb&rYy&E;YZ5kz z+W(J(Nr+!~V9_?^Fcxni_fRf0?R&$P$hlGR2#LQP4X+qgWRDY-mORNK$gTMd^^ z`?k&){Kld6S>WHJ)CN9Etscn=|2~M)1QBLUYV6h&3H@%;r_#W5p_e0Cv0akbu59 zx&FDA==7?%?&ujuSS~vFBS9eA7`v1~|9Umo{Mpb!d`P?6O^N5N>=`5Sv81=`&gQB5 zddY5Y1Gm!Kyzud+Ny+`@x%``+-(^)e2^Hi8mAT2=x)!$*R3D%PhtW)d{V%1q=il*T zG*5`S=NPgs{-D(Tj(I)0{r+^e>q_El_OW&YbQcM635H7t_FPNU)%kv0|H0E$B;Tg| zY_dUH?Ty2EsG7x2UuK<}ymGScU)#E#aKof>xwQYB@^&gIi9>0~oe1p#S=GeSBl<-9 zj7k6D({d!g%IDnDl9E)!AdP#eZ$B5r&yA6$UJ+dh)x3H3GqemYR$(OkgtC+}j&~2@>YZ+sl0EV0Aj{Up z|BFxaMlmwq%-MDcG{YT?=^ReCHM1qfO7=4p+Fmc@7H*+TN4Ny|yzF;ORF33N?G_?Q!2Ge0C3brxY4~iB3bip=9ncNUam5TnF<<`?@pdrJ0+r%nqD!mb zsmlx%`iWnJYj!6Z_?gA*?y-d~?FWmgtw-K+-V0kr)Q`fY^z6)Ympu*&0SDK^&vgym zjO#b&ZzR%Di&H#&hQVm zH2k<$l6`)Ie;{373(SZ18R6&fB@xWT>1F_7i?_Z=YMx&|_DFD#Gu$Z;7y9zKTjCGr z+}>jp+*4lWXF=4cz|Wnu4OTzaWDWG#>1tK5?pxk;fF?1 zU0J#izlw;ecF8$3PYfZp9eOE_mt1*z+3hBEhuf}Oao7Z6@9G6RQdsYC>D_ULdRoXz zUCyAm2@C9bd!8Q8gC=lVlSb^Le>XR|sdn^NgmU*|UA!1V09Y{ksQ4HgUOY+ysO2ku% z7@eWaEnSTeC}8-V+sWVl_noI(C$|ajvqOnPo5uFmSNe`wx#u?nsOukf)#qSo;7<0G z^04ea+>VhyAIJGQ!G~jY=Z~H6*D`Ihz#cH2+Z|XtshU|T;VGjL5R!lAY%9dZ4j2PP zUe!B0(iJkfIV&$&<|0W^Sj>#PTP4PLmn(I&QRF-)cfl0$IqVYe`A_-CTGJ1vy?5)@ z^TU@H^AfI(aTuvGVfH6g)Fh!lY7~=S_wqG%XzV{2O|EAAzaX`cAN?8L*^0fzN7R~< zaEj{LPO)m)2gR0cjLVTNy}wX{IxeVU1F|zIEV*4Fbw+Knas$9>E~ft`)*r)cXu}7< zj#AW}Z_|Yy1OR##6&4#gb)>NyV|+@%snB0eo$2QhbcUue<Mf0g>PL$yIRJXsO zQ7p0c8@8ss@uZX`z}{`Xt+2YkF6ez9C*51e3-RxOc*wZRehH4KZ5Y$JLJZ z#i%{RIwJuui$6V~1V)5moe^;q#0r}HuR$HBax%yhpYx6~ibbrM8Gg+UxQ;j0daUZH zL<^#qqGV0z{dd>#U}KJ9+Jj^VDal83eqGauk88~;gjpb+%W#e9Jp2LWjOKnijrcTZ z?$bfwd!v@w8|J54zKGFxL57)XRe{PyHEdC^_jwo)hO;#5ujw^kZ6{(#q4RhFLn z4|y<}hyD9n_t%}ip0jCfc|o_oMKg_@G^^X&p0uu0e9Qrzsw-yxXB4G)P#5-FIFT_5 z8bGMUV|4gXn`fPw)0Z359f|*m&y{xc)|+qfNL56$v6*J1y`~XEn*-*USCW~)T<$Gg z4+T_b3w<+nyx(~2e>ey~5H@GH>*%z>DarZHjxwc{RXyKS%>SIULT5nP@>jDE*n^0cKaj{07eW@-s0NAmy%*ZQ8ifOhIs3|2Qvp zb&Vy*W+Yg^axzfdv*`fN@M1BpAAcpT5VPewO5kMww^6mz$zB}q_r>O3zaJp}du_i! zUXtNuPbvoUNxU3J#h?fA4KI<{;U~!}&6x)QKGveNSXu#F9ECR@_LHmrCnvILqnGBo zd>k4pg>_Y&9`%605s404aaktRklDxo8l`ioKC=5zcy;%X8gSTj?1OW!HUH9 zcWq!VhHqkp4gPgr{#0<^JsA`O&EdM=Cqp8$Mi1$ROK)LAir+ctOi424hM(wK|wEeBy6QJw9~g?2-5B zT~rY~ayz+6bKs6s+^Vlf1w4C1@U-bmu+krVVYeGiep}ysjnac_-ay9xbt0MGtzpw! zX(&>U1}4kPI6#C$i83GXZIMv$(d3Exm!fAq{fDAcxBeGJ|4zAxE*7b_nWAPDHOH7b zl<^rknJS|?Vds2m4y)v9tNxw>CS>nMLMEzNYNM`tS%L=B?W}kyg;&rZ>%qxR&>u=k zB2lUPxd6Xq^Zr-66cf3`aENQSCOFjFuomXoPW!?xugJ#6~_tKGrGo4o}IfR`oLIEpi!5s`PWH2!G?Jl(WgzNVQw zcq^h_vJt1Us&SM)S3KM3SJ9s(l((9|hQOg5ZX>0;;6_J2{$0gfceAy*e6+?%KE)XN z(F|fuhKSq`?O+i?I^dHC)jglbHm|Xw>_|V92xis*&H=a3E&E%pxG{~zmeII_k^g^( zlh~RNTP&#Qk%;4qT$i!Q`v`7xlGMC|IaNlav;;)497;k4gx8z9|Ky~yii$6;a*BC1 zuuWAzoC`AibGzx7MJN?B7~4gE@o^OKv+QZvC^?E%ZpAyZ{Lt>oer) zceaLUxho!vl4!{;gt5nH?knejJeBzv3JK%hjBOIAF(rKm^HvGE+jqG!N^u(S(s)E? zBYH<5qcErAISj;#NUPU0o82MAeys)bM0umC&T;GTYZ+@)n-lBYa1buZFA`pDY|51_p6w>!iJO0n~N_0v*9{eM~ndO^!k7Oy!@%APL>Avc!1 z{;AFlYboBt_y<-LdUnH=Wkd3*f~nW6etf%d1pKK^J1m;`RDyT5bU6=;2c@XU{w9_a zd_{~(;d(jCRf3!}96RH#ucd5y6ECYr9Nr(>bC3mNGZtGNOvkzIBwzoXoxD&e##MEJ z_-8jOx(_qGN$>mf+CCm`GovD-h%~aFwVe-|zi9>fh;NRdT%(Dh_RkH8R&GXvo1-`4 zud2W;>;TbU^axlJOpQVRd%J+tS(z7;GY8Zx|5M8{y*VUh4OWvSI(kVjgV8C@j4Qi> zmDj)H@Bz!)juX<`wm8i9RSo+N9;$eV-pSxpp|~H$4suV?1Dvfm$<6sxCqw2M_L20- z%K^VcbUW`O^)+x&vzY+AOwC$Ixb>q>8$8Q1l%wYV-E`0z^nWxR>@MT4zVnQ$FQI4e zP7^!-PD6WNBjN4*aN$5sV_ry z4(NMZsJqU+8$N%chf?|BxjhUbH(UwbGMnd?)WP9_u@3AqYNVn2hyBTyPgU?U1K!T9 zT?C80u%)OwPJC!a_AN~ z$RVC7A;rIwr+7X2(KZ`<%Jx=VCwAOFxS36xyb54}kEh zWzW&HYG-QAjn2y0rpS%;IvtN~3LBb2D7+q}cgie0WjIkYG{(+N(~)7k5r>_@SY0aE z2nor3$(v8Z=@E4k#-(CO#4_tRZ4~#5xS!@taZP6Jj0)>Z0uAAWGf zgW#FoJjrof>pNtrQn-8_)%P6pWewiv3@StMo#L1MXD`|tV^{7yoyAt^=ZX$!!$*(EIz2MT(r?equBZSxANfR_K=Wet5L&~4 zL1HVQOLGe&*N=csq8IKg<0wgpF4d3jDE{wI3$y(=4<&Gf@H!Sqta_qbSw>;4^}U<& zB2(L`b#%*r7jQltALn3T^gvHF$NPLX_rub+=BsySqrY{h-W{Dfc9|?eIl^{04|!}j z#dbPg^6m{S6>qliBH{>;07xD-SGPTx=e2t_)|hxvjo z7QeqLUChXD>^;#c-y{8a7>rrszNZ-4okk6CM}C$atu42Yp&8X}nP z2Dgsg=s%bix1G~WMKC#DmkZ2MUREc)FZASNcJfYetW1Wy)Qy))@69(BIz)ba_ns;* zu{x^w-TO#$%VWk*N2wqVH35?y`#Pvn?daSTjc~HgC7zT>0*{15ItY}&l7YY>y)}>0 z;q=*!)0spyk2i5rP%`f-jcN0L_FD8`s@#%dj$OeHqWZ*z>!WYt?swt3h?9HE&v5IN z-U8?k&^6=sNisxX;_91aGJ&L#UI@OH_(v?Y^7`LxlE(p~XI7 ze#-xYuXg~lZ3&`8Teof7wr|_EZQIsu+qP}nw$0nN?dkX4%>Og-<4-+~=;;^xArZi;Q-EWKg-0@l_Au*3y4mGyU9+*!CG54P%jKgvi5J?=QazF0+gq0R zCvEdr-D6DEAI;UbmS?qQlIH@ZaL5p+-R7->wSzhHi9xTTNvWmHJh#KGsh;{B-8P+K zBRfHi$w}e{(MkUn_UBj@lfJkgT2!*e?nho?(}`A{Z*!gCki_7Ukr8bJ-Fu1GvTj^#BaeKSnl4_vy`dr3 zLut<~xcW17C_$;Dxm?HeS}Ek1SjDM42qT3hNpEL1hRZT)nZt}~m@GXY<1cOqsSo9q zv6m`iFD=El?}q2+x_F~CZ}e4V!Sy|}F3AA3YHD!3+}yc?guBD{((0@9bQ8(z0*iJo z#jPQqC2T(yn5(JKj5G!m3WJ1no=;I75vE?phIWScWxZl811P~z^?RCp0a2QZvk zu7aQ0Xn+ZvpXp(TGW|t(!21=4^hEUAL4M@^L#e#qre+An@Xn+bWhFfeT#0H%lx`XV z(86-DHEeZ&$z=DL(<8MOtQVX{cX@gWE>|M#4;0vZ;^kTnHHECuX4n4zOt%_ z&jkc(Ne(cieP)?_;Pwmqnayyu5=G^FwTd#qAYeYyXWLwfUc4R>)&XMl;VX(q8}+W! z(BT=)%>H)0SHjoup_j*W*?fc7eOIus4|mx&4Ds|3SmG$(G-ZMliO0qt+hJ+}0{e3p z9P9uoue<^*dJe);QJr49Ul!GD+-hS4Fv}xrRuR=`eYilfDINax^g#$x90Y=pG8oYW zC2sGb>)&D^?1)FFsx3LV=WKv{l5_TnrZ&up9Q6RrBwMDT)rz(-a+C95?t}Pt{6!|XFL>(_&H_sYM|04f=Y9KCZafZoP6#y zmwZ$lW6^(8%WK%Ge$KSVG@+EdWz&KW6iXcK7IOk+I%P&+RmQ~(_Xx6hy>BFV%VrBm z>Mw9N-oEkYz)A=K&30&C)u6nEQ~e9!2fHQQiWo(LBUCai=Y^E4PdrNjESfKko(o|b z1_xg&nqty+oMQNPT}yfrRnrGA11b-m$ZvR~OgF%I3O&J$x;&;%W}4+i5_TaE7C_Ol1y`%JZd&!k61Mxb(0$N*s88zmq-jNpd+~B;vD$V*vq*+C686lLVj1kua=g|{f^AL7iVlRj)2U!)I|&I ziGHL5CDL&=jdgz6x`zNVQN~aMLzv3T-SHjQbo38xhfmn9%_1E5lD`l^FdK0Ytiz+u zj?{pA*urCMiAU&u9Guw%$aRUl$nce%B6!GiF|(iIr_#m~Lu)`e<;2H?GgOO`;RXC> z&w_W>efE5!?k|LqGEkmPvTeP!Cr0$cOoD{F_za1&C=^y*^I;VYeoWoz_fy`&edZpm zhc2s?emgl;BQtJ)o?5$EZE3^lB_OTqmW63<9-~5FK)Z%nD>%&V2YE$cULLWCMrztb zFSvOX^4di;23mBqQ$2JGK5{bQHKtL-t6t&XaFZ&t0%jevG0+_Ew5H{~@umh3M8GMT zG7U~9i;9#N+I zZ7wft&4qD`N@&qeK>2JZf6)xRtLHOtJun>Br!*0DM!cPbUJrNZvjg2DX*)V^4>_67 z3sJ5KTuG<)YZW#>wK2<<)C13fgNV_c*;HR3#;VMLva)Nd^{gnld=n?&m>DYK@b*A_ zAR&Qy#CrJ>BR-M?jesh|Z`}V8hmDUMJVE^QV(P?uChsmh!0oCV7|`GFOQ5xoI=+W3 zI-sW(-*MxKS0w#Cz^{z5tHRwIG|d&%7pgTjNL)sr}7sJ2qkqS50JN43Mae`M!ejs5I4 zjSQ!g1yP*QH)O%1mSQH<)TxST?+;x*e^z)oQ->a|o$Dd*$e8?tu zut?VmgZo*&rh`oFby<3!CeuuN7&LS}x8mlXb-hd)Ula=hfV15lsl?Rz#dOBu)X#c}t}to8HNxU2!0!pSk>q zcrv?hRTvu-!R6*RAkKZ;k?U~>K<{S*=$3+F+UN>1W=E1V+3tM%CwLJ?6o}ohg6sTw zrl|u#Po7|E_~#r8s2E-GDa2P3v_So&ns)-^^;Fur#S|RbTi8Lo-G)dmSi@5zr-u-o z7790FSYI?(DiASs@1uYRs%muHeL|y%D4;5TK~-8xD%~%rb~-37PE|~aGife$`F+rn zejS(QHg#X#=6bUUzHkgZAfietuzhi>Vfd_v>$h)Nqo!Ey$R78+usZ|itIiG$9ccu#M zHk0l1?TuP=t`xaY81aH4KLAvm2#1~wyL}R`?2R;TM)>1%2#2sAKn;Kcc+adjNW2p) zYnl}Z7BG$0zw}K{pPrhF9#xAqz-Ah{(z7t)hW}ZQ*u+-sFXBvrM(lcYM#efIAoo-& zg%0A``qO-cbZi|*m1_s;^T&6r{ZvVMH^dz@#OlCZ8ZJE2ccuw@uXhJ*;KhtH_}7?r z=H)@LKeecPDaq?N)t^87<_}4hgp~_&nAgGxMhXyc!ou!LI}Fc!}yGWSx5t%g0Z|!B?!Gr^MD-wPbVvYovBJ#(3iPQunEr= zW1b8dla7hcXgj5Yqq=JAwYI!}-p`&a7q7N0re~`oZ4um$=5u^vTsRh+B29%fhJWc) zCuOv`zcDFMj74uFonQjpwIU83!+8rh#W@~AtU>Z$K$(_K2K#KdL;CCb`)3T>hr9rG z%Z*ie<#jIta!c6ai?DX2Y)P7;fIde}P&hzMRXpDwBCjK$#+ji{ey-~!W`1puhE==$ zC~XM9)Zn_a6R7fI{#uXJ4%{4&c>6iH{Dy5ot!K#mH8m{h=`(~ZM0ewijf`AB0-k|` z+H6gg>a2iRUwVsD)JkH!(1DQ524hmCREKbhJ%sQ2Y&5z$9gt3Oot3T7X@M|6Q%vwz za0(?gKvNNQ693Fxv!iO!5=}j!y2+?TXq!bz?Wf{$te=>Y0LW)L2hy1qh(g)6{Wc8W zF{apRb|S7y=BwRh12H6|kdvGIioJXW$|~MU1Q!h;!IPr2Kfu9K1~R@Ng*smzIxBVf zmG}rBFB{*g$S(GJt7@ZdPa0b*TqcRn{;u++fZB6x#wJS*i-%8LWj5&a$q(VlQS<0|dx9pBj+tNf9 zbi_gl^(9h=8oN^^=zIx}Up&y>R;@+E{w&sREi!ecNt5u35Uj5z8w_h5RaAWrMk@Ji zI3q*3t;pnG>-V2HS+9ove~ZX1B%bBry@tDN7T)rmeMNL7lR-|>=i*6%8HOOHECi|* zB|u}N;W*7A0hdlIaL8bdVS#TRyRIQhMGrB7f?<`P62vEXXB)Z?klKK;7GTw!DntC2 zg(wAI;^C`L;zwp;cwJyI6P91h<)NgH)c+s_P8YiQ&ut;(yWXF`zmsnfk2AZhDn2muoY1U!M^An{6Uq zL8YOjl|pXci!V)oI>{05(tJ`l%?Td1;q|>u(Q1`a>l-uTeaM~L`(~Yczow$7Zu}t^jsu9zmzo+Bs8T^q(-?Vu6G*9 z_#_69=;C@0GKYaLYJ%fEuxwRgAxj&>!dNLC>RMwaaW}wRBH)Y3{-mteaoSw_>I1)= zMv3d9Y(d3BX(+5dsX(sqM=!8{SW0UH_Rsh7j*twfh(w|o+3 zWe%Ie>@m{tEF%)9n~T%I#m@Wu7Y}4=36AI}@pV9|SkTwy<@@thIb!OWgz8NGWPy3Q z$M?xvT!ZWLSB5QnRbGbGHOehdvB^i3XJ|{znUSN0^kx(>9U?j7?Y7(giahP~HQHLl zd^W|G#M_HhOPBT0C^Oc8IjH9j^dce!@Wem4S`^;VAh*V zpu4P`M=$ZG!P0m1OyAcE`&0E%WoOWRYE0;rmMw;TCNI&$1irb=~nzVa-92%ArAb z{P6EPNJET9*lvKG(TOI;93zcli55IvScH3zgIg9VEP~}h@V+B@kv#|eIAcm8ckb9p z#-zAbY%wEXYAn5)QGkvzRETieZ*?J=AqmN^o*JI_tFP)Tr}ZRmy$@obd=A%%$_4s* zp*Dzw58?1Ap;#;;g08oRiVfKqYdROF)8WLGCL>raA5+2cYid@Yq_vhf@8|7q)~BrN zukXu>#%h9W=So}dJy}tp_;7!kl($@!;?B@~#9-gdY!46|sQyXF!4kV}A+*6J|5uvo z2t@6gvXDt}j)W4_Ei>aKzohFVdA}PG4Db1%Xip#c&x_wHE{PGy#8Wo+E@QgoZ~!1qacu=9eQETC^NGvC`ek2Zfr1P zQ)@EZQF;z6!-XZh@pz~gS0|P3UBfsvZfJkM>+nG(Q}R0%MFk!SAf<_JRlI<4GgYIT zDzduj<0~kj2sQIH{k5G*3`N?)vCQ@M`(Pu#KgX&~fQ=s&7LZNN7&N>3IYiKFpT#l} zcbpWM?S7Aa_f;`MQ97}jy4I(A65N7@o1lxd#lJZ#f5AsG45{Xa9>99B_m?5pc?laR ztC3V=#i|5kxpinGx-3& zUAVn5Pp%73PlaMje}$7O`x)S0SlBA2mPY+Ch_wlD1aKz(r7-LWyUk0RBi9YipC}=< zfEiy6HN(uwz{MrFq_VuNLZO0$P%OwhkOJJpJDRB?rG5^INS-w!M*61nD!?3lll9q> zxf|PyVliF&tG97ww(gg%RVw;NI;;@lj0MtlD<*FJYk)$g+_~7=) zFQCprV8Fm2(+@jMW$&`BX5&OgCEdp*B!7Vf2Jni}D6LNSipn?U>$aXi3Aixr--w@F zzM?IHYbE~INub`QRfD(hz1i;m&joxvjGp<+i}K6MWgE=SC@7fOvYg1((nj`BEx1b& z@{=@kfD<%|zi&J69m0h<_k=a;gx~#S(-u_B=A35t_!*AF-9orIQ0VDT(2mkeJQy|u z9F!VmSWv3cd>_n$f@ut)1ERD_Lb8vX>y}nuMY`0NGNNiB9+&=AiKuz zo;_6A9n01L6!gV05suv0r9(5ND)n4GB9(gW2YN(dFD&c#y#O{4DCrYdyXp)tVl7B| zSB8vk0+M)eFgJ&v$g#8imnVuya*`G$zIot@9+curS-}9gJYV`k$iQSOut<8r6ZZG{ecA>8GIBWZue?5>`s#op@*}WV+4#ZALlvsO9?PMSk^bY_q`UE175g) zz1?u0^}F46z18}SeI^pi!-I|_$y6$;8qu=RsLfrAT z54=-n1}d6BEaoi{^XxhCIlNUwkV=~VsG)d^R#|DT`V?mvER{tb2XZ>WF$jQ!(B z)$+d(=dJ(wk>39C)2Z=a2%VAt{Mg?8_}N`r|1Si`)lY~YKmX@YZScPQdItX)^>2@V zqMcm~1kLUZ07F$tqiT4$sqyCxrKA4as5Gz2oi&h-2wEnEqFHWKkv6k8mO|CQqHcsF z{hO7Mre~PuE4f|u_o<4~;``t}q`cVtk;7U7>@1pI#`x-$V3{c?TURH&=n6m9N0yX_ z3XB>}ownYgSL(+=-A(+ZO@UZPYf>F1LETX`s2f-Dd*THmSZGjxR^O0w@ubbv}>iGz_VQ}CYhOxB5Bc+C#PaNTYQUrd;%7vRYBIAb+ zJQ6`(s4YB3rqCHmgohCZP&6CU1MGK)91>N{zRWBv=OF3vnYl`IXABgkD8+g^q>d~x z<*i}0+!@+zU8bV`8&MsgwtgT#>L2_g{;Gi`att&SOKk#M!}Hm^;L*8cFB6M)`Gv^{ z#VoF>F;5IhPs3m5rj0injZ>@uw4Zy@*5WAD)6;c7YQ{r$V<;j8GI*blyi9QE^<^`1 zW=ojHhjZZq8v5HAG_)*?C|$S1mL%FNUeG#0cJGl<6#M-YY8Aty3;SL)u^&(;=o9E> zd2)+n1ebn<@yDtmN4CFEuj?l3BnRq#k-KB*%hBSHt1B>)r@$ssQ(z=Yf=MJNLXQ^# zlSoQ{9?tv4laK^Bobrvu$Md&on9v<7CRnjv- zlAW}pIb*WO=W6e3m*)Y*aM&Z0%ogIJI*BcjVr~VOYFZ6fOv8NkMHaq(Qk$#IQzsR& zf24*o#8eQ_mRtiKerCf7hR7_a^(z$008k+{+UI4Zi1E#!(f|63g@sP`@BesL^ZhQT znzPYp<>Zfbl2%Gl-wyM7_`n6zn?g2Y-h?f9UGPf7#O$rwPlY0lVWG*}!EW@cO1LPQ zY}xZjkgzCm#9y=TeCy~sOF_=E-)|MYUa1^;Hj3XHW6?)+k|4TU0h`Ft;*lpQaJqdh zk4z^}C{kP8WFd_iKiih`JlzRV4CjWu>Gxb*zofrwUcbK1T+&!J0AIsI^kgG2=lB0zoPs$UUq@oa> zM`19l8(0xCTARx}>G2ZfBFaYiN!cj5JPc#;K6u{nZt25uda?4g1QnLdcLzyVvk&vg zc%r{C%Z;(EBYW`UlFX5{;q{YZNW9m|utF!cNY0%zwA*7dKLIljN_$WX( zmPzGS5L_S`AKM;pgULxmkD2n2Uuw+%q&BS_$Fja-)o~*%f|2gnv zKPi)-W63{jnH72EXMogv97>j%hOFulNPNHEx6N^sBfHD z8OGBK2vZR2!Nc(=v@ToHJgbp2oxdu|jfGRgm#X0;6&1!p;;qiBnsa=cKBKth2W=li zWI8uSV9+dnQh^t_MgGWbW|CTRm=+u_fEp&Y%z({}392|(AhBz{`lTcWXSEKEwj+B^ssWrDYtX!>WR<0cX2;g+r>+KzFMk7CZL zU<@Zrkvy_m4FrOyXbJMrHXl;}FfUEGE6zgd#5Ec3RjNy#oNFJ1rNJCg2?mIK5uJhd z1dCvgPU5r|$emDJ?ECwF&y4tTBQINksmutTeKn#1BHFEU9_{T5PQcLhGj!ok1F!y- z7GzO12O?70pHI07&!iI~4>t6w2;yw%9`rRNu_3krX;;7$#b5jTT3(TTi$IOl+M)UO z)CbSwWeSIhMY&zGIq3B={nh*0UYMHm@VfYYdnFv28*gp$MlpWCJg zQcb-1AOPV&;wzj_g-Q(xq$$`mcLB%d# z`DFrClOz`CfY*c>Z=3E~O3IxPj=1qfvPTahPLvXW`kKI^ z>&t*75LeLrirdT4-;YL;ahiK|rfPn^h_FQNXKXlnSrBc%7_5=1!I=kB!yF&p^!R+= z&0C0k@!cx3H~C`I1lMt8w;@;%FF*i^eA=nXqn)Dj(o9RAJcO7 z{eCqjY}q#F>G|TE;!geh1BakijTkX*vik-6o{@v$210fl+Kqhnf35f8k?vc?Dz$X? zZ<{vy28%J?&eLsMa@yd>-!Vmz^@S?mORpXFJ-UuH9H>_hQ=dOSOJMup9nS2}PH4w- z+58R3e)`>1dFY`=iPO%A5s--R2~KlT+O%=>12WCXywKs5r-HSYqn$^7ss)v z08=3A99d?!MNZJ8mPG;Ek*g;}RUNO9v96E?7AVAFc1s^Qh>&fOd_~>Zr~9lA{pA{6 z`3n7ObaWEV-@+srkgF|f!VvmM3`~MJ#{imC#I1XlDo%v^q+fPnQ=%b$58hrbE$7h4 ztp!|$Q{g9X+^4qdOE`r?Cu?^?T<2WlI>~>Yf!^@N3|~FYMrW-y_fbWW2WNkFacQe) z;x0M}M7|ualOsd$a*f)BBs2$=Ue&ZtWA(Wj=C_P6OAFZot)Sh>mKH_au+Olkf@wch ze-M)k;>~pkpE*X2aJ8y@>O%iZK2`)tWckEOiwk(6w}R@k?b7KU`iLbFHR=44aJL;P z%%@VNb_pl9Xi0vAT}~V;v8*@T<+nnr6RD>ei+<#9`zP}8Ta@t3odDaVDC3gcWk5ws zSPNxoEglK>&J^MZN!DH=mDN0M2!;L%cf9rVHMwi)D*hCU>Tdn!c~|;Uj73#xnqgGK zbBj{vP#4$n$KB^5cjdLoF*Z51QG2VS%sg%`>YtP5!3J|n!IOSV6azEk{1wd3-R+ZF zUQMj?Nv;)nyo`b~5hn_qkz6dF>FK}m@~Bm0<_xf=o40DXd!=fX7$KZ~h&yJf&WsLR z_^F$VPtkqnR(u<3yH0yrh7SIbK}EmybDj^RAzN|l?}?6o&GpA+^P>1%>@4~XB_WPl z#BDv`jwAORuo z68s0RSK#UA(?+5r8c#1SjdZhn!oBb=+s9rvcSDkLi(p=KpS{_gv_MeZ4k9TAg(TXR zcJ?~oDVT>#aOu;pMB2>{v2`+`B*IrSaklrLKDT7ZYIBUH?H zk8ftOxlTx*o;JmdQJjo!PJw2QcZZyI-qb%h3$Dt`K6|j%H1%w%c{Xpe-aQvFeLvLW z3j?xZQhvxl1r1=bfT~s~W3Yg#U1(BRvRkO9MPBRS$k>JBH+%sXd~GZ2wD); z6+ED8qYXDhJd^L}58I;EZNAIb$L> zFO~JVCns2h)sx8t8?)lox`-daeT$D`jbeT^!a(U9OsIyp+66Xg7Oys?MiSOyl|fPR z0AJymP43Nko;UH7QRk&_2|daQ2@x8BnmC3>92KILMr3MY-&J$1ri9OaUHVnl&9ev$q0s6}B-lK8wjqLrLpFv$LK zON*mfz5R#w=0gvVZg}3#-wR8c!QN}QW?-kjiW1w}(M6AIOE5ee=ggTNTgDDTNZdr% zsz&w4i7$AlA2>O^-A%g~>66t|+3?e%B~4mFGxKmRQ)`6q=-pMfrlgxwE*wbZv-MA~Cr|iNo61w#R>W?^k(NI|h%>FbLw@u` zF?&m>CUjF&!3DE`0piZ-zd0&8?r11|l_8?38mekdUo7PaGHO>M$z(IKU#S|GO!wr! zoKDXl0CmEMw0?#!3Hl4-AbET>oi{F+nLCl`!1~KRbz1TjaTyHSGWhYWFTIFmzyn5q zYCc`RE4bFge5zJQP_3cSM6Cv=vd2GKOqoz!vC+g>GiaP8M+DY0_}H&g00!pX)APMS zulxDvm92)E6KviVwy}YMlRw+l6yZ3_WPY+mCc<}tU?6O_k({lLb}Zux)26*rlCg3H zYB>UuI6q>yC+Olf!MI$+bIl5m!Cj;qS%w2%yplW`LQx5oo{o?@%~Y#%&x-*)KZ zaKgUhq9;eFWU(F>oI8>@s0l-qT|4NwcS)S|L#~7+%-COjN4gVhs8%^blZX3lHqX*< z{EtF@7%KY{MJTlGfS+Iswz&CSRUIl@&@IqDXDK{@7E~uvF0(0XaFB~JT*AV2&nYy0 z$e-<{U3oM}{0`^PjxQE4sTxb)eU0e|gnsZe&cg1sq)To^3^N907S!!+SNL7s1a5{& z;L8aRP1|i?iFYwy!nx!Vs7UDMEaIeMWex$#Nva(pfCn4V5!{*5cY`wb6Sn|&X0itB zWJ7K>zq;v`=g3)H5uHpIc63gl)EhJJI&KW3%w$eC22)9Ub44s36BvT(@B(HQ4vJ7h zxaRYD6xwm7*?_`5R$(+Z=vC>bf^`|{Q1)>(n( zCfXMUaZk@uQRff>mpj&P=Ke-m{%;{tpI8N7*NjiL{%;&2XKPmNI^ui&JH|d6l_vt=gU1d{t={#Bj%D>(Ih8i^0+0_{2T06oT7^xs$#?%!K}R2cD~o+H-~Js z7s*Z88a$zN!pTY-unm5_ooWPPEYP;A^T}0yiy}fel|o^GGsEQklsK^;GD%wXf5a{$ z7(6wm^~IxsNkzq@YnV7fu{i+88-_r40o^gIRmF6Yt*JNEn(M4IMepjZ4A+M1ql`B= z;!}*VCYsd`^qlB9&~YMRMZgLI=K4-rQ5`yO9aDtCI+@}56Nlv;LvDiB= z_-G{)gJ1$F`jOMPW2x5WdEB~t99v&Z+#gjOAIsC%7!a>>8T#6y5BYkm;E>RT7&uIL zm+a5lFUWb=)kpu{Xh30T+18BDzQ0!v9t%TzV+`!E9LTneILmwjAz2awtqqN+b!0_+cLZjb&Pj!#@7YW<>hPv)9fN;NJR?fwL3*&oSE z=^%EWZQX@f3QnR@go6qZ6esL3Ok~W*(@$bjwrlmO84dT7_2YnwC-2?NaOx~_`a?c0 zrOBb5Gu;=0fw5?=-fEL5Cjyb>SYI}Y)5O|T#F&Q{4@``CU?`6Q_s~VWF?`tf8wnx7ojR7HbSIb1U~cOnNGFW>j33P>{b-&x zjYByA*aH4YM4*CNv)hFJLFC%PU|8=W7ezkpt(*lpYbRW(hQUK5B<6Z@o0S%^u zV@9*7RTr|Wf7@~1e$O5xf=to#VLkQnr_cu`*Y;a+lRO8sU%5@J2*z3i*b=^#sCat& z>uFmv^;>WdNTo^`0$+dle<9QS)}U6@W}nKR%IZe>R^!&7aKxExrpxw750OuQIk@AI zuG5ffDT6YrEGq=SRyA#P+a-%%np*^t zE^|MSG}Yc$S=*P^49@zFBbPDU!7B*JvS_+0vpG%USfPS_0oO39&c%7rz>1-{I#?sb zEVuh;bHFl<%2M0Wx2odSPW#yT95ySjc$C-ZI>ilu<9ZmP`|k8dZz>3=$m9Z9s_YaE zvc(65!G+qO;%>fEwN(}$!*_9M$(wu`rRW1aYz&=+K_8qbb2gnVyme10?@|@^S`7m1%I|u(ev{SVI+o~*CDWa? z%ZqMdAoB@%U~16&=aoc6-dda#C|(7^zZn#PC)hQwi~hmm6>0Hjh4w&&Y;C`*4PkPnHd(|Qi|DE~F=)|MP)1tuJR6HII1}7pm$Rwi& zNGta}ln9NGKqV4!2Vk?u;R8hVb^HOxGMvC&;2qtR!>uD&AWXySIgl^macQO`X(2V} z7%df{8&quuMisF8E=>nCn$ACOBOXqrzkJ}icoGczc?4h6Jhp6*in2$JU?l!8#_O#Z&=T;mSGj$ z3YrxZD@P99N)o&oiz}~|+}P>9d+LAd3yAu;RdE_t7WEve81wV*>sHo4PKB$Vn!cn{fK^|Fgv|acy z@h1tJa0U4Fl%yT?`&w!&v`KN8Hf=aMYJC+cqHA`yQ&o;7C+g#{-S}C zNxJMJkEk-o5`|BDf9os!1vzIW_VCG$tTIC=%R^#G8)3{mUQcF>CLH#YMV`AZ?A~1B z`PU}wm5#z|JmJONP8n}}UDjx03a-B-LxLiN0jVH`?hYV8WGV*g%LMKG%DfmDk^VVx&r9ITxu+dP$uh5GkPek2f71p%JpZR|M>H-1{lVukKj3)P5Hmfi^nq%6J1Fbx3bG{AcdS1p7u4=d+{n;ocA6vKX za{&W8njYff=~okMs)nOnh5S0hGP~UGPs+Y{=tpbtI0{%(cZ+mk^2{H|_oPTxgQPy(6 zOD|Zcx9sO9PAS~X^$etRi5 zNI9fE-=Bn{99r~GIx5y`N-)}zhb@RoZg-W^r%ZQOx-oE^&t8U)!~X_ zrfybHA!>+A5#y95S}yW}7ImyFh&+SMqKbquT8){aZS!+H^5z+emC*OW>z4qql6~q# zhfGCqDb*Y|kJ?TAN~uSr61Q38_u~Q~tqj%G8R@OV&u%kzsu~rLurV{ggmr1LVkn2Q{U~=Xw&Gt zfQK5Vu!KKu4}ArqGL|g`D0>*C8A&90E^20~f28iH6O22EZ@hjIC3vL;@bY*;0?cnK8Z(-s}P>dG~KkH+fD9Q($BO< zj$9x=?PqSez9z(Rb$#y9%f^m2bPW`$H2#=us6hWTHJH6V*@5hn~o=IdON=7{9SihdpPs;x+& z|ABt2kRXMo8bB=RUp*kEfR2*nGi0cVr2_+M`-$X_b5~657y~l(e5ARjL~!NWh;7Y znc3RE<9IhaL)y@;qrSdOx)bCb`$`E@VT_<_^|ka=gj5U3{0C(k;iTVBL*n(Y87ovC z7XU#kcGJu`AmnIj*~7R@1I5}j<@i+&vIrXxLhr8e9B4rwn4;WI%q*2j;b>9T9xI+O zO>7pjU4_(c>#w>RmY+0$ZgxK-xSnj)AA;FMGk|(C9I-43gR7np*64w=roqBL;@&h= z>ckQuaW2Mlc3lR%$zkFQmMUGXPXHG@0ZAbQ2&eK5ARd0xh>r*GXc5eCCZ1}YuXT=$A%702 zG4^AmoCd$Mg}EYLOc4HbqW{RL^ia{9!ZyG+$T2~2XQl+5!S0_AQ&>`ixLH)Nv5>TP zP`9f){f@X2UHIgXV3viyp7ttGu2MQ}-p<$M>TyjIoC`EC$BBAcniIn_^NCYWSNCYM zR+&Wn$FLkz>Yo(fhwocxiAEW38PjcUjWC88t%QwM1wP|#zVTFk-JL#06@e6{cH*e;`< zT_2fQJoxv~nGjFStpPP!j7oFl_tdx*1~gnS*uZ}AZr=1;j~_$X3@KNuUbOhZVYP&e zfT8qTV{7z77>|ySI9G7o@$({59e#j7n@=j1(4qDi_S`wjSn$nmKX6q6Vq>pF#ioRd z%CY!N{fac&=X1`^mV0Y9lF^gNQ}+AWr7iFA|x?OWxrNYsM86JBR#eVUR}xkzQ&LyXsly3;U!yZo5< z_`7#BhDb&kFDcX#MuBZELfWL2hvgojgq1jbKK6dEYCZ_;UovV>^i36|DT{Z3%xV z`#+FBnG~>nxqzM&gz*V6Nh6yY9MYTovgg&>yThtu89sO({CvFA(=tpqAd3*C zS}Y(MssLh`CB=~PaFknXp~F!8{4IT-iD6MO!unE&oN{8l+IE5ny7 zyBt~MNYR*DHXp_`ygVx%S~alJj==WZM=*flCfMYMCou>`x&FZ%l^W_kWz}ej|fa*%8t=Aj*fZpcBZw(Pi*Rj`_iK2%?heJ@^d9xS)-Lb6f?5^{Z zjzXI`Z#sU&Dh#R2TPd=q+M*-6Ubgo?51(+(Lc8B6m$5tTEJ-oJzZjmf*@SZ1|Jm;v z{|b4!loP!3Kw(r&*^@tnwAi}}EARWg3Cy1Ywz6~RF;m}NEcKU)kbZ~pRvKW(jF#yU z-O{UIY*ho)f`uv*ZVJZ;b;#)?;Oca}#Dm0Ko4a_i!6&`(YER&vfOhB*YyW*>INH|R z-_jXAGu*y>cCH}xV?3=pNxPJG88vg$F#hgrd8@?_)FLn>203)+}dxFuapQhs_F`E7LgxJ%TEw@MGq-g0X{c z<3OMFsA3}T3go6+=u5lOV?cIZ?{UT++&_`Z%gxIm$xjs0UQQUkeM+2u_zch9nI?$A zR-8L660QtEdQu{V4Io8q1Zdmvn&VIF!ce9JNu3r?IH{)eDvR~&)Jzylmz+g?D;B_- zN>Zkz^3hE;WE+)j6;YQxtA*^Acx}#|1RGi)-zDdyVb1K~Fq$H$Lg&Px+oHvlYS^WT zAc&|G$t6KyKy-3o`+S+NM&a@xF`J`9D*9C>>`*+aE^s`y`$mV;k7Y7SUOLNPm>= zO#6ZA6yw{~Dn?{!kfV|h$09iw;%740E-7}@GxE$@@`=5OGS8U(z{$4rJ8nMLj0w|& z6QO8r?4Sn*F5x|9AcsSssXwg0=&8BtkSA6u+Do{S;jaS=%pPq1Z%;uv1jw-T#&di> zJ~Tv*N!)>l01rq2Z1(iw*r!$|1QKuJ$L13cgp24Kr?#E4^E!B^T5vs#(nsI0oP3`U zlaV-Z2d$zISUk*Q$mY_hH&vBRnR z?^1G4r4CE#E1_cI(b;{v1*2JtO{JUxM5W|@$VSey*n46d#(5s#`8Hc(0o8YN^)RYX zx70H(;SNuJbV6mqcfvV}*;`!C_}(%HCS@h+huxeK?WyNMj7s!vK&2xXI&vbeEH?S= z`7)-Ymk_EOXd$o~!atz@FY(Wic(wsqH2+$TZ)FA%FIO*ycFJLfZscJn&%}P;l0L9O z78%I+hV`vHW%n4~MKb?{dOT#2b86Lf^Z`HDh;{6!nKu)kfFPqmfYyUB##>|SIp4!?Y2AZ z&m*<_x#3T+sGHmM(YAHt2P^hkCqAxchCrA0)KEJeissYnL1FJsd_Jl~7(#Un56e$Z zC^4+k)L*ngq`^8@^UVQJ2 zVLn3LDutp+G-#%9Ugh!NnVrw_vJ}y3IET9t^c*zRgkIyE(Jo(t+zMh^%IfT4XYwF z3{X*I*kv=6vl`v^@Crme-lF0vE;osuvhm847)3Sq|6vKX|DP;Doq!4%qP$}+LE0nY z_RNB}?%Pb^ceqT86X@a}j^OM6&JnE0f)P@AtR|t8s6U{bD~%q1T;^c9!Oh1Y!ouOfLA0U~BqvkgW{&~$bP#(YM z&$@dqX<~PYqnn`oKN*5>MRNQi@~%R2q;&GY@jANdApDy0+bq+3orQX(K8RT+z<0}Y z1M?lA7EBKgP=bJbO;Zl&2>8sQGA$>hZ^1{eQ4<)$GxpAE(?eZL3&A&qu{6iDnH<^f zh{%v6v=9Fg1s8#ceT7Ncaxt@9#Y6RaGkm(;KYxgV2UUS7+pm9jYcG4{;g!Sh`-It- zpiNG(W<(vv4@~f%JUX|js>!PNY8h!Jj-4MZSZ7vbZ_T4Bd`KKh5VJA*V@L52P$?t; z_5R8ES50gtDLoyi1DA2R$=FKzSZVoJ^uL0>y*$zeS_oOR;%VpwP~ZGk_)BH6Q$A9L zh^6V*7x%;&Z47khSlV;TO&7aG9InG=+tbq00{p%9OXumst2C-$jvh6vR@r3|MyVMH z%n=1A(iTE3sqq1xE}Z-f-q~0vs^2G2${Uk}&JGZX{qE5G@C5c`+2CkbR1}PCrt-zX zd(+GvvG>|FPGrlBm<$oe8_AmIz%p8f!MM^%HyF{<*kioseM}XXcR_x&v7YUTPjRt8bgu(}@*;WUVl_o{Pr3s3IHg z<;4@Hf|QEqzA&JpK`b7SD|4A)_=hd1eIEI;6LDg79tiMLUS}3`FkMm_wq+?1iWH7q za99{&JUMrnM((iJ`F6qSX?-ksy!GkXp6UwK^KrGM{qdC5^*(K+eMge9`@63k2>sif* zn6zI}y0KfIS{1?m;Zn3mI&Zqryi4RtG7`f1>%^D^dkNQhq|(ksbf?F@nGFake)8=Y zmaX(@B1R-E8+V{F&-SlFUfUB>@b&T{E&CK*e)Uk}5!uc=4oqo7j=FB&O%DtBWNrKbTXkQ7? zmV9Mv5Md%YvWxF(H^aTpafcm1K6`TcnjEyA!^uB(3=}SZEwByRfq1yaoH=yDv54`4M6>SBr{Xda&jNgl&ix9 zQU*@~v$N;t=VK;x;!SZmMlQ?v>McQYqPs^X8LzB6oJM)BT6<#p0(n?W5TrWZR;Ony zHpoBMh+2hrVBbH1U>;^xGC+3jU}IKCUNWdq3L$c>9s>Qx5khWeTgKGFoO0GR<8I2b zAQrd8Rrb@fU^vh$D>wF)WiOkJm#OTKaAd2lsa+e4`$zY4m z(tL!Ggphtau*o+wcHD9T?^5zk^BkAo`F^2O!4=Xkq;fSWTObUKm?AWKomBO0_c(C6 z*t*VbE^80Q(w8p9)cI@o>t8N|7w+G0v8BHbj?=^=o_ajs03kb~7AfRKuZY~Dt4sKW zVZq~BVpYy^(c;f{&tHCB?_XPK;U0mKS|f6Zh=J3-ku`i4kW^9X9E3$%`B0G~U8Nc< z27{0(X2T&g)yAA3?;2e*kzxcFO0v^BMu)I0Fcs3DN^4LB<`mK%*F<1b7|zfb8MCg0 zTb8x~=XtAsi!WQ?d1ZBBTF`JPQv9{oh3$XH8dvv&(x!^zWoOk)0tF@P_`0BGuYirZ zj;{vYL$gBrycBB@@;{WLkWn1COfyP37g)I@IT41aBy6I0@d5BoH?F?6Q8oD+6HF}8 z)upRzve-cibY#V1N8WlD#t{I``@6bL58eDC?`EK`5Q`%_GF-I@25P`nHY<|kOQ`-g zaIE+X9E~k85{jXnmj43Ba{zFJPKEeCfg{j*IcTPL<3$=0;nJW!ClhsWc}%X6yf!q- z*U4Yt7-;!(TUA|MNZCc;8nd-i<}8v81j~mu8b8lUR4N5y$XJV|5~^KxG=QIr_dHJm zT)DK?HH#yO6ZY3~YcF{oUb0mgNcRIDIWnc#sT40F_eL5}Dfs3PgEq9rfVg(ZjfsKw zEO~4$zTY_x%OS+|d;wYmyqwq_KsXZhMgJ9!xIXpBlExs52Do`J-Sr{xOI&jY`c{w6 zbmt}X#;yv)@h6Ylo}C9P%xJoiSgqcBZ*c((Y$wnicWJJRobq7VsiwMdxPsw&>G0A6 z4dmh>{WvlQCt`!ab496$q)@FfhmRw5B$%2)@@@T$KT2QqIwIuy;b?AaUP0jClPku4TG( zi{nds8`bg|L%3G?&aD-aTZiBxqCWVf3LLw_!AW;lBvEjQz^Y4D?nv-hWm)WC;*hIx2xWllzFU<(MR1KKa10ht&UKn!$Ph|j%u>kwcTJip-AU&3CM3PjI_i<<2>ra&of39X#NPrBCFabay)P9K5WV z)OkSlOglmT19DjbxEy)ko+PZd=V8xTu$QC?j&!k?Sc7!JKhcz^TA)b6)z#iyw+tV} zM&fU#xmQh6`0eD1yem(6ILF?dHeOv`ty%i@_OX%X+4`7WQ!CH4>Lh6}-3XO> zbDjO+$yOIQT`UJqO<%x$NVr{EiuXIRoS{*>a#Ud4Sf+Kok#;i@sS})CXVTsBKTbb3UySQI=L#Dy9e~qH4s;(T*L4{NF;bQZpQRb`Br}f#Q1aDmB5V zzAC7MY+24Nrxrso`BVrR-ej`TUe2igPb1i*0Wg9n4=6$z6^5lr2f$}xZ5+NN3EbBQ zkfn;x0jR%CJE*Ab3s^jLG0zkv@jOD@<|*;)u~V8fD=Gwg#^fFr6}7JezvxjiCcq}Z zGDpEy_YleDw|jM-LZ6fl^vVmpu7k)jlE6B|n~`5+3<}sj!|`(9R0U6^p^Ku9aJu}o zdGn(Z07@{b8)lX*#NN8al$WP}|DoZrB_dNwI1T;-RuBIDlfX%nF_;jRM4l@)Ui!Y9 zDT3|)R)T%e^lZ|wRw@X>NZi%m$5lN%1cVb=$+%F%%@%2FxRZ``Io!7YtetJFWU%7! z5S~3AS$COtQv-KDEZO7~VRYvt2FAo2_aT(V?1c%wzCl9&G6!^trd>zj+g6eYHVgGo zL6p$KK8!G#Gl2tRw#P?8d_vEa=wNVkZIjNE3?ezU!|04ny#PLWYk zqq8Q2g1xYiQOH5<$Un9v3fEf4E5nQ0wSyv4S64ErR-&0kq@SLno4)vVm{Y8ccR}qU zKha8*WuPVp1`GWf>|uF;Chk**JJv&WBxa?obea(^7OQ%^+!rsxfcWRtCFz<)=|UBX z@>Rf#nvBqrI;=?nu2Nq-+&N%{Zf zp=uK39|3-;E`Vpwr2YFuq7s@T<_kk2rbOh0@#(wX2Si1 zz3oX2RnK8$^;YVZA;Y7iG+ylTQbTQ0S_jq!YbcJFz@aDa+qO1(RwW`oTiN^3EcAYf z$H}j<;=pUK6M(rMUonYm6bdM#&+PI$F(u?_vB1OG8hOD-KnAGO4MHwnNJ3FXw0vXi zv(!PtB!Jvr=||w@;k4J>pa9l|XCU|DjC0f#*-GpDC@c(2G&3=&6$W7mMIs&Hm?S|% zb+lrN;ZpFQE1*g~$o5e=79}yE2>#gj>D6SjB1I)vwt)Czsg)G~8aBAuU- zUL_3R`{|=hi6)0xOo_Eu>ZZ0G6Z>bK#XL@T54huiQ|s;1dj6j$+45!J6?wcgIz_IE zkG9#{@FVSQ zpFKPTw6dYJX*G|hU(UH4YWmsiQ@-Vt@wRio_0$TVj0Pq@UPRztF~|`c zFLuJHls_tfQn;4R3Yk)OAU>8xNMDg-cq@RP6RmN0_Rlffnk=A`XqZ!g zx9QEQZQC}Xu&GD_W&6VYFBFXX2MW&T#r-!FEMxu)1!4au6x@~Vgm+y-+>yBmV_5Xd ze`$V8`4UWowZv`>S$5Lrc$`PCgShwP>|jj#32=hh!2f?c!2|zS6Y2WvGVo2$_fM;R zJ@aMvRKb@W1@f2z(2RxtpYW6?0)=beT_Pvl7u)lXQsY^Ab4lT(GKv#eLh+Fqr^cfK ze(XBF;>mAby)ZZ*FSsv*)iDWRqpx~|gWh`sD*^S?2RPjR{ea%G;>Pa@9HkGL82fuz z^^FZ6*}cb3U;X}`flQ}*OKaIfJ4d^e=HE6oTwheaqm~6xgYQ7=*6$?-5asmO3YMK8N3;7LKW+PU^y9fcTl-(aO30D=!enZ@M)_ntGTgi5fe18F z-v8v0ERb{L3zA_sggbn&L7WnNuqrf^<(86&GpkOu=zg_=0glEgU6Q);R=b>}{LBr)8j#TWcW#`bL^ zULP3^pt(YRLLzLL8Jpal?mbYVnuBkc0M7cFpqAR@BdEsQXUqkZf8U zi6Ct|FBP?^4ouX4#T{4Zzr|fea824RpSPLc*1Ka4jG@HNw~}jAr8LF~3|$rI$`7&* zQ&{v3-K##^Ki1K*T8lR9CXd)0Yg%$STOSy)(F6szEXYBeu5Mi^)h%*Pi-Wr%-su)0tlt=aj0F_Xta1?Jjt>2#8<#{C)P&l8`Jd4!Y1gXj##TO-G9 zUod)a)|kQIpI9YK*uWCBR$wJPqKK8>Xe={z~|=f-4*?T~If0c`6m& zU;(N-Y|fr_It%WX5Jv0~4tcr<=OZxPlrTEUt2`~sMscmnxdNBJLF?Pz4m^kxfgAg< zVr1(3a`{n@4Vb3DB~anvRLAq}Z)}_9;M3zOfNfzK6eCi787ZoGhylP&hWj@+^xY&J zHhw@1g!FLmO#ID=yEZr%8(th{ZqzhsA@N@PO&hGUbxP`%n9<8$^Og~d&F{5p{-bbL z%MF%!T$ryQ!rdM)3=KIg4p=NyP9svFpSV_dF4skCUmoKWkr?;hI`~W!3Uk@z50tAw zYh21j^k3?BqAc#ooi(D55l+mrcn;+3#g$!t>hmYm^C`gTXe47=J_?x2_q*~255)C8 zTaM(-r0~H0xR3^=Vwd+|ukhu%r8H}Z<@vz zhP&<_KZWF+-1I%W3pw{6*=IElEC{rddjwaz1n*i)g3uBF_PohhP~jlL}wPABcd?c6Wq z))7@Bbu#TO>V`!l&Fuz|Hx{@e%vXaVzODO`7LgoD>AK}V-O>wR`5pO$*qTlf`VFnh z8$GKT2Xj3BIb(z%a`)bV9Yx&=_bbLG%vJXMG{#*F2Q{fWx9gPPb)b(P79(YL5+Qu$ zvRz)#;QV&~{PF7+pIXBjbHif^3U-%t`0Jjmxq7HMMSZx_9L{tTl3{t0cLdlWca=;B zYB%h}$Z3_-8*vHq-=z+&C$`0+a5^$Lpxr{#vB}VdoiyM&lD;No^fXU-iYJPDGtzQo z&WkAjQkl@HpL$w_n52QT;frRI;@R2d&nIjjss=uOC#0bMajF7E2*iH5 zRrXj|@*3IRh`Rrf)JqAh&i*opCUZDTmG8ibaN*W=f_~J~ zuYd$sMiaQ;Qz99qJN-_ z^{`_9v2{Vn4L-A96`Onlts!RNa@|AMSKrh}{rSOM`ZItg~)lfq&=5UI};W^@$>NI*1IsPf3ieb?54MqNqclZpfDgIZ?Bv7$HkH z-nE9BxgJ;kd&hsl-^8+qC`CfqL6dm|FZ=dQK9-XY)y2Sbn&u)Z zneDj8D_i((dyHd?hcq0S9mouAPW>jz>|Vj)noR0!QIMbV-�J64!~UoJEcN7p+T$ z-e}OobY2Bbl$6chO(?pqF8DXB%XirWrlu64cNE#3{fMAG&c1BRKk_&(RQjeI5*V@? zDu&PFx!?4t924+TQxgj4e7_Hs;+|TbMXYvZ-}tNRnAy+>rP4AH|E25rw|=I}=`mH> zxhuq{egEN*YBt@ZRCPsId!<=Zn}F79elU=+Zf9y%Zn??Xuu`NJM2Iityh^lK7lGJS z!BUgz#T`nfaBMB${nQ+Y(8@J+w8ef& z$dLnaAi{p3^U=T;H1sz^vb7fZrm)h6Hgg2=!Td|zM zF^}admAF$m|1i3#v3Y@NfxIK7J!oc#A6wZXlWtfR7PPh}eK30!3NFy2&QyjR{v*2` zTEz%#%R#F)GrCMV}w7_w)G`>G)$Ah3&Ua0?lbMuoX z?W)^@cZzy)D&Riz+lBRnY~0a?#(+m@I?G-4JkhrEh`k{PEwpTv)NM&;NG9D`0_@qt z&xeBDh~u1RJ3_B_<8-J+UA8q7>7010;6y--5OstRJa)3ryb>wSBr~0^%PSKru)r$q zH#@|e!I-;iSW21;Q}bO7qCV$iGx1R%G#Wttfp(i81TeG=T08ivl|l@*MTbRTD)MDK zRsD4KeoL-E$x;I$2v0PjZ#Akg%XY|V`xFpORK`3x(9x6R8k`^3VmbS>R17~wVGAw8 zJl-hRaO~OE1X?FoiK7$$C$gvY?h&=m)JsVhlX|j_` z^HlK0xOMZl&Q}KU!qXDX+|BZmjc63K=-@;b*d(6yRi-AA5Q@C2NvKqEL|cYxZy@AX z#(B5_p1B*@AKUSaUm`usv*;K&)^8G27Zvxx%4uqsVnD|mG4OmfL=Cn&O~!yD*$eX_zZvdoTEDj8j}b zD$1+zbI$2a@N9!n*GH3p0DO8;ce8sgiJGpVrb8p|?MzW52 zjpc8;%MV)1Yw&kxp4FAI2)EYtgqHruhkiq&?HoHFejE0EZ(m%s)K_0;Ej3+V%(CuZ zW?9#t(`RFEUx(FzKSv>NeqoY#ecg3THP=kkp0)qK{;+DRv3p-Pc|q013L}s-Xh7Fl zb)-oh_#-&n=WNiypaV!rz>{*aCYcXE8Sox*Zl~<={CP74(=*YPA?hK5c_N)U9(!O$ zCxagE4CYK6nuh0K2u(8vu+SIwJn>_d`Rt2pt^4P?b2t0VcT;Y)(gMC-A z2yH`&YHMX7)CD|9wql^6AWi5$gl%CU%EsBjpi(&I<)02WVj2a0Pk~X2Sf@`0 zXq)D$-k7?){6wEfOvq-Q~bV02wzXO3Dn;PywbcM)x1MP`cIw&aCZ0q#2(RxuaCqFp7^1z3#x>c7RO#~0$(Dqr!@zz3Y+ki zz?@U>pTIM%pCfM zgm{sEdrQix(v+|AdC*i}6-mpOm~Q*qx+sD#Xmv^@)?Xvr(D5VxP#N)DH9yDOYd*OG z;_fOtVf22PJa=3q^+p4BmXuZPa+a+tU@8MO+biFTbU6-xKO{kSw8tRGR1Zg(L)BMU zMYOOTv%;J3MhWUkBcoO<-1ge7^N+&Btg}32UHR4O^`0q*LNW;uNzUYOpKM!bW7qFi znRp0$U8iI3=QM55Ul`5HcYF&l)!4qM1-$6dylGnV2Ik>HRn9TZ0L`lL4g^Q5|A_`0 zZ2pA?r#UDbl#{o~=4q?d9K_Z|w*=Etm?lKamFq77*i9%-I z=Ll!FM=L=UxF+-#SCv&D9@r0C!c}8oH95}iElOAPsyWZiRpN5`qZTs^cEAd`FjO)s z!{h_I&X8CJ;^Dq=gy;A+xybb1YT(Zbplmw3N zR~dn2F^z;n<*x?RYI-)F3n6ze)z4|8%i+)j%W3<-zvBf^n~FE#0E3jXs2$YgGw%!& znmY^ESBn-yXJd)!_4>Yq99rh6oyDcL6{dck`dgm*^AyYj^K0tqE6R(i-zuQXTvNz- ziPFgkc7tjHBI@A)6Op9@As&{#k)7igQkls4CQM}d&lg)GlUx9=ea|}_bNT=jO#ot!23QCvKWhV~ zVfG+t;nQKDfO-_u_rK?75|k+S5Yzpf-<NUZD$@yh09C~h@D=K=P$cL3 zxg=|IuPqPhlzKlHhPLce7_mnccFwo zk{)fOAqhzXEfr-$I5J139N#mR)V!Pk**(W?cXd4ZZOCo-jMO|2poh0iS z4euVE;ueiX9rr14Sb3nsoK0}9Fh6OLEf~z&zG&aw?S@~CJtOUq-tAZ0=1>hUr__=0 z$GX6+DF|hBii=rH{kz#K$wUyPMH1h>;68; zl=0ww_&w!ie3UTS?NJVGZ8VvMYwc`%dW&W{Gmh5G?g*$5V~la)x>CJ6J~Mcu6S|3} zX?C%YF*Zr8V}e+P_&su@Bo>Rs|E0o&oGDI+m9A6%G1Dafocd4L=jh!>@DRx!L#kW0 zDx88^ftPpPHfgQG14g;$494w6sfczFeDlDsky0jLDtJc!E#ugnbyaMr;dt=YCYD&KlxVwE)QtQjO3c$pJ#TF|pYQobl=WJ7fKBL;}gRMcj; zH*U@k#9q}p21faKUbkn70r_0B&^O*O3&`!vmZ8C}tR&7%7N9u35fmB|aKMxOYIUOV zS3B<|V*6S?{gDxIK}pW4+CG2=U?JV<2S6L}d#>FV!x(d(l%_BpI%8sv1HUM`5wuc> z!;k`lY+(`1JRsvB(s})#2rx&AAAI;!h*`q+Ay4msta|y2`*HhqG{6E1C?r1Oi%d95 z7^o83c&#tc#$Q6J>~9Fz_Ye=FMEYGuloW0^6+(H*2_(2sCI?DOFIbMgK}EEhK2Q0= zKmWk9Y^)A~pEbXRUCNA-p3^_OVs4IF#mzWsE-~mPG{}0&s#74mVjRAfxkEHnBN5^{ zm;SwoN*!^k_tlW?@yAjo9S=`Ni=5B0)||r*=?~tnOFQn_5`eamBnq?JNohn{;bb#Z zK#M*$eH+))$@(C@@j9iG%Uv3uUUpV(1<tGoFoXm{k;6!(d;KvT93#;FixQVA%D|L8m#EKV3)Q5hUjzQL4ux)R^u4~Yn4 zqFE*i-Sl5Bfo29aplra>o)H@E0cy=mA!SO1!0!c^1TIt(t6z9n% zJabpjc5(mh&qg7v0sd_MfBUmZfIkC4{!f1vzRCagU;Zq0@#}`uiNtCD)V`=kTbJEb z+laFfpuTEuP?ZL9DLy1e!4T}X&D`=z0Skm zA>Ym8yx-gF`c`m9*J7_#)eCQzSMM$);e5%d$28*P3dQhcT;3}Pdi`{FJH)QGES7AQ zo!vm;<%-?1oUDFmAFq$c&mq{e6h9DPs-TInu9kY=iw}T*aV@K^=uU zGr_$V*#8>{AenuCQ5X0Q#&TH}JEHK1N)m0R`1#jfzr z@|>T52(u2pyk?3x)c(k;a=Er3@Rm$AA`3NxxC$6+!k`aM07%YSH%7MkCCE-;0U&`f(JYZfdmlC?NRy@~l z-^imK3K2|_`kCtjxS?wBCgiH+L|;MT#DJVp0>aGG%+_R0qbfka!vy3kXmqxMJV!Bn z@n89Sc_$|(8!yV113v

PoblB|%i1G%`qw{AV^PwbergG#$0SY3nb-B1%I4$%Z1O zz{cm;E!HbZSFJa;fz6Yts=c~AyQ1bSXMAAsu2c*j|K<7FBMbdlH4*_MG~wXleZGvG zUZ+@6Sdy@7)07J@AFrrkMp;Z#CqHXh3iKN|&|lzJ!vFJk9{=@lc~?r1N2gKK>^Nq~ zgk}B<;0{7V#q5twrRz>ret&teN+IAj0#0?~v0vOTXH$=KL#4P?L@Npo6Co`slA%lO zVkJse^oS`wes;vX%Y%tcPnl29xqv)`8?rzcw%)t^N;E*_d1iRE;}{{(1R+^U?8iub ze3@})Nk*UXJsf3K)73x#|-lQjdWKO2v{g^d5rJ=ze~^_b0duyWhJQ)_)}GA zl_$j9>>D@qhQn&=UdNZkv<7+sg9l+FwrNqLhYYRH}ziKQroc~Ek z9bmRho3)FJsSm-+9x`$1rGf8`LDuFIuGxx88&-AsDRmUx&GOBl)!r4R_s_{G*w|C( zqm7b~2|TJbvjoYTq}47R%yQ|8E>y?goSJ2?lm}K55Iw|z7x;+k&v7wPQSw5km(dY( zW0p-G%*@5@&_h|~NJB1X5Y7{{MngYfi1e^2cCGs{^h~MQH zrKbdog*e|(GX<$TO=5n_NWd0s3YUPIgVe&P zNQOv|x>_!uIx<>Gh6em-ZYma=Hrq|NRMV1v#wPYwDcl2Vs|QnW@k@sNGyw^^P(Ke; zR{GYmSNI0sF0@AsCp)96 zi*t~guN`F|@5P!6^GLYum3|uaxux9oM-f4MHZeT59_Y$VGL#9S`*k=ErZ4WI?x*UB zV~KnuRI+nPAqx3^AGYB*W*DL*gnR;w#J&nM?6} zA*YVjQ+DY}HKhsP!_`mLy-#_N*oHF?Uc3zfTAD<7khs8K1HB3zeK~&H{xxCr{deXX z_1fPm4oieE2=4g<0=k9o4MH%6(c!95{4{Y{&47xDxr7+OT_rjcY8Ji9 zA!nV3o!<~{N&sf!f4n(JyDC^$!yRBhxlI`DGj1RGoG{kpVk*b;OT14B z$QoJKO4}UGLi{7sXC{sS0#SUK*R;%A!(~7 z%373mE&M1_&dfj9sPZ_jiK232wC}cOYj*d9~*;07b8bVSt<#|K=($+^(y1kOh`_K8hmaF$7x zdQdLuPV1@V3gxSM9R1OMfUTA>4Ig#IO6w~egxY0Wz}--*y373;N6k~A{oBH@w85Tw ziYS+bU`hlrMD`{RXMz9{d1xzRZoeK{>2u(zit9xv6#{2X_3XEuqL6o^i&b8yCjV?E{>}Cm91O z`T2TqrfkXPG%GI8&?zW;bt{p^vkIZ9BrHap=Mg#CF4YKL}K;!9Wgk zy3^YM%&=5YR2>fGtv!tuiip$r>QSr$t^Hhkp}Q^#{Jc!fb*&#Zv2qKXi0nIeXtLQi zJWyl7id6qaw~oL4i*E5ubdu1|xG3^%b$!Nq?el2#Nsa$-=dk9s&k=su^|n_SX!~tF zh;DI5;L6$Vv}(PP>x0Pjv5h{?Iqf{o6jfXx*z19T+JC$tOC7PL-PqG|$@csjflBCw zTQi}_Oe-?)@=)RVhL0APdlFOq@& zYCoE0m*jJ~wvPM{MBJy2iRgNJAitGN& z&U+fhm_57zeQNFM;^N|$pDX1iA^s_Kqd7*Ta2iZpPT|j?an+7%S}-W3B+x2J%~uCB z)*$Emj1J96fbkMMXOYz11|f6YAD@rVK{GBxt3=@YJ0HO`IEV80X%i1r*6x2HFQV<< zaB!bnND+iFrZQ+FYNUw6JpU+iJ&$+kP^;Oo-9M51hm_e`8q~n-8ZJ}6+RE#F^6@Ln za~6i8aR|_#b&Q(Knlg#B-U~}Y|#v-f< z-B#=Gu15t<{zw8paDdJW;RZ6YL`KTT)#Z&193QSze=;+XqK}nQxd(ejz@w;nEjt$v zT4O3X=HD2XbV8A&@fc$^s>C&?J4XcPe1d#{@y17BioV@Z1=JW8st=#9$*$CNg zPgf@yDYWmmoo;S7Yi^I1-2Da$CeCTYzDPUoPi}76fTE&Y=?(2!TygT{@L>}x8Lk*$ z#+?dP;0ch@N8T80X+)Z{J&p{u93u*>&}bn>vRIxK!=_`0$CB$U!?m8cSa5{OR6xg7 z%QvZ2wd%g{9EpuM6iobW_qmt%x8bQ+?kh1ayox$j=QQ_JBD^bb9@3n-=u2=b4wt_# zpxh%yPA1bIJZFwdI^4rCQ8lx)30kQm4s0*F*ZMYCA6}Hh3(o~7o;+!q{<>w;826WuB;v=oSl{dRfxAqo81De#J?#~(2}xUOzkkasu8 zyM?WkoE=+~k{+HTfkollAf#rob zw-*9ERW`LL6Ml*LjTtJjV_U-5EY!h~BSo*aJy>le87|v#H_Tt*;O3lP_*z_DrZ_=U zBMFzvN_qThwc*3zTMq&2yH7Wg>91xxp%Up`jLQELgVic|7o0c3pi+JVX=QY=IN=72 zE|I5GBwK)^`vYSP^mx@_Gg9_IoJ<{UK1Y8xo`)E{6grt^Imzwmo)!dto`f3UxO(?+ zDi=vh9pgJg<|K6UwJ?I$7*qx0P43Z?^C>EO9$kU8)$HAsN0US?)uO$b6pDnv#%GmQ zhy+1ohGe%9d=honI3CRH3yly62udex$}Sc0_npv`R3N>QjzLKclj&ySF#H)o*a-Y) zrBmy!p|G>56zx8Gj_j6H#(A#=3V7@em*`MMo2cVAL@80jhJi*ke%!~1N=zw-NM=*d zC`XP?RMu9^4=?9zDcvhzK22PpUMpZpEib1E^xRxQX9aBG%d31xM3X{tR+!K(l=Vh6 z>V@}QCz)LIeb(dkJ2MJ4-I$344JxU%#oNP(w1o$b4Qm(p8QvsUc%h4;KcL4yiVrN$ zBugzc2ChJL_RUGYq8afQFVu|dL%nZI{0>1^;mloTN9v3K+e-HdX5~Bz=jx~qwkE-r zwDd0gPdZ$~h7$&SSA(?UP8qPa4|^0a;_g{>&}AAu5~fjoFIdHFIui;9-t?QsDsei_ zzA<2TXuo&+alpvu7}1t#@D5)oq*PpS`DWf%$_r73r`D1pqdUnQrh&4k#nwDQo*^c$Gf@+K%e<}k_X0;w@0)nV1OPGT+ zpqoVa-1V(b*5O_#vjRgl4Jv)!s_AE56xzPw!y_a?4_6QgNz_xGf(+}o0CT`9fa63t zD|qq%N8ZD_fE3UIACmF?&Z@@ZQfkmDO>UIOL{d8iEtj>lVM}E*X`AZgAdK2n(9_=* z&w3R|dM)SNH4U%OIj!uj)CerQ0MP8AYiL9FMQ6D~*289%gXYYReQVy<_7caXuJ>^E zgG96_u4O#uEM4CFH==R!7^g2O1+of|-$)sdqS<)0#XnVD=t%{ocx(-{jfkMvO5nGf z%jA?Aq_p)f^kF$dN%8xvj!EDXWnO&&qxj^}K<>cu&O@j~5z(6=D~7>JLvhxu^M%T? zmpb2yn-K{T_XtFL>~nDWP8i_Qz)9h3KYm;3^T9qWp?O*Pov#Ez82+Np-wGAASG+bL zNkoYR=`&(>J)Q&7xVSwFE`~pZA4e)7;|*kM<^XxgWI0Dt{b?jRnz$_U<@l}dU9)37 zXyrqyOGKSyN=#vQ3wEmXm-pLcyA}wt0i1@U%L6l+oV-)AY*!NL9bvTrg&Zy*gR81( zKILtwcr5snt$4b;NS+WMO*k}crz~arN3A_YWdwd-m&z$hS7|?0xlVlhw`McmQIqc@ z#&18?mjt^eWEB%NOfXBvSb9IpKbMt77&^>(t5^_9N=vm1EN&xiBWlhg=%TgX&)^<- zD=?X=Z^>!>f=uaXR@w&_s$hjVOFoX&D~s%&5EV$cCy{fTBzXc&wcM&Ez>@^MTczktlEkLpXBmG|&+Ro%mouD?&(jXO8UFH>AL^A9JP=PY z?WSC_rN+2mwChX0awNELzV_&9daL5z?ygXWdcjXVm2k3Z2*0tMYlfeszao=yo%MeL z0PkUFDrcJ!F@2#w5$`<#ysh*1=_DOPGTqAWem(&GcywTdGN`;!i*XZ zaKgjk2Hs7${kQvcQ{6dK!Uu!H+=63*Km9;0_QP~*DNx`l!H<5>IvtxTB(W4{_oGUv z`OhQ^!M68_D@LgaPeVmX4*qNUsG4iAnHIJkF=7xr4&6MVc6(D|0mhl!{o=^tvU=2ggQKgf^lD_WCz$Y(?ZfggQUNShm zBeZvPHQev@$0`CdvUC`X9vXj-HZ}WR`-|DchL1vty1u0*bYJTj>YGsRcby5IL!=Oa3M#+O6<&}rs2IAGMHJ;j#}qN|rEBQaI)^iv#FudG zib0!fOU2njjJ}PL2&>#-4HAm8WBnZ4v(PKT_?XZ!BQWq%T-9(047AE6Rgfnr=#T8^ ziF}RGRYu)ZcpgP_z(W~VD91J%9;JrR8n0wqa0%4Mhz3R{2ie#VKTqIceGzZ@R)wQ> zHae9UDi;5D5-FETctkE`_YMUV)QA*xC@@s*t*v_Z5A5M@TkE0veIW0ARJLha{PY}{ z(iO-BH|3hL$@z)X8N3S{zCx%N!`C>Tx(kO6wIc+z&%m?5Mh^!2M*TRXa22E@XP{mc z@Vb!fBv1v77ZjCaNl3Rr8XDNr)tkkXbAudh1n^k2@V&xl5LI4bNg;*e70pi`rj}Fv zx3Hvyk_0D8UpL7F{0J}fKLEoAwd)18KI@yedlw10V;;rJL6!;^Lr3&Qq84e->MS*< zM?x)6fZW4n64T_VD4r2p4nuL9(0^`zF2*2-GKB`;x+Kga&rC*&R9f^+&pi6fsI#kP zLE|?AH=Ch>&KmkRg=4tx=G&X(l-u)Ffnmg;t8lYq*pTYA>GT}`C)AaVcCrS~vZ-)) zJ7UyqZ7zfZ#&n!<~EZEH-{q zd=X%UrX9BWrnaP~aN$|-_Du(0BJ`qCETy4+og&ZFOKfViyj+gCa+d5AgV8`UF|n!7 zZu*O>Lf-eLJ;?NZpBZtbd_S+Z&+bkw65AvJ<>`X^AU2t9zx(r%l}@j($=0l;8JU)+ zi2HY~kozZjOK)W}_tM2Czx=vChP%lFZw6f^8Cy?z=*8XU9Io+4l!2k?mZUrOlS#`? zuW2o8$^RN13P#KKjcl{GRFEIWOk;sCjQl1+(}%pTi@dDLGr_msvs6YDnPrxgPSsG2 zES^ZVN4LEWr)@7**%Toe4@|b)BMd}F1&m&&I@Ziageo74;c=gi#RegFJs~Rg=B(2~ znv$b8t^Dh?LqKr)Y*aAZ=Qr~)xx3U0AePMkf5(zh{nCj2SreMo4dJDiQI$+LUAA7# zR?y#{zG(R1Tkhn9E9V5Y)+w4=Ck6JQGeBB(`O!GM$v6LwP1nqZerLz<37gtc^J6P_ z=Th(;lkP7UK2BI~%hS5IXg&SQg!G5Rtms{mj$w>x!u)y+I|_thl`!x zef^@fXqN>SS;fW)FX!DdxENpO{G!?Ic8n>8c~;Byar0|6Buo4;QG&84ZOqUktTPk; zGBw6is_3y>Dc9TaasOwE7WyKWL;Zizb{9Z#EsDD5ad(H{7TjHeyF+jZ?(P=c-QC^Y zgS!WJcMa|~&EET*d(XVNZ>r|iR98bt0+sHhDvMt0_x)dtyXtVVV=(*g2!2}M9l@mk z@o>7PzpDn)N48m6dk1MeB8l)%_KhxiUyDCigBs4UvH zHAGSFs^FYB4!>k+i)!pIS3>b8a?MTKV`$Xu`N#GQU(ZVO*Y7Fl9aS}@OuHa|8dRoA zLbV5iYpmjvd#Hx4Z74WW7AdV$a0L!Z}5(WA&8HZ;D=|AeEODT-jI3S3(>2=nVER?%=)yJvS8LHL! zMq?J(uY9eHinpL5W!KZ?3>!%90PN6XZ0~z-G60SCXtPK{QWIt^Obb5Rmo!r?M+NIR zttm{a52ehE+IS^*yJ=Me!&PQjEvf2#`EK_FhD}6iAT;oBZ8Q%SD7xD`^)4)6sSq|F zqL)|8<;<4OMUbUeMx=f!2_B{|5SyF5JqC=>(RljSs&y- zWVZgE5s6vpLdM^*(KgZD#-zTT#O;JDme7|M4F$qK1PUAuP?p=y$=7RhG$3UhX>4M1 z2ETGfunNrfMCmjjscJHuKb}mkNQJ)mzcqE~r1!nV?whDWD4fKDO1^VZrWaMwEeoR1 z6{UfSvZ@{h>34>bTHDpdh zlS4O=F`s>u`UnVgG00UyfR-XQ2`#JMnV3cvk#SceMdMdaRR@xU>k`-apAxQ{iLO_o zh>h<{h2`(gcO&CndtLg-;CT+Oo(bXG3`< zZr7dx6+bU&Wdv$u=oGTKP6Am%#XSjGMa{rXso2~iQHu0(bhN#$ zsL+TNF9VN2F^mZG0nW3Q8C3Y%2GfqBTuK8!shnGW!lmTCAYst>FNS;=tfW$$146j9 zz8+QOq%tbKK%{Q`H$!%iO&xJ@pF(8l6Ibh+#o*b?4MEQrg} zgE!&ihCP*a#WrwZI5M@Bret9uLFHv74J-Mq?XPW<0Vc1^-W02ks^mJ)I&XbVSWntJ zTz8F#s7Zn2!+C`6l!C4B(P9U+N`!;m-=&oo8=Mu~z~cQl-x0t@Yfq@62D6HwB%8#m zv-jPFJEaNj!bZqDIr?TA!X_F#E8JkMS9i+mtVz>>w2Xp9z5uRX42-{SWQ&*t4T2}0#3ZJFYOPzML_9{g2A%t4@s~6P+8;X3dmlhh6p$2E=D5Fac8xZQ(#DCR`akJ|h0}|Md@@ z)u&55X%AnHyoCE)hs!e(t){oP^PfnHLf}EfN)Wu@!o&V>t%QNdQ!ss+h~u_{#-vtX zlb|b>rrg|bb9J~Lbc4YVJ>_BbTlwlZ^z3?f0tQC%`k`z0zkJNzc<=`uB*fP<%Pw%l zs%?t-6_g_5h)d%_heFsZh^l3gh;31mjZ=+H0WzmXv_Ge_Zr(2Ll!t`N958f~F?2DH zwWQxo4Zi+XvBwyeB8^#=ocs$fCwlxFFP|+Of;BF`rE92n@FC`wW*UjezrlT--avt7(-8 zj-ES>)nv4y$&V}%)SJjjo(0PQtw+-f?XDw6kltW?x?Wy}=?RJV!!d7gX#eMT@|T=D z{V`%zT1*{KOjiYqZ|5=XnHZef9HJmLL5n@i}-!c5Ag|gJhq@ z)9;;hXXWOdPgR9J)Iz2*Yaj@wwt)qA)3FpYodS)43tXNU1O2^6VGtngIXQ{~BNbAu zWD^eN_kdBGMb9ipxb{1xmg=}tTZ%fOZ zyu9bbYv^VRp>gj~&-K|a_}A%}txrfE>x@Zvh_rn4918Gnn8L;>Y-x4nrGoK98KgkN z1`cE8;tzrW`W%DJ8m2Uh04GnS0cFpvpt#<5Sl+2S2wiEp^~d^{2SVuaGLzTTvIL_| z|KtOZJ^y(#<`xx47KoVAt17KG$Y9{AOj&WCew4=7?`%AB$mCH)Gc|Bp-X3Nrs z*Ujs}puHUuIk7l(M5HP(oGJkgc;%~ zVu$Zx7T7U8lNea`t$THHuy)@n#0IERabF6m0j4>3*8e;Y!I=;1mqG;S9hHfg&XJ7z zQQ6!wghu%@Pn^>A_{f(%#%2b51n6jZBplB2-0IAnP*p zsor@vqd=YK0iPP4Xz|hCEc;*=^yBQazi6rhtNZt$=D2lFwEf&8cn9$fY|u-GmJH4q z?^QzGBO$sp0gn0p(=oG-0jIAWN zU*XQ5&5U6~et$b=M5Scm+TDF<1m1~t-{ZTegYeZ&;lsFMUt8s8Xfp?>iOn<=9kc>K zBZ;jr)mE6sN1yii4tngdy38K?zuKK@=w@ImBHKwgMCh`&zXjr2zv=Z?vh1W8jYMyE z-b)*Y+78h@Ey*U2E4yVZ)0@%zh=?1}14>B~AnHM%6WZ*}zHeAhh>WR|>!s2G@40QX zL>?**cm{PpziZd540=Z?G9?Ouy*_x3<9;`E?j2K2e2>r@XVBqE#gd6A5{W&=Yi}i7 zM=&4qb+c9|{M+&+s zVl$8xcaBi|5I603B%sO$WI7ThRzzZ3^uxk}CEu7n3Q_(54XJV)hv)|7Zuf@XizgfZ z3~d6RrfJ!j^*Y)1XOu|Bao?DQ)*K#mv6GGJKB?NlYHLR$aE{=h4G9y&Rjx`g8vLSt z*@xUMFGmUCpj=~>*@oh*YSz2L3Nu^wB9J}b@H)jm-{nU_a&%%ClVuNAfVeWWpf#FKQNb2HY+1 zk3K3)FxDWKX%oD+mWqlVbFX{rcfL+nU2kLYKF~T`5{(1wB zQU26<4&BPB7f12?CQ_E7NOA3om=Ja2wf80|zY@;q_ixEy|Bg(55jKzd!;!VrB}C33S|Pid%AD9JH7Bz&X-y!GSyIy|N>-b> z2_#(zrv`Y=Iev(3S~CYZ&nxFJdenXuLk4Jl=~>MFlWo9Or!^`%R5dCBt8-GPY^{56 zyE}D@d)Tb^wB)`kQ*HHxY?Y}oU+Vas)``LqFkXzUO$}tx%t%T|Ku4xfyzkpZ-o`EZ zqaxhfGO`L_`Dm$Vv@HdUI)Y-2r&2_#apPsBC%9%Q+k2BVt@nzD;z0^TwCfC!@pD(^ z?ELhZ3CmYe%I^;F(MB;>`|paxLLBy*1~iiBzWSB#S2V@$HLfdtTpd;W2BlGM3BPN& zFzeiO&FLB0j#ow?h^K_E4RJ>c_*5JyerN6tn?Y`3D(}IN^<60I9s?|MyWeQMYx6AkLs!;LcrnqjMJi zPc?Ft+9~01+?RxIVEUQQOlW9f;!leTa9O?f?neYFFrl&aV4yFx!XK}520p9hcz0LC@XM>4*ewOU|0G$kam zHEt`pDeTp7NGjzA`%zr$hST9q=kb89i&0G~ISN3Q5u>LMv^0szj$5Gm#R=y6G~gNA z;gX%(@rHi~UM$QIcX5~EvKXenX)dcixi;rJ#kkXbyGQoYG z8P$k9rpmVF=lzRF$a z+pQINv>yIvP4k&WR)FTVEG#jHKdGKkF=qyNn_k(m(OcZgpp%z21LeIynj%$}Up7-R zTNG_Nl#^9LO<6Z$)JL}JxHmp~&u2EOep4M4Z*^kAAy0!G;>2etWG~|D*0($W<-O3;L;81p7iXmJNH<=R1N50>*DimRzx6eXU(hb|8l26{if!{@b5bYLF2PSaw5Uy3_q9xOne80@Mx_TN;xdvXN2?< zK-0L>Ow`^=e=S12!JgeOdOU$X7*f03fBpX$B4sAs5HL`dv!n8q))sW?kT8y3LR|Ud6Xm+f7-0$(9Az? zm@8^DBlCBb6kajb)eS?;ENhq>usVj(X@O~amcgF0L^?)0CU*kXV0cxP8btyr^9L~3 zRD06SWQqwbU8u~tq=oXzP&W`iBxa_k!p4a|@+gzjJI-M!B--Z*$VWk`F~zSwxMVI^ zo4B}qz#d3s!o?{JQ`e!sn{HtlY@QevZ>IEhaN?VdGy*YXd8Ui&wL_OSh%K{vGT=NxfXF%`f% zB!$wOm+$)?!8nPv?bU0jz}5|Sor-@wAo#q=W?EFfV#+tVbul`WIfS)tNxXc4CeQ)j z;J`xy6J-j~r)uSiaS{>F)tgA_TE-Z$U6SW0*>|z~H-z?oM-)pZg)wL4-inNOh)NVu zgqRw(Q+aXcD49~+PX@&90*=ITvk??h8#k$E zHg=R2T#u0?S$X8qQkxvX5wz7nm8!~^D{a>)auaIXVx-N8DN&mgEtE8=${lmyn5wi4 zvx(d!-?jU4lf*_%{Vu-Q{=rqh=_%thD;jH>3Y&8C034L(`~7%~1I7bM^)rVn(*_HV z>71gn#<|OZ<&$w3HKK1UqD}Bt2SiRYPtU;zUb}ohKrBXcCM%kNhsIEGxg@mKPw~ix zU{4-}GW@23;Xc|EMJh!4s_6E%fI@^t(FE#oZ(%%!B!)tVkZH1{&!pFoBB2 zj}ei{BRnfbEY`_$PE!*pcam6zuO(+ypMLr{g;snHm}FK9;u6_Ky2S}*A`s1`{~kFN zVLi=X)s31nhS9j~J@QBtw~GD*{fBe&L#NBDwTQ*DE|rLD8i?~)FXUB_uNYJ>b#%(d z?Es?ntJMeJO94Z|AO0LXWW&+LX`f)jsbH7}M(o3SfNBnXzIq{~3AVyj-)+(Pd7lXw zCeS36Z^mV9x2MtQpeM;or-^LP7)UhyqP?uEI2wgjs3;=W^?Zvt)%OQ*xRuq4zEiJ| z#o56#Lh-JdxJY+W5#OIk80}ACcFL&0>GWAa?L|8W^~`Z8Pj>ci#zUw8ymS~l87QY+ zt|Ir2yV9wtsFGV5oDM@{=4TJ{&L);PCb&?w>h)`A%IHXk*Rj|pC_+$l`z{x0`o5Kb z=?XT2O>}kMdNF4u>-%rAc`Q`M2$_6`y?S-eI*UFe8n0BMsz4$HRbL|O53zP32BC^Q z1O=cJGA>Y8bTY1NIP76|vuxd~krGX_s}XVph)Wpi8p|EsAT_HXHD}b|wzv00Ku$|p z-+vQ~&MD(7KY1!u_2?*gTbL4ZJ`WJhF9bsL8)I(X4>-)P4)>wL<0GFp%L>CFHG&{r z12Rz8Lg4XYD~L-;&=k4Vaino1>f-zd*I?bC7CK0=P8OpEZIYFDCgX3SQp7Pz0fgCx7rS3{2m zuZ-_lfS(#9_@6(79m+0c_6CpjA>irqV0Ai3RZUSZu-k~2Ra5Z*Ad{6uTl8?h`_kwbj=mW=Iwh559bcC zL`}RHZOgvLaJihBkPCP~5=n{h?@=&aOqN_1Kz#3hDmxvtk`y@Si%n{N!QfL zoMzywM8MElZ7VTk$j4c?`2Gu({!QP~YWzpsdOEd_OU>oz`WGp2QBo57 zR;ZB>Lx2J$!j6p?-X}D?Dcx}?DKkCVuSzolI)`R84|jLJR)e1zF#csQ7be0d7@t0> zs@nNgi-URh=#tWc)zp>Y2ETNph*r`E^8{JRiIY`xyGuTrOf!*zbU$G!5%lm+%efyd!Yh$p1)#j@;%9 zhQhMNFBKsy1EljJ`{DC}D)}asc0^TRT@+ovmdjdl!~*3-OdX3)#v#h((E@pX2YMT!M;hfFK|x6XtKMemn|OoESkD4mM~6t zZ|ZhxY_QI@;t;U5p3G4iHVrs;@X559&kTniOnEAj#+{9y)uo)z(dm_EC*{v9sbFM! zU)$82saxX`Fh%`XEls%^ckQI(ssC1k(_-+`=g!xu`>Ji^H+8Sw__b@RUAy&l%H8kz z?)A12xdlE|P?uBk3$>3mY251cS1pbxnV7?CcCME{w*W`|HBDFg(^2on0~~b=p3eWy zQQz-BomBqgsOO&3jY{wS<*1FnbnDRpmRfM~s)QdNb$g_A@=urxP6P~?AOVM1b1~W{ z@we>u8F6N~ft00dSNx6vDVzXce( zDY9YaviA;fn;V3&T=Y@4>_|=dN6ImWQg)`hIt}FGw~J&C9Xpt&{?IC5)oHsr<~O~ zhdFWWIcfZHN*jW`xkt?B0r4vkkp+&Zl?d`G!9YIriHb_#2O7i{>*0uuqZ>DSd9RvX zIY0aJ$GeAzGa)ORddDdqO8opuAS+PEMd>Q+zjERPfJS<2kwIxAL4^GTndbOZ}dmy!4v=$ku1?P!p=)4rL5Ewx<*y+7^zGg^Lce0Dr1CHQ_CJr#bfle{1q{;7-Cza6Ut5UA%0bFJj&*E*Qrr?P&e33T%Dofx3}ytqJE-J|p(3h_ z+C5v01&mNpiB2J$fdj9L8U3eJX+-VqVG77jt?@?ARa?5kFf{2Vb|~QzB)OM!as!zLCZmDkPD|y4eev=a_^ri!@Y<6ftoQz|5AAU@Fra4t# z$R;_B#sqC)HTEoIe`EZttU9sHbnD5b=HS5*(HhvO3q0MnsAO9#PE3P4}ewI@Fqm;25zO; zjdEy zPoO5E^@*kn0BAbLFoQuB>uUt+;0TXbd6)0@!EbV0QoW$hTxY?a2+Kl&9PFuhcFC?t zLahlFu=8iGb629(9ii=%j7wFgTGbG&FBle5F7pj)L7j}hUMW|O%evD#>aObpFe}n` zmqB>LdGmDoL*$)j*U-(jm&tYDD+hP9Su7q||MXo<+)d*up*~l#psL^qp#?S|w zWVRa$xM941In(Qm>=h2TikpTFAK&wmK#$k$Rh~Ic+qbRF1TRx=UtINUDl!_12X_V1 zouV-Gjn|bQRMnT2-l6KM(Qv3^$OlS6yrX-43B1ykXHg0iXd|YK+nqN$kWb{pdShs1 z(oxk+gs9xdTCXX8nEi@%Uqt>~*=y_q>;Q+F3S<#!K5mw8$FhX&ovxSpPbNihKzuVN zAF5#VHegp$MQaX(Ar0DH(%|@+oK9l!@?{G0`A)eui)S^;y<^Ud_j6Dpe{S+v9X3+3 zKEM%n1?vk+L|OlA88&eOTFo7br2NS@+kUC8an%Zt>=mrzRJ9+Q>x-MJabFA&0JG-% z8A-l(uRk*@Pt;>E(1TKTPac=5zcT6VZ-|nS4*b&Q!^?>h_Aji>W34l7RPxyZkZD3) ziU0jwp73#(0y;|~rI}mwv@1hzxIzW@_gQj+vQyA{lR4%j4p)XoE;Haf!a9)MU*{2K zU&{B4%Wj)Y!)u9lf#dCvgC5Fw)2By{w8)v5aIhoUMA`9vPcU=&fO%Elq>RgJ_|g?R#z3pbF%Fq=!O(CgthtnK zZ5H)pvnKGu)eQ2^=vXb?a+igMT>4)pU9Tc=jBmdbC{^Uzl-PN#)0d-G?}9BN#-6g1 z9MmdjZq2y;pr7Ek9*2LGZ}lap`|>#Bb9uMcy(#kaKGmt6_O0Stw9?$d0|ez>8p4-< zC7cwyd+o5HDbpX~CCYNg9u8Q(qa>|w%bC@A)WvQ&H7vP^*dVsnb@qG3m{<|H!+o86 zZ0&FqsFcgluxew(z>KNKr>ZYl@TD7EYg}d6dr0!=b$m z0;*3O+JV@cfX42t<9fQJeQFE@Jdw&_2n!Il{w{Ln89BB~h=#g`t%W5PO1I9GmLOrx=}gE(t#?0~cW~u@z@m#a&w(o5815K6 zF1%#UKrZ$1S1_9TF&J{AR4BVcQ_uCjkl$#9q1tc5*Y3mhLluIS3vv<8NbAUE7Y{S~JLx7v3 zzP53M%H+OMyF<$B~;t4K=nN0=ndxy{+L8137vn>*koRqX!RCS~+A4a|VhOt%xK@7TzZC2Fh0KJ{|7l%jETV`QY_QfhJ|@9&-Xbn}0>epha)aO#&?R@lurR^W zj0Wm7XmhGs0;wgXhB79?Q0q*JbRnk| z@~Km*XV^N|r}KNY6AdB5JESpG7!}_zbdBGZ2@-*_$e@8!!>VD>jf{s!i$D^EA_+jY z=LIX>kok!U3vrz|VNU~ZkXVRKvIhco%q&<2c|?8vsQ+3Uu%qc`@r$g5)lf^_u-)8S zG|75m{EQif7ENcg{F>)LUUe7S7sHZUsE|HJ2O)C?zOHnk1 z*2yGT<(*16e*Vaj5^4B_IveQocLV+udsJ3=6Pz+jqHV%bfCA|8Ak=oZ6hiynUvJL+ z;1{F}YYt?B*s(VZ+3;Wfc?@T(Fe=f|`q2LQ(BQE6PDb=no^}|Cp-<({7y^hbM5ut) z!@^Z$pYB`M_Rys!vH6X2Hw4t*4>|LpafsdH$IGCNVs4>8;}KYrEM=Mb=+eX9R51R_ zca71%Hb9sUb1>$4rJKLQCvYHypePWZp-9;N;W(K>h(J^R)mYVBFex)fmXUthg3?XL z8)rmIEoZ2vQ9+N=(Grr#k7o*mRjj58i(pI{38aD@m4b?%yzz+fl=gy80dG5a+jrtw z`wp9EQy{7B%8+laUE0s5x4Eo)?Ep&xa7DgmtSRuXkF)>Nc{ zT!gkd->Uo@GTvuΜF6%JVlLGc6k~voTu5#Xqkfg!F1*aK}({PlhHmIB@=*T`iK` z$!*MB3|l@`k(t=NadudYjxWIk0_2Su;Py%$^Bi>8i==M?T?}ca)gmgFZco1#F+c9L z&W2A8Ho6DIA5M-}X{c#pu)?C`>|@`id8`@|6+>KqwIhtb#c;MW6DAjr=zlJ=gEwTN z%Q`|kXRkU0Sv|bEd8FTXx4U`#oy?w8LAlzNb7pR7u{_wQc6WWsQS{dYKyW4Xm!TQ< zUx0J`bFKM2`cuaf@t@sRg;ooYti3FgqF25cY~ow{WH!wVzprR4XLWafO#m1G3v!5& z@5(!u;umEjDzi$r<<9i?xDU`-C$2MY{0{XBK)*=jQfB+HHovVj<)1E`lab;s&v0gjZz!oE}P3_*YDhhZt{?mJz@ou!mycM+*>NIo=bb4eJEgp~HTlN~F3wai* zM`%0{MaETstEy`im3V%hC@p-nse*M8vAPqX4^VFSiE;3re%iYRFY8!kbunZ&(1oD6 z!Dj7d>OTsqN=_`Ta0Z?;E{BUEMYO7JNK#&{dx>0?O8k(B!Z6Wmn0R8{M7y4Cm7De% zlznpql`P8I@1vlkA*qkP4vZCbxv2qOid_FbK|j&(xa^i`J~Gah57<^nPEQVg_*jA8 zT0Tpnv%X5JL6~cFG!Za=9!PoPZEsC6;XGi;ryIoj1<1;NGv06&rL!kg>P@J~FC^Fw zfaY-QT(Q&Xu7g&0dh1h;i0dS5+?0zP%j7~f73N+7vi%A3o5ozFuS zjUwj$Q-a)RN^6d+iy4U?n(B>|YXV~Mqu-uSY$8a|{8=0aI3;g7<$MFJKTB`g^j+2bAq(lPwc!$t`zy>QQTpv}ayA8^f4^7h+ z?konYn;EsSzkc~xJoMm}VykKUve~M_j-xHYtt94n8p{dEKGxh@w33}A+L(@qQEomf ztXFND*9POEXx87Bsx#4el*^Q<-Rm;e*heZYTRy%6dQ(>5zD)mF^Yqe0QDGIb~QJNukG5EfmX zaclL*V%WP60y6S$@rT%K#hhPyw1DgWOFx^hg9TRSxrU8Zq?jqh0hIbjBTJDD7BRM+ zdEGZ0x1L+(ribbXl}%Zm`&ac%4ixKf;$COJ=wBHkduh3&KsrY#XF!DLDTu*HD8gD^ zLyt-RkXcF;j>$`OxL5fbyyf zbNb6749MqXfcXgiT#WU)5d3kC^ACbBv|V;Gid1X}oO0%U=o86*C{@)KG89M$>xfG-Tjv?97|D}Mq+k0`opi7boR9s4kXpGD_CM#P)#_Fz?bDs__hQxwBqXG_o?ULM9L!J*gjnx%vcVJKKMgMy8}CoTl=p@E{k*Ke7eSqd)&11x z%EJ`jr?letDdD??E8lL@-HuFWWT9_t$XSGXAh{RN!HQGR$ZWHe{+h%nU02+{H{10W z56RNbAdV&4t3Gek^;ONCUZB5T4+xJJ#1?%DP8XG}Gg>C@cWijNT;PG1$Q@716nKo{ z9CJbHF6?Y**vEyE*F8`i~WVxpu`5`h?-@sxHR% zv?S4tG%j~HtcCjlE{RPc+(Yfd>W0ax#%Cc?xx>I9MbkO0J6@0@5#pOA+nLl2&}+;J zn{AWxY!#`M>&1S21CC%W&}15Yfc@IQAsCudD#V#8FYV62FL`6p@}Y}GU^P_3(;Dtj zy*XTJ%djQsv>Xg@yai)^Wok5PtQ;3+sU&{VX@V6EJjnY$WZL{tob)NDq8!jdSPGHy zkQT7Swn~tPh20!67;CMR&Cwu$gU1}9W=ii_da-wJNRFUZ@_#^H>ML3?G=N%hOCOvP z-3(M|WdE=}MI-SBE|r@5C$l@C;Nkm**tf$Rb``|lP5}-^v1t96UXl4&yqW)o6oZTd zX{t1S7U@F2JUYRV^oG60LHz_8PCV$0FW`Mt4%d}qkf-IG6@v(53DJv9%_HWLsJp3=tyB7U-b$4AUtXo-4f&1=@~7@_0ZyN% zi0VhE?*YqPog@2+{AYUCF4WFx#2WR@X8lUVp83QXCL5n>pAjiEjB}xSn>3slh%1P5 z@)xkFJ}C5R{LEz77hJ6unovIwWIUa@JMB4w#qcs%u@oP>(*CRh=kjAkM@pIu2vd!M z@4zDZOF0xj1-KyGdl-9btH4Unh)PBOYVZPJZ{dD-KdgCM1MTFcBsEbU3esE|g(9}V zIK_5wnPu+$dc7UbRJmnw zM{yU%7XJ)?&Dp@TP*p0*&V72#VcbpQK>tRCX1+=bl}83aNy=z>@Oe^13EY)2T$Y1& z`u>Y|1_E;9(?a=6QXB$VU7BNI%>90P>O~6j1ltY$tA6f(7~jbV7aIusfxWe}NdqSv z3pqULc4dt%fv?D;%+f`m83bfFXoi1$IO9U*4}y(}O41rDNdYllI8K}*c^_pI`Rze+ z)CM?;X*JgLhIAV0i6%5P*fOW8>z!i(ocYi}-hyAb_UQCZr6<^GmTasIZI?>U)@?9+ z5ezC~DX$;y{$QTq2CSboUJ%(BXv?%=Ney}mMU6QBGXjxG?+{^>KY(Rx{y}&^Ur7_oDvfbBl?HSRD!T#uYa;6o3HlGv%Vc> zb~K+yeECBdg2EU9>52*udGsr>;Y;-Jn$AyRP<>+|cm&O_QeSAg$OaHn^c@tXuN>S# zzflnOMEiV+$%9YMF9a@a$0rM86Mu@jL2Z>M({3;_zBX6xkXkH8_g|31g)DT)OVd0g?F^G+(d!PIlX9u&)s?NY`x>-KvUM@hQGX`W`Igu=>V3U1aH6x|}DS;XqH z7t+b=GPIuUlldxP++6@dX)p_k8mIa0|okbkApX)DCa-W z-A^kP6H<^5_4~uMalHK=uGp0rw?5;*s;+o}+7Umt3yH<(<54zRV$N$}ms!51e&&HQ z3?r1r3;(?Sb_r|!g;bm}*2t92(?-fpH;itOW-(ZZ#8hoDsNe3pR5CP|Hj9fOcKend z!nCDCjz5h^XDe*7gZ%OeV=ck%xYUZa`2mAttYWv7Udb0{Gw_>uNM-!Gv`pxF{cSzW zP5IsvQMQM5mMVf?A$i>JUZl;;p8;?0XukNzx|h3UsFr0miae&qw`A~@kUIWw1?#_H z?z!w9RjPC6{PPFa!+Kj+#eF^*B+prm^m?(jPkTs4Zct4(?;X?zPjD*wpx|UpqoT;s zVfkZ@rKUGBSzD(9;!`l44sWBZ*Wuw%A32?~>mL#Ljc-n5B>Py}})nmmYI}-j!41mc!pVf!?dA|1#$juvu|1Xd`4Qqc|PMe9@2>`iT<$~}T-=G*0dl-OJ9PM7k zNnN(akYx*PJ8AW+10}zJ)yd%uw88zPG3wwEiVj5!6z+>tk?L0+R-H)I(4-vz|5%}2 zD@uV)0bB?G+wg-^HmBSB7d{cVCaYWRX$uz*N;vslMAgf=B%t6|QYqktK^xtt0L`c>hc|9<&xr(Rgx_8W*RGW$%+k=kEgG~sBR%Kj8pDE z>%sX5q%>0aBr?YyMo!illiVzXg8HWRZ5lKBD;5LNKgaqwsx_T!iBPB)N*l^U@4u zK^;xt=)gH#e~{851kyyU_wqQ4K*r3Px4bc;qZ$~OY+ga}>$_z&MNU*HP_ZLWHh;oE={PTe#c#zz6#&4k1H@UD78RRGLx)p&&zb zn!O1B?dWK0PhFjjH1<0Y4%sl)m=LJ&dfIrtELu)OiKLO4PZf-wvUmDSqbyGKe4RRV zDMzj(_hYe}6ATp)$j18l5rA)v8)n8Ck&j6yrP44TCZu{M4>38+8j)}A)9xZ?TwJU1 z)Vl8cYA3@4h+M!kY6<|lvrL~NSB=N20RVK(QU_2ipwtWix*8f+ zx2;`1E3=_`K+1<+c~Tno6 z>3>$g>uE;3(%EG`uLMJn2^t$JAa$VSt_2N|+$>Qd8R$}#lv!x}8s_nn=)v`d1ld;$ zL>DuVQvxH?ELi+)&rAG+JceVy5cNlfUa7`_vBtNBcF1O{D`j=|I2oX-y1u+f)$I3P zz){~9(L<1d7#d>)0Mu=ob#I@ylZ`<Ft5tggK5i-(RXpWX`SNSj~>WApet635Yjaic946c`SKL`C+i2IPSV-J3} zuEV~mT%}!Y%UJu=KQeE(Og4?oq(n51;lS%kcOtR0#EMP6c!m0dEH_lg{8>E;##=ap)mI9qA6J< zssNa~Mm09`7tGE4H_UBwz%We4FvL98LD~%o?NM>WSQ`6UvmEx1%k}&(mwRvs)&X$2 zD;l3Jm-lG;e|EXQ|8cpIPg(!xE_a?gY^s<49g(Pw5y}Y_~(9*Efqc66Ey+TLU`Hd&p^dF8U; zr^-o>OVNDv;tvyAfpTPUv}H>q(azmF2&3bU;@1!bV4(`FA_+<0ttq4z%85?D*t||% z^nBd%Wao|z3mEY2e19x)qBJVr0ySlU7zk?sl_&FMs~Tr))b%kVH$Vmv)AAznN z;4Wh6eX4qefSwBS?xwXtVO)oJh+(N-P_*BBah?GyHXf-Chl@VXooF!zJ@AB3Hu0!W zC>HCcu-GVczUZk;`h7rvYehdIIW?h<`O8qqDsd!vYBp_i3GtT_uFa)>e?3Lc?j07t zQj;<1swFGpo!VI@u9o^PhnjiLXq~B)>Q}JvU9hTjP6_2^$&}8&m9Xx&pHWn=SBC0d zHMW;;m4_~T&fh4YtfV9WPI$$2yFGT$Zm3KtWmu1;xA4Zv%uLy6%B7Mdlc{o%%~lN< zN2}K5#UvnY<<6#in$@P8 zM>Fd@ZG7Qub^gsm$+*k6zT?it?)T5@M+&DPx3tuVm60jLL>z@Kfv9}l3{l&yiM{{e zw_5$d4dG6xOKSW*u%G@G0pM?&pg#TWJ-bm_Ag}db{uWBJ1s?n#e+wE&fR+aEw}apS zf9t}-L}T!CyZ=s)L^1vU;_NMh;_9}x-2e$L!QI{6gS)%C)400@cXxMpcXxLP?oMzI z@O7TOU)kR|b$*;0)x9Px=xVB{)oadqU*j@V*nK(aln+VoUm2>4@iUyWvvTT|ezie? z$hFVP7~cLXGdnMR=!5*N!CEXu-?Ap9>Uzg6M-0Y8%e)C-dH<1L=2C_5=7V?E;SEq0 zE#xfSJ7G$BJN?o=C2J4$7taNUTf7}7CW6gZe%a`=2wI;#?Q>C(YsZiLDaavTlb>f< z%A?_1YW*sx_5_Ewe$F_$em+BRA{!NSKtF?>2AhhyY-a^b#|V;M{Fh_6IS=RO5Wjem9aSA|xt@$I@>z93WKu8KRD(-_!ETIL4_;;*aSscT5F067hk zlHJ%A+|!13+V*f5nR>|7y6h|<25`f_&$^2Oq;s9smpT5Sb1%hXqA9XO{zd2NWXMXD z`{c9_4*xGYcMnMCdfWe{b1Cau7s0sXn}bkl+^#`SgLKbX&IHhX(vOnq4a0>71x$RB z6HF$DN$|ixKZ9V+6?mjy5Qm~u$T{v=Tp@~AxIIX1eUa%sbHMvm0GNeSh%COAl5P;0 ze>44wK7ELFU&5OTSI95+ddj(sfr)F;_p?`?S<3$Rw`fSH&XAEHb}|~5wrb#4T6bT1mgFXBjMjMyTL=o z>9WP;NrPf-!B5P_Jr>oUQq9rjMpEl;qzY684xxUZ*)f#P;gRAP$0hT@jFFhb5#-1P zVRMZXOkDx&s0RcGPeqtn?IswnxsNEW&=iZ4q~JP$mdg$($0(zV1sYFaVmq{Pi&)2GL2! zV^RE`vn}6W*Ha_IJT@3Pg*x>w720lw(h-3*!VOsq?kQkSNd1aQ`DmmLco&hvuj=ft z>HfzKJX$Mmj|FCqzG?x}Cwf%gppNMg3DI3RYshNCLl?V$nLY-3Xla}wC-too2;a&8 z{()~-`z9+gLk*E5{FfD+*K)C9sxA|^B3=s=JisN8pWFJEEw(-4;Qo-ey<2v&dT3?DMos1=MD%53`Q2{dBK zYx^f_X#nzzXsu=n*M(b!c}I=T&>Gqy8p5Wm-Y9A zoZk;lkFtI*yNzaOs}Y|&jq@CI!3#Je5)s{+=J&w#h@(c*hH=WsS8F#qHpo*>OO#^B z6F$RAjpALEMfaoD#&9xZ^rxo&<-JMpw6mhx)JST0v&qAyWaT_foJFRD{LT5z<=8~E zHu}!l3C0%7K!B0C*MhA6$f_?JN5qb%zvHp2!o>OWY{9lAO!(^&lo&2|iDrrVnvm|A zvz8_)u@53M=ibYaIZ+8!r@~lxi6C#~Bv3G&kft(2N;||oI|uEG>Zw1DJ{Tx)afy@u zD&+f>wYsJ^#qeYXe!slK8|p`kf`h-s~? znI7Bt#hqFF#0(~oN(;DZaAVts z=)QKCliA5kr>!R+QJKRjdB*(X6z)BgNbZ!p9R18+)XHmq?(&cwY~RL1>iU7bg0%>t zBMDH$Wzz7@<%G4EeSMnA(+ST>0@uT_a=tWu;knE7V zfsryf{5JS!JB#(r^?rjMe47d6ysTi3=Nt72g_+()7>1 zonrD#i2!PWP2#^XR^|PQH1w21FW=!Osq?2M%Tgx3Ri?EE!oMHif$;Bdu*n z5qGy>zXTWNLE?Wqj6=T^Y9BQk?(O^xoGU<(D(v3QFN|Jwnfp3Ka6qqTIAy;8gz;s| zOnAO~U~qmR;EZ-~upBc$MM{+AVl5<#z6mRkCi;d8NR*4=rBUM5h;|9QTrF8-8ub)# zYCjaG3I45RM4O5;4CAmQaA;%hj*NtV8e}0ox}ZYc^J5*f>p8 zC&5AQmiMf2gLkX|Zx9;(Cn~6aM3-~_g9^Uvp!3w^AZnRxX(@K@>4A5SJ0O zK|L)kH<0IuyFMW2+-cnZ$A&zD1r`ei4hd$=#qX6&02?dncY+c&gN6+a=Vuf)=+`0I zTNgd(XM`ID($9qiW-QW7vmA$ES4qscllHF6 z1E~K0$3uh5ulB3Ke?PP(?yqNbRQ-FUzz~Hgr62P#C`TM5YU!M4q|uB2qQUhibu7m$ z`do}zsWYi`>_cjD402=sHK#Sj3c3oSTnmS{MlWen3nC;sAe*DRCJ+u9`7~Ap(ul>Q z7eBSfk{|o--m?aV*e5Dl(ks-KCbJcYnuqtMfRm%t*})=S7{gL&8Y-3l8w*CO;_Y0{ zU;2v$uL7~)wsj&Hi!}TYroO*e@O-xa8nBATg5f@MPG z_E#!y9w(e{`z)Zzlm9WlP$WMr6c$VzZy4Q^z;x-npGdu+NPAwx42@f)1Q<*cBR=EZ z?Q zqXH3XKy5SOAwhwWF-Bl!7~V2GR&XGl*0+H+ez!KyPJZHQFA|Sz-zrwQB?rGfMokgEE;t%03&V>%3 zLI;^!K-VmiDZq2uEdj`~el1+C4052D_(N0T=+(p|hX?)vLt_xgRgd%roCPQ=kkjid z|E6fu`L_mH8K^>qs^%XJa`|cRe`}D-U5vw8(VBfKGeHa*6D9- zE$H(4P7IxBKZ$@8Q$^YTA_7KhibWe5~Qj8f}(Knlk39_=L%GDO1=-hv{#g z9kS*9YrH({aIK^H3&4u!&eKk9-;wst)CY@s?<}?b@cwC@vs9vWq&4%PAxOI6gKhAE zILx`G7HP@0G_?5oks-3x4*1rMHQ}1&bS>xfdK)yqRo&);e%~Y)xkO3k(29rr5*U7= z0p@GR)3jw%y)UGM*Jjy*YDjpWNL3RI+;{cD2!hNb079Zdv3(?Pnl~4IJ3FjcUmL2n$2B6sd$sa)_ zzEV>_i9D7YqXtR4@3KNAra?>k1iVrDJp zxNUvgyaj4Xowd_mfCOcP#no z*dJ^m%|Ij=(%9c7CU0W4%i}~=4F)49vj1F&F#pn#&zOiE!#c9LVzXMHiKi@kwtSA& z5CbSK7C&rw4%`kVRR6;yqzxm4Qw=J#@e%VE#Z@1}&Hut67`RyI(EH0}U1V=#9KI4${lV(!+C`y8HLaief zb^oI7g3C`;4C@MP$U`SSM5VY_NU9lK)15VRw?i8FHG_2vZ4FWyP*; z;QL_hb>O4D0ORHzqK)q+lP{6U!UQGKdtX(1L#HbJ1q5@jR$+fm`^V>bF5Eye!pMv6 zl0cWtrQM9WX{-HU0s_D^2$(TICiwpY0{#y~7%iF)wejhIiU@?y4QOJt%cF~#q@JXv zslfEb4(~}yT#5p`!ieoLNa|;c*Vj(755g}*aQ%;@n50pM_x9^(h&7IT+J3c6v3!=yp~Y!*@_aM z@kLKmB*Pp@Z>DHzX3SG_R3Tt$&UBQSQWa9JSkFGfQhXSj*^cNX{#eKyel2vlnVL!h z{h{tQbsI%WLL86SrX6T3%tVwD5gREkdVqv@8?~M1Q4VaSV4(`qNxw)zYjHYeh%1er zaT=`vgZ2(7V@1WM^P;Pej*wGdDmU;m?NNM*&03+qLp~<9e5~vj)JhbR2~32tY$rGv zRufxO5!9j=OccBv7zlGeT2U0fHnJz0TcY^Cu1=Y|vxtnEnLzdN!tLI_n-rK+()c$5 zmo&(OcZG$XeZ`BxS!K0zKYcxY@rgB(H$#5vu#&VKS9lWma|fOd{XqF)TAcJ!&QwuR zQe6DY$yoJaWLjCKqQO+OB3<z z1qjaCpAl+#4zadu0G%Ab2CPH!0g9pC(aL?(kD{ft3QBzUT?$BpA1|7`f zE?2&3&ZiB>8P2E7veD_Y=qeZm`Cqt6oAd+0;J-m#r|@NV$m|vl*Wa*f40PWB-X14) zjPsbMgo9ur=8%O2=J$u=Bh8emI7^6fnsA=qkWt~B+V(CRx$MKgWc8OZwAa5WaNv_s z(ZJ4Yp6C0IV zo=I(CA+cl0cV~QT3NeZ)G_748;yZeFvb0#P>ozh)eWm7hc)9exkUoELSLKGwRsz`p zH3z-890#qU<`%bv@J>>jzh_l0>nt^WM$V(>fCRYDoXm8;+hSWH#l zX{oJVlWJgL-^Z58<8+2KS>IFb>OpZ{B8fAas(T@k!vV-$GUZ$j(g7-R5)+sjswTO& z4{QY<8#7{_dPmIQiNN^+a?ponW+9RTu5uCh@zuZa>axDLOL*b%4KHO8ETZLZsg*WqnWetQ<(|ci+-NUjp6&Q zJO@*lGk!E5Y~YF={^sEJA6#8~gb5&>TquRlWWbWu$R#;-@3ry}(-QVogaKPd!$W5q zk#OG+)!}_?*PLq!(z@^(#+$YCh2Ji9a7w^qiKClkVKhs_|B>n!*>4mO&mtqi^vvRn zBVhm*e{{yhX4M(#^^Gx&lhf%qv7R%gRsyn3qT==}rJ0lwe}j}VpKcPl;j!=r7-C9h z=!#CVvMrLtpu9{E)=0tOj(C=_-y!^n$kS$=P)J|(2HqM7e zx!~pD{0aM|9M3p>Esf=GRB~&XQXj@fmbm%p-gdaO%Z%XS#@)ER`h6X~EeP?@j$Z{zFkc`|DA4(wPcH)$mC^qZVgq z3U(vkgRIL&Hi$rt*-2gd{JzW?4M{_lx361iXCplQCH2T_E1z{U*MvxsjtrDqLHexz z_3+$0yc_%vh-|Q#pU1t9J8kZFnY=?fpE!3oaBSlZVmFs(u~>{)?pX_<+qfb=ZsG}B z-JTO`ttQ*;O>aXNQ+XHVgXaAqd2$%1RP139P8xG+G;`>?7^#h$#A(s-WbP!|^QU3D zuf<3?;L_*)QXWpF(t?nx|)jcIWe)q|^u zvTJ?*)^tn>>LkmH2%Dn{lT0$*Bhk`9J1O2b?#u|>Y1fQDBav~=5;pg^TZYL*`-__2 z5A$(=I}Fi1)hnH6Y0sskPI(v82SQL0n9~OWoH+@FixcjDh=-0{WV7H)7evokOd+4O z$m(EhLyh7hxK;Pco)i0tQdBvOD|JVw>2|l3K`FKTjx<4yEzdA*lCcQLuM|6?^unmxmMOch+`%y)HxycFj~Gy z^a94laiK!YF}!CvLZMNZVTel;Q?*$h8(D^0${(!3nG|{C9te4JX_U_mCqbO8BG8Xc ziR+WoHcxam8-GoF=DgvPWdVDWThCjXr|jXgmy)f|YRF1AVj(?nuWC(LT^p(KQs&Lq z(dX1%tIV|_7bEF?$aAhA3~W(D63I30l?7doSO0;c;p@u_+tLrSeInzFW(j3^n%H!& zzuctUu)5W~OjoEU-eK8FhQ(3pA%A}XQ&|aTsE#GJfvHAlGiud&lq0Nyw=1y{`7q*RfiM4 z;N4&Knt#$SxcM`iP|BEP$T9W&D(lz_1*p&^LT-Xs8c;3^UP_Mjfaq1z>j{efL|>yV zphEwlXBKfQAjD%BW%-&xS@ubSc4%4r8f@q>!&-6T^?vnpqVLdp=az+Fj|dj-25#5} z-)I2#OScuV9^EqRmo(TdTZF3s;5(4&P2uZ^^rGw+5+F_*U}GSC{^|wF3zFj}XByV? z4&i0}aig9~KE-g~5k~BcM8>mRTLWb&QB=3^;Cw`w(5BIY2x*;5S!!m#YLI&LeEx7d zY5K;o{TSHN>O<;UqT~5s{*p2FZi1)p zlvD3cnhDR0M~z(L-bcxxeGHYAY-NH9`gw`#gRdblgS1TW2XAY+Jm3-qeYI{3;Q2oG z;fV$l^!{|Da=NZC_^E-}Ks%8nR-~7tY0X9Nt$Te@F6pMnb4i~V@Ur$9!@T(0EJ7X6 zz8WBQ)FxySvmnb&j0Ww#r(6AD-DPsuZjZbM5lD$vChcP0l{wG#EfZ_0q{Teqcxgd~ zC917GYG{ZQAUQ90g1h!v6ILHMqfCb2$Y|j)(Wrgd08EP^BJuSU} zPk}vokw^S^EjBhmvVH5qvlc^m?D-hRR^a>uTw-aUglPKCW!MTasU{?@vlJkbezU$x zmr_65Y8YfzIdEZ18Ek%5wNeM&-jdl(5}wVxN~4}V@!FWD?b0jXKu$-gXBiAED`?%W z4i%xK=cMLBd@EI9(dUsyP>o5V&33PFnf{8)0FwG8{)_Y%i7#Y+BwvvEk^GLZfWtLgUywx-Z0CDdARxAp|#%P z)ziT@>4G(B>&TjXe0CKC>)61iLbI+nYiF7*4{-z1rqhFkt)pa1|Fbb=;gdtUl&&L+~<%rR0k zk}8Jf_hrJpc^K8^i*3{@hDb~U(Nsj!MTP?3T<37qNXQAnEtiPbstS(2rTx*R48-Nt zdf8fM#*`||(WGy_zteVRc)t2J2Sd%E{dwVp^HsXy8G98rBYNIou>*2gQowJ6zDG@6v*J5&{F%c>?F zekHc_UqzYp<&tsa50I>5>_3m`pr=6$-&)woVVBwSX3e<$j*?W%;Qy0E*j+yJ^NX6O zU-P@A@pX-5Fva$}Jc%k?fVs0@*o7xPNp?4G!WR9F(>Q6j`9O+kw4zQg8@DPg=(JZp zt}RInXTRdM`mP$*@3O>O+_YIvN0>nHCMB2%p;dJ4(0O z)NMMwPOLaGaUr_xKWh~E{(rmVR^RkU%d2?DG`j*TAe*WOhirHe)i zCll@(Cg6nm`EZJ(+?IR!OjY%@ggH$}6wYEf&dMT{xZw6ULVs^|x_fz9O$;I`SiKp1 z7QZy)l+sxO@BSoGXXj+NubLZHZOpWq)B>aUG#S|Dd&?lm1#>E;qg6uKhIIGZiIsBw z_I;Jh=cyBPSnI3aVYTZU!b&oi7xv#L?EeHV-!UHlDFkt3nv?h)EO!e!ed)JaqsNF4vS_(v45+1rdup|7!IC1AaKgKdF)An4fFH}9w+L&o{4+>!Fo{0 zL}_HL#M82@Ph>wg4j2y;O0VbPV#scb+nNuUx-^S|!)`+gg-6C3Z8$q3>~ zNL)9jpU_7Jh6oyk-2dfoVUfe4?0mO_AQO=?1ZYh4hj^XPngMVk1GbDXa<`AnV8!4gkMpPW>N0?~ukeca%w18`m7F zyrUz|ZU;%HySGRB&r>rDMx~Zxihm`N4x8xQO9z8v9A;F5&JWNi6ysMeCO&e5 z!<=+fIr{bJ+d$OHy+qWy4pY(HaUES^wCCJ~d6J&R8dj$AV6UO&UN*grZcR&l=ad(& zXhwO*g3DQ5{Y%E%tzSjQIlgJt&M-}Js^gf<=fpRaBIfB^nyqPcV-*s&CL%&~kkV3;E<6lz;0(?te-qGU6*K*SJc6$1Ta*oN;M<9_lxNvkS>Mqq6{H2Y9iIGi2|aiJ#cc<>tJuZ#P%^2NzC39S>AJO9WrzGw#&Zt z1M?;Ymm{ceD^c<3%_0;`c;j?e%|3~Nw=ZJbO>A3RKT;@5uUTi-os?XRU})`i9AADLBwWTZWL{yvH}Apb6#b$*D+{K(|3Z~ciDh4|L6NKI`b&KU12jtW}lyw zAGC^$%^E}c8G3tMOeng8>yc6+C3QmXb!ETqtPWaAUex!3=Z_QQbrsji2)pJtA|dH5 z1CZsjWsJjZjXB9cBTn3D^Hm}@SkI0~v`i6A*!#lWUE67$#-A2O9()FVn&mHz-VJPk zvu~OwW`Hf&;IU-RVRe*Yy{6mWq?ks1T>;;ugkxIJv(nXp*OV|)!;`Z;{nNa}$gTYT z!+h$L->rM-0}Uc>S}+s z#Z9@i2;T*acW)s%AhVRyvv{tqY55{dp<>dv$g$tW8zZT7*^A6miZ5ZP6(Zw8sRV12 z?0Tl_RGUKx#u{@fk@_$Oo239eOoM6RI$QUH0){H{1dXap?O3tP;u1A|HB&_#Sr;sD z(kBvg;megy(wX}UE1EC6Ovf4aHQ-LEL`z^-Vut9*T%$9*Z5M?2$ngJwa_*;9(+-%UqWQRk zo85vV6yzVAHkcmbqN>CcWQY#cAT-R6A5i1a|5+mEX4hh?rP}ItYzNbbsm{+zBlb8= z!h~R_4KImo(#sBPs=!54Zj#8aO$j;I3FawdFw~K$NdxnlNu8$qPO9#*!s2FWbMVo~ z8HBL>R-?WncUst_`h(+jWq6J+;rfPoGmfMKA6}_wwgLQu@kywn+t8ulH@w6KUlJoA zp%Q@bA0O8w*YCBy3x9seDW?nxthgd|>we#CytCnsxNLTRwBv0yBidOhwplT1&V7HK z$BS>ZMg}aMy^+HljoimFEo|zH9G;I#hfd;*HV@rx?oGj0bf`H>e!Sr6WdDaZrq{V-M%YbpdJGK`;~Tmh>rD2 z_Y|~*#`)eB52AfN1z?h5W>P}SbD>{;OrAWSx0Y4_B0BKML!amK*^^sqxnud9Th#qm zshNstlX2=-s(VbrjusmYzCTmlH>tNP+dbY9e7={Dw3Zx&0}*WCuqTk_b*4fg+5Gs3 ziv6j(D&Q?~!elBexP*bIqw+7AFj~aikeo$uz`thkj5UOLmCFvS zxDi&VKV6&L!boz0p{Sv%O)njfyCC={weyE{R<0nP7LM0mO25C<@fM88!k;jgDYcD; zVI5M@Ol0lw+034%5monW*eI>!n(r?{vTS(VU}ZB~2*7y<(}qt(faVXP63Bu{%k|(g z(Bp`lv(L%q(z}s0l*4r_I-+Lt^jr#x_C^$IpbnWEE-i};^{I(%5pe|Dp)FiSzX9t< z&E}U+TnIbaaPDls(Fo(JPK7Ri67A}R1XLJ8zq9jJ6ePqKl{pd;dGY#ysh13PG7;7p zuGMj|I}G?%3)YpBp1mL12@npHga?Qrd!lBS1O_KlTdzWh!*j>gO=h!_d< zEzsFIydAwyVGb?|k1Z0Zy6uk0>9!qkJfq3DMBQ`FqB?!kNeQlA>306MHu`Ee-(*YU zmw;BIq{Hcuak;kb<6s7oHd62Dl`=JiOy>SHhRrEfq@mSr^q`etqhGY``!H59|zXZQK*NWEo0PXpxwNym6+>gH8Ni=703sF-WFx@)Fi5?wo<$1pLKvp}0@WsQMi zyAj+YWY%m*TrXEzisMFM$xO3kb#5$1gT@u$*Y2Psx-!kMx(y%tBW%F2#*=DFN4Pt% zC@c3*2=-iD{mO)tB;r!AV&MkKhB{U;BL^_WP24Y(XZiE{lf$LCns6K)$suBt``2Vl zkde3aeV24Ei-@ai<^?SfZ)OsJx@SfT0(t*k8L@>NAMR|3L6bmD=G-`VI(op-U0ZI> zHJy`>0BQ6hjzeI2p4ZdZ=EMS)y4LHwC)Z~tBjFsn4j)qH06zrw^Q(W+htk9S2X>0J zs0fr_M3Vz6h^w!RnFa;<*$NtK{Cra2yG5xqBH=thgH8*<+3Kq`ct2J;15}eqm(co8 zX(FZ9=#>F(uewCEyn;ZG;M)P=pm}p+b+K{o{)R2O<=MJB&4RT;Da6C$QIg{Kx zmL(;$T+T72hEwe8kPOD7ta&|uAY_6|6e8T-Jnl-kO2lJBV$%^rEf7aD8x>jH@iImEE7d?C^)f$HV&m9cq zXQ7E$19Z{6xH@2-Kt(Zk*r)kZqPu746`PPRw@dy_BOfs?Se8b0jQSk%GMSL}g1=R0 zTilJdo%N8jPkaoOg_NOoM>OG~aI~VqR`A(FBmj zO%q@`0*vIHMLqn6x0NxuDJ!Mvz4g03+?A$@!wZ}QSra!Yt7lJ}Ml!{XR9J2iFI76r z-57pbDVfo%+&o8fzA_Hny~JXgOfb0=LYZh=00yVNpF7vhFVg78+|`Q}#2vCX#sw+8 zF_oXPpcFxbGGFt%Fv+!r7z5XVG5U(^1i5ZMkH&sabsgfoJ*=p@#nIu)NDe(n)~M>u zAN}Y8m(mzhYBDj!N^JsCcBg_Sh2lSIf2B*7MAodS?u-SV6wQZTgKIp_G@2j|%tBUu_qz6$a)*~IVOpg*`5v2BN^qa>5!N*Obs zHgYX?rl(yBH_(kqGkRY43tOFV$mn1H6xGPC+fE zg;r97oR=>nZmVU)B_*Q@m=Xee>D?uN7ceL>{)rlL#=z*2G7UdkJY&SwW}O6$dUBy> zd!@u2@)6hQQtt$lq)5$O1lJHhM_;eI{%a`>UA?gNtc+!CnIC7&qAA&QiFRl^M%o=& z|M~($TE*Ws>2_L`ui~+}C}G)D)@h%6B`0&++a?KlN0ti4Js#K5sNXxe{MimIC57`D z-b9Ubp#NP&vz=kLoC!;vY&wR;*V>XKc+OnH+IPz0C!pCXpC%?UbSg5h#pzH)B8CTT z7{>~DRh!us)hJz~X-S_*>VrbFsu!_Z^K-@tC1MY=bY{S ze$4SZZ;eIt74-6HGtI~7pB zZZCdpZMV2wdAYl$$W>geCdV4gmjuX>%$w=8dmcX)qwx%fr%&gHzE7unG=92mueEtU zC8@a| zl~*)_@7D%CSEj@|2KycHlTb5KCb3%uC#vh(i2#;!oThO?EYEzV%#;IwHseccdy*>o zANbWkjUO};{`sd6DNFZPC$k*%s_B*pto7;M*o(|#BJDWQqV8Cj2cjYV z$uA!z8;skm0`Y6iT6Ym)w`INb- z;mikgIHj7s*`gu(es}DToGnSXoqakvU`4T!?lDgn#0GG{E6Z6mIC3zM2edA|nBj7Wc8dhAf%^udO?cdJ6G%j9wstdCpBBoh- zl1Zc}Kukaa%e=eK^0RJvuL99OF3*hgsMtV_Wp}x_SaNDTU2Iy`B+SaP#T~F+6Rg6O zx0i|+ryCbJp`w-SeefC3jFepNNpH1U_IZQ5&l4lP!5g(7N@9Y9`tFs*Y-3^r(U9we ztJXtRU61XGE;Mp7K5L(6P@sJso&wWdYcFw5>pETe;d(+tw68qJprCMGU3F2J-JBl~ zlv^dO_Ij16aXPZs2duO)zt0dyXH_l7$HOCc4Z5B3WmhOwhv3}nb|nm1&PlvZh6HY{ zZNpEn;bEb}mtQ)`e>5?qwT0mAfC|fyNF^&SBdTJejxLgp(&!iWjxKI)IG89BItD91ID#TG`y)@>9)-A;}K7x7gxt6caUS@I&oZ99td=-CrzaX6%>vf158 zG5;)xib+QGgsp+ibraf`x1a3eq;gs^EIK12nLE{3Z%jYHSfiOhIdGQng*i!5TQeL! zMsGU^kHVcKgUuG+@_;e^A|Va2TpUSt)Wf}h1)B&B367*Hw>7-mf-?cDX_D%>%(7F) z097Bg@|a4T{^#9ShmY-Y^5?uNO+8Mz1;Lv-ewH#buIdi$bC-Uiy+st@tzbZblq=ac zqhd>EyiNM8Ss&IcvNl8NDw9}!$Eyl2D2-$5JL0k^SgS(gE$hcE9uCB{Ghi&l*bFuZ z9ZqEuzoVQlv?_|Hhq|#!40&KBr^;(ah?H?Ylfu#fla^y?z!{ zz1oIe4o9?i7DxLGj&j#>y?1HCuN7GBx@o&)to++QCV({>3nl`<8F%-x_R=_LBPTio!1zXGf#?g?`cr;(;<@YBwXs?LZ`Q*W?Vm zdLs>qP(&S*gTS-cKt0(kZ~2m{#kLQ8!^_4vE&x%ktioyyO&Z`cM!2^xpE%vD92~iv zdp-LC+cCFzt}r|V_25*E`gwgcoNyjKn=C)`pkS5e8M30Y$jix>^I07K)~6m!2?E~z z+pRwxbm*(Zi>EagSDD4x~wM*z$P!W_KBxOx!M^z{5eol9b zs3$c)IFBG^RwdT0Z7{lW$iE9v;ms#aQgBRSmw>ml@kEFOhEhLdITZznqrHelU`4?{ zNM8N+e%}m;Zn8fKX-w9UrPPEiOjX-rFTr~s_Br0MS4bpH984D)Lo!Agig(Q8W=$*M zW`s=&FBeAxKPmtI*pxVTsyPz15^O~(nVuv+g!{fAorME42vW0M?<(_9C1@&G5;*y< z%2Y7zPk~5l`^|*h-N}a6w>uHw=I`cDUvszzwT3*npcz4KE@zDo+n$+3VpK6snxW+KOi*5MliV2;{Bg&p2X(57i&g(Gm zc}L~>C8cY*KX&!jvLvobky#V9{;1Jpm)X3JG;=71cr0Po=0i6pyQ?X3e zpu)GD3s^U~QOV0lmKoF*3311s;d@OA*lVE0$`ZmbYBY8PUc6naqFUIk&;3>m+IqlO zToN#rNZ`Cv-uF0x@UlIZ>*!J>{tJy!x6@s>&&Oegt?~FI2v6h#5Lb784?X#g3cC(6 z;BSx;V$cHy1ruxyH*h2kMG0MOg{vf}=ufFNk{Fw)Kc37;DtoCv{>bq6u)1WVF0RgS zp~y%>LWAMrj`4{6`5g%jcAYA?>m5(;rBS%0f~6hOH{mW7ErsLMdm?Wd1^HIqW6-Sb zy-e+59%JOU?y^q9AxuL}A-XB~R)h7&h0STUb;5`jb%&28HLukwL*h%jH4MPuZfwfHtRA zF|v{~q$3r%x!JM>8mbl2@m4Kq^K(q%+KR6-KbK|F7~!*h|GaPhU5~4=Z^t2YLd#c}!tdFzO_z4?kD0H6n?y5A; znU$g0RDd5$P*e*DMgFG}+{2K&XlmXM64apJrphd5lG~b_nVKl%BXcRn10ji1#EM0N zy3bd@JmP@&V2wGSKY#6s3jW573Lr(*GZE|`= zrSVhiy`=%lw|xopU1mI)3`1V*e24W`ZJ(87dh}3HnsOeEx340;Pv{%l7Bg}@FSlN= z6VHeD@Z0LjA+@(cR?RY2{o@G1Iy}Kaf!_w`PzMD2f&VO_1_m*p1I;0S4@%83lu_;i zlT?%{_DhGF6Xzt)vK>&B_g~v> zjTCapnRm^+ZP&rDjk@rfdTzT3zLK9($1ka1tXxs=e?Rx-z!DlTR+)*-uJGd^V@KBt#O((f+-3OO~*QvwViz zDUwoF85R-al(=ltUQ#lP^{EH@Vss{`A#2Zodui+EQ+LuwFc}(MG7`;qt4UL9^Nzsj zv-B>rX?6|Trxx^prF){qGh&oTuwhPoLEnIV2)Fk8ne`xco@8%6V@Hq@CE2)?5wGk$ zt7ETu&b{YW?}EL0eD06!odG`IlkoztdjPFE?*KY-I7HjTw&WFVJ+WR%TeO&mhx-}8 z8k08Y>k(#SR8sLIJ_}F*$lg+B*ZxTK#_5V3u5WB@ocz`D$<%Ct7fx?6m5H&wO(9T& zxdB22RX@G^w*5@pIU!S2gr=NE@^RR*`2diOuxyykn{$j-1O5i18o;PE=^|p9k%dxD z9_*a<&Ncmrf1CYwefd6$MW&Fck_QtAi=l#zY~oz-aLk-u5|;k zY-sZao5C}L%8Q}hf?9!)BfX}+%ht??Wogj^u!M~zyAzsTO_FgsYbA(>-Kcd{7xPqI+pfl_Yc@T8TR_Z~GF;my@K zbgUP~CV{fNz+ib9_tOKew;toJxz;1W@H&=U#iH?RMHj114toD28FW*vFtFLtaJaCJ zm|B6<-0FT1;0y)K;zwuZn`;E1no!`lw5qMm9ao&`bcBf=#Ea}Sj+@UY^Ac1ukoE7i zWIK$?0>yi66GX{7iqrdnUGTN8AQwNMdOdf#Oa}4X5IP~Yw0JMxW5MXR9^1o=Ob_Ru z`Xe1A+olE(rwGx!^-_q70;FEJUGDI2%%7`}#vkmQPRf?e7MdHyMka2pXCoJWL5zTuF_ALQHTx_ zj5}A~W*|7W*@j-{BC85tQ0nsyE+j6;Z5PlfqmUN$ZiI%62863*n&T^^k-uQ< zl$Xpe312!aqwv+XONWOgRtwDb1xQ}dMpb5QT4(k3 zBmE?Zv>vt5yQBNGguZL<{#2f67QTeDdGEGwMf~k$yAUbA;-OMvr-+vPEn3SW+Op9@ z?+x_ID8>W_+U($j|6=Sf=)Zp}RwiYIr`UR)6M1V2MGKtToL*HRx9RP`!I-B<0zrS_ zI&CB7&jD8iE>*`&+NTQVRuE!=^az1nx9d9!*^oHtxy{* z^ekP&@ZWIF@?V*-v+TiPQOkJRPIH1Zk1S`i=c?*q2=7F{E+#PC+yj@1eA1H?&8Pes za>^{Pjuxn3r@X`>KZODeE-gs*y*8TRXC{!oa1Aq0a1^2?;vMI?5HHsDDQ-eqN%inC zS%{%sCc(AG?hLQ$3DcE@ws+R=H!f6eoogo z!aN@-q5T3%`JSJ}zMf|L7xu4V^!^<|Ad5h6cAawxW4S*~tHhC8CCjX<$W1-q7tH(- z$Qj^BReYA%w=4O7n7aqyO4oJK_p_t!j%{@8q+{Fe*tTtT+_7zp*tTukww+FLM)%xn z?YY)o>+XGS-MZ)0Q}ZngU;tBnr}Kj*(|+d3VJ^7qR0vH1Cm*@ye|;s@BH6f2{N9_ zM-3zfV{4tx&peju?}wE;1==mfe90A|9`_n&3GA~4VrOAo?&lme(p_0X3*B_ox$tpf zTxE}X70Fmy#RK^g9O|xa*FR>GJ3PIt1bNjN_0VOfXtpV`$_!w+tZnjVXX=nRVNua9dYQf#pc02kn}L08Of8= zg(5BQsuhTe)mH6x%de*7^NtnUe{^{~45Rc)AWlClU>-eG5Qw5o*HPR5fur^{$o!py z=-s!XsUh@v(RV)jdF-GC?*PRoC9;DL5z)~=>8QX%XPV{VT2ja3+j$WZiK9g_MIv=d zYx1f0a?F$@kKIG%Gn(1;X6^BpI|Nj|L* zm5*@nFaQw=X@5zD1iI(go+-aHXfXxsEmP@iNvIn}VJ4LzqAP!a9axF(p6K{p+lW+$ zqa)$Eb=b@k?Tx9?4%5uQHe`7zQOOnSg!1}3YS>y6Ox=iDi|=!k+haqA&DVpAd@p%))jMLTMT=mZtCQ+M-8t_Wlb zGtlR}Et!ZyS9cYU*3%p+x;ObBNWI8MR;M9w-ns|SKEEJ;!F*e|M< zLC@Soc6ci01> zeu(ZO(_B_mZyjVbA$$N1t4ao>#voP=YW}f@Ads<=F6ivo4K~jY!H47h9+t04P z8oL5PY;0B5%McqX#+0-F9FPz?71}@Lyt?DyH=00L)^g(&Y+6hn#yFDSc}K!4%_Rr%d_Dn zf5>A2>t7#}h?UmXjhC5baxyk{UdCK;-MbZ1GF8&1YOPkJPv02We}ArB>PQ%W^*B{G z957m^cCmzOh0sz5tKc&ZME!&M4|WD6D5Vij<&jpJrNhP_-kl}qslD$0DOcmN4h3w&}UA z*b@Dii;^;B!E%dh_<10xJtBLoM~&9Oc-v0x^@IJRon{MF{Gockk9Xu4hjuI%o#ZOx zd4$tkj)heQwfHT#_9D#%httzDp%^NmA?~U7YdDL`X~QXpFkvBi=-zHCad;?b3oEGg zhhbD>y7@L@^b?EfpB=Lc%51Z&Sd1bPiL{w!rr$s;A~&qVLvZLa?aAw1BpR|E#84AV zeei^m`$fAuBv!N$K#oZ1u9Vo+MNntZ4f(=r=ZpLp&*Iy!c<`HfaE6!i^&>U&%Zivx zg)6_##$Pr^BZM&%m+1w2j(ad*WS6>LErm zr|ORz{1v9v7(o7fESoBvfmx!c^_Qa+M^eHJ%{~3G@6lbVPkajZ@Nq$-JzVo>U-VwJ z73H&b5%BD=_1}h*m9Oo$!cH~ag1 zDm||wU{QKdi^eK(_Z)of_O_dvlfr}XKM`SEx{+%|9|2djF4zB{^&M>!+@&e4iZjjJ zC$V+<26&pxm3hSjxI3vV65PdC@((T4x^fyJCoS>ZEHYLcm!?M*ucK}kgsto>tKG{S z&?YjueP(zaFm%-b28hCj(b*C+qe#c=qW0p*s87KHe_*` z$QrLoN3USach02V>NP%2aa;1bhMeXM>!&oyVeOh5S!F(-6%)=${n$1=+T)bUp;8u< z&i%nNFv4FzIV8EM>czJ-R_z#vfn3~PjYtXhytR#Mg_cS(J1Cvwx z?+DpH%*|3Zmk91$;zLA)Ajjno*HF&0Hy7mXkkYqrA1LzWTaBs?o3u5fV8>Jg#b*oW zh^O`dIG}e zFj$|;rXO#!<&`0Href>j_wQt8?(FqM>;q9Ec7imi4<)NYyNTrT0%pskEQ$tSC+G)s zPec+=bRDE>NM84Bl7{j0iMFgSR9WsNZpcH#43Q@fPCm3XjX}1-S|j})+YHpYc%?9b!@G%;cZszg@WDCRkp#B z9m1%#vBIdLC(P>E2NaIU)@*^OF-jo5N0Po>IJaBF*P=O zH;7}A$lF|IJ-Qe=LkqJfhY;eI|7emDn7@zQw@G8Oz&QnG1;R20B~?-N*`;f*$Vqv$ z`YIPCZK_x`Q^`tr;Z4&MBxSR8%kXDdByGWGV&IYNHpMbFkpI~{v@m)$@96h%)CL1w zPt>sUJ_OX+9wZcnO&e7l97j!lYT(gjeitSxq3K6SJr*jd!Blv4%CNSSi_h-ITBltJ$Mbs)$tc2S?l=qC?s{dYE(JuP~MYZB= zou1gneP`@gITN@9l&*XjUpD%Q?SAaZp9?n$@PBNf(_cx*LEnZ%>fwNHmJEe z&nFLB(r-G4_V-GEn@6NFym`hpkC3-dnYouu5VWwsy@)Z)^}>b`9HJWTKSmmmYOcm! zQRPNK1+-e6s9Tg8A_6{&YH_OSYzfm1S8ea5d{XDE?zjE5C#>OAz2X>9WtzN&qAwO{ zC+Q}C)I3yN`b6iZ$gH;YOA)>Dq3Sf zK@3;p6O9HmnwjP9#!z|u_mxh|!~sjw*(<)gN0qi`!a%BZG{cxpapBUR?bEDuaMi+C9joH^NhV75tK_pj~X3WVi^e&&iQ9 z#H=sF)aFqIo6Ygj1(m7abCtyo0@lDN4Vsh(r*NCSqb$})Tr#&8B>q^hYeg8Q`8ARkhg{9*6ZW62O>0l@v*F;J>pBoldk%aFha z!ct1kg0A7XuSLOqX+VF=MVyc9&M81Ab|tx|zp@SXHMeAgZKcX&NMSQjCbpv)#SvQoV)wR-VOi{1^{7>DJ(;VL z!MyvNUE4&wO8h;!ur+rh70*hk)9EH9L<%L4Q+};%2PhHp+~6>? zx9&iuAT$8kkse0!3ExOW;Hlr1wwq!mY&8O%(3!x~dnVVX4XM}glNT8#a`8_~oAVdy zA7BRXrr)_N&A#p!fJg~BCA{lu{a{xO0%)P;R18BEORm=5E&jFQB;i$hn$Tc6_GQQ zIAXez58|XC!fDEMiXy4NILTDmFcY&t4&v}uY<6U{<&jia$>>2a8+bpuHfPmT5yp1w zq@qoqOV|wkYv+biK-^Bt{F!A2DttPx zB~H;d#{e|d*GU-=N{aEEV+EGoQm?6-KEg(EiNFMdNy^rOzA;n&mvrucPdcQKEw-#LNrt0IN7 z|H|NZf=_xovA5Zx80$RAvk(hx^u5N@BWbT7Zqu;ZYEwwV&-*%T>nJ%|o-EE*Pb=N4 z&;=B-oQ>ZYU$j>^&g2{cLK=nE44{mWk8gad8G*|4X~u_k&XxSBQxHRcGl zay^awr-86JX?+k(TPkEc4eT}Jb9urv@OHGL*l+)s>PHFm^uoXWPW6xUAsq7947yF& zkK{iv&D>}%@T`*{B7bOP+!M#p7CDrG6`3g#Hp#V5oIIjRnJ^3zTg6t<2h;*==^I9>niiu6^8@VPL4s!z| z1Y?WfoxGJRfs=GE7rgCIu*;gE*d0l~y9p@azZVM>h@&UeBdmyYB%KYtTKIsO zzE|PjGySTdxZjz+(OuHN%=B&8ftmjDF+DKTXOQ_zrq9BOeTn^-Q2%D1%`>FsjcuO| z(<08ebteoSpGlALn!NxVcrgC+GK!?l^C6+mcBI|W{2_EHRbWXmc*-A6AoJ_Aq7@<< z`CCqfN)Bx|-B;5V5qcbAscX^3ycwjn+cR-)n56lD#M{Gf$^P`f1M+7gLmpdbFNb9f zZ`Qc%+?v<$92MBy(SX?4BH=Say%#gBlwh>j0C%#-J4WzeykgeZwis8aI>!UAJBy3S zG{Zu{a5c@PnN_|1a<+}AItNi*jQS9l?&mJxu<>LledRbuTN+gyicl99{(jqdl0b!V zYD441s{Lgs5`*w0ChCl%wU0_Dp|$SI@RJ?5XKM5f)AD=f6?DQFVRfpKV)EeDG*)8y5>Z?tISLTxT)HvN?P?Q|(ub6`1f_*VbLzT?GW_}|3 z*C%x!t4vEUrFS)&X<-@g)$gl1v#!(mrs&wQx9exsHUeI?fwPFbg5DK@&)nQE`9Iz5 zrJQ2yoSxLX6%U<}26|nNRD(RnViFWm3W3|#Ola1UIoKKTmQhNu(4gw6_*)i6cH|th z6q#EslseuG9`;}3Q_%7t^M>g~Q7(xetLHpEKYixbgy5djy?=-BXlnQPi~+7?(hydx z@!*l3OAm)hQEaX;vmq(=N?KJ2EyZ?k<#xhUBIf;{t^ZQL5IW{IR@fSMKZN!#USLz= zaBQ#;FoiRDIz5bcfMwQ(%ACv4rm*8qo4XBSjnBZGAlMd@_mLAM8>F2=(t9T7JJwqy zx@LTgyx}T|rK+zlB3js01Bs;sM*)m1vqS|rTi97?88>BwJg}koJ0V{wD;b%N*zL(4 zDFYJX##7VL44R9@CzNGgp!R;W-OI3z?0D5*?jam>I~rto%iOb4mow<`#gL-z5lqdi zGiw7M?3meZaEo6dj<6apHhAIU#Wfp;LlW_KIvDgZ&$GG$GAT691rn3)z@1MV#g3FbdYWP zFQq>5UrPNws=t={-wgg%>QlU|pp8>y{H@ey?Rz6O9xC~>)c1heeYjOpxT&PIRf?rj zm(a>E6WVu_JvdZ+Z^^mSrXw8v#L)fg^6DIx<9<%<-&;34t5^0d?>u7FxW?7nFm$Qw zJmo%F3Yk#ytJAX7-Z>_mzzx&14fRlPCM%8{2*i|Z1^LtDIYGoWh1h3?sHI9 zKdUZrGx}oD;ujuzp+X?P_|&T-vODeyF;NtvzQ(qt>D6G<+HTdu^Uf|_)xjmp;XJ5> z5$L}hAN@o@$-Nc!D8IHz?agd+Q%|n5rrgV?C`o|apErwOs*6{pNxe3DY^$Qeo&_6N zNHW0F$L47=M+!$`0jO?eFw51rv1eYb;>DLU`#e$#cqnFqekc$7!}4`ua9evJOt#%U zSF{yVc*^Vp(#iw3D5oa}dE3U$(X5QeR4^?y4uIXq(y3fcBj?Hgib9meezl~XuD615 z6^UX`lm0{az7;HtSpjP4k4u`y=@N!#%H~Q7F{#Pp3}_VXM0W$U=ta%;M`nWXs6dT& z*9O^MGpusJMU93Ug3MqxZErpkya*MssNy(r%oKGH{jK~$^+Ck3R?~g>MA%8>3UfIl zy1Uf}up^Sk^G@BZX2@>`9N0gvx1`^XXdW zW%|v$m7aH?jcF2Wb4r;8Wm?^a(Q3-udJl5rUIIIjG)}|@Zpl{;ZM*Xc&ECYySq)Iw z=}HXlWWxQY^6X%7C$-jS0zjLSwq6(hEtUgfs<+LHRg&&d74$u+!)Qm6Er_)02*2)L zp`Sb!_8&UIzhwO-t-rGVk=#_FhV(usj?}?s0*jwhzE#n}F~EI@&xNKj>+E@Ww}=Zk z$;a^6@PO%>aQY)F!jida3t7HpsUqD{pWcf?cJb`i?{6<9UNS2Db}1dCmjD$Jc>@))czso3so*DF z{UnwiHT>*_*d2LA$$9!eld+DdxfWNW78k$M@$sYUv?P7T@Aw2uE;i7nYJFr(kC+P0 zjA20!k3Y$Z5B&u=S+?E0A7Fodp`G}le4=wKcU`fbz?z@`pKE@|&3~@>R}yikKmBLR z4~fr39Egnl;}wPUkKZ}~2&|73a^8mu{uCbp9i#v$2h&NI&)}(K7CDu{0lY2Vw+%QbuR4czj3702o+cP31|+k!BL@&Kp92OXYD?a<2bvp*m{{b?77 zdY`?P02d!GgPN_zv(y}XOGNepkPNe$?FtJA+RL$biGKYbGCatF(VV7PW(1e;?VL-x z6p$@<5jcqORKMs9lU1e3)E}2>mSAVOvh4$CK8vCPLYfKon`J!_@_P-nY{z^8(RY$U zNv67}rU}1L%plmeeuv#}qPVem=}=YNOgB^9JPU{?1Tu0nbXU#m&<+SQDZR7B&yA&J ztqKPhq4f!Kjm_WK%4%jCQzEdH(dY`eIk$?-*@x6DSgRz-t=H|5cy4(l;|5;%Ws!%Y z>m9!U*1^i!*eTFf8jfz*I4rKE8nn#TYEu*k|3%DC(F~0FbJ`P?l-K?i^DkfiiutcE z{$0$U_{He|!1eA7Xw;z~5v3lbnB!`H7eQ9`lFM{U40^Qx1N`{7KLM z`!Rp>#s4KSzxCK~3`4`h@s+0gAh`jqHY>Z6xag^xP&3W^!-9ba`&Fr(zd1TjaJRU<<1P{O#?B?W;BEn85@~oOAfm!VG45YDgQ?QYc6_-Gr?zk?$ zLoU$fh>63ShIehmPZwyWw;>+62?}=5#IWk<%MPxcICM%T&EaJ~?H?pSPVTo&O8Q#e zx|eY=eQa2E6W(pxC6QM$8oH_=52cO@<->>lajGqqB{DM7GMUvk!uM=g zvCGT&k*&C!0}6*v6n_L!0*rqG*Z z2HX@Vu-wF45KLbXt6g0z`w+Q`2W{KijA=3RbfF)l>ZvZ($^MaqiiyUA6rS|OIODAS}ZfT^fZk&8>`zw>25cC+7*>&HkEr@JV|OnpjOKk) z4{9u}6^Crag7j;C7KkLI9evS2l`mmHc$A-C%)DN8K@0^d2vX-&XQ;AKaP3taY%Y>B zhg0hP)WuQ^fGjCD%e;?B{%_GCKW*ZgI2@@CzukST>T6es=*(WjmzvowNLE|S##D7% zIeGa>6cS5gO)D0s8q^QL$JMv2IgT}-^wHtW$n9+Ec!E)aC@n%X=){QN8(bN3<|rM^ z8X+O+h#yppfU*#%(|7w9?81M*4@4JN9}M_u+}ImgnU6wUBxBD8=Y@v=eH(K)$T&K zvgfFlx=v;jO;UJ>e`07I-eis$T+Jmw(Y8^@ylx`$6}E!6+bketp)?}M0Eu*e7%y?# zy|unsynA#ypYFVcztc`N%xr{F7)OXNY57V=EO{jE?2nR$neR_tr#_;liL4`@gm};J z4N6|khg`AXUSfujYxb)RfJQv4=6+B=RDk%W9K89Fi%a%mB+pdDZV1B^t8(uTC}L5B z6#e3RT8fF-Y+His05tDG6m&h~FLwxaPMI>dLgn-i?`;(s=0e3Qd=6 zEX##vz=Zgw000y7-R%uiQD>H-?WVfy2v+t8^G6Gi)SV;T@>geUD^_xGClCVKnBfQE zyY4WXCKpvDzTiKKD{{$11$WV~VxxHRhhXd7tk;u}{Wwl^DDlShSvQO4G;-fVkPxJC z2LWK54f@9mJY9WHsGN5n8HVs-Z->P(AwZ9wuE;jyNZ1=7Gaqi-#`agqJg&`DF1d|^ zs~Y>G^+Rf`*9%wc0B9eJc?JQ=_gJWPtBx@kK+@oQe)*HbzaR|?&;IA6fopZOy76C0 z12*AieW9|{bEvc1v$6V{CCX$PV`Y3CBed?$u1+iKLyyenPWQ!l{&@5+X&rr zuwv-XtM$BM^E=^{GZ;cI+vG@w=8X&vO3csT6kW*il=KgQw`3?-+uU z&Y00>mk3cfvSjFR2JQEH_I)sxmGhyQbb2*yhf-j9DEUBO?hZV!yhcO;OFY^x)<)kn zsee=9LLuT4TmVf}FB7U^e)qZ1ozW6dd6O;-3-|2zKac~J7 zS@-9o@7&NOFm8K4C735$(HS#o6^=h&@E@QlY>STJ=K?T>oikV4ILmzM0JLodH2@4G zM9--^!Y-C`$FDvW6`;pFiZT}+wo68FmQ@wnmGLD_*Eb6xqer%)h%9x5woGw$^+rqz z`PFI(rBB%ro>^nODgsCl+4ZH)CLB>>2FE_vZZ1I;eA5IDabG*X9b@+krxq>Gi?=O~ z0I&A0Z9xbJpggGOU2jP$b|->;wNVP+UcNY%*h*`EQNpYAj1#?XQQwb>t4uqYzaXNK9l z(rPcH5^>+IJ(WWS^3HavB%2NHc>VKFt)4Mt=xLo&jnbxAe&CpYF?FY3Ry|+RTOP>1 z*vHoOE2IQo`lOo{Ih1Y%)#~v8P410O?BT}Y=9fGWbFYBtRE^Vp>Ye7HePXR@=O%2; zNH9Ga+(+SRh?BiWpBI4h$@viLbA?btK4(D>S(9%**jxO~xq1G?jo0zZJyEKwg21wr zMtW7z?Ang(*KcZjjKmO0N@`+x45IxS%jgQ}(YRSxEQv4P`+l=HL zh1sXlwlk6yT>FBUB{|WNCKcO?eSWsasqFeq5d+SnQ;`@M6G5Y7>IqeZQe@tW5^k1( zDzvCcB#0l}(-OHb!>Ky5!>Q7KB*;n?WRr36rulrVj&&X8B7y=;_k5xWK$?zzXOVHT zKBqodtmvrk4s|#(kt=3ZbE|ufVLmuwQW?%pFQ#Ug=`0UH$z?&2!DA4?sO=S2;>yKLlPiURc7zIrr#E3(ey@2JhKnD=UszAwWS`VZu zI9vv3&mP1tdr+FmsU$d1MUUmp6uaG+8Py|=HRrAOo_0YYRb}rmI(D5(H^o7u^1-nI z6j1XF?25$@%ri6Y5id=1O0g|f(=4R?DN1lT@@r-d;^#RTqu{W;rty%S#8Fjj3t^FR zosTq}ES@>@V^@^O%e=G(#j&47rk97R5fvc)PUDzI#ow9+-7Jk+XmjJ0(g=D}^;Gsq zQWP7Iy?N;SSig7G=zmrG+^#qrqxM?5ypkYYmBKa^exc!Q=k?H}D80a5ly)xWG#dW- zK~-<9M^!^>f0H9lGaef10nPNN+rMPkL?@Y*XZmMd8C|d>$=vMyLMdvJ5#`*uI3b}P zgZ?3Pn_PN?A{WN>(+U}sV(Ok!tZL0tlo;8LwExgXGAuoZj$ zTUB&T%gvLC3nWrS2$ zsMJyTacC3x07&yK<$n9^JDw;7nys2dD`N5|vm0c2jl~%TIS>nyK69{@>>{O@P4Jq0 zo0w-{FSW(!Col-G0Vs_>Y$sK$7pW~yCWyO{BV@)(cCHZi)p0;&tHj@%JVWc9yOgo3 z4cA>;JFL&vpRUhoGTk<+sPTL9WIh&(=1sIaJdB@>l^zzoiB9DFz@PXR+`v)%Z*D;B zHoO_W3djuzq4NHn8!)XI(EiO0;IAB-0l5KFb$OJU)`%CY?Wo!fFGmjaM}+h}eYL|D zQ=z3>&)nogrXe2&2$I%3QV06Oug_0rY2nPd)hk~dSiNiMV)jKIf-EdqMc`HJL5^#u z{21K`>rP4V-Rs$0llP|8n0*`^%`2qsaVp7ciw><67+*K5Q{HfJ^bY#O?a#7>m1-jW z-AI~5pN&Oxs9`jUhZsCrsHO#}UAp8%V#`A%8A&w{8=pC_w;R;tyZO^h@wHe91Xp(7 z*#;`UQYy@yy13z=d2C%Jv(fg9-7kK8(e~a6Z|06$=_pvJ&QRP6E?tlc1F?pRFTIY9 z=*@#{%ekT7uko@kGfG#KZFE$ASIcZ@|vmPWu{B8|o`j}Z1-~`1$6@U(d7;@8hxgh0*1sGT{((`2H#o}H$ z!D-x`Y3ZGyXOdzP8`W_e=wIG_(y(Pdg9XNsj(3TZ(jv z{p28Bl0t3vCnO>Q3xE7uWR*s>e}+Q zk`BcLVi{x+JB%obb^MuJ_pysxM)HZO3an@KF6Ki=U#DF`er#wu-?OO}D?`FLnG#=p z1|WMQqH{UW`)F-g5{;X;kgWEAxkxrJGfn5ItuzXP5jHN|GbTVr!GeAIJ%dePgHRpO zs>EpL#Df=umT2{vD-HF|)>01Wr{{5NL>`Ukt{p+u0Q5{GW5noY`0$v+`Bx}D#zr&?W5Fdy!$$CLyIbrr)M+DD=j8fBM4j`QM zh$-COIF7$3u~pnL;V3V3-j{IbIlaH=9inSuu+uPF#Hndt$(`5-V?74D8*?i;ABNHH zD1_I+3eh9uid-N<#OkEaZQ~U7Q7eWz{-m1S9${17;J9hRLR}9Xcj5+2{WUV1$ACL} zqlawu)E_MIAK=0L$+8RuadW<-a$mx+F+Q5n_)@j%$5x(h9G`U_*nn*tA?6307Lz@6 zhUk;~IV23Kr6Lrbm68b-iO>Dg5rUNdrXv_DPP1l)ujbTH%eS2v^hzn?A){13UbL#A zd1jkXhnB*lS8&Q13EZ?epe`f}INq14g-kx9OD>NQthrEccyo1;S<3b`0D8QqHfAwS z9KP@DeViW0qEC5Sx6V^@y;4?eprsCB^i>xM3?6t08x4+8s-K7uRG-+Y8dzyFDkP<;J2A7Spl@e#6{m3K#zfj)xfWX>-i zfwj@IF!Xfxmyghz0`w7Di%r>O{=r9R=Dl8cIxJ)fyk0P?V-6DWV)GWxNN3<}M~R4jn##pZa=mtHS-@a+Ag z4tPO?yw8vvLS0+c2Klc%h#x)zB26-iFeMAmE!?ZEM}1O+V=3sAqYAXkHmwOMrzJUD zQogvyMC#RS5|&;kTu;63Z4!D8z6`-i;;`bJ(*-3yO#aIj`e+j6A_H`%&Cuf{a z`2R&j_(y|b+HhLbd%NSiFeG2|`Y&by3fz(`6Ii)%bZYUTq}N; z!YtA8RQ^COUguiCtZKJI3MZMs?<;{Bv#?O~2dM*ZhiDvlv}AJ#`Ew^){m2C*b{SFzc*vJifxW9iWB=?%+7}T15~TS@FHbfKVZ~f`g8K1!0DfZgS-{&jd&Mbv1-EmXiRxQiaw9Z7)l(JOBpQWncf19RR_x?~NCLZfq9KKh`BdPFp{;Uu zO@d)>SYOgLbB6aVC19f71Oyg8o-R@9=09ZM+Ingl1mw_rMix4=~DHeDjo-jino+1o*Z6jM}8?>5!}4C$b69Dr_v6mQn(TL z1n`8urvz}PUvCL@imC#f0;h305j~j1zO#o%xhCRfO~4Vae{vdmQzMD=g*vQb zev$wzK!g)xCDW~sCfxSa$(idh*Ms;y{#N|0H}&UO<{I_du64-J(lE_q<{8DiCkj_x zbMb=2BfmESnLwsfyuj!N_LBgbTq4(EXLRo*W2$&*V)-U5&0l{tD3VR#Va%_s*$du?uT%eYEXM~B8+idxWNdd zfv5wn+Qn%{D&p$V>g@2>*RKXtnn^yBzQ0F}CL4hEUYF@{O_80=#`L^IpSv*Mfyx?! zfGm_;sJDAPSj#)Dd?a@>%y=a9g^-`ppsLJTusXrWe&Bh_`d(@P)3E@4H-Ti3y5Bt_ z%<~Iq)zBj9yrVj=1-**5rs@W^9)wK$ZN{Aqh@RcpZd@Po6gDjGx8&i!D+DyI<;W|_*j=IVAj-C$Kf`zJV| zFI;S#gd1o$V~zbZ>%gl$++)0MP8-KjaN4(wM8W;6rgIPj{RmeVh%7N8z|B&e>%a+H zkC3l9f%!PVsTBcAVUCeT#DzRAk0GLdunae2^&WLq*J(BLNYzx+ADq`V_*4$h66G3_V!xt%kr=~WcCkCm zY4~W2&e{5@#d5(`D5g9~J|_#XI57&$F9wmEQPxt%DYA;0Dg3dPZ{1&>Ryq_@;L5EM z>iX=Fq27vlN~;3XZ$Y<$l5FWDSD1l5Z+L&gy5c?Pe%{mYKxm#MXsd)mg-tP0h;ZjY z;d2o|z{5%Os`GMAZN8J>c`|>FR>N}Vn3KKU2P?3wA{yj~#DyfkMfD76i9i61!CuE) z%1t6U5NW~_9sH%%12qz5JAcJsQ&p+RDPNym+XYaA#F}?ZNz-_+ftPAvCa59b=a}*y zA1vGR$hQ1?HQh@~Ka=J1DbK^+-zq2PL+V0=tKh)!nN=*m5+ulc-5P|K0l&xpJ5b?= z#Xo=wYqS3WDu~wsL4_>p5nCaZpY!tjKZ3CT_d$iHo4f7Z|&^SFW~Ey-}8q|iq*uBN0^vzcsw4mdQ>a*kk(`~ z{OTPQ1bFMK;Th7o%Fqd}yk%@rD>y%69VjwB!FToR>^$XuUInvCK}*rn5Auy*ko8Os zA7=#(44KVXy`A8vzF{(%I8<5+h;k(aITlNDal?S2;u%AstTp0GnwYI~zA;4!G-_Av zf6wl!bYhCJ<+f4}IxzgqfU}cqh%E;t9(nVv1;K1lr^pJd9$4p5yl$S(2VC2#_IGTe`~`86=MX6I zl5SyoITbPS(%g^z#ckSxZB3HT2`cyQ$LMU+qXi{!@s?9DdJvQ8V zKRQ`5jv0WH4&@pxnKh?_IYcEA%=5tu3LH(vAmJm$8-~5@+8A&R9z_ZEVPuf>x!&?; zsOh@|I*Jlh4E5J{MWBl0WfOV)@b(n3e>Nh%$zYxapbnBRO3=;u_l{03kZD?;sAGSf zX6(c^UHVe2yp}3|<+vAJ(Y&0(6s-d|&-A`sqYlS!``Ygmbq(<3C^*M0Z1J6CirH3H z&DN3a;K|3Zzb>=e2SAE)`qm-F zOQ$fS&w0X)-xZ$0L^Ix*7x7>UVX z=R#9j85NY2I)_TNUt^>} zy{P{C=6`V*rjO_B+SDB(4)W_bk4$iYCi{UY6rjwv@UvFCXMz&O5?WEMC5q(n3;i2!&*f8Xi32b0`?6|%h6~iz z`j1+m71X{9SquVD-%T8S188ofN5iVsrT?+ylr#fjGGmvJ*29x!yu z_7DWn(B!NuA+8nX;)+HWtfwc+^ushGd0kSc!Uu4cCtaTjPR-cI@!4^zw<5T-QiARnhP( z{;k*3X=FaoY@)O++_@E#d(ozDalm6?^;Jh2a4@rGaPf^IgLb>u9VrRBGATt&^YKnb ztr!ecN}3+I@7ep&ab=j+Ik?9F>$7$}m_}S7JCznOhx`_$1+9@|W$H_<`{K3IpHq-y zCiPfuk=4CN0@?$U`?_Ul%?!3|WpCfvJetaN6U1R?7CKX#_S`MbpHfbPb+_|vU1~>A z9RqKufbGj8ftxE{^~eIg*mRsV#f*m4l5<$#H+kFE!>Nd#XC1lU#_POC=hn3zb%98d$ByR}*9 zbE@-Q&(AB5i{MD^*0opK)^064zOV(~^W`YT9zKt#2$c~dn8(&pzQ7E2glT-}MOA6i z2@RBloq5=Oj~p-VUzo)-6E*kab8GrOUM>c&noezQJ+i!T<1IhaW>8>4Mddl@1lwTH zRCH$`y$qVXOg@bz_FTU<^ut*BNrgejz(&anKAsC=5C6s{^3L;z%DeI$GMQ^{5bi)y zkKKO!PYqVW7x|X^khDB{H)r09yX=R%7L|R!y{c${Pd>bv;{7-G=HK=|Ytg#tdsd*eRkbgKt^?n(kag+BT@K6qgWD9=iF?~& z_+6Xut=AS$)8TV|Bt-WeValnim{!=HZ!60})gQE-P?sRB8sjRs<8{!IS_^Iu`|Ceb z!C_AHP1_fsIr$*|puN#nP9&hD1;~CwPJ?aL@Sy5&&~5#3`RyBvoy(Mu1~R!l)~Bx^ zVWs2AAhYVy$BIlf1MI|#`eM?+vxNmxHV&C=^pfQtW9xkD|5tH$0hLADH42#SMvw;S z?vO?irAr#=?(SB)J0+#NyBnmWySuyNJYc-O^?m33YyIo2nKcN)vtaH$d+(WN=DGvS z$#LS^YZ1HfAzHD=ZZ^56l=UfwJI)RB_jy$))nc=D78yfbrbR}aQ4PMTMyHjlYP{UY zJ)-pMoW*&30G2!i>)EWm-0h`z#nCybn{r{WellwcmxZm=4MV?P4$UD;S*4kU*Vpd? z!>e^JhcxO5A#uex4E7KhTTVjVV9f~ zp6CyOp$Gao+z)}_@KIp6gLxDfin49V%-OpE0>eE(V4yOIFPk<*fk6l$FvL{_4&#zo85VD9#gAbZvGn*o{W{QDcf!k8*?d872T=F!B8>z(7*+ zCx9XP7r-zF02s`<#PWDcGJgOJT|WSZXTJjspMC%g`9A;#?1>E5?*M~Z$nhCdw9p>_ zgYYka;S(2s$xncR0RS)@{{R?x{|mt2`!|3g?@s`OI{;wd7W@G)fQ3E*3{p=31I8Z! z!|?wCz<{s$1Tf&%eK`I{fC2Zv0}L^zTd7^0f?YBi!I1t#NP_RaZGK&=G`JOBuCp`X0rZcAOyzO4> zgbezIHllQg6FQ)8Gc(byt_m<+tH{}@awx~%nttVedIf7INYXY&?=!ywM>mS?TnC}9 zc&#roNqM75(>gpeek!^8npmUMMThlF@%QM&R&`hQ_|DGjL&k?pmkv_5A6A-TTHN;5 zn{Kq?y09_*2a_T&NMSQ4=;k+{<@An)RY-}8G&;0-*H+^g1KS{PFH;^K<(d@5w08lo zS^!>aY?UFH>}!i%9w~3C8!hBQL45tE`_ zctfKNU7xvt4vaLA2F{bLsfX!#gBZYcLoun-5{J6z4bLEAt-gHq(F%M%iEvcDa__IM~TpgbsvL&J-@QuSMy&qe*PKo$Z{d&n?+f9pq$x*Ie!As$$Z zs(seVnLs&OaTqn26Hh7J;ZR*`aGjNTZ#AlYU@Ci}61b6=1`3$|@hbOg zcl>AN?8vo%foNqc;CSV<>(ojvWX`N5JpJlf=KB58&yEq~gx-eNBfYc0%6~GmQ z%$w~MlzSQNHFmR8a}j(~a^-0+^7Org1G3K?9{rJX*(^0W0z?wtcVU>aLW?KfU$CJu zMpWV!>_W*rYGiXA(S-9DYW4f%^6}Ro_9Pl2re5mu4eek$<`Q6eHF7i1FXpvOkD)gt@hY`uec@=~E&utP8e z_L{@-%aAvMK^R{30|wu(hNlaeEi~wu%$AzXP2XvruS?p>YBDdi4Uq*}MO_~b#B{_>nXhH(#6Mmxc1U`b! z<|dBE7xL&fa;wQz?OdrF-^s@Ke%)mo-6cF2S8lNn%RZFiZbjOa{3bIsYTQ$t%zBuV zQeWic&zY-YON<8Cv}tgq6}$@wlZss*mw}Khw7#4hfl5nR%kAi4RDzuS+6)B<&d&k3 z1J7BHwK}_N(=Bcg%os$%l+9>-EgRwZB{104zT7=v4yyOy5Y`z`MEeB?om|n*;^1x^ zDXprh@n!1|-?GrC$_}zmJ=>EVr7%E zB(AKyU28V!LIYq+o+EZqw z+jAMd#Oe0gv&$iyO-g$zUc#IN?K81ZmT^Z?5LH7f4R?LU3YN3YjbrSJ`-XH-Dn?vN zxdynTK*Q-Y#urzzdBh-$jtQqY)lbw_MM2u>NQA(u+^#R1Qk-}xqXQ=EU;S1&Q) zP+&T7L9ejfm!q8c*4Gi&?pb?~#Z^F;)pyj227gw@|7YB%vF<6+;&M zRb|!%UJF#E_}9^e-S+*87ifde;c)?8gZd_C z8Hqt0sl}Moy0-k}P4Puy=|z7m+9tENvIF<=pR|S;V|kk%zLig%RiospSKNCK9^CLw z(-cnA*bzi&FqL@xb3s#`hDte_1(EGqt%MvVC1W$nI$Oj^^^RdDo3WH?98p*ydbZKG zEZs2O{v;(|G)>e2OMY^f*;>~59+_IL@0)-QCb!Zn%vQKo<0;Q6ueABXhcy!IGk+ih z+$zrSBos45lFQ58gyVyL76$R&sWmfb`P2n59Mq&NJ=}8^5hZDZG+URsl$taHQ|oWe z`ttdvAE+lw?eA6TLNv$2?57S(74PmN<`ORC4OK%aLn*%!$Tr6;ew8~RStYx)#=Mld zQF?&Cv~;;bVT7q4GR2gw!MWw|nK!2#S6C>|WUX^0z8(%uyw?@p=JgZE;DO3ut9r@* zRu|^hY0=W$0lS(DFdq}LxA!H4R#iyJlh{CViQ?=)+ju*rvnqm&2ZNP^Q|Up`@+dYy zUxGO^27J1=OW1}B_Aye4qT<}}WV+gTxFM@D<59>k&=AuSOP*^up=%-ATaLIHf!z-F zIgQ6V_C8r1b$s(VKs1U@_;n`TNcliCHj9Mwl7+3gO?byRYm`~S2M0|{m7KIbl^clC z!(cJ*@g3@k_eVTgnoGfi_r3m>CW?hzly|u@cq5AAC&w!Cvf#Jd25zZ=trPbYWWaNS z=#5;w)7mbIejCG>B_jwjK)G6`bl!iyHlZEht?s(gk+Q56jchA()pFKtU)w-wY zT1cRYrvKR&xx2E|Hb1nz+X$(7_!mAqrkPD-7xF#Xl3OP8wlQ!)xG5HR>v_4dP_xkc z#;8~=L5qM}4YkVZHsIIAZIw8lnz5a3iY_}5k~kR_MWa#kjFu!Tqm4Ye%T)2V$doD{ z831pU2>8vQUT^r>uh%&UD<-OUPuEnP=*&##)qGwP;!_amX`}1PK+nVU-_6^{cVlyiejb4G!A#AXmJw) ziC^UJ4*ca{I|Jz-sRqN?ZwKYR!%GHsokAt=*& z&y=(qMGVPZ$Z1od&C#&uW7#Q6rxNFu{{5Eq?Orplfuyv$CU~@kZDzF?`~&y$vQFe> z0*A4WYI@sDP~6V9O?1W^3nCM8^OY!LmGjugN9A;DjC&K7E;>uiB~fwIw8C8iEpAr} z#hArsBXzx;rU5$4mUE|-n@sIA*m4ovk*o^>ST!R^`I#C~fSU@_+pGN`!XrZrfjn?g zg(XHp&A zIB01g!1cnX5h(#MQ(#FXfh>EB;M*#k-XRHbo`INa+cS zPI+xdfvM5RCMK~4JlMUP%n1;QrnUZN8ShJy%=u1m13y@_D%&~MR0VH=w49G2 zE?UyA$tb&oS2#k)2pFpP1pnh+X$>c-J=14&`aNcrD969u zo|J$52&~bDn4-_wKKg2eJO0H-?_fLMVhNouzS;beDde~l>N+Iy!A?7u-<&T}c#yR> zy)MYuh!->lE@YWvL-8!u0JlrRcQ2S7nhHL)tWMYJ7BKs)%b=rRYi#2I7OKJ&2)4nU z_E!#31$6(yTY3$WSN5+t=ro4Ps;RUASs_%mFw7qpmUaL)W+p{k*Kg?W z$?-UOCAYd#9k=qC^bF($Ehyf7q={ zyyy&h)e4q5duwtPjtfT!Y1I4~1OKuW4ykIb)uGL4+`#7jlJ%Q_$oSyn+>S$k+I6Gvo2N zo4{~D0KY-LXR!M|XwMf|N^IDy#$SgQ$ko;N=iPtE`qr^w z4A&a4=u1=ICnujn@{($iZ>-9Umm@QM^Y zYSfD2%4k0&1!WQbf}IE0@o`2;Se+rdec>GMD$VzbFr5-PXYVFuqCJ$JTYlD}Qo_R0 zqKfyC$B#djrsrxOVU&Vhe!Nc-gNLQ^0o;}vCs3?2tl_21a{GmL8D6G?$0QRvnIZWO zTvr=~<7Cq;UZEQZp)KZ1+Mu0!Z8`TtMHIPe?HnMHe#>Hza_@|Ebigkl1#4s!m+e(i zAv)SRtps71i2mHkO~ax@FyT|I>6^Px{Och|>2LWA!349>Ux4KxuZLj)=g5T_R)7a! z)_{g`E*g#y-h(%a)XX+c8*%5S4O7-?JEByUc)}Q~v6}HebU@>h5kJL^B_@;yqLzUm z_`H`js86#GFn(ug3N{K1PoT)DhW%n5_%%Jj{9?O1>K7HLE{FgkpdYbDJtSxt_~ik% zPH6!!X~`G8ElGS81|0U@uaL`vE|3d$pNU0_#WuaBf>`(2Elgq)movOSO4Vz<#QLbg@A1f(yOm}eD6;bU0Xu&n6W zc#n|=<~6&G2e&Ho`URV>Mzuk7vl!?S{Nn--9RL?#tmpuPg@TZ~`28p<)#sh5AX5~D z$1T4#kKLb0Vj-ybG%cimx|Z_|3W0x#E6So=M?hNXAKA-YvfQsc9)$!?~4PTL_ z(DnE=LvTpVPaViWPe-*oKl)aNgUu4H=UMHG@@v)jv$PG^hs&Or@eV6sx_-xfv`Ma1 zRS$lo!9aW6cBU%dECTN(|JEQnC^M)7l2r<7#>Yip@MU%-=!+kJC!>TKp{a9Aj4!rY z^-;xsWBc>_P&Nr&&tt=MfZ@hmOk1RYDapn!ke6PB*&(!S(lqgPKo=YFyy?CZ`&;G~ zH`E6j|GUunz?`1g2{H-ug>fHR^sUb3HGQ}YJ@z@0#I;MPwc(cC?DjYnWLPX4HP5a6 zRzd6jNCQ2N=yJxbVvH^1A=Z^kenpf!BbGsR%I*r+6x-XfEjL=;UaDGarg zPaVAQ=X_DJmD};$1c_mY*yF0WQ2~21r&pg{IIotxSKW7SQiZRmO~#0zF^pPX-T|#= z6P!BHTG(W6)f|&UPG;HggUQth(NT*MP3m?u*J0G!vC0@=(f|z2FQUjZg$v;z%m{ zvQgIfLay*ad~LFTc=rj*q6D!kHT|zgeR4SHl{c<0kBQZ=B2$Go>5;&!*!KJMZmA*>vKhtXp8Kr~sdG3J_R@{6Wlxzhhm}0J;@DKV@JI;VxkmsY@90r-qF3bIB^@G%w-snj)xq49C(?~N^Dt4%k=q__G zK2vR<2^8_kD&co1$(cGaUaiWyDy1TucrU3cJwy7UVR$wWiq7a0s$`Owwm+gHJ1I!O zrUOlyY~U=*_Bye$F7iBAi@$?iEsb^W#YoqgYnz8&+F18V+bjgzoPJ~i=!hvE^XG3^ zbvanq@fJrhy6{*N5OWmpj3a8ssw(G)W%9bbEJfm`Tep>C44g7|T>AZ6eD;kU_vm%$ zx-Yr{A#SR4b$a4vjLt3#xmW4^1G><#^*o`EF)kGIB|?uhUEIVvv)moi=QBz)<7({&w4h65D^<^qT$4CWuidUULN8|iMgIMGv$B^t_PL=z#msKG>I8&-ff-wB^h0Y_bo#_ww^)0U0n*)zPm z-|Pg#-Dg2w>0=bT?xGK{)>Mo>y~zg=LBJuL(or_M>PnCHR_-7hHAI$|35wEWAk4wX zouULtE#lHB3QAJsIV?Y<7O7BH<{4|W6Og6FN2z7)a!5?UV(C5#uH&AhBn&(l>@c`OouyLHEAmGLQ{ zghwGyj!($o)SbCAI=n7=n^9eQYk~Dzx05wg%0hQ?*?jdg0#N}7O5V2b1?Gl!j;b*K zr^r;zEmi+W*x}-8KQKp^s<4+ud;5mN`sJcsf=pt$q~R#Yf$o#AE?7Qt6?MI0r-Z9g zI-hl;*XUnVW^@9kL&0DRavx8C*#aAn@}P1kL`2=HWt?>lSjk`yOqf|i-ZFo=yh&{w zugHafN(SE|qP%}a+e0&6wLt!XbxncWG&jfVq{DAx`3vX~@Y7=P_UIes*s&5_lvZlr z?(?kNpw9mJDAh>etW((gdqK}Q*{Emq%VY(ChRD|0aUKAl?WTWvV}`r+GCO@XGmF-7 zYNk|XLCdLkE7#;L%UyBnlu^p!z}cwPEY3I+cdm7*7<(vFe83E2pq$21jGpiNnMDm5 zQPJr@6^C~MvLY9mQo!47`Q^jv5rf4izdJ4^1^~xpCbZ=KyW;}l`G?~o$^7WJBml)M zkJA9sA3giOX2$}8)QkkNN|Ju zkCXAltTR8ED~c8jyjhe`)N<>6Malq}DBd}iT-UFlm-dSZYt2QiNS&l^ro-Xm6FOS) zG9juA2>ruj^F|L7fKxL0T1`Rej64fI{y-PNU>2JG0IIIQh#Hg0rh@pWEVMMRU;k( zRcsDmzU*`^jA`jtQli^_H(yS~{K~&cH}lhABQ@Pe_t(~_{a5hrUk=QDek zU}MAtuu^F3h4bzYV8Y=5`pYy8)ughWN%B}lsq|oj1K~21kO4KrV4sEx=W45Dk7S-0 zWF?89nXtYoBo19|nNEXILt}(D$+%f-2_S!gpj`*L&nZ{s1 zDR%%`GdajdBWeJiDRX;M^IWz23qOxMKFZ^1$jk2=D)5I>PQb%u_d^$8d_V>8n`Mya zlGP>naFKcKGU`49nvCKx2<|{23P8MC=V(4u-EZ81Au!ZwJns5l;q(%Sd&ub-nHjn5 zh;g;^|9NeT=DqFnz_n+@yiP(vp>GBPg#&Dq4JHR&-g{-<3i6&tH2cHgzFI=7|0sV5 zquN4c4_>s0RzJKg&vO#3@<9UR@%x{Ch!b?T3~_HbLl+1b42ci0p$FwDy=mM)9g68_ zgkDqvQFGKrv>Cuc%QGDybXNsGJ;9YY6f+(;Z<}%{UFES4?6R*13*l`rv-+r2i0;HH z*)W%{jf%IzfTtIt=KK}mZ6SWH$o1Xv#O@0U!2$B~o8hmhsreX}BL|ah?LjW@Y{2;f zz#Hn#+z5CDxz6qz_bv-TE_c;=aU6!V<0X5L7T3Vt8nxcF?vVAqf1`2a+9m#a4cf2E z-g&)?&UMUH7}D^z^PqDfc{fy7ap0t)-8}|x+QO2YpUh$lhy!=Jvi##81L6)ETs{u? z6Nj{s!Yx6e2;2pk5HQr;fmsn1cBC^Eu3#-B?$-rxv!#O$1`z~zVFFDb}RKB zm5Hz+?BnYI2G6~KEk6j_>&Lz{m-W~anL|*&@h}mjLfmB54;b+S?3on?%VWR?x-G5r z-FLnBYY-I_XLqF^XTr_#)QOk6029e{9Z+4*MT1>i3AHxqL6SMefspWFh}`9dbpl#pjy7If`pMqc=dWwEE8>hyC;HD20yR!l zH_3JM|2@)v?4J#%3^ALCr&oIlw{ht4PRD7$FGK){d#J@R5d0~Zg%jw_udnrhkeaC;tG>}+wu<~3f;?rza~w7j(ltGEl&(vQt5b`M^)b}!WQ($J){@|5%qAjS7&4R} z|AS{`<@rMCr?4HL?QqwoTNWolm|Q0RyT(&(F!~MqDjz@Wo8WC2cXU`shlP7S*HHWI zJC~Uw74XBU7C@VuE_7HB{-XIS?7eeWu;+wCWR`F1@?CJEXD=#B$kAnAh}v!Los5Ia z&sf9bphl}y)NB^Pz408K?dJXVEkPc{#X@38V@m9hvtu|3H+EU5)g}Yv^mfR{_A}tp zqLA+v%*df)3Qcw$Jb8*c2+WU79<+(Fj?wRf2I+isDAA;4d_&TO_IN-JvGXN!7yGmZ z-KnR1AXx|7ec2mfL0JnJNj@Mt*h%l+)<0hD$G@h|Aq3~~unn}_)cCCRTL zRRaAFLz)fwIHdP+!DKJF%PpxR5Evwy{K@P;KCWNyS39b9)mN`mYtt9#-1_mtbC&}( zo9MVPf&18p_cWF}8^6?oq;z~#ov-2z#V1a3bX%}>mIrpWEyfS#it7#2hB`d{$h%NN zv~-5LMv+!*-=syBdVEYog12(C`!s-&!J(Hy3qei1Q!mi06)54#0NH}$96F~a%q?vN zqzLT#{ep~7>haOeY?JCNYOv)Tm&knWgR8+Hg6I|LQmr(wqw6L=r#Rq^UgC0NSf-uF z(L_Y}^Juyp1)JQdrTc2$cA7n|jY9`9Y83_I&$^3?_C(MDd(ipC;RfDjDQ%}0)ht&$ z*w172$5DIO(ad`n4E;bZ;PaG35+Sa4J-DBl?m~jDt+SQV!h9e8tf%20gmB&>KyOiB z%@mjb`aKyu9?jO!smTo9&fmwZ5b2x=Qh=g>xRgWLN%=@TVA`=_*rOL_>q%@I9A z7cx>rNWTS!h|k?Dn`}0!n)3IVL9AK5{^4+sx$D)NFO8b8Lfzt~8le525uef`4KAR} zn7nHzgoAADH!1=Co&X5ksi2&-FI)!6Qs`jCfcSu(BRFq`aYrT{UsKA>rD4#gxF^Bf zG2u#>duy&KkS3}nJ$oi`2==FSe5EJAY^tUEjNeA6N$ozKJ6$XP$AN#i_7SizeKq4e z0o?V!l^Mn;DL|EB^>DLY*w0l*LbQJfeN)qJqfK59HF)F`yDIVl0$3+gH$AMxiasqiO8GsEf{9)MK1$VN0BlWo*5b%eW zhZ*nAB^`Tr@)T?WEFIlJ94Su+t+`qZK1ON9mD@XDiF37}{%KWgB%^E8fh3wh93#1N zy)rrv4NiY*O(Kw+V_@%3ISKuBP=qJYfN0Q9j~nkiZV8S?Z*D4A>R=YjKHZtG_Q<>? z;dh?_yPtBY%lr6>Yw?aBWesH_EcK9(tLuct{{AW$7rH2!Tq3Lw<-l&2SVq-UA5gxM z?v4V~Dv~LSLKZIPE^i`mIf~&$I!2>04yC(zQu#GjlQ*$p!wh|Vl{{DGGb~$jN{FTiM2m3wSZ!V>|GC=emr;T+41lM;$AWzNFBvz~IdJ4Hq?3;h>YXNO;8#vFe)|S$+ z3FNV-ddeWcmFLCDH<>UtwVHYO*Fx$7Ug9~wwYGmWWQ$Q_PHRkNQ@uMiey2%jWV*jq zEn3|3DW6IrO=NG-C3KsKrz8qUv&}XTKbu~!0U!eRJ)p+ZZaiTL2NyuwE5(2YIQ+h+ zp=et`8amKT+Iaq_90W*7(FcD`Lo0dz%V}us-_p=s&+lo-@y$*u@0pkl1|@#ez}-#< z_Y(O;|A<1-&4I+hRBHg_i&wx(^qXZ)=aRLQ(W>c$u+1I7YSU$)@82m_7s|LN;a?90 zNAP2EK%2-340S4|gxvA5w^qDSb7c56+?x)m$xI{xfmwXjD1WJE=FJn(_gi*>@J*{= zkdIlvR&z)XaW~amix-2OtqB}N9e2_ql59n$_^}}e%*A<_@ks&fQ&@uB6xg2<;8Orw z0s5K)@E>)F^f8{YJ7WHGJTd)oszfOq@>@JXOn%njy%0m&UagS(al$0~*Au26QI&V` zTU`_H`>n32aQso%XmZVe)wLbCUv(`Jm=9ixpiZ9Ck zq2EN}Tp&M~ShZEe9-3~6q~0^;5Jfe9FQYl+*`L4mr*HUgpJbFZo-Qlf(p%n1stg~* zH0dI`4BEXdS%^sr1Zwjog}WdNl#ILULnM*8 zOo<6HOL{oCKcj*Mw+w7X5>6gd9SrC7e2G1&sO4nPZdcI$?u~=LcJz;q%P1RgR#?XC zdX#tme(mfCy9wLPt(0GnZTL{2{PwBi!i6DvctZwe!hM?6n1jH-wlY!U)=*7`vsUZC zeqr-)x5ce&e?&k`&Ib$OVmpW@EZ;F4AfpXj{c=&n$rh<6eFxENM;LtbDiv|>C3|FQ z#E`CRItBYb)=qBDQ?KM|@gbwFk!0%+$jFCYgWn!_!$909d8`)>&WF{KQ`EMSlehg9 zCL1K-bP5tByzfi)kU!5{Q{O#YzdKFly&GA0xH&^8i>YplDJ#11+YU$H)_EKG&=v+q zwB|H*l4QAdqk_p!u}HQo720rv3d-wW7KW(9byznQ;d?rLda%>B>wA+UX)mz=c&tB3 zd$3(&TuNR*V&ULg>U>HMfuAA?qVah70uf97Kv%`Vb$(3ZEhvT7^~%Ei126;rD($tF HAkhB-TVtHW diff --git a/data-raw/interpretive_rules.tsv b/data-raw/interpretive_rules.tsv index 050eca8f1..f9754f5bd 100644 --- a/data-raw/interpretive_rules.tsv +++ b/data-raw/interpretive_rules.tsv @@ -1274,69 +1274,3 @@ EUCAST Expert Rules 3.3 Expert Rules on Streptococcus species genus_species one_ EUCAST Expert Rules 3.3 Expert Rules on Streptococcus species genus_species one_of Streptococcus Group A, Streptococcus Group B, Streptococcus Group C, Streptococcus Group G NOR S LVX I EUCAST Expert Rules 3.3 Expert Rules on Streptococcus species genus_species one_of Streptococcus Group A, Streptococcus Group B, Streptococcus Group C, Streptococcus Group G NOR S MFX S EUCAST Expert Rules 3.3 Expert Rules on Streptococcus species genus_species one_of Streptococcus Group A, Streptococcus Group B, Streptococcus Group C, Streptococcus Group G NOR R LVX, MFX R -EUCAST Expert Rules 3.3 Table 1: Intrinsic resistance in Enterobacterales and Aeromonas spp. order is Enterobacterales PEN, glycopeptides_except_lipo, lipoglycopeptides, FUS, macrolides, lincosamides, streptogramins, RIF, oxazolidinones R -EUCAST Expert Rules 3.3 Table 1: Intrinsic resistance in Enterobacterales and Aeromonas spp. fullname like ^Citrobacter (koseri|amalonaticus|sedlakii|farmeri|rodentium) aminopenicillins, TIC R -EUCAST Expert Rules 3.3 Table 1: Intrinsic resistance in Enterobacterales and Aeromonas spp. fullname like ^Citrobacter (freundii|braakii|murliniae|werkmanii|youngae) aminopenicillins, AMC, SAM, CZO, CEP, LEX, CFR, FOX R -EUCAST Expert Rules 3.3 Table 1: Intrinsic resistance in Enterobacterales and Aeromonas spp. genus_species is Enterobacter cloacae aminopenicillins, AMC, SAM, CZO, CEP, LEX, CFR, FOX R -EUCAST Expert Rules 3.3 Table 1: Intrinsic resistance in Enterobacterales and Aeromonas spp. genus_species is Escherichia hermannii aminopenicillins, TIC R -EUCAST Expert Rules 3.3 Table 1: Intrinsic resistance in Enterobacterales and Aeromonas spp. genus_species is Hafnia alvei aminopenicillins, AMC, polymyxins R -EUCAST Expert Rules 3.3 Table 1: Intrinsic resistance in Enterobacterales and Aeromonas spp. genus_species is Klebsiella aerogenes aminopenicillins, AMC, SAM, CZO, CEP, LEX, CFR, FOX R -EUCAST Expert Rules 3.3 Table 1: Intrinsic resistance in Enterobacterales and Aeromonas spp. genus_species is Klebsiella oxytoca aminopenicillins, TIC R -EUCAST Expert Rules 3.3 Table 1: Intrinsic resistance in Enterobacterales and Aeromonas spp. fullname like ^Klebsiella( pneumoniae| quasipneumoniae| variicola)? aminopenicillins, TIC R -EUCAST Expert Rules 3.3 Table 1: Intrinsic resistance in Enterobacterales and Aeromonas spp. genus_species is Leclercia adecarboxylata FOS R -EUCAST Expert Rules 3.3 Table 1: Intrinsic resistance in Enterobacterales and Aeromonas spp. genus_species is Morganella morganii aminopenicillins, AMC, SAM, CZO, CEP, LEX, CFR, DOX, MNO, TCY, polymyxins, NIT R -EUCAST Expert Rules 3.3 Table 1: Intrinsic resistance in Enterobacterales and Aeromonas spp. genus_species is Plesiomonas shigelloides aminopenicillins, AMC, SAM R -EUCAST Expert Rules 3.3 Table 1: Intrinsic resistance in Enterobacterales and Aeromonas spp. genus_species is Proteus mirabilis DOX, MNO, TCY, TGC, polymyxins, NIT R -EUCAST Expert Rules 3.3 Table 1: Intrinsic resistance in Enterobacterales and Aeromonas spp. genus_species is Proteus penneri aminopenicillins, CZO, CEP, LEX, CFR, CXM, DOX, MNO, TCY, TGC, polymyxins, NIT R -EUCAST Expert Rules 3.3 Table 1: Intrinsic resistance in Enterobacterales and Aeromonas spp. genus_species is Proteus vulgaris aminopenicillins, CZO, CEP, LEX, CFR, CXM, DOX, MNO, TCY, TGC, polymyxins, NIT R -EUCAST Expert Rules 3.3 Table 1: Intrinsic resistance in Enterobacterales and Aeromonas spp. genus_species is Providencia rettgeri aminopenicillins, AMC, SAM, CZO, CEP, LEX, CFR, DOX, MNO, TCY, polymyxins, NIT R -EUCAST Expert Rules 3.3 Table 1: Intrinsic resistance in Enterobacterales and Aeromonas spp. genus_species is Providencia stuartii aminopenicillins, AMC, SAM, CZO, CEP, LEX, CFR, DOX, MNO, TCY, polymyxins, NIT R -EUCAST Expert Rules 3.3 Table 1: Intrinsic resistance in Enterobacterales and Aeromonas spp. genus is Raoultella aminopenicillins, TIC R -EUCAST Expert Rules 3.3 Table 1: Intrinsic resistance in Enterobacterales and Aeromonas spp. genus_species is Serratia marcescens aminopenicillins, AMC, SAM, CZO, CEP, LEX, CFR, FOX, CXM, DOX, TCY, polymyxins, NIT R -EUCAST Expert Rules 3.3 Table 1: Intrinsic resistance in Enterobacterales and Aeromonas spp. genus_species is Yersinia enterocolitica aminopenicillins, AMC, SAM, TIC, CZO, CEP, LEX, CFR, FOX R -EUCAST Expert Rules 3.3 Table 1: Intrinsic resistance in Enterobacterales and Aeromonas spp. genus_species is Yersinia pseudotuberculosis polymyxins R -EUCAST Expert Rules 3.3 Table 1: Intrinsic resistance in Enterobacterales and Aeromonas spp. genus_species is Aeromonas hydrophila aminopenicillins, SAM R -EUCAST Expert Rules 3.3 Table 1: Intrinsic resistance in Enterobacterales and Aeromonas spp. genus_species is Aeromonas veronii aminopenicillins, SAM, TIC R -EUCAST Expert Rules 3.3 Table 1: Intrinsic resistance in Enterobacterales and Aeromonas spp. genus_species is Aeromonas dhakensis aminopenicillins, SAM, FOX R -EUCAST Expert Rules 3.3 Table 1: Intrinsic resistance in Enterobacterales and Aeromonas spp. genus_species is Aeromonas caviae aminopenicillins, SAM R -EUCAST Expert Rules 3.3 Table 2: Intrinsic resistance in non-fermentative gram-negative bacteria genus one_of Achromobacter, Acinetobacter, Alcaligenes, Bordetella, Burkholderia, Elizabethkingia, Flavobacterium, Ochrobactrum, Pseudomonas, Stenotrophomonas PEN, cephalosporins_1st, cephalosporins_2nd, glycopeptides_except_lipo, lipoglycopeptides, FUS, macrolides, lincosamides, streptogramins, RIF, oxazolidinones R -EUCAST Expert Rules 3.3 Table 2: Intrinsic resistance in non-fermentative gram-negative bacteria fullname like ^Acinetobacter (baumannii|pittii|nosocomialis) aminopenicillins, AMC, CRO, CTX, ATM, ETP, TMP, FOS, DOX, TCY R Additional rules from header added in separate rule (genus is one of…) -EUCAST Expert Rules 3.3 Table 2: Intrinsic resistance in non-fermentative gram-negative bacteria genus is Acinetobacter DOX, TCY R Additional rules from header added in separate rule (genus is one of…) -EUCAST Expert Rules 3.3 Table 2: Intrinsic resistance in non-fermentative gram-negative bacteria genus_species is Achromobacter xylosoxidans aminopenicillins, CRO, CTX, ETP, ATM R Additional rules from header added in separate rule (genus is one of…) -EUCAST Expert Rules 3.3 Table 2: Intrinsic resistance in non-fermentative gram-negative bacteria fullname like ^Burkholderia (ambifaria|anthina|arboris|cepacia|cenocepacia|contaminans|diffusa|dolosa|lata|latens|metallica|multivorans|paludis|pseudomultivorans|pyrrocinia|pseudomultivorans|seminalis|stabilis|stagnalis|territorii|ubonensis|vietnamiensis) aminopenicillins, AMC, SAM, TIC, TCC, PIP, TZP, CRO, CTX, ATM, ETP, CIP, CHL, aminoglycosides, TMP, FOS, polymyxins R Additional rules from header added in separate rule (genus is one of…) -EUCAST Expert Rules 3.3 Table 2: Intrinsic resistance in non-fermentative gram-negative bacteria genus_species is Elizabethkingia meningoseptica aminopenicillins, AMC, SAM, TIC, TCC, CTX, CRO, CAZ, FEP, ATM, ETP, IPM, MEM, polymyxins R Additional rules from header added in separate rule (genus is one of…) -EUCAST Expert Rules 3.3 Table 2: Intrinsic resistance in non-fermentative gram-negative bacteria genus_species is Elizabethkingia anophelis aminopenicillins, AMC, SAM, TIC, TCC, CTX, CRO, CAZ, FEP, ATM, ETP, IPM, MEM R Additional rules from header added in separate rule (genus is one of…) -EUCAST Expert Rules 3.3 Table 2: Intrinsic resistance in non-fermentative gram-negative bacteria genus_species is Brucella anthropi aminopenicillins, AMC, SAM, TIC, TCC, PIP, TZP, CZO, CTX, CRO, CAZ, FEP, ATM, ETP R Additional rules from header added in separate rule (genus is one of…) -EUCAST Expert Rules 3.3 Table 2: Intrinsic resistance in non-fermentative gram-negative bacteria genus_species is Pseudomonas aeruginosa aminopenicillins, AMC, SAM, CTX, CRO, ETP, CHL, KAN, NEO, TMP, DOX, MNO, TCY, TGC R Additional rules from header added in separate rule (genus is one of…) -EUCAST Expert Rules 3.3 Table 2: Intrinsic resistance in non-fermentative gram-negative bacteria genus_species is Stenotrophomonas maltophilia aminopenicillins, AMC, SAM, TIC, PIP, TZP, CRO, CTX, ATM, ETP, IPM, MEM, aminoglycosides, TMP, FOS, TCY R Additional rules from header added in separate rule (genus is one of…) -EUCAST Expert Rules 3.3 Table 2: Intrinsic resistance in non-fermentative gram-negative bacteria genus is Chryseobacterium aminopenicillins, AMC, SAM, TIC, TCC, CRO, CTX, CAZ, ATM, ETP, IPM, MEM, aminoglycosides, polymyxins R Additional rules from header added in separate rule (genus is one of…) -EUCAST Expert Rules 3.3 Table 3: Intrinsic resistance in other gram-negative bacteria genus_species is Haemophilus influenzae FUS, streptogramins, glycopeptides_except_lipo, lipoglycopeptides, lincosamides, oxazolidinones R -EUCAST Expert Rules 3.3 Table 3: Intrinsic resistance in other gram-negative bacteria genus_species is Moraxella catarrhalis TMP, glycopeptides_except_lipo, lipoglycopeptides, lincosamides, oxazolidinones R -EUCAST Expert Rules 3.3 Table 3: Intrinsic resistance in other gram-negative bacteria genus is Neisseria TMP, glycopeptides_except_lipo, lipoglycopeptides, lincosamides, oxazolidinones R -EUCAST Expert Rules 3.3 Table 3: Intrinsic resistance in other gram-negative bacteria genus_species is Campylobacter fetus FUS, streptogramins, TMP, NAL, glycopeptides_except_lipo, lipoglycopeptides, lincosamides, oxazolidinones R -EUCAST Expert Rules 3.3 Table 3: Intrinsic resistance in other gram-negative bacteria fullname like ^Campylobacter (jejuni|coli) FUS, streptogramins, TMP, glycopeptides_except_lipo, lipoglycopeptides, lincosamides, oxazolidinones R -EUCAST Expert Rules 3.3 Table 4: Intrinsic resistance in gram-positive bacteria gramstain is Gram-positive ATM, TEM, polymyxins, NAL R -EUCAST Expert Rules 3.3 Table 4: Intrinsic resistance in gram-positive bacteria genus_species is Staphylococcus saprophyticus FUS, CAZ, FOS, NOV R -EUCAST Expert Rules 3.3 Table 4: Intrinsic resistance in gram-positive bacteria genus_species is Staphylococcus cohnii CAZ, NOV R -EUCAST Expert Rules 3.3 Table 4: Intrinsic resistance in gram-positive bacteria genus_species is Staphylococcus xylosus CAZ, NOV R -EUCAST Expert Rules 3.3 Table 4: Intrinsic resistance in gram-positive bacteria genus_species is Staphylococcus capitis CAZ, FOS R -EUCAST Expert Rules 3.3 Table 4: Intrinsic resistance in gram-positive bacteria genus_species is Staphylococcus aureus CAZ R -EUCAST Expert Rules 3.3 Table 4: Intrinsic resistance in gram-positive bacteria genus_species is Staphylococcus coagulase-negative CAZ R -EUCAST Expert Rules 3.3 Table 4: Intrinsic resistance in gram-positive bacteria genus is Streptococcus FUS, CAZ, aminoglycosides R -EUCAST Expert Rules 3.3 Table 4: Intrinsic resistance in gram-positive bacteria genus_species is Enterococcus faecalis FUS, CAZ, cephalosporins_except_CAZ, aminoglycosides, macrolides, CLI, QDA, SDI, SUD, SDM, SLF, SLF1, SLF2, SZO, SLF3, SLF4, SMX, SLF5, SLF6, SLF7, SLF8, SLF9, SLF10, SLF11, SLF12, SUT, SLF13 R These last ones are all true sulfonamides -EUCAST Expert Rules 3.3 Table 4: Intrinsic resistance in gram-positive bacteria genus_species is Enterococcus faecalis TMP S SXT, SLT1, SLT2, SLT3, SLT4, SLT5 S Since R to sulfonamides - TMP result is equal with combinations -EUCAST Expert Rules 3.3 Table 4: Intrinsic resistance in gram-positive bacteria genus_species is Enterococcus faecalis TMP I SXT, SLT1, SLT2, SLT3, SLT4, SLT5 I Since R to sulfonamides - TMP result is equal with combinations -EUCAST Expert Rules 3.3 Table 4: Intrinsic resistance in gram-positive bacteria genus_species is Enterococcus faecalis TMP R SXT, SLT1, SLT2, SLT3, SLT4, SLT5 R Since R to sulfonamides - TMP result is equal with combinations -EUCAST Expert Rules 3.3 Table 4: Intrinsic resistance in gram-positive bacteria fullname like ^Enterococcus (gallinarum|casseliflavus) FUS, CAZ, cephalosporins_except_CAZ, aminoglycosides, macrolides, CLI, QDA, VAN, SDI, SUD, SDM, SLF, SLF1, SLF2, SZO, SLF3, SLF4, SMX, SLF5, SLF6, SLF7, SLF8, SLF9, SLF10, SLF11, SLF12, SUT, SLF13 R These last ones are all true sulfonamides -EUCAST Expert Rules 3.3 Table 4: Intrinsic resistance in gram-positive bacteria fullname like ^Enterococcus (gallinarum|casseliflavus) TMP S SXT, SLT1, SLT2, SLT3, SLT4, SLT5 S Since R to sulfonamides - TMP result is equal with combinations -EUCAST Expert Rules 3.3 Table 4: Intrinsic resistance in gram-positive bacteria fullname like ^Enterococcus (gallinarum|casseliflavus) TMP I SXT, SLT1, SLT2, SLT3, SLT4, SLT5 I Since R to sulfonamides - TMP result is equal with combinations -EUCAST Expert Rules 3.3 Table 4: Intrinsic resistance in gram-positive bacteria fullname like ^Enterococcus (gallinarum|casseliflavus) TMP R SXT, SLT1, SLT2, SLT3, SLT4, SLT5 R Since R to sulfonamides - TMP result is equal with combinations -EUCAST Expert Rules 3.3 Table 4: Intrinsic resistance in gram-positive bacteria genus_species is Enterococcus faecium FUS, CAZ, cephalosporins_except_CAZ, aminoglycosides, macrolides, SDI, SUD, SDM, SLF, SLF1, SLF2, SZO, SLF3, SLF4, SMX, SLF5, SLF6, SLF7, SLF8, SLF9, SLF10, SLF11, SLF12, SUT, SLF13 R These last ones are all true sulfonamides -EUCAST Expert Rules 3.3 Table 4: Intrinsic resistance in gram-positive bacteria genus_species is Enterococcus faecium TMP S SXT, SLT1, SLT2, SLT3, SLT4, SLT5 S Since R to sulfonamides - TMP result is equal with combinations -EUCAST Expert Rules 3.3 Table 4: Intrinsic resistance in gram-positive bacteria genus_species is Enterococcus faecium TMP I SXT, SLT1, SLT2, SLT3, SLT4, SLT5 I Since R to sulfonamides - TMP result is equal with combinations -EUCAST Expert Rules 3.3 Table 4: Intrinsic resistance in gram-positive bacteria genus_species is Enterococcus faecium TMP R SXT, SLT1, SLT2, SLT3, SLT4, SLT5 R Since R to sulfonamides - TMP result is equal with combinations -EUCAST Expert Rules 3.3 Table 4: Intrinsic resistance in gram-positive bacteria genus is Corynebacterium FOS R -EUCAST Expert Rules 3.3 Table 4: Intrinsic resistance in gram-positive bacteria genus_species is Listeria monocytogenes CAZ, cephalosporins_except_CAZ R -EUCAST Expert Rules 3.3 Table 4: Intrinsic resistance in gram-positive bacteria genus one_of Leuconostoc, Pediococcus VAN, TEC R -EUCAST Expert Rules 3.3 Table 4: Intrinsic resistance in gram-positive bacteria genus is Lactobacillus VAN, TEC R -EUCAST Expert Rules 3.3 Table 4: Intrinsic resistance in gram-positive bacteria fullname like ^Clostridium (ramosum|innocuum) VAN R diff --git a/data/antibiotics.rda b/data/antibiotics.rda index 9a9e74d3d5440fe9b8987f1f4576eb878991387e..f09607b95e65fdbd20770e5c6c9f24c3d958705d 100644 GIT binary patch literal 45412 zcmV(lK=i-;H+ooF0004LBHlIv03iV!0000G&sfak;eW9uT>vQ&2UJ%gRpOV=m z?$kECL5*@;DY6ZZ)ru;2!jPgi=r9@0TSJ0=V_3wbPgrED`pD3=@PP40ko=Jc+(M4I z*-0asIh-}*Vffz< zDn*t!a~(lDubL;}f137oGrZr4T9&S34!M!4F?u-1!ZLPyFrrHBeX58)nnq!vrusH;_}mngUO?3^-^Z7Xk$sT&J3WWcQ_ zt(#J7fR243^HqnF7eS}}keeEB+BJq9BCJ_1;jIEJNZIH}a&g=1?UnhP0<2wSU3SJ0!R1N|dUlAiluA7KoF2#(9MkEFfINIiZHuQ%oetg;Bpg(>^`3Zf;yVuUYqKl>$`29OF9vW|a& zOb~zH-ZQUS_(T;~jQOxiiat!gSmo+EWB|OU3vUp?d~?x8yyCE&qo$QwY>O4C!!eM1 zD>Fdna87FIN-1siiVxFdpr@p@7s%l2X($rSQETI?rF0$)FcpZu!uCpci-knb?C&^I z)mhp+&?qXOq81iUy?V~1=As9VSJ7ulq7g72ZE>}?;icjwUAhPXVKX!2ZR>=8&5X@k zJb+;3(%QvB$_h2T{aaIROZ`;7Zy?h)t5oSHgl9-cF7TQ^R7c%7Gj}+c)x}R%UOIr+ zLT3Q`kV+8@l$I`ucsywKE^T4F&el6&ZhER9!vOyp$p64m7T!@6pUd#$tjWKjiertn?9P(UEM zXpmxnR7P`eFUiTO?Zv6GuC2!2AQ+&lO)05!BZe?nlg#h{&B0z4B&1IDh8b`#v+M?eCqwmhc|I4WdR+DJ(x91EmR*oWu|hkKrd+F7xOl6qEcBPN z9c7T%IFSF;IQ@re`gT_%ePo47^0dwuD=aXzzU95Yf`A)jKJap)k#h6P-otVd@cP zWLwBjTH<`k2c(M^P%G+OSDbfnVnmb@hE}7g(tbyN1@d;{3OCj_d6zLxX8-tBdkZ+P zaW>i!oH~|V%Sof-TQQm751;w2QO#*4ePCZ^NE?)8A0K9IvFZI*Na!hG(qrN?w*2O_g1 z@u=&jhqVt;+y09JNQ}>OWi1ii1BTg|Dqnm$Jvma{RFYkJ1szRxy-k667fc0bsze97 z21e@U@VR0~>V55Y4}+u?uRgFL)bY8*iA#j{{WESQ4kh|r2CwA2yOBdhe+|<@4 z`ycHWr`&z**b3{VuUR@JQ!$uFu$^@Ga`F>JDi@dDpBj^a*Vh1l$o9Qk`}c<)QEcPPHP@34P2vVnfMdV zVG}}dC0>4=OZ_BWhK>N^*Bjc(nB~n8prVX_5ekHP6?OLe5l=ySs7jby@ddvCXrIs` zdLeRhnrJEimBumL3auPQ^K3Uhn^^X#|cX*=PKzQu5 zKd&GyJKWoL13#$wtsKwEmdNW+xflmK0*vaJ0)`aIk{*{={mYmPQ7Cp*^`n-odRy59 z%CN8PvFqhmv-U+Imi9j%uIs8!{ReK)gJcmyleNNNFaZz`sAiMw%#;bZbM+-d!%#7O zbf1R44C@tf((As>N`}}C_1s5-4%PiYFc-4AoO3@<2tpkePavlnRA>@l?g=(^$X&yl zwWdJ%*EG9%Pt1N-9cB|S!yhzXlZM!aE4xn*NWWva(=gSY9ts#DHUMn=vT=(8-Psp` zke|+|!w3JlIJ9il|5GsFY3#UM#4K>zl*Onap_*;Vu~|uBKLAJ4>f+R-m?=asY>-D^ zZ1GC{iqr>TfxqPYtyiDv_q0v|$wFfco;E$&IIz5@Ag|KkF`{?uLTx+H*e83J?*6 zP*O~-*XGRWXCQE<8mtx*Xow9-+6%AwZQ>?wcBoEqv?XOv1TOR1HhJ;e|65TKrLSPF zo~vJgdf))^hiKku)Cx0jo+%NYmYqsJ5W&cF^N8nKRq@87E1^faVkLu}5KBA= zW2;XP3xp`@_7w3M0gfE`BNTInqz_0EHGF<33+NpF3YrMt2$wn8X6cW|^N5>RaXu+!Ol1 zX;)Vfsq5UxlQI%Dh_zDMW1M2;nzhzP3fLC|4Q+yz`TIDGyxg=dzS-*veegw#gkSf$ zC-qs{gT>xG>m4Yb_vB2w?t*OW_@)gesw6&NF8G3zwpC8vAX3LZF=U1=<6pFo-=8qbb0b$EDqzz&3w)5u|LI`PP_ z3h!4?H9dXCi;6F~*DsnU*cH*w(|~uxP#1O7y%V#7o2-WvOJvVQffQ&toWqCxdqtz=z@kW%3r`WdQkGpuCik6l3<`P%T%`FZ0rf&^@zxiX&=V$@zx+y&|^{|L2mjH@T3Vr-6w zKAXk4xKM#1=B|FX+k&6=FV>2|0qHwyv(K)09l;+c`^IclpQ5M z98gsV1ehu^c;)e}$p&>ET9aw+H)pDb%N?=pIO{q2=67|bckpB#Kd-T&#_yXLK3No#8AM`G*?jUL3^p3){YA;S+F&^3t zydQ9@nWJ0^MErt!z~5O~TD*G?{!rUdMLP$Ow3n??H%b@qW0XSaSdtVR@^r zNG(Q7P0IjIx@2rR_kB`{nsFB)#5V(QtP`+@R80OOk)Bn`(S#5~Vzvo0A06urFG#m8 zt3mLytys(!Y0jxWN82NJaDvE2~385AAe zXmw|_29cP{Cmw(`4;L^FFTmey7H}fEW!B>RZZ!Wa=<)iE;+9<}CkSzl?>_}SdUTw( zk2i^-Si5&mkkapA6@xb?hXU?ulQCBmQc#f8d-D<6E1Sd`ofon`3L`n&kwu)o;+ambT!q%G9O)c!_cjk`StZMuKdqxLG+a3Jj2~LY z0D^L-}*ayi7@JbE!r8vM^s?KWKy-)XCjtCu#kLlT%$_$YX9GtatRZz zYIs~33O|fqz2yMr9kWRh2TDD~2;UfKeb`f{m%u|LwyP_|Y`d{K=1$(KiH! z`+{TW6whT2-GeN)9?yK-LX+ZfxYiI?d8?YM3H@KjL}!|L#PW9)^t!4v?6jg{4}Jxp z@Tli&Xh2I#Hpcq7N1ih??%5wLMH zYBFl|q4!bDb_ZHu5+=rna4I4c_FT;YS-9Xh{WnaY!%fjWGqXI;wQ25|y7(18%l!k% z>Np*DzFG$qgTT-Zf1SV!^6+skG3ZzACU*GPdZVJ}^F|fn+n73)8ROslk&W z64a*$3%*ygEn85MLNI-mC^eLyJV7uLqduG)!>=4R>r~Zu2}k*Xzwb|LtHtnfdieUt~k41W+e@vLX6*ko*l( z?z>Rw?GB_aDQNInGN4qJ&oZWb|B#|5!R+$6bcb5?}H^qgXu1; zeWZ()7505_E5`X@c^>XeeMH!Nh`}@^@Er18;i3mW_#8BW$*l}K0WTtP_jAwL1tiDxW%QoSuILv3TQUH+dZS=0ffNUJ@adIHJ%C1%fX)><)Kj2`RmkKkIe<^ zyV#7-lPE>Tl03*hYZ_XfP_)4uGUUGOb>Bs_sob@; zcpQj(>EfMfc(+fcGY6$mT@dpYd-<7W^}P%QV2`+H*%JBG00=s@i0v%E$U531FXf?$ zMHod)k7r4_*Q$m@yfrU!zsIRYG&B|2lO~Gsu(2X4@?NM9uA4jP$_o9C%}6Z;Aarah zWli!g@wpJJ*0ap$s9aS@`1b zeMVzc+G#S>@4xls1aq_^;vcm!KDbuP*w)+4?-HPvWcLca^Pp~Iyvq9fI6`0^<2C)NF z$kUZ%PhA?jg_3svdRKn>+-Yq*i{}G{(0IOHv9ZuidEsUyv9f}f0GmXFf3GOb#%wOh z-&d~Uyl5Rh(wW}PDC*-oj+isumy&o9hNb7}{DXY0X*7zWU+iphLJ<3*FT%&}Pew)P<5X%$lFOB$?b|CI6{ zbitL=R2@(YOLxYs90eOlwJubm&#EFP9WP)W4CX^@vcfV{Emcs`Pj3U~R^6a+Z>BU? z1micR*)+fteT&Yl>WYSgcO|_L!|E6_7cz@Xbl^TuBq4M(awt3Dgc;4SnzacAT%(!> zPX?-lK;S194CeT=2l8a!z}$1!ljjhXzg8o5Qb1TKV(7GL$w+CsF2cZ9Oh5b_RropE zf-6}U8!IP{A0QLSgblH7@cf1Zm!^r`gy3gQ=YgIpuXQ9gB`4i8*uW85*IlIrm3>w2j_|&)t`h$fvP@r3VjgV2j3`5XI?!ssF^vlc zL4C&3E{0#XC6r5dYeA)b6?}9&4T;a(KMy6@4gG|~_M0F7`x(*M1-P6PJs0pLLG*+) zaZNN~(sNHA`arZfeUhPf@vndKz%n?RxxV#9f#LBTSlir$`=jX!8yju7c6urM8sT4v zlZZDE77&pyuNtpUui^8-3@C_i_N5K>r#QxV=-5(I+*h>9We*W>{1n*Rm_D!TD<%3a zSkJWi==fd&U1!Lg0FXsK{6Z(>@D5mj*lOVGwj!gYH|@-9G$gPQp4{~+Xmx_ed+;V7 zQBSonm!(^ZPf_bL7(Br;2{sjK;82e4<({UjGGZX0c}PDU+#N>%RrvdWpHm{>gBdk| z0*|IZ66;e9PeB*70Q(BSmUx-ChZV(h?Tm6Kb(Z5BXxnLY>F&70d3#7DZ`5yMbIjcY zPUp{$erq@GZIV+@lh!9x5S*C577>@blUltK_At>MRe7q;KBkk1RVcTPi2{AhYh@o0cM((V$F+3bKqBR-APpW96vg#g5MO*=nOdL+ z(!3EYwVzr!e2P7w^_)<&wgjiARP=t0F)jJfCTyL4D1PvB)8ube9n*(VfNxo4v$#cv z^uPF0i%T4E)%NT!7H#xFVO~YNSQ89B!8lycMTWVo&##uuc4KAGjwk?`<>9X#sgYB` zYW3mpKl#CgfZz)ELHBc-+*jUtGI07tJ{8FY|Em(3uy=|dA((B3zVLfT;J-_O%>UYm z6O6O)xs>sd1?d-IPW~mQh`qU@ZpNMjrvvzxHC8+&b>DR|EP@G*NJg?XxFo8mPJ*{uZYK;t2LQ;3Ghu2m#wR? z3xTot=!|(Suo_&-fuyj$nKvn`c@yS*oj6JLZ4kP1kk~E^7q#GcA=e(mdR{$uR9Z= zc8lPIQOH@F^xxDw!1~f@vldf#h;mU()hx%0A;m?6kt%nY{71hkx4)#Q8dcrJPr5dT z-m+iusEYb*i{FU?aZHXv9;x2%LMH>-OnKJyL?rB7uE6U zbDE6w6H3ai!1P*b2A7%9Uc&lkl_lr%Ep0FLG|Z<c^EoQy!8i)2p7ec)l>oC=1JEP9YH8`nR%)pIvLORlXGUzOl33QEBEn54oS4`TeuFa^V|V{O3hvd(1{bUf%f^ z&g-U)@L`&_B5uJ`LP*s(UQVQD;e+ay+)o!yWJIZvZHiDjCR!`$%&S6$sd$ z9zO)ym%9{ce7CV$jfq>zRpP@qlTOs4T)4C3aKtYbvPwsQfQSN~_6-+<`sjPd6^(m{ zEOXGTUQh+J1scqT0N$Noo0hZZmJ&5_LO55=PzZtGS5ZDxK!z+Km{d0(Sx-}|Ewkk5 zcTwp<(}1m)d^+54>rG<5uJG`dd@WR&JFh3MDSmBtuPWfyKtKJ7-@9sYg;sCqGN_|G z+nuyPX8|v%!T%B@2(^I>MDRn#XH5OxW|7Q@lCmlMd_BoDLYM>Kj4*_3H)pZCa84Fz z(AfGBeV^>ebGh*K!+zAakTJdJr)B{PVmn8+WsgmmjFkLH3V6~fH^}E=455(Tn zPHy2|HgNdEW$?w{%S=Eo_Det;y2E5wNw3s7BZ#o)I~YYu~A1|AaQKHVvz zRxic}pEB}}O!h4#zJD#0)DXh(uj%qS0XLR$Ywm9`gXO>KEf;=Qc-f?AgVNIZ(f4Rfrwxe^vR)vs8Dm6s?d8};O1I56A^wzVRGKt63NAua_}`+3c-j?9IM0*dHRY5w z*B>(Uqq)(GD1D<3l5c0C;QacuHY0d(# zoilH?dR~^TfANH;$f(9_mW1BT1^^WwD;jAJ* zYmwEt3iZ1o>Hn*QDq|wmEwnm3ilZV`y#@JTH9>6*l|HgD zWNV@DtFcvmB}AmeET&V3%?M&CT;wfk$z(pO{`{(v5gQRd$~ zJTmU|o#Yswpdh*a)bMG@B(;a2;v2No1@3LjTLU21h7)zA>Xmv^2et}cLOKU+N50d| zk^5tikDa`_Zz*1hLEkWUo%tMz#(x}g`l+031O{HR^c~$_sLd3|fthmnL@KVW5vn=s zSe%I*(}9M1@5AxsM7RI()>1bla3*rw#^GZkCjSoPrrr1S1vUoIm+t>;$xF+55z(Q( z?Y!Gkn6(u3hU?HaiI6G5jJ6C~C$v*nnu4*vrZ`4o0kSQIx`FN26Y~vq15Clvt?gk? zHrl!RFr4GDz&0Uesv{nnY>P6OZ>}?co=Smk{zkwl{d8(w&ZL~1+9Yt-5${0uK?b`) zO{hdMcDXXuhnnC#*A`o5gc(Lf7bI3VNYp2(&4ROgd6o?xB{Q|3EqIV6gYUGZ^qECD4TzdrUBLHcsh-0Tc*DM&rvV< zY(%JRz!L-pEiGfHs2;-PoX3nyZ{AVqbUeXGX1GfXtiegNlT_s6X!Sw7lT1uh9x>jj@Y2{rJi< z#31!;`z6vUg|fY}Vn~-=n8kl9wI`e;pk;vN_?Pv=Q6O;J|KCLjL2~jyd$M0S1D{E? zA!ub3dVB|3@N!v7{U!kZ7scIFGqVtgf#tY#vI^1zTmXE93f6Dv;%wlV{>7zL`OI{8 zcX$>mYLHel@U@xJvPf1O6zx|X^1u6%oU<+x(8*KR+6}#6gE0VyekGv?003xgZS9~s zML|>aTKuu@kpYJG}-UTT;&b zjujXi@lCa!4Tca#3-<|l=R@XAJl3OC|H7b=8gdd9H7L>L8I~)_(!#r@d36o@)8C^@NI0dY)Ob z8l?=*AKIps$Odx55l|S>HZI|uCJ8n548LhLdrQT&gp6PFuY7PKuC>@uJ|YYRT1q#& z_oU}jT{+@oJpbwKIz@_e*Ul&`g3j7KB3LVKEZhhmaiQO7u=pDYckQO!48N;Nf}|^l z(_mp$lV<3%2a`fjNq^p?Wy}5MM{)6J2Sm30q%5fOxg6Wfs0#?O^EGBhSDFcl83Qs2 z;kyW-p7>QkLsfe8oH$IXMMpTc#@V3cg4=#^gVA>@qstIUy9w}%BMPm4Rdz5%r25>M zz3bWJ{xk=#c)4*98W{%m;3+WIP7M~O#E0Z1Jb$jX5}r;C8POnrlh`U}tWdQ!?U{pJ z{0!y8b`I}(B;+jx(gA?g$8zju7t|{+ymgLW%@_Vcp_{&8VR9LNvjKKf2esrS!j;ql zKaKngWPTSb!RMJmn<><>Cwv}VMpL7+VJ#UmI50Xqe(a6xXIew|LMA#qb&FY423)up z=-MDNqWAo9;Qgm0jm~Ucm=b|iB~|Z-K-NAEEuPS+y@Rh>jYdL!%C})6&ufoI_;EVr zm-rPl`G3<8S!`hWiXd!dL_&$;MTKaVYVp};d{h$E+BrM*c*!d*`L*ZdpzqH2WVy5@ z!5cj@SLRMA%Cbo5AF0p8Sby`6IV?(?3IPrZ?yUDM-xaU-#>Qitg|>+)yiQ`J(Eirb zXJ0N~4+AikrLV@?;L@bV>c1ut+rAD7K|~nUHW|oy>uEYxX29cIde0YIh#sut2>(e6 zf*b%@#MZ}U>wl>Qa zf>_en+>LrEhl#wyrB`LsJn4914nw90T6X{jT2|m+@9y(%{B_Rv@JZlA;;uFM0^y}P zXHh{z@3$F^jVO!N^9t)pjpnCazNjG&=BI+NpXDQYp%852I!<I6xkWf_W9tq5< z72(n>Ww-S_YS0{W!P<*nt+wiZIo)Iu*XAA{4R{?q-eg}(@0E?#{_n7`<|}BIfq^l_ z-$z4qC?26gdUtMOQz1ih!zCMs{pYf|+++IxEmW$o%0D)WT!3c8KP6=r)&pJ7E!7G#oJavBnj7`LQGDzHv_zn4@t$_@?RX z1onGE(u6z%Wi7(if%Snf%NgoOxZ{9CSBh43`rYq!3Xk5O&BB=!X-yp7j00!Hc zGfRV>VpRYYoOu1p6XO!r2OMaAl)nKeu^qgoxu?bf!hU?fDdD99jn!n!6yZlQjA`Z) zo|u)lKpPTW)>0Y*SyHioT_fD3>&6NRJ`IYn?+>_cn*QHV_DThmTsdcf-$z+!rFT0oO})0hyl_+7N%pS}C`&a4XK+v| z1hBC(CJYAHkP;RK87gGU3y@d~B#m518r@X$AIZ|%`%*AEro05l0y$tNM}o#RGTtA)+f296Db50u; zmhu0J0YV0VCl*$>&GU~gcRF8S58Q(I3Iz^0v+ z4+jXR@!_OSqXmkjBv@-W)HX*Ez4bLm7N6SJne!~|h0ZY6e*owpOP5-0B7j>*FyeCZ z?|DN@Ue#}3k-SbO)%XW9p`ilDTCX$ZH{~4sS+JN=nkQy~zbCYz>JR7zejq!r>W^`6^aiKp=hc-GT%hiq-mPON%{3xOj*lADhBLC~j<<9cnT<4XgA#F0GmL8I& zogP>SC~e|h5`D1?GI+wuEUg3;5TAn5-I@WxD$4^o=hndcx)o{;BEPkv3meKgROO$OWwl7j`~wpdI=q_jTq#nKh@{K@UIHw(rtx>ySy9Q0zYX+8}`<)+7D@y z#<64L5u09U4PYFySPYKYSEC%MxnlBjy1KxWTMzztR17`@j&C{)W;MF#&7OK+5Jj!K zs}+1UV=Srh6!ED=Fq-E-Tb7q=$HKLB+AM!7jjE)ib}E^Em3sBTP=ZLAT!vl!6K|sh z@;=WD;GY&Sy2{AYlwQARuMqnTyX6;b$G}hKm=3qOB&0%wY%2UT5q#tRuTx}RI4Jsx zS;=?z5iK8@g=nml_RTSwXTu?cG997i#+1>Rpt4YGDtPkHugbN*Ot$pLEBEL4#9-QX zEwAY~XwZvO*Wfmem|68h{Vo}=Ih%rq3czT0;<A2II2JffogJ`wi?h z`D!?}nb^xFc2t=MA-=kcpH6CDgoPkNp{b{TlJ=uxBrjBId(6377T4y5&sLU3-IuIQ z6c!4O5a@PE-@wpA3f{YtZ<I`MUo$%NcNxN>4LxnQT-$2 z!_=Ijd^)6xkZtNhyV6Kg@S6#2g2c9EIaEgI?(h*Fp^zke*t3IPK&RWPKRwU z7#F@w_V^(64;wBs5?nT&HL7C@^H$hht^2%%!i)R^Fh8{lu;kDIMRG*zYD2=34 z$00zBbkAecd5wG&wULcJdBnTaqbtjK^rN#KkCN8#KJ3v9|Co+Sl=P6&E$w+@o&Ty=XbC;h zo==KrSr0gFaWo)qOoEo|?aoI__Grzv%QAro(Q!x2rvFDa-#|kIbk)5On83 zz|;db-n)0SYHeW`ZuQaPZ=D{ch1CaZ6>P*PxGguze<6;RSmWSE&HCtVFxSYw{**Mm1DhBj{#*2x#54G+2`ry17o1Fp-4id~YW6U5s-*>(7h z;1!eaqmPYNG)C_&6Nld*?&w3Rjp@7^FEmy1bsfOX@jaRPouA8gz z6uQH;{y6mAK%)<~%><3;Zxa@bvVa}z2^*vSvPbSUcl`1m^udZ#bBNZe>xJ4^6Q2>GzA^(+DBZWjKby(L8oZi7C)wdQD^&=)LfA0DEBs+I%PKloT7>_^?AnSL zNYG+1!lGlm{tuVETmXCN3D~eu1w{s@t$*UTvyJ>am6ec!Q+dPM+uO7J6(FGh&`wk_ zJZ>S*Nd}bQfJd!Nf7eLIOnw^R15Mt#?%hvH&-`#?Ew z|L9iAt9w*pRT)jzej?PA2QR{?EFyjQZNz9nC(NV5l$Rbkb zosB7mmE5&ZxHVIck}c5e_TeNF%qgyicd1UqX6pIvmL83V4z{#*>&VHOkOFZlW388x za_o4Q)W1;=*4n)K*AR1?CElHA|AG~;N}sE{@2kwXX-9FDG=QSzkh!zGfo3A@nJa}g zKNZ2uVa6+2-=iW-lw)?lX>?(!4MG>|yHmG1uqYXkapD5$fnOolMYGhsOIWc{<*UBX zpqVW195IQ#kTt8;E46+XHdonmcp#FPU@D3b^{SOS_e_hr9QGu9d{%yta=g@p^jS`G z5e&!o1I{fN*+^oX0kFBxl(H(=I1U7)XX|nr4AxU(`orFZj#aKF6T1x!y~~c8dn!K$ zkzrbUeQ6RhCnKUI@~{etvso64hPBkVoN**9K1zOr#)lcGu5`%*BL!V-sE}26hoEeW zcJt&%5vWMco)2crBzx76YG_aaRFs8JJOze-d>Rlons=!c`!^%cz{Y=G)<({33*VW_ zoV2~zRi!>MLxIECn(EC`TO`wK(KkU#S6&zoaK#wnR$?iT9Byp+q9!yXl7Rsb73EKnnt znE~|Ds67;dp!h4cG!Q|UPR&+EK-Kwv6>jd@padX14Yo=rIsGcu9QS?p(CQ08pWTQv zlRmLt_Q>*zAbS*o0PDhuf@GH(Jz_WTzg@`ro@&OMbVVvVnaQhzvRalGinqmAzXb$k ze%%vsXi9zzy9FqVqtu=A76F=6XD z2apZ33rz89OeJUfHjs8z>rAA!)$=g?t(b~2PbzG5IkE`MO1inRR?Hy7C~3dbLy_&o zFnEVUJ`^E!$HRhYKiC7e(f-PD6$B3R4Mt$4*`=Z;#~FJUgPEUV1%>`__p62U2pI#?~X)L@64#tHMShsbu0gs%BnddoIqX^ZyIY;f1fksOm9@WUElG`Vf(9 z)ueeLsqZQfpbz*$3H}0Rdp7-tJh`de&bh&fm6ZTt)%6csgvfr;AxzXL@qgszR!qfF z>ZZBap}q+fJ_E6UmX=jbSIC!zTo>zkLcvsG>SJ(*ukj5`0RPqxtpTBMgY0(QU~OPd zS!pK!g>Vy8VXWOMYEO(Fg%DmaFdl;&TgMop^e|P@c^_-7+6Hyt{K!8?VTLZ_$8~DP z8AQL(SJJ>MikgALr6CC$@OTyRKv@&IDH9z?mq_Gpxv8hl87?;;Ga71v>O2?xKsB;_ z2*-37NK%5mI?H(`tzgU)eI}C_b^o&rHs{!=L?XR({eS%+i9K-hG}i#A<6sJ|G>e_t zj#3P2&#A?A0(ee1YhHyCNAUeZ%U!^m z-jmXjs<#X#R^3 z#`~_+7)WM2i2NtB0=_jZy}JqY4X%ZD`p<;ejzOb9N-en_e(MnP^dW?r_&?)TLt@?o zS2xE2z-g5Z7fKXd(F`WLKANK(-^rdQ38x>u;D89gE62f>(B;Ei1o#aCD6Ax^-=;Ig z*|xjAXS(v<2{<6aOu3*U4deduyI$20 zJ|~|YTMyS**QQXse+^#(;}ADHCu~^l!RLIbaA{q(u?_9;2?$vtJ`T8*h^NG?&3jNL z9M-G|s@}mcM0M%GcBAuI6$SDuI%6MByH`#qvaM-)totGanz{Wr(8JD#J$cjmkF1gB z>Kb+6r?`rN>Z)m$;k)|I=@IW2VDA|&G)^|DZgQp-oWWZd%2cl&1vp-NcuwFck|diw z_eM(Vd+64Pv?J01=46<)A9EO;8E*tP_F+9bwf$aZTJR<_=nKRW3@F6`Qau$=cp6ss znO3Iv#!)}BzXg$OO}2{ahPIu}4obcyiI__pV9B?2DF~skrNUK|2`i@jolCc>MP0aL zB_tr?LAL!j0O||X@n__0U9*c~y9NfrD{n-(XoEt9>g~|I*cL zE*657)a)F3MdMmM)Ur+6H3bSheY@C@AHvp_oh?9OTmRxmjE-`4j9vZ~fXC-ZAseKF zN)(`Res!-I(M7(RRQ#TA6Y!gcm9I`WssRmVrz>V2-^79X#=Ek7SvC^U6Ox*1!Cf%2 zmp`gy2K#k}KyNcB(8#zAyS}RX`l8leojyOF`TJGN`X{wWP4iXV{6u@K6ov|5*bnBT z7PQ!dTEXJXu7Mic@P*?DEi{eO-57eR*X$%x2ZVp>T!)Nk)O)Quu~at?dUVA#Yeml0 zu<>aAcyM%H^3g$^)#9>b0t;e_F%*o=dQRvi6V$WLC$61+gGT*Xo^#GIHN;NvZCN&V zY!scY5z8*Pt}v7PxSrlE`8N&p%7hO}#b~vxobgUES1x5XbGtfxMP@av%bQ&8s@BNa z1$|l^hsCg_GeSe`n5NqBL6FbtsY&rZU>c!bx-Lk+0_Y%^fQ+a)e;XIuuc7(6Uxk$W zRC_-(n3peB1TtB(-DjD9ki57=QV;*0Eds`>8B*g_fZE3(h|``VDdir(R)2uLvNy#0 zZ#0-m)=)i|NKVjlAAWV>;}!_4db&9b*-~z&AK*kUbc@`bre@(f2RN!e$p^VPFXvn4Q zSus{Y*@$Gw295q7#Wy$pB4Y>@m{a576W`N|@Z;j_Ak7L@F#g}?UA3x(;AV)W)wvVB zfN7fq$NwZUHn9AwL1_H%2+`gkiJPRTjI_G0Q2%em4FAN}N0-?8ch0>^D}Rd9!Lmlb z@R0gLR(C9%6WmFDhlAA}NUcX7!n_E@H(#$bdRb3AE5+c=d*ROP$1bULoCDu5gvpSxdC1tPC_l}g>UM=i@9HO7u{Y8}~(>PsARipgV2sXYHIlQZcZbAvtQ z)E|hGHH#act|9<_cD4f}KMQo1oh-bXHzE6x%oiuxGurA448o`ii~PuZtANH*nRoQ; zFw@9$Rm6cTWc*3;HNV*d7?rE;IFTyVvj-Z}Q?J@?U?l)knTvBy-ku-P`SNE1j3M*u z3j9(+=di?p=rr93g)B+r*d6rOqyz~@a#+D`hI-~sr}RBxJhU!F!PuJ#19Ha9uEyA> zr_NX zAfzdnvbq@s2nEctI9}MTie-koO{qPa%LBdy7a;dGSfX4U2Bzqb*@Zm-jpn zXp2lCfvXOhFeY4Gv{)j325CCi&f!4k1hc(UpfQ^W&uVQXcVCd8BWLs&yJJRncpAbI!v`!6o4;E77C8cNbP)GlYQGy{F^^tj6E85vDR>)rGMU{vg8}~ zKshnjuOg<3LSH3mz-0l>vUCl&w7ydbfcOK7|I@;(fs`=HCprA-WBT9nAAYOcht8BT z|0NN`S-|=E_+N)?%VT`oT`guhJ2#%s)x<|aTAR~8VTWlo0nJgJi}W*>h0pwZMN0*k z7;h_3V#QIl@T|1*6D&%izGChI)Aay9K)}B)2#=r5Uk4B(c?wem67;s2!i9}w%+;q9 zI7YziXE1@uz*&^@75Qk4SFM1|ns(q{(1bqUK9jGg48s># zT(1x3T;`0pj}v(l47+F8GN8$|n}26f~ORDkJ~__i0}8*TV=wVOLSiTScgl z=L8J34%UejiNjnL>@=V959JUR-Xb>y!uFs9RIjGlL(eTq>&ZXq^(~KO`^0*UyfEMF zT&5@@B`g^bcJ+}_5Mw<{4$eo>_^_2FR&FRZmDynAlJcuxE-^&*~c_!~fOt^R6 zs-gq>lRDk@efxaxyg<`=6t+O@5=({jf3=TlC)!Zzxdb8R%%?{+{q^qP-3aC|0+Skq zYqRCD3h%qv;y+J=nLCm~Z0OGq$g07uo)px6tOq@ox(%69#vQ10)(0|Q4UQCYssy!5 zy>xpRSN901mli`iW>5t)FpRZ57YI~P3Etj426bO&WZT3q{j4{T-U7%>>lUtc)m+M~ zH6*?Top5D%NY7)iR{`!u>oFs;E3fE~lHjltYcDNVgb0f`O`Wa`-17$w-o2tFqVbLlhf0J$qFqaouxp z1@N=x=$K7V!XXh9nCjd%F>*_j$%X<8H0a^`=0MfQPJB_X`Ci7i9EkKgCX7&Aa!dO7 z4AhsW-sQj8dmgcPbcA=3+zB&l&tU9u&IetO5jtR>`uR!&N1t#}?FM7rfS2lE0YL__ zdcfnp-jrWGpkLxuB@SH*_CCUhGcxkH)t{e3##9T=Av}EYt5NY30^GHb^KOF#WD zgw*3}P?X38Zk&lJ%?#*M&V7Ope-^opzfS3LKI-Clui&XIn=Y?tfZ#)2eQ6$2jrALs zrM8+KMUgCP*?yxPA3MYok%PJM65U*J(Vo`V%<3S@8pauNN&uZQsxyznX$r@LZKt#M zCH*0V2JyfRdJ&WVs?&Z!6tg)QH`P{-tiaIC!Vwe@;xWz**vG;2H)uXqK7l#`A=@O` zBQn3qe65FMR37uXH+7cj`~aIc19|0g5yvnJeJ2Y-36)7o7I>7J7zbMNVKYA8v})9m zs8p3osO3<3Yk}RB+TGwOQob8r1^;_wMKSqQ`E3S6(=5jx>BzKONsP+~X6Ny>x#TA6 zYE&4N<(&%&R6|%%PpL~5`5uYiu1gbt0G>TQxn)OFcRZHdRP!N_goHO@f~Dm7lt?ta z&?{}f))?05%AA-A?XoAzrAo+COPyAIp*{}9s!=2uEg&J6tXAECF2D^sX@}_G@pkUq z31~8M?m`)1lne?)?dB#v^>N#`9Jr1{-`CTY5#E1CQMKFjs{4}EhMYoyXn>u7B*v0n zs&bTpVvWauk-KF&q+%|!$GoP_acO65l5)!{4kC7(X`t8WSOvSE3+GT1Q;RbN%XTF2 zp)_iBMr{oEa}+H=n@Nd{p!X*lUIRyAHjR6>>@(qp!3P~Vb@ZVtbhH=CHiT?V1ta1F zjw8cTT#cX+A4%T&xeGw);ouu#!y!FLSEL9p5rBLZFT0pW1`kDmDmhE3mCll_Vz6d_ zzJ<`!+n6OuIYZJy9hC`W4c=g~V#%RlMMF@_BCcZAoYUdXs9*~x2;aOqUzxvW>{t%0fKU@&tMqs0-)Apq3$oQM5KGmD zBQQP=1ohrqRFhb~m!zs`SGW69t&r{+>OBI#3i5O5sFJP-c|4{cdLlxF9wSUvq~2(F ztz^>T3Gko%F|H$!;u5rN8JC#&JwFJ(11cydy+or(0s`_Avn@^ha37o8a1#jP<*FP> z;45{2caUH!&J8at`jK#&ew_muKwC6RRxSN^+JfTr*CBf~vwrpOy67ZjZ>RJoB>S&& z{eT3L!NCv0H-_ZZhmwyj=(qi+8gHM_dfd@0zQ~)OS#p~!$X($Z^Y7i4`3MT6!Bc2z z1s+7bJIDL<qzOM zlr8^Y?}{)BpB$)@TGuX%a>%e*?_K(`bHC{i)U0*Y2eF5{kAOkSbW414(j+|9t$Z2& z7$jcLSxc>n4^W$6Iq9^aK3&sme6^Zu161D>SwzV`|dpPB(RP&3X@ zz7c<{;(i3y74*~WGt)~D3Y}krDj!){t}`N6qxhA>4#mfz?`+{W3XwK2b1 zi|Q}^VQHX)C$x-$oqsk90bypl&rZH_To2xr zJmuz0nd(?=3X(w6o`PsNl&Mc^p$`^6=>`noa%h+7HYt=Lo;sI;K64#E5nl8k=e)^8h%PqX&-9r`ZiArs8tqwp|}@5 ztx{d0&HMgxa!w~f5vysZA>A#kg}P&=XkYrEvC}Fo!u=+J{pyE(!pK;@l&|5A(Ir*zuxniZ|c7)^z+oxm=T zQJ)ER*Pet*OCB1%)LF3SkPqQUrPLY()>qU_jp0)X5jY)+y`pyX1#$jP7{XK;a zr0C5$l)Eqbny;|O{k9_3Yj?chC*+5NOGsf=PS&`{g6Ul(JvdVo(2Wf#e;V9niQ%t( z5n81)NIja#FmI6bBa8eMQ1H$<*P8sYo7xPI;5a(Z!SntP&Psb!{ zEGz#sIHuYfoTvS8g2F}}QgkNwuhLqo$Eh~ykx({*PFHVL1gq-CF+r0&coCT$Q@$Rx z3EWJDGkOH=;%>m0agVF&#G1605d5w}O)0>8Ls~^RQ73kY);9sz@7-GfRlV4J>O<+G zBIB+)0ooL^NwuxnuHJ}+TLwmVasgsFt6$}{%Hbil5iXv7r4sGfIlg{PYyzVWgTzwB znM>;&AKA&xsgM%$i$ej>5ucoZypbxfNchQ{`zdHvTosYnP9EXnl@?g7a=D#>A+_DC zR!iOH4pr|a2@*pU`FBQwu6hyg<`gANS|J#vqLI+zA&v?rH55T#!0&)fn%bg2l&?$S zmtIp;Ao40duYCks9=d4)P@Bdt&x|-D+rNhRt(lLdT|1rp&RdpO{5KGUmj-{L`EJ9W zA`jAjbac?9!oh7{ZJy72c^K7gU$Z%O=jjGIVYXFm|DSK-c;9W!CIH4a2M&zS3D|hH zu881^k*#Cj4!e2c|u1T19ZkRrA#DwVm;*@`<(z>S{ZZ2WF5fTFdE*<_E`h zyEDib&yUtoX;SlORi19Vh-ya`m?`~n#V-3Hidp59i2TX82J*es1Qx-Z#EV$p)V6PF zZ7jw_-XSjouxcl_h?k4KuCgMdo<<*xq4J#WaJoB_Y-`2L=AacokLvn$*J2zXrV% zZLjI;P2&w@CN2x?mGia?{UO;J04nKCzYE=9Ya2a(<|*60>#rka;@&z10nc}XpAdPe zNo&bZtjlZaa8N)(%nkV_HGrl4GUFQ%nQVGO+oTTVp_!Jg+YdIo+pv!7>+9b?_$voj zPhD?(%SU*^1o{2xfuXR)Udc;)Q@0+5(Ew##*lup{@dGT>e0Qn2!?tA2stf(It-o)G z%8LrtKiaLW2RdSco{(xoJ}9fCvJWAF)K z>);hy@lQe<+bC8+In(~=3bhcDVs-v2tR{Ss3O5!~-0*V~{Y-bj5T{HUz)b8rc+RcH z67rPAM9@U309P|YKToMUEaRTdqBzQdSoxd8z9AjP(H}Jx`wrMSasmeaUP9RKANE~E zyr{MNaVlCUhe&z={CTXu(B|!w@fDDU@19%a`L!q>-q9FemwakJylIUD zwr8GKf2uo!&53*YrYLv`_rPr1#A8&zY{$T9XL3(cVBR~0F-Ou`Sx{VIYP^R(KEy&l zWp0AfH$&_AD|I^E<78H<ch62xF5FNqbusLdE3vdFhfCyLAX=8PgO&(5(O*HONcwR~&)M{7+l{HqC$w z!&dx>cQ<#M$KYZypNKnWC?}*x86OKS_)=}MxBulz3ONL)DEYVKFuU>E!u`Rc*(@`p zY1>f1Rc?$?kRWxkWD{1w_XT&(=OlI6S|p7a5_q_o+&ft6nFqBWhQ-Khp z#(t+t38vZek)<0(JDk`Rqit-1rMLqs2ojD_~ZLA ziE8mbYdu9nH?0XH%L~F&$4U0TNyNJ(>bRlQNGe+s>zpjP!zKO>9`J1Fz~XLoXhK!n zs&bdU$U>X4TCO>)|3{el>;Lr~^YscssAqUXXX#`OE9^t+)@C+nK%h~DSnOL}91o%$ z;P6aoYpmi+kxie0sE7^3lJ-x#AO)j5`eCb(Eed;d{Z8=g4GA{nn5q_yz421!if238 z{e!;p`nWQXc)Lp>D!wrlpFNqrZ|{txQu3zO$9C7~9Z0SMUaiA}&y5s)DFW(8n2?@R z%34#Z{^lSqkNXx6Mq#K?h9HXb-zk79g{}%w;&m-frGqLNR^(g5P=(YH zAK+m2>KL4cqni|ku^mxvcv|sH3gdLmOmD7&A%Q-=>$oerRFG@nFU}*!CN6eL?Xbf? zwXEnS8G@tr$)>wy=fmHAt-&`27^MekSai1f>TNv4pSnoNrUGGP8(%8`52Ye*9Qmo{ zeTNfLm8+iS7Plv6>aG%BWY5{vgCmO4YY!d5RR>w30ha=LY_V-6_$K3_0UM<{(Up1i z2wT(IMaHv4S7Ek~{bv2zNXHSa`bN(T`T-Nh6_8;&nPbA_nx0d?ux|&!iUAPw< zk^u=%odbd^ANxbGGLhc%O|(7hF;Og7ShR(xz%5EA64mLWCoBrvOEbd?soUYIzs{&U zVujD2+OQxeVjDk=9I+fS&nm&qFAmFgK80dk$Uw2#Dc;sB%+GNp9At}QOICq;*+KGg z^&u`X-Vt{3k*|B8apx8O81eU}Sgpk@X*ni;sK)ZWnH(??!jRKVtL&zq^jgqzaO@d> zOIY&bl^{O;f!eP$J7Hu0cA4wu5IR7(P~dNEcjZ_0O4(#rOYnWG%29y9kpa&~T&Jxsfdg=;il>XbOTvYNN+`g4ui(?+jP&Uhv;0EjALFfp?GI8$>_ zdXEM>URH~f1bqps&Sj{UD!+ktP>ilQOSL0=0hY>#U{B%r9Fh<-r9u@6lLAyV!C%5$ zLqNstlw2SR%6(WMBw8$J@x2bQFw|p2JQ*Bj&9T)6kWl#5E+dz1_F$XmZ^}X7g-C&1 z5cqukf|Gy1fU&D|e6I`mY;lumspuvZ$d=$8L1Ri;j{&n9;GoH2X$(kjHs-qrNAyC8xmCu}@b0t!=hLBwgh){J zV0wGtErhLcO6^#AHyjBTm-~S?l|376gf}NRw5#04(Y7faAkL zkm7gx@~j9B<4hsN&cEsu&F}vVCfx{eHL5k=N2;t*LA~g} z;c_^z!#f*Ft$f1uIsvrftW9((JR`y-NgbLny<@O^QqUl2eJ+0;ywkPyiixcbIe}RG zHariMhIp<;2B2kuA~~P8YaSqWg0~UwUK4Fn7t<|BBD+8Gn0g_wn8<1pQh(6-v1#tj zD=>vvap^WHJqrxiPgmA-7l()(=>$6cfEmBt?-~0-a$^5DfqQW<>bECtcyp@FrCay( zSTt{pA3|AT<5k_uGLF1jkXa^mWiM*|s~`eW6Z-ukP_ZS-PdO#xjJ%yp--+Zt;)^=} z>-3DAhl?({`U8;6Bjsotfax2VV!Xka1tFjD`4_UF*#jDocc!P1L1I|wicm3&0TT=m z@TpfBq(|85)yp$-Rh7YDj!iyqHk+M2`^^1TW(uX;qgNbqXL|uL`F7Os??B4-TC3Nl z=63eofR9+m%cB=P?n7VCC-aI5baQWi$UK%sv-608r$~QQ-ISUqTcE-U=Gt~$)Te7G z2Z`hru^bPxD3d$Ly?3esq7|>6E9avr%jsmJi&6}{H*bTyqQWSC5T(r3q1T_zxZPlP z?!M*=6Mst_W-33kJ=bPCU`<_JvD8y)e}zs#lA$_Z%xsvK_{dO_r?$2U#N6x>BKleZ z9$w3Za}Tb3lcdRs`&7LG#z}kAMtfeyh^e17d@qG7O=D#`wg`7<~U(^|qW@-us&BDO&4qEZWGhi6u#dQIAU{vvtg z6XL0^^$}{5K}NWQnQQX2yE#$+Ar4z$cds!9SOGh6&9Dy*Vlte%?b&v9SI26eTph}F zWS45bYsDPz!jxA8@(l%r%i2Cv+LfJ-XGXpWMvv{l0x7Re%>~4h(b2CdA}k!3gS~9X zi6Y=Rbo|#{?dIQ{NOL-*0YD#sgnLSmAByHfx>lZ?!2fK%0i~By^I_K5X9qOkUBuy) z(rzfMpluD-LmoMGyqwdPX@`4MUPn)Tr&afKw3X*wRMXYW75{{sk<7aKJDEvt8ZWT~ zA$9azD%JPwlA`Ae0g4XVn=l?voqvxun&83P79%) z)xVzmh=`ZnPplAaSv)7SstFu4Bv0HEfv35BV1jVjQ zEu%nhn4_t7Til!t_adqOnG1k#X~r`?K1$ShSvr+m;%VOgp|>P-N^&i~JhHHH>y~(BnaZ=vQAhD$?dCa4MOU6WN z*DU<~AOq(_M>Q}Yk#{U}H8>lc$~(xZyE4K2V!W^t)G{=>&Oircc6cDS;mA@=0E(HB zBw_nJ;oxD~;)B@};@jwF1OiGTxW0vHf=v(LK9DLjp;E|ak5Qj(2~GqU5Qp|%hJw3j z7^E;MLM;t|ov`JU{eL^4<%Forc3F(+))uxyLhil7@((2N;5iS{#iCQDM2FJ}JvIpN z%;GWec|w-3RTb@S76_U9Q>q?Ul$!OVl}Yw^yZF@72#1(cl0sw<2WMBIwJ#({#$g#` z$q$fJrYkZ>0A95-~U;4w0Exwiczy3;` zL}4Y(X@Dj(uPM^eA8o@F0K@Df>W;U)M=R41(6>iBvV+Ho2zyef)2dYV^O|mOk(b{3 zp&u4o?;U8xZV0tSs!ZviQ-GzLSNp1(kH5w6K=C}w^F5{01C^94MFY~eSZ2s$$Zqmh ziSGDuP5L_X1p|bXs90mq2TH-3lhB1Ph3`V;{mxO@Wj7V=*nfzMJI4dhpA2QQ_G{U) zlm?ls8x^Kv_y_d&YIsrwSyi7^n@T%|496T~^nQzvdcuT8Xd{4T9w_|3f8dOTu}s3E zGO5H`*ocf;d;|Cz1>f17?lM%*q=;NvB~)9Uw>rVznM6Zq>#@)ofx_S{J0KxZWiAjW z&njA`YZoDaFSmZL)HrMV5>_2ltkc7JGoh@n$8=p@e+nj;6m}uJDvrRXD0|XkWd09+ zy1#)xMHV$ge9c1I0JWLb)!vZSb(qx{0wPJBxuYjUb~0KyzqkN#I@eGM{VT7mp0HyO ztwsx>ux%dbH{7c~m9F7uI~fN*YH_40`Wgq`k5zl3x@E;75|jE##4e7n%q2buO<`Vjn>(fC?RN-+ zq{Q&C7)8;=eZ4w}WeEowWm;O#$811Y`OB2nw^|{#?r2C*&^L8X7kNq1F4$|4nng@z zmH-~20`i%u^bfa;N3dBz7kwF80iAY`9=emCnN$hwQjc|oFg4YfXO^3p@5v`_j$bKG6{QWhA-88wM44W6CzRo86_~`Sy7?XKr+F`5{|jC*APtf23}g zV?9%05H6lOl{Zjmf%VS)C1{s;1lHT6T$xDk>EayhFSqvlAG=-G#V}ItErL_z=Z=`< zBCC$3XdvUrQ>vJ_Ew;=)kS9?Xry?`GkR#h&P~7R6Q7t@DdJY~tr!T;J=?Q3NfVCZm ze_%z-C%ZIzIM@&^wNZPz@Buc7KmU}m-AuV?jPNPwq}ITSRxT{S!4?gj}DWl&PSgE4PDfg~EV%WWPcs4aI=$rN?EriOD`l zn-^um0>IOa?;*_IZ3oR&7dGq(~9i*u_pO!!D(Ks+DgVt+%p9lmNS10=rG z2VDT@`h0i8QTSCp&|0=@>(LlR)8mOKsX6y5_Q%a?0dE4O_2@);;`E{sH*G)ahAr`9 z7*(Ewh_O{t@TN(*-s21};gF|5JOFxp;j}vElQfCcl=HPkq+P6v!v-!H)UWG05>&N? z>8Rm0rhzmiE#Q|(ro!AUL~2Zlw^m@l{q#1B7=@zXyY zkUJ~xG9})W_+^*#*7QCPe23)=;&c#br05(8|5)ND@=`gJD5k4473A+NH&ASpDJ@tl z*)jj*f;qFNtVDdfE_aKoc{%I%9zy3igQ)r+_k}HONhsFkO=dg%nZ$XC>usLY&Y<5S z;#?5dKX!l%X_TzaamOPAeo`hBmmw9Ni0k+JQ3%2u8=Co+#&<&G5cT|tf7X$QT69{M zaK@=NO%yby0$GaUv1C!f68d3r+k9Io1an%B2diu^nGv$InQd17IFUgO01=aAUl0-h za1U}a`=Gtp{VJ4*u$IJKvFw6B>b!8is`9P00hPx`8EXvjVLjC%(9hu^d#-37R1ftA zeds^V@L+*MoU2Oo;4Gi#3_L}74ugpJbtKQs1_HCpZR|;!Qew^Tl7C|xu*2dn)f&NmD=FlPZHXWua=388w}fzMwz=vD=f^}_Us6CF9N+1~*i0pt^pL-Mo#Z_QphhrNScpzDf%g8yCEi;b!qB^uojh3YRtf@xryDjZN-YDX zx(Bl~{?s6*{qqG$5r#Wuky@=*{5SR4x+&G*o$jrcF8dP)K*3D3AL;!No&b7yN5B4yHj;HVl zl2_@#`?zF&^s^Gp8yi1?+E--rB%@n@nbDl#G843*2b~|oYUENcmV?%SmDV}SgBR_GCy9X}0G0JmF9TL&kGEpT zCQpfPYgO6_q*Ttl6G&2mWJISNwrI7~r*3N9l_cvxP2fZFL0MRX>g_QXD?CvU3(YS& z1}i5PgFg{ucNuI8QPm7z?>RHB`0b)a9qA&1EStbISz56jX%KRYdoezHE+CB4YSClV z4c|$vw>I<#-+(QzA8XlHSs|1_Rg>O7ZIQv<0AJ4_7!&w^#8CKJ+{2_R)WqVDBaN;y z>qqKwPuT!8CE+ATX4ieriSLPyJm|C_dS;@$1HjjRCTD2r`LdTt6SJ${?DZ3sG565D zJHiu|x~SY{C;NJh0fE~z=(X6;x0?@_$r3kFAK&>wZT#Ip5Xk?-vCIW5xKu@LJJ^Tx zrdVZ3HEDd+Q*BSP5kxr74HF8*q%tiR?~9U}uJq+u`t3r#QrRI;hZboM*k^DISqmYb z1|j)x)F*dkSP2=wf+fE9clGKF+k4#z8*Q#7m;Bh5y7?Y;rCNLx2 zh18}}% z-{uu4qb!@5;5&!#jU~YUEFD=O2GCgYK#un#;WDK34fN$C6H*vh z9fN|qn0@xMp^Ot=PU>NI_}nKZ*~8uG`0C_){d8T$p|6BAQf~(IOG>qb{4$H4DYga- zU-fxay+=iBmVrS1&vDN^5KPo(7OS6Sj$fS&U8I86+`ouP+fF1)qT&V19KF^TG{*O9k=_a~UVDC`Razj+88kssz) z%E1uW#u$`2aag=3l(*Gj{x1YVmXfpE^2XVTnhT=x_^W7d4`S zRZ}5LG$1nGViXt$*oIj?t8gYIDQe7ovys%WDu`=1{U|8sWR24G7F!e_&>l7n@OlUm zP2Pa-%SkTNo^qP_aFs}thFn17ajXY|F53RqpJ(5>c6^HRUM*dO`Q@hDm?(bSh^umN zT8~IF>w23rv#9iZy1NR0zj8GHRRW3@-%dw-g6D!>%XTLF2=`Pj_{fxs{{9>(sKpcm zBdx&-@@5jj=i!afnmth1VeaxTn|CX$*2Wm3wUaI#^1-T|)Q)|GW66{Q>{VFygx@>C z%hG$v-qO-WY6h9MbZR$2w4br8)YeU#v>|3ckm!%{?U;UD&cYo<9t4gyJz_jW$4!TJ z8@6*G1G~_goH|DdP%{i!Tir#!hxm)qX+(>0?d{aB6vHt%C)vP)vKr;s5;Xlw3}tzh zv?=I{c7|;3sJnYM)V)QP5`MqbH4&kWJJcJDm|-d$aQ6S^=XYr9e{l!&=2O;_1JZ>d#-B`_g zxOuY#P5f0LG0y@h7O@h}J(g3#`goUQovhkO1z@ouD|~(a${oZDBkz$dpc#COJ8rw< z(V&I26B`4bX4W>C1oUrJF|K!i&Dcs(YjwuAnD^B(#W{yY2TJw7liad&JP|<2-HswtRbJzS&@Hjf(gA%5!@j z_GGpBu%Hefp&_RIl8mql2(oQ$+u;e?gTsT@p=_)WH+R)rB3RC=;Vxb+rl2Ki=N({q z1FBP?F(DRUfophiCIvisuLBGCE6K!xc)xkf9;Q48BqR<4AO1#Mbhj)%fyQ0b` zmGElL5W;J+-c@4aa@>v_)Q@z2j$H9b0z{(ltQQ(tT(G#quZkPL#uIBR5UT;sH6;wy zDzEjTr>Ab<9oaCmsW&h@Dl)RNFg8Lda{vxIM<=T&@>Z`Mz4Aekf7%E5#z5eTjLxY_9B9rr950&peGB@t zpIL}Y`1Ag4E#P04O5u44KgRqP;AT576@i?5ohNAXOs%H|zOT#O9a0UGhtUVx!q!g; zE#6jXW*V&B-{7lmTSFnqO)}`Tz!pylOeY{)eaoEa+-FD+e+ZO(Obk52zQO}TROvi4 zrv^lxLin8z>0Gr!d1bj0d;Cnh4;;0XX$}|!3?&Oc3LJ_HcgsafZ7t58fLld6(B4c{ zv2rwq%a})5;#$>&nCFJb1O<#>9*>7hK{G#|e=>fO`e{89pH7{KjG z)`xXavS@<8zvUs(zt!-$2(uCq;`iP~^Otkzi($KL_~SKt6F za0r8(s#VhrC9Je)Q60cYJ?(lc=I}?!&~w`>NF7mb1IG?YAKT!PX!C?VjCDkSMS-JI zR>i@H=5DB8TBg)#*RdJ_dGs>}nO6ZaY{A)0a8Yx$+8fX=n-BnBYp^Oy! zrw67qm+Jy|k@#cl-I>{&qjJ(*4UTLu7ui-{DR4J~UNvLf#8f1Ax5JC!L@9lDcQ{9> z(J0(KOZnvw;s(m@NuFx^M$L?M}&(5T|^HAH!^m|*OHkxsq%7fhgZ56uX9m(Xt znl&q{VhWZ52=x}x6MRD>c{P9%H6s7RFX{f?$6(jedtn*IuZ@V`enzSv zA2H=b?0+k(VxID(jqKB#@vd1sULsh!)cCSQn{uq~pyB&)T~Ec|mK7|tV=3y~*E(D7 zLnvMaXTMUW{rPp()EF#%(zq_G=bcZ_CMTL(0HNBSDfK)9P1A>!1)9JH8(j~sN%)_} z%N+5dd!mg0szzTE!mM?D#~y5|*Ig{Y>dZ`qG6yPCzbK^j)hV_kzo9cLNe$Yq1kodb~3?KRVi!DtzMiDuyXC<4hgo2pl zVFyL*VE0wvk!$8((q$%&cB7vBXem>U62$Yg0`LMZbSnw$81MQuE5f8IK>N~Ep34q{ z3fDb@eqIBTu7)E_h5HdwmS!);rPA8y{HO#~#axk`Wm`FD3}8ixSU6T)&on?-9%g%n zK?UieM90YxZhCPCT3P#%9|}HI;~UrRYPcnL>v~G1lb?B_vmWEeg2b1q?_BTzS7)Tc zCBDi3yC|m}4`tX4RVfL6DuxM8W&JDHL+fUlQtt?4*arvMjkz(JKzdUq-bix-u`iJ) z0+D5T>y`aeI}&QdnFG*BjzQ{{poudutaS*Yip26laIaZJ#Vg;d59zJjWR0rsF{}#~ zPb;11&NDhpNP?pn;;H&My|AM3g~tZe;K_0aC^&$RxHb`4YAXqj6ECyIuw=(WeZ$5| zMX@$AJYRz%JYUd*&z3bEDcbC?bEtbUuVLM?jM3$UQB=tfLGK?VH1I?=f=`nkER(Cw z5P13gmbbSm-B?|Pb$^~8EMQ+|GSfvy=@pGNvmW5?Do@q7_h%7&br>swmrV7mpgb>B z@IoJBfI#|Qx1UT=BC(peC>1(a<3oSXYP5rM3GKgPnH|~;T~1&`a6H{P+7dK&~|FC(a^x0RsJ;1H+NkCabCPq3xfS)dG@|79#K4)zc z+rJNVKg6F(Y?rav0_V3B}9M(7y7C3WHmF`8`RP+WjYWLDX4991GJu!CiNMy z6Ts#`u3Fs~DC|5`QM3vtK-x6XMc_oedr;ehn?#m$pJQS@a~Lms8(M&WHeX9%X14Z(inxQ#kWu43!U`O?;wz@y|l= z>dyN$`z-OOD)QzV7AHiCMmo2_WJ*rVuQau_Bzb{{IBWb|lJ7`t>$Ex-(Vv!u);yeA zYc2Mf_@&u>fP&vwrpo1za5%5PY#1UbVOHrNc<}9r(>3g{2dWsi zQyGB!VKC!9JKEf~E7d|gv5oP~%1>7`v!^(*vh3fj?|LvdOwcNHGlDHNtv)z$sK!RO zZtW;qr*CVJDCNF2X&hRubR`@N7xKk**OdvFPszk1}brExgzYtH_4!SL_)&8S7?|6{Ztm5uXO%91MrRr0i(?-d^ zJU93+8gX~=3Kn5K@EgV(chfrkLpWdm!e$N`h;u=E*(Ndb~DV38Egc~YT*CxsL^w7k5u(J!Uys%kZatx8D69xT}!Fr;@ zpo?xZ{)y1FhAIV(Q4yJ}g$OA!nCFj>9B_ zxv;UNBI0+4Nmz`NGwiClVe>Q_7|&}Ogdjj^ZO?VGn5x~Etpl$y@nw2)ks?e9*d?(xQ_C84%Mu!G>S&8J2bcY>+BZy* zNwbymsym8S#8*B}>z6pagiGI5xEm&{A+kp8HEFmQYz`45o$7G*KjSQ`W4Js8o=BWh zJ#54L?;hSyi)v?yCAa5pdx%;my(0+k3*$5r!id->H4a}0nSmX~FoN?3ehz^#%!8Jl zt}G5(prIFWA$>f^JvK*&nRo~0EQ5do!=KJMGA|b3dErn*yFFQ>g4_{kQn|g5afH^; z8=CL#Rc1oFeOvZe%g+HUmOcLCTq6}dJt8flw1v4az<*O(9TuB7J7-10!*fp9r7_NV z7ml{$<9C?JIgYp>_vnW@i9)Zb6BJd{UZZ8R&?hDcAs_Ja#f)yn07LUs!_>SJ80*wx zG^%kVaD%?Juhd z&%AD;3^l#$d|xa^2S^CNm(8_JMXY)HYCPG1%HZ1D0Is@|m`xU%>UV;OstdQBlhxwE7T z+k3(1lg(oorJS%Z#{i`>f8tD^dvO^Y<-wJP$5ij`0^N@|!2s4h$0g+BHBa!U%TA6Q z(9@wgMeRHRpeRW~ypwzzBKB_qO7_x}x8^sDMc{&BUx@MDA}e(r#qZse{l`NLfZ;^gh&Uezw?`z$g7( zfK96`v_DV*INebbTiUS7&547q00UEVof||hgA;s&=;$s~JduYErjfeDG#Gcw2RS5W zpwmQJCPg4@U5@BsMq8aI0^|q?sUvbKus&yrsaMI8z_D7a*=t5B7EIJ)c*dsA?mNsM z3S|uZC;Eu+Q;wla1a3B3cq|LC`S=xKg(|R&GHqJ2BzOv%S-1akV^w4Jm`V&aWuV~@ z(>Yi8p`cp2In55efHDUbRbfZzAhXuXc1ZeG$9^F^Q>cQS59dBhMfW0tH+l?UiKAlf zj~OdVKolknEc)KsB|~^z+}F8yOz=!WOoJhPe!j2Sf_J)fh+OpmxMmW_x~}BSD1q=k zyi*!lLFY3$!NiSWP3Y%!kO~Cdu|Gmp#VBiuaht^4RBpmHSSv>?CrG_4rST!5MR36; z=hP6U_)x<|fPMIPL*XYC*G4lX9dnRnHdPd)K&uLcjrBN*(wPp&BlFY^0KE+ldRJ_4 z{-5dqW?KRC!4Q;^55tXzq#PHHTuz|6X$Ko}nlwao{7zvFWIt7z;gJkWUPR#05wbcR zZGJ_mzOeOJ4*(UCqyn-WZgDFfJdXdMT2+f{IKb{ycm(iLnYp7VDV&}zxa_j)EZENC z*hlc)Cvp)JmGGiSmz=;dcVIHaU8d#`a+&TOEw({(KA#k-UzYoYPkL9#t%?-m1%C%@+WeGkB6uJ7lUS4k=wS`C z?Ne9snRb+4R`4F0g{alCw=S~os3|OxB^9rjcB}s$Ami#L1=LZ4mX4!dWK~QMu^5Al zywb;>cx+!0Sno-09PC)H0>(#Xb$=1#+Sdh3q$t)t79^Ba zz^VqyzJBH6ei|w;I2ARJL9LCWq#gtMt`9^*mOtJ|r*W?4+zoPk&epYFwp*sxDw)`p z*a^^klrb6KeSZJr)7&$W1X5VHwEv@xmVE>N9sWWXyL7!etX1uJ7-jm0H3HycAG}kG zkuHXbUdxG#e&VUv)Z-K(?mWaV5$Zj=jV$D7=0oZMt12p7!31OYj4s45Fogcl!ffX@ zTgHv#r$qd3iy2k2?O|pX3Ce6d+Jzq~sKspq?{idw1Xi}~Ng!ozqxNx1lM`6`bSMBl zflzww#>Llv<&2`O>Wwj~^16HcBm_i3s*y|9j&uEFqnxEZ`_rv~v}L3zoe&D~TY_;;jWR6QjSOkHvl&#%-P?ZIT=8)DslPmuhy& z_xHDZVua(bI5z9tNVU&bw0A=~ddnc}!z!T>VNalFVupfl_+z3|Wqkb%J&|%=nhi_7 zv?2?x2%p_ZjtD_PoV7%B+cT(gV#DlB8m@W9+eGhmh6ciFR{2|vn^mXQr0i&3+kB3i zp*JC}(o=?wTDTAke0{fCfwDHL9_DXbk)VLR8Dji&#AbW;K$I{N?>5r8635K6wjTi< zHtT+`1^E$KcFEv2h{~)l#%K%83}-7gvZ~P{s`(tg2qhW< zcLAN>D)576a0yOY|8jkM>V-%0^&>`%Nq^GR;QAzMY>xg= zPAecjc?xhZa>OW^W0xM8=BWBo)cbsoukz*xJFDNfkk=QU=Kt(-wGtgJ*RaPRqGu8k zBQq{g3?#IkmKG&4K`IhSgN{zq;N0^f*^EeoT}{{9i%;=TyG zvwCF4qII19A5v^Z+%Fh`C7JVxMw9pAvV-w=h?v=QyHpQuCu*AA(d{mj<$YkEi)&3vl|7inl5>#Hw%Cup5#OOxk^;dfYz% z*MOhXeuuBf2Sy?eCC3jL9zYEVDx1}`%cR6SVGoTUuLkvodjK${&7tPlW@+JekE9}P zgB1~w4#UF3tLoDu-iKZ#!DBy zCmOXXed$88FvA>sqg-a;4xa##bq(DN(OESOlK|>?q47Qm9xK?o!7YTT6Q7ft+nHWq z(Hbh~pWi}=Rp~>5wQ7&B$3lM4ip{v&}?C?Rs!csXA&e8AV1Y!X&(LQ{zJq7D#B?geg=-m%(`KwaRpGYu+b zP7Zk9((L>`(CFx==3UiszZ^Ch=x31p!~TYY7)OWlwpI*N zZI0$Ua_$nfO7v-0--u}iqrvvTX~I)n>8i1^=8U=oghy)AVfFuG^bJS3DjaXzI!tM2 zBe?opMmDThp`D^={xZ0II4Q9kJ$A5#FRc%0mnQm`NLUeup0a~H`3BY)j(0?rK0A%30u-34+ z_gGgSIw9XE>hmSmcsJO-ScCzbT$9gxN+XWzfJM*Y0I9z>4GJ96pj?Gpnr#A!Wymy5 zU0`mu1s;!M%XssP3TJJ%Ozr-XMZmoQ}ClMV)N7_~*enO1Clgg#nR21bo>I(drW9%GK|pWS+oEq7T0~ z9ek-}TM&qzWB=EPB%c~^OI84*_B6CjzV)&bjRFWzUzfnE;@eIDCQd(>A!oVbIDy;Q|o+ZGr3&Ny}}-Zn=K^m7b)Rsu4(o$y_rLc|j=2P+coL z@c-w}k_BEsuc;`#;8S}?+P7HGE=-7G=z!(pV3`(f3|M}d-Zt^YeY}DNryn%yKlaTP zfqOk|G~vsEhSWjGzH3}S)^(_bS3(!P0%FzX*Z6V=N1B!^kgRn@lqOg*fnmQ2pX3wU z9vWevW8eb_p{}NyIlO-Cazrd0B zT?7+E%hSg4FiDy=E(OJ*X(OX!af8;Y|ESv7PRSpANbPJ@Cjor^>x$|z(DoQmat88) z&uT`Gfi{gvm@DYk%_CNL4JX)l%@rw>-t7pz0)usUMeDs|LLf(Kfvmzf(1WIp%CAR7 zXLNko4GyTFQ~oE2glMs^0LFseo|gQ+FQr$W{UT*qk9wv!zq=A%f>kxsJg0xPF{@(j z54G5Pis$XE$N@Q1j(qR&a~URgvGcNyD~4(+5PHgIr5P zSGYuASGJ4@G||@2#axsA5ILn+2wiDg!KEXxniKuo2nvH?5Y|6I<&VpIH88JOb3n5y zkcZHSV%R87%%+jr;d55DgStAN+^CkjVg2{CN_s@^o0X*x%+yE}6y*lmVoZX+;u?=+ zpH;Cd*n?0Fbm*>^r#3+|?J9PnX@IfzEOC-s>zH{~18d{JQA#3q$t&1 z+TbhI#>VIE(7dMRKrhmZm<&Z@8i%|=;GkNwvl7U2CUc9H!aE+=iM{bmL&RxI7a;4t z7LH4*^U%?v?qGthk+VdTaqx?8zXWOC5oneW+fu$m7EsGs`>ovKz%h*8GAIGkx{Tgl z3_+RdVt`CsOrE$T#jm(v&guTEr|P^swui{R@Vsjg!F$XajloBe==NOCQm4{0?>`&i zV4l#b_cDcA(30Z%`?PcED{h<&HA&?ncW5i)dQ$cS)}{Xa-A7mEY=j%0b4;njA@amD z?m%sCCow}-&n&sMi7=60-WppY{uUmv#W+xg!+Xw6}08va~(s!$~uuyj3 zq8ezOYh2!(?RnyU8#H&Q%$1dNY$4hBchd8Rt{>|@z(=Vago;2lD*{#s) z`g^5_eWH4ihovXGIX;cr6fbTo3G@o!crgci7dZk3$Gnj1Uv>S6&Ukur~9dxGj_%&l!h|xts6)a416X;T5QMl z{{rtvgN3M-1f9hiN)EI8`4ay2R9#J0w1wwQkGH04yO2R(QUSRIIt$o}G0s<}v5o!z zA{mfe#^CX<(-q3r2*?lfI^I7dS%j?X`z93n8)HJhlC*U<{1vW)>k+UTalH z@}n%z+QrrWyrQ0L`AHv6wD7jQ6%jDlbNOSs%ddqCnMVe1nisAjs^c0Y?lsw6jon^d z1y)4jl#e{#Lje2;X@%x71Yb0e#wvIHzW@KSxZI?!cvT=~9H6Z_om|sMj;SK0P^7aE zwY-_nN_!SiK>TZZL1iu}+Qk!YNo4Uhtu>8bd;i0P6@5!7joIjuM^n1+1lw)9M+*Te zs}xMi%QA9Q8%i}FaaR70UW_S=VL}5piu_ku&0$+Jqk*vl=Iae<1sP{j%(U)y#9PK^ zpB)G(Y*J|W*`GV~EeWeb%E^wbe60sw+ACtUi?ohOlJ*52qTz4gHUtDYpeKmoIn5er z2^y^n>uH&l$C>YTg+I(m>fu%wr}%Sd{R#Ty}cg6=-HqRzk@H zxyK=ps(-1-tnl2WY&QS^)1z+n(}v~CD9JL|ifaj4=o0eUZ2OQoz7CfeWOe;OsAu}p zD0O0yadi3Q6AFO&kdlzr6R3U%?sF-7GFHCwwR?-Bj+#%U-J&;GByuXP1Pz@-7SX`H z$@{_>E_8rJwH?nkR&`6x-1`SC5N!N_Xj!1ff+I8gQASn_O;uzQx{|UQg{5BfAdwRD zoW^F;pNlWzN12ek=v2>LHvB*st9@f?gY}b28K;Ff!Z^OtZ)Ju*q#~Z12W=rDHz~pK zNWvVGc1aCZ@Ff1i((NEIlOC>TCRIncIZ#6X8WGLJgxJ2JcZ1=LRFYHZ?+Dh$%sosB zPEN}Y@zB5lB)A+u%!^Uo(p+K(hPPIiYHfPV8=&4hTXT)99bX^z3o#pSZw%GZegA~I zG5$9?dKuH#prL~JrQQo4R_=13Pbboa=5OOAa4%_1bNjha_RhDEfP`9&H-1LKOn#1Hp5= zllJk`M7Ac#3iHR9{eht_#k;Doo)~99-a$D!0KdzdHniKtgD5k}*y9K`*wWdv|2G_;0vJhI z#YuJL)kc9x4PDFgzSP1|bZgUw%#sJ_DDomfIWT`7`P{4Ly(yv$7x0%EOtu zc~kBES3|*xOXNa2h<>?Q$47Ui?0oFDobmX@poBDJ)#sqimhZDRm#I|fD|9C37CyF6 z1^fyA4~tUaJqW`qgcT1j>RseO#n4W*yDqw$t~&_k)TvITb`%V~a)C;mxS2u}H>1*M z{2oc>+)e5?ablnFxa6W0ZT0r4c9o&lsahUna>k6NyHK!^B4~zm{QY~?t|KC}RbHM_EOxj)rscq7_Iz%&D9@Cl`GT@o zq$Z2iRy}IQWf5`}C=hV)6R&;yq)*bh8+B(;yv8n(Kv7s`)F0N^?PIs1OOf#g*Htfvtj9(1&MQ z3^Gcygotl~{0x>{>m9qK8|M|>rC=hlRFz_m3-nnH~!w=8tQ;Q&0A zL&H>Yy?Cj?5A1?liLM02(_W{=5NdHSP0oPc;%9d#kC9P-Zxheh^vjY-#p-%XmxJw%U+1;=F$M5a~%yy_gIiQU0dNXvFFNk7GGj zQLuPZwsAi}xqc_q04>_zEaK{?4{|>=A!RYKP+kt1u2PxJi?63&xhug&0+TyQmn4Vc ztv^7s2=>lL!a|uR(^q5 z9Ix>mffI1AVdiXJcGD5)Gj4R&hc{7Pfn?R+$7Un-`~-J&wV4PF8V}T*58NT(OIv}D z`2W)ev+hUM!r-@DF%UQ8udc6z0Bvr5x1EAVS@f=94uivuAJ!`VZ%Rn4=~1 zd4be0Z2c55Ycs}fjwv#c!wyb0Aw>o-wtzp(CH1PAXzdRV-u8-QoV|jcjTDX3XSlC+ zh_fsXmTUx|29;76S$|6y$3kHdjs_%>U=Gm9XXf8iQ-KAPQ=n!0B}kB_jI|j@VYb?6 zRi!t$oZ%J44UXx#cKOz`siQAgFT!8nr#o@Y2Z;@U+I(m*fUVjju+rrFkvrEn2LwgCsLlBO3Ej;5b8L0HPc-&4rL*|4 zS=JhSIVpdi1G4sWs|`E5=F3n97oqfRNqrCK@fNl1Fr8GXvv!f#&d zbQSRm^R<+?#TupIt%v0MLC=e8?K zA%_ilRWjzp?p{(udWL$p*6R??*?abQ=PGGCP!{b?*vE!UR&C`yP2E@I;TZL0|TnQ>{0^h?LN zdX2U{+1&y64!SLwBe<%!Rv*{>LjzwZHTWzNoi0f8ILi9tm!p3X7Tq~FJKNBGmCgZN zNj^2JmEAWjRxT+V5%UI9#vEZ_$3MvT_seO)uER8NM`pGw;;_=w6?WkN+JSbbR^zNjQroM4`@!M+U>HY4u>Qe zp$Hx;QN~aSWzGF1d!4mUHv-@p#E*Q8`RHdo=kRawi0J;~e5tQxKsUEG9A3|tGU_Zd zd^uJ#rPeX&R@|W?b}T^s=R1?I-GlQpp|+y6?<{Z8HHtlkZI81A!?O)8GYD!@1v%-e zUZ^|1=}0INkgq~=n=xrYP%eow>sYY(9&K$4B~SXe+&xq32LWA&QWOo`k7++wd5Zv~ zhr@y$GgYaKlD?E6(VJPar1T5MFT({Tm#HiALKXOVAouY9dZXzuvHCK;C*eQy&p!Fl zWM7_s58wKtBx);4cfb~*2x~MGb(EAuzi;AuD_5e~mBK`hD4ZD$)pR9=C|o4X$?QTH zhzGR6ZK0R=l*0t(d=9-Y>(M%kCd`!X+(+kLgvdazrCV4cQg#{qjpkrYJj*F%;Y^pG zBMnSseraf$C^-G&KF4sLzgcmS|K#vGcgM?7MjbVdKy6dX;3NZMbzCplY&1-PmY_Yy z`;(0KXP0P&S}%iblL%HuOCBWxNLwc?dj13L_g!#BWMsLdohtf!R*zuZE<6>1#7DA!H6>9`ZAEx zm+V>*PHyC8b3fkdsra{z;Q#E7#@+=FOQ++}B>mG?Rztq$P5P&$T0YuK?+R+{Hmc(2DCJ^O-73{E0(8XwGOtY`}=+zjY<`ef6c%xVxLrYKziQQnLyev zE>ygSLIh+c_`jv?N8?Jg4dl)P_?$jeySPycbclqHQ~RL_*K>lM5^UFUV7ROK6npik zh|AQeph%kHEml;cNG0WFeXksT2;Nnj6#;OH8;2;@&umbCjJ|+{!g^0sMt=^BJVgx5 zC;(iCxn(RQZT&6Kl0e8}g1<8LVeDOCTFajMu?JBc^0ZJ8fUWtL+c?5!-Sit!AwW9~ zI+*(^|2Vd9Y?o3jzP90Wb1YAFfV#rtTteRG%NhBJY3!7RW^B7X1k%Y8*O?wuCt9?x z(~tWJf6<@QczB-mU^}HrrrG|0;aGkCY-;iKp8|J?pD&cWn5^iCvwZ#&`|V`+YSMeV%kb~PpO0CpF7ew# z-H5csmY+r$!*0u5JDwxv*>fndHR;=RmcgNBvq^iBa`OJNvFLQQ{YFPmq>OtIgcsVe zyS=T~16e?U!^7yI)bkJWs9J@G2FF|Cvo<{#d;^s8oA(9 zbc6j^wX%l=++vgQ3O37Z;_wE~b+|FyN!JL2RIIpv>KYG20XoYx?li*nF@TYNUd;WcWg5nKu=4PMbnXrDG z1c|EkMbuJYhNF%D*SL?DT|7w@ntvx7O#x?GBM6JTtlcpa#GqI~RWNUQv5)GAVo=8x z6irb|?ypE?gr*_t6-ZjmjK#3G)zh0SD|P;~48leg)8}Zrt4shY9AUH(+tQ5Vrz$O` z{ELY-r2<05B#n8GiCmt-hVbA}IjhGm@QsVkqBhe%s7P$ZvwO)LYN%)QYf{W>$_KD& zx_UYa{tJv9`k+yUpd`{UR<(L~ym1f??m7J%gzYfAKO-8#K7-aYtrGpLpb%jnC8qC^ z&FWSv!be-Ib>4H~mONK=xBrN@WC@-EIq(S=&aOaPT>#Mj&_w7nZWpbo65@WPrEn&O z=5WbE&Py5-*?{eW92%gR#J_snLri{1qz52U@#J-k*lecma6?l2m!MJMB-1RpAl;5x_KtHHT`69phG+jD)LolyJdq?TiPFPh%J8EWP#A84eChg5z>GAyMc8&+$#eE{K zE7Frt*ENcDzcF!iIffeJMxsIIYz-gz)3qZ~f3&Dco%_M6TwxXa&SX zHlbzi;N6O$Fh8QgsvLH_WtE-T=s+2LMqE0?k;!lcNz2v9O45m2ZAO#GfSE(K#QG&r zzlWy`>R2PJP*{^@+@deyGRGZYFuKxd$pschNiAb@`X7z zTT45u^KEB2{H{#V7A~<)J+wfFaZgU!bm7NmBw6r?pI+Ky6~q5`SYs@*3(1Zp#)8}h znhm3QEruobeyzGSTSO1_FJYu7q*r-E8M-xy;N6|2m`w@i2(^pAm_ zLnaWHvE9!Uv0_{2`ITG?GkY~4oS2=%7?-h~h_DtS=VoRnWGrf})v? z4bZOYq8$*p{jBf#^p(7A17QKnF<~a_CZio@qxQr@m9W|Iu8wY9Do; z7Rxm9>PGz#b5CR?_&-&*ln@I$JH1<2;5?of7>R8{Ji+&~Y7QSD=sg9WWCEoMPJ8m7 z9MU5~rnOBeRcB9AvjeX@%em_RUU2>Rv6(eeLBQ2Os`6rV9((s-BUjBU{01} z9n4g)_~mwvt*rn4O#xPp6DZc*@Rvt@iAeOb7BqREpmI<-kV*UjoxYF52Z@G&O{8Zj z5@!)I3WuA!F$?`a%WYyj_w-}Ri8#cM1jYFoDR5f9yy$n1*3VIvazj;kkFNRW)mHz5 z5$jsq%YBr#iecG{E;14bM$I4xe_M-T-oh3)z(c=1yGvxsmE2%mp5J^18N6HRN)I^M zkuB93Fw*&I#2Qf3c795FRP908z7A!Mg;;UT^)C3Al`JiuhkTm>*#SY z5grQop#)qFT`#==LZu7xtYTtu@P%2F&vT*!eWHYx#P8~A=-~ikGKIs$zuF*g?DPnN zaX1DDS*g3)0u!^m7cX6UA2z`esK^Q`S@M#E*o66s-~)pc5>M-nb4t27+?fb`W1$f0v*;A|V*!?c|0(u*1 zf>-=#XUgjgLy>17($cxoY>y}&0?T1+uEHCFnX$q|f$<@|VrOH+`KUy$$EG8>vrSwH zVHCMTG8wttr%&RWXm1=UL^Zk^lUxpQcR@VVAK!r+`ZLFvaYlm>#?By1ok1#Giv=vTpfS+O5ek9%z>pZT)VE=v$jw$o_R(&QW6`UAspYc9erY#Tr+ z!BQP9y$neOY0B!}GcTz2+z=^=3VGU_Ywowk-xhTx^;*lE^goFe1f%&oMI6MlfN6Z- zCiNw%%+fcyo`X96MZ5kwL1Myr&JQh8$eT+pA!{L;PPq|Y4#x+RAx{*gC8IRYY3hR` zd)CgwH8KjJRKQchFCFUlQ#g9YUgi40@2ii1XMbF4nH#2$0|?QQ;rB*$OZ(D!9%?;! z8lz|LDJ-GKYFl3Dd1mIRI3qw14poAmMTnaO)Je8>G~-V0_>fR^&L!~f8O)q>jPXTKSsXFp zmFcAn?Yi~2pT~fn?#Vb?yFeTdrGNLpt7X6r`!c>AnYPB-2ZtGX`Twg{Xi=*C2g#R~ zmzNhROE3|r**Wv{`;XS%)b|fE@bMn2nAWwq6}j3euoEWy-*8W;j&1bN;^}<3T;Cqq zaA}a1H+@p?&-*ca1)*oaSSy-)-o+?>*@s9?cO|&sR;T3#Ya`%xm6hXC;`lUh+b5N} z+I8G_JV#6jihoQ zUnGuNayD_OA>T{RGDwR;E4o8VX-;tSZvbN(jU6K^yPkip?g8RyVsi{If63<+R;pk5 z6k9N@AZ0sJT&Qaz@Aw2+sAa7jWalvha`gQMkU|3-pxdR(*7et2M30i;Z zfRgcwVgVMr1@p*jVj)7F5X9!lruk80d|{}$xMylUkf<+_h*jABhzk>ezXdHcu!a3l z4NxOP{b$TqN4sQfcN7%(WW*>(%PDn6yx_9FiHD98yi|(-!zWfFhnYa4Q-Z)oJ#ITV zZXtBRUz4y^46@Ub5{3bD;K=`Vu$P}i#(f0?%ahk+GRJb zQx)GT$v6%Mo^Tkwbu6ZrUN9Y$NF}2hbNJqa_g`8T!^6P{bIoWu*gEpBlPY7QDi+vO zvrJCI`)f{-B#~ajp?Y<+L>76hF?h47ZA&Yh9tq5$NtEXgXOIw1xF=O zZ9&P6ZukX$QN8?l%iLLYqP^{Yvbb&+YL7N&q6nwNqfts+T5JwGf1G0U%N>`SF4Vs} zvEbe1uz8USX#f)@uEV8<&DXGE(CggvK*SR8Q3U6`5+Dj3=4at*@(wd~q`l+;o2!4V zR2Ts=^h%3C6`G2Z<$xX8sx&r^;h319!I@ax(5Zq$OqRkCp*UT{WSd}W{Q;?GHzO_y z4bh!Ga2pXLmwT1VHa$f}-?!jG!tc8R?E{ufXUW7WEt+%`z#cmL^@JjF2;Nq$Q|F)u z(Uj`#+W>`THWgP;L8Vk2ssygGpg!*-c-+tIAHQTg*R0_1LiwKny_CFrpVK4B9hVzo z<5wVpzeaq{dPIle{AL$E_Jbkub%qz$zun|G(ty?E$WsxkFT<%m+9F7;a=A>QOZtq8 zZ(H=dW4*BLm%@L6l*kEOD;q0kVFyVn0uOex89#81JI82vQZ^o}3+XB&5#cuK9Dil| k000000B>ax6956d;sSuf58etv3_dUoivj=u00045S~B8Jz5oCK literal 45256 zcmV(rK<>Z&H+ooF0004LBHlIv03iV!0000G&sfak;eW7vQ&2UJ%gRpOV=m z)Cw1$gJSr13Wqjw8e6Wrr*Wtw+wxIOlh>QFXn$kV9Rc!9^Kq4N>9>>iI^94`y|&yx zKE$9@a$lupo?;AVS?~89=6?JQ!V85ll3h_vJy%(kt>jXn{|z0RCdLYW<;&4opKoPp z^w#Z+)u^STFX{o}NpqdTNd&N&K=5fSVhCw{r~oF~PU$kdhAcay2VD4aNP*Zj&WTnt zxpv_A#bQreAA8{v&H}}g@C_1oVwoJ zKQeadibD>PX9Flm;^^N6#=3}FMG|(;%kD82n#$@^JU zSLzy+0bBv;CeZ_z>P>LJbm3`Oif-l!0#=Fh<|v>Cn3$k|`Jrcr98XZ!JfaIgMlVqW z3c{Ie-u_pb*&l?QZQa7M^zj6Fgd=MJFC1lEXYQDZqQk}E0zuAEuTJ#t7N6qCu1sR? z?S@n7UNj~zwYAnUn6Y3*fqb5#kDn6L8mb0++8!tXvcy>K{Dhl!hP!Xd;D}jiwPE^T zPAlk7l)Mq)vs~{ZQ%v~4yV)|?7-J%ChIm+W{7IKa{=z`9+dUb`j>mOWtcP?+WHZ~! zV}U(RaN#=WoAU}*fN#B@2yPEgEKM+2ThyJpaC&QhVDv@?Yu;ED^i0M~>{n)96E!%X)-@-wGG-b%I&AOC4`3dq;+VYjf7-OvG^hDwaaH zSRnOUorhx-H@bJ|XZ0U{(g>LGOvRu#Bk@#FVra1V^=COnQ7mxeHSIuu%| z9y0^u^MY`-fj9C?cU~@+OJBhX3p_QxKzN?qoZ_PU{ZJS;>028h&F~4}HQ%{md&#q! zSFIs3I;4&wd7xUlNXHDH8~Eug2B2rh|MTiBr&uq54ZYI3P0O8y$~8}lOJY!k&wuS{ z@ZM}pU}&7SEuM_=PtcVb4__Vd)3rDQRxMh=nW7n`=+-5HqtDaqk+W*>vve@S6(MX+?f{(Vv%^Bh(uygFYTYAhO|-xMI3w4%{KFwUW3iQs$(IJrrZfS> z_${crrJRmeWF! z-~wXl)7ERvO6CrZ)-SCtGp0TNSGF~?3zuQ}6vT7bHNbf!LQZQhhYAQ&Lv+ZRzH^$W zUCfWcU+aj9F_@hKif*_Q2}p&f%~LdD$7f+Xx@Cy|fU;)rtyhpwof#Blyah9008qQ~ z3Im}g17k%_LeSRdk_0ZTn~Kd)`6H_;VnCg!VFa>VUqz!=0sux9RJ^o?Bp9(bh;M>o zS?fr^oNCuLpOmXb%b5fW942iYlob8VkJ;+O3Lnp-g{t|ed#S+f}0$%Gg``1#*y(k@rt}Z;DmWM^t>!PM1=H~k& zRCGi$WGyZ;E75&&QVU1M2^dk@FH?^%6w%_ll=< zAnw1ZNK1e#17@LGCV7tqM%~FjZG2|JZz9hlP%hU^2Uj!c?H z9b3O?vNhQlK#DU$l}-CH2n^JJX_L{3Qei?x86$b8z|03lU2!9a$!8kr`tUMaxw`$D zV2r3*v|X5)Xkw$_JQgkCUUn581D-&VoTjc=3OJzPAVgXhti%@;0^aJWh62&ul?&r7 zt=A7bIpGxzaM_4&*#(7NA#EGG3{LyMkt(5Hwe55 z1|*msIGIKo<5ye@1HT|d@ox8zo3y0VRr|^O zwEX@Gi?Py{3>n&_Jl{{y)~%R_j9C-ZzUmO2eY`Yh?jPrA!75T6vVKFdZ2K}!^>WMT zk0`~0p`3lv&AW6NFsCfF(mb1xL;Xbl!l_!-SrgHUq&tF6vw>fR+xY6KK-)WD*moNN zbhU7%RY$%H-NZKb$3hRLPQ@ulg%wtgD?$NzCJqQ$x~k+U=>m|YD+Jo5efS;$Q^tYG z-r`1jQPqXt*43pi0RptZ@K8q=nV6}QESSFCbwVzRzAuN{L|hTGuIL(q|AEdL5*xgx zuFLIiVTN^~&DjFH6rAVFMZn3Ja~Ix^^2nIM458U7;Z3&-G~wSoq-@yGA_b!@JDLJd z4f@tHd7!aj07%S1X`l>cx`#O~ra_3TXwwntB)XBawi+NWyWRD{ctAdXnfx7{O9fsu zFl7VfkX>mVRXumAxjR{6Q&o@TqvPL9mE6gpANz+~%IzL4P>JNJE?gJqF3}E5C6aEt z-5G=WLx;Ci&W{4awtNjw_J z4RCk%r8B!bl7}OZiOXCUDapeBUazMuL(1siGcg*jJ70OW8l$=(e#)Rc+4UQdOTU?nU>{PNx z#k~8J7fIJDJf><5r0>bZm+b(J<35Xf^@byaBTHX>lA%;0qZGgkzA~%TFQH`U%WB^_ zNtCWEjPf;vfBix|WtZ703Rt|?5kT_gE|Xa(yEUj=Cr(LHMGDY{0V}6kHCpCDSbZntLgs|w-tJ=UlJ_~ zkp+dFX&Ii!rG~A1WByxwHtD0!#Hq&GW#ipVg(Qxq$fZXdilya2k z_bCNimUra)<#PUBuG$ns8j>Yn8o^1p_m?m<`WWfFd}f;FJ@bbq+?G;)!H?QlE&bf1W5b6cbJ8rSr+xa>4Oa=*(Sl+B z&e@TX`?t>F+hn3lyIpMrvieP7c8qKUJ?ENWS%Rx1jy0bYW}0=Z#yjx@AoFywFj-ap zIh@b&a{{&VmtJZUj;1fLa$o2!#)12mSlxCJ`>(K;@;My~6 zvrV#+wAqm9tT_-Z)ieyN)PfTvG}Wh(kz*ZYxty&yJV{kaDc31AgC&8B*k?A?+PY0n z|0gwagRs!?EG4M(9!{&n^z5Dm){#Gj#)$7^I(8_$!@(4?o6F(3wY;lPsJ4!+Cgwv^ zD0{(-kMTTi=2PpV)d?c8Pyo1CG<(A2o-3a>j8w!om$1099{#-n74Dem^|Yr2Nn0)E zl4xd<ruQuU17HXKiOaj}yc`a!Ivd%ZJ&2qf5R2!d`9c2lGX0rZQs^d;d!k@)?OgI=CUw@i)0X*!Sa^*HP1xdeM9F z)v%;j|7_-Z>VO;f@`jd)qy%S?{@h>U*xPWQ)S*>f=ns%&<|0DOSv*EqzXcGW`K$N$ zhUqf|Z=e-kt3Ez#L0f~Yv>*(p`>yo#4g%vvz>u!I7Mx}Ghaw+Fb=NV3}WMd+Ta#LY}JS#QE~3d!Fvk6&X}jWsnwCDZgT zKH;+v$(ptQyh_vfebV_} zs*+pBSj+}^Fle~$XS`w-BDq3;YLBMQ6x}F-O}`92&@78zmH%s%z!*caX1-HygXY}T zM856a-uuBOB4yK3mK}GmCg8({?P8bzNOd9KP<0Gk`)jGyQvk7ERt2^V&`_?Pp(Yb7 z)KGd>Z<#?P-kq4vIe8^+w10?AaBbo%N6g_PqpJMX{Bdi@^KpWVt5;;}ktE+M--|R0 zn#D#iX@Bw*MX=t|-NuVPpdQrHJGUc}tNVI7R{MfAKndR&WnbGVNMF>?JO^zCJ7Ddu zNeN|f0SCPx9LdHLpu#%u>Kti0uL^*oKTA(D;D|+%!vFG?j7y)@7{p5=@Sy2)5N<`w zgSer7dzG8g-{_AOX+@Cl-y@h*Jfg#FVAQ6oR&;#o z#q)|opMk6{Je|$TzYr`3=d+fM$_!X2t%X}1!7hQO*FlL#^D;{^u^}lh7PWkJ7$y>iQ!`D)$pjUc1fRa zvrE(~smqu2I@b1m4cVD?$>?-BPl8lIRGzsN>4XLtdk~Ad!Y#Y2g$o)#|Drp9l6E?- zRda~wF2ooVhtej_!d44gmz zO|b{AiFOE?DxI~3@LY==XoJGz;is^_7g{O{y?wp5V$_q~D>L=uTq?aDh-$p_4&s(~ zk4#U^=MBOTSEEyx<5;YDam02MtnotU!=%L2f29uMJKs2nk3YUsV4Y2NK(mBz;k(Y&|<|{MA(s{~8XQdpA$#)|?#GVY+ZD zDrL7vKSPLRLOkg@vcOBIa&|n}*}AdDLKMJve;m&$biQ&bw6oi-Ouy`#K1f*)F{g*+ z4)!x{J*xC=QKIrJU{3U%wDhPrlBVNSZ`45#BD4zhG=kMwbEU`M0u^3yvh}J>OsG=c zSo~4pSsU3}qI$lY6exI6j^G;p<$n=Yp?od~)YjF!K=GDCt$mQiu8*E)QY5$l8>NSG zsNn{?OsxILqisN?-!oYxt@u5^PNj4VaxR~AXfU_W+syc@TgN8v>cLd+c;M>Q?;b}G zNO71ZLq-V35EUWoaTG$N5Bg0#R|UhIGnK?v=!SUvxXgdPv1Zrfz5b(TzS`An{oe6w z#LV@x<^aDy3xSUYTnRlE*WR}dsBk1J#+OKn{CN7`GEa)Of~*XDYmVlQW8?r=1FE!M zNIs1@)lleAvJT4c1c2$J;pksb2xsf|D)_pHYcp&}(qUGowQGf&pmK~Uq}-J^SUh%K zNKoMu95&9lz?7=XONX{68ZF9W|LM7-c+3D1bz_S#CgOv&U8F1YN{x)Ah! zpSPUwU-!erVz$6LNe4^j0;-;By&l-Z`0!oEVdA>JX!g_8DvM>IJw-Qb#?MR6E3KTg zxv|u}7*ADiAqbV#9loQu{vSp6KV(dn9LH|yOW9qIJAL^|$v}M-FuOdh8G&~^+i{yK zk|^7&iKW$jr%(@LVZ69mrW0R~N6S}C*eQTvIm^#O5ivdc1YOZ!s#gW{AAQ$Fuwy(d zVaaujJ4K7GMfuMp#t+#kp3EK6V^dE1cRjE3Y!EZP6Pd(Qf#}yNpf@FYXK(uQNiEH2 zRwq32<=txl(xaTtzJ6_y27hsvDF)JMZ%A=m@+sd}f>hw^W7ZHMhV?GlnlS&Mzir(} znTVyetHVsZ#2RU`$foBq9}N!!Rc)aQuzM;{`qN5^An-Kb=ckJaozgvIDRop!lw zzr-Kk(>T)jD+L&Uak#wB*2f$k=z+PRExhJIwNWoAg=IR1={7(z=|EvFLc{HE%+uzW zhm1$R?``k?7WHhlT9i_fs&nDnS$kYChAUn%;_06t)dJtHpC5ZsCcGF_^iPC%W#9P< z6;5y^vYiIrwrj1DYdM#fY#Z*WnWY0F`Iwa#RX~LmRRJKIM@-tgz(8S3@9-d8zG!(m zld>|AQWF_B$^p^6y_P*f!jUnYcsuz)NbyS0@lY8*7s&5wr=Ip>nmK$0g9WM(BesxN zLo22iucwN=cUm!9E@PXOP6)b+c05zoBAtP=-5fqZB7=+SzQ7cvw^b}N+$z)Jp5wr;6L_yMq08@RDd|m#YhN1 zY##3sM7c66j+*^IKoe&wj_-0y1u|4)k7bZ8Moamz3r*h1u}x5`*=!~e^AakVD!{H!j1d1XAeB4B zt3a0(nC9)Qo5_^NbI(8x z6I;=+`ur#p1GsSF%yi=N?O%_i*0qRe;cB*L3m|no%%T%E1K!K`>3%^~3beMmXusBK2AF5ZDu0r?1^HgQ(qEd=cX>%7BA?f+(*^+r9n9|IAdUS)8O; zZ#1{4jGg!w(x~Dq=4CQRhOJ~%Y&r?#3;R4wOz+Ga&3j^^Kh7Y%_mRjGwc-Fy5~Z&O z@->B&xai-9C!20D%G3|<<1jWot=DvJ>Y}CTA<>jRDywzPlN52%M(CUadVfCEYMs|i zd9LDVu#A|RZ1)T(vu%kWz1lQaXB9bCmXecU# zq4r981~CQ1H)GdIal89~_y3hJ(;?6S^uzQZ)bbO&6p4{gKCnwkd|cmYYpBWswN+Em z0gm}Xv+4(v05V+m*Cx7qvmkbB6m9w;MQ|?j7(4K-=#Gj`)6bEvW%5h^hN52Nnmk`z zTFpQ?ckRs}xYY&}vx=DIV5+5s*`dz&^-s+>H>RENKl#H5!f2-Or{5BHE8absqMR> zi@3`XBV};~_f z?h>u&xyTJE7BrkG-RpZzkAsBA#Zu9GoP?32Sv|bl<-mTlTAWA#{iqd-Ew=Z0s?z>K z&P1rHCAXS;dAcyv_ucr<;cl&JeQe#s#}1J**-Lr^+xRBl%l+?|eJ1K`Kj?H5Na!QD z&HZU%f5kgMBF&k~q`e5PnRI#M{2ei*yoPmUM%=}C&}WHUiTabkf`Ye8w7;%9C& z`Ms~=%%=Nand6(TLiKLL7{eu}EA3YEPM^-Th1IM?N~dh3iNQ2u@$Nt@)s9PSWmRNhvdXV2|9bEOwfATlFUx#P7P6B`W5(aVeXCpUL$n0 z+dy4|l{|nUMUYux#H}~@_5G8tC|~6-*LaEJS%+gq8g;k7MB{#hUu?Qx!GC1@SVTjb zbnkI2*MCDDiC2Khv;%0vj9|VeIG}X76kETjZ@Ltt^_wroKKiG8;5-?ayP1{mr+ON? zKRCb!mS4=hd%y(3?&kbI1prA>G#nuWHc8IL6Jy23&}OQ+sa4U?(02o=rT1PaImFhyn|_&lYF-S*1eg3?4n^2X$p){ zLv$pz<&HVBdGTyB-8{|}W$0w6erfAjRn1__Dt=33@OfG(as{j{ob%H&8mKQ#U_9K^ z+^yafm1M#41YSdM5EHsCo4yr=6R&xU#WrWBQFq>>81r7c3D|P8IRmh{OXZZczO5jW zyvITrjx!K;m5S0xZ`#k{yGrkAPjrydD;2Ta)zTdl zStdO{T~eb%-wYH^oX4)2nsq9_yKHxrXm9et^zqiV7z|E0Vqk}^Z3tffYs#q4cbT9$ zE#2-jiT$f1-Y`l^>kz3}oLEhe?9}xu!Q-5_#G^Q{l4LHJBX1vMqXQ&IM&om^NdhJ! zzAR2X%4Pl0v{gXO6Ca%oMnI}|im>ysQhcrb9o8Dn@a*d+Uo~hM>>C=cN>gK2YUShZ zsJ5Ju3yzu#oaI2jxIgt#etx-JBq)5L%(|BOggh0)nvDGyehs&|*|HOc&!utz%s)6- zrjjS6%DVWo&^W$c$J`Egl24l6hixW-fR4Y7kkwJe` z>J9wRRBL4~zkg0+w;PmRqUc9fm@dmcO=M@#=d7EiS9mshCN(p^O@6<1KK54k#*MX( z)BDyBbo|OxlXd7;ax0%rZ5yri1vGpDhU4TTh*&zjINb+U5Vd4k5l0OB%VqO>HFro)IvgZR8FMW({s*edbiUsZcw( z-ToN!R)Io^N*@1;GV6ES>7r}DNojGdp5ceN3|~2Z#yK_MA=(i(FmMAvIZJG^@p2S#IxoBy%Yw+PZ_)*`9MB zIuVeIRi*!6ul_6xZ32uo7l*EL*#j$nqm>d9EJFz>JogBQ1a@lqjQL)(Rl!x!HjX8k z^Xjk+gdzd#3giOJ5p34HI<4(hT(v=L*A_ze)7o)bf)I|3hTz9j@E-^BJq%|$o$}MY zO8Qe<$&zVE?s1lq-Vg4A$S#Peqw)c4&+zHF-(S77C29=n3Y$d2Jze~+zqOhkNjTw&!17AU+0S4 zTfZ~WQ7LdR80i=FD3uDMRI1NVQUCDH(VC}=PQ7Kr zFKW*9P*L`;0ad#JAoH{1xQ9UQIzqw+mGsHK=_5%^8D)fuQ$!1nuIoI$QNc_JGCdq7 zB&^O>Ubp&^Mhd2BspQw>Z~(XOWwC!R4g@q|9BP$62Mkp&|9*ndSf+w<+!*aqE}KG^ zKTXYM`B8`#v@gh5CC-0enOr)9NS#(yr3uye(~GD{Q0kFA9+{`+Jx<%SALCeYSb4vW zDlt|YN1T_S&I^p&a#@n&F1N@#o?jg3*S2)-2;4y&>M4C!P@}6*{pt&r8~7}TS@D^3 zs~eF0a-!me!M3FgvHHg36@5MJ^7MVM4$&RDM=m^HbedtIql-(nn9MTM$l}TtEgbL? z^X19B$`*#(4~9N-doRh2<3#bFyp0D|$<3SgH*8APHH>G$@7+fXyqQEy3(VIa+%|Cs z#2Zjf;Nva+@KJ9yY1e;~^I?t$ROw__28V+a79gcophPx<>S7)F3B4p~;;euqr(pLJ z)Z0eG{>*3gvDr}{*}jz=1-VI?hxf$bXuOiq3@#cjJUUBn*3tH$7rUmF4HQa{c5@ge zz;Y17rh)+n9N%K~OeccPvwEt&@bl*_d<1o8Ega5Car?x^?!7#0E*THf(<-pf;z||km z4<^!@MWB$_eu0d5IqdSt!~S6g&d0sDO#>r5V6CguDdp>Bv$>6tDi0e-Z8qO=`JI5c}JEB zD9iI-I=t>_Lj-fd$xzVMj=7qt8vbIA#pF74aJE+gIzIGbesDxn6Q69i|E@ zMYRdddB_p<(5jS8wsL12XpLoBY_chRw+kpFRl$;vCUbvJOF!Jj@`c`# zv-RXKMBpiaTCzQJ7diBQBS&OAXLJBEE7`EN|kll@ke zGjhLs@J+KtzQn>c^^;Ehmet1TY~qR2oW^ z^%=4cV6rULEmQ8@nlu8ND{c4}FQ$HKT62f)yfx;RD3(p;D+zk$w(eSHhScHwdGu{4 zl)JkXUL^B1*!E3pXkmpw#-uughmepa?=ShMT#M5VI`nMWN7d1=k|q>h|)XcCW`(r4`Y zOFn)@wew9AJjHP5u#0UN49P43Djq_90Bj2Y} z!x|B6gOmGSMR?3(mMvty680~gt5Y}J>8v(8j3?t-@!E>9{adqQ1`VutXz%gJCNX8I zzfA2fzYQ+W^Oc}YKuG_oQX5f)fnk9Kqs^BS3mY83;IFNqCM0SVfj%}#f49hwP!bMx zG1Z9nZe`j4r?tBe|}kONfvMELZKRWZFhG+wC3dZVzGPTQ^0qXRD! zu52Gh#%go8aO^;tgFuF!UWm#-yT3ku)s9Xk)4|nG?p$83V8)H+i~5lMa7JTT8ENa) zm!%piYN#RR81z1F<2%l?uN~*+%>{e&-`AVQ`$oDn~^gHy4$8jzQcW@_RtGm_TNsCNE>e8 zGIhK~FyK5>k9#G6ewU|#t8TUMHhscfau8-)xp{ifO#5!x5GeNHGwLhFZgB-m(cLXa zY?}3yka^~G6JDzWpZ8#nK7kMYO#oO0Cdg+bc5Ow!GVtm|2}`^1#erITYS7cj3&&*k>1{y4T-+=1r;)uB21^F{{X= z$cr99YamZ<$1BsW&ItvpUts=0>d1xrN0b{wWG`shCw;#4zS(Sq^>C zQWMn)f@TQ%{`YRbGis_mJ3ppBQJL!(mHk`2Y}6`2hKS1pe&_lYJR-5we~frHJu*2! zi7H3Am!*T=aqlCS%Tx3qPAA!EXya%F?=%h=BlvSU1vk8J{!b;Vm>hWiygP7dgv zq_MIt?Of*h(X^lkjDiJs6{;8dd6ly*K~FAupLe~DcLFz8jyE#6`t1X;!cdnK#@@dx zQO!k5vZz-SG0WA=nV`PxoLocu>eUvcFB*z7NAD$z-#Hp!Rj#)Cni3{&J-q*CU@yX@ z?d~3Ubv97FYc+Bx;~1a7{kL1^*UTGuNRs|p_L5z;tLk;epd@ub@WLi` zU{xFBB|z0eB}#(4Km!s)7umh`;nDaXV%yenewi|@*gr^dM2A=9NCr9;O6LZr5;HHm(QX6@-qA}aoo9}pQEQe4hnk{l`0LdKM%LiS{qQhuiuQ0NgmLJ|s zhgUAofI;#Qc!r?^+bdAa$gkskH|k-BDcpFMS%S)6;gu)mwy#WBaAwI6OZ9!uM+ds7 zTjObWGs}E7`y)0}(>_hk%JL~c&>corfeI%*tS(ak`mu(`o6#?{9i@MaS>DGO3b6uo zT8P4CA!YhaYOGK$(1>}m6w$Ut`TJ?=bqz67AWly5hIw}W`8wP(u%|WLEI{9nU6@Ua zC~cQ`IWa!~R0{h>0AvWf?3z{f&h_8HWB3(EKnodevgw`~A<_LKLQt;Uu>yM7J>4Gw z763-G`sM&b!H%c1eIt~@stk=Q^56t;Uge~>5T@)g>(hSUa~3i^(|t-ZUae3~`TG*2 z8(UmwYI$JZMJ!xlD|q(Ka%I}Uh}9#S@5IR{?ndJ*fThczmB0%udCK;{9OTZcFUs)R zMKOh!cH!EEsQTy`!z%IhDUnKOv2lyLu9^|Gp;ZT3uUtoYSB~5k+BUA6@wWrc*enQk zPJ2Cwb)1=ERFA%pMuohcd1IU<0!#ASi=>MD*_tUV-MX_PeZG(5-p~FUXS?#gqvMI{ zID7#;S2P*Fsh_awZo*faL306j{gWBMLWI#qwKWQOGmtG+27!1()G{Vem|k?utOUx3 z>eZpGGhxE_Fi^J*_R%~9zo^q)xX9*1DGzF?B1EQ`a0R<{!sba$o!dK^JUdvIKlH3d z@)2c!OiA>+dYUXstK>3F0w5Sm_Q#W#V6R|{ss9jHWoYW z_C(w8M4P2Xe`RKGG!)<%?|jYJ?OP8#W2 zk3AifAF?b}@**;dx;MW-{`WIpjL@OOj+^qO@pIOo`3_4`y&}HJN0Zf&4VKHfE8_n;(6ed!uAw=5iSPrcDH47FhJSl)#CnloJY1p_fCMeO+F==#ytedw1 z9!3xTIv*E0NTBdLW=519)6Y`jutE_{GfsT$jqxvjOARF=a@h9NGha0ZN43Tcvm;`a zN(oeybi6f~srgI9VpuB+u&ax5BsV6IsoGfQEu>z)$}@f_7zA_S9#@i~yt$2pi_@$| z^d-+XD*Q1Q_z5-!(rm!Ix!Vw6A8^uB!RTrcbobXNwW0^06(ZE^&`m0?lItGe_t`0N zI-5}ryNK%+87FJ?$x)h|^{aE4p``hS5fvwqmGD+Sek0i1o2<|0HkhJr7p9H_lQ>I+>8)ljEyK+8By}w_amPC%5!gP6 zUa(YO5N%UiB?gS1`B6?8DF6oy>|@#jussk)Aeb*B%K3qZ!*APwaajzY48F0_?$y|ga;eFL@Zx+vLZGpGbpXpQIMgei_e*ZK3zH5g$+(EQdc zyRA`a7ob__{Z^!wOBr-fpfNfcJb|T5KW)5jW67~287dD-1Mmie)JbLwP}-_PKlN@~ z_#L-U`Duo~d5tqy5IrSLqoMbZsI_kVvLSEXOnWy(^nY&K1$ilzp=iJOt^^sjCvJ>r zz%e4cFAJxT8g=awF`PBHhC>b?%q;4W7{op_EMb8ptjNH1y=K`5f&SWfhg8i{F;y6+ zQ2mu=)8XXebILn!YR3-pJ-6M>?Jo$iQ6v)^O5$e#uL-ju;5GXo z@Ezw^W7&I6g;8>WQU!P;SHu{aM8uToZj*eZ;S+3IlC6YN{ao=ei~(AW00)R&qZ>x+ z5Zj0Ko54+K6Y~T;c{m|^9I{yl)vrDDTc-Qw)3vy@=hZ70P|qVx4N?V1I3JS&`P#y0Sw502 zI32l$A(*P$bZp_o(1szS;hp4b7?VOQlgSETb_%vg4l?*e3*W30YfscDyCJm%sUb;V zLVu34hXbeypqt~v#5*jZiV05@olEdONY}_@-+o8syQQieX@1HkS1Y{(Q^x6Ce7kr!*G2C>o=N--ljZ0_of`F$8`)d zgi2GMw;80y(zz2|@2FMuG?fye9v(u?8*@Bo<MBW5AC^jd#3SrM>%xb3}5`t2Ldk! z+juAV2l0(Qe4q`zB(BJz0&ty$QET-uj9Jd%Ely|CkoF9lqAX@pGoILSI%M(%4OHtD ze^E}i!C&TS!8Vhom~KaQkvE)E$*NVjspGm*3EROl2ws)n2=AEAZ$qIXpaM;BQ8L22 zVC_S?uDkb!y=Z^}-)||Xh)aPw?B0i_$5rJF=v-20cA|a1pt@dBi;DKI1NV5qWo7t@ z%uV&eVA{9p#UZNUAn)jFfx^SfAW#GV5#}`rVgedkT+Vyk&gloVDFKcR-!Uc6oudwb zh6qax1@RC#*Had-wOKyHEOA2H;wD}Y`5m+gChfXc8npo_AnqR(0#EI-Yoam%&lH)Zy7&Y&O~yEtf}jHi#|OFMZ48^Uf|!z0 z3}_p@voU3q7}1Zn00ELz3RJ=(Eq>lHr+|P}>LrPeYQi#z5CB>eEL;*L;8z=E?anq! zEEO0ht-$u~VF|{V+CoK~@4tJUKS#12GIK4g+1H(AhPedJ1bBB(-=T%LheE^K$fZW) z(Z4TRS5rCRL105TNs^P60cZIA8x^bj=Pa`I;mJ*>qvTkSsDq3LWDk8w_{h85VXDok zK>$3$imiOq-jo9DdGN~U>L7v8?hSd zIAJ_YUPmB*p)J<%63Tb@Vid0P0q2}~P}qel<9Evc-CISLx!O%!XU{I52u+U2o3Mwed*V4~J#`FGHYqo<^tEpSBh6AeAQf(jA*TwyK@&PVnmMQlnw@L@^4He* z&ysb4cjyDf0L?C>D;i;RUBodXw@cNJ<_2 z7xHX%W|cVJM_q(wGJUIvkfuRnM75FKhi*ykD9$+qKj`;AZaX{r*eLz&m3f0;+;^I! z6;GfCVYZ-It$IFnCFPVQ;~lCqd-AQ^BPON^whBGTmnby>xwqZ68JNm2eB?V5Wqvks}A`jK<`*KF$@-EJ;s9{CkQ` zoBa{t_8?W$?;b}|XGEoo+N9oFD8WZr^nn&tcG6C4vmR^bYRR_IpSg?BQo&V*@EdP| z>_S)!U{SCS7m3OP$U5AkzDi5BO%;2a22Vg5l3Gl8&a_m-LQ_PqnA7Mz4j@=z3qB)VHd*;idHOaTa8bXO&-uqy>f> z@o0A#?sSNAUc8ooMX-Eo$ZQyl2M*AjjplektxKjT2(nLy9p7|*o25V8kn=1KJyZ5O zNyA7DC`}f;=;xSK(YF%5ayp@7E^2Zna_Em`Jd5$^m4-I1xLiyVJd`c=IA=mnt58%$!E^5%JadowadfKWg+oeGQ zNvpSh_K#@Y5gW|e@y}Wj`-^5PN0vf~_GUh!k*#TM7>D0XCP$XP~UBRjDk-#bcl`vSK*EYZ8=XSHS)*mhpj$z=uY^Bmm^Qj z!k>8?iJ>8$)`t(UF72YU;XMWU(1!(AgQJ=$fRIaP^y8+wcPj;W8t7vWl ze?gRwq%wYIs#Ydk&MY15o?j2XoYMA4aJJsa4HBs8dsQ*KpbtW_>}dX3 zH_9z3axc|YyO=EL8b_d4e&Mi;XA?;=VQ@t_jPZQ=l4iJQ>_BR6e4>s}cI-Nt#?{Cz zcGJ1~kdBuHEQ;J$t1;V{x_ru{ib{&daLmB^05d?$ztg$e31lSy#WPHc*86ulz$0MO z$f>fO`ufOH%TAV7scdYV@-#Hi8;jAh&IPw*|AR1;pp2dTmy3!dyG}L-z&tCOs>Kp%%oy<<` zEE2NfElDo~Hk8sYEUj+eh06>oDY2|g{cxvgM=#SXjL(8kKH+9gp_8{1LHj{|k>DJj zl13XO3FeW0UhSz>+-`-BLgqJdD(xiOD8hS*W&cz5M74|o%QV~;DC(dH)>hKV=G@b@ zf0}_RM`t$4_o&aGvAGdo%PSuBaYaTgV@~_wlXc%CI7f)_9Rt8!QmSN0QpBWNOG!#8Au3J+dWut&Lh;_(#p(FF)=A-Vo;R>c7H z!2=Of&JvEAd$zn&^Da=Tk+SyEOujZa(V~*72MVvGD`4yJ)?|5~UFUA=bh$5*1%Rq= z8)42lP__*jzOgcNb>z`Kh!iTWR>f^FH$RD#_YlfIkRNV*H>&-Djk6s~{s$F}rfD;B z6aBy1YhO=#^I*x+L;gWE=z5};l|EF@i{n6L)ESvvL^w`yb&G`=gI61o;$snrdK;6m zdWE1oES`TAAW$X~i)^3jCMCS;GjV4p{jH2&P=duka>z_^zGO``+<$X~LX zufthQYC=m$P!k&xGsrJ}d{%kDEkX=`5Yq?$UA{yX{5peA0~*d@D(}i9PI%Rd(M&O} zW8V}8*7NTsD*<5m_gsOTpd7{U2~R+n5V$oBf(}(8V!*!o4T6%0Cw)k@{t9wWZ?_QWq<20v(D^t zF`Oipx)mYc&20zj4Qc_}at5F_d#2D-dTY@q_Oge!PDB6@FfFCIL#MZpG2WLoU=#ws zsf#4hRcVSof4RRO%?lzT8wD~@>B#cG)0h0Lr}`k$(vdQ zfzKqC1@mu5r{_BrTQc)bq}!$|Z|L8#aJcaUN`f5SUXbo(-*3QdELH86IUKv$wBk+g zQi#lecaSR)A}$r1kf?tZ9S^@nwkkWUI#{+Xxq#f@U>z0F%ab!)tR5%YEp#RLZXon0 z1!PpclEAboX8DK+(VD_(?bgr4krpeB7j&ke6)z~{g)IjTh20#tIFSUSASpFL!!TIs*abiTz!%Qhv>Lp&KUTJw-l7_sxPRi*#X1yf1ARQxo2` zxo*&(7;5upg>Gmw;|GTX0*@sRzwr+w%pm<_&He^k?`#I@C__>^Qg;tr5B^*q_HWv6 zb4BlSz}|#*(0zkrm$wY)T9FS44K41B>sx-W|h#>-65ke z7g6RXP~PN6=s9A121gdG0KU)V>$a3ZooRWCQU zTI{zj${q@{RMH_l0PE0m0JIugVO?T9KW%YX^Y})V>*8VAejzIH8?bmC^NOY%m*_)_ zvr%7_1vO&k7)F8srLTty>(QyB49`1l`)Edt$NYmh+S02m=kLZxyHcJFWT?=&wch`|o zp!TL3O&I**_m)jZ=5HKrbHu3WhY=gy@z8#Z-ejweG_TS!4;kC;zbMU6Jtg(%U{|*T zq|xp3I5z6Z0n8b)g9TeUH@$*FvrBwEvb!5t0|FSzs?zqA8hwnUC}gI4o~*~LRfiVo>R9 zAQOKRNve?oXQma7PdZn=POphGb52AG)K7#g*!3?>savBUzxy-}Mm(f(SrWF91}YG= ztNNwXX1|=Igyn1iOAaA-B1by{S=6n@2Fh?R`} zN0Mzn_TQxTU%(CrnIjz+^AMHFeN#&5taYC3h0@UK-^P(e0V6yxHMF zQBMfVx+?l#@)gsRziZ0M18wDkq~f~F6A8AK&@ie3+<)0qPCay($GpX%NZ=3sr-2_5 z#a!qtP``q;Vw6Hrv0L&4lVyThgGL0r9tMVGsW+b|MtUn<@3m^SJyz5*Hz%ecVu%~* zw)E5U-6nVyL4F}v_0~crf|i?fCr`3Wtapw1(D4!H5M&tGd|co%q3!!oGnfB{Xi9r+ zSCyHC#34o&WFl(yNQ6V4j4{~yi=@cgUcV9l=<)%wO@S$P5w||1-z6!>;EJlm^2M`g z2$W%?newaOn_EMzSPWt7YPW^dY@Gc+VVMeH7FX1=G1c2Dv)wXxU!9M?Gk^eRbFmiL zu@fN3_P*r*NB2l{D?pFAgL%e51#82=+-OlCrw1r@VPZ77bNB*b@hJW#AWJEHW`S7}Upa;OUtE{JQ z!!=jAV zP^yeT>q{cEGs0*>xH4}X1)6EWmFMEFt3PEM?q?j1IgSeQs)<7U=4r*c5!3YnyBF49 zn#woe#4Ny$)Ga5CHrwei)dE~2zac}q9v=M91JPDKZPmLc?C!#>_7fD8J3Z=vVWMR$ zdFwn^7x>44lCRr<`5d~s&{-c8PUFTtlFYi4RXGjb!8H?|yhO-_I?y%QN^T=K4mAsv z68|9H%9`UduB$Tvz2v2o+}wLP@TvCVt`M%C^Au|0%}}_q$dpX=|K4`Ruo#7KzNqu@%%KVNQhor=1dU?%uCEfCla}>zI%aZ$M#}t}B8$TeP7Y0ug&su4N$gEEqB&t&h=bYO4BKkC_ zgTG$ROXFv8eghrHE!e| z3hnA;9wNRiN{z9cGh7g4$#RbKv?!xr)5@4Rp~N)l90Nf(Lk?b)*R8wZ;Z7gwc7Ik*hVY!N`{7b3qe?tZz2)dSDjQ zr-&F%zVbSmit!KSb>)>?HC`?WGt2qjQQPIF3_kc%-H;ksvU*%r9!XNM2 z9fT@0DJCD3b4^ehbz$X1VP+`#-vj9cKV;e1?U~hBtp4+6)#K?J&Wgs~0_ul$QF;^g92nn?EBUqgJ6L?5 zQi_@g(v+r%fCOMh4cfFu-0p}(Yx}@1R8BzB6Q9Rat+s#?DG)gPbMYD=ZuvZvu*iCA zvZ^rlN;BSG^E^16M2$qiYl!vPmK-7N8xrHUB}*yqj?NhfxE4ryHt+ZK{)E-}0~Y|r zHp^d!$8v|B5u^I)ykklnewQ)oa4k^*gDCXifMykuVr|O4f7vl6{6So%&CPbq=-B{e z;!%SpaFT_RK+zPmaBbs$5&tyQetpey#O%Q|-vJe&?iv*gL-qlNi^=v|p= zEBeQnfs~%ogF?8}3nDnd(ld4Klc7lpW9zpqvbD#a!(3i5glX|8bGo;KH>>~3Y z_ZS`OzgA6y>M(JrfkdZA-86QWg0wvyy*8eGkJRdD+WAUCWkS|<`Thz=Xn8jTU@uLR z?{RANWvYgnG>573oHAYED4pgTJO!aOr-$zxu;j$X~G>;2gTj z!lFNNq2ePXSNBIvGRI`(} zEM7bP0DH?Dzr_Cb(<_4+*O_o1ED44UIsI86*8=iJYBVu(W7#w%o0eUM0_3BJrFG~K zl4h?SJ##5dcWfC4%BBcdkx_9EH15Uqaxl?e@idtrF>?f4XMb6upai|tr|0@%O6&+ZNSj8uFLxXuqztv7wYe-DsrO{ zlD`i0O+s(zgseHTY3hxq2B?qa$G@>$|GrMs5_2u0;Mxaahk_&?vbXa8KLGA8p8Ks&QboN8^Q*SAb zZjZ4P2*5ST;bu@?dfeUu)Rc2W`bjY<4*Rq#L6N?e-nNSsCk*Em!Tue84j2;!rtq$l8DuL_QJ=z`A!f!DTiEo-yDr}r9x}EZeVXacsN>Ba~u|=@6 zvatn+H|C(40bevH`Dl*O;en7BoqR!9$ndJqVNOzp^gQrqy1&!~Cxa+;mp8%OjMlTr z<i*ir9ef5aOCGBNqSHY{akzq$8Tse&Mf*`dR^S%OKL}4t1{NqH7~M2`!K!T zuJYNaJo<;xl9UX5)9+`|i8tI?oj4syYAtdf5#Q^XcrbF}ZWxD~j*8a^4mmDUbWYh0gTlT6B>x$O&ty zh0QkDibBo5<vl!3p7mJy)3o4aYAoi?FvEs_WGlN zr_~3Epcu{oE(bQ1I`s)PmUx&W9p*LClm^n62iB|3g%$b0;!${@Nc%jI0uSTIJeOYy zRj9URqVZ)xEee<5QApSV0HH)=Q--eT&Y3(509tWKmempp;T$gstK~)+7;wxsE|#0z z#VZcR&@q{~tYXj&m5MG)WLrL*TxTr~L;$y9;pC^lA!-+gS*YkpP}e)W#9mttO&fpK zn`d+CkkJwO3!yn0DW}CCd4y8{>Xr6}YXIPHi(RjWT-o+@Bcu941Ta$OJn(16vb#My zQ0{cYK^%_X;vT*`F9T9MS>?B=56bh^dUs>P3O+8i<7%;boG^!|N@|)iD<;f(V)`pZ zIRj*b>$U;C)GY_j8sF_pH*IO-1Y`KcI2bAgL5zRVGd*Q{JzF3)fp5O5AHG!`dkjYD zVB+CUQh+%+$I1EA))fIMvQpCCTAltsO zX!Rt<9Hz(W94z2Xftjkqh60l_Vlg?*keIpYoVWk=mmirsU@S`IT@s!poNSYIpG*-^ zF6$HSP!6?Qtnt{zOtnI@qLU#!lL-a961eP9Zm)M;r@W2!C`**i_e(Jnbr~C5AUcY1 zr+~jY)Nx2){y|5iIC@J%2{;yfVXGB0PA=M=Zx%DF}&o8HLUXlh<<9w3;->;J_Cf0>1 z;o(z6EmNiio#H@|@!cJizHORpL#$hyQbpyO{Itizf_%ddh72sun|^GhzdP8w|SrkGZUf?B^j@LEgI{_c&5glX+rqY9H%hCJFG7 z#`_r?=)wKj*ndpSADq16>xvy9`zha*o7giQugSX^7 zj(A{-|H3)UG_<)7|Ej2R(ZlBGkpyj4_c{BcP&8E8-gkpK054gAp%wsbo zz`A7^-rdeQTe)nxg+=YzGt%KchwZ}mg$#~m6eA{xPBs++rQc!M%gw!W6~S$vEz;Qp zFb{jA`HVgaigvp9M+Qz}X{BnT)1`0NkgNz*C114$0&+>a7<^$zX6(|oyn>K^014~| z+sA3M%Bv{XWz;5%q;dMaTt8wbMFZ#q-TV$bnVeVhl5rS731=w*^zowp4Vv-HZz9(U zIZ(V@0&-7&P1>C)1a+bC=xreb4@}dVR*%Y4qF?(lQw>K#qMUS#u1xBYW#ryYo;#KI zPd655CFL13PrWOM;~QpUAsGxv6uM71lbgn#l+8rLL|j59$lVHnJ2n3t)3<)leiW4Z zE#LDn2nEXUxFxFeH;$+m1nhBJuqjG!O>O33_hRr77K$Mp&Jda(^#XdI4$nx}4m20K zVkENed@d4to2^^BLT6u$Scac3O!gh;KnY#qPDr`te8WDJ8AAJr(>Qn{cHQ?^b-bB9 zw}u}RLvqn80NW-LSQyMN zl!DdDi)q_#x7zEn*YNvKSw*F6$;W_Far6lQVEwa}UZn9_v2Iq;}C81?!&tI~r|-b>{!?8hx0gHDNQ=WNC= zF>3|WpKV@KqsPAvFpk(L&E|OSN!SLbTOEOvn00t*Zh`>n3;S?jPV3z129&g*&4|ta z%(Feq+M2$NEb$7$fO$H5ea~KrC%_NzQ&Fc1?<6vgD2_8}xC71#e3O2nXuSzZ06vgC zkrxaRJ4WZ%Dtx3oc*1fa)iCsuayh%$n`7--bh7@Y?$_p7f0rXEG@(9KLNA>tf-RbX z`{`Jq{8Om);|q9Clp;?|ZR-TvnZJFF@}yH1?xBfM zp?$~|%bj=V9f~Z3eByhln`HaPhow$5eAJ{2P!yG6CfvIjBiFfi4`rUN>umwuHo})S z6k;Q=F31>YMT0`_d5F4*Ub;sj(q2pW`HS$C3es>I0d}s&wzm46N6L2n_NmHCQ}V3p z5CmVP7{LYMOkn+@!6+f=haoU<=pB+B4{<_qkq(iN1OsOleZ3B0)B`L!{lfFHD&5Ka z;(vf6NRzRz?nSLXL5`*}`F81JS9gPMt{>RH&IBL}OA)$14yjBR0fA0e2+{v2qJ095 zBmNp7$wEeX5gl4DfzOzH_!1Ln%6f1!X$DTpYgX7XX-KR7V})q%kaJ%b(o_YT!xr_l zaudJ-fMHK^eGeylv%)J&ZX8d{q0U%E!wT6%aEl}RhG*7&C{D~@A~Q23kVf0T-tWUn zhUb9?lW$)nP8azPuE5!3ifFXtSd#&S1?g3w=!=%Z)+fe!TzO8iz$|l*l)p-&7$eVn z4_X$kGRPoWRq#*$N~PDUlx|k#!EV7=ZcNBc6=kwQsVekefzn|qoy|aSN7+?zu9fZE zWrVN+YIK|;ziKd3BB>lFvf{!)8s#~{qYx@Ccqd(|^qUhM81YP;CaK#nlC>rv`%tIj$d58<=Ef7w2O%!_H9`7}kij}LID}8Dq)(kyajlXR&yFTw6_Nddoq3p0Z zNZ=dL3_=n&Hw7y{3zE85;&es2>V&3q$vqPj={}Q&{S@J$HlL9^WLuS9gYH z!i`-cL}F0X`-pkXHPg432-Bn6{+nwWJPdFU&-lCEtA8oS`kkGf>$~s_opoDmLvxae zWh-)B;d&U)E?^#qKnFlY)UAz>?+WY_!AIL*sg6xxZ;8t`8{i)w>+h(rj(8Y!F&;RgS@RcS zH@5n87=)#ZTAMe3Sn8d)8++gb5lbsF!-9C_FS>c)4W0P zRad_N_rZGnqD4a;9&80&y^=XI@IqW+)I*<835k%;6M67vjNABG#kKj8VI6qnTZXw0 zp;2^PiC9+^^b_uLmSxjGXZuJ<$hV)on&oOjosJZp65#HnMMObQ-5iKxZK9CMy)j(M zt~QQOu}{w;B3E$mzJ^owqu_!EhW{LH&V<4j2`Rq`#WfaW7aRPmxR%bv&BAqPvf(Eq z%0Z{xt9N#15|MBsH;_SnXxd9G7D7N98$}QL!p+zJP$NsDt(=xz~|PSiW@3 zos=<<_OQ3?*^7+5?SKM>y42*4`VJi(36U#TN?974x20 z+)RmM*NT5@=3x)KAd%(&>6o)L0i?R0*;`(vhd}G=wZ|OeRo!#95%5AxOwrNmIL<4Z z!r~LJbSFko^*S(c^AFrhpuV-jWyhf{$hsW{d3zuop@*_i3odv%4KC{{*R(P6jMCuvXrPnb1>^OGA(^>wmQwR4Z%YM~Zn8Ri=;uu^2bWAWaoBCA zkg2A$Oi_(8)0xt}0?KD#F3?`orCU(kNc#)fb*)kXfd(1m1;VX%et2&T)OLULEy6Yv zRLrw!)%qAQA=D#s6D5%zcrKVedBDxMjyEFxR|y(Kr0CA8S}DtUK3flF&T@Mb2i!}4 zo90q9GIP58caaRP=LS}-rQTS+gtV?4NQSsOp-N6)OzVVTPQ>Xps3$~#l}7Quy6`PF zM0BP5YAr&%-Ll(_>Exw`FBi;v1t4-#`ekbIAboWqY4mjLhDgGytCb~e4LkKJG%6;C zXMFrHs2Yf_eK?kjfVRHI`Hsxmjm`u=?V5aNUp9l$ytezoRqO6YA@SYxB#pc~Co3F; z9kv9{(#bTfu@ho%KQygOecT|$sBUWDU;iURS^?Zps0e3$CjYTh;)((d6E-xMq&mQG zsu6(GTxd?!swBTp&BXY6Xw4^(>Re}nM(`;0iShAH?K*MorEbmvN)`I2)ec;#S+Dlq3hR4O>cyGY-Nlm|LUw>Ai<#yVnA4ZQ6Cjq>uw2QnTDs1x=)%m3MG=n{i_ zRwJO?r)U!O|4kZMHI0@2D}bbAaLpQLj^AxBdI3>*>Qe_gY!;D$LU~%@PZ0qh`2oGW zAV`Z8FUYIALn2~gM?&Di8nNO1sz zZaU&F9S|0(J=3GxlB(A0un~Itex**rm)PkeLN9@ElOxT|Ha2uLpB^K>$zgW+uM&3!RvHW!PWG$@_FVJ6Whw(m*Y&b!Giv z1FwiWR`ui6c2Z#J1X7PKgp{mOU)LKh-js~ogmhXq`zt9>^Oy5iS!k-(muy6@>M|(O zQ#Lqi&gLKA$5ecaro0j>BU#SPmZa4OlFXX1h&f+4!grYD2z>f6z33`TK|O;J%Q3$> z*|mm&3oTC|_X*OBnR}P2rSA98vEib3=#6N)6%m9o?4KycD?30PY{FfAtRgg)d+Xa1 z-EC7bjdB4A>NIN|M%(rcc^vAcl>4^Y83Lk5G2MH9;omj$w(a`HUv>ZVt8=5vaBgy> z(fptArK&*8C}V3`wQ=^0ZQn|fB~nDhe2k0@wO&*DyDLGoSS*JVvqTtm}moo}8 zFE^v0^qzE$&*kR&`{nuV#2T44ODv)wPMtKFjX-L6;)1Aq7QINfR*8DPe-^yefr@me z{#ifVl0mr8yjDf}ws#a`gN`AYxThsydIA~4yk}_(u6B66Vq!K0q7gP$4IucA;hQaM zw4n6*qI^YV!L`Xgs~Y9b{|$?@+KrFG^%_CQ`kvu!*kg1OA!dgmP4NXvz8fQ=Jv$owtGcyl2wpdcCW2~s41s8hCe z_}979)GT%c({kbOF{gJ2A$%ics%d{DJKtTJVM$h$n$QE{9W23yyrUPO{ug#JG_05PCf(Wj7Cj(y%F2~#ZF zJB1I3NHy7L1+cuApB36dm#1HXZTC9o$l*w`b6E2kew+&5wE_!L&9!>%O!$aM3aA2xJ~_xA=>ewTCg-@`{SeAn1iTym{c}^D1Z@7Kyy^H?Tj<{g z*xyXpEa1JxM@>YOVi8wn%v4R$_Z|+B%Qk%p?f^{%QIDI^({A;rA#vjC_l+70j%KgK z^{y;5F#i^!Z9?0}jz3Rh$1NjbiuQ1l>vjM`1w4}Ohl`2~-J6`skCY_rX9pS_rnZC! zB?a=($74ys%1v94d7oSvByeCNzT6WB92&Gl*q$3()aAAs=&UTSxShgmQc`4`dZfO_ zt+)8D+7FzSKfTr9KDqI1cWj6f2E84eWq+VXa}@|tHe+GTjezcAPU_J>4IVTOfjDW_ zn_LcP?n{UHx$b(=SlN`d9H>N=DxJ8 zn@HHq^M$Mz#cT4@izV|{=62Fk1JTL5=LZkVokqGhdiv0nVBe_wuO7PEDWBY?Ht^yP zQG?QlGVy42L!4O+SK@?MOQQfx&>JZ~hg|W9A-`J4`zb{|f295849NR2*d;xID?m)I zcKQ02<&vd9uOTqNo6MbYpq(7XTmPCJf(Fz15Gxl0PsjL*KX1KU6|EzOuN^$OHbpVE z>FAy|YM&|_?Oi7adlJW^a;k1A*LC`H^l#YW`HT(Z{3w0F$L?2dCSNLTcw==1X~tjF zjdYgux zA_?ziNFczhn$~R!#eXw4(`a@3tE(?JpEo`Hy^T!Dg)0%aI{VsHrL^V?(J^=Yuk}5p z{9u6Wn>rrLY(Wq~1M$J1j9Q<3 z00Y#8kyumBwCJJ9@#T{6SdGdSZiXII(OGa_aQS&5s;pHj@ZCnAbG^fe=dX@0Qy#6j zy@wi5@1UvYI-lo1pdQ*i&`6r2zJRfR%H)uZX0{9Fgf)wmT<41I?6It9=Ygm%B-CJ= z|De{!G%x=|1Q7A8Qy7V+8jjzhj}hlwo3oYN+q%`;JvFH&F}Q4$j~}g>Qc4udd>Ygc zDy174mvi|zkpPPM)xqxHQkQ^%;)_c^wA9K;j~Cy@7cg5TWknmb>8B#qmOYy@csyU; zlgvJh!z>un)zuTa@0flJ%0Twg3rvKyPBMC?{?{F?IshesNZy@)I(S_Cy^o_^<{QT* zmF$wI>tvK~_4*#x9%`v~cRw$}9M=~WfxK~$%{cUNrs${$9-`dW z_j#w;|K3a66>woy^vI`=+=PR|%m+$x{BH2XrEnl(-cKBV?A60E`c17vP7|p|o8-c| z&3K~Ni4P{RZ|KMQCFN7R%K{8wFV9z?4f6Z!5O^wJZ)R3r#1_cr}N(f|r&3n^XLKn~PnQSk4%E2LVfk}h(@RoV% z?0yBeX$wYahRwxpQ0GDr5UlN5l|J<#lq>M1`_rJW#SCDs9B}R^u$gD|%iPqJB?zu^ z@}X+T-7W#)B3d__v3I+7swT=>?(r~|@ug|L>9!eD|7VTfS$l{WP~XyB%fhC^UvT#s z>9w0vIxc=r3Zd=Dy@O)NW4%W5P``xQi_ANcyJ}0rcFl+(`D3 zZfh_bHnadj`T0*LU$g_qaXY%$7J6fw(Sb^&J(|x&)8^4p?oLo~Hg~f|o{7Fhz&cF& zk^w>V-_TcDCapBeWgy<*g&{A@9_4;F>T84rXyC#CZ!zHmqXAinSgzP{DBjl>1-39k zpwK;OXG4~C*%7lDX%!SFwJGz&tWM_W+UD#G0BOF;NqN+~?}yaUCk}hL5GKa5Ji9TW(1Lav?Zj?`$~YK@0Y7;0?4Xo(NeHc}E^G$ORaN)54A={3j4M}bxA)VRaXYy#`(?Pw<(5%A|#Bu zthv);y1+HIb}xkw1P_{>DWzohAsG7v=LR2DoGt>5NxqwUN8U6(RtBSvQnW(8>B{`G z{cIeWrc3dL=}0%OTa$j=eMDo($b1WAQ>7Pq-($bo@f$(6#MnB>VrkzAHjz8cCz zuM8tq+#Y9ZM6p{OEvXb~XQZqTK-w^KD$`dD%~!OjI!GlzKndyKIvbz=dqo7}1HxU@ zvn#NYxk20rzU=w}aX=#hQ@*gewvlMQ=ibBD93$LsS?ORKPK0`!(2ONT76ZzV#Tv*$ z2AE3DB*_^4MvlvTQ!C(eUB>*wSwPrbfnQXoDkJ7hVBm4-fBpl}z+0DbinfTelw#d-pebxnhQqpBBeTtD z!vT#TczJ|82_m#Gr{HOUJsy_7CWb{P@`rk8t~_5v1LEn@pmx^)B$8Xcoko794@}XG z>}p(Fg>{D9-6VGVJo`{AKcx+(*cfPfP^l$J^9=aPqigP>MK#t3A$(+@8hM1`6Y%;I zZ&Wj>Sssz?T@aw3`g{(I;19gjnRAI`6_|193{|Z^aCFy+V0oBPc>hcO>LG!T1U;dqww1sPdr-uYyUzR*G@=st(J*PRRj zwiOG|vwEF{2`g$85@E{Q|L|RVVUl*hf|zKu5(O@hvCyj2xcsn|2HbVa*tn>iEuU6% zl4QDI_yXaqEc8#TS=odB{UR1_;2;yz@}scMicCo9K9h7B5wV!Bn_1P1HC)+<@7FI3 zp0~TRO%u|(96%mht#%EJnKLbrzj4!Gl%*o!at%N&$qR7VI0kf3FHryo5*^$SQ#)Fr zw@nx6o?cHHe1;sEdcUGk{ACrVw!TLmCE8)J|I^-&!!1~SU=JGwdn7&`IA}c2^3t&e ze*Q8N24NV;nmGs(SG-DUJUSv(3#;xMxg0UStfOPazkMu7kgs1m5A?HQ&vK%R58wH!UH@Z#d5E6GGYwq%4h83;12P?Z+ObxN zhOI6LO_pH@f^x@ZrEN?_t%U)cAx#_^UM-||K z5yQwz0;{L#cf3o+Ss-2(5d%ljWb@m$A7yH9;G1y6M6k8Zty$uzY#L#(JrvfECQ<}p z7;}r#Ywnu1<>&yq_<^lV#^+vdmN#3-l3$f!roJTy?t@Q`CKC8M)v3xnxQ~ns1~rsS zm@52JJzYyh;D&a!UGyZl>`IMW*A)ir6ZpLhj-dmkk=FUh#Py|zOwflN3E>ug8Rq;D zTyfgHD5ie??4h2-T5u|h-!lbgfmj4sn<$a2@#;&2X}SQX2D+ec7TxHL=@!cRem;F6UI{<6aoCdXKTjwLiWM#qC3bbGjCd1&^<==&$3g(qT%bffIJ1vOY5kFoqa~d z5b0-!wcRDEN!7X8)3^kpZ%AI~antHZJ1{O&;lQu)$i1`gl~t5xilaJX1gugwNS(R&sbutr9fsZB8_ zc8nW1f(qPYf>%e}=otNG*zMvncDN8m&}{(z{uscRN=;S7k0d4eIG;+?1|pFu95u{a zK%I*9-X-1%q=McE3Y}j!4c2X0H?#D31i79;gz^{bNK+Gv-3PNe_QA*wvYLER_ zK@CatNKA`18G_8NiHTF}L!5_Bv&pui=63RiDVh zf<}?sBSYcvs$r>}8@s7+u_CeiGD$<-6GcG1QlOJr`e1OQpR!NX3u&Ap zV3|r*p;!c>#wE|$_x|XQop&g{G^@UD4A+W%3D*h%{jWJ#ZOj#_%|eU^S*F!Xf8>W( zVKbGPj}ncCTbNM}cF}2lmjsWaLPQdlhIF8NF2FKr05CXPiI#+Aw7`Vp-+|s=(J|S% zkaO%XpJjzAv||)YetNbcIqA)WAlQ~X|w=EE+p2$?2+op!5$i-SYiPw75 zLWjwnhi$6&Aq&QR6VX}`S zNZmUdm!YydLj`XN$_Lias{?KD@XkGtfr9&*R9gQ((z1H%#t? z0$jgKS0(SM+QwR=v&TG`vAx3~iss435Cf?Cq1B8$Ybzf9dev9@h+8D_DpE0r!cvRl z5!z^R@tFpVTRob*TdLQ#=5beYyy(Ro%G*XYqHiXojClym_}s)jK%q1h9qfy)$-MFR zdP?P_NY**PQ_SNN*Iaiq*?O#OJmjWi3}a|xc@f%mis#uOsMdc;t)xI zDrkX478Q^%hlA-S)T9lA;dns=G_5HAUZ^IoP^<}=y&cH=UYv2DKZx3)nG!t4oEa$8 zlQ6rRSYc(G!}nKBHS3`5baZgtV9hRcxHgOO|8s|J#rCIhurGM!=V&7~pYaHR-7^I# zs_;p_Dj@4AcRZe~2l`Qj4jNfuGjd<97wM3^kHu&?#a>q2Sui}L7U2~#sDO}BK-WG~ zn6##=gCpdgp3b#(D2G*6PF7kbAO*N1KExq~5A?8Ok5D9@t?2wpA;j?l!J_t$PxNea zikiUIphE4Hu#5vy-VYr0uS6(H*qjL&;%Ucikm;p<7v)Ku!iVG=@M8$_(Ss?7`bBC< zm#S>nTg%4C$ko?X)DFnxI2bOVI9SRo5X7$_oO9NaZl|Rh8e#W!=?)cSaBixDr%KBo zm9L@GnrnzVWSuBFQc?8g!!9dqHjHZ;Y?@|jx27p61D2IP_A1X{4XPySlH(f?;kmGT zF|bC38*2}3)=^0|sro^wD7IZz`1k?P>EZg;1{x@wgEHOMS1|KVqfY9^T+0$d{kc1p zrc-0N@$K(#Q&}Mi7Go3@q|df~fJ#h>SGz+~-x#vznk9D&p=fun3DbdaBOc7viZWU} zX6G)Wt%4)DWKz&6EriC!m4(Tah#@5tA6#LKsLl9`g;5LbZH;UYdrP~evAl!JHI{K- z9ON$@)Sati@Wxi;E7?G2h_ko`G1{Tw+YCzd1qgk78!VlF)gsJC#F#*6IFvRf&=5XRhaja}0{KQ>^YAkxBPSj}AB|SbP1$2TFCY9(p=Q~u zqmUkT>ZJn}TS>*>@29f&ZCM*v86Ib8<3e!W)j`y=8>2PW{F3JA&F`{k%~SUKwgJ!$ zivIG~EoP_FD{yaM3lf_-1^XBt3q91~(MQLH#7i`F%_1+$e_h1%lK5(a8#0_Bx2om4 z-GG$sJ!Y%11Y(JxgREpN5~L@7Fwh9*LfSoCP0We}?q%!0kuP2Z!czb9j=$=-Zh9qe z)$70wEO*_aLi5CS<}LfvRL%Wy!#G(nv5xA6!N3$4Km^LZm7NPH1J>Io3M2oCs(cTx@)4$PxPqY=6{K zM&Ff*l+9el%^c$x@52=&)sBWL8|c$_$(_&7%L~$yA~i^G|Kq(_|9ww zfNskDwon2^Dy@ObE`5sWku0SiNTi^tEI!u8`=JjfT`0P6>g%7)E)!W1TiSEi>KMB; zcrdhY;SRurfkVMhpI7(=?=ID{sEi2RPxS7X|a^==>!-I`c zP?4A_sYPLlbVMkXPQ{pSco_Pe5yW^MGMuRGXfX2lQxTJ#Id^GQwqvHukpJ4I7Xq)1y)W9axQNw$eH^&RR+ zV1b6q-3haAAsNe!FNMA@c1>5B>}LbS^{>5Dx?7XZ1uB<%m~Uq|h6~HQ9+u{twHo zy5(T;ta?strWrYMY~4sAVMZt48on3dhi$EOhNK9KzNI_|!1YpG2fruzwaBsnNJ>-M@m0#l`YU z2Gb6Lft>+S{{5TyQwh%Jga$}y@IBZ(dX$}Umx=md}_TTn&hOs6~wgXFR3&}%F zz2)2TJcD0L)s}(t3@)2IV@iiWfC50FMpa<401#u)7z)lHsuB~dBp&x4{c`-dRunZw zP1uP=u>OydGFvQ`?p{7CiNiUtV1Tf9tN@6AIpv;OomO)2R&Z0_l;Q56|ggL#< zxjG`1RTDFSTjm*5UOTCxNFU3(NS?Xi!tp6e&?N^0ZkjNG3Y)1iWs4g;&r6H7V%;Pu zQda1)*pfC{3^uAwxj1@bovj>~XY3cwJQ-Se`Uw%edk4}hNbG@=H<$&#LZbh5c*u&D zxuB^j1RiD8ozjdE=vBJHKiYi{y43!cHc9Q_D~TWU)e$+^m3J<+Ad}FKe@&1KfG>_w zmjJ(|JrKpl^yjAcexVW#X1m%{fj)(|V>@xTqvjcDQz1-wp@6v!}# zVDDMA`{#mnF`}`mjDn3EfG%8_(NMRVIMK2AH4B-KnnV>H3`*=NJ*@BT|M?2U_*Uke zY+}hGzhYxeRx2{I_Z~{8DYejIzWwb9`%__t=D_6B906?iL&B9tb6%YQT#ym6o87Pu zlfEj9eu8_Y7}M|pUGaK`VrPch-#bG?upGh{EJV7-*knSwxuU*y72JLy-EBCC6gsly z;al3$p@^5*7@->x3jp}6pW50XUyh6QK_#q3lg3gKeetz za?kI|V$okXebvL_+4@h^Lj+FZelG-Yf6%DqKpsec+o*y1R^J5OY6V9gxbVOX>lO>b z-qoMJe#HRNYEU^EsxsdK0Iz`}iGvjK&)<`+L>*cj@5SbumywE|Ce_;1lLZE)j%wXn z`|&_^=98N>T+WApzDk}p6(_op{}Ld{Z#IYy+WN| zzWFe?`C#_z&h51ZobTuot$_Q)!c!z2faU#Glr_R5gq#N|H=$jFXd;2#GxM#TrsM%7 z3r~45B7EZg|Qrq{2VWrPCD!ExFi| zqg@9`NjMasEqDctNumI{-Z66fhqia!cZ*%)ylS+eF`!m<1eC*`55{P!(Jy0eTHVc$P2%j%4Dnj%4 zy+F@dRAvx=Jx|k98=?Q|&S~G_g6+W5ePUnd75aK2sik?35^fMNN9vyMT~5~TrWXeSGvC0ngH_TV_kPcWE(TGeFzZVFQ>3j)zXg}`R07V4#z}N9;Et#k$9S{> zcDXy%#r~DUl7qPu=BAZ?*14U!e1aeh^&35sN*4lapb6W%JW(2h@a9<6Eb@V@WvUD} zu_SPJiz6{0isP}Hq>Sdv+^dI%#XCbypcJ~a|9@|P+q^!IE~;l8{3lDdkD72Re1Wa` zaI~L;F79(xz`{NFUW73Lt{(W=()?w%Sq4uQwi#qFwGRfIcb}<%P=?yvqy<(O_#V+q z22W$JAHdtvuzI!~y-y1kg|Q$ge~Muk-ICwuxkxm2K|LVYqB|0Bgw-C2^?2rsmMq5< zCs@A7?lpdJm>JAySwoHtqbl1m4vu!IGhvnvdW@ZsJr{E=N%KkD7$D}#eD+oqRK(l|H9yDBdSe!BC2=r|BHDm446Q-n2xy@i7bgL+xm ziMi76v_wp3mZLd#PEho+MUM~V@T8eN-`y6KS6pt_TC-m(!N@OxO0tI$ zlf%O6NK6|>G|?rpJ?(@L*>WqZXj1WXXp_F;nJyl3@J&4|9Ys;AdI@A$ZlfR`FDL#w z*3(WB#YvPJWq?f0Z@;^47CDTjFtcw{4i1qP;>1@n+K}hZwf?&4e@6U+W4Q;JkVF`i zWHm+URSG#^B&MP!Nn7yjXVZ;mr(Zn3+H;#{#}x#vGF~rnNzoS5YkS`{VOwOW3O+sQ zzR7D&Xi14voBOPvS?{WEXHMre&GDLd&qSy5A@&<-?LsXk2i^UZ*_Ps3x9Q8D#n7d^ zPCl>^99@3Tzc{zBV=AR)g&74`%-Ck=wP#JG8m5~|Yjw8R zA2NbedkV?gUXFAPx(mx8&Jz%09bY~^2T=|!3>BC8ecsJpSLVBerI|T>1_nCrW75aV z4vHuql8v0i6o>DFJN;gMH@oZ@?V2>7xpub~`jmd0hAWKRp|e{ASu8_+IW54hNj;k< zT?vuRB0hZCB!k;Akb*%Ceo#UYOyyZ~l5n!r;;X)({0)NEw(%A0-gM>+f&=!SC0HQ} z(=51+nDk;clhkm~Cy>DNXqi_4|5E2$v?VwDoy#Be^FDgtT6P_RPE;~4y$4{?P)!m3 zPhrK7Z?nT_oDu{1mBDP90i7y*A80`}iVW^qw#qKG=9#7&xb%d0&e!hdm}7szs?>uRkm zHzZWsvB8l(qz8G?nE3{%H;+|1wrN4tuVk4axlk6KTg0N;p_u;=A&*&753bP~Ju!!c z{7A(8jfv}p)@*w3$$hAz8xqt#wCH0oCq8?Cm+E`Jo&gU+Bt0y6;g;InMmBS+ZYpD^ zyupG4CU9+}D2GeyPK%mq`Jq?(FwPwLHkH`;uw#BTgjPK0jOq?soqEL4idow{)tvY= z2sfKjy4f(s-2zI*JAJ}zkBW60zV|*C8%XIbgFpn2Uxo%-@IP9Grx=rDh3593M5da} zG$`VW>kxn999p^xYFWk0mBY;+UU##zh%V+rcy=ccs!wSO$^iWFF+E0~ZrVk)+#=CfYlLj>@`W(ma3;T0+t+}I3d)|@R97h7ZF2+6}eZYmCC>qkdy|c z3MNm!M-(X|Hr*5DJ^HAZDYXww`GKrG3d*Z@A3fY%(2pk7L57+t1q)ihbwi0gaNYmN z6jljj833kVq42Aq2tD%J{WQT|1O*NX{sSM=ho3X~X(`3P zWyTiR=HD>OEWGGEW*SYhUpUXTO3_F%h*mCpx*p37U?qrybb6ufw!u> z9EoX$Zrf0eZ+B%}y+lbVo?CANTLbrVdDlw8(R?7x0^3CoQ+WLSBk#tboDQCWEWPy1 zL?CQU8r|k|wB6+9C0F1Xk-c*|f1EGUsn8#-x}z!OG887SD=} zPH}nGgO!34S4FG_g>T4Yww;(iq8Cn@*f}9u#$4<_L+%Vv)@Wbg=+NYWfFd){ zrNC_1WOr&#CH(n0u^VoQEoi5W1ZOC^B-ISIVbxukOa%&V#OmuM<#kNM&tN~qUv~o+ z?zhZFRogtI=&7MkWzHEld2i&uEK+OS?_YCqdbnY6fN9Do#;LN7ZD^Oryrag#Z=n`S z4v{O5(9oGuG*bzf1hN%9Ky7*goF0M3q@`qURDL4$hcIH0R<7k5+WV~9$ho6Y+7aCZ z=qMUNRmn-&0FNPj1Vf4Ud73?R%Cm7u8#clHx>PTY)x`!66}uS9_}hyHykPLhiiP)@ z`>Xeb<<*0fHESujXA&mSsvLjP((<8%YZbd$i7ZpXYNd=Ru(w-(m#N-8C93S>rQOxi zAI!p$@d*6Zc?^z7j^skEv=<^9mP>62!(w&e4dWbf>gt1Oja zAZ;B8)F}E*bRN82O9(^}Sh9$|@!4a$Cdc!ZIL+#+cn}GMY z;So5*kcpD6JB`3$bFYYwlOhJ&LWOU6*{rC-C^q;BcGNw+?sWIRYwdsnr>J&n0=ZO` za)6vm6MGJbtM^Og{0I<5QLKG&p-hUMG9rDAFoD>Sc~;jpOnO?9Z9_;xxk6Qb*sV!# zrbh5HoALGA8J(N~+847Zi?S!Oud4u@{dy5cX%ZI0YvqDNba2uGHtnPMEzeM5okcGc z$KlT*_)_I4yG!GJ+k_3F!L(ZfyTL@0H5U%M;qJ@@|sG6hDlD_(hVF;0lwurSF#qd&t1}m_m8tUFonfUqcF}L`*-`b`eRi z8+zKy-Qm`j<>Mh!8u%Z!$S3QivH~R+j|W!*xn_Ld0IA3SLucqtcw-fl<437d*>0Q>$)7BwFX1>c9Zouj|XzcJ_7cp)Np&@Gj8cI#=t#E|dLP{rhF zU-9T3oTf;KFRiZ3yg$?!4Ka?7lJgui$`vXhrBvXsxh4U5N~>A3`dMhPF#Qx1wLu%d@!5aJG94!h@B)M8kBR+66rR(uX}8csMY`)_ z9w#|+DgGx9xF!5@rRW?MK0!IMu2$Cjn)VR<566)(jf06$cI8!teIOW~#&Ukz3V(6iA7Gqc74Qyz5kk`QbwOIl`Da>|_*$9F2C>mA zv|Q~^7a7id#!QR9*RMcos7Q5=dzOnuX*Ct7Y4TJcrsS%FqY~g@Qx>pVH*i!#2)~0x zq;Rw7RKVb7meLI+trR(|<=}Pj851_61hc9^H;ixe*0eDotz}O2|C*r%=74(8;iiqj z^G21SX8BTmRIxxFq9*-84|fjOV_U(A^;EAOJyg+fQmM~JY!oNo52ZZ43oO>Ud`J>B z2Za0DX3!9_``uw1iwNg|*Ud)JAJP4#R&A#Hk^MRE56@2n#jCwnT^A{_5j!f%D0e#? z_srUSEh-6_zd6TvpRi`a`kS@sZ|d_MpBfjCDyag0puqrG%F|=%TWc8l_nn$JX-7XUIsgb#?N)7D zh;fE~AZp}674k&X5qxA}$pyt=KzqUhtc|H>R~G#>%c`$-pnCQ_nm62r$aL6%vkLYb z63?p9NaK0|HmxbIHBFYk_VBm2QlR@Dg4CD%#aZuOn#L(x=6P=&aTX~aO-XCm1RSnj z*J_xG4UQ?`;NaZT03WR}1{|Ob*MZ+2xWW-oioC7L72~g3-d~8G#T{4%4e2UUZM$#H zwTV2Fxo|D}hSTaH!NTV-WjujKg5CoRQRvRMR8MPyu%HH9Y76(DvJ=nt@=*|aYq&&9 z2I(4uwk^V$HE+)yFXC*It&BQ>|FnJ(1Qn&N%2R8rr#BF*z03AcufCTW9;`B;xtICB zo>NY;FCGg9kc?|eYY7-rSrp-WafWhTN?}5^+ZN9WbS)y<;_lIFtg3uj>;F*-k=qjj zuD4AVDWon!f&Ai(@~E+1h>_bgh9@S>+lnamD&(ey2ovsSh|&a3`=*ZQBtAb^4&z3~y`J}zBlQUZH%O)bqn?{V z8|0vOIWTDD55dZ%>#?9ym}}^Q>mgQT*?M8S_KWn8GXADWB=NucM!9WWxBK|@qid1wpj{)_m=uH#bouX!Z8^S7#{A$W6rk^m6G&*!s%wyqgR0RSo@Fq6PW5NZP$w(`)St$)~} z)6J8#GMJ0cRnfvb=BC3qioLP%{Y+w`@H_Y_fU8$ST=(f;p2u=8bwg$1r(-xMjmGU* zkoC;aebyNn{;D*!sI864v`E8rjiOo1M?8bdOC#Wut!t>esOJTF)ErDNZ{~$ZpVNNp%7OGg%L{+c zEN3LZCd^@CsQeZ9MGd?ZfbHsr$A>cNmfE$A=#tcjQ^QAv-P@Al>Hbk11Mr6{9@8hq;;Zj zO6qnBDR1gedj$TV9#@pw=rMAm*b$urq6=HFQO8$goahS|JDZ7;QR}DHDpoF`!=Od2 zqslTh>0aewgwuhzBO8hWbskaJ4rt19Hvq-O<7zU4E~)YOmllP5`m^`sBS+F@-lF%^ zaFs39Ih-1LlwKl>sX<*UUEwQBk z-@5YM`sPz;EY`FLMD}2d94ehvz$0}A^w;39a>)Lp|HfL3j!%o2PI(b&4;I%4CKG=o zCWwJ_2JUa~i}?Xhjg8MYG7|>7QQeL~4Hgf5KV9@PGaE#vssyqFG5`0B8^L>rPd$lE zqNaVWS4Z48?JiijDqtECdHE^(*grM4LEc{6c`lm zuEa%-%fSgj6u#@zM)^;b-64SY?*9AzK79y77gi=Yi<{2175Dc+I~2<`C<{{Z1%aqJ z&duNN*f2k|+PD>;j%BH2M}+Usl;qR+8aJXyWu67V0^TQ=@JDC~+*25J1KAPmP_`CP zs2wsZ{OXaMgHFQ3sJFX#RW*{fwO$XIN#oQkvPgOr+a~4cu9Ojs&K0o@O^orm;{U?s6=_RW>&67Gw8owxmS#xmhEj$b zTt8*YR1b{^P2xn#H~L*$Gh950PZxULJiTACvW^v6tOaUed+bv$`~A}l~k#x;@XvxV;$xU z*CA^OtZ4?n&o+S7PV;Pxic8D4C!qP+<_x5_*B6rTmmE+Ub&YhM_Z!FJ+?Qt^*@G5m zfwSbaiqB;VQp{fvXfEtTa)OD#++KdDu?$P_G~#{+p*`b_SqvcqOXl*wn7-d)RK3lq zc@BhH{LTZ(UP$HktPo%b7wK$Hh!8Bv_n5Et3{9}2ypm0H612s-gPUP*P}0k21I}hN zTIG(er39;6HwUYcVYlh1ktBu-$VN*%qTOQ+Pl+Z8_RwdGoNA?u7Ufe)d172ngdmM`~j7y3r&2H28&i2O zw)8ItJIEqqUurzBfieAdA}o%`{lxPXByc{bungNKot=QRXSrLs%2vmpU~0e4kCmFJ zYZ+)WzL>=o`;2{opL2S6NpnySJ?S{|a$>aZ0!e@``3r96(NuH?n8x6p+fdnQ#A-*9 z^`JrLXS(ZdB(A?PaIcwVnUc~H#th?OF>DH-FHMV*kL6Ti(7?#dl9=6>{%z{_H# zM1pXd3;&pR(d54@!#yp7Txahpg0RaoPH#cc<#w8m;}($f7#I1NdSo)BFS}OvC5zx9szeHW)pO4UAjW<39!wZ{YM=L&kZymfQK>{Urfhq%&o*ee$g$K`~ zGIy*naa5dHax(-~Ib(?nD54Tu`xx))qt?-pU)mT0KzA-(ZZQ1KOzG}mY?|bgs{k*Q zHYP?^_#y|4DCi~Gpf2}g4{tCEt`aoTa0wJ>bi5ptOyZ{krw+**DI;3M#<@4XA~!d^ z*9zrvyHot)D_XZdpn$-nuPsYPj`wHyW4E9`8q2F2gQ;C+G_zBzb%*0X9l_B*9#Jqo ze7>LP1OE6GNVO*MNsf>-HoF7^Q@}8e{#xdY=9!gHDdHsK{uf0;NG{Nm%<4#1YHWn? zV5S1U=*B#Tc&~&m#z)3T}V?VA;8qfqJ;O( zyjM1I>I%>3;3%E9(_6e@O z&HbU)1M#4@^V+P6>F&J}>p%G#^5KE1JmdgC%NExWc-F~jNI@}IGOc&PHyeGw<;uly z_)n%*+N@mwHnI~GJf+fg^&?HAZ`_UW&%*-aG%50Iq1S@Iv)rfYlP-U4OVDOCPO)PW zn5W!y;`*i7t#Qsn%VnX^$~Ym+6E(gX; zk@fD6-~WeE#<2YQgJb{rPUo&T(f%tA{}zzZ+tBB9^aSBl5kAYy+RpuTv5nqhW(VK% z&aJY;@}O}d|7xttUi7j-Uso#BHhKn(9_id`Au$g?V9h6?oW{y}7vBU%*2kO#KAhN3 z{28q3DnF=#n!*C_@Ee}}To%yt-O4ABPKjxrn%2_%{{*lNs03k2NEy;XsL--!B64>K zG)n)kUq7xsbodYRWsfn8?Pj}NC7;n5%su5E~NiBXOb%?V5#3$fOJ3EJn2X}JmHd3S0N@O7^reh2<* zxOq<4BN{%yUUlaH}A z?cO$nm0bwkZ7rj`N$j~Y=k8*dMvBVBMi}THtg!sGeP&eCwwdBLqPQB8i1t<9&S~j= z6OvmXjA1Wk#Edc#{jPjD6LbOg+TFH9LsLfB6i@YU%6f8xoobv5forUGT#j^n4{K#t zbOpta0jC+?eiT#$V6!0)iiE(!LS{3=AKm;1f1lgxTMdX3WkkazD5;+SzhV#12^3uL(S24D<=th9`60ws=HdOxO6NWl2Zii+gr1{k| zl2}vgm>YfAl5x!urKJv3fN`$!7fd44b{)w{tE0*?eU{mM`_-KWIUD%~(YXyjfv&>a zAYfTtN_`8*cGMK(Jx3|E`~cQ1L~nDWGiYFRs|;`_MG52(S!e5(x12AC2UDAd1N`Pm zJasa~xrwOZLaTbGxLONfFC0u?uLmyy$9G5d-k49S5Yc`+O<1D~iu1l->`L9cD zH)>9OD9%bGIn;~t*rJALF+Y`S;t4Cy@{eANbATK?`*=#Wm-rZr>}O zp$?0?KXE8+TVG|0;%C(Ve}nbDTJ5)|Of(XOnj8x6LLi1!ZAFelO~WX%M=nwv*=&yT zHYg^H9QBS|C|7+r6#;dpR>syUNj4QjQ;5Mh-6VwLYA+st6;_|l^Gjis3- z(8i#`lVRM;>*x3b$!riLhB?HAb!d=$Gld^WD^olNtfT&P8{C)zO9Rv4jts$-Gpnjc zXE-~VKgsl1OkX<#Z{e^mU8po-!7ZL|fV|x4U@;?XISd3pr;7hy-D)g#L0O5#cG~JN!S(V|h5ZSX_A_aMz zOUqs}fM(X4I8R59x>BBJIpfC!wJ(=M^t+Q0@38vBE^&Op^*zyD=`XR{zuro)DcA_; zjX3G}{hK)8yGmHnj#Y1`>Y{ZOpS^H0;|Zu808_DqA2ey+XD_VOu-{2Q!0KsxQ+)=lDAlFXr=LzxbU3wo)4t8(g>pFQ8ixNqMFzs9}}7dmp#-@$z1>_5d>d$ zG$XTYet2c%kLti93)FHHb;nkZ6d&sy(mFYXBt!nrIIxiuA812AWL#9Gpt_5+r! zlK9)`SKoc?J`_$}P?YS@9*bA~A}dppME9u$w1rxgA=g#|#`oURr+AUC=QB>x5 zGodSkrUUJia2=lvWp~8MF6UQf9F)1OUU%`>3noHlFwhynH2+8!x+z>F9FS_1h2RF) zy>6g4(T^s6=D-HBBDlmI|Azi%E;V)5`X#ICA|g+6JY_Uei7c zEnfv+oKQKMW;bol1)EIbppv#V+t>O->NR-m1qVF3@Iy6bi4#l8+=A^jz#J0Tz}+@j zklYio5#&dIT)fb6NQj!#q(w3P<8P9iRpC_`{vhZpd5s)=4m8T`6hdZ~<_VbTthh&Q z;1!^)ZA6Ca?CBrMJGbuP(+sV!9sSO7w2BP!k^J#8D(bc@KIPtZtna}C5*$mN4TBGz zfi)5C#j&D+J4)z_`WfJ_`7nwG-oTVlmKfk#acGsh9wvZS+H+&^x=1-T==fxErd~wV zpnT`K<}n+uK0YVUFlW7;`2%8`E&D~Z{@vV*?h^fba1f>@F;H{HltxH>U4rS+vQ&2UJ%gRpOV=m z?$kECL5*@;DY6ZZ)ru;2*)2K>ne1aTn9AoC9GPBXaDFrQ%mmt+I|!iYQI&)R1JJJkGM)!&Zz&0R?>|GHCjUy#4QAi%P{Lo!N5AX?p|t?p zTH!sj|IZ-=sZL64qdwOemhL!V1H-93i^_8778yg-R|{-g89SzxFm4z>TkZCREg zrl)rX#dLoG3U1CC>88kSxalOca5Q2eDw2=T1mR3>xCYm`0OO%oj6{-fc?S|cw* z{f`=RsM!uN%}0aXyRVmqXb zW?svC;{{JNlOTAzC|$+;y_Fmp7FW*wQ6rf9rot+5T(wvptzP;GFKqN} z;+x?pfpdTE9kS%Q= z4{w2D8wu*A72@ zLlRuFTzOHCn{D7+9iAeXi=21s_t<>6T8Ta=J@{UjHG3JLCY{}Lc?KS$;m~ZW@VRYT zRC=x9K#%>^X3}2Iw=IlL$#!j|g07*Fs?jFn;pq7YL9hk^t|-ESPT6u(IG;ECqf0&( zEXQiE6lE#=WzL}MX)~&^F%%&bG-v#1{b>qV_Qa@NhCxtIR&EY=}XSv3fNz}Qc}t_ zONegt70b6R{H!wpRm^qS2aWkt;uy$(BVlA`ctV5)1aPT`jn%$KHmp=b9TqmMfH?d$ zB5YvQpQsTh5>5?!G80l+8A_Amb>!!_mztODKpt!Kbj%}5e>ULDRUu$QNLmU>p*T~; zG${tr)(j;5wC1Z=_7l{LesJF*wa8BgP@ZETO(#~NIEouSHbA}XxOsJ1b0hw)zSm>F z$Rs-No|vWw*shFCy~D-c4#P uM$aT>{Xkq7LMy{7XDEg>qHTq_LWLyjkm^qQpD zxCVicHJ}hDE)4yOf@d}RlC5!f#KqT$Ez%$`CF~*xVYwQGriguMo9$7yo|4>zlLRKC zcGOxwX1YsjJmj@sS9ne22D%YJ=s&&52pcsWa~RU_wY2aTuQi%#*Qram$$xr!Vk$7!!SGGMSJO(ac&bm15cwl&^#>)NH=rwdo^iav!U3*Zq!c@S(S z*1?jJJj#n}(4?otNEvboyO9tqybpy{DH_|r#)(V(r)%L5n?$LG|Cn}3@pDZroeAFz zs=5Tb;=OhPdp|8MWJnie7{9gjXmF@jY2^IV;R~RwNQ|1p3DB|w=9Y^Y4mE64Y~0nn z2Le&y$o=*92WhY_f>bVeAs_!8bBaY++vmF0auQ>xc9UjQB%$ztZ&nhi}5AWimBt_sx4cS+P&q>V^WoVLfYzh+l%v7)+^&4AbX29B%n+Nk|j{33# zC9k3^GI3mWVWhBU%SR;UG^&0*O5Kxc*LTfm%Jn%Cf&kUJR$5 z^X<%lTaVSTYsYoUoMiximmg!{t!vwvT9y9+FIni{uqltyA>gKMY;L6d4~hT z^w1?v^_1LGXrPL-lEX^7H(Ml!IkIQ0TlY`pEdh$=OaIHTuPwZk5AGBJ{}oHl8g^#u za#jj(1kabsrBJUk3f!b)PqH}-uICHg;(<;3;oqG9FbvPBzbW4JufY|Egj=b9AeycD%MOoF?#jn_4AWZlo%BU3Fl>o$6J`->t^P1Y`)c z>!<_n?S?abZ3M>-r)?0hUtZ+S?6i{Zzcv%5e&Y;BWS;>$ch+o##X3CUONzOuf0d{7 zT8%z`4P?^3s;FgW03o+2#T;8@Y6!IQATU4nVNID2Et@iAGz8%Vsg`+udUyF7$&m&? zqlkrIEo(rZj~IFr&37~g-ajIpFLm^<)?^utr3iFr-_H09922u*bx-Y1SS2(1SNzjh zHX7b0ZNFY!y?n~yLU9wOmExd{fMxF zacz+2uVM29f*^%AAcKBrI~XO(I8W4!TkVC~;_zXmpg?a7a=BAfuVKZ8Q2B}@XfIC4 zBrMkMlvsH7xM!*2T8Tq1BFHsgoy(z$HPvp#$iKWKbY~gTMEzlV%kRU6?2qzbw4A+j9&GL~0q8 z4i05PhsHR|*a>4C3g#(bc)Lcx1RBk4epiUju9D29Bupm7?*J+TYV*m|dt$uOCm=D; z?7rxcOy=t_RV?pN$L{xh75kYm`SNIqop=9W+~~<%1Ey&^0NS(mGUqzAzkv!&ILM1` ziW><4KJNC4PO&ww#L^htNmKmq?_zb#`KDn-A;-y%@L>te2Q#$VO`hc+X=jgP7SA{% zuTWSK`%+*VPim=|q^wC73{QZbo)3%4IZ90t6SftPl%Nk!sgROr#5CTTE+VTOfdjn% z&!~CHq5M^*Dm@CqALRn5zBOZHCjncMWdNF>brb^Ly_^swHBy3?Nd@dWHlugO*(&u5 zsdCCcqK(m62Aq`HWMYq_)rFGO;3FPKGCw*Jbo3Lb+zmFSq7w-qQZp0jg&Er0V+Ypp zwgHpM1v+?O#yt4`BgRWsDXcYGuahy!($htOYMd+iz0NY%(%>JITJ?e_!kGJukX&Yn zgxeLD))qr*nnKm$8&~XN)6QCW?YjMg2d<|1zE8Vt(OT0k&8=5yg38mGpNzyuaFPQJ zAtCG{42Tw5$a4`b!2#brBmcxB6SFi67^hq!u@8Zx>oAY0OD8D@UwHcNWO*-YVEQZK zCa6(-qkhP%BB=CD5@&_SWl;*nRH`oQ)59aQ^uUQT60B@4qQ#IMgfmO}!aLs2M8!gA zBF5M7UL_@O>piWC#~c>dkWFAL)Q?yPa0I0shj$F59|q(58H4LOxvHtzKnNVD-*fi= zyUUP)f+9qKt1v@{I^}~>|J*5Rby$3r9i3bUQ2vA10oJ$PCO%oxedYd0liNga)!}(f z&5(ROt4JMRM|4MsGnRNlHy<<{z9QsyAs=;BIh_b45EJv3Iv6}W2(LI}lWKCJF`&C| z2@}v0_e6kCGG3Gi?qnDG=$AO_T(9`KoMdY<84Wbr4k$ivAdfFV7Ax|9ME7KC0-;iW zl)~6jdLff>GC3NQy-0hArDx|VEQS#$!i~g9VFbOeeh$DC)-(}_?9oWt(cT`|fQxC9 zh(_YCAnDeYQQR=#*C_!0V+oz?>WBPpdfoQ;gffFWHn5bCD%6U!?YC>^0}X*Req zMUksR7Q^wV2i*W9g7_2#o2uWmtbwRK{nG|ex_Bm=}b0TzT3gjgI;j1UTrsJqQrvQy^pau|0IT2Rfwi?JCKch$kUc>o7`xF z;jFIbGl}$E+4;Va54}r`DA1lfjlX?$1-n72T{`c(Zm`%wks6D7LL2DlPQO-ckv0Jn z-Q&%Eh*#u(vvc^Q1(u`kGFVvGEfhh^p_$occJUnZDoI(g(pc{QUCM7%b|Vmf!YP&% z{ncoC&dnSUvXR;(gKwMD^yFA=sunb9?EAWIqUVq7@5OmNIVq=03xNjk;4q=B-?R92eVE^LL%+3szt9f5z0vGWorz^funP z7$x9^1>HnuN7{6;A=3od$AzN64<|H=9rRiq{>n9RD=(=w2nte-=9#t_!mLe7>)QSjkAVWvC69 zo7oGCDUU)p)L63;XgOHrFyd5qS*139XaOV*9ep;wYUdS(V|~y+IcsOv`EcNXbs>GW zV3&>-a7kPEtX4%b+LP?i7>F_$oC-x5%epm^gvDL2Z z(FJkP4SujJe9=ye*Yqk;w>q4Z4u&A+m%i8mK(GOB zsgxA)Wcs%Rm|HUWntskacP8$<=q&jDzp;1Dqmp{v`4`aDDLI4oHL00_y3c9j=tA%gR>-(Bv!E|a%9UxC%Q?@4-<LDO< z&>X`Vx)U~WOw-f#$xQ(OPpaXpl6gLEtct;#enCkMIf~mQtVC{So&WmZHm-#M8gEh< zCWXpO6=y9|CeKMua-he(Itof+ORJuN1Ky1-NK8-a-2pll`%b=3^RQctYQS&h5f(x? z%d?>bOMNiUeqWUAY};2{9AJ3TWHH3e@Nu`P4nps0x*Uwein^>fYo6{MH4`QKoM=hp zS^s1{_TRwl{(Z319DLQ&LAcEMrYozfke5!Gw+dv4EYwN9wzb$W~77-{A543#A-jSFgdSdQ@Cw z-CmTCzHY`Uq?0^VEAW_Lgx+}1wb%?u*hGD>V|EdCQ~iS4Yags4X=@fJo33)}mXkgY z6_w#&!tDYdeDcOT%-y4kAu=lj4sXr^v{nvn`bXr=ek~B?x-==2&iH#`cE1cQX~6;8 zJ@!FA@P!J8$P*%`-aO;uWy!W0#(?a&HWUI0UbJrD7894FOe)R@EG^XoeMTZ)i^2 zi>zkgkRNh#h^q$nomLHuOKGYB%{hUs{4I5iOP+{MPU?}2jE)sGY&sA`DW%sU*D)Sp z62@|e6k&-T^OuYV3w*j%&i#yUju&JN&R60SiQEZJiM>}C*V;JJ3wpP!{Ww1UIxt_YwzRs zx2Oje;~uA6_!*0~y8cD%QU*PrWo=W^id4RV&GYG=-$%t7@Y##e$5^z0_4Fy#?Vdt; z$=sn^&56X^tW=z3<7o`rYekvCMVlQCLc zERp3@w}Q{wk>NFH%NO*681=xMH7I)xIeaa!w-{W~OJPDy1aUM05vjq|H78R|4Oq^( zoY+mO)oLP9@)pL3tr?WqK|>nWUY}T8-{k=IH7Quk;%o1`5#jpl%&Ms1mqDT>%y?h* z*QA;h0am3Fqr>M0l6JNl@3d;sz6+;K@!L6B%aL=@U()Q*L)mXIiDkQzHPBbRbXOeY zcq@y!e!3Nefb%72Ie}_K6gs_c+2}`@RbsItOF7Zi>w5{B_zb9^X&YBY+oLX?zPmUC zA0+u51nJ__mS32^7S8Q(qU>i6{zUJD+AZ0aEIsqKalLia-jd~QHI*s=9P z(P_@GDVu7(P2CNH`a~VI4l{IRI@yNppy)gfsKAn?+!!qk-$hOJ5+39*VuZ)-MoIo) z58l1g6A!p+c)wi@(l6Omx>3g(req8iEe6*<8v)A7)WzHn>nX_n65zY6@k0R5iCz`Q z=>HbQ7a(j&^E=n`5iJpD?!@q~35&8lF}EwckzRP@q%)C`0$y+5ZN3aV;1C_R&D*+) zR}nnMzwVuMtdl9<+B)b59BLXBgUi;RxiY$|cnmYj_@kh@(#x%rMFE&a;ssjqy;B6gnAr!6sc3g(mFH%~;`oyA zYmm6Vhmw^W8~kRq!JfQA&nrkEF^Mq&)ouPjDJogqrzI$r<`^;Q7we@oW2*U9uqp)G z`*1{YE&NriB`ZhahcNNa(3rGLfjRy2r&$>dr!Vw}7)U<@grwW_V?fRxW)G>R(8Iz? z8yf|wz^B7z+eg`Uju>2#e9SCq<17@LW#bRWUDBd-6?O?U1W7v*4J31-#gQ3N?5bJ4 zU%6=h;()3Ok{Ivaci+H~W$;y9^h7^_LcB=7R;6q)`ELPTR+MCI3y`6*6`TF6`(A8g zU7c`Dgyy@@2d@QNM7DMvLI6t$X{X2<&85<8v=WoHN$XWRqd`wRJ zTgu^WnSk1_X3hI-sJ_ofSv>B%3!YIYk(v(w?7{RLV5+vp9Xl^IQo19}7_RLG7sVw< zY0?xOt3k=i-v(|ULT)0TxTT}l8#l+CF5(+woX`-oagwqpg@9TYZ>csru=%Ww89m(= z8bosf5&B4g(I`S*@^JzLfZ=?ld{oEF)^l^)Hbx!NlGiYR#YPSdK(^Rv>epa5*6(Ct zH}T>o3b3!{b{%b$75nsf2%kgdhsk)c(m(y|GJiY3ji7od66Kh2@!nxFEG@eH9O_KV zDsOZx9MhMB0d}TQ?RQ&~NbP?c^kS>;0MIx5M|rb%$sU49vlNG3!a9GcIA@=eZ}|%h zTW=zGoiA<`M0IEr8u3XSc)Nk-j=eV7L;l)eVNA2lKpHW#zqK0iIQ5{4>nxuiHR#~9 zv^O`x?$K~Jhe%fPh`@nZKf--}Kp1uGhIKZwp6V8gSv&SslxQyz3^6w1KcPv^I&0A z@OCl&s3huqqV!jA#IwtHlxt z4qa!hxOHJ^JXF~o_TIP-v0N?P5K%T5RMK`O@L%SPhJe+N!z=CMOeko7iZ}|DI9+98 zjbX!!pf;g1Fo@C$kY>I50{Q?D4mDc5DS1FG0*VvKmMJZWdB~C@;m=;S84C|VUXq9z zo;LK5m93eL;SrbMFpUa)3f}hDZf8eJbn~u%2-Q7SY(2M2EDd-$Lal$n_+|Tl$oNcc zjFqQI{v#b0flj;sAPP~x!EqLG&;)%cm$ty^es#hOrIJ@{Ie@+6^aXvTdfc`c(5^pT z2;|E7=2y$p7&oo2LTVqnJo+!ymyIEW-pa~GvKgr4Rq`YXbh?%0ym`CPKe=d9=F?OR zu6)MOUF)=pabg};(#S4_c$KcPaT-Nu$7axVl4SA4I@uctgvq!zxh?A5nAPSa*CKN6 z%z-nwB>WGB4kZ_bMW=NXpmkb?<5x-YT~?Hi7s_=f2?$yJP#$y+37YSDKoG5K%vKnu z(91}J^V3ap{lypS@iYme){9U5{eF3{=-o(L2eI@QoAhk^oDi~RZ zmp_%#wp}ED73k}yu~?P4zd z*;0WlF20Qw2@(Q*4|#3_xVUO=s{!n;QTJtu(fD8)2-2IoHXnu2DTYB(HD0;qf8SSl zgGZ%Ci(>_6$Y#~n9~BChuqMxgyM+Y48B*bO8whVW(P3Dak0($-58Gy1^03 zz`4Gwr<6amHgzT)CjE_}1HymsOxqjBK8KVR>ouQ$L4ej^01|N()x*YR4UoM2>UYDt z0=JkaC(1UF=c1C7jp%6K4+6;94@Nutsb~q*$NzXNIXq4O?P2g)^TXczF)3S+Mg!x! z;v&;A)>kq8uf<$sX2=u8f=34#^#202;nr}{ajonzD?qP!#f1>9ve3>e zO;c#COfj7F0+4c9ON3%Q+?!TDTWy*xqC)V?b+7B!RDsD{{YldqCIw>DU;3J?*TCbn zn5UVS3EBlp33W>EhtEsb%=0jsRMn%pJv+bcOqy&oW#PqMparl1zw&i1dOJ_GkE{+3 z{Ae&KjEam@MGA~#mk#T}?7ac9*)I1k<{@1OGNqUwp6OIb;7&fx#tVJ2>D|Te79K8y z-5~=VOLbTG%pqoIJ1a+&XTAQ#2NW@btGgL$EJ%~phL~@O>FIQguS=w71L%l$Q{OB} zY^20|bOWrf7>8Rz?(OBj+UHQI>Z_P&#O5xOL8(=_PNAZ?AD1Wy1V>R7Z z$3{!*=MSZ4?g@IdfrjB8@{37Y@v-*V9Tx;i@*~xT${6l(CX=t&7bS`~%QC)N_I3fM zdfbHh=>0`q-AIz@~rJ`i+1-Qk{ zI>exEqLf`GZlf%POwsnIir8G89uIS?4)>!K{&-2ZC_RJGH*$m+Jc9} z0QdjijY2gRhIJ_eKk|R;qq}J6S9^~aaQual;1Y9!HRf?S64-Tv`DW(XW*w1j?FXhUZRF%9ikjPE(i3N=v+tyBgJT*>nxV#Tv5+M=$(7E6 zO;kb-i{%8i0(Kh)nLFrw`DkQ7wE_Wr1QG;)#V*y++ljaKK4{YPj|66`<4gk51b&jF zt-_@3=QL-`hFB0BFxBA|+glpX3w?L+X`%b|;v#T(Io<`Ve&c9b7_09{$qOd5(SYIz z!zx@07{zC+2#(?;Z!wZyGm_yFFM3EY4SPVdw8Ki;?Qp}Slr-uo3Z1uJt4ywO?*~mw zX{M--Raf&tpGj7I)>ZEkJYU;H^00m~2tr(ond$iK`u-3AxV|Z9v-x3jfKUpEb= zP@H+ta~qjnK?qXpvW(&A?~=*-Kw3s0EeJ{XsD0KQ3F^i4o_C5CfWev`3P@Rl$DkOW zjO!wEhM5RXX}+Q*$8qDBa~8j_`#B-nN7cg=L=^^SaaRD*J#NarY~yRl9>5+~Xpm`q zRoV9MHo~)m2Bq>xOrTUH5yII|>EdB<&Zd;hX;KnQej!6-mAoOmo4EP z>k+yMTe+w=eAWt?jF=Q71Kg>7BI6)W=6z~LnzGMiQ=*`DHB2;zhPV5eI6-Ja1#}5AJ_fmS0LLGf162{H><+Ndt z1aHo6U-t;@0v_;_#zM~T!7nR^z!XxQ%bM(|ZXyWMXyiw-jsa7j zYXV7R(NTjV19r?m6tKMhMVMBR$`SGLL#QohY3l17>P#Qx@byDVA&+YBv-!;5e17lj z0G-}8fK_ll>DDX=WN3yFQs;x2In>l*RWd2d5;eCt;pP)hIjLlactikt{lN2pKiusY z!nuOwnzz)>!;HwI#Ig|(ISv*wU@g%M6iebpg*R?Togc=}heY_X0wiYA^FG?}5`QHC zeA7i#mmBCRrttpx-?u5boM53^cSbd-anP{yA{;<2pZ@i_X`Nv+$o z?YVsLJ7s?M6Mg+lEznWXbV5@BYS2logtbsqMs>RYm`HQ>i~{{{+Tkb8rF9j40X{@N zqnthgk#aV4BZy)q_c+gOO+IsTYwSI#?F^l%BA^U(Ge<~stEird(ml;wtU_Hj3!l3U zrIg37@LmvUvK9F& z>G=?#qewo40>r=p+(hE#0=1iJKe;LC5#T$jVbS=Y6r`+rS?~n*(Cd3Mzgl8CP`v~2 zs*JD?F&!q%%P?i+vG0_x3#55k0?j(^>eCE4wxE0C&yiTqq`l&z^dOYu^;t>bWWO>Se^6{V^p%Ht!pq-W3?m zm7gMn&)1}6JwQ|9E)M*_v=!1>G`weeN?=|B3XdWSGByxt&fNy zV_9QzZ+u~LRH`u2f2H7W*j1fwu`t3z7JsiMuV9e+Gysi^jMrh;tb6FZ4TYPSX{;My zDZ?S)+vg(na}0M)Xq@+>xLlwa=zY%0#xdgCaTr4LN!FI1Mq{8V@KnGG;MRQRQOA_r zMrbEeJvqc%E@c;(b3CRp{MjF&WqMa+sQKH>{e@$4+f_ZVyQo*wBQbOtRYmhdio{T@ z02^V*e=!QI)q&$L#fBo72S%D@ae@_vw^D-NXPF(XBa%YsyN9LVtf4z1hX_Cmn$u4%FiJ8G0AH$KYbQ!BVh>u)j$~^ptd2L|E}{tiWN& z3C$H7?aFZ!E;G7xelij?;!(yV3VAz8%>^_|K(Dod^OpmNG0yjZ98M%p$c>%_??aZX z8NlpJIm6y}5n#a~@7Snlukl!m;+^*bwoa$Z5Shrwj~BlEa=jT8`q8wZ-Za+q0jkT1 zAJ6zV-h$2wRQR;0{E@!RBKIEaTj+_ddevK6+4V%{UB%EQPf%EI5p_ceX;rXh84q`9 z5!xd2_G^TDisM&FeU2`q$B!kCXt9Fo#s039sQ6`bSUNCJ6yHBE1AS|@rr6Gad*1LI z94Q<01nQLONpX9rCu1i;rU2-XSUmu*&6i{k(YD#@?)#x9@WjSdo%5sLH2Ob@P@7MO zrxv&bb#@etUfOd~X+#n0McQNb3CtWDob)dly^S|{^O;E+H7)66K94ipF6uGk2SX8V zNw*=p8*(Gh;NX*Oe!e!`DLgv`HyFPk#!Zx2(pmh)02hv2eu`> zCg|1JqV3r?^k)`5Y6(iU8lfZj0&lF0zvJdyckhw{h`(8-c#FzfU0a@HX}8j@C#2Ki z#rG83y-Yge$FrAXPYA>YixmWWUgPpXMl~;?8No>mSM_vCi@iu{^q-iWT z2r$`X-Ik;B$PXEV3DV$?G`YbO+tm7ri8vzV!2@upWzbJN5K?EgE=4!*69ykgbN~_T zZ7?bV+gX_pO^Wk9tAyi3%m*m~Rhx{^UF8Xo#++(2f_oQ)dD!mjp%*^I`PP63J}}jm zg_;*>T7B>~rjL5LyzmG`wd%AwF%1sTe(q=}-F}^3n6Ui`vsC_Ymuv_sxjTn%tMN?k z$RI6wf-N|r%9e2^0CQG^&m-Y0QGjPQeDR~t_df*2aJi=$Gb#7ySS`AEW9QJ+1GFs#aW~qPxj%B|B*_ygdrkO zw15}nO7Iuu;=OI`aCpcMOIeu}0MhE#IpuT|xu>WavTH%#&IV`7KP{w=e*9OP1{vzy zdPBb!&`yYgvVJ@!-o+$`){2l%Jo;BR%%#gZYY|NCm!U2mVVLtP?LpCK=HH>}2WiZ+ ztuZlGb0P{86`^|~qqtXX1GWiU$qF#eMax`f#>h1*?Q1_zI<`U6pcsk|sneI!@3tXy zD0Z7S`&x2V90Cebi}=4a)XZ1UIzojuSMCra(vNn8LtyO-o4hmHifoc{Zw_}R{i*rw zb%OKph>B)Q&e$Y<>A(y*hjgsp>A+F2o{X!TarJlEc1t?HIfUtz6afw6PIq)97Xu^X zJJLAUQ|7r2F2ToHKYs@7QHyY1QGOVemxSUC-vA29mT+Z1nD19gUKK(v z|Fg+9X|4_N!n3p^GY34UXUADpFn-YQk@4)5N|_6whUPm{1_-wXIVOgF2 zV%j!iAXnc=>ys#B7_d12GaZ6QY(hh$VJOUZKzdlM7Myya+PHU5N|&YeY{Z_Vb*C^q zB%tTu74B%yQjdG7B!z0ehb~*~np+PU^e7~(0H=PxceUB?5aw3t!l>3<^OoOrQO%Ee z{UE7N80d1sBK~nzWVwJc_P`$VAUE_gV3Lx@AH)3b#4imJ3~tiVLTg3q4vSQPl8Zvf?8uJ8fv2wj< zM;1eTdHeI5oE|^^(XLp@5tt#y$2-}x8<+#^tdIoPwW^v6gCd`LbskLxmeD*;WNkN!+(g50k zlLxhS0(~wTYcKB{ar(NSDz9pOtZ}6zh}kYi2U3Z?({Mu`9^~Fav@bFMy#hyiKBZ>7 zN_|GS-3T*_f&PQNBeH?UkOacFkX35OdJBWL@urKX1VH+!1;F@+beK;iReJ2M>5!eu z8JT$WYPSEwLYdfTa&&-6=w!rFL&QV*&|mcBxMtDQ5Azi7%)9OTt929-w;8iCFp(t~ zzRNt8`L#2oIQ&+0DiwR|lW;q)8DQe}DANd?wbyizT?zt7NrYI_+cL|)dYr3Bmm5!d?9gjI4KQ89Ndhd4e4kp_R8UI3U~W{MZVBsnqB1RoNUCY%mZJd|4tIGY1ETfH1l)tbndQ{ z(I-cs#DAMspFQvPoqS$=j&1Pak29RWDU8EMR7^~=m9$^=aqAnVavK9F=br`2-so#Z z#mq{MP@TkBxKhInwnSDl3{Ad@^1%SNDyA}U^=qL{Gtnz+UsZZEG$*G;nqUx|M3*0> zFrb?k?9kRW(Vt4Be@ZD!7ZXIS*|*2`d_w;I8S=n@@KD(VURz!x6a*29v1_7I$aK?j z&O@NxWBqS(dUEfir1dK0j|;Zk?(-}@$JVE*63wlHI3v$;>%tEWGi#hT=5Y)lX+->_ z2f0DXOQ-Jp!rXO)$}YBnW)5abHKU6eeqL3eDSFM@TUe!D6Tfsua6!JcJ}8>jDmLGF z2(IW#NF$&ToM$B0qJI?1tWuCF4&^F&LzgUHLe@+Y|^Yyzxi9C=7dNqo{GzaWBGw%c$BHr ztaC1Dd#nIK)KNESHj5KSTUqWjU)hd`aW2+0C4;AgcTsRE4aA7jSPR$e+^uB1?E;=l zLhh5A>$-4XzvI(F3%rXu4+r2Kf)V8(=P3@LzE?G}W+s{R%3g3{ zvV$VNp`LMA@pd8i0W}O_U|wb;mp(DZHJFLjtW;l+XT#U;bc{xX|WtAz9LTLQ6Fs@5{W$(p@DOmmG z8~37a$`}-W2hlRNGH?}Z=$~*|OE~bq5y4hDjeD(3|6#xy%O8xq275bOL_)hO;bNsl zExO#Bdk!MLgd(y8;3nC>3}fr|&Z6w=zGje&DVeR&7cgn>@vGEZ3H4>}QtxshYS`4z z_~ZiWS@L3RGX8J7q3yGZv<(YX8A?al~K;+@Vn)(L?#d5}DToEsm)Bo7l zRWH>4N7X`KAX<3}0>Aakr&aCUWgn2PDQ*NMxT5-fo*TVq4D{x;dvUyB<2VPw2Lu{2 z@1@?&`K=C>s@-B=h4P z^q`*6Xs;qN{|^sOen1Cp6GXpH75;YzD1d(dN9GF%D<^kdSwdh@?g|aZS564J`XEQd zA8R0F69hYZ_w8=DU#E{QigL)3De1vsNd9h%1LGwA-hU0E}H5}W%2W|85*_^ zlnI_tU(V12hb2#cN7C2Nvw3QHWq5YEx!>9c;EuNo{|?B!n$#b{mxzil?IVzI);V*F zsT<5dbky~u1@jj#0zEd*#cqBi^ge5?OBLUCYn=BE z$vAjEFubvd5Z{nTY=+ay5PJ}X=CXzE)f6&^qP1C;4=G>Qau|%*COd6v+HUCKBx2c^b>)>+Mj=O z!EuH|=y8;)9r&ZcxGYd|tz-s!MBktWm`=lS5Kl1pl32!+AlrF4 zOzA;p7TgFg*^j}G(CEa{kxe)j^%g>TBH+&sy<=YlrJ5k+QuY|r zaQt(dNfX>ELqFaOicPsdx85GezlASa_pf3J{9Ue{MW#?!s%b^iOEz33{JI z3Bs`(EGp(uae{H*Vxgv7A@scs7~<2J$do)*k@v@49-xj;K>-6fTNE^R{dJAKQdk;U z`8p}V_N1YJ&&zA{<6U!8@H1g+5vy={N8}p4!mvbTu^J&j1KGmu#et;%g$KL?2>=ru zaBrOc!lFCbKslMb;NG8K)Sh4Dx>dP=GKyq1zFO0;U7d_EZ!8|Oy-yLH4x+wjH3@RB zWMdXJpDB}Tp*k|#-mk|w7~{#bc#C(_*e~uq2XsDsiYZ_vlRpuK#@K4G=dh_$^M$Ty z;dJkQ^R-u-`33;RY0ny5dte6onp$Xv+!2O~2#DgR(l%d+1fI#pWZ;nJZEnKFW!E2; zLZH&RZd6D~%S2qVwlNx@CQsiZI)xh+D*l3ySSs}`y_8t6UZM%3OVSt9v!u1=IF#n% zFZsN!+{24#y?rM0aK)!?gd7IBglMCh+>O!{bCf`;&M#Q&I(y1X@tHUJ>VDyFDFCR< zV)u9N9=HT&Hz13nukwM3Dx0=@ouRWlUl8Id#9ScmzoWX=w48oSBq|YH=o1k>&lbsR zvCPXkse6k**?~~~hP@rL_i`8UEL)g_eLbyoC94!i5WeJy`v6H)Jf2(&*~)mP`5+!yUiZly~}i^s@b*b)b7-mo%ce zc2Ew5bCx!QC+tD;ULMQtUs=1Q@I`&CrSXH9^#>f6A*?9n*INB8$b<{^Jezq+=@gVB z*hx|UaDTqA6lvgWHUoRW!p3U9FEy+uC&bF4?!40vTGbFiNn@rtRs)^C6!Q6+OE)MS(BO)7t-ZusYq@2(Y8kCQ_;b^*#9Vol$)Y8~GpT}vN-%T2E|T0}1hXBTd4ud>l4Erl0KG}BFRLC5`LeM-_k4~?jd3Z#*dgcrl2x18X zG-Oz~tX&*-8Ks2bE+6|ibuZ-#Ze~8FM$DFVj}Y{Czf>4D??s^E%h%`OX8sDkbG6_f z{2KVgcCM#=9!pa`P+l~SF+fcp1OrNS?mR?VNZRiNQ3&8_YfMJr%1MQoZ$rO5ZbqKa z{tir$*u^VM_^xfCh`s;oX?NlxE^Vou>GdT8B&2EMe-j`Tybi^i!7U;LX0Apj{V-cT zwwP)g%I8&D`bYMI50EbC)zCGTM$3fH|zAvTd#Z|#;!-?~|fTe7lZX!}ZHXLWNBfK8ID!r+NiHLHe{@;l9 zG32w$BYE2IaF<%nX34k}r{3IMS*e{fyHxDM3+MC*#m`!>C<6ysz35539lzYDJsk8f zkJAZ-1WP)TuuNu#v@3rRg#>A?sK!-J=hN{S(o5Icu@ZZ_bF>FTB|pPsk;6X!np@8P zZJjX_xT!T8=ojfbR(~4>`QR_dDjFBqvd1v5aViG^El4-Iq2#7+B3)f{5qSeF)B((_ z2kqqXkhLBO@4kOgZNx!_S8Nu1kp9L`1N2%RdsH@zEFhj!WpT>gicJYNO-_UOZ&dse zcwbUqA_4^)m5BnE-@hi(*Q9{0@eQ}JgB>lkKoCM1{CDN~tHf!yDGEhF_%60$s626m zz)bp6FnE%?0+Y2=1S0+BgXG4xB#+Qxky_i0T6%6opC)i&t-VwY3#sY4NX0v6hjt*e zu)`=OY57Vxlze?2$}b11D-7aRv`UEu4CQa|K556PCbVs4=8RkHDi`HSJRuDTJFZgUzsfuQ&Xv(%7tle7L|`mDR2LN2Cixb* z6N}Ve78Ho$I%mImkA^y_@V5>JTd^0oPS`dusMyJ9rN>t3_#93!j{Yg4OUtA&q;MqQTw0-4?vwle7=V3M;YZ8kW?Y7%FRpArQf#Alx%Wt<9M6hN z^KB_FuSilrGPoVtqCI^PfJ}_x_=l958|`d zO;$~Y(?j6pBP(ZLShXPAVGnVB)>PlGw}o`V_0;nkxdYJvYmot?nw@a`jeo{65M~_3 zk}osEIHVs{2D{ggMEsMIoS+@Q!(ElzAX5of*`wMqRg#$tys(o5Xd(`wnKd;D!F zA<(y51OF*TzOp2l;p_6Jpl|doNr|U??wvG{!n6E!<$MgRD&9}vwA3oRnFj{_!u!bU zQY^$~4}Kq$nZ&bKv)Y~ewtPO6qWD;?QkEGJSCeN$E6sFvNCj#&Q^Hs4Y6IXuQEFEG zQYlj$aL~@DDX$va8u`F7y4zMU)x$?1tvQn$eqXr>%&I==s`tLAK9?KVKL(#A&x^gl zSg+_-d_?TAi!Q;>m9w(A{mhw?OY}fa_On54QI#V_y!p9oVUUa0oNd9l=^#_h(JqG3 zDoRR_>MVBch0s6fY~7N($z0QRoAWNmn=6P0xt$6HyE5kVhO&SxxcPeuH?6er_lo@Ew*N}T9! zc$#?r;2>|E5|7dMXkr$Cyvp0dRey$iM@IrCy{k?zPE}!Nx78)UnDu_f)Z)y;y>ru8 zD%+a;w^d(I;f?Sn++{hu@Hr7Bw_OpIj2EjL0iodB^oqI3kk2f)BkDF(0|L!!M6_Nt#&77s7M6&Z{m`pX#d_D zhinb%5B1T#6wHx2)sllD1wXmg+09qlaw0(k)w6PKRSCXu4F376M!i~ZzSd%!Ck zyCG!PXkWMW>qWGhvyl^ye~tX44*r8x&_b2prk4Dl9FVp}p8&u5Ip40O(2Dr^e$z#J z-fU+}Cj5t#uyBvWAlpqeQi}2joo0Bol4;ekZk50m(_X=C{hBB}kwa@wI&@$GD$#mi z!$RgeGS!z{sTh1eclP3}cM2EZ^YDv5a$Dg^?sA+pc-(<^l{Aphnu$k82m(q`?NR$0onr^)VP&4L~D&F`p=3M{>1oFR4uOq#@XGM zUtxo@JW)Gi)mRzUH)~gt5uC~72#nav{BhJxKw^G+xEc2X2Dd|{IUZ`!=gnXI+%7>0 zG=?^)>u%k6Ky==dKoe+UC)b@NgtP3y{XW!i9sxAriGB@}JyK%X@Y60>p-G*)nTyvI zwRbC`NLFhWQzfiPfDmW|+R%VuH4ei5G!Vy=h`)h&_{a3Y}r zm}DPDW4SIEfVFw~CnTvX2o3tIja7)Y6(@9917kU1Bt*8oXk~8iF)W%wK+$&+8%?Yn z?5Lm6(eU%yIn>KBp!}B@56Fj2Xx%{(p=t^@`DKBd1-WLq%>$=sXqq+WHk}n)vY%$) z8=PXzmwQ50WUusvfqO9iGnTea(t zz#WTD+2o({e`#?PN$xU)q-bjx`Y^uSPDkrI?gp$3aq0DZW*ZCud-TEE)j?k6GmAjW za8Rg50&_n{9rT@{r2JQpH_qlOVr`#7E#VX3JMX~;jjd%SYQ>@QF#-(}rxPlAT5^cW zKi~WmBawi-TT(VE%Uo=SveJ^j-_-M=YS6I#(X?^JU;6ePQ-W{Jb1}ftc6l_+WR+R! zhC81ChD6Hguh!iCIQPMup~;DK=R1xplTxgzyh9$um5*;kU|Yb+hBP?Z&Knr}Zs4(k zczImUSRvIdgYk0vN)jB30ZN#-kPSF56h-)S3bQOxuklrq_uvWl+|#&Vod*8RyZCe>@yg^a!e!F| z%fe7k_#`9pv(D@C^m56o)nV*AY*IPv)Slz=go=|KF@;GHs?Lp58rt{C#lUQGJ}45y z!vOY@4^zaSe0~655xJUVjTzqH;2*Y!5OqFmTAP!?U760}sW~0U8vK7WckF?)zwZ9! zct(`!gjhH`Uqx!emj9(lGK$(`a@n`u#~ahz<24^>UOY=TX1Wb*7$a6j`f*H(o&))B z1A9@zCiey5L!)N_d6o(ivNU+i4)HxX&Gv&st#9nwL5j@WxtV2n$u0T6CrxcG?3hHF}xrN=c{A7RUJ34 zIbiTS)c9c!$Md!f(Qf5JBi+LEy!4&n;m~p10+n=`3q(LYZjSPYaGB<8O+VIyoQm=L zUM^ESIvieBB-{kBxwxhR#&i~icgOxkj%HM5dfO{RLnIH70PPS7y%q=~#f7sKm&GXF zEZzs)@ij3Zak=HWVFRLP(<`@>;1_?xUDmd0Bfvt60(w} z4<$FwfvW~UG>?*08kVN$wt`aHb-{9YpAr2^cz&7Wr+8R^RO0P=Z?s4*j=ZjdwB=h7 z?(rZrBF@EUTDl&{jyE=jf}*lB=wqXeSuY1a7Gv|MI`mKv9Ma;LSQKb0alM#w=~$&f zMOVaR!Fy63ItcM|g!iR7IjKxw23qm4*O7*S3FgJ3=hpJSj+t3sHh%FPBXR9a!N12nBh!*m6gIYvhyYte+=$L1pV&V?IYMHmP{=f0a3gWDm0h{(zUQQv(U% zMnfVKG1J1+78d7^*Ica}(ja;#Zn;;p6|qFk+TyUZlYX|&M7k%4>NSYG9S(=^LC@I? z<##%KMI{{>RZteIl_==0+PV+uT%8%-Y?JT~QmFcl)W5FydH>0OQgtvq~pNMYaX)vg!>`TqG2g)!*I?bD~9 zeJE&-8F#pe>ncMyh-pxVTWrmrsNsZqvRKMBLhFq%^&yje(iM1qnDeXVR;cFBcS3el zsEXpUHvgngsLY8*xz*>XSbpOq4m3M$yn-><`3?*pCL4kH40(MxX$Km8PKbI}aCreZ zgY#^z4qknXo;d%*njv#Kx0o1n0g}Wh!jvm*ConPIy2m7Y7kxEcy=l2lEdfNFO_&LS zaT>+fIgElHH3f33)(XI5l|t;nVN2;P;(K1GDDc}~AR4-9bq=8O8=AgmD2sr^*d(xa z8AJEfg=D+4R9rJK#N(f-z6?$JySS;Fbras}Ld_ebcGt;y(D1FhU9<8<(&H608g8mF zbn!L2{aq9Az1-1*eAa+-_4SJf-@(zlK|H1Evk_2>vIsFMq1D?dU1`;260d7Xl=F2S z>FcTj0O3!k*g65?Tdo+b=A#tU08C~*VF_q92DhYQfG18_BzVo0^uM)4X04KR_}`jb zAqQ=Aw3+JeUkLVwFLr1rs;k5>!!ancs1^((4Sft>Y2$dO_V16z78~oOtSi#nF!u4j z^pKW`N>m7V`$cReDGgLn1wz#R?vnbsS*llVHKiVzp_mxd#1q;N`NWdT1Of63aT}ew z50Ty#r=*@qWa+K{a&<4lTI}!R*im0oPraPl4 zI>^Jx?ccZ%rckrl-cQ5t1y5}_`n9i>i!F3&2%VQyJT=$fPiYT5o}pD#(k%d>rbr*H z?*3P_@IJD?Icd)Sm0MCFi@@TSvs#QZQD)#ah~5UHMvwh>DcyBqE192le%VL1qE~^s ze%IYFGJMlQB(A*Q+hV!Yn9WyrKAY|D`psQOfrcX!cH96fiw9O;0;_Cpa+e2^_pykp z8B$Z-fA-tShCV?mGW+-LQFqB%Q8{PAM2*?{+F!HOU1dQ}`H!8>8Dtz~L;)hF$VkYG zj#(+*vPS!u4obwsgR6`|EM+Q^>dX02#m5zB&&?&iiVAt%{QMOMbFU`)%Boo1v0NQk z@_+VP4*3ZHuS`NN7gG` zu}Qz2G*No)M#1JSWX;XSPNS&}!&5r9=)HZ32}5yflJ9zn zJ4Qb=9fnlE212iYMz){rW!5Ka2=F(bf9Uwh>Gn+ih$>PK&O5ov?#w4g3M3(dgFB&q z5=xFV0ko-qEDFg#6H7tzKjkm#=82ood}3WGpC^@Wip9xYPf(>{0otyCme7oc!y>Tm z#?15uRC@!c^bG6u;pDtc#X(2)1uG8^Ll=fwxh}bpvT8F+KphV#B9n1*9b& zck)<1(Y2wu3hT?9%aj-zN?BTrfwkkGN+uMWxPhdPeyaXXVAL`2e3!7mceeII^mpm@=n5y zD8rbZ_qH^?jg5KksTZKnyRCEoNpWeTS8n=$T|#&>bhg-K?hsxbjY#&s3-H(g!T1yU zghf&qwZ5hKr|G;yQw$fV;q#;_zo8P`W@51I4V<7+k4|c)Ut`oi@7)^qBF|2R-pm}c zyt<2u2~FrWptB^_L#{ML+2<5#h>!QLYZ+YhkTqouvbO#d{o;G3_C0*pNNhJwTukiq73@sLZPS&P`KH(0|yD<c^akPp)xx|$XA5BWt;?X;=h1ZO==hscffWi5sk0^&m=nrRl`EPxb z8vD#OE)ni~sn^i2>9jZgs~nTGvRLcYA{wFDrsUVquCc806vdL+Oel*?*FGp>%JS~` z#Ya)WIfB)|O1+>S8sRATKl6AzZ1fdNv%0nualAqvX(tPzZ%E6SZv!q)?mgs6N(`Mf zg`&VXXvpsn|)pw z-T#`=_u~4J`>6%fi_j#m9PF;fNdTYY@@@fn3N)6__Hb7jkmDFG#{0bUz@9;ji81DO z2My0%#T=v90tug+FQu;03B0oU-66h1gIW5-?RIMBG(j85H*Ud}yjDs0!=VPUL45$L zI5?w8N$8jcfWw+cnA1W> zGNB_F6Aw!R4t6)#L%&I(Ce*XY{wp0)&AF8ja=XOHO+^U!7uEJ({{3lEkv;u&Uyj{9zWp zGNO(R+tBLpWrm622S8LZ0a@%^s=45)j#MEBhMzor&)J3I#YI`5?Bl|t020gRXvW_L zgDDQ;2C!aTgq>ptm@ivcd|xkyb5R;-tYvDBZ*=%!PK=1#-914R?BOsuC!P=$;2cML zXWhH${sKnZdL@QYd}3j%PtDpJhRDgFmC&n-)~hVE(nj>W_#1Awlow-oTsH4&i9+>B zL)05ImBY8IEg+?iKT-txNP7-@lq?v*Z6fq0c&(}IrijE|t@^n8J5YgFz0yhm{$^sy zdFSn2ywSvKLN3ZtCK%&`aAT#|G@Yf+svL z$d6|?gOpz|yVe+cS8Y{T^OS8S&=eX|BvE2}f2Oc=tt6Ob^=4AiN^INv9EdaSbUTYa zA7ApBQnUZ+zZB+~mDNF|Zn#)G){-mn`e(#pnR|MtyLIh6(`Ht3i3l z62zP3ALT<+gyzK}e*_f~lJh!#!I#!yDAP#}E!4Kv-mIfR(fVN1Xe^w3Pa-P=W(_7==RT#pZfB;jSz1~jJL7V*ZB=+aGX^om)IW<{$l*-OXNjiXeiex;sfEPmrP z@oAwUc@o(|%_tQBRBBQ=*-lOv)<~D}AN7-TM)_Y0tvrS7W{$nkvh85`eE)6fU1M^< z(@vv5q!X+W7^IU69D4*B{^z*ALpqJk{9ukDxubK*w~j&x zHwR_q(VE=_dh@#lnbZV?@ST(1SvwqtC@m7g$m8cmU_5Hv8uAgl*~jtTNT4OIa1aZy zj@I_qXflOk2}Hhekbb{_G+?Hqn72QVt6Cudcre$Hozb6x=4rK`>b|38PU|J|m(Om$ zj8hJlS_%Q0{a%ga9m()v{;ZYiq+LEkK{#7XADj4$tALKlw~@L1c%SBL|L?MniQYLY z==Ex89gK0`vD>SSE}s2!w1h~dG+@bROLDY$MY@YU#d|3{ zPIb1VfZQQ`&t>wcfsvc9vVeq)X$}{>Bh0s8zDS1SE8H`sJc5+XW6_1k1El{`2{;!P6BF4ca2exR0TYLyhj*@Fh1|kZCFBA$2mNcK&xNvRP1k7% zYf=izvLom9=d_f^c}(*3efX+!1cn!{h#2&?y0qN&r{}uOK)Dzykq`j{XR#c9!tYKg zyC`ywhDXo;I_TxJ(Z;_P4c`miNUtnbd@6#mvqob16;TrO-l+&=?+KzMY}2(sOt;5s zMsDXy!Oc6Mh_xi7DoF;Ono((2+n7T_FlnBmMb=^;rCdc;(rA8aoQR*&%_w7 zgN*sM@i0-5tlUre$`OACDDRc?5IVPj!Y|8;x=>k2$*FGZpy?VZ1j?DIN%vc~27=f& z8C&FNE}8*dzh4fMkdVFsZ*o14DYmfeJVuHn96h7MZC|P69J2Sn7_J0sFovBn8};;x z$Nb4JC4XSm??M?I;9pk2#9*L4T4wX#2yK(K=ust(XJhUE%e11M?l?#BV)5xT?a8tg zXM(=o31*Dmvqqq}-{oK8_(OTIK~o{^P`@ZH@o2Y53mPCj%?DQlTx)#Ej;cB-e7^is z>-SZdiY=uHBRE>L!|`8J?eq|S1FF}ryO-jL26XL1SQ-Dh zVi#-iBO2-k@f?Al_!r_XLk2RI0Ot!bXQYBGN&X2|e#uh`-|OySx*N}bPT8H2nWjFv z!Wd3ETThq%;EbB=x28qEhJt;oDz{}lJ&|s(BziFhAv1+2jpy$0%|{T04#RP%#J25! z)Y-G!2cm8;_1T=);JF7e*PLzvNflGIngpE7NE+MZ^TFHoa~$HuJ{0L`7e#*I>LY<3 zm=i@FWb6fTYx{~DV0lG8=%~_q@Xl_%sfxSFpTY{)S+;VGE#(HHWY`$))rHlvXH2TOoUQ&Y9 zc_$SJh|}{V#s+(QiH}L$L#zw{t_Ndy)L$}2*C7ny%wz%F?bhi33}!Z~48JZAMeOv%69)AL_UJQyMd=KC_hhLAaz&A5_^fc7>|a%{ zeT|dE59m(+xY+Y0^QJ=f<;*tGGDuv` zyUx?MOL)Af&;Xd|SfJr)T5yt%AjtE)X<2knfqro&XtFfhZfezM+=&H1qo81Aux#Hm zFa-N3EW&;*g5CIx=G})+9xB>JjZwV78Adj_)hk=ErbvGpm_Kk|lHdjsn0R3wpmL#j zA#?I{N!Uwui9kexx_o5`@jUA#Aa%Y=%0`Po@5+|os!$xCKW*E!M9){wqan^?Z~@5J zhiomDk1&_j0yz|WxCzyL&XAT1dVEdE*zplYGEyZ-)`k_uqyKS#Us<&dx_D4$qTgmV zvMmIm5kRSkVz9;MV+9k-RDg~g#e>12d~%v`wjcJOmG@?#8bbRt&J*BJbC_$x2?sCs z0|X%S)@0028&RQ{vUO?;eJH%uD1p9_Aee%^0wT&nPr~v$qHE!_oxs|uY0VBgq|Gf8 zzFXmT@`w?2EhZEd?ciA@VkY}}`0n3fVfXmK&&9-04}3YsM6iV!tP84m_m{kLt(EuB zwea2y5l|*SX#2kSig6J&#PnSJweEvTB0LqTQda1uo}sHPWVuT?0__4UlRztF;H?%Y z=&LFYI$JXMz~m=W3=>CGPf%UjLllV~?@uN>%KI=Fhc!;d(@R@G)D8FmUF zktF*K?Z8Z+P3PprFfv3!_-~pNJqwqn@&sl!V7CAiBh}pz3SU1fxcLITzN(rYA0_a) z;7cbYYfu~8@2RH3TGm}16;TF+63V>kE2f0myP$cMHdrlTe0pn_P18||vuG$5Mk*?W z#%xL#&JCmNb zdTF->n?$WbKhujL8Ps1sA1if_2nm1aE*%p_2p`KC>E(kcd-_&hlwfVik>a0+Prs~K z#zW#ZyNW-7S8>z^{j|>&PFzwW#D^$g(8%Vw7|746_4u#9N5*Dpn9Iv9S!nsa4~V$T zJs`9+3hhJ_qObMGELkbDPnUl9d?@@X&>Vdbu;K zCy7;qv22viU@wOx(d8Dydevje>)7vXaJ(l@O02J>RNSu$z~WTsL$Z zgU7{il=^JHsOlByx^ zUWepFcOJa@cq}pk5XIUc{|2{{IU;aQ+KDmt4S9k;zk#L1(Zwt=E&Th~G6Q`(Ie|%p zWji-I6Pxj%t0o51b>e~NT_R%D)~}x1@HVJLcs?&6-BrN-wIc-U#nm~& zclgnk<(PRYHrnWY#)=^CWdPM9Ge_NlmujRG$n4CLxp&!Xe!THzp*$fzD(A(VzDP;- zm$SZ|gs=s$%v34+^u-yW4SY-`L#tF8IjmlF!hc2zye@Def(z1YJ3+wtyaQ$x>aFq= z);D)RZ1X+E8}hqMOyDg9%ha#@57I47+UF0W2*gGUF)B1gON~*eziz3-2UW9Jk4b$o zIL$I(|HNQRYSb+{-iF`rR>|E!_6fiX@##)8h1sagLQ=;qJ@|+@W0om&@uBEuq2YAk zd8iSP)|&xXpIcA5sUf1{~*3{C;k;S|Cu{E7bWGk{ac4+0tHP609hi=$B4~_O>%CisM zr?ooDb}(XYv)O%dwZRS|d{Optcnt2CXWZXVeT;S&g6a2ES!o@mZc7Zpd1}Z#?~EyH zy{z$=f)q0qA)Khmc&4eIuD?4#!bIO5#q&T4tzLFh7ymQbwP)fEM8Yt6xu(hkuRZj8`q$K!20%F4=iUkCTWy^p0~ zHd}w~tTX7X|9Ai=576lmS2Zq8k4}asM7XOjc$d1Z2MEHFAKdZTO>uCtIbX70z|$nm zPlz@~Sj3 zf#)Hc%R#3IY$|A+F_a>L$UZ}VCet5yUBX;yd);(MNT)tLH&icDJ2UkGE}*od>c!_P zA0rr^Q&cFDY<3boWt;E93HoI(kn_OW4Z(*D=Mi`!o37@&Kc`0nElG?AX)G`0gD~@v zRQWi4s4&P2i~^R{yr$tNJ^~O^oQkci{10T2?;}xe{4=@^k@4>y~Sm|M4F!5=lkdqo1FmYK%x0_7D6+igXZn}G!fas z+^MW+D^K!)?zM*i7n^HIAO@MsqB~4m$JbMZa$V%@_LEy%ho~fTx!_zIqFaj@CZfrg z_O&K@6UWgbzJAW;Npays%u6AyU)FX=!Gy=@?;F~7kXn;TFxM`P24xL4=qf#wdNTS) zlt6|c_$JIeV38pKXigg7e^~1ziSmxVM&k_2XY3iukEY?rtE`9COL)z#(?zR~&x7^R ze_Rt4)Jzx+8PQkcq5vN z;#Ag;Zi;)#*m4a|?lhuhDts17E+`aI`sIZ8%>~p)XJRe!eqW*s+HM)0im10RF?hmh ze}Z26Uq@|7T%d-ZfPL<$Qw?azLEZIKyrPg2I}p+Cq3!H$ywY>UMX$MQ+a_t(R!+tn zMwrUG>U0t&XoHA3u28daTgZZ#_ydeI9ayeY2X@(`{TLkR{Se(0|Tn^{s%NRAPRZ7bXHRIq;WTW#4PqPW2smMZkm2@_MZ zY%A&(wbBFXb^-T!xSwm6B>r2xOFucPlNWNm$VTA(q#x*9*Y0QW5)caEpxxyq-Km3> z+eL$Z=wygtNCw<2CmT6eTKei*-^UmSX8L=>Q6MbzUl$vK zY%6_&OIp04Km7D@nIe-PYLh{p!BA2j?2x9Zz{EU@QTbDSo8wt3{j=E~MEUotF z1&*@X)kAf5KEt}s|1_w_Iqy^8T= zLq||P#Oy4hzKy$PB1FFri$j$`6V;x5Ns@8wa5&QAX;#3X*Aw4w*Nd8tjWE%!X(_j1 zvv4emySNG|z`l(3<%jB|+yIHxO^bFo9>VT!-Oz#Eacon1`qzi_U;Qpa^~SaqdoRQ# zfF`6WI>`6{WeuF#!k@~IRSYkA9#A1Q!+iQU=rA9q-bbZn3*l*o+r-BI7BMtn6kjY8 z6%kC|J7g()RaZD=1oS!A9$-u5RM3WaN&2D630KIjaTj*7+XQl0aca>9&^$<}{5H5c zw|_89P6?asZhQI^Uje-}(&Q7W5^RDLTxh1qx;~7y`Z9NjOKu{r=O}nA$H-wU&;Xde zZwFKHX-ePsYkH>hcHK9a&=Q6R5yq1s*Cthh6xebPa{lEq)~5{}ZjS$(c4wR60ZSJ* z!20AUaL&Awt)qVF!EyeIZU9ZTGbLRuO=}Aa3$M~6kuC~`68l^m^M~BkGqp}{nQPzY zsmx!x0wW%}dwdRu{?9=t(J03(z&Pr9MPdTb?Y%E?-P>=KWQz>y0KERNsGmfi(*@!@ z{-S7IqOH-ib@sV}d3vJBSky18twi?4cxs+P*)S!*&?p|#HX1MM!}YfKHV|c6w1V6M zNKsPvtvjjh{~IXUrThSw-w;wFVUBK(BN9jy8{@7$jwD-AACk2xWyv!-PU#>A7(AjrtB z7jS_;u@$Y;HnIp4SQ|>QY*u$HF5@yoOw$O>Q2M#0&6oCGA4JCMtwfq&1@VyK+RbLA zjA_=r-_H3QNGWGs0@HOUCS-twmB8je=erL2*OnQi1Ml#43_NV%0i=a zB^1}w>C;gF56KCEYTt-&7QTW&roN5VllQ8SCEoE>jK_IZCNKR(r1-B?3IB$~h#fXd zXwN1d=4vPfwVv&G3d!A|OLh)FXt*;ORYUSc$dliu`tO>SM;UrzJ0*RiF1$fua*J9f z)!7>TRhIFg{Xhi~j%+klDTv0;aDB&4TLEHKX#e>iwb!{&g0>52r0VqM(Url|&^@sb zoV-s_;P@YpiLXN*O~`2oK=Y^mER5vG4ZFg`A&+ClrnGAhOi117(7ooP4t@T90dqFg zDab@XqNy}XbFo#x?G#t5=@vHtfugH;msOUGkrZ&kF#c$cZ*l1iWlK`*K%&7G9#TYZ(B!B*hiqZcK5 zpN3R-v?h6w47B(_>?13HUI6@?46?aUDS9G%w9^Jw$BA*w=dI6snhH&L*8R1rCQc3F z53#rA$JvW|F|bV3sfSC`-F^O)=iB!4q@z)nb(x$HuMo`M5XB!phSKV7Y6AV#d-J|! z$Zo6#nUf#kW*;vl<6wnv!1XWo5*D@~YT36Iol6?z9|uO6kK&Vts-rbT8twc5%rDmo z<@!D(CWJV43C%!zJ_TU*VY46)Bpm-Bf+TPc#S)jHPKlO>6hu>rI4c;?cTMRK1WlV% zS(A*5<0HrYn!t{9Jm$_?D>aYr@-7(~7f1+7GUuQ{Zplsi^xv z3uDP@O^ipZ%xu2gvsVLt*9gOp`d(c$m^6r@(kHnY^CCGr&uO?%E8-53a342+9S+?5 zVhpSs*6F8Sf)R^SP>FpvXRq~ zE8{pjs47-PeM}#$?b&e{E1yxc@&wWlycaBiN#lw;1shT?$V9*9=6rohxiOQCNf|E2 zGm3L52i|#f&jSiLv(-SIIAE4F`D7M;#-gL<*3*KuLCB&8TN=@!ahj@7bz(3QP7bcB z4PW_V;C0`#GBK4IhkBYKx!E7uw?sGhY80*ubI@Wf%|zImce-a=o$NQZPyGa+08=K} zTz#trw>XEG^B~jM(<&>gyUAVT2aGaKJ@rUrmI}=bcAb2)%K_SL1McI{nvY=mJj7t7 zD>12gc|ZiWgaT=I5CvpC@3%{p0rYFh*H{tYR12r_kaQlh)3_zS=_;2va23do7AmP^ zD}wUFdi`{NtLKmO4u?C5>*g^ot0@FbHC5?uL>0`eomf0zT%1}{e#fQ_ryCos4fy6D zpKF86Bopmvc43?6expP)vl$`)LP=ntbeEv^4Dk5= z^}MKRbR};i@=kfi$ulhbo;XU-uxG@2Odw!W8*1gJtmyF4C()XaUqX_i$aXLFSKxAz6NlK;wh)kZQ#vOr>Pa(Vy{(R+mfg z8L>KuR+Z}{=Wa-%nmGRSZd(6JWi|D~PaG7Nvten0tHJf5bd+%FV6D1`fWvBYp7xbn zO#LlpqkSbxoC-NnxFk1>4_M%x8v(xn#;?X|p!FrXKSet|AA9&{;~F88lw1_XQJ>9M zs7bttBx?{2fXDBj+w~zN%){@fdpmhH9|-?H>SUe+R!lhiS38Rw>F-*y0o#GK*SKDv za>!e~BvKrYZB1OkUxQSuV&2I@W5pu@_-QTgN8N?sFhmTj({L3Nq5j=uoCYNpEjLJJ z;dqi>m30?rc-1l3G-UW%F^Jd^?3qNOmO6E}{Nj7N(Z}&c1dpE!h~0x}TXYzD0ctidhk>r{^NBIGd%;AtD)h7`*`9BT zd(c1(I&EW~Q6M{V3OiXiwrJT&w@9LN^cAD11XG-4G|2i_OzdPn*+)z!akh?%fApoq=t{I6v&Tj0RJz~W1ZC^KxLs=Mvg!F&26 zHv8+9&px#~Pz$c0#IV44l)s#*B4JlmcM<5Yh^42DRg47xPYBv>DC_h_*lrWabmR*7 z+opYPpm1d_JN$KnRRvjX>9{s0Vd|G_7v9wB>0OxXykaGlK-?vWkn~M+fe^Wrq4ADI zVn9a6Ag7ZY@ewnwK5_DoaWuMrP)>p)8f~=fnCy2Ysw!8g;zj^^(5g+TU`x-NGyrHC z(!y&|?=Uh%lH+bBKKNl!{2uuRsRI;}1T+MP48+bjU`#3C$AG%6sH0}LcN4L)U6&CfrP&TI4rJrg6jYr)1 z`RK(yw8UamOj;rgMw4rX{szFuye$a>+*QtoJ2)!(!twq6I<6^`(hr@AQ@=sT?@Jaf z`-4vsT9S9IZHuVzh(vV!Qj_hII{#_pV!3=~pQC9Chj0sI07Tpru9Gj@Gw@3*B^tb1 z5q)yFi;`azP+a6>SUPNNSxTMztpE%lAS1BY&&Z{XD@&BUvhyto>#?(+k0K z<1@i-{+*ga8AOmYXtAv7ri-M-Cl=@gi(H>kr($cd~}-Rma;&P|Q}D_!R+*N}jbFlpHyxWkgB7sKX|)5H&bk? z0_c#`x3?Ot&#(kb3Td#9@PWJa;|hcC)~w-lDYp0?EGr2Xbw7t{eA4Bu{MIhHj0ZNz zat)asH7XH8`FMusR^&AJYWl=Lq8*>TTFrAg-h(9x3xFc)k>x=qaA~}^FbV$(4=pZB zZGD~eI)`4b(R?03P&dWwj*{R6$F#Dzh%%)H?198O6A&Wnm96q1WNahgq1K6i7mUxO zX~3-?i&bbS(NqkM5iK*ne5R%#sfTFvp5rgr1W-33c|t2;*nziDWO9JxYu9fLi}CPe z+c4_;^1FzXJjcx#7t=SyQBJ4-NDptvHpH@!e3yzSxR&Zg7hdz_^55rD1gLBeEh{*k z^(8{>tQGtXM#rW9_G>qz_D*Eqel+lkP{>`D)C`&Y_rjntNMa@BV$+nlJ@4ka*`wPA zcDDHE=`Q`_&HpXcGttSbldzrG&l)ITvei6xLU*-vS;W{U!H|J zQ}2=rUaiMq&#GMPlQ4 z6_S9s@sub)#0YW-b+XBSDb?3Ne(y7U%+!d0iUrB}i zN!|kej(tB$#bq%1|L?m~T8r+bDjL zzE?fZdqL-7_GcW+S!$d%kGZVy)s>zc}^mb zOT4**4Pu@AzLxRC3jd!b)0Wyh0ka;HkSVF;98q3X1~;8N8Gy;)+mI+p9<)6}QP>5W z<;E8?!UIn~0{qn1AWb3oGmNjUd}6l^ z;CP+ROZU@xum>guOm#I$Du?UOasRG>3l_Yfo0 z*Gu)XiUFQkdsPzA8;m?NDx2R{-6N*CdBJnjs*)(y(?mt$DPlc;eb19y#U@3 zBfC>WZlv8j@Xe+atgr9Ok=5J30H5v-h>_M~LYH^Zfs5->9Xy~C_?8W_Fw-_sYQph@LmLC$9+;!% zc1^tM&4qm0WrlZ%9fa1UqwaVDg%Utw9=iid>sOTz9w!vy)S@?y|7fWTPiny zR^E1x2om04uugm}PEb9yB7-olWOBx#y=mlG<$d$3Imx6Qq@RpX6m;c>LcK_5 zg8o?_a_Kp-I9SuXqeAx;7K5U*R>hLcV2iHhQP5KRA(ess;f*5GZ}8A52rGG90{A5e z%adKxeD^s{D~%d4(PxSy4x}k+%85#;SaiHO29nWKQ}S&K zm)FVz)x~7yMsgqfu4~AG11t`~^9U+WPUJPYZbd31>|E5lVR z7y1U_GbB`{N0ZM+>>m>BH1q)V- z*;W8OiFFCGZVpIO%}L-*lptrG^5ywH3#$@IHy&2DM^R%|$w^Kg-RSE89jK9^NHo?N zH_q6lZ+pt$i0run0|a{tfmb?Tl!}jabe(?zd-1tuVV8RQpk!;u&IL;b4LrOV%Cu)K zTF<9HPH?xFE>;Jb5ww!8x^nk>SEA(N!`Z+M5Q8NXrxq1R2GS3A5Vq}RI)@@H7-4iu&H#DgI^3mbIljW}PW#{W?{37A>mP&p7obTvNgN?#y(6 zJYnaAO#ojT_&>{gx4_V2!P<6urH_H?#jBpf8he%C!Cyfw7vY#_B^ zuzIR#vtMi%-I@MJio~66)v||xtX4Ebf&;Kxrju?5(F0hDU~vL9-GgHT;L<<(U-~B= z2DJa2>&)Ct2{D9~;%%)DIn)=x#mnIEBr#=Mv+= zM4*9~n}cXpCm46EQ7)B>v)l=Yx8>`pPHbj4;prF`S=k8eEtoC7%s>TJls& z?IJ>c|5k%K?m~$(XUf~;x&*hmnjixe zpi00BfK7i%6x4=*gSFLD%0BuBb;Y`W0l64W5DvO#XksnzlheksNY*1AL1f%)Kq@zT zKZ>c?DuHuz_toiTI@-xKPaLLANoTv8IWSz;7lZhvG8H;MTtpon85VFnU z0Kks+rZa1pFEr9`5Zb1`&vB?Uq8W-KtwpuD5SW@r8dwqUFaQ8Lx|Pw<>oYEaWeI!y z(~}LZ zAeKLRlWjdA{6Z5w?`aICBJq7e$1D{IJ5!k1xHv$0^h{*!GklHvbw1)FyxA+h4;bS8 zKA;3EOk?3!4K?nZoFW76Z#gd}+VBHdN4;rHVrsE3fijr+osQ$o@mfmeAtdmqXveI( zLLHp8;36W}0w zTTJNpJAo>YaB=Mx!?(K*k249L_{#RMi_f_53%dOEKKtvf-DU*=CAH0@P&IkE z*;%+35s5LL`PZy!c?#O4@Hhuo*HS~~K|(pFIkoy1|F9`#?$-8GN1lT{gz4lqK z8Hq|{aJ&DFlaG5vaxH9(Vto6G8NHzGSASm`1sE>*wTj$z5udhoQwJVq7&yP09aI^ z-L9+KvAs~OW@dc%r_#|mCcAoMZ4qHcT*~{r`J@D*##VW{N=yfZajuC9SdqH(8?TTk z2Axz-3zK}3u!%#Y6ax%P?l7e#iY7E1_7*J>F;Nlf!o$V6mUf%cOLgSAL|NcJ z6^2b9OX1Gwg&binn;P{tZI~#R=iQ-d!oSD3$n_i!?hSmD38s(i4_faM|Kxo)Mg5Y( zoHLY&6O(_6#4M7%ZBv0KrggA@4^F?@6ENa3Ckq~mS&^03py3?|IXnAn9|@V!u^)UE zEPcWRH;PoNtHyT1NV;m7gwVD7GV1ZLMA|M`0wnzOhy~b|;CRZlAMc%>y^lg#UOa?pEn$c=+Y(uPYT7ke zXv#=D>W;utH3w=YNK4{x6F?wiUz3lIpUcP*{RPFQHv5WPv31uweM{_00*GWD?V@dKDe1V4z;~HF+ zza6a@gxz{EO^|gK5Q1DlGglI4N=B1KKtP(|T))qA!pZkTUAOa+?n+mM?)ROOQASKp z;r2MB1H>=Bt4K?c~Ghx3d) zRx!{Fr1JiSKJ9s-p%J^i&Wg6WkRZvxpFWv0=`TxP`7}G`t`AsLH>iOEyw|=o@m&`U z6*T0a@i;9_wKnJjIUsvB7HOQePtz{z@ISmu>qerX?96j|29P#lTX*c+E#yJoD`v;9 zU&!h@Xo_qfn54AuZ{%1N)x5b?nLMx>pw#HmvU)&;!kQF6)%K1+_p2a)NKYve#PIq` zw=6X-WCU;={PwNHAPAdOdAwG9nki%+i4n`8ke&_1f`V1H+WSDlCYrfA!}UrPiuyZ% z`tWuvYD>X~CDTe|gSXg`Ha%&hT8%wpTvIF;4?ZZQP_38YWUJkCY&{fP$K93D8?l5Q z;SGXNd2@snxX`M#-bG5gNVI~GwZ20(rI#2URBLA%UgM*@j!dq&-r`i=jjbsFs@4ju z7;ZuOiJX?A_2m9p8eA6UMJ)FPDy3kghQD0JQ(5C}yP87U+71r=)9^k06n-du&JrA) zRjoWHl%{txm)>{qY8yWx@GMn1BJ2L!)^lvFwm&(LM9}8W(8&f4@Bkp=lYKht0A5k| zZ2@M|8_W@nkqhJ(Og0%Sh$flqqyFZF*&%G%YRebGx;5IJG=(W$JRQ-pw$>L(6~+RO z-rV3~c(NjPaD(<*gwKWf+>RcJjVLM;c+bw!4+;i=nH<6|BTr**H;|}6%%&;McSKJ! zVs)IP9P`tRy*-fvyLB^(uu6lM@_+06fkE(`)tD4h^)KRZ9*QAt#@4#bi}|hI32k;+ z7eQ0Sdq{D-kZ;yOYQnUjKPzAIsbJTk?r9Z>jNcUO6-(xyyzhsZX6!Uof-zI`;E@mk zYe}jfJB@~U6BJh$&ue~TQa60++1`>Bfnab@vuol|k~{PvbXp-mR|!H;NtUb!N@OcA zZ=RqwjK$``IL#y>a?%%GF!o^*eR+>|dOr$-Wl`s(H2e&qS_p-jn%q2x!F+`9n4M^i zsoVOjTZ-Jntp6SNyfDZm^$LxysB72ks&$s@2noLK_z&2(}`_OFa8FR z8#CYK*gSg)_JT1x3f$P)Dfz6`YmYS`{nyG?)bOZq@R5tm?SO@fj!=75*_l1BlIzpo zE$g`yg(HQypUNItZ6@wOI17I@O^S=Ksbp$Kn+U1;FzSX}8Vra5HT<5$r|%2x@##i~ zASdr*l^kuQ(_r-h&CWm%CQGEh?0f7hVm-d)xRoIfS75ik2DBI`x|F@t%`L#aAdrUK zS%8JjHMp>c^LB9ts=B+$4~>c0W~!rGTiV~Pa##L)=uWcXy5-|qZ?Z%kWI1_$$@jbp z!3X+dC-fP^B6PWB4s8DVYG)9605bV4|YaPU*x2#l{BkUMQIPS6UMmn=E ziIUR!2phwS#}JTCX~Cqma5OTn)Xm>mnpj*<2$n!`0|Kz7kmDSMSmIeu-I}ayldg+s z_bamS8yV^kYo5m&zgq*mtpqCTY7Rzz9W3lEe?U)DC%?mqKXAr97k%G%t{KI&EDCop zIV(t)tRvX9?dOlRfeUPn zy@UslM58=t;T*|>h`h1ZaO`kv8y zdI%^(W+o*>TgGZ0I86X{u)Fq}L+ob9E)TY%V6vhi^<`LjZ)3vd?)Yk*5Wd%1kOr*r zMv0jlNF#kc`F&{Zj#lW-v|(=R>E9HI&G5f>5+vAwFc!iy91M8;Mzy*>rH3Z}t&Q&V z3IuX1aoc>`3b4g{)eWV!K{8bPAX`YxBBOq)PGKa~$e1VlL)}Yiw$&>>^jFW7;HV9n zybUN%V^RBLxKog~Pge69O*Qc(tu)82(prqq*9L1y;FU;fwY^Q?8!o|oMwI+=k1y>Y z`Z34V>w@;ou5*_TBQ_m!|E9`CA5gGA-~itbGD1*sPY>6b`ocr8S66JZ@!BEA2Xe_H zB$a`2av#%s*g@DU*e8u*7rz-%ijE={!vnM3;3IDIqxH%d4h#Hged_RVs5Z|6omP*} zpEdIIU_e>TnlB}2a7L;M2KP%_@o@u6UTiHevNIOAn}TRMuoG)Wowdk_^7s~mAEK~Z zG%b$yPxAtsV6`E@>HCV@fgQBu<`?ea`Mu1>)hSLpyk=}%7yC`1Ak|d z-tI-Mz&a%rxnl12h(5c}YvJ7k5cKUATl7UCaNDvM9uxQ%(yJ@|SK-0<>XIg(J0y#&kL7%_UNn*CydKlA{;ih8L zSR?DCK?9bKONj%H(C$cE*zO=kar^MS6ZZI++(A6wk@EbjV-zhPNyY*2u`j!q+$VR9 z54BpOs3vv#u5(N<+55XHnv3&ayhC`nulX6QwoBx5utKSBt28*hQ|G1Sfd3#`6cq`M ze$VY~QMxp)2FWfB{H@KvPlEyEwdhH@$On|hhZh3kkEB|>+%1nV0?5oX?dZC9Vk9x- zu>O#-tzl2P-(=bfC?3E(lDdyk+JsR6KtqgpKPDC)r07@-yzl@3t-i3^P#?F@XwX#u zd_qqQ@Li+M-E4uKOQrp6`omSE&g6n@DR+B~*UGHOP;b^r7uiAq^9TnK=eE6HGnGc6 zSG+(;6X~&NcOVtHp4%^0+OkT2_j0f!bKKP|viC$vrzhkeg7nbu;tzF!uYj_1VBMDZ zZjxJID_Q}mqmPA-H8pmX6BPmso8tD@Hk2Y%f9`S-IR)!ZC!BwLD4wUWJkTekPj1!& z{?)ob?U-A(-tG&sDBI6D{De0KLn;DuvVqVBR@Ar7c75aI(!QhT=_Br-t)e!eh7YNn z|N5_qp*kUfmiUwrmv;}2+*ht`!NiVwwAGcn)b>E?`hxcFKo%!B^vW983`+oL0c;Yd z>+{)D>BK>9#JoH{w`o8QS+Fu0w~lZki(UU0I!9`RJEv+kno6GRear{Z?)nH(s2* z1&7_SsauYW|4Rv1l256Cn2BflVzawITa?N8*R9Z?iVxUPrR!YgYxvN2Pmb*IU<6B($z~Ig}55|#grX+?TjkZ=*#n0 zz47V0C;sXp(lKXQdGxMvKItzx07XN<_+>%(6jR$WTv*oU6> zZwFrKhg6wu9jG*+fwTnlhK7~WI9#febuZ55EYAucq}f-}0Jy?7Y);Nzc!tQG(|vXz zco>nG{4PodY9gW2LvQ2zf9q|W_B%MrH>o@VX=O@2EW8{fewJHFJ zswO{20@79>F~;KU;ud}Ai5ER$`7yE3xGw% zw(1OY=h)-i+g61|+;guVh>nGp{*%hl8}hv@luX!~eYYy%X!V#bhXLiaOmC^E(evb& zuIhn=xZc(;RvXG8E}#GH{_a_KLtp))h_7nP`r_k5y+$cI+!4*@XzOs)sx~~EXy~(R zhdj{Nz!U=f7#3fvPpu`i@!2!q;P-Xf4LfA>2p z|E>XN6dq`~jWWJU`l&8kq9CNO6yNn+z?(xCJFjp8XbwRX2)23|)H$XNp5jzJB(6a> z{?yp^7#xfxM6Ef^N7aBU{#`YyB|?)@rjaM%YDFYeSD^#X2``UH!mSgBJ8JKyof2l2 zjn+g&Mhj~2G;j9_OI;hIl;=hLU7c&Ks&tun<8ur1WT&JnyackCEUR)P^?gx00Qq!m zNsrw#@aL8>*V<+$_AeEEN<+;8U!OJ^z!OM-b-W^1lAr`jCqPtKsZ(@W`z-)^sw2|v z5WN6PkWzz@>|NVN00)z?Lp8EAVxvl?jGabeV+erEGz>ZJwjih0M<8@HzVrjG*wuK| zCR98X5I_h@&}Kns=FxEYVK6ouYO_IK+GAn<;C)5l7swY?k^VZYNYkr?-T`|4FB+~g z4^^+an8)MWH%jzH z!3p?j6AGlEHs8aD%45B}f;jfLk82;~&nk?S+?G{`!_4^Q;;BVJ*RRc9XG;_NIf>8zA!4257j*zE#R8d_H zw{qkJSw=RwYT=k6?7?8JMByqiYObFM$HbKu6B7|?~{jfCGooB)0NFuV1Us6NXn9b<4OsL|;b%Gf^<= zKS--=A@MnV9U1~h1_w>K#<|L2=yy5e%6Ikkv4{8nBAn8npS9Vd z-G#YP_}k`jD4_E&S}6?iWh0vGO5hR`;275Z0DJG?Xki9Ow`24V@R?P`kq%k7FEse>d4hU#L@ZSXRAa1GA>28Jxe8&2WS~fM{DJCP$aCHnNJdV z2OS*%8hv!PiD^>tNA4*$$Tw3rRnGuKvj0etlzo`a_o>cDb}~$pLsbq-FE>gmBa(lL z@G2R`GHBzLkT>4gU;RyeeAW;dc2~~A1j#7nh^9~RFmy*WIf4jx1`=&?mK;urA3)6& z%|T2Vrm5AaMD0Ki0hcjj66Fb2V*FKR*^6tFXbP@(IyG0muM;ky1x>t}1JaH_H4?cF z%umI22fDY)g-CI36PAc`WBzDqBPA9m(0+a=XaV78@z{3Gz5ivu1)f4$k@T;W>cH%c ziT<{|OXy#DVH3k@u10#xMqsUbEbTq)M{)$g8Q^r$gn>aC;U4TIPm5ea`uCyB$dlcQG&GET z=4kPoBuaaXrlcu`8c%Iq!X-$9h%31_VxO*ie;HZ<0rhK8=9Bk>+m_-{f>6#EmQAP! z2Bt3btUiC6jK9<<-SbIaOQMZRVN1%j4IRY6;`HOgs02K~W1F03JrZc$_@~}G}hCnL(J;%x9!Q>Kr z*Nl{5xl}N5Sk>-s%lG85EK|&m(U4vGx^_oPq_7ptFWV}4h*g;1{I_g^WE@GJ96F9@ z3o0jRka>O}EcI7;MSf|%}XCh}KPIx6bs-y*m zPT)r@CBPLxLf(7(m0A&fwvuxAtCp{= ze)P3yph)U@Mo;1_*u3R!a*f-rHbJbJgeDvC;f#6Gbl;oiJUV3^R@zsnMpS4TXw0gB zunUsun11vm-j9BfKzhd<=@2XLRH^Rg6xIo{R4s+3iERlro} zQ43$2DvNnWUG$T!OSEb~j`M?@8u%@EBvwmYd#3Sw6vawnf9!%WmKSCs^6AeCkfNOB z6Ipy->RuY|Cx>p^5)zaVB=aVXE)#L9+K@(Oga@z}!c_4M7Wp?oYhp70nv@@3u^W(D z_}Hn32>n}C4$fGxiAT>I>v1FAL)7-8mHS1LZDfbs!zB)Onfo|M6V8@pIEr?{B5-`} z2!~+n)c-scD^6~LC5!O$gA0K>^)YQ2w4#(;3;JyoY9Li0{zQSQS{zUVKEJg{Gk|L- zL~=t%EfWy#jtmASC(xdS)(Xmv=EIz?^^x^Sq{%5C9_vm^-@$W6VY7OQmOGJOsinBC zCw7(tnKHzK#OXQ>FaAmkk?a`qoC9Ii*?Vu5+y3m5UhuoYOfy~U+f$Wo#u7KCOfv{B zJv^;sm{Rw<^b%YMYQqSs70x{P+^k*sRZI#FZk#|*{YjN#87jmf+1;N44i^}PsZOH; zIRiQs*sB z!4b}fm&rR4K=+Osf<%^?OOyTwNid1H1TVGqn(q`(2SZ+I(*C>==OMC(mmoQlPE>Fb zhRyV%;Nc(lAdch1_MW12$dS}#dXALhx(RuCqSmgR-$$l$i2zY4`B{sK_w8`|{ zxCC8N&kzMLv(~6$^Sj9Vs-M3f<=ARLq9|3rD7Vlna0XHl-ribAe6bN)!_}5`6|=%$ zY(vI`?O>Zb#%)z^-`5^H);LpyvcuTbS;qi2AS9bRFK%aqjA<5>cxQY+iA}TK%%EO@ za{p7*%N#i|fX!)(I}&^;EDJ06W}nJu2F!{G8j71q3id-$hdPm;o&Cex)HDqv`pv2o@R*^J5+x#7Ym8B$3~5 zf#n`@6qm|BAp-QHKO}{jpqpHw=^d~2T_wEgKh8XrD<-LdtjdxR>FiwhxtZ?raMkZX zBgm8B6&^-3gy72+iJ}3)uq=B&nigzRx9mzh?UThovOcMFP2NrKZ2o&bZLtn+YF#SA zY(zOjl6MoLb#@*gSJzegj|eJurUYYZq)5L-M3LY|gE&J>bGS&VketLtfi7E z{wrb-&`$x0T+3p8;`oEuc63xK1dm=uGNboXr_4rl{+Ia|FEY$ewmu^!nNodN-Gc@F zSw#@jpzIPAqILgY%Rh6@kgm1MMLz8n)otH@_-^YLIlOmI(g9Y1+f6>8CVCEGV|1|C z#o>U?d3SwNtD-9Dnl=*#OhvhmkT?bC?CWCG+}0sb@jc>2jY#;neu*umoRy(>MDfL% z8oQm|G*u82JelY(jhxny9k4K8UB@=hFmrvk9l^dVca$~O7*$N`tWrdzYb&0VIYzL# zPSXC2lU)TT5hBMs%3mIwNS|Km#NM1_4t$5cfC|pEuUpShUDdF2+{I*0Kue;S?;ukX zMxs51tOlw8kU{v+K-yW9q0#*D^?K5JnLxy`pZa8uq877i@KRu3MGL}KlAlz$m1tpF z=-=)SLE#|x6{tCf!4wQX6qd6V0XDohw+|^a20Vs~K2bATJjZ37(f z-l^N(V$uO4Oaqc72ZbrO;-Y|Ll}b*!7>1c!HI1N=uE%9lII-2H+$R@QwA2p{b0v!e zB(4<#u1oQ>Dt0&5gW62Umt~Ns36ENdnOg?q>mkwKZaOo!DIn9D* zSb2T;&@#I+oyxYZP%A7t2x4@|cYxEw*P5ezPykqX)3Yr2uq8o%KzA78&W4tKLi2LE z988Kd82BPH757SMbLi23p5ERGfn!ijdo3pVEzuW~y`U0K!9KUe_qv^NnB=|;syU!W z2wSRvp}5c}Bwc2f==LI7GI?1Iy^Y)-5iF2Ec;0k&S1GcE4_F%ol20Qk{YX5OxdYM>*F8eE*%B#dufqV|Zj zK0gHkKtaOi&BNx)q&>HyB0rdVUbowv;bz^y^`Iucsk8B@t_a$9Pblx6BrtAvC zFB7(^Z{CHCA9dnQl+6CLi~4ZCWM5gECKV!QC?_wCgp8w!K;Ey!2p%6p8P^D8=L|)W6>abgmcedkgzpf0_Li zi2@Jz;tD;1e9&L=M4^b%ebf&(^u8I$F#XG$p~8F2+Fx$!U~AB%+^l*jgzg@}cgs|| z^%)zFcm4;0&{h6#12sEm%c+e*ZYnHsnFnQPMcM&-RsjLKJ`m}tr9C%jD!(G=qAqqL zPQ>?)k|2<)2;tob6~fS=$IyDtIDJF3|23osO1Af}g<(Dr6I+{#c^N z`4j~(_%ue=gTEUpP54KKVxhi*K?nd(V>Z8R#Bo^*b}0B{7gG;aJ@0(ts?w2;Draps z{g=&iiMFJVS?{M?&!eSY@0oiCK}K2`fmys&GP$*_mv5Ks>FL6bIO}Ah(RPSQ#IzNu zIoVi!?Kh!wSF#Dci(VW2e|fMu93wc_@1wCQRK*5n#klwuxq(el9)Mxtgl;Z>&9;55 zT!Z$?H46yWw@V$?%7N)55njNemj$(`h%8xGO1#YG{gy$c0=a&Kqd9vc%L;$%!o$vDFT z=ip1@;i%cZHNTc5+;OO;MT14uUx3UVFHoaTn5D1l%WV{yM6(#gae2!lg-h82($8)Hn@s7dDuw* z?8!yF>qC-r6JO9ZUb*;O-?Z(cySRy*cnXin70bTYWPW?I(GNx=_U*8 zPDcsHs@vg~2bY$G1x%biS1#8E`hGYe5|^=8=4h)*)=vE4-Eht5^GCVY<$C=PhnH#) zk<3)rUzD$m3ohxK$-_7h=xDC!AjH#L5nQS&VfqwX)gkCG;w`xQm0D7NLHVowKvTpK z8@cCgvwVHJ$D+aJe8D@(dwCo`08zWpzqyh6nF#ddFjLSX7?}C}1eMQ8sk(cMWrwQh zjvnbpu^WJ8)boZ}*rHa+AGr5Q7%FV&jE z3;jmEbuDWNpQJTVv-0YEI|Hn!q3D|2+n-_>X_?hvguR7yvmx-Gda=ZtZNOX_5`nul zgVMW3|84@`#O!3?zjF(Wt>#i>n;lfNHt}GR|2ss!1

Olzhx4Jibv1l7B|mM~2c> znba;rt5}Qvd3DD9u|7fehaHglxv?XD3$~!OH#X(|jYz$0-$I(JbbC$M%UY>kbFd|x zuW%LTid*Fp10Vz4*9%iFEU;`};w4V<{YdLFc!(}?98hX+er-Ls@_v3aQm67G}ULF+(wcsLQ3VT=nn38pu45^s{KXxZSd^vx5O<~Y?$WQ$fO~;qgLTV8hwDUe# zs`sC{nZ>zMqwBJB0snL!aSt z*)#`y@vw-Gtf^5s$LwWM7tWc?QOU%?kB(QeH2PuF&~wV(t-Ix_j|RNAsUNRHHNGkL zb)*nqx#?iy-_2+E=}`L}<;tT6jXZR|VNo--A^9=1HhvTn+)p}wlq|jq30nUyrrsq$l;k^6 z?if04GH-4CGrK`M3*$6kaRqZn=aYXgEH?_waf0zzFimtW4J&_qgsl$8Tt{g(jA=bU zmW#A&HEpDXYf~P;v^Qx#^{f|~m*5;M8%Qyx-GPLTN)Z8c`@0zs+JFt0JUSh3RD}31 z^nVGwW+)NriTK52uKm+}BueZV*VRQAx>wY6dbMOOwqpN7afTLzeM_~L2yv00RsO^Z zY#{4>vcG#W?7x)XuVQPJC%&Vrz8B>mdo;L%0SjScsX67;4=rpu6?XF^2ZA$Ck||`` ztJCq^tK5@*3pm>Q#sPN~%^9r|C4J)Lfy?O1L-dstG~TvB0U91hWcx~1lkmpDan9un z?oJ+c-Ge+g&)q5}mBI!4|CMSdf@EosTh&Fsip7fvN_b&xJw5!tjMdrBUm+>-DL38c zyyAy{mPrsN)CMT9Rb7E%@eVq+k1&r6_^3c}A5hQ)X?0PYm$?GA{z17ybvw(uYM7#N zJZLQ0q)}Gvk=^1|)}&OOQLnEPjN`l{>awiN!DU;~Sd0@l6!53*#iS0cPj+~u#!52< zB3Mm#XE;1~)-9M&`S6Q8Tw18MkTm8r^X4GMe-L>z zXpUXJlY+W&4z5DbuqsD%^R;BNvkHat2%ftfZ}b*5cb3<-5je~e(9gr3}h7Q_WaO>5MD@Iqmbmd?Bv^1snAm%U~hh zK58QFL7bSFY{X0IYEQoBq0#Ki^HErh*~`l@Zja2NSL6}Z(;&2cr(XM|aY>alGfRpL zd1ZJ-Z<*$_%;YTGXWsNpng5c9FCy)>5Uw)@oHzAoL--i@v#Zz(!pc3`#ia#hJKm`R z$n-gtM6g}|Y2*1lm!BAtm-bs9F5ng|uBlXBUk8yFZjajIA_&!(P+^p1C!fk5ZlD>X z>~g;LM%VR+csz?yc8i&z2#B9zeSb&Yf~&!)4*q3g?BOQ-mSfU9fdH4G39>mk$eFLZ zyj73<%wqzLLp@ z7dn9Ls3Jj0Xpl(9X)6KN^RRynYi9Z{|Q z0X(kCxQf%m)2(>bQPGd9hmY2fDyWWVj@9fd>vC@=x1@9w#{V+38%}R4M$H~NgmrmZ zM=TbB3gpW4Zwbc|PiPSPr`dt%u<8JzBN*|w6WKAcb*5*5i~Q?(?1m6GzQyf%cph^h z@;`?oZLf@#Irexefk}%!KHdA0@txkZZMFXBp!1D3F8AuVu^lDFBMv}=w{7RKI*e$A zqBSy0nd=rR>5A7V2t9w{Jles7Xi)u};)K6{?|8;MVP$^)!CSgpN4a_!m}<%5acCje zw~*n_a428|IO&9Ss$Xvtp$}fLFApr0HBlIDrAA;#`V+h|Rxcv5>DZZG0AmUPfdB!t Y;sWKu51eC3d_FJ@ivj=u00045TEk#=i2wiq literal 45392 zcmV(rK<>Z&H+ooF0004LBHlIv03iV!0000G&sfak;bgHBT>vQ&2UJ%gRpOV=m z)Cw1$gJSr13Wqjw8e6WrwhVr@P5m+HhK8~`%Q0mv*PCM*owI6Yp)+R5I%=k5KzvU^I|#lNfby;cMrL0W$xVOh zi5@J4vF$Rt$g$SdqzrzrY{wSFWqPDRK-DIQ2&3PDgeQ|gu%d%Cf8j` z6RrBqeh-r|PfIDw15#sIn9zuyj!X;nxzWy*$pPIvqB;}t0J%Lj*Om0x-|}}4{BB@s zo8NsdG^3zOorw2&%N_C<`uMny?~N$km_!{8ozJ`j9A%>8f57tE%GGSjQ9EBXQU6l? zmJiekw6Kb>^#@0J5{~f{od($3E3zk^yJpokuiM$nUTGXtnQYl&3!+{*oB!P+Vtk+Ro*#wFO=mc9Cvby#BV`$^m z+FIjUh25&Sc7s^|GCE=DZ;tuv;zol^@2(*o;tbpX+`$IEQIAQ4kx77PFz~f+V+j_9 z^}+sbw;&+OLs8VL<5_)N;J$BpcDY_wV?e~2y)s%U@$-p$mp(PUk3FWD%@AD2BC9f2 zv7A<-csT8m8k_xRd_V`#vn-wq1TfYp6@*T+ik@@uMA5k0nbXt6TV{9Q z1AnTOrqpU>Rz4W#U(2Hc1h{Y1?!MbyjAb$vR}0K(?WoV)Ue-SBOOal2%8W1R&G4Do z3gx2X2&Y48h%k&hs1Rtg27_FNnc;1^AZO&{3Tl+r3^hvjU5JM$SQ%bBY{Zbk?Z)mY zdnwMqjE=Kg4S9+x@cGN#D+I19JSfr3x#Z3Wj=Sb zdGE?oYC?kAGPF8aK?~XG%$~p#&RSc;-*dHcj>Fe*qqjun`g-lT5q~4n+Zup?^_Oy& z0(V6vzo89XAM~cSeW;o_v{|apu7M5Rz_XzC{m5l`mSDu+N9zQPJlj_X#axrL66W>C zrF2m63e005P?uYn^=!Sw##eqMBjjErk|ju3{h-6d_$#{=2I}bupSEzvd8a|Gpc*mE z@x>P@Su_>{I;P%I2OCbb-SWiHX zxq;Cfa2ka$8djjBx6d`XCxz@F??%NEbvhgv_K+lvu;OKe4VIv8 z)H%bd{*G|`^@O5Vqy6}xK|H-5T2_wiZT3~mln%A6eJ3rvN8&xQ(2|vPUZz#~O0=wx zmm>M|sW@1kzBs>+UZlaWk{A({KO+0s2S-eFl|LTa9NEl?C-ab9T0pP`6-+r5~Eu>JMn13XDJFl~pUrSKONQU)d`qP6&T~Sj>o2zFj zARo81f6-9-(tMmIxoy)!iQD3$3lP?LEuL7C=mBpzip5@DO$%)m;2~S)ZKTJ_W%=cE zih}#_akhPc@yI@JtYmPVl9R^HTDD+N?Vl?BkNGdtrnqd@4)CG_RMq0nQu~~dxCT2d zqs;5O9{R_dyoK~9*8WSB^Ef#+>FXbS&HA7UF`RP{I=X(odisR-Cylil6DSJ})>$B9?++&Dm5-ooQJ(w0Mdk|JM;)$2p0 zV_n|HP8KTr)4wZoK4?k$ zvd?0_(~-I*4%U#$34)j-jV9M+A`$qMzeoh(c_)(iEvr)b%_)57&Jc*_F|Rhv%(i$1 z7bP$Qwhj>-khcP=QWPXQ#b??)FGXM};-@mg<3)Hj@wwds-d!W0LDhRwA^f9TxCjFh ztQiRWJqHX%IZM)ugZ!O08WCH6eIo={wjj=&5x0eCo3K~R09c^fzSVb}MMJqeRp5a{ z4|L(FrA+=ezw+R4gxao0oXF-2~Xq%6B!Px+Rd5+Ca)?VZ=7EH0Q(~xvkni=CGW*%uY`A=*?-@X!Q3f zc$zqhI)HifkApDZ>gr7@n6gnr;;AyF7=mNvxe8ZzgHMC1Xk&zW+hoQzsbhVduSd?o z;f+Fg#Ew&ZQpCWoWYFJ_Mqz8)UxR0Iu;pD@WHCWc0!@sL6eEj!?GzpOfz{YHPbF{FOUO90^odc;-ZH(srb*-~6$un!Nt&r3Se zy8kuz^?D zwx`MC!W0rZ>_5p93^^^-s!`~G=1MT;La<>lIv@9?J$!*oA+uO;+dxpYD;P#oQ!Agi z6J+uaY`rg^2I&u9RiMni+-c@de%Zu<(ndwHkiSkEUO(>lI>)I`Ha6`5rI3oH5^J)~ zq#W4F+?$DMR1rQ&KdQy)EkRD7O%OCMy90sf&$R@bvowi2Zoqgl?!O-g4-H6oWFnN) zalWKnaVTIwuN}jM5>q9oo+w%i%w%(503T=shmYXh0Gk4a?f@9984tvXp=Wn zIFuX5$aB)$m-C2;nWeq!A~uJ*unN|EZTs@ml;Qm(+R5S>k3Nj{O73T=IQy49?XsaX zEv+3}Gz2+UF&hY3bHr9}#kg|^!8hMAilJPdrYg4%O?&o=qW_Z$5OeEcZKXXHzLjXm zZN?jipRCekXsOS*$QGgaxBXztR!gnlnNI~4dqz3)iegIPKh=8^_}m)c%>bA30E-?Q zD|ewQf1nmw8OpBXi2^JG-$WcyM8O&8U~PwZ7q<4;^?@~CE>ZRbPSuPLeR2t7`4jPn z+g!S#`>=$Hj>B>8>d+FT1b{?-t5ptphoF?oZG8=K2WD|nC+~2%+Wcd#9>yOmK7AQF zFz68kgYQe)(=dI%>k=4T>bXVTBz46!;Nj{cY4<^~u#@|enKv$^NztDH0)i^gb-gU{ z+Epttz%s3+{RTgFs;CDh&*af@r|ip5*J3HbIt{_2_A`4qWG+IHIYx0%b01Dbj@3dy zjJ_Gr?#RU^2@|jzU#?XAm@=>q>lC^Shm;JccJqbdI8?0U079t_M&m=fxG|VJGX9*+ zi`GBGG7o*7uEP$e z^CWRAfkQ#>jA!6r!#ua?=)Qoj)Fsn@$T;)(53q{pgD8JPt7>ye@wb_PDp&lbb?Wt| ztOtniPbu;Fq5R!pY-^0e=)`H;g&>7buh5Ps&G@yP{qPd2Hm>!TcOj1rSFFuz{fH|` zP6x#WZV0>i5I`-t#YjPu2A+0h!AJ8i-~t6$2o#d83~qgZ5!meOpq)#F@iZAC z1#tAheue4XUuUwoxCj~a5gn%Do@Tu8qNy2G6RbH(MOaHar-Q8v1|we;4?wLZxRxF& zPbcw2V!{tX)?YR3a_gV%Cmkc5%Qq0<-l~tTkb~?y3W!`6+rgV! zSzNw~P*qzxuA{*RvRFcueQAA9Gfb zq=XYRGx-u-P9tL_0ViiiQ%sBUyp|g*{vEaf8fOH%&OKd-f-o~UB=1d2edvf+#x^P1*XRO!V7zs>tL@p7wpSCK^eK_ z4PYiD5B)LV;TJgE70W5_QR<#}aKzqpLYdT_{RjR$b}nLT??~fs#>joxBZpko&ESl9 zNwf}@-qibn%jkQROWc!goD5RrDgeu>X8^I3p@X9PV|LQNY?TUqv1x!$IzCL;X z7@CU)!~y1?H2i3H|wv_av~3in@yox}F}5jlk{#&B1!J`6F|$K{XLrgZ==XOv9WKhxNhw z@5rQ>9n$Mf7OXNh?&^Z3nrUBUoHk7I>&Phc(vsTX?XGEmS7R2Qd8szb3raMMzn>HK zLCe_Chf~Y|WA3kVoZW_D2;UVpQ`-L>1y&0xsc0SVe{B%kNTRXasP$w6dtEsBUBv)2 zD3;iHvHCg8_*u(A1Rov%MyDq6;ul7NGwqc!DfX(k5{QX0Rf&_5rGpBQ8p@LBh)OY# zopeP&PAwev06Iyl6L0s?*HVXF_aK3R4KS7-H$od}q6p1a5$qX7GXCJ-IBEiDnNh0EJqE#@=*Q*{JeaG?;ios(&#uu_U`U@N@0DgA z-rO9w^ul}&$4(94`B*r4ac9(F{oISXu#De5lkvUGRXecEPDQ;YiRD1AFHuPz=)c=e z!Xc+#Z_K0LA*Fxm@bS@9Y{WQ5>Vna^f~?;a8@YcQABrC}n0faBG&C7#9zgjke06Q8 z5H}0BVFNb~A%U^|xg>(~NMJVAbd9F5NAR8hm;8A)n~9}dIFsIl8;zc&`Ki!hTh=Ze zTEP~SkP|56)zb^wO+UNfgPz}m_uXA1J6mkyy89jU^pG8O0{^G<3b$H@vwL*D?y`xM zXgemR)1VE98{qQA{34xY<<36a{irwrchSItlw5w#MQ8z>%dJ9=se?j}o8Dpo{WoIp z0y&&+5O>m_uI_6zKM^n8$%M6W9a=WZIFogA;B>I&z6hIyw^{2(6VG`h!uF5M&dz3g|YuV4xYP>(Xg zO%!`xEUMPY7lZ!@bK=FUlam_aG(G8Ku-^-hqJctC{7`#v7y1?IPh z_>gScCskzky>GK>Bar_$+I{XeMOWQb2Qu(e*_|v~pIZ+BU#W6!LY!X#PAYbK@PW6i z)dSLicYtvKFge8SMCT#-N^jP7>5ya3u4Q?iVVJ};G zJ?(qWAtjKA);XpzB0H;QQsgFOLK5J_!A)TM5g0`y!Ncl|uCm-vJaLRH2`12^?;e{o z$USmEWH*D9;D=DYie{86b+16BA_L3tqS)-mOZFg&#QETO#UPK5VV)QHnx;5>BoO(h zN%WO`QWxIRK~xRll0)*=q)Z>|Q{`B28y_G+&IhoFwec1yN%)S-*@j2Ejl3KqQ4$=Y=VFj!{6fic#hosJ z^8#e?5&lyjR6(>?=Ssi6U3S{!bCM$r2fXgi&B)OqH!R*~tQLwhaF==CspZ6c4mA2DGA9Ug>V25g3Otz3*=><{#OgsoRJrO4Y+6$kcb`0 zn&Cus2)aX-(PrBo_vmNkhPn95E16pxd$J+?K^avezx4D&F)|fiMjHn|yc#(qWc0$zLnDNc!W19UrY>>9YPrcCJ0wT*ok<3;3sORm{#sTJ#9r#%P4&hDX0LD zq~>~xGJ2H6e_9?W#y13)-+wTJEjYLDne}g1=*XT`LsQV{|1H0#kWwBzL&*-5s?l~J z1GZu?=( z{UKk%CN?_+LB^{kA=AB>o7NKiS)=I{-j~Xpu0BfUbLh zt6cqOfl!yb(B6}_P+PqoM*&gpv^deG>Y$^ErzXi^a`DDR7#6ZVpsQ!^=KivFlxSK?kqE?m49N7TPHFP1C$IW|e(iY83cKGG|Dr%NJDm zg1q;cBv)D{zDYY)|DM-RE;!_HRASf?2rg4U*bafxK)Kk*Liw7Kj((J7vQa&uqR?tp zn_et>Q;lY<$t9=D1t(MhT}3iI*jf8Rl1>_&rJ{UeA%!*@Qrz&Z!C3fuOZtJk=FMco z%6mZLxTM79cMH5PD5AvZO~GQ56b1Y=4$d}%N{z{=09O;tk>*AHbZ0OZHIjO&vkX4C zU%cxg4vR=Fa8BL{b#0yrKyLS+jiHv)h8iN@N|=mb5BnTP5g$FVDlrAcyddsM1Gz?% zZt@a=}C!_7wb%M8E;Duz3n=Ga1-*&aF)*_+~~Qr=iTFO+R7oZ-&s$L7VT~aApq&J;d2&}e z>@D+(7$|`vN9=((r?3&xgjjObRvB+mVCdZL}PwH(-U+@kmP&pZ_|Y1m3r%c3oa&#o#x907`!#j z_RV*<0<}IK9aDrZ6%pOTlr2th4P1eQf|%!9S3RBBCLy1?K+|YIN)8pzP*ZC$Di;+} z6qd%VM()}Ud=cP9omvFizgIgdxg6wAjo_%0GHb@I6_ zC1+k4O2g2<2h$GI{A4N$9E98M@w!w2pPhY}#rM1(G5)q35o5{pKxK6*IR6K?xU{9$V@vLzgh~LUK!~w&SmjrB(*)Wx^aPSw1F& zrI-s1-Lkuu0=AlJ{NPiAq7)F#^;2bi1ZYo+levx4kex`1O$8kkvsYfGu|Dg;El5?4 z@yDRzVbf!aBJZt`rH@lZUZ&>ml3{)8>la>7$`FV(-)UO}G1@NtdnVwH4g-d$4E;NN zLC2YE)Fr=VAoz%%fhuxr@31tY%%g;S7ZFNQZJaGxblta7uDZy3wc^TxZ8v6|Log;LNB$7}7kR4=`_@ovl= z5Hepvt-$$w5N+%qkz(2a$wE38jUb3mm=56ZZI!RECvo>Rk_P|#W??|MLKb+@&7W%D z1OsBH#OH;iZSNOJ&Zob%K+Xs>S-0o7GE^qm0-Yt!k*TMH@?vTa7pKB(w$vfM9{<8E zN+TZgH{`&Yi6xkKa7V=t^LSK@mUCI%Ezu$g_xKM9lwQKkiGkj$$%$VmJsf1~isk59 zroeq+OaZ?i0rsp@VvGm$vH{Q*IY-{@gm%Q7(!TeAXX_RsNt}}pTJbJSPuDLD551YQ zndT&I?JkolCwr-<2tfO*AXOvr8A&ux6XjCbGWohWggce9ZMObr?IG&LiBU84EZ^(5 zR5d7jlLM$(=KIhYif60lOC3~xLh*!5*`8mA{2PSO42*~{ylK{%bagjEmTL`-P_89g zpZ@HyZN=C!jH)EWe-y?H1Y_aU&Zxd)|AWUP5+7qmjKKhF930f!BhhAgQh9vW>Eye_ zc6x+VK;ebUY2`ysx9xhaFxp%{2i4C1K?^$M({ms?e0NtQV{8=6fMJcVL%>=ej)P3k1Zg4$rRm)R5rwvQ>Nz9ABpQiyFE-oF8jA2s$i$#ayC2Y2_tL^F7gBJS-W5_ ztZL>~ZQhI36$()?zWFgcB9H;W%Gg|ToodFrd|;D5$|0;mR#M9wl9BgLKKMfdbZ#Ic#>ZPsa(DZDRh6mC~*FE zw?P1c-^=7CXk@Zp8#sj~*bng}B3~=qtd}UyYrBXaiVJ9xgldLEv=n(wQW6BjxgM4w z;``qH)DBJ@)1H+0%r7iAwwWZm>QjPrf5BEzr5&`(yj#ve-A#EKnctyHsn z>27&zN#JdAD*$OGw*DVyjwOEs6flUVl9RscrA8k+`tD^?!njVc?8r9R1>;obD1vsrzp`Y;?7HnJTyF*~jFsBr_CyzX?6 zC1`|JW+veRYg&C79O^b0Fx*uEp>y2*!W9Olw~$VbJ&|!Li4wxA_PjwlM!rF!1cR2_ zCP`&zy%va#M!DN-Z3R{4iwS69S#M!uKtM<@3p z#D0@|-kM#CRPzsKD6vorW`Vx!|d6y2sB-GxjV)DF4@>^>F+EGaW4&Dy_3Ub z(mV4YwJ{>BTJ&mtP8(x+miSfY&wRf0F-KtVCPKqx!#eBoj^#{y4yMK*hVA}xFaId;!?G*wZS^V1SU zoIFfZf;S&3onv1S7x*b-0SU(@w3~Az#Hr$A87|(y+w-Gk9r-a0>Jl@ZbUgP%>Wp->^!I7X@4Xe!haFtw zKnQd_5d|VkdGbBbTLVA)241RM(s`8jQYVGXh>>y|FaB`dLLwbCYk zvtKL`YSk4SHSNN`3&{Gw1rrUf_E6z)UosirrjxXxJ-P*0BI?~nwS%e?9Zk3jkqIAC z2%(DKUik%}AiM4^pxX+#8kE1W56HE9ya0M?gBazt+LDA|ETIK}$pLNMr?+>h{(!Oc zAU?xOFQuS8b4U?Ku0w(CZjlu7EwI34>&9j_`Ygjnlkzu3lSneI-U_M*y{^uP@FFKj zO7ND@9333(WrjC7R9{z)acd&k##J~(M4TuJfsy3iU^(v%Msud8yyg1%dY;T+GtA=S zxZe^{Mn-8;?u@PUv+>*6OpcvT`=}kFNDVj&0MiF8ShYvB68|+5btw(Nb>|KsTORf1 z}sG6Rb_942f^hDjj{WtNfjhhl8d+?GM1gwS=3EfiM6$xhXK`sR7mx? z@O9*Qp?J2Al`8^!lBD2#59TkB@<_@ zgQH#y#*kl;zIicL{UXJA($HY%0(5T+_umGyLMQ1SkE@~Q6{i3*T1Td4U=VP<6fYSO z(+yV!?Rqm)xQ@tI0O`^*BC(>1qy0dHBr-x#&i7S0-`jX7W6Cxf9}*E`mj&-`hyG5l z*$!gHwEL&Hithva!{rh+9`i~fl6J)Xk7GJshVIAwMQ9(A zoocb__3FVZxWI2bggtcc*SEJda8LdCh*05iMDOot5YcZKOiv4I@GA0LU4}?-PiB}X z8ZC2$M?}$_I2`b_P7g%$yb`z^TQ`u$>yG-_a@q0sfbMD-?4VMOr2(S9dl%+gGAo_|;v+Vm?3bftviZ;_sq>F~Js1Yu} zPZ}zms4RWFHgbK#y{R5NN0jg~{1A)L7zGawiQ!KashoHbH{Mmd1}n4^D+8@V#8RaY z3xeRU7(n`U-81`Kji$w;VyXV-Pzu+W8}Jl!4v01537`DU5_mC82lR>CH&72`VUcp&l+?w_wkoXhSU-Ue1N5ze z2Pru;N(8t*MVty<=S6xutDxkGf3`i59vOV8KNG3!qgyR^J$wX%H-uV|irfH9Fcn4* z#xIdgf#{9ztzXoOaB_=;6ttQc_62$k=){)gpD-;c<5Y z2VsU>Ep4jS(GF+tW{%m{kV6e0CVX)i61vtY4uQ2xE9*1zglPkw&-*6|^RhR7)CEHQ znS-^4xbi3NzEZ59>xxCW+Dz8wGlBen6#lD z{xced;8{(2We(wOF8JhsdeKD~oQ3T5VDph!pjEQA8n9RB12L$h#`sv-THdltIY0`s z7{X%r^Ig-^t)3iNxv9BBiLIKQqMHe|2-pZ#_bB=Jg`+yfjO{~MX(*6jRP?5@MT+tL z#`J>fvozs%fY)?LlGZiL3=`hE7{m@qylplZ0d~#+#NX>hTxXFgzr~M)Gwrc27`43g;_|azwfxuTGs z)BbU~3owGJl}LK9*>eQ>LRYU=6sF>n(eVKCS;c)tP9*2`@CLaCsOOA#DbY@In7!6N zT6)ShqG>3c`^?jLQ%KCKX36)xW6FwA&7=;SWxKC9^Hnbvkmcy|BExD41tgyZNgCmx z*>H_{?j_h9b{utph%J<=Io-elf+a6R1gM2c_~9m!bUt`Qtv5?}6jx0pqf=PCnK%NvSoS-R>!)h8Iy9kREp9x$*?Zp294{Q`P-@=K+@c^0?)x$;ZiO|9Ju(z zel@9Zmg2)cH2qikVo2l78&G*#c+u$XSRihCLloVpS^xXgkGAT>>v&L|1rE&c%FlQT ze%$zSa+A$7ZbNAL235CJo0LebU!Q&|=1zSImY|KqmME#Q2z|R##e8B88%H&)mvhfU*qaDO5qZeIH?2&X!7S* z$h@tEUD-1UgL0^!<2uGdrd*X1L$=Gls%?uXjLFm6=sI~ypNE<|zMgLgd6Z2BFOwGc zwz~6Y4LHbaC_n5ZPK?>TAozv4(nJ%R>g}c7cnKOep_;Zp-?Fatarp*3+BM=?kM7#X zn&QS0FW3_&bpy}#zuXMR9HY5GP2$=sY;*5t+Mclh*8L7{iC>!W)qHG85^r$uj5cNC zHtR0(Tin#wm(SiYkydz}MNR$y3Utw8{{?^03jH#WCPpRw*I(}9qJwVqed!w7{Lp|Q@e$xJ*Uvi5QuO+;OlDSnD7#SH`; z!o_t;LmNHmBVK)iJ{_Q>X3EkX92XXPnOCBKx(r+_<9y8y24XFJB+9>E?EweJg7{tMA*C9$IKs#KRk((5ebO%Nx8m6-kDvnnl z-ZfNbheltZ(460#E(Z_d6k}#d)dJ2n5o2)01eIeB0(7J}Y#grlGlbJ)a-@@390lPV z4cP`X6OAXv8G$L!t^6BK6$IClDEG*4diBY|9G$0KRisN2b*er0lG}nS@v?|z=yl#+ z?DOQU4?0IIA64&F-l~DVJxK$xooGDir0yt#I3VfvPuZ9yQ*NRA0-pO9;v5lx?aI<) zgisJAfax%(5LPf=A|sL)C^x-BndN{N!veWws5XVUU00ZvTMK-T0^Nr}zAcxDgwA3wt z*{mO#6-waFQvmUlP$3^o!l|}`PNM>-l#^9%A*s+HL+*hkHugK`20;jmQo%+361Tl8 zRVUl94i62izhVnDHZzlhBVjc$+}OInO|}8W%O3!ms{{kkR}0-Xj`DcQoqK0N&VA1`{blZpHU*R{cYQr^2)O`-U5gzK7FB5v2Q4otI`&4W||7zEmd^$(z z0GNSTh85|W^D9^&7(p1OHn=AI14E#o$aIYZ^@F4!hPSr%GK&Fb+ud)oQ&)43GU*^; zBLfcFs0JH(LzPj3(0au*=w6{Pv&lr6a0-uoTp@o2LR1+?^0nu;mnMneg#QxeDRfVmvG>=Ps2vXNMx@9>bVL1&*%Df2Ib>NtYf1}N zZ4uTBKuYTg>)3n#1%+`~@E256boHC%VO(K3tgNGffYLSXfi-e}&u5NxsNR z1wcXOr(<@9m!>)>wroXx~jvZ<&I5&1%_zI4NwhErk%c%G6%EGWsxpg8ae3^ z3gwES8Q-?NMhI#Zv+QM=c&s!-(IRP;3A!VL3N(Y_AN6i|Y>(N~^%V;>TRFb3&7V1& z;AKFFJmPM8Y8#sE?!-bL74G--q`P!dn*jrOI2!tvsTP!s%eZJzaOzd1W@44nR%!7D|)Fh?K!kMyD~?06DZ zytxCy{c&LJ3mRm_D$euz{p2&mW(Wns=z^p75SN#zWM#FPlEkDyaDIx#<5gbvL3zOZ zan3wxFIN>QAfb-glGAI`BlsNYd1BM)wuK)|KlB7xI4upeh2KYSqt=(FC%Vmg{$5H$ z-hNM> z8`coLwv1^Pzi=04PRqA$EVtY^*3D(CXG(%t96HGAm~7V9t5zl~)CK2;o;lq$C2==gefxJ^4_I!(g3mwMPOXgyOYPNU3Y%b_7knoa@Npxj z8u}r)DIn8F-4Af+$hk-43#Aljol)%;l8#KE0~2vvkMn2vVHokl8l%-C23zBn`TTky z;8}!ig%qu#5)PuB zN<=wgbrco3YwE0A#)Rm@mX3Pzwz!vc%m#CdxGqBdzJbXp8YTd0v=8>P%0bp97rikd z6!q_u@#80^G1wZ`c)icF<@8R}!IZJGH+0NJ?=!Bc*Nzl%IE@%NI{%o7zMOfs3*T+( zUt$Uwvlr~k`E^YHV(9v(wicfLH-6tzEeKkBjGe@Frp-W7#PJP`^pH2JM)gQXR*8yU zoC$R_fc~Ii)8>*bwmS#F^*P(cUx5q(>geA{TWdKdHQGhJIRGp%-Aly&5%?cWNgEWJ ziFl5fT_2SQJMSltLuhd8tsWCVGUBR21sNEtAcmXo{MtGH>21c6{XdWlwO@|h{w11D zpyHLqTQ7Mb>SVYbp^?x~+*E*g^58-S7Lv(X z&+AONh^g!BKVJ}wA#z{qFe(-zO6&UiLfD?n4HdSsSZm!s@UtcPcmYpI=E!AyU{9& zqe*+G9AltMf2uQuNV9Un>pz2BUv=wCQlUeKP_1cnH(d@F128hEk6Yb9OOc)u4!-n> zF5NraT!~0_4uG>28I2X;4*dPYO;20*5PVI8O*7qo{VzQg2Yz)0#MXVoIuCX55(wm)7FV)RcSGz;*hTJStduBaTOIl#FaiSkxN*Yd zX$t9>c?J1N-)ZWLMYyeK7KPZ101M|FrUQs(I~mu*CMp>b7sBlKJ_iv`2i+MSXn-o>Cx zh-x?0=mp1d#!y3cosFTP zCVZwG${HU*!VX#OI|0d(>8kkMWC$8l3twH5CviSzCB=WcJJBS~y=n;W|FiE-7>!xi z^YRh%??5i4<3$u!G@@$K7w_)f>N24HdvO30e9951arlpRj6i;-OO5AN?3icYwy9h8 zF=^smI1+EwZ}A4Dt)g(!8LU!83z6>2FZFz0Ownj_d7^D|{y?UyW%_9z47zN1ic4Wu}oako>!{ z$NK`}q==d4KQAy)X|dtRF{K(i`zg}!%=7@ZRqrb{j8h2Nzk2eo=esbpt361|h@^3~ zmtr_E$>fyBQctku`E#4X-HeM7lX5IN8g$Hqj@e#EXTliNtjW`zaS?lUFc%{=)=4S7 zFf#%g64B7$V7X{a4GrnFY=97RdrHYy#ww{Q{n;Rg0kk#faja?%j?(S;N6xWuiZ-~g zNdFU~3p_D%Ksgy@#Gu(vxv>~{N!B&NCuu~^9om0Z z+k0j2*d+Nsxv$YQ_ZmNH9tX3vlL-_@jIws1S{#=0W1E6TR=iUKix{Mwu{@)|PD^0` zKO+428&BCw6)?W1JS7bhRw4}31UGE2KxyK(rPSPjkRpmKL&umepzkXm{y{G5IHSIU z<(wzkY)A>q+K#UL;f1rMIZjGZ*La;sm1EkQRyy}j(|E#~x6K*&TuA5PrCuWvt*D7#xn%D@KnT5B zK|Z2gFy8%r6(H4#3Hg}GTGRc-?OitJWVI!)ER%#P+e*5=c-v0XEjB5ig}su3bK!;t zsv`ur&JR>F*fPW z+Lpk#6s-ZiZVQP3CfoZX3U6@g^6@L?S(ofGR0K-4#`i6$J=C_%`owBT`h1||@C}GA zbre4I-4MDTY&tcr$~Wp|lXy98zm`Wo^!}gU6y}m-x(x5U9C0t<%0HV@eiHrsj(KmH zFK%*jG{m4_HLc-nkEz34H;}%Wdqewmm%qPcK#1sEj@_m{@sN=WZK;~`{{3U zQs8G`f)+yAhF*}8;g7`jbb}XPOUq<HfZuP)M8$VrCb4}OGAmiQ?G$hz~A z5$Y%=lu&`QCR@`B71=usg$W#Ff6*7V#0=XIeh3E^*tr!7!s%gh166LjxadpkWP^N*AQGWM8lQO!w`Bw6u4aq z)Y-N`Up1F%V3dMW)72-|pY&2kJq-?aeZN7H#I$54&-5)}%R~esgoY@S3v%7%S!t^_ z??4^Ec=R3xpAh{Xv4$IrQ}acQpc6m}coZ zeY=H7eNQqN{DHM=6lpWK)E5-12x16B#5;jU`bT@x==%ipSl-Qh3D;05L$$zpNlQmJ@q;%@`HbawLGC!4YA0 zlR44V5aR+-z~Y5;qABP51j~h=uj`%dqpFSc$5Rz*K-Lqgb*c>i9C-laZgpme-#fr< zNeOrX&{TN;GM0UArTCz z)Wc&v_$W>d#{!mJT(bi@3#odoOK9u`?yq9g{l?4t{V$}Sipf??`lTZ>-S9h8qbmyx z?f(_wO2aiCE&&u{!#B8Ant`Nh3Z^*10+PzcX_pt!4ajI^*px$nw}4{y3;07YDYM#n zdZkN~NarREe#j~0uiQh~))}MB&f4RH@zu&}wc@EuW{7rPh;aD?eBB9YrMQAz0DRat zlX!Xu`#74=)?$T@Qf3E2ij$&8PukKkiF1xvHU%LfNm#P5s}EEiHUG}GRV76NDc(3{ zbB;U5GTr}Tw}Q~pH!J??tv*-yMmp<9AN%q4N`ND7*M13vAu9vi;Pi6R$S&=u{6T4} ztHst$GZp>o2bKwar-Q#6-e3%CsV%-(l|5c?)-baBtO=l*uC^@@BZGvM+QVN}UX;$3 zb1#--{NZCvvF4uXp+(>&u7c&a#^r3pftIaBt^W;cWvHImy89f!ST%GkKfIj(BlW7z z1XcM1cPHM3{{LK&*A+fP-Qu8~#FSxqv*qv7VBH)2yp8*y;OH&M0@XmL>n18#5YN%X z5>lw8wOBGUQurpKR_u{RIHg?@PfFL+40UOsFj99hX*GZpLIc!xVI<5@)M$d_EM;e= zZ)OuIIBa4ntb<5>W)#09`O0RXWYXn zBkD8tD98-e~YF}Z(3^vr;!lX#{EMqXjGCv2fO@hl8? zE(rUPkkFg=!S37S`+XG%98rtZLl*~1WHGbfCTHE6T~}2vF&s3>*-WcUAe6V<&0s3@ z$CM+PTrmF)A-PXC&9WWAp!RiFgcDCb=STr0y+-cT^-)P6I7hAs{(%!sYWmIiFnriJ zR&D@oZ(fEcGH_;y6e%iJaA$g zm~zW`ERn)mT?kK+ez;CYd%+*$Al=%tMWKNvCu8KY<3LZ-kLw+sfx=Ppu`ic&$fDh< zQ7YuxLNWt1YDiAkZ>I&XFyR$ouNN%F{x5XOh=F0fafb`7oO3i=ABJw=*o&z*Rxwbi z9kK#JbRymz{Cv{aWphU)C4R$Q%Z@}gs?C$|@^6V-!KsB%JV3`XO@~3QV>&JXgUm3K z&F!bsM)@V5;!HO_Szj< zCs=kw(~o+A7Mm(P*-L&;&%y*} zLv>tvRJa-f7d?i|lnyVR_in2~MP+@%_4k4UDK;m8g-nG9^W4tuyc>tSR7gF%$ITxP z*Xz`)3p1}@Sf%=C*|Ekcx8`AtUYW2<)&PF9Hi(RX_%~3Jz*k7%q6K?DDYxb}0=!X{ zr$=7kpi>U8Lu|nG7vc8;&hAyOjHvWqskRpJ>enh)t5O|2jP%!RWq)K~1iC{6wvrL*c=A86 zGGQt;vEA$3=qUIkp=a4kN+kzv=IKZyOLZ_o~MO zlZL)HQZ~i%e~73;LuIwQ-6Tj5)RFw?;DMx^rEab&$eP2Zj8%{)d7-%XfbVaDQ@!L3 z3&|*;x(RhmK|&AMmH8HR2UcDk=ZIl@P^x;pdb}DtKQEGJK_K6vhK+xNd~|Nu{#ZGZ z%@@04s!7C;OWW9nT9;jDj7R2Kg`QAl57WTEMGQht*r6RffcS|jJKl^WHk_Z-(OiEm zwX8;ckxYg5*TYoX3T>5}=I2-c7~#;aeb^U!QxI?n6YK7bRD^3L8q?ojW|jH-rttL* z=_sHABdx?)+YkMTO+)XqhK=^9DyZ)>*$OQcp6wR}qa-<-)^y)!vVr>*ACD<$E_n+%AF7JMME0R70ja zlTvX9W>^_tt&*@*O8%3)Fm}1R8{0bkb7x>$@0uLHC&{*d>RyH%oDO)W9Z)T^5wLTq z(!C3s+`&oiY89!|vfN5gbgM%p-x;rM{1yWmvYAfuH6BZe61Q4hRqP~O*RgR)jl*Ix zVx$p~YhKR7nwXXi_vqK&Jei$C8VVHg4JB`N@7%P^gIvVp|DsEx3S~!X)KjcZ1;^sC zGuAi#>)@{ZrsG+Q9F|>?vh4HzP_9ngylE`1X`a-&@+!eTcF!r-N4br_C9;o6H2*mo z#3`x*YO{OK7L^q?H~4n#zd27Khaz`%{BnwZsX1GP)?~|?wYW?*MQf;bkHas;v)W!4 zF^Q!xe_1WdvmRt#nqwqIEYnCLRCR?lbW&KlZ6TTR``;she3O=Tlz6e~g7iIu{0~M6 z-*TcqK@~7+6&MxDa`O$P>fonWNKjpO{M@u7@@;)bb^A(E5cit649U%uF93!3k-OPT z?!LJgYwi+v8x8a25UwA>_AMfah!vcLyE%@qBu7SZq?&4D8-poS-1xf8! z@#A*LY{`PHCf&bQMo#^Ysle)YP(Bqk;+d|Zi)s_L=}gKXHjBQgK(JvE=t*0(-B_54 zezyjHfqw$f3^Am?4={kmt=#(7XpOr-88q03Omfala}oCc-{(R8bDb z>}DZ7qMt0sp{%7W?&9_;K@1z2Hgj0(!R?|(Gu`VAJ!{PG1@?eyAxfjo{pq&uIbgZ~ z)1O=Y=w2%xuhIbba%2BXB(qQwp8Ae^7l#b>Jt_{emI8b@GjbT@s+9dYDKx>9=k+et zXwZRN`F^01_DZ?-7dBQqXwF2LLx*e&M+gI5oCeo_o$(!yDOZHMrhFqUtbp&bU-_ol13(N|bFzujML>@1y z_XP?XHRFdbE{1olQ|#W#PGAl;o2IYPSZsfNs0w?_G}3P>GBMyP)@#<3)vt1iboruV zn#lbHmqaU$vY)p1MNF%+q4!MGxu~300KvBgzabH|r?p~5Nm8F5w$_cr5p=*WWy)&i zPrl%Ui+0zOT8?@_Y3Ds`p&{a93hTsMdN)DGd$lx`r}SY5&!MT_?Gf4`mRc#5zBB_&9fSIJ_D8AS zy4(i}Prizqqz~hNf@yz>``7_d+_=od6}bVxG!{+^ms0EUs%AQiIG5YKqw3=CT+Dbf z`0`O&Rehw=Nnn%L=Hy4n9yy>??w#Jdh4eV;WX<2#&^KX{{$~ul!(jlgf6IX|MVIVr z4LcF*W-klo+4Hmr3 zwaJNkLM~QILQVnl?4!_4^R0CcC6whE8|cd_ z5g>{fBoAgZCt^Dg=d6C{N5D@Vnr;>kY;#M|N#P!9id(r`0MWxfSc=LwdGtA;z+z_j zVs$|={i2oT%(9irFL%$KX=``}fN?jh%Pl00t-Cj0fviT)puwVb$EJv=b+80ROeC@FDB2`b?F*TbX>uvvyiGphK5G>^;N2Oy(wunPeQ7*cgD7%Y+L%#b2xXlyd5ct^tV?jUyZA?wHM zggWd}VG_QvD%9@F@==ivglEU&o7q3aY+xbOl5=R=VLPvuIyK@MbX-C~7C3k=Xx|t1 z+wT5K<*92?MaDMj<9L^7kXfKo?MqJ%ch7okqDsLfa?kN%usIXSF1J|)9z#6&h>`JCIQMNNAYrnKJ%luSHZvxA z&IzHu5jUUsvplLrrrY^8Gzw=$r;R>%K+c;Y#u2E`Bo}lBC({n|LSGXdRY8vvg1KEB zNj=)gyc=!rI!YsVtpRDTdkOb@h(p*nFSjZakgS=C0j%mtzc1;{%P}*tCp)WQt(XZ( z!*UA9 zN6&C?hnQ~-6rIX>pmD#jj*cp!=sB_U;yZ<~s5Z-?tf`t2tH&{pF1zioGdPkgAa_vK z_YayrS{xlgv-E9Fp?MNPa*Y@xj4U9JlOs@FcJICbH)JAsH?tf+sJpL!)*8*GqBz@- z9(s+13EaWIStEuhulCa0`?Ny}Ufq+O4e{_tyy+T_KEyKW1R}Q7x{MlzJ`~BdI&q5) zF~O+AduAzUz5(fncOIxjn*JiGCL9rS7ry;>Sh50)gk^egrVg>l_oWQiO|wc!>ewSI z?|W)Hc+Z-=P7Q8v5;FuE-*>q1$CyAJzWX(^a3gx%PDk?9k3Wkkmg;TH_BPmP&yoE0 zfqc3g@)Jc}Pt;52J1Pc0UcerC(@>Wx08US`&+^tBmPH+nHvCnW*JU$7oed6a^0t4? z%$`-gT)^2)El0Z@PoP@-fJ7)oLHDwnhw$pt?PTc#^v`{d-p9ecRF191Xb&iWRuL(vZ;X$Ifc8P<2##l~P@TzBcRtl1x0LXzthntBQ zHd8Q?%^==xH*lK|jt(4c_NjEa$^X*4khfm<6TFKGHq77r4m2Z0+2r~C3OER+DP zPJQa}QrTDGU%7XB(B`F=K>P{h@4{rBgLg~ez7~xp`ijRRu%~{QMt&7OTTjA{a1~|G zZ&@NS#i`uYt|aVl%ONXvAGO`@x?h~oKBMvg}n3L-skKAeTL)!b11DOt1yIT z1IUkMc(c5S+AEK*o_);YECvfzUbJ5{_7PiCYIYri+HuKj=tp_opY;#{Je2Ox`Ftgd zS4C}8UE5Dv{*TP2331@4?tTex`_YIHq;~mxz?y0}Fc8wEpj$8wX1%fR0i1|qla(^) z9+PF9W9+od*!R)$($-wMPA}MjjD*kbcP=;0qGHW2dH5N^a8f8capee~mtaKQK+mH} zNPCs=4(+oL(8Xv^4+;FQTYzb8%-2qj$SJ_BE}z$7x^Gk#zE`v3>$YSaO7fq^PYA*D zMZtLHPZG~+uYxbe1fDGZ9MWk3+2l7t$OE&YdHz1J-nD9-E1kvQV9IJmaOExbh=5lPW4DJoocCoRBz7FXxn{@IguT~G zp$CdzLvaCh?#g#k+BCNvB)8hr6}R3^MVPdg^0Z&p^~;_KC37hKv&Q@rj}U1DD-oWK zaSldeOFY9dXM;%vwe~E<g@`}03kqep8Pwmv_~{K9TBfC8K5P=vz6$oGR3M8^9q;*`O2ywZ^SNK>upiG z-0(B~aW%hU9pkF_FS$4AL_tdu0!E{M`#;s`%USx9X{S+v{y4%`xQCG0Y6cki@Lgt% zCj?R1S706|m`>&xF$49`(o%F4A`zu?$Xyib18lh;`5&N3DVymwX(8gOk@n<6fS;>M zmOZUp>`m}l_6B-4f2yHEq06i`0w*GGh`)9kHLQSf?V@9Eyb z!}X^xo`HLoqUmU2E6HTS1m))tEpn{-OQ1g-xp!BsmA0?cFr^#Gf=i)bB+K)^K$ zQsjxzgTtYt)cV!`9-Z~mPpQCc(9tg`Q*gAKYE_w<&d1yM{0&rCA}+t}GY6^6$^Vh_ z#aFzwv5zfxan?dn6H_F8Oj?WaI+29dbXQ*#!G~&p#ERh1Y@ zI!$M$Yak}op3xf6pIh5=B%}$d0C?K@GW12N$8>joa#ORIvcv`uFhrGJ&YPmGCm`ZZ zmMW*Ok4xv^Aj2~~!$MDw{5?k!uCyQ=#}jY`@YLKMOce)=+noSr z%kGGw+3k{Xja&$pS@{{trpeh2FyhoT3tnLK2skP;IFV6Uw=c*yzppPVq;Jo0Q3?|V zLg%oR&j1o~BTlLgfzaSy&t~?UP>o%1UQ%?FJ9o3!S+#kKWcM|(UPJ%@9X5&O)xRB` zySR4gmHMahZ?GS@Xl{lCCLUyyV30Yj04(I6&Py&{V)X|OnVf;P@ZYZru$%7=JCsBq^12p6S$1!ht!shO}xoe=-<6cO@ zG#$l%2-Lzs2qB83kalU$DLZEsBNI$yl#_&O|24Cd4!UCb)l21j^3-bBsH`W5F(=i7 zx7uMyH25_MyfAXenEAG-8-50B=4J7CKMhX;v(;4=$akrC?0|2wXXfh6Q=#^R@1#RL z`#0IO;YDklrU|D=4LWxXlRwf zTK;x#*X8e4+)~y5)iMxjW&A$v!BvUj4jL^ks%c^`HX#$a|-tAigQjTQ*DirLW)gbE4d2GEktXkbM7QchRFKD()a|JSwsQdR`k z4a&9IOWId}8OVMf&s-cZ>6ISlGhuvqNSIQz6lcvV+wThxII5E?)z-tf1TY>%$nx=U zOKe{Das*%PL0r)~iB0Yiz6d8O+x7Ad4rK|ax5PuTZ20c%g{^*=^(7i^9ot{2Eh}O} zwm!ZLM{e(x9}l%F2E+C0NFvoxphA!jowG7+u!_bF)CbT@=C)GcN0D~u`u^qb6;F>s zuCS6s>9hQ=yL#jv3K$%Fc3Ll{@92M1=Gu7t2{M4uRdmK+_+^|5+l^RKw*?qwfi(bE z3Y(DwDD?YsW@!tQBvi8boX4EUp=UDO1RrCM@o9{`jZ;wY`+9Ebngx$YGPXRb-0!)NVZNpfb0BjN8EWj$ZCNT zUUA3HM=(#_3iV;gc_mnCm(OV!#1%nPSGUMHVTJ;v+c^mOvlxBnajz?ajaw`4eR!r> zJgkKv!@-#2ns-tFvF$Iu?6mUuHCqw0rTPlGP3Es$rW8q00zS;t4!Ak`*zZQtR?+yY z?DNfIu()UGZJZK=GHSaJu-brrgxyHglP!E6>k1uYn=-O7ce0YbXbZ#;IIv_FA6ikD zg-ZIwmolhss-|o>UNbWzxQn!R^Bb8_$BiJiUIBIiwZSH;MK`$+PWGzahtG!;s}GQG zOwAk67`&?U#=_zvL$>AD#2gWj#K&e;SBNU|FWXu^-j&3lU8nqxeXo3o*Qm ztzMl526Ot=aMlvQs>qOm#!T>8C{uLK(5<3?T8kj{h#(VOqHgSzm{DrIw)AUAWN96I z*&U}GN;2%alRnFF`_rBlPPe{ThOE@bWFcLgVicHPC_5il*}IwOJ|0t&jPpVzX@twO@h;4u9TVJ+3KXGoX^o`P zY9lwdp8EPyo(dvnWrSYU-oDkRfk!z~L%R69G#Xo(4_o-Sd;i`;>QO2kEhNwkVGCvB~MZ}Y^jrOT>3=Cw4{V+?wzY0lkDJ@?8b z&Q?9;VeZu0XwEKdrAd<_bVU2)LwZ=>(adUABWQZTPs=$@BwPr;v^1v4w zis9Sw6`3<g3- z?GK#dO&Tzs=40a0g|VZ-OEr-VI8zzsT&}8K;`J5||P)D1m7*RQxR=7__QBVko*__{o2#dbSB9zCgVOBQPrgV_v=JAN2czvm>jUzZ-5HGX7a&j44@!lB{Z*GjjL#FN+aYg^i+wF+w5BIMyC zoEVyqpSXSah*G)yi>;HwySq*}+Kh{G7>I80-inKK?;CDA$eNNC!=|cuN<;47u@}6}MeCGV907!72;|ur>QFQy3DjJ34-29Ip$_yll3sJ}z#l zQLZJ+Iq3HtqGWI`&5Ds_k~-gv&oOFnb}k~2V7V#$OqZ5769|1C*{jzU7w7SVCEP$& z8y0YTL%&Q03xSj^=}w|~m7 z&$ek;t+djSTY}ULNmY`?<)3LKH?9%XQF+QA#w&x?+uXy$`eS&zezk_3FK(=+MehIi zF_W&uK^>b40=9HM?h=yhyT^?$LMBcT#m@T{NcSNwd*8VIl>H}BG6hOrGH3ehsf;X= zA;LqOfgbyUsmoJ*rN1nj;*Su#y=Hd7elkJ#qYc9=Bu8$;io^+w5^2s zH~|Ai#=QzX;$KX|?RvtP&rvMaZ}(ar7&6GLWYOpFd0QO!BuG4mV8gw&YICqk8Svfy zIp6L=IWU0eN}>*-@+EbV1~Nza(>;h3?2sorlp(YWoRHIxW1*`tm%3~l4^B1Ta`}fC z6As!JvEDTk2Q_f=t#>J25f8Asra>b(Yfl@}3=khYZXM5*f-X`lb7a<4^USZpL@fP< zP;Bbm27^+Q|J-hWAHhM!$XEGz8}?LXCqq6kujtOPw2Oy8o7wBwa8E0!!qv8j(Xgcz zqu`kFwfUSn`|W!kGeJo-8pi$ISmg#0lCeg`x?d>HaBmkOcKK?%GQUs9LRHamYW}E| z#$gl-_C4H?Ytg26F5c>(ma0C@d6-l1+_8TuWbtdsl18f zeG*mQz^D?u9dt*!PXeLL@z7swcEP;&i$<(k6NPCz`8S_~5t-iX={-|QllU+d;nb}m8mC-A7V~1aXZ{;K|4(i5&~g*=8>$X z3&UeduYZU|Ba7(s=ai0ZM=W;MXt|Q4nA#P+P;-Z*@S`<(z;g=q?%o=_h!vW7V-~zg<;8O zZ|4Ds5c_G?l_LEsEG{=o5R9fby)%N3NA1tIi9&yH1A^zGyMiVH-<1l*rh{wy_3+`K zoTUBQAgFal21_rQK?@sBk#^z=j`}3a_{qLKM0J5dS*-yq`DKF*TANZ{$Ptq!IePCE z?RDcKSJ4ncMNApb_1NO?@648A{pMI|a8VyC9wCpBnU6Qb5PZf}oyFF36}46Z6Z22~ zOSK^W%+I^m(=DAOiM74d{U+wIq}@waHY%2Wvq&vLv?XI*2oxXwNYi5t&4FJbJbio& zY&WK!Tq$edDdZDdrvpG%#PdG4?Byod{L(p{LQg$mhmp zKW;;Rlx{X8#CMGaF#n$L(9g~`{*@m|#8%+Fw&Yh$&hqc*#F^k}dn1mNjhJRv!x#*E zAi;p7{A3wSBrNR#EIKj5u%RNr8^uJTa-Hb**k0H{^ka6WbN`-MqB35If+ zP1anmzX{lQ0O7YqZAdBNr;HfsR{ZCqe(i-=PAz46wXuAFZA;{q6VTRAf=(4DEFS2fT6rY%wWjNx0}PkCCW*l^ksb5 z?r3@f*9%eP(Z)w_KGkoKFBH|2otJ)BX5&B-DZK!1jA(->Ui>hT%*T-0V2`dj%;`*% zq~Ihh;XGcAlK8BmYs?7$&^)VNi9d%G8uSmFup?Gjpf?cM!xn5k*evT__69n zxHi_H^sG7PD{(-%WqY5gT{1l!KBsDhRWJstrZ`i6w_cFFF5_9gcRt5n?i16aJ0`|@ z0K1)`&{qZ2_4)%znZ~3YJOPz`sMtq*>H?2Y5Ts%)yfAxiKp8 zl~6F=p#xT{H>0*nM7!B`hK730Jz}5BT&Ia)?*8J=)g3|_7eL2X!Z4B{1~=INHzSA5 z)u+@(rtgeyb%0Ql$BYPHw@afY z3g8tgX}Zp2SKNKEt#*3ZBX@%j@U0XAEoo`m$2Q?5|F@Xg$4c4~Ze z`g#Ls)>G9HFfXymT&(z z%>GCKWaP_Z7F&>ibtfO;1hwO!9bZsGm8uGfL7*h?)`9;a{k08?o5sh&zjq|bLHuXc z_j&q8MdE<~7L(2Dha5zACL8z*p3cDP`rstn7^*3r&1E7?PvXz=c&foHy+cGMfIgt7 zP!W|kz!+e^BJNx+bb)CD06SvY3oJCv;fU#AU$_?mUZ#d^1c*+o07zu=ux90s9bfY< zl|;(zaI1+T*x4=h_sl(ZNXd?g9m`ciL>4d<*h&*?WL+GqdG$+C0XCWWRg*v-E}f-~ z6`*=hVtm|U0u}(?$BtJlQT2Lg+ZHL*SY5LT*r`}?bP0hK-38275Fndhd{dS(@5xtr;k`*)KzQ;-1khUU%-~-Qf8QdgIUFAj9BN>R#T7vYD?`zfW~B z@w9UO?T zQM?!OE9fFr(W%#P%l*zQ6e1A~O^GK$-w5?YL0;qy?_pFAY{+Y-oCy$bx{a;zJr`

>U%Fa_v@3x#AMjoAvwYK@oBOE|{+OoSD&UXGcS)}(2r~T-XITv` zTXX=xGSBiZgyhm16klKO=D=~Qpp%bfD+JLmV2gUw8xh^g}50D%Tm94`h24FxWn*4`4a>o2^wE6b=?TNr7cK zaFp(dF9mX1zI?EzEMkJoymyShDxQFH0UjpT}yQgX0X@<95nSs zEH&fKQWT^LY9DQ?a|-p6i(}7*mW2}E;5#31bK!qfC9At4<7{Zry#wQ1{28w{AeAmT zaH6$oqfwISY~O1rG<-U!k}jVWmXOFa0@{my@xb04*c}RS+Xz~g<~b3>psF9AKAwA1 zTK9|64>mW?4_qC5C^)L}Hl-4JG&5`PiTxG40DsSY68DCB5zEXFnT}|ZMS2Rxo4Sk{ z-fPQK71g=lU}B42`O8d)1dPNIoEHTI=k)$FGeYO-J1xUR>l2N^x{>HW7|`+bxJYTf z|Dv_O8A}nm_y|xEP9n+kD6c#I*2|vr>L;`X_)3+OIx1N%v1J}}wNh`HVnhuYlet7n zf%Ng|UuFuoM7kZ-KtWPMwDv`@`+#|I`;bVFo=b!NIuB4V^YePS6Yj27oza4y@%i2Q zejH#hu1D&?sb0koUM2ppn9GmkmONMY$gA^l1ov3tEcmWV@5nUU;1O+fu`8S7FwTPf z5A2Z(H!}8|wV(^8UQU|C3>7yWp@LLv`}?9}d(T?gVc*!y*op3mLq?d9Dp^8^V3}@) z-R?Vg2F9qEj6o4QL+qj-Q5D@?lMKKvg*0!TwY$EJ%>f0%?MWid)gcL%S@3C=!-)^p2p~PGU>hXv=9QnPUHdrw4Kg2e(XXsoV z%Wy{e^KP`~a|L5G8OMptG}MtQ0GhHlyVJSxFXPHbi_8Egxb^B?B3)>!vD$B@?7Ui z!0obK!yHIMFLBCzvb01Z@ikK5wH}iYugO*Wh!tg6eufV4hL|5Gftj&mo;?B<@RIg@*cE*Hc!D z>=+pV%M&jRm(mpS=4supE6>6>kkeDE@}O{02ZM%3G+;4MlAo3#0-9%VQ!-4Ab=z;_ zn|jL-Cg2A#>=(CPvRAD|Hi#$(M~{Th%I#)u=QP^$h@1n!4NjUDCNkv3t#yT38%Y^D z_Y@6=izh`JFUHZO^@yD4|AA4`w+0FtyjmJL4>!mb#Rt^$+j-79FA@`4g(0tX9MO&Xb&7ar*JCk3qaU`X*jCl5PZ641d zd~=y4VDVE+am5IzM5DSzR`%JbDr{45cz*g0Mc>`=3Wi&9+s`2um~JvJL&qPuJkiB* z&)wW3B8v0tL5A#r?!WFHx;$rjP=5*+Ez^qd<^kGT4*B90j#O-#PZB36OxLAD*>gRq zGV99`UWDJo_;jZ|7993UwbT)uLH_C$6Em- zyZ$EHKsGnZu>;=bF++6ZxsquS>cQhvifjnYUsg`&sI%ckh9y#iVe^f?ApR=_0MzZv zC(%VA1Bq1~fp451Tb9mp8TnN1#>XXnT5}9Zj$#zYyeljiBc0Tw^^d9IQlVf&^rcS^ zYiXw6oBgSt_4_mzcZp^(D0-~dgFgRT#8YZAx-=lFoC0E$nk`O3*gCS?*4}knaTk^- zl^w+)9%lnQUpkS!icLUWAbICvhc!OlWL*l-wffcvZ5;Zu51Yh+d-&>}O>o>!sZ(8ta$`$I{o+SLIEz}9@_h2BnQy@dd+ib0d1+&0n(6NT>0 z^DjY~8sCtH4Rev8)Hi)U_x)HwHMhgXCQy{f4A2M9TV0{um*(tMKQ67Xsfpl9$5rGH z=RI`NXX*#`a&YN`Dq~=10ON!PO!O37fCvNx)0#9Q-!!8fWQHVFwx`q7PX5*#MX+xa zQ9CGHay8;^&kZl0b!G&|}lOh8SZ*QMXpXv7N zata{SqE`Fqm5VRbr-FhBE;&+yq%@>mDMt{$xL!h*JoPRbY6<*{e0Zsa$U;hA(vrcX zjbSR#5Z{^8|FNzTs|hG?I0*+`EWz|Y;2u)|FF#`knzAz6j&~d}08&%Iu^v>rH&UNu z9?_AD#L8J+AICA_Y>M|{5H26W(MQ(uJyH#FFGhkvg$}te1vLuW91e%l_)@NA-Z#ed zJZOY1$kiX!wLY!96S{gw?D&|1{rmV<3`f{=II}VKyhbS2{PXweuMeaQ(8KdiF3M(m z!$?Fu4DOk(BIvLPEw%*@!L}SC_aVq?9Lc#^fFeiuNzZ0hbQ-KKKQ+)5Z$_uuqATUz z!$jiZ>n%eqq}HHcw|)}pigtN_N+ylR3Xj>>#IO+@X>Eu2>k&!+G7ai%UGC^bj&y7_ zT6$1h?Szti;i)&^k&7o`9Q+7lwc?$LtM`A=(o<=2bi@T5@F3w4a5*6Rd1*%gM@oYkK;k9yl<8CjDT zv1(MVOKl^)!@%xgStUxq(?~mH$GWh&6wO7L*hTJP70`Crp=iN@O}!1G{i))Svc(5%G)8dyWiy&z!K`VCg7Fnz;|{W_ zF(EhroK+-=%fJ3`&t8_&1QGZjnn~#ucOp%35P!+pkQ`)-qBUOz;V!oh+1q^q4zjpn zrfR2N0bO=h@RN1}hgXCoCK%~;v=@RFaAE$kk6jYh8Jhn~2!E1Vts6_(eUoIalWCM)6@w?Z;97bl3`rU^o(N0 zJP_%zvH#kQk=nwwsvR~Lr>I!(7OgP3vYI3-$WePDdhOZ{ee($Nldy;7PeVX1-1q+* z9zPt6LypremrGzlrG>n`C zlvK{E@EFJLn4R+tBQD)S3kQzSC^PWhVf}Z1Aard@Rgg+oB!8Z{zJ7xd$9wag#CzDwNs%w>|;Dol7dFlA2;J zi)H-i3u04S#55x{2J8vOY-0X&|Iy0Is~1MQRuVH`CnSC>Vsyauo;En`B<`*kkkOws z0%}7xL%vq~*PJ(a6ba0V*o|^BKwcfeeF|ADB0i$#mFsjBEsGcJwXmvF~w{}kBBAhBbeJ5;wHV8USXC)gi{7dshZ_6BQQ)Q8A5uvI1j^H`$ z)<3(`Fn?YTX^7kyI@IJbeJFiyd#~)&pDYnQj<`_6jMQT+wCzegs$poOJX-|Rby>mITMIgTb9C0QtVwgjlwutGZyo zp?>SvIm5r{YD7bvI2G7^Os4Sf)EmO%y8;5S{`peast0J)ExyO2=?JV~)+c3p!(BVz z0J8!B&_$|DvzWE2Ut3R3>Jq5+k}A3y%DwR=EFUVs;?X%Vl(dYYqH+Y%wM9yIlKWu7 z#nJ|Ocx3W-9ys)7LGXk4+MyG9hQ^2{JHlZn(t?r$OOwCF zwXv(9G>WOlI(nc7Rz9f3{IUDI^QWE?!v%N7tzGO+FM4iXmo=YBMQ^g;`nb(`JrD?Z zL%tePPn?tUbf>v)0mfTZx;ucJ{fYjxq~A`D#9o<{9{S#;{cMnouGshIyhk>D&lj2v zX!-Y4HQ*7$rnan2=(|lhL>FNg^W4k(+J*!4wJ^ZZ_ z7{S(35N_rzq|?e!V<0lk-BX|dV)SO-(B?_ptpoLiui>oydRslH*P;)*p7J`~lRoRl zNT^#6u>($eLHRS;3_8_W{&E4cMRl_H(?&-S8tJ44F)h@G zosw0e^KI3DYT~Q{)=@?I3{? zn(Cr{LaT2_j-&VsU)XEnhS*BUagKHTc~SK|=_y-92?Q^k{>hgs8(AnKPpBR1eO#L! zjEV6OF4g^Y^U&N+rCr1mq9SfKn8Jn_Q$R{w3V_uCcdK7y+Y=xi}+MPh?u zXiCkB?GpbUBmju))Jz_dJ%;p3J+OHWgxo$v?t~P1GOn1We=5#MSp}`Na@6?6<2Rr} z5tw4lC+)hDmww*srbd>Fs}L1n6=sma7GzM_uIlgzWwyBiis|<9EN6EAWy0;UL*iN^ zlN*HI@gLlaLEeUqhZR6>Vi2NnZ)X&NZ15RjC_N5kxy-_Tis9ubG5~Y#i<7{dsrqGS z2M(V!+EQ!oJD=ICXGBNscERY;>e`)TDgj$79=A05RsROmub?v=JdZwk9P=Rg?tP@% zU-lf?N-zcNeiSvIxW84Zlh6WnyZ(Zqq^bfISCM(8W7*?M0Gc~M*BAE|>%grzY#P@< zAQoj2AM0Y0@Ytm#j8Kg@61`li@j)+vN!<%}Mb&s)zSNPfIe&&H1jZ`{sNkf#C zuMY!wNWQ3h(aOY=?w5X%48Ja|rkqZwnE_F%gXlT)#7~Q9PNbKrjyvKN;cY{7?&>TY zy(Azx294CnMxIBs{{D0*18V2bPQ(_Te17C8NShR$*+Ey(Nox2pR>(~k^W=~>u+UwI za3d2?wtk$%d3C{*>p09=5(wO<_5=!_j3X>brB@ZQLI-I1n(~6lczHgn5ff;~pT#lc zJ#f+Ui_Eq^>%&t(1!PP^b|wk96s@Qb%t{%861-g2Ec3D;#GA4D+1qvkwll?<0;HMAcVF9^x}(ED6Ae>!(e6(_Eg2ewF)a!4zq^S*xYi2 z5)nj+Qj4(m^h79ZX)CO8V?;K34Tvq_eHHd^+5gNCWk^n7lrb0Z9*)l=^$r`A|JIc8 zp{doAPyPE)z$XKK;?*+Ywc>Iv8D|414;FJ!p0R&5773W!If59x^tl?J>Hq{4L^2t_ zg@=z+{=#L%kP05IpD+EmYOh?>1$9xHW!jpqGdhi+n&998>};jSR8yw>;}XF|&_aYMov~$?*4HCZ=Rp<}Cb_ z^S@LamYY!9%mRnD!hz5S#4f`oGQ@DyNE_vsB3)as0X8>*4|noy0>2FCw9G&-tWn5d zvvp$ljC_wd`+4qJ)R;YPT#la)X}XmZp?*Y_Mm&enry6-Cy+W$D%qED5lfg4j3WRB* z{KMgaH)eD(uDd@KgqKZm5B8G%!>(eLGW|>ix7Bb~*|BUrp7;h5I45?_8UWH(MlWf{ zy!RqWwCX3MAiIgbg5;r}aUJSM&{`~w3q1?y6su4h4I`VMJT(93cAP8x1`9>8np)x2 z^+5pRK9G2G6ujo1P&$o5Kfv(7%;!&9!RCbh?zZ|`^rE}J7u?<-gE~rsEBW94=POiC z1cGD)5bbbV2Y!+T>CXt8><;`O zHKq14dT6(snKkGhGI44w8(fZRzM7L>l9kVTuKE!l7j7Bl2rnubA$_uwZtHZRC1S;< zh(#gUhFcjs=R}GOKo@_r%~d+|^Q|hzF*i5Lp4Z#Y>Y0TWyv3F2FiZl=;p=z3mGT_t zuKQn5XR0c`BEb;2O3S+y@T{k6JeH&r(}{~&diC&v>~e64ZNlDYFn#^z7xni#6fK;; z9s5Xw9#CN4qFBcR)0HGw5}qO)E zi)<ipQDYICtG<#tTCFo){1CNzvEBYVIVZLri~gapt3Qe#(%Zzi$qD6H=oOCjAwz z2=VKuUfjSXA47wMF@8+5a&ebl%R!@*p-4xcP}CYL<%_dONktcTorCoWcJqwGUxx!> zT67jSSxgDuR&t3kYkSg<4>!oHL0=I|$sXmKgn3=NDRc%$@0LWb^UP$Ls7lPa1Z;Uz3L>m2>Zl1mLe6uTb%A8`7BPFm| zr=7*Ol!Ir-+&U@`X$+Jbva7$rei8RTPsXsUAi6WwHIuH46jdYxL1q#t$uNQ@)R*FQ z(E2d4<^e(g`0S$t5`grmTM<&YEY@FG2#Az09#{FXr?p)RfzrcdZX10A<@jE?`s*ShmH!JOc5^8 z-0T6|o6b zr&v!yCB$=BF0OBp&6EjKs?>+twDkJr52+%xuI|W3mW(_a|1DZ)2lDa%6pP!tY&SMK z^+Z;1zM<_OHP4fBd5Ni#(*H$0sz4p9E~yS?5wYV{{njEa;|muu?wsmKy1a?qF`9&N zUWzGzMZ(q;ojFam04RO3kMNGp*uoU*G0vQbj4#7OmvdyRqB5<8ht<=Di!QWD#o(da= z9=FE4fPE7M`UW_q_RjDvrB})(K>)($>CzauX7SF3xI~A1%R_okz73oGn>`5zg_x{r zeUw{ZKD)K~F2C#w^6EE}wnf(p{l)aB_HY+Igl4ZPXGDZLL?u>=k$QL^(W@%|b%vQf zO9Y?lj!%{Cs}o=?<(9N~ad({gfBU8pFUf>j!i2x>;lu}_7~GzGDe&re9Dg&XRQroe z%^Z_2d673df-5gWRzi~Umh7KcETgbkI^*kgcMf;I%f-&(sDkr@0=okxVjrt_>Cstt z#DHg!0vjjiPAIYSc`VXXIcJEgkc|HGTzXa)9#yyWSKzX)pceD|~@~Z`vVI4-Q6imt%c%?;Y-;Kbo=N(FP=ACHWt@ zo8Jf?DnNFsFgmwx!(B2fsTdGft?vx;9Fqgk8 z12}&=`IbCbCT*JCT1$C=RYo=*V|?*mlUy#Qx#1>i;GyiUJ=3^uI`z~Uq!OiRm)I(| z8z&vNm(gguRjnhm$6#X&5hhiZ&nN_j@|0HHM;ao7HAlYEB=96QSuj_KGT{!nBdhvV zt|eIMyuM7%Jo>koRz();*X2IahMugBX}BN|ZSCS&!CP1u+)Lvi`qH&jp<1KJ z=j2M9e3VopdxXg;ediA>iET)-l_%*Vxw)I1zhn=`utS$c73^~XtA$_I-Y^+2g8wWb zr?f~}8(Q_(_U5|tv_w9aMlOfTMX`N?p-1=Fs7NZfI8#Hmum)mSMn+KaJU<9Jq^e_; z=z3Vvye0lAg%KQ7hK`eDwBkrlC(9DK!v3u{86Rb1-3cf?@jfX^k?UCGgSjiQVTVta zqgfTG*gud`k#NPyunh`f#C9**(r9#W*RSIWmT?wwfkdDy_{pR#bAxME1>Ep@D_GU& z5&h+De0S4zvqCd}1uh`n*;ieonj}NDC@=n^NWw%^tfTpf>4(C}yuK8qBYRXcwg{U7 z?T2SYM=|GqvjHS2`*4ngaq!4-J6{lkw?f?`iVDr+i9)R}zj;NfS3>lAx{%qSw2&0N zx(1A6zckvnlPCgEAtaBe6$u@X(fMe*5r zM~`)<4d`rlsw{408LTh5zEsxAj^4b-)7oqg(q@%@@qdV1JLe$rJjiyeM1o9|5?9aM zKqgwGQYB!tOYd>*$P}#obTUQf7U%OMj)$^kFbl~sOu$5)eU|1cxDaHjFLD_62c@L2ch^?2tL;t3 z(|q#nD-`ra(h=XY@NEf2a!olu%oj@t1ArfP$!5`V-^1P95Jew^>qK559YU@BZ4n8f zyk`cvZfqJXos9xs&{Lr8V2ZWahCcEQ%vY-p6TPm!8ds-hC#@?24VT%9Djq`jlt1R3 zNDe}xu5&aOpk*Oc+_a2*3_Bd;r8zx8(IRnS8Pwe5Uf8}X^cU;q2|D)SX8!blh`|Gf z>IgTa&XURwibw)i%fBzS+36eUw8@VXKhhO0$(knP{VA7WjrsavMoi6kA+CbgxoqfK zWpoxAPv`1X!Qv}^UCRhJRXnZ?v-xf~F;puC_Q61sSL+D>YJ5Oy3DryNGfg#_=|;ib zW2eE;GSf0A@`@>hEq(B!`8)`Etx!C121T|>Aq4R1Ecqz7xby?`gd$3e-UtGXIiU~5 z(@e6>KB>OuyBEa-xW<`(c&Scdb>Jp=$J_-SGbaOflXST^sTW z$12~qN+;)Lymzlx*cP90?yL{Q&v?>jnjnr;e5y}AQs@!pj1>*idqBU{Rl`ijU@Hs- z=Du~6U@kHh2}a#EH|Fbjv9M2GxVzUbKL55rx8j8bKnUZ|JqjwVIIyRhJM8hW9vV_& zWee%$l_+%+#q??GzKQbt=F6mqt1UbY^>Dd#xHb~tAWLb!{)CvrmAet%6NPDlVv$6J zO*z7lsEtcMCbPn5@3y>*0Qq%)U`PM*yK3s=bM1Y4=YbElN12{hY;7i(22? z4UNbR9`Q69x4F2UnEAc}Rs>k#SYI-fpUoUDHVvB*UHfYxE?N!V25ljSZ+(dUZ%_?! zJ3+-OcL$?@U=u4JNc~^%h;_6!%0InNq|aZ7#iVK*ko2(>3)znLKvbjyOzCho3AO!s zc>-#D4sTwUqU)HZHZ<+lN9qO=($)z>*d-sIZZUOx2G;^@^~%Kcyx9I6cBFyJh?e^& zKxlX@Brqz=sUEns`sp3b) zJdJmg#&C9S>i``s#jmMk`NI^AzbSLV&dYR?aVm{4W!|oWu2o^QyWTy9P67D@JR3P#pMz-#? z8)vZ{(~q}I_ff~=@0j9X^dws{_dbPA>_QF=HEy-FuUZa*pxJ;1CYT(9zdPkhod?UR zKwJm+gwDkjO9lDz&cl>JRkX@t@7slW(LakFdv)~`aW*m9<%O20u!2onj9GcRLsi3^ z-}Do)Vh6QEK>tTm()XL=8On$E3BN1388>ZG_@xQ!-WAX}b&%2xCC zC_x864n*_GLxMfKoP!xXNRFw^58h(B7`9FO+@0-?7-wZ7{5zo5!H#`eeM7PrHbSi2 z_FXg0%ccS-H!ByFuUGDl7qlS1QQ@`bA5^MA~KU=Rg-#{N_pBw2|7UiZT^N8aAMNnk)n35lV_W^cp`A(6OQw zGROaT#wXyLq><&}tLxtcq0OnuN|_PzqFuVhE0Ma)W{=V?UDTY3Z~!?fUXZ=h&dZZt zw8pNWmDS3l%rwtV=wo0mCf6g)t;nk5vj#o<^M(9<(!lW&n)a_5AA(divRR3f4On8( z=zT^9iVNef67U9$0&+VaV~Gqs`C`$ zL%jHLLDriteZ0lPubdUB3hEJ=+(%>(4Ya+!rr?j@z2O8=8Okjz2{dsLd|`7v`J;fSsILv7)ikQbm+xv%@!y74=W$HDkVtU*64Y zTbhcOFG*>4iX@iYP;o+;#;fGkP=f_P#)WD>E)Yj0DX;FU-8IYVOakFN;*K$7ys>8N zTH5=^5Y;z~ac@mCk~Vh2Yw;FqanO{Xg7NnNI;m1Wm=IMv2!0DmgBBn6Dl(FF+2g^T z12tWpDOJkE69RE39K~>L`qZ=L(uZRcg>r$30Y5m}S>m|zw&dadLF!IU>NW|9BO?20QRpK3;FM{_~mjEd>x>{2=Fz z=LT}HTwa+XXPSONwvL|hqHgp(ru*g**D)XpD` zWGXix)dCJOj>6Jl@P1m3FbxzONR+u)8kK1R{l(n8yZQhxhIT7VkG8Ve2#J{=laetQ zR;n$$y+shIn{(jhbfV~STPYH$#TTr{fJEF((-aCsdE6#Y(YXf9SI!|^rl-t%R6OsZ zN3XvG)$>0re}VvkKPCmrSG(a5ldz61%7s3MebH_>l|quqKFB91y)#(A&!&v%pdL=0YUTmFRXkcLPtDCDP6+ zwYnrUKsTUV(2~{MouSz9U&Tww9=Z^)*4DsI4PfoSR|1F#oS$Vq6@42TKrRrqyFPbH z(vI7Wr{gjc-q>!#C!2J{UF$m!W0irxg*)?LuL=#4Wa#5`+@nmd1TmVukGa{UydThZHuINoG zTl>C^&nKd5D0+jtdik>)9ieW%$8eb6W_=RXSL~}t4rM1}Rm4P9Q5^`<*Aj1ATlu@L z*2(I>{Blxz690Ip!GME~q2WIv|9;0vNjmi7)C9OCBWG03Nq0~TW-Dc*?46%YWh;Yo zaG4|HN9}KqnvQ!qM*r=!|9!L>3}V=L6ho}1M4kZ9cunXlleWAgQMO3C;oO?gA5A}f zf9=)i0gxcQG4C)Updg8|pJ6HFT+(dsUdtR5@#%n$W37O3Q(0uk5evH96+(tqjpzA# z6iA7ATE0}U_BFlKDdv{b4DYwd59VIlz9Y1Ql!z`?tukgE=nTePVs{tZO~j=9%4Jt_ znHz~-Xg`i}*dCB+9p({DL7}T4P}plZhMrW#`_nbTk*7YLIviYn^^i%8*>z3D|3QIY z^h*FUc@=FK|^8%$=MAD}iqQPYb{=#8}E22U(^5{aqNd;xU+Q+$j`$c^@KCSWW zsN0PUn;@oJ89Rx`8kq5;&{VNtjbu)CR#+qA07KX>wGO0jwIyhwE9)vMQG0?xcNyg- zw0`cokQOv8t9`s73;_59qrUk@Zz?%!NsXG@u^jE?sih(ezq?DNzEA4_48vtY861F*Y)jMy`o0Y}csYgJ`J4&RCg+V)G zLKiZLOHn5~wXz<7_6|ZIF~@Hg^+o3B?0S9<`k@nR2T$gvv7j}iHK2HTdDmTsj*~@E zllV`&8Cr+LNN!N)Mt4!WzFCA=Ax8gZvUbenrtN*5)jFJju6U01a<=&+fROt|eugSy z!Su_=7XvMmXO{Bl`v9lWZ6>A{`b!9Uf$g^cjCCoxWN??)Lg@Yb1l>k>XhS=-wK;vg|EDr`c} z>3-s$a($b9*-K7&0l#rmWK@PD{2_G-8fJPETH)D}?4^N~Vp8QCYUySC&M0jM9E6@b z>!UAu$lmZM0mG-_MG!7P&R!w&!-K?-K#x}E;=~7o6#C1G&S>S3kU9NFzk;7INJ9ps zqM-XSI>44HHa=D-X1&T^LiM8P!Y&&L-(FOUDaDgmUle|$<^&2Y`+#C!24_YfNN3rx zbP5AvVN2Rw0!QYZ0&Sn68Z~8t|`;K8w8lf(%zG7|M!B=Zy)2eC9n+z ztYz`22%VTi#d)7VvG%t(5in1`te$P~5qy_5pU30&$Jrib$XJ^t7sNxLP|uxtX3R52 z%ilP6e*5TKtLsxWhCYdtNO4fO#%qtO5S&hNP6!h}LCKU33)Xv!5+a&UJT>$b(E&in z;bt7&w!N6FlMQ`KUW7&NbpSk|ygzH?WCGUC(KaRc3$fmyL}GvWf2+5Rb^Gr5Z4eW=Y=7+E1o0B<`?39`7<{?#*p4O?sHgE40c*d7pBQba-U?bbMRycb{NEJIX6k&)9elr+~Zq|8_$~C zZT9BNG)+?^N?`%3JoixLF7yZXZmS@Ub;6ttiYRag|NiVJj;yQ?nS?1a=Y)`U-||0( z_9miVlVZ(WLrNI*79!I6_xnbC>%TdTRH!m{bl6z)hqy=Z2W9)mxE`d9+>Voj>YinI zJfHqr@grx^(ij*THr#_>xo(1yZ@ks>om%R6{RS>f0WeE^8o@MIyO5+;Bd&Dl zV-}EDEf|E%bN!`9F53T*D%!mr*~WGKmY-M?FtXDSbXJfc7%l0-Rgw?)%mlXlV&R7H z`@1-?&@YRiA`tOdgolBs4gHt6Gnp1xRt@v^K(^YyT{JsNnyPu=1vr4U~f|!q*r)upuK2NhN zSx%2J<31=;rESBJ5rbT4v_!}djo*Fi-C;Az*#4${Sq$46Mt%Norh1?@IEJcgcz^~1 zGXu7QCkF$32$V^SPOp5E*YXe)_%*m~p5q@mBhnDI%B*U&L~(7uUf!8yXU-B=^V&Hp z{Nr;vlsr$-RyeP#0Z)>2BJ?-x6N~uHhj(Wdz-XP-&DiS56joYDRqQ2TsN!)(Nq>e7 z(EaBG7u0{}>~<};aD%*dma&x_m`w#qm(J>&yi#9_nfXJsa;tL16zy6e_5q6*87EA~ zP;HsYzeSf7*Ty)6XJ)#)G&pin!@W5tLdzpRjXDQTRN5jS#LlOz7qte_QT^E6o^BuhnN;2f`OAAmdbx*vSbmU(&#(Nl4!D%$m)b&5V zi7Z{{9PMF)#y~wqJ4`2mQtlAOxm1-pc()RjDG^=iVH7~3piBil=c9c5t}Gn8!(zFI zsiMzsR7RW$L*ngSuy739XIR$(zhE!V28cwp2e-(-76T!F!Ezab4f`xRirIB7#E8k> zamfk}L0f7{{4P7kZ$h|p? z=vR|p*m3MRc=I^p4;I|hVNSX3ppZ7ap7Ff+;5;2Y{%|)|T+5LmZPu>d^gkSfP@;vF zFoMlkQ|5_CUpd+-JSd;ccZp~0Y2CFq?HEeI2%$MI_(cHAq#z8ob}zMI}0p(r`6(m10* zc$Ru^$0@!S1@*e|H`0buHHollL_XFWFD>nu?5SkAA~{wg65^8^G!I zdGuAD-t8ZBEFtSGj!x|L=%ONI?>Um~o9B{Wi7NgMua^0w?(l&i%)??M%#p|AwvsM7 zpq+iY_!p`4wAA4Aftct}eBS(}+Md*&lZsLnp8NN)vo(uoOwjlGI1Sd#G#BR3EXr1j z`n9eqWNq@DIG$b^+iD}r7y2MpO#nsQ{Kf+S6K`W&)W$@MFQ~#|#k)}rNWisP<~{X6 zkbQqgzXzS$$S4=`r=GJA84pV>nUp22o$D0dz_rO+i!66Y_t7eofQPxWAID` z%|fDyjm=NT*Z6YosC84bT4PsB4p^P@RS;v(@WD>^p-@R5SgM+LkwyT;11bcI#_GB{%DDRG#ij2zXo6w2d+u!OMImuM|+w2N2l zFhP0i)#6vNjF$8|^2mBWD3gl^N5g&KZfo0_G2=wsLgpa1A^8L6C{TwdeQ4EOZ0d5p z@7#CdFN}dasU2IxND~KWXzc_q{E#I!zrXUI1v#mRHk*96iWU2R)aG4D5wsiMA1tO= z)DeYxaL0r@cd*C52o?I{-`ODTS7)&YU8ogRyZ{9E<@=8NO1X?{inq_>hPkve-g!z1SH;qC=3e-`Rbc-5Lm4+*$A z<$g0xUZBmOJm8t3zC|M9Tgqw_pKTv0Vv7;SaA$U$W?xz^e@u$`x(1`e+nAT}Bm(pC z=y^OE{ms4U_;}l$`PU+rG@@=-+2-J_ovvd7(4%@RDgLZm49pN_F~K>u*)CEP;gT_4 zd`PPiBEBQdyclWVFvZ17S?*b4*t&6)(N#@vBBG6zrm&(6W~H*c8iyg${baO_ttrAU zcmady{xsnJ*kmW(Dp$WogVPx8Nsfqi_AzMlswvyxA8Kc(Xm1g`rb=ZeX)FkyB zA_59M<|UUDGGJ>Dq9#{JqH(%&`v*+c8QjdSU!27ELSS2T_;6sZYsM0%690HLGY6R1 zxXmvS;Hwn0U+`OB!|BL1Z6TAPd55>5gD!(t)-w)F$$zJ9ORBkqn?X)=gwgL{PS7$0 zB>Pl{57>efsRb23;~R`MPh9_$QQ}XNu&hZOS*U@0_p%_n0?tSk`-RwmG=o(Zt%LSO z(MGhxZbu?Aet+S_&`Q5iUZttGe(dtI^dBmlgB9aj*BHS+Paj)ljoGQ2+~DgMk37%( z&l&FP5AGA}I9yWV2-Bu*lNys#0*F3dmS8nEZBa37hDbSROr@-35jqO4Ltnoyv-2h* zBH!%tBbC*pe`p|zTvB1>hzt{Xr>_mKvhWvziI_%eK7$BmMpiogMU``OG8Uq^V;_a# zyVTHC2bfA^!Gb95h`HbO3Oksd8PlhYdh!Zgt^Px#8+u|CAP(p%AQD>I1J2=P*EHdp>h(eTBr^X?Ph|zs`dZ z=jG$IUGcQddO2Tsp;)`)eX>{xd)vYh%eo9S0Ox~gYd3;4=`R5~%Y9DxL};b1Ru)9Y z!K;K4Ei>C6W?U37$3o9*WTI0nRCgjLSHg76Qc&JR)7&?|1((S5l`SBcn6fGd4P59q z8O>}7qa6OF=*cbVyveX;5Y36)H9nB1xlbAHYW$%Ni#CO9{n(Kp_mTwjrkPUytkE9T zC_jwYT!u{(V9q(0%SoS*Bm3{B2%egvqBcKYUEw&7^y80J2bVW=!GkARV$jGnkhIy9 z`|;0<5|N6{1_3;5XwpY@z3(e^uC1f;T$KwsK4}}=A?t?cU&}g4sBW3jX-Ck8E1wdj zg%@>tbGP9w3*fW~ps!uHB=Dx0p#!E0@8z^m{u1qo6;iLNdvJz+#gnMzFMwviS}#DS zT}i`<(XYPkrdqKZ`7u+Il!rKxhrj|*aTWOwpOMqK0$l!4tp0ZvAu)v=g)PY!p(Cm| z%?3K1=ONkX8vzcb>$*3vd%WN$TVj3C(0gA?y5d!*I4wa%#NuaZP}e%?v^7@`i&P8 z=5OXI5uv9o@)n}6uXVK#a&k?_N`TZVTUf5A$Qs=pIhr1_$Ui6GS4>p*U?mb@5>k;6 zNO}66Ep^eEvTK^*;!=(1LIeJMI%RBtGHiL7BVJ*l316Vl$SG;#N@S_9JratT0jtTD z$8C8YvO+Lkj2EM37p^jSe5cvHzC5xO%K8v9&lYU%MUIf23EhV6EwbpYPk)l|+&Ql4|9g!?d7WGc8xCkVPHN2NEEssg;D3`zb3zpF`H-7jOU zEtG4kL+69Brz;wSx0(Y%nXW4pBr9PEdnX&W2Au*0V#xM$Es+B3HHVvJ07SoQo8=h1 z${lK9t2K{mO=smKF@A_@~EbCIT~)Qk8=%c z@fxKFYF3S>X}hcOm+V`|=FZl($O@T=r8M4VxJ<{IAEsNv5AQ`O!-3#cC0dA z$*r?x-5*k@0R*pDG2bgM;7gP%9_8Ao(|M!-P%B1jI_BQJ;R#_V9R|p^0%xS5;m5oL zkuMtnJ%7S-kt9E{lZ`niwA+YzsD4$G!HAm;8NUP#~w55|6ZIda8!$gr@lX zgXw?G)Uqq)vcY|_&kNo)^%ChY8JT2^0$aFUPl?ug6(+;o$dglr%L8bK)WwV-)jg_kC#&JQP$TSD{+FwqFc`}hc`sd|8+keaK zIiPH2nOg-{@pI!OCxwzg=+1yB)9^2vF{~3A`@3MbVU_%rCeQ1;i}$gsSn-H{ORanm zZ}1kwPO9~7%LHQk>P2{?QFwP~i2lK3c;RnOgd$Ce^vRNVWGhyzQdZh#vg_IF*$F)E zGwXc0Q=f*70ROh?mPaQ3H*hsy*G$I7@adAapP5bGI4`U@YpQz~r*g%03;1EZq?iKu z?#sr0Ra>=dt`4CPQ>(?8&QMp~zhUyPzz(R&0{=@@2za`_rc>20pSGtsF)F56FMU<& z7JP-VO%C+^usLbLZ>cfWZQQG{K$RP_$M1f=<`6`h=x*MoL(c1)@l34i^@6!%Eo0Ce zHcxEw;qPlcux%>w1XH3wg4ku3thRra8_l}$mVnn!*TQ16jvQ&2UJ%gRpOV=m z?$kECL5*@;DY6ZZ)ru;30_gHVxT*q0(@fSQk0CA}&jKuj6Y5Rw8s+GDvR%trD%Xd<0u_@P0NoUbTPJA3M zt~^~)z?Avr>S1}uawv<8XH(F6*GylzIr(QhHf(5Xh6*U}l?i%+?B_d=s9)snoCo1+ zz;QoKer^8M%~1)0+v=k2eKb-}9ZF==mDAYOY{)I_sa6*8a;&bDQhP9gO-2W=StPlyQ2cFlk^}fs=JA z=vaSkv|o$??+FHf0NHWl+*`=&sSzRss5y!&yU@d?WNB;({yO`NkSs3?YI-JK85UWW zyvilkb#C>rHYp}Gqac zLP@Z#nk6sM!>8f1dydi?;wwv;MkZO0)!HJzE479bsIlmn2_o);@7{1Jq^zv`BE zO`t-Xj11y)a{xPv8yriFj6?Jy2U?EB{I0!`Y4$c!5ldu0Iv=0pCe?B{P>L8fpE(n9 z=o)UtnNU-iNU-D&gs`ufqAV}N?xcw%w18yrGFg&Ny>|Wtz@2UIsVsG$+xU)po++^# z{(h;MA%7yCvM%|iK)#@9K3CZPsJ)_2nQZ?LFgvW}URVm6q_|w@r^?m%p_Av`*A$*` z?G2my*@)Y2+L!Ol*T=zB3ZMK)v2o}3YAJGsV0^3&%qOW>wqTH*d8Y95`B(Xn#bOe9 zJxp<*NCHJ61LfGxqBG3IEX{_%gn7CPV{)RN99jmKJfZh=m0G`apzgYs%`~+2rGIhO zA5M6-S1C`B+{-77oWmOoEC!q+@4e6~+M6$Z^o8rJb$$M*Z4u8nYCUjLo(Sc9xRZ@M zG^4g8O{wo2#Y^VQ9w%Kz_EodNPZkL3m7W<3Zl39VoGu{zb4U_x zn183^rv+=Oj7B5C#}nB`K$dTSa1v^c8sJNKB`y7{ zL5>pI7v}vzZZ6C~Nh;GzPKEf^@k=6!(Ow(B;$6m;`?xWgNRDtw5|gyQw5A>rvW&l= z1Z&zRsQrMDrf73kXngldkY2nmj~OQ*H$y871M|upVUa6I9TbXU>aYtF0-U~dg4;(} zxCF+m#t?+%yCZF+sghPdm0reTDALp>aZ0=?tZkyw1vIN-ZKxIghVLy% zpA!C8&e!?E>kQwfI`N^d>EhCrk9myMzU`jAaZ332)k}=`@ha@Ynh7Ai28e$`c`)t! z^qw~Ep{M&1ca@#r2UsQSi+K2gRLDICM5SQ&==*nyR6gTGXgbXC{AxNA|9K5tO9iF2 z^8G~DFMfD&?bJkDVDcl%Lf5&2@KH*2u>O2rD%N9SIeGbl1o;8+Zp}K{d>r00F|q^d zTLQ(TEx0e3bf}2zM|5-$J0mSbjvlBdw$6YC@WNMG7?=N zcg6z*oTl-BFT$SbYMvWhVw#`&v>2}2%OMfa4A?e! zk_L56|1{OI@LwwL7DG0oCL$JlngjyTlYTaVBq-e8xe=0hdWP4_rEyc1JiaLLGwgH% zarD>~o}8o&DGGZ2gML^09iBk(^>Aed}4MzeH*m(d>$ldJ5 zo$Z{2-P=>R0uS8LzWxhnNLqohBe3_A+$!9Pt1h@8v}@EBPwXTlAfr*_bKjNMb(pg) zWZzvl~SSH@dlEG&<=B|q5-WJyYpc6?utWd{TNsfg^Thz z3k%6w>?r)VWuG#3BRt2F+r=-m`N69uVeZx3gJb}vf0@T+zM{xcY70!M;4^W0co%z| zu%Q2j$Q2|xzbAR9E+Xqx`~{cKGq^=RPs=Xs;+y@Vsxp~A&Pe?c5QKa4wzPGE2m2pN z(=xV@@7#j*G|icagw~exy&2wQo&&_xDoq;~)s(zBm`l~QUl&pCGu7V$P#$}L_PZ0H zC@%90ugIPPGyY_QS+#n|2{>Q;_lbOgvI%;#t|>wAd99!ES8|yj2a541PGds{OKk4n z8RzOD+1%#cum#Ov!EFAz2x>yyoLfg`BlanX+=zxv#er}D=oaL$x1-!2magW>Gt!*G z9To~~@BmI;)+8)yKoUQmVK!9GcS!w_wys-dJ9Ax{sLJYBSn3p1yxe8Bh^21 zTi?HGdoj17 z>7M?L3^#7bL@06Q2~42c=E)-Ii_+n4sgvSa8QY=^s}k7tOJm}bKdFseFJ#l65SShw zP9yCJDQv+^3|+X*)%lk4_QmY4S^cBwZVw&WAu#qcEebkoz}V36rCxBFW%hxo`Hh%R z-G*A3TXVW>3y_O;Z6|-n@%Pp7$k&)ks@BzVly4|c3s7&HL?|IQ4pH4@R$%0Kqv3Ig zYDi)|Rj!rU6_u?G>H>B4aY;qw>5=QX9=7YDf+}{fD{J|w_X?MRNz|I)MzUIs%wI$e+$oH^yHNEX<4s)mFzy5W zE4k78{vvEch^=@9GalK;1$^FeOrnObPlK_0vXtB7u;BX@MXm1qVHiHnZ>We!4aP8b zcOxH~w~Eg{0b8o3EpXF6jpn%r+KpC@NEX^*NDG?HZE`V=N!c zZyMt{`cEq~UZmG(6!?bp9HOK0$QNw|@I3H|xq znew-wZ}{@*P)3?g_=d2izJivwf@MP6L7Cu1dF0u&?l!EO11&f z5X)B;4I!HRryFSy|4T5D#$sl=UJCBtoB>OR6`&xJN(D;>SMh5ArH`<5v;5RE`q`;-<(SEKFmuq-8Gm$j-kMzy{DH9taD{7gB#h@Jv;cmt5_uu?cfUEEF}3#b z3`^~0u|Pn_g{2v5_>e__&Bj*p9!jhMlf0`E=mSgdxHCZA*XD4d1*Ir&%;C515bOAIL!x_1r3DppErd3s` z4SOAyU2)Nrxf6c$C<3(BTOXBR!Pn-G{$?h8JGI%0|2K1!oz~W3+a7I3JAJ@zf#W5S z!E?s>_ArmH3YP)6%~c>GLlGxY1Z7#vj)4WVRQZ%02#b~kd~H#)T(z6T&FvqDhf;sv zJ{A-Gsosp8e=4>@QvJ|btu&}o4YOX|)9z5!@;rnY*`rEjixX0=<0IPH4tY2_JXJH+ z5RU83s(SivWHkykd1Wk%)tTD-dRUdv7UbxkPE5<5YFSo0d?+2wzA_1UrP>QI$Z|KI zw?vUVXcmOsBvG`ziyD-)J8fkI>jLGkA0aH+BJGCERml35yFQ!X+#+R80*HVE)p~?9 zfq+v(QkWp8)(nI@%T%0h4JL3#T&*@6C_qQFY686FC1#uCGWWt{*NFX%DJykMJ6Sjp zxmsUYD20w1ZO)gnaQh0VLsy*8G$r6)H14H@+{#m`YUPt)r};+leRh6HAp8tQU8%3? ztZXhGvxFysLV1%?E*_59=_t7^DOl@u1SN{L^}qzgxy!29#H79u+#puMmKhojhk8~{ zZTTg%Ux^Z&%urJYJC_}RgGG$wenUD;06KZmGIr2{M(Ah-5Fh{zQ%_*igxHs(P?1H0 zdNR+f8Tta*d=aY`Y~Fz@UrPp)+1KgA+yaiCo2QW|VZXZ(Gb6MCKIt6%=GNmH*##8d z-Lxkb&8o(bEt@!Lv_e}D+ZhfVuLEJDo(a0XPy5=X1d#ya9q(-Pi9~q|gl?Ky>1-uI z+PZ_JlzC7j6><|e^S48>fR9o7&#O=IV4pbz9q#8lokHwmpz8!Bmq6bI?F`FSpE=TJ z@OU=y4Pg?Er9-VUpyDvME(Ce9EIXN6w+QF^}tb1_J1;;%qP8w5{9eNPN32w6yGpk7P1 z#qPv`CA(;vx=(>m7N#2hg*j_Q%~R3dYXUQ*J9s)f+VFy`0q@9<{8VDPVMns8DUVV; zS1~u>TC53qq2TGNq6(Z0lSzqw`jI-a3JJY%02HNizd+59*-^to(-FbW`tIZvfS9U) z%PMT&wJYsC-EEN>8P?*%te$fhx(&I%X~`vXn%S}0*{|9gEI}zCntnb%KKcQTxajv> z6z@RLvyndp9?Z2f5uq3ggNYmJCh?sb$XD)~e|E8;HAX={+%5=RJmb!RWlUY#C@OcmmBs}^x_ernadp@bq9GR1|bJ4 zaGcaWu($NcT$>8u2NR?N>8PiOq=>}EEicwm0}X0=r6VeLr8xY6t@)0!5tk8wv0FMK z&aszOsWArHWlAW7Rr>-(1LO@R@2}U<`)qZaEzgw1_n#3WP<|%~^XM%zLy(=KwrxW}6Q?*k6sAkm&e(%ere07m~+2iGo6BdMs~m^FT2<={SI zX>>_9m;?Q)Og-3@kwSJK&rW*xZGCrpA0RRlWZfvFYas9X8t0^wlB4T&&V1q|vrOVTj`H28sHAEA;SWB`Y^D3S$=_#qtCD|ruQzl8r>wZ*`zpe{ zV^_hZ)qH6P5yzDW7O8yXNx!mU*>dtQ%*C~Ehy|AXK6I5&B1bis2y(8PGdo>UF(o_Q z;wJ!a01O6!g7#n7y~cC_(mY1xWww2!o8lY`j(k=8CxO&BfCp{T;nNKPFBN7vryIkN|omW#5?;5`< zL{ne;UC=(W&qqMl!x#*Iv+eX&t9~PA9spB_x*B!_t-YIp zz??}7rT)Jp_(oP%N!H!KeZ}iPj0EvyRMi+5*r zwOj@|FQOU3WMsc!$j>K4h~T~HichNu%d(SEt=fKrfe265gIL5EQT;zaCjnjFq*1mN z(SkAocKj+MR4KQ1;?~pKn@=XxXaTnS#MN;v+2Lae2zxfg4%J6Am~DWkW!W<(18HSs zKbAGTbD9+e{m1O%fYQDH*9kR(c3joTBe8KliYkYUy&(rJ_F00pS@+%mnJMz6sn&uK zRRZZP563Xx+%2{*B@1|&lB<~kDS0Uae)d`}(7)xfxNU~o;P7~D?B>P| z*Z{2zgZa%~=c7EnkS-9oEmw~G{Zx6Az#qw_ULMee-_17SuI8gEmX7`SB(srVFLU?3 zFBcC$==@i~Sga_kH?)Z@Azv6|@nQH$+6!9TexZauGzR|VrZoSLXO2yHU6N7*#mnL# zZk4dcf!s=EA7g}(lQHdnBU4L}WVI(8>N%7aZN3&d47U}g)Y>*;llN%B-7$8$4ppe z&D7njl+AnOqtXFYd_lHc?PJuKoum-ym`k$M)^r}Y*+Iv3@X;)2Q-Z-gjcDN^R-3Go zkaP6Wc<1S~g;3#d;nEcGUMbT<=PkR&&Y)jS73r-dDvc~GlVJm7o?~@oD2K~HB}DdH zzqF(So5CN0@MnO1{z~M8KwuQ3Sv++-oPB342Sp#CAql(_In{s>T9V2cAgFHQ|Fdeu zK&mhzAig{$ITDc;X0BJABfPj_5xYS$w~#~G<;)0@%^^0n}~O}TbP^DbC?%UkO>KS>C9J_<}#gqNc_Uj;zHkG)999S03+CQ82QndD-Xo#QB8E09+DNHKDEkV+)C+Z8Eo@(eWhc=HgC zV^_)6YyIDsENMNWv=?{=jkB>x6AJT8l<-CqGOhh-wC(d+rHT_y{e@*m-AW|GmJFdt zA{quE#l-erWL1ZmPhG4o#);#6L!)D6k%$Bf-C_NqGX!+B#uwna%9O0~Le*m%;G3dA z9o)ZKb2Cx3M&g*ov{kryh4-;2_B z`NAdgK;D7@7U8<)?2|I-cHfyj}!Eq7J{MHc4qpaO4j5vmdZf{ekDkg$n7b>;fl=6PpQA zbz-oojYyP?sGTyW8V1B6>~f0@_W}!kY6&z-L$yWU>X5eVC!ZwuDaI{x+jdfj`oGTE zVT4+6tL-Uk-PH@Lt(li6hDkvOTzU;Rpukjo? z0zJ$QaodOu;M}@(D!q{6z=`^YUjO~S3WVAn=40S@TjoWZGauY;y62!}BIT2>-bAZ4 zH*P$@Yje|p7Gbi~#NAvMtV8jq338-Wo0SY8Us(FtH#g|ff#37Fm-FUL<>e-n2}?0) z9{?k3s0fxj(7EtnoutL;jU%;$qIvl;5MgJb*IYlPFZ*qtl_`pUaLn(xf+iixk6xjO z%}?k>tKa{NZ&t05Eu#HjihT8tTA^F}x!Dt-!GH+a3I^nnFQvn9=$lDJB7^U7*9uj_ z@JDC7w5^NvQ%tV8xVoh}HvWOPW%T>2A(zTU|KQ~j92cP z@D69_ju;JQSm8reyF;e3A(qLAh)M{?M24tND=Xa+Jaa59)_qU~Qefo4&+W!ocgVu{ zgGIb3OpSj&_{|X#CL&^P+2^yGu2KEV?l!$BvCi){>c5`rEE1#fx??lM(>s&JnRW2Y z*Lv@D7^;TvF7VJRyG%b%#{9@EZWSPC&dYf)F=0oaj^%2{ORurmh6C%3j z&S;7jFGGn&J_$p+>rxftD8}~dYywF!zLn6fjp|F3kYS2FWEr@_l#Y|HsZp-I`8^e) z+28H3vx<5e_nq`3CU^1>wyBKpZQ42OJ-Dpn@Ca};;9}OM4G_16BN*jU$=YL$!I?+q# zR$u{Fa+qKhg>Pv&fB4I%bl*f#oD8aC_HA#T9Z(L+cW?Iy3LemN9Rj{;%TgvtN{cXF z|7}WS68xsbbkMp<8EIL7n8t>}831r($eqj?JhTk4L1u%kz$$+C?UYQ#zgP=1PF(jt zi}$RCG;He*wSatfznpC z=~fV#MAA&&09%Ltb0qY|nOJ(0|^*6@XZbKd-x zm(I_J412?5MKkB*Iy9A^!mM>Kr4E^r{wzYUKSeXHC|A%cZ%lnGIq5^YmM@7AdJ5e+ zm?N6_$wN=l(`CrE^->$I2&XARc2jOIp#kmk0RdE0UAt|jDM&&2L?@&Pk z;moB!aiv$vPijf{CKF+(*;h2d6Ieo!Uh%l9U=?oAA#lqE-rj62Mjp3t@7dJ%yO8NRa8O!;9sse^6*DtmW$Ju zFHbv-YWn6>muMG2)AojL3Gcq}6)I^l1{Y!@3T3@xP{>|And_h;9j>f<7N;;Eq6rIP zCo4;;(^16(rQNkI$5{es-bZ>0Z2~&{7-z%XJjfg1)dsMUl1a+PfViq$s z+R118RIUGh08jIw+yV;l#j}D_*oY39J$rCZcR!xT*|hb)j?oNB?IP0ezi@O>E#AJS zNhyHF%IZgxV07iG*4bH8isoTlXk_0 z@ZN~R_uKVAzGq&^HFuBsIR^C;x!Ng|Nq>bpS}HITbLhpZHW_>Uxl5r(b$8!_CPSjxtn7?;@@}&7~P1$An6&f0jsBUtDC3F zlRqW*j%acf1sm)&OGisX28-GHz56!cW+5&o5%)JMlQ#Fptg5CZjfYcUoFQe=zaYHp z2wp8!K1*=h9@g~V@CXA1)=v~11}M}}fY$0M^VKfkZ8fxB7c`@g$4sg!I>@hIn|H3sxE z>^af#K|?6m95uNUbV=igap=bgDA1{tMmx|E8>a0d5(^+eeHI$QZs4(xp`uis$#-dx zEroy#kTbpx&ytg!3pDicOE^F{_z1~HfAOYv+LQBkWUKoH$09o-e=a;3v6y}feh2$+ zFmIQo>qX64JY7?^p?5Ag8{dg}6Z>eBK8%w`U(BuddJQ<2$tu7$-cymh9>*hDVn1%U z#Zak0!@*diF?U!uFfSg)tJy40G7lSQwBNoJTW$-gE8R zZR|n^>LE}=mE6s_HvQK-_f59RXksXY4TMt!V6Ecx7a)3AopnyS(=~eq?%TnYI-;_gSK21k1zYx;ve2aK4Sk0KL{)iAL3;ZaW(wHq>%EQ z=ba}lZKqmYj1gr(-e8Svb?2P+__70eJ_x>K8Uor4!!nRwxvG>vsrshR{LeD^N}CGw z>n-{9VGuBob6q*^j_JtC31|aF5v%wIrqr$sWyet4D^fl_a9ONt$=0G* z{?LCZ-K!AwEsAE2kCg5j50tgsPd7sCq>z9-u+yr5j1w;o;r=-=&ZB>&s2x<~XSWQK z?gNT@P=lc|^9~3nx4Hp1bor?KU)fsV#!;D#8w?bK$-2axW{d zk+eWvS)3THFfkxu+55P+tk?V>6FKD(00F479cADxz)!-#HZf32PT3N&L{e6xCn{>}@#HffDC=d_$^&UPElOwTwG zP840NCKhVw(x~|^b4D)q)XASFQJFGP2YTD3sxG|rt&U3Kv<-^#Ab|YW4D4mA_jh@> z-pFS(cYPJnE1N4H<^R()8|8NCc++a+kPKy?DJbMgRu(PhB=1Nm{0qg2mgN(c(iMMW zP6W$@?OaEKw>)0q%wuR~$be{eBv8Y39v#(dlpB@9oHlpR=P*VF!26=GYtOQOoEJ41Kjf?uXOOthY7qY`8KS9y- zoN`)D&4h`V3YNzFDJ!oby)H`#;hBNS{?+Skw8eiY1I~_Hs?lgn1iQ-dTOn9jJna1% z=f+r*(& z4#rqSl&o4p``Xsi>yTPn<}2%_OkShlKC!iS2%U7s9+RrhHChwp*ULNKaoVak*AqE! zWvS=v5Nqc(~9_v>7Y%%;%39bPgJ9smk11fhQ|jaJ@S2V_KIZJjti7}ShTz{c}}5z21M!md7&md ze-w-*H5;;gTpZ!XWJ_0CG$5i!25_l(OdoP63>E(cl5O86KX&S4H9LkTIZ zA+&cOeS4QzPXD5q`y+KXYAXm%Z+CQPYXF_M7SS_9%Q8BsLb_m{q+1SpKBd@ea*rc` zC*Kt@>&r)xf7x`5D%w5~Xj-$SazPy(Ki9Aro}eCPQm@Tc1@yPq!v(OWF04WSH<$z? ze@KaQ=NgVZdSmCF7JX=REZhF;`p+5D8x`vW0bdZz-i0<5g^Uf4BEyrZ%AYol7(mqe zf!dM&g-Y45erYhi5fTq5$uaB_(c3A&8Rfqia`8e*gYFnyOX7UagA((}3_4%DEkzvF zOCUpeqY4lVwQnk_E8>&bs599Bu3PSo+INezH;(%p`_|P-IhMuUa z!MGT4sfe+)?;@QV#hNnW_Io{buA(<7`6b*v*2r08Zb0h{p@yY$akFkM>ovJ~V&tNY z0Qv)&P8Fx~w22|zDP#y3^xH@YUuGWk&PtOK4n6-kGlWe+xzE|ABM&SNMqm`&kIJW3 zp}m4wKs!1wa$rWDvYpf1T?{3FA`_ZHLP`pV%3F?_2$4{C#K|qg7a$zL+0i$ zWl^zrfNr6L0GcHJlW+BgbZVDLkd;TVSGzPSsm%Npilq17N&OGjvJFxWzS@~0=7LcT zrF3mQa<+HIfj`Jip39`>tB$>EV)XC*;B#dSp9tHmT*2M%84)8(pd`JB1(iv*3c+*y zqg|~VZNH$vLl;IOJ)5@6v$NT5dRECIdB;FaDYAshN{M*qy+?g!P+X!5mTWj6=o0*~ z&{*aeEA+9u$Xr;rd^`3fT5HhC3Xyq`Bn?syu>Adr^5U<${%E%k?e(<1tk6c^+Lt2~ zwPn)*5qsp`@jI2JL**x1KS`WSk5*##g5(|FvePS*k*Fn>ZC#WXAQgWhjEv5-)vMVR z@~%`UQX}|rpWbs?fhY5GddeJxmbW(d=f@sv+y;~qGBQH8o0K51CBy-rTz`Y>ZrJaj)iqta!!y9n++iL{GF1{E-%a|u+zb)64(pNQW*~W z(jr<&luMiU?$U`3wQNnh-B!;O4R=aVFZD1CrOf6z?yn-z0n z6uK;0v4n;h(K(AA9I$9|KS=5@B9+r%>C7UrJ!Zs!WTknF9RQU{GBQ=f%J(VWr&?kY zEdX02?&4c=N{V1K1Wtwa^cR(}!eCtJH7aZ*q ziSYBq+KK_rNN3s1*@+cWi-|vwB?d?yUe1b={%YKZfbMc~9?)*w$87ZDPGgX!L&&re zYnmrLcD3kXf=L7hMgGmxUbI2E6%zVOSLdIh)b1#UGMos|05q{QC>vRI%)MTJ;P87A z)*Etlq+j(<4WAYxl=aO=ALXD6eG5AD-$T%zpCHHqSCgeI>F^m}H);pWy5=r5#Ll4dDH&nv?H{pou$2lI?3^NnxkB72%6JE7|_FLIBLfGC$zCaaP+5lEJ1GQ zeC>7p5A;eGc4MyiQ5BH8v>zrXF{L!h!}XuPo&WrgyE4hYNtQCZy2j#4u^0|<8n73e~b)*TbGNRn8Uw-$U% z0{f6fTMcYUlD>KGo*XC&p5trsBYtRI z)WnNODok&J#QWU#a20706wKz9MC+;^CSRWg#xX;aaLUv5b8SJ;#{o{^@lWUGA-bXSy6=Xs zIRVbvz)0Q4#I_3+4gD&B%MSftIDkbAj|*I9*Ym`%a?otJ^+m^Fv;6eNh72gzW)G5^ z(U3BYBZ*Q6hHZ4J*I`rEAMDAPmJ6K$VolB>H9Y-HDIR-ROU2bruWtr^eI3utl@l$A zmgP2zmIxqMBaioU94tZjlkKxtD=3j>eE~$x z}CcAr#-d_z6k+@=|0j0-E8tXp4ssozEHb> z?p1Z?l1TW3cnUG?*p9T*BvGmKZCt|@eiSwhxlsJj_l!;Fg5C$u72(1wzJ~_?Uz<2B zp2LSnOo+LyvSf=*%+sVEO+Q{ZhT4bB{d-aEs9D~veYXZ~U9`!4jc8YDwT^+O~bMaPo`7Ibznclj4 z%~c6Hn(EW1y*%w#z7;+`Bt!GczOM2Ya)nTLEb2&9+%o>Uq?3XD`3z~QgQ2{>*@#ZX zJikeDQI!;*;^tavDzOzH9%mqO&JB->>Yu-#zg#`JMfu%=UmfCOS)8(D9}{P=53}jw z#2A&2(W8jrNtmSn(j?1c0pY1q)y)HN%TKyja6vUg=tf8#;0|O1J9KpDwA>y?yIpy= zqY1uHI6Lh&+#xUK%yQvjzn{SGiJ`Ys9GX@sf1cyZh62<0j53yVXJ<&oD55>AHeZ?$ z)>ie(j-(oer5hr4=Y`!Cv=HS#GAn4_dgJMJ>tQl3o>|sU>qvjxnT=w6&}VMux370- zcjPK;)8ip4^<>V)qt{No<%BadOS7?9l(Otv(?)cVxs3W;9u#5j%H`Fv4hWML&qsts@y>^9g zlLB+Jy}Ci^wFx6L0INCb%SS^nrPCx{*TRbVaZYV3;xUGW>QP&X&=ItxHGq| z2EZiUu>m+dvIAe7uUd(ZSe2Z1n0t{4>N6r&#?#{Yf`A`FfplQvN_iKSTVcdjt)phb z{(OZKabyJFXww(kUfk~jJd<28RtOl!-z+uS7s7spxv+cq z6pi!SiEpX|kC#fhZ<(pEx?p-;AmF&#TX&emTymyPfVP`K+2SAgMLEW!BjZg$7>NjeEohEM+7!3-TXJ8w^CZ^u z!a{5FPjp@l&F-*>nh(@=_{QzBH?pINH=>R4gE)wgk*jeu^+aSy)9}GpBX@)ZTFiz> zJ-`f4(V5NaOh^1(0h)L6j3ka37N8|GArTb?ip;RQICcGC7Y8~vLZ9jR#8h3X zTKVp(s-`b@n)k$0(`v)CEg)aeL`xqW+UP0pnA4=gN26{5Z}~+^)j|(zk4j_r)oDKP z0R+HQ{il~>GeFd>8LFgH7G#_;v7j_5@VgfvP(h$_RkMpruymn>%fW@MC0rB^WIR52t(x6)d0M_Mh z$x;4!h;q`L4QiS`eU+NsxdhJHg!MpnFv$d&EphaU`m?VAvsSMU*7nnHV>E|BY!Rfw zlgqF{Guiy#DwaX*?Mon4(%gA1^Jb&OoFgLSrFTchb8_nXqGXV-636bUt`Dus=!@ zhO>ByNp35EW|7X0p2P*XPCk|Y5=H3F)BR7|JIPUA#T^t3pD?W{8Jb~&n5sW!=06ZE zYrlm(3qaHe9!~qm`G$OhJ(4)910tlQKrPOXIiL_Usf^rL7#B}um3{24I5g39V4)X= zwlc_Ovv`$*A1E$uHk}%+>WqR>s`sZ5KvN)&LZBAy=+ZKVlGooNT)Bhy#G1$bbc-T0 zv()}7O#Ol$7sgpRv=U!~rRSeJaJmmI-%|3V@wetdPm-CY>#N3sJ^Siqamp;-1 zysO&UcUL24(kV3gPN~r(a0@8_4^3=_d*@jh^ufo)IBdP^#;5#+!+0II&~mr=i=>&Fm)(euU7;52+a*hc=3BKehgKFRio{GHR_oHO?fm?QBvBu2I^rli2!qj3* zI(7a5?BtR#kC1F3O^~F!xkQkq`0&c3WQIvYO^}@KG40X#K>+s6T z*wgq-`aG0?sY|i?qBfN}&2x;ynqU44w(vtwg_@858Jc z`8e8^l}o+f51vIzAea!p9zEzkH%92YLs@Jugsz`G8!Ff4$;|TGtXx|B>EPZBU->#N z7H{(UE5h%~r_P&5=mSM*P3&Qto}WVE;wo{)^#fWfOA`ng_LTrFK+?ZQiEc0RGuhy+4m6T?C5HJ$s|)78 z#R#KH%BPvbhPM!~v2~&FeCEE-XjjkMw#9fxEw3D*45Rw_YuPR8?Z|C@be>hyXyw^- zhkXU(QEP6Z|8r(1Ivm6ZhQB2DUs1H!b&Z>EpqAcM7(O=HKJ4KQFE>S&?&;hzsHg*& z-KjJVtMvF{!~`Ii!ig^!wv=4D_GH9&joD?ul;DMY{o4FQaWq3qhXZ-Z`K2Ft+0qrde=T@UGf1jx~}PHQ0~AiqJbv@tg`4GZ7}K9OUP z;yZvM2uGI59KR9(NA6VpYqWPQEk{{aB@%2R#;F#`nOiQ~qc~VB)38OWWb@uvnv}(r z7_H?D9pF?sEt{y6cS%H-Ye07J8c1rYiPU01 zoO+omRge-a$rfvb31XNC>7c$SrgzD7z?9#niXTaRoVQl35^UeZY%`Ky;IR9H?Q z_loQVCe2%2lj00dv3v?%I_gfh3GKZGAA24S1LOEOvSbH)OR(?Qli;puhp}+;$I`R) zAC7jFpn#I-0DB8{Kitx&tL_=Y8j@C+=Xc&S^Lz9rr>navyBTa?HphWpKHAfOXay|sW-8Jw{ELQszE=fwz z5!{(y2g#GFW%4*2qD#D4Nfoi_!*&!RJn9Ny5&uNrQv&QWxP3NnU^^5bk)i~{pcN`H zyL!->6Z4w*2B}Mv9Rkg6@-*(NHyX(i40xtePu^IxFLow*3v>J_QUm`Hk19;(AlWSe z)z}AlUv$q$Lz}rH*j#BaEQehVOhSW)*N?ddwd6tB(V7dVf1|*BMS>IsO$Qpg=Q^}@ z_8d}sgIocZI|}dC)*`xQKKnaRr}OB6Br2Q8419)a7@H8+H~+HUaSN}5C}Ve*h6<{x zJa_SqDw|DCI}h;r?xvKV7s}vt-Vtplmn2U>**ops5g4jSDpy3eoL?Wn{DV{_1S&o4Mr;5&vB!y&Pj~u zF7eCIA7{FOiR$MjsMs82b|7{CX8TF-U3aMrLDh3NW9+)6CGinxAXpG>bS6Tu8xWPu z8(75BFPvq3v9f1P;qDK9>U&5s18R5yI~{X}MsNotKQKh{?GWeULZQGXQ+9kidfZ`$ zi@4dAf@AoEK+pk3zi)(@;f&9aeQjm=nn^#h-`rFtxc+7U1ZgtITYzH0kj-HbZ6zA* z)sWVv@1v01dC}G}YX}J5M%++=AXN~I%KN0iX*#-r0n-5Z7@~iQ$uJ4i009$pXt6Va zu}Cnx`4vTqP1AxHw}X(xpO*064qN;zD;2|(Ww*&;es7K|xhm%l>>z~gr9ZeC!Jqz4 zil zR6smW`hEWpe39ay&_B|jc%FD4hy80JM?q9zGV4+iK;#WTNi$spwV;L*sGnx$YxVe* zAx3stQdS0dbNf&n;d0NACCb2a>*>>yhlJ+t0w)?RJS|%Kxu;({@ohxlY_Y?f_Qv;T zraHPSffv2{n6xlT8YIo zv-CyKK|dxNBkVLJYpsy)nDIadVU3(&;0a#a)w!^Ileg~fDo)>y{!=!bzFp#n@MiJh z1lE}j{A>5JlSP>^hz>*Twec;@zlB+gO8S0JUG!9u?YEIyHe-RwP=(s(~)H=Qgnjx_YAAKi}|s2E)cDr3WAYV0E{?gs+>uv^=49gz=Rc}LNYT9oit933qM1&PT7Hk|@;oSl}QxQ8JG5cN!=ny_yX<>7c zT(G==6!*8wAgn0urA_!hLf58(lWEnGX!!zrsC6vgTEHQ&F4lmz1d+3xcOf<3Kh60+ z0YPgje1MuRosEVzLzj!*duQUQ)ym4^Of5INNBH`y2VjkVAOVk1G8N>h{|s?I7xiqQ z;i!O1^jsA}Orhy{(X;?b&vip^^aC1*=^jDt6Z9F~X2xbJ0=v}t8r*YV@4I|b%n&-M z4c}v@giQUfQwG|^59#Xb(d=-3&=*BAK8H&93LZ}A+qqrTeuhlPb3zV|AJ(b!5$RXNI56UWSCdM_RerMDcnRjBQry~BHZ1-j za*ipqSePm070d^kVwiX&)3CN&VI%>e>rqlva>Zsy3;A@IpeaG>Wm1&3*iAA%93G)k zdOiK0OTeTeIUO`54rhjX@TJRDyM}dmYrz~BT5-@@v%BhM`@P(eYT)13`NMRSB%$jx z7p;Q(dP9ldJjwo8PRL5gWCU}=9nbze&A{YA>s3S@2DrqK2U@S;f%QxJ)*JqeCjS92 zLSADB-Qpla#%5+^ns+#W8`mM=3W`>)E%dN8=>B}d87n11Kvu0pupe>CH9{$M-_gX8mxnH8q55~$qSgd z^A;rdYK29-8Ukk?{dNKSZrwD~=^g8i6T}>EKX8~KZTMdWOi-yu7*1ayyKYnzj<&VB z){GGaFnk+ud;EGb|DxlILXm?L?Bka<)kJT?R{_m%(PUmuK|fwDm`E&YZ2W^*x7Mc` zB+chIV>eq?jFpE-`1N|-pva1-K)3YkWkK9hYPljw0`S1E^#L9mkppnuQwABaiIJof z|KoO)`qc>ymy7iEf-|oqhX1*XM(y<7)=BJgpOFX@y|L={LJLgAk64nuUbkFM1q+6~pymE^Xxo2K)dL4HCeBaw`y2WRUsz zQnOxQG$c4f9&sUz5eUAruan$PaTaEQGu-y4#{vjb)6m1Lzc^gD;wF4k0h5RqR)6x; zweYE+7xKos<=3pAyI(OYI<8GHf)_2z9Yjv;7StDNi~Qz^z10;f58g;KVQZFz#Of=> z!UeaamwURUY*a_LR5VW!kmm`K%m|I#t zsT+tI{4~2Tsbb%o<-1}V=vHkEYpcZ?&OK?`pI!+|)P%JV$yAS|iLXFCk5*~kz3#II z0>zO`(b?sqtsGAx<%TMGNj}q^N+4H~Hc9}23i%l_1e`lYu*~8Cc zDR<>^X>zps;g3~-x&mVF#G|MDk7V4jGbfQ^so?R!xip@+P_#qV#zg@u1O1awe|O2t z;T61b<0A0$Osh5ImyenBY-I}A^-|h-WFVICFOm_kl$juI2gV}yZ9-4eZTB(FC5$YN za!zX{#ra6gjWsHk--F2VN{rl`TZ>DY(erra_gpnVNT`64X}M2}tJm5tWPMRf@0mr9l|@X(Wz+X~UkE%j=9D5lq3EUx(jE!a*9~#FkCCy-Vag zbfJJnWXxF~AQBmOo%~zGtT7g`-F_?zG5DN$CF%+D+;i%qQNjIxUtIYAsa4S*!3@_6 z5w&A&h|k~{LcnF%izf^X?m>A&Q_RKGd3dWqrwMJCj>=THTSMN z=(x-D6-|NuL={z9uY<4k#{N_s;oBB-sj3`MSLt}i!`W`4&A_%y`~wM8R5(-qGu=&L zjC#ld5I5PNZXEA9W0kpv)Qak;xGuK7{E7~C$c!9{!IJBZ+wI^aEc{$U zwQ0bZ>PhmO3b2n8Ni71^YYibNh~_a~-q|hVrMKZM_OQ~n)l>%pym2FW zf$=*9Jrjv`)-?Dh5X%h;xk3;`s}mBNCwwk~^}ypTQ)hOF@u{lyJTGsUS}x>9-klSK zE&l&Y9R0$3c@wi=ULolLCppBENylwhaFh8rh-aq6SmrkICQWRhoIyw^45w)reSr1d zxg}VUbwFG2Nyq9$(8k1u2Wu+AjO{baxw$7dWKzOT(t02Ibt{PQ-EMP-NFrS-Z!;oY z*U`ythN(FJvIqGN>?$1W%Pzn;)TsUQXD<+mGQ#;t4M8#EjdT=%aOlYny|fuxRqtHq zp)kq4?A^VZkL0B99v6sOSm~h%Q+*u~aW!ewz#cg2PW!Sg&{^t9sQm_MlPh1UJp}!qn*3-ep99in67soR;v}Q9 z=G88dN^8_MDa?L0_RxcONL4XYS544aaHV0w1|d(iSDTMN$Ak~jp}?WWQpx>Z1={Db z&Lp`3-{{{};6s8f{XY}cFvTR`|NSk4J$z@s)KT(Av(JD-8n`$|#^y3$Ftwy){`hh# zhG4YAgOe+JH^T18^&Y4dJ830#3s2>oq>2K;Wg8BJe6dtNJPl6;BLI4;#-s1N%R~Y{ zE2wQFyg4ex&NrtTQvAcsH@rP;ddDotK>JxO4kMYmCjB&W<~$pZ=_y3X=$*;LY)has z7b`!Re34;xsz5VU>Nk3@x%%Oz_Z~x^K~bL_b<|)aR}c;T?_8X+v+l)e?O=&BKG$c- zeA?v9N0D9M}W@1t0DH7&amFl~7E-;I;Z z*$4sX9`cMfVnnX=fm;c)D>Qq-vruj@ z{xGssye0r}Zyd#0Wm>{rhSI#0fjPax6K|GMxCNtAQM!J61s>5zy%Q3+}&egYn zp(lMiRSP|r)oA2=XBE@U_HjzilTHUHeMUUbu{I9_!$6VK|iNOOT9?az|~2^4jD zAtzdSG-ZYHCR35%gOolVU8qAlQ6KcAg?X)u(kG$lD)Zo*wrhD&mZ4M>|N=QrGH+CrxzUogYCc#Gn;ZFI^EFrg|wyJ z=-$78oo}(u5Dog#+hX-I_fJW+^c5agV+~*VQU*n$Ws%`0L^W92;xBMH_5}l)ZAyxE zqO^L;$IigQ!t4Zj+!}%dfJj`*y@L$1);5niD(ok?G?Nx$ZSO zW|C6oHO4FJnd9|l*Vg;fB{l_lA&&wV@Bhm3B1SLhI<6@lUvXXY-%NLNK*T?N9AUHO z6TX`r6S0gU$Ybz+bhN5#$qCin=KUia&mc2)_>dlbp%ZN7#UR=Ipa$71Z^cSY+w<9A zdZC6pua0d?v&tWNz}|dsqJl6R%S8RW#*I;uZU9poX_TQGr)r`-QCbxHa41P z^v1VpNq?Ge{bs7dEkQE@FVKyn^|U*1p~54kX_bov=a9u`@INt!tsIg9ur%>Gz^o@)9W~%|F`3SEt@uBqDVOz zVDNE;$YQ-KwsF;8;V8fJSKW3-p%^OwgUySfji|lDfu$0j={nGprGVl?KfY#>YXwd@ zZ_R|&KlqFFF~D_MY7U7BnB44jP-d%1Rw;KT)6s_j5+)Plt5JPWqaChg;g#JM#M5qf zK>>)OCwL6X&O{(f8nZXm3E@{GG?Baxzs_S%5OY`sBM2|}87Jn4&4GfEjJ8Q*-Usna zPsA-4EF9*|v2{>=A;a)X_S?J)qSuW9= z=p4vydus!4agD+-PZ%tV|4Wh4?p>fk&RX!|E`HXc6|szV+&+1Z>>qP4i&3|S={!pa zmxu>AYfgZG&yj&esG2VczA3|zgEAmF8dko@$0&6QO1k3!3Hx}l-RF}Wy)nE@+k`iq{e@brU6C#kL1c6{ zHbW?pXn?6v)tN=2PT}t5zhg(1xh#*3G_|Zl{aJ6Pn+={sRaJsmnBLhSjVOiy29>K= zi=O#YLI&@db&ogB4x?{$t&TDD*+%`+iF5^!We!h+#j5i&&1e0q6{Dt~c!LtrzK@gG zs(>o_K~AFy@7xEZ0j7Qne=0hbesVLC<3BiPak9)YO3rxgMGaP=^JDuzLkgQrn!uek|6H4KNu))P?FUZMSR&^&*>}i;1%;70K8@D$WfJ zCtsCMB@KIQ&_9|UvBuRK>bkL@xS_F7E99yoBqJ?Cwb7GOrKv0i39_R^p6(i^rU)i@ zwrqL}_4qEdj{u_-Wi0K!Ecsr2AaX|1ZPTFTbV+xk7;#bY&y(lpn&lz8hlx=(7e?v1 zgTj}7U*T|Ic|Le8y7f`127Ja?!6{)XAUv}>vNB6+rCTEvKyWPsPhSx}-15K@@D8i9 zUGEZjygPLP#gu0(=5!cNW*(_#I`$N|oS^b6A}~?0#3G4Q8pjABo}i+y&(QWZ>?ZGt zX1Sab@gPB>AlvsBF*{!wgiXRV)LnB@%N#ai;B)S31K=qt;S<*D0J^xMA0Jee{POty z?jCNNnFNe7ngOY@hWeaBH}#4&MOf(9k{y?;AucV>{xAS19Uh`+_tbCpo>f}xV3BnJ zG)E7+x9c2(AINVXPi8<6+6ly_Z=fG=S1DrhanD>b^wqKk!YN% z+X4kDdAf=jRgaIA6rTECB|A%Eb}jPL^v--V3norj)2bqnW*L(&T8e^3QnOYC?lzhw zt``R|yI?FYbs!J$uDf@#{Tq9ZZ6BMpH+5fJE1re`u(HCT*gV`g9^6oy?{wR~Z&_I; zKTG+4%IATmR;40+Pgu+#CWHLX{~l51Zm5CRh@~?qgyuOWMJ#r;BscnP@8-3C zhq24DGlV*m%wYG~#-IPg?PJ!Ke&ejG+s)R1&UY)Loauyp_~fkc4rzvjCoo1 z-6aMk;d;*crR$uW4Ly&h$@G&F7C>A+%m&-%xm}}2wLj39OPqQRK5ag`G#zA{%Q!ZF z8CE2Kq%5hn$Gggg}sn{~N`t^NMtC=rlpbbZL`a;X2 zx@&+(7j)ysPKJ)-705@5DS}`obiV5#Eq##X=9z<&ajH1AKpng!Yi6j$J28av?9#f_7RHzlZX@3EQsUMkFauqEmALR{?gV<2*IQv?OcY5UAv+%e8ZmN;`SoRu*sej5 zu@fzfVyx_VLbhWvG#2H}D-vf6!ECV{+%0Jm3~Pe+l2t+iollK!UM{a@jG|RsS_m9Y zsxE#re%FFOIboVs;fsJQ$)(N5(Y3U+picBgcU`X}opaUNSPh>sR9i3UO+K>vQZOr} zCwZ;jvTc3Rz^nGdF9K0NFyumw9DBr8zs^V!%l3Kc90T~Y4%)4ez#4D>10)L4QU`Sv zyf`2`ImUUh=e3q%3>O?Yyw{BBnFi1ghrdetQlbp>+#A&PomCrE_H?BP^3iTht2nJ9 z*~R+>qw%$`ePO-;H3@@|cKCn5U}zHu2%A%INORXBbQ`+%2y6NJt55_ylUMIt1R1pKpR;fG`qcjm{Ay2LAJp7K!FOSbM}PTP`73IHyWu==VKr zESoqThBc_#pX0f|_0sBqL5<47alJ89($dF7a%pAZrdt|U4-q_40|w{Nn{AX|88j#X z4MCE({u>X4zKB@sxYLpO2Wz#!#4x2TuC-9FU-aY5HZG#-DFp@sD<(KRpr3OZ>OSZc z$J%q`r`-k{z1f?k#-qXzyDm~?9Mc>^<`NjUjK+_e0t*b8~d2gGdiqUq`5o6z6@>4d;4%6UW zk1dZIMy3)+AyAop!&Fg;#D(Roqtw=<_PRH<#nv+qP&}jr!)uJ+td__HeHeJ(X)8)r ztd#k5FM*n@1EO`rglAkk{Lp-y#-wx5lo89M6xT3$7}N%^gWdE60eZ&oR=&E+cG8>< zJTOcE4{Jd)dxfI*)sv(XN}mcRF=H6wn)(i8Eh zK?VK!*xd9)+w6PMg&GZcopy#uL+KwgBbb9m1D-|tpDiGLqK!HTJHumUXE)6T3W(R$ z<_I@@jJXVm1FXxh6>&U>wQ0ZA%!0=^FaEnV zjA_q;dzkh1xXFKmm*?8Ozdmsk4HMtcDDK&5zvTK*+{7QQu*;2st<73mTu~%_MLrbc z&0xXPv2v9FJzmb!@Q9$e`B$eq46naq1q}X@K!V$RfivlS=u`v7M_STl>Y|*;v@CwF z5x%S>6a)PMK!nZA45P`-b%E%Hd~rO$5X8TXdorHQH&fM39wcuB z2xs)#MScFF>Au}#;t!Wj^i~B)fjk9wg8ps38@^z5tj#+74VKDiz;dBuC!3C6(>f7Q zA5I9*j&}i6i!!6-@E7_cw0*8Qgt81(bT{3H7m1<1FPXuSVS| z_QLb6m>KB=u$_MQ;}&th)8htGhw^;Xgk$7wNS+m`C4mB%$}8$$K#S%`jx}0#PYy;< zI@e#E;icJN9t8$ZZVu!i6-W!G!3Z$NmzPSwh31o?up?Gl%W$V$yph=gX(OPS%o_oI z&_w4kL3PC3i~h6)&ib4GrT4UUmVnA#Gq%~YZiOcyfHW@sPuhL3 zy4IHh(nK>`X8JIJa?>#JLZ_sO-RrHQQIljUmX|uNRDDBhAh^QL%&y#JbgSfb`cCSm zoNAghW0e*haAMzQ{YOzh7J(9o*==+49niTXG#g>5XWI-%|9RfEM0{MuAbv1bL)ftkMjkkP^i)*?8}Ls_W_5J$;u zCmN5llU8b|bh!O}tMJjZG3F;`2K9-S8^f@*8W>*DRVJ_J6F4H!)Tn9_kufxvw8h42 z7tcaptgufbLOH!5^Iql_G0!%we2-v$QsafeBbN!jhRvT6-qd+z%Uj8gkvg<%Cn6g# z-o^^0*L4U*S&Udv%LmBZsayyR7luw`Y(HtJcy}XiMdyPv4~($1qnx2a8tPDJg0yudKk)Vkm{i&l7@MCr$N;!qx^2 zeD!$4cd+S+v9|W^>TxaWHJ`d6L;U(jO$QUm%GAlBOnS5Aq#4m=KhAMz6KyKw)m&>! zy=t9Fsn$^xnI?U1ojdBmEmhscuZOrrow`RF4vcEc13?0N4|_MJbG&4J674+2=3~}R zevE{@$wj4e1C9Y1l+=g+{VAGLKuZ<@lwO`FE1`ls!MwjBPgK7hYBe(uionRFwsC8@x zs)z|I(v8=fFt+z~KRD?-FP>*LfJ_H|W0YUbn&!1?BtLyRb@ zV?0iVvynwMiX2A8iW7dR&9N)V_cT%w`AZfN8u5xr6rhxGR{U3&Z$|D~7&y zRRHm3#Pu;vFkVAb$99BxT~^2EY2Z|<~r}7ffcS_ z#%;(Z?);Ufd}IEv)G0hzgIk|lO9BkG`G-xUaqej7@D)cW(QuQ%*#Nku8Nq%eg63f))q{<({sA;=Wor*e( zYLyipK(#mJx25?7O}Wi8fG@nG>RLdWysgM=|HK7S+Z1QVQg=;90tY!QwDw3MDW6F0 zU6Yl^z)q#7;KB5}$hvLQZG;PxIU?tj6|+Hp)0`nBfi-zQLsd_8KPhiNJB--xorR{K zTAolwH!#-{u{4F0x6#_)VirpAMHSYM3!IPeCpSk*O^vUnOUl#tP@ zb?*WmV%866plfhPNi zMNG-k{%6Ow-g?XFX{|v{%`&l5r9Mt=_knW>vSj<0S#E z7#efI&uC;VA+GC--ZKi;msF}Ykm^pUc8craqWhJ;6CkL>OsM;OwjQ35^MQuqt`%<2 zt1ogUTM$yu#Qk~US9?1Y8JwMpv;^gPpJUMRbHmxo)i4ivYmTXU`wlM7RVJ`(I^?HG z*&eXN)r-)?mR_2}?xNAi8j%`5XSze0Ot>WkQO@KIaelC}6QU|#nx6vQMT>iVkys^nBu^cLvq_LvsMQrle;i_SK6p$mnYCXuoAtcJ z&;<~uhW)IZN_4p4^2nZ*1eGJgSt(}ezT_!(GIhxJ@u+-f6u*WU;DpuxF z(ZBnW2TwI=TO~s0E}Dnyk*;Z8q{{nSAZ@A}K2dmYGOBRqm^Dru$GqwIK&u$rrT*3X z^}U$r2~+`|Rg{~O8(z`AJgaCy-ElM-;Rbgt3?A2VDZ@5Ex^5Kz+GzJa2Y@p}Kknue zGL6is3L6lLtGrhTnKdW!WKff*-3<`MYiqPceDko{d2ZRFNVz#nRoDZUPx#Y-H zFLPnR#&r6#Z)IjrU)9^EPKXHI`AJChX$-MVjGdX}-Cust%bVNsoT9#dgCt>|v{B?r zgM{qy>^s=a-_ov3bKtClt=BhrqzZNVx5PH}ZJ9>yf4;VxbSs~2WF7wgF%`Y*TSqd{ z#!;`FkD7YPx^2ZMwk6r_3=L58Vt zMo-o>PlQ*1)<%n?<+*#CMYpDZh93u5nW%l`5j{v{1vcI@vbEK2x?#f{V#1FC64s=U z5y=~|9<{1s&PzJ|VRKS2T&8SNo-+Nw{PqTt8TSq^BUPFi}YOvB6#tXn` zmbcLcB9^iIcWgq7e#Y6_K+Z6$1aYPPK4YD1`HJ*Xg$?rQ15%(<4yoCEdjWlnD=IG? z9@iC>=#houZ=mg>xdm2Xi71Gr=b-r1%ZLOgy z_9mEin5L`Sdrv&A#v@0z9U>X4T&;?OF5H*v#RkDZnL=I|Bu3kM|G3Ww+;2+;DD#^| z<7F1X9K5~8988<1pt}7VhAX4hL`YV&1d7}{*g=3v4{lQbKPx9f){)^7Bb=#T z(L!s3fb{x`=X0-k2?2`zo8Z*vt zy<9StPM9zrPF` z>z~);$FaP+FXkz*03tNhJ)XSY`rRWWs#OFs3^O5Mi3jD8J{yDXL9z|}qyQ6M zIVz$-Ky;-egMBTB zn&|Yc0@@m|DBit{Y)SX=-vCIF13XD2+@;|3y!eGautiYT(@I6&flF(;hA2h+39#9> zk6!F7&%t29k$kEp~xp%w|4JMA=*zYZ+N^ z%|e~4a~Gk2S6HOIfQase^HalH@ZYo-yzac;Nmp+F-y({qaAwf}r=EyoZx#EU8IqV# zj<@ZXU6H^X4$nVfC9#N3%<0V_ETc)oLJ8Gfil{q~c*75Xy1Og5jQD%M1WnqQW}*0$ zX%bG)+HC`{C6hr-f}q zCnQ_+hVLbQZfE62o{6+(jvyvS)}xnlJPja9DOSAxG8Lw?{_Ep*0H{_i(Us^LvQLc7 z<1y?qIr&@jrJXZ@5U|}s^tM<2@uiK`)H!Blddr2rmm`iCcgJzReK;otRV9wr$FI>Z z%0&Vg>}ssgZ=;yGpYh_DQ~NhwOS6VE!spI z7*5yxnqmBMSs6V6wVz%vNMY|-<;8)TG?QcZN?$VYz1rT2|HlG_2A7f5tw1?%KRUZ$9uf(B6F8t zhlr-mJNdX~8p|&1QC!ji|E1Z`OArl2vQaf!LSqAIxYC=7fa+$mg+thPoW`{gI zGq(;a8%Za`2t;ILh(D`w-tJ~w4!_RyinhTA{Z->CNF-Z^-NReOR+yN>zFGW?s&B9E z{{euBQYXP7CO6#cdb&I=I-+eq7+@Ny%6;hU$8BzLWCHn;j+Q0ip3&O zILs#=`U2aTc);|>%v?QEL!c_^`be$eB;W47Ie|3>BPhDipTUU|Bt>kQvn`B-9iG#y zPc3eQ|6qV2f|>aM(Jg0jbkYl-RvO7uk02AqXvnt(1dhU?(Os`;ucdI&wP;3J*px5- zrs#NjeO;AWyBr{4VzKf!GB0}905TV-N zP)cMPw{IfOcMX*4>+01WJ?{>>AzBwza-6yQ^B-qlzEE#)Me{Kvyci<07TNIASgOas=N9H zNMtIR#a!~Z67aIaG&0#{m1EDz-nj?%OL%qJ(h7547*{Z~rMy0R6U7(-P-k?LAwI{T|uvqHoTb;`{N}5`?wv_YU={nnH4crzFiiJ@i&VzWWre6 zXz1#*_e!>$Z&gLEaA~~V(F>3E9~qEYYMS$Zjsyv0z$0aRlla2_7kP9^009`?Lo z%QMCRWp%IO7lg-z+;F|)p^Eb-7IC)8Lo-=l6ko=~B}(Z@ek(6$lsi(+71PDunw*wD z>mLT9eXq3%A1_iaP{UvOsofFlOR}80&fNi&r>1D5iPQ<6kf&-F5y@E5V2-CN8< z^Gzu_=Q+8kLc>`2=K#48byC>ih(eN;sDg}8)s1ch45RDE+(bP0pzDVnB1=r_l+zzP zr3((ngAR&f&s^@qD2N882plRNg*c!rm3Pu{XYx`o zjJ|%M(A7kN?T5{Y2d;?0Mp>6rasK2eDGtamTvkTIKg*E+xh{hbakh?aC!(A>mmgE;g>;7C49oy(Gf zoQX)avjH_|ot8!qAh>t>K6A8q#)gfezc>JtbOd!hM#zx_vt#wL}&4v6GL8U2fb4onA@fsD|q%b zb&fB(Ex4OYmkhWF$QYw~C+vNglJ!F$ZPGEs2s2Ru_D!0nwL=TRdFmf=m4E^pLgPM9 znTeHUAKMaa`bz(-2gu7$-?jy-#t)LTtx>>=RhQ+swC0NNK^2c~ko1_k z*+8YNz2(^l$5A_okeX6FeKo%|gYblCv~5iyD6b3ESh_HDUp}J79#gnGs}Dw}7S{nR zZ({L8KG<%*7WsK-x^D>5TwpBhsHbMXYdeiw9kqiU1A+UL%6BHcF_LRCT(xt|qij8xM`fNkIZpU{Bk(NJRRYLngWi7Ppp^zWy&3JS+$1Q5u$N4ip{hh+i=C zi!R;El>*1kbZ?;wH+z^3(0zj$QG1_|NT3im_8I|iI{kQ;B z|Ci5V2+|FIi>fl*Xl9^iNTtZdIeYmO=V@Xv9AUSL3DG?^=A^oTWORaLjf{jy;?TZh z9q%~%T@LaKS?KRl9m$$IG4d|+oAsNx;GqQw#y&{O=~FXiNqT-xj0^8%&1W!x0|&sN z=-mjJl3>puf<7+rjI=_*OK;wz%p1rkmrk;r)WlbR`44_c5&InwO<$tbwQJ0Au#x6B zl0M)Sb5Fm%Rju!Djy0>nL4~!!KZXS|QZyW4X~{6Ud`Q=122!XXH9hgwz0at?SjgRbjuLl=PBPQ*&M4&M<7F%1X+Z zs6?2m{E+M5s3Oud-S@voWaR>_D3M*0<}>`7gVmx=M%dKw>z0FNXslu`RG6kDdsQoNz#uYV#1#K`*$h=EY*JtDNPQL>4Y$N=TSGF z^=Lyu{nU8c)kT{Se^CFUvCbkSaV9s02v@G5(p<2@??^q7m)xqoI8?9eOX;5#i+Mhm zBYhtr{OE=XLr<_HPU~GfyA;C=43+9(er#dAgN6d|pghOCR=CZPrcwY;Y%onU16a+I zRTg(7aKUbK30~x3mmIg||C_k_hkQTfa!60D_Wz(;)b;yKN9~#(HOfrB zt|v2lqWl?dOizYiUtghhIZb6a{n?>{=OD~whp1e@Cuox0R=9-b7;_#T^^|~F}dtV{)D1lC&9|y2|8Zk|=PLcXnh&oYhaeHnxe6?z1 zzU;XVpGR;yua@RIWDd$>6wwgy>wwf!yKJ5ho(fdQt1(nAw)^I%l7r9VZJ9mb%x;C>tk__~xGggY&+lj?pKGo;y%2I^+Vml0wO z_eGD6CLKrDfX7yQmS?|>p*`S)3kC3iDk(mYa>?wbdG>6h4MLtHWu5=MPl8h$g2xYX z`wxIhAF>TVnO^hZePMdLYJY=^mnTn+W}rf#{{xZ-`>x4V@g^lB)~; zjJ4SOqcfqMGf#s6mY%~N&Uv+>J@qBfeK#vcEBu6U5pSyf7{*M~z;xVug2^srWghWJ ze5S8sSlj`q8W4nsGo*h&Mp`~*xTO)Q;+4+h(yHMr^>5M%-Kw392XEm=&Bofiz&;O)qNieAX%l88Y7~ zLs?Pv7|{j3bE?o$K}QC1ie~BLRuR5B1CZ{Hia=VGl7_GbWR%M1|LVFeQx!wS{a54z zM`o1NEN!0&{+Wosp*Qgkl1;R{u>w(Fb5|idt+wCv>oRw?S#2YI?C%QpM+sk-3V!oN zmO&g!fD>@wcJ!#FPwM_3q-9xW(fVu7!BKnB@>n?>y95M`7L|)VA zJ4~~Y!J{lP+_`qL$*j?mT{5opRgye~ z&Y;K(w34%~(HvaIx<>317fT!k$nfB3-_dsh*}^QL+z-stI3i~cB22`9+h5jor1EDLY(GZO zuEYM@E!9^I7`s1GsQ6t1w1#Ysi*`mslJSLE&-`AokBjacxrew3om)3_4+0&j?u{g8 z(}3tn)h)29Wl;&lm%qs0HEKyk|DWr*Sq+=vlBE02@z-y_4zkqe@>tdgO_Oz#Y_GXf zDW3zunw!`It)s7X?aj`yL1Y5l5C`JIsk%eQJ#MHpr>;V|bSF28JXwllJhC3?GPfF( z26VU(3+b|&$+6#4I>zTvVF7p=fv@%et(*yBKY7TI{|f)xce+o|DZAd;rNML9JD5ur z%NJf8vHfZ_KjX|Q=}9Vh<8oAhU6e>_p->t^ls(3Shb0#@jzVhE`!imI@30_(%vGv@tgB z^G~@HPwnsk3b0{O-MFzKAS6_O*kkm4#Q;$0=LX&&$mCQRvEk3=NEUNi)vvJdDnh@! zywmaCLJ_3xr|zAmK3bqq$ldHS6N=E>zhYT!h_M!4gX0aORQJn-Efmgl+{sS!t? zUylo}xKEqz*>d1I2I;{C^I?mcAvrJF*z^*BL>ji?LoeQb+gULuYH)Iy>J7+L@ z5Y+w+Vxa-o6ejvT=&frt*Z84r<9dN-Y_p;Mai64<^Hx!bLnT0622> z8cg~;B8IRdYVNg6Duco5W-vGEwdubq?wXznD^WaPzh-} zxXRekvBd05e`)WXuY8Loz5{5>gGtc-q0$Vfe*nG7%wU$UyovMK=}s))P}4D1@bM=Z z=wo(I;s+tg98=%H@G2H;osf+$LP)_6Nc0Zx9MosAy0V<|Tgf-xc^8FT>E(~t4< zS{IA!F9TYG{&>-P2G+){zMk)8_vgf4{N3-w)%cEEW0=LbRNrK$EMIo}AJ8_yuQcjw zKh`KAQO;V-R)I9c;Ps1onUy6TpiOM@Av3$6Bq>Jh^~b9EI$lts5Y%b_Q}{{{Nj?~C zLOqy8+R_oYjs^HEjzgs;JI4?}?t@U}vTfxz1thNt6&&H!o|3XKiq6U(o@9T z9a4#M5MZ=Bh9|HiXlAy0fKovRkggQ*QsLJAcos;Fk1v-1CHw4G+;Fp!#!?NA8Wu${ zf5_%W@=JU@;pRz?uPiwLHqV}=am%cp1PqAsNn!)K`1cGZZ%6#!mV5hlG<8h3oKzOI z7#j`NoMPMg)PU|*NbHSk$11QPWXAS(RvgrZ`W4>fhD71cWEN?r3+mcM-_P-DZxl_* z@PQqGIw_@cQ$h9R3`v!4Q;Fq?&7iG!YeO=?5w+@pTnkecJ?FzKCbhv>Qby#DzytC{ zP^aT4{=`#y$Oz^5rq7hIepJ!hWMsXW-%g8mHK%8SQ#=JHe>!U!dpLh0yrR|^?p=j? zFsBtt>C?U#hoe8h`}iG^WoU5+#1}QT;O39sXsvr5YN3OI(2gIWRa<;dUJ!%?NDm_i%qZx}`rB1{2)FQHyH<;Hv5>N0`>WHq?& zac4WSY>AZV`qc8o2idypD!saVoL5C>?Hrqdx&0Oc#IaWz$Y#z@-Vk<2yN=aVGmdE8 z41OalV~ltyxu_sv6KpAOlN(pK^U$sMvj!-Qp+>L^uz2*kzzSF&yB_M}db|R3*A5G_ z{!fdGmDsa7%s+7HN=1H}#Qhrgo?rrmenD5>D;F3bqP$-_ib{lY@Z zC(`lB=asTa>|lf1=yJnYsZ$uwqtr`Q3nwPwj?B$-_888VeeIKsDeE6*pSE|78WV9L zFvq!+b`NrFeTv87(>5Jc5{1g7Z8}=7a_pgw?ytN}lP`!wcy4R@g2f|-PALM6BiIu2G4fd(Ml1NSuvAQeI zf5Pgtxp)yGrf8m52Z5iqCGnyf;fE_f32;jEwtKb0A}_eU1{^M}562^sO#*+DKZ$MdUFDR0dd#uNDW6X! zWbeFk_*zUOA$_k1I~V)=(xu;YYFJX!;#>|2yhc2^d9u7M-?W~NO;A!?zb{(IY-*G3 zl67=t%r#-9Ol}onhAXxFXx0>izyHJI2czxN``MQ`M;$SjGrS^QbmN|qEL)lr`&7S- z)z*uDNr@RIcHKW*w%#uQ-fM>BKM@3-Hl|`*{bV7D5xz|!Jol8alcd)fFA=e-g{w@9 zPwqY429*EdcfK`y`mHbHt9HsaVVQ9rppi2QrY(p6WA-YOn*p0 z%}Aa4zX)=H;zUv~QaKdn=&ZKIWsi@rC&eA;%j!XpETtAz_x1D^xs|T0Q>DdrM)51E ztP>>_FU%FFuxct>wi-6eFTqCf{2L8)tvcX(PnUGWf7^-$X zq4Zaz{L)Yg|0ZjXeaVCNVFd(5ob({9E!=c^}pGj=jD(5&jYm?vVq6!qCF>}0VkwXs`w>;9|J>?!$7M}gPme-QYQVo zlQjUWLCy^HaFN#x5((4O$FBvZ<4n#dLVOQ9N$LY9B&4+Zo6D%k*H_AkNH` zOoE5v`Yi|!cAoKjv^%mg!)+1CY96ca(C;UFJav!XtHaP50>p5Z$79Lt6__jMiInk< zQ0T!%E;LOu3t;Yf2Pq9gB0{;pJV*lPH+L=&TYtlNk@+OCmRctuC$<00)z!PnA2Y!# zYPs@bgHQgaD`$t63BrR%#y=mt<4H#Wfrp+3|GE3j7~NF1?6hYwoh%yWDUJy$Rtfy=NMP%8BQ1vFG!VceGE*E3pQ zx5^y)!50bsYl|2cn3-Apa4eU{gOK2KcsllTK+t1WwsDz*diyZmt>h?u647Jr3hm*J z*pGKry744e@k0jK6H{{Af5}b%Dk4vexqe8O1SraeB^DgB_=%?)Tpco!dJvNa7KfH6 zYVT1%iKppHNkoaWWuFvZ3RlPIq3toz6iUGYg_Z9u$Nzx*0LrVYf>BO$x@6OxX+Vm- zp8${_5qUqaA59JoeAJr{+*p>Rm;lw?yp?G7{uSRCS8*7}1zU6X_;NWJm8t*B#H1I-a`>E>F?o})mu8H6N-F<;7rs2+}FP&{u zuJc0bfk?9+qv{}CFCa(3Ww`17B?#+YK4>W8Xp?!bAZ?(EDG&F}M#Pj|pq}-^PYm>E z$>MjF7b&b#`fVCgG5xY?%$=6p8L|!}t}nFC=rIhcB{r~)(8f>fBMKQ1y1HdJy#2O~ zQTC44h$>DFI%Z-r}h^uoE1^YrY$vq}=KY^xgj^Z`GePM9V7a5F}lJ)%&s z@h&$vl@w{oM7=xzh2a1W%6qQmpLcnquS9$$b^gA`pda z4?FG>&yEFspUC;(q4M(Wg}~(1VqpfScwXc2;!V#ph}Av+X!nU+O(oF9xd#HK%|M< z7P>WUS%ua!*w2U;u7#I172x{x{_yt|&kZuvQC}t0M_fa<(=;4b4G_bL-^#onHcGU~ zbw~$#=q{Gyxivw1VCx!erVt&CmiW|M=DC(qoVyh08zb)teVz-4ArgyLSG&wI+8&0C zoboe(Z@{-eKZKs5ruZQ?L#Hk$=U2`{0+63j?{JhSSCZzINU?Fxd|yJzdpq~`sK~|s zT^OBF*$(3s_2BE_Yd`W=mM#Xa09i95=Y;|schZaPfiC_SD`Y@H92=#GL5#Ow&h23- zL7LIre*#QD8>RhGePQCU{J)sM4tT_IHnV2n->BgqPk_>2bPwXo9|j{!LuW=d*}OpV zIH;n({yCo_E@1)s-U*4gb;$sKB}S2&I94Ns@2(8I1m9|l&j;I5qAvR;4C>}m{D^!Z z=xmPq`DPVx5B~@DH@VI1uOt&lF!-~67?6=zJbb*1C!$>5a?&_h=KP^4u(K;;(as&lgXu$jZp z-?rDvnOh*wplPOou@>ipQGq^tjJoV$-afRHxqVoeH3Q6R%EA@UqAv21HN(4_rJD0P zG1u{3tPj}$oe*dIJ?`ifx>ha{zG)ZFk;SMqCP;Ec7jTKWSh9&sbG#KT90Umo)q@G= z4eEyUKx7%@Xl(Tryoo%2gYV@6t_2JMdPRhA^Y8&=uxl}dwSKrsb7E0Vr_+fX{FkG$_H`i$?-cjllJv%Ryg_~?>>F>!XjL>R40VF8^1R)jm?f} zUyp!unDDoDaFs;IBGa#2XmJ8j6!!K4XcUS8$UzBwu{)>y4 zi}myzC@H4__#J`d+8#o@?p*IHHy@u$nC(#6nmoD3K{k~s$YPKy2KqG8Sfxq~A*upF}TYa}L8hA0`V8E&KM4 z8*Tjrx_P?qTJ#2jBCyu7oLgf4HSiZn6m-v&zF zBYEocHkw{3pR;hxH=XazZoRUqwU3(Elkw&a6RFu*2WSVn&kE0E%OoiQyie~E3|boG z3;mo;i)*_KfBx;9Kyf3Ig4bJTU!*Iof*Us>-`UVCmEK-@XyS%v91c5hd3#FST!6=i zV>CJUxHO*L%5>NeB716ul1NABlSUwu_@vfAT(2XreUcHU1my2J_$&uC$&F_l5GKaA z%U=o`WC&p43*5`~`Zk;wRqE1x$%{3TSC1~Sn8V-49Adp$V zIEK;@^*>Xwz>Msj;grWi#V}ZJO!!E5?XI!zXi-KPp(u^r*XfS+cg`Ohh0^Rr_M2g4ys9o^FwCyA^z(9>V4 zx2$PKsBsk+p`dUDRm%T`JpKJoiV)uRPoUzjBE=GLyVpHM0|T`Wn`GhMc%Ah_9MsNa z=ja>gaGI&xi=i>vUu9!&F5Pu??+Qjy%5Lu;_5#~EOqIOi>`E#mN|$ywP&2V6-#tfs zm5ZIpvu`cCnclUA^@FilMmm&^&hJ-b2St*Iig9B%bw;29wJ*?AHa=Pyir&X_UaZ^$ z{2Gz`#P_+!Kjdj@+!Uj^v42vI)VZG0)@9A9IBY`hB7Nr<~2d`2Kb< zriL=n{Zl*I#N&FFbp@YQk|}9@?8O^dBqf(U_A6MAc?zu2*(YNmjDI33H)Jm zS3yK0fpvrMGfyGB)3A43O==mkBNFF$YIO}`>XVc!Oqc9bf|C1mPt0jI;eS@_(ZSSN zP!?#7eOJkFYkujs~*Mu634EhQWN#=o}Pf5bB5)RZATHl!- z7h5S<8$s&-h0N=rbM)Qu^dnrlxIGjA@t!)TdD)d{MN6rka&ZGD*u-Ff4sh0IyBXxoMqh!pMC@@7CjFT zh1A}y3-N{3G)u3&>6{mVd0Wd-@X`LT2us60RU`x6PfTv{rA9_v3G!8GZkQt|fJYb^ z_xsI#oZWOlb7Kb#bDwbj$`LeubuCSU+*&h-DAKyyt5B#a-;jVocTgLT$ZIqBI$I@< zat}c2nuTx7;-s<@X_E+BFnq%LEY3CHl~6Fb5YCjE1bdoS8v9X7v8C|}l@LY|h@ z>yQIus=v3JX}-|oX0s2fSS0k-09}Q}#i2<4;R7nP>QsuEXKT8?6AeRRzT_PWZp3QA zNYDv}Z~5}K*1Z(=H0QST3)jl+Ur+!*Kg)e28MNlwEjYB2*d}i7c)(POJiMSLU6w|_BizCiS>D0kslFoPU{wzQSvVGYqxsIbvyDRymki)H3uH409 z-4Lxr?Amkh9@kXRn?%^LxnTbh77S`iNlgz1lwpJ+zg=2YXj^GtVrA#^c1$wF z0sj;q=fHU_l&fAX9;C4ST`$iL5=8z*BuTvg@X(Q2@SPdQ#42+Mhlu*b=N;Ad1aLa6 zEvc+Z?c$m+KLysR=Q*C|hX>qQ5aU|r24=`v=qtBE34E8kTrFngW-AdM)d?!(5yYW$ z{f6!fEQzqhRQZNs%!@LHvKn;#n)_cP(WG*Xw1=qRf+{dUe`6$mcR z+CibB61zB&hMs`fJ;p)U`u=K0PgJ{VsN=*?d91<9{5cU&9hmxk-IznhQF18Uuhn{L zW>ZHZUF!*e0r+Q|fFob(Js*6+p+WSS9}zQnUoFA75OFx?r;`5H`~)lPhppuqF)A0j zk*L|xn_GAN`Xc*(vFnjd=B~Zeao6S2DUT{ku*=?~w?J-gFe5wRQig1w?b!-dAZT~_PI(G0hGPbDJy@TB@I|c@^aO6!8a%|x}%0s3j;#_p+ z>W52?mGDB2)!om7XJ8&L;DGdEdJYocHr-DakU5qnS>X@67OgLoE zd92u>kQ?yt8g^H2r&k0)8(n9se{jO{Arli^8>QXDyN|x$21*@b zR9eeD>_V9(7$UflQohdM=^yb1mT&nQGIm11FQ5e%+ZqiH#6}kv%`@A;k?1o3ao^hK zkx8C26H@K{pFutY=HvV*t=$M$0eqG8z#-0Xl4iT6zl^6|jeHf4&_b{-)LHL?@Ir|QNIX&Ljp!6$VnlvXnjUKqr|<|O=kczkD^2vTEy%FRzRJ80%ae1!NDv` zc4%lPTt=igMY$3sPhHDD%P(m-Nx?uB%72>N^r(M&!0Fv;yPwVcZi^AecoEbIvk9 z_9oa*FKBZ{9qvy6X9iHGWUaK(6sYeoP~+gA9YSYFTt!N#6hs&cmcTriUQO)}G5|!f z+L(D~HFtPD;*1;1RduCZ!=I;M+mK>J58|B%90&C?#ntjIw*%*6vJ(8K&B?~_I~fw= z1m)owW`%9>O-~I*VZsm6p7aL4^Ao|@O`gRUA@5prs4FK05~^l3#KrnaPBCJ@&|AAI z2uH)$Vf4GdYmf4)fU$!R5OZ#MJoamjwsDZo=IUI~q>Z3pMc~02A{+1GP>m`3R{BOQ zyin#pRHMOc4BTe}9at2%swnsbp$#844Ls>`DZAJ!w*a7R;{tp|3zRz&+z*gj!EDX@ zt|UKdNtx#v`O<^!nP$~T&^v@%Pa{Z_QAJ45d~t0M zX|cXWz#tsF`ZJ7sPhw4$VtT&|J<~0Cnfta_-bRo=7#RBFH!H46D3*RuXgZjBJzYoJ z%l~ygbtg0?obil;s;a=&Ts{n+6XNB&auEqk$8hp}KTfDFZ#Q#Ox)C^ldZ6kG22DrF zEO${=&-j7z4Nv@%a_)aJ9Y20r7;m}$)UX3mDGpg~LS_G$v)`~p)=QYAk;?+p4(RQtT};=S z1J^QG8#fH)@&+nNsN**1-?VsarN*DN#P z`Tvf8xW-zgjceoX27Q-(^pw)DY+^597%EkKHIs&3=-WaErK=t0u_{ej0+N)V%7WR| zY5q8mfSAm=9a@i#;wjxm*5T@z04AeMETl7AIKNKFg_o zdd~f_*BP#_o~sMR_p{?84w_595-DBOQNqs^VURR-7^R1@_O(eZO^f?wk|tJdwTeEw z(TQx?R`>x5L@v<#t5xw4@u2Y%&k(5H%&aKTtu9L=7&JNSt1O=Ne!+m7hdFPf5~hJK zM}5Jk1}4~lk7@$j|K;67`GY=ye|OGo5a|7Qk8QJcwYmwlX;*kA3URK3P0=`&ays}` z%s12tVl5g^psnj@Fr3l)D)?cMhPWz3-&!hb^+%cw2=CTE{d8_cUhO)sZ%L|(r3Mz@ z(Z0FcrFd(M|KxScNf@`(n?%KXy(6l4$N5IUj_QU940L|Rok+#~qqV{xnH!Q~gXvDp zNZ3A^Apn;9HOY&5NT?O!5?1**fq{RKu0(QF-{GP0*1ZNSBC~&UK_=vfA zk3v$QJdRtFJRH#4vvJ{`O0GrOD9Nw^;$F|()dwK$bync2SLkcL1TGf$YhI=aKzm*b zg*VRs`u*5DVw;R$csz=*j30T(=U{iLmyE)dVb0%pb~%U93ag#sxW~Pmzl9`4cWNTN zf3<^}9y1vTJ06zR-OFTH?&rjqPwdgqJk0XuUdkNS&<3bTLy@msgS=LwsSibzKx#&G ziQ$X}6?12s*xVvCl!Uhr?6kDZ%FA5rdUutlTT#jFuq>K3G@`5kB1_QFyqw^9C1}&yI?{B$2U^`o0Z-+FIZNhR6DQ`R5&EgUk$5kixYV9G^((Tw=<*4Y9!6s8vt09lqv?f1%lG^&7k7ESDm%S2Ip zwPl2OaYgS^zVtQ08hdsi<7kNjY0I`en4hHHw#lbR3YDicZwQ5o#v?gN@a5vW{xo={ zN2B~y&{HIwFzyTV5r)5FS@TwfUc7D@;Y1x{p3D~o3|3I$zb&)&+$|m&MlcNvrZM8l zHK`9$Nk-NuFkB?bYo`H`c2u{tjF{8GjoT$tYSan{^k8x9bz_lJ)o@zSA~OK1`yqv~ zUk7R10x(pW8&mlVgPh)o^l%s|Y#>IRO)ZvUEdFp!;7-Z$-|(zO_wvBkD!3H!MX*Q& zE@$PO615GQ3U1GZc+s?;%|rNJf?`UfNUu2M3aAglOP--((+G`zGR5xB;THk(dmf4? zOYXhn86w=iug}emZX@22=MKF202Sc714o&$Y<6rcY(SG~9)K_@ZmbGYKax75%d`Y$ z&cJ^;)ylDwqk6zx7l(ltob6)D>8OMnvb!r~%kVbIjX`4Tev_Bk;@qqf>t^vumtzoP zsU>T|^@<=J*M@}&uqdJtkTarmmYKNcQhmb3LDxK;vEf*!5F)Dd^vaGVL)qD8XK4Oo zyHv_PuOX{}NtODTeUz+|b;xcw6z#8Tb{==8I*87GaQK$1&%tTEs92H5qk&?I*UXXt zdu~Y@BreDngmPsp5JM@n7EWxd6!@^v(nm3 zj3Yim@u)siq!qS!njMbb4mbb?&tdR zbE1fYn6y@^!4ZR$5OS&Iu#rOZ6~;NXTsxwrhFFpAb-tEb(=~`cUi6u%k$|DR5L3}w zg>nuV@U2Ay!Bz3ZH0Gw-rhmqR>on-IA{L9z7_FjS0-pVTMBc_07`t&L5VD$@ zz&6>{pS^*@7A!Z@l=c$OE$jRmQB;AtViQ%Ld=d$$ZgDw!zgYR2Y=<6c8urwYO1a;= zyEsVOQk)ZXoxB(`jaH*{b|l81n(l4$!FOo$y2FZcaIwarh572H{@mD-NB7lLBX1mi z!bvtd7%NXJaBKMY++l*hp4j!9X5C65*{dW1gtVpn2#NPn91{MhWPsattt?Zm!&zGYaV2-+CSOp=)YU zIsp~7-&poFZXEm^p%TQJ!Vca*Tr%9EQ)k+h)(kBn$QlKnRc?2_!y6lX{Jp?Lzkqij zLXeHMWM|FaNakD7X|dkLHb~ToFKn;mR`aop7j~^L*qff_rk&?d1 z_Z*q*+a3z!W(yu^n!3I#C97`ZCJa|DcsrL86hCU3h5`aO6``IwGF~FC%2KJY{&bIz zcMUU**c(f-JY@>T2jxXE(QuO>_vu-i8VDE@$8^BG|2+oTq!y%i_b3cym2O%YLnrRG zdP_N1n{#mAR64SVP)ST`1RX1n7%!Qeip#9ktizCuxVQp6jE2z=>cE*jx1(zan*)9eO0a~cym?Ww z>LI|yW^}6kQPZUHEfmI56PO!h6=IJk@@6^k%x1eo)};8D73n$@QJKXHq>l;7gV&Rv z^_7vH!q0uOAtw-d$u&@nCqbUpE)DJH=jw zmdE6rN-ax&WI=L@uBIbc#C>Y;<7*RtA-!O{S3+{aSx0xT1#x7)E7LUdFyH}K$sVxN z{FGQFHCyy;&v*d|iP39oY3#4V({1qi0<p`3&nHXdrPUE~Y znGsm(!3PDjyX>?6izXjS1dAfE_an5y!0quPVvt|NW`@Uq>Q= zzaC;I`6(aSErzI2%Eh-Ob}L}z`_*sYNp_WU)%r}PKu9csmAZ}EX_T=mUbYjqRhxGU z2zZ7K853uZb3Vm({H4c9gIPQ8oDX4`Lp(|3HJ^DFW53Pmbn?t>_rHB$u z;b-c}8kM)Gs>H;xwVUOTp1}f)w<@oNIwnP8^qqicQZ|LvslCUTI8nqKR>wE+b5T{! zGl!GStgPaS0(B9wR>ba;FsoSQ^|Nu39vg9GzB$h%!cD?O&Y%RktAyYCN8()tI>@Rq zM9LFOPz#~13MuBXBY>^*9GJ-HT51=F5=KIQFzhxxy~nEk`07;!aq6@X4JQD$KqZNW zP3Lxy3e9KmdC44LFUx^7Cz8Vl=nFj=MYdThhlzJ@No|r z>mE-`P2D=}ftt0=&;4@@1lP~`GJRs}GlROPy$eMsa`$|UGa{E*VQ^Hj1rjc9U4|!k zz#S~g_6dpl%J`u%0<5>L&?T!Yge1 zs%&(WxUHff0K3g|TpqyV{g_wi10_3W65eMPu5m@ogaZ5c=>c|$*WQt@{e+B(>^lMi zwbZgBU8rr0AkEAZDR$E&oY#$JHZ#lr9bbUuf1-xvw1*4wC3TNKvCGw_LrON z-(|T^Q)%2?Pbgj)7H;b<`xvrezj|Cf2yJkqqP@xe;1vkf5(%wnhBbcIB0}j^ zuyzeB39sc2KR*m9c=+B%eFP2O!+4rZ1wefs2sLF%LZzEtbbpMx5AMess?{&~5_cyR z3PS6!ZXRgh43(IvF8!5f9gVP^s4*GlpXmcbSCf_ zz(N{I5=ijDU0g;fjyNc5eJ$kGRCRApmkOTgNS2r;tY2 zZq$j_10D)C<6DAa?opmeFHXnar-98mIZ%Wp5sO4ssq96UjTr<<99#BFJD%>(jvb}E zwqsWBz@TRQWMND61oNVi>RW%zzN$u*N$ms`OW3o7&+d=uOr7}T5&@X-XciG`%pMH}1JQ=dU=JKLo9Hn|Lm5#_g-zrD zl2@9w+N)r@th-R`wJ(zPdFV_kcgFuG1Px7?0>Fn@89(t^5}w5R+kA|keD(IY|Dgt7#?pPd4A#F?r zic4iFp(=FnI3jmhwexE62tK6jb{|w|x^8YkUeF+^vV>DpdJun(E$Pk7Vrl9vDVIPd zo=2|^;65t^5dF(l<`943Cvr#jgJ`l(?L)f*`H;VJ6L+P-8YNtmdN|9ynC;G6?R`jV zbJhzcS9)(FhfalAZj21vHf-xkoZPyeaZ(2^{&f0TF`4HV4E@EbFI+dfM?2k-H?o0? zNVLC+kHjayy4YDvEN>%!G+%>7Wj4TmTb>qUoUr}}7Z4J&J%n8|Y046kwDqq$i;$2? z&=dpM&gGl?3~1|_Nliw|4EfTF*?Q<16eWKLgRd$Y2Fk~drc$gGpAG| z4N761o{xtgd@yMw6<;maWhQIdVbf^{ZwMf|o77|f-mU6(h5sv7D2XOgAj_QG$rf@O zZ7C(OiQoM1FOg>TdtjAr>&+jADs()vTikG5+J`K&*L9{|uKiw(&zeBD!xExFEGA>g zVX+w9*T0!FHOUPV-j~PzSUhFHqanv2sNc{OSf6<5fGjP`Camq|nPU#Ziwc2`5S~+* zu77pN8p0}ZLAT9TtvhmXMK$pb5Z|@ub_b3OCmB+Tk zrQt6DdH)TBi~tghVlZ1t(r?hG;}t)8L~IZDkq^mBc!gxqwcPG+mj;7{17dRrUCWoC zbHZVkqS~~W3pL}%%Hv2uGIHvGX>hcnXgDAv~8w%ISA2ESvDL2!-Kw!0y zmOnG>JJnruH}lg*g94cx>zeujpynqGAFm8>a*(2;zi*gs*%X;-!%DWiA&%B3Dxd+n zOt;gg8jo#YXpdWRgbTyed8ME;r;$aTM$)M3G`@XNL(an(p{TQ_X$XD;jO5MG(^akS zgz;zymKam$#JmC=TG@V~4jJ3qxn{Na@M0Nj>Gj?#Z4gs~#LyCU-BuLNL6N&Xj ziKNAoId##q?@$>4R0O7`QV69gWg3XE;X8L6fws;YNr9ZOJ2@hb{fv-<;l=LRDqHDD z#7)_c^;lWn*eI6d7K(!-71@@&?L%Yy-|Z1rWhfa4vK4*9RV2-LpbeOoq`r&(4uxKyw*)0kb0f+H~!nR0N>i*>^yi3K+{yDFmq`x&dg^UWJ zJCjc7VBI6R9T%$G+yICrDy?jX#;ue3pvsHL1M1Z#iKMh6hB!ezVq2!aq6^6 zaX3{5DS?SO-u~LJCe~pJN6vhO3-ZMv-Pn7fog?ETQ2QvkQ{x@kbY5TV#lThPUtjJ1 z22V0ZTQYc6FFM;)1b6Ov5*7)xzn~zWGc2!SQRbEJ-Q;C~wB7@%}bISpE zVd@^#aiUN;Ol3dsPnt&LxMh{ku{7MvH!|wCQ1h3w|Ys>xcvm-|M zH*0y&btC>ca1>Zj6j;ED3i@JijtvxJ&zbv5s7*K+x{t-Za$)f9?m^%rpV3$aDtA_02NhiTK-LRHj@sH7&kFlT~shLqk z%Uv+i=X=(TkQR4iSFfaS`RKs6js^tjev0i}ur1M@!>{_Fe1qh8E0HFhjB`~GzSkDf z=2zWzJ^cd#2FOWZj^n1)hriGGSrts5GJZb!Lq#N)PJhL4Gupjt!TJHdQQJH7(&z?<+t1g1!XiqD;yp&jlUJ*vKso=k}ET@Fd& z1fa&DC|G(!c&;ZMM}GRSYhq;p2;S)HFE^NRJNvD#oOwi-k;J;-UCDk5$0gb^VQBWg zP-A6+scWK>U*9;)0Kjmm!-9z*WG#mn*T?wh@9|!1FYtHxG2|pAh^ev3VZ(ZcIfXiN zfwUH#gP2+3rua|@3zCqum)?xaNMS?I4~#6&{^3KGTQ$^D(_qItxGE^6fJ)tQ5yLxV zA(6?#7K|$~)mcbzY+mrlFaHudH4FFFsnX+WH^p4e1E|;w4`QOEt|?deO*YbY_fe^0 z>5@EVr1YtzoDA4+uMJY>dG(R_;bLURPNzia$YtqHi-60e*sgBX^GlMaK`ieC%4zN} zCTIupkZ=jz&_O<}p!w0TuEU+(1OL`*SldEP$g828q>#f@0&z*3ir$-Vty1sHj+E={ z)E%$)4j*32o)=jg0Lx;$qNj-kKZ9_`G)cw)*^@5^=6!yBX<8e06JC`fNxeB;&1oRc zc(Y0X@%#%Q@2qP_GLC1bd6VS|x7dGO;@_X3D4&Xz`GAITxu>#9X%rCK`4iEMRIGf8 zMnP?#U%k1`+ha+dJ9g^7I0MDvRKQW#@SPDMWvt4_IRi|w7-d`!@~JGKS3~~do$J4_ z?t7GiH^Q~;!#JM5T%@Sqj>l%BGvKf$2yshHXFQd9kyn;EqLCC6gXd=4Fknan!QzR3 zU1dzGGx>s~kW;Cm5&7=bUhFlLPmMi5JQ;~jHM=6Y^Ju84t6NRj`y!Nz!i2w|U@K1l zm5;w4qfD{`$0b~&k#rhYJ-Svr4lvPfcxJo*ZoMHKJYt;jrLAj9r>>mx%gnUxl{6rI zENK7&jk3>zxiz`IC@8zxu`7u0k$`>lcfyN_&{j%4bariaNO0cT5R_roEI;gKg`quS zgSNPf28O6&dR^>_TWF!md)izD2(D2v6&eAD9b{dF_sZX;Qf*q;G^OZ@i&4V{o;uKwsV&K0?OpwxK+1 zn;aczhMMy+&S|;@DJI+4Tu*cAxl{1h$wzeURbQ@|mEQ=rWii{@k@0PdP`@<3RJZO> zUuKI_wfEuzgjr;x!5f9bX$Mh75;xH^V*(m^Y+gCgeo5q&2|wdi-uvv0lrEWxaI9x) zI2o_bSgQNWm_UbP@zyWs$~nwi2=U{EZsgOrev!O}Kl)8Rs|M%x-~5^6}@7hrMVOjJIrH;RVxm6y8 zk?Zim;y;)PtM?>|yp6#g2|L!+?e`EVUPY9#FXHuhQ$g%9R@6)FRl2kilpI5`mTQx9=lRpf!-Z)q` zovZqbjthxbw`yFSvmd-u*Qt*^ffXk^vPS?hK+eAq>0fg3&Zcfk>(S)fnKz2sj=W85 zUF3_{U}UthV_UeuXUrFA6WC;M;&ag2K&BsUL^tzS{EA z=U49KP4cl_>3!Fm95(P8XZW9l$D966<|9rM4c73+O5Q?s%`BL&%Fn7YXJ^_n8!5uOPNQ}T)3N4scdz?td4cLp;z$% z@$Bae<}}BX4qg!$%Y-RnUj#p6=>ePg(UP>Pe!-VKTCW1I$@ao*Bq3x)1_vKQ!mL2& zvPjto(``e5Lh+nJX3+-5k_XYVdX9tQCZT}Y*ZPkT5Lxgb?0L1g7gPgT04+MG4lU5% z_cnQ^w{f=*{-ok94crn`jlo)AQd$~Yxih;8CL%3%1PTIXq%-nRgo?;w8+<^7D}(DW zXTzL|AN`jwJ#nFHvEH^0!qmDF@@*^4pfouBD9#TxC&aTLgZGY2I!UHq@?=Q&fvU0Oel9povHw*hI5NBd zC`KvJ-pnJ_oI^=g-=J5q2iH*pLg}5LBRM`{3z5vr{Bdp9=HHvm~|39PL|w)Pf^bp8zXe?32mzMFwZ8@2q$OH?qJjf`t&3ekRVY zr6^w{cvfrNDDxASRE7lf=~22X>Bkk*u@aF_pf{#Ij2iuOWb*Cs)iV;grv|DK?ZkD6 z?2HvBd(o~Jg)p=tbON&nTxfTiMCgO&^H>Avu`nknngorBuJEH6FXbJmQLy{KF%p08 zfBL2hynNZl$zcDn^g3u~wm*YEv~k?4OOZPf-3nalC}j|44DX7Q0UrOWfcdBcct`1h zsw^-=OF;4_zVgnC;i^msGo)2DgnqK1%k>g@mm&C1;BKaFXeRvStF9@ck21xKj^Yj< zHR+Z723iVhmRr6<`8_LNHt)@I2p0n)Z=fN`2}7yv?gB)FO5_dyQIE=Y+Cn)G6rXJp zGWzK@12f;>(+S`uxBel9n}hmv$~BHg#lrFXY(O=57HoaNL{&&saC-d@s(BXZrD0cW zJ;rjRtNQ~FmN)eXY6`<vRWx7sdsuAF7NiT;VSq*|5gC%h&vgUxXkmHyGd*!l1*?=REf~kvOC1lM& z?c#T^M-uFr=B!ei&LF{dYr-&;T^=|?$)?S`-Ko~mP+>-G^b;FrCb2XifjMF+B;8qx zaj@&+lucB8Zj(*9 z5Kz@bzLO|=Vx{&}5#di(Pa`5pL0LE1Xxqwh8Quo{~&qPB} zGVGF`NG0bdXORKnMa9O`gn!dwpJ_zCC~mrO6>o|tVPzL;1JVeu!}+9u!OU?0S<~0A zbK;%-H`YqPS6~eill_fqCRQ04a-rEymBOvi{<(xa%NPh3xsnI%i%B;q(QDF*glh77 zw@#opTsXF<10X8Q6M*ZLVDs4f5P>X8;9JaHeAl}p?B4@FKEui*2C%- zR5$P&OAhN4l>n05TDs(Jlbw!@{RU`Q-ILX8?S23pVU4`rGf(7P!;) z-m8E4&;k$-n_0i}d&~6FiiB^520_Tr!I_7OhNDIHxIdCC!DNI6BjgW5@hdRN)K)?1 zqwnzn-ocJ$yIS|SgbE|%`51SgG{GV?;o{DZxH+r;-R!OL#}6hfX@-mVW~|zD(iMB_ z*tZ9NE~T($OxUPdHl>k#KUWaPpU$3^qXZT4oA$VSH#Yq(I#ml|+=v2F^!sBWypxh= z08wQ!Ru5m8KW6+WTkUp+z}w#W6X>-y4Zv-liO|g{M!A8S5Ew%V$EN!~V$^PsSbN!* z7@S*$?(gjdh(U}gtZr)2NkG;9l5?Pksf8ove}~y%XMxCWHhZ>)+2i_Pb#DSC-?Iz0 zrVHC#1L#JFX$b~HcpCT3_isv&z&2y3yHF|jrk+e8X+BADQdMX;i&zV$oY}dTyj+q& z`>0wrPD()&3aHGhv!z7ya}-g)bVyNW_l%;5CR~jB;{`rL#gu!9cm!YZ5znN;9r9q} zU4?Q8vaAX|ofed3A!Pyqsj&lP8e4(xCWB>eq&TI(uWHM}(E0(s#?G~+pY}mgauHN( z3*vEKo7<|T`f(+=Oy5++hU>l%*l&R8)OP_R~$7YKD3=u5MpMqhVvv2T?}{RM}3W^zKG1 zGb)wx3qzdy)R*UJ2Psl@KH}|3!&aKRkz*6u#0g4=6F8UF5Vmgt8B@oUXIL=rH}Zyp zuAxf8NBGeh^*~* zjjM&%E$P4@0gyXf@+}}qj9;olrZvDAz*}5MSi&a@G~tu|abo0F9yZd}PLkCl%uaBB zALJtd@gMEJefo@B9ikB|0hldyvUmH>C|CH+q=~5xjI#{;vN*V6;!PYMOnhQ0LhoAE zp8~x~#Ab(G8Bb~n=w^;%Q1`$Z%=8S{B`{!^bv*0m1R(@ywuvvtVj7Fx6RyI^hEbSA zv@hX#o4-0iuiX1MzVcfXK#2%^)Ke*<8=lQ<@avt6?1X_DTVDh#ISd_*k`#i;}yS&9DRBtH0XCHzzL-!~wxSb^t41p<|9_ zx#N6M-9IbRhsF9hEsHe4B1SrLtBqYSK0jV#H{4>0q<T6qFl3nKuV}6ltK% zXSR(Xp1DuOkz4@grUThI>`ZySBuT*Rnyse za;g?X{8D($H;}ax2d{?eq(1nI4KMN;#KtZyQIg6kx!m+1w$MMsqhrV72Pe_^(Nmgq z7-I{@f57yKdmUA4Vde+(MyvKaEKQi#rJVt+s8aic4)qm_ES+eX0`}*-lCU@*owuCY z-KN&KB_;da{-D_rRYRV&)K$}o_5*|On?s%C-S3Yj8?I>Tjwh4sw}2QGI)V4oI8IK! zbBXaO)--4zZ4H~u4`kFA4R68o$Ts&7}HIrbb_ZYZ-{s-g%cp}MZ%EUnt= z+gGeHhaXb7gKA5=HeyLT=Xd`d{W1{1;lo*4)EXlx`GBM`q`cPAJr`yRExc-m&l?ch z237^IogR;I_-*=_+{m**%!uC9bS^*!QY?y}C;uq?T}BRhYX zX(0zj#vuj3=#^=ndT)tIclY2@Zf?SZG#ka;-}JR|JaLS4QxZYyAyk&`>yoG8cqPIB znMWdBDqUr@YN7&xY7qUH^E@02On&kM{BISyJxaS{F8JX6E!J9G;dZAw-vIxmU5rFK zpnTGlEDH{I#>lZWJMmMXKZfa%UlG+svll=*_bLK%}j|YULNYL`|(uB zPApFv2Vj?ANgV+mHgXvxLmLGM8QL0YK*?&e?wTJi54-gpnW|+>&!=@Ou0~||I&J&6 zKxrR{nM00BI}x9!La2W|eKT|9kBppr(e;(g8}7Txj4hhWj%V2EaqxU%$zj@&ML}0@ z*(JIkuV(fyrP{qxG!t&-6rcp}Qjfl72@K~Gze2t_2{bSDld4_V=rDxiWeZ9@cycL? zGC+Jg`*(jT#}s5!QtyDMVS1>lgJN$1tez;9nJ5A9-LXvC(No)l`>pkQNERGMTEURC zgN_O%XcQvHm${ZzV;~qMeo7*}8+d62E>=kY<7*I(8>Jx5P|nSApC1%mv#|K=ttyxuI_6OW}fL02$+dYS59(Rq-RCT6<7V?$nP>X z$0Kd*#D;=XI;h|JR8mrywhmSP!!@eX=6y_;u;K^F7DFBPVpr~rR4eL7Sg1v%j z+`7K`oqkwhKz8e3DVnk*W&n&tb2vH_@S+N$D37&7tqjfB0pf1b5kjjL z8DfVehi*GZCnFLDq!SA#u^rx#hgjqbseQ-GFGmK|wQUG5wPVvLS5C0hd2{cw7I1~~ zJH(7%DCnZnvNIf(J9|imob)y-Wp<(}`t@*uBvDD1Q5l!m=!{jo(-w!55#|TEisTTs zVO;$k1c^tXc-bK+fCr1?eI031RRV@@fW7k`%f|-ki;zQT*6QavRRnknuHobnPqsM> zxkQEP@LI_~j+c5h7~ zobpHPyDBDdkaUipp>LEFKDbU&hPVMwp&5YuFW+LLCfS60c~>0%R1DC-7%0a)5!94y zchL)lo4r$3DB0(A0uJm$CPf9ZkC~#Z28QSab>eW#YqKCE(g?OIM#~tD+g*H7f6v6A zfe*S2w$yky2PhP5fiX^aDNh#gG~>{cK9ucQpzMX!$YOE^J20|*n5O<7yI1WR6(BE zB5)_D-S+@}aRc#ql=Z)l^^+qy$UNG*;|Li`irfnf&%P;R{F}Y+XTW;VMg=xJoy5@ZHHo z3{>$Kw5qEk@DD1_gW4Wx8+&Hm_8p=# zUf8!0W5$k;WPn33Qa~<5!mEdDU4|NKVK&v190`ai969G=pb69)=$5hpBrNT4UkjFp z2Fy2>fc1F`v{`CED_fl55RJ>+{y^{olvqOs#3uy1xAue+Q}Wil>V;xR;uHWIQX^=~ zfJc%{wjF0+HbldzvGXoPMQ$}$IUo|zNFcwLFGq`+XEhoFT*uw%J{btiNQkcg;1;=k zQQC^USZ70j6Zw}sH0Y%j>o{^X%(t%jKVGKSkmez&Asj8Zr=N|1W8Xq--0obRj*^*s z3Hu%^J{h`Wi!v0%nP}#&q8PQ~1;7|FAOSlKE+4&#heh z(WPlW8ozu*elN!H&gH?2%mv{@;wEY`{^N#A5=@ELx}sod4b9|;1tiJBvUupqHrT~E zP7T%$T)U0uy}x z?1UUztgc4!C5a8vLYpd%*&P&Z!asr8+Hu887uYwLsVq&d&R(g0Ci_K+<_+(ELB}W- zNdIB+fWBD)0ng;^npF*}0-@1%T`2DM`B}3z{fyrM;^HQ# zz(blpy!?aAGKrM z_jCRJsMtAfhfjS^0~$9U0H?jQANsDdLWY(?E5ygxQ17`HJinhR$3r`z?KrmenGhql zMD?IPFVlg^WSX4r>Ps_cao`;WRf#U!9$%0sf&Z#kleof0 zFwT%TNt!NY-+ClAI!^BjUMB6uHB`dTwF^)L>LK7fmzEPlX%ET(voVoVeRy=wQ`PbJ zMq^*QCL>miPj?EtdM8YjtT83&~tEL~9AM|#OBL=id2ftc;$1|#!Q z?IGXJYjCDP`2zhWnwDsDOrprUB0*@W1zAscfhSzq7suKJM_qU0d$At=G1Y?--YOOI z?Yn_|CnVXFttzi8C;KyM!#eh`o<`TH9~L6k$-9pVn$6M=n)EM!jP+z}H3i->dVCGZ zYm-eqYH<(3-u2`KpuUw1<)K`_APjCd_(D2XWg=YP?Fx<#1C{1-3w^N@oee zJaHXcc^z{#1W>w7M5)c}ay(4D6&bAP0Yv*du$7ZYvhLg1xZ_XJG?oX7CnM57M@|d> zmf38MXZgbqd{+RABs}bz|2A>NXCNU^^j2$L!3E8>aJEDUO2LpYsT$=gdxYZc(4Xg# zx`pU$Q_l@-hf{Tk61vX#*aBRBtS~{x%1qZmkQ~C$jzSR0L6de35z!Yy$Gfk^M$8Cx z;i%9hM)nFk7va!=3%oAJgmGqQ4sPx-wW~{TKY(0F2qPK9-tuVG-bd&ss`>Wxlp_ev`P3je*W zv@#0pRrCz?4ac6mrGMRl%=XG5WIM=!$1E?U{$T{$eMsjNe!k(&RbW*lX>v2GZusA2 z_4)h6@4-Lc?vr;Rb+5&J5J?^SRWKlgce8(S4N3>weXi2fO}qfYf~5i7l8x14>H^b7 zP%=48(?&_{5VJ>y-ltvX5inj+J@2cI0YmnIHPCrx3s(igl>0hsa;B>Om7Kz)-g!CV zjHU}Pno6Ix@; zQ@fKqFOxOgBG@x02eQ^Rav*yRpt&ZycfG`L#KJDpIFy|zRqoVR)UfH#^%=T>{E;a;rYY!|11s2Q&*PBN4Ddydm;}KFv`usP0#CGL2mUI61UN)l zdr_+PBc3pXvK_8G_rGuKdN%a&y5nueU0uZF5*XBL)nq)=^y`*y)N1L5TrD`NkO?9LDz3#Lk!O}syEf|j%g3)K6d$zUkMEkvu7Mw z|IB4oK`J775?L6po!77)-#ulfjs%C-Xc$dymfih{v@d%C4z49HB64`&&$mA)r+tiT zseBS58Jqg6{cU%>AqAp6Ux>cd4@wWbxd#F4q_F^CD&qd@3M zDnBSy)IR~kewlzn>uIs-!63%L>V>prC=X?8#ctS#sQ;8?hUJs&XNUluYr;AEi|LhL zQ(ABu3`Nm8u6iy!Z_DAL(XFUzslo6515B-36+B@_U~ox0H#wL&L6LM4aOiO|xr}3$`9M$FOE|yyqrNFaVZ@Je^ z43&!nUS4^6YLIwA>0nATiWPnEQva4-DMDKvv{1OysiHH?Zp|Za5g=>0v5b&)0ayXj zcRb!L4+qqnv7Nd2-=KPv5*WsKXGIKdp{)h4=Nja5Jn>Lj!`IjeMY*kGEsjhFjh&+H?Lq2xPx-A1nma+$v(ax)Qw7k|pX`si-Yt0ni^ z+Twe4EkxSypiZ231o*HBFy?B3K!aK}}9SfllA%(Sc1(L@;4 zl6`r`6vy#)X?f=0Jr(L&z5EnZDZtw9&gdiN_OL~Pb8s`;GG;-tn#m%rM+|P`{k1B% zf5CN>^DBjhE+?%;c^a@jh_z9Uz>%WEfdSwtv&NUJ}#6+y%3N zj=};L#}egQQNKnP&=V}b11l1sWxj`<^W6*TlSg6s?ZISJu><)Jy4KB}`;~CPL5W6+ z5KBCYGcF>Le@k!7__I91P7?fg6m@Z_P40b3^9DNmRI*tesJKwd-3gVZ{5Ut2Y~Tyb3HSR zXDOsi=G?csy9&vcj!W5Pi2qaDY~F47XRWww67VN5o8xh1!+0`^qB{NmIqrU^9Yw~- z6ntRiuL$48Mdkq^ut3H|V@}f&9`L!^p}GNzJJ^MIn&!#G(Ww3)GuxjqV*`!+)$~PT z+YBoT81|WKy!CU%dm9yCHyJV-l#PZT^p;t>KIdTz9mcj^<8ynLZgNnZy-#k;!5cp{but!PyQHxEH1zxij+`gv~GlF?Db$_Y*)YQzEWg6 zr?)YaY;ylTVi2>QhJQI7>vTH={KuDsTqf=!X!E@2BhMu9S-Sh6WX}893OE9Oz)fVS zwp*`L-3QxXNSB&GKFqf7#F28+x1AD4{ZI&0+9&95E{J6=SgDIU605y-Vx9CK)^MZ^ z7q?gGZ@T&C|C)BcTESpqf#?Pu2fpF*QEuw)%=s8ZTpBM6I2mJ0Txyn<|Fg>Dn&K{g%+f)8zi(fD%mIJ%*jY?cFT*)HKU5X`oX=7C8%f;y7`F3JSN-iu0~&#uC&HxmJ@ zyhdkqmP;XJU;UKsJ-^bF{?vzrDb}xOI;8KEztvf#yYKt}O=$BPFV<&O>#5P$qg#}g zcV<8`Bd|}NBd&h~I-=*K@JjL7VaX^2)Eo?#W!l9|MHO37$Qs)o3ywZsoT(>kE|JOG zClPr44=`z*ggwO)ro#zv6YKeYr>7{{?#u`(swm0GL(*g{kQ?$rzJl`LCnfzBw!$V-WStM<3UFHts5Oi?f0@k4joE;|aMr_z%WHnY z#3T$Hbt#j_Qa4h!@#z$XVPdS*{y%Ax|K^P2KoCvf*ngE&V=?EIN%%|+guDx5?Bpc|Y_qY3(ipF$UU<8OaJxPE^YwB%1?CQ{cMq#>6Kh6!1+iAV&% z9L$?b-`4uo`@Bg|VXqA0)7l(iab2ibomCq7fCbR_97#_@K|HRkCQuJEMSVYn72|Z` z-VR#|Dj!`KTT1qye0C75*y+>{X9ETChl=x2Tk#mwnSz7^dVKVydwBSAvT5!0=MLJr zM;GX}M~De!ANU8cxRqj%FZQ(I%`_^G?ks5i6wJ@zR{025X8Ab)evl?KibzA2B-=h~ z`)1^%hVHy$h#6Z(Qy*q7kxF<-hTnf)Q}d}Z&%KIr*+-*nxGm4+@X_M_qmyv2@s%SCd5d; zEgPEVCuqri_mSVAiY<9dM;LiAa<})mwiU%ekR59pXP=t^5qfWQm3q+g+Ejhx*L{&& z(Bs-h8K&zsZPpmI9TSsmuu-r#XLIP_3U~FC2s5WO<3MKR#W~Wd(wuO&d<e@{Y)Xa!R~uWuuBF^7crl8hE`?Om%z z62k?~L?HiIK0>UZpIDkVl?+A^`_xS=56Vx9v#7 zTavN)q52GiGu28>E(#0peyOP1Ih{7dVAg7TNY~RKZQd4J*z$ogTMT|dtnaMILFR_(!0ks845Lg{a+`?@!FY- zt;^`C!p91coYMRI0HKy~#Cp4yc+8U8cucHQ`^f0KfY)gGEhivwhs2}XrA~sH5uqP5 zaOYz2iYhOtVyl@Wp_WVLVMhZdqIt`{U39peG*-|vT-Qhr?KzE+os3TmCYIn{*qLXs z`y4tXlPrjiY}|lU)P9)fle=Ax;qnCt1+0s2Ug8GuiJqmQI}@Jnpik za_tBs&@|ob`J>#}Tp=SP9UAl^jZMl4LKyGPYA7H;_ygw-GM!*Dix8&`lxm~7YiBE55VM!bl7V=2Ms z#_7FShF=U4a0gVw+oR31Z{9`|kEILz($*kb&jGLcCan3IV(v}gbU--$Q{pi4 zKya^pp3!39=4Gh9#UDEOcOz#!$s|@Z&d1G~H8W)t)h4eu1F(71LF;Kal zrF-fIi8o;6&53WP7|W~7H~&4NEhZE)y3*c7uD9ESlcG*4fi8%o4?>iam5;qk0_P_j z8Sd1eOQ19*CX>g@GnOye99vRigO=j6AFXI8nRS`BjtMY=(M_AC2T~#%eB#V- z(;ywTnafS!Vzeden7H3MKN8XJKqZoqmhQNs7>Zwk+)o1l9bH4kk!*Mw^b3QrrYuUe zBOH1ajwciZcV^;<;h-01ywOE1EsI^H16=4gcnZWX2 z?#?)A$Sl$@Vn|9CYppzTQ(5O#QfG#HhY|{Da=_4Heq-7d>klEfVpRi6PV>!@d*=wl zY}QkIOKQH4QEh#(NCwCWC6}|)g6F(rAt6t4UFhW3`*RnVyIKNY*PLBhizcfPqM6Jdg+ifvKCThxXWtb#v}#C5~~mb7eaYsg@hr2N{U%qL#|m0{|v#j^~~M)^^yKu6fJgbT?7bWb!YDob^yQ+$9KBr88o>#a-riP2A}xuE^F6210IX5MS6kM` zN!99wBVxXLHF{@gR@6XX9SjJpax{GAUT*)2OSqii2sU;sTS83u5_avm*4MwfV|Kb$ z=laWT#Q8f?+z_ewpfWE&N0*gh#&HQ`4n!O8v!m{Nq%V#ix$++SSZ6YOL`b;{PmhnO zKC2}2K$#&nE-PWm(Sj&r-1c9iw#iA*e`aR+IL=);-)L9A&^cst*` z6QN+UcJn=Rg;;eO>8r6rK%D|KihwZ(FV9@j{JcNRUdW=MgR$^B0r9%8>zWKqtSz6Y z(#S5KaS%5_nH@s3Hcv&c%EC`bPdaIoCtHuzKJ<0YROEZJz{OI7RX@J6O}&Zp1#JKR z1e5F(zRr={l{A~I?Nd(^C6jC}l{q*y3WR0o;^N4kzPzJ=6j1Mb%~j ztA2JVr2EKL6T%^X#FJfZWsw}QD1O_SHCQUhDFijpiBEX7sk0Q%K0%z z%NtXObCbnh{TQ76hcQo1m4eUQc!!L|%3-zO_ZNpi@r4oPeu@kXhS!wNYzfBR02=DA zv|2Y?0T`F05!c`RDEj58hBFkUb#<+r1!22Q+3Gf90bGO0mYUozP&7bd;$sX>6}3&d zDG~?nJ;L1oH?ol?)UByOnA`L;O%u zEA|>Us8}3wm*fVrn3F6}2kvw3^R0`2m|7B-c=+NT;(#Rc-#q)_6+~m<+ITQviffZ?4rNE-_=c7*D~;SQ_#8)f_|BO?!nH27nK-RjNt@ zjN@yvh+rPvK*gN-4_gz%ILl&!KkzWf;yXrD%%Mf7?b;g|%WKfQC__Rio{*)_;*Dxh zw+aHrF_<51lqr3avc0JCB4>cDp2`c=6$y%r!UJ&=gxHaO!F&GAEwo605ANJxU@_My z`oj%s6y7v}!E!0}b2JKwX1}x<-zJ;uB98kP9XjDg>C6;LXw#e89KH|&cdH7u2!fYA z!g#E5HwMC)Asdppo3Eg}eW#-?k5^^?I?K@4?Z{s&Pn!*ag&FF%PC$ljNlal}sn6__->g$2I@kh7N z2Py9r#RPiE;>o5`igdpbT$fjQFSNgY&%y`8 zv&B0`B=K|ZlmH9PGy$~C%VMcA7^($>BYCGCpRxC0^SsGn_=agRhRL*Dc`;h->|~r} zOQJUC&31dYtZi`)P+}*;RpqeW#=^Jh1h#}KtG$Hp^tp@-!Su=EHko1w-@iCoOmxZC z%r7IeNe5LMw=UZdG$BupGALr@=0;1_*667t7C*|X=x0l0En3j2wodKa;PV?)#EGnI z-g{>s!l(o*6?sgWx3FoVkJq`{ zgE-(pGz{1oc7d!QPVK3(uR(-Mo0XcUFS1b-*}@pCsO3J=B<|;@DH_jWqM#IN;-G05 zO@^2#ZYdswRLi-|TrulQ6#%e<7H>Ztt32Um8ElcCr5HV_R+8np0j;9IH1b$HyjB5K zRa281E+)n@UqCs6|KNLZMiVtbAb`YdC@$nL@*P%Tyt1`2L+$(vB}|;LwWx~+ay#h? zeR1K#TY7aE4unj_fjg7^H6=J9YUQt%kiYE3%0ePBo0qes( zz~x{eNu6%KV*m#=aeku_9SYc`q8LAccS+&QC6jc5;jl^J0uZYOqm7UPMB|4hW1z{0 zP`Y9@U431gXHr!}s))GZb5fkF0M{Wwa8|K_y0j&Q=P8V8b|1LP;NI;BeC<; zsV0Y}4j#fW3+}&>L1FL@f8T+{6YK)ViYaJHb;$oK?+PL!z&Pms^Xe}dL8B*k-3NvfW4{)u+U zk~C#0`8ODWA2zL=PpdH0ocr=FSIVmzl@NjfkE!U^@7nPWb4jABJ*)Cm;D_pCv-Su(SL4Tm<=+`#ch;%UCzsZ$#!qd5WTh_u{{~yF(~UP#3w`^y zVE>D5_lCu5U5i%h6rA$YTP&cxcC>C0pbG*uq@)c;{`% z8|T`+iy7d1)k>V$U!_~(=$03>A`E1v@aw`YvlNl|b<(dux(jND)8UEim5U=Q>D*S9 z>8Z?^w%@E>-5HVnx>&Bl^R;ve?5GN7N&;tB7X>gIBArAD)o6#&v~Ad|g0ZD>yPJs! z2fZetqNC&4&YS(2ez?k;9EP0a2bDjUFHtV$OQlONWSu`Q2p<%B^WLsTMKn*p_3$MF zujT^1IH9S2^J6$8lzlCuXSA(-Rf!7q_70J)G8n z%j#ft?IQDkaM-}TOaP~Hn^+Wq7bcB@J!t{= ztNxb9U1E>&EQzIgp|wX@J)mA+8vtJG7fH$CWjRX3*1H!%Gxyp=7H3*Q&|u|aMFw<2fXeS1@XV@DYoAMrN)Ni}$r%IW1yFNsRvX(R3y z0KGv{wuv0`4+`ZB>m1dc_Q z=RX6oFPX!n7~b8+^?4Sh?Wqor&uq;PpPKSqK3z=$+xEsqIZmb=sJl32_yu^bCQa68 zioo|4$NHkW{!Kd47Gp$^iLR6wcK=5PyawD+GKNpi$}4u4<9#ZOuYDoiRdMq_SJyAM zqlwo})2WqtJD|i<)6Zc~38%r9WT5YlJl_HIYFyaykwX5y3LkDbpGyy5h(t)6XO?r5{k^=&eq+;QCFXw?qKOs{sB=57Q`_ z7T7I4wy`1iET~u9%^h08F#D&_HX>rr%^0TR*fBJl<%_&&pJm}+XyqmotkcX0B?h7X z{i_|EBGAQRSFqxi;Cos?)}TD0U_cWz%CZv|a5<|Gh(UlDV}h`zKHn; zp6|bk*oVpH33UqYyAqFVT$UA0B6S3yh7^{|#hwtI2s#C4p#RfuE}Z#L3=7JLb*0F1 ztfj0NpB7oX5^0|yA%U;(o9&0gty8;IanO7CeTuXxB#*oQt)C4zkW8q+#+fGodCXk0 z`43c0W4@aXK`rvQRRO%uGe^dqXH`oPB3=8?$}qU=Zw|w?(w9u{a!#UIc*EOuF*m9j z;JY1~26d&m;@i?LBaER=k2iQ#iY_8tK_GvIDFfpm4@K#>n)G8}unNlTm~NxbVVNSG zmQGBNpD@mh2BL|Z^LX+**3yyUc}|~z0l-!T3q`Szi@=JEU0H)avYE=mDEh1(tuKsQ zfmDUka`WLnN#+x-l?X%B1yU49kYML1dADVJH(ot@oq-d$k3K07CL#lshZD1sS$;D^y}N!kxF@3a!mY)>2*~LSZKwCzwzR@Y0J(}YswQa5p+?QmrUR10f=}G5?oNn}&67ym1$xNm-l zC5ML}>uH|B8?#MrT`sDg2OouDGz^Kw*_MzCj@?j!kH%8bY;vJo4z<;kR+l6lCJQa} zwuE(lw}>>@bY29wnA>XLHc7~H*#sA$x&xM65i3UIb(MbMske1aQXsl$#Zovu76muQ%L}tJQqN0FlmV8qhZCoy{EJQY8O!gktyduZKbv*eS(OnxbV_u z7XU@!pKVQUga93`?o02}KgB6NAI}z=P#b@Hj?#M(iApl~#>`2LK+)xnC~K)Re1~&Z zxJRvB#%28}LWIHA7nni+@$J>cyU~(=<6EINWIyf5-RCJASt3zi!Fy?Li+YNAo8gq0 zP5jPqvu=lP=gocz%PT}*dADnRdh7 zoQ1j6UiF6HqJ)MSC745OdDSsQMn19Ah~$0t7oWX6X5>$YDGAX#n6LGkSH$`(-h;Xe zp*U%A`CRBQcdVH&7szj+2KiIrcw-DJt;MLixj5f;5ZU?-MtZZI*imY8w}(U8rPR>z zTo11@b2{4oM$RT27V7!|&AVAb&X=b!(krRMD{wne$OIj(gO3Y>wpBmtbL$rO3}A;? zRakR9WYy8->;v}L!TGz(p|+WkYm^&|R(7@cF08X=3bon>kI`Z->+7W(^>tY|qG@>u zsbL)|FaPt^au+C~Ab1O#3W9u1ba$I=+q2dqnkWG_TevNEFEHGaCx;h~5%_^#e5k#vx@3Cn$v-vx7xbDbn zDyUt8-FJYZ=5|lg&zi$c#-dm#`g4WSVy(o#^>AMEbP$;m;%{%NA0%o0xQfjH`Zen2>DE$jGiYDVXvU)`Yx@V5AwSz;CInud<>wwOcQXIUhKl; z4w$tK-H#jRnDV^nOy=&%zxuAOv3RoW`sh$=SlaoQu!Oe>-iKGfm89%hd#4m|wDII$!L0s@ zroFOJbQE2~jX3zGa#)0pREYP3yf72gTz*{ML-a`FP%4JuHVD>a-645vRKJy_7Atd< zrPYG0t^4lEHUJ1%(AoZ3<(!gkl3V=tbiH@wpqXUf#a|-q^&LQvH*S5Y{O)KE2NIqL zN{Wk%lnswxh2$8D*sj5Y2?be7%quT8DWgTyc@^WdpWF!0C}$79^a(3}nEXp-L}`VL zU|7NM#Bhxj*kUTM7*4DTycTqF%Uxt7)V+}a*x$^ZmQhB0BrR(m&q2YL;KTsWewq~z z&Me*r_tG$^Z2Ex;e^;e#&0PIm;pG1AaRzl;Yd=%f48uV^W#?g7-dYZXf35k9BjP<5 zCTCy{d>IRu@VZFXcM@KgIhKZ) z+=ht}W$e{snvKnN;9!>FJjMF&2~@-x0kbqW926Wf5a3hf@lX5+7-@)|F7xH}7Qfwq zK0T-24I$52$be%*b)0sIU_=ypsRMR?#zY(cVSQDZGUfA?4nJri6M2JnIt8V6x(u}; z2K_0Vl7b3$#ZuD0*pn?^7E5m^f;h+L9r%Lcq*8OLTbYiO0~fiE$(Nu4z63B$+D~+K zcb3L1xw2l+6K(pZOk+4DE?95cLk6toP_y;^1@zbgr~ZG>fcSURP7y2ylx^>)mxs3D zNOZ23P!CjskH}q^14({=MJH2qCEjraM+l(@{`ihdPfXaUt}@%^UVL$N zFWkuMJtM0U;H@nYEYRe!i7IuWjH49z08&%%H{|idQPikr!r=QGH|$lkfc=ImazkC! zDbwNqiulJ&_N7{~n%a4;*LM99OZ_;vGx*dds-2HQk1Lc1UK7CI#TP-X0QSG*&P*E#) zCL9}?*C{stqcXM{7A=~~w>hA+2}c)W!Glj~laLS`oSn}VgD8YyoC=n#NAA%4_s|yk zTJIiJrk!Udab@Hg^NBDt@|VD^JO(lBZ_Q9sBh z%Ugd!Vz162hpwk$2<=(&ouNgy`%@xwp;V!4iq89o0`(HHt1Av01o!U zlVGg7g-c}_`C_z?>dHz>GOqtf#+>jch`jMAYUxtjTlA{0M(qqg3!cuiCcUvn{C72J zD3+GyPBNq%5~BWzK*(QASG9?-Y>q}DWSrh_2}vIYL}{<;iHLV#WnQHn^X{8`CH~Ab zTx*gmP?2@PIcHFQEMV;@C(c=~&b7)O5P*A*`*nsYx7T2`5EUTF5poIz!^40PEP7M5 zvz?z<*O~pae8iCkHpdUl=Tn*r=f0y4Ue5wNznq77Q`i*%V5NgZjPg^VlCg&Wl8(gk zT&hZS?zg^wL457|R54$!OeB5)ix7FUV?wo1ov;#OD;%t9fn#)HuLMf$!$c~qtZcFr zElE_8?sAeXaU4mEs8T2eH(8w;?4}2M@)2b%b97!u_8Om(K4JZ)@c~ag5N1g0$QZi7##KsfgByi(kvV&B^7N?Dp1g z??oAW85|tH8|zq|Q|@L+HFxcem`KpiRKb8%L$^hk2_<7d4e#_IRu(fLyVC4olq&U??t;nXWj`3Dg=8= zH4vEpLFA!_i&}%|a;R+hvD24vNr{`j!31emAnTci3ZaX*(pv00wr@L{{I-ko&Z|8? z31W4S;FEYIdtr40`K%TWFHKGCCxY0_|*x%k+HOwt^lPF_@ih zGT1C66Q(ssPn@VG=u9OGbh6s*$=_>E``}Dn#VK9hsuOy*>M9gtrh@;VySun>giodT zO6LO}^W`if$PoIU&UQhjDO{+CXYxvgvq|;`OB(TZY>uw|fI`5n}FU;5kq zEF`P2zvaEC_@zm=hD-nl@7cF$CC)TkDON9MT}%|WlbCg0Mma9$e)DBA@ld`)Wdn5$ z9Um>U5N#S25tp zPYt5Y^$1r-anw?;*}6DaL2+$(V1MtGkxW;%8fJk;pp)&uBSC*;paR|_HLf@EnFSe1 z2-Hz~{of0AnzZuMTVgF*1{s0*FCL)T8m1J}1zyPIq1_$&AuZ2?VTGJO78v*PoJ0-t3Z~Nd*Xnl7@HNLoNb0EJ z$iZI~+aoNT1t=T9oVYvPRsmpn;rWcv&ZULv78xJ`u^Bucz-a$-3PweK&;g}liX{BK zd@_qFI~h;bnSkh-RzEy#Yq5?)8DMgZ7?7ecf8`GU|FhLuK>dmxVfTe8zBBfEh&^ef zqn4Z6=X)=!2WoZUIftS)7^8ELc47`!qkGazdwfmY6Ao=*v<$L>%GEz#v>ul+{CJ3r znh($Z_z}|d4TvXR;`v>!T=KbI+iddA&jGaqWr+#s3}grraIrXcDS2C0R%bCBGb~Ee zI(!M~LV;hr+x}2kcipGs(fO9*+=EzL4vW~&VQ!4nk%Ww@b+5V7sLe76`uiO}`~(8j zd)HQXiCQL1SlcG9a3%s%uU6;bLB=#g;1Bl@5Vdz=!Kgnfwbs2^5~;Qb44*!g@?=V*xxo-bWg|q5Uc?Mq;X~YJ^sA8} zarr}sc@0@2E3`l&vB4gF;z(YXi71kpEn#{&oqIVoFSj$%Rq6_?!OBvy2zjOSqWPQQ? zJ)^Nz-VM#KQ+QXtNhA#f$jqW2K1OccZ?i$S?O>l(`GD(DXqC}EJzLa$)I?@#T^5zT zJ3Q|#b@X7VNjV)!y1b;MH<-u}vIsL;N%d6M(gc~NTh8%M%ffA@+I%7f}Q&9QM20aRlzz#ai+&Db(_IyW>6 z{VvO|;YkN%A2wV9=6t@lqK8H{D!qa0-aMF8L2@*_`u8Dw=4}Y{0+ZLu$t*dfratNT z2gYGff`|tHmXD{lJN^6JSqnqBT)}f`jxlOvw`H&uKRK8-c?S&b&2WeyLD(OVvXJ;z zfR0OJIj=}(j5c)5a-9a7_V>ikfoh=4&z;w2Dvq@A+m;$6KYPc%$?VF#ebx2;jx?MP zdVo?V0rzLIJAI&g^8ey2@+Sq$W6o1J72;nJ|8<{@m}h+~TL(BmFi*BheFnV4jR(s3 zsU6(9ugAo{R3*bvzt4`kA*oskvN-PL1^g8Gu>Jqqfw^rFyBO`(T&1Mpx}5 zwqr<<_H?rw_C}jOH`!vVFUnZ@7y2qd+C(v@_{rl%#b#RrZ09zq7V3$CX=U{^p8?i? z`2p1zs7DQd23W9*;GH2%oxyQAiOr3`2%F+Yi}h&R(PC#wWEc^R>UJ|KKYX%i|BNk! za!_DHAu&594MZNV*kv|Jd<2OTx5L1bgA|5m=A=G)2t6-f-f_LyFcaREQ_+>!5Qt$| zw#AVKdv1qBvozodzFClUco-z^pT@I{(StOJ69M*cta;OtYCCY$e6aQQlqEUUcLPkM zP~AVgeQdDXUDwZ1D!nw|@PlbCb$Sl^=Rtmw^53K!bP&_PO7J zr@v2Z1Mh*;8`W*sJ@p?PIbF9|N^_bW6l;ny!@Hl)r|*o>`$JNi21oSAM+(_V-VMM| zPBlS6P=1OJWr8(dB1<*AZS-|nV|}5-CV!PH=G#*{hNUX=RL^Uh}h zBYAR7T_;Q%AZx%J5CDgy9-*)Q0@V z!_Kvb^NMwyQ%fVJzgQopCKQ?CJHI;Fp6SJ1RNoR^k-N*0>|(X!(QfypUSboePQF)jsZVijkpx2&zTNTQ(!*NiAEqg|1NeVZR|Q-bWa{Y` zEag(E)dh7 z-WUt>V%=~gG{7h~U87-DFk51a&NYgPlMLOGhOdbz1zqzq1Us=(aI1{wE*#`c(Hoh$ zJDeIM+pI|ZEQ!QaD%MN%JeLf3d-Z%)m|yI~|8P$Fk9o!5sMK)v#x%}Zec;~xFAyoW z(aPgGZdWHZPf)TtvU*!{)pwlpeY~ci;lRsKk%v0ToQ_2Y0-S1+Sb2Yi+L){K7^axH z>a^A-#;I_LOyfdTv9Lrx-rc+_yB!Tcsk~t7au_hscnbd>w%#;1I44$~Qmn60@}u3w z^J@WdnzN#03a)sWdsSN5&D3Y^(!d8jDtz?h;)cle4^68Dz$~=i)kX*=dzlH74JTv~ z{Vpkjo0ncD&xfBqik8T=G4vqlNSWr6?lQZ-*}*;P!NGEIW5shsYH(KK58saIu|lou zQuy@jfFrnD!g->dZjIQ|x4X~g8wSaUVHs!y1r90ee?^nSNK4}azhw*}_V>eOh`oUx zu}Hs%C%|;%@Ci?C1}B(#b6Z+fnCox_qS;s1tWl0f$BZQ9>1&}k9_ujg_to9yr0wmC z)B1nR(Apz~v4!RYmi`>;@2g6EILL#F74J_oD0p@YWD?XS)FHS7nMq5cc52dE#h@zO zu6y?<8aF!Kf7!a;+-^TPa-)pc4WF>b94u~oqPQdaJsg62LjZ^Q#4O6 z7X9pwxa;(pd5_i1rV3GB!Zmuu`XRA`81)<_Fg+IgE&V0P7m~P4=hLsmoy#XC$k+Q< zPNN)q#4F!Vm%cjcxp~{#+|`N8RG-ouP@!nV+OTW&>4?`?HSR&te;al*fw1>6Egh%Z z8!-uhDNrUxz#Lau0AR0?Znb(QK`SaKJ$tF}j2Ni_ zACUfyK3jNPke(rnlBLLO)|M|)UJYdN4+<2-gfS>ng$;7&TYHb9n!cCM${$({%Uhxn z)n%sz{IEp!3>%WB2!~rik)Y0U0)UftD2Rc_H9F-YoW1%e@q2_JGQTEQ#MC9BWf44Q zG0P&1V=N3stBOs^zOwpf2nCd;xeV|CSux;4kPihEYtl|p_R-U}s)mK^=K;X7)^cJ( z4*~Z}z~2|1eYLv9IhGQiGAT0OfovyY)&NS^(QLsM@|NMb1b)#m$c?&CIT(42M2C&B zRhdR#dKjqN!g>fBs(^N|Lv+z8&uxTsa3;r7QIX1mJFDS5_0oyYLzM)ii2iTD zAvJ|b2~h9E#sJ;b{(%}67jazY#v#C2P@Vra;blo3lFL%}-Odl7uuDjm*_1wiB<`Ms z19G?iBUiFRJ8?qi7ldkHQP8*cu$^mz>h7#1+bzFN;{q;K>Zv4|{>dDN?+|sR)$hmI zOKcKrYV5(yLs+5&~ zLJyjOT0pr4nRJ}42?#cT6nNq14N#O&-x*v)_W4-tGii|6c!|#wZ>4pr4jZ5s1Hx=( z8udQeU(^2~BTsC@2?)yZouj!^A>LtGVxjk|C%IXyE<;fEif8(&;;DWe6f^|8c{!4U ziM|ko@T+Vvw5CY4EujN94&t-6)Zgzr z^M<3dr`pzecAEnppoJ486%{GYO-$ez&k-l60)m98(`K}Gpida9UtSGrGc|c>zevP3 z#{5De{0Be`V#~>cl>mk&m#pX@HXn+LNgke$?HS#Mo}?_1K1`0japV!m1+{=zNb`2b zvxSgZfGIWm3UPK5n$VqK=+KCBb^D`Y5*zZ(iGg)4GJa7@3HTbGeQuEq`e8HVfE z%G+&Y8_DoZ>eRn=&>kB<3nK8sd=>hf<`Ywe1kB7gLRap@y;FM2(udj?LPmeL|5w$$ zL|;JH^`&gZpU5Dd0C?N7pUuTC|M|}QiUd^R3)sVUHOM=sI=i_n6j$VP&Y7{rE=-P_ z&XlT+QOqWGjK_NJBQ#C@P-*Mrx5q9x3Q^l~CfTr&rgcklU0l;>(to@)vl`d;`sQ-z zE+y-fiAd8PLyRAlBKd5a_Vo7uy*LpU{0hU70#hP7L?Y-=?DU z+QKobuVob=uG=>=b(`b2d;YXRZ)}7KBP`cO?xlO<56zO2THIdFXV_fJADFhf)|$S% zqILq>P^N#It{D^<9K_;NDB5RH8B~MG!2VAg14%w?pG3#n?=m8AkIt(I9jQLTRU?5f}BOs1&*%mdN$*#45Ky z$OxX6KWZ(xIvteJ7eNPY;!I`ZnP1xGf4UYnZYD6IwfYBnIHc!YG7>5^ut5k^X7e5* zHNm_QNHp4kVWf&S!V7>3`~?7Xs|tP@rf^;i9J9h603^@{D-8iN7hf&jkpdm`beKtO z?ru|}(UlhUzbF+JK(Rh)Zk@L>teV@W%n6q7Wo|*ZsNMf01nNo##Q0;0G3hu2;;f4) zy#rTSgN};|LBx#DPdv3Vl$~M9H>O}jE<{2s7uYn| z$MBa>NpX~$hpOZ-C#wn7E-(LNy0lipt1#RVNGCJix0XUC-^5W=UeKGZrf^#`bVzg} z1QIQ4CR!t0T2luHqm2x-etqAX)HlnJTB$2 z-QF*x<1x|0N@LsDS+?9q4t`TD{fhU?ktIMk{}96}zn4EG6$67_-j=I)V_=g~3DK!b z*(8gb6^-~m*wyUo(`fx2%!Z)d*JmP}`iQf=^xh~_l-<`NpH?cXB#p9Rn9La%OC%xwXtylXqE_YPPCYJ)sO~Hv z$-9pV{%K3BXkf_62B=eL8opz;+9^p^Lt)cON3{ZjaSi$9lwNy>amg z-2dbBU;sQ2>kusT>7jI~l!%kB!UxE}{szzO4rclq%wQdT|F3s^l#rHsSVEaN27fZk zX7TFz12oE|AuMJq;3&*P!DW&s#Xf*lA9Km zN#?sY(&XyVl*&Ax&l_L?OM1+-qk-07I&AHUYzdhDBfx5mBXxZ*6fgu1W#puSE<4Nt zAhDcoCUFEY|4fnK3H4*dUM&w_RWg|p?I8xgjEnqg?V(X64T~{P+qyKeOP4V1R0_N<+v1|wri?|KR=CZX4{=Ym zr1JeBr0aw^^$VU%SHmZU6PUf@_OQi>ot|&jd|2MCm!tv+2WT9Y)qIa|rIdOC0E3u* zs-13Gny>KvXY*J%x>2p%6hw(_9|jP8((JIZiMMRzH16B8bsBBzx(+T{uzFn85)Dj0 zbFuPffCBS1g9?6U?_CNEG^$;Rv{uM0mSv>uev<_Jh9k{EG{#Uzr|wN5kv}an2Cda% zs6nJu2j@gLOAJJm9>lnqdlhmSyDt zG?q5;HFaXjnW*Uv6(GI*(`oGMKpEE9RX6?!yI2d~w6FZCA{Brd6s)7@XjQ@BoC-3X zdjdEv2fD9W3*}7Iz{x_d zbJV34ugrQqKA-dJ|L8R?f)4}Ewskg^VQ0!Eh(bx_LLz9>dj;7n_e{= zw} z?RNbJ(%k9g0k>RDeFECVC*dAsz2um1X}oM>LLESn2QZ2H0{|Dm!Yic|HQSl*?S6IE z*vB#!eMZK5Kv8z;sU8G%34sLG+nWU5PtGjPREUK8-b)6lo_96|Sew!xRiKMFI%ilpq34fiXE;c5kI zW+!KGDjjjb->$}Pv|e-Q4s{+Wo^^?zOT!NI6VCbxeeU)DAxy0w^o7t@nr1`vJY#5p zuVFTF180>YhulzsJTr^lbHzs{ot2NeSh+W0B4)!;%Oo-PCsWck9&X<4zs^29M80vN z4tJ0{uqOIO*9rKv88(lu_iuea(wLfJb`Scrb+9e42!lzPxL8&3(QPxw>myaP`MAxC zqVwT&ioDqw@i$=?RaTHQ9_`8E0Tbn#hGPCVH9{;?FN39P~R}T&EA(H}JCA4piTn@s%3_gtPCE-4G2F3Hdn#TziTh#Vu zf=LQp0OCYG2T7y3)NFhnS5e*Z3jxViET8UQ<%Fe^VvEUuZ+6OEVU;|b6UVO~*wf@{ zw&Yh1^w@T!OsSCCbXUE#5*vt~i0_`_P(vX2J#Evcm$%_vV){D_k@wfBW`6Qc?4EI} zo^hy|#zmwcJ!EnSpD_)eZw*aAWYO-{yj)GhJ}$0N&mJ!oysEI^Qy7JNu~NRhRwq4UdNb6E78iG3Rh*aSytKRWKVDGe|NJ|I&;z2v-HM_9o)`S@R5t z#fGgwf{ZZ_!hkzK&K9DQ_%(!7Nvjy$D}Q`wD{Y2TB_(bCpBuzGZ)(SNhD8ZePM2&c z!0=nWz#sl-Y5`CS4iE94LR;*Rd>P_m(?`?lYbvFZHp!wrGBu7C`&#UF8bS~2)GjD8 zA|7)sLXpdTR*59k@G#yG*pFwKHp?d`gGo6^eJ}HpTb43@^vo zGDo9?;-;uESv#VXG`pR3qxOo}%F@KbwVR?QGZ*nDm-o_6(!S5$QUV#7KxV-9&Q>qE zxg7_*XmvWPtWRY+t?*_4u)X)_=FEwn6Eta4LIs`W;EWBNAJ?A?8$$mk#M;QaLwwPp zjW6K?O!~-=rpSlPO2m{8B+(_6@O*}cY)}RmA59tLkGV9 z)xYwW5~g+i&NVL_>`8NIP9tO!HGXtagPr8;|`l3l_jU z@6)039*75a0Zvr?aDE;TF-0=^q^nv*cB-rYiRYwdbBWyLYEvsVieNid~%+_n6yEh*&ZoqJv4 z8*iOTuMoZPpW%;G+2y?{m8P!%1J&F4*h8ttqowOLK0j#Ab_=_AcT*&4CPu@obf>mE z2fkbds}@?iZYmD~d4)vySB#Wz&}439gZ2cQamJZi3z~^ZJ+5uGrv3zJ9jG&0Qom9N z+(Rm*Z_XNJ_DUOe~glli8$i~33ZdipxAHL$*MC&=&Q z*@bzTsq&`(A&N~$>D{zHSYSIfX8y<;HMkG07#8|=fBU%?uXVU9TbppLY)Aa7x62Q? zc#E9>x8NS*b#%E0N_VCFf7nCB*dMp4=j|Nr}%+(j2=#k@nKcA~n%L5=nWJ9N|KWGDJSl zIZgO(A)Q!S9@*V}`JFEKkR=X|@%Yu*2hv;g?~T#E32cVhdTf?lMf~j|cM?D`Q?vR) zyG`VGeOM-gakdQvCQvN+UYn!!E!Khu*lGV;k{uF8;={i@N@oi?AKApIWmgsrr%G zMoUIq#VI+aw9N9Ig;BO6qKFT|la!IjcddFhERNPX%^B9sX@`9L^uM&a2DWHyPdl|; zWFwY?k3h*uZMG^n9BuXSlKMTEq}F82;osrYjqoXfOf1cWR?Ga9d58ie5cg~&oVN-*=N~wMR3f2h2%vQGH}gziV9xboJBH+Hb|i=?Kwn^b|Rmuq#0=Owb`+M%!w69D%D^H%UIIQ+$we*oHww}y_dit4TybE{??7_aL zbokyX0AMBMz*+|3=@1Y*b5; z^I!Vouh77>36VE4Kpvs<=U%cE-c`y6pfItrFcK=*^?Ah6Vi8!#D5XvV+)tYBxk;S~^gX(s2`0U*} zYZ|j$pIdf6#HsCzX{#D31tyCK{CkD)Y%FQ3lTMp{p)B*s@K!Xqh;iuWNm{NW^0*gm zsud?@9dv0ZpJIVdXr17td+DdN)K@tH5LlS{K=70;cWm6*QgRJ(ldB(N=Oqnm68!Un<$td{W4>h%0ebj-e0YP|Q5`uzq%bIn}+s=?1sipO|Rj zI3Qjtzt(0JX3d-gk~Gp*@-goO8jaO$n|n2E@Plp70v#4C*NR5iAb}Nxg!Nyoi$7se z?AZIzfbx@;R&-s>wYOoI{1;x`96?fL5j=b>)l4OxCg)neql_lKqQG{Cx{4n1NwuZ1 zXg}lb(<361D7Rr2oqo!=&wd>Nl&UU+k%OfM1In2!p>I`=jGJpgRW)pgc%$s1k~|Pj&vtu_8&u?j5YSXX+(9((dmHv z-MY@KA)hHkh`6br#N;e^J^D27XsukoCWL{RbKLA?S82}I44hv-DJhdicsfsXePEPV zesHiQUkFrPR>hjLWVSqaipj=5z6MkK?h$j*te_OXmD0c{B!p$MYzy2$uh-r>>~!yI zfP#z)MzN+agQF2n2_gG~5=T`th5x6-L!z(<37S2Dh9FY6!}_m}c+v~xujpchwFSkg zZP8tc`b{g}b$^phj2+y&b}0#4!Same?XP-g3jZuU)Fr0YV3rD2qGV~RTxeojHp+=kI9th^EF$>Sv&McIS6%S zqTyMHw4WgNDan(H!XG{n-^&LeO=ROF42~$#juYhTE zBhZ%dU+ph?Mv#@5ikpkyDrMPEi8-Sw(U(38h4PFvGMmB~hj3NV3@B=C}kg z;Xxl?v&-BMdwWD0A5iD(DLCzAae{bAld(Cdk@h?f)bpq7>y2ciaV?D5bFVKcwDfpYCB#=^C0Ecx1S=}p7@O&lnGIX@IK^=WjK*-H zDT@B9H`Jr2RYKJhl-gi_y4z@txStnkn-(X5otlr)QVTHhFW?epF%DGnRhl?P{=R#_ zQT-pNpEtSg_#PABzSnC7R>OIfA@JG&ukcFnSQV4T666%Q%$|d0B!be)a+9%K1lKy9k~h37?+Vgl2Mq7!bQViItu2;i!o|xX8g=1m5&7 z;|vXhkl5+T`3DtbtJ_kAR$aLh7V&ZvT_XBSWmkvBp|jBgK2&{gl~pH6#ml*~p#%}V zs}0ewD~G_FWs_Q&CaRT&AwG2ty8ckdRy;PS3(x-xz2#>5gN?t5Y8#JWzs+=?SSHBY zCFd0ouAT76XSjkv7BNQ=X^>8^70Z?orv;d4;ll`Gf|jzOQ;S_{GSA z@x%jd!2aeO+lN<=^{+iDD6W~1sXGlj;G)1ZC9<2i2h_P0`xYPAC2DD4O&}Pi$}=B= zzh`tamr{3kYUhRGa09I++_7M~Kq1_9H-Be&7+2=P>@sf+Ff%AuB|A+A$o zqOcN&7C6rDcij)lS%fTPdL@-uI#j<%8vh9Tuh>oyAV_J=;VHEm*q?H0c<1k}MDDwQfMdjW;XDLfE+?yI%mK#&usYTXDsS}x zsNjh6?=S`5yAB+0pB2!Fh9o3fvb1j|zf>u}CPCKUh4uASDI|~*YxB^h_s?W-rb8GS zr=hBCzO;4n-muP^gZoV-6rp_cWvR(rbMCpxwwSY8kI$0@;5~K$16Bq8H?RKHT4Df{ z4UMY7B7w>Nd{-^CPKpvoyJA@2o{zgemC-xpBmbB3fXedJq*7NH{QufB-NMZ|U4S@S zcHsC6v+$;A^Vvlwo-POxQlNH0KxXM_6{YZWbd9PD<2~fxvEKa>rqu^_`3aq~sRt(V zq_NQd1oyMcB0C>pQ&EeJ(I1C7eEOW)igCU*&ZC?CBid%7L`6pm6mGT}e_419m*sAm zmrPOW`YtHreDzxY@yyW`^y6XM|3WB%VtmsmJVv_ z5Um#jmYGxLc*=kp`&TYVYBb#Hp3${kLLYOVNT8nrZ;PUVnx};591hTkFA}W~9{Ptn@Gu7;=K;tb8ct z+Ngr>ujW)Y6J$ybdZ2{!JSq8c3rnF(fVx|SWNK_CRYtiwy$GcI{tpXkg{jiVIph#) zF^p7Xz7GK*`Iq~JNqX(yQ`-vC(A=S_yT_1cX)nQ;h7zqtm<#Uvvq4-<>+@SRC82$Jk4KangF}U$^4zJz(ms%K6L6#MF zJT{i9G?S$}?|t3gKmc?phmb{O%&<7*h5%jsl-Ed>?1#h8MnqS6tpaR~5SdPk8mjRS zl3Jz?Ik8R5P7)Ly3~mh^W>={dX*BDrj_sU)LTh)ph;n5VGnXi}32W?wJD3sbeG6e# z-qSk&w+J3i6%nvxY_(9&nvg%OG9EyrK-+t4>z8&D@s8=~Tbph?Ex#O0B;6X?zxZ;obG&|5?E%9}*G(GdR^tUsWqD7i z-XX>9wh4-PMc!emP?$>49)WpcOO9|HH8nl$~aRW7UcskL- zy~W4QFqh^EkkNR|(E+NL>b@R4wLLgIb!a6)hKn$)U@U>1BYa4gbNkhu?x~M=FpinC zB8)4|mR-XJ4M$8mbowmuf}U$9;`dk$boQT9ToOTl#e3+y=IYnfG3q@;C=*DZoQy5a%Z#vY<58KEbDDgY!wPHQp9{SW+kI~M1w)*ix~)15?BycJj#|BA+2@*m ztaOzpUOM%E6d8Z6tHc8x6w>8yPv^Q;-b5VaRz{1}$pj=2lzNI!`@r$Pd;l#Se~mY| z%gHi&nmiHkl2n>IerT5w2#7-giLbA<+u*&vui?Jpxa!mEAfkJR7q@%Y*DL{DJ0=Um z2PBZ8@{>ViB6wECu&BXb`p(DTcFj>XeDu8}09D9FT#^dAQQ%+1r5az2?hz1jWxVu( zs6s}1tlvQ?2E-HIDImbdi(5m;~~0qn`+}Xmrz2stP}|m@v87WJ$VMvIknZz z4bsgXn3s>4(fu~AtPl|j^;y-xEQw&0ijgS@dEib!bLP6TXS`ei_G>5nHmXGOUJ3xN z+^+3Sxjah2jUDn#9_gL6@XSd8~Or0S}SbV+tkSie|6>LDvym(52|`D#P5f! z-8jQyhq8BvQCsA^sa|B%9IHEk8Srn$&xFb4H8xWF-hm(=fQQqg9G7gQ5q0_#!}cK! zgCCmrlBGxR#0HKgS`%~@*b*;vHac*C2uuW=PQpvJ%xYR>1l;61tp|zk${%0$0 zl)6u?ez<}qJ=9T_t}j#vtq;gfSelzsU4XYAMY$ju{`FY$8Gb8p{Eh=W<_z$($CH5~ z21=`sm>nH@eEDurOVE&NUVlF#koU7{LnlUrU;x&X(|K{iqmdUo+HQCt6LdD{4vg7Z zTw~l(72+r;)8|rcHnJu2*>VWtfV2j+Lw==N_HlDCEyl|WgIt`~V2Uka`a2So>}hTp zbaxmmGY@e9IKQb;@SQUUhN%7CZDp(Hd*?ha$WK;}3*1qR*CeNc-2tps_b_JA!pwN8 zFpvHIc5*h5#q*{UiK7$&={UJzivT6jG@72>2J^^_*e_dhp?mTgTrt_#o;o zSVqI3u{Emk1G-GImatX_{*Y06IrSpF7JP!LnHvy#fnj9V#v|!E#fYIShSi=Jq)_Z3 z)wJONH5VqavUssGM+Pe}Jk53SK6@!Dt9AeQfW4!lASAY3bhPOuVo(tWwH_B1BYEfF z9JzpegS;`K-~)hly!bgUp`lpVT{T?6vyPP_Ol{pFHh*iJ?P>ZdLs1fxQeaR>ORM-fo7#_kzD-ko_ zVE$4t8|pdLa{JQ6cX@)BM{Xe_0F#O@DEf0_7PTUedRN)lQDt9ZXwZ znAA2JZMNcIEsC2klm9h$NQA9s&_3>Dq}S*?uVW*htwc*6+esm5S;1qd)5g_R^zIo1 z?&_~MBREP5q>K|b+vE|tyd>jZUMktndp-l?c;&{-k2M@lzkVm{SC4==*Fw#Ru=Wee+Z0^xzPot&tK@xrzewWwwi1IkF=D~&IMX)%7cpHhuyqSn%wPs|gH9j%|MM0$ie_8} zUwb;sbia0s>Y8XR)(ha+yYgj(84#`?=c1v(j{k)T`B za`zTD2`{Qg8VMTc23Z?wlZz}UU)=?1FntGQxq(zb3tLYaywrl$4<*aC%o$w z3zsA`uq1>$f$J?xGl%;*TYR(4irFw;qL&FCP9k0wy=QK)wteP9(F4F;0$o#bJm~-{ z-l^CLUxt&2(1oR1Op|O($J2{D53||SMe9;BgoVRy2{$%oc1e=6U`A8&Ca;ftU1OhL zXO%kA^0FfFB<-ZH44m30f(_)ZkxhR2GfecAMlyaYkG7F=^UBwrz|AO6H)K^9q6uP!1(uUtNue zycOMogpeEJt$<4(%>cMPKVK}$wx>_!kgn?)^$=l1p$Qc#P4%}h$OWMGN2C7a65p*9 zwV$wlNO2KkqQR0t4;28ry9!RV6?~td%#Vvm0SO=2! z8RVlXsD9QFLG_SDL?avO(o7SU1|YS~2KcL`#}y!KoWM~XuV^uc^bpf(wux|iH+fnH zQ|^^GlzN5W$~W#n=%Ug;ykY+}(|k}m>)~_(ie2}oJ<0^K?@0i{GN6zVWc$^};|y{4 zFXUyrl#1e96e4Z-_KEK%o_p-jZl$X=$ONQv@}TohT{^(ov)Mdrz;UKA=!RORWb{au z6vK5(rO2eYUkaO{l)Ua#T=>HajHX+o5fNeL!PtloHYi@g*Y%T8b`$sb3j2^Mh8pM= zC;P7FiZrFP`xV&x6Q8Oz>px;S6c`4csVjK2`yD3Gh0v-vnsEJ?REFXh{OlDG-Ae|m zd^ak6^Y8@O3~bP&Etf8>K^g&xGkWOP$#^fq%6AI!iM7{w1sz#e{6T{|l31>&vXBYP4oSmXkYgrgM{@tmh zjLXP}(p!0fyOHVM?6H+WJwT4RA27?E_NmmMwNPACGxl79YZ&pQjC*}^AL(Rsg6^Gx zodKF<(c&sdRE+DV7IhFhFJMKks$^vQUdq+y+qeD(?)Ffiku@8CF@2iUd?{{6jfsmj zbVMX;G_>kS!NG4WBGUck0ikpC;3`)s>(E0{4{&m|@3#lFF2}VKIN)LaP{%5lzI%8| zjzp+U*TqT0){teYsIX36uNLJ8AZ3ylIlb1(o+I{ZY4!b}N*?%arXZpPA<#wC@Zg9| zxK3#Rk!=+$Y3D+{OHnq%MnM?zb~8zeUCF{G>NfQL=o*g@xdOJm?fL_}re8-;cO3-l z6`h?X_Iwb=Wb|epTuk`x16w4t`E?|w$P_E@$Q|?_46CU>0KM_`!oRc?E}DWDBObw2 zL*+;KVG7fhz8ovOgL(99cr(8FmqS5{KhlJ#nGn%8HkXHAiYc%ox9UqXHKrdTCy8SmI$4SJ+~Xb8iQRa+U$K(BHiK?jl0ZgrM8Sb*KNX|23_xPhKM z5`EmG=d!Sp7>!Q~sUIwrTf9LuP*a0iX$9C5bX<^C!}vGoFx`ICX2b%g0in?fXBNXI z+TudF#J8NF1S?P(y|;%7XtN&OeAcH6HHnGB^N{$l8yX1X*iip{(j$d?xZ*UiQ*^N< zg{f~xqYC)|(@TkTV7+K2mYa9GU(HDJPO1o`EYx3vbX?ERdwsWWN35&QRdQxx(><}& z_V#>@=G~LU)gOrGx{S2%XGLU;ZzkbkmtB$8&sEXg2rVey3XuzIptmZ$u>lO-j9?2;*o<`p$e@_4zC^&aj3 zO$EoTvTi`!YAbL6#wzDRmrS8>LK)=?6g&GHs;(?pu z$0f3NnAp97+*JHeS+&uO!hquCErsMCFK(wj$7C#`(&XqvfM4||eH-jKgoJSHVr7*B z;HHWy&yHb2IPa4_q9G5tlY=1Z;DR0m$gcdyR|ch_RHlexgW}@;-nxzc z`h~b@mdLmV;f3Vda?UzOZMhTimDFVX{}h>s2a*2q-3&7T8pfp%jwNKh3k3 z3;dTnx$i0sdA74pxrULo{qgX)toy!ZBUw1q2aItKQneh}0!efUN((>Vk>EOA8<>0x z>YitSzyyq8+8c?Yd9U3TR=buGb~RV%He``s>Ov8wB)l|(baJVnaqsKXTZ&3)BQLkC zGTMJ~AfJSPpzyGmv@d}`9Lw$o!3{2U&ZY)X^z{f0^~|#naSM3;LA0%SlKIp-vx2N3 z3MeUV;(~37^Bzc;!4!3ts5tJvsDpeC^E3J7%D!c~g^iHZDbg)=;pO1OP6=q6Zpc*j znxly_VC~H`b}i%M!CyTEO5F{6lV?y|+WU8O_RZxp5|@VY@wae#{%q=LcRGaK_{Cm7 zXdWuB?f^#LX#_%lwyH!>w!^(6DOp~M)DWE_MfsM_okxK_vw(yFas`v3W9L0FT%cNr zQ$laM){9mM4DK3wN8lRSm!w!`8GX#9M)IrJ_f{w3>hBI69Hu197ny;X~dDWu)yqagp*JC19};0MXB=^Ob+U8gQ3sMc;`J=shN7^O8=;AIYBetGyz15XmDm}Ej^)iDdNOJbAmv(-V zZUx_Ykr&TQn_nLD&1V{sdGW;MACS_Fh(%=*q5HlUk?U}rf^cOOiq7%JHTNN8bfbd* z+T1XYitkh61hCF$qe|xLcLRrRvWMV$vv|agm{W&@z*r%#)-eg+58)uhMc9SIiRwS# zb02s8LhAo=dm<_5dkPaVDycAj@k(Ic(B)+TnISF-V1Bb>UASP8B+vhvn+3w{y$V2l zRqq?2C)TU8$X6ac8_#xc#VZiDb03duCP*E`-)H_IAR}IWl)!NtABJ!YQ$9r+FZ0w% za`zE4{q|m5JI&5Sw@TQa{6iXnNtgDykWR-`H~RoHGF--rTjwpWercDiq#zW>VM+;2 z9yX`eGrH4S&se}7fHV6bF6D=>EHs}u#GwWLpEUE2;rMHA; z-zDAjZp@qZLhfC~L^RPWd#D@@#NjE-P1g-?MpSoMXU9ajkG<*f{AWH>7EIhI+0b$5 z&CMHMk9Ga5pX_yv}0 z=u}&1Y$r{bAza|eL_px)U;@Puh>v<}Minhwz&a(8RMaN_z$(5w>&iE9F8%CGRwAQ0 z|Eo_98Cmd%q4ay4@+(hiJMx_W?Jc>}-kQ2=);Lc{xn)wJkSrc-OgWxO(>!93U zbX}TMp&6ngReUNG(QUR{cVjJN3TzMok6Z#ffkI z&UZGl?PhdqTTeR6ic{=WSGJ1ge0EnZ!>H?!7^$+Wz<#?EOCRbbdNA|PrA z$_H98VjBfPFtNvpeh2wTDjmzecTj`gw{0ta<>8mNb+nDiQ)pf-+op;9Qsw!m4f5b# zA`DdrVqT$;qB%z~F~e}b8|o)~@&wvi{KJNhO;`zIZG8|fW-c#}TL9#^p*h&iJ(wi0 zkPOK@bsZdaP#Y*iwJsmwjPgQL|L6Pe&H)Uy#9z8v?&OIY2GBIoKk+oAI@Ti3?4Te9 zns>EI>k!4e|2Vk6-C!H5`{`%(@@m%P0j&C~x17u3}v1cU4=nl ziQ^IgHOL(F;8gZ8>%Ioe({Xtr(x5vZyS$T5=@BtTX@h8d@T`{LxA|51=(V~Bsmj|Y z0E4a&JuW5{sP7RllD%NbVd{6ql-M$pv38Uh$pgN{C|Gh`4^gub)G6sOHU6FQ!&s|b zhVkC;#rdh$Ed{JV>CVuMusmyI7M}e;a4}h- z;y((Jh`SYvNMo@18h(IJ$9v(m*G!!Ha4y|KjE&{96U%j8Di$`4v5lm08n?sjFuw;n zDZlP+>SV^`8WsxbKO*A%7HX3^H47;?xd;H>Ej6l-)L63@lzdpG6cDN^<7!uY96p0* zv)ER1wi=zV#!>fr4jLc9#Ny0a=6Br{r%TH}F)5In=OFXwqW3u3`F1W#3J*CjI{U3AcMSBzm&S9MdPOP7IZK*gdAmK5IX|fbao(6*)@5rnYfZ-s z{zsQIrSTTPy%x{eWa~2{?Cqq{(c}yCg^^I&^acaqif%qB?+PAJ7n>Ch?*Ym0i?3ar zN#uU9kuG`p+UO87)+RtXh72=k%``+~tfyP{K7V2j(PADC%0{LIIkd&}ZJ!LT)&awr zmFmr#O=4}%jl(dg?gSa)DWyB_r~sioPDV#2q@HQv@)!0Pk;7$)BbUII7y~cQ#FWO8 z+Lg)T|C!Yql32S|d9I{{e+l^n|5)<9)|@?d-nznA7qD7Oos?cg=UpKQ`mK?%V(9n*=y#AFm4Rh1N^$8rpP2*}k-3m{~ z0m!zfwmap3|3J3sp*uh&xwOzTd6TX3vp_@v0?Giu)fCfkVK9k@5T4+3?=hz~g*r`% z!ma!>@bu#2tHW_LNdPUy^K)J0PysV#p(JyNIhe~uJ!gHw))vua6(TfSNeWzA_l3Gj zuBd#8ulyHD5){D1$dVqmS$U0m1%Sr}>o$##M=-;aW51c7oJw-En{-Ibt*)q~;o?@Z z=YL+L1TN|E+>2?_rTr4poYRJ%TKK;E3NDb(>Q+yOknku1l2Qct+{aXTb$=!U@B%l2 zHW}wimp=Dl=?gVhH6g&NB1hJ zHUpL&Oq_^TNAwI-nfeG6z8{FV3n~!%I`6^a>Ihn*aCmRk?%?E7zUbj$Uu3v-Q$|`; z1N|PxkmR=-_lSuK+KJvrg}y+#`V?~GohTB-J3{rqIzc3;nDGjWN0f^f7Jq2y)}y;$ zKdULC+6R2p^|f>&3&yzVm`hy7Ydq6bcVs!8LM-Dsm^T92l+eA^x%0X)$oKyq$9xLQ z;GgcG!UID?oJs|3H^V5=T!kVk#D=a&sqm_sEMF4YkofSzcsktQd`{+10IS1kZ}mcHutt6WfzIZM#`K>biDv(R zGAmKSzO{p%QSc+rjCd)@O!+oW9Wg@Vp&v-5Fuvi$E%|ccH^Z zizTv-JGKZ)!3HMiLUdO?5F0tZLeUM-TS0r^a|Ci5fPlCo+JDa&t>bAUV^i^=UM|&FaHRuxY8oBK zps2cNFJxtX;U+8j3uU`er$D@!v_=R`36c@+&4w<6r=xt_{^3_t>A2>BV-RHP^)B;T z#PMJy2m`qGQm%bF2CMvldY^``A@9su4{(tDqq-c1lN$3z7!}nV6)MIH6;g!Po{k;R z%qkz-Y6!NAJuNpw7*1ky*VeLOgO;9{@Fcjb(yp?P-r@{ROX9;MK<~ZtUv~G4{{Vp8 zfW;9EfbNO`cP)Q`Cm%$lfe-xa)6;liq2t~q}48`PTHbCYkg2?>0@em^^l z)7$l63Qz6l+=3hh-|Kip1^X@hn-YIg*!~}af)Dg2v?A6gP9VNaYQf0+WS*;vS1Rnw zd{TS>1a-c@nQ(;sNcT<8Z{8TZ)GDp`Qs$y95uoUTdX%<1Mb5p6!wzhsk?hV1ozhmx zrUEpI7R{_-P%af_b?PnsxqFzEufQ%1oIU|K$f0%4cB~rkaEH|)JWTe@o%I9)dTf?Z z9e8Wr>@lOWrf2YlM zv_V+6PcfwN!uQp^<*iO{6 zvhX7EZ_mXGxY_%sOlitM^z2%V)pE(H=ib_B%h+0LGjPMxGJClkiRIS8zga1y4sJh5 z(or0Ot!CfnXyXp~A)~OeIu;uOgRzGMvL$EJth`K#Zc=k70L;PAo zWmf^+Xk|3Zg=7{gh{66!fBH$Z`J+2vY;3%(Ey6kQpSt-SH`4i{QqkGGpILj0q3-Cb z8GSWK{?N{-cEJx{>?5ZD(uSMe_|UAfNuxR<4BBA&^&)Ez;9>d+Mh*+&r&;H8OREf4 zdZkqGWSxA>!fc{2`yv`9fdp+ZQg`v$#9NRYhoW3^W_%_$w52TY=cE0Zea%D!EC|R7^KYu!Xp#K zy0+g?79^K7%j<^qLZLuWqBwTxBd+vN>XZi&9ktAAAQ#7`sa039yk|ddu77hRjfgxj z&_fAM2aoG|odCubfAN}4yluZ(QK7h-1+UsEY5J`gq^D|M+W)0yYdB$nU1G8Kz-|(; z>};6|>>#*1Ga7zklV;>jVJ`GdI(rV>RR8ZdBf6<_gKw29&_c8CP0cal$B@?-ITL!& zFm8vn4PQUS$8-=3Syskqv8IpI0?zUWFZ0L=gyWOsAy`R5x=mqb5B8`}_aTiPWvit~M7h~%By>&Jm+gfrOy~<`tG4$U5xGpEa z&@CY9qkIB;19GZ~sLFf*6S(UgnZG!@J17UensGFNHT7j`^jalv{o*Y zJd^VYD#s#HVz?r4S`=pHL~tZId`bvR`wK*yhzMM+y4i9*zFhT@dxZWU7D~1i(NeJ98~4T$izW35rKm&;VDk z77p%=vVoCJApIJgglYq&q_gdVyR?geG|lqi$p!y!_fGLqTVa(c`U;kAWO0Wi zbtzH(UL;iJ;zap-`57z#?yc`oGU7o>EX3Ny0Ys|kOdy7MJIyDJ`i|kNqi994kehA> z+mivc5W~|&IIb?Y=Ie4SMa;!oJ`{@qh;B|3AnrmyLIm+Nt51|JZF@lH6A}2>t`jtb z7!c?u1l>>sFVMuM#AWu&5v)JOOnEi24nnhTYVLGJuWxJYv`4@2-uiJO3r;$SIEqo( zV9`_!#;XqV-bw1LQ&2}$uDI( z8=U)x@*qAtO|P7HRT*06k(3>IWdiNTje0ju4eWv2IcXtUd~3xND3^zB=SdI3z!;hU z5sswj!?}-?kZha%Ut`pJ-6q}q&ql;Y%$JKo~wB8c>?TL1D z)>78_t&ve=hef`IxSukT1${ePzxFX4Oc8KXq%00NM{u%JES<%+3?N zjOZdw^QH&6C67X3NaQ>I6KONwr!7!Suen~KSnyzkv)-i2j-~M~-9^z68+D{WjWg*a zSo7ZKvA2bi_9d$G5A~|`%kbE>nc4TP6!2Mro z-HZn8s>mMl5g?XEs?z6h4=$}-ROBroXs7+5RRGjOt_a&}^8f6*V)$lgYzS}(G~`x;skm!IUp7&ZbhRIqf=pJXK~|A^BA zoDjxy5LLRH4ej6cU-Q(r^$a#)I z4q}9%e40-uCSYD;nHvX_e}v84YqVEXT_?Jxt0xtB!}Lc%of$p?f=W++0p&xxUsS=8 zOy|ePp0&5?IkN?^RowJiId+=3#_A%j1wOYf!4ieKN2BSqr7Kk?6Hjbj^=Nro^{~N` zOUkRX=2kWkWh5^j8PQ$D^c*Jv^qG?6&+x#vAgQUKmp9Ya;o?>D zs?CEYDi1z}5wB%b@v&@@XLCUzUxPC+XuKl8W1it*_s@nk;V|I{l)xIJX4!=XdwYAu zNt2XZgUjH}bK<~L-$Gx2v+U~@NF5b$x3)+@JXQG?zD&N~i{eN6aD+ZscB%##k2IIb zP2ZrxG+7arf}x zz=E{D1D}aBc|`^=cx~gRQt?L^5Q{z1alDftaOV4X|3hYa@3x`kCvKrEw1kSM2*SFlVsR1k!mvqLe5qF8Z$ld(UFTA;XF{-Ej$r_KuH) zf;|=x)tVzpjnMed@nsaN9jE4l7wkAm6DdS7)oa>nz!1H{bG!`kLLJHKElgoSw7z?R z45n$c?C({r6`9h>53$c2#8IFXyOKCR3Ol=3Cr-ceqU-Q4;gAFF%cV!7oW4JZ@OKtI}+$;aDc0KI6S5@v>YUdepPeWZe{c znACypA(lzz6RWZ&e@+p@1;)&C)6mC+W$tTi1qQ6?MK|{ZWylG))3i1j7yrxx*R&bj z`&{ZkD@W~Lo_Y&@-!Xf&jcJgHPukGbFeAlOV1cA;=*Y350!;nmZ>-dIKMz(y$KmtS z6eI6e)U^t7u^U-=qX)~n4kk9df7(I2EJIqab=q|YMHM&cF~dT6B|+dIk>dGyM zUk)IH5Q52trv5h~a&EhMzG*?|J`dHP{O?DmCB!JUQIb_Q|Y_A%(M66Ymj$vUJH zB-!<5c4~FBoWa|=ftj>M;WdDfcRx%DqBDq!@{EvTQFmNp>sApBUr=Tn%y@)4qA?r1 zQu16P;hAhAm_?Y(BSe0SCqplJ)glxPAm;BOKMc%`Hu9&qt)aYiQ(MYjh2_yCj%;dT zl$8VZ4n0{`WwjVfR~c~T^8Rz!SY)E*4L|%POuxdzJc( z6b4Sv+c{Q7!G_)@g)Q{NeM}wl9J&0LAFWpmu6h*}V$_Poo}%m9r`b2#b>#!5T?S9K z;j3RZc?ou2!JWl$`psODOQ(W)cA$nH&blz!t^6c7*&Pq+a@^3(q+85Vvj0}Mb zqT}RTgm_!N9LyrTpvT+Gi;RzuVHJ+trWf7}`?vEPZYShYM8-+3?rI(%zN-p4t9f&% zJHDsm*AQaNS9RIYZ&x~84Mllq!OIkNMU%3{9!|&vPvm}YFSKOHZUp&9VP$pV?}OGK zsI-=)NH0iDl>zpK?L~Iq$REF1o8?t&$_nIXhmPWW1vTW+FS(5&j=4S^DO{IpANhNZ zdBvTeQeshfzmj7d%Jd#O;cVI*-lM3iU%q(#X5RCb8tLbgSS_HS{v$1{cw2M}D(~DU zt?Ic`GnZ|$!|7t~?inPdoR7@DkhTqkD_rtwao3Kf(z;_El<`pD!wmZs#~ozQV+s6k zAn_~mAFQlgbkQ_CpU%<}_kitzejT8*H=QVLp6^N}^`6Baqm+qSPN}Pr{IS*aI>Pa>S)$cE%ph6+}tb*j3PN5$g;mg!usXft`n#*%X`qdOrvi5;(sHI|5=Zm z-en!E`4OCJ<2_4vM61&b6sHT>SczUsMPC8tJAc4!;qxM5k!cvLF*oimZH68nUWinKo1F{wtLcO= zbUznj`jiytdOWDj+xZeJL_n#)mOqI@kd4tlHz|)<(~)ibeFn$CpqU*1k#Ki2<;+qU zqd=RL_NY3ae4tzX?*k?e12_wS=V}M^R+XQ(41&LgxC((!$8%sfx?=$ag?sWCE2D~n z1NoDMwr3#5pRDufSa(iEY?XRGxhmn5LzmNenb)N?JZ!uuOL1}`v?9RZ5wsCW4|33$ z$BqJ%3mP}HZcLK<*Qb|gsMA7e?YbdE21fkc!#kA_i-xi##$sIbEAZeTA^g<*8Oi5ZJyQYS>X?}r?=RLCB{5z^1p8s8;6kjgGK2RM%9tAfWbL-SxL>OUzt< zF`D8t`V3cu2?WXII?XEfN4UEX+OjCV_RG}T5+8hL6qv=eVzTBp6vc@yO0-1JAPzGD7h~yz zHM5L4LEf)&ICzrKQdsFXdTv=xY5e1+#zWHa&n(!9!_PZ()ConQQxrP5=o-_vY?o6% zgHNdRwCuGReds3{nZcD;+L9@Mf=n2woH(up&}tR@tyBX&4LLZes^OXb8^yyT5_-tg z3?gO4a8OS09#NlZe1~|C+-rc7=VPz;%FL1D3H~6*;zS38doGm1b(MQr$>LE7R!+-5 zp0bj8z|on@nG=cf8C!mwLFL6<-J%y}j7S4baP%h}z(OtYuxE8A@L+zWZO_?4=$L9j zVs2_;HK%mKzy^`=s-d~kvlBpy1PRc; zg8eQk8M9+;M6`|5GI+i9h@*&or9joB`en3#qAKmc2za*WY!ajZ{qALK^J%gI=UI?k zF9>@l7R-uxo};!Zd(cffY)&$zegBAbH}BF$f-m0PNQ3gWydtasYzo%$c(V?wKpRlu zN2ltX6{xIIZ=XW*qfw2^EOlUt6w42CceZlm9T>>$uTm>)sLUI!i{q-!$WxB@ZO%(! z_dK`Ld&b3(z!vCexD^B~Z+B+Dc~`U_{ITs|YqNXRQjed{m`jHfYDO1NH0+t{+9jR` zV=XFH=;b(n{G2H~%kU1TWvL23ZFb%?CF*;@b5cry^6X!%BhuzVg`1eE*cOg?lw$To z8$wT}UU~Qk(f4*#>$h^Qs$S3Ao3JNL#CEjOm&8>z*>Qfg$VX?x7gIq&3j(7(k#&w+ zJ)zXei`lhkZuGT$ZjYor4!^WiKFs@^B7*q4#v8xzR+9iFE_Z$M{JL?i)v1YKoEekh z?6g(4iYB4Z8$$vCp4?0%J-aR zI?YIL@HZB6V+Px5dE?i^TH$8{F_P%3fqz=50r*04-^V^(Zf)OyD^?`lr|mzM zD)*Z6MMBrV5T(xcR*H`xvYg75G)9sbd`hSv|L{I;kjiq{SNpn4mfumgwa2drH1=?7 zs4G}CY2=u^N66Sf#4Ek=nre@7kWfRq=?ANZ4p@G`-zw%{?BSmM?+sMYbIp!HsM)NB z6EhD!ku{G&ZKbVkLa5}Zk{}=6YMG({00000WR3s}00Dv11*X;g0{{R3!dPz-o8wVH L0{{R300CKAyDutn literal 72708 zcmV(hK={A?H+ooF0004LBHlIv03iV!0000G&sfa={{SQdT>vQ&2UJ%gRpOV=m z)Cw1$gJSr13Wqjw8e6Wr(E%FV2UFzSHS0`ba%U$BnF)VO-(vG`nxdpxqz>8B8Li+{ zdHKYTjy3O~+r)0$InylRlR{A}CVJV`m zyJTU;J?x+YZv;IE$1{_n+W(0G9Ug(EG|lSv9SUWl^>|yjHhS`OY`cCPEXB7bp8QEk z+n(1+GtgsCcsXspMaW@@0l((7CcUXtb0lz>F5!!H zGCgv=NH#lDN2$Hc@--~!C|4IobT^AoKQ6^!1^N?W`G+wA|nQOVyqPNRyGcD zh4lATHZef)7$8g7w`-nvR-Pdnaz&7gU%G%FPu$opo?_sfh3=SzQcB%MW%x6q=Smic zvx6iE(5n*nakGm7kO%!-U~R`&l?W%FU?c(DZUN(NCmffaxIne(K^<+tH;Z4#)kN)KB?TL}`L_I`7`2OzVa zB(SL1jQlS+&}RUup?ee``YQYl%LScwx$pNipTaaOc;{@5ilY|g2&KJ1WA>Fg zIv;?S!>C%+A}VE311FkY{%6WV1fI>COP-*_VgC>2>Bv|MQ=?RC!XWeIODbVSDR2C? za$>@u!&yHM7_XUa6*Ffx%mA@^7Dp9_OYF_89-oUx=m8xqY9^%xngaw=K$u9o~MicxD8$JW+fzu(T>T(#~1pw z{sHou##0e3SRYr3M<(SPq?$XeOwx=34QuA!gM1^4|)iiE^7C!8kx%%pd z4=CZF7NCW@r+$>=c&4;{!#}rK(e9x*8i#|1GD}pqVg5QCwD%JE8fn@$ZoQgzAB!F{ zNHPXa4tcvZ7MtmjYn-(_4oVUgKP>LZzScLVGJD>2OWx(`LX#?UXEra$wY0u9z%(4F zrH8oMsJw*$!7!;%GiYC*I7mo8Lj2u5a?)%qd8nnnDe9ZC%NZfnec(>hSl4t9V*j!s zFCU7Jx5h^KFxJhm%NaNv{|Dp3yFyQCW@lETJ^t27XJ)DdknJzA6XPtKjh%+|$*7X@ z2++nWggv_>`79SB7Yi;~wz>aINVXT1&t4bfT-Sd+J%8?x-#@s-W%xCJI6+8A~4Fg#!olL7B^oh7ws0*D&m>xwgT$gL>+9wSK(6 z!%1-sluG~y3K8?XWs1u_w6N>zA9quOjN-x{mZYPRqStB!s6o9sT$2F2JLMguRv)YY?+q{%2;>zA99#&ue*m;tC4^wYCH?k`ef@sTe`CN_sFL1?a4Gj*= zdd$Vw{1<}se;z4FPVCMUfHL8_um*<1t=Ai0?u8!uuS74nlA{6pGeZKi1II}U^b@`8 zudc&L!WBEy8SSLvhE5AjtQajRwBG+>*Opyyw{Lro-39`aGHS`2?er7>^n}Gs~cX0tWyD3uk!`ffYRC zOOKO(34)}QRgfgYdH(cIAw>TaAJeT#BhZsrz)4s1cIXhI9Wpl@VBoGu#8y+}S1v;? z20oVckWv`A#UmCkfL0XjPul&L*C=T95Bvtlq@fqtzsUO}5A)eor9!1#t9P2Pwx`Pk zXViNmm?|e*1I!4Z>+}2Z;g3pPw_O$Wv7PembHao1UsecQ2H$RY+F?Ww z;ePge4b12GhIV8CLr53HLfv;5 zZ8*=B30Ru$8W1arww%S7O>UV>{$pli)1wdAm8XUL4R|VWU1%8A@q#NQf?91Ek5g1` zV>BIUw{Er|Hc9&B&fv4zEs80P+lGW1@)@7)C;nA7Y0miH_J(p5w9wxhGza+-!iW8h zqNcV@0EX;2)oP(oJQl5_OcK4xdrFX)$0w$6s1VmI2rn0&~E{iULuAUTON&W4-Xn~dLuRn1`P$3&4?~i4ukd$%}r$7y!L%Q z1W%lB+l*(NM%&KCTKsQ*s%n*da=_`5zYQi2EPJYz6owSQNp`2gwI>Ri7ioX&zjx}W z@KNcNtjvT+HNOV-J3~wg;`}Wn?W=5`&EP(PSv5n}lQGauS=3=PG`K{2BSOaf3h2NY zpGnRVQqon6*!&C2Gm z9g;s?nJ$NTw1M(nqmXP%Nm&zuqy*+O$ai=6{DnwA=G3xz-i|-EyUN_Q;l^8zrr~60 zkO$r&DseRDbGszn)~wLB^rz{~?Z~`ti~eYWE)pXJuV3A;{))30d0aOuF7y0`SFqi#PdDV)n>+7qJ{e z{g%6qstKz+YPZpY^^nWw5LypfiZ@=}Ax<7KYOh3sjn`j5quLZ?Xa3mPC;Z8=G|U^v zpiR?044$M5dNVB5@eVfA1tOZ|R?RfT5g>G|>`Fb209!7Bm}L>D#-yI_)DSRySdvnl zmpF!${v!?yqK-Zf5*+vuiu8-QX-atQ#JA(Mr{B%7hD3LG_`zm7a+Z%c zLf+7}B>*lF8nJ2o}s+$ z-4B0_g_G4_WS6HvX~CoB8_M6=(H(TzaaC^hKn8%6HxpE+4W9oDh#^MpT{Ha|j;1Y2x4m7$Himy2uL=sRy5f7MC61394$J=HvZ@ci zhY*|reNG0JKX;0qjZ>*H0u>@7fqxO(9Z4ptm!kKL91o5cpzF<~el;`(Y;sn<$_lkJ zTVSVM+R!J5h~rBljN+1!+>U8LbcaIjbno8GbkUh64#AUUAa%>~xXLK<>vat-Y*b!N zdV!Z;Hi5h@FI_i$bazLW3%?14va<p+?ed15;-lo0J| z(8R<(y;W`^61$cbMt0iI!Adq8`lUFaamO9!?5aGj1!=DFC9j{!R;Pp*%g~=q{kJTx z6t1v&mp`jwbmHtqV?)w97LF+7baX{2-5aF}dt?!PvbMXPp>JZz$n@DV!8KxsL)V6- z9<5;H`tIcgc4EtUH!fX`t}T{xCvBr}-ZQs$=Ld}G(Scs}X~dV-X%om|oH2-Edpv#( zW%&Q)RR%?xdbrvtF9*@th$Sy3cnwf&vZ@3b`lpd1LMAx0OD4r>!hivoy}GnD)U)UD zwKP_~=3hAtS9g!2n$fepqVRzw)2(GSsyOJk?i#h1DIgsM54j#Vzl*($8*NQR?Df+H~F${ zFWEpPr)ch@K2VR2nAV01ITv@%U2o3r7Hm=JFoL~wCbRIra!5LSM~C(`F)58mCA)-s zT?q}yS4mkiA&m9ety*ZN9_njQGJShde}oXSQo%#FyYiUVOuOowK6{YXk6^c^04=9% zfvLv3)EePIu8sEswRhOd=XgHGyUZa+P$Tx#))06)fZ5gKUfpjbG=mKzt1;NyH+j^)@k{Y?%ugEv zhha!KNVY}CX%8&Z8U2@Wfm$T66Qnga3HbQ!&+XG)lNGvck{`{wgk8>wynH$JRrs9~ zjZgxuqG9)4wzC@2W@ZMI{Nwj&E55REzy_ssSD6L`>&QKawr-(vk~a?JG$9orA`=cV zai}9qJ6^FbW7o|dT$JdkFcM;6>KkXgSIMHn(R~i}ozJ)+0fYl9DP?EUC~3Q7VEDH= zN+DKVs_0ZfWZeeM;T|R%xUCn|G1Pz10Q&u>tKzatr(4K@tNf~ts;-N+o8^4c_|r)E zjJ+Ff>2hn40>+I@Mc=tck9U=msJh-Bu@4ypp_6JF%J=ze$g^Jm%}>e-QY}Ku&3aB9 z9s)sE>E@Av$at+6pWHl3D3^0x$I-f=5m*m{B0d^lH?s{)zou%!hYI5rGG9zV-X`20o6`{AA&7j_pNL6#a4m?n)ZpYj}GpaUzj8JmEcGQB9)-`fM3nf>VxJZtTp_otWC{j3FR?NAmHQp)i zWZi47E^@v3_@^j)SA0kg=h^Kf;7-c6IGs~Lo*f62`eCc5Ah={=$HvDnCznyB;kAm} zOwMk*`^N7ukSX}ERj?#rI^P@gm&+xTwLYq%pFUE>20iy|UGigl<4drddh_2HkazGT z7Ao^+Gosnr3cb3mUj(Xo6}}`%ZF)E~O(45}>f3;eAX?ui48SOm(qihqddH1Zk}wd^ zVmR+lXD!VZk^0toW>ou-4_^X|2#&&8n5!>)*l9u7aHS_9(op3jCPZX_@C z90FPc)50~ih3S~}9R>B3l||j&|CtwJ4>X8PX8BbFBe~)-DTNs)eU}O((=2O)?ZeE( z^i*8`O+$x+xM?KV!z%JaSzN09Xr@4g3sk*9fpK~&4TWqXyHC7iKx3EYnr=KD+0BG{ z8?0}@TTdJd596Hl)}mnjRERX>5#pWdPG{gSA=sWDB_!0}bV8htYsxZqe|mUPWxcl$ z*HoK%O^C~GwI6c2yF5*ca01}NRH@#$Rg#e+mj(l0btyM!9KhS9GPDWP2O|epQ?iAI z5`a2IZg=Rn7M!%SycLN?PXvB7wK1b&`@3G-FuHXFV*kyi&RVzO2P+h5e4w6-6j1?w zImkBUih)2x+)Y`mDoYa6 z3`mX9m+7sCStIya_zTVdl_*9Jsr-9RXOM@%y^vj)R^;t5(gSL?!fLyqH4I@4k%iaT z9+OQUfz4vNwG7iSGEJ9$Jvmi+<#lNKou}0)Lf!eVlmks%gx`N7tF6&@2GH7!0}(bM z#jpDhLRoq^-~+$};Uhz#;o(a;OT|b*pNd4hx5`e6FR%bZ9|UrfGiUX*y!VWYAZj{D zBltEl@Vs|R0tb9$+Tqh$gT&HT2}=9^dtnG5OEiu-f?D6b0r7L`oeH^aQh zKbx=Nb3Y!W3#YG&0Wpe5A+9Rsv`S)M`6yz#|J8IQAnww!kZuEBsJQ?F@|Trpl6!-f zIn}E5ciYM5<@gO746${*CwnO9F=GxbI3qOPPg5laUkZ~q!D-QswaAAUf*E$p=OJ*L z(>jgd$dWw!D!(c_RJfsLS^R`gn#mx zUri_Vi9EWE)LGM{@+E$m6DXJFtLa5_#N0xiiqYmW9dZ#9kYS9h2iOM0!vdsUv&783 zivwU~QOu{F17pu6@~yL0M8ZHkxM|9^8&%cW>SFDc19Tf)qib&)Kfd+ng+G6?lA`F`%fbxG!ROKhdf*k~xfM>yHmi21aFb=#Y0_tWE+2&iebj%`g% zV+@JG_}T{4;evrC6wt~r;l&#QI?6QP6LV?1N`y#H zttQvm=q2SO;m%as;?C~h{tMZmLLLN)NoC=UkJ6gHBh*YyS96daB zkT$5D=aJue7KOr=+@Zb{y15W6Tm(?M7!_bsxxxDkcO?TGXVZeU+GT!u zG;c8sPG!3s@3w{Q9eWAEMfiPR=6@P)ZD6rfSkQ-^#m#`!;jJa*I1|6BU=1oazs!Jh z)w5L;b6}vUsoW(Ue~PpSCCt32A;3>D6hFzUIBgyanQ)*@G}zsD>BnF!)fU4LpafI* z_BChzBKTe`n@V+1UeVo#Vw>?@NrgQ$jN1xA02-}PhE#$$wJNJf1bLS zh2B^=imvn=dcTF7TmGq|n~`WtynA#jrPI&9BSf=*ire5&{-x(e2%dxpBu%J;Ddc{I zRrQ264N^+u){?-H=^bG7Qj&vMJL@h0U@BSgSpe7FnWyz;yQE9A6g6=zy(7eBHc8N0aW;i6KRIeE7hpef;kn8WZaMLS8TA}qg+rg z2vdK}9iiou92V&@Pcbn&v_S#W+F#KRh^RoNB7Z=z zl->UJWCn698wrlDMjoDAZ0JoM6;Gay@bvn)Tq*U0c}UQQ>5orSFqZN)hW;+--nqkS z#@#Wv%6PWizubrBAn8>ZY*;)hhM9DDUhlC~MF}-2B^9K4>|T>c)Urk_w>Z5HV$VTK zIllVcnq)w^l{LA5la2@i{{#{7=8?|b6FmI_0DiUiz>s@gg=7=d%QY_b3FC$(G*usa zD8sUuy{p*iO=2W)N{@npwvc=sYTn`X*&P19W@Vf-vAAeup-m z0tume;|5XTwwmLXK2Sqoa-)+pg^N5fJ?Vii6-Ou68o>&FEE6dccxK4Xrc_rq%rJOX zU+{?#bJmzq{468Iw{o$`3^TI%VWq`XiA79_BFg-OAlri>kQ8g3B(Dp4L&uWfWNS9r zPd(cV9)3RFNN_pktLsxn@iVUy(t);sT?vD1$GVsruj_NW**g$P2sErf)$J%jFIFaY zuwO2_8u`mkXn!C0OaLdVTs2XoLn<;p9e#kIUQa%?bS;f-bUGZ1iMH9UvX8yy4|EJ7 zQ!~y0Lu9S#J2<`16Efi0LHglrffWONK!SRc0t3yHb#NQd472H#cFR_owN-GQrz2nN z8BizaPtbMaKaEz#~o4!CA){{EXh{dBAB2 zsT*twkiO>Gm67c>_BBtq$eaBundh5D(zs@vji}ifsM#Q*(vAwF1tgKr=X`2e`)!d{ zrVI9RoWeLTTq%?!_n<&@NLuspDPCHO?@KUP@Ad-Az5j-lwWEr41Y+5ARjQjNx)wy^dVpVWU+5lsZ;2;qyE<_SpUHJwSo?w0*F4#cu9$OC}&eP41 zHl&%T7<@e>3x}hz+sjh^SkyzZ7D^I(jn%nHqN3vpbKd+1Z$GcW&#wW~+(70-ZKSNx z9-I6y)6fpSDV^*_8{e+6k7<5 zB%HbV{tK06f`11QqJ^~V0=8m!C9}otUc7q?vtAuX<=Z;Bk5TxnZ$wJjTdgY&D0S?6 zVo=pHzN^h8I2%Q3EG$ZXEb1*2hT!XeH8yw{8$+Vj`%)JO%?f$BP3>Pa67|w+y)>B< zx~HIyR1&&kly;E@fSMO`ZQ9wdPSz&tTrVxEB<@R6w2mj+eI@@}VO_kXO(|hnPxrnC3yMd$9?-`>zVw$W zGk9(JIdN>6DT`~BMzD1GY{}LBgsf~G@;*t5Sj24LPt|#Pc@xP6H!@E0l^lSycab`+ z!nOU=?&}s`PNCfyR}Xu=jfjsW5^%lBz}rsRPUlV2oY9$IbSI4<|B)O3bF?IL@TDA$>ijn8N9D+dB1Z4U$HT zh;wW}7>pV1kq3$S?r?VO)yFqmY5mIswI=gfv2qC=-73;FDF%b6l~Vn z3@QlAJ#r4w5C~Rmw4D8Q|Iyx;J*+LtgE&-E1wOugbK?gWBS`Nq!xru3EvWC6A}}dn zwF-qe40Ca$4+Es6;!(T|hlkd-J4=tQZ$YQHxx#l~8_`gv-9n!F4~l=%c-RNGJ0=n+ z4&eZj%0rN}^Zle;vP>RDeHN;ilBI2m(~f;i)Z`u6{6ClsiB1B$p?<(mD4?w9y}k4r z9Y2mrD<4_*MK0U%O4^Z2K8Kmoi3_d090;aSX$3#AL5gh_fi-rFo&bk!edMmDn|VQ; z$b6zOZFR&&0XQy*2dhskeUByueYtI5V4(7s9cEvOstgvi)T}W9{|t(y>s+lrNGk5L z5B&}lKTR%^FWkLL!v(LGxBpL{8tf*cj-uRqwh-rKH6qRS)Zo?DdQwz{Nlo-!YWSzC zS@v5_-8^4i5}O&dl8OPM;CMWTb&*$PkBhji-=o?b7+nQel%zp(!c{RcGypO=WOEk) zJptPW?@q)_46KC6Q(;}X+IUeh%ybyE@NBl-=jG&yjf^}9UXCG6ZfBrD-ZERJl?tq% zod?9=u?qQ0S%zB2pp{B@N2Yr}R4pn2WIB?w(r znoRLp>A&tQrBntv9tSZs+qiTXi;MpyXe5EP@xLCI7^pZk6Oi<~-I`{`Es0G}p!j#vI*cdk>QTzKf; zRr~P=_3rcA$xU$!bJI+$98$IzgE1M}Hn4P+o&KX25c>|%^BXi_Jp<_Tg_{b*dmqaH zv7i4EOlAN)prZ&jWG7(D=@a;M5rXSsh=e1n-CX%BW^mKKNK>njG~?cFe%8Z4jKkv* z8yS`rMJ9^Ww1`S{QHNVu~cl?`5fYN0mBf`$d$zYBilWuVyZi1<2;QtQr$G-XHGPa;uN7ichLDabvmOm#=g<4ZVzy$n+ zbpCPb#^deZ@=E>v>2&*6jvD79yHnR_T>x8NGx$1Y*1dL?b$yVS7q-Mx>&Ys4ctv_8 zV_OtVl0qxHH|1rc>2oyp`xpFH&eHYy%fca5*ni=k4n)`!9gpmPe&q1ye?2JU?k5Y(}=C7}x&tP(FY1<}3(4v4Bu_{Gx ziaN>R!u5a|~3J<>BUNHGiv#mPI3JLlD5iX4|?C-{^#I=L7-0}1+atq#0 zegtFZ=^71?5%lcKKJp=auy+vYMj%nOjRHHCRl;w{bcC^nsP8ZJD*KbeP6z-B%-Ozk zKa<~K^9aLl&9DaIT$j_}Xiv~-QrF(=_UD1Ue%^N09Fi{8f6beH2l1r%olJO<&#-#f;FYYueQU13sMj1≀a4zN#{TbMAm=?0R~gCU?>K&w^y?tZ0is4j zC(L*$+VxyIobc?v4#Kps1fL{e^vtC!Gb#RI)I>(pHzm>utV8!hL|sj$j%BdBQO}Bv zwz%`5klJ;Uw+BqLjPaylaErf!KHlhPalXNPaWKuSb-(`xX@Dewox3pH_nHeug|aTBa}dp=8eDUcJHpsC080yxHTQ&zjkYL2;)a`x{#ar4`J7=syTWlwL=x`>?2TD?y}dkxUJXPsyaW1Koyn@N#Zli)d-^r%Cz zo#qk~Q?uz95eX6YC-HWor!Z$okpf&L4y&vp>Z|0SBKu)C$_f2V7k8@>yFUb&vMA>G z-`lw&Z-S&9#}5knB^b2vUZ>3WC3{(ZphX;BI?AaH+dvsfQq#Rcuq0a8sl6g1B8Fd2 zfi8fa0O(W)yxqQMr$GT5eTKSR{8hW60{CiPoh5>lUZE#OpDIy4=R^_u3U6of?5}$9R{0`w@ z@VKc8WHpF75{Mv5*AD;W2t)(APt@72Ok~xHHFGY7vK}r~htH2Fd!*!1$czLH&-8L1;1m7s zhJi<+(LCO==h-l zKyp!PFOn)g5Tf8cX6QHXIsE2uX~_OFu`;1gF8$g{L;fEPJr;X4@s5xLNP$g@`~HF~ zOPc@TpsK+!WeUcz!3Qd2`h=^Z%cW|xg3f%}ER=vin;7ae?WB2)mPlY63uftDW}1Rt zPel8`FlG(fE0sTw6~%-o9KhA*rpe)t^3D~o%lQl=rSgQRk7bJJ6OMc13Nvd{Z+A~^ z&t53EOA6*MyU#1X)PxnQ_Rz5(f2|Kn7N8PBK9A05mtL0@2UV6xccbjej7kX*ExR+< z-)qCCWKo``B2`R7a*PF%2KbEln@0{DQSEuI z2jY0X^Dvv|&Z|4Gy#m>Ku77U829!-NUoZi6=@D81)IU-6zWOES39mE%3CxP<=AJ4b z48Oslg%CdrgR!jahM%PQwZSyi8@B1Va9nOL#1x?+0_``4+}gV(Tz0+Ad&jw=$}|Wl zYwnu{eR>b`6m>cKRiWE@as!WLX#gVnYs^Elg05`Y|H}UlzR+W16~GTC0{wK22mhW0 zmKJWv&D6_$$)!Pr#0EI~aO}1G8WP7BZjdPOF+u!r)a#%5?sxGSo%F~x_cjvCY~R!{ zPfbMy^rsB|1dpUUIZxq+cqgl(IQ@dq3Yr^!!m=xzFOMBYEraj=@-4Jifn`RRHHc6V zOms*x6bcGye90Q;+{yPB+G3B$ItTcH4e#QpiWj9KL+pr*yS2#^&bl4cdQ_ijC}&dYzs3F^eIcVc&VsIAGjfKL zV_;b>-sW*UndYD&{PfJ_Dx__GSUEoIUH^SyP?ID_q#`o@(N4PL3c4#QwzjHqO6x4+ zm*t8mE_$1mJ1fOO$Hi$pKUgnOad=>B;H71iA5RE7#M&dZWoPc??Zc90N}V+?y=Os< zzOLAjYRY7?ahXI8_l`OpfSMeE4s=@cbw;P~uGoK7^dC-zcWle)f7-fPrz1d{Qlr0H zxFr-It!f7{YPQc+&q)z^=wy=Jm{hy`Utd=Aw9^#nV=qH;+7~N8SoNU6&5Kh+?1U5{ z@A7PpG_ES8_z?U=*6n^BBW~{SUtC^mkhxZmGNFsBa2;0bq6C*?NPFr>Ec?`E}Rs780kxZm%w91 zibwKOQtM5{LWM=ko^tj#QINy>h~ef zqXS*$HW7r0w#DU=yeOwS@ljWZK)2DLMExS)jEF2%%DPovrSn>jDR}01D^M6H_?vN? zR5Dw>UaSip&i|KPO5;^Y0`!-}x0c6WgqYB0u5wc{^7aB>?B;xJ#$YGym34#72bm*g zjEvN+sv!AaHaMMb0u8h}nVwWd#ia~H5B>kfSmtExe5jGjGKMkG3|Ki!niVFD7MK&h z5UmD073#v(3!ZblLYb+-;aNSxws57dXDd}52_Uj~kD216PTH`p8j8&LxxzmMVe_Pw zm~-{MXeiI7*JIWQ%Ir^rR#gzrX&^6O*RCkn<294lwGVq=Ni_}d%Ad^^uXE3#QsgTY zJ)&ZnUrR_^gAk@Qu@E3)_0Yn5NYphdBR@$t9KO>qM+x_OX+5gj6{_&JlID(qU_Ho$ z`IIlawzhwxvS^N)YFo#t4EaKlF0>?sAtn! z=uvB4idWYx=Pm>#Fq~zM*MkIq-#pn`WNYz}fJ4jbc%^JxS4h zp#}SWQ8*JsZpWH%l!rc2Q`Q%BWNa%wZ1;$EX6PSPK0#%@8yM!<4RG>A z>t9*XFq_#;eYuuyob>1-9Aj?z_K#-liq9wi@-~@vJhj28I)+DCr6N$8O`%T!K)sRA z9eC4*-Z-!O+DFd#%_Lrt#bup0V9erE2K_3nA<)N_n_igeVQ}Wp@x!lv+lk+z(NmvY zGFFz*Z75j0428)<-7lAZp zm;N-D`9u{1hpc&~Un!G_JfPoM{H!KuZ0<2cF44WzoXQHRhO6>lJlSe zHQ$kj70ElzEkFgtQdsMmL4xx3`v^>XAijwhveq2>3o!_A_^$GnQ%T&kiDj8X8?2{_ zF7gR_W?A%g8TLI|DP{u$ zTKT)KxCsW1=7Q#MIzz_961zN(FMFz5bN@Cs!(u}1>lXxx@J+Wrb=0(e*LA*ZKv`~+ zl?dZBU(Al&mv(>(V2o|2kG$-3?gZ%OH_}M3PJ~Yp4hSyx;h-CdtKj=D0qgz?q(m}3 zYeAh$lbJX-O?X}91+-*!an9P#4`U}rBN_ViVK^t8-f_2f2 zhLSyq#F(JEZDByn3Z<-d>tO(whw*RBd@l&V651?t)HZzs7}X25q{m;DWgOC+zzwD- z=eL7CvJ+k)rn0m%BH+&G2Vot;IF=^|F*KGQUWu?)YLSJ+C;jogw$XyS$BgOiqMU?0 zW4;CeLK)d>ngL?t_W^5D26FT#qDH+A@5E|~(ib0z!Nd0l148GaX55Vad5q<}91 z4_mSaPcuNRSTVqKg{(lt%u=TlT1j5PR$qTFs|#qCatUKEKLuZnB8;Jn&-2l}s@))@ zSC%bh0ID$Xo2NE88^WwY&XfM>b*nPx+GNTHhj;*;TLOwq8ar7w*~PdBKH5pVh!EIP z5o$jG$qsz&1DIgqK=OYH#|sI%GPbVb-!)}a;_OT{7_F;(T~!$q`Rb1N(sKkw#u>CE zlsy;$tY?0<{IklZb*S=<=M-HTl8tm7%eoCiaA~Cu9S* z&A?64+GckqyzP{cjrgpY%*y3TH}N9=X5D<(1(C0jfp>{CB8=gD&_BpG9HBf4R?H_( z@M0KG035dt1_2S!a*-4-bW+`OHT)r+8y^=34oqqL+Z>PG6QNECGg3t3_h2#_T)KJp znZ$(!3jNBtvgK5jGO00awhqZjmHfw)FTVMZM4qjB_)xibq_9`Mw#e%LAsOR){rTBp zL!gi0U<9;|uljuc#9k%HQ7h}WARo|*tR7IS)#^EWe;QIO74QVU(&*^i*qlU zbpT;)+RHD43yr=|6^V;NF#x#Xo$hM?R7EhOPl3(#%P0Ek76$U>v2cubz1_e<&w3TQ zyB>xuse8omK;2h}#=MbT=Kd+o69%x8F)X2gX*xfr)v+AMsBo~Dp;Mgq;+duf#*8<} zt?3H4fUbD!J%QY~oMgIr+zYZKCI6N9hs@?`iDVBQ8R?r%!09aq7kV znlv=~W0nZAMxBINvEKd+m3jO&4_WCvG^B zp0}USMzoMg^&)f_>JH8glWrqjWq5P%V6JB98ws5vpapx1->(!Q8PB3-5ki3k3UlxA zB@1hJ%f&i0OIv1Rq1cef}PzbhU>&=U9yk`@BO4%^f8r%=OOS=k7uYmv3@0w z^j4fkI1YrxU4GqpOnq0aTu0Cj0th$EAVGcK8IC9mdZ?mnNo6~jhvif(Iz3j#3?pup z8vc;-$dlGGWN_o=Y(78H_8u@J8H)iCcY+va$fDSx&BGDEz3BT&!Uz{34j5Gs=AeU9 zS08&GMJbK#0cd}fp;PCMpZwEvJCOzfz|d8xwEt{&S1bWnV2}8_sg@?~WCVDs7jUN$ zrk5fKh+zMr>lJJg;k)qBywetPB6yjlf(z;3vrH^>)8aTIHc{hZ_W2X6>YYP7ywS7j z9k8FCW!|N zJ>*T2d%e@+)$VhOLK0{7%Is8j2FV;Q-q68y?7JdZ;+nx%~F`;Z|0#Ip|K!5%Q z5CNhAn58Py*>ac<=dwHh`}+>+o*K6g4KkAe{tOLT%c)k`90WGFJ#X?-7%^O$HsdV1 zJbIBBruZ859&W9OhQvliK|uu$`DtQ`lGV@xi?;4E?OqCy-S zcBdQ};lC67jQPrUSE8Ctk{j1eo4;B;GE58hLTQmjj7>Fa7tXj|^4~7OHIAyVvs^ir}6WCW2(EogP zVpzZA0M0wPk5wM3O}Orbe@aNfw-0JBmoA<$mD3j#$%xV(Kb5A#qw)txs*p1%q zuIqsAY4XIVwuSr%Y@uq<=~G!@CI#8KdHpM+R}N0<4olVcb#9UFQ(>XEk}=rnNuiHR zIP*;m6SN3@R?7$V_#5;XOxzK?vc-1s?&ElXa>R>MPUN-|rPe%%*(hs5-Bi7v=-_WC zQiMPcBe@)si*Ot9qjpJ%b>KJBWDz8ai%p6Wm`*4*L-+uTHaqtMo~Z*zHOxOv)4e1- zPZe9f#i~4>_0R(eI3@)LR3NM1js!I75FcZ!foC4n%qER$9OK#Qx)8iAn2+yDTFLSL zW&BR5F6Q03*Nib=Rv*;$TeBQ@4oj7~mWAA{Hd6Y`ntkl>H})9`MXZC_c*yu}xNC~( zs+NdQAd<}=mFNlL6bE(&?;7)4_h~rDBi|~k&a_J!HzD(Lj%yloCJ3_&w(?|1`8USG zG(j2v#UTI+wc95c0(Q*}`V0o3ubxF*6BxGS zWm(M(bitOA1D)w5jGpU*;eTIeLdQ z@mwPt8{Xv2Fz6Fo_FwsOa&ODjw0ywUMm8eoy1h$X-+l9loMQeYnb6jf0d^NwDT`D0 zR|b_(AS+f;@5Qu@gK|2YQn&y$K+3;AR9CE(U-!L3G!KC=eLzS)KBb46rG~gmP?s_q z-!Shqe7RNGN%>P>)%Q-Hd9kAmyiPbB89+u|c2Z)0_gbXVnP*>uLynM{8Bd3GUZN9y zF#scOT|A8wu+xkGnsyKN+ZE8>)5C4>f#JKoOF*g#r)hmY_LxFT=`>xEL3s#i&JO*%}NHvJJF)H;6HqWZKNCR|q&U zCY9RyJy^YH-id%nrz;$STcG+1XT#vs^0VEFlOXqIY=4*Y)#@Mtzl=+R0sIHPcL(3w z9n|V~vbeKYN&E&SZ3r?AhX@OfpW{zrUINNDet1rXd4UecRGbvFI9bYaXQxecH`iR+ zj!zc|_>+o!Ay?uuJs#*C9|3O=hvi1EI2HE(Dc*NNLcG9=#x9sp-I)nF_Pjt;!d?|$ zKA9t{4ow~DZYis)W!k6qbYTT0;N|YUOJ+;-?sw}wH+d3mfDb%qVq^Zs5F~%-PPCuY zTQTBR+gHZpJJeYwzS*1VUse8%oUsj=`{3- zlmRiUknBgajX?w}YMO+7JbD^*z5bsh)CpHzdhEY@E18*13*H#cJy5~-O&%ONe|v2Z-AG) z9tRVo$Vih(O(gkB7RtBC#GIbeN%=LP$vxb8jn{^j116p>X9JgnGnIzHGE;x>$3n3@ z4NW|4xMo2o6>cXD)^6?P0#*kbTm*4#w9pjY)5yz(D`n=Z`kRG-C?(N%Y}&8^JiCD2 zN0J9Laod4asyc23Z5VS0s3l&1x%v?lJsR5y4J@e>isdp}W5i+lG-zcB)~3-!yX7b3 zq}pcoeTGBBJlhN3kYxq(DffdB)-|D$9}AgK_YH}@?fB9a;`x<&IbwZwd|fFIeF*P? z&3RnznR#mnOaIDQ#b0I=;3}26Z&k=OZaR+n*p6D4S-|Xe~DTJq&v&}-FtlU^2F#%xZ~&XL>Jm+P1gbG}Tom!fte^D#VP1*y;#Fh4U~P zsR_EwcaX1_A9vv#p_*x`@jENTqShk^e$r!&=3EgnkxhNm^&47dkz#Q)sDAZ5XS#^E4b0`ul^3v75X%D!Fn)7`f=zxsk@K#GyM1Smg`iIyg$MB zOo5f;7`{Hpy3dbZ;1}jwo!oK$xS&cjC852vP3{3XwE2W@RVrdfFOon5DcN#7*J0e( zYK_^gZq83;<$Jz0x#VA~eUBy9l~#t4LeILQU8>ACdTI7_M(T*&=v1o(@dU@AXOMo* z-j)>@D~ElOQ7MWaHVayTd3ZBOgvk;;JTN1TT*xDyl9ypAA^#r^sKWVlYsvu3Rvyc; z*c+3IcBQ*zewM2b5oA!{*>(&WrGo$GszFf547b&aNi)q@Iz&y>WrfkXjbWjAcnW%l zM{?CGB5$uO!FuW_-v0kja{8aD%lKWnEKq0?1B3oO(jIiupZkP@(ka}E^5 zg02!*Br@ejOx3%2(Wcrp5{}m|2>{KHzsz-)qfB+MIkeu>?uNl?8kqab;1TRqXeefYr5&odQ_o`8jMz1)ln6GYiN*bRo>}vN8Fggzdivcww(B zRZNNQ@sMtTQ`dMD!bTTkTR6~_dyOr1S&YxkjClcG0s#m!Figl?@MzDzU5ZW~Rd@e) zyMv(X8&2K+El;jGqAqQK$s0!1%|#Ynl@|J)E5M?Q)OpD3X#lpJH>IP{XZS1~Gz`@JFUvL5=!e z4WtTaY60K!E8Cm&|we{i(+0w*&yVm*Y^wSglNanD7z5A|tTfk1vEiPbTnH9TB>KavimV;f4OV+uub2 zkHb|Q7KKTf&-3tbS_hvu&1D;$G1m0v+qN!5?fR1*OVX=PRZE0QF34YgFGy=p|H?S2 z#n_p=nukPUEK|Y}kIt|aqFvoUysb_>C~(|2Zk5%LyckyxXFFM&U8vLh(u)Wwqo{ah zcYcsa76CZr+@}<_C*Fr!9?D^lva<7ktt$-YCgB;+wBr?n*`ZPrY<+7!jFBuW7H8mi zp?AhJ;`v1js&i;nWa+o2=F3SRw?8iuLGSay#^d$#00axN*lnqN`;zUxPG8}TriJ|d zAt52x$~wgo?2yt&F+<_UcAKqB!(!YMJ$!noAVWfORNB3Gwe@#Gt_ZV$5mn)6bb5Ju z8HI-<6-8k{f#h06MNk?i7oYR!>O_3U#PHq>*D4K;A2!6*2xv58&?jF-%2SA<$`@9; zwV$Pss@gj^ydsqnDn-S=m&aBbgub-#BZBvSr4$`C$kO?(V0e{LkF5KJk{&65R{7FC zpI1Md&Le6i$=RJsNmt$Wk}nz)x!lA{Ih1_{*>0bc$B7>c2CMt0({Cj4R;oo2MWS8V zVn$@45=l^V=i2il_zM>dj4S$7%fL375BbjV5%~@5yO-EPO=C~Q9j+ciD_b?C_neKW zC2f~X0&+fNQsq{D3tUtf4&t9l88i6-nI@DSwnnJ&Zi{yFBRbx4YfG+_F7%;fy43>j z8#gG4YJkuw1!2=n(c@O))?-)}-a5C|j4PA;#Ge$dfg(S7h5^2<=wK))4u1A!^!P15 z&W{Lf5S^C!e2T_7n4&PYb0d+e#?Yh3?_Ar?(i6jGcl;wG%oUogRz-lZesZGd_3UjR zOcX;4ZpOOg?c|~%Hjcq`ZbAW%)R%uA8-2=@!Hdy0O58ckCTqA>%f9Uw?Z8P$cdvt| zx@>((7-8TA-p<(w)6**kqot4ia?`mcv3F~tI@dE0pnDk{+UlJp7n)Q*13<@XqQrd7 zlpWsPG5e&W*yLF2AHM%(&Fbchj{S@Doa~#$l#W#&kg$|25G2Vuw{LP+IJaeaF9*Z0 zW^oiW+-pY`;_x{!UCLY8M80T7$mu z6u>g!F0h7p#7|T$byQ@wcJKf%P!=!;BveWW)(Y&na+s;i4ceoDkOwipjG z+7Pvnei}MI%_8#SGNsUXVPT<@n85fTTa18U%bvBXNp=qUf89qQPV|ZN+U+@e@b#es zZ1wF@l<`_ahRStL%Rq9`U1%-B|J8NwsB(8FcM4;FoK6xv-(mk{==1fe{Hz5wlujlu zC1EMx0z@_kIX2Z!PgD46R|W4fx=nwz{NT#rHb%G5yW{S<-l}5N48kY<($%TSNC-Sk zdP|}PQ+QcX@(}E1qvxy#nBiIHBRA?U+LXYMmz?+_tvAGn!oLqW9 z1meAEj%p~2$S@hNp5k*>&BKnFRGmSl1Gsc|)+5f{I=)w! zSg_~1kE9IdJtGPWuyrb8;3s3{C*Y`H0nn8`;6uQ|Spz|!r zIr9FkR@b}CBPTD=Eso!X<1XcR&sy^&LB*1|%ap$~phaKN=JP+p!mC5g4rU{K`@zs( zh{o)p-AT#fO`Uk!Z@iPu)@)XoFMjIvuAce^iRExazjMt52Xvl1;E<;%Dp9WyRaw1B z_-hc-j?=ZwM#VX}VJ+kEsynGp*r-0J%QyVUsbXN`IrB7-2UHv{+bu}HrAdg2ytY#s z5c%T_{y;=JNBJLCTC+wCGy~p}Q2u5hxh5NZIWkz5SG39##KgEXtlB?=i~V#?``@ik9yay-Pr083x_zvE^D zwf+vePBSLuib+n&;7UZKghr^Q=ZZ9*Q9LsXo1kd3Ybjp+VG-kLfK;dEcH zUTL_XeI)%}0EV5({sx)X3~rY^v#yGc1ig4+j)(NBrh0l!wPNC>_agl}j&G-Fl19PA zrO1Wj8wyj=J?KYhEOORK6nZd6QR-fEy^)`F@S+W(YI|^9yTFGHrqFS9CZ<6h1n|~A zfA!;?Na+AvJ#ivy~AVEFta1x4CRQ$gA50-Wsy%`#I8em!@5kF z@@WBy(Q=a*`%Ei{c1;;M@ZW`?BB6cqqlMO7w)FJi)#SqH7j^^zADKNWthnX4agEK9FEpYtjEHL+ zoA1TuOQt!>)x8e}dqv4|G*c)0cMs;7fQKdI_z50NcilOS{*g{KmnMKoELz9qWVcD? zqzcbp@(V9D(>$t#hqS-?;iIFq5_EF=-w;uaH`{OkdV`(Hf|K;fKHCBdRD*GAmMD_N z;5X&~Ls0Ip3pL52$eJ%0Uog+RxnZ4+iKfe`2$m |rXzzM;QWpaV#7KSUs^!F6lV zTV>Ouu>dU-`yiI>&O#tD?J8_Ppodxs27OZ}=^8aR;tU}(Lp_Za&_71XpecrX!M5UI zT@YWTc1y;{>)wNtPCTh%9pLElqfvqW^(1q!e$!SYj#iaYT`u$W@{;GgT>Imo&Gtj* z_Rl-rb>6*(gRhWrXG_n27aXkNzsj=g-QX}wWFi03{b5pgaR_s!q~`boI-2HU9Lj;gX)4b}&}>lVal72%^=`rU4#b1mBtlQkW5McrLhe?OC+IRKfiHOEr# z83YiK3rjb4+C37Jit1ZvNbqMANog<%%n~QTqFM6u^jWV3S*yfR47Icb6PLN^&OXUofh1E7$5(2bi*<7@a9FTj3Ne)=F#xO6cN$9f1lTNZxRCQfS z(CE%}PFC;@ap>j5=xEQnS}d8+TgGPFc85;e_DAv02rjl+;i!`!H089de}fFMK|vwNFB59)7Tjt`OH`SH$mFBWTbK{wNp~2^x(V zhD~zYW`?g)4_A)%$jcQea4}K)_pl%ocg4hL0oHShkqM@K+~x& zuayRjsoJ<$5CnwkSoooq*)5q@L^g~{8u%6O_q$LqXv9AWbLG#DTBTRS(a}7+J~t0> zxgIJyn}O!p1tRSurfZQ|F@t#GMnLhomANzjw{+;%_v&f~n7@7MR#*L8F_ z4MGx9sIv-+NeR`@HFc?_ge~N3q_##$-9!)2@J;ICQge?LTUENO9{%Z;WILf2-pD^7 z0Vxz-mUNIb?eeO3g?{2w@f9gs+jiYdc$H-;Rt~w;Wy50Ug-R@DckNExfaEMiNB{Q+MF-EY!i1x)78OUs6LT(KFbJ^njkfDj zPkItqwoafPtsqR8Eim_8S&fCZHlO-=U~dAd|7L*b+YTg)6h>|~c#Ol4@hQrk`AOo0 z(2&s&G}+Zh?pA}5pzlv*TY)8{`q;AX9!4WoJY8IREGw4*6wbY3bcpQlk9j`SA?Zvz zA>*0JdxM^)7C3^cT&1Tf^F~spfBQE$2lnAW<2F}=4CzKg8drxD?TD#hBw6%o)`}ru zIGvD~r+IsA^NMD=NB)yV{%uO*#%f1M%^x=Og=PAdopaQ?qF!$dCABocm%jIjz?Fe# zWsRF=e*y=P;w!wi2s)eHPU-U8P5}`NX`^b)hgmFqdocwkY+v!9{L-##KD;x${p&WB zqphtd)Zf|Y2Ona|gH>VG|3XRID!<@S0kPYndA&x7ugjb@Z# zQ8G`wEu)hFJ#}43RIql3sT+lFVIlB;ZLQ{~cM{2}*i^9u-2(*kJmXtW`U9}Q`*fkV zpR$giC$x%Tbf6t7s`w>lOyhGt!1ZNMnbcBEpsZCtf?IEo1*OXU)OJKE$V(T7;61BDkQ^k z27Zz3jgUXww^i?xU%kaA-_}89pwkGn6l_Iwdt6v6hZnUlCJY%7Ef05JXzDdz+C!%b ziafj9E{*t#Mni5<-K1A;Em2&~1^n6_IK*?6lc(mvN@uC!5H3R6B8*NxdOX4hCy~E? zqs|F&CCcP?MonX%!H%947ewz_&t82?-!$U!gL-`NgZV?AYk~IGi5t!Z{9ufkPoTB(J{M&?ggR5W zaR`nkgI9_OIf7Hw=(H{DBMl36>_b24`;B;bqua78tp18$<^Ea4)|ezG;eNRI zvXO1&3WoK3hcXQhzIZseyC70sNrFC+CC7!l{sBsAKQ7enIYme#>9Z2wE*`M`lA~ib zirdq7oE^J5NYz)9Olp9xZ_=&hZJwwQzNPiWDKjM6y^1@x_!%hkulZG*p)G@x(T?!H5w&76Z*f zvJldUJT{u!)#eb`$WayMudfp$w40Ij;pQP)WeDLErRcO1 zu0=_=OE96#X?S0`OHCzjutj9nR(sQ_*>X%j23QQ1|5Np04`K9J;+vk zU$yD_r_j@R4U0%FCG$N|WS+DQla&KFgA099v$r8g<7kG|LknvNad{<8qR-DEw#8L~ zclEqrpxH(p|BN_bh}Xql6&vj{)B(VUC0Gm8-{-$f$18f6)0RG@IyNxuJ||V{L?^!k zxx?a6vTWe*xU2`}9E<%Bi0&8MQaRXG{9i)PV5B@cUN(iGQ(gqOD?GP*9*u@ASa4oQ zJt-1d9jLFObVyG}C@xR?_>lMhFo~hjLe3I#mdvc8witGXO6>b&@)SA>^jHvl{635Y zQPPZxSbF{}wN&+?1VDcz5H3>Iy$V!Tn=qmM{R!#mMPxO=+r=uxjS#LxHCc^8RntVZOA#?I{axq?s~C1wZ#DNG zZsB5~2KTRsGA#dFl`e~eqKwT{3nhb~mTN!WoWu-5J#IXCk`P?VM*9&okv@gDuIDHQVF48DrrKiw`q z)s$R#;X^{Zk(`=g>_|s93%MKH>-e(|8NnLkt(>3*4qrT#6d`<}B!V7o^~?ZiAI|_R ztP&l(OKBWt>nkB^l1kRfO@$Rg$v%i`-s7u{~9xs+y9C9h_2YO<{aEo;*fs0Tdh(*N+qIYQ`$m-Q7WV4PAcTS03CEM)aL zW(q7UwiheKP(N$*Xh&v~E^nfpgLEKcX}2@aYuLU0ZSYlS0sueprB}bA$n?%zBK-9X zGcbGTWkF-MPpJpioNa?9jFT*x)1JNu{AYb=S8VJTC>U`76^PS9sEx~TI9>nl)rsLQ zE_cKq-?)#9=~8exV9xWeR!d-v^--3{o`~zSL0?xv*QxU0KMt%QsUC%d^T_%68(9+k zsVFF2fc*(ZfnnV{cdpY3w6go80&qse@bR(n?k)V`X4fD_-GKN&Ur6{we{}8Cd|$CL zt)&@eV(_HIP!_&^_T;p7H*K6saKr1 zB>hxK_nq*)#}@Y^NdkN?b*5q|kPIA`83x|zw60it76&(%@ zIFPlI>TMnw>k+#}aq}0V3=mX}Hk17

>uB5m0Egdzt|5x8JL5p-F+hG&)<6Scxs z@G~~4=>BH@HpHrEhkq99zv`grk@{9eqX0yuq(z0WIJNjiOY!MOI;&kpfg5V+kwco6 z7^)7MdGuJbmx&;KN(b~d7wWw;3NV(eRwrapN0i!u zE=?OUhQm)Bvylc(>BG3?suSCMz@{A6sO)>-ZH(pyIDGj9%mpuVb z@5aBszdf_0rR8iRt`#9cUr+ZPI7Jr$I+|iOyT{j!hT*|E;8s`E2zlgI%S>7NI`|^1 zEKriDA^iyvtQWwPNElUC1Uy;jATF(Xko>NY#<`-PGS7Z+Dp#KXBv?6RA3)LS-?M9Z zh_G@8ti!))YE#^zjyxa3_$_$V9uwCJwzmEs1gMZev(7>$yruRiWX$hsI95qq|o@ zHdb9d^O262Tj-NZQeT`I;cR%zxuUStU)FS-JtDh3xrAaiL*tsH8!o!U!*%g8v|tR0CnK-Q78wB!9{iaB&_IY zUzN;e3pS+{Jib$6ai$qh)*{!8rw6|%*!rv^>QGzth`6~f0FUzBda?il)nFdYIDm7_ zD2f?%bxXlO2)udX{Lz%RwbyYcqu7-X#7>tMqIK7Z@Ehm>{8ZA?*pabq{O2&TX!Y$9 zb3A0gl_D7c9uHC5yWrd|g{@A~cw#Uxh+T2H?3jiJ8uu-5?KXQO{MhDcAPf~1_2Lt( z#Bckj!>1B)_eTEki}TCNZCA;=EB7*%h@IXV_^<7kh5R#nS1N1v_iTP3-w-lmquA@Z z{uKkQ&!@#V!J!pERCm|O&j8&^fw(iUcKA8m3e1oYgir#}l4gzKxigJJXA|6c3Y|fp2 zqr0mD~)$KU4S>TT&j;jRCPZbmend-+}Du#?q0C;Onfi1PUXL112y^Dv zK(}TnaEu{K%t&#*XyAguA03$-dN?&&p(XVN6S@%Z6NGO`-^Bq|9aV>S&<}_BLHmRc z>1Yl_gY_z#XoR+ zUQ7SwtcQ|7M2&IJ?Vo@?Ws@Bft>vG(Ns&A5t!K?<##PMP*IbqET`F>Jw}B47K$0k9 zP7LFVO6e?CZFCE~l%f|~1V@))ZVvCFCF#rb zh?vC{aGVtqf{m!mpjP;h9yFPHq1`q1I?cs@1|xk_cj;K*%}{|0XiXi6U8B9oblA)^i0h+%5SaF>Rc; zDPPgM;P6Q+TYpq=+eLMb+DJxz(g#y5M|KCTlp7?JPbwc0IP9u^0$gS8rjLSKXb}rW zVx{xYOA4IoIRz!yS;p|z2@sHxGJC{>+K&i-#tod3{&Pv4*bqI&3_ojO$C_#(@aSmB zAQ>cxk>e|G8Gm{5p*TvM<7%@H)Aoi&&M7v%3GcfD5$Ls`WOn((77%9ri5gZGVf8{HyUmerwnD4W2R*`ty)HORIvB!R9mHtvht>5|;m zrB=u<`qj+kni=~g4m5b|uBoW?m{=S?SV?GgTC2?eCkz>;9ct+tK|>;Jh@%m-%#yA1 zp{VOxSORtQ(lFGlpD1dLt*q1Z9`Wk0CuraA4I|du+xpOjAp%7l%rv>%(dI1E5nRRR zcOuos-ccHo%QSz05|5-rK=UdOSG%0`W;0%6wv0B!1gmAKX3s|D<3dsu3_9$u-}d&FIX?J)`2hgbcN5(1CrDZ;)BkUq%}=gG zGAOuSo+%JR3f(Vm?c2$hs8@O^3d^Stj3^rs#0(fSj)14>6w&d@js|F~Dwud9sY1CN zC^FG=pO253wkR#yu1E8L9osKs+5@+ns+Q0Z=d%XPmgvb2m{}aRrT`*)@?kMYtSTAN zR(O1zbpy;@(T(GIb#@6)W93fjf{D1-(|HvLV=e)x;0+eq!<|Dkbfz4lp)Xb4FuS`q zE1lw@tM1OPgvV&NmwiR@NBP|Mu|UoFf9r$k?{@*^llBy|-0(@Vj~03Xhx-XZP@W_H z+0!j#9z+wP1Xg>Jl9pdcJSWTyn|3ssNFBW;8bXuUA>N0y1l|he_E-~)j@XYSj=Pko zL;*&U%ILtT(nXz%v*5)~;6JE95oY;t#pjA2RCoPtf#^s2B2@h(yM6Z{SG)cBxSdP& zTgatjZRSJ#A_^Dh^9Qpu#fRna>>Me^)tz#uD!#&gD>jfhQ0ADnAQ_l`s?t3|aJ9+{ zMhWd14{l#d*|bKEI!ObV-2bMQbH33?OVXBHvA}C$ESiSCt zD@5$JSA1ec7$any<*`;vtB>{v0y^dS6`oz98wpbk<0SitYp&!`%muHVlF19*H)J$< zB_*!prfuDHhd219SM!r$-Da>B>nN}omn*EN;bg4cMPoXsaAcuF2Bu$SJ;l>e&s&a! z@rUYU?=wWkvyOHsMX4r>kw*-fIkkKmo*?aX;C|?PE2b7W$c2-?l;_7fzcVY1oL(1F zpY-L!{!eOF58fPpRH2eVi zb_c++vPhar>+XM4J%LjWKzfa-TvCKzrpPdf73O^-p~@WH1oWJotEGo5g$zhZrwrP% z*%ZS3V^38}%Mlu)I5OaMS>TROLNjRu2t?Q{Iq_faTDR8EQdmq^`e-sbC}Ue<(575D z9r!?lwTdUmq*zN?Pmi{a&5|A@^Sa)kgnh!v_*sdPOSm4r?q?lR=d0nMf_17tbG=Sv zFX;*3#lEd|RuoI4xf*}cG$dkHb=eCplcA|OtWyrXZb595%)m;7Eq1jphiWvay_+s9 zi7cvwI^-aM>HMs*Z2me;s%4-5kcX!La4sQOWLsp=||6#RoSO zBM~8Y!cL|W5o27#%;G!N0Bh%B39c7Pl~CJJN|gd4qornZA$PlVlXR-iB#aw%Fm0s~ z*Mn%VmO27(mPb#5MsqkxE}((o9qWEj1uhe)q$7jp+QF`7(x9ti=;pO9oi8V_J&asP zw+A*;Qk)Q)?Zy;?{Rf~>c_dK1&D zUcy|FPiaEl4$sPxz;~DVkwRHuVOPSg`MNq4TS0=dmD}J{GR{M3&T^AwkffPnp)|)qLffQ}4w-*fU1&)Kf$r&!&?rHO59||M=qw^k;AK2u`1w_yZZtdU2>gP$ z6L0Ek>dGH)>A3zM!NW@~^fsKuAHtJn4WQMaJd*CizKOmFekB7U)XIc+PIpH1KGJT?Ye$UF+}C|RV>%j_g&!y z;@vQSWvS1aac$}Q^~Jf(3$%Wlv}s_G4HXj%{6s1RZ-wA!H@AKKU~uqUY?btu#pi;Q zVgUJ{q8w1Nqh2w-%beuunD{?w1d|H}6|;sN}3cZjY@?L|@BFQA>(JiL>v{R7NP}dzk+MtcH6s7+t?P)1V9*rk zNrkFN7784GUMJykReJGMu~61oRM_N-^_j9tND#FK^;OVx_lvNy*QOgS}tL<;WLEJgly^;zH0IX>q}G9@ILl_KUe`ePZaQ zv_KGGmbrkfRMMU~kZydi(zRRW%7ul2uvsU&24R&+en*(7;dOo6H{#kf8jw1xNyE>z zby{1C_LG#oU#(KD)~&E?0quJ>@{x5J^iMTYdOE=P?58B-c0d1mToA5Dsm|4 zSJB`Ju>(*sjn=}q6k<^E<*AIUu@1kWNZ2Gvdn*JEr#w8wm1qSYFzq&uSW?zDW#Zr~ z;{kd@rAVjPYDhU0%Dyl-P5E+sMHTfy)@7h1K4(C461bAvv zk+q{Sd(v>v#bD<|CBjd+>!c2`TUBl&N_DI%H_%YV%$Y0;XNc3&G9%8q(b**B)9#EAQ_CrRN>}L1I5rOmv;Z)N>r_pDs`ehk(AO0DT=`#wg(4SA%@pLEk>V zzWVSO<1}<1c0`NPAL*HEq6gciTPgUy7Q;>sq=~+Y$)FfOn(S~p-t1!$aLSNJ2}MX# zGmfn9!KpTuUaA=^kBr~>K+uGm_RomO`!sMup9h5jV*ouFmP(} z$PUdC*S(|LBiYqY3Vc=8=ZQ6p#KT+y&}I3#>FldvVuDEAO9iaS-Ha=s9uLS}TuJ>Z zJX$i7IqrM%<@}Njf%aiKMY~A_Ez&&tWbWb_N4XBUm8IpIbkLt!GBVE`$2L4}7{R~z;xNGdvYcwGMkV_5%NVQlb4$-dVpV&#S->XLe&_<` z(UH^q|**?*n868>4 zYrPT*CKQykFvq%(%54F41DmB(pu64eF}dYciwCK5wO9|GOP4nQLa9S+Nf`>I+DMGJ z`fn0=U6uXoTf6l7;&g`dWhUMuR)=0*GdKB-kLK@R(@d5&^x7#;eLQw9@GUK90H`m1 ze>C`C1)mN=(chgzP@=>=vRBsj2N;>Q<`Aqjt`^Ck&CRPx|JeZhb#!|^Y)pP}^P3z} zSPSxdy!!`(opbYM$UO%QkAKk$qNZ?+Ss05p-~xnS74SLrHk=4OO|}?l!cHM^vsNkL zNVVA(86a5D+Jx|P4N|dC$(&gO!oY{&`GOth5ISGt#PPz2&Wt?<@>@~R^MhGo)K2%b z(y?Cd5erUn>9cGyw@Z zID7x(l3V5#(CQw?*cEF};;J}XPB zb*w&FzD(kgb|X~mT)PG#IM)p>hIE@b>r8~29<@zD|5}|%JrH#F#d4%W2^7%RRL4Ks z;3m~6_F}=C-pC5sZI}FY(L3^+P#J^XaII(iC85;_$F#o>jlEl282-B)X`>Gv5GZly zXB`G$K<4UrU;6R9a8D`nd?scWBwBccS9HN*OrPIjF-bocg1AKB)=;72hk=~G8N({& zH3?7twf=>~*qNxeYg%F9RIoxlR#ZY@vEq=^7L}9}(NAjrO?Oek6|SIg%wgSvAMQR& zg^R}+7^rz*S#KBMS2zUmChIPim5Hrpts`ZTYDzlGDYMf&)Y40{rV%+rtLw=FJfyHi z;H^9TFsC$aO5m4w=y*F;CWfez5QfSPtf^fr;U|{x@Ld;GB<@(mU#{OtA5UQcK<_j( zTxi%Nc;raJ=Cx9xT0FuzZH4aYkMN&y>*~Zr=GECDi)Ddp^SL8)Jx=F6dxU(6J0-{* z>gC7N>F)ujHrs9%RAlbxeXjB`p>)GN9yKV>71#Pon*-@tz}IECNm-jwXl*gBNVopA z7!(_`!O%p%K=2uuMMy{ipz~VObAhwVM*#$xf-o3d1y;sjj&3`HR-67Kb;D68|Ih{w z2W-`_)Q=v< z*i&Ki_`gpj@mG3CpIw&Ka)su%;6zqfJmRxfi*NWKZm z>`)1_oUiPPeT|Gg_bKjn)T(1?b150=j;%EuR0hoTZy1-$=a=ZX0{+=!kH^$1)@^4Q z>uo960R^a9G9_3=G*Pt?psRPI$^EcEyzc4G#5k4D+AepkgAT9!XvHRJjyGG+gQtG# z5b$QjUJdqDh^neRe`VnP%QwExJ)nu!|~;fApX6AbknvhFPl}@F8{o zr>G{~aX1tQ=gO8#3AWOmRR~|H_&7-F2CK%VgzyKxTR?jUPuP1Dxw0r8#_2CRU~M0UFx`VL^9A z-N{H*!KPf3XANHtjs2YxCQF{0v_Lun6Fb=yzkx(4(B};R5W`7PodxseB{LHJsS}p8 zMBv;YBj&GxOd;^LU3=)5u#=K~quHZT*i+xja2?5yp!WUKqnmiUW>o$8?^HKDi2cWz zQ7*ExJ=FzxK{%@CcbvCu#ZV_Hk$; zf)wJx!@;}i|LW5D_viFQ*-5rq=iNM~WS`ybdMh|`8h^=L5;XcYBpbB@3sWn_2A1Y{ zQQ&0R*zoR+##d~&^=2oVXrG$Fs3$~<^$DC0LSHcrLJI{T8s~V*jLIwVI`nOcMH(9? zMESRUsJi&+i>LevV2l(c6JME{UhN|CHtiiS2h6ROTqSmnkn;fD-lBon1et3+Po^vY z;0SRP9|=yuvMRsk&s}ygL=U)yR~vbI)&qW+ppNfs9`tRnr|1YTvs}x|?$FU9X@zHn zp9#!976_JLA~IM`x{8do9eOQ@O3RA|(|>&Vo^;+vD%Fwt0t^^l1s^(2)e3kML`WA} z((mI$^POFqy{Ka*gzB%?+S;MrGays<_^6sz;cu{p<<Ys^OI`nQH}PsosZmhkJQ zc>}=4s->RVED4G}9nl4f(wkK%m#0aM? zAe+!@NG-~l-+mRlKO9^mf3wJ8~XN`6af2iCb>V%s<_RL=HcF+MG>O!}ml^kQ0w6~PIwU~h*(Vd=& z7u!HE^JJw4jF3&y{pa>Pp*+i{2foxyrx$rJk3CJopk5a95TxtNPkopc$(NsHLQ#dq zVHUS$`4?N`NF}La&0=1xN^N>AHS*Ll`^v>V1z2Zva8|q)NQxO{z)SRfXka9q0xrv> ztl>8ndMLeLJ+FKBbPHiGw}JMQOb$$)NaK}GNe-%=R%cwuqaiGdgn90!-)C)gT9hk0r3Wlm z+jU^Uha_BtAhSQD2*G$8cwiHZ1Ua<9aiEeH~Bk3Y|6-xfT<*oT9`7eh6 zPq<>47BntSn2t1bK)xJydeQtvZ2L0%lN!XfadkRQWa?i;ZS{bwL3yA zIRGyc{*VAb)qWx-07h&n5Ck*^=pnbLfk~Dy?7>Q<7N#O$pe?u89YVQDGBwJQh~H|e zja8Sfz#aceu}jR`EJ#aHHUd_bSY`(Xo}=Hb=n-!~4hy(k9+zc5R}`6sX`CdJ6b6WU zrS541qn=C5aH02E7?=|Ftg{`AZB^`_Ho77gFEw+ysu_#j8x-9V_8u;{GhyUF8ai5~ zi9TFZu8brMcEWctpD6{I=MCXx5#BiB=g~T~U!pWj)OL@tk?HbuDsV}Sb{)>>s5f!W z1+8#)nRRAmc>VDYVlr}T1X}@!sF?*CV)!?@$v(gIWZobG*^jh#Sq*Qvn9&ogtH^+; z$a|DYb^Ox!*9|$IQFwKuxNMceJw!n*42p1wty-qxKTJVUGg=g@b_(e0{BbfT1MY7j zfFxxPB*QT|K?0c?ol(q&*S|V{#?i6_Q{at*ooyNhNN4+EadGP=Oq9#^T_$leiqkCw zg*~krpST=%JR@^J^bt@LC{AK>YU!ep_?mm+L*5`mP^t;h8d>pNGZcABS}7<`zbw=|M%amm_&)p^i&Mx!rY&fb>2x0(Bf(#LC5?^{a$F| zln6)2G)aAfILf5Zu-XikHFi6Z(UEqf4>zt7bgg{w$VrIIK*VD(ZU((y zooD|0T}UClphFbl)vK9?#pmH5?@ufT$p=4IPVl8W6Fo5m{nu>RQTUym`d*U#hA|lx ztE-X!WO}LA3b-5lCR7xwp1n2!l!tRhH-PJ9j475>^@9|s27}5L6lq#6EPNkAwRZzavdHf1ol7bP4$NwZVv+9= z;aQA~BN1S2TG`f;D5nRtSPwH4V;-kT{G5s*mpiKD#$(WgJX6`*#cZ zmg2+Ig|i|AOpSsduB%>PxXZBJ-9G=M$otZuv-!Ceb1?Bzo+hnOAsb{T1-3-?zR=l7 zO@J&_(RL=V5y0GrtPnmrB<~0hut<_}WhFg_{utuEyzI)<5shNjtkN01>ImmN-w!$Q zS#nq)L*eug0Y9+YyAQ2GL6DV5(wY>5xC;UMTY2}wCz zmW?kHt>Qwo7gfk9a&HqG_K$8~S&&!zMF>LY;8!a}2Nt8Q80`wd=Zf_eD2xF-jXQxv zaHs~M-Jm`_GV!R8QrN>y7jCglfxr6)Q8k{L8S$M3d-W3;4p-!U^u>!Butw7a0Sx|v zoT*cE{Q5rem=1ndTun~j_OKt0bo7F91G4LePDc&*VNO7*^|_1kD^zYDgDVlKBo+1V z{wHgo5J%+zWG(Du+Gmi28Q~=xBJLNxki;@RvSB;wKo_~%{=mlgocc~GGrM2nFoimf zzJv<`2(eWRWpgX^-=X2Ja$CF8BQu186K2(l#9niaRy((Me4afmBvVa7n3*#dAK^rC z#&%A!2I#0Q_LYPOwUIf5^=aMv+YM9uHcPsB*2S42wzsHv@$a^CJY1Ln$u2&X zTdyFjka!BU zZvQsQag1li3S05g2%CgQ0gB5&Fg$R@n9_;-8nS zib)O18`xK432)1s2{OJ-{t*Iqn1KChhsJSSl~KH2Q|Hi$Y%wVL4I&6;1^g^Q5oFa%J-X42*wznr+v(rtCI<`}d+Vk`7({rA3K-sXL`A zuywbaEQ`T2ZV?mJncE?DC$9=R?%;t`x;2baD$W#Q$h{0!#icv-DJ^>{GLq}N9?I^9 z?|e2~9XcK5O{P0ZU6pR174p-aBuG{2D5taj1}AMygtigc`=Cjk83+yvoy^!TRlC88 zK=bReGE(-&jP~{dJ_(leHtU$#cVzqz)C2+Vyf1l48B;tZTA_%V#7Fc&y<4}}v%um6 zausBNf%0beZAzEqGpi*?koVqnpyHJnPq>RSxzL2XEEN<#poFpISL{n z534zL)ZQ5qhoXU1QB0M9A%z=Pj+urlydT-)#5z_-kJ(+{H7DfDF_bZTq^QZ*Hq3hwozr7LRSjLw-$DjfW%&z(fe;cP>)d5k25VwxQ;pCmdWQ<)ODy_Ry5h)JBawRuPwr+}Sx>nW6!l-{* zZ*zgvxp~6QAd}!^2AzrgtL9l|$6>z0S|#Y&6JB-2#HY-#-T;A8{iX-hyA*Wo6;;Lt zDqs;6&~1|{PmFU^W9sU{uFp8DIAXQ3@sh3QRpF3@B+CW|U*lS;>;AiWKjSx5;MO6J zw52DOu5t2}ol*Zssm4K*P%X1n!m~A%ODVDAE>ZaFwpuhTg``!iDq(`=lmeFVs3tFK zQ3o&Z=xwjH`1gPzE;lS?@pmSif?T0;p^UYHC<)zkoBj3VPoKQ%Bnd;tT{h-9jYI5X z(7iZE`??eRFY_4;SAWg*y}=P&zWdr>)Tlj+gKdf|3v+qUsWF{;x!8lKP`G8TcmTt> z$!Z5B;O_bdRrZMQSzEheXVsoa0z2|tABCdNY2j`+#$OpurdCi=dt)ctRy_NwNxUz< zMMQy-Vn7<<<*Wg^UA`E?QW~{|4Gk0#PBQ*LK^&*q zG82GpiCTSVB^Q7plq}2{1^P$Y<8W_V*T%IkNmlwxwe(tkf09^=cl% zpVM3+t2<@~yFOblSt719M2K2YC#baO&^X@#2M_y3>j#~{Z4FR|AQm(T{yHb-x~R-` zlW+kRPs&k?D#qz0xtGN#pSg95-^dc=fGoF99i}nD(CX1Z-eAMq^5mb9+FxTQ|Ll&m z4L-vxQ1c9Rtu;tomo(8r%E|9ns5-icGqKc@JSBDd`9dt~z~zwm&o|w;{44Y+St=Rv zUOqcSfW6xoQgG3QFuDKrtcyB&=On7SURlHeMh;qCb_>Ak zDm>>Gv&^;Wb7i!+v`{MfTU&{hITv-eg+80$a~+=lYaRs1E}Br8i#Ue!(i-O!AqBKl zgtV>QcecXw!_bsy%{$0NuHJXjs9KHNl$mN=j9E-Ek@&U-7;2j!!Qt1>%w)RbK~&9z zP2R@S=!#LuQ&u0TNxl!Cp41hWsh-Z2Y=*g#xGead;So7Pqp$p6fz}5gR~BOKHl~en z$&X^)(ADEP@#YyQDiWqie4!`fZyHuKjmh6W9jk|J84|rrcLox)Rw(EsNdgweBI{~O_A&bfH?I7CuxQ* z|HQXB|M-?=d~KqSsZ8;93-+23lbD#zE7V;(qEbX5-SkK+eF7Y6g z1#c34r5{|e<}INsse9OXwMj#LoD#HPNeDzqEbZiaZii5}{r?3eqImvAxQ`B=G8O+#Fl*pu~~xo{!d ziYnBqG}sU^1fM`8L2X_)_LL$#7IEC6$se&Q*PK$p*#5#%r*HV z^-x=3bCfiQ@`-<+=HWQjPA-gkMjfl|0qrzq1i{?;y0OxqvguZufPIIyZYS?OLYz4> zlrqlmr`N4*ydoXuu;R#$b0^b{w%wTnh`SznWlB)vb< zh0LxT8RH#(Xhd8-A2iY?(av7}S-c)=`?JIZjcDzb`+Hksy*_vp!s>45zb2{p%)z8V zYQ%z87AZOwP~+z&qArIuika7 z>m`HJx`p<3KGj0x3H3$+$vXMH8!mx_?)mb83&j*S>``JC{vT$f%&f6JioRs=q~@IW zqXK>~VF=*k)KdG6h+#MropF_Ts%?S$X>L}RXIB3iQYA3QF>fW{r-Qew)cV2O?%-zK z(Tb8nl-vnNVF5OfL+>!gQh?QER=Ckh+juHQSdPxa=<7O`}o&= zaTV?N+p`w0r8Hh?K_!3aF=W*nbw!k|LzP(Inh)+A1}QL4#hTNh<39U{Dxi-k03v!| zAO-UcGMv=LyqyNwYgG%%kd_=BAn{()ZK*)s7<@iKY=`tL?ioS9!RL{sXJ_(M3@Dz- z>cx6`&71;*AXPE!+0cU%9I!B7l3kpAD$NyYCny#kEMi6)OQJrv*QR^V+P##JO}YAh zEAHfm_4^Av&T)7&@^x=%;`t}Q7oK?QqyWZ-zuc)dxn@_nyDCRks#JSODPdbcF09?J z0BIUitkB9R_s~k43R&=^UG6-yd_zZn{&J%V{ngC=EG^;(Q-D9@)TWdxc22S+LH72RQ_0 z+r`A;n@Qy&US(>tMI(lNrk{>R+AC5%q;B$*Rw(@W!3BIAaoEPv7Rw)}oBp<>v@uSt z(>YNxCnW?Mz?<*>N-CQ(!aPPFnb?+PkAg44;0!{L=FrWGYsAee9@IHE$h-HWG6?r``Vs>VT*n(a$!Sok{W}zSGzjG~3jOeuQzW%kEo}AjGf!uqNgle?|#L6Aev` zT$Xj_!%-1cYIs7@wJY&v|j!e*=Y0)!n=#pp_6IsVkveQK{Vz1NJ=j zW>+D8epxf7Yr}R8zm0!`Re9AfJZ(K@PSR{Ci zwu)^Jq|@>MI8+5ENbQ^+Mk}e6&2*$fErk13PrYxwt~!a0*0FlbtpASP4nOC!nF6K4 zCAKRc%jj}1s*m#63Ti{=sNP77%&J|BCL&V%^cl=QGqVz|)8W46IrTrO9j!lU ztJ2_>#SYZdxQj*%n!bh+0F8lsYzZGZPv#rONW=Z4kf!WW!+L@t5;^0o8AC&h!mugg zXSaH2S5?$KmK(*aeTIi@BjHRB>Tp};VDwQ+&}pDN)&4EM^+)w)tB@z*V}%GSY?lR) z|5H(*!8xHuypk6&r%y{l+~?ti@!JA~EOWy2rkEU#=}mK@&@^nq5m%Vs%rc}45>TEo z53ZYrV_}hX*8$STT!U|O+A(pGE^+V&u%L_IY>V-$lATpgxJ?t}zAV?5Agdk-2oH1U zWIFfPhe7977Bf3uYfdX(|H>=BFenk1^dzIxkbZjM(vI?@$tfkAq-=+P86tjxNiSg5-R!B} z)}g9cJY<`#5QrddI~nNoe|$+&NlRoCL}EfBT_7vKH^KDeAVI(`8nA$^-Kz-6;`1bm zFq1k1W+hl?Z&wMo^ZZ8Q*#iP%-%|P&bpntvK2)wpZ}|jtnwov@-gu2hEC|=0a>{H1 zTW+GjyH*mL_*Ej{IL3{x96(mYL?=NA5 ztM}-UM8ws1=)vpT36Rau;VJ%sOHo6Af$a=f!YkKdqD|x(N$haH@Y)H`F|;&t`=)E{ zT%dW}nZDcyxu%bE#ir}u{2G_XgQJY`+F_6x1%?8k9c)JQz5XlI;iC7dN?_-W;F2oi z8B<5&Y=u=m3XPqXpJ2tdq1axa!RsqXlyy0Z2Za_m(Mbm?mw%LByGtY{?mG|&H0+MY z*GsZx-e~JVU`fz?oMJ zkSfUP9#aZEsdaW-b{WOAe@>0cO#T#ro%Wj9tPwE%2>2hI6J-P>_;}fk~E>hiL*s1n*!sLcacJxTXIZOXTI zo28r3q-^&Q98Wg3Wm6lOL#jG@&YD}-#wY+G?36ggbd`9p$j()a%4k;48iTIj)6YOB zgQ8a#!7-62Tjic981LYt7k;epl#ZR3&R4C-l0?rM-Ep*)*2{~p={D&g_wxa*1zMe* zn8gFFXP@#thfz<`fWgIV89l!B#Aus<;cvnN5H4}O#-$*MS5|Bodb;)x+GtU0Gs>s$ zhZ6VsJ#({DiPs*)oO>*V^uy!4c^C=!8Fb0s&2w4j<@M4;hCs>OK=0hAz1h{Mym;9A z5kFV=OX^fN9lB-HVttF9+w^-xoQn??4GbgWQsU7P)88lTiZ7Ru#-2NzYkG3L?{*~H zz?C^h_Q@24gvRt){^0=0X3pYqQnmZJ*>r}e>rv8xB6S9aKaY!YiSXO84tKDX_=FBH zKlBw=t3Mu7%%4!_!{ML-Mc->XnIGW>5Yw&EPWG@?DHhsszxCQ_(6>eE^-6?BSbb|% zsZmvll~;XTaEaP#!o6o@$`=hYc# z`=Ve0zf`VxiLZ!S6`3DDLQXl-3k1yuseb2U6C}cry!eWURl&lIQVV-0gQjh6aR%?RO{_V<)yM4yo5_!9bwrYwx$0B&(B&5_Jwu}0vbJhx;GWjgH3=yyHrF&~s z6ZObmY_Gl%gFMjEF(F!kKq;I6dcf}9I>0m)Rr-yvHHR+FcS?g)FzEh`yGxtOl8Ek# z#UWF8LC*yRJ?9Wsi2-r!h#Uor)X}TsH3XSM=m+K5i>WLaH*rAmmp?U_wMU^a ze>P$vhN54X;_U2~rZ|eMB@hzPh;G)^(nTTJukln%^%4uM?-z+oZwE_DIs^Nb`5fEh z4d=|FClKihgr7pgl}+EpH*Mc0pB31&c!ddNxoVSFy#Mf>#o|4;Z%!3^RGlpiDawsp=o| zFW1|k!wJ;V)K*CTuBT;=Voz-)b(q;gR z$t80w=ba`hF@(w%^QMt1q+SCE(Fw5By}jDd0lgu?h5zd!TKA8f7zbmA{w)1$)N2qf5fH`tcLv8Hiy=w10q^t)}N2-4VW*!RLpxy4`F`?p?J%L zFxzEB1v>trD&_eXX3pmIz{{78!%el5c89~(^DoKR`dVuv;~c)|LA1AxaFyo% zUug-4l)Y#)Ik9&^(rH-{k$I-69hIcBcis+M|;S%Yi6Xo3XqzrJ;_LDt%M#JCOBN zaN74ws(5AZDcnO~G=UtBsGDR{OtQRD zZT@kFYf=EdVnE$YEx}~Zp{DH%o^Z1(SJZbV=<`~_-{__?o5VByeIS_RUjlqdROn03 z_0}hWkUJm(fX-CdSl+(w=vZR2>b%e1?>|1(BFHxpwjS<#wzi*iPKjV-hzSmecJ6-a z8>Rm7aPY$$Glz`Z=f(7G)Vn*>b(zjDc!7P*>bHrsxYOGC>ZrgUPZRCBVr#lVafE z5k^)Zz7{*I;&&WKQTY#9OH?TY%{4BXKp|c+mjVqlub7w4L0+)hVBL8Jtw~6@*sOH+AalF8Fxq*TQ$AjfBN_()+0z%a-Fs!gMw+*ezOsWva0nLVmTU7)W2%u`#z(WH#h514!IKgn8T8wy&P!R_Jn^MFO>tZ=!Vrj@PFF+a>TGlwU zQz9R2J>%RF)RhEj$LZ^t{ppKC7z$PwwdQxeJ&Yu|!q7qYKnXHfn$&JrUrMDb zjU8$b?Wp>*K0CNGO|=_IJ6(+T!FQg8K7j-|dLF1E2-oard%>tdiYKuN845I(n?zZs ze_{|slJc(p=6Sl4@dKi$0tZiz}Xd}R|^g!5pX!lP^eMIeg9Zm)@`nWKNO-?g(V_!Yomn%FMDugj{RO6r@CHtBb`^9c z`~L?Hzd_cl1&RvzXu7D3q5u=xM-QD%r#9kDmavk1n|5`rFhM~SKM{zih3*#L1_rX& zk_(;gJ0WzcWUK!S78ekimOr!%9yQ6mqURHT+>yXQAMW$(#}+CAz_Ihi84Q%$t2cZ~ zv=2qA611)}eQ=`jTeLO4K72bX$dH}D+PY}J4~`%aC=17mnNqplRh)UQA0@BThU+ec z_Tt_?%>cmq1k&~sy6n$Du(X?KOk>6-Wi5U$TM~QQI+u{1n_S~s8Sm)sME#Y+DTY@2 zSw`3nYIQAbGR1LEQ&YU3V%mdqdggF!3me)XZ`x}&52J=WfTN3kWT;PO5Gn4}`#pGd zebSD@%fknTD#wYwfTgV713nf;6VJpH4tD6SKEc`0)h-$VG*6G*k1y-dpZ+LktJki$ z-=GmW$$wJbBAWQqCl}_2pqzdEX3T?hw9)p}l#Mp=h!|c?8sAvJ&<|Bat09`tx?DS| zr!}?A=2ZdPrRv|rLzu|i*E5Uv5!X}kA2V|aNlIk0Z`HJifeE~6`vXfr4I@k~1!ZTA zZHW%CYEwY#)Dm2F+J}rgeYsl4fufIU)gbDh6=tqKMCZvs8;ZH3g}O!y5zSR-41~J} zE!#96ZJi#+OmM2Bix1x6LvCAYJ7yjB=M>2JdSDW((_d<7AEkw;%mf3k%G&W$D9g0Z z6&-r44s7KE;mEV9Q@faHjQfciBu1+*@KAY$qO8V z`=fVazqhmh;Jk+fh0BZWnG}&|*zUo~kmqWfS_* z{jt$&8kK}bWM`yKg|9>V-gkSThc%BxRJsVdrC*%3%m_mq=^^O0x6H`V8xrBz0&ru; zFP{iZ9?0Hsp%kwM_G%p4TX<0mufzQwx;kVPnOMliCv9H+3^cTs7!CrwZyz&}4iZo3 zQ@>jsx_XCf&^lY-(mjCmi5&x_4pZ)x1e($~XC^Sa?OcW{I?$_eHk5{D7Pv7D^hMHK z9l_1FZMV@twf_kTGfi7ex9GhhMBgQEL{Fj**e%3*oWCAzMrraInb^Tz->F40(+;~r zp&c_>%6lw``{z?}rs0@ahA6noimSIhSM%>tToQ_Xc(?2$4iMitX@i920dogOl9{>b zyFHFmuw=TIMP%`mgiAj`M;4%4LQ0{x0&uypP{>Y)NTMo}tdR=|4PGh}^C(jv$Ila6 zo;;>JP(GDN4z5#AWqmK@DzMtTPM}~gV~%)o$Bkh@wG9Y&dQ0BQuJPZpK2}+y576Xf z=%&!OPT`i^Gp86MQmQiky^y#xEr#M^(~c0iyU19ss(~8E?(sBsCC`V7X$hU_<&z8@ zzYPMs&u}M5#>hBT4~gL7b_sGAdTZz>aR|-r*)+I#r@P}~+%UG&FBcmSy`{d6nm#h| zk5}5g!NFHMFFBaR(psp~GndCb!j{|Eip?FjJjIV;kti{7Zu@!k9jQp7Dx;I|RdhQ2 zo-D^tY0k{34Bre0SpO$$ML6T5Af$nrn-w7n93dGGEPuzo`-XtPn45Z(b5Iw?PSLmL zF8JuXW#i6r{l{VtbyGw;3?t{$3xn(%n=sl5Ie@JBWvI*r5z62d7F44GZoJj?UyM)MXYVd025}=Y+^zsvW z$ai!@LWJK%$C5Smm|_c6{v?#!a4ts>i~F1UGN~ZyzT1X-R#$OK8pkP10L+B88*o}b zn6?^`)ZlA6@!sUd)y5tVVW09#uRn(JhYmZJ0M;P(K+R>s8MCw82Ub?w7%U)zXl@_3 zc+h=f`l7)xJ$KY`nysk(JK6##ZCoS?Sl9H3gLF8R_}Q%Q^uC}<%cJ__8ySPY>5?@RCbz%VAIycDmu3!O9Kojcw>x9e$A6N z<4YXHa~MP|qrw&JG0G1DYJze8!Q^-d9~k@gm8ddKj08Eis-zxQRIe5 zjmg8V7x4mNuswwe!zqD}5k6T~mS20r>sG=LaVl*TPcqgx=m=R`5S*G6JQW$1=#ZsS zK^15;*oB&Ft^fa^PD6VA`A_*pSKD<5+!J5kQih0*-O*4A|066cg>Fiu8+M$>xPeuA8P795gp`yy=ISd-|nE|<53;34!4{^q9L z*B>fk-ZuVkcvgjbgMLFm_cyEvV9!^hwb<;PA^-0CU`0WBjTPtp^ag-GMP0O!aMN=c zWtQhnmA#PxQ;s_zdGvrtoI0+`jDV|O{tM|avj&0Y7(a!)pvgB(1FLdK@Nzx(Xgx+OG#e?U-ggd2cDy%Op?2TH8izB^-H1eL6XR*XarhiB}*7_ zPS6&@bikqy?zk>HY9OZcsmDi>V`qy3Na&B49q1#Z#U2#_&J=J0tP4`LiUKS0l=s@) z6XHh+{jZF?=D=+FSbcS>osrLN0BT2Tp6N3K6W;TZDH@!Kib|7^LLqDFn*Q%}o)^V- zFBDIy_?5n#6rB}iE$q#PA*PvGV*H3KYiCF+%l=YZ+Lvqv!!xX*gM)pU#i z)lm}o%Pv_L9Pl;eAGO7qtvdM^@)Gr!--xQ3obkg_)MOj$e$#U4mn-F(LO&jKU=pWW zx)ZXcJ-F}kQ~~JJgv5xl)r?SB=4n7ftf4FFA}&Ayv!NlDR(KIqZqTUu>bem+uA7E+ zPW;)tz4Ev6eJmSFb2CI4Coxd59TpYP(ZPTd#6FnO%Y%=SA(D0(BJkZ*%i~up!M$sC z+5b}2aJf<^?R|sdFZKlb_nAw}p78F;v4P~=2fc_C+A_y`EdaLHa{IhC=^PWv5to zPE~83PY`?<%n_jQsWE2G2HcJ`gG@_FOM9?W3-!Cc+s-yhze2Xm@C@!-9-|-6c4K%s zP^gKmdDcO1@GD~2FYnw8m6ZQ>fQ8Vail75pK`@G-F9KGTM!5(0yODVRM? zL2{lm`?o%=LcDUC>|ScRF3-V7YME=!0q`Vy#Y!@^GLEm$9d+lp{XAu1xp|hX^+^jg z_@1Uy{S|BWluE(7ZlMy4%reY-7kDRsYCuUUTR$sjM;?EBAIcWR+YCH;-;A`(OJS1Y zNRj+?uk3%onlIC%CwJ+ZGl|YrklPmiP>Tx&Fg}@N>2N?!EZmba zqwZrDyx+Oe4-h@?^f`rdrK(J z`q8q#fAbco+dX-*FrHM*V}$cGw-*NFNwvpInAp&%9iga7JEW9-5gMsDaymo*|H?fh z= zf=S zD#{fP>4s4ao`39J$WGR8DQ|s7B}QiEnR5as0Ng-05EQF&CZ^SK!8l4xzXaL@r&{7d z<<79vIjjT>gkr4!DozElpW&6?X^|JVU6NGE!r!xwqMndzPduUsW)mscpl=M+YuRi5 z$_iT|;2HVL6au4JR?M(0d;Oa?n+JwP5FRaWKT!c%+ zxN$DH)%9N%^lx8a7TW7=x?sy78AQ2FiJL}ZsyfpOiQ}f=;$+i5>8OOpvvyN3t}MG< z<%`W9TdEe&$qnA${&`@0KIZr5<@7gFtr-~gbm~)2yGF3Cgc}o5^36s0k)ljq2{nFc zA<)A>leM+E=usnCK}l36rPhrerDkxQsj`2!1n`>-7n*+_J zi{l8rH*2F}b$u4-Oi7M;T9P`V#`%)Uw>UWSpq83NRr5M3-y?8W5xrQ__8(b7)<&l!0OQmZmmlf9^HC$nK6PVDCaG$FSmxeEET<2{0(4bQbiE-#wh@& z)no|iRKYK93%P~Tr&^#p=S4I!eX>AC;%EnjNZt~Ajo!rm22!)f+iseyTUU|jH{0R; z-)Pa%e9Ka;NATAzKvj9{!5GMv#F{R3-)7W4x>BnFJfYv^j!k!lLn}-+J}K<-Q_%DU z#DN`kC5yF3GwZ~I2?t9V9(5(T$qX|ospOs#!8WSK5e`G^=7{OSQ2Vi0J! z&UU2zfz)Qc@fGWrFW|r}773av+#;?rLd~B59w3t48OB*aG@^A}jSJ2N>ZcYP!s{(2 z1Oc~n1;t$={$9ia_9`JE!JAipY*u*n&)_S&?OnBRX%XObHFkGT{d#Cd=67^y!pbsFO;6GzH3_IBPe7xhy9$sIzU-ct;{qFdhGDz{)N4CU2=+ zse#0`0cMNXF(;`=(q87}iSm=@yQ)rb{R%5^t5Q&A)Uk8_NTKZ?3Urfd!t9HFxGy;h zY=?_8102T^yGD>A-sHVi4O>FlM;ariqb@j^t06LjR~0YlZW3eOqIGK4a7v*CofK{y zyF8WqPX^8fw;nMj4lq$n(yhDAR`X*TETNflyakz=Z18 zI=_etmI|w^4c9TkR5~#fL~$C^f0gR}-(+hvIgl`hq$x0@I`{T8UkkbdO3m<)uLlVz zInozg?MmIonl@Gq5E&`YHTF5Gf+ut3um>P@+MiIc)+td~10T>t&=k4(B~OAJ%FqI} zv+1DBb+0d9y#K*Qgir+C;19imEe4FB)13Qw&?VRTOyFXhv7SrzOlFai!OF#v34>h) zT}d6Bvu57>2f^Xy>(b-Wl6>Ep&e8Rw7n2N)jU2?KpEMP8{U=s$Z;3myn432G8~|jn zeaYW0`7aS9o5!QUO2R=jGK1-(yfhqXYqvPkr2uLQnei8B05yA(mA!8QQD6mM>wYes zAFA>+a+hIzye5Ua`7ejCqR*QA8WkXsZZ~yWxBfAFZX6MqC)K4)734-!UM^qq)x2mWJduM1s{_$1|w zm7S>n&-SyiY!hx8&IR!qT6YTfJ?iVd{-22-fUAK>RYwAebO1gcR3!!iI)^Lkfs%~* zPQX(Q^W^;wFz`BQBD}WHsIh%#lRTnemjX!_*Iq2|FkgNt)Ayrl^cKB`^K3 zxZr%gX%9!GUa{t=0V8ml-v|*3h<4ihSISaFRrR|c*Ep1wJZc+!!9(Tk%<8qbBMw)w z=|Fe3e4Zw~7?66CQPhLbxl&S1x8psG)1~f7Df9R3v?Y4$>6yNL)cSl%YhrHS^9u{* z%*!LY3ud2gZQeAAh{UYit00KfYgJBdiHWSj@vokbT&eI*bk49;)59Ykw=9Vg>t(&9(qAznEN&t-wu^E0D#)JygRnZT z9K!%LK+3<-8EFFpz6Y(!&I3BTWOVH8r*eMoQ1b#Q!%Q80Kvx zFN-t0!)s_l1B^wxZKgOvkvuu^bK35|x%w8`3(TJA(+e%upS90+22FA?aJ>PKJnj+B}$5*}f|G-h69hLZHNsS=gyK>4KcK zh!BC&07RvL#8ji7Sk1Xod42X(#1``?epyAvSfthT_mzNZwQ1<|9Wg_@6 zalP^GIM1W0yog-C5 z#a01b74|na@G%zD6|g3n$K77k{bS_X7KxdNB5Dv+^$EU2(HdXTwMlA~*kD6a8`Z8i zZ^Sq!>tCzs-4$TUog;PZ?H+~PkeY;LfuJC@wV%XqkZ@T+l3M8DBExq$wFVy|zN&C6 zy$^p7MsNgx%+_E0kD_+Z39vt-CzUr9C9wno8Pn3`94VADi9dOr9@%&xW))N#U%2Is z{%+K%D>U&sj*5ESkKEQmt+}`@zs@y&gBo9ag!2;sNy0?e#x;c3oMi;{wR$}gr~f~d z4Ty-&+ghOGVCJYLGK&fueUc0UkMl5TSu#-3gI;HHf**lwt$wa3Tv14+|9z5^ zCCoa|-d;GcSTr4_D8*(Gf3Molm%M&9s=u$z{e?+efpdwzAp(!Rhnox-bda2{cvm1( z>+O?@sZzdYRP-uq;rMAs3Zs4sZc13AE>M&;mXs zMkUt~cBTC>jOZ!)dniRjZsDOGpuzURjr0L6PJTFRJ^>)Sl|U&bB?z7X14U3(^-7em zs<+!D$}TsOp>U&%wncoenk}8Wym;!Cl#)al0bMd=ifgtI1AN>LKKWh&vgc8vE1>`e z9X`ZO%Ca)k*q0{&sHihemhjVA$+R8bWt8yNl#J9|P`*oALW6BW+B*}l%O!-PFOd;6 z7O4UlgR|~o-*xwlW5LsXqAd|*>CGK0j&`^un?{=gyC@&sX~AH${S%1jaBBiuiO)MJ z((9mJUz~O}jKga2z(L==eVhUFJ^a2GhVK*!zbML!8+pjGP+2y55fI~xE8`YG=neZV zKkP^r*Pq-2nGS+VdZeRV7RhmPm$NW9Jg+#{G_K%D5DDG!eK})oF){QDJ=FWfaaCZQ zSV_BWCRuaqr?xfe$~Un^fM7L6iUDHe$5<#S_sy1zUfU*}k$ zd{Zj1LDBY}BZ2+tQ^2W29Cr3r1K&?cqg2AWu#jDSq;+kSZ4u=uzXK*(Bzq4B$)|b! zK#Cno?|Efxy#UTh*lonppPI8EiA1}7o80X|@G$5Gm23@vUMS=eJN}l!`ROLUc;aYK zkwR;R;?iOCVn#Q~c&r>Tym$V2w~wpTCCp>VxtNkH)GDcVOfJ0A6oHb}iri92O}6eF zV5snK1zyE|i=;*+Eb z3n~6^9<2eao&$BceN`i^x+M9OBp+Pgwea)&Zp0d{~S8E1ZQ zA{U28v2VRWO9AePG!+)i()r@R@2|bcC5ZE6Wmq6M`{KF!W8zDdVx#;U#A*?@eWjXD zLX%2*f7H@Eu9x2cKSpD?=i+!z(2j_PW!Ya00`IA!y|mdx4^Z}tZ}v_ZK%b`Z?|%q9 z&C+3Qc=k^$Y(KwmtwwU_gNk(s9ps~W07p3PC*}GgO9CuwcV_7SorZ%mc5A?rhaG#5 z=S+-1LeJTYJ1e+jdVGJ=eH)}e68aQr<<5_(nWBEoZV1EZS0&y;Qv?y3>yZ*va;Jv* z$etW@yw0zuK-{E-MA{ba4Bd$#r| zYv!{QgB;zkGI_ONB^!3eR9t=gZ^cJB4G0NMFJY}cVEXFi z{<-|zTr}HpewkzOEg#clFGc#!x$uT%)2iTG$8}mlzeS-0+D{rWAPQEutK{ z$Od5u8O-mfNc!&NTfq2oq=UojUvtHjOETh{I4rQ?n{*tZaTQ;sR&vjPcJWq#>*{~s zphGr}gO5H%mZCQr58BLvaFBxakzkn0-;+6|?9Al$0KP3Z@QGJl*YSz{QI*`Y?#Me& zJT*-)97Y~)@BVjxP{Lm;q0-6JB~Z&TPRcxKkpz3W!g+3B!pX<@M#UplC}Q)il{M6D z_~KUs-S@~Q=1jQLTW$Og|1o9x0y{e&PY-EA-`(=-(Y0CJjvz%{FhkrP{A3w{WeTXb zP9}O$KA*|A1XQK-G#b5bgIx3}`1$i+Re|O;WkW%0K0WPfMVyXy1E<+qun(GY=))k zEvZV3XDZROQBrt~qBpx``WdTf?E2!+#x#+(Fu_Ph^&hN5hJ;)J9OF=0@@f@qfsL4M zo~+UBIGDC0mT#PGcy z{=NDC8Y&W&dTdeTB(pS&rrz(Ya=x*QJ?B~q%f<~26|m9g;LO=S2&AIHwQj4J*ZqGk zuNN|_m9Ky*t;{g`P>~2>;}R2}QX3l;g*U->`~Ea+YKfi9MU7gj!hsIvuT;Wb2ul`seVvgZ-C1k&R6Ub!rZT21*nYZ`!HhMN4Y*! zW#fj^?$?DzNc_URgY=+1!M?>wvY-rh!xpn+GwM5zWD=nu8Q4h)8j*`X_?k&`0k!ny z{=CsLU{pdW)q}B0+lLlGj2L{hm#yt*z;a6X&LoEyAks6&jUl%ehejwm$hm29+>^?7 zh?Jywpo~qy)IRqJeg#stwf#<`vgrVe13-hj&}xyOpzX;YK$GS*!=~NM{DhPL`)i1HR2{A7*I>mn)dsK}s82rmn;s%JBg?Kuz8mkKLQzKC;bGhZ$vFhigJNp=MSg)+edz_kNsPdp7r|nH}irq_3D1cIl@WXc@GST2^bB~ z8l+E@AE*&s%S8rvFP@f8bf@3QPysN5L?FF$Z!|@%EA*%M#rpLH4^FeX>(iM@Lo0$- znZnLbn9*@pUtgam0j`PCYdquKvKIl5dKpD!f30Zi~|R?xl*F&&vlZnsX7) zf0l|quMGR4X^RgiwyiESKJ+CF3-A+#PWi18Rln?xX1} z{dfW)gNIB>bkI><*;vOaeK5xY-n@meae93em?+Fb;(1{Wm832?KBZ>rybbrXngV#R z3phc#iEN$IA6ZNA^gYmcxoa%go%0jLdY|oXarE1wA|n+r)ch2jSA+`T)ac5f`94Tb zNcW$H2}d9DMYlqpy&>A(u!TLVqCMe-y+oI{D4SBBEd`h62g9aqQN`;|NMiH3|&>pExG{ z#=<#uWjfz(Ez z%OL{+w+Uo5&=Q9>X7QYe8VeNmDJ+rP9MHxZW>P8FF@~iZFI`L86r4jCY{NE4ME)uw z5Bnp#y};#^i6r_*XH@Y{5h=)~dFswY+N@qzoQNTp2qPb!pJ4{potECw1~8WLA&<8 z+w(9t8JU6Fr?ykNC^_+|8hlFBH~4AxUzM42^$!Ld3L|q+)7M}VW&viXWf)Aq3y zG}>9`ZWaoS9hup-%8`AF0t{KdCR5=;nzXP9u+hhCyuGb$OgcZD2^c>_mK0!z=Yp@`%2!*yMdNcV0%&?dGDh(PqNhdY{;?n z%~HtvIIP$f+av3)I;{r}<&{$svxop7>nY*`dP>XEG%{cY_JJ1sP!NhY%jbHHSG;ppK8 z@SEpKl1wX^o)-Qm;TX*K#?+uR=j_MFJ38 z?vB<+$-l23WjXt=ifyAHRj2oqPLCkEX?Nx_DiZcMes5q?3AIXI8YuXYY!{Sur zl%KpUZ@hg(7MCxvKOAR#o3M+*dp7 zGn5s2=RG8w>~{}$A9+s8w(*DvS7`$l)syH`jS&?8f<_0WVK57BrpRx21D^w<1l>TV zv&NBaag2ihj(lC0>z--k2rbLKKB2^noU(%fKF*)=&WEI5B6WOf_#QZXfJa)*5x$^+ z=a>&mVg2ytNE_j!17kj_MW95$OEfcPIz*$1jzF@W@reb>_&DW6d70yRTGaF?w17TK zCz+W*I50r`)o4_vHlYv<)(`o+mR*%e;K<_6$}C0}wBf-xrmMT}cToH}KN@43@6SNY z3kg(LmT(03X8ZnhPF?lDLtcT6)aD`URVqn(=uj?V|L^b`RIHGruNP1zY6373} zc~d!VeR5~(6-XH(3jg~kgFCk!1G-tv20T84O{<+&%vrr?f`{*(<-ivU-ON2C9z9|j zj}yn#~5Faone)T80dZQe=6~T?qM7-oP9>sZ!>zI#Yhg|i)QlwrB=LUh$w>0~^ zQ9Yr1r(HrW_HV}4iY@VXY-){GE`0aexWuGGO^+c&+cknE-efw}7xLw+%dJ%d`f3X(l!TK=7XQ!N0*KTwkYALycLkIw6rha`*|Gf8=*JmvBm?WU%A=gQEg2EK}k5X_XY9^jo$qM#Cl1gMsm{!UiT;x4|0lVXxBpXo-P`_Nx1&{X%!c3I#`dhqUbeaQI{9 z1*^9RMEMiC4Cm`39I}-we`o}&X+H^J)$ar3!dFioG356ce$)K9sPYVDD(gJQw)d<* zEk5u(FJa8**R>C|GG9O6n%i2wPy+C)W7=#2gOU#poA*W!2Av%sZ#V)2MEA&Q!r#Qg zbQ~W97%f#o`BOvr@TKP~=%8!%)C% z$wQcg4z&n08XSmm(^kl!2%1IK@#_!+uDVz!Z}uI*#@Q`Y1>TSag?g@*(^YuMX7sf^ z*W#>VkCIt^|d>VN*{;x@uaQVd}nJxmfw_vRJJ3WVoN9Rul2C?wLvP}nmym=$DH ztRADAF@T+?bchANoccs7-9_PxA!I#al;m&0yEN;qV0!ADea45!{AilCNBE8oCl)qho8!!WuXv2~wum~`Ihe9iaUZt;?XWuc8`fiZSN6Jf$MQ!iI+D@N{zOy-~0{n-a!&;sx9z5mRUC#M>}3$8QaPKs6!3FNu~&=oZ6ebLi|x zI-l5;ZN)-a>B``RveY>N+C9XG1E53rt3q*T66h#Zn z-)wf0?RLT{hxY3LcP%N`IvNOlpP~eb$#cLSJ%xR}3n=?i89SfF*?|%Lhy4IY-6o}r zN)!D80yekZk}JKepu~XiCx(HooLJ3GiH0EZ&K=NKfP@5<|I^T!$I?9RYMtA{onYC*> zrs5<_i{eg0#nM+kc>_e=sVL7^0vWd?HmUW0laT4r+m-Hh?SVnb*1&sh2kMRv0jIXxmz%-8rBc zWRf@sS{#UrfA8j@LQ@#Ga_7BQ%gUipGsC5ZDWji06;HkfQBq3-w@tvu zi0d>}$HXyHY4=0)`b1(znPfGOzCg4kB)b}{l4SuLq8E+s-dL@dmo;IX0C<$_kbXWD zD7V97vfN}{H2Dn4oeU!CXFOVJ$n$Isyr55+96u`h-vt-e09u8AW+_&blPY({^Nfx zx=}L%7bsu8la453a&nhAqc8+TR%fYk!Om)0g82pU8y-fWF5Orwioa-QGw!MLVMN{a zCZ<+j33kG5Ka`YEa6~~Q4J3Au|-lHVhCu|$uAd^g8&6t@zF8*+g<;)~P-e&|= znCM*|>=vuWVv7Nah{LTDb|=<_!Ar9`{{LCK?gqg zVY)QR7yyhz-WEa{tFw zwAy4D$!!D&hbu3*p@(ZWA}il-3N4@T)u0n3MM6mCS00o4+ZK{ed*XWEsC}hh9i5xf z{H9Js*uap|7&w<6SSKl|2Vc2+Yb@dI-LZ8PQ}Yl(FPfr8A^NxM?e_RPN~GBFCWh3g zBo!3IWznn8myH~9Tt{yQ;y;rT;|(oT#eJu6%S%pHIWu)tBL*^mE}Mm-0~Wy3f-Nd$ zm#3ajf_zmIQMH;2g|e3NQYq(iphb{HjqbmAlJB4VFTIiw7`{o7^BedL&4ok5aVyt0Nnr`; zc@xJ^6bA&lzep@--q^v;wVl;`=n%b>pcq0WBiP)@o&K4B6m{?%By}YX-Hb6w!)SAv zs|TpU-GAR4N}P`aJ`qQ@+?6z|g+fP$c7s83OF$qkJ>jO_^9yt15yMHlM)f861bNrP4aAXXA~ zkO$eHQPc=6f9BB!gv<>n@{|}Z3t}OUj(5cnOK;X|>KX#J7-gQiMsJ;7klLmrr)e)C z=nc+|B!#u-z(7zw9Je>?mmeW(yloM7!~0zD0@V&koFNbZIy8d}XY9*pue=|W@1V}> zzhkF42wFb>ygyfm(;+P%G!udP2J3><`szmvMW?55)+JdpIyMah_=H)`sB409a~$&h z`$cVuUiJ7->0BL&bg_gg2nX@q%QnKm4bcHG4vAQNqbjfW-zW_I)V+4HZK0=zhpC+O zX;d4S@9Ad8xK@n=aOfv8c~~QB8(V#H#$%-OJhfe>^ru@Uq7nsQXjjEYTx!DdnZyg z&)U+OxztiX3eY-1jeANF+o)MA^$?6dpmal7<4KJc1OgL-?_{zAG%_A|~tzvcpit+)8Ev1GrD-({?tS(kd zU-38+!@O>{6fiU?RJttv0UULED(e(#*5Zx_y?caVe^dO$#Z@d=TfB+38WNt!B1q@P z1L~4^qnm(s=ThNW;+54YBNZZP4fjJbvJz?kMrskqH*m1ASa&^a*}wC=lQz#?p691D zAMb*xIWU-U6o1Nsv49{ zd6WI~1ysSRo2R0rhH;pVB*~`t3eL|}6KZf~6Vd$9$?llMGOzMP3t!_0NU=-}Hdury zQZd-cT}ar4Y`O19W)b|;t!Ia7N%TX9ns)Ey#D%wD>o0A+Oy;auboJp2L`t({TMy73 zAQm6H#mK+Rq;OQY93kWZ#d;k-YrX0NH)cac?{H6UaC?zZee6%9&VVIFutOvr+P1#V zKsWPvQe0CpA!nt$n;E9-#sN5)g|fI}_YD(C_>sTCgU~Huh)hIp%23JOQiDK}6@w^4 zG4!Gu9hil<*`2kE+ol=Ejwd zfs53&p%B^~DmZcSeL&@}ZEAN)dYdp0=rc_Yf+Uipy@o1cNMm3o>7joze=6|F=KoaZ zhZtsPxFt~M*PVZ1{n-QA6fcghy}=PLYb*GeKEC~+NkL?Za(;;}?iNlQ$m5FSsgq%- zViIgr4qC?cHT2w)IulCCD4d`ijGT)?JW$2CZ~w4Dq$kF@8TmV^Qy&g`o28n`W->sL z%yp{Vse&s-4Zki}`FE&e`0WUTqXH3J^*8H=PUXv{YmqRn8VNq>2auf);<)4}9gUk2 zxZNg1LB!**cOc0WTb$*p9W0*8?-z)BE;?GPF%u9u!flb!gH$?O`>e8dmLVw0hNl;~HiVY~N)ummw%?Q`lXHu`lz~3(J>g)15*O>cx=fQV0PJ!w!(OdPq zIymb_JTL%yj5pFJVW$gmD%@s5eeKK<+{Htbz{+=dy4Qsdvf;byi7vT@ul5yc4B04U zr+s49B7KnU`(FvGY%>;K(U(dT>;@G|M2Cr5ir}H82%+9hLoK|Wsq z))63pInwyF**}rCnU5}K;5`rd}K2StR9+-NkM*<#zYYm??Iy9{9Iu{ zlB0=-Sg~?)&c;hewumXa|0%=w7;bmLT_8!q*9l+!%d-}HS;6yy#6mZ-NU29Lh*W%) zxEM-L(NER#(&w=PDVLO>(IdhrV+DLefF-K&C~^m9A6>khGfcCR1Q1o+!Z=2o24u;% z?MHYt95>)kC0iSaK6Xp~%Z?mYcS_vyqTTBg42#|`|8GG{lV4b4ML10KaniFNB_0l} zD;~YY_ZEclCYV9mFCsaA>=ctWR=Xc8VO9Y(f8i+kCn-xd|H-Skye=L$f^EvewLdW8 zo&NyiOQ90*Xoh;o%Tq%VU85>FomX($nH#LnTt#k0JQo%U?84njR%5T4&iEuCDEne1 z)tf3==aIRt#uIK`=XMzcTccmXXOGWZ_c!(G7K5P?Z@6KK<)e;5V$v z>N+OpnJz*&vL!?eN!}jWuG+7RPe_Y1;SPYQ?n-GHY6((R-vPPM&Kx%|=X+7c=(o)) z7v$J3_R!P-HJ13wUE59%f4-n5fE$l-%Xo#+^hLdl>i*or3c?_!z~Qs8-m-lnKZboh zYwR*Hv^`w3Y>y){zn62~wBwq%qKI;CUwvv&(3sa@n=FDuyqlZ;M_Od7Z}rc=84oem zf{gHsK_c#_cVY2$E*89c8b_> znp1;cILeLat=6D;{EAn_1Xw=kQS#`1W3olP_^-}=Eh(6~)wr5HClhV{mlXn2@gYz% z%)7avMmV5PM&8Ekvkj9dfJW~$=5qrAWf!~`Wes_DN>m*tBL)*^oy$!&R2Fw$Y558B zis5d&So>&ADMiU8S9^Ta_JSBK!$6Yit);km=k;X?x*F(`fO9i@NqOiV?SS}zyhW2P zNGE~aswGK=y+l~7Y01R<3cl{30R@=hGo+in)f@}R849x2;|-K|8;-y{VSzYE2zB0Z}s_0$b7^nTruP64Y2qvG@osYiu@Ae&TA zK9bkRE%GZ2_i$Q;MNBiU?_uC>WA2wxq$ebE(#&d_v0#l^^DSt}9=3dddqr?tq%fWs z$@lI96K3c9Mq*66RmZY6Do@!%Q&f_zojgAgnWdzyab9~#D;^G9*3(BW{}dM4_|~Eg zA_*=dqW&OD@C$AkAj2Fh-M?Y^(gax0?5zO_Gqbd_{x{ai4aUnq5t85=$@4H4=&9Q_ z7wI&>XbL48E*5+cE$-swTmU~}3w|gIPW>jQaL6{ZN2vH)`L$a1ZH~G-`E+{Y#}c@y zPlIf4?wg}Air_phX_Wzz~L@^UE z{4usGf_9R}Jp&tMD&h9lCdmcaxEg&WU`r}4bskM(sY!0h|A~+!-$fj23S%z-tA~Lw zLgZmCNf~2Ouz%QdVcqP$N(_mD$S2`fvdFuQ$SJoHd)FhhFi~09X@m`hldS2=4t&%n z;2;C?FuU%}()Jaw4{c3zg4A)<1(-~Qw*N*uA$J4#wW}No&w}(#9oe;sv^Y%ph!!!)jP9VO<=Q{xX18!a7s3_iCgTTr3dyAk|n!I#b z57u(Fdw4DVN5L#$h8-Vm&MLSXuIq7?g8PD5&IN6Oi%D>90l(6%T?F-DmF_CFlXSkm z9b112c=@z62INaX9-8)&4#F^5C_tsX$9a?$b@+K)-RjFRG6J7*yPhP#D9}Mo%VCtK zIM`1aT;Hi8U;QqrhJ`zYhU8}PT#B&gAtQIXTJ;BI%u5=kLrXO;Bd#DVi`T6dt}Up9 zZS-rf{QSTop5@a7wPBn@MkKBPX|$Uv!q1z^&HAY)Hh9ux2i*3rGvgTG=(W;ZFnzWGPX6%I|Rx}muz;`{^a&H?#R+4INOY8&@})`=SU2X?%YcAL%fWc%BQ(=wo+F4ig( zQ%!Dl6KN$rCxz(X)fLf3TWK(~Ai*&nJ#`i1AcxcSqjU8<|whNeHlUnIf;Rqnyp z-=u+}Bx@9%$OTMPhm+5BGvp=RgVnmkb1AcJD<>}$q~XStxH^lSd)CCKhL`o*1uu!n z0F^0uM4ON2U%xDAXZq)+JC+(;A zkL$RG2-}<0tIA>UbChqj)XZu{`H) z0(4Usd#wkhmDR9oMBGrBq)uuhl2nQz{$d^d&9H#sMV7Nzf+xM04C&C5> z6yfUxB1Ql{N&Hmx;Ne71fci$0|G;eWvfw78H(%09q^#qC36udhr2z z=)%`%EsKZ|e4(vI_+Y%6xjG5}l!CC_mt$Qp^YA_9o;Ca5__f$G5NoQ>>(x35z8g_9 zKJ5yFM^tv@g*eiL3L6jt!uAmI+n|BMgaVF~^hmI7Q0TmWSZW`Usp(a0RsW86!ylwu$YeG#}x4h}@$%n>o)al3vlU0#4e zT}=|v3v4dd{-}_OfFrw_iVnfeLLX9hR&X(g;scKfjdfc+5iNe%i-!uU!mhg)qg#eQ z`Yd=^Fgr!>;Fkn@fH5$G7Y&fh4*dT2Zagqqq=sB7v{4!jKW`sq=1d#*Z4vRxP7D4> zXJiqApz}jK4)TUZqf-e|6#XUflN47XsN`HD!c0l=5)TNCr-+d(0}Dx<=1H%+e{gPVCKArDEh$l6gY2+e-_YZ1`Bt+FV0#T-k zb__7(j)xWg@)^i<)Tr3|NxgyGIEMo~HzI%(9`)OYief-^(!_Un0LPUopz#yt7PV`H zm}&KxKH{dkyzbqBedDcF$#Orx7}z6b?J-036$Q_k+r%b9Om>w)DkF@FnI^#v-hAXHLVT6>YE4$(i@66)LlqL?a2SwT=`18X~Y6f ziN4su=KHi^1vuu$yV`lE7O3P(e+)gUk>JFzI2Yz7Qb_E2REhrY<;-mIP^`WF_!G^T zwt)0ZPzayDXRK(Y5dc-LOkCn|A=1_c72TTrFv+;q#9;kYffc+}g^p6Ds%58pTS}Snm z+u@KyF#6>p!kF&Mk%>G4A|vnAofOcN-V0!XH9sHC`PM1!OpeMM**u0u_PCoi4+{$?VOSLrt=V5he!oAr|+=BF-s)rt_<%&uw%e*jZCj8f`*{rCiA@wI}rUp{i zMV&Q2gz`Td`;sH4MZIRWH7p(&%z zk3=_$Lx?8W{VP))g--*W=0NTFj(&kE&GOKGR#~k<&%OLth;3}P+ga)vvtZzTuM+#d zSO(S45y6{+tb-tn`9hu9pdu%bq|nEMJ%7UQIQFl+r8^FJwW#P(8I`s+o~2<+z<~FQ z8_tDJnQLzJa9X9L7A|iY+V3ADZgU@_rkU&UpXv00YyZ`eT`_gNhz{6$(7`Gw-zQ{& zGQ&}Uk{HH~Ls|105AZV_YZd3q8%CFbI&{$+{tk)0R;;b(F54b~L)6Syqp|FcS3UY( zDdHU5^%g(`bQK+Y?Qf#*A>vz!nS8$Y3G{{wH+eDAZV^={m;=8Y;iL02PWbj)(ehn0 zyTu?{iQA9HZKFS0C8X1d1^2}~?`|15q#xHj(P|5B^xD>}4kW*e@dZYo7E8UjgQ*779IUn;B9F$sH62wK{JYf_pl!pC! z)GJ_T8$Oaol(kIZJ5VdE;|1f*by9SQVcFFThw~>F0RF%mF0Rm{1gU&)pJzHFVSImx*{5 z`e?YFRaI~m(`W8ijc7gy()${rdXKtYx7~9_TkJc$mEBhMrt%n3qqO$*oLhrYChMYm zs0Vrx1b8@|C89rZ3F8j8*ESYyN^m5HxH|J|wpT@?p^uXN+UIC@^e&=w~$#PJ^R68I*QL=zg6IhaJ4$kG6R{kTXztmPGa@Q3ey8liaim zUGy<_R0VIRO~((f=Qkm>2u!bJUUc$@QSss=xa#7)>l0rzK-BPZpdqaY^N42~@wRcI zHEbyu8^6X`N`{^G-Xq-gH@kwEb6b$la^9WIwqkwfBkX(8*t#5>PxZ6somnv(E+v7j zRZ?JlGbfe|&%x05j8BMYOUjtBwqX9Sf;{Gr8osm80Nefdw8P-HNEfutcg%M;%Z%3| zk|};@i1CPY#K9ErA+Qm9YkP?@NNqyFl5&l3X6*_xe}8ZLK!m!Brttbe z+^}(C)vknX7qs~Y^hJhB7I(~-va8T$>INQgto=)_wyQ!Z?cQA09bIwSx9cPja8~_7B24r2R^J;LfDq3Ouz2qdF!1x3c zPr({E7eWGz*c(_7D`D+%ux>h7W1MDn*T4j#6u;#yr6_@%pJCpd1m(?!tZSKA{Z_4y%lf;w_B=Mmr zA)fTB8%um6bwS?|9N5W7HkLE<9N>;uF!(Zu3#}r*1r9MSaFkochIsWwaPDL| zDBwpN{gJ?T;&9{Ecrfnk)NkTvb_l1xY;i8@poAgplAu&~Tq4!=*oRD<+L?gw`8+FV zbv~_!TSaboPUBSDCP&g}Kv|oE?ZqxSnMTpJ= z`HOm@XXN=T_0>01PZO@vI>6FA0H1a=Ga7URSiJ%pS$H=A(4#_fp8p0L7XhKKm66kK z4hXybK+TbfQ+NY4;Lm6*W;k3UpCgq?G{F0VJX=LPXyX&c%etT5^zES?SFRuPY6kOC zbCCcUQ-z9XX80XSE`+oI0c;Eyeb|~@oHuM-r?X}Wgdm*sIdqh+tz6V|3du!2hiTJTa)sb0;AK~A6~ibw-_XX`@QI(}V_pu8 zC(WSCkm7mjRn&pF*i?Wn)439JAKU+o3jAjFmL>;k^WC-@d4?*BgFY6s%cD$%uXzYi z?m6pegPPt3DnE_04KMXrLf_A|k>)0qGQ`wH;k-Ua=ktWGfT z!gnI2Z-T&`In1#&pLsU-N~nXExS0cr**#R$h5BKgU(Cw4hjphg=J2G+nF^s#$N5HIu3_riRV1 z43MG#T(uR5^Yt3p;Xm=L#^NkUZ{F;Q`%!)WK@y!r@9!z)Vg1rx}l5 zE9S?G9oLw|y`13+{qegr>#-Pmg+NTukj!s}hXpRh#D4NYNjwHrQf-B2> z@W0YB)7wQIff~HV6GC<*+A?6lZp*(!?pHb*GIbOb)?e4psYr3Aq6g^PHE2RYp5DMr z;7Kgrr$*;?ytDwfJ&pq^=S=UVx9I!_W7eP)0hUKnk<{vqt7(|kLx2`QA-Huuu3?>G zljOFLXzO}ifL=)i^h$2MGU$Z4pVLR8fl-Jj=3`QS_`$-=|9_x~pXTE~A2w?u=_>CP z0$N5qnN^p^V&$_SBp;* zy5-PtgJ9I#kocOIb87q-%DUMSDLpav)^Mp=lx}EQLIAkO3s1TBhFB``R5RoJBjQCxI<68 zP@qG01c!Wtsk6}clN-IGYXZzOFt8M8$sK){&)hw<(}PP(f4IB0YM|(#vq9awxA6<> zy-z%Hr0oNrfTYQWtY?*=eMe{cE49EiX@7ZaJGGSHDko6@^6o=+w5d&MhOAN+6wUCEe*bI_;meGuv3V*+TbWPqM;Xe@_cpZsQ+h+%q}3(mM~&RI4K}4)UnD4au4JJlZO6DRawGlIV8G7$d;zjUMN2a{unNA@*Bn>f>F?SX5m? zb`#jAC!K+HoQ@W|B6~-S%R`Gu=6ba^S7DlH=LAh7df-99!{L(%)FXL1W4CJ)KYu5^;=V9{(@X>{@Yw3 zDE8?-E-`!zty1y84!3mH1#pRy9UVnG<6W?n7F0+9|8-1!=_;Rv6S%&XcW4>U>(uE_ zZP1nBWgnYuh+E~C{7TNAcRlF^tmSE=a2$OjSdxqH6Xmsd~Mr!-@0<~)f+=Fdm_ zmVHRYm%f~Tsp{84FOf9SY(4k$;Rr@ZMYyzJOfl$gSQ`UQVPRozsvco)RJ`xkh0?<; zF_I6z#0OQ&7X0?rNan;wg^)Rs%sys$x$x(J_={;@P015s8d4Ggmoa%ie^FjJe9Tk< zME)d>O!=;@Xx>@>#k|MKH#S}7LpgNZgsY@pGpC!08qVwW$*DtSYlJc!!62Xezun@y z*4PJ?=(z0RK(k{NV7mTx3$84#XHUc~+Y3#++xrO-jMdFTNql@k{>CaA$hKej5*=$9 z;*Wm>dtdW@2xz$R4j;g$P1n8h#W=(J7CWY64ZQ&er1-AZ2vJzA%rx7qRN<1r8Jg_K zS3rbyF^6QoXGI4slJcmBe@_M(VqaGm*NnUp3H$7Xe$HBJ*tBza}g^7h- zk)oHSZ;!#l#L6~%<-)4BX%K2eio9Se+^}oAGJ`{WjAhZslD)GaU}}~B!#0aFtG}^l zpvApOe*cC1@+i`77So6cutFG4t)d*6BR#Ow&v?BSS-K2G@IWjtf)IG_xqWMMo!*$A`hw`R{? zKG%3Zn4OcNd<|{EoUL6jzJ%gS>PORLl@YKc)6r9r_TcSf*PZt;aGJ{|HSlh7{TbnRW~x^KPX=ko2Q#RP4C$FN#|5-xA3)}2usy2ASEzt%Ueu4m z1Fm7$45<~5ob*!k)Eh8YnO*TBaj$zJo0F6Sn(L1dHb?;Ag{@@R=~@&OVj$Yqg3pQ^ zmh9L*Wzz!NZ!1`!ibhoUSpHu(<{JzF4$~2V`mmlKr9`U>rb5LgA7W zNa#JRU!`~3s?QCMlKqj1o(8;EYJ%-z0?(;jffQp90d9vlwJEh4*5vTMw#vgXV#s3?_F91YRHM z(}<1=CcrqCi{z+%&Eeb{@S7wcMAg?7!j{ZTr|7-rK}{?MViDuJGAmuJT|$UlTuH3Y zTMF#h$oI{H@Zoq}pb<1 z*gc2AX-K|mB%KtQqv7cp{^N!!eJbs)hhOQMEIk+Me!`Xu$wI z;C1TtU+&4r*1adoreC2Jnrbu;Al=nyhrXq9NqW@D zB*asm!$C})+{4&905kGiQK6ISDys*6>yIZm4!d47)nmw`AM(+BK)yG_^?#XKSe4ic z#g1%H@R6!R|2iLWBjzHIR?mKi|IrG-)cblsmYn*~TXvDEoCKiKj)jNtCI9Lux&Isx zY-~lL+t^G+MV*&~P|}&oyg*`G<^C(AGR_IYe4DvVE|EDHFze_ZB`bfh9!E?&TNV7C z>?ui6qkt00Q5@Uk9U8F1BB-w`vnbpn{-*{yL~Do90L{n}<9AixNV-{)uo>XD zx`{$d+xGn9jj2gVHSyWkUm2ukV3~!@4~Z=Nc*VLcMf&+QT|Q!3z>xWcz#SYXl|IHl zo&S*oL*}?gHx|l>=1?1@`bS^VyCg8QdDoNM6v_X6YqS%is#N%EN+yV@24uuEE|%o=j)t%Xr4O)0jyO=0g~M=#P*zo-TeI8S%TZy)DSbE zW~Q|~LxT71*s{k7v$;m>bKKD>YIaq>e{u>Q(1W15?95aSrpnqQ1chx!fJ~WHm~}&s zx&fYIpt;mDvsK91Ckeqa2Ki$hQ?^zoj! z7&5tIcls9!j3hd8d_Q{YhyC9&@BZgC6e;Hr-;^tyVJcXswW8ABY?cs2y`ozOciZvk zFxCa7Qqn^b(#YpEMero~`Sm`jQZydt(>_V`nx-~3IXrvxtD^4?2@jpEMd#FO%u9g$ zO2Q~`<``r{pr+oCzV>=QU34bQj%*?KHlP~|Dh^cwOT+g*Ie+(O%0`U2hRW-rU)G~% zeh>CT7@6oq6-(Y+@M5@U#TGK8@xo3oUJ(r{(yiGLRDtZ9s{>_lobi&ZmzLEsS*C+$ zN3|z73)yasvEG`}T%)3Fd_8{lEMgnKk<#E?+pnO9CY|8;;Arm+0mRUTGboNf$SuA4 zB1fJ5jhIh_%2%Oj8MU%EzSU05#!5ZzR*^HvU_$MUPC^_(d*JzM2_tQmp?HtZaOubmWx33avtEo zu^=S~Fbv$ViD)jo*h)nStvo!^rnNm$5`xXUFASI0bd}s{vhWRl%Q(S~ueqV&aFv%) z&{AdQJTTP)^yJ0qM&x6}_RksV_#L2x9)Q3ZIP31tLQkaYnvdJyfG5L}OD#l`z4ZDm z+_Oh^t4F&7?Me_K4O*71nxl2y9&sVig%$@CNLR9b?M+7I>vw$#J?$$nVj^kh;zcJ@ zwrJ1Axeu0w{$px4Zq;px`9XHp8SxOh^YO<2TcXST`3{r8T_i>H?1OY!4^^9{Z%X{dtLa>*q-mv z7fKpQTJL0V3(Bb*mylr*$nDnNf~67=#vJ0Lh@pJbtpj`v)kKC94kaHV#y?Fr5ZELJ z;jNfY)xprSgV10362I$TH@gM=jB^(qNYGweuD7}NN@tJ=9%wf48>NM14iETtDqD1p z4~u6cBEByQWlr(mP4B*v*7sjgloDt>};l?tF)_{2=5YYkp^zqcFl=CXAFkzRX!+d+ngL{bdCP7AZ+ zU(v}H{GnUu@37qH%lY-FVO8t=U>2kVm3zevx9P*e!jY5PlhV}4@ZuzGWoqLM(utM7 zH?8jD?LkimN3Y=$>^AO}znJ{B}lG@%FpPETy7GWU=I9kYzwx}C_H1c8YYl2Giz{7!N8jrr~nMRbb%MF zQ+gey&9XWw%yEyKx-QS2Xe{K?)xR3ud*Wsfw$;S14JE0dqYZ4`&=_iRt)Jq8(XSas zG1v=x5T<yoW7lVk^kiHGTu76FrqR}%ECuL1c8u9MKK~e(b#74 zQEHF8ZhNL*cY*y8eeX_!ZHhuAQ~Jx_zTUgcFLfB3JqNV&No>DSd3G!yuta__-{gQ4 z?vS2?(BUNc$1c~@9s*O{IP5YMy@SZRV>VoBQ7ABH<)ISKu!S-MQjJ^AmzhM}SZV|o zQ(YVENLa%LK4D+FZ2)-!Q=uxZ8EIcXJAP!D|SXI=iUOqe{1{C%Xq9@S~#0O z-{t9|L{&T90^ar%k)s_Chh?NzL^Ymj=ekQf)2F|EhQ^B(u{dLq@ycylx$+VPKTXfw z)jJ-aHJ&JiJ?`^x@a2{(hLP-l;2{W;L0KlvjkMP04~ z+88*j5Gp|<5!*2&S_=-BozB>4$2l4Gb|x-(cwQbPUVTFyCQtX1+Af0bX9W_9tjuDh z)ka(HT_~M#nk)nNju?~h%)%f+1WkTLjb{Ta7fpzHNebz(g=REJQ{WkJHNYlBxhsw! z!|z`;bS}p&Ku}htkbrLl(rCGjNxKkUI%~=b>Z}h*@GUwzQp{eepF-Cy@g#{ad zEP0slxFTka52+|8F{tL`Fn6NPpunMTwpK7{_)|^HnJN)gwzjf+wTfqYMwoS&J6Tm3 zyhTOJg!56MjRV}J9xfSb@%uKyiMf`eg7J2rctmeYH#EN_q1;nk?}HH(2U|`wI0d3` zeIECUW|0xg)Yuw^6yr?NPCfYvv&KXhSP1?pSH6|iO{;v_1f*v z4S=*zOV4349o!Bl6lmHNyot%9*pQnzwH;`NmvzYd$^&9{kz(~0jO7{lRd)G!99qA z8%{L97$h_^i7XfbUv z-bh}M2vly3Ao!M~X5mr2$XlkvFtoGXo7Cob@L z1Si^py}N6SCSYRY0|r;d3H|*Bp~WNcRF=(a1+L(>=?4`t0OS?8&)2`FiHMke0UkD9 z>M977mIafJ0_ju?Nn=N>J2mxPOk21Lwk4eU(CjJjb7^Y$bcT!b1CAU)an%zTl@&Gt zQ#D`0T~525j-+YAT;Vj*(_N!-l*S&nWjK_ADH%|9vH5U@{TgIT_N7c9^EMj(7dLiT z=}Z;r_q8AjP3nL1_=1c3ZA#+zq@*^~mwQpcd$Dp?I>dIu_9K}sA(9(E72vI{Vc&EA zO3T&{whPDvdeUp~s8X;=93AitueKS3W-Uer;^<@|LE9dyT4)Lz`YdmuElcDV-hv{N zN`RP~wzqrIq~F*dHGIcP2xDoTa^SJ89oh#ZRgW(&$Jv+;l+P{6T16>}9^vdb-norX zBif6d6Cl0ua+C}LZh*C=4C-IN^C%E-fhE@Tsp)}z*CqrbIdlX6wCWYQe@{AlXR}V< zT(O3urDz|j){0)!fSHv{seB(3&P8w!yjJothzK4BpD zrZvO8{jLuAQ2VNkj)RN^q*TGrIk-J82&eW|9Z}Mu6@TV$IF%l=4FZf!)?=ndYd)|2 zBP9s|A#R=PuCq8J5!h0%v>;#{II3>h@U%xJOI3;$*ela9qSdjTmW{nhz{7XmKjw|^g3f$8S!&3Tyy;ipb0g&ojoH19e zGjFVu&DN>&qX}p2+G6@af5EM1f1zmI+ia|Q9ztR`3I8-VW4{Kt!5SN)Dirp1u)O@y zOg8c52Z5!IALDbm3CR&h2dtu-A!Lfbg%Ui<_|UNrVE|zV!Ge7WRi!L>R)#`NYvTg9<sW8x*uXq) zWd4ZbLe$?Na5C@caM>kQaUySTmR8Zt15CqS_Pxd?V9JL+7+Y1#j#5HxMsmVPIOd`b zT4tKz6t9XEA`mLM7eXM3;!$-i>fo+otJ+8q!#8_=yBl2u_Q7_{Eh5mevbJ^FpJC91 zydIQGwukm(=;5&Q5lXL*tR2rK`^1BIHtvGzEIXVSiBRNW36`5Ohfm+UzaA_4 z6jX|utQz!%9serd0}IR!@FcBcQ`Nr^NCs?X|AKY)BM%;a750bizhC>y#qqO;h^X z{sIGG3%%wSE`>IkEb3l#6H9^BacRh37dutz@EMqGSfI78h#QZHH&1tr%EeE+sYpRV q(jt%m0001DzRVc_0ou0&$%nNA0000pbA`&A<555Z000000a;qY^ym@* diff --git a/data/intrinsic_resistant.rda b/data/intrinsic_resistant.rda index f7b18c3e4aa9f1088012a7e7993787a585f502b2..8f059d053abd1ee163c588e574d21aed364f0b05 100644 GIT binary patch literal 66828 zcmV(tKvQ&2UJ%gRpOV=m z?$kECL5*@;DY6ZZ)ru;2{6NY6B(5+TUnYHZo@ooOeSNQk!wkP%z^zPH={ge{DglK3 z&_N%Az~K8>6dxaj>OjINv_xmNmYp$;4guBX=4)beFY9x?>E&I2CWk|uR30u;Mr_7* zEyZQ8I3O*`$sJ_UsWT9_4aKxMSyRl-PEql7OA`@ja6E(Ap201`FR+sMajnB~e%4q& zfMV%3*C2u6o8sxIn2p}ECSR>1AbiP{8G3mA^-7>R=Y zHeeWV>b)uyU^${C!natg|2l};BZg)Ng3*xG5n9#cqk}jjq~6(?_2+~F1=^DaD2+$8 zy{RLrGpzF&|C<&m{G6%nS!O8#N^l5;WLb$D;W_=T?Hzq%oT?o8M$NC!_(I2&$&gJf z36e&RL_L=AQA0^(mm^2xO+Cf_Wm0TyB7uknGSU4@X#J!2xMbHyfGj#yoboWVGCCi` zH`s?XZ;(IOXQ$Iult2nU;V-Lgl!iz~tGmV)=^uZ;jGKlylREts6^M;^`tHENM5nyD z49Uw8E-8;X@aT$=x;(V)F9@PkWAGzq42Qul(y_UVH*yg=Wmq{m%(g**dH}pV;&z0* z*~;y;0d8WYuds`6Sa_dIultQ9x9vd3ly&2A$^2*}s8LB~bC1 z9lPG^f}DwLu{>@LqbPL zgP35dSWj|JoSUB$4eab$`9L_0lf7~r*mXPC04&yk=d*v{07g9dTq9pS*%d$pk@b27 z%6y|etD5ORa%sK<_vaz{u4<89%BQb+!~Q+!~_ z1+|W@FE|G(9faZYcY}bJXy!U5BxYaBE>69vo5{&2 zxCoPWEI$mN;EaLnyU8U*??&C z)E%`YF1TM1UA9zhsT3f7ShaZ{UmkkKPAT|NToL({2??w=kmz_*BSj1GTp#JAcCw4x zmER0INzS4AbP#aMOm@+i`r{5J#r`inyeG^Zbl2ldh8T(weWiTIqMtc0E%HfO2*|;0 zK#!p5A@yi?cNz;y=<}=r(srQ73d}6C_;7D5L>Z$Ek%=fwFk*FA5ZvvEhRci1umSOy z&xdcwG=}KxLIL`k_(Eyf?of_x5tnTi4{nC^$vh|xc`lUnR%$Q-=AcdOctspj2IfX| zKf-{@1pCZFyvwNGtUjGXIDPqzKPiPXs=eW~2_r8^Q|AEWp%8ekXOk@Jq6EAXTOs?u z)*1arbC|VUuHwWY_#-^SM-FEwyvvYk(=|iRA-VTTzki3U5vZge!9RV-rB)VYgj>Ca zIgkVBS72*$_EQkqHOMJ*P-^Ah5qj}9>A4#wf}j|r3{g>ze)Uj@#g(-Lq17KTaVX_W zdsFI;9*Z>_*U21_Wrr*JqQX1n2Lbum`uK>R_6WAdcvwTB-b$Xyy19NaX(_^nxN z-Du%YiN@Gf2ITXe0mG(7C9*?c3N&n%|2LP-l}hl4Wu9zalYfsmyrH>#C}qf^-Bp{4 z6^70C^W+DVs5ef!>%N3Wm&+>nE+~dN1W`iO{(y+eYKS4_;4P2yAOfqF0GHB#jAd~9 zFZMQ0eD8rJf46a9^ud@hL{h@7UHMQkTKWOEg{| zZ=;UTF2+3zb0m%9w?J2>_0;6TwUu3ItTh!2lA5df+Z{gqpJQ4+-zaS-Yd;5KPpFR6 z0SVpvc1fR7KDabqxsmAE*SrsA$9hZNvc_5g!${!$F}jZGBv9ZC?L)#jU|&Alt#o7vMY@vWn*vzZFC-i{O^C9lRBul&DC= z2>IBrgTrbIq&i5V!v)s=Dkokq(=YBnq&GsC+ETjDSdwXa@79sBX3kfDQ#5B`(Q{gVd^+abH>pJ+!GaCD?Ogepx50{Vx(j< zq%*7eK_aT#!e`B0N8&d(D(CtuzNkz*Jy8gOp3>zmg9LLa>U7SKyLY)ur00~}Ex5`- zxkiNQeawimms&#xxuzueVi?-#&6OJN+aJ`BWps3n?tq!3X8;oN-=3?H_j!O_P-|B* zz%gi6Lbp&KPe?E87kB#x3R6PsDPK<==x~Otq#Bk_|7dm72cKn?mTfI1c-hppLT1o( z)42B%GNn>TI;ZW_=Zkp8ulNMkRcTbdEO*dwe`{S*)58;K-N0h}(Az5~-RYb88a5kS zAk=iQ`LY`|J_ZEk=Q4%){Sh_{B(<35`Ja{N^+8ayP#`%n$fp0`u`E0*{xcLdTx-)t zPEGm(D0}8nR*@q*rr04rAyVm`&fKB`m&#F{LZuC3PgPy=D(-GAt<$?^!>@@fa+_m8 z1b<1b(vdlR245c4eY>l;YubfH4^WKv6Tbb8*+rajsDSs(58(YNR+_aSqH>EebGFV9c;t$6m0GeMIvTBViljU0O@@JNe!Xp#>+ZK16i^M`*l zy=5p}S))F6Wd?$~0sLdhcVJ1nyl(YzPsKJljdU=^`pQ$;p=`;|ETk4pY_`OG zM<+wa+G8->-+ckRR(x)U7z1E5agoA80`p zKWCx1{f9EnSV^CU6E8G{T<9tldt4${IW;$tq>%qXkZ*%$E{X2yhDlUGXb$i$Im%&8 zo0h`az9sKD?2Ynxu-jBE#MSzjV5y*l`Ny?aZC|FOZC4^+xquR74b^$$jWF=r+k;|n z14r8rF!%ab;^c`_8p#0ZS3eglcl#x#{q}V}L5h8<5H%eHcrngat>x0kpdhR}%Uj83 zuj(<$W`x}SFga)(zZ*$iRf0uR_A9nd2}UB>keUaz$O9{1f>cmnDT6o50y;beG_{n%D+G-A%=ez}bp^5Pj z3Z_%A!%@;J%zW_4cqa-Wx>e;f97GF?yHl8l)FQ6 zaY5y1(ZcyfQjrO{=7QgH_M|+;h#@F;?(p*0&1Rh1%;o0D2lx-i3z7WlS%bDnL5(X|1l|U}y!pXK>QG?1nALZGX_>3P02QIH#-}dx5 zqoE+2hx`sD)q-HUn2E4-6qd$T3LF04(tVivAsmi2A+;E|Q$xEUrExU1T8^vzIV>LF z9P02cjIh%rPHXi0Bf{PfDG^NQIKD_GJ)Nft7(llv=CNj7nWShR5vhfmm|Vx$V<*$1 zpPVZ{nnFdWp9iHZADcxw(YTo8v~M!!cmcL5+Bv0JU3|-K*qNjco*8IHhoP9|ou*Pp zbqPni&YmGB2!hxalx%QTEjL57zQ!6#m+C<4Z)GI)O$rUS#vyZFpWt&MUkoi19cCL4 z2(@HY{WGp@FTa|7pqjvncK^80>-3-DDT7lrz){q|_OTaQcrZ3Q3|2+0l*=-*?Ld*| zv`1}wmqF{(5*dV@4qp{7Nv=f0XwSM|DJv7TTP7z=^t7Q)TMN^=Ud394C(PDj2tzaR zy)XBR%WA)V!NG&9!`%>hcIIl9WD94Jp_bQe`r!4c80^G>#JE@`rp?D zFg`UB1gu&dz=3T?&})mC_O$n1Z8o5UY5(AZo-Q|7=>w@zK90@be`V1njoP}y-Txf0 z|Ki^k@EgyP$GrQTGm=ycnZ9#sit`M*bMUqH9!feBb9fvs4cW(^8ATW^oAX^X-czDo zd*ae(kl~(h-cRi9*V~9<6t6<7YcPB25H=4xvZ9C+Y7Gcz={`zWD@+bQGoAgh8b?=M zGr+`k4+U<=93_h#iaI!%66wlpE6~5}uNBwuNw8m8Bv-z*nvy|=B<8GbI@eHmSeNhe zLENJ{uZVONQnHWkb&)jU!|Ur$IN!}Pb?%YN z3_u^ZGMHZ3`O}3>syxmFl7#%J6Xh)|8J7+x;N=wN6j(o_L*lJ^U?;TosCq4&Kfg6PS5FQcj{ufZN|by3mU4b1&QlMy$!{wR2(VW z82#JH8t=xsW+=8I!5)(RzBOmAQD#3c$eFsUhxX<5WIqpmcamOMm@Von<4NUaa@d+p5B+@hOyqh1C9dco5_U^+ec{z1vMGxa9#1`wlC zJmk7;0_A#Xq~$P29U^zwvd8)Sy>ITFO6$I=%(Wj(`QNNS*DiV1LA*&=F5he%vUwlI zUR`RT^)SuJ<>5u=Ow1Smp();=--o!U9B_PV+C7#5}zwFF1BM_2_q;M9T6<|?NhzgH^_;Ejx|0H2{kgPGM~ z2%oVEAe|dwVu`12-EP2svBhb5kVr&@%r>+EY+ z5gDJWFJJOAts~&V+4~I%`eMFHmm9rhfI=gVJyvS!&9bCmXfPB!U5uXNCu|)6R#BD5 zr(|rxx+I?^uh1mhb8rq5yK^1x*ql*0_!MDpdtj7Rl$gDIQ{#x?R z0@#VMg*@3FQS$uW`3}$ltFfL$mNBA;9I}26??VlDto?Xt9DNR?mrs#tU;j~X79M*_ z%zb?53Pj@CqxCzGKvbcFuXmPf+m>9as2M z9z+A!1hK1fG%fh@(fo=v7Z&iqE0x_cK*f)CWulrJpHm+444uQ>l+!rD$XCL6^=6>V z3C26PE=}D85bze=q&8$zU{N!$nK5paLYtb_$lsG5O3DXME_U); zvNnpXHnvr8jr zDx+a_x4Qa0z5zZ}ok_JDk*jXwUA&wfB#W}|&V2JDQ;3ud{(>u{zDHXCIr17V6`9%q zK-O`SfuWbH!K+XYprs;b;MZbI5^cl<;x^ij_tOETc%Fell$&I0pg6i$HG|i=%s0y~NEG@qS7awPH2qvqu*j{A@_@Z8G)Dy51W)9an#QNwFh)iDw1Mubk$6wjv z%_^S}XZaE&8_P$VEVTsfunF2gz+FH3r{oosx^@j`r4;Ji=A8JSk#KHeyWij$3l>PPT9cH3^ zdNy;y*1<<|kfKWnL%m$(K?DdxRJIKt<-!RtgaB)X#5VL>tVZFdy}X-h4exzrQmzJ= z4&88c57QnEmjb8a#zRr(Du?GbrdLJFPFF`2u}mB$@#XpPYA3=}TMF=eZ#@P!drBf^ zQEnmwV|u#(ZNH9@5rYFVP1gpJh6c8WT7!X)e>7R5KYUFcxW~@2(6*Jcu@n~icJ_KF zHYl4jq592d-R#gTCHaAV>ebaR1r&~{|8S2dEOUzlz~WYdpkHtc@#^*;VV}>h;{&Ul z?2mxWbW3$7cSQVki-eIN7Svj$&NM`azS+#Fu+%YW2?P24)ad0v)$_jW1Yq-v4=+s6 zP;>4Vit@Hzcrj8PqFHBJ{n3FK2_yOjw~cdVyZbX84rZbBHMOZE%>FT5hJ8#^(=fNp*sX;60 zE*{c7ZJy93=T$W#N4{pHgmP(8`@b!w9VUW^s%tF--EoXd%?l^o5+V_gp!5smPS6~A zFbua6B!zC&!~;nx4O7jfSTA3&4cA-ljiAtIqIL|l1<{?)Ndhx*rS+^;kRpW|yxN9a zYUz&sWS>o^yLV!(FcPZK6eAug?NM6vpGb~I9^rur7;pc0X6_Kz{LbS;v7Nle zsKpU9i}qXuXy~J`jWF4v3owQ5V>Sj&*(5X8mUV&XC60g-aBs~;a{r#>yT7^YHNOE6 zMa`x7 zhVsU|6diJf2e(~rlZtqBLUe-w0@$?lzez>Eg*+ty^L$a$Tu5hF5)u{bVP&5<2l#JS zm2p&J>@+e8jD`a<_t6Q?>P<;r_pa*n?7EqCr$*00&*@F;hO3V*$w@1O6(X~0On|!P zkVoe7ro9JFAh%up%x@833S?7Zjv882%iho5m^FHRd<)8&j<~N z28i7$o%{8V6-11<#Nf#F4;rR0NeAW})Kr0zz`IIT@cqoiKxdp8>YwcEFXxa>Jk>a9tn6piQnve74Izw4l zdABCV5WX*`oo{u=^3&~Uk^HfRJBbTl6JzIk`3l;Hr`y~1f&)fSsHJ(SGC+kp2{yVr z#KNB017RuzoWP3lSd~09Y8#Rw{Nk(M-0U&q`Vo<x$UE0G^s#g`PPk6|jF)gY7hp|4hh7eVFI`HCfAPVx=SVMI z`>``>^3;UQW`aEgsuku7GS1(|?@r`b%bq*^?ob{jsO8y}^BC=mLBl`J`@ZeZE>p4@ ziI*V0rgVG~Lt}@k)v^Po`4!M>yEwgAd6HxfZ>dk?1avywKEGyXoD>XY1C04lT%z>f zdSw2o^JbG2sGEG`n$^yB{&ud}Rb6<_3fnJWClIpC!7n!X$*S8x0%`O)f)j}8??q~Q z4qGF!d3zG>Rz}}TS=~_Oh=P9ReB^A<|Fa)CT=tJDc`p;<28?Hh`$O!ftidgK54yJABESsqJZac^>uny>L9wDi^Zq#1SSXMt4Mn-=8sp;lJ?vWUb>dZN8YCL|)H2Pj z#U199y?7dyDq%tKC`@wce`w8DM}=)6d~KyCaO$}pE#IGcemAOrylWrxe zZTKmfD=~n}*pQdZNuY)lnf_0NpT<^*KN?WrF*f7Ig8zo?JhcjpC1#7d%_RnIPJ!enAP6>oPp1`_dKdp<-pzL;wrK z!PujgY^pDe#{z_`H;^S}C@3E}Fcju++d$9c-J7Yd4o=iO*Uw=EwZUzO5hal6CN&~7 zOkp38x%He6+3&76x(kQOXV>j(NeBBrALBqqqDlF_UBF`H@s|vTOXi_qb*5*@7LC&6#j^mpVaE*=)IDZ zkAw)o!aGG1yVe!9dGo&xo&KsywkV`sfnwhfq4~Dh2Qw`+gX8U0!?c8;1}&cO7SZ(0 z|4ZO-4kt5`ywnRt?sHmopF{3YjV~IA3h@0UYVj%yBEg?X4YnrxY7O`6>~ZXe%PBn@ z!Q%8#cutq!xl!xURa zu++w1?0$Se9*6?S+c%{?Mie6yIHoWTrlFGnc9LJxcKK&s;0BoNcQbcIaFZ>DghAHxhBKZdOL;R)<1v+UiNu(jG=@P4WQdE&IbG`!VImJoKb^A7Uw!>sZpEim z^=tgVF*TrwV}d8B?s7_u-Ya_164N2{I#@PavH@oh@U~etP{xSBhx*`svD?t<0uxRCe4Y;*^qPV1pJI z`7Mh;o!)y;6veYLzO#HdtKZOQ%6ZdipvLb!q16R0R1qUClgXk7aP&)Yff6A*vymsZ2U3G)zJl_ z^V+@kUEG=vm%ffoxZL}EP7`YawK1ZRAD|9=V@EG4_qb;gIGaRFF)GjEZyi%fWJ|h@ z_~d8X+Z-xZzJwe3P46{MNF6*}Dzjk+H-VYY>Nx$9xO0{A>vkxJ*lz&jC~H0;@olMr zYG_cc3DFzC&LcC?)rM9^j{Hpiy8KDjuJe-k^~T^k{#YoY00KfMrGpoe2G=4aXz!q( zQ&6RfMu$2i2%*1+Gd~2R#Bjc7*f)k+kG(saMNWd56budvR3*0%;deD*$ih8R;B0v6 zz*bUf{(YM5=W5XofTH-ge_&^7_C;$pn;1PwUNoYL7ysk2L0NHn>}f-w^m*0eQFQSY z*RXd@lYud?7GQ11D6IG~l6YlqQy(b~Aul#dbc|b|NtN^oTz~T&rTm%3*VI4OwaZj+ zerg2hV{7#%;5qU8Kq=Z8l#v+zCO$cuoI6mZ$;ATe+cOWiNad2QQJceW!iet@m zGr?2{%vFg*Vs{{5D5T&l$-|_4&OVsZal)u!YajW+n|V8AuZQb}U=bUqvg!&$=T;ki zHC=f%3>0f}jqbBAHGXjN7a|~fkW(oZL3!Bh{LbKTkU(Nj#e~=7iU2Ej28@5k$Tnl8 zieSXDGsx47_l;-c@pl67{op6@Rzi~^{LcN5T}34*;(UR1n?Wl)gf08@9qfM!-SH=x z+C6l4d=b;gLovxbXs)BC)!kV8B$EAJ>(YK2f$>TX$!%?|*MmR>uY4BC+t$p0XcZci z)jpnM34U(B;%j;rv^nrVw{GTR!r4g}I7!>Ja?{wv6!#BF7n(<>4_^|N?KJ#S5OpIM zO}`C`dt|t3dRj*SWGnu%3ZEx|5%qz+Si7Bz!*wA|lj zk~I`krCC`teCBoW2STXmz+f$jlPGqk2;qjY>vcLn|Jxk+&$_(JFJ5Q}hB7c&Kt5m= z$9ine=E9zMK*JHZv%6o07*yv1IEt`hrYP(NSAp=sOW;&U;klDpDxI}h(#pG2OxIL< zS1g{&fj=ZWH4=rv^g4(*X{hOczr;jH>`?<}Z(KYyGy{Eq#n4c=!b?gqG}--J@48Jj zx|Adhd{76$I-cU*@n8wSFFDjFdq<`5tc=V6;v4TCu!oNWr-!k zTy2Dwr_^MRezfZka7YNK9|U!auC^VD0*{&3U}k)JNgq14UdvQA0uft{K6tg>R~aP# zq=4g23hCB=No?|@P_etsU5mB)lPY*EmB_B)8AO~k6pMr<5ksey5#2E=nO>nbf=f58 z{7_=xEa{HmeID^c$5hl&vRfujxj7)d$?d5l#TuL2450GfvsTL*t++7<>M)ej|v$eO-0~x!#&K4il?cKC? z7qWFBEZNN|gIVd5`=>cAhRXm^xWKbcdXuWgo{1Wj{+r9vhU^ zWZBfeh@>d>x8y*Q+64QrG#m)+2B5C!L3cYh?4+3?5~5zJHnNsMYCGRc{y;qAfm$&E z;+r2k#DxpK)2F|^#>l;+kuE~J+O|quEMIy5^ocMwdqRLfVAXM&)>|E#YMQN84y*#K z{P*_zOBp-VYd_h)tz+#E)|P=ZF32kcQSoFtgxW_UZc=V8e`ix0`#AfuGvVUtlrU!* zkjX?7mVj4#G`+lL%DXH+7yC0$EYz|v81U1j7cCo`XS=s!e|Z&0QQg6{3lZ8>MII@9 zAnQSL%b*wDC*rf8$jS<2WX%o;0rI9|}b9uT1?+ zUA@nN%V)B4Ea;Z6^GkY|{lZm6s(Ru!xROG&s?hwvF9db6ZeFLCFuqY*EyL zRJi0%BW&e>|mrHg{#?Jz7`{Bc%ZQaoD1O-`q2ZAv%3NI169aTB2D+b`-t(gi-vr=HZ8TU z6VW2XUA3zsHZJhD6%$TrssHLja`{1khdc(OOI<#iWCt&Zu^8dh)n+>ND;$jwrpv}N zs61*-ikr*o$RvvC&%i#s5Nf--t;GVkW`U{?UDgX#{2gc(t&+TqP}{+Y!G z;GPAuu-~|EntO>yW$Gq97vnfkUtRI}xtpeA%hxA9Y_(yFAQrSx0$Q^q_rGR;aI3#7 zdUXiBwf(|26)Iy;@^wS|01OK4|yd*5$JES-%e5V^a*wtAsDPO|>T;2}B z5w)4SQsJdiJhX=)2LtpP9teN^WAFUS*ivDT)i}O)SwR81RjUF-J5hENHlrLqcg|B% z-A&^96%*kbC3p}dMu5F>tL%ocx|5)Q{&%o zX2r>8QcDvXUp#4(IWQqqs+VY*g^WfmfK{#H8^5p- z#j^KuFg&U%#xVlId8-dhFV{cP)6w@2rNdWoEr$vMhD3h7on<5y}!F zoOsl{2q0eAj>jN50FK0Hz4J_Axje4Q?Eo>J!*yS++4UoWb0{{smtwby3EBnUYBqCp ze`5c>6(VF!q*`^H--FNZ9lQDi(di}MoW^)vCg;7{d^>B#T}p-OjMu@oo5A~2hKq`4 zTMLMvX(edeI`VBb5hko8at8#ApdVw_4&u;yjhnYH7j=CRZEs`fhB@HOyt^M%GS zM8oHU^rdvyGuW&^s~eh%U3%nt!$i^y*c)%XA|Oxq2Iq`J!rmNeI#>F_bshZQYm6&c zdBG`2)f@%AM7gh~1~F85*sc{3jxe*I60MesD!Jd5@3K9=JQ}aAVzq*u3ixOPS?#FT zl{d0K$!oXE!UMxeNo`wDg8EE61uYVB-T(Xq+xiQ!`apFs*WY*4pF%#{nL7TCwGB6# zbTyqWjzLrV|Fc+|o<}@EohCXsj{pCrk`F}zhb7RUz~1NQVWT?}NEyBiOgRaTL?_E- zE6nudHLzff2fi?|1@&<}!B8OgH6l?>nLE9#Ou^gLBu{JJl4L;E>&J{&I}3fS$WoAa9m*5(K59MK$@{i0O%i-o_;T_$4!E^g6sCJ`kwqnXMSB_WN6%s?Hx9WPPSW7-I|g zIa3YLWcU4ag&~soU^hcme=xK%5CMwtTDI3`y+A2{5(&8*E{lk^Qi&I=`$lp^CGt8u zT&F95OwJqi`6x31(=S6F!sadAOrpEeflwwz#U|1{YQg#hibf3?DaQnP?u_!9gtHez z1ov4!U2NKyHoLz}d8dd{D6Jp9`UI;}N^7I_n3)ehL=L(O|5dx7B8C~(G28x{fh%jUKZEiqU6|%m^K8HPqz}xk zqZ-v=O?SkVEB-`DA9bHAj~Nw7&muV;(w@uSAHSbj`1krhYZAD|9mq1mm@!(tHwC+W zyOq{}{mrwip{t(+2MDz`!{Bc$W6}WEYS${{X{M^TvRtwsMC)O+$UbwM676R4Q^she zQ8eNK{z*mbZJU{0mGFKk%#))Fm)M5%Yq3{uM!45k%~z-iQJ)VJuCqJ*KURD(i7pa@ zP$hEL%qpW5UlWtml#U8%QHY?9KjH2WD*=wlyZR{aSq~QN&fCwGw>rs;SJ210ZjO_r1t=?_Q$%ci5Dc#T17 z+V2AH5aFu0OI9ak9JA)c$&#xm@lKk_(5`Klw z^m{;J7w!FUT;cw6HI~NwDc5#H*y@pzI)B%;u*IJBiH>h^}+BjBp^hq`Nh5 zrsN**a?sXZ*#ov`)BK#DpZG@mF}W`l7LIeMi@6 zr#vg?4(jHM(O4G{N8s>AM_0Wye!iiY2MGaHuAlF!4?55m7NV3jeIc%3wwBzbWay^f z6;p7<5PrJIUAqY5`Us&2rjY=-qmgGjDr_-W$a?XN=3q|}GCPdaD9{Z#>qY{`t8@d8 zphX_e#B8zxdn8`ByIe+2FlHegS|ss~f$@|bqxBKQSrBB3=Lsx~W>CDL)VCzkC3OmVV< zG^>bMHA3BdwleaOZMGj+VXh6vD3f(VLu8cnnI&>N;k{_qc*peJ;e^BMPxIk{HI0*< zKazDTBJ#R`tRTLB^>i`V;pM26K#)t|ra9H{`bup<`BifU`1OkhvJo3p$q>pVY5Y9i z8XMwzr2OA>X+B)NJg%N{4vi>dr5zKUIkYYlIJ?*P18punr!NawvRqheoV zmIpjhaM2uVNcu+fyF_@2L`5tY>$72$EMT&fty<@<31N?{1mZ8oe8F&~MEMcCChO|} zzKRS0gdPU*U4!I86Na`R6V@0@@o*5zTVm}lx7=i?cR_+aW;?4lcbevExNu8uy^(Zt z0w9pUNDzU9cM-e;n<2+lvC5ow(SYbq3=_qKA7qR#dIg9V3Ae~U)vZ> z{x!l&F4+IEAqO~b=aT48SUI#QCy{V4;i#r(=U@ zv8z%ecy`TSj$Uj#Awr8USm?lSLrf!$3juvWmR1)P2JXvkB|S;dbkp68AJKe;Nq2KO zF_GtvS5%Zr!uut^r7&0b#pYktScw<)P0M$C!mw6S6xX_uQFyy!FF|oH@Ous4X*S#wUgy%Bu(#`f>AJT=c3@_7H^XEZkEi1Rr0T<`yP# zj5vX8{7?CZw-HVlIgZ^^%-H@c7aaDd*{JpoP>u`q2 ziXQ84sx!cbY@?5(pWMEJT{m?qAzH>!2hJxpe7ax%$V~NefJN^@-iMyEb#I2+?SER- z_37RiF4YIGlOtO8_z6rR?kjuoPQc-Y*~s{GAZA&@%J!d&aC}uT0|U&6?@`jK4V0)D z@Tczfl-D3|0u-fs!Dy73lp2VRwH2;+5 zTl}tUP~Y0+LMyTr)+i^rxN^mOJ1jYRdzNG{cs`XR#kLtqgNR*IKqU73dhj*_6(eV&l2UKk-&vBX*kD7d9Yha zM7W?!w#eDtf*13I=mW>+F>_cN6|>EV=-_l*VBtEm+>p-*O-@HHi&%)Dnj>S{!u*ay z7~FdRSD2}h{e#})S-pgM}E0dT_Mg1hqRJeIu5!fJ~ z95CcW!)C2E4qA}eFZoQflcb$nF88L&!MtAFGh`;K!Mb^v37x<7&V+M`!q|u|xaijb zsEjaFWEqxtE=2aC;0G7#EMtm3C8y8XpwCdae}76$te%~`)MF}_Re;U*b4fLlOtUrT zH{^IFuZ>X`wJE^TROC)FDOz#qgVqWKc9cL*jjk%`XFpO>=~37?1_sq4w^`90)Y2YO zfZQI+8#BE}-eaEo()T!M)W9krmFL!OaXn_@>P!hFSQ=OgZ;vHz+MhNU@-RVRI48>b)KJ1EMII>`*!3I=t_HfhVmye2f13m)myFq{o9n`#&>7tm)%0nRP7s~A@gxKaWs zWr`2i3(4mj#LDlo=Qo+-%hA_<1*@AcI%ezkQ{!Rk=#PeSR zG?u@mwY~3_$t!XW(HHdngba3iV*O}T8ct8OQ}G{kEa(I6wTz&1hGU)W6N2z&{x02e z*qa@#`xWTlfU{U;?KG*K{j1yv`mEOqK&ys`GUkvtPp-B5a1R1jc0^NwRHYGUW}coY zzIntADHVJr4JG++A}&eCw{5lF;<)AheLhFn8drQrY1+TIfZ-}1$=R!rm%v7@i)fb0 z#x%a|yjaKJ$$ta?I)Jp}G(td>*aA7@J|oRnAW$6vDae3BdOvccr9(nk!(B>4@}%eD z&gvVfYearY;5bOM83>rsOcPl>-$%2S1!}tOuAM^+WFsu7G42q)QVblDhkSZ^$cMYVq-`Z zo}l(F4xcK7DehUU!=`R2){^f#*He7f1u2D-eWPN2O3Y;>?2ihJFksp3!wPAg)@oV~ z!OA8VtYVdwfVf}yEn3~Kyz41II7;02G?j&wsiwOgHfXw*VH;CGB5n{=3>3H1KVdW*^PyJ;0 z%4m}EpZ&_#05;6cVBQoH2y)w0#Urx{JKw+W1=c*yrebYhtm5O?E@n~&E^qH~L^~(8 z5XZkHR_$eW{jVHvfa>udxrD*0L~f7rQbzRKK4XkDlW7t%JR>@Ir$C$4`1Cc}!U$~P z{dqjatpOAK(<2d^1F6$#9M6PY2+iF3$2{>aZb|?%K+L~M|Mw@yBsmpaiXlF=E2Y7L z1!`qr%N&Q<`k-4|D}ZDL_zYYLrdYG0noW7wvPJ99~A-&@jF%-+ih{44~EwjAoJ)*&MiJM}%DlL%y;D;a@OzHBUu+=ZP|xCO=z$c@m$VC10KQa{}6| z6E@Tn%C_yHUYw#2!cTA(RKYkuKld3tZOduQ9Kq|jco!(ZpTxOH;RC3Z4Aci{bo}KG zK}&GCDT&6m%$64Oyi3al^q}dtf~QNF(UD-dNF-X4t8OGxiAx=m7wa~A^ZP02p$x0y zVun`cSkRUr23*Cqgc(7ygjY@m_^of!dBcmXGdyr*4>E!JG1%Bl94+HiIhHzGh~6=` zn$_+Br*1!7&(upc?xirewY{O(`TR$#FKM%#34t9qR@BacNbnUU+gg^Dvonu!F;VBo zD-Z)bZNMb59l1${u`5PHNR1bE(CAsiN*S!i(XDw&gUGfq&cMJuNd!8Fjp*r$rkL@N&(8_T+zE@ux;nrY{x$a0+F zI?l`~HLa$6E6_>{pKA=jTF_zwuZ2@64JxvuNaGb~BC$CvuQi-{jVaY&)Bw(PmcSF#m4f2)1q&FzPKfQ906Ej~9~H3KH?*yH)Zl-GjU|l}H8n4n`~rH!h67u_Utjd-<4fM>(5WttmFE;#t@lR4RME$#NvPQ_y>e(M<>3{j~E z$w-!%!{8>HFP0QYPRd^{PThbIkn&3c1?OpYRDt5w*l0NT#jQ-0)R_jZ|H#X(maZ20 z)eh@2vA)HkH>;q%#I_$^DLB2R!Ao^ongJ@dHBPD4$@NIU(%@=WhyR{PDR;_(ugx6} zo0#o>QS?)AODM5SD51gYGBZl~&nWj#{&aQ7b{InnXm2L6>&qXVW}D|&MJFzw45a@= zSe_(-jQ)Mv%{FmUhBoZVvJ+@@GSSV2cChK zY7sdtFLV+R{Mh5ivsfs$qIqGlim84W#x^XdcxlgIhtqQ&P(*SS7kBR)dPr+robt%@ z6KH*H@GfwrrjL_+TBWMsO6Jajm)QEf^YSXLvBM2WPaldNZ@g`1@@%ii4Q}@OMW^5L z*B}Fad=rI~GsvJlMDR# zksC7-dK+(K?3XTZR^@^W_t6JXwxR*va249#@47^X9KJlyvif*|dI&DA=#hS1hqfAB zznWx+_7se4mMKtc6PXH>6-&?%Y(y@LRI)SqT^9s12=k~RJ#%R5&%pF~88tPo^rX^O z5!Z>|v`;*<;~%JRnty2-#bvLFVb1wF&2v4_K#CrG(T#}|iq2JkQfI4t{(&F(9F1^h zFaj>ZS3y$2czR=@YFD^7@_8aNp}Jl7 z$6Y@*OL{W2G1h5!!OWm-AkfHaMa7$9=7-%hYI|Tjq#n%!s~)5v#p3sxDF91)<%sOy zo?+XpR*s94ca-mdT5aMoVM!_>c}VkA=V*HdYe*qpV|Q@ zb61v}-vqj~P@M4$D643(yP9gLEqT}DFF_UrVdG}IwBFZl9g!6M zqT#2FJfnItGM$T3GrT=-=2_!iMrD@Zji>2KWh~R81rol)8B=wG(8iAK%e5wZUCVx< z6DiVvQ(F`T*_k-w;rdsH3DqI>A?A3%+G{F8X%5SGF$nm$X)}(i?2HY;f z@+?#HOY<3Kq?^BPJmegv8H^FgZ;6D60d6}P=MG_)Lua>XYo{-gZ%vMk=epvQdBC08 zTE0+JG;LA}Ag0AKpRX&1@#UU%af>(Wnp@$D1boN^NTb6ObtUzgVPm&L4yENRS;?(h z0JY4SRs5<9^ubkjr)`k%$l@lnK_F6RYkiW%a!8i$r_TJe)JZF(x zCl?*`je&);w|g<0|Crf`L`kw1qu;ELhh~&99rK@Fkp+#2i^NxR{r{%Xw}xPEIWR;x zFGB|s9m8ihOf`y`y>7fr7y0oR<;hb12M0EohMFZ=PAqC0Bp(H`T(oB&D-Gc04$Qsh zlkvC0!6ce=6jy?rQ@_@ATQ9oQM@MBS`be}$=RMj{b3+*)@JjqJgt8M@beaAglea|Kdpd>^OM50KoeHpmCV<X5j1M!H8f0Zgr{bi1^S@O;cI5QNyYeHv)& z$zVu|WZ1hS1>Ge9V(_b=?;ko>S1=@FRHK8g>P66_Koz#V^kv}6Xrya{Db|Mf4u!t~ z15kp>gUtn=SYWbnSdh>YXyHP{d{$I!(#4S=pP~;N5Z9o4S>w#=d9DoTUjxt>5(S0m ziO-t8kjNljm6l|Mf6WpDmW2yX89+bz?a#9sv7<)ZI8Zlv?~ng@>0rAPxjh2ti-iz# zk!Z-N+BBE;w%74+GlsNyrzFxsUd%lm1k*D&T8%=N%leNDMT7C8V8cgks@ z>Y}+9miEeBSF>(hpwGB*wUu0HGAi4lKdPRY&#~jHzK?^{^SReTAljL$`jv5r#S;^Z|0?0&OS$j|1?JW$Tq zpA()7$(BDg+@;L|0bjO>SG;qTqWg&RbG{tzjJavvG9&|{4HmP|Zs4|c(xNtTBQr7) zWKTcOc@&HpQlCU>DEOPI3UsosMTq+y7pB_kn!Zi<{PZ&rShZiN87xzBXv|0Narsx$BKWOproA^AcX zW|5EFuP;>}R;&SwJJ-++OZBxV+D?Q3Kl)7Ml3@83dC81-x$6eSe33Axs=A*bbZd=cei-W7<;50g)*mtk22O0(6s_^w~HW+Cf ziyGC(K_{h`p{c|?uCF`}^}<=|NUm$+r}+7?gKBCz^EQA;dlgR3BM+R1*OVNY4i(cz z!p@oH`}U+E%qI1w)(Z;=PfymrlpWS^q;^9Ym@*hfOli9uT>mQL(;emYiz!2E3gx|s z5EFKGA;J*vMx6E7R&LlYR5*fVp6?L4qtG$DE-rNQrIq`_e%26@=^RGZE!I|wmryhb z`yc5>olWt*{^B2)X;`hL-Z`eX>6XjT(WUa4$@3*9Jj1O(P#P|)n@5&w@vh$=i$#RJ z%+5;i9-xS4kWKtuGF<`+C)G>lmgKDBtUG@19E?M^H$3|ke^7<5dRWk8XU2FhbzMqo zC@Bmx+zt3`w6!!NMNaBAxvTH#oM($VkWDhMhSAp4p>>$SWmH(<@$kl4O|`t-45rB^Zpall8ulm*h!%0}2NY>7QL1+Pd1 zkbD~zcP!cg07hrPo@!Fx=DP7YNtCMO>1o0Ww*+qgCqJHbVdbh zC6FpbtKQ60&Z#0A1im8aoBU0QamM7`KIh%6Ydd+=^F@)@{NDG3{-7W)F@G#ft={A! zVl(eZ3DOVOj||jlFW?ix?bq)T{Zt>qdX)O}|Z1@B`+jB_g&J>qbVP=JI!dq`R#U z7a21c+%pQEJGDerO-fuATb`}IL0HMNX0PGJ+DWg$24O#ge>FOH76q}}cX%fzF&nR#PVc1tb`k0uk9 z^%VFDrJ0S@Gnh#X2L*259q3p+Sdr{j+Q9CS8>Xm$MWK7^3jG$e_iC;Z2y8H_l$(I# zostN%<^}l8aLzoJ8BZVo->cw(mD_R7W}j(``@zg)fyniz_HM_iQ)PlHBi_ zO|Gaj(}owooWaWK8Kus6;i%x44yj9N_~AnmvCpc^SGnmZZbvs+DN)PQ^S*2|7Me5cvLbt^>GRbO9|!hy=`i7rxQfxK=lVp<75f2&%GaAL zTruVtdoWY1VvAM%U|>)=u4?Bdg@eVW`3mS*57F$=b6QCGx=&@3;qDVvs>z(`1Go?* zrO$B>u7(#~BgtcV91)by5-^yRHszB2xm^B|(sqDeGf(8<^>4}OG21S~V7CGEnK;PZ zbrTzY%86&(IN}b_&~d)GFf%26hmt9EcKa_v=LScQ{b?X{j+I8EO=eRCpnXFqgXd>f z!HmAX)#jo-A+4j<-Q_<|*d1rYm^Cb53+u5zOp%5=Zhbl~AMAisLxD>^=&o=3Xlk8B5A{lUnl!g=0LLVXRFsuAV6sS2{y*TMVZ zvHf$>bwWE7j~>|-I1k)}EBMc;o(PbL9hz|rqTtvQ+4oO->2KM1F{TveE2x8htGWf8 z((00BoU8TwwD+`e#R-_g|I&|kl)h(!O_6V+c*Wh~{Y2*n`I zaQKOCmeQryjcCOQAc7(cOQcD7YuqF02dcs(REW;TKc$(%-8xALn!k9V^070KkDiS2 zK;j7Zued$CEx-v;n+U4jo;g33>*$-IB(F(mt;qil3!l;Pr-uH%{Hn~l1)IEMs>S3@g zqiRc|eO9`TTUDgi{P#qnx@<)_QK|E_rzGGtS{M*yRc^mb{qWCa9CH=B0cv zOaf`~CoeKU$`yVy`X9c~g$M~!Ulpp6Y{xQg26!7|_=K>!tt>#9I?%!A=443!s0}a= zr8?-H9bb-g;*5c-9b5uO!i3l$>jD_S4Tk|UVIo?Udg;dRoK8M_*_pZYZW&5d?P-su zwV#lWQJvrruW%S17^803=SB-c@8dGj8@PQCa68rY^7b#YQuABjJkEH%U4Kb32)k^`H zeCS`59dYGb+ynn34L`Y}hAa<~WyCzbC~9GaoaxVN=fRw=UWrSw@g5x`<50vWagfYk zO-9KW!XL^rE94rLW|^t+IuynsysIJE_oaCqnR(!q@p61l@H>%yuI7bXF3O6nss#Vw z0W4FwMYky8>R-_}hs+--^%zh6dFf;O`u7Y3jj-z2vKT9J^#05Z@fYHSl zW9(6*3~o>LclXM69V4TpTWkev^M^)LSDh79U+d7|va(i@VRi;_&W@U6tf2D(S>|{k z!h6=a<<4i?e|?~FdVKcu(o>I2(hdXWt5Bn30XXh z4f4?=<$MO&QPWNQlzve_()~<)4<-T3+=%e6%zsd&6SzgQW=+}r>q_d&?G;YQ8qP{j zQu5un5O>INGo@9nWrvZRZ(J|I916g?;7}J6fKu{plUjh5O^QEVUWT&+c-m1~+XCy^ z;bbf~qg{gSC=TRA1&V54lV>fd2~8lQL}hP6zY-;gnyct$`Tz4!v?vzuq~}*gAF#v0#X5t;yQBGEyBFJ*mV2_?C-7Ikbtdf_YwB%jGQs)uo?V_e!~`;% zVLAW}@G*RsiW%vR|;Zt)@mBc>Mzpa2cCoX%HnZ5Di~wb|LAP! zmnm%osxNp!>t1n^cVZ;fH$9%JOz-fj=A^~=wrm~W1PH_UQ>;(XBNj{>KF789C9m7( zLgfK9Iy*%+excef0R!VJ4d{Mi5rftdDX4btndeo=BRu> z)G_9S2W2Npwk%#O3GX$Jj1?)uuXVTswq@6o++Y(5uwcj%h-_ajtns3btprGdwCt8k zjkT7|@zFOtFHI46@%t|sr=g^97JavW-OuUQ*3<+pXv8ew6}M#`!jAGOyuQ`QK;;<% zMQytsvOme68euub_B8djNt!&+$F`ATv7%lq;}&&Sbqp>B=mLUshry_waYvWr+wXYQ zP%x+I`g)*LXd$=@e7A{gyjQjwi{>_*? zdP+X2;ACOKZ=0W`Z^9Qh?K)tVaXfQ|l!^h0PA+FID^h{++{FV%Rn5MkW19l5ab!CG ztvX`bejr|z=W@x|pzBNdScJ4S4%(9@OYFVmxy-vNT)e*Yu{%hJH+yJeUHWw{te+y_ zuYI9r5?jGpm@85F8PNO&sr$kela%RegsRs&+2RqKw&U&J{#fy;noxXwyKqdRDE-k$ zgXT%u5t6!KX*YddJ5R1Z_a?k?LS&7(syo4_!GDPv-fLO)u@baZ=W)9(lP{<$3fLg5 z)*^2CFTdlOOi{0p&15BoY~_@}t`>8jG0nhytP53fq;}wtQ0iyXfNMwk7@=py4?p9D zdqpD~^vBav4dUqN4r}_Ud@iM;5I%>M6Vx&esEV6;hf_$4!iZwWRUXf`dB=Ab%kjC1 zGw_dIOw>1{kh?wLSV}ZK@QuH&jLyTC1Y0^+?Q!h#1YkrWMnLSW?VVj&b#XCu;&j6( zhshXYKWH*b5lTf?%{wS%mN|F%A^?6`uT!%7`Q~%UF2B!t76x&o-0O1YZ*L@-_?Av2}1*3*R`b05pS4^PP#^1=ao-~@0 z=qGQzy+xKEVTT-rjzkI;od3<9Kq`4CdcfMWP)7)oQl4y3@ZUco^!+6F_R6YAFR{r? z;uI5&z>UEe8C|noDn<;cWu$zHWk?UE)C(d11=RRbcmXfY8iiy54nC6=#?>g)(dWa7 z;swt-@@zOCFF9ZcrjCPWE!)#B&8m|KEvUoXr_4VflH2r>p!JDK_@@da^npwKQ%eD5 zDL>!U83A%)nPs9H?|_^X2-fJ@s{!oE4)6%)_j>tCd}$`e%K=rL5?zqC^q)=Wgf;-B z&w;f<*+-$;?rO6M$BNgux($S5F1sAw)Z!wyi?(7i-SQof&F9{S4m zUJT?Ae_*`OFtTv5hk^tSk25s?45C0I6%^{{*qh3p56I~xdLU)i=2ZK2@1VZg%LSj_ zG9Q-pHE4HFWAeO=X3bO@T3UGs(9%Eh4?4>SE(%@6)yEmPegxQ3G`z?;FvayD^w{{J zXQlFZS~H(jFz+45fVHL>e^0rHIYz!QjlIJG`DY>b*AnZ5m3YJUWVVtt<{uB+OrkDz zuT-b-a(|D(_13*g0y$jGI*hF6`rA;&^NgzVyV@vC-TgV(R68mIIR!}F!P+?ShRD(! zj|kQ*n(j8Zn&Hj6FyG;p@UaE+R5JjAcADEB+B?ji(wB%$(wgjd%V@2_6to^Rbe*3j z@Ai%|)*l9_ZQE6=b|;|bzZ9^*webwk_1bzdy*Wb3SwRuFXaSjf-NK;4#pHsCJenao zu8Fz>IsF~qL+T@AAarV3;q5pG0NfQX5gN4Tw4lMh_M2M7UST~jU4Ju=pPcExNMGi~ z`If^J-OTaoz%QOne*2WiqRa%8VOm-HGIwB6J{&z#~KD(CkW0ElLqdEABq03%Jp=A3{A#nl73RH%s*2 zGn>DL!$Ec|d^I|T)n%ush(0ghwQ=1ojSvw;{$36?%Fe@>h6t$v2W>yIlF*Cn?Y`|0 z7UcrF;b9J0Lb!vPRE-oBP=v^MsQbVfAeVXB%@_EA*UTVPw8Jl9+Jz~ohmu@HlFXhK zJrWm`FWs+e`YtZl)n9Of?>+PCiaYw&{g>A_(e!G4L>ap%ZyOrVc%c+@MZvZm5x@YA1lHz-JNZ}D72IbiJ#ru{^?rXKm@dE|wS zmwndSt~WMqpL~#Q>9V(j14^#QwWH9`b+`1aZy%{I0dP>O`eAHj>K^-&5WJh)y|9b2 z4DLBS0)Fn{cl-$HWnM(w+0MY4Y}RLi5O0j#LCQo z`_CHNbS*9@&i6S7pZ>aR0Ul=DScRx>p;hSD7iI;OS>8~Gt()oStK{Ya>POVw>r8-^ z&LO&H-JJ2SuU>&EG|W89W?aGll$F6kM3a2jm5|)-C9z{wdO#$@-7+w5@}$d_vcuum zLboec#{DVG2BTbEH~#sdzDP;u&kbKIUX@JE7_^@?niH^R2iWP6PgW3h?i~)9 zN+rnPJcqKC5D8!kGEKp&Vcaf8*!Ga5zu!%6HFKc_FvA`l{~ts+9Loq-Dt&!=D5)Qq zX9=ZF(p=1lonsloGvMk13Vq>-okr!REmE^v~+2shi&x92jcAGiYO{ z>Vk5E@d){`)+p5Q0M!#2N^k+vJHd@jQbLKB^M@HFGM9`9%_xiBQAnu55YTY}bx}|o zKISIWza>yrB1{~PWN4pTrTT!i*rzOTeT5w|Oji}lc!UJzsPjBhul8kDA|+C>2VVki zzo~Y-mk~o|KdE%v%O=TIH`InRA(I)X{|m1a)M z1D@YK1ph|N30gUg!lIN_+IwGNcExe@Bf8hWAD)W{Q7L9#1OPiG4IYqLr40^Xq+i0# zyPl5|>WS5p&2%Cf>+1CGW4otWC|8EHwDwAK(7xCI6_gGwHtUR5-bC@ZVJ8;&b1;R5 z4{wuyXO`TG0E7)C{$d18HFeHHi}N6b8eBA#Np5KnE%f&5^^*)6fo=|vTL#OcRS9q^ z)aAV#?w^cp?>R8aMf2`1Pnp4q-f^#mKd72b@Y0JI-0p4!*s-`XP zGB<`~`81`azi092-R?%aur<8|IHMYuQB7O-13G}FrP>N3Eca4mI_AM8f^gJO(#J~q z`Z%G&!DAh?bVE_>xeX~{1u>RCB1Jh4Km#b`Qil(SnTluX;R!`Dgoj=CA4_v`CulTSRq-aURp*Wp&J6Xb zLl}lS^%1KI7U5oy9zDeLPqO(MNwYJjc-Q&%T~!d0I%xVQP-@y|_56}nKd$xg=}ayz zz#0je{Q;KX{u$v(lTZ~qO%9Tm8Wgd19lj1l3`k0VT*qO=^%JZtlV#zT-3r*U{-xW6yR+W8JeRHkX6gm^7i9 zNNTZO{7X(R7@kQHT2kFgx|47lO&%*9rW71SjfwhKMRC>A(otv~bhK^CBhIAn!d6T;#~@UR+p@hg!gUbKLaY4?#|*`An!Kjxqelsd*k{?QRw=+4%=%I9E;!zbT_ z(N$r3=+0mZG3d?a({PV1h-wb`5^^&IqcUOCP3TxCrjB#KkO^ku0>w#9;|Ea~L-Qzo24zci+jUE@n+DCZmjdJ{ZEJIJ;OAe^6 zsI{;Ok@j%Fs8xnI*z*4+XEouEW8L64)a_h~7SKRch!}P$A1?VYmYG^Du8xiAADQ2(yByCI2O)$&Fdy)@4DLu`2(nCkRUE35GX&n^GF z741;2w{iW;*SDRmFfNBn5wRBd_QV zPeEXdpaE}klw2GGWN`M0z%KF5g-3$2K)I(#8!whOWhuZNh<5Wn6Y!8*{1Q&+7mPtN=tELd)>~IYwnp%t6THMy0mv z`Bgu&-^CH>KWe_WffWDorSh9pH^xOGw;D@cgq#*9bT@|Lia~lR>KuzJCILylJdJu^Wd1DvlZ5r!O=6;QMX{B;{~fRX@XefU_2siEy6>cQ2u&3}5H5^GvB^JDJC7!d#HAB2N3NtZ z_#i{QF2GSw4}~X>3=a^^Y&&23MUc_87h0IIHLo33O4EPkcS0(jefH zZ$3E|xzIk}eU08{(DEOz4Q>ql=C%%f&;&JDXv}~Oa{hx*L8B$rl0+V+{cK3{G;JI{ zvgTwEl*oi-jtL=A=mhWPhxR_y{1N>PuuEj}9Kg=rybeCsrMN4X8KrT4N`uWD9=S-q z$_a}ut&v!}NL}rHwKTo%?SEuHL5grtNnM(BwC(|IRX z-Q{-+V5#xOZdTxRC2w9{M06muT%bl+)b@v!=0LO3n$8^<4FC}`iy^m2W-!*(KB_Hl zLd{4+YFV2SOrjYPNTvKX=M*o(h9!Ihm6Po~c!-{OziCpq2>4;Mhs|S?$_uwo)FTPC zm&eE#zG;9+z7k8A;A%+00s6W%if9>ye^EI#~gde-k6mk4j<_zym(16`eyHnN*EOKgeyvln)NvE{n~M z9x2DK7wsZX08n)s>P-g*xHV8FCmu(?!NY6cG!!NFkj(c9i~^x8dD^0=u0ra%%dk9y#L@vrFWI<9Nc!#Vl}!&2j|n>FKF9D zc+GY;xaLMo1UsxCiUgB`xCEWV-JM-UL|%GSsE3B{!vQu2`uv)q`r`V%9_tB2VROK> zXU*Nfp$}*oMzwM@z8%-OY`q4p@rmQAi)l1{-5GjpZ4q#i1*ucEcfiYKt^z^&uubS_ z(_@$*OrNeu8Fm97%FvlNZ8UMl&cH9NC)8q@ z<_96%w5d?7!_S=op;_Odv*{;(q`L2mx)7k}8Djj)YP-ERvs zTzk&Ru{T1}6durad&)~?&ce_4Jzd)HVr^I&-h-2RvUw%{!lOTwFy-A>uy`D!xu17_ zhUdS3p-ul&+5Zi%an#!*lFybQ#EVBXoK_26lVfb25)xz?#1#K-wY{8=1cx$IIPxD_ zi~yniA}p??`Z}P}KWU9{K}*78?PSZmUdo0Z1HesqKGcMeOvoGTi@mi!&&|$N5P}K+ zO~4rJJMkXKE#KY!i_BA)|r0J?7(*lp>X z{TspLJpUBLTwGuc^m1o3Y#*Zi7-1I2GR#aDYL?D;cfI~I*lw(X1}$X0!S8fwz|JXk z?%y(B{d??*0r)(^4XP(28;#34olyQLa>OE#&_@zF24Iks^upF_dAkpaJX95+%B`2GL$n|$ zW!6re+2yg@B$4u^xP2*73~##v5-gdgp5xt~f9}gG4jI@{NLx>_hkPCWoHhy3akg_C zBW!#Pa=<9CTfS*#a*1UPT4CWU&=O_J`q}2!t4D4hJd;NS_XKF_320P3uZpP2cC6Al z4iqU87;4+hSKy8D{U6BZ?Eqkw3wtpVe0)59nBT&RUem6Gwm@r0-;RfGDU)awU;n{S z@E-vrUryxl1o=~2mo2EGqBloH)lu(Dw`D9A93IxyDVqZtQldS;4>(vYLtT-aE7wPQ zwQQ(WhTDT4xYq09%kaA^TI1=oI%E?=@d$&gb0|SM2=s)g)PhWJVAB zqA^1YAGSF2q0JX#`(>et5#0v3m`4x5)HUt{`Yxx`!1%X}jBz%lRu|s_Pf$g>>Kfgr zZ|)mE!JO!)h+>HWkorE>h-IRO`h5Li@ZYrInbU!+DkgtWN)kSE_N2nqSqSSgOonhy z5aj+Q!huU$1u3t!%&;>nw7@`YAEL5Nrzdr=GOs(Z^Q*dzH`~q%I|Jj2tNnpUATYRU zw*%2(NY25wN}4xx4do%wl;*+631E0;b|SEkxogs82mbGRGwB_1r4l2<8cg{OWh5s0 z5t^LJf~eZn^L4-QZA~{B_kB@Zr=ZhxuB|G?Y&Fbe#dsyC$1Dhln!>wTQ- zYNW7BJE@Ouj3th;9A2rw3bWmY;H(Ld?UA#~L?Qd>qGyz(#T6In@lzeccBa=A7X*#C zOd+k%LwnL9Rv0Xx;Hje|3^m%Vt;^*6$T1jWJ!Y8)s+3fk$f+~2KbHza_R65dXZ9U) zAYG_G8m!zd`Ay92gV@0<8uKJ5tLL5>x5O*P#Wg5pC@&b9u|ud#K!Dg) zB{H2ECvL|)mB4Zh5u|%O`Rexhv+J~_w6xyc*fpDy$#0c13I1W$gS@d;d(6DZ% z6o#1UdLiX5A96;HWBvx^0!Z>?n5yiU;7W7ZPVVK<^tHoj5(%4ZHVehnA6XiaC^ zZc+54XMKK%e`f{#SQzfxN0?KXIjS-N^r1q+qFsr8DL0t;ncF0HA1K#!k*O4g6Enl) zJ~l1KhNoT)IJDCrR%vM?bFMceH3&kz*z;ULV-}nc0CFdE>cfjck=jxINDDeuqcPc8 zm0;xR?rjeHCJQBFy6ep0j065xfmS-#Hk6uN&pQDA`O(UW@iR$v*h;@IXtRoR@g!th^Eak_HL-MR6u%cAych~%3e9~$8s|0Ze*ifD3IR}L3Q>8U{R(`!;;MN7C~D1KD)-p5haxh9ZCqCTFI@Jn);ZGNv)*n{EfK zNS1{_HGn*dQ70P=nz?vIw593$6H~r(gN!U-9%Is|iHLv8B-kr8W(?-NBdAul3oL*o zC#y5!+>{$*uf>T66-SJ%6WnP@W197pj_-?xk9x7HN?;k7wSIrlsAFO^?FK#P2QDe) z`E2|y=23u|3;h`#Gs23lXTF*XP+E)(_AJmoM#5|Ymx<8AmbxzAImDswXgDK42bt&# z<0ZT9CvJujP^O~A=GfBCThYj`)+wkdupuHCD77N7soZ3H9QgXF`okw{Xa}gt=tXoK z!kKvCx2+IIv`Gkh?;rbrzmvBPx6-7c5#=9#K#eLVjmWl7@Z{_8KdOq$Pj!x8Nn-yD0$5B{rJM2A%5?Z6M&eP(|FifT8GPw zj)JBq1UMExN0MJ4VV}b|u`wiy9eCiThgQhDE_twfKSiV;TSz--1Kj=V={5c1z2 zgFd8k>UURqr`|z|njQp@*xbL`27GJVWk5Kb`Mu~p*5&ky@SGf`3zg{89eV3^gQ8hP zENg+RsAMtQ?0T~fn(W~%mOqp9hA3luvjmcX53!)%p3;5!M$4nRNvH*!k7#5`1DM2U zVBNm83As_%70|FKZ&P~w!Fk>bJXk=6LI7jHP^Ym}xb1btem+Y)zTQgJip@}sxf0->x$@3VRS9n0KoP0f~kG%>_Z3HBw|9qHuG>=X?ZHN8$opv=gDc*qf zI=Vm|QB!=Fh0L!*SqP;B+#J9kVQ^g`-Z$!mK75Y`mA?zMeaX%h9X9)tMc1hD2j#`H z#er<+J_d(7Djgx2@0|$_jtPgYRzK1Ra4(A2H$;AqF9VRXEnZbBSe4@MZNz!$AdRWi ztCp7h#|5$;>dD*i>%p$7=MPxp+UkG9UE!=yp!=N`a0;Pw5HxryT z;AufSNJUubvT&7b=0(e($DB2>$``POdmL^n*1-mps9bH$ixFM)I5=s1jwSSno*QOu zN%%?zE9hpT|G*|emld^IP2)N<+khoz90&I4JAWjwTO=7vzTAWFqrPc&8k?6W)OVM$ zbGv2>)3sa0Ql+tSYj^aX7}l{~e9||Gl90F^iQ4cU?M%I1va~6Ank*-y_@lM~4@;{+#Zp^~#n0?B@GZRjqobD}IewO){g)@hWyz zot;04YGuxoW*<~j4BtA@DI}j-<{pJDOAg$8boV0MOKij-S&}mf!(h+Bw)L9O#SgPw zGq-_Lid`Hp9wMt76EnUXeF}oLXUvD*C&xBqeoM~T%9`>UJ02xk;NxRmHx$6R%5`Z3 zP8CKewY?f4qV+5%;WE&rj=roz`Oc0<0*DitBr!%EhL6k(#`U{nKpgk*+Jvumtf<0e zV)xbLMkgnyL^QMdK$RjQtlB5f#{qcDiRPviA5=3aypC+>u#dawEaf{54x{ zIvCBG-uyB|V!w|)-@^Gmkn`{$BAhq|Hwb>&kPSGM@NQ=3t-SNdV3YNyLAs(}BQOAT zGXaSLgBL&HxgX6!@=B12lYgQjE&q}KN=@J8N6{A>#8r^v^JEXmHHO7CWzHR%2NW%H z(P&JBd&G`?S9n}JoJUHVfM7QzQ!I9rX7gB9DOVN{N8tjOPBE&|P87+WqK04oYy+bb z{Qne-B1pN360}zQjxASn+Lg>My2J0UsAxWhfa(7~pV-;I)u6sFXr7SDf#%O#*H`0wZT-&CtMNJK=f?`PY7^ZrR+!%)b~+is6_Yca>!#n>O0bB-rOkma#L$4Pybwh zeo~Rsn7y3F62MT5q#T>F*On~(16By&`LYafZPa%T9OOE~M0~e6Q7&8%G z7Wwff1}K&Dh`m$GD5O3rgi$VM5+2Jh>Cp$ARTBtxursulp)voV!h0A*Lk%C52H%r*^Gr?c<-ul7MpfrFn(AgJFo2F=OK zDExYGnINPh4j0gf**ky4WD$VV<8dR3NUk%3Yxg6iha#Z;o%N@DZN77!K^i+v;JR3= z2|z+vVSbNTWbdvg28VPaG+$jL^7$`()Eh?A*5tjVmdc_cm3d=NDUZt~g3 z-$*U{4_CCN1JX)hSSW^=^Zk*GQ7laia!Z{e-ZftqE}O?AjQIhYN+k4fMgn(x@)p03 zZ+9mJRs&$lA$$bGq*X)OWzwoH{1#~apxnmmY8t(&X$PfP_S55U1Y9xXSIiGsXg%uC z&@f}Dq{KngFRg^nHy(S!0g%C+&BHWAH1Kfy{8*B{SYK>FQGBIJzK9^d%xUU~Pe1xs z2leIHlQ-vc`md>ULj3fI-~0_~uHENnDpBspY|5T71hZNc;WyDygbViQ^KhHvXAdMBa* z?U0dFRCl)@V?OYRheimIvzmxWcvN8x*pzsht$aTaYikO*q8d5S*hr-XDl?!X5iQ}! zQ(-&pKHgR6x@Hb?e<B*I_cLgA%REl+X8V&%sAOVHtUV_4WD=^*4Td4hvF* zhFutp`OCKh99wOe%&X?lu&%@<z%UOx1&y_|@u{ zx~%fM68}EG%;vpLEc}Rkos`)q50^nuxB8aM*CnD&mCohapDJ8MHbgXsc_D;H&LJJ>)g+gZo1!8=$p#9gFxR93ku!+{ z|C2bi5$IM54eD(Jvhy9arAm}taI%d3NIml9Wpa4p7Q#1d%8z$)O;Wa&3W=2u`9tl^ zP5$}MbNA_iTvUT3>FRZIH96=aHOR&2*I8AkdZpi2wWlWIJ>0opRvh1WK$dR-Z!6z}Nnf;4=uW6nQ?B!%Y2k}LJIIFp8nPQIF z$;zg8*K0RRn(;77T!XVIR&SN4!X!7#CafjEI6vDV}dJi2Ine>V~Jra^%Hx>fP+- z3#>BIJmT-s8pKvY)f{?ldiUnjG!VqpQAxkrgLlWvn*Q4IYO0^;ePXC*4or8TvR1Sb zma4X`2s@D9T&Or8E8E<$iZ*eE6SB*kKv#X0>vNPS6>X2LJL3De4X-~gYwO>EtC_XvMAItk(M_1o*C7I{1Sv~4N0q1HV3$Th`J(Y>^Y&kKY zNb)~5HgDL;N(1ljfJ@Pu6*Nx`UaOW)cXx9y*^Tu*u~V99J<8)R^@Pz@>_8p8E_KyH zo(+Eq4A3b?v{)e;?s%<9*YSfzL|uH-sAlkTQno~iHq?8xt>a@|jSt-ugj)rQ{l4jf z?GbZPCU$BVwoee>N8}6n224&eN&wyT}r<<+M#jYsfsdXAzlxbAbs5jTCcJc`hiG}LZV^tnmaM|*_ zMiYBb)$}W0QvsU~DLSHU`QHfj{u%9@Co~N}d^=8G=^JgUFu7OE6DQfoULniChP1{*E32VRr+-E45#0RTHN>FGqvZ*Vj%mEHNeTDk`= zguM4fx10~GO!k(>kZJe z(kh;B=*l%~(Q90WX&0;&v@8KM=t5ipewVt9I~xw4FM&`z37IowxQ~;oYL|~0F`e|p zk+7ELIPCAqI~+@Q;qUAWsx>5Zb(!*a2qI~s&pJ>J{A6#h8Q0{o<+E8m!zyPhK;N;0p3hx^#dcdXN6zkME>G z9amD+iY6w9L)f4n(Mw6ZXjg9KzSVz$%8&CIp;oyvx~iyJ4_@RrQ>|D9$kMv01~91`X0h$K$&Y0BszG($6KRYE%IGF&#o$T5c)Y9Lwwz)xE1r(D zymhugIr?c(%2;k-@g43VPe!n){2lwy`aWj2 z{!RBPOS1!N!l0LDhE7>SlwBkN93nJqF4q*)J|dc0S$ zWmstAxQ^#z0uTh5RX#YICEV`*zxv10G)Qr4WV*^U;yFXVO6Q2)14=#D#ga^nb`}$- z#&RT&jD1HsKF(53ktW8gdKQRnA7@B0!0;4bR!b5~$&<(2FCs{@8Jrot1PThf2xt2zLWJfv-93@~)J%}2F}u$NR7!EF!VA9tLUHmG|LNin z8AB|qFy+-0tkp75#XH)r~)o3_p&Oa@NkAy zINBp-H#!}b&aAENU?2ZL-Z(=R+UE&}zGxC{Z8vzyBB<@ZUiHXS1#%`?F*i-~7B+-B-`UY?5 z@LhB!R_#`d+xHd%eG1xCq{y{vU4g8*QC!)X@kn!PB}XTZMy={44c%ZU&kv`lT)}7`uskdjcryak#X93WTan6|k}t^KHx}b@qqvR# zlobV=2shL1lr^?6x0#UY7n8%?1kf(5EwU7~j{TwuD>!_2`SJE18IZ5vpZ%`Js4SfB z8G^R$mY+8`)=>@V`&>^whz#zK(4@I%S1R3UOEXn~4OlcaT)R%ZOJ~4LnLKVJGD|iN`(WecAy$Pzk`~TR4guK*Fn|(uVajO> z`MVhFg((Uv^|_{WNg+z;rrA<%wa0;_+TMr~k0INHx1m=LaX@!X-diBy9FWZ=U`X=+ zMly}34#03c{fIR@rmSyg_d{rX0pRoJG^`D4WAWB4O;IkT)e6)H&;uzF^=m7tN#gMou?73Z9Lr|O$d`6He^F0&REx%*v{NlLTPmU zb;iJKxJvS#*++^K&qA0MmV85s@M@-{U+QEHdG9mp#}=_R#4C`xVi7Ei8;q6UYIDEp zpSw>(R}(-BE-Jt=1UtwN3-jSE>%Nv_Bb?O$b~?+;!!;vcA*o=?Vm7TV6vwlZNz{fE zI%Z(e0k`(bxkZiyQVKPU?6d-2kYUA#;Q!-8_ofO8vTXwRe`gfg$84AXm zia0MdvSa(y6eh|A=2fx(q_V9PrB34%zUTL0;Yw=|TF0-A^y;1eke+KK0vNiDqVKoQ z@{|KiZ26~v0P`C%zN>%rg>qD^LQD+}$47YDtFED_1Jx|GZCtywCs%`oqD6$4;YTGJ zCN2#fk>?De?Rbw2xGPHSIt{w$G*M@)W`(f?*DXYy_K`R3zQE(|e%2yiVQ6 zlH_5Zw9L_Mx-V#_b2jQ8s1BA8wYgh0YsXHXHs?Nznum0>T5Xz)^zeUi-PwV_3(phC z!|fkfN;&!uh7h>`dFiL|BzQ<=i*1MlpsK%{S=3wc?BV%r71@X+0B)cx-b-9^%Si3z ztMg9MKz#YPRk1dksGE+v4;7xGRvKqDBuK3bYm_!^Affo>k)+M{WBe-V>~Z$2oT|@q zWfSeN6rf>j(UH5@>;C}6_a=N(Ag6^kxeoIl-MBy^MKt@KpM&~e^T+Lx`||;!S9LBy zJ5hikRLXV11qPIbd~2T5Mtou;1xO!(4y={jvdJ2gwa`Ix=^Kxf#pKJ3K!is|cPnJ7atES!=Tbc#%BUV&Vc&}7XB!U>Y>Tw&b)RBu$ zgY^ioCOoi6=Nij9Y`T#^PP|K23z6sJj zwyW%@MWH?<@ZPjdiSf;8Ppk6E0n;DvTH@ZYE||p`awW}cHq{sQAbklFttsW>7?z7& z854M9dKOuFp3E9M5rtqMp2?~KK^%k+q!ZG%LU&(|4+pc4g*?dt!0k(-l^w)G0V{kMU@<0{THcXm8 z_e1jT3d)xp*pd$re;#-&7TABd0CKKGZ@{4Fbb2R@Su4$L{-QyzXRcsdE=&Uwvu)F1 zQF&+Cl}v9HRMv?rbKw(NBK-h-_a9u>(iW@9DACW%lU~8v&j$ygpj(B``yqQmAOoL7 zCtXndtpx(Wh~!G_@4}@k5_pvihpX)hngEB{fg&3-c zzxSm(5CSlsk8I-UbKDd!SRW{@2?OVKwt{Xy=$+h92ZUv{uv-ISm=KI2q#S{kJ^ru? zl{6l%zrwU~;y$_sk0u9)o-@Q!mu)ySPv0@zbj5?oVj)ybel)rv+4YxGe*y5aDBa;N ztnI?$#nKc4Gg^M!c50!y!%x)V$5szAWHK%V#8T}a;b|NvZ)za#hZgP@Q;N>Bd|cea zK#O%!UKsU5d#db+Ao#9k{$4++ANYh>eXa4||F}^dwEYv{YUueydVX@n**v)}iFyzy z7RtNS+spmstA-6QaJ>cQ{rE#;kk{v5pT!ZM*wKUD6~5{V5PNy3&db1iuFvbiICaVd z>G0uaUU@g+0`(MXliJNn z3-chfL^h@4`^w{lKHDbTeI@4Qb+VNZE&=71~2}S)DjSQJ~Y$|}A zp_!Y#B*E_tthBX)d01%y|7-4y+TLzHtc?tS7a+^93!4yW8ShTQ~C%oxc_?&BL%t=AjN))JyLsx2Totbyb<(n z?mf2;ctZXs)n9PiE~;4-pW-?o?VmzQYJv=$GndF1$%kNOUjDQE9dQ3rFQJRLm=ZWIf&8mw=Z^mh7|Z-nb14wK@)*iL>V-rQ~Tz$RSO)`-;r`{PVu?QafFqtn0w z=8xwa;RgSwLiKB=doaY`N~h-?P!CA1M)2j>-+WbEY1{q&09Br(&TiHAX&xPh zu%f|a(=4-=tbg5YVs{_c=a9?1y`tAsQWWVdn$JEwao$6_8ySeM~Lkw>zw{7;LwJJyh?%+z?Fscax6i6rE{n+ z#ER9$xF+-&nv~-RZvEs_%a&A7sS-1L%4GRuF=RhSe3w$TpfMCRh{{cjNM5HM=Uku1 zj&0Sm9+mw$?z8Z>5|yL70Q^~X$_MJ)kHUTg}4BU}B)n9-q{T64%*8>PQ_hQIF zA(G-X2Z_+!tC)Y8IiuP2B$_6UBqdNy6y{7lSt&c-pHeR0|9l;ed`9gtQsHan_jJfEo^e*%tH#E=hj4Oq>E{5$+FXj(N! zI28q9kG4}9sFe54Jz0n`PBuSW$5qLzNSnVCJ*Bk32LiS)IIvv4Gd4Vq4e)Zwt*VfQ(BQAmNF7F{W()51NV+}I#=lvh=kQL(_LP_CT0IT(+6TR)jmHi+ zN3bVz;^ofcJaNge8aXmFT*d6>KJ zQxV(;RM`!mHFzrlS18X+5UyxJ>A`%jG;8G-yAZp{_3oj0L=5|J>Ymmi$kE$3XG^=y zfkJ`DI3sy7K+B!!;fJn{Q-ZBOVz~cC(w~sn;PVj1KMNZ>;hFlg)qxLv#6r{r>=NtzzjJIB#+=UMe7;iFFt5vOuj)%>b4i<*aooL`f~7);c~< zHNGZI3BS>Ep*75?mnaDbjrws)!{NfQCb_3)g$Jr@CAn9;>z&cM|LjgdHAXo`jfkhW z3Z1!v-@E$obIY6($`0L#pcQUkZoa_t;RgeluO=h4NJ>85kk-<-7>r&WlPzz z+Py(7$~`8DZv|#eSlWYzA#PC&k(C-Z=Ecd{5TtDM@V;Y}2t!-zOsU2BI<3`;ei(FK zd}edvWn(jklV>`Con6G^t)d;QgZMr;&nz!(UV=Z5uRt|$f~6gNdvXNykk@6%}9t+PICeY3_*N>p|TB{JcA07wVliG>VP{PUOPkSgQU6#0q>q zG>VnbhrN>{!4pzHj}I9bc~sW4{SC0aI9bjFJFkH=0<-r0V^}i{7j@B$YuM{ z6!vUr%;~z9W@VQlr&`Fr$?uB3i0EfA#QKO9MP?FL>7oq<<~YPPINAI@Q!24z$tD*J zbB&Sxlfz$m_Ki1;_tWD1upucc_RnUA?Ig}bsd=g>)}4WXPl}5bUno2nc5fD3XFfU z#7hR5>rFIP%fw}ct4Q)h04t~F!o?#ncdzmbtNOLWxmR8vN1gF(rvhZ}EbMtAw#}+F{kl>tz@Y(YDQFAlG&0flAVo&;~VM4hR-8@ePv~FZ=TKWf6%n(=? zna{Tf2(kz&#cYqQJKyb{xj)8hvU=eida;`bLk{FD#=3BgiPN&LR(F6OQZZ9N11R%! z7k@H8K)gPL{yk{Sqj?bN>Px#VO<#3^2eRewgeR~Pqt~nHY;zXY{w|{xC`&^*B|F_Q zSX0Jnj_4nObl1rMGkPgn2%4d0I-}{*)>RJ)mGD8JCn4Ug2^o?%q4x%2rlY{=`v+aj zySs#IbS9;2rVCBzOIHMMK8I=M&Uqv5d&=fK00o)=XU+ngl9R&i+uGKjM-XD3vb0(A;5Q^S;eWM5}fI9H3IWzaP&>cS(E>YMJpc|`+;HNI6q9U zf2kNbzWTnsiyJfFjP*t~;Z#lUNRBJ=#ySl8xeZTnV>YEOD8z1j9Me@}BeZuRl;9=V zY;5petw_kRu7~N(GZ_87OFD=qSbOS0`E1xPiqO~(jvVTjigp_r$#gckntOTv^k4fb zOn9$pB#g#non%Hr?mryqSm+skDbnx~XzGxWsQztGpA?>zo@SyDENc?!5&~W^@S*Z_ zag-1kN-l6-I!L3Q5!ju4XKtrux@hlPLSBHDq5Wef%UZ;DUE+~ZMW>_k_(R@~2`R)} zJ5s?C^kpm$*3RdfX^dP0-9Koy@>YJnM2YWBJ`(ESIXDOi8wMfHHuT0F!kYrW{s( z=10Zi7))U)sh%?JqJI~0+ln7?I}G%gp7LP9i_7X}#F?R@r;`DTj}rwWMAg((N2#xG zdgdP`7r}#S$j-_=L_H^aHrgMMp&!E;PSU(W6EehqMpwNxsiUGk6Gohi1_m^G-iCXg zDQ^&y{ref`R=;jwaI>>XfNJFy6T(7vuq( zcwyr;2k#M-?B-|BUXzw}u*EFS7OI=HddyfqO0RYnupBuzUk46MVdZ~4fa9o1_&USH z5OeDj+8TC;13Xgi0IVt+t1WhXlZq=fKHAf*>$_M(6hC4qeHqkhjE%F2*406F+7Pd1 z6**8i0_}_w`u!m)Ar|X6^phlnF2v)C zeY2t49k=0DzpBRQ0_3ycZgoogk+qS`S#-Hnk@IPoIqm1-L|GmBa+rao!&<2gs3$)y z9)XC^?C7R$_sMV(J-U>+Ao^H+uH`a=MPjzzT@$>NuU1BQzd=E#9(?`4JF$WO)1%^C z&y|qB=}!=J zrB~?Q$&`=Pfp8^Yz*;6zBziwrtz|%jX^ll7OTzs)_U8PY02HJGbP1rU^n1L zf*fgW?2F|R0~9x2^T+2&&I-Ox|4s2Rfn+%dgn5zRKA5?AuvRc-J=EZHXn2SccEPud z8eQU=srg~J3}D(d1{q}45W`3Ta>Oc~#u{+3ux4*#u;-c&0_`FVr zQqheDaJ8_1`#A*834^XHa^V|0gJzAyzDd^=ALqJlJm=PQ=tve}XY&&WvMi|3)FKV7 z0-GDgt70952G5yllOuf-K&F1$*5(>LR&8WW~EU1_jfv{0t#br`n1dLUo-%r{}@<%6x zk%egnbDq&Dhx_LG^?+;7%@#-M1w*d zIQ%TJ=;vEO6;555?fUPAiQFh8o@2%3+F*#FT6fqFy~RGqisv!Pl8N){Ozuq~xih+` zFsB=3G+{s6!q?i)_>TetP96Z=cI?ho@W%)Y>v@B%TFk48Pzk?TYYN`kqsTC&RE|3I z#D--YM4L>gyqffbq(T~@LhR_X_T63}1%|tQg{@~&p0}ink4Udp&CE|tN99qdY8e3B zWF1xmL0J~D^d-JE-nc^tB;3IBTD5u+LN?!6I_DL~kDR|Ub zsOUytVvOb zTE)O7ri0L6&wiyaPjadbw2{q;fzihA+0+3vfv87#e9z0&-_SqGXw~QIn44>=O*{Q;ECB{AM?VaKJ$E%a+9ku3 z+c3EV*1PnucmU-*{&6lo>o6^w!X>#-DCuI&mvwzAW+ z)Oao)W@D!qviDAACfGtg*&|CM$DqSmjvF)OYaI)Wl;Bd)R=&*BiWiEIA2foZd=&IM z{K%r-R&A{&ruvMKSGJ{w@mT*08G=VFoUToJr6=XnBRT%iF7{x_X`*pjDMs-g`IbvB z5&mtsQQ{ZV{pbB_;XIZ^7kJrfik#Mr#{+oCz2g_S1E_U` zQ2s-LmaQ*-Dc3FcONgJXRXHusYM=Up9mTwU4_~~u(f%f{gF)>8g9TJK!|dtSu-R)S zP@;&qUT0q$HGN;K;wynR&DDU#RSr2CVW#UGzzu6E9&8_C_=Vj3kWV7es>5^2qq-S- zT0+0CbJc|G8Eema$_33;pD4bwW%TZXG_=E2Y9LE6&%_m5B#p3 z>@HapCEoouf{T)IF%9eYDPK!4<3I5d2!jFW(WvIXWZx?r3nRGOTCw@os~PRKgyPP7 z1enK0X2c`ctGcx)L14!fP*?w<3yuN*OP&FHd-y43A`W%=rKLmFZi8+Wq zq()K>7;sl4nis>m9Av81atckR%k+fb{E{I5NuQ5oO&-SkV6r5HvFhxO$)&EL-tO+^ z=QvKC&@}lh?*xv4`!{ZK%1Z}2w~CE=n9mtJJ83s0AJhgCkzWKr{t85;m*p0bNY2-p!K#|7xU`4%YiV&WyL(e z41Ka4=w{Tx)O`>CFGLCPhOfx&d&PO01%Q)x=yp&H8(BHs7<5}pe*ZjmaZn6=2ZX5U zX~ZS$gb@t|8dD!ONYt%8q6H%Br{V@P0LPj~lp}qbw9siZLC*SF`h9FO@7pV|TfJZ5 z@54ri37ch1!;f2Q9~YRS>Gu#UY7Ve=2J1dC?RqQOtZe+4w-*2rAm)B($yL%->p-M;MdE# z41ORsG|CBPxx@i97gIpXW^b2bEUoo( z;F*{VkBhNI*)L1qC;MK3iG-Re30;>`8RC%+En;a**~n-3QUfB;?2&O$3E=hFA_2sv zD=CGl{A+Vw1&5(}=UEK2D_>VGd6};jB6$Mc%F22Vj_Z*e28R0;bH+g@q<)<~13ui& zuQl+{c8pAdYY!+aXYJIdYFt)Xi;}gTOH1)lrofOFDryQ_SbwzyRELP9y;#aP#4E^Q z#HHZLuO?Y5W=8<%8-qIk)83>WiMnbP5#{{o|JMP88&7rl`sYfmMns9lH@pMH?M`9J z^$vb=))w}Vjb*`D*B)TL-s;I_>z2_wW~KuZG(XfIvr%f-oagSK7&0iCqSzEY@g+z; zd<3~^c$a2Rj#|lNnHnjN=5(*mD{# z`;$JTyEWzH47oqxE9wW<$`rYM9}yMrQT0j}jekkB$1Vm`!NZd@IWJQ{E0TuQ+cK(# zQOU7(5APOWiQQ;)e@E-Xy~Ktk;k-ULB3p(c<@21E9GI@`gBAA4NyZnS^Ld)0ut*e3 zW#*|xtMMOYk8Waix+a^OcXF%<&oGPsBmi=F7GW_5l+wbI_BBtsITM#romn0nyo0Ck z&erV;uE3C7Pg1w5->`-NZ9l=ekN+rlfM`NHKUIw>B*2M>vOF4WcCmCm9K4urnK~6R z;u{M&0!3iRCpONjzmr87Comf7a+ZHYW3~W>lV?u6c7JADa*d5{%*nm-0PUJ-bu&vC zg-#rb6A(!^*yOV+!l#2O#99e!{6C~l!bw)cdqDjQ#bGgu@QM@T|C>x-{7Cl~5Q3B7 z;n5&a92`k)=GaILdU93PwQL}ApJ|tGi!zPu*Hgocmj<9p^ zTI?qZxSGJa&}N8ME#JeXSR>J^H=ix-Q=>}OJwC*IUy!e&yF(ZKGzQ*Mr4=(HMFAw5 zZlV+LrC@#Ep+z82#VzG7bl@LRb!Bkc%TF5m$#$ea)qVHm5Ws!Mn3%-(B!#=U6jCZm z;o=85O6H|ZJU3F>yK~g4R%|^qaH{%L?9SST14Y#^)N17=vb0soIBX(nm{gIPRP>Cc zjsz3Q_GQ_cP|DQWyXm(fOR+$}WnF#X2SsK1C|TXvizHlC$iCX7z?`tX;ymDVC%Y{! zey9~J*w3-Q+oObHWG{_vYYhm&!ym&|_w+|u`m<5?>ipco^;e;~)_S|Ftjlx$HOXuh zW7$QPlH9epl*bmeH*;AOs2aw9b>V( zsYZD1GoKh^iPTHk;3C8+aybs3FarTmGdZ<*=iw2H^XrsfvMdhcZ#sDnW19k`7HSA&JN? zqEir@Rr$pBFxt}R?F~Yv+Z_djH;>0wcen5HQXe|?sDJ_{9RkzZVVgYn?>nnFpACGJ z)0ra`!<+Fr7dUem&_eurxn4|6{&WqYjGKfu$1xMKVXnalI7?&i+`ayp!QHUA7gdO9 zjYM%QmKHwISFnyVwVNj_9398~1W4w4ox8tc^z;t{3G&^F@Y}P?zt$SRnsVL7X@C5r zqbx|Mt@tIWSkkryV9TXQuw+a+kCCU2?;D%Fzs8;hZ(fI|zB-IjhYlgwX z&ac{nUDvXXV_hxEZ@%zS+b4BLQ;~P=uhyJV;-~_VLAXf{l+evt#XArFkq+&hbSh|# z-{VO8q<(36K%zud0i}Uz%YvUH70ARRS8>gFAyIn7={+OpT3*;1RR;VIL;?tK7Z-6D zbZ6%cdD2m-<#n23!p}#J>J}-b_>@$uW47SR!UZAY#HEc4Li{QuSxZz6=>%2(UCEz# z+4P{{?@1nUxE1aGmXF)Py=}^rEba=tru7{kl*;&LN#<@a>9`6g_Th3}dUyIqZ95yx z_h`zR8lGx9xw#h&g=)pXnE9ZWFJ(t$`|g6Fw~5_Fif$6g&^V0#VK z_Rt01OQ$Y(KR6qkG&33JE{RKe({6Lui+XPRG`{bE(j)nj5TBpR)eZOc&Jl$KSsMOO zpilBzEwt_s;M+U!EUdB4n6<$~SCM&Tl}~NapBuG3X4r`)A~{M7e<7!@V$K2~?2SWOQqN`)*sKxNga?lw>osBO zMqP8T2Tq|;RUw4OUE7?1>uERj+#z1@kg7W)SUbV_3?jR-J!paih-KHL&}!}Q8@(PV zqZ<`kIne^a3bytFaHOT|HD%MjYczeifwYDn^#G#>MruFR}u?4Ku_i8`*Cr0SuV zQ%2p~7#t~Xx2y`1SP1;=foeK8BwqRW6dF#v73WXC``@SYnW)8nS=TT9uz`C28vCJs zTb?BvzRK8A4sANB%U4bJ5ay*Hl${K&D38MMrZT-=IMJIrZd}eN8q2wkzoqaXTrIUV z-cix+5S**7ifQSzaRDJSrM~ZI4-ZV|h~VsJp!kCq@?X>gSO<{hPaP^cF>c^!B z|F<{)Ia3i>OB4@%lYM#w8=yfwrDfjgU2vyQArU|2Gs&-be?8uza%jF*-{W`GAqwkh z7hBN*5ovdU7^VWz@d+0JK_UpX><4z;C9~ep4Z_fZZ_uNv*^Y4Lu~Oo`=${&4Xd5vY z?u~qAq?O;A0_Jj7inx=3dix{gW!7&Hs+x0W=Ow-Q5gX@C=gKKj3HoNyW_u>Gih z2Wf-<&G9fe4v?bg?(6NJBkrF8zG4`)-nenqnD|OnN1q5rr4>jXnU@?WJ=7_n33bHT zqM!czIYj_P{csE_SNrb02D&VzVwxYC=me1By?ASpxtDAwxcH2oM)kdQtVpJ(jks=p zB7dch-oBSJdZ>~jOog>SZeKSn)fTWo!snb)ELe6`64OcoJ05QJIjBv%3$Tr&EDbcU z0W0N*B>t&(fKHL7s^O}4jYfNz1RL*iY0ltI{%%8|%te9gL;P$CNmf$Md>6Vz*wH>m^;zETx3S1tpyC_^#x5{g+B5$1(|vV{qQjf&vqR#{ ztG<{xp&<%#xk)TW8%uOCv9eolLoUQUX)eMGS-Tnd94 ztxJTi@+Y02HL6f5l1SUl7{{q0Ui3s$L)STwZ{217p>d!x0)l7y3h=5Z7mD+fVtgJ} zKh^%03J83XPzi(_)`MrM^R)5ZJ@{+ymtR18uL4r1yf=C6Vv>+BuUm-ZlxpnP)i;M; z0B`>6z$ANDek9M05ffJ*B=`Ca*g`^mtAjGDes%h$I*h9; z#->;b(@&HnA71c~cZEN~re(@#KQn~ZSDmGyMJIzMU1@$3Y$?I>xWR*;$86L4m(Tel z#g(#CNJ4){;EnDIW!;63>t?>#$>x^y8Ivgj4Vo%RLz+GNjX8%^TM zT4^1>|Hh?FMFgLO6bD1%!*K8=zAF z6ZUXeC7)!e1fXxgH|4R0tn%SnWdC)Q$>j2r4K-vT2bh@wO}hos2dp>&a*WZ5+6oKR z9ivs0g@p-L#XBQ9py(}ph}_gzg%DgSy0UAb)}5&3pw*6?*d!ZU(YpYKs@Py0Cl?5& zp)%f;(tqlu(}Uno zYz1-2?Bnb!uP)U;Ta&WoW&98-il7dF8|b++VU~8Cwek^X?F^8kn{QB(dOBUw#Yl4G zKj)5u0AYhIQ9A#OJ@MD%_8xKq2Hg%3qi%1NRi@P4&QG(5)_#KKNtu>jo&~v)s8v`c zBT{3>jxvZSd{K2F6jF}C%3r8S{%E3kIE5TN9hFkorDL1DL(zU_(D5@zIIN|526A8G zl1H%69pACkH|u+8rb>1}TJeGql^%%E{Gm6hUakx4Ha#*w)W`eY46FMpMtef+5yO9W zEV87n{WuN7tXAqet(die3a|93&e%0Bf-*SdmscOq!nTftG+i@?1Qv|gU%tV#8|9UE z2;pofBbwjQzpUmqhY6xKe926fFke)Ipo*9cn}S-mVuC6 z&%Pt|qM723RM;toDk}@YkoTcv5wTX>uQIVvr`|fok_x+Xnt7(6sZ&vsugK-j($T7Y z6(8tD{^KQYyd}k%Hr+*QFkQrlB_K2~$E`CFLe9-|l4S(MrNj24pI1r7@bV>B0QzIz z&xp;blb%2y5T_73vH|7$1rHe6fvX)LO90m@hFP}anR#{*IXZ&L`*FdvaT`1qH(@iD&FmW=?)Wf3E5X31C8B3LldsAfF(K@QoVz?D-N;oqK}vHgQ5n zG6nHMM~-$uRX1BtZ)3gAe2<{0F*SZ1OxYs@x!<8+7KTHcrMZtt+xQPu!0v$oK)ihl zJ&ytM!WQ`t32a<;D)h`UPox;nA3~ByAI4i!f0U9}WpaS!ml~J5ivE+~CG}kBDe6s&dEtb?RGvwrX8;z6fP_6oK~;tZd01V~M~Dy-u{gZ)6GA zY-8K#Zk=IjL?_G_ct2lj+W{paSAk8vieFalR!zFSxj*0>%kLH~wbb@rdGq<5OS83$oGm{~eu?ih6={#L9uhyu*5)mPKJv z_JS&^Yp~FB>8!$Z#e}cO`fPLEDCvHnksQwo)F<{eFBIPr5=yfjOmuy+4MOW!3rh$l z&9Q(YnixXRXhOxEJ#N~`DF_%{O_YPakWq31In*^PzX4}C2rF%C4+li?NFtR?^h5g< zj0eWy)o$@#V>cedb43e&7^OQ;m%nOz)&PL>YxFB%2k!1)mIG5X7tEHqIaj@tD6Q`c zX3svYvui>xXo)?!!_H<8hg~dWPcvC*LJkqIl$(8whyYgYfJmJj@Mzuv_Ui$1QGpnw z-KEhsm5M3wlS{R7`R2fu6Cbo|U}w)F6@>BczpJX_D$2XZrm}XlPV$B3nW`nTMYb2# z+)tr89;}hju`JaB?MC^Sjw^18zXC#`SJKwBLNBoz9dj|L#&o5eQeU+9y|dZ61uD?J zy}eJ{&6K`Z#4WqN>kOx<6*mLJNf4pJH8zgPNY=4PaUMNpJ($T>>H{jZQ6I5^PxC8&^j_6yah544t{Y%6nTE^_Lg z>3g--&$b!<+#segK?M*-+PDftx#+Yps&E(XA2JA!64*-XK*QU35wr$(CZQHhO+qTcPZQHhO+jIV8E+>+}bz}QBR?OF_OQ;Xbk#7%CCOGIxo*kr`Cm@BtZFxR8bGD}$ zz0oVe+&+I26y->Y<}9$?VEoYv$1olZd2fIx>fn(tL|0B3y%iLoc`7KtKWJ1Wc~BR( zn&BSHxOnhp`$YNp<hel?SSPtff6}6Ion$?Q>^M+cLz2~hrT;>T57ef`_D7r^n ztbE2q(!2wo$Mja+O@i+DN5Zdod|_4Q)Vk^+H=I}K_q2vJuhY7y(PCKo?~o>g4}ncU z{mCvUO-Q;RQ9^b-;1%W%Gi;IPnqD+J)7f-}bo|P+T!ro&0xkd5TS~L-#y{s}6wI8O zKT-lC=KU2{mCcqHn|Qq+s~21*mq0&GK;?;pwoFGjvP*qXcJ~5{HGz1P_fHxzaZIC$ zoD7DzL{kyifSDPsoLMU-N zh?5GL`k=W@9DI%wa33npOUv6z#Q-<5$ZlsIrS)dcje%?tE;DB*Bx{D#tFrEEFfDK1 zycN=+7*tEvuQuN#1tQC}d9-kGfM<)i3AuMQEFaJ{J3`V`7EG%E1IIgvD`< zj)MSn>wFC(MkV^L3c^+Wo33VRJg7yE*WG(@-;hP-{L zeT0cW(MlJ6*LX7}VUT^%~ER*IDf17Nf zTyk2;&G!Oco79b|LstGw8L%|4i0p~RbGfUnNlRI9{|NFhxVPqM$6x>LWH&{;&8+M) z^Q?MBfG9z=-3dj+M-3JCU5^#jFj&RRNVi?3`z*Vg`XOK%e(g&xlCIyNIs#bsP@GY6 z^N&G+XJ8GQLzLj1Jg5}u_sr7{Rd!jMt%DY&{w#{#Z<<(`p;SO=;u_(#`=-`+qPd^B zbbguPvez4HF`#Y|H0JL^g7hkGDgj_=-{8e3`Djc}ho3k5`|5|yZUZObEki9;^`Tes zga<@BJ}R#|4H}gdXZ{p14zIG&7|< zB;I>R-ckWx1qY-d<(ll+L*vd>5asfwVw_<3N$r~qln<=8NYO{ltUa&dhi$*fvFAXM zte?UD5zgS&1W^oq;WKm}V4v3Xvpk=dpPJ4DI)f?y$RZ?ANUWbM{Rc-yDp(tQ^G4OoMu!%Ncd`#aTrwyP=!G{IalCbs7tusi8-A3;PivT9 z8*VnvdVhCD329@$OCHDr!upR}d969xp8Z%FQ9NyZa9zTn@1(N|;xw)OPI}T{0Q6Th zq+LOYJ2jzh>r`8pRe{tRGS%3^%Jk$%nlLc#WMjKdT%oM{Zp}avKz8qkiI!X+ed%kP z)b>sUiOFW;WnO1e?TsLpwNSqBCzio>Wfu;Y5N?sS;}sIP3LA#A!3HBx?F6riBE%Y0 z2n(pf`B@BBXArAF`#&rZjYV*JH4hF4G(nyAJL#=9r4or}a@&@48`n9lav=02!{8l^ zb_KYGKdvWBS0Q8V#ZeEpvIp?abJ`W-3=G zJ-I_55CmL7$dID*NL3m3!vYSz)~~@2J6j8Ttk$! zXl()4TPr8D+CRU3H4^^L&DK^8c74uqo$5@D& zsiBMfb;Y<%!DsEIu0%Rb4axD~n}sPS*4rnm^!`v@hI71Q@}DKz6_WSCB&ldNvJY}z z;-tgR`OjmVe$Mct;%{YCkS*Anpd~JdO*D5spS!Xh>@QLpSE>Fqgo8? zK1Eg}PeMKD6AatX~gooB4FE2E?mMp3%0GKdzX*$Li6kQi&^1c_q$yYH(LzmV* zbIs6FDW6N#!gRW`N!3F-(J_wxxQ&==tTWYWanJQ2@G6sLq>>rm(7HjslW~70>nch2 zcSIqAl;ueq1?vl)9vdRU2wX#@`E;&ZKxbMVphc?5b>9r{iPR`J(DCxb`vEAN*ZTS* z4zXtty=75MYcg^OZni8E(}tYwy(MvTr~v*QfIlu8cof@eq&_ewmqD?!WkIW~wiAP~ zsCPVZg0gS_t7SKxYi2gYA?LK29FjM1?0ZG`u|j&yf)vov_iL>WT9B{y^w8{}yMGzZ z+paaAuM9x?jNCtgPX_2A9Ru)9aF}t6;!>_?wa<_mdJHf0>3^R)4-;k<%QSlk z7t=r!)U9_rEg^&}dnGcDF+=h>Pa}|1n)j{Ike@>pd6p|!xNs5EBYubyYJThUW^t;G zK@kdr?1AlOrv9w{>ubMn0l2jAQvn_fGh1D)k5Yy);p-UV%$YrrBf*AP=3)i&vrnMG zLeVYjM>Yu~8)YCY^L%q%`^;A~dEP~V-p^)2I>MpPE=B-Ou&p{lN|&?!xAHtCgZ2{k zW2)!e-#d*q1eD?9;eNM&?UmCFtuxLcV~Fh4RWl0zCVR+jMb*>_k0V7hWK(^ zPhUxtc))Y8duj8{m=ZlX^bBDbpy<|4X`E=LSGhqqzw;5F7m!1TxD+H7I)pTdxV*Z? z+^UaVt5f34+=kX@gvrBp2CIrXYdMEmoP6&R(7er(jwHE_ZMi5^u!UvU6>t-PZiF}2H6?<1$1MCsVSO0$m=3wU%tgq}$&Q@`#RWou%06?$T zDLiYE0uH;oHQi~O$k&e@wJJJ0X}U!c&)>jvYeAuZl}#-oKg2yg*~eVEH{`EM>$EmQ zkch1$8P(Laa|1b^_l-ia(tJ}J8}+9-3|aOgDmQp<0#K+D1hk36f)yI;?Q-#Qa^UNP z@?Tn601+e#9|w&ndCe1`>%xqN!({DYZN)4m)ct%F6(;8_KGI9l+(sxN9t}VK2Z3sS z{HEmgGmvs|E-P{BfhsxQ`I>#2#Wz2zj52fn-2`muXf@lNkJsyqo&{G7&o__pa2~)C zR{f17uM-at>bOmKGvhaS}N`!l~rD8%g>E;3;g<;eO$yP#4_Tp6a zvX{`yIMA$?6rdae9Gh1C~cv@Y<3w4)3W_Hh)5x|;o7V;QU z7s;#vZ$sDkcSDRl;;vE@u`t6!7!h5ZqSUdW?M!6y|gBD42Zat!ihU>tB-V+wXEOF!S*Xk0QsJt+lzB_NP&8rg;7jt{DI2rrm z`hXz|MBg;qaslB3g+LKjcq>jA?2hY}J1A;MaKH~JTVvec_%rE>8dqL@Uv7KbvddmQ z4|1~I3XjN-;dc_*DmSnL4J34}$&9abb^QiZ6f_c}wbwtf;9kb-P97y3ld77+x%Z+d z{fm#PL|hWi5he>v$qX;#=Fdw+l(5F{jI;bcZ-XR^dF3TsO*$!13u8M`~|d1l}}jloNB|vZhW=z#SAd7D zPFI^_zx0(ho8|iYt04$)7(&o(+gsRQ2{MvMJH!@ZhO6q_nN!Y!DJLXS4x)tXA#lw)@5i@yjh5W8*cC3u1_jrJRQx6$8R>dEk5N%R;N`1C+){^r#|^ z;+h*lLw|0H@?sf-lJYU6(%su>>}099`^69@k|haMqa9CR6Oq;{iK$?Z6`tGPv|TQcsVse|dDcUS_C)9m%J|RsXTPW@FD0`I|lT4Xd>g5I0`1FC)a4 zC2u>12D=p0Tv$OWjXWlL(|b<(Pjp&Ih2K3;9tzE?FLaiqV4Um%TdgEOS|X#V8#pno zVlQqvF#^^r%bz{DCf(`4=L^)MX)QG$i7+BMJU}=5icrfZ6v8fz3vzUadMz7~97>cV zeDF~1Dlw2j0%~rkM8ec)LBaUU=NKahyTu7{P>;3`;f=A;@)J)d$@cRI^KeogK)A4m z>$EJ}UaFTQDaM$DrK8_4xAR5Pcv4HFd`vT$GHjruaz%yYA<7F?2rzAmRFj?f^A)~p zYl7CM_`R^j+{>njkR-xzUSVu16=iZYE{60(^RHcs5G@7c61_ubSbA!Cd9EQP<`1O*TH9nLJ zWt9K0%qzG15~E&@N>QIGgDnJ6axr;YI$IVqZ#iRh-`5mig?C*zQdUv7@UVVA&bYN_ zos8xbt9@s*VMabS+(W0dV+XFoM{K6Nt7T3kSonCU|r5ixf5U zMLM3Ha6lIFXr{&5po*}P= zQXYe{m*w6WxlT8hyrYxcww&X9bMI(jd>t<~`YR@R_Vq-6s6`dVG}0A7j>FZ=loY{R#lAzg~RKV z0z_&h>>71Il;<@#>|p`nF;V$|a@VLcUI0_o8@4F}^KHq4zqC zTimTu`Fwo_-Kve7-2kala_07>M)Oe-(uQ1(=D9RRvo?#^Mya$4#JtC#b?kPSdywY1 zW`Q61&B!n^-i4*PiaWJVS34Ov6a^#_i%oJEdow$V>hD4#1TQ%?afW+-ZpwJ5^J6k> z{V}8!yj8mA9yMb!0x-4u{#b^x`o))Uj$GdN5b!Paj-alak96L%ukMpsDT0+@E1u&#=H(JRiJBc4WD!^Qozq*BGA};uinv#>8 zx?WKMbYjzmdSMyqyIyER(ZRf|T;j;uPHiC@0{JdpEb5?kg~RrryT)H>QxT%l||EETVv4!8MUB@Lj0=H`#t=0=U!#0&_Rt#{XwOcw0@wG&YM0f% ztiAiRmYWfwu!bNz_0XX_=|em+cGb^*#h;TBzt&JKO5u2CJl7-JjHyI6Y&_0>;igJ6_sTM5xC89*JC9@ME2d9-PIE8A0$q~8_phvE_NPGmVYLvZ8J%XKiNFF;ty&^x)=yK znI!iP!+%HYr!)XU5YFuS2%a++^pqw|S;xB%pe(Uy&u}&+O&Ov>GZV-jJAl%8_{$fj zs;HNpR6_Wr4haq%lAzWxF;;>_Xg;5Ef+8T(o&L7P#<^DFZv4)TMJ(fhtk3dx3jJ+O z(z?-zJ+p=LIU=SqD{UzoXre8v*U(4hj@IP@6u*pxx0Uf=H6OJq7>il13+J@bHv28@ z-~grwY#TXph4rqD>DHKUMaqk+fI;#%cDtMe~nb?`eW zd#x;5cpOg{cWTDTv;w|WiXDR66=_i6SC=zU9KYVuYm}qamFKpV*#1CyQ+Y+}(uK?V z1}HCp>R=S{?!^&b;#ZuH~7*1w#YjLbc-B6QK4)o=v7RFS99B?0J&7>DvPFBq?0j zn#5jOair9YkGESi;8Hzn=mtS0-IFwL6e9%MuwLo*_cwc;S-m?-{-sPB1>FFgr zJigoAFCeL&X{kD74g#W17>2a!%e+C2&^Uv=BKaxX=aton;;zt7iws&HG8$AF3EJ>a(uePCd%W61T?GA`dA z@-HxZ1M!#JDKbMnWmv?j?~=$jZF`g3C^gj;GO-)Gwyg|?{996%QZwm*4v}U7 z5icRA)%00-eFb_ZD?5zlSB>&c-pk=R+1y(L``s_sW~>6l3{I{a+u9#JLR(2gihTO< zu5Q|BFUaa-&gA0EO}vknVi$8I3B)q1cP@cklA~KH%$fbQv!q{YADpKpVO(d~wwK2E z@Zgtj0;Qn`5WkHXxcV{2qOJMC@l}ghz+*idHWyLC(b$R*2w~Ld#Sh8e?h56upxqhIHCO zrUL?sc?ZX5O>rOFPhSxp4Jo+H+>TJe=}vBka7u#y>>RY2+Y(DWLF= zeYfJg{8Z`A<@3(m)u-o3BgWXriwhLd5hlDIAz6QR-!g(`D8g5q6};K{gKW)DQ=i@J zboO0ern9W@!m!dk*sFkOcP7PHw7{JfkKoe^5#>!*iHihGOx$GyNpCT;S%pX3u4bdLnVn@~+)y?H_s%0JRl(?q{E97mt>tbXE&1d;cf4NZKd@cl#F@f;V=M!T*hTFcU}&k_cz1@jh2Hpz#~fsQ15uwi3g&5ntyTS)fX z4uB3wVYA++ak3vu9_NHw_%np#p2RTi7DcvOrVLv`=ibfnhV8)i?CbrjMjY^>%F9D} zc(14=1q1cBDMA|Id0=xUk@;`}3dEG$a9KB63mw_XxuetVdoB&p=a#Q9c;TNBS_Yf} z7Xz{M*-b^G2I=VpDPA+ zR9Ki|c-l5;n5<&H?l3)pnus75)?m*Zt2PG^>9dZ5PVXJ!nf($GAC4nggnAIz6go^A zc@zt^LET+r?{qt{oq>@0XIY4l=1^N-y#QF8Gw?MRhFXShe*}Ix1x{DqI$E0}v~wO* zGxZoWnAJDdo4bx^0oUI$H*#joG^g^9T)G8 zBMMJNZ0DcpP{$xuE(ZDs(9o^Q)S4D{AazOb7B_{P2oIaa3ObA37^^+l}pKwwnqqcl_B<$pdsx1U=Bjlvdd=e z@);0d*Jx%+KkyT}A2y~#S(TvL(MrSS;OYAtaoAixhYNv8pGTIhjn=0=I~EdeOF`}U z0&HF0C(mz?|F1-`5#X)bGWI@36i#*S^=%C%Icv&ptP4Cv4Ru^RW_JJ4)%&W83@MR_ng;M{qXENX#SZ9x_||+hvtCJ54g<=F=6c&>9RtcF4f!KTHE=q~ zKbO?TW)7Du>QUmlw5r1##Ogs_np0XBJx`im>I;U>eYF8i?(*EzV!!FrnxMxQDN7A( zBlFaXV$gsG5>8lob04;`W4eVUZa^UP^~X>(>6Q*3z8qA1Z?Pl2VIY7Q>2-OoAyoPN zZlb7@4WaSribZ@Xl|0HW`bi|t!wl>XlBR9SNQI)cvtN&UI1GGD5lvso_!dEPU ze!zDdG{E?-4x``4Xomf2*$EE)qZm30+#-qgWndl#hzVn!@kq`$uT>Q{{ACP7J0wS_ zd2F1h76s77%m`Yj(5oDmqrQ?_3(=I?K@yrs?jH|I#V4K2&m{^`BsQ4!M#d8-3~p36 zU9sFfjVAN}VJp=;7+$!bM*)7F;3~>4v!S$-;w+lWm0bEt$OQPyt=ww@a{;J)fb+T&Aaxw5{ zpNbzkn35KslH{w%N0?+3R~oDLSNlJ4++=i8L-*WO8A>${H#koDPxHjJLX|99k}bJ~ z>?I!zc3jn*D{nIP`jDTiay*rh8 zWqX4WlL3j~gSDOuo2_3TCvr0+&?iBTyeohZqcnI0F1Lj z)_v%;$R7jJ^?AzVIEZ4&nvJR%Hyp^Eq86T4PZW;t8(*SFAJX*pqKS@BbrY{ojeH&Q zHcu`O>j)vaS&h*KE{p%+H97~w01qj?A0fJkMi!J`PG0At zEd_2_#8wTvRHbrZ`0Ma)wDRp_CjpQ(@1AzI8sARiJRxzxt|W*~Pc_ze)`D3ngSUA}wh`s{w8;E}74f3#zQ( zY*nyO0nf4^#Se-)V=u5iZLg^h8>+|;l(>XZW|4QNtsD?b#-+ri`)$Qj@0a(89VG4k zB8h{EmbsNY4N=_dumqo#(T>!uFrQLU>R14dL_UzNzjb`URNIT)j;h-lsv5h;u|P6JaE9U1IOyEuCGm?NPWXsIoT4n+4D32#k!*;4O{m=smbi z3b``Lpicg(*KsNH`U_8g&01BDcc=WPX0OVFKYtGk58WFKLUNMIhHUG340gpPrd2#F ze1^VwF9&K1L$_~u-9)9b(QE0xgF|oqN;Lsysqbk811HOaSwUHx7|DB*a$MKKp8L?1g;uq)njU_)b_ld#SjD!34Afh3(fN6&edK@-iisd<=#n zRB8`qr6NU9+PQ8sZtA6Zwr6(_Nd#!piE61jg(B=Q-Ld(!Xu(!TDe_ENtx`-&^A;+d z({zQ!yS&nXeH;h`#kwVvr~E*GlduP>t+9J>i?dgbBR+SUPHkX-gQB;*bl?NMu|%#7{{D=`5I|W>wK`Mgt{aa)0wT~D;)B?^Yc>RKmw}Kbu5@`W}_gHsPUP30K%wlch?n+5=WRYoTyCY8z@e5 zoAZY$NgUa~{OaeuC(;G*Y72$deQOAb8;Ii2L5$p(8Nq`($PL6zXL8m zplUFl(iTFJm_`hp;2obu=bekRq9p`)s+RhjZ4WLRrm|M?WGEx}Z>ZvFCg^o@3b7M^Aso-^y=VUi~y zE5)mH9FSIYNg)dvZ~Uk^-9{vYt|P!T-f8_6-7@@LdZAG z=&zA0CDHL{*T2>uR)w5UDVuz_gz*RET0{K3eD8@|@|4@l#(ibuI5|!rms)%3i76ej zF_5mHQ*=ud3q*UPJRE?@!OULhkT)5>PdJl zD2wRUr*kL0!Ck8>B!qNg@D{6z z2jCjfPkwvHnM+@=`eY`pRW%WG^@^Co@=$7QI8(<^uE#V{vBbum>yI2aFmww&u`64_`< zge-wuBB4=ssPHgFcMPb#q#@DAdvhfHc%{=a$Jb8!6Oi_l&3Q51iwWpqtiouzu#}LE zkA#upl?7LcQ}4|wltOi(40>DWRW*QnJ{Frdkz63`FU;|c za$d=sLke@V>_S!(^&^-25NbDn23oF};9=Si___|bn~;UiTz0nf)9u;J!YvW*^q%(X zX6>9(q#aa_a{S}UpDDt)tm|ssIXV=dN zJF51iY;hGnQb#{QY-rx^Ae0qAve|}O@)B8LJrRsAT>#U{T}KQ8@B*`3R^q7xHTP+g ze7R7y(OQlV@mE2yZcoFCP}lOXht=&YOe$07vitE9pieEfO)r3X_9Y*?i5Xe-rUF6Y zgNn!Pt5dhVGiWetA~mwp=zZPToaQ;ACUS>SmQ^nszSu_))Riev2l5%gr=T2!9k)+~ z|0Jb#P%&2VHag7BX4;DO?^24rDh?XZFuZl8(E+x3R=`xWSQe2fi?V>e$jY8CyU;`d zQdB5nuPSmm)*&0Ce?AsdBMXCyPa-+=ZNVakXY>nABQUb#i3o-)nXzy_>mXkdLJawU zlxo;gn3=V#;km2n68$-IxgWhe^O8L|vi)C)CaBlx_r-8yEeEk+1usB+=4mU8#0oS~!wBHgz*VsCW0Yw*74k2tBNSuq6l`={@JNBRv$Bu?wyx}-&U;Ydn)c9fkrtsH8&Op{7ul5xFJ>88Q_Oa9#d;RM(k~mBfxOh0jCrb;LB{F#&NmQN}B)V3T3)X$ovhtH875J zh0e5;>k%O8GTwI+5I3T-A#`OpL)Mt*zRD!Sd5PPM0^lE2$v)n~5YiRP74M(Jk&q2C zs3FA2^ZbGxs%n|Pf?PHd?if9mT1HQ&L`1p^C@5g8fA@Nklx*un8C0!o`^#4W$_FA4 z1-HRk;v*?59@W0lHjnWx|KIo94L4OjFPou_$jghrpH7M6SJ9L4JfqjVYG$Kt(gc%e zxcuP@kH~pJ<2uZPI-(()sbqR2iotpEP|R-+5u--qKw)5xbutvzGq>gFJFwFh09iOQ zS!~jSMlmO6w)mN9JZsPSt*10>B@d)+hd?{sq{u|%Lwax^6H5&p^|oz6Di)?KU>JQ$ zrY0=D*6{|-@`8o{Qi!zOB73re{=DOSdu9s-2fVrW^e!P?KFfy|2>3sg7`KV5$=JAl z^~@C(b^M>FxVoc5rswguTMF(<4Lr}U)6QAf}POLI>VBH4oR6o=-*%P`FfBK5TAd@96naD5@Np)5F7=i>>~ zkVR1uYF8)iUVd>h60d3v*1C*tq`O}$(3(zvhelPq^8s8wRuVTfs0*DJfCt-1nvOPO zmuoR3h(RR|tJjiuunlr2r!$+>=7iTmv22(afv<3n^*I8#ajE7q_|60@&|$SupM%S050Kq#tkWg0i4AX{iE38zU`zunM_G9@1y?sKC{i}(9hWE%VJt$9K zbB|ud=^{P|9T$C;^o#Z;Xk==d=52Ni*u4pyj|6UZUxyJ%@R8Wzxxa^}W-7bZDB5IB zjF2U5xK3jZLL+y~5JIb68ir3<$m9YBlW@lLrB|wA*hQFMu}G4?e5tn4%UH;w;Y;~@ zP(9pkc?py7S|#R-1D%-sZrxwG9x(KRD1GpY{kV*4tl)8$k5w46tms#@JZlul7;L-D zy<+^$A?6N5S^AslvoVD;5Y;&e;tWpUU&!}gRMSU~*8hrPT9r>iBLWd(8vVmZ{W_~y zi<~1oy!QApq3><~h-rqU5;BdpUK;l25X9N>B4(((eP5&l^tJwI zm%&N57|9vZ_>g;Er2Y@dM?4Eu>jp?T87(}$Nqp-_gno8Sxt@OGXUwAh; zs~by!%N*Slv5GUShA|pHwaI%Wx4rLtPNyH?Ca4Wj+ElEUz`eVtCp>4_c2C*{ zU|#VxM_2F+2@B@Pw*$O(IRbJDekcRcAHo1P5fTZkzj_gX!M2Ob5|U&LSwfog>X7}5 zzli}o9cEp-k{t2#da~DqDJpsDcsymE)(!r%qX*+k2`CX{A)(XoJSv>=f@nr2<=uXR zz5<-}Z9v&pwO7g(wh>RI2UA7mL$E$Wc8X3yBBBS7WhJ&3HPr*hPbfMX<%+}*xU9}e zW;K09FOq8q@cYxT4Ym52s5{RlX7j^X`36sp_=8Bso&Dt2&}hJx$mF)ya!eC_BslLW zwBQmbcPp@&zvhE~22Zph?wI^{gjF%awgPW|@`VO}1DNltz81%p6W;|iW`f+pgnVFC z5!Ii({Oj*@EFa2_&kyC*ccW)SX%O6d9-KB0nONxkci>M~%ZD~Hy?7W`d6yly6t(qY z++}r^Y~=w<@~=(Yq%=nuS|u^Io0l7#aT?bP2m;-Q_VkTJ+UW*kf&wNb0b8jd@EoyK z@N}VGf>Pay7_M7z8Jmm%$+pvv*i5iGARzLJGF6hC)gF>Aqdv^R00n#9Sqi%DO!<$V$JYw)071OZ|zhGxCcNmOS) z5T1wMu8efhV5ooeD?px@+Yg>?$mznmR@o1Tw-KV>&$cq7si|1wi4Y|MqSz#A{Q!Pp zQaMdd6iSzN^#280URk=%D2>%Xhe~}4`pudOM5uti1+PtONsQZ$R|VQQ_>@SDH9&ZTwXEyz|v*X zzt?J)u&7&?PbLN%qJjJRO{n(%;Z~c_T>Fi0bc=JIVqKX_tbbZ zVCJ>PFxdXD&52?+uB7x$G8(cM?Od&CRnwuMm$O}P+Hs|@uQbYv-nyGdhcl*;;xitGl+dmL|Qx_si4W&Br=^W2%dBvIU(((8}x zu?d3?I4u`eT#SOO(goop36PG8(MX(}5dX*LQQVy-YEeBYXJoD+3?mz`$K7z5gwtfMv)iiBS(jHdF!iWGi;dojN;C&bRv~6AKV~um{6zS64UPM}@-P16L4024W%an~{NaNJQZ7IOg}n_(v3vZu z)h~ptQAvXk6lY#U=HyVrl|#T6U&N?JuYco`l(Q9cL{Z4@eM`V9I_$vV2`UN6^Up!p z+|^Uzs4$&IL#N@m+DKE-nd=}K8C85rIiRdwNq1VZ)?F*UQ`*Rv97+GB?`(*6X%^cQ z^u^EY^(a_#)c>U5Ttqh+8JE$Ghv{O+A=NIx@QrxPq$nI|qOEG8@V5<;xn7&SOpS&7 zL4h%28IDdr{##u9QWXsG4VJGWyhBR6i~#QGIy1u`kMWp(OhEowwoz`KfjpowUJ6dD zc_qwN9q+&XODGa5sSd}Pd?Gj0!S=FS0_v9WI^-GGxI=bz$5f`zeGlS8CUZyL_ezZz zx&6v9S2cx1li z6yraKtjk+oQk_-gfl}mDkZYYqZA!)pDpRpYV@bHX%-(}K-DX@+sz*|k)#}5$KjG?K*vENM>nd!J{75)r*XCL1>d)oc-|Z}J{f}V(5$yl&qVS&x`#*@VczYFq z+y7rzN#Wr_f55s-7F)+imHuV>uGDQ>`DzeQ$-kdkFtdvFumnGnVu~)|2J}jv=D#cA z;@pTqvISjx5krnbr7K5WomEaPIo#{=aI#OuvQ&2UJ%gRpOV=m z)Cw1$gJSr13Wqjw8e6Wr%(P;SY0RE^rRRT|VRk#iK@E#_y=%%<8#x4EOO^S(ShZ47 z`YFYAS#!(ltaG|zc!3tou zMs~?lQy94G_swXI2GA$9wK#Wb|i2YBD zwG{1FckYzCjT^w$UE#MjNn?r~YdjnlC`HWc4sS|N=J$Pug`Lb=`1EBrV%RFrPqLXr z0yHYW^ba@i7?&4A*)=S3Nf=dM_M37O*TAC_e$RQRa^Z_}u@j|+R74&S|KWY_Cokc3 zt3fkVt&u)`7pkssI6wnGk@J({07wTB!6d24?H}my9P#)iZR{m;GfQ z-<}4V0Cf{<2)h$hIV6t0N>A^B7*Yl~uG zh?naUFtf%UNl44?ldM(*f4l5W9j-brI%Cp&3L{@f&fQYwZo=A~>XR(t$TPD2xi<5+ zE%X?Rfh>@Fpwe#YsntcRq>p?2!Fn`@nFT?#L$K={@(qG&9hB`vkp`SoGxijBtz_#T z5@oV13%H(pN)cK{>EFCrOZuu~dgxrP2W)>>?T844B-#<@Lh$KKlPxDBjmETNjqL#o zZ{7Jn)5n8lW%|Cs*Ek5;X$%-1wMH=BcQ)Tv1mkDQ^y65!oWkQzCPQEEFgNH|Ps#P8 z+Z2b@(1!O^oQ7p-Wfqx=m#J?AG*eQza7nR-vA|JY_p}j%t(8bSDb1Eu46KTBPhM%WFjE{#a4<4 zZNrYPDA)7yRAawt|GYeEpGH!iXp3)By{%lHK;XRx^gBZ=ltc2(m{YPG=dx076(|L0 zat7v2NU(rs!);y(OtW>x+T43R%W@wU*uj)iyr{zib={you)@J;dKp0GB1cfzS6K&& zTq{o~rE$w7^cCJ~6Z?}5r!bk@3lp6PFXPM0#eS5-%sh>7N^Vog?)q&_%<=Cb6CxbopW`?aeIz}h#CDGe^^^Y=08 z8d?Gx|JIlGW^h-ZJvtL|c#%ffn2-YN=8$2cFUXjuHbVV!9m)_U8=xpY9j8zUBe2_N z0TZtF&Y)5!CHlwPSw7sFKsZtXsQ1&>l0R&AQFZ{<#Tmq~b?H9? z5OWngF~j7fRNvi;qaDJaHpUi3rjsVUkH90{6?!ff&#04e?+Q`P3#o146j~3>+=tCORPl==`_S(b}b;6 zkSiGmPgOq8&-bEqCZq^k3+k52Dj&MOA-K7~0jxq&9%aw=+9ndsxh?iVEN!AQARQ?3q)u}O^ZWxXGn^q$X4UVHy zk7l{AR6n;_w2}O{LYhsPd z;255@3b{A^=l9A>;aKEU5174CuyCI<;H`9+8Ms2$b`yl;1hrk2J5KRl|Cr^_7$45w2QK-C|%p_&tF- zBO_EWawh&aXn__qK0w1L6ctS$QI=X=TK30cksji+IKe9Q?}_#ihVB0OSrNK?GvBm0 zfimFBr-QW81g6WkKULR%FiE3M=wfQb)|v0vkeeUiCy*+u!sdg*1RSUIy>_fe7oI!-?9RxlF&r*Z179QJ?KhZQ~fJX}5r`qaRu;j%LS#od+jDWQ_Cfh?=+l z?G-ms%{d!FR;%(^L&$OsaT>9{W*D3*Epy?m&-w-q zn~Ut~J8kw4CJrR}t$;24(}E8|PJbL^D_cW3AYv{y*8Q*SK6t;Athcf47w~g%-%PfS zp5!2DDEM+DM^QiF4B$CzjjKBo1^{kEYnHi@3;N*}O>eoNsIr#?1Xt!lwZu zBQ%q`^oF03OrD|Lu&$an1lbm#qw6pm1;H|gN>t+8!gzlyvs#(T7E!dM=Wb<;V!rvz zz1bL)>)J>Y>WLFKyQUamHG0{xB2&R!Umc3V34$!%5c6mD@m;Us!s_7JRseBp*YFT? z^k;2<;)pR>4Ig!L0pu*COVDd)CtGYA1tmjVBP^I3y#k1if<-G9rSs~U z9)!TV3d`%8vK=y8N`u!>Z{#jAZn|63UDE(#6x(U70ED@`|ZVC+}xb0vaOCj=el_)_g z_udED)e`|nxQB%mjS#}W64DYcn<8p^S(5`XJ~+SI6gTIn@41!K%kXA`c_%A&@%yxI zVJCE(ThlqKsxRsIEK&7(2L{tmzWE671S1yF;lU|}C+Uc_+uM4%O#N+r@U{aKHCZ+} z6&z?d{-M4;U)U?n$1E8UkzYN?xyiP?;dP=1Zg;?UQ_3ZkwSNPawd zs}uROqG zJHjPq82j>(5lydCD?Fwy?MEp56d-9+ME0_U(cNMqTgw#FZtlE#U7J{ZGu_sDphppZlLhNes5h#&_n`FSSTP2=*! zRw&n<1iU$PZx6D}&JXsCs-@bZoal5J@`*PGmr$0gSZOo9>8vG^YZMBP!>TC@On!1b zHLJ5FsNlIRI+?lJ%!oL}2ty3&VZB;e!_51w{ts z1)y8$q{6iB?Oc(=Smr#dy&eORmt|KyCC1AnZQ;)7d;9xtZa>3SznvHji;ytyqKojUHXPjK8j>S~bz$35btLr$S> zyn0yEto|M$9ut*(0SEC+?WXmj3H!E(8e=+bZ#`2-#KN?x^r*D>pvbxB1f?Tf6#_4l z9bd!SCxZ@8fTJT0s2=R(Ilb?lhkTaSu7Pf$t*GXwc$_H*-Q-Z%+?6@zxu0H~h-5Fm z+@^NlEn8CGv@Iu$V^51GDa_v*ESwBW&@zZdPU`3WS!_OdHN;lmn4u!M`_Y|NsPAg6 zEX7iCl&l_c?|E*xqW(6Vg7I+WC9s1~SsQ(C;$@=N@dpj3U8?6|OloZ-S(gY4Zd%4OEry#be z3t}@pXJ8NLZ|VfaQnAgJq3^zIaEa;*wzbzlFA3?HhK06&Xa$AF{w| zg3;uw(ROA@+oioHa*UdY4iSukERm6?c*7yl)}iF-z~@!?oH^XHS|7qerT=P_wb9gP z!^}0sj;w_$Lesa`dWBl^JhN%;BCzMLP4*>o>WQd_2C$MR(XXm zt~dwe@rd|*UU8uvWzel?ay1Xx{K)A)tJDrXkWE!2iL$+Ca3$2JM^set&wI2lg7vW^M6fMlbV>|Sclb!D5GrM4GFh(O0gs~%1d(FSY|0;{b`Dik8w%e zmG-8My`Uj;L9q6s$u`7+Y#{{zBZiztc6)Fo|>!7stu`MTp-G$@6&L3W2Uc z95gzj{i^qGs)`ly!t*EtltYTx*CUQXCrZGOxg5Jn^pHpFxW1gq`e@`bSltg41b5vG z25U4X(ulPo??%$xi8eUaaXR*vkXKpG$_D@-R}&8Ukob6{hV*R|L(%vLG`g9&oeMnu z4xbl2wS2QP!Q|0F?U<{RcB*JUqJblh#dgN@ulcaj;Q+urabjCRK_JZw zay8zL{>o~Z0hcJ{-ghg>TyUziap3_Vm3iyq+@krOAY_f?^KpX0ql#n*uez>_%K&Tdq;O^Oa~#S#=nmKGzf zI{Nmw;%9UT&4~qZ$`-K_9PlHi+yr}TVfYEa`{9i8K^fWmMtZ=M6_#=(}Tl*)M|yA zd~6O?!?HTSEmco!<%SG!!u8x_(HK^H5rx-5BfW`=`~qeu&qsBB!){nbGZ2Nq-q$PO z=9>hvceA*NV(wnifmO?{ZV5SSAG<=mQ)#461i`U(s z&Zk#iVZW==y%DifdQPgvIvsf9cuOoQP{V8voC-2Res@FaJ&p^HV*L+U{{H!tYAfQl zLRo1$zS!Y_%qT|b0A4JPWzNX4G(T@FUBHAN1sPG*z@~oglB*?^jL=kTY&coKU#C;D z$wFC=nIl00#S-jg{FnpJxO#?)ZwPYZ?GA*oRJby9QJN~aVSJ{Xun{MgNUkFGWZrs( z^qj<-pl%qD$2^sIQk0&WY1$ZK!{Rx^$As=^n0XvVaiS~^aXP@N5NNYmwtW+4kJzD> z3#8w(v=r4!NXZ<}4D{PDs-T`4qfpQ(WzNIS)9R=uH#R!CR1_Q4L$Tq1_+<19xZi1Q zbP7~zH=(m51~h-qaVims{7D-~@noj#?4$geJ46;G8DmY=j~Ds9?lRBmDX&F1;g-K_ z)a+{+9_WRhM3HDK?wbWaul0+ry3C@?ygcvywR+&>-h0lQ$xoKi(&>{Iygy`Sx*8Vr(gPY-;@4CBMwK2s`VQ zc{!cc`7efUbU%@Y(Vjz$jIU@>nbzI5psVfcdOGu8QM43|5Mw#rAyR8#DFR*uy<7{h zLoA24MLM1iO^y_CltnE~vX6n0p74$5=&qMLf#bSLAzr__gXeMYR@rS4gBrdQ9BwC; zss(Nt{ulW-?}Gr6GJI-}QRdx`9baU!V+#8Pea6ZRS0& z%$e&CcQRt8r-kCl=%$AN{2`v-g>D+U$sw-Qg(6mm;V(Jd(>{}!(J=@|R|Wv!7Ip2u z8uP#&Y~=_=k;mN;wp;&@TXl!R7(72eKf{`g%>P)$~Qh;W#PJP^JnD+!+Gp`&BFNU_spV=6;B3rf zqlkAn8Z9l{*nn+U#}bX2E^~C6RD{=L$6^twBFOUT=YoOoKp@sveQr^ zLPc+u)Z=^uWA+?Zfz*UuMqEg;)|e9V%f$`Y8w}6@{D2?|WuYg!_50Eo=1^xYo$^bt zlEH}!dbq<4S{LO;qjLCpI;K;$9s6RnZ5fsEpKnU6h|Q32!JK~hl9MSRZL^U zEN?MT`{T1ckqoblGf~*2yYzO|Xr8}`@yJ~g%Gp9nawAqe0f|FIU{n{9$;=vV?P*mS zEq5g8luKFKM&0Lv%O?SXFWpT>-Tz)uFVWG)UfQh)pmrL|I685x-ct8G1yL>6O?%F2 ziVs9qeN_KHS=0J`Tw)OjvWxi@jMk4k(9Wj5Y3I?s{w8i)uQh z8^C;p2h^p3+;yXNh03Ir=!hSQcnj0_YJ@W|6g`fl8G`%JZ)LK{7_^L_?ivBWvt<8p zKdW+fX6Ntmupp0wEUbj*JrCj;)}c7|4Aw655}Qp-yS?VgkTmXyRYCU?3Op~FMl!r@ zZ&TB5cKYHRo(y%ONA0h$-<|CRHd)0(ENu789;Y>QfhfcNvUkfgpDSf)Da4@4BCPWX zINFvL!58?uT!*B&$0B=lrRt(1dmzOta3W6>$+Rd-HJwxk^=(pU!|QF z;UsiC&R7F49-`I%3%hyQGR|d;Ofy%PGdSb5?rF{5n-jdw@i=ABQ#ZY7O!)OEYN|44 zvpa-INYK_T$ci;&@zwxTSGOYI}=U z?}&vl!e#emwhVnY#+1TCYIX0Oi2RHv1%K(9-xh>RtTv~I3Ptorlf93tZ!0G0oxXvq zN}Fzn*#@J0?)64R40O>)G}s`DShX5d2T;fq;=HA=D6K>8?;m7{+JB{ZpYZ6}q{5rjSXuBt>k1b~g>PE#i+7dh|qq81UGBjy;Wx; z_6;RI0>tSvYxB{`zHylwe89mkwk1)AG3|TKh!%jN)!~lrh?&MhhYNh)UUOx*sE1pKB!VcY-+c^RnwoV7QDC zf+x(fd_gZ$t-_Li9QQ&6wWNzI`Z{shJh5jTA6@>)9IFtTx zCIEF>t)B){Ayw&BlRsFGL1Ze|k-iRk_G(9#LHr$C;97*~J$qAo31VjlfGg;fBfSd< zRK;4$Q#Fsc@2pEpQ;cpMR4N8=O=%%X21h%EM?`bym?=9f9{Uavh>lGw(-^cj^t~0K zrgQQ4#<}wc10_tmSTsqYBK(B(SvLP(mC!OR?Z-oi1!vPZq8|uM7{giC`a0pV7(Lk? z7a*HVTw7vJCPMiz&SpkI<-|g4TUdHn;Z`XRB&z$@_BuX9TyBHOo)BVe_aLLY*^@+U z0h9!I-1$o`m}d}F0t$#>EHhbxnV9&)p7_2mTo)|)*OuU(|L5M(l;)uXe^}o_$D8n4AZ;aT zEb-o|(kIwN!`y$<-!>~1Qbh$3Z^!K$3k*Ycf*>u`EVcSaesF&GOX|2bIkHPpCd4V>7_ryL|b)Yhftw4sC8VCr9J;!ZO52!*hEpBC7XE)gLL2paZeDQq~UbP{^+WebCEiD5uH=xD)h(uIIn8Oh03}wsh>56 zm#~iMb$WoK1ho7{@ZZQlY1k}-h4H>K8IkoF->k!EuL``N$j&4q^XD9@v>R~h&sTE9O-jd0P{heDeZo6J6wn9H3AEEA{O=%apha>mR_18#?A25@Bn}OX-06b zHtNhegR%2Tw>J2V<@%60wq|vl`iMV1$CHaKA53o37%1 znyOcBKmxP9e+T-g_O(9tgLf1u%GcU9d)_5-Q1Ad*XMeh!vlnDEi$DbyC;!<8LYa4s zhVGPKSFLa*#U116{UgVmcd*>bB~Hg)#tW3 zD8ORd%mnhJ)X->vckcMoj%WVzEsI&Xgy;f7TxSc#%3X@?D5?Wn;F*m3dwTqgnH!~( zV3|ClOTCda9JKShpS$hpE^D^kq{!nk34STWjs;ZN6)fNb`IS1M&4zn^hEC1WRVT8z zR28UhL+OEGkeIaN9k?3Px$k{*S>o%uvvVaqXTq?XguQ>j#KD&T9P zud;fcXG|pVE+&3tfFs%-OoKvR1c&oEq7#B|qRHExM2_wFiwlb0&)T5v2XjBDS1K&~ zzFz{R%U82}NGX-NZrB%z>T8`^{ouxWPvqx#AC(G>dLK2kun5c@PNlGbychQmceKxq zJG@qda?t%)sT#BOBSQsDm-0V^h>~U)Dwfzqm#w>pDn+VZnHC9Vn zvlQJxvql`L^0aXp?D)GBR?M0zLBll_h8QQo4fo?@?6WZRoGbkaDZ14Q&<02fwatikhl0M)Q{b{N5$Ija#(%c z{qayV{GFnv4AzsU!aoM4O27UOQ`GBt=PrTH;om7G(1x=D*V9s4axyi_-13*C3i`?!quvRqgsu@Ed% z_ar~++@gYfvH@cGoE`1WudFtIT@_8P>mP0?b)?q+aUliq8$q$2Hb~`m%=W!$4a$kR zr!}UBbLT$ZkIb%LDfh(ey8R3+21joA;$)NqK!h7)h^XwE$GK3BBi6X-*21*OJoswy zx%NrjI(F1Bs}L)nYzCx4i`n(ZD9IGK2&?Xy2yw9St(Q6w|4RZ;OIRd*1=5>A(^Cz8( zHD$VMLLQidP6!XDZr5eJ64EW0Jn!NdS64f&8Ny#VV@(aB$tZTLTYJcfbnMKvtSfK! z&7sf>QE?zrlM~B>j>go#(3)GC;7?nFHZ6@bIfUc@{+!qiP&obQ#u2=N!_U4o&{J% z%=3zv3{JYWOBXTY83cGm77a#M=iItX&9TwH4`@Q>%yoC-MKRwP?g32c=LD$f(-QG% z_VbVW29uQ8Xr#k2mFQw4eAlIyjVj$=5m5&fi@;SbV(KZQ-oUf5uAYX9H$yrF6Z=6q zrc!MHc_vC95SGPX{%S|rO1zT#;EP;UMxjR%v7V$_GfM(1yc~)FX#~@6GK*UknU(1> zetLa_B*%_>OFOz56Vm;lfYExk7|+DA@J(~&bF-!~sB$&arrg|9g5_+^1joSfJKUZt zmz({qOeU#Azv)u$@h|arij%{{8=1IQmOH6U;DI*UWlm#;+{u6Cm@MBkbray2tU6NI zYY724eb&5o#1{4&Oh3VLW7(OGJ9W?pxR=#HJ&uCm@Z&>2YvA>u$;x=PFU^r#qQ;Q z!c94cNy6Xz8Qe<@Z1r9^jsJQ*%F{|MTAPw44BQK8Z0@PzlO}(jVuJb$rfm zM$|s$#jn94=CUWP&@XMOG9rj|bF^9=n9QO$SZC^aOht=*&a;a#UVrN&(+h37$)(9QjoG4Qh=u-lpU zs?51w3ePB0Z3I5HY@N?xcwfTb?wMw#Y-m9Vu2{Ix;4tUux3u2GnL|q9?iY zX%f)Wtc^-qB4By{RApHk%Z^Yu`}?ZT;bV3zie)|3yQX9Ayr;2(me-$oOHkW)mDKll z!04i2FpDrqL2Nq9YZ1r~)5q3YrkDj;h!{TQfkzBE|KVs zjvABPcQ;L1WzD`Q!tH0qZK99x0nxCbM{Bdtox$VtYMIg5@mQ1M8R?KGm1=etA@;v3 z4nx6rh%K*rX`5!!^+t0W6S-LbuEEZ9upI6e+8UH`j_X+}IWbbc8k=KF`a&u?NeE9{ z)2Sq_hHOXRu~g-D@8y`6a?zl7O0@|0DNE6*Tb;`A5o1?ksPh9yyR|_Ah#@`jWOBpopv3y4zKw9G-?fJV|FN|vcdpvA3!6-~Y160)H^JL1B>qceCU zPPdz*FG{~;MD(0n(%{s)W9b*{?*8c8#Vg-~m4u+`06si0glzo8?*D)3EEQC?)<%=^ zv#@I|Ny%+5Xuvhrjz+;~-D^w!0~RQ>)KwMO7iNM5Phg~d^JLw9BCtFMl?i{ty1+4@ zEDxZKXAi+lHy&TSO`K#ECxf*NZ1|kEr&LqddPK^O_n682T(vgwU}D4SwT3fh9(kkR z%rWB)yV-DB&XYx3u0&y4qs?noBx6F$v(U+OgIIY?CbL#^)6?_|@lHyx#JqFWj(3PG zX3Q^j$(~9xZ#&&GJ>(G@rW_2KH6Zc)3Dp+JDT!}$fjXx(8SqZ6OhW(dQge3cN-pnGYg2hU^}XIfHeX$1D?zXlwOpK**QuL+S}hrMnIpFTg`ZMLgSgr zN%H0z?qB(Zg@IQ*m%Y!l8R~y2zW?FSM_g|oHe@np77qn_!xoB0rsJAqNakLsgtAM{ z2=t!7f7)DwvIfWmJ7?(;6G5RX4 z0n1AzMUpX?k__3ZA52Q-T1OPv%UPX8Eld0_BMZ^K(+hue)d|$Pn9!U!t(H2@GVA`r ziGKPpsymUj>@^Kar}b)1vXK>>bws-Uo%-^WS_t1+;W=i|Ak`-#Tm-5y9B^nzSMGE` z)v2#Ap;Y>>Ai73s&7QdFZ?vYw2t;N*PZkSof;&jbx#_t3x!0h7j67QK!IQAf`VoBE z-sNR8vx)z$c;zBoOq|V>v;FBlNEUsC%uu3?%)J@!ccSx7ktPfrbKDz4$Rb|&tv+7j*W{~d>eUk zG4<=Lu#|~%1v)L#GT=QG+tlME+>}ixRMm#*U@d*D)jXS1ltsROWXCPNnegby1aiJg z%B+NLV>wP^*PgZ5b#`lwsF(D)sVgVm6+u~fJGTF>Z3Of4o#A$8BejV~o``2!6AK-G zXZj;+MS=bSjBowuQCeJ&%~tFo*)@|IRW?&Wd5Sle13!+z7~f%N@sKULW6s8V z%cHGDDymb2TCXECra9eR9^9U{-tuV{Mo9Wv;lv!#OpW+4fLtgeqeCPM!g^iL4U)5zOuzhA{4<|eit zzu+nIBZEJ$g^X*KD9X0!gG3u1kSdqcF=LjR9h-@fFu;lIobj8djC2Yw!KLrfO2sYOKx#GX~o18>cD(|sb3@)q_Z z0w)xU?7pekuEbhvkUud}<uCVRxx0Owr;&D|EU~J$)urEqxP(&A`25^*?8M1PEUNk9}s(X2eQQL2T zvEEYN*So&T*M@4bQumSIJvyk^0<+X!mZ@WfIpKkl;X zrAh#cw@j8c3B^$>(cx9AfOV?KXo_IXbKHGgye7@@81J7Wo3a0cFSNU8m34 z=clkTewjCmzp-dGRSP|l7byoxgZ-o4t1ABOwcvBeg69U*L;wv_;)UkY^Gf9ORN$9v z#k3=yc|qG3u3rZoGKROuUgV~->guPP7Y&>yy?-m80|xDWCypCMsXCXB-nJ(tDZj^J zHLX>so}cy`K z&Ucm7F|!#6?8NcxH;lxKeds6=kizlG$0#1$R|c6Jf3?XJU62_Z?v{MPixs{%Q^XCF zi8WYJ^$Vf$C3YvNnu?eqMP!egyMBE^>!XC9PeC%`(E>0*qu4n-U04)Z8Z7VUy&Stc z{qS*%@R+}pGB9&+uU*c&{}QC)2u+sICm@7gOI-&?KDRPUG%VvAS1PUsS4vRFG+v=0 z14;K50;k(@GIZ84pP#DxhpYR>neL>wVZNS2l%NwJ@5ls-aFFbEDzB%hRAldmQaffj zecgt%shUqFc75*>pv9i4!ZVRsv{FDtUr?uNmiWj6iL>OjCYrs-a@dmdx@=U@*Bcla zL=UdEd2-nf_-yL>RMmuhZP;j*E=fSL7le>SOh$;)wGerEf1GV;@*Ro^Zud<{#%EN< z0SM}(t8bM(4X^kkuI=~{>*fL^2T7{sdX=QEOYQ-POvv6IKd2RASl)L@JhN%XX%7&) z(==yPOP5Wi5keLefL+rr!x@}A-gy??=YDZ~F+aH?BOzI38qLhQ!$D>c-D-<0h?zc* zmt1L71eFp*>_DH;053XUAK-RJWX<@}ODBmWG(NN4h&PZ?ZQ*~t4Ns1}6R{zk)St&L z0O4vAdTnF1gXNGvpAFCsw{ImFf>A%?ezYy-HY(p_4U5$H3+r#BhjSo&L}zmF`o{WLKgVw$gSxySBeg5;v**yzoy;_I0OGS%XE z6;XGQOWpM+UzJyl-YQ4GE|llg9yi?xPsg|68M0=J<|cf~=_fvmfj0{v$Ss9OpO7uY zHZrK`GG%|a;9qs!gT0HF>Oa%6j-34Z<FVqk@ zzBcp8?XlYd@#cUaoX3~&6Z8Qrc$!7eBSZ&>Xd##tZjKY`m_1_CsWyGe z?gCN!awnE^XhF)-J3GWfK1WN*lT6;$kajRMF_m9$ID1^MbSB%;lpBR#E9sO!cD9{k z&iI!zy(9NPld^gdE8jd+6=>U}y(VPCTtbvmh0xeu8uTZ}jE~Vbm40}%>Hol#Y|z*P zW0Ktb3b;?pjy~Y@43V`xSk;agNm$!n27_uLnbM6}>Dbm_ zDTY6ci0V9p|EI9@OPvmCU1`3Yw`jPWtEfoY!VB%`D@dbaHHT%;ltcYp^ z4h$eOx=)q9MLBC^Uqrfi8aw&~?@^y<`EC z?vgC$jKgBYTOCUa0Q7Yzm_FvfQ>ja-QU$Or2p?~4oAngZ#)ins7n)CQh*<#D@&XRr zSc5@c#G!Zri!Dq-c87NP9MD|gerC4`b|*D@rcVVW;ys2B#7`B(PQzaE6u1wC9xPO9gO#u9~Vk8n1l)}WtZ$fWUNa#HwUoE-20 zzS7smfZ8CS;%ltf$emPQLevu>>+JqmUv*-=o?3=7%M_>7FSO_~SaJ-T09#$YQ-C&o zl#1p&NgI5-k&FmkAIFrzGGM+Sr8Ew!N5T_pjEp~U>SqCvBXl7d9gzv~Hms@cfDeEv zQl#RB=?i7BLXe;Nz(%|yJ(SRnw)VlL{+3xr(q+Fby&&kfC2qO}ETssE$@OUn-#DC| zZ1~Sb8d|ke9H5ze-UWGxh+J~kb>QRP57AdAJ^;^`?E$s(ULmLpt-b#hiLuVvXlN8N zkUcGOjjY!*p9{*Q%*tXPQn!~HKB^_qSE+2pGFpgQdSz~J>~hJ0uch(!NK>*Qt7N1z zdN8x|m)}7^B?3-g!h2X)Q?khUmXQJ!x>&yc9IXny$`9x+(&Jo`E26SGJK4}#$xL?@ z2abBf$gJ2opGfvXwN6c#0lRrKp&kO7DaRyK-25#NE z5Xp}NZ*at_-=R;dQh@4P80)yM9@%!rrL zft(nnHJ6l%J%2GP|NlXD)kuIA1!&;NjHvQoEQmLa6$m`Zlt;f-t6cIhH-w2_p_y2$ zJF5#5&u;;BTiEmnr8JtGZOzF5~(12V}p@f-UGD@(Nzq{0D)mCH*p^)B@c$@q{ z`*-U5DHYl87yPqUp-|><(F*)*o1mF~BSkG%X-{BA)@9FV7!z>jSQ57sg{niX(Hq_LL@T=VL)I4aOkFIwr^V2mlsnS^>WzZ@Cg%1KxKox^rC|Ycf|T`bB}Z9Qo!{)2 zq%IWqx#WmNwqQS|XxVnxL^_pN-Nt44=FU-t>J2T-$cU|S;kXC=n61#{OJL1=*k{v0tB5sqvGn;9yLH!bFld$Ds1r)+RXkVEaVZVg;P zcFoZFtvpr}RHr3y3=HHI{w7s=xCg_+U+xrwM<#+;4*!!mD|@>L6LFax={z<1UpKw{Dj0x z+Zn+cL&I34L9}^rxszaoEBlRaxd4OKJ)#EVbvnE3v!q53TP$+bd8}!!UESzxIt14H zFx43*bkksQq0o_k%s2rk)1<|a+0s}yQVe`y1yRtfIZrM$ktE?%q?2!%rK-!6-MjC@ z`Tg>rCM1`Af*6z0 zeDUT1#n6O&t(#;%(-473b%ca)u@gtiBSD#io;O-?-?6eZJ66OPmdWy9JijWT^B#?b zS-O>=)ciB7ZCpHXvCTu$zBp(7I3($)HgZ1}=G_K}Yr;nP1NfP*jy}ik83G(u2;jzx zPUaU2BnUAWj-p`%#)r{h*}-C7PZ9BviC*oE*`J}NRT0mUFLTy}Lk_IP*cI?@Y57_! zBPmY}_<^*J^0FU^l5uT?%ebWY7|m zq>x>o*}Tprt0_uUH7xQtJQtmWUVie)CpQr&RlJlTZf58S{iMKAE)|>&!aZ?#89*AY zLc{eGVyl5-98}LII@%yKv|eq+-Z)Eb;Izwjg$(3i08yE8beWnx6 zJEYpAFpl?{Lzi0R5zB1*Z0LW_3 zELjU0b>|eJtE{;FRacLhUJlH0{e~897Q=Lxf`p+~fMK{aXwipZVeNe^5>sIwxBrm7 z@Cxc=dKN(~Zgsd?nBaRn)OZwn#2NDeAP3)_u^x^REN4owOZHC66rT5g(cMJLed7aX z3qi0_%YIf|kE5giU$;QHSSvqrhdR{bS2c}qv8!Q)>0fEE3xO9O`LVdcK8qNB(t!G9P&gjRy3QJ(QZYQZQj^a8^F2}Aw#~2Ux0!nN?FbsfBlEg5II+| zyp#-QJzDpDRjye3PTVlBDg;j6Cp)3Y$W2~qoGmC@cHHo0n+N+m%i@**aAK~W3~=nz zEU;^~E3mA~h{CJvE;kpxW@4q!*S86*&QjWM9nP?BrL%PW@(*00 z8NU4mJ%Mv&WIYbh<4TM>3cWC6=tV;LGXKLQg^LbTl=BXirvx%nCXY8R6L(GGR9ufk7$@PA^6;D_Zydj zB%E334Xc<`66Te z&my#0_P>nZ+^e-y?dRIG;VL#`cIWPG7T#^FsWs-RL&fGu&#l(hy8oar!2$3RUs)^@ zHdh_w)$!ud1~G5|1x(lI8+${{?AWpGmoVmYRjw(}=Ji<|ksJ#nz1m{-<90PWJP0K` ziBw>;?2$58z3ehDwF4~**2~3a-O9_>)FP~&f3q5QgTQ7 zg|QSHY4(}pA7L0-v*uL-l{o|6)INEegJo)nd5WUu?H{jVCFk=(#-P-47#9O=~($44wX z+#7z&|8&XvtrQMnOe!|0xYas2Fg=tS27{W%>DUdn!cQ%Bw-gzia~ZW_TQIR(;7p;> z)yjF=LNI2l+@`#mXHRygH65y`QG;{X+!qGp%~9S%(6e8-xH7D&?dT zT)ltWLB4~`kz;9>H=BvCN3t)EoJnGH(5Xnccuo1b!R`!2Y;Ck+0rr5H$G`&D<%{(4 zIK-qD=XBB|m{I_XgTKdXZISSu7P>UV0ccoFo9e)~n+bHISVKBiG#^=mY~KPHYuR1W zL=bmtUpU%&D_`$3o?&)VvSNVEGI>o`hoAdNT&u{PjCSL#YS|{ZImXph5Rn*CU+&dy zw{v9y(Uh8RSs=@h8n4ecW$43>PU7IW0DxLczh)6!kOZ4qv@B0}CE}C)fcHNZUO#tp zMeFu;e0s#BWTv#xX2(;$bBo_K2SL^khE zHG$n0p?hxsgKAr|n7)qgJB)`ZXA=_V(1dek-e2hw^E;tqrG*Xn09MRCMKuh)ues*y z%D#s0Z(CHS$VLakOcrA(f2`8zp2?bg5le2v$HIk18q7cM6r0vkK!pSlHnj7jC7gI{ zi=VxP`4OCJzWzr9o(`pTzMuPp);_$Q6^W`sSP5_A9-gEAZLQL_o-#yv`4*Oh&Asip z2355_w=eRdGJfpHH`ALoONgU!YXksokPVFnn2)p>66nt=V(i8~3pm)aVgsBgAB)Ze z&rvobh89be>AHRXkl39W=5kN~pp(sH`oLp6ISLIdc?Y^KcfY_alt=Frgz}!0)LYWi zjfeYAc?1t@n@_%2)i?9BHf0QT1Su8T`MRK$#p}~3M;M7o2*ZP#;=ei`2T9%yu!k+` zTe2|uOQ@|Lq(U!{O={!{8*3gY&gkze1LEk64w!cQ|4OJ6N$-G5?0rQoZ4#>KiK`QO zd0jr#|B6n+1LnS$yX>yz7Y~{%s-)M=#?OzbLT;SZ@LxBp zBROj8=Xd2wRPg_8z=U%DB3J$9jnX|u*feMGuQjWSQvdxd&Wbbgmg(*22iyZyEBV;%i ztv(|2OjfsEas`5O&PQSS-}X-z0AGx^M2Vw!6!RZe@ce=Mz4r-xx zAq|qptSMs3D!YI{={;UEGz~b5he%A6Q^c_JM)XZH-=Ri^j5yk>_DMeHNgXf{sdUl8 z$q1#docs7c+fXCPLuaqprx{hS1Op8)sKN>?dg`&v{AHNP=w64Cr2geVea-4RUSImedMozG0C`H0_a($yZJnyCNhVo6tt1 zl1jTBWrxr;lh0n?Y_LBu=fOeM3K!i&pJ^ono`lg@tbq?qIXGc zh`l=+$b3zbRRJ}??^GnVkQ)khb|z9>O-bfOhiJh~gFH`Gt^O36lA*j*xdyQ~E<56t z)X$kY^@7E!d^Pu1=Ix?G5_tBP0Lf7{FmNHuKVmagAbyQIqAyJ!sDo;b$eR8z-J0`I zH%vK?xW@`~cYX4V_x&p6L6~)YNh~CQyV#&(Ca%jyuu&e?C<^%IaJpIRu9=>M!U3~m zurK|6lOCbJD>bDylekW@H_e6C{0;>=8Yy~89ni<+qm5kq~Y$29(omx;hIz3T3zP9pl{ zS-UnweS))r*AZezBiK5-GUoi#ArLoNmtxp3qW^MH1@6Nv%k`ihoe*BZye$HcR0Nj| z;-;5LiBx+;cksI@k3qyEO_N#IuAMlJv7I8eZV6i~&To!>r*K zwYKMuD?s9B1nWWG@G+IC)KwhE%Omj^G$IDQEI-Wi{k*&n z%+uynB}+WO(UxC+VrBDpgD6XFfVhz&2n+AU*qn!5do3&N9o>i%?oIqUypocnGmzL@ z_){be9#gCC#t(FA%M4Ay;b)nIcR-eDnD?!JC%UN#8~?i( zot7Y=t+%CW#BhVN1mv^*;agge9A8@3l}SVwaI_wvOd|h5{5EizLFgu##R7f@8tz!2 zJUAR^jN0*0Jf{szDl{|92k{z5f^%|n={bGF)?@KptyvFM8aQX}26E?Amp%I70M z{v*qSitaz0rk4Vokrea|Gh*t+LGm?i9hlG5miN8quN}_%I=#S4zR88i-^p#^mW{ar zBY!`&yy4o}PPLGIWY|5~teG!{|x-FS(pzfJ9BB+4z+9$=uqiHfX* z5ACVCk>^-j-}1S`stS57*J|Dte{a*|o=lUSjix<$An}iaU+atP#S^*{EWt;$3zyEI~DbZU27bH*9B4ZdaFL;w*`J@$PJ=*3N&uPqiuM!w7Bxu zK0^pJZe+crp%n{NHNA-$h^xCF@>5&*J1a)e^O!%PYvg|LfAbY@1T}# zQ{j&1O9zbCfhM6=aD;0#4Ess#mynB>$SbnQ$^IJ=vVo(Vt+ktY6(-H-OK823*ySXR zF*60$cac=f`wXdjA0D2A6P;G!GvPX|xnqP_QaZ6Z`uOTAv*yZ^wp4FYt@sjB6hkPM z*S`zv`IzY9YUUVQuDo-fP^LiHUkKANa$-qf9gGeZ7b?uUT2unk5l$5los6#&B8Zo( z?v>WspRcpjtUF=IYA+Wc1B#^tW$3O&C&ebI$gUNZM*$&?;8~G47+FxTI~joUDTXkP zmIpy5i};G9tp8YBjnP@^%g71?2<~Btg?A-zZ@xsMTi5_VkM`vJ(8Vdpu_Y;0#PB^L zJ0)Tsco0>(r9lZnIb5J9>J}|?P+*fV{HSt1F_^B`LJ;Dcj?ULawOVnz{ILidi$|7G zfSVRocWLDPECE>KkNp`Xs6bq#dUWletBbGlrAKdL6=)@E{n|icZQ^jFY}X%q1B98f zmdKz}5f3RMXaxpk$?}fbsOHIiU**f8m2=CQrEs` zix1N^C{L4X#H1H(-ZbYXPofcjZ`Z`<$KIK`jPjdrWa~N~hmut4dyED4bGH9tfUl$n zkiAsd%!KLK$C6JKbRxDt-i)19($J38#(};=0%w%p58oCh^r!;@8+g(S(iWp3e&RhY#8ZlA%kI zb6VMnx)kjh^X5wyt7wK$s9@1#tprUcjoq>+4k2M&q#WxCi=k?r26;gouYDQ&eav9M zKxKJFUFSHhD&+%5?e{4SvL>LjqR0WjM2~U$DI~i#!qFeUVDo1@zv0!6?R{18ds(xzn`HL5 zDHY6Bu}B}|lYr21wQGK!g_%|~jT}ci0d!JOL1tU1Q}k}(56Kf0o-p)foaUghp%EJN z`Fu#V3;*jf?F3LpM`6+AHNO|2bA_8)^2wzQ3p`lyf7=oZD*}V_Q7inZO`*_NKeYFz7H(W^DxyuB*e4LB@+{R|*M+!LdsDF!xx z;N{O3D^lJ;m~7V~URZ}n|1^yZhAlN?WX*`MOU)(3Lwexm9|?$moF+W{A9|wz`aL-e zj>r}Bt?VP6OG@o1kzOHmGlOEqW0f*-=MlmWm=o| zsf5g|8CILqD1Y}{A(Mh5mT_r(CV!Rv#76Y3Vj{m#(aUV@myM3kIu&8dZS!-k-D#}N z6I_05oI*r`LRR>SqbJU(&qAt6X+VB_j$AjLg!*T|8IF<&OxKKL8gV}1^y13APReB5 zA7Eu%WM(KC)8CW}+Lq4m{Sc|Kr3pdZJB3>Ea%pHIk+L0)`JR9&jH>7|``a?IDa01X zn6HS&9QuCZyJUkr4dslb3FN`~kK0=J-oOf)+f}UG#%>M$!f;{>c=vr&!app&K5z*_ zPfQN_rci{GqRSrMOL#HZ42;FRc?cIBW4@w`{(&ol7921!Bs^u}CsnbPt+zJeQWa|3 zoYE7QqQtrC>A(Mi|E$EeHSu?M#%UG`nH%QR7pFBjUMmwhd=D>dR$Y^p3hD%mxV_({_CAbNV2|htqI8m z%j74QowLDlcJ}G^x;ST3MP2rW8s}d74etA&ztY#aM2-Dl(#}VobRm79$zqXG zzLlIOGJN#Xu!8~=LkOc!gf_M1D*|_H1>B>#3Mrd0pbuiL6U;{hiSmJ zCFag?Fz)hwgA#+hTUJ7!GjNShft%m zo2!wP^Tdsu&BARYrNO^vyB(U|GGm|wSCpLy zktKkU8@9_k?+zf7IqG#LdA|ZykoyeNS6!=z zE6`wo<_7ZW&WVmx`%9kOohC#}pjp_RuD^j2E2fyhI$HbaBrv;|UL)e$ynFRZ>@SyG z?8nbh?8lT$)Y~}?GG@7#-xqsK>$iwTOT`7#5meT6vBA4gI=Y5szKqKx*s>0!bS0c| z`HVH|z{gCXPJ4`Mk&hphP;rOcJ?Rj!vs&`uB~%m72Fpa*&r=N3WbHk1Q-|uvhu>%D zoCk+WH;o)4J!}Ah>mKLGfFL1h*N}V@sgdFI)QYps)zW~8{wLy}WiMI3X9h@YjulNN zNM5*v1oX+esaQgrwsgtBj%}cU$94NYlR0x5iTUf*R8-U{ifY6kJbSjtyB?RGOvoL9 z@I8>z3tHqB^F-FWp`+lL{B7lfYmS0hM_9xVV}aa6qg0T6Oo-s6FX!^h!iuP`7} zFpgY#A8&&OtuN-LPG;{AW)~;=JG3D z5M$Bg(Be_b#2Xe1_tx3drfrY}CGvbm`sr6s=j2hLQr}NQTnz$4=~^-OwdVx0cwos94P@zmi#I{gl8ho1-4mBRN44J+SD*ACi{RV_P$xLJ8?70 zwdAhrpq2jiBK5p3lQz0OpYp?!&F8C9E?<1>q6j!!fuG~7%TYNKU}w;%FX_ohEpnpp zfj@aY|6*xfh>6ZV9CvKnqq!Nw(-$pjB5$~>zBGh3V(7m4yyLYdjyM?tdX>&N#Ru_i z)PS9p%$5|)KrGNqgH&zYc_{C$>b^9EmRqUcrl_k}>xxH;T-{ZK63>47>OW?5qt4AL zb2CWGY{A=Q1cZ7*SudU=nAc?6>UQYvJ1ttrAQ|?*UCQvS&E(37Iu4iyK+Wjry>*%}An3=0&MVAa)D-wVYiAlBMb0%Pn|K-Us(8E%O?pjogQ|FK z2Q;DEGC)(8px)}!wC4>iZy9Hrp^eqBZ`Z;oz;8Z-YKrs+M5_&^_Xj!|@m%YP@hDnl z<3>u|_!5#-iz82{MBm7!Ca9g6oReqjs-CzO zHAN8x(CJBi^*n%ZK*I;=tZsSj%rLGM9*!}Kg%i@TtxEONc6=4(coN!h116exH#qZo z^H(P3HMt!X!b(N)m7X?#R8IU{i$YV`z;Lku3&2x8Y?Pf34#9e{Z^Da*afVMY&wj%K zW~$E#OuXMYrlJUhlBDADnHi2w#!6fOdwd?1m7^{V#=5`@0?Y(~O$n7q)BCiyM3#Nc zCNu}yL&*4kIGFe!Mvjxphy&SbSkzRTUMx`b8< zrW{r%PJVIiGwTJ)5>{^NxO4_uM8T(3=aaV#a~cL|9?`+}v+g-jpUs}u%%}tb35^pU zO(khNppt2p3?XO?9Lt?`h6jt$T4J^dOVIz?MXV_pAvX7@^-2EABgZkWoZe`T4rmOe z<0I53mxI|@UO*iJgF-_Wsr(8Id0x7*jXejcSHx8@EQNsFJg@kX>moJBO&rK$a~Xef z`xu^V^}(}Y8mRh$zJVIePg+M#i;Ivreb}8auMA#?&E%;}r?72H9Z4r5b>;_D(h_!= z4vuN1h&LyL5TX2DP2dt$KrG3Km7MaR_aPxIe}SrCsK!nfF%G3}v<( zF%Y|i8??4;ZLdKq3-Y*(mbRr{bNvR(#1f9D6F9IYsV@9E1fxxkY3BEJGCA%SP3(T!4M=C3WDtzI>D!CfKo*FG2yHp5=nNF~tFMvrNTzX(oGa zWCWvd`;0=TLD73&Mb!dO1N#>* z`fd)?H5WlDBN*=kJ_mHY&q@vx_HKnlxTdx}J`QU-ZpBlnHxvbL@4A^p+ASEDsi9n0 zWYR%CX+oMi@&0)?wN<@*s-8VxIxGOFubv-KifCUzdxBpNTQh+I$9?@92#Q;FwDz*d zphpdjR%ej}@Z}2?#Lt=DgU=)W#7Q?6htoOs^Zg2xx%qQBwS$L`fv5G$m7r~p8+O@m1oeM*J)1E1 zRZo=;=`IH5C(EP)H7J66oag}|$hs4-D?-lh=(#B!2bjlZp1eQvKXI`CW;*{^=Fgx9 z(Yv-2-V=&5J9Ia;MKyKhF~eZrQXuj0UY9sa!O7}WG<8=X^c2h@Nq-^YwpXs(P{PsX zur?1;((|_6e>-!oCR(HVm!-UPmDY8r!C@E&dJx9nj!T+CH#@YH@-`^??=cQ`L9>#^32(#evt9WvVzH$BBPUzQg30-&Do9cF9W8UY)ETnhZ~}$N!lUgu zEMO(>*|8)%2c^BQEl{FD3;1*oK1 z+==S}BGKUzwiV;FKTv{rk@S^NF@zKUwBKPz0@%s5xmCT2M;?0)8psA1_GeATwb0j8 z9F6NdAu z(JICy*p#c8+~=EPPsi>U5EKX)FWWAlb6q+a$Ex87hoOwIlHQ9L@;+qz-=y@9o}pH+ zp^VqYdNAe&Di2fWdIV`|nmCpd@!cA>7*FGjgmO`+AS(-)0a!-_x85RA#ss zl*HRV}TA)Q>n6UJK95%9z%@%In#>N_k1?Yrn8h*6GPaAYB7AtZx({n9q z6Qc-e1tB&=mSWH1{Ry_FRE;qkokv%}UHZ=E&dV-Y$$XbrdiMt{n+H)U{wCu|a`!K= zAZf7%B_7}AJkLSm`vB6UNVjR~5x!tTxD+Gwf6H(XVXw3C9M0-YtK@w0!^lk~;xglO zB5b(u(wM|uW3|&6QhlQy^1B#_z4BAYThdj|N7h)(66LdIQ!sHZk9kdfBc+v#rYDgC7I6=>zCXYK5 z3t7FtOq?)7_tAr!Na9hg6reb6px|NmBP4r}!!1!RA4gm1W`j5k$Ys3-^g3pswxhXu z0c})y=V}QP`#5-_Sz59g%-g}*D*fvCn%?c{dnwD)rZdbE9Rg8lgh?nMY zK!MVFS^_mfmP2i2_?~4&gd^f(_uu}s^w_K5?~iLWv)l4s53KTnybBf%qA#HAfXLbc z)YwM`8xsP?jP$oUof8gJskN5b%<6oeIpns9?*9zqr@0PHbKuM}`5O}TdLPn90!8B> z1(@5KFZy8f!L+hTezZ$n`N;ccaqN!g-|?_qjE1TF$^HVg{8Itkm!^Xt?nub<9?f6T zw=t34|1VCdcEuB)N`q`@PUJk6^_j3x3n9QXbk=Mjk(=3Wh~@~tSQ^1GiA*(D``CL! z3akebv|LjKaLQ)PydWheBac#s{A;#?_~ySj3r$l)ST<<)(zTaJTEkL$Orv@WgvFH^ zxsrOt05+yc^&y^uDKYeR9r542lb7L-kXY{F?QT~I7=sU}ne%#U@n7>GR-#20sJO&E zJd}sfjNey>X?>U23^M|WtT(r(xxb4mpkM#eO!Z@?qDm`SDsw-THlQa{IxjxKa}pEn zL@^3i=XhBRFaXT0zUs@rWr$>?#e9xs3=ZxTY7E8UaUfh;diu~^CPqG)6TM{1zp+AF z%q)svY*YJ|l7i}HzUoLhI7^KvcwK_fsXnS>-E5C9vJ2r6Q!34?i`+b;@ZR%_qeIUL zZjrP&TX}Dn^>2DFDeogtEE{w%7$+TX|4K~lvZ>B+!U$BhD+YSrZh=oE@B-^nv_(+{5zk%O(j;sFm48fWG(SeR0v3{bj z&VS)3&tjdlkuMLI#-D_L;!9fB;N;ka0ltZ1`=ci05x?DY`H^61da!8=kg-I@ zO7c$X+fO<4XJfwJj3Ms*kC*g`&F*=}WzxePtJU-RL$hY=vL$x6M`MgQnUBu04BB3H zcCUW8v%e#)@3Z(gMyy1DHhY0^JyVydhCy)W=-6`&}kkOB!^@! zW<(&%6v!kD7EFs_j3Upt*)Oy0_~L=z%e&PCdw~g~s(cJ+^}i zx#i}US0+R{zhQ(Ky{Nt|6>n8}#XzEfNdO@GN6kIo}_m6jM35NPIE2i$0uw+PPV+IS^v?8h{)41HA3b)Gs`%Y~bT~~A zgVkm4dkagJPne}{eV<7kb+f9UJ0BG{6Q>+-xeZy*MhvE3Zn_EE*0{8p%AvyRpFQ&f zf9P3z1xkhZzFo@a0*XwR3`ORvH6(0++2{ea{<%7_>)wcFUt@gFoozHvVC3C9&^>`q zxf#*vIJrqcTz_3N0=YXPZbo!hTQpt|2D2>11{YQXI-RbMT}XT7X}eIHanGTh9h&y* zzN2@sEcgSo7i%n}`!vzbj@?d2vs~==<#7=f2IYdVdqSr$5~UohrEA2Rq&p?-VK}nD zVXzh6m*O;rHOStf06T}TrC7od2&y4F1+H_p1^UpXD}qZjTF|L5?{Ld1_5!30Y=JvP@bC9RV#qkwV{wU|gGX&6l0E6j3BFs) zfal7fgjyz>e24E_m$yE-r0>S zIPVK9yO7na{D#AoiB?bI`}$U+U6lehpzaUU+GvA>>unOFd|A4Z4yRhWp5i6HOKrZC%ffR+r_e zy0oU)c!7ArIJb&jZu5?wX_~3=W6qy}ym|^~&1PW=(ByQBGF|eQ z@L1j>+ONL{Pp6#0$8g2^A$ZVVJ)K8x~3N8X-k()^G@?8jxWf5>L~Wln{#EKyZ$ z?xX8VHJ0DaGi$t6p;-lShgQ6P4wj#UgsJl8xrd+s_C_QC^sGc04X|vY3$7RL-53lS zs729oh)dr-<4?HP&#R+;5VvMyOmM_qCL4|72MAvoV7SH?f8|vj729s(NL_twx}W|e2FgQ%WEEmCxxWT3Qi{RE!Zn7nsvg1;+qQc7mgt(EunW@4}nJ9|Gu z+L|MY_Ap4A?|zW#_-Y?ux@k{ZiW?@q#@4`eM|MpA?R8)-H;pR?S?@x&Ba`N=qM5T`zcp+*fTjKvi5=FzEY^ikdUkYL6QCghfMhqLx>5;x}nLc!u`} zMY~T`VNO_ZoRlydjpL4to5M*~6ipT@Js1A0YqI_zCR^1mCGrA7yd`x(>&6aNeIDnK zVDqHfetvz}KwTn=al@n}gu$t-$A3uu<0Wq7lS;=*+eH~Kf3!+e_W7M;9S z7F6z=+9#$8HRQbG4hE5`60^;%{9@)4yhsT0d05`xo@Yo_oAk&lP%{l(A8p)QVWB1; z?i+5T8zu`MJxi-!1EZ9QgnW!cq?foap|yzxP-{+t)(o+7q8?+lISr5F^V`Y-#~pT3 z8Z$F}53q&B0Dz*%sAi9b_S8Io60D-WK50zLn7x6ID#Q~)U$wHEh|=~VSqGc-oh&G< z0)gg7r@O=ypp^$e@AETYX*JjxkzU?;`l5KGviqXp$AvSv?0>HZ8b4wbIkUnFmF}Mm zaER&;z!ecA8_|1%Odbb3fuu@-MIf=|Pzr~j*5_)w*h^1(K~=)0IthG*$qk0>oUVb` z0kJ3jfD=f)p%gvRjb7|N*Ao(t`?6|=r^nYjoTm(5J5*YxI?%)-M0bSmM1t}8b_4qEut&IBho0bCmf{QWSvEM3nw9u|6K`6ER2V^W$y+p8kgY{l zvy9=9W(!#xbnN|W$zsu;)R(S#R_wV>`+ZlcTQ4>S5Us`Q_-g)`p-Bu@K1(R01<7rH zSK-({8E5FFGH@i0?CU!dwztH>FQFA-B6;jFM;juXyLuL8)zo!mHa!@^s?LXe=E-XDNU+#iC_|%&B-c)aaE(s+jhQj*oFag-ntaF$s3R} zCA>U&ivyYLZCisK9^tKS0PI(eYs04pHSNg#dU2TkLuAVrpam9mcsUp9o@_ z{q)vzq)SJnJpeGmUMWxg6_gKv9FHw4r`2QNdT=T1UZQ?4VE9@rTYYw@uO6o}NSUr7 z+nmK0?O}eB`QbR*s&{E!^B11l{15P`R}f0b83t18?^dzT-n56Q-r`CTYUvwK8hPs9 zhWEZJh`NcN3R1o-Y2R-`tDPF2Z#$Ld$tNYGCKZDTjI|k))AkThz388hH_{Cx2}7)t zl(6$#a3E1g!?kqD1VA{TkLHVcY7+jQWUHzv&o9Y@x0u>e6L_68i>r|&+K`Lo33!6w zHi#Q-F*)lKCl9~7B_&unQ)$?ppmVWvmcWtOL8?) z3Y=y49QvYBapdNS-m(q41xXJrk|N}RDQyq4%i0j(Qa~b%^**!GP@_x``6mTZxWbbe znmg(6Xj}DRTm~VcKoq`Nk7%nGC)7~jnewFQj|*7}0`p4}Q(dY3$)kCTg)(dFy<$4O zSaw6e<*Pr`0c6=&d#YK>%Rgb2>vB7fGgdi5B5!=2Le^&@l@dfPgL8|+Zoc^5tBU8_K&|8%I5IqKelaFRZ=cfh-E?>M zb3SWnW=YnJfVP*R`AHzS@`Y8^);la*oS z{HEakot5{=7EFLODTt7|+jU2(m4f%k9|h1j9t*q{Y8ymD+Ad9p`jrOkcc@{y<8mBC zHL(latj)CBr(4qq(|=mK4D{q{?YVth#p~|0IA#lUxBN+xXary^>H9*D&sA(9%jw0X zIC@sR>)&-ESOqfB&_+$yeSK-LVHqBgVBN2KrT{=z$}g%z@Aec0>d>jucICX+W@cH= zsXK-H0$j8#VLmS6BR!wWdX&NT*Iqy+6HVo-VIE&|6gK~%l)reA=J3R6BayEE5-(iW zN+SI15j6{e$^9)1Cs-`1h=#&}F-H(vjA*nQ*;J2W#Hp!dH;}|c%#v2ub4ju9FopaF z(`30C3t(ix{EK8c4R0A(=O-cAFCJ)kit`;^(7?~^h4KPuJ1@WWE?FCF=^^I+qaXa{ zKf?meyDD(#eMQa|U1hF54i&oXK>bBr<8d$*Q~59Zs+6F^2)P?Z6n5VsV6W|W`aN;% zWraG{4{`E2A%kXOgsHSOEK`S8jMXd;$%kd5ZvfE^d57J@zaKt#&vTST1?acU>{}N1 zExi25WACXYAd`MHBgXnMgvtB(J#Fzgf%(h3r>va{Kh48g`&G%&3_EYaMS8r;g_q|x zSXyKAA&hhP=M0sqNBG8x+lD*&{N97(^dvtXb3M)Q_?(huwN!3^FDt`7jTZi-I{LJc zmK@k?Jz-eC{u4Fe%mEqUnZx~Cez97^{}c~S5}v3N0->y3Fa(`u1FQPF+=9O{_MNd&%Y2%nT**M0Gm^xt#8-$xTi!(MT#R7sWCWj0i!XR6) zBgiK$C$LVBaN&M*mx9n;NiIn*m#ENJqLue@-1r0uzniM^v+-=>mw((E84ua0@s8SX zY_w?cw3mPz_6r7UubRnv2gV;FN0(H2m89g3T+Y>K({W{-wuZ7I3L0UCNwG{~i8C0m zO;%@SGBlVHsa3TR_EDkGOf+`56e5bp1C+;+&^mqcF|)ZAaXfxu7p$4#;)`goEfI(Z zlo*YY;|pd*r*0qFEu)zGfh^^RfFa<#`J>wRjAi^l{cnHko>Jif+fbz~6Tv9H!i<83 zE1GL>45nz+dS4g03nnR+>cCtjKbKL31Y3$e?Tcc@5AD-7cpFJH7#9gj8z!!_kCs`Z zO%{RLPP{T0M4S&}=yj8)=u>)R20*uz&VRF13K_kesho~rj@O-gvO=~o*IIpqLkDuZ zk*fzt+Avf1aPaH4)>xp|6H?Z?Kr_O2FV`ImPQnyTznD>tM@i>QHW%bH>9YRb;I1*- zaw^p*EsXt5zToIp2VMh(W_*OTkp@i&yBKm3JmLnq5wN6E7(r<0V;|?WLJf5L(c(V* z+0h`0ATJh)1c9y_r_@Je1ecLxS(X1hO@CX|J0IL6f#uHroZ=y-0x{ZEtDl>R-jhHM+L z)Kvkq(Ff=x*9SAJDFWRwx}{%Z5AKE7?`PEg^S|HIz4=#1RfBpzFt#&t!`D`ChW2zX z5{f^b@m82{fFq4sM4#a`SxwBnP4GxNA0;(3>=+LY%NX}q`odr`Q-p!bBIFCn zQ+?YK@@O0fap(J9avvKMI>+@u55i64uMbEJ98c-auhc4-f5YY(J`UC+%5s~5^kT^4 z$2;uEYP!RU*Mb)gl3)NG2uT=Jwv%b0>$0oZ6uOUob%^}M<%%jSRLhl_gO~@Q0d=N^ ze484irB6+Bq0Z<`OjZaKUUq0D)BA+#BD-C^4#*DWoT5G%ldVD7b(<6-JHYcdu0EWC z%71wPtuN?L9QeX1N3Gmzj>SivMul% z)B;G)Y??()PzQxtX=c5*1jp))pSQlK=|=)_?@Wa6s2ujY=SF^;8x^NbPVzV#!dX!W zi(uJW02X`p1~I%>XuWhU<7tKBuv|lE4KR-X3&fuOONd;-HrYgB>@8;`xP#>-Jz6Zp zK2kI90*GI!_LD}?qT6c610ox6Za*V;%ipO$UO&mN*D*`#umm3 z2s>+tqDQCI`wbG&vR7xq8ya#qVLqVB^BeX4qq8JMgIhyI3r~;KW^|+<@$XiVIR<}l zWb1b}UKt#Q9G@Xjj|~WxGRZMFmqrtRGiN*Bt_R`V{Lk^xwvFq`G4vz(UpbqrpXe=^ zSTu7Urzuj022(M$qR2!)s=+59b7OLe&;6)_*WE7*vCgYrOG#gNPBia2ZE7U%t18D8 zAk7Kl91_+N&;_8LJ(v-sfAt6HsXx0}0NdDX>O#vu7hFN(Ef@*64Dpn8@-L^N*wgiK zoclsM!upmg<~~e@Vw*8r9m;+eypGJ|66X>TIK-lhA@$-mBLCpX1+0$22eUps;;^va zQN-EyRtWHf<0XWnI5u!|Ixc2CZGwEVG2^+T4r$ygiA*WV1d1rZAPf&AhGAC8$ZYXS zrm2VMhi$+ABNK78lYzm*yPc~T>&7~n=JwCMY&D-o(=JJ4dVyw=TspSxt29!GcD>cu zfD;NE#@)i(^iK%S!d>iTgb&aOUhTCaj14^3=I0=lE+T(ue-pdX8{_^#uA{Z59jJkM z6$^S3*c`Iqowa_=7&%jamPkZ3s9VBlowp*-tu&PBar@4jES|^6lyHN+8zoug96Q4l zeheqI@(K)8x_oapvJ5dycVm*VQB!DxZ%#~%8E>o;=try+h9rrVrHZ!z|8!`=4zVxj zO@e(mDrg-w8=~3SScs>S-gR<3H3qC z9PGdW1Egbg`~EKD4J)-a7T$THmG_Q+f36-cmqK)m91DY~o}h8O{o4iMg0K7=jk zwNw*IPOvmp-6$j@P1n7G6>pkZlI)GuOG#b>PS>De)K7jzz$QY7eZ6Q5dI!08|0sCWKD`h;8>ZxdW#Md>E3v$# z#gTz|J>`+}E_Cqlxz6=*NTk zWiP593ZcCNQBjl77H6#G6}IQC!+S;=H=1lPFno%D&y;to)E5DlQ&ziU1OBecy!;rk z)`EC_m>D>Zfe)#E)Ue3*T(VeB{7PO*7yY+J0w_dgx>Q&#YrAc3?9o}<@TsX6w3r)a@aofY5`VY=?-&BvZjIlu@ENs@cDJ2)fe?Q}4i zOpjsfXTd#9)5JmBi03A1M}<1~LTRVfhFS?r*h76A;AR?p9QY8(JDCuN3sApa-Y;x0 z>=V#K+>s{_eGe+*b zs0;STaM>fSw$Q%O-$VpY*HK&stQ6Mrs_$$nP&)v>g_5#VDoN|rT@t*j^GA4}I)pEC z-WukRLOeobt~dUJic4y*uWPe?l44T;6_vFyUnhDTzQB;o{fd2H_pzzLx>Sh6YHd@m zTytv4DDt!#zGu&?55$!{MZB+LcC&B{9rO#e)v6q3|0F54HfCL?4oX;}L&NkXetkxJ z=#o3D{#1HRomrG4jZQXH9fvRR_x zQ-0xOJ!jljmRW*^UmWJk>z7bis_<0Ik8~{u(u92NV(m3$p?B7~fWr)C4a%7S-M!t` z`Y)0Y%t!sm07b zFdWUoXbrPjwPoSU*i5lhlOa+N_B&Z65<%>^Rq^#THzKIt*F?Fz5CP38c(%8kYas$` z0864yEE>E?X%|>eVsoFh!Wn7ag~*8@RNNhE5sszkBnyGVYgT=?28PDf_g5pT4RPQ^ z7$x=eC(8s6rtRliQ0VAu3Sh^`ha&i_D`j4C=7D!-z;TvvpReT*Fvna+uRJ+s7~DYY zcs`4Ur8wwctpj?*|HC=Jy~k==!=FT0J&ug9B%f>qRi;q!2{U7bJpA3IkN^)Oj^*nx zl)@72ewD7>RW`!G-^;iFx+jD&uKzty2Jp?+079qlTeT2LF!5+L+RW2gSiinatggfL zFoyOJ`6ZAyaiH0eJCF&PNq*<0N`>X>c>T&~5!9ko+cobB1q)90#GlAEaBeFwQvPq&7w^dnnpzU6seoEh&3h$Pn7K zR%Pg^z9#d=J5hAl&6p3{v`sJD2N6W0|m_COPXwR203Uq&P z2_!&!MSzH$2}Y4j6zn zO4XcO;bpeAokB%^XnX(IQYoe-W(YJEm$rS2TrT4ZHyg8}Q7O)xZ|P3$@quw;JeJjR z-c-()Km5#N^9gCY`n^V8^G}MW2gP6H?8tf}L5$5QbQjrjJOYR`mIx&H9Pry&WWCgj zN5#=bA?t6A|aw8@VOx0&<$K%j}DQIw-{N zl0F&YCLo2R)oYc2j2(oN-_l-R{2=`kLnIz+3x-^_lc7R6irW=q`w@g~vq?uUooYqQ zqjIxOp(z8zw)%qcJ;DgY=}4XUx<(bQ?3C!JTSfbXp1Fv*57oz7H_92AXw&JX2vGC? ztz*+m+Q3ky+i9}hRp1ma3~T>11~vvQs3bIX_a80C3iMF!`cus?ylBXkx-!^d9IozJ zFIC&MJz2u71PR6lQ5&u@U?v!*8ZrSsO_<`H6y+V~IkpzRrvRgO+{eA2H^9|huYI=2 z04nk4^Hded8|bn#4)uR>7q5aKAk%FZg)Igh{9A5%*wv|nyqXYS;0{Fhs*5@>;$Vtw z2S+TGZDK#MnZA|POkE`YnyeEw3gpcLI+F4OV=`XaF!^DZLy8~lPG!Dop@!hq_F+4l zLRSqN1PD^vB64y;>B%Tw#NIG6UUAJ^BMK>+4S}v(hAaM=>@77TrMoTk^U3;3|Jtj zR&gI`{;dP}qcMzzeqXou*TFAoeV%XMhIxxD7Yv#qRWD@-g?@IE4aU zy2Yw(skHdb|9}IU4#Ja!K>z(1_E=%bB(A$W&ZNM_aYoJq!t|S?1G_mm>l!$ch@rb6 zzzsR^*Fr_p_<>QABu!@Mx-(L^Pdr`eo1rITSLQ=ajN~aW6^F-{B5zqXQPS3;Q{B*G zHyh6Ln|VAw;FWwgN}*RxTuX2CYe(Dk<|6L?+I$ym`yZd?h6#%oW`+k^$&thR;DO+0 zQRsa~LQ4bB_V&j9<=+gc{UI2cQb3TJQ94+ZjsmbLMH<|lTM>6+`S!361?6~@7fqzd z*9KQgAyPxRYQ9E=+g)3F!qC5wwg{bG55jG9Q$<#sFpH zE{2+iS>26DFDk`Q525B-$>L#XKnyAEF+aI8y`tMoPO(crmI;MAb1zH7t;NiT5H8_(8Fq(G95BOo99O}N(G6?KkxOC#`w6Ci#-TvQiJPM;d4QysV{AlxfoPC+B&eR8F@P*iAv2Zi}NVpZdOn?nErw5%J6 z0bjD^H1L#D-f0B6CZv!D1NkM53~VgdW?D-bQ0e(Iw58OPZuLm- z7aa4&#laAS|7O*Z&5RJXQ>D^Zax`ZGUo7T-nZwTW3?gh5zB3V#kR4`Jv0x-ztM=CB zroo?>GZvnH;p4Wu|I8hH(?U9ujyj}FzZ*}HY762@;N}v0v{xe55U2?VPlJ%jDex3d zgI};D*}?|WAfpehA!ZMT>uS)kkHDC)^FjSIv(hpY$Wyq1q>iXzYIfXcbp$(ks@o1s z9-W8zx3U}oA1UHVUpZ5zsp@m_uOo#)4@T-Qu-R|4>&l1;wF5>0zk#r3B3!SF`&JZ*sWu1GN;{2?rI;n2xL+l zU4LV`uyv#C9-cNmjI+?DVRl5Dt@nXrQJwpc1afysbYKqkIh#m)M1h!JX4FRApx9j| zUHnLvevOIv-7O2 zug;*a_?$?W^5n6m zj?UfXA+eE!jG^j$6Q}zQH3Eyj8de82|AxOvzp@y5uN!nwv>9^pwu4EyA1aXRu;FPRqOCcCp(@hKLMp-*-w?>F8ye7x>ay9#G!vNc|C!j51TX*D$4 zH{H;VvBC!IYfFz0$vtAscrG!K`l1jALZaWPosrsd6z`UAOA1@U+H$}fYSe~Y5W7JP zs}Km1Z}bO6^XW!JSINcI!#Q0W`k^si4oUz|RZO|AdS}!MOQ;7|qQ5YHT8x+HJ`NWr z{5XqCJR%Me2T;7Wu{re;==ZY9(D6``QlEH_$Wj1wu(6aUc?BBbGC0uIaJddl z;AahN9F{K)@9k1>@7-rfRo!%;Dwh`8ci{ zVs>BlMUM`lU4SUW3_JE`tY9j*qv{?mI@3e4{XsdLNpA&F;|Io{VnsF{U(ZvpXrtsw z@K>Z>li_ZX%P<-v-CP+}Dn0Rlm<;xg zd->Q8B(TGX7HeaaVI)-6=H`LXC3So?x*IeNFcS|H&>+=WSkK(ygu@qaog!k+(4_l0 z3rZBW2pusw(MXbW|CSqV;8KzP4g$Y0pyvz|_fnxl`#!nogfHOw`k(Qn(UY(~2VyI<4k z&(vtFE@Jj|@4xceNk66_K~odTovbV^54<+jg8RBvq~x+NG)x!@Z_x}_2AWq|GPrUp zUcZ}J=qIMZ_O`Kf#Y);%=ANNF5FnlxmF>NgiUEnK;0W6T0G5&R?;IvNKm#JowSc!$ zFjzLdbv>i{=(ndjPeOD zR+}G1ew7lrv@~&4@wI5{x|Dz&RPQKko_qlY(`p2=hCcquE|uzoa=$u5*#7Fl)2CE& z*`X{Y$%VMVk*EX%ws}#tU;>i3$m>wG0GKR4*v(uBtjPGubaKPoJCyT0H6f{Y{uNDt z=t){z^w;u!H~3VDK4l!;=S6Scodmf6vUCPp3x}8&T zl?CXEz{hOOc=B#RcKKJi)?7Vu95WNjS{f6Y7abfR zQpWt(J;O7_meKITD*roH%{k^2HBW$degTfp8M|N30wNzYMNtwNHC&|XZo06Y%SOI0 z1-nCi_I>WoAaqv~_2XRFsy%qsIbsl9WpbudwA#PX)mUt#2EyJE92Ut>T~A1YSs+KD zSbL0M@@9*mkExo^m1d$|`!aJAIh<1U8V)t4V8C0JSq@aNqE&=d-@#ux#W?W3P=iV+ zK8r+8?M%lX(x!pljv=H%cj2@7ijD{{22Zs5CUgDf_yx8QZnQL&7^UhNuRsw~E2!oC zbA$vv4S+=3V)=$Jl7T;@pqj9ZzK2xq*zfJzmt`}IJX7;~F%2or3PD|Af-w|G9a&e- z8HFk66_aL}Yb|{j%Uy8Oso8zaH0xjr$bzhBRi!BR} z@4@&%$${y?i-@1m7Gmntg}CwCuGtnbAKz_0cqA0;W2`m&N1uCJ5;b*ANMCF zj!e6apeQzQYqZIAUL)N}-q$6hFq-C?_oDHAT7yT`;R3M&;`rKd_*njlWS| z?7gnbV4OA}^`Uvdg1AM6*Kb!XxI2~->RS4H+7Fxgc8%2ZHlC&Rh*>mz$+hN2ba&xVt#N~AV4 zMrgj|_JfPGBQpJADl=@*gu*HD$#N0gT#jzP>Qm5y_QEFz-`MYqTcgZ+$MD_Yq9JR> zwUbs4_vE+KbKv*HpEM%5b%@upzt?Vw1PhEIAZx2!>-%Pgj+RrN3kV1FbWMGbDRC6E z0a~zcrV*h*`Q(Cw@>B+Z-eej*qw#(jO$Y2-`eiGET3w~`g@PkqL=+`f=0|A+E!x)s zQ%eof4Tm8CH8w?giZ^$pBJbA=q9X*NwHbd}z&^s;EZvCB>uJq;(!5`wks)1Vrxv^S z@76{Dd9b@1Ckj*0ySR8aDbWPas!{*0>a|yhMrWb*E}RelCJGuK{-8lwCwF&*VPi9(>6c6qLYr%Kxtng1TH`ff5W7km<+(1in@7rQjfb7BNO|Cls6*y zM*sqWF7pO3lp^n#PgDjJR^Y;D(P#k)>CtJES07O~;s3>nv0-%Qj|S)a1g6W`Xwo8= ziV*JAdz*=e&BE5LNY>NTUg6RzmXlN8;xLfA-qJ{yfA8x09^9ioeuHMcm2{vvHycNG zvA&W*o{fkuu(Wd?Qe1ate=uq6N>b|>S5slii9-y6(m$Eckn4)Z9es(d{R!@bwUF(S zdTdmVlswallaR)KYgS{YQ%YW;2=bicQ{m@4LmwBdh)(=q?JYvTU*13lBY=S1HsrKh zhxM<@3L)?V7dNinrKhwYNCkCvy2<--)13_^6PwO@F14D%&Qne?hoLYRz_H-aq74F4 z*(0R*ml%V#+2R%)%-z*JR3da9vXpLheQdYYgpTAj^8yd0>rbR|Cz7c;e6*_=`L9V3eJDQ0 ziJ@aw)iM=BEMK|tBv`I4MPJs`esmnij4fGI!BDOm6w(Or47Auu+L>bUaHdy%4hWnhA zM*}r0+!xvR0(_<4=|B>rHR?etYK5Nk4YHEdOHXE90kjF+B*(crC#BLAvrgsA{^;zy zrbg+x?T165f99?66N_#E!lCTLn2iyyI=7$O8#)&!1H zZ?FgoziUaA3pR0tJqw;qkO7Ufh$rXX^_La}R&czrGRfx|PWJ{?;5QUx!{mJ2v2-=_ z{(Wl)Xg~`w)h)DpE`sLSpn}j_<0Dv8!d>#gRb*p`P$RK&2rOm->A5x<(XInyA^mPu zb=nFHobrGS%k)^7a9)fc5vgsFvVi*(^X9a8(%}q|d~62PESONH5UHWoBN?07vwAg~ zk_n~?%N*Ze9BPf%-b`f+GsQWhSE z(PL0G(MGm21R-Y{jPoa&Uw^jl?dqJZB2s!#D-<{@zm6-Lm><$wZ2&t!&oSF;FBE5? zJKej(xvMR12Ao6|m^bKh(y>dX^-&Wi?}bKxPC~(fWI+%+*lV*DO1HYB>tKoH%0ud* zhDn-!-iC8LZF7()8=l;q5X=)GW6P02JhY3G4Qx>7W1X0*@GvYj41=eZA)5z)YTY(b8AOXO@*wKSgffxO2m_!>0JqF-PT zW`3Y`i>zPz!h;8D-}kyEy3Dm#4@H!)E3<982<|K-`2LpvMvoGz48SU{se^r0KDIka z^&>n7fqDGM#EEKwr_jEM8_WO(GAQV1^@;&MM~UEwiiZ7@9!|M19-0T)#ElL{$@opc}z2?j_)Qz^{N%2P<_n=Nq5S zf+lRM{W|NHfY+3aOoMU;TdnU>n|0zhqwTeFs#9hjmb8K$~Ly z;o43omPDIPjo%$tT-_BxK-`Y2iQp0cbN;gPz)h}%nVAwkF= zMLrj(6=9(tL)qQx*I&%ZnaJ?TInXSzT;B|{$+Z;kR(LrFR8LqNxb-WPms^_B=88Qx zI#}neA}AtaBl!T*FiB&_(2!EW!A2B!;!e2yaRp^{`Uh za5h96K?tFi4%9P^m4`5-NT6eb9vLM781P+%VM-7vnhpOgM^vK_o<{6_;nQI519s1JK!|D18P1Z4^iB+`9(`iX(WeB4hwgxV<>r_ zh8h~q+tBCh);}h>yEZ|*nj$ssn**pv#*9MzNv+Rh={od9yH5Xx+zAd^xk8n7z*juy z%kYh}3hik^NIXq6Le;Aase^-ktE>|0;?LqnmfQRNPh)iN9BB1%_4DaUV(!6>{LxtjXI$=6V3fyI@jz`-hkn*>%&aP%bLXeBAF^=K|2Myy?m2)o&U zLaJQ&ds;o$=-eA>`~cY~BZ#&_C>!>IS-H`2(1eA?fR9EwA$>X9{Rq>%d~lUHd|OrI zwN~FY5bmPm-&B6sM3#RC5!nt77i!Eyv>`r2DIZdw-qT*{;6ax^bL6&tC`Lf1zsKB^ z>7fkQ4`q~{EM5E#K*mWLcor?m{Z&I3L1bK_pxl~sWoUZMj zDK-gNDjt;&z^J~63Q2x%FWH{Gx9Oqb=ch><^V7hmM{GxpQhR7F7i`#A8nxLKh8Q@pq~SNV_!EJ?kTb@bRh|*C4JJU54|YN2_=Ben7jA z8s!06^A@(UreF-my55)m`2*HSP%ao#OfHwhpCN*k24bY8U7af!+pjh?= zyIch~62tLDIC?_g1Y205W51?C3e_P)dZ?H%<6}~B@1>)psekhx0W|jyE`P^8cw_qu z(u4Di@iwWl$_XDX2?cc^d@?B)@eSH?byJe6y0EhkGq4l{XdSFVO|8}(cC#4jve#{N zkNpk-M2(gm-^U`6iFM2np!WgM+@(~o?0?J)1@sTlzz^@oiER_BTJe<235v_O4w8$( z{q6whdok7G2Ks^Sd?IF8=OQ2A1Re|K4?xnb%5r%g*pY_9^k8G*m~+WfzW8E^=pEil zG6oAE3`7h*9y+P~I#uNGV_h)Z){OWTd#cxOuNfp6o|1P=xWe0v6Z*Ykx27yr_v4e;88X`l zavoEz40V(lCH~3`fxJKOlM!Lv_3^jY@yEqYS5GF!5H|LdX^bdLxx_Ijkhmo)t)Dp~ zMsks?sfKYzW#tKoc(l}_fUPF@PTNP50hE|^WU<-rRXM-$Y$F2-jBmhS z@?J#>P6WN57rffM@B*H+E?gjh_+xw6PdTYI@kioTn|<30IY}xQN0Px0h8X|7>of{! z!CoVZ7i!&$3zKhE>Y|Qhjwx!6LqK~>v=Uz=yI4`!114h!bIe5~2-7x=z^5H7 zb#otadPeCNNi>tJ=>&inKKuY-Pu&M}(70B!B+WuOD#E?m6o1-ZA*eG(6noktNqo}( z>SR1}{kI3qG!Pdah*HpN5sT9kjf*wfzNihkfIwV!9L?mjw6t8w-v);=n@C1!_&hJm zWdn)+&LxWzNhsq(Hlr&*ipU?Sewc_9WTWim-~0*?q<>O+D~e7Ot>rJwV9Dj~%9WnPtXMVXf8MY-2mM+PgMfT zd?Dk8Qz{=QG7u-Y+J>o6?A)aq6{?jhKLj0v7jv8(eZ-czY!1mAMEfM=n`F|kW%GB_ zLy^i3p5XvAo+6BX;1NJzxym8>g6G+sLk8&ef*F??Zy43~Fa$&igGAd}|vv z@OQMo$DO}+f&|>ULK!1m@f9*ckgf3VVMVb|lGektx|B!K1kcJ0E+N?~rL{ zDIv59h`q%3$R^OQ8?okMgIxigL4JYUzip{AY`!-e~9v3#Je8K^~qG?&nz92xta5! z#OAd$Tm9PcW>(oNGOX>}Z$=L^k!oDGxC+@?z(?>uyF@ui&6xJYDB2jE(Ko1Gt{GDJ zWjg;Y$tq6-gfkg8JmO};oz#{`TlqiQdkd1!W|brI<5eEUyMtk(zNqSKu*2f zZ6{N9z*t0C9~L)_T2EB_qp{7{Pe*E9EGzEn>?AGhIrLUhAY(8;l1ofoEg}JYy%bp- zlN@agG7ZG~is`Wj8>Zuiy&JH1(HNfzN@ky82I&aq)G3Pud-hlq$j&G9GlUke_$m38 zhsHg(HtGY|+^lRiAE+IGii>DLCxgI|0uc(rkPyM$+n&;-UYnbq_Nuk2EKarFx zd=upK!+4Vdry%?ds$*ce+C^N+;szm@?1@PZT>as|?OU_BL3MXsN39jaLV>X{5 zeO+EarA5~`-hj0OkE&ZuV3io}x_jvyO=lpQc>AW4Ebyy1I^OSt|@e zaWm6+F$inAZ5O7(rs!mwat{3hgvuJ2Br{B|xLm%K6bDHCyZK*S8^N2zMt|&JtY22g zFR@Z$rs$wYLdV7)`i_er2V_@4DCSUR915F2 zeMNUeqBBHtCs-A;7oC_|{RfzX?HZe=rzL&E)g)3NWl%veG5)6hHZjI|%j(kYIhB00 zg=s5_SemGLpXNek;Jhge$h-Xx#a~@)e>$|kgE|Zd8nuh(z;y!xfeFwv{sr28gC&(1 z43fr98m?p4M?fSYcva%rPa?Unk0;yQI%L|r(Q*b=NT;3QszPeH)pY2tC0rHESPNnnq+mlzO&AujcppbMFsHXBIru@2|i1 zhC~ARfyn*eC;&naKQ}6sN_SOquHK1$JkRm~Jgxy)^CkgUUsxOLVil7`$VA}txba}d zqQ+sbilo!Bt<1d&q}))T1e)C_p>o zx1NtWsOBJSmuEJ#pv^o^@x?R!Z9wyPzSSHJR1~3$ZwH7wfkIjbL;=rl{Z7olncNcY zzm>c`CR4wf18J60g80A`;Z&ZH^s$v*1kyit#;!>F?7#-x}7CwDB@0dQe9}9>S!J!O2uh z+yv#$we*BsJc6fHkvV%BuwKq(0|(CxqE-RqzoLJJfOMEMh_V-oBU1`Pk@1kI`sa09 z%-`sb^|bL|^f#5Ddr^FP+=dIe<@s)(s*};xN4e3czF(pk1x=3x;XXY9>t-Pq;R7*b zW_LCM-SGN~fdg{rU^0P3%PZu6pLUa;2s;5K@|pA!gpc_eHsSB*c$}diQi^^HdmwU% zrIV1PjKw$>r6Fr&|Mw}?-wpX`{ep{)IyWEy zPho3u*=PXDRQmk9ZxZhS&v9ceTjwJLV}lt_P!}-#G@B|)vK=3BqYcCgWG?8OSx69t zbjQOy6$gt*aq@hnJ{}DgKn^r$Mmi}*O>B2WSt0t^ow={ggIOooCPza>iZ;1i)f@x& zjy0!b*w7F@ihsTAOk^xyF3;jztf`TO=Woz7*+2H_+`aZfA%f)Q!*hKKf>w^$8vaKm zH|;5*7Ws2{=3jZ6-cXjRt-HkgBJk`GcE$q*>`@x*6(Z$mwQl^$rpS z`8A)&+=(qQr!Gf_nQ%}WlBvJhSVl-YK|Zr=)-`tn+Ww}viOtXK9Cw5@DN?SP*9 zf6T0;_pfOrR*^XU>z`Vm6SD#%(LDqVqfV5oS=W=-qM_6u%BCq5gf+{0wlODcxD8Gy zsfk05oD594;boa+sdolv2cfkL7X!@&!?xpF@)elHn~?B$nq-go*(Gp9x_8$G8U_gi zY?uJ?M>7yKcxaokx12{MFs}`JbOiwwb!IHoKuUPt=%a@7W_UiILPA;vF(7ydA7irebP0bS1 zl*I^~gV0TNU)SjOz_@R_W_rZ+RG^sll59jBh>v673AuwI-_K9tzAd%$9ZBtrKVkzo+=rW45W zR^!jd&dkJ;=t!Zl7_|{yU%ejcs)eRtKSy6BQ*l{qfAcz!ZQ!~C;r)Qrj9V8G zvUr}eXexFC%ri(?n~kEqMcNsEVP8`j%hdcu__UyekyMuW&mPzel#bkBmN|bx9Lv4{ zI^cA4CF@jPB8gi2`^$sGW!}$vR##CPW529LX*h`I=($RS64wp3aUyXhM2T3j+vE!q zesjG7wYkSVU9_iQ$RXTe+;EBE(02JdRy*`=Y>-$vwtLfTCyilZ7MZpm&?xCju|z5P zzsV8M(RzMdh!}%*4^6VxTyM%8<&(GgCQco?k~WwGW?u*BiX9=PTI1Bu&yLG2*r!#A zd?MRuD0AA#Hl0-ID*C&_;F0HK8%ym=5?35^eQvU&+baJl2XOX@Cb7%11>Yz`)m~6! zjQ!At%C?53mvERbJh%oEYK%%&QYNmNcEcEs(aIf6eF^sMjnIC>PP*h5{I71UmL{k(LFM1A6JWKH z66z#=@5SSZeISHOK;-vRxGlA(4%R|<_%W8$YRD4#sR!n)>2As)IvtrVX4e=bl(v2t zEgobkJ09Q1Es0R#L4(DZlk>=QmvPm3@(nNr#T>T_>*JJXs&iHW-BaW?`OqECbs(wY zb{H0-THbQ1oBu=A>wug_>;MMTHfS|GJ^~n&*A2|Gl%wp8#<<@ zC)#i5zgMaby??k`e#0)ie|D2zD{%BLawHr5M@+WiP96YIB+zn7`ax%{8R7yX>HVt$ zFHj~9)qHMCH3o#Q=>0?jkJ6h#yg62yhzNk7#Vs}9L5Fc28>tBrf_-m@e)wZk&_Sf@ zkhG|dZEc#0Va8uauD~P!RTQcv=dSOx7-Cw_V`dl{KTL3R`w&DheVNyl1)1Ps5K_5v z5%Jn!NRfD*4-=G3g}sS3GF`YbC@K~{kSkmb6;G%xwebbTBs2!!6j=u>I#ExWG+l)U zjaU;lXnGDFhWYgNfZM}1*QikImpK=4eLKDw_I7b zaGSADr6vdxXVf*$uKULV9R17Pj9+s&2qa`nib_8v(V{|7`b(FuT(?D7)(i$KH+A_< zz16fa0q|S%`{uRH3skB!(BL1O{-$o$77d*MQ;(XF0^vKSO+A!BfA*$wKf$FbNmW=Q zo%!`()U=vEsmMEh5?DBSZAs9uCaJb+-cpsz1S*pk06&`~O*jh<;C{bpdXc_LSXRi9 z7Y>d;izZU&78D#Bhm`eY-L>b@N5Hw3TC`QB{XERcnL0D~3uDfk-ALQwBZ9 z8F=*aT{^8arTdVssSLn8Uo(2$#&L;#iDP?6tu&lmF@nb4(s}nX2mx`-jhyQ&5g8t7 zpH@)ura*v1$L#|P5RLf{9Gs7jg%m7@j!U(e6uw%CA1_ZuGaGbF2t%d6vbWa2WS1>0 zN;G=GOj0)~Hx1ddr-G?))XS$_t4zO>e}{>Aj!taDND(k-_htM3XluKGVbiv$i!9(P zr`E*~*%0{~!D`)ON^k5VVR4Z5k=ryoN*s_-+76&zO0!gLJ92VAI|1XF#~dYyr;>P~ zc4fJ~Ut%q1qz{j!LVG(EeL=T91ghOCR8bIv}sC>Dy@-MgQ(UGSa#JCnsgTY-L-D> z1kRgP`Qu31`?)Aa&i(|T+z~G8Qf+J7vsi*q=S&tLutBY)0x?B~AwGR)4Ri?-CvOE| z9oKM?Z%# z=N6+9@KF2wf~IOd&0(*P2tUZJv3#!0?XGfX11X$q81byt<+j ztW5n%5k32N3a!K33dxCYqXWMK98`dmxvr5q)hptmL2=Vu+g}>fQslLj-^tDon2mD4A^tiXAjZw=q1d3*kpS(wuA#fRZ<9&G01xUEg{^7+ zpWdQ;Nm)+Tv}?JO(G|m^{Xc!x5@POwZwWDss$6rodZJ2%&UDHK?k40-5v= z?k^!IEqY>4i#G*%(R&jet9!~&)1BhoYuvdP$L)2{a2wY*cg(a1PNldtv?7sgfd?(Y z0FI#EQpljIuSP=N(%hO7f1^&W>RAXAO4rg#0Z#N%K}IjTPo_YU22_Dioy^Z;sR4vW@lO$*oOGq?~e*LNp;p=JJ_ zpTHJt2^i>=n1FOd_obdL?u$KFtr-@lJe4Yk-i7LC))Cxk=b;s;5b(a)n19$}2(N*P zCIp=tVyAFue?5!F1%t)7GUeywjApe~I3r=`w>b7*1G8LKL>90Yf?B5HQ>H%+siFkb z?{TmEvXrueIv~eINexj3ae0RwlV(gXZfG_9HV|42Dk_kaC`tj*s-R$MKA^7Lm+m77 zmnH>{-gXmsrJTB?nCJC@ZEP@yZl{SWG^2C734};hP)mC+I z3_NYn{Sz84zNP0f5xkvE&YdpuXWhT&ryz|CGu}yTUrU|A0+qC{oNVB81EQg3ouiqB0?hdO zG0$=)qJAqRGEuhnDo|OttAfO1vEv;52U0QD&|ank@*nNJLy#zO^CjB0ZQFg@wr$(C zZQHhO+qiApw%v1QF^h?qn3(^(i1*&&t6fD!R7T~mPUhldo)arajSpJfVKG3DRvOii z^$ZEaR;rJzB&Cs$Sy}4=wS4r`E6%K~jRiiPNIy>RnTX!>OoS7V@e6kz3Wn3`HG4>9 zgZHRhjXvF&-_$T#cbVHRZpgiyJ1^e~q4>fMx1Z7KeV>8CyH6Ox9l(*LCTf;bS3`0q?$+pYI}}?WBRD8IL-Cx42cyr@XjFzSl{54QfDI+Ok_$v(HJT zoPCN$Rpq&WY-Z-CH(aZpEk*XG+9186c#dtfpLImy`PRrj3q1P5!pndTCL$dP$>Tj@ z4IT>c1`sT_c_1+cD8GuwF5*Ia4q`JaAUc@Ra0b&R_V?D?iXcegohaziDd4bCnp~TR)o-@V^JiYspDNSo54;YOIPbFk)KZ3d!5Wom2+m}t zo29ftIkl6cpM0$HIU%5xU{0f*LW|mkg}gbI_@=ebKS#!5w~TbVa%qq;%`bUNcXPqVf5RU$dpXh@Q2G6gi={kT$mG^>9iI;`MhMU zJ7-&A^=`19evHT5bXcBmV&*;k5*^MmLx6CrFyMd}PgMd{=3@$6QOA#M`2MOWX~h-u ziQdBCE@8s;WSRjhf9OQ(8I0>2hepa80V04gaxY^>%^ifTmJ`}pp=9Ti#s)ktYY}wJ zi+KAT70_0|L+MM_#n(+E^0}yty_ll!fuvXH&NHV>c+VA^aY4)d7Y+UH?ik^mX6Z9p z=fmurJabhj1L4gWj1HCLUcvL|(>{YWTA_%1(ut>NB-$T1N;agYO>!z2VYF~bHMUZU z%VeL<$?(O9vwud5)in%S`J0FVK@TX1zkJm)tWL1EfpLUI>u=@N(oK3u9w{8kNjxeO zRS;Nt?jY7FQCrt!J!t9r2S*faxC{;Ox_ofi&Ya9qO@~S%NVo*L3P?!#q~e9HvUuF- zi7Z=ZtQODi%$l;C)7M_fE&ISRcc11cnikJJLX_rjfc&~X7EE>HrR<*snSgN?qdDg# z*e;@dK}aC_Ylmy>#tjqf{3tvst+5`XPqf)QnxoER72ZNush@~5r12u2h*u3gV)Zc} zw6d;oF4z{$8e~8T(Hbp6SK}J*2VpMw^&k{kjJO zfZ#G-E8AFAXlr~DmcoxW-|qJZ;9m5X?%ZXX%h4j#_$DMgH}mnbQil(rZuY{Xm5#as za{N!!D|CYYj9pKR-NPCS^$EIRy<_ny3cOHi8Xk4Y5Fh}&P5#_b6VW7siU8!jBtj6g zB8U#*1r)S8P2;<-!qv=Z?^wp6tniH8P-&rHd`45!p^lheB17~%@uen>KVM!95k=WdQ?hq- zz(cALQQF$;SNY4i9KK#*Xp&}nV5w*ct{Zo^EO%UUf^r8g+ZEY^Gv{f=pGX$M3|Sp+ z6rWtAl=ecS^*iy{4=7Z0k@0CxWCNpy)y4YY>oUWS)EqNGgT2`7&X!qZoIqTdqUC?; zd(AT@XS1WUN<97tBm)Rq^ow%Q`0_{Y@GpmZ^r5=eMiJ7e83vgRjQB9k)As_PhVTJ_ zod=wmtAzMH0eG`P8s0FYa4m+_m|V_=;2ygr)5*skjq~WFEWQ?FpZI8_*&2Fc&THfk zk`K&!#*;j^fzQ6uto+ZMz8mjTLW6kmggX9oF!NoA854bP0#wdXDqa`wdMx0` z9?6Vl?xRD)TgsB%f^5|5!weE0dA=`p@^jVU$iTskib1XKi~H4L&IwO{m#NVboZ@@W zGJ_jkJKDiqP%V;R39U=N&F}(#-p;H435g8D4EOF?bws8lo}4!2al%|HEzKSynrI) z`)nMHM?IMuam*SxuVj^QhleNXze*Ip_yQ7;sB>{Z`3;I58R=~ZtY|u=SHJ#|S9-Wr zB}04XUPH$sk5OQe+0V<8^!wB(;#*wG1YgQlDA)nUjz3nSdZ|mQHGqgMMl!taThV(e zlQF)x#2Kt0?Mh#<9$CYoP~;uy^d63mb38VGolcFwo##upPO43z6kn`42ymCf4spugMCnoW{r)6CmGobd2U@)c}y3 z`5=<20uOVk60pxCS|2Q)u z7)2cVWR_Q5O80k&Wi*;T?jigWgW-6R>(r{8|3nMo?)pMJT~$}U4QVF%TP_fJZ}`QZ zqabg5DMa8)-AEj|{L1KS*K7slJcImFSUm5Y(Qy?Sxq<$RM!$v23e>oURHc>khBe(Q zuV2*uh23nZHhW@-(l`4#R^QH<23PK}B5IL@h0rK{4yKa}k!IHHmERV-v#%wgBHKU@ zi!I@EE4GP>kl76`IDxuZH1 z!7fPNE?3}3XLYC$*neW^NGx;n7}vzgR_FneBvT{F5M%2X3Tfo#jjWVoNlfjv_!irZ z$bkiPko^P!Zu$u3HrG=cJ87O@-F}Be(tab?1_ZzC<<^9jDX0@Psw#{HRPAaLcKqqWOV?aUvmXmv$z=B*igj>3kNk@Y5R#B%` zH1EV{@7ur{yzb}wuq33Jb*NtukcaYtIc=V?TIoShv++I}M8hdMQ(684pR9W{4`y$% zJefhI=~}MtS~{&9(`+5M2*yuqk!O10YYP%oGNd-lC3;oJE{*N{Gr+-ctb6xYIYiu%13;N!=&hM{To3G;bbexjRI_qe9$v-igRO=y9-VAPjiv>0RChRl3CAAeY zB%pnfr`h!34fLA)A*2NHteuy|%~-v9Cod}Ba9$qpp~`TXzn7maov0jY8UXqC+-Z1W z59R#=xV{+h ziLE83a)ryhWbhRY`avNo=%9-fz!Yq7B@Dn-h30SSL%}M!(u2CQHGLdBAyP$0|F%6Q z{7H?J_07!E?cw*sMNW+{DD?PPQxGNA0;R(*MR>E09XjIL1Uj-yO%~LhIl~}>_#C5i zO>iW(=+md6!Do#aekl^f1HIHR38C%TOXAU13oCFmM@DHbImUVwjt^PH9Sk=4WH3QS z9%{J?o_Y>nUWUr_7UPkPethrTH&5V|{A_F++=RDsWP-BYUIqAsp!GCVcb?RZ7JG8X zk@sJd@21#F0+h+faD)7Xn^$Uw7{qnp+5H6fG6$4ekcvf@Ll zBg^p(QO}yRR0(Tog^aJ1Xe3%f36tM?je}WY}z(F1pB)Kunjp z9$M_NGp$Dk(bcq~!|*A#bnLtBy3!1lXOD z!^KO*vV+>fBQ0=bk8ReI=a1>dZus~Z>#A3izR5!duYv1%2ceGlr5cGpwpxhamWyAbJSZnfJD#1(VsD|f{kD_@x9X>mhX z6Xz!~3scJ?*y`(XsC9{Y+z@47(j_AL^qbQ8qCLNPg&gyw+-GODW?Ly@b?63DkQo79 zR;SB28$RBNs5Ka1>TC&O9F$Gr)p*g9p=Yzzov`eZ;@|L%)OzL)Cr1h_rZ&|S>fvMO z*$hZd!LTl4sP(~TLc@ip{&89aO%fiKh>umis&$zdIer%Pyv(g+c@_k=a}d>WAsBp| z$-=vv(vvuO6Bvr;$#-x%F!fWLVyodjG{&2v8c58s1TdQM!HSxu#eWo{_5aA5?e)d?^1XwREzguX6!Q9pANwP87d{_ z)2aK(49Y*5USzl~`=i(j0}|Ai#De;+ID(&RhBv zPdzy89$Gr2!moUfY!_I?+AO-1?IXFhiGEdeF?+8l8Uc*Gnal9D7zuzy>UH2C1G>tR zj8k7=?)8HAW1u6=DA^~g^uv&?+;ZkD+H&5$6d_y$z7(>j z9ocqUDv$r1cf?K;e_AhsV*F{{?N_c|ZE$uu`+DNk8y?K5em*&{%9={f`4{>FQ%?HY z8fSjnZlfPKyZ+0XK-t@b^kVfT={O%<$1e`X4O__!i6Il)PO!78Gq~7ltfHs)2v)7B zFL|gn+QvEbdLAH3@9S({1aY@ z@7(d_>#>uXLIicPlt9nJ5TMcGtJ++X-p{bTHp&f^vt8HSBX7R~ifc~m-ob*LKPAX{ zr;6Sa=@!JU8dSLxbw36-k*|HxcE1Tl5w$!SGnLi={TEa7{SzOmrd6fo3-(C&kGPhK zhO`;yxvl>K^us*TsFfp^oFR_)K5E9>wFS)}nHw~qMq8ZF^T8oyA*m2m1z$e+mup9y z9DuI&02&CH24O#ZEitw)jT5}di_dOkJ-9zEi7j<{`QGGmZp0&j zde)XrgpsrEd0SY&d8yUI%VS1QA!%#Dx1-s~_4D@87iLX%9}Uzws$Uqd@q^D>M4%P0 z*NJYmC{QtzDziYv7=+acYNlG>8y%%F+4dj^Cu#Sf!BAZ5qBD$K?CO0yM?f^_;5M(Dg_@TBsqO(XP&7B|wyvmUdBh%QHuYrK~#vY8$t-Aov61_*q zPvTtp`%vcP(od1@&k4-=m;2Hp$PJ$e5 zaWK@!Mt`F0=9Vftw9olF7CgqADejs9p{RQT0e5N?hv@xPwH{#C4A~X)4B2`iD2@eX z7YJs~%C1Lpq+>tk_r_wyat8Kw4-{HH2S`28@IrNqiDEO`G<8{atH6h`#)wt;_Hruh|BAH(uX58v&PwQ_lu#8)+6c8j9%(E9SX1u;=lYo^ixPLqwRo;SpUOnpt+csk zyAkkLIbJ6RlizSTW0Gol=vR@Ww6$huXuP{Cr?V!i^t7vy#7L|}wJRmvpZ}=kGhMEH zQb|NrTK@9{+Ps!>#@1vU3U;U#pNc@$<8E(Hjbh7IGUpWii?l?4BoYR?7IHRgG}|FX zR_z8kx#;;>b9{HiTt03jvuonz^J+bLGph->BbvEemcW@T;*XA&U5j@Y(4LT!nX4E^ zM4%rI2!LEyV$NF_-4i`EIg!#;bC2R)!tX`@awqg}sqqhd%X*q+Fq2;t;%?~H%dk)I zPI#R!2TuIdl7{?uKlEQ^Ja`7dOd9Be8j%W3X?@u?NN&83IE?9ZoHN3QD4v z^JoU6h41|qPR=~Lm^0ZlSY=tDNHfVp%l0fYk;;1*lDEdHMuSv?FZ+IbI;Xxf+MU+e zTj4_!y7Z%B;Sg~ml=Nngl+Brfj=LeZG2MEBEOqT#1AE~dq{+6nL2U*h2df68v@wAI z7$yHoM&D4uT$z=xD%D{-22u9G-sWs|@-`S7nc^?C=@TZ}HE}ekk$GTgw18zz*?82y zNP;1!$3`H-gSHU7lz_Qs_}JE2U%-*50pkVD#|`_r^vSMoc?{OMDodu7cPQ2TRRE{W zbq5cD{$x4dad|e`Hl>_#EIwW_RDL1n%tF?)@X7=#=EWZDGE!x?bW zIaM7jJ!@SY@-pueoe1~_HLiQ_SL~R6*jaWY-o4uQs z&En>poeN-Pyo!G|R$T=ptT__+b` zn=rFY$DhI}30JbIc=zd>p*bt7m(1R<2s#M1FwI_f#W2;4X=l;WCZEl( znw56tCADkC@=GmRy2HQ$jix)s<;amrEo1~#GJS}dXlh6efIkpWzJsnG+U-KEjsh_J zw8ut%X{N?G=G^G(I0&(=pi@cj;niAWq^86xGB|aU#xY9f=$n`apY5Tp}Wgt z0WDEooxwWRo$eV@PJxqFw8@_YE^P^Lr8Xid21h00w75M4QdfUTG<;0=Ap}T%+)Xax z*Xp%Nn72cV5b48aL{3dEf0(AePXSh{qat$_c`5tJ`c5%!79eCR!E@h|LTdCy>I}Jw zjX@F?J^W7YV-6Hq3W9vNVYwcqg_B0qUyiP*`pN{f-{-@0P&0fPCyQOo^FS%>@Kb-@ z9QC{`mu%q%ZE@iwPBps4h`+xz%*`Fa--{fGCeN;QeQ5cJ4z`={j*uVgxN(z_3mqx^Qz@abvoG7V z5i@lG=XV}`>>h{!=E((s$Q<$oVyMf8h^0B4tnyLTPED8`uJz*5=OpR?yYl&Z?z%G> zTQCE+W?MJ*wu@+c(*W0n*>Qq5N!Sn-_X~vFNE`SXk zpu&5_b}HRODv2+PJ=>yrt=0^qd_diuJXCJ6`thCn2NT}jg|P-aaU}6Bhu^EF?av7W z5w5X0`QG6^;WGf51gNV!iDNO}PvK>ZV@j@gNVM1^Z6Iz|o3PA8X!KrokeDQyGjpve zr`!q<0nE)rM!{UsQ*~l!sTq^UOq9A&;pN3$oN$m^*9WN=i^=Qz}NFO(a;uVS0I#OG|`=ojqON zzy39(VWYh~_@RQb@rMN{g8nj4$ESXbSLuFE+qf;mHDk8t`w$qzQS6scXn%mLZs3@I zj@^SzWJ6>`0Jwngr74*;4h|vZvRKMRdptfec8oQbBzE3e-P~Afcp8OekUvA9s6ko@ z?7QvnRR0!xq}_<1)yB{OPA+Bzk@9D$;>rF*4s$Z zB<3qtL*3knh(+HJ?ZJz`4FDmgNqu^z^}#}&a*phJ!4hJUbx+rxUvfYHOK0ykn!VwLG6WX}ok@zIz^3(xKyN9CEuD(Gf(mzkHxG6 zP0Gmh73eQWIGkxgmXvFTO?%3M4d(@_m;p0F_n_W`-&CSr@ukHl`*ItgGaP14Y8%8y zB}!}O@RfM=G{UngMfc7z*fhGP(6k2p7f6?;Tf?iAXD;7Y&Z^f5f^7l-tlU+_wkDp8 z;WQg`dns5)nzd@%q5>-+$f?a&lD0$5a+`cq6>5xN)Dr3rJHHhCNv}goyt=*4J6+-3 zQn{HsWU~>WON|fS)V#q9xy<9l0A`hg3F#eUt(>>__5pHi7eddEfUAqZN+tbWKAw?Q zGkdpyEPz*4a_vD_yf$2hdk9ns2*yXvl__WjHsSa9R6CY1YpWbrKQ;^lXUzNnbFkq+ zF1!!1U1RebOJ=kX3CAWk_LE>ZfIkslB&P}O6o{e6oO?nVaMfr*NWw*-^q@pOT76p#8kHWSjl=9QVmS#0Id(iY(u=? z^sl~l;y%({{b7^DSMUOu_4v+t*T$V8Yj-aM5|uo6ONeJUE-7m{N$t|BsIn# zNtL>I^tEa|O9P#scvBNR6L@B&V{r0caOm$>0@Hb#(QplS*~`3Dg~GW)smPrAHwm`m zU9Dy~BeeC;8sc&78CSB+J}wA=Kgf9o6|U^Rb}FYtohF@iA;7T{M{DsR5+uJ8BLp$! zCz^FvMqos$Bap_Do4~CB>h`9jh;c9MpH2bsQq&y~Zt~tmxwgzX2Ts-Zig*rrNL{i5 zA#T)qX6-={Pq?&-x?4Qlet;X`Ohf%nwPZzbPKTIj2 zGWhr({{n!#xZ|8}+$co^5Jkc~5d((yaT=l}?O;=Oux_Z<9Z)?L27y(FJfu*u=W023E zcMPh4#=*TFtwV$HZiPeutvW_3RxEB*={oajYb2{z@}}bL5w)~ElLvq{TSTiEcy_=u zN6+r}2!ohCW6!TArV~GCVpoa&bi7wcIbQ7bT)(l8Rao+}9MD@dDP6D{ zMT`f1jcn}>A<0Fy(P_Rqu^E;BS~G-@o1pcV3wd>&5E{CS{TY&r7|F+CvLjovYjI)B zaiH=z?ufm!nvpFmR4ZX+MJf_=asz|qR@Zp%sY!~Ge%z+j-(952wf9*nq*hZykV2Kbn{*8ifitFna5|8P)EUu((?_EiQI4c+ZZK?mu{2UWh%6g?+aSgux*W-Q<1K zD1IeNlQ80kgXpS{K}e2WJPf{FcJ{s5ItLimqf&G>0lyPQkBbCVc+A4$2i_gKX_HGk zkdSJuCbS13Vdyj1Jc`;FgP@$xmHR%NCapdpR9-{tDE(@zd;jj$oc8ez>!m~X z{MvL_Wuv!zj)2`pnj`!$a5diZ1hpZB{4O00N3k`njCKpbM8trDpynfoO^TVs$HDjx zM9BcM^L&v+tUP0nnivwqEcmyEGaykAgMeT^oZg@-tVGEOODLpPSs6xKnFF+jgR5N5 zL3nI_WvU|vnh~D9mL@)(*t~x87?TBtfg-5xSJcPi+;8t3LmORI{#Kg`BX(w*CI*>w zWz9!M+&_)zGAfo;V52fl-7Y%j_7aVNAjEeo&ogN15AAD0*JzxPPGx=$*?3+tAIlSp+tXI%4fk=GTVc_7kb0Y5wT&sse~ zIoAtQ7M?m12R~9hVttVuf9~r-b?uN74;N6l!mDd<mg(LEYHrJ7}+9r&t} z6@kg2m`+6BI|y(gtVTJD3Bh5lc_Fyf5}}~W#B1*=O(H$9svD~|x;5d~gLYAMYeJ3) z0x_YhxQP1ikDHZwsYYPt?+QxiT?2>Q}stc8(7-U&9w}E--z-O2(z+F@O!g`gJ`I zT>mmD6y76s2Z&RGf9is~Bqh?579dN~l4h zk``CQ9WX#V*0s}UkZs*&CR|$3$c@Tf{D2NKtZ^wAHT)s#jStFGJe(BB6J7F#FspFv z7U$wR8uA3b4Vfreg-%|JS+1i!juc(ON53s|<89C~HfwaA7A)Szepa8MB;dsY5pv=I z!%kr~jGfkE7Yr#J$7V9@0Xgeirq@paP7)O?!RkF~&3k;RHH=;4PHA+A^V5N`f&OPX zDzMHjgZf_G;+kQ*XqNARNvXf3kV=GplgDgj-Bd2Qpb$sC)0ga^4f8i9E5~V>8j^=% z`*fPKJt}1)ltk#KUN1zWI_Ix@l-xXR(wzI*@$GJr#Jb9n1b}#Ttay8 zO5x0C9jWz``0XmJ;+2jV^-x%cijOQt)**ky7j9P_0TO?yYd{uZuLoUXspDRK6T$f# z%tXT(-!yY`FO?4dvSf_TEUsMdMNCeW+9>B>^p`%dJg<9U!-P>JtNLJo6v}l4>Q*kIELU zE(TY{)G_XTDhgS_LQ&;oZ++5Ge#pO;>1KAnz3god{yDCd@iw++?Cc>jR4V8?BuA~?;FqyOO&g|Y3W~qeX(!LL_l2qmAgmlq|T>D0U zCdPn=(omz^7@F;A4JX3UC|LsWk6^w2%-9V2e(UBD)!8!XB{rche z@~^yJN&qR@4cy4FB`?~9{{ZNNH`YLk)2Rk}CpeX9a&(pKffC5h&Ak}_MDyZ2YUiND zn|LMHd^=%zNX}>ZI;a~b-bdQbL7ENwmQRQezwI9TX-j7vOkkQ{$;KYk?$|u12Me^X zzxfl``&UP`*IwC1z-9Y$Ovu>qT;;|zM-t{ZOMBK!%>)+F%q?ZyDMneYly!*RxRK*q zB!tRoIH57OJ2QvK=j(ko%%Ac((rw#v{pULW&Lr=52+9T^*{nL$1Bzh9zuzy^^Bet; ze7J-&*%WjSk?b~qc9jZ6FSCyL4b~)rJ)I|^z!JF(0GX*9Nj;KH?wKI)V+MK2uE&?4 ze+HuCz}tJhPiMpJQL%`te7p%uG2#MNsDD>JXO<;;eSo-AjVqAy&VuJD#V?yunRxc*(keao zK@|Ki`aGe%(UYa_MIR|zqYAq?nGfuFCCp5@Ho{vRCkP{|vn$8Kht8C=VXs+f_-K_f zm(l1lQR&hbv4z9fZD8pXqY_7qPcLDrBGS=#C2yb~F5aT>`Fn;4DuMO}o;Zpk_Qi1q zYpBDGBK4jDl&{&6jcY`8qgQ^0WP<>+wg$Yf7?WNE|7SUYm0n=K^muS9JRU{wnBv-< zCn(s7UsU_OTwfK7w63_B*^ zQ&4TnQ|O?W25o3wsj?{NiVhk{QE`Snn;0Z-vh;gWsgwg2BpI1vw=xCMec?G?y?u~Q z|6}QscbweW7Smv8Z+eEj#{rysu{?!k4u|8S=hog z`2Yk&Ti`R~=s5oD!9B0ND150Z@cxk_tSbx@;*7vIKNht6@Ys zV#anG;Af9ea@kKH+rL^c%7|ou7>Pa&kXvz^CX!kD152Bpd-gqDir`8}|I}th@NTnTNFX0^t|W`R9A`e87{((!<$78)MY|)MC!O18C(wm) znGI$aaLFnF+^fHWl60Bt0%L+9Bb+*RRZao-yrNoOVo@#&U9yu+)8L_(lAv;HX9u(1 zC;@)P8CpG25>P4vk}rwC4(cE9dgll>1^halcp)Ptrv|RdG!AF!|2lbNB2C0q>MG+E ziNr{W2C9It-!{G+y}mh{+KC^e!xn-`Zztwvu!IO?kQ|<@s*ac|v((xEq-#^wm*DXV zN*xger4XAAm>hBb6W<=<{+kNK!^>vSXe+Q;wxYE7muCr3^%|YZrLNunSO(jW=?+r{ zE(NxMg|Ml|B@p(bA&R20KP!feRWvmcE%=YB;t>gg6z;%e+AvO!$sGhV# zXGXlVCwL2vs%PI+Hi|A*ltu}tNEcJTVep>`4v(H2Rx~oJcK)e^?e7&Dy)HDtANn|^ zLysk~Y~t9<<{4Q?ao@0=U%jkW{hetavDy>vy5xu^Av?yesfDBDNdeYx`;A};#cWJb z5E6YU&NNWl7NxEXAG!2_@K#wysBs+p(rCtT^GP=lC_uB}SR!(H5j^Or(lJ-T`kJCF zSR0~eKc6-$sWgP_9BC(SZR#ZwX;=X6uUrzVQ>i~$aQ$o8_I+x3J ze%TIvcdbRj)0o!)@|~m9ad^kResl67$pGJ1P)SZhmepB!NK1GWH3stKq-Bus$fC4+Q=K^+Qqyprtis_naxg3MBgZ& zz6vp~snMvbKFD zW7Fe?a-`Ll2;@f*>#KByAz&B2C+P18A1c7@Y78aq<61If6{H9DyvSN&D{ZoXd9m4z zBnla%`xGEf>i@mdtw2i15suVh1LrbqROx%A5$)O za&lXEV- z3c3yZE4fch`&+i9B$2eG7=FNfY2dDo|4WHzI^>qF4E-7KvTq2l} zw=6ok%7)JPm+^C*q-R}s>9UbSr@3$a)(SOD!{i}CoJj~YUh(Wd{TY5nv@@1p+if_p zPuZA^zos=pPjeneUxBf)Iq!oYBSr5V1yKPAOtcM65UlRWd%{|fR9BV1nq<|EFldQo zy&Q2Q`}VnI#Clg0Qz7#y>5;xv2@m8hubBN{=`!ixYjw-<@WZ4^Z_f#=jG!g;H+BQI z#D8M)eyM@40Ir;r%D#JRy&19c+F}@O|Ic27YBwR>t?7%T6UQOHx)L;Db?Gv6dOW54 z4`$an!Ws;gmp--oqRBqo(0oVBOf3oJrT5d|LS21c&aHZt8^992)W5hPI1e&Qs59|g76qQSF!rv>J&EVzh;=qVWYjoy)@Mr^I~2W(Hmd#BDdPBLim#1kl@8jGGCY`| zFMe;Rs)*6Q0md?QFZQ$sC87h29f{8mtzb91v*p`H%7Mno2G>vJ5DSwg9`jVG+_u(pZ8gM+Wadx-Uf^O<2L0QVF@_&9NBB=%LAo*AGJhfbbH^Z@rVd|ck`hI@Haq)xGSQk z9NY#92&THeA9vWG3C7ryZLQGm>G!Vr!wo{>*s(IfqHmD2`vo-1<1x_tkJdho75KnH z4pm0;XXg3J@_JK#G74Y!RkLrYRkx;92%ASTkzhZ(t>aktuok>NXb5pUw&aO#apET; zup>xnfDydK*xZl=&=m$FDIw+AL!EWAy2In2}{)yjNL3YJcuB0ZC}x&s(dcnW(pvSEZdwHMk$X04e4u*39) z_enl+menhdT^tHr{{2USnf#RvV6%XZ!(3c%S^*58FBd=Sk(Hn-wG@?pO0Hr5DKB~{IcgGFN%_( zYqiGFu@)%A``AX!*QX-2^ItqI0>SrfC7w4*V@NLlDJtvT7OuPD9y+~BcwQ+}!FXi2 zUxcJL2X~D(=)b=y6r%7IU*0>PnGAHQ{c$0WK>`1c>VE>Uy^I*ld;(%+jXrMYOanQF zwnpf=siJ!C`Tr_3(q`sX-Y)_m_5U5>|3~5YFU9=-@N@s4hgN{+Yy3~b{tLh6e-idz z#PWX<_Me3P?@IQ6YM9-?|I7X6ze6(KUIpOx|F2zAc%;xDx?1pqI%u^;8vz?@;q=Kh z4o~%7PSpPJ`@!aKLQ4EY$qeKtld5DQ!Z~NA?a5^+cGFnnV0{Srp&>Sd#>x2X*xsZ7 zY7Asb3k!Np&KO77zMc`lziV;KFb@FmAp#_2b^!X{y^E}IZ`Pp#Kk$El2&kd?-vE?9 B=aB#a diff --git a/man/AMR.Rd b/man/AMR.Rd index 47f00e30a..fca9e335e 100644 --- a/man/AMR.Rd +++ b/man/AMR.Rd @@ -12,7 +12,7 @@ The \code{AMR} package is a peer-reviewed, \href{https://amr-for-r.org/#copyrigh This work was published in the Journal of Statistical Software (Volume 104(3); \doi{10.18637/jss.v104.i03}) and formed the basis of two PhD theses (\doi{10.33612/diss.177417131} and \doi{10.33612/diss.192486375}). -After installing this package, R knows \href{https://amr-for-r.org/reference/microorganisms.html}{\strong{~97 000 distinct microbial species}} (updated May 2026) and all \href{https://amr-for-r.org/reference/antimicrobials.html}{\strong{~620 antimicrobial and antiviral drugs}} by name and code (including ATC, EARS-Net, ASIARS-Net, PubChem, LOINC and SNOMED CT), and knows all about valid SIR and MIC values. The integral clinical breakpoint guidelines from CLSI 2011-2026 and EUCAST 2011-2026 are included, even with epidemiological cut-off (ECOFF) values. It supports and can read any data format, including WHONET data. This package works on Windows, macOS and Linux with all versions of R since R-3.0 (April 2013). \strong{It was designed to work in any setting, including those with very limited resources}. It was created for both routine data analysis and academic research at the Faculty of Medical Sciences of the \href{https://www.rug.nl}{University of Groningen} and the \href{https://www.umcg.nl}{University Medical Center Groningen}. +After installing this package, R knows \href{https://amr-for-r.org/reference/microorganisms.html}{\strong{~97 000 distinct microbial species}} (updated mei 2026) and all \href{https://amr-for-r.org/reference/antimicrobials.html}{\strong{~620 antimicrobial and antiviral drugs}} by name and code (including ATC, EARS-Net, ASIARS-Net, PubChem, LOINC and SNOMED CT), and knows all about valid SIR and MIC values. The integral clinical breakpoint guidelines from CLSI 2011-2026 and EUCAST 2011-2026 are included, even with epidemiological cut-off (ECOFF) values. It supports and can read any data format, including WHONET data. This package works on Windows, macOS and Linux with all versions of R since R-3.0 (April 2013). \strong{It was designed to work in any setting, including those with very limited resources}. It was created for both routine data analysis and academic research at the Faculty of Medical Sciences of the \href{https://www.rug.nl}{University of Groningen} and the \href{https://www.umcg.nl}{University Medical Center Groningen}. The \code{AMR} package is available in English, Arabic, Bengali, Chinese, Czech, Danish, Dutch, Finnish, French, German, Greek, Hindi, Indonesian, Italian, Japanese, Korean, Norwegian, Polish, Portuguese, Romanian, Russian, Spanish, Swahili, Swedish, Turkish, Ukrainian, Urdu, and Vietnamese. Antimicrobial drug (group) names and colloquial microorganism names are provided in these languages. } diff --git a/man/clinical_breakpoints.Rd b/man/clinical_breakpoints.Rd index d6286936a..e4dd1409d 100644 --- a/man/clinical_breakpoints.Rd +++ b/man/clinical_breakpoints.Rd @@ -5,7 +5,7 @@ \alias{clinical_breakpoints} \title{Data Set with Clinical Breakpoints for SIR Interpretation} \format{ -A \link[tibble:tibble]{tibble} with 45 735 observations and 14 variables: +A \link[tibble:tibble]{tibble} with 44 089 observations and 15 variables: \itemize{ \item \code{guideline}\cr Name of the guideline \item \code{type}\cr Breakpoint type, either \code{"ECOFF"}, \code{"animal"}, or \code{"human"} @@ -53,12 +53,13 @@ Some breakpoints in this package were validated through and imported from \href{ From WHONET, imported were: \itemize{ \item All CLSI breakpoints, including ECOFF -\item EUCAST breakpoints between 2011 and 2018 +\item All non-human EUCAST breakpoints, including ECOFF +\item Human EUCAST breakpoints between 2011 and 2018 } -EUCAST breakpoints from 2019 onwards, were retrieved directly from \url{https://www.eucast.org}. +Human EUCAST breakpoints from 2019 onwards, were retrieved directly from \url{https://www.eucast.org} using \href{https://github.com/msberends/AMR/blob/main/data-raw/_reproduction_scripts/reproduction_of_clinical_breakpoints_eucast.R}{this script}. -Our import and reproduction script can be found here: \url{https://github.com/msberends/AMR/blob/main/data-raw/_reproduction_scripts/reproduction_of_clinical_breakpoints.R}. +Our WHONET import script can be \href{https://github.com/msberends/AMR/blob/main/data-raw/_reproduction_scripts/reproduction_of_clinical_breakpoints.R}{found here}. } \subsection{Response From CLSI and EUCAST}{ diff --git a/tests/testthat/test-interpretive_rules.R b/tests/testthat/test-interpretive_rules.R index d2fd10856..050751f06 100755 --- a/tests/testthat/test-interpretive_rules.R +++ b/tests/testthat/test-interpretive_rules.R @@ -130,7 +130,7 @@ test_that("test-interpretive_rules.R", { # azithromycin and clarythromycin must be equal to Erythromycin a <- suppressWarnings(as.sir(interpretive_rules( data.frame( - mo = example_isolates$mo, + mo = rep(as.mo("Campylobacter jejuni"), nrow(example_isolates)), ERY = example_isolates$ERY, AZM = as.sir("R"), CLR = factor("R"), @@ -143,8 +143,8 @@ test_that("test-interpretive_rules.R", { )$CLR)) b <- example_isolates$ERY expect_identical( - a[!is.na(b)], - b[!is.na(b)] + a[!is.na(b) & b != "I"], + b[!is.na(b) & b != "I"] ) # amox is inferred by benzylpenicillin in Kingella kingae diff --git a/vignettes/datasets.Rmd b/vignettes/datasets.Rmd index 1e65b6c37..8c0826196 100644 --- a/vignettes/datasets.Rmd +++ b/vignettes/datasets.Rmd @@ -180,6 +180,7 @@ This data set is in R available as `clinical_breakpoints`, after you load the `A clinical_breakpoints %>% mutate(mo_name = mo_name(mo, language = NULL), .after = mo) %>% mutate(ab_name = ab_name(ab, language = NULL), .after = ab) %>% + select(-site, -mo, -ab, -ref_tbl) %>% print_df() ```